[{"article": "Nature publishes broad review articles, called Primers, that cover global aspects of various diseases and describe all aspects from epidemiology, disease mechanisms, diagnosis, screening and prevention, management and quality of life.\n\"IBS considerably affects quality of life and places an enormous burden on patients, physicians and the health-care system,\" said Brooks D. Cash, M.D., A.G.A.F., F.A.C.G., F.A.C.P., F.A.S.G.E., Professor of Medicine in the Gastroenterology Division at the University of South Alabama in Mobile, Ala. \"The results of these studies add to the growing body of medical evidence supporting the utility of IBgard\u00ae, a novel formulation of peppermint oil, in improving the symptoms, patient satisfaction and quality of life of patients with IBS.\nThe consensus report, entitled \"Irritable Bowel Syndrome: A Global Perspective,\"2 guides health providers in the best management of IBS through recommendations based on the latest evidence and resulting from a global expert consensus process based on best current practice.\nGrowing Medical Support for Peppermint Oil in the Management of IBS\n\nThe World Gastroenterology Organization (WGO) issued global IBS guidelines in September 2015, which recommended peppermint oil in managing IBS as a first-line therapy option.\nThe researchers also concluded that, \"A novel formulation of peppermint oil, designed to cause sustained release in the small bowel, was superior to placebo in causing a reduction in total symptoms.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release implies that IBgard capsules are superior to other brands. However, the only trial it cites compared the company\u2019s product to placebo, not other peppermint oil products, so any claims of novelty or superiority remain untested.", "answer": 0}, {"article": "We could not find the requested page.\n\nPlease visit our home page to explore our services.", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release establishes that this is a potential new way to augment melanoma detection.", "answer": 1}, {"article": "Master said each participant was asked to carry an accelerometer to record movements and an iPod Touch loaded with an app that would ping them prompts at intervals during each day to report any symptoms they were feeling. They also completed activity questionnaires and summaries. In addition, they wore a device called an ActiGraph to monitor sleep.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The lead may give the false impression that the study broke ground because it suggests\u00a0\u201cthat the right course during recovery from concussion may be resting one\u2019s brain while still getting some physical activity.\u201d The idea that moderate physical activity may improve brain function in concussion patients is not new.\nAs well, the story suggests there\u2019s a new app to help\u00a0track\u00a0concussions, but doesn\u2019t mention that it\u2019s far from the only one. The story should have more clearly explained how this one is different, since parents are likely to be curious.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/060723/31robot.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article appropriately describes the emergence and history of this treatment\u2013it is not new, but is becoming more popular. ", "answer": 1}, {"article": "Magnetic resonance imaging measured cortical thickness and resting-state functional connectivity (rsFC) before training, after training and three months post-training.\nThe findings, published in Brain and Behavior, further suggest that changes in cortical thickness and neural network connectivity may prove an effective way to quantitatively measure treatment efficacy, an ability that has not existed until now.\nA recent study from the Center for BrainHealth at The University of Texas at Dallas shows that a certain type of instructor-led brain training protocol can stimulate structural changes in the brain and neural connections even years after a traumatic brain injury (TBI).\nPrevious studies have shown that cortical thickness and rsFC can be potential markers for training-induced brain changes.\n\"For people with chronic TBI, they may have trouble with daily tasks such as creating shopping lists and resolving conflicts with others for many years after the injury.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The novelty of the findings is clearly established early on in the\u00a0news release. One finding is that changes in cortical\u00a0thickness and neural network connectivity may serve as good surrogate markers for treatment efficacy. A further finding is that TBI patients may stand to gain from brain training\u00a0well beyond the initial injury.", "answer": 1}, {"article": "His father\u2019s eventful medical history included a serious stroke and coronary bypass surgery.\nHe wanted to be able to go to the beach.\u201d\n\nA nephrologist at the University of North Carolina School of Medicine, Dr. Hladik understood better than most how kidney dialysis could consume a patient\u2019s days.\n\u201cDialysis may have prolonged his life, but I suspect only by a couple of months,\u201d Dr. Hladik said.\n\u201cHe said, \u2018I don\u2019t want to spend my time doing this,\u2019 \u201d recalled his son, Dr. Gerald A. Hladik.\nSo after considerable discussion, Mr. Hladik decided to skip the three weekly trips to a renal center, along with the resulting fatigue and dietary and travel restrictions.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "What might be considered \u201cnovel\u201d is the fact of saying \u201cno\u201d to dialysis. What we don\u2019t learn is if \u201csaying no\u201d to dialysis is that novel of a concept. How do other countries treat the question? Are rates of dialysis in the US that much different than other countries? An international comparison would have been welcome here.", "answer": 0}, {"article": "When I began training last year for my first marathon, my running partner Dave Freedholm, an experienced amateur distance runner, impressed on me the need to vigilantly avoid dehydration. His drink of choice was Accelerade. Like Gatorade, the original sports drink, it's packed with sugars and sodium to provide energy and replace the electrolytes depleted in sweat. But it also contains protein, which he said would help my muscles repair themselves more quickly after the punishing training runs he took me on.\n\nSure enough, I never felt much pain until after the marathon itself, and even then I recovered within a couple of days...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story states that sports drinks are not new.", "answer": 1}, {"article": "That's the tantalizing premise behind Deplin, a prescription form of the B-vitamin folate. Although it has been on the market since 2006, Deplin is generating growing buzz at psychiatric conferences and among clinicians and patients, particularly those who haven't responded to antidepressants or did for a while only to have their depression return.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story overstates things when it quotes a researcher who says that Deplin represents \u201ca totally new way to look at depression.\u201d A brief search turned up a study that examined a different folic acid derivative (brand name\u00a0Leuvocorin) for treatment of resistant depression some 10 years ago. And several existing therapeutic approaches,\u00a0including\u00a0supplementation with omega-3 fatty acids and the amino acid SAM-e (S-adenosylmethionine), are based on the idea that individuals with\u00a0depression lack the building blocks needed to manufacture sufficient quantities of certain neurotransmitters.\u00a0The premise of these\u00a0approaches\u00a0is very\u00a0similar to that which is driving research on Deplin.", "answer": 0}, {"article": "Every healthy newborn in the United States should receive a new vaccine designed to protect against an intestinal germ called rotavirus, a federal advisory panel decided yesterday as it set aside theoretical concerns about the vaccine's safety.\nThe vaccine won approval from the Food and Drug Administration on Feb. 3, and some doctors have received supplies of it.\nVirtually every child in the world contracts the virus repeatedly by age 5, gradually building immunity.\nRotaTeq \"generally appears to have a better safety profile than the earlier vaccine,\" said Umesh D. Parashar, a medical epidemiologist at the CDC.\nThe problem occurs naturally, albeit rarely; it showed up at a sharply elevated rate in babies who received RotaShield.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 1}, {"article": "\"Now we get into the speculation part, right?\nBut the BMI, which is a general measure of body fat, has proven useful for thinking about the health of large groups of people, as in this study.\n\"I was surprised as a scientist to see how clear the result was,\" Borge Nordestgaard, a clinical professor and chief physician at Copenhagen University Hospital and senior author of the study, told Shots.\nThe risk of death for people who are obese, with a BMI of 30 or greater, also declined, to the point that it was on a par with some people of so-called \"normal\" weight.\nThe researchers came to that conclusion by looking at data from three studies of people in Copenhagen, one from the 1970s, one from the 1990s and one from 2003-2013.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The biggest gap in this story is that it didn\u2019t put this study in context with older studies raising the same issue. With no mention of past research, it makes it sound like a novel finding. But it\u2019s not: On the JAMA study\u00a0page, over on the right-hand side of the page are links to \u201crelated\u201d research, including a large meta-analysis on the topic.", "answer": 0}, {"article": "Back in April the WSJ wrote about the race to develop ways of detecting Alzheimer\u2019s disease using a brain scan. Currently only a post-mortem sampling of brain tissue can provide a definitive diagnosis. But the hope is that a technology that could be used in living patients could help rule out Alzheimer\u2019s in some patients and for those that have the disease, allow its \u2026", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story reported accurately about the novelty of the material reported on.", "answer": 1}, {"article": "Researchers said challenges in measuring the effectiveness of mammography screenings include increases in breast-cancer awareness and advances in treatment.\n\"Among women in the screening group, there was a 28 percent reduction in mortality from breast cancer during the same period.\nThus, the relative reduction in mortality that was causally related to the screening program alone was 10 percent.\"\nThe study, published in the New England Journal of Medicine, analyzed data from more than 40,000 women with breast cancer.\nResearchers from Norway and Harvard University compared the death rates from breast cancer in four groups: one group of women from 1996 through 2005 who were living in Norwegian counties with screening; another group in the same time period who were living in counties without screening; and two similar groups from 1986 through 1995.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 1}, {"article": "New clinical research published today in PLoS One shows that over-the-counter magnesium appears safe and effective to treat mild to moderate depression.\nThe study participants, who were currently experiencing mild-to-moderate depression, had a mean age of 52, with 38 percent of them male.\nThe study team found that in 112 participants with analyzable data, consumption of magnesium chloride for six weeks resulted in a clinically significant improvement in measures of depression and anxiety symptoms.\nIn addition, these positive effects were shown quickly, at two weeks, and the supplements were well tolerated and similarly effective regardless of age, sex, or use of antidepressants, among other factors.\nThe researchers at the University of Vermont's Larner College of Medicine conducted an open-label, blocked, randomized cross-over trial involving 126 adults in outpatient primary care clinics.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release says that \u201cfew clinical trials have studied the supplement\u2019s effects.\u201d It also quotes the lead researcher as saying, \u201cThis is the first randomized clinical trial looking at the effect of magnesium supplementation on symptoms of depression in U.S. adults.\u201d\u00a0\nWhile this might be the first clinical trial in the US, there have been other studies (which the researchers referenced in their paper) that have looked at the effects of magnesium on depression in adults. Specifically, they mention two observational studies\u2013one that took place in Norway, and one that looked at adults with type 2 diabetes.\u00a0", "answer": 0}, {"article": "The SBI also provides a medium for the exchange of ideas among those involved in breast imaging.\n\"Mammography screening is not perfect but has been shown to markedly reduce the number of women each year who die from breast cancer,\" said Elizabeth Morris, MD, FACR, president of the Society of Breast Imaging.\nI encourage women to speak with their providers about mammography benefits and limitations and create a schedule to get their annual mammograms,\" said Debra Monticciolo, MD, FACR, chair of the American College of Radiology Breast Imaging Commission.\nWASHINGTON, Sept. 29, 2015 /PRNewswire/ -- The American College of Radiology (ACR), Society of Breast Imaging (SBI) and major medical organizations experienced in breast cancer care continue to recommend that women start getting annual mammograms at age 40.\nThe ACR and SBI believe women 40 and older should have access to mammograms and that Medicare and private insurers should be required to cover them for these exams.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Mammography has been around for decades, so what\u2019s the news hook for the release? Apparently it\u2019s the start of National Breast Cancer Awareness Month. Although that\u2019s a pretty weak basis for putting out a news release, we\u2019ll rule this Satisfactory as the release doesn\u2019t pretend that there\u2019s any actual news here..", "answer": 1}, {"article": "The Mount Sinai Hospital is in the \u201cHonor Roll\u201d of best hospitals in America, ranked No.\nThis is the first study to demonstrate that among advanced cancer patients admitted to an inpatient oncology service, standardized use of triggers for palliative care consultation is associated with substantial improvement on multiple quality measures.\nPublished today in the Journal of Oncology Practice, the study also determined that a systemized process of referrals resulted in significant improvements in 30-day readmission rates, hospice referral, and receipt of chemotherapy after discharge in patients with advanced cancers.\n\u201cAs cancer progresses, patients are often at high risk for physical pain and emotional distress,\u201d said Cardinale B. Smith, MD, MSCR, Associate Professor of Medicine (Hematology and Medical Oncology), and of Geriatrics and Palliative Medicine, at the Icahn School of Medicine at Mount Sinai.\nThe integration of palliative care improves symptom control and decreases unwanted health care use, yet many patients are never offered these services.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release begins with a straightforward statement that\u00a0this is the first study to demonstrate benefits of early referral to palliative care for terminally ill cancer patients.", "answer": 1}, {"article": "Cholesterol production by the tumour will not be the only reason why ER-positive breast cancers recur, but campaigners are excited by the possibilities for a treatment if further research corroborates these findings.\nThe scientists say the findings are boosted by two studies which found the over-activation of certain genes linked to cholesterol production were linked with a poorer response to the anti-cancer drugs.\n\u201cThis early study raises an interesting question of whether cholesterol-reducing treatment, such as statins, could help lower the chances of breast cancer returning for some women who have developed a resistance to hormone therapy,\u201d said Jane Murphy, clinical nurse specialist.\nFar too many women have to deal with the potentially devastating consequences of their breast cancer coming back and this research presents an important opportunity to improve the effectiveness of today\u2019s most commonly used treatments.\nThis discovery may, in future, help reduce these concerns for some patients, by allowing doctors to test if their cancer is likely to return, and tailor treatment accordingly.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that\u00a0statins would be novel in a possible treatment for breast cancer, but statins by themselves are not novel.", "answer": 1}, {"article": "This establishes a baseline time.\nAn easy, two-minute vision test administered on the sidelines after a young athlete has hit his or her head can help to reliably determine whether the athlete has sustained a concussion, according to a new study of student athletes, some as young as 5.\nIf the time is slower, even by a small amount, he or she probably has a concussion, according to neurologists.\nThat situation prompted researchers at New York University\u2019s Langone Concussion Center to begin wondering recently whether there might be other, easier diagnostic tools to check young players for concussions.\nThe King-Devick test did much better, correctly assessing concussion in 75 percent of the young injured players and inaccurately identifying it in only one.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The test is portrayed as an inexpensive alternative to standard cognitive and balance testing which can be administered by adults without medical training. The story also notes that \u201cin recent years, trainers working with athletes in sports such as boxing and mixed martial arts, where concussions are common, had begun supplementing the Standardized Assessment with a simple vision exam, known as the King-Devick test.\u201d So it\u2019s clear that the test hasn\u2019t just appeared out of the blue, and has been used in other sports populations.", "answer": 1}, {"article": "Want to embed a link to this study in your story?\nThe findings suggest that ibuprofen-acetaminophen is a reasonable alternative to opioid management of acute extremity pain due to sprain, strain, or fracture, but further research to assess longer-term effect, adverse events and dosing is warranted.\nThe following related elements also are available on the For The Media website:\n\nThe editorial, \"Opioid vs Nonopioid Acute Pain Management in the Emergency Department,\" by Demetrios N. Kyriacou, M.D., Ph.D., Senior Editor, JAMA, Chicago; Northwestern University Feinberg School of Medicine, Chicago.\nBottom Line: For adults coming to the emergency department for arm or leg pain due to sprain, strain, or fracture, there was no difference in pain reduction after 2 hours with ibuprofen-acetaminophen vs three comparison opioid-acetaminophen (paracetamol) combinations.\nStudy Conclusions: There were no important differences in pain reduction after 2 hours with ibuprofen-acetaminophen or opioid-acetaminophen combination pills in emergency department patients with acute extremity pain.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does not discuss any previous research in this area, nor does it make clear what sets this work apart from previous research. This is a significant oversight. As the paper itself notes: \u201cRelatively few ED [emergency department] studies have compared the efficacy of the 3 most commonly used opioid analgesics in the ED and none has compared them in a single study. Although opioids are considered to provide stronger analgesia than nonopioid analgesics, 1 ED-based study found that adding combination oxycodone and acetaminophen to naproxen did not improve pain relief at 1 week in patients with acute low back pain. Several postsurgical studies have found combination nonopioids to be as effective as a combination of codeine and acetaminophen.\u201d This is really useful information. Among other things, it tells us that previous studies have found similar results \u2014 but not in the context of addressing acute pain in the emergency room. In other words, it makes clear how this study builds on and is different from earlier research. That\u2019s important.", "answer": 0}, {"article": "Publicity in recent years about emotional, cognitive, and memory problems in aging football and hockey players who suffered multiple concussions during their careers has raised the anxiety level around the topic. A lawsuit by thousands of NFL players who claim the league did not keep them well enough informed about the long-term risks of concussion - dementia is one of them - is based in Philadelphia and has raised even higher the profile of what doctors call mild traumatic brain injury.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Mixed bag. Although the headline calls it \u201ca new course\u201d and the story at one point calls it a \u201cnew approach,\u201d the story also explains that cognitive rest has been \u201cgaining traction in the last two to four years\u201d \u2013 making clear that it\u2019s not a brand new concept. We\u2019ll give it the benefit of the doubt on this criterion.", "answer": 1}, {"article": "\u201cShortly after that he told me I could relax and that I did a good job and they had retrieved the clot and just to relax and I immediately started trying to move my arm.\u201d\n\n\u201cA patient will come in, they can't speak, they can't move half their body,\u201d says neurosurgeon Dr. J Mocco, of Mt.\nRoughly 795,000 people suffer a stroke every year in the United States, and it\u2019s the fifth highest cause of death and a leading cause of adult disability, according to the American Heart Association.\nRubbing his neck, on the edge of passing out and feeling numbness on his left side, Reisch didn\u2019t know what was happening.\nFirst responders asked Reisch to smile and immediately recognized his drooping mouth as a sign of a stroke.\n\u201cThe earlier that patients with acute ischemic stroke get to a hospital offering the appropriate treatment, the higher the likelihood is of a good outcome,\u201d said the study\u2019s lead author, Dr. Mayank Goyal of the Hotchkiss Brain Institute at the University of Calgary.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Novelty is not established, and it\u2019s not even made clear how frequently this procedure is performed or how long it has been around.", "answer": 0}, {"article": "Cut It Out (Surgically)\n\nAt 32, it just didn't make sense that Daniel Sheiner was exhausted literally from the moment he woke up.\nAfter surgery, Sheiner says, \"it was a whole new life.\"\nIn fact, he tried a number of different types of machines, but none of them worked.\nBut when she sees a young, thin person with severe apnea, Aurora says, surgery might be the answer.\nA sleep study confirmed Sheiner had one of the worst cases of apnea his doctors had ever seen.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains that only six patients have had the robotic procedure \u2013 at least in this one doctor\u2019s practice.", "answer": 1}, {"article": "\"When parents have a child diagnosed with an autism spectrum disorder, one of the first questions they often ask is 'how did this happen?'\nIf a parent is also found to have the abnormality, geneticists conclude that the couple is at higher risk of having a child with autism.\nA larger part is at this point, we just don't fully understand what the genetic mechanism that leads to autism is.\"\nStill, there is much geneticists can't tell parents.\n\"CMA should be added to first-tier genetic testing for autism spectrum disorders.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly points out that genetic tests for autism are often performed, but the CMA test is relatively new.\u00a0 ", "answer": 1}, {"article": "She noted a second study in Nature that used transplant tissue grown in the laboratory from stem cells to treat damaged corneas, saying it also holds promise.\nThe new procedure described in Nature involves making a slim incision at the side of the lens capsule, removing the entire lens, yet preserving the empty capsule bag or \"scaffold.\"\nBy using a less invasive procedure, Zhang and his colleagues report that they were able to leave the lens epithelial stem cells, also called LECs, intact.\n\"The main excitement for me is the ability to regenerate an organ or a tissue within an organ,\" said Canto-Soler, a retina specialist.\nA certain kind of stem cell, called endogenous stem/progenitor cells, when left intact, then begins to repopulate the damaged lens and essentially grow a new, healthy lens.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story says the study is the first to use the body\u2019s own stem cells to regrow lenses in the eyes of babies with congenital conditions. This is enough to establish the novelty of the procedure. It also alludes to a possible use of the procedure in older adults, although it is cautious in that suggestion. \u00a0\u00a0\nThe story did leave us curious about the technique in general and we would have welcomed a sentence or two about this emerging field of science. Are there similar procedures where the patient\u2019s own stem cells repopulate damaged or missing tissue? What inspired the researchers to study?", "answer": 1}, {"article": "Awair is the first smart air quality device that monitors, analyzes and provides feedback to improve the air you breathe.\nDry air can also exacerbate some illnesses and can be a problem as well.\u201d\n\nDifferent sources of air pollution in your home could include paints that release lead or volatile organic compounds (VOCs), carpets that harbor dirt, dust mites, and fungus and even nitrogen dioxide from gas stoves, but these aren\u2019t the worst culprits, Lahita said.\nAs soon as you see other colored (amber and red) dots show up on top of the green dots, your environment is getting off the healthy ranges whether it being temperature, humidity, CO2, VOCs, and dust,\u201d Ronald Ro, the CEO and co-founder of Bitfinder Inc., the makers of Awair, told FoxNews.com.\nEvery room in your house could be susceptive to some form of an air pollutant, but now there is a new device and app that says it can help you breathe easier by tracking air quality.\n\u201cLow dry humidity in the winter can make asthma worse and children who have dried mucosa can acquire some nasal infections easier,\u201d Dr. Robert G. Lahita, chairman of medicine at Newark Beth Israel Medical Center in New Jersey, told FoxNews.com.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "According to the story, \u201cAwair is the first smart air quality device that monitors, analyzes and provides feedback to improve the air you breathe.\u201d Yet here\u2019s an online article from 2014 titled \u201c6 Smart Interior Air Quality Monitors You Should Buy For Your Home\u201d \u2014 not to mention this or this. That\u2019s not to say that any of these products work, or that we can offer insights into how well they work relative to Awair. It does drive home, however, that Awair may not be as novel as the story makes it out to be. For readers to truly understand what makes Awair different (if it is different), the story would have had to articulate its novelty in the context of a marketplace that is crowded with air quality monitoring devices.", "answer": 0}, {"article": "As Albert, a pseudonym for an AA member in Georgia, previously told me, \u201cThere\u2019s just not a lot of widely advertised options available.\u201d AA and 12-step treatment are \u201cthe most well-known and most recommended option, so that\u2019s kind of where you tend to go.\u201d\n\nZemore\u2019s study begins to peel away at this problem.\nThe research is by no means the last word on this question \u2014 Zemore characterized the study as the beginning of a deeper evaluation into AA alternatives.\nBy showing that there really might be other effective options out there, the research provides hope that there may be a better \u2014 or at least more complete \u2014 solution out there for alcohol addiction.\nThere\u2019s a good explanation for that: While the research shows that 12-step treatment can be as effective as professional treatment modalities like cognitive behavioral therapy, the research also shows that the 12 steps don\u2019t work for everyone.\nThe good news is that the research suggests the spiritual aspect doesn\u2019t fully explain why the 12 steps are effective for some people.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains that about two-thirds of AA participants don\u2019t derive much or any benefit from the program, and that\u2019s why this study documenting the effectiveness of alternatives is important news.", "answer": 1}, {"article": "Dry eye in the Beaver Dam Offspring Study: prevalence, risk factors, and health-related quality of life.\nBased on published data, the efficacy and safety endpoints in these trials compared favorably to other formulations of cyclosporine A with the advantage of early onset.\nJerry St. Peter, Vice President and Head of Sun Ophthalmics, added: \"A key strategic imperative for our ophthalmic business is to participate in the rapidly growing, underserved, and dynamic Dry Eye market, which is expected to reach $5 billion by 2020.\n\"As a clinician who specializes in diagnosing and treating dry eye, this novel formulation of cyclosporine A would be a unique and welcome addition to our armamentarium to treat these patients\".\n[1]\n\nAccording to Dilip Shanghvi, Managing Director, Sun Pharma, \"We are happy to see the early onset of action and strong efficacy results for Seciera\u2122.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There are several other forms of cyclosporine A solutions already available to the public for treatment of this condition (such as the prescription medication Restasis) and this release is arguably linked to an attempt to enter that market.\u00a0 With little data provided in the release, it\u2019s hard to discern what makes this drug novel.", "answer": 0}, {"article": "In recent years, doctors have started to focus on inflammation \u2014 the same process that makes cuts red and painful \u2014 as an important contributor to a heart attack.\nIn the study, 10,000 people who have already had a heart attack were randomly assigned to get injected with a placebo or different doses of a drug called canakinumab.\nAfter four years, the people who received the drug had a 15% lower chance of having a heart attack or stroke compared to people who didn\u2019t get the drug.\nThere are a number of different inflammatory pathways, and canakinumab targets just one.\nWhen it comes to heart disease, however, it\u2019s clear that inflammation-fighting medications like canakinumb may represent the next generation of treatment.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The TIME article, like the Reuters piece, does a pretty good job of explaining what is novel about the the drug\u2019s effects and targeting.", "answer": 1}, {"article": "SILVER SPRING, Md., May 18, 2016 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma.\nThis is the first product in its class (PD-1/PD-L1 inhibitors) approved to treat this type of cancer.\nThis trial measured the percentage of patients who experienced complete or partial shrinkage of their tumors (objective response rate).\nThe Ventana PD-L1 (SP142) assay companion diagnostic for Tecentriq is marketed by Ventana Medical Systems, based in Tucson, Arizona.\nThe National Cancer Institute (NCI) estimates 76,960 new cases of bladder cancer and 16,390 deaths from the disease in 2016.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release clearly states this product is first of its kind for this type of cancer.", "answer": 1}, {"article": "The procedure is also non-invasive.\nWe have shown that skin is a fertile land where we can grow the elements of any organ that is declining,\" said Dr. Chandan Sen, director of Ohio State's Center for Regenerative Medicine & Cell Based Therapies, who co-led the study with L. James Lee, professor of chemical and biomolecular engineering with Ohio State's College of Engineering in collaboration with Ohio State's Nanoscale Science and Engineering Center.\nOur technology keeps the cells in the body under immune surveillance, so immune suppression is not necessary,\" said Sen, who also is executive director of Ohio State's Comprehensive Wound Center.\nIn lab tests, this technology was also shown to reprogram skin cells in the live body into nerve cells that were injected into brain-injured mice to help them recover from stroke.\nResearchers at The Ohio State University Wexner Medical Center and Ohio State's College of Engineering have developed a new technology, Tissue Nanotransfection (TNT), that can generate any cell type of interest for treatment within the patient's own body.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "A study co-leader states in the release: \u201cWith this technology, we can convert skin cells into elements of any organ with just one touch.\u201d We\u2019ll grant that this claim is novel, though we thought it needed more explanation.\u00a0More description of what exactly makes the nanochip novel \u2014 borrowed from the description in the study summary \u2014 would have helped readers understand what\u2019s new about the technology.", "answer": 1}, {"article": "Two new just-released studies offer fresh insights into the best way to lose weight and keep it off. Jennifer Corbett Dooren has details on The News Hub. Photo: Bloomberg\n\nA diet based on healthy carbohydrates\u2014rather than a low-fat or low-carbohydrate diet\u2014offers the best chance of keeping weight off without bringing unwanted side effects, a study published Tuesday in the Journal of the American Medical Association suggests.\n\nStudy participants following a low-glycemic-index diet, which is similar to a Mediterranean diet and focuses on fish, fruit, vegetables, nuts and whole grains, also saw improved cholesterol levels and other important markers that lower the risks of developing heart disease...", "question": "Does the story establish the true novelty of the approach?", "explanation": "A number of other studies have examined the metabolic and weight loss effects of diets with different proportions of fat, protein, and carbohydrate. The story did not mention these studies.", "answer": 0}, {"article": "But after treatment, the group exposed to the bright light was scoring sexual satisfaction scores of around 6.3.\n\u201cIn the Northern hemisphere, the body\u2019s testosterone production naturally declines from November through April, and then rises steadily through the spring and summer with a peak in October.\u201d\n\nLow sexual desire can affect significant numbers of men after the age of 40, with studies finding that up to 25 percent of men report problems.\nAfter taking baseline readings, they divided the men into two groups and gave one regular treatment with a bright light box, while the control, or placebo, group was treated with a light box adapted to give out significantly less light.\nAndrea Fagiolini, a professor who led the study and presented it at the European College of Neuropsychopharmacology conference in Vienna on Monday, said the treatment may prove useful during the Northern hemisphere\u2019s darker winter months.\nLONDON (Reuters) - Exposure to bright light can raise testosterone levels and lead to greater sexual satisfaction in men with low sexual desire, according to the results of a small scientific trial.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions that light is used to treat seasonal affective disorder, so it\u2019s not a new therapy. A\u00a0little digging would have shown that light therapy to treat male sexual dysfunction isn\u2019t a new idea; it was the subject of 2009 paper involving the same lead researcher who did a very small study prior to the one in this Reuters story.", "answer": 1}, {"article": "MONDAY, Oct. 31, 2011 (HealthDay News) -- Doctors who listen to Mozart while performing colonoscopies may spot more precancerous growths, researchers suggest.\n\"Adenoma detection rate is linked to a reduction in colorectal cancer incidence, so it is an important quality indicator for colonoscopy,\" said O'Shea.\n\"Anything we can do to get those rates up has the potential to save lives.\nThis was up from a baseline detection rate of 21 percent before the study began.\nHowever, the second doctor had an adenoma detection rate of nearly 37 percent with Mozart and 40 percent without the music, compared with a baseline detection rate of 27 percent.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Many studies, both positive and negative, have been conducted on the so-called \u201cMozart Effect.\u201d And the story makes brief reference to past studies.", "answer": 1}, {"article": "For more information about Wolters Kluwer's solutions and organization, visit http://www.\nThey note that surgery also led to an average 76 percent improvement in the migraine-specific MHI score, measuring outcomes like headache frequency, duration, and severity.\nThe new study shows \"continued positive outcomes\" after migraine surgery in appropriately selected patients, including large improvements in migraine-related disability.\nIt provides information not only on pain scores, but also on functional disability and ability to cope with pain when performing normal daily activities.\nJanuary 2, 2018 - In addition to reducing headache frequency and severity, surgical treatment for migraine leads to significant improvements in everyday functioning and coping ability, according to a study in the January issue of Plastic and Reconstructive Surgery\u00ae, the official medical journal of the American Society of Plastic Surgeons (ASPS).\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release did establish that this study was the first time that the\u00a0PSEQ was used to evaluate patients who underwent migraine surgery.", "answer": 1}, {"article": "\u201cThe results support the recommendation that people get more than five servings of fruits and vegetables a day, which would likely lead to a major reduction in the number of strokes worldwide, according to previous research.\u201d\n\nOther studies have shown that high lycopene levels may be linked to a reduced risk of certain cancers.\nResearchers measured the level of lycopene in their blood when the study began and followed the men for about 12 years.\nMen who had the highest lycopene levels were 59% less likely to have this kind of stroke than men with the lowest levels.\n\u201cThis study adds to the evidence that a diet high in fruits and vegetables is associated with a lower risk of stroke,\u201d says researcher Jouni Karppi, PhD, of the University of Eastern Finland in Kuopio.\nMen who had the highest levels of lycopene in their blood were 55% less likely to have a stroke, compared with men who had the lowest levels of the antioxidant in their blood.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story alludes to previous research suggesting that\u00a0lycopene levels may be linked to\u00a0cancer risk, and that fruits and vegetables are protective against stroke.", "answer": 1}, {"article": "\u201cOur study essentially shows that what happens in the real world is very different\u201d from what happens in clinical trials, said Hillel R. Alpert of Harvard, a co-author with Dr. Connolly and Lois Biener of the , .\nDoctors who treat smokers said that the study findings were not unexpected, given the haphazard way many smokers used the products.\nThe researchers argue that while nicotine replacement appears to help people quit, it is not enough to prevent relapse in the longer run.\nAt each stage, about one-third of the people trying to quit had relapsed, the study found.\nA government-appointed panel that included nicotine replacement as part of federal guidelines for treatment also came under fire, because panel members had gotten payments from the product manufacturers.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a great job pointing out how this study fits into the recent history of similar research into the topic.", "answer": 1}, {"article": "\"Vitamin D supplementation trial in infancy: body composition effects at 3years of age in a prospective follow-up study from Montr\u00e9al\", by T. J. Hazell, S. Gallo, C. A. Vanstone, S. Agellon, C. Rodd, and H. A. Weiler, Pediatric Obesity doi:10.1111/ijpo.12105\n\"We were very intrigued by the higher lean mass, the possibility that vitamin D can help infants to not only grow healthy skeletons but also healthy amounts of muscle and less fat,\" said Hope Weiler, one of the study's authors and Director of the Mary Emily Clinical Nutrition Research Unit at McGill University.\nThe only other factor found to make a significant difference to the children's amount of body fat was their level of physical activity.\nThe researchers achieved this by following up on a 2013 study in which 132 infants in Montr\u00e9al, Qu\u00e9bec, were given a vitamin D3 supplement at one of four different dosages between the ages of 1 month and 12 months.\nA healthy intake of vitamin D in the first year of life appears to set children up to have more muscle mass and less body fat as toddlers, according to a new study published in the journal Pediatric Obesity.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release claims novelty through this statement: \u201cFor the first time, a connection was made between the benefits of achieving healthy vitamin D status during a baby\u2019s first 12 to 36 months and how muscle mass develops.\u201d We agree that the study of infants who received supplementation is the novel piece. However, it\u2019s worth noting that there is a body of literature about the association of low vitamin D levels and obesity in the greater population.", "answer": 1}, {"article": "Toni Weiser is a veteran of skin-cancer removals. The 75-year-old retired teacher in Santa Fe, N.M., says she\u2019s had at least eight basal and squamous cell cancers scraped, frozen and surgically excised from her arms, face and shoulders.\n\nWhen a basal-cell cancer reappeared on Mrs. Weiser\u2019s nose last year, her dermatologist suggested a new, painless, nonsurgical treatment and she eagerly agreed. After 16 treatments with a small radiation device held millimeters from her nose, the tumor was gone. \u201cI felt nothing\u2014just some mild...", "question": "Does the story establish the true novelty of the approach?", "explanation": "Although radiation has been used for years to treat cancer, this does appear to be a novel use of radiation as a first-line therapy for these types of skin cancers.", "answer": 1}, {"article": "May 14, 2012 -- Acupuncture may allow people with the lung disease COPD (chronic obstructive pulmonary disease) to breathe a bit easier.\nIt is often marked by a chronic cough and shortness of breath.\nThe study showed that acupuncture may improve stomach function, making it easier for people with COPD to eat a healthy diet and maintain a normal weight.\nCOPD is the umbrella term for chronic lung diseases, including chronic bronchitis and emphysema.\nOthers got a sham acupuncture treatment, in which the needles did not enter their skin.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "No background information was given in the story. It is unclear how this particular study contributes to the existing body of knowledge regarding acupuncture and COPD.", "answer": 0}, {"article": "Drug list (formulary): To see a list of covered drugs for the plan you\u2019re considering, use the drop-down menus below.\n\nIf your employer is offering coverage, contact HR for the pharmacy plan name.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Discusses how drug is already \nin use for women with advanced breast cancer.", "answer": 1}, {"article": "Microsoft stresses that Emma Watch is not a cure for the disease, which afflicts 10 million people.\nWorking with graphic designer and Parkinson's sufferer Emma Lawton, 32, the researchers developed a watch \u2014 which they named Emma \u2014 that, according to Microsoft, \"vibrates in a distinctive pattern to disrupt the feedback loop between brain and hand.\"\nAfter a speech that both heralded and warned about coming leaps in technological power, Nadella screened a video that told the story of two British Microsoft Research employees, Haiyan Zhang and Nicolas Villa, who developed the tremor-interrupting device for a BBC documentary, The Big Life Fix.\nThe watch works through a combination of sensors and AI (artificial intelligence) techniques to potentially detect and monitor symptoms like tremors, stiffness and instability, among others, according to Microsoft.\nEmma Watch remains a prototype, Microsoft says, but the developers are working with a neuroscience research team to undertake trials with a small group of Parkinson's sufferers.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story seems to imply that using vibrations to treat symptoms of Parkinson\u2019s\u00a0is a groundbreaking new concept. (The embedded video by Microsoft is even more suggestive, with one of its researchers saying, \u201cI\u2019m on to something, I\u2019m on to something\u201d after using the device).\nHowever, vibration therapy is an idea that researchers have kicked around for at least a decade \u2014 for example, vibrating shoe soles to help patients walk faster and with more control, and a vibrating chair for \u201cwhole-body\u201d therapy to treat multiple symptoms. Perhaps a vibrating watch-type device is a novel advancement, but at this stage, the research is far too preliminary to know.", "answer": 0}, {"article": "SpermCheck Fertility is designed to help couples determine more quickly whether male infertility might be a problem for them, said Ray Lopez, CEO of SpermCheck, based in Charlottesville, Va.\n\"It may provide (an opportunity for) both physicians and couples to take a closer look at ways for men to step up to the plate and optimize their reproductive potential,\" said Dr. Robert Brannigan, urologist at Northwestern University Feinberg School of Medicine.\nWhen a couple is struggling to conceive, it's the woman who is usually the first \u2014 and often the only one \u2014 to be poked, prodded and analyzed, experts say.\nBy detecting that protein, the test indicates whether or not a semen sample contains 20 million sperm per milliliter.\nAlthough it's not a comprehensive evaluation and could give some consumers a false sense of security, the test does provide a starting point while drawing attention to male infertility as a legitimate health concern.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story claims \u201cSpermCheck Fertility is the only FDA-approved home sperm test currently on the market and available in retail stores, Lopez said.\u201d The story goes on to say, though, \u201cAt-home sperm tests are a fairly new idea, Imler said, but SpermCheck Fertility is not the first one. Four years ago an FDA-approved home test called Fertell, which is no longer for sale, offered an evaluation of both male and female fertility.\u201d", "answer": 1}, {"article": "What is the effect of Topical Curcumin Gel for treating burns and scalds?\nThe author of the study believes that the effectiveness of curcumin gel on the skin - or topical curcumin - is related to its potent anti-inflammatory activity.\nThe process goes through a sequence of acute and chronic inflammatory events, during which there is redness, swelling, pain and then healing, often with scarring in the case of burns and scalds of the skin.\n\"Curcumin gel appears to work much better when used on the skin because the gel preparation allows curcumin to penetrate the skin, inhibit phosphorylase kinase and reduce inflammation,\" explains Dr Heng.\nIn a recent research paper, published in the open access journal BioDiscovery, Dr. Madalene Heng, Clinical Professor of Dermatology at the David Geffen School of Medicine, stresses that use of topical curcumin gel for treating skin problems, like burns and scalds, is very different, and appears to work more effectively, when compared to taking curcumin tablets by mouth for other conditions.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It\u2019s unclear from the news release how exactly this research is novel. Since 2009, researchers have been developing curcumin gel for topical application and studying its effects. Topical curcumin has also been studied in animal models, such as a treatment for burns in rats and for radiation burns in mini-pigs.\nIn addition, the author of the study Dr. Madalene Heng published a book in August 30, 2011, entitled BURNS & SCARS: Improvement with Curcumin Gel. This book contains numerous before and after photographs \u2014 some of which were re-published in the recent BioDiscovery article. In fact, all three patients highlighted in the Feb 24 research paper were drawn from her book.\nFor these reasons, we give the news release a Not Satisfactory rating.", "answer": 0}, {"article": "Thousands of heart-failure patients die each year because they aren't able to get a transplanted organ. Now, many medical experts are touting the benefits of a new mechanical pump that gives a patient's own heart a new lease on life.\n\nPatients surgically implanted with the new pump, known as a left-ventricular assist device, or LVAD, had a survival rate of 58% after two years, according to a recent study. That's not as good as a heart transplant, which offers a survival rate of about 70% after 10 years. But it surpasses the...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a good job by comparing the current device\u2019s success rate to that of its predecessor. \nIt also makes clear that a device by another maker treats advanced heart failure\u2013although we learn little about it beyond the fact that it\u2019s used in Europe and unlikely [another inappropriate reporterly prediction] to be approved in the U.S. very soon. ", "answer": 1}, {"article": "The brain controls how long we live.\n\u201cHowever, if the mechanism is fundamental, you might expect to see effects when an intervention is based on it.\u201d\n\nPrevious experiments had already hinted that the hypothalamus, an almond-sized part of the brain in humans, played some role in the ageing process, but what it was remained unclear.\nThe work, described as a tour de force and a breakthrough by one leading expert, suggests that ageing across the body is controlled by stem cells that are found in the hypothalamus region of the brain in youth, but which steadily die off until they are almost completely absent in middle age.\nTo test whether the decline in stem cells was causing ageing, and not itself a result of old age, the researchers injected mice with a toxin that wiped out 70% of their neural stem cells.\n\u201cThe mechanism is partially due to these cells secreting certain miRNAs which help maintain youth, and the loss of these leads to ageing\u201d said Cai, whose study is published in Nature.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story heralds this research as a \u201ctour de force\u201d and a \u201cbreakthrough.\u201d Yet is it accurate in a news story to call anything done in animals a \u201cbreakthrough?\u201d That word implies relevance to humans, and this is far from established in a mouse study.\nStudies in mice are essential but many of them fail to show similar evidence in humans. Likewise, stem cell research is often seen as a magic bullet for some conditions but there have been few cases where the preliminary hope/hype has born out.", "answer": 0}, {"article": "Dubbed Stop-af, the Medtronic trial showed that almost 70 percent of patients who had cryoablation remained free of the condition after one year, compared with just 7 percent of patients who received drug therapy, according to data presented at the American College of Cardiology meeting in Atlanta.\nThe Medtronic device, which the company added to its portfolio with the 2008 acquisition of CryoCath, has been approved in Europe and Australia.\nWhen it reaches the area of the heart that causes abnormal rhythms, the tissue is ablated, or destroyed.\nDuring the follow-up period, 97 percent of patients who got the procedure and 92 percent of the drug therapy patients did not suffer heart attack, stroke or death.\nA small pilot study funded by St. Jude Medical Inc STJ.N compared the two therapies in a sicker population of patients and also found that the procedure worked better than drugs.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Towards the end of the story, there was a clear statement that there is another device on the market that has been used for a long time in the treatment of atrial fibrillation.", "answer": 1}, {"article": "TUESDAY, May 25, 2010 (HealthDay News) --Giving certain breast cancer patients estrogen-lowering drugs before surgery enhances their chances of being able to choose a breast-conserving lumpectomy instead of a full mastectomy, new research suggests.\nAfter the four months of estrogen-lowering therapy, the research team found that 82 percent of those women in the marginal group were, in fact, able to undergo successful breast-conservation surgery.\nIt focused on postmenopausal women who had been diagnosed with estrogen receptor-positive (ER+) breast cancer that was either at stage II or stage III -- that is, tumors that were around an inch or greater in size and might have spread to the lymph nodes under the arm.\nThe investigation was funded by the American College of Surgeons Oncology Group and led by Dr. Julie A. Margenthaler, an assistant professor of surgery and a breast surgeon at the Siteman Cancer Center at Washington University in St. Louis.\nThe 352 women who participated were monitored for tumor growth before and after being placed on a 16-week regimen of aromatase inhibitors -- estrogen-lowering agents -- before any surgery.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t provide any history\u00a0about\u00a0the use of\u00a0aromatase inhibitors for presurgical cancer treatment, but neither does it inappropriately attempt to portray the treatment as\u00a0novel.", "answer": 1}, {"article": "(Reuters Health) - - Exhausted shift workers may be safer driving home at night when they\u2019re exposed to bright light before they hit the road, a small study suggests.\nFor a third test, people got a good nights\u2019 sleep at home and then went to the lab for 45 minutes of bright light exposure before a driving test.\nIn two scenarios, participants spent a night being sleep-deprived in a lab and then spent 45 minutes in dim or bright light before a driving test.\nExposure to bright light didn\u2019t appear to improve reaction times or sleepiness.\nNone of the people who slept at home crashed, and neither did any of the sleep-deprived people who got bright light therapy before getting behind the wheel, the study found.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "One can find many studies of the role of bright light in reducing symptoms of sleepiness, but none of that context finds its way into this story.", "answer": 0}, {"article": "Whether it is encouraging people to eat right or to exercise, they said, the hardest part is not getting them to start doing the right things but getting them to keep doing the right things.\nThe results, being published today in the Journal of the American Medical Association, are heartening, but Willis and Marsiske cautioned that the biggest challenge lies ahead, in getting people to apply the findings to their lives.\nAlthough it did not examine the effects of mental exercise on people who had begun to show signs of Alzheimer's or other brain disorders, previous studies have pointed toward the conclusion that anyone can benefit.\nIn performing daily functions, people who got the speed training along with a handful of follow-up sessions significantly outperformed those who did not get such training.\nIf anything, the study suggests, there is a bigger payoff to mental exercise, because the brief training sessions seemed to confer enormous benefits as many as five years later.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reported on the most recent results from the ACTIVE (Advanced Cognitive Training for Independent and Vital Elderly) Study.\u00a0 But the story did not mention\u00a0that these outcomes do not substantially differ from the earlier results of the ACTIVE study.", "answer": 0}, {"article": "Ideally, the order goes the other way around: We test the idea, and then we implement.\u201d\n\nThese states have the fattest pets \u2014 and they might surprise you\n\nLong before they conquered the Internet, cats took over the world\n\nA kitten nursery saves tiny lives in a city aiming to become \u2018no kill\u2019\n\nBear breaks into house, plays the piano but not very well\nAt the end, all the kids got a \u201cjunior scientist\u201d certificate, lots of praise and an open play session with the dogs.\nIn the 17th century, a Quaker-run retreat in England encouraged mentally ill patients to interact with animals on its grounds.\nThe strangers were the researchers, and their mission was to assess whether the kids, ages 10 to 13, would find their time with the dogs to be therapeutic.\nA bear cub brought to campus during finals week nipped some students, causing a rabies scare that almost ended with the animal being euthanized.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story talks about prior research and even gives a Freud anecdote about the impact of a pet on psychotherapy, in an attempt to make clear this is not novel.", "answer": 1}, {"article": "A government panel of experts released updated guidelines today spelling out who should be taking a daily low-dose aspirin for heart health, which also offers the added benefit of protection against colorectal cancer.\n\"The evidence shows that there's really no incremental benefit of going over 81 milligrams, and in fact, you may increase bleeding risk by going over,\" CBS News medical contributor Dr. Tara Narula, a cardiologist at Lenox Hill Hospital in New York City, told \"CBS This Morning\" when the draft guidelines were released last September.\nThe task force looked at the most up-to-date research on both the benefits and harms of taking aspirin for the primary prevention of both heart disease and colorectal cancer to arrive at their recommendations.\n\"The benefits of aspirin outweigh the harms for most people in their 50's who are at risk of cardiovascular disease but not at increased risk of bleeding.\nSpecifically, the group recommends that adults 50 to 59 years old who have a 10 percent or greater 10-year cardiovascular disease risk, are not at an increased risk for bleeding, and have a life expectancy of at least 10 years take a daily low-dose aspirin to prevent heart attack, stroke, and colorectal cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There were no statements exaggerating or suggesting the novelty of the drug, or its use, for these purposes.\u00a0The new thing here is\u00a0the task force\u2019s recommendation,\u00a0and that\u2019s made clear.", "answer": 1}, {"article": "She's a breast surgery fellow at Massachusetts General Hospital and Brigham and Women's Hospital in Boston.\nBut the review of female patients between the ages of 40 and 44 found that 50 percent had an above-average risk for breast cancer, and therefore would be eligible to begin screening mammography at age 40, said lead researcher Dr. Jennifer Plichta.\n\"We believe formal risk assessment is essential for women ages 40 to 44 in order to identify those who require screening mammography to start at the age of 40, and those who would qualify for screening MRIs and genetic testing,\" Plichta said.\nThe finding is important because the latest guidelines on mammograms advise that most women can wait until the age of 45 or 50 to start having annual screenings.\nThe researchers also found that 32 percent of the women met the groups' eligibility standards for regular screening MRIs, and 25 percent would be eligible for genetic testing, Plichta said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Although assessing someone\u2019s cancer risk is not novel, the researchers were trying to make a point that younger women should have their breast cancer risk assessed. From the story it appears that conducting such an assessment in women ages 40-44 would be novel.\nBut just because assessing all women older than 40 for their breast cancer risk is novel, does not mean it is responsible or should be recommended. \u00a0The risk assessment tool used is important and the presentation of the results of the risk assessment is crucial for a patient\u2019s understanding of risk. \u00a0A discussion of a patient\u2019s risk also needs to include the possible harms of screening.", "answer": 1}, {"article": "The trial was funded by Mayo Clinic.\nBut when researchers examined cardiovascular disease in this population by ceramide scores, people with the highest levels of ceramides were four times more likely to have an event compared with those with the lowest (7.8 vs. 2.2 percent, respectively).\nThis test seems to provide such information,\u201d says Allan S. Jaffe, M.D., senior author of the study, cardiologist at Mayo Clinic and chair of the Division of Clinical Core Laboratory Services.\nIn this group, the rate of heart attack, stroke and revascularization and death was 3.7 percent among those with a low ceramide score, but 16.4 percent in people with the highest ceramide levels.\nThe test, released commercially by Mayo Medical Laboratories in August 2016, measures blood concentrations of plasma ceramides, a class of lipids that are highly linked to cardiovascular disease processes.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release notes that Mayo Medical Laboratories first released this test in August 2016, and that \u201cthe present study is also the first to test its clinical utility in a U.S. population.\u201d\nHowever, while this test is new, many similar biomarkers for refining cardiac risk have been proposed over the years.", "answer": 1}, {"article": "The research falls short of concluding marijuana helps wean people off opioids - Vicodin, Oxycontin and related painkillers - and heroin, though.\nThe growing number of patients who claim marijuana has helped them drop their painkiller habit has intrigued lawmakers and emboldened advocates.\nAnother study, published last year in the Journal of the American Medical Association, found cannabis can be effective in treating chronic pain and other ailments.\nMany are pushing for cannabis as a treatment for the abuse of opioids and illegal narcotics such as heroin, and as an alternative to painkillers.\nIn Maine, which is considering adding opioid and heroin addiction to the list of conditions that qualify for medical marijuana, Michelle Ham said marijuana helped her end a years-long addiction to painkillers prescribed for a bad back and neck.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story establishes that using marijuana for opioid addiction is a relatively new idea that\u2019s not yet properly understood by medical research.", "answer": 1}, {"article": "Any opinions, findings, conclusion, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the view of the U.S. Dept.\nThe researchers acknowledge limitations of this study, including examining the different quantities of exercise participation achieved in the LIFE study participants and not specifically prescribing different amounts of exercise to different study groups.\nWe wanted the physical activity sessions to include exercise that participants could do outside of the study, and we hope that learning of these results might motivate others to try to make safe, incremental changes to their activity levels.\nThe content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.\nIn addition, there were differences in the measured absolute amounts of exercise performed when comparing objective activity monitoring using a wearable \"device\" and self-report of physical activity.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release noted what was novel about the research\u2019s endpoint/conclusion: the \u201cdose\u201d response and the search for a \u201cminimum\u201d level of activity that would confer benefit.", "answer": 1}, {"article": "THURSDAY, Dec. 9, 2010 (HealthDay News) -- The bone drug zoledronic acid (Zometa), considered a potentially promising weapon against breast cancer recurrence, has flopped in a new study involving more than 3,360 patients.\nIn one previous study, the use of the drug was linked with a 32 percent improvement in survival and lowered recurrence in younger women with breast cancer.\nAfter five years, about 400 women in each group either died or had recurrences.\nOther research has found that healthy women on bone drugs were less prone to develop breast cancer, so experts were hoping the drugs had an anti-tumor effect.\nThe focus was on disease-free survival.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article made it clear that zoledronic acid is already in use for other applications.", "answer": 1}, {"article": "So, the investigators asked, could a scan identify those whose actual risk is lower than what was calculated?\nIt turned out that the actual incidence of heart attacks or disabling chest pain in those with zero calcium was half or less than what the risk calculator predicted.\nAccording to today\u2019s guidelines, half had risk scores high enough that a statin would be recommended or should be considered.\nThe study subjects were nearly 4,000 men and women ages 45 to 84 and included blacks, whites, Hispanics and Asians who were recruited in 2000 through 2002.\nBut the amount of calcium in arteries can give a good idea of the presence or extent of coronary artery disease.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that CT scans for coronary artery calcium are not new, and that what is new is the analysis of how test scores are associated with 10-year rates of heart attacks and other cardiovascular disease.", "answer": 1}, {"article": "She said self-exams may not reveal tumors early enough to improve survival.\nA scientific review, published in August by the\n\n, highlighted the downside of doing breast self-exams: Women taught to perform the monthly ritual wind up having unnecessary biopsies.\n\"By the time a breast cancer is large enough to be detected by self-exam, tumor biology is the most important predictor of outcome, not finding a tumor a few months before it would have become apparent,\" she said.\nDuring the women's health movement of the 1970s, the self-exam gained importance as a means for women to take charge and rely less on a paternalistic health system.\nIt defies common sense, she says, for scientists to conclude that breast self-exams do women more harm than good.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Breast self-exam is not novel; neither are the recommendations being discussed. The story explains how public health education campaigns influenced the widespread promotion of BSE for every woman, and that such recommendations are no longer appropriate based on available evidence. ", "answer": 1}, {"article": "\"I think this may be changing in health care,\" said Spears, \"but because migraine affects women more than men, there is a stigma around the stereotype of a patient who comes in with multiple complaints, calls frequently and wants to see the doctor frequently.\" Men, on the other hand, have been stereotyped as going to the doctor \"only when something he has is real.\"", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that this is the first drug (if approved) to be migraine-specific.", "answer": 1}, {"article": "They\u2019re also studying the cost difference.\n\u201cWe are actually not surprised that there isn\u2019t a big difference between the two because both therapies are effective at relaxing the overactive bladder muscles.\u201d\n\nWomen can choose between a surgical procedure, which is more expensive at first, versus regular Botox injections, which are less costly and less invasive but which could add up over time, Amundsen said.\nThe Botox injections freed 20 percent of the women in the study of incontinence, compared to 4 percent who had a nerve stimulator implant, Amundesen and colleagues reported in the Journal of the American Medical Association.\n\u201cThe prevalence of this disruptive condition is common and increases with age, from 17 percent of women older than 45 years to 27 percent older than 75 years in the United States,\u201d they wrote.\n\u201cForty-six percent in the onabotulinumtoxinA (Botox) group and 26 percent in the sacral neuromodulation group had at least a 75 percent reduction in the number of episodes of urgency incontinence,\u201d they added.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story didn\u2019t establish what\u2019s novel about this study. As the news release states, the study was \u201cthe first randomized trial comparing the efficacy of two FDA-approved, third-line therapies in a severely affected population.\u201d", "answer": 0}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.\n\"It is also important for clinicians to confirm that a woman's complaints of worsening memory are in the executive function domains, are temporally related to the transition to menopause, and are not indicative of some other pathological cognitive impairment before prescribing a trial of LDX.\"\nThe School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $409 million awarded in the 2014 fiscal year.\n\"There are approximately 90 million post-menopausal women living in the US alone, and with the average age of onset occurring at 52, the great majority of those women will live in the postmenopausal state for at least one-third of their lives.\nAll participants served as their own controls by being randomly assigned to cross-over to a placebo for an additional four weeks.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Both the headline on the release and the lead paragraph both mention that this is the first study to show these results when using a psychostimulant to reduce losses in executive function among menopausal women.", "answer": 1}, {"article": "TUESDAY, May 4, 2010 (HealthDay News) -- Noninvasive stool DNA testing can detect two types of colorectal precancers and could play a larger role in colon cancer prevention, say two new studies.\nSome of the study authors and the Mayo Clinic have a financial interest related to technology used with this research.\nUnlike common polyps, they tend to be flat and the same color as the colon lining.\nIt's important for people with IBD because they are at much higher risk for colorectal cancer than the general population.\nThe DNA stool test methods were developed at the Mayo Clinic.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story didn\u2019t establish the true novelty of the approach.\u00a0 ", "answer": 0}, {"article": "MONDAY, June 27, 2011 (HealthDay News) -- Brilinta, an experimental anti-clotting medication currently awaiting U.S. Food and Drug Administration approval, performed better than the industry standard, Plavix, when used in tandem with low-dose aspirin, a new study finds.\n\"The study highlights that if one chooses to use ticagrelor in subjects with acute coronary syndromes, it would be logical to use aspirin 81 milligrams per day (and not 325 mg daily),\" said Dr. Jeffrey S. Berger, assistant professor of medicine and director of cardiovascular thrombosis at NYU Langone Medical Center in New York City.\nIn this latest analysis of PLATO findings, researchers found that patients who took Brilinta with low-dose aspirin were 16 percent less likely than those who took Plavix with low-dose aspirin to have a heart attack or stroke, or to die within a year.\n\"Of note, there is little reason to ever use aspirin 325 mg except in the acute setting of a heart attack or stroke,\" he added.\nThe panel's recommendation was based in part on prior findings from this study, called the Platelet Inhibition and Patient Outcomes (PLATO) trial.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This was the latest analysis of the PLATO study, comparing different combinations of antiplatelet drugs, including one experimental drug that\u2019s up for review. With more space, it would have been nice if the article further differentiated ticagrelor and clopidogrel for patients.", "answer": 1}, {"article": "Doctors say bronchial thermoplasty has given them a new weapon in the battle against severe asthma, and many patients call it life-changing.\nEach time, a different section of the lungs is treated.\nIt takes place in three steps, each separated by about three weeks.\nSince then, she has ended most of her medications and has not had a single asthma attack.\nPowerful medications and frequent use of her inhaler could not prevent repeated trips to the emergency room.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t make any inappropriate claims regarding the treatment\u2019s novelty.", "answer": 1}, {"article": "I'll Be Me ,\" Saturday, November 7, at 8 p.m.\nAntioxidant may be most effective in combination\n\nThis is one of the first studies to look not only at these biomarkers, but also the metabolites of resveratrol in spinal fluid, to show that resveratrol is probably getting into the brain, said Dr. Giulio M. Pasinetti, who is the Saunders Family Chair and professor in neurology at the Icahn School of Medicine at Mount Sinai.\nThe main goal of the current study, which included 119 patients, was to find out whether high doses of resveratrol could be safe.\nThe only small concern they found was that patients taking resveratrol lost about two pounds during the one-year study, and weight loss is already a problem with Alzheimer's, Turner said.\nNow, the first study in people with Alzheimer's suggests that the compound, when taken in concentrated doses, may actually have benefit in slowing progression of this disease.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that this is \u201cthe first study in people with Alzheimer\u2019s\u201d \u2014 which clearly sets the study apart from earlier research. That said, there have been many other studies on resveratrol and Alzheimer\u2019s using animal models, and a quick paragraph on what those other studies have told us would have been both interesting and useful.", "answer": 1}, {"article": "The moderate dose also prompted a drop in the ability to accurately recognize fear in other people's faces, determined by having the participants look at a range of photos, the study found, but it did not affect the ability to perceive the shifting cues in a person's eyes or voice, determined by having the participants listen to a series of audio clips.\nIn fact, those who took the drug actually rated themselves as more sociable than those taking MDMA.\nThe newest study explored the effects of MDMA on 21 healthy volunteers, nine women and 12 men aged 18 to 38.\nDr. Michael Mithoefer, author of the earlier study on MDMA and PTSD, also urged further exploration of the medicinal potential of the drug.\nA moderate dose of MDMA was found to significantly increase feelings of loving, friendliness and playfulness, the researchers said, whereas the low dose of MDMA boosted feelings of loneliness.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story at least referred to an earlier study published in July on MDMA in PTSD.", "answer": 1}, {"article": "Researchers have found that delivering a fecal microbiota transplant (FMT) in a pill\u2014a poop pill, basically\u2014is no worse than a similar procedure done with a colonoscopy.\nWe just don\u2019t see kind of efficacy with drugs,\u201d Dr. Dina Kao told Newsweek.\n\u201cFor this group of patients, nothing else really works,\u201d she said.\n\u201cThe results are sort of a best-case scenario,\u201d she said.\nOther efforts to take the \u201cpoop\u201d out of the poop pills\u2014to just include the bacteria thought to be behind the benefits\u2014have failed.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "What\u2019s new here is that a pill form for delivery of a fecal transplant is being tested against a colonoscopy. The story established this.", "answer": 1}, {"article": "My entire head throbbed and stung.\u201d\n\nKaufman, who lives in Los Angeles, visited dozens of doctors, trying every option, including pain clinics, holistic remedies, Botox shots, and even hypnotherapy.\nThe aim of the medication is to stop a migraine before it even starts.\nAnother advantage: it could lead to a decrease in the amount of medications used by patients to handle headaches acutely.\nIf approved by the FDA, the drug could be available in 2018.\nHowever, the price tag could be as much as $10,000 a year.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains that this would be a new class of approved drugs that target a specific molecule thought to be involved in migraines.", "answer": 1}, {"article": "Italian researchers writing in the journal of the International Menopause Society, Climacteric, said they had found the first robust evidence that low doses of DHEA can help sexual function and menopausal symptoms, suggesting it may one day become an alternative to hormone replacement therapy (HRT).\nWhat we need to do now is to look at a larger study, to confirm that these initial results are valid,\u201d she added.\nBut they stressed that the trial was small, so far larger studies are needed to confirm the results.\nOver a year, 12 women took vitamin D and calcium, 12 took DHEA, 12 took standard HRT and 12 took a synthetic steroid called tibolone which is used to alleviate menopausal symptoms.\nBut sales of HRT drugs have fallen sharply since a large study in 2002 found higher rates of ovarian cancer, breast cancer and strokes in women who took the pills, and the search has since been on for alternatives.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There are no claims of novelty made here.\n\u00a0", "answer": 2}, {"article": "Naomi Wolf, author of \"Misconceptions: Truth, Lies, and the Unexpected on the Journey to Motherhood,\" blames insurance companies and hospitals, who she says deny women information about their choices.\nIf something does go wrong, in the eyes of the courts \"a normal birth is a risk.\n\"One of the knowledge gaps is a clear understanding of the indications for C-sections,\" she says.\nThe courts reward action,\" Block says.\nCaesareans impede this process.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Clearly C-sections are not new.", "answer": 1}, {"article": "\"The issue is, can you detect these in patients that don't have advanced cancer?\" Venook said. \"The answer is, we don't know.\" The numbers tested by the MD Anderson researchers -- 251 patients with pancreatic cancer (five of whom had very early lesions), 32 with chronic pancreatitis and 120 healthy controls -- aren't nearly large enough to draw such conclusions. And getting a clear answer, Venook said, would probably require lengthy and expensive studies on very large populations.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes what is novel about the test \u2014 the fact that it has the potential to detect cancer at an early, more treatable stage.\u00a0The story could have done more to establish whether there has been other research into tests for pancreatic cancer and how the new test builds upon those previous efforts.", "answer": 1}, {"article": "Photo/Video: Emily Prapuolenis/The Wall Street Journal\n\nYvonne Felix\u2019s eyes don\u2019t work well enough on their own for her to read, recognize faces or cross the street without help.\nLeaps in augmented-reality technology are being used to help people with severely low vision gain back enough sight to function, and then some.\nA next-generation visor from eSight can improve vision for many legally blind people.\nBut when the Toronto-based artist and mother puts on a new kind of camera-equipped headgear, she looks at me like no one has before.\nThe visor that allows legally blind people to see is no longer Star Trek fiction.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty is made clear in this way:\nThe eSight visor, in development for 10 years, is reaching a level of maturity. The third-generation, which debuts this week, weighs less, has a wider field of view and just looks cooler.\nThe story would be stronger if it explained that this doesn\u2019t mean the latest device works better than alternatives.", "answer": 1}, {"article": "The comparison groups in the experiments varied as well.\nThe medicine, though never approved for use in the United States, led to birth defects in some 10,000 kids in Europe and Canada.\nUnfortunately, medicines to relieve morning sickness have a checkered history.\nAlso, inconsistencies in methodology from study to study made it difficult to pool the results and draw firm conclusions.\nAuthors of the review found some evidence that ginger, vitamin B-6 and anti-vomiting drugs relieved nausea.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of the treatments analyzed in the review isn\u2019t really in question, so we\u2019ll call this not applicable.", "answer": 2}, {"article": "In an average follow-up of five years, they found that the rate of unusable donor kidneys and the long-term outcomes of recipients varied little among the first three age groups \u2014 around 18 percent of the organs had to be discarded, and the five-year survival was about 88 percent\nA new study has found a kidney transplanted from a deceased 79-year-old can be as effective as one from a person 30 years younger.\nItalian researchers retrospectively studied 647 kidney transplants, grouping the donors according to whether they were in their 50s, 60s, 70s or 80s.\nThe study is in the Clinical Journal of the American Society of Nephrology.\nOld age is not necessarily a barrier to kidney donation.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We found other research on the same topic, so it\u2019s not clear to us what\u2019s new about this latest study.", "answer": 0}, {"article": "But there are still hurdles to clear.\nThat medication, Topamax, has been dubbed dubbed \u201cSleepomax\u201d by doctors and patients because it\u2019s also a heavy sedative.\nIt\u2019s by no means a cure for migraines, but it should be enough to merit Food and Drug Administration approvals if the companies can replicate those results in larger trials, according to Eric Schmidt, a securities analyst at Cowen and Co.\n\nEach treatment is now in late-stage development, targeting the roughly 38 percent of migraine sufferers who, like Novak, have at least four headache days per month.\nWith the \u201cexquisite sensitivity\u201d of an antibody, however, scientists believe they can block CGRP without triggering dangerous side effects, Alder CEO Randy Schatzman said.\n\u201cI\u2019m very enthusiastic, as I think everyone in the field is, about having another treatment option for people with migraines,\u201d said Dr. Elizabeth Loder, a professor of neurology at Harvard Medical School and chief of the headache division in the department of neurology at Brigham and Women\u2019s Hospital.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story\u00a0notes that \u201ctargeting CGRP is not a particularly new idea,\u201d and cites an earlier drug that caused liver toxicity. It was also easy to identify publications about this new drug target in PubMed, going back to 2007.", "answer": 1}, {"article": "Nov. 5, 2012 (Los Angeles) -- An IV infusion of \"good\" HDL cholesterol seems to rapidly remove cholesterol out of plaque-clogged arteries following a heart attack, a small, early study suggests.\nAnd half of them happen in the first month, says researcher Andreas Gille, MD, PhD.\nIn the year after a heart attack, about 12% of people have a second heart attack or stroke.\nHDL removes cholesterol from artery walls, but current HDL-boosting drugs, such as niacin and fibrates, take years to work, according to Gille.\nStandard heart attack medications, such as aspirin and anti-clotting drugs, prevent clotting but don\u2019t eliminate an underlying factor: cholesterol that has built up on artery walls, he says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There was not a word about whether this is the first such research attempt to use IV infusion of HDL cholesterol.", "answer": 0}, {"article": "\u201cThis is a simple dietary change that we believe most women can understand and adopt.\n\u201cNew evidence suggests that when and how often people eat can also play a role in cancer risk.\u201d\n\nWomen in the study reported eating five times per day with a mean nighttime fasting of 12 hours.\nNewswise \u2014 A decrease in the amount of time spent eating and an increase in overnight fasting reduces glucose levels and may reduce the risk of breast cancer among women, report University of California, San Diego School of Medicine researchers in the journal Cancer Epidemiology, Biomarkers & Prevention.\n\u201cThe dietary advice for cancer prevention usually focuses on limiting consumption of red meat, alcohol and refined grains while increasing plant-based foods,\u201d said co-author Ruth Patterson, PhD, UC San Diego Moores Cancer Center associate director for population sciences and program leader of the cancer prevention program.\nThe data shows that each three hour increase in nighttime fasting was associated with a 4 percent lower postprandial glucose level, regardless of how much women ate.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This is a tough call. \u00a0The news release\u00a0quotes a researcher saying \u201cIncreasing the duration of overnight fasting could be a novel strategy to reduce the risk of developing breast cancer.\u201d\nSo that is a claim of novelty. \u00a0But that claim \u2013 and the association \u2013 are not explained adequately in the release. All they showed is that increasing the fasting interval decreases glucose levels and calorie intake.\u00a0 For that reason, we\u2019ll rule it Not Satisfactory.", "answer": 0}, {"article": "And other research has raised new concerns.\n\u201cOnly a minority of these parents mentioned medication.\u201d\n\nKatherine Ellison is a Pulitzer Prize-winning former foreign correspondent and author and co-author of seven books, including the forthcoming \u201cWhat Everyone Needs to Know about A.D.H.D.\u201d (Oxford University Press), co-authored with Stephen Hinshaw, Vice-Chair for Psychology, Department of Psychiatry, University of California, San Francisco.\nDr. F. Xavier Castellanos, director of research at the New York University Child Study Center, called assertions that stimulants are neuroprotective \u201cexaggerated,\u201d adding: \u201cThe best inference is that there is no evidence of harm from medications \u2013 normalization is a possibility, but far from demonstrated.\u201d\n\nA.D.H.D.\nkids.\u201d\n\nMedication is already by far the most common treatment for A.D.H.D., with roughly 4 million American children taking the pills \u2014 mostly stimulants, such as amphetamines and methylphenidate.\nOne possible reason, as the report noted, was that many children refuse to continue taking medication after a year or so, something most parentsof such children well know.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The key point of the story is that experts are applying relatively recent study results and theories about the effects of ADHD medications on the brains of children. While the drugs themselves have been in use for many years, the story presents evolving views about how to apply the results of recent studies to treatment decisions. As the story notes, recent research might encourage more parents \u201cto start their children on these medications early and continue them for longer.\u201d", "answer": 1}, {"article": "Sabourin Lussier, born with spina bifida, faced the possibility of kidney failure when she was just 19 years old. Her bladder, damaged by the devastating birth disorder, leaked uncontrollably and often backed urine up into her kidneys.\n\nA conventional surgery to reconstruct her bladder with intestinal tissue threatened further health complications. So in May 2000, Ms. Lussier and her mother, Gail Johnston, agreed to an experiment under which she and eight other patients with spina bifida would receive partial, laboratory-built...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that transplantation of reconstructed man-made bladders is still very new. ", "answer": 1}, {"article": "Neither treatment prompted significant side effects, the authors said.\nMONDAY, Dec. 13, 2010 (HealthDay News) -- Acupuncture may be an effective way to treat older children struggling with a certain form of lazy eye, new research from China suggests, although experts say more studies are needed.\nHowever, while this approach is often successful in younger children (between the ages of 3 and 7), it is successful among only about a third of older children (between the ages of 7 and 12).\nAnd while theorizing that the apparent success of this alternative approach may have something to do with stimulating blood flow, retinal nerve growth and visual cortex activity, the authors acknowledged that the exact mechanism by which it works remains poorly understood.\n\"But if it works,\" he added, \"people will certainly be excited -- although it certainly needs further testing and further studies to decide if it's really beneficial or not.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story cites previous research suggesting that acupuncture\u00a0may improve blood flow to the eye and has other potentially beneficial physiologic effects.\u00a0And while it quotes one expert who says he is unaware of any previous studies of acupuncture for eye conditions,\u00a0another source\u00a0points out that acupuncture has been tested for glaucoma and myopia without much\u00a0success. Readers get the\u00a0appropriate impression that this is a novel approach to the treatment of amblyopia, but not totally\u00a0uNPRecedented.", "answer": 1}, {"article": "In dark suits and blue shirts, with serious expressions on their round faces, they walked to stand next to their mother in a very beige room outside Washington, D.C.\nThe drug, called Exondys 51 or eteplirsen, allows the genetic machinery that produces the protein to skip over the mutated part to make something that will work better.\nThe company that produces ataluren, PTC Therapeutics, says that its drug forces cells to make the proteins in spite of a different kind of mutation called a nonsense mutation.\nBy October 24, they\u2019ll know if they will be able to keep taking that drug.\nRegardless of what mutation causes the illness, most people with DMD die in their 20s.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that this drug is unique, in that it aims to override the specific genetic mutations causing this type of Duchenne muscular dystrophy.", "answer": 1}, {"article": "It was unclear what the mixed bag of data presented at the American Heart Association's Scientific Session in Orlando would mean for CETP drugs under development by Merck and Roche, and another candidate in early-stage development by Pfizer.\nHowever, the study found the tablet triggered an increase in the hormone Aldosterone, which helps regulate both blood pressure and bodily fluids.\nThe study suggested a \"clean\" version of torcetrapib could increase so-called good cholesterol without raising blood pressure and causing adverse cardiovascular events.\n\"In any case, it is premature to announce the death of CETP inhibitors on the bases of the torcetrapib experience alone.\"\nCardiologists had hoped it would reduce the buildup of plaque in blood vessels that can cause heart attacks.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story correctly categorizes the drug as the first of its kind in this class.", "answer": 1}, {"article": "\"In addition, since this study was conducted at a single center and the primary [change in heart attack, stroke and death] was not statistically significant without adjustment for other factors, more studies and replication of these findings are needed,\" he said.\nFor those who meditated, there was a trend toward reduced smoking; however, this was not statistically significant.\nOriginally from India, it is not associated with any particular religion or philosophy.\nIn addition, 20 people in the medication group had a heart attack or stroke or died, compared with 32 in the health education group.\nSome studies have suggested favorable effects on cardiovascular risk factors whereas others studies have been inconclusive, he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that transcendental meditation has been studied previously, with mixed results on cardiovascular outcomes.", "answer": 1}, {"article": "Participants in the higher seafood consumption group ate an average of two seafood meals per week.\n\"This study helps show that while cognitive abilities naturally decline as part of the normal aging process, there is something that we can do to mitigate this process,\" says Martha Clare Morris, ScD, a Rush nutritional epidemiologist and senior author of the paper.\nThe study did not find a significant difference in the rate of decline in episodic memory (recollection of personal experiences), working memory (short-term memory used in mental function in the immediate present) and visuospatial ability (comprehension of relationships between objects).\n(Chicago) - Eating a meal of seafood or other foods containing omega-3 fatty acids at least once a week may protect against age-related memory loss and thinking problems in older people, according to a team of researchers at Rush University Medical Center and Wageningen University in the Netherlands.\nWhile epidemiologic studies have shown the importance of seafood and omega-3 fatty acids in preventing dementia, few prior studies have examined their associations with specific types of cognitive ability.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The story states that: \u201cWhile epidemiologic studies have shown the importance of seafood and omega-3 fatty acids in preventing dementia, few prior studies have examined their associations with specific types of cognitive ability.\u201d That gets it a satisfactory rating. However, it\u2019s worth noting that the story does not get to the novel aspect of the findings \u2014 the \u201cassociations with specific types of cognitive ability\u201d \u2014 until the sixth paragraph. If that\u2019s what\u2019s new in the news, one wonders why it wasn\u2019t addressed higher.", "answer": 1}, {"article": "For more information, visit http://www.\nIn their commentary, the FAU researchers emphasize that, until recently, the totality of randomized evidence on varenicline had been restricted to eight small trials, which did not demonstrate a hazard.\nThe commentary was coauthored by Dianna Gaballa, a fourth-year medical student; Joanna Drowos, D.O., M.P.H., an associate professor of integrated medical science and associate chair of the Department of Integrated Medical Science; and Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll Professor and senior academic advisor to the dean, all in FAU's Charles E. Schmidt College of Medicine.\nThe authors speculate that if use of varenicline had not plummeted by 76 percent following the black box warning in 2009, perhaps 17,000 premature deaths from cardiovascular disease may have been avoided each year during the last few years.\nNonetheless, since then, there has been a 76 percent decline in the number of prescriptions dispensed from a peak of about 2 million in the last quarter of 2007 to about 531,000 in the first quarter of 2014.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It is not clear what makes this commentary novel \u2014 it is effectively restating longstanding public health concerns regarding smoking and reiterating claims about the safety of Chantix that have been made (and debated) since the EAGLES study was published last year.\nIt could be argued that the release (and the commentary it\u2019s amplifying) took a novel approach in presenting a position on the issue of whether the 75% decrease in Chantix prescriptions was an overreaction to the black box warning \u2014 resulting in higher smoking rates and higher rates of mortality from smoking-related illnesses. However, since that\u2019s speculative, there is no real novelty here.", "answer": 0}, {"article": "Philip Gehrman, a Penn clinical psychologist who was senior author, said the study proves that rapid treatment of depression is possible. But more research is needed to figure out why sleep deprivation works. His team is now conducting its own study. He's not hoping to use sleep deprivation as a treatment but thinks that pinpointing what it does to the brain will help doctors develop other, more sustained treatments.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains that the study was novel primarily because of the meta-analysis approach.", "answer": 1}, {"article": "Related: CDC study finds opioid dependency begins within a few days of initial use\nThe current study of the vaccine, published in the Journal of the American Chemical Society, follows eight years of laboratory research and studies in rodents that indicated the compound could neutralize heroin at different doses.\nBut in light of the growing drug abuse epidemic, for which, he says, \u201cwe have so few tools,\u201d adding a vaccine to the available treatments could help.\n\u201cIt\u2019s an avenue that shows some promise.\u201d\n\nAlthough research on humans is not yet planned, study authors Kim Janda and Paul Bremer, chemists at the Scripps Research Institute, are encouraged about this next step.\nAll four monkeys responded to the vaccine, but the two that were receiving it a second time had a stronger response, hinting that their immune systems were already primed with the \u201cmemory\u201d of the compound.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not suggest that this research is novel or unique. As noted, other attempts to develop a vaccine for opiate addiction have not worked out.", "answer": 1}, {"article": "But Cao doesn't think people should start taking aspirin to prevent cancer until more research is done.\nThe association of aspirin with reduced cancer risk was the same for women and men regardless of race, history of diabetes, family history of cancer, weight, smoking, regular use of other painkillers or taking multivitamins, the study authors added.\nThe reduced risk was largely due to fewer cases of gastrointestinal cancers, including colon cancer, rectal cancer and esophageal cancer.\n\"The results of ongoing research to develop more tailored treatment based upon a personalized assessment of risks and benefits is critical before recommending aspirin for preventing cancer,\" she said.\nAnd the study only showed an association between aspirin use and gastrointestinal cancer risk, not a cause-and-effect relationship.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that the study is the latest in a long line of studies that have reached similar conclusions. And for that reason, we would love for this story to have focused on aspirin and cancer risk more broadly.", "answer": 1}, {"article": "\"Sometimes [the mother] is a bit uncomfortable, or sometimes Dad has to go on a business trip or Grandma wants to fly in,\" Lavin said.\nAll of the women had previously had C-sections.\nOf those, more than 13,000 had elective C-sections.\n\"This happens to me every day,\" Lavin said.\nMore than one-third of the surgeries performed during that time happened at 37 or 38 weeks.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Some of the history and much of the context of the use of planned C-sections is clear from the piece. ", "answer": 1}, {"article": "For more information, visit www.idri.org.\n\"We believe this may be the most exciting breakthrough in leprosy treatment since multi-drug therapy, the current treatment for leprosy, was launched in the 1980s.\n\"While previous attempts have used vaccines primarily developed for other diseases, this is the first totally defined vaccine candidate developed specifically for leprosy, using the latest technologies and offering no less than those exposed to leprosy deserve,\" said Steven Reed, Ph.D., IDRI President, CEO & Founder.\n\"We are thrilled that after 15 years and an investment of over $5.1 million, made possible by our faithful donors and partners, a leprosy-specific vaccine is beginning a Phase I clinical trial,\" says Bill Simmons, President and CEO of American Leprosy Missions.\n\"The vision and support of American Leprosy Missions has been tremendous as we've worked with them throughout the years, moving from our work in developing a leprosy diagnostic to our current focus on a successful leprosy vaccine,\" he said.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This is a mixed bag. The release does try to articulate how this vaccine differs from previous attempts to develop leprosy vaccines. For example, the release states that previous vaccination efforts have relied on vaccines developed for preventing other diseases. However, that may be misleading. For example, as this 2011 paper describing the history of leprosy vaccine research notes, one long-running (and large-scale) trial in the 1980s and 1990s involved modifying an existing vaccine with \u201cirradiated, autoclaved M. leprae purified from the tissues of infected armadillos\u201d (M. leprae being the bacteria that cause leprosy). That sounds like something targeting leprosy pretty specifically.", "answer": 1}, {"article": "Ohio\u2019s roads stink. Here are 5 options to fix them\n\nNobody likes paying more. But it turns out, if we want our roads to improve, we might have to.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of the treatment is not in question. ", "answer": 2}, {"article": "Kale and oranges are high in vitamin C, another antioxidant.\n\u201cWe recommend whole fruit and not fruit juice,\u201d says Farvid, \u201cbecause maybe one of the most important ways that fruit decreases risk of breast cancer is through fiber, and even natural fruit juice often has no fiber in it.\u201d\n\nIn another study also published in the , a separate group of researchers found that among 22,000 Danish women, those who added two alcoholic drinks a day on average increased their risk of developing breast cancer by 30% over five years.\n\u201cThis study also has an important message for schools and the need to provide students with the opportunity to consume more fruits and vegetables as part of the school meal program.\u201d\n\nFarvid wasn\u2019t able to document a strong relationship between vegetables and lower breast cancer risk, but says that may be because the study wasn\u2019t powered enough to detect an effect.\nBut the majority of those studies have focused on adults, and it\u2019s becoming clear that many of cancer\u2019s drivers start early in life, with genes and even with childhood exposures to potential carcinogens.\nThe findings are among the first to look at how diet during adolescence can affect health later, and highlights the importance of establishing healthy habits from a young age, especially since many of the chronic diseases occur over many years and get rooted early in life.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does note that the study is \u201camong the first\u201d to look at adolescent diet and cancer risk, which is good. But it misses a key point: that this exact same group of researchers, using the same set of data, published a paper in March focused on adolescent diet and breast cancer risk. That paper focused specifically on the role of dietary fiber in reducing breast cancer risk. This story discusses dietary fiber, but does so without the context that would come from discussing (even briefly) the earlier paper.", "answer": 0}, {"article": "\u201cWhen it recognizes that it\u2019s gone inside the cell, it says OK, now it\u2019s time to disassemble and give off the RNA.\u201d\n\nIn a phase 1 clinical trial in patients with various types of tumors, the team gave doses of the targeted nanoparticles four times over 21 days in a 30-minute intravenous infusion.\nOther teams are using fats or lipids to deliver the therapy to the treatment target.\nRNA stands for ribonucleic acid \u2014 a chemical messenger that is emerging as a key player in the disease process.\n\u201cIn the particle itself, we\u2019ve built what we call a chemical sensor,\u201d Davis said in a telephone interview.\nBut getting the treatment to the right target in the body has presented a challenge.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of this approach is discussed appropriately. ", "answer": 1}, {"article": "CHICAGO -- Many patients treated with Byetta, a diabetes drug by Amylin Pharmaceuticals Inc. and Eli Lilly & Co., were able to maintain good blood-sugar control and also lose weight after three years on the drug, according to a study.\n\nThe study, described at the American Diabetes Association's annual meeting here, examines clinical data from the longest trial involving Byetta presented to date.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story describes when the drug was FDA approved (in 2005), so readers know this is a relatively new drug being studied.\u00a0 ", "answer": 1}, {"article": "Mango consumption helped relax blood vessels in as little as two hours after intake.\n\"This is the first study to demonstrate positive vascular effects of mango intake in humans,\" said lead researcher Robert Hackman, with the UC Davis Department of Nutrition.\nMangos contain a mix of polyphenols, including mangiferin, quercetin, gallotannins, and gallic acid, that have been the focus of previous investigations exploring the potential health-protecting properties of mangos.\n\"Our results build on previous animal and cell studies that point to the potential benefits of mangos to promote health.\"\nThe honey mango (also referred to as Ataulfo) was chosen for the study due to the high concentration of polyphenols in this popular variety.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that \u201cThis is the first study to demonstrate positive vascular effects of mango intake in humans.\u201d The question is whether the study actually does demonstrate these effects. Given the lack of controls, we can\u2019t be certain.\u00a0 This concern is addressed under \u201cquality of evidence.\u201d", "answer": 0}, {"article": "The study appears online in the Journal of Clinical Investigation.\nIf studies show the same thing in humans, the heart hormone may hold the key to an effective weight loss treatment, says researcher Sheila Collins, PhD, of Sanford-Burnham Medical Research Institute in Orlando, Fla.\n\u201cThese hormones are involved in fluid regulation, but we showed in this study that they also play a role in breaking down fat,\u201d she says.\nAdults don\u2019t have much brown fat, but a new study suggests that hormones produced by the heart just might help them make more.\nResearchers found that the hormones, known as cardiac natriuretic peptides, caused regular energy-storing white fat cells to turn into energy-burning brown fat in mice.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story quotes Dr. David Katz regarding the clinical importance of this research. It could also have cited his blog post on the topic, which discusses other recent studies on brown fat and notes that brown fat\u2019s role in regulating body temperature is long established. This line of research is not as new as recent media reports suggest.", "answer": 0}, {"article": "For now, says Weiner, there is \"no consensus\" on which patients should get the costly new PET scans that use Amyvid, and large insurers such as Medicare and Medicaid have not made decisions about coverage for such tests.\nWith growing understanding that the changes of Alzheimer's disease may be decades in the making, the value of early detection is gaining adherents, said Weiner.\nIt's an early test for those who already have cognitive concerns and who wonder whether Alzheimer's disease may be the cause.\nMany patients experiencing cognitive lapses may also be reassured if the test fails to reveal amyloid plaques, he added.\nOnce that happens, physicians, researchers and insurers will need to figure out who should get the test and at what cost, and who will pay.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not overstate the novelty of the test or its approval by the FDA.", "answer": 1}, {"article": "The manufacturer of the sleep aid Snooz'n says its 2.5-ounce \"shots\" contain five milligrams of melatonin; Unwind, a \"relaxation blend,\" has three milligrams per 12-ounce can.\nThe chief ingredient in many of these beverages is melatonin, a hormone that induces sleepiness and helps coordinate the body's biological clock.\nNow, the field includes a slew of new drinks promising a better night's sleep using such ingredients as melatonin, valerian root and - think turkey - tryptophan.\nThe field is too young to identify the leaders and the losers, Goel Lal says.\n\"You've got to turn off all the stimulants and also get into a natural sleep cycle.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The family of drinks described in the story\u00a0are a new delivery vehicle for these potentially sleep-enhancing supplements. Most readers will be unfamiliar with these products.", "answer": 1}, {"article": "Handedness (molecular asymmetry) is critical to the function of bio-molecules in the body.\nImportantly, the development opens up a possibility for a more selective cancer treatment as JPC11 was observed to specifically target the biochemistry of cancer cells, leaving healthy cells largely untouched - another improvement compared to existing platinum-based drugs, which can also attack non-cancerous cells.\nIn this case, the osmium compound JPC11, with sodium formate, can selectively produce a molecule of a specific 'handedness' - thus manipulating how cancer cells grow.\nProfessor Martin Wills, catalyst specialist at the University of Warwick, commented:\n\n\"Although asymmetric catalytic hydrogenation processes are well developed in the materials industry, this research provides the first ever example of it being achieved inside cells using a synthetic catalyst.\"\n\"We have discovered that chemo-catalyst JPC11 has a unique mechanism of action - and we hope that this will lead to more effective, selective and safer treatments in the future.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release clearly articulates JPC11\u2019s mechanism for action for affecting cancer cells, as well as why and how that is novel.", "answer": 1}, {"article": "THURSDAY, Jan. 11, 2018 (HealthDay News) -- Injecting a calcium-based cement into the bones of some people with knee or hip pain could help them avoid joint replacement surgery, Ohio State University doctors say.\nThe procedure, called subchondroplasty, has been available to people with knee problems for years, Vasileff said.\n\"People who have significant arthritis where the cartilage itself is damaged and thinned, this isn't going to fix the arthritis,\" Vasileff said.\n\"If you inject this substance into the bone, you're basically providing internal support, a scaffold protecting the bone.\nIt is much less invasive than a knee or hip replacement, and typically is performed on an outpatient basis, Vasileff said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story started to describe the novelty here:\n\u201cThe procedure, called subchondroplasty, has been available to people with knee problems for years, Vasileff said. Now he and his colleagues are testing to see whether hip patients also can benefit from it.\u201d\nYet, it never follows up with discussion of said testing: Is it a clinical trial?", "answer": 0}, {"article": "Dong notes that pulse wave velocity and blood pressure measures are complimentary but not interchangeable.\nIn what appears to be the first randomized trial of its kind, they found that arterial stiffness was improved by vitamin D supplementation in a dose-response manner in this population, they write in the journal PLOS ONE.\nThe varying doses, as well as the placebo participants took, were all packaged the same so neither they or the investigators knew which dose, if any, they were getting until the study was complete.\nNow it's time to do a larger-scale study, particularly in high-risk populations, and follow participants' progress for longer periods, Dong and Raed say.\nWhile heart disease is the leading cause of death in the United States, according to the Centers for Disease Control and Prevention, blacks have higher rates of cardiovascular disease and death than whites and the disease tends to occur earlier in life.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does not overplay its hand here, but does say that the study is \u201cwhat appears to be the first randomized trial of its kind.\u201d This is a difficult fact to establish but since they are essentially saying, \u201cTo the best of our knowledge\u201d this is a first, we\u2019ll give the release the benefit of the doubt here.", "answer": 1}, {"article": "This new development represents a big step forward in personalised medicine.\nWe are excited that CURATE.AI could ultimately enhance patient accessibility to important new combination therapies, saving lives in the process,\" said Prof Ho, who is also from the Biomedical Engineering and Pharmacology departments at NUS, as well as a member of the Biomedical Institute for Global Health Research and Technology (BIGHEART) at NUS.\n\"No two patients' profiles are alike, and as a patient's body and the cancer itself evolve during treatment, the CURATE.AI profile evolves as well, enabling the clinical and engineering teams to optimise care for the entire duration of treatment, an unprecedented advance for combination therapy,\" Prof Ho explained.\n\"The implementation of CURATE.AI represents a game-changing shift in the way that combination therapy can be optimised at the single patient level, and we have shown that N-of-1 medicine can be a reality.\nRemarkably, CURATE.AI subsequently identified a ZEN-3694 dose that was 50 per cent lower than the patient's starting dose of the drug prior to CURATE.AI analysis.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release says that \u201ca first generation of the [CURATE.AI] platform was previously validated in the clinic for single drug optimisation,\u201d and that this single-patient study \u201cdemonstrates that CURATE.AI can optimise multi-drug regimens.\u201d That\u2019s enough to earn it a satisfactory rating here, but we\u2019ll revisit that language under \u201cUnjustifiable Language.\u201d", "answer": 1}, {"article": "AUGUSTA, Ga. (March 9, 2017) - The first year of free lung cancer screening in the Augusta, Georgia area found more than double the rate seen in a previous large, national study as well as a Massachusetts-based screening for this number one cancer killer.\nAlso, like lung cancer has been coincidently found in CT scans for other reasons, physicians like Thomson and Schroeder are now incidentally finding cardiovascular disease in their lung cancer screening.\nAfter 15 years of not smoking, the lung cancer risk tends to diminish but never vanishes.\n\"We want to reach as many people as we can as early as we can,\" he said.\nAs examples, smoking rates were highest among those without a graduate education degree certificate and lowest among those with a graduate degree; higher among those living below the poverty level versus above it; and higher among some minorities such as American Indians and Alaska Natives, multiple- race individuals and blacks.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes clear that the Augusta screening initiative was modeled after a previous national study and after a similar, regional initiative in Massachusetts.", "answer": 1}, {"article": "The screening phase of the trial lasted about seven years.\nDr. Stamatia Destounis, a radiologist at Elizabeth Wende Breast Care in Rochester, New York, who was not involved in the study, said radiologists have been quoting results of the Swedish study for years and the new findings show breast cancer screening is \u201ceven more of a benefit than we understood.\u201d\n\nShe said sweeping changes in the U.S. screening guidelines two years ago that scaled back recommendations on breast cancer screening caused a lot of confusion among doctors and patients about the benefits of mammograms.\n\u201cThis indicates that the long-term benefits of screening in terms of deaths prevented are more than double those often quoted for short-term follow-up.\u201d\n\nThe new data adds to evidence on the long-term benefits of regular mammography screening.\n\u201cWe saw the actual number of overdiagnosed cases was really very small \u2014 less than 5 percent of the total,\u201d Robert Smith, director of cancer screening at the American Cancer Society and one of the study\u2019s authors, said in a telephone interview.\nThe study of 130,000 women in two communities in Sweden showed 30 percent fewer women in the screening group died of breast cancer and that this effect persisted year after year.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s clear from the story that this is the longest-running breast cancer screening study and it\u2019s the first study to show that absolute benefit of mammography screening increases over the long-term. However, it would have been helpful to point out that the first results were reported in 1985 and there were a number of subsequent updates, as well. ", "answer": 1}, {"article": "The ACC leads in the formation of health policy, standards and guidelines.\n\"Whether the best use of breast arterial calcification is to trigger additional testing or to directly inform preventive treatment decisions, either by flagging high-risk women to their providers or by reclassifying traditional (heart disease) risk estimates, is worth further discussion.\"\nEarlier research had shown a link between breast arterial calcification and atherosclerotic disease--even heart attack, stroke and other cardiovascular disease events, but researchers said these data provide a more direct relationship between the extent of calcified plaque in the mammary and coronary arteries, as well as a comparison to standard risk evaluation.\n\"Even by the conservative estimate of 10 percent, approximately 4 million women nationwide undergoing screening mammography will exhibit breast arterial calcification; with 2 to 3 million of them likely to have signs of premature coronary atherosclerotic disease,\" the authors said.\nIn an accompanying editorial in JACC: Cardiovascular Imaging, Khurram Nasir, M.D., M.P.H., and John McEvoy, from the Center for Healthcare Advancement and Outcomes at Baptist Health South Florida, said that the report provides impetus to document breast arterial calcification in mammography reports, to improve education of primary care and radiology providers on the link with heart disease, and other actions to establish best practices for incorporating this research into care.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release claims novelty through this statement: \u201cData from this study show for the first time a link between the amount of calcium in the arteries of the breast \u2014 readily visible on digital mammography \u2014 and the level of calcium buildup in the coronary arteries.\u201d\nIt also notes, \u201cEarlier research had shown a link between breast arterial calcification and atherosclerotic disease\u2013even heart attack, stroke and other cardiovascular disease events, but researchers said these data provide a more direct relationship between the extent of calcified plaque in the mammary and coronary arteries, as well as a comparison to standard risk evaluation.\u201d", "answer": 1}, {"article": "Prior to this, Yu\u2019s team had performed targeted MRI biopsies with the patient being moved in and out of the MRI scanner as the needle was guided to the target area \u2014 a sort of stop-motion procedure that could take up to an hour.\nThe new equipment has simplified and shortened the process to about 20 minutes.\nOver the past five years, he has developed diagnostic techniques using MRI technology to investigate difficult cases like Harder\u2019s.\nMuch like someone would have an MRI to investigate the cause of back pain, the technology gives doctors eyes on what is happening in prostate tissue.\nIt was elevated from the 4.1 measurement that he had registered for a few years.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release does not overstate the novelty of this procedure.", "answer": 1}, {"article": "This news release is available in French.\nIn a study recently published in BMJ Open Respiratory Research, experts from Concordia University, the H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al and several other institutions* analyzed the exercise habits of 643 participants who had been diagnosed with asthma.\n\"The issue of exercise-induced bronchospasm is real -- but if you use your releaver medication, blue puffer, before you exercise, and then take the time to cool down afterwards, you should be okay,\" he says.\n\"Those numbers reflect the population in general,\" says Bacon, who is also director of the Centre de r\u00e9adaptation Jean-Jacques-Gauthier at Hopital du Sacr\u00e9-Coeur.\n\"It would be great to see physicians recommending physical activity to patients with asthma, alongside traditional pharmacological treatments,\" he says.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Studies have already been conducted looking into the link between increased physical activity and better health outcomes for asthma patients, such as this 2009 study and another one from 2009. In general, researchers have found that higher levels of physical activity are beneficial \u2013 both in terms of better health outcomes and decreased use of health care services \u2013 for those suffering from asthma. The original journal article from this study states this was the first time researchers have looked into seasonal variations in physical activity and its correlation with asthma control. Patients who undertook physical activity during the winter months (rather than the summer) had better control of their asthma, the research report emphasized. Although this point was touched upon in the news release, it does not explicitly state what was novel in the research or what it brings to the existing body of literature, which is why we give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": "SATURDAY, Sept. 29, 2012 (HealthDay News) -- Researchers say they've discovered a two-drug combination that delays treatment resistance in patients with advanced melanoma.\nAfter one year of treatment, 41 percent of patients receiving the full-dose combination treatment had no progression of their melanoma, compared with 9 percent of those receiving dabrafenib alone.\nAmong patients receiving the combination treatment, the development of side effects such as skin rash and a less dangerous type of skin cancer called squamous cell carcinoma was similar to that typically seen in patients taking only one of the drugs.\nThe American Cancer Society has more about melanoma.\nMelanoma is the most serious, and often deadly, form of skin cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This does appear to be a novel approach to\u00a0reducing the treatment resistance seen in melanoma drugs.", "answer": 1}, {"article": "2016.\n\"These integrative approaches expand traditional treatments and offer new strategies for coping with psychological distress,\u201d said the study\u2019s co-author Sian Cotton, director of the UC's Center for Integrative Health and Wellness, in a statement.\n\"Mindfulness-based therapeutic interventions promote the use of meditative practices to increase present-moment awareness of conscious thoughts, feelings, and body sensations in an effort to manage negative experiences more effectively.\u201d\n\nChildren who are at a high risk for bipolar disorder or other anxiety disorders, such as the participants, often have poor coping skills when confronted by stress, and only a lucky few get help.\n\"This raises the possibility that treatment-related increases in brain activity during emotional processing may improve emotional processing in anxious youth who are at risk for developing bipolar disorder,\u201d said fellow co-author Dr. Jeffrey Strawn, a professor in UC's Department of Psychiatry and Behavioral Neuroscience, as well as director of the Anxiety Disorders Research Program, in a statement.\n\"The path from understanding the effects of psychotherapy on brain activity to the identification of treatment response is a challenging one, and will require additional studies of emotional processing circuits.\u201d\n\nSource: Strawn JR, Cotton S, Luberto CM, et al.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does note that mindfulness-based therapy for children with anxiety isn\u2019t new, stating that \u201cthere is some encouraging, if early, evidence showing that these techniques can be used to prevent relapses of depression or anxiety.\u201d However, that doesn\u2019t quite capture the amount of work that has already been done in the field. For example, the book Mindfulness-based cognitive therapy for anxious children: A manual for treating childhood anxiety came out five years ago. We\u2019re not saying that there\u2019s nothing new in this study; we are saying that it is very difficult to determine what is new, when it is not placed in the context of previous research.", "answer": 0}, {"article": "At 6 months, casting resulted in measures of ankle function equivalent to that with surgery.\nAmong older adults with an unstable ankle fracture, the use of a modified casting technique known as close contact casting (a molded below-knee cast with minimal padding) resulted in similar functional outcomes at 6 months compared with surgery, and with fewer wound complications and reduced intervention costs, according to a study appearing in the October 11 issue of JAMA.\n\"Close contact casting was delivered successfully for most participants, substantially reducing the number of patients requiring invasive surgical procedures at the outset and additional operations during a 6-month period,\" the authors write.\nA modified casting technique has been developed, close contact casting, which uses minimal padding compared with traditional casting and achieves fracture reduction by distributing contact pressure by close anatomic fit.\nKeith Willett, M.B.B.S., F.R.C.S., of the University of Oxford, United Kingdom, and colleagues randomly assigned 620 adults older than 60 years with acute, unstable ankle fracture to surgery (n = 309) or casting (n = 311).\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This treatment is not novel, but the results of this study are new. It appears to be the first to compare these treatments and show the results in a well done randomized study.", "answer": 1}, {"article": "This data is clinically significant.\n\"The migraine brain is hyperexcitable, and basic science studies have demonstrated modulation of neuronal excitability with this treatment modality,\" says Amaal Starling, M.D., a Mayo Clinic neurologist, who is first author of the study.\nThe eNeura SpringTMS Post-Market Observational U.S. Study of Migraine study, also known as ESPOUSE, instructed participants to self-administer four pulses with the device in the morning and four pulses at night over three months to prevent and treat migraine attacks as needed.\nThe U.S. Food and Drug Administration already had approved the sTMS device for the acute treatment of migraine with aura.\n\"The sTMS may be a great option for these patients and allow doctors to better meet their unique needs.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The last line of the news release is an important inclusion since it clarifies that this is a treatment used for acute treatment that is being extended to prevention:\nThe U.S. Food and Drug Administration had already approved the sTMS device for the acute treatment of migraine with aura. The FDA has approved it to prevent migraine as well.\nIt may have been helpful to let readers know this approval came just last fall.", "answer": 1}, {"article": "WEDNESDAY, Aug. 25, 2010 (HealthDay News) -- Swedish scientists report that they've successfully implanted \"biosynthetic\" corneas in 10 patients, potentially paving the way for more accessible treatment for those with cornea-related vision problems.\n\"Human donor corneas work very well,\" Griffith said.\nWith the lenses in place, they all had improved vision, Griffith said.\nThe study appears in the Aug. 25 issue of Science Translational Medicine.\n\"The patients' own cells and nerves grew back, and there was an overall improvement in vision,\" said study co-author May Griffith.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of the procedure is not established.", "answer": 0}, {"article": "Jan. 18, 2011 -- Low doses of the antidepressant Lexapro (escitalopram) cooled off hot flashes better than placebo in about 200 menopausal women, according to a new study.\n''We believe escitalopram provides an option for treating moderate to severe hot flashes that are disrupting people's lives and quality of life,\" says study researcher Ellen Freeman, PhD, a research professor in the department of obstetrics-gynecology and psychiatry at the University of Pennsylvania School of Medicine, Philadelphia.\nPrevious studies of other antidepressants have yielded mixed results, according to Freeman.\nThe findings are published in TheJournal of the American Medical Association.\nThe new study findings suggest Lexapro can provide an option for women reluctant to take hormone therapy.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that other antidepressants have been studied for the treatment of hot flashes, with conflicting results.\u00a0It quotes a doctor who\u00a0says\u00a0that antidepressants are sometimes used clinically for hot flashes.", "answer": 1}, {"article": "If it gets to that point, then clearly things will change.\u201d\n\nStroke is the fourth-leading cause of death in the United States.\nIn fact, giving the drugs too late can make matters worse.\nThe other half of the patients got standard treatment, which didn\u2019t include the procedure.\nMany had already adopted the more aggressive strategy over the past decade.\nThe answer could be in the patients, the device or the timing of the procedure.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of the finding was made clear in the story.", "answer": 1}, {"article": "\u2022 None 6 things you can do right now to help prevent the flu \n\n\n\nThe drug uses a different approach to fight the flu than other medications.\nThe flu virus spreads through the body by invading cells.\nBoth Japanese and American flu patients were included in the trial.\nOnce inside a cell, it hijacks the cell's machinery, forcing the cell to make copies of the virus.\nThen, the newly copied viruses break out of the cell, spreading to other cells nearby and repeating the process.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story gives the reader an adequate sense of how this flu pill differs from Tamiflu.", "answer": 1}, {"article": "Though CA125 is valuable to look for recurrence of cancer, it is not recommended for screening because it can surge, for example, during menstruation. However, guidelines from the American College of Obstetricians and Gynecologists and the National Comprehensive Cancer Network (NCCN) recommend a CA125 test plus vaginal ultrasound imaging for a woman with nonspecific symptoms that could signal ovarian cancer, such as bloating and pain. A CT or MRI scan may be added, although these are expensive. A biopsy is usually avoided because it could spread cancer cells.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story\u00a0mentions that the tests are combinations of existing tests with a \u201cproprietary\u201d formula (essentially a risk prediction tool) to translate the results to likelihood of cancer.\nBut, the article should have\u00a0talked about whether the tests, other than CA-125, have been used before.", "answer": 1}, {"article": "Nezhat advises women to look for a surgeon experienced in doing minimally invasive surgery.\n\u201cHowever, if the surgeon is skilled enough to do the hysterectomy without the robot by laparoscopy then the outcomes will be similar.\u201d\n\nNezhat further noted that while robotic assistance can be a good \u201cenabler\u201d for a minimally invasive approach, surgeons should have at least the basic knowledge of regular laparoscopy too, as there may be times when the robotic equipment doesn\u2019t work.\n\u201cThe robot will not really decrease human errors but it will make the surgery easier,\u201d Dr. Tommaso Falcone of the Cleveland Clinic, in Ohio, who was also not involved in the study, told Reuters Health in an e-mail.\n\u201cWith minimally invasive surgery by an experienced surgeon\u2019s hands, the incisions are smaller, pain and suffering is less, visualization is better, and recovery is faster than with open surgery,\u201d Dr. Ceana Nezhat of the Emory University School of Medicine in Atlanta who was not involved in the review, told Reuters Health.\nFurther, the average number of lymph nodes removed was about the same in the robotic and open procedures, suggesting that both approaches result in about equal surgeon accuracy in staging endometrial cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story states:\u00a0 \u201cRobotic surgery equipment only received U.S. Food and Drug Administration approval in 2005. More research is needed to be able to compare long-term outcomes, wrote the researchers.\u201d\nIt concludes: \u201cRobotic-assisted surgery is in its infancy, and it definitely has a future,\u201d quoting one physician observer. We\u2019ll give it the benefit of the doubt, although, as we stated in the \u201cAvailability\u201d criterion above, we wish it had given more precise estimates of how widespread this \u201csurgery in its infancy\u201d is or is not.", "answer": 1}, {"article": "\"More than 30 years since the discovery of the antidepressant effects of sleep deprivation, we still do not have an effective grasp on precisely how effective the treatment is and how to achieve the best clinical results,\" said study senior author Philip Gehrman, PhD, an associate professor of Psychiatry and member of the Penn Sleep Center, who also treats patients at the Cpl.\nReviewing more than 2,000 studies, the team pulled data from a final group of 66 studies executed over a 36 year period to determine how response may be affected by the type and timing of sleep deprivation performed (total vs early or late partial sleep deprivation), the clinical sample (having depressive or manic episodes, or a combination of both), medication status, and age and gender of the sample.\nThe findings of this meta-analysis hope to provide relief for the estimated 16.1 million adults who experienced a major depressive episode in 2014.\nPHILADELPHIA - Sleep deprivation -- typically administered in controlled, inpatient settings -- rapidly reduces symptoms of depression in roughly half of depression patients, according the first meta-analysis on the subject in nearly 30 years, from researchers at the Perelman School of Medicine at the University of Pennsylvania.\nSuch drugs typically take weeks or longer to experience results, yet 16.7 percent of 242 million U.S. adults filled one or more prescriptions for psychiatric drugs in 2013.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states it is \u201cthe first meta-analysis on the subject in nearly 30 years.\u201d This may be true, but there are other peer-reviewed journal articles on sleep deprivation in conjunction with other treatments as a therapy for depression so the idea of using this therapy far from novel.", "answer": 0}, {"article": "\u201cRadiation dose reduction resulted in significantly improved swallowing and nutritional status,\u201d she said.\nWe want to help improve our patients\u2019 quality of life.\u201d\n\nThe study included 80 patients from 16 ECOG-ACRIN Cancer Research Group sites who had stage three or four HPV-positive squamous cell carcinoma of the oropharynx, and were candidates for surgery.\nThe study, published in the December 26 issue of the Journal of Clinical Oncology, showed that patients treated with reduced radiation had less difficulty swallowing solids (40 percent versus 89 percent of patients treated with standard doses of radiation) or impaired nutrition (10 percent versus 44 percent of patients treated with regular doses of radiation).\n\u201cWe found there are some patients have very high cure rates with reduced doses of radiation,\u201d said Barbara Burtness, MD, Professor of Medicine (Medical Oncology), Yale Cancer Center, Disease Research Team Leader for the Head and Neck Cancers Program at Smilow Cancer Hospital, and the chair of the ECOG-ACRIN head and neck committee.\n\u201cToday, many younger patients are presenting with HPV-associated squamous cell carcinoma of the oropharynx,\u201d said Dr. Burtness.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes no\u00a0claim of novelty other than it is a \u201cnew clinical trial.\u201d\u00a0It might be assumed that low dose radiation is novel because it is not standard for these types of cancers but there is no way to know this from either the release or the published study. A brief online search revealed that\u00a0a partnering institution issued a related news release on low dose radiation research in HPV-positive head and neck cancers in 2014.", "answer": 0}, {"article": "\"It's pretty encouraging,\" said Robert A.\nCurrently, food-allergic people have only two options: to avoid the substance that causes their reaction or to try to stop a reaction with an injection of epinephrine.\nAlthough the approach appears to be highly effective for some children with milk and peanut allergies, the researchers conducting the studies and others caution that much more research is needed to prove and perfect the approach and that it is far from ready for widespread use.\nWith doctors standing by in case of a severe reaction, each study subject undergoes careful testing to determine the maximum dose he or she can safely tolerate.\nThe approach, known as oral immunotherapy, involves slowly desensitizing the immune system by painstakingly ingesting increasing amounts of whatever triggers the reaction.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Although presented as a novel approach to treatment, desensitization is a long-practiced tool and has been an active field of investigation for a number of years.", "answer": 0}, {"article": "Investigators conducted a randomized controlled trial in the pediatric Emergency Department at The Mount Sinai Hospital comparing lung ultrasound to chest X-ray in 191 children from birth to 21 years of age.\nFurther research is needed to investigate the impact of lung ultrasound on antibiotic use and stewardship.\nAs more and more handheld ultrasound machines come to market, these results suggest that lung ultrasound has the potential to become the preferred choice for the diagnosis of pneumonia in children.\nThe patients were randomly assigned into an investigational arm (received a lung ultrasound and if the physician needed additional verification, a chest X-ray) and a control arm (received a chest X-ray followed by a lung ultrasound).\n\"Our study could have a profound impact in the developing world where access to radiography is limited.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The novelty of a safe and cheaper alternative to expensive radiography that could provide equivalent diagnostic precision is clearly enough to warrant this release.", "answer": 1}, {"article": "Dec. 7, 2012 -- A drug related to thalidomide may be more potent and less toxic than thalidomide, which is often used to treat lupus skin conditions.\nThe lenalidomide study included 15 women with lupus skin conditions; six had lupus in other areas of the body, too.\nOne patient withdrew from the study after one week due to digestive system side effects.\nAll had received standard treatments, and 14 had been treated with thalidomide previously.\nHe says about 75% of patients with affected skin will go into remission with these standard treatments.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did discuss how this seems to be a novel approach to treating lupus skin conditions.", "answer": 1}, {"article": "Abbott Laboratories is betting heart patients will benefit from a new type of arterial stent that dissolves away when it is no longer needed.\n\nStents are scaffold-like devices used to prop open clogged heart arteries. Most stents are made of metal. But Abbott's new device, called Absorb, is made from a plastic-like material called polylactide that is commonly used in surgical sutures. The Absorb scaffold\u2014Abbott doesn't call it a stent\u2014is designed to completely fade away in two years and to cease supporting arteries at six...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The idea of a bioabsorbable stent is not new or unique to Abbott.\u00a0The concept was proposed in the early 1990\u2019s and the other players are also working on their own version. Although the story alludes to the fact that competitors might seek to follow Abbott\u2019s lead, it doesn\u2019t convey that other companies are already quite far along in their research. ", "answer": 0}, {"article": "Doctors said Thursday that the increased risk did not outweigh the benefits of the drugs.\nThe drugs, which include Depakote, Lamictal, Topamax, Keppra, Lyrica and Neurontin, are sometimes prescribed for chronic pain and headaches, as well.\nThe Food and Drug Administration undertook a combined analysis of 199 clinical trials with 43,892 patients and found 4 suicides and 105 reports of suicidal symptoms among the 27,863 patients who were given the drugs compared to no suicides and 35 reports of suicidal symptoms among the 16,029 patients treated with placebos.\n\u201cWhat\u2019s really important to say is that bipolar disorder is very difficult to treat, the burden is enormous, and these medications help keep people free of mood and anxiety symptoms and allow them to function,\u201d said Andrew A. Nierenberg, medical director of the bipolar clinic and research program at Massachusetts General Hospital.\nTaken together, the risk of suicidal thoughts and behavior was 0.43 percent for those on drug therapy and 0.22 percent for those given placebos.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The focus is recently published data (http://www.fda.gov/bbs/topics/NEWS/2008/NEW01786.html) showing a slight increase in the absolute risk of suicide and suicidal symptoms in patients treated with certain anti-seizure medications compared with placebo.\u00a0 The story appropriately provides context for this new information (and educates the health consumer in the process) by presenting this data in both relative and absolute terms, as well as citing a range of sources to provide clinical context. ", "answer": 1}, {"article": "\u201cKangaroo mother care is care of preterm infants carried skin-to-skin with the mother.\nRelated: More U.S. Moms are Breastfeeding Their Babies\n\n\u201cThe effects of kangaroo mother care at one year on IQ and home environment were still present 20 years later in the most fragile individuals, and kangaroo mother care parents were more protective and nurturing,\u201d Dr. Nathalie Charpak and colleagues at the Kangaroo Foundation in Bogota, Colombia, wrote in their report.\n\u201cKangaroo mother care may change the behavior of less well-educated mothers by increasing their sensitivity to the needs of their children, thus making them equivalent to mothers in more favorable environments.\u201d\n\nTwenty million babies are born at a low birth weight every year around the globe, the World Health Organization reports.\nIts key features are: early, continuous and prolonged skin-to-skin contact between the mother and the baby; exclusive breastfeeding (ideally); it is initiated in hospital and can be continued at home; small babies can be discharged early; mothers at home require adequate support and follow-up,\u201d WHO said.\n\u201cIt is a gentle, effective method that avoids the agitation routinely experienced in a busy ward with preterm infants.\u201d\n\nAnd it\u2019s safe, WHO added.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "From what we could find, what makes this study notable is that it\u2019s the only 20-year follow-up for this kind of intervention. In an indirect way, the story touches upon this.", "answer": 1}, {"article": "The average age of children in the study was 7.\nBut the most immediate question for Sobel is \"whether an olfactory impairment is at the heart of the social impairment in autism.\"\nThe findings suggest that non-verbal tests related to smell might serve as useful early indicators of ASD, the researchers say.\n\"The difference in sniffing pattern between the typically developing children and children with autism was simply overwhelming,\" says Noam Sobel of the Weizmann Institute of Science in Israel.\nThe researchers now plan to test whether the sniff-response pattern they've observed is specific to autism or whether it might show up also in people with other neurodevelopmental conditions.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does mention that people with ASD have impairments in their \u201cinternal action models,\u201d and defines these models as \u201ctemplates we rely on to coordinate our senses and actions.\u201d But, the release notes that it wasn\u2019t previously clear \u201cwhether this impairment would show up in a test of the sniff response.\u201d Fair enough. But researchers have published a number of papers over the years addressing various sensory differences between children with ASD and children who are developing normally (like this one, and this one, and this one). In other words, while the Current Biology paper discussed in this release is clearly new, it fits into a continuum of research on ASD and sensory sensitivity (including smell). Discussing how the new work fits into that continuum, even in a sentence or two, would have given readers valuable context.", "answer": 0}, {"article": "\"There is a growing concern that amyloid is a guilty bystander, but not the actual culprit in the brains of people with Alzheimer's disease, and taking away the bystander may not help the patient,\" he said.\nThe leading theory of Alzheimer's disease is that an imbalance in the production or clearance of the amyloid plaque in the brain initiates a cascade of events that lead to dementia, explained Dr. Neelum Aggarwal, an associate professor of neurological sciences at Rush Alzheimer's Disease Research Center at Rush University Medical Center in Chicago.\nIt's long been known that a protein fragment called beta-amyloid builds up in the spaces between nerve cells in the brains of people with Alzheimer's disease.\nThe need for a drug to delay the onset or slow progression of Alzheimer's disease can't be underestimated, Aggrawal said.\nThe big question is whether or not reducing amyloid levels has any effect on the symptoms or progression of Alzheimer's disease, said Dr. Patrick Lyden, chief of neurology at Cedars-Sinai Medical Center in Los Angeles.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains that the study was \u201camong the first to show the effects\u201d of the drug in people. Actually, another anti-amyloid drug (bapineuzumab) showed similar findings in a study published in Lancet in 2010. Although there was a 25% reduction in beta amyloid there was no corresponding improvement in function.\nThe story explains that there are a dozen or so other therapies being investigated.", "answer": 1}, {"article": "April 9, 2012 -- Taking soy to relieve hot flashes has received mixed reviews over the years.\n\"What this study shows is that ingesting soy isoflavones will help you,\" she says.\nNow, researchers who took another look at 19 published studies find that soy supplements may help, at least over time.\nAlthough all the studies looked at soy supplements, Melby says that getting soy from food is a better bet.\nSoy has been touted as an alternative treatment to hormone replacement therapy after HRT was linked to an increased risk of breast cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story at least quoted another researcher, whose own work \u201cpublished in 2011 in the Archives of Internal Medicine, she found no effects on menopausal symptoms when women took 200 mg of soy isoflavones for two years.\u201d", "answer": 1}, {"article": "But widely prescribed sleep medications such as Ambien (zolpidem) and Lunesta (eszopiclone) can leave people feeling hung over and inattentive the next day.\nThe appeal of orexin antagonists, said Dr. Michael Thorpy, director of the Sleep-Wake Disorders Center at Montefiore Medical Center in New York City, is that they \"target a system that's more specific for sleep.\"\nThese new medications -- known as dual orexin receptor antagonists (DORA) -- target a more specific region of the brain than popular sleep drugs such as Ambien and Lunesta, promoting sleep without affecting learning and memory (also called \"cognition\"), according to the new research.\n\"We've shown that these compounds improve sleep at doses that don't impact cognition,\" said Jason Uslaner, lead author of a study published in the April 3 issue of Science Translational Medicine.\nThis is the first time in years that scientists have targeted a totally different receptor in the quest to combat insomnia, said Dr. Alexandre Abreu, co-director of the UHealth Sleep Center at the University of Miami Miller School of Medicine.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that DORA-22 is one of a new class of drugs designed to help with sleep disorders.\u00a0 The story does describe how this drug works on a different part of the sleep-wake mechanism in our brains than currently-available drugs. However, it is odd that there is no mention of any of the human clinical trials that must have preceded Merck\u2019s FDA approval application.", "answer": 1}, {"article": "The ability to control the tightness is presumably part of the reason that patients who opt for banding lose less weight, at least initially, than gastric bypass patients -- an average of 50 to 65 percent of their excess weight in the first three years.\nIn other words, anyone who sees obesity surgery as a solution in itself is chasing weight-loss rainbows.\nAfter a gastric bypass, there's often scarring that causes organs to adhere to one another.\nWhat obesity surgeons do feel confident saying is that no matter which type of surgery is chosen, and whether it's the first or second time, the patient has to meet the operation halfway.\nIf the patient doesn't go in for adjustments, the whole thing won't work.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story indicated that the particular pattern of bariatric surgeries discussed was a relatively new phenomena and that information about long term weight control was not yet available.\u00a0", "answer": 1}, {"article": "Available from: http://www.\n\"This study is a breakthrough for the management of children aged six to 11 years old with Hepatitis C, demonstrating that the new DAA regimen is highly efficacious and, more importantly, safe in this group of HCV-infected children\", said Prof Frank Tacke, University Hospital Aachen, Germany, and EASL Governing Board Member.\nFor more information, please contact the ILC Press Office at:\n\nSession title: Parallel session: Advances in the treatment of HCV \n\nTime, date and location of session: 16:00 - 18:00, Friday 21 April, Hall 5 \n\nPresenter: Karen Murray, United States of America \n\nAbstract: Ledipasvir/sofosbuvir \u00b1 ribavirin for 12 or 24 weeks is safe and effective in children 6-11 years old with chronic hepatitis C infection (PS101), 17:30 - 17:45\n\n1 EASL Recommendation on Treatment of Hepatitis C 2016.\nILC 2017: The study evaluated the use of a direct-acting antiviral treatment in children aged 6 to 11, for whom the standard of care has been pegylated interferon plus ribavirin\n\nApril 21, 2017, Amsterdam, The Netherlands: A study presented today that evaluated an investigational dosage of once-daily ledipasvir 45 mg/sofosbuvir 200 mg (LDV/SOF) in children aged six to 11 years infected with the Hepatitis C virus (HCV), found that 99% of children (n=89/90) had undetectable levels of HCV-RNA 12 weeks after treatment.\nAbout The European Association for the Study of the Liver (EASL)\n\nSince its foundation in 1966, this not-for-profit organisation has grown to over 4,000 members from all over the world, including many of the leading hepatologists in Europe and beyond.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release explains the significance of this study via quotes from two researchers:\n\u201cDirect-acting antivirals have transformed the treatment of adults with chronic HCV (hepatitis C), however, studies of these new therapies in children are required,\u201d said Dr. Karen Murray, University of Washington School of Medicine and Seattle Children\u2019s, Seattle, United States, and lead author of the study. \u201cThese data establish the use of the oral direct-acting antivirals as an important treatment option in HCV-infected children aged six to 11 years old.\u201d\n\u201cThis study is a breakthrough for the management of children aged six to 11 years old with Hepatitis C, demonstrating that the new DAA regimen is highly efficacious and, more importantly, safe in this group of HCV-infected children\u201d, said Prof. Frank Tacke, University Hospital Aachen, Germany, and EASL Governing Board Member.", "answer": 1}, {"article": "Drs.\nThis is a very relevant finding, as over 200,000 patients still receive whole brain radiation in the United States each year, and the majority of patients with brain metastases have a limited number (typically three or less) of brain lesions.\nThe study, released on July 26, 2016, shows that patients with the most common form of brain tumor can be treated in an effective and substantially less toxic way by omitting a widely used portion of radiation therapy.\n\"We discovered that whole brain radiation added to focused radiation in the treatment of brain metastases \u2013 in other words, cancer that travels to the brain- reduces the number of new brain tumors over time; however, patients receiving the whole brain radiation had significantly more difficulties with memory and complex thinking than patients who only had the focused radiation,\" says Dr. Asher.\nAnthony L. Asher, MD, FACS, medical director at Carolinas HealthCare System's Neurosciences Institute and the senior author on the report, and as well as Stuart H. Burri, MD, chairman, department of radiation oncology at Levine Cancer Institute, began their research on this subject over 10 years ago in Charlotte, North Carolina.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release fails to tell readers that whole brain radiation for these patients is, as an accompanying editorial comment notes, \u201cfalling out of favor.\u201d The editorial goes on to note that, \u201cIn 2014, the American Society of Radiation Oncology\u2026 indicated that WBRT [whole brain radiation treatment] should not routinely be added to SRS [stereotactic radiosurgery or focused radiation] for patients with a limited number of brain metastases.\u201d So this research, informative to clinicians as it may be, is unlikely to change the underlying trend away from using whole brain radiation in the treatment of these patients.", "answer": 0}, {"article": "Additional information about clinical trials, including information for potential participants and financial supporters, is available at http://www.\n\"This is clinical validation of the potential to stably lower blood sugars to near normal levels with a safe vaccine, even in patients with longstanding disease,\" says Denise Faustman, MD, PhD, director of the MGH Immunobiology Laboratory , principal investigator of BCG clinical trials at MGH and senior author of the npj Vaccines report.\nThe MGH team's findings set the stage for further testing of BCG administration, including the FDA-approved phase 2 study currently underway, testing multiple BCG doses in a large group of participants with longstanding type 1 diabetes.\nBut by the end of that short, 20-week trial, there was no reduction in HbA1c, the established measure of blood sugar levels over time.\nThe study from a Massachusetts General Hospital (MGH) research team - published in npj Vaccines - also reports that the effects of BCG vaccine on blood sugar control appear to depend on a totally novel metabolic mechanism that increases cellular consumption of glucose.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release suggests that the study is \u201cclinical validation\u201d of the vaccine\u2019s ability to lower blood sugars to \u201cnear normal levels.\u201d But can a small phase 1 trial be used to claim validity? Phase 2 and 3 trials are also needed.\nThe news release also notes that the lead author published a 20-week, phase I trial in 2012 which showed only temporary\u00a0HbA1c reduction.", "answer": 0}, {"article": "JACC is ranked No.\nIn an accompanying editorial, Deepak L. Bhatt, M.D., M.P.H., executive director of interventional cardiovascular programs at Brigham and Women's Hospital Heart and Vascular Center and professor of medicine at Harvard Medical School in Boston, said the program is groundbreaking, and follow-up studies to further pinpoint the exact mechanisms by which the program achieved positive effects on young children's health will be vital for implementing the program in other areas and informing the design of future global programs.\n\"It may not only be the cardiovascular health information from the program that is helpful but also the cognitive stimulation from and exposure to positive adult role models, which in turn influence personality traits critical for health behavior and habits,\" Bhatt said.\n\"There is a need for a complete change in the timing of when we deliver care,\" said Valentin Fuster, M.D., Ph.D., senior author of the paper.\nThe study and editorial are part of a comprehensive Population Health Promotion issue of the Journal of the American College of Cardiology focusing on issues that broadly impact public health and the prevention of cardiovascular disease and related conditions.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release establishes the novelty of this prevention intervention with a quote:\u00a0\u201cThere is a need for a complete change in the timing of when we deliver care,\u201d said Valentin Fuster, M.D., Ph.D., senior author of the paper. \u201cUntil now, the clinical community has focused on cardiovascular disease, which typically manifests in the later stages of life. Now, we need to focus our care in the opposite stage of life\u2013we need start promoting health at the earliest years, as early as 3 to 5 years old, in order to prevent cardiovascular disease.\u201d", "answer": 1}, {"article": "Editor's note: Tune in as Dr. Sanjay Gupta explores the signs, tests and lifestyle changes that could make cardiac problems a thing of the past on \"The Last Heart Attack,\" Saturday, August 27, 8 and 11 p.m.\nThe 351 participants in the study suffered from high cholesterol but were not on a cholesterol-lowering statin medication.\nIn addition to the soy protein, nuts and whole grains, participants in the diet were encouraged to eat peas, beans and lentils.\nThe study was published Tuesday in the Journal of the American Medical Association.\nTo put the diet to the real-world test, participants received a one-hour counseling session with a dietitian and an illustrated study booklet at the outset and, later, received a 30-40 minute follow up session.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that this study is a follow-up to previous studies of this diet conducted under more controlled conditions. This is nicely explained.", "answer": 1}, {"article": "\u201cWe hope this can be used as one of the tools to identify children at risk,\u201d he said.\n\u201cLooking at hair tells us new things.\u201d\n\nThe research is part of the ongoing Murdoch Childrens Research Institute\u2019s Childhood to Adolescence Study following a cohort of 1,200 children in and around Melbourne and was published in the journal, Psychoneuroendocrinology.\n\u201cWhat\u2019s less commonly understood is that beyond poor mental health, it can also be associated with the development of other illnesses such as diabetes, obesity and cholesterol issues, because cortisol is also central to glucose availability, blood pressure and immune function, so identifying these children is important.\u201d\n\nWhile blood or saliva tests could be used to detect cortisol levels, these methods were sometimes problematic, especially in children, Simmons said.\n\u201cHowever, hair samples are not only easier to obtain, but provide us with a picture of total cortisol throughout the system across many months rather than just at a point in time,\u201d Simmons said.\nIt suggests hair cortisol levels may provide a marker of trauma exposure in children and identify those at risk of developing psychosocial and behavioural problems, and who may need medical and psychological support, leader of the study and a fellow in child and adolescent mental health at the University of Melbourne, Dr Julian Simmons, said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The news article didn\u2019t give any idea of how novel the research is. Apparently from the scientific article, no prior studies have tried to look at history of past traumatic events and correlate with cortisol levels. Even the hair test, as late as 2016, is described as \u201crelatively new\u201d by the researchers, especially in kids (hair tests for cortisol in adults go back quite a few years).\u00a0Other background with regard to studies using hair and cortisol and mental illness were reviewed in the scientific article and the Guardian story might have provided a bit more background.", "answer": 0}, {"article": "\"The bottom-line finding of the Alpha Omega Trial is that [omega]-3 fatty acids did not reduce the primary endpoint major cardiovascular events,\" Kromhout said, noting that the ALA finding needs further confirmation.\nNone of the low-dose supplements seemed to stave off such events in most of the patients.\nIt is during this acute post-attack period, he explained, when patients are most vulnerable to a subsequent event.\nAll had experienced a heart attack at some point in the decade leading up to the study, and all were taking blood pressure medications, anti-clotting drugs and statins.\nAnd they're also not just looking at preventable fatalities but all heart-related events that follow.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story did not mention that the specific margarines used in this study were formulated for use in the study and are not commercially available. \u00a0", "answer": 0}, {"article": "The key to making the therapy work?\nThe only treatment is a bone-marrow transplant \u2014 if a compatible donor can be found \u2014 or a transplant with cord blood, if it was saved at birth.\nFor the first time, doctors have used gene therapy to stave off a fatal degenerative brain disease, an achievement that some experts had thought impossible.\nThe patients were children who had inherited a mutated gene causing a rare disorder, adrenoleukodystrophy, or ALD.\nThey become unable to eat without a feeding tube, to see, hear or think.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is a strong point for the story, which provides a fairly detailed background on how this treatment technique developed over time, how the treatment works and what sets it apart from other treatment options.", "answer": 1}, {"article": "Ultrasound waves applied to the whole brain improve cognitive dysfunction in mice with conditions simulating vascular dementia and Alzheimer's disease.\nThe researchers conclude that their study, recently published in the journal Brain Stimulation, provides the first experimental evidence that whole-brain LIPUS therapy markedly improves cognitive dysfunctions without serious side effects by enhancing specific cells related to dementia's pathology.\n\"The LIPUS therapy is a non-invasive physiotherapy that could apply to high-risk elderly patients without the need for surgery or anaesthesia, and could be used repeatedly,\" says Shimokawa.\nThe team, led by cardiologist Hiroaki Shimokawa, found that applying low-intensity pulsed ultrasound (LIPUS) to the whole brain of the mice improved blood vessel formation and nerve cell regeneration without having obvious side effects.\nBut there are currently no curative treatments available for vascular dementia or Alzheimer's disease, the most common causes of dementia.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes how this study builds on previous LIPUS work (on the heart, nerve cells, and brain regions of mice) and goes after a whole-brain approach instead of targeting just one part of the brain with ultrasonic waves. However, a quick search of other studies show that ultrasound has been used before to explore its potentially therapeutic effects on mouse models for dementia; one of the more notable studies was published by a research group in Australia in 2015, though neither the release nor the study reference it.", "answer": 0}, {"article": "Of those surveyed, 13.6%, or about 27,235 people, reported having used classic psychedelics.\nThe National Alliance on Mental Illness estimates that 30,000 people in the U.S. die from suicide each year, and worldwide that number is 1 million.\nAdditionally, the effects of psychedelics on the developing brain are still largely unknown, meaning they could pose a threat to people with a predisposition to schizophrenia.\nIn 2011, individuals with advanced-stage cancer were given single doses of psilocybin and were found to have reduced long-term incidences of depression and anxiety.\n\"I know scientists are supposed to be objective and dispassionate,\" Hendricks says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article notes that the possible beneficial use of psychedelic drugs dates back far before Timothy Leary was urging students to turn on, tune in, and drop out.", "answer": 1}, {"article": "This is the time right after her period and before ovulation.\n\"This result emphasizes the need for gender-specific programs to quit smoking, as well as taking into consideration a menstrual cycle phase during addiction treatment in women,\" the researchers conclude.\n\"One of the factors contributing to these differences may be that women crave cigarettes more than men and that their desire to smoke is influenced by hormonal fluctuations across the menstrual cycle.\"\n\"While overall more men than women smoke cigarettes, women and girls take less time to become dependent after initial use and have more difficulties quitting the habit,\" the researchers write in their study.\nAccording to small study conducted by researchers at the University of Montreal, women are more likely to crave cigarettes and have trouble quitting when in the follicular phase of their monthly cycle.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "While the story established that \u201cPrevious studies have found women\u2019s monthly hormone fluctuations can affect everything from food cravings and digestive problems to joint pain and a whole host of other health issues,\u201d it never really addresses whether this is groundbreaking research about hormone flux and smoking. It may well be important and novel research, but the story doesn\u2019t establish that context.", "answer": 0}, {"article": "Records covered the use of both low- and high-dose aspirin (ranging from 75 milligrams to 500 milligrams), so-called \"nonselective\" NSAIDs (such as ibuprofen [Advil] and naproxen [Aleve]), and both older and newer types of COX-2 inhibitors.\nFor the new study, the researchers analyzed prescription databases and health information registries including the Danish Cancer Registry and the Danish Civil Registration System.\nFor more on NSAIDs and cancer, visit the U.S. National Cancer Institute.\nIn turn, prescription histories were gathered for both the cancer patient group and almost 179,000 healthy Danes.\nHowever, the same dynamic was generally not seen with regards to basal cell carcinoma.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions previous research suggesting that these drugs may have anti-cancer effects.", "answer": 1}, {"article": "In a small safety study to ensure that modafinil didn't make cocaine worse, some users found the once-a-day pill blocked that high.\nThe main side effect so far: insomnia, not surprising as modafinil is sold today to help narcolepsy patients fend off that neurologic disease's sudden sleep attacks.\nIn addition to blunting cocaine's notorious cravings, modafinil might also counter the damage that cocaine wreaks on users' brain circuits _ damage that in turn fuels the cycle of addiction.\nWASHINGTON -- The hottest topic in cocaine addiction is another drug _ a medicine already sold to wake up narcoleptics.\nThe prospect of that double-whammy has the National Institutes of Health spending $10.8 million researching modafinil as a potential cocaine treatment.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Treatment of cocaine addiction with modafinil is described as new and large scale clinical trails of the drug for this use have not been conducted. This drug is thought to reduce some of the withdrawal symptoms of cocaine addiction, such as fatigue, depression and blunt the desire for the euphoria or cocaine \u201chigh\u201d. ", "answer": 1}, {"article": "The research team was led by Hoon-Ki Sung of The Hospital for Sick Children in Ontario, Canada.\nIntermittent fasting promotes adipose thermogenesis and metabolic homeostasis via VEGF-mediated alternative activation of macrophage, Cell Research DOI: 10.1038/cr.2017.126\n\nNote: Kyoung-Han Kim's current affiliation is the University of Ottawa Heart Institute, Canada.\n\"Strikingly, these fasting-stimulated changes in the growth of vascular cells and subsequent immune alterations occur even after a single cycle of 24-hour fasting, and are completely reversed when mice start eating again,\" adds Yun Hye Kim.\nThe fasting regime helped lower fat build-up in the white fat by increasing the brown-like fat (involved in burning energy and producing body heat) of mice on the high fat diet.\nThis is according to a study by Kyoung-Han Kim and Yun Hye Kim in the journal Cell Research which is published by Springer Nature.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does not make a claim of novelty. In the journal article, the authors write that others have established the ability of intermittent fasting to promote weight loss. They do say that they have identified a mechanism that might explain why weight loss occurs in fasting mice which could be considered novel.", "answer": 1}, {"article": "Even More Evidence for the Health Benefits of Drinking\n\nPhotos: What Booze Looks like Under a Microscope\nA glass of wine or two a week \u2014 and not more than one large glass on any occasion \u2014 may be safe during pregnancy, according to a large study just published in the Journal of Epidemiology and Community Health.\nIf women who say they are drinking at \u201clight\u201d levels are actually drinking at moderately or heavily, that might make the data on light drinking look more dangerous than they are.\nIndeed, these kindergartners were slightly less likely to have behavioral problems and performed somewhat better on cognitive tests than children whose mothers had abstained.\nWhen researchers controlled for factors like maternal education and income, which tend to be higher in light drinkers, it significantly reduced the positive effects associated with alcohol.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The study does take a novel approach to studying the harms and benefits of alcohol, which the story makes clear.", "answer": 1}, {"article": "Article reference: R.M.\nThis study suggests that IV fluids could help women maintain hydration at appropriate levels, reduce the likelihood of c-section, and decrease length of labor,\" says Dr. Berghella.\nOf those, about half (or 593 women) received IV fluids at a rate of 250 milliliters per hour, and the other half (622 women) received fluids at the lower rate of 125 milliliters per hour.\nThe higher fluid rate also reduced the overall time of labor by an average of 64 minutes, and shortened the pushing phase by nearly 3 minutes, on average.\nWith a university and hospital that date back to 1824, today Jefferson is comprised of six colleges, nine hospitals, 34 outpatient and urgent care locations, and a multitude of physician practices throughout the region, serving more than 100,000 inpatients, 373,000 emergency patients and 2.2 million outpatients annually.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The nature of this meta-analysis makes it clear\u00a0that the effects of increased hydration have been the subject of past studies. What is new here is the meta-analytical approach.", "answer": 1}, {"article": "The results so far are very promising.\nThe researchers are continuing to investigate the use of this drug to treat Dupuytren's disease in a phase 2b trial called the RIDD trial, which is currently running in Oxford and Edinburgh.\n\"We are delighted to have received further funding from the Wellcome Trust and Department of Health to test whether adalimumab will work for patients with early stage Dupuytren's disease,\" said Professor Sir Marc Feldmann, co-author and former director of the Kennedy Institute.\n\"Our data have shown that a concentrated formulation of adalimumab injected directly into the diseased tissue may be effective in targeting the cells responsible for Dupuytren's disease,\" said Jagdeep Nanchahal, MD, PhD, University of Oxford Professor of Hand, Plastic and Reconstructive Surgery, who led the study.\nResearchers at the Kennedy Institute and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, working with clinicians at NHS Lothian, have found that injection of the anti-TNF drug adalimumab into Dupuytren's disease nodules results in the reduction of the cell characteristics responsible for progression of Dupuytren's disease.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The novelty of this treatment approach is not addressed in the news release. However, according to the published study, this research group appears to have been instrumental in exploring the role of TNF in this condition.", "answer": 0}, {"article": "Cardinal says older adults need to realize that exercise can greatly improve their quality of life by maximizing function as long as possible.\n(Canes were OK.)\n\nHalf of the participants got a health education program involving regular in-person sessions and some stretching exercises, while the other group was told to aim for 150 minutes of aerobic activity as well as strength, flexibility and balance training both at the study's facilities and at home.\nThe authors called on medical schools to \"start preparing students to prescribe exercise as effectively as they prescribe statins, and for health systems to support physicians in addressing inactivity just as they provide support in addressing other health risks.\"\nThat belief \"is pervasive among older adults,\" he says, even though for many of them, meeting the minimum requirements \"is doable.\"\nThe exercise program pretty closely followed the government's recommendations for all adults, including older ones: 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity exercise per week, plus two strength sessions that hit all the major muscle groups.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Yes, the story establishes novelty this way:\n\u201cPrevious research has suggested that exercise can improve memory and reverse muscle loss in older adults, among other benefits.\u201d and\u00a0\u00a0\u201cPrevious findings from the same study showed that the exercise program lowered the risk of becoming disabled in the first place; this one showed that it sped recovery from an episode of disability and lowered the risk of subsequent episodes.\u201d", "answer": 1}, {"article": "It's a \"close call,\" says H. Gilbert Welch, MD, MPH, of the Dartmouth Institute in Lebanon, N.H.\n\n\"This is a test that women who want it should be able to have,\" Welch tells WebMD.\nHow many lives?\n\"Because we don't know which cancers these are, all cancers are treated.\n\"Some will benefit in a very large way.\n\"The vast majority will turn out not to have cancer, but all of them will worry.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 1}, {"article": "People who were given Flublok Quadrivalent were over 40% less likely to develop culture-confirmed influenza.\nFurthermore, Flublok Quadrivalent is the first and only high antigen-content quadrivalent flu vaccine that with its high efficacy makes it ideal for older adults and those with a compromised immune system.\nThe publication notes that approximately 9,000 people aged 50 and older were enrolled and randomized in an efficacy study designed to compare Flublok Quadrivalent to a traditional quadrivalent vaccine.\n\"This study shows that Flublok\u00ae Quadrivalent, produced with modern recombinant technology can provide better protection against confirmed influenza-like illness among older adults than standard-dose quadrivalent influenza vaccine produced with traditional technology,\" said Lisa Dunkle MD, Chief Medical Officer of Protein Sciences.\nFlublok is the only flu vaccine made in a 100% egg-free system using modern cell culture technology, making it unnecessary to use an infectious influenza virus, antibiotics or harsh chemicals (e.g., formaldehyde) in manufacturing.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "As noted above, the release clearly describes how Flublok Quadrivalent differs from other flu vaccines. The release also addresses the novelty of the clinical study in shedding light on the efficacy of Flublok Quadrivalent to a conventional vaccine in older adults.", "answer": 1}, {"article": "MONDAY, March 12, 2012 (HealthDay News) -- People taking popular cholesterol-lowering drugs called statins may have a slightly lower risk than others of developing Parkinson's disease, new research suggests.\nIt's thought these drugs may have potent anti-inflammatory effects, which could protect the brain.\nBut there is some good news, he added.\nThis effect may be even more pronounced among people younger than 60, according to the study published in the March issue of Archives of Neurology.\nLearn more about Parkinson's disease and its symptoms at the Parkinson's Disease Foundation.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There were no claims of novelty made here.", "answer": 2}, {"article": "Neither scenario gives doctors an objective indication of the severity of the injury.\n\"The idea is to get a point-of-care test that could be used on the field, to help the coaches, the trainers and the athletic directors, make a decision then and there about whether the child should go back to play,\" said Papa.\n\"We were looking at different types of brain lesions detected by the CT scans, ranging from mild to serious injuries, and found that the biomarker we tested for actually corresponded to the injuries.\n\"This could ultimately change the way we diagnose concussions, not only in children, but in anyone who sustains a head injury,\" said Linda Papa, MD, MSC, an emergency medicine physician and NIH funded researcher at Orlando Health and lead author of the study.\n\"If we could find a simple test that takes the guess work out of diagnosing these kids, that would completely change the way we approach concussions and would certainly give parents greater peace of mind,\" said Papa.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There is a robust body of literature on GFAP and brain injury, but the release does not mention that research at all. The journal article notes that \u201cTo the best of our knowledge this is among the largest published studies to date assessing GFAP in children and youth with mild and moderate [traumatic brain injury] in an [emergency department] setting.\u201d That\u2019s useful context, and the release should have included it. Even better, it could have told readers how this research fits into that existing body of work \u2014 is it consistent with previous findings? Does it expand on previous findings? That would be great to know.", "answer": 0}, {"article": "Other smaller growths in the brain continued to grow, however, so the patient received 10 more doses of the CAR T cells injected into the cavities in the brain, called the ventricles.\nThe patient is one of nine in the trial, and so far, many of the other people are having similar experiences on the therapy.\nThese results are the first encouraging sign that the immunotherapy that is helping more people with blood cancer might also be effective for people with solid tumors like brain cancers.\nBut most of the success so far has been with blood cancers like lymphomas and leukemias.\nThis is the first time that immune cells have been injected into these brain regions, because introducing anything into the ventricles can cause dangerous and possibly deadly inflammation.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article ably describes what is novel about the way this immune therapy is created, and why it offers some hope as a strategy against a deadly cancer. \u00a0\u00a0", "answer": 1}, {"article": "Taylor said he thought it did not find any evidence of big benefits because the numbers of people studied and the salt intake reductions were relatively small.\nFrancesco Cappuccio, head of the World Health Organization\u2019s collaborating center for nutrition at Warwick University, said it was \u201ca surprisingly poor piece of work.\u201d\n\n\u201cThis study does not change the priorities outlined worldwide for a population reduction in salt intake to prevent heart attacks and strokes, the greatest killers in the world,\u201d he said in an emailed comment.\nElaine Rush, a professor of nutrition at Auckland University of Technology in Australia, said that putting a spotlight on single trials and generalizing dietary advice for a single nutrient such as salt was \u201cnot helpful.\u201d\n\n\u201cWhat is helpful is for the food industry to reformulate products to reduce sodium and increase the nutrient quality of foods by using real ingredients,\u201d she said in an emailed comment.\nIn Britain, the National Institute of Health and Clinical Guidance (NICE) has called for an acceleration of the reduction in salt in the general population from a maximum intake of 6 grams(g) a day for adults by 2015 to 3 g by 2025.\nSimon Capewell, a professor of Clinical Epidemiology at Liverpool University, said the review was \u201cdisappointing and inconclusive\u201d and did not change public health consensus that dietary salt raises blood pressure.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reported on the results of a recently published Cochrane review. \u00a0It indicated that several guidelines included recommendations for reductions in salt intake and while the experts quoted were in agreement that reducing salt intake was beneficial, the results of this most recent review is that the data do not support this claim. Good context provided.", "answer": 1}, {"article": "Blitz said debate should be aired publicly, and he is not rattled by opposition to plans for a regional approach.\nHospitals take over with more sophisticated cooling equipment.\nMany hospitals and cities have been slow to adopt the heart association recommendations.\nCooling was tested as far back as the 1950's for cardiac arrest survivors.\n\"And if they are aware, they are not using it.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s clear from the story that this is not a new approach. ", "answer": 1}, {"article": "Source: Brightling C, et al.\nWe already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.\u201d\n\nUltimately, the researchers hope that the drug \u201ccould likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms \u2013 making it a \u2018game changer\u2019 for future treatment,\u201d said Brightling.\nBy measuring the sputum eosinophil \u2014 the inflammation marker that shows how white blood cells increase during asthma attacks \u2014 the researchers were able to track the effects of the drug.\nAs the researchers tracked the participants over the course of 12 weeks, they found that those taking the drug saw a decrease in their sputum eosinophil reading from an average of 5.4 percent to 1.1 percent.\nThe drug, known as Fevipiprant (QAW039), was shown to reduce asthma symptoms as well as inflammation, and it improved lung function and repaired airway linings.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story says this is\u00a0the first asthma pill in 20 years\u2013that\u2019s not correct. In recent years, several new drugs known as leukotriene receptor antagonists have come on the market as tablets. (The 20-year statement appears to come from\u00a0the news release, and a Reuters story had a similar error.)", "answer": 0}, {"article": "I\u2019d rather have done 10 rounds with Mike Tyson.\u201d\n\nRichard Burt of Northwestern University in Chicago, who carried out the first HSCT for MS in 1995 and is coordinating the international trials, told the BBC: \u201cThere has been resistance to this in the pharma[ceutical] and academic world.\n\u201cI couldn\u2019t dress or wash myself; I didn\u2019t even have the strength to carry my daughter.\u201d\n\nShe had needed a wheelchair before her transplant, but after the treatment she walked out of hospital.\nI got my life and my independence back and the future is bright again in terms of being a mum and doing everything with Isla.\u201d\n\nTwo years after the treatment, she has had no relapses and there was no evidence of active disease on her scans.\nAt one point, I couldn\u2019t even hold a spoon and feed myself.\u201d\n\nWithin a few days of the transplant, he was able to move his toes, and after four months could stand unaided, although he still needs a wheelchair.\nThe treatment has traditionally been used to treat bone and blood cancers.\u201d\n\nBasil Sharrack, a consultant neurologist at Sheffield teaching hospitals NHS foundation trust, said: \u201cThe new treatment is showing some remarkable results in the small number of patients we have treated so far.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "A round of similar stories on patients in this same trial \u2014 many with \u201cmiracle\u201d headlines \u2014 appeared in March 2015. It\u2019s not clear what\u2019s different about this story or why these results are being reported now.", "answer": 0}, {"article": "WASHINGTON\u2014People with mild Alzheimer\u2019s disease who started taking an experimental Eli Lilly & Co. drug earlier in the course of their disease fared better than patients who started later in a clinical trial.\n\nThe outcome may bolster the company\u2019s case that the drug, solanezumab, can slow the decline of memory and function in mild Alzheimer\u2019s patients, despite prior studies with negative results. But the new data aren\u2019t final proof of the drug\u2019s benefit\u2014a separate, continuing study due to end in late 2016 is designed to...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story discusses these drugs in the context of other drugs seeking to do similar things, and offers a concise background on the history of the development process for both drugs.", "answer": 1}, {"article": "The U.S. National Women's Health Information Center has more about treating menopause symptoms.\nThe research included 53 postmenopausal women, with about half receiving traditional Chinese acupuncture twice a week and the others given sham acupuncture treatments.\nThe beneficial effects of traditional acupuncture, according to the researchers, did not appear to be associated with changes in levels of hormones that trigger menopause and its associated symptoms.\nThough the researchers acknowledged that they did not monitor how long symptom relief lasted, they suggested that traditional acupuncture may offer an alternative for women who can't or don't want to use hormone replacement therapy to ease menopause symptoms.\nThere were no differences between the two groups in terms of vaginal dryness and urinary tract infection.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There has been a lot of research on acupuncture and menopausal symptoms.\u00a0 This story made no reference to any of it.\nJust last year a significant review of 106 previous papers on acupuncture and menopausal symptoms found exactly no benefit from the treatment.", "answer": 0}, {"article": "Beaumont's center is one of just 28 proton therapy centers in the U.S.\nThe facilities are impressive, clean and welcoming, but the difference is the people \u2013 best hospital staff I've ever encountered.\nIn his study published in the International Journal of Radiation Oncology, Biology, Physics, he and his colleagues found, \"in circumstances where surgery may result in significant neurologic or organ dysfunction, patients can be treated definitively with radiation therapy alone.\nThe proton beam is sent to the treatment room through a transport system consisting of magnets, called the beam line, finally arriving in the gantry, a device that rotates around the patient.\nSaid Tracy, \"We were told that I should prepare myself for the loss of functionality below the waist \u2013 including bowel, bladder and sexual functions.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t make any claims about research, or purport to present new findings. As we noted at the very top, it is not clear why this news release was issued. What, if anything, was new or interesting about this particular case?\nProton therapy often gets marketed as newer \u201cprecision\u201d therapy that has fewer side effects than traditional radiation. But with few if any clinical trials comparing outcomes, these claims generally don\u2019t hold water.", "answer": 0}, {"article": "March 21, 2011 -- Long-term results for Lap-Band weight loss surgery are relatively poor, according to a new study from Belgium.\nThe average weight loss was below what experts consider good results.\nThe critics also point out that both the device itself and the expertise of surgeons placing it have improved greatly since the patients in the study had their bands placed, in the years 1994 through 1997.\nNearly half of the 82 patients followed for 12 years or longer required removal of the bands and about 40% had major complications, the researchers found.\nEven so, a majority of the patients in their small study said they were satisfied with the procedure.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear that it was not reporting on a new or novel treatment but rather was reporting on the long-term outcomes presented in a recent research paper.", "answer": 1}, {"article": "A female testosterone patch showed promise at boosting older women's enjoyment of sex, but concerns about the cancer risk of hormone therapies mean U.S. women won't be getting an equivalent of Viagra anytime soon.\n\nProcter & Gamble Co., the Cincinnati consumer-products giant, has worked since 1999 to secure U.S. approval for its Intrinsa patch, intended to increase sex drive and satisfaction in women after menopause.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The report makes clear that the patch is not novel\u2013it\u2019s sold in Europe and has been under study and development in the U.S. for at least a decade.", "answer": 1}, {"article": "Professor Bartlett said researchers are constantly looking at new treatment strategies for alcohol abuse and addiction, which is characterised by extended periods of heavy alcohol use, binges and abstinence, and anxiety and depression which contribute to relapse.\n\u2022 This is the first time tandospirone has be shown to reverse the deficit in brain neurogenesis induced by heavy alcohol consumption\n\u2022 The researchers also showed in mice that the drug was effective in stopping anxiety-like behaviours associated with alcohol withdrawal, and this was accompanied by a significant decrease in binge-like alcohol intake\n\n\"This is a novel discovery that tandospirone can reverse the deficit in neurogenesis caused by alcohol,\" said study leader neuroscientist Professor Selena Bartlett from QUT's Institute of Health and Biomedical Innovation.\nThe study by Professor Bartlett, Dr Belmer, Dr Patkar and Dr Vanessa Lanoue (Queensland Brain Institute) can be accessed here.\n\"Other studies in mice have shown that tandospirone improves brain neurogenesis, but this is the first time it has been shown that it can totally reverse the neurogenic deficits induced by alcohol.\nTheir studies in adult mice show that two weeks of daily treatment with the drug tandospirone reversed the effects of 15 weeks of binge-like alcohol consumption on neurogenesis - the ability of the brain to grow and replace neurons (brain cells).\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release points out that the drug is not just meant to curb drinking but is also aimed at both reducing the anxiety and depression which may follow binge drinking, and suggests that it may alter the reduction in neurogenesis that excessive alcohol use can lead to. It\u2019 important to remember that any claims of novelty apply to mice enrolled in this study only.\nRelated drugs in the same drug class (5-HT1a receptor partial agonist which also include Buspirone (buspar), Abilify (aripiprazole) and Seroquel (quetiapine) have long track records in human disease but no established role in the treatment of alcohol use disorder per se.\u00a0 While the claim may be novel in mice treatment, drugs in this class have already been used to treat anxiety in people with AUD and comorbid anxiety disorder.", "answer": 0}, {"article": "Also unknown: Will insurers pay for the expensive test without evidence it leads to better care or saves lives?\nThe newest test was developed by Genomic Health Inc., which has sold a similar one for breast cancer since 2004.\nUsing one current method, 37 of the 395 men would have been called very low risk and good candidates for monitoring.\nThe results suggest the test could triple the number of men thought to be at such low risk for aggressive disease that monitoring is a clearly safe option.\nThe company will charge $3,820 for the prostate test and says it can save money by avoiding costlier, unnecessary treatment.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story put the new test \u2013 set for discussion today at the American Urological Association annual conference \u2013 into the context of some other relatively new genetic tests for cancer.", "answer": 1}, {"article": "Six patients showed a 64 percent reduction in \"excess path length\" -- the ideal path between destinations, which indicated better performance -- for locations that had been learned during periods of deep brain stimulation.\nCurrently, deep brain stimulation is used to control the tremors associated with Parkinson's, symptoms of obsessive-compulsive disorder and some other psychiatric conditions, including depression.\nAt the same time, we studied a small sample of patients, so our results should be interpreted with caution,\" Fried added.\nFor five patients, navigation to each of the three stores learned during stimulation was faster and shorter than navigation to the three stores learned without stimulation, indicating a consistent effect, the study said.\nStimulating the hippocampus -- a brain region next to the entorhinal cortex which helps form and store memories -- produced no effect during this experiment, however.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that brain stimulation is already used to treat other disorders, but that using it to boost memory would be new.\n\u00a0", "answer": 1}, {"article": "\"But my question here is, 'Is there a real benefit?'\"\nThe authors also noted that apart from an increased brain size among children diagnosed with autism, there are no apparent structural differences between the brains of autistic patients and patients who are not autistic.\n\"We still don't know precisely what's going on in the brain in autism,\" co-author Dr. Janet Lainhart, an associate professor of psychiatry and pediatrics, acknowledged in the news release from Cerebral Cortex.\n\"I would say that if this is geared to, or opens up, any specific avenue to targeted therapy that can help left and right brain communication among certain children for whom that's the pathway to autism, then it should certainly be explored,\" Bono said.\nThe study was limited to high-functioning males and so did not allow researchers to generalize the findings to females, younger children, or \"lower functioning\" individuals with autism, the researchers wrote.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There is no claim made of novelty here. Nor is there any sense of how this study fits into the broader picture of autism research, whether this is a significant advance or what patients should do with this information. Is this the first study to look at this issue in patients with autism? If not, how does it fit with prior studies?", "answer": 0}, {"article": "It also has a very low rate of false positives - it is 98% accurate at ruling out RA.'\nThe Kennedy Institute's Professor Kim Midwood said: 'What is particularly exciting is that when we looked at samples taken from people before their arthritis began, we could see these antibodies to cTNC up to 16 years before the disease occurred - on average the antibodies could be found seven years before the disease appeared.\nWhile tests for individual proteins usually have a relatively low diagnostic sensitivity, a more general test called CCP, that detects synthetic citrullinated peptides, identifies a lot more RA cases.\nWhen inflammation occurs in the body, some proteins are altered in a process called citrullination.\nWe decided to see if it could be citrullinated and, if so, whether it was a target for the autoantibodies that attack the body in RA.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Research into different proteins to diagnose RA in patients prior to the appearance of symptoms isn\u2019t new. In fact, HealthNewsReview.org reviewed a WebMD news story on early detection of RA in 2010.\nAnother blood test for RA is already on the market in the United States, Canada, Europe, Japan and Australia.The JOINTstat test looks for another protein called 14-3-3\u03b7.", "answer": 0}, {"article": "By March, Ramas could hardly walk.\n\"In the past, we would have had to wait to diagnose Parkinson's or chosen different medications to test, which might have had different side effects, and this would have delayed the timely diagnosis of Parkinson's,\" Xie said.\nAs part of the study, recently diagnosed Parkinson's patients and healthy subjects are tested with DaTscan, and clinical and behavioral assessments are done to identify biomarkers of Parkinson's disease progression.\nIn cases where a diagnosis isn't necessarily clear-cut, the DaTscan offers important advances in patient care and treatment, said Dr. Michael Rezak, director of the Movement Disorders Center at Central DuPage Hospital, where the scan is offered.\nThe DaTscan injection was first used in Europe a decade ago, and GE Healthcare made it available to U.S. hospitals in late June.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\n\nThe story does note that the DaTscan test became available in the United States only this year. However, as noted above, the misrepresentation of the purpose of the test will likely mislead most readers about what is actually new about this test.", "answer": 1}, {"article": "\"The remarkable thing about the study is ... these were quite high-risk patients, but the actual [bad] event rate was very low ...\n\"And I wonder if it's worth doing those tests when rates of cardiac events are so low.\"\nThe 10,000-plus patients, who visited 193 health centers in the U.S. and Canada, had no prior diagnosis of coronary artery disease.\n\"Knowing how well the patients did in spite having a very high cardiovascular-risk burden opens up the door to thinking differently about how we might manage those patients.\n\"Traditionally, when you come in with chest pain, some sort of stress test or CT angiogram will be performed,\" Nissen said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story heralds this comparison as the first of its kind in terms of examining clinical outcomes of folks getting these diagnostic exams.\u00a0 It appears that is true.", "answer": 1}, {"article": "Cancer is the No.\nThe test is a long way from being used to screen for cancer, but the study shows a way to get there, the team reported in the journal Science Translational Medicine.\nIt will also have to be tried in larger groups of patients, and patients with different cancers.\n\u201cThere is a lot of excitement about liquid biopsies, but most of that has been in late-stage cancer or in individuals where you already know what to look for,\u201d said Dr. Victor Velculescu, professor of oncology and pathology at the Johns Hopkins University Kimmel Cancer Center.\nThe test still missed a large percentage of cancers and will need much improvement, Velculescu said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The idea here is for a blood test that could detect early stage cancers, based on mutations in DNA found circulating in the blood.\u00a0 That\u2019s certainly novel enough for a story.\u00a0It was also clear there are some other similar tests in development or possibly ready but not FDA approved.", "answer": 1}, {"article": "ET, or more than twice their 25-day average trading volume.\nData showed that the severity of the spinal injury was reduced in the first patient and two other patients were able to resume their rehabilitation programs soon after being injected with the stem cells.\nAsterias is looking to show recovery of mobility in four out of every 10 patients treated with OPC-1, compared with two out of 10 achieving the same level of improvement without any treatment, Chief Executive Pedro Lichtinger told Reuters in early August.\nAsterias bought OPC-1 in 2013 from the erstwhile stem cell research leader Geron Corp, which decided to focus on developing cancer drugs.\nThe therapy, AST OPC-1, is the first product derived from human embryos to be tested on humans.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The report does a good job detailing the therapy\u2019s history at Geron Corp, which also conducted an early-phase study with five patients suffering from spinal cord injuries prior to 2011. Asterias bought OPC-1 in 2013 and just completed its own early-stage trial, the article said. It also notes that\u00a0AST OPC-1 \u00a0\u201cis the first product derived from human embryos to be tested on humans.\u201d", "answer": 1}, {"article": "That test can have side effects.\nIt\u2019s saying that, for most men, the (albeit small) risk of sexual dysfunction and urinary leakage from eventual treatment is not worth it, given the even smaller chance that PSA testing could save your life.\nThe same European trial that found lower cancer mortality with PSA testing also found that, to save just one life through screening, an extra 37 men would need to be diagnosed with prostate cancer and treated.\nTo calculate the total number of metastatic cases we\u2019d get without screening, the study takes today\u2019s population of the United States and applies the rates (broken down by age and race) of advanced-stage prostate cancer that were observed before PSA testing was introduced \u2014 that is, the rates way back in 1983-85.\nIn other words, it tells us what the current U.S. population would look like if today we faced the same risks that Americans faced in the \u201980s; it finds we\u2019d have roughly 25,000 U.S. men diagnosed with advanced-stage prostate cancer each year compared to just 8,000 today.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story says \u201cthe new study reflects a broader divide in the medical community.\u201d\u00a0 Does it?\u00a0 It\u2019s one study \u2013 using a statistical model that is not thoroughly analyzed in the story.\u00a0 In HealthDay\u2019s story, by contrast, Dr. Otis Brawley of the American Cancer Society said, \u201cNone of thee studies can be considered decisive other than in proving that there are some harms associated with treatment.\u201d\u00a0 In the WebMD story, Dr. Barry Kramer of NIH is paraphrased saying false results can easily creep into such look-back studies.", "answer": 0}, {"article": "Thanks to members Drs.\nThis is different than studies recently published that say the average response differs.\u201d The full report, published ahead of print in the Clinical Journal of Sport Medicince (CJSM) and will appear in the (British Journal of Sports Medicine) BJSM, entitled, AMSSM Scientific Statement Concerning Viscosupplementation Injections for Knee Osteoarthritis Importance for Individual Patient Outcomes, includes the following notable AMSSM recommendations and one suggestion:\n\u2022 AMSSM RECOMMENDS viscosupplementation injections for Kellgren and Lawrence (KL) grade II-III knee osteoarthritis in those patients above the age of 60 based on HIGH quality evidence demonstrating benefit using OMERACT-OARSI Responder Rating but the evidence should be downgraded due to indirectness for those under 60 years of age.\nIn light of these issues, the AMSSM convened an expert writing group of four sports medicine physicians to review the latest data and provide recommendations for the sports medicine community.\nThe lifetime risk of suffering symptomatic knee OA is estimated to be 44.7% and approximately 1 in 11 of the US population is diagnosed with symptomatic knee OA by age 60.\nWith this knowledge, the American Medical Society for Sports Medicine (AMSSM) has released a new scientific statement that provides guidance for physicians and healthcare professionals who provide care for those patients with knee osteoarthritis.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Suggesting that viscosupplementation, which is not a new treatment, should be a mainstay of treatment based on the argument that some may benefit is certainly a novel (and a controversial) idea. That recommendation puts it at odds with what the American Academy of Orthopaedic Surgeons says. Here\u2019s what the AAOS has to say about viscosupplementation, \u201cWe cannot recommend using hyaluronic acid (HA) for patients with symptomatic OA of the knee,\u201d with a \u201cStrong\u201d rating, based on supporting evidence from 3 high-quality and 11 moderate-quality research studies that met the inclusion criteria.", "answer": 1}, {"article": "For the study, the researchers followed 57,872 women in B.C.\nMcRae said the findings add new evidence in support of midwifery care, and support the development of policies to ensure midwives are available and accessible, especially for low-income women.\nMidwives are experts in the care of women having healthy pregnancies, and tend to spend more time with their patients with a focus on the overall physical, emotional and psychological wellbeing of mothers and their newborns.\nAfter controlling for differences such as age, previous pregnancies, where they lived and pre-existing medical conditions, the researchers found that low-income women who were receiving prenatal care from a midwife had 29 per cent lower odds of a small-for-gestational age birth compared to women who received care from a GP.\nThe study, published today in the British Medical Journal Open, found that low-income pregnant women who receive care from a midwife compared to a physician are less likely to go into early labour, to have a baby with a low birth weight, or to have a small-for-gestational age birth, meaning a fetus or infant that is smaller or less developed than normal for the number of weeks in pregnancy.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "We like how the news release did not attempt to characterize this study as unique, but rather characterized it as \u201cadding new evidence in support of midwives as a safe option for prenatal care, especially for women who have low socioeconomic status.\u201d\n\u00a0", "answer": 1}, {"article": "It is the combined effect of surgery and chemotherapy that works best.\nThe possibility of a 50 per cent cure rate would be a significant improvement over the current 20 per cent survival rate resulting from more conventional treatment options offered to patients, which consist of a combination of different methods including: chemotherapy before surgery; post-operative chemotherapy delivered intravenously to the whole body (as opposed to localized into the abdomen); and surgery that leaves minimal residual disease in the abdomen, rather than removing all visible cancer cells.\n\"For decades, women have been treated with a combination of treatment options, resulting in poor prognosis for most women with advanced-stage ovarian cancer, but there are many survivors as well,\" said Dr. Narod, senior scientist at Women's College Research Institute.\nBased on an analysis of existing evidence, published in an opinion article in the Nature Reviews Clinical Oncology journal on January 20, Dr. Narod argues that to achieve a cure, rather than simply delay progression or reoccurrence of the disease, women should be first treated with aggressive surgery to remove all clinically-detectable cancer cells, followed by targeted chemotherapy to the abdomen (intraperitoneal chemotherapy).\n\"Women need support to endure surgery and the rigours of intraperitoneal chemotherapy, but should be encouraged to do so whenever possible, considering the potential survival benefits,\" said Narod.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "We think the PR release fails to establish novelty. The perspective piece is a battle cry for adjuvant chemotherapy but the news release misses this nuance and, as a result, doesn\u2019t emphasize current standard of care as much as it should. Another thing that is missing from the release is the extent to which the specific combination of treatment options being urged as a standard of care is already in use. Is this the treatment that most women with advanced stage ovarian cancer already receive? If not, why not? Presumably doctors and patients have a rationale for their decisions. If this treatment is not what most patients already receive, the release would benefit significantly from some discussion (however brief) of why the treatment is not in more widespread use.", "answer": 0}, {"article": "\"As the kids with cystic fibrosis are living longer and longer, a lot of these ancillary problems are become more apparent,\" said C. Michael White, director of the Evidence-based Practice Center and lead author of the study.\nBut with antibiotics and other medical advances, the median age for people with the disease increased to 37 by 2008.\nLungs are clogged with a thick mucus, which can lead to lung infections.\nIn the 1950s, children with cystic fibrosis generally died before age 8.\nCaused by defective genes, cystic fibrosis affects multiple organs.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 1}, {"article": "MONDAY, Sept. 27, 2010 (HealthDay News) -- In a head-to-head comparison of drug-coated stents -- the metal mesh tubes used to keep clogged arteries open -- the well-established model using the drug sirolimus came out on top, South Korean researchers report.\nIn preventing major cardiac events, the researchers found that zotarolimus-coated stents, the new entry in the field, were less effective than the sirolimus-eluting stents, but better than stents coated with paclitaxel.\n\"In this large-scale, practical randomized trial, the use of zotarolimus-eluting stents resulted in similar rates of major adverse cardiac events compared with sirolimus-eluting stents and in fewer major adverse cardiac events compared with paclitaxel-eluting stents at 12 months,\" the researchers concluded in their report.\nHowever, they said a limitation of their study is the one-year follow-up period, and noted that a longer, ongoing study pitting zotarolimus-eluting stents against sirolimus-eluting stents will provide more safety information.\nThe researchers found that 10.2 percent of the patients who received zotarolimus-coated stents suffered a major adverse cardiac event, compared with 8.3 percent of the patients who received sirolimus-coated stents and 14.1 percent of those with paclitaxel-coated stents.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article explains that the three stents are coated with different drugs, the zotarolimus version is a newer entry, while the sirolimus one is the \u201cold standby\u201d. \nIt would\u2019ve been nice to read how the stent with paclitaxel fits into the big picture.", "answer": 1}, {"article": "To resolve that possibility, a new trial is under way at 20 cancer centers, including M.D.\nIt was only open to those with a particular protein \u2014 present in one-third to two-thirds of glioblastomas \u2014 and those who were tumor free after surgery and radiation.\n\"But two years later, I'm in good shape, living a normal life and still returning cancer-free scans every month, thanks to this trial.\nIn study results to be presented next week at an annual meeting of cancer doctors, Hassenbusch's treatment \u2014 chemotherapy and a new vaccine \u2014 significantly prolonged survival of patients with glioblastoma, the most common and aggressive brain cancer.\nLate Houston surgeon's work may fight cancer that killed him Surgeon's trial study on cancer is hailed\n\nBrain tumor took his life, but his pioneering therapy now may give others hope\n\nThe death of Houston neurosurgeon Samuel Hassenbusch from the brain cancer he treated has been one of 2008's sadder stories.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear that combining a vaccine with conventional chemotherapy for the treatment of this tumor was novel.\n\u00a0A story about a clinical trial should include a link to a source of information about clinical trials as a service to readers.", "answer": 1}, {"article": "So are lycopene packed tomatoes really the magic fruit?\n\"It's a compelling study and it fits with other data that we have about risk of stroke and vegetable and fruit consumption,\" explains Dr. Daniel Labovitz, director of the Stern Stroke Center at Montefiore Medical Center in New York.\nThough the study looks promising, experts say that we can't necessarily give all of the credit to lycopene.\n\"This study adds to the evidence that a diet high in fruits and vegetables is associated with a lower risk of stroke,\" says study author Jouni Karppi, of the University of Eastern Finland in Kuopio.\n\"This is one more reason to consume fruits and vegetables - at least 5 a day - and it's good to include tomatoes in that mix,\" Willett said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t hype the novelty of the research. As one source comments, the study\u00a0\u201c\u2026fits with other data that we have about risk of stroke and vegetable and fruit consumption.\u201d", "answer": 1}, {"article": "By doing both, the ability of imaging to accurately plot a tumor\u2019s location is increased and there is a more refined sense of the tumor\u2019s extent, said Nathan White, PhD, assistant project scientist at UC San Diego, study co-author and co-inventor of the RSI-MRI technique.\nIt corrects for magnetic field distortions and focuses upon water diffusion within tumor cells.\nGreater blood flow is often a requirement of growing cancer cells.\n\u201cThis new approach is a more reliable imaging technique for localizing tumors.\nAn imaging technique called diffusion MRI measures the diffusion of water and has been a standard imaging technique in the brain and an emerging technique in the prostate.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release indicates that this is a fairly new method that operates differently than other MRI methods.", "answer": 1}, {"article": "That is the process that he says is reversed by resveratrol and, he hopes, by the more powerful sirtuin-activator drugs that his company is developing, though many years of clinical trials will still be needed to demonstrate whether they work and are safe to use.\nAnd higher doses may not be as safe as the lower doses found now in foods and \u201cnutraceuticals\u201d like the extract capsules.\nOne serious uncertainty is whether, in the mouse experiments, resverattrol in fact acted through the sirtuins or by some other unknown mechanism.\nDr. Auwerx attributes this change in large part to the significantly increased number of mitochondria he detected in the muscle cells of treated mice.\nBesides these uncertainties over what a safe and effective dose of resveratrol might be, the science underlying the field is still in full flux.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story reported on the results of some new scientific studies on the effects of reservatrol.", "answer": 1}, {"article": "But, she adds, epidemiological studies consistently show positive health effects from fish consumption on mortality, cardiovascular risk factors and, now, dementia.\nOther dietary intake and genetic propensities probably account for the rest.\nDr. Schaefer pointed out that the kind of fish consumed is important.\nIn fact, fish intake accounted for less than half of the variability in DHA levels.\nEating fish is not a guarantee of having high levels of DHA.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reported that the results of the current study were consistent with earlier data.", "answer": 1}, {"article": "TUESDAY, Feb. 28, 2012 (HealthDay News) -- Menstrual cramps are the bane of many women, but new research suggests that a form of vitamin D may one day be added to the meager list of pain relievers for the sometimes disabling condition.\nAnd since the study period lasted only two months, there was no way to tell whether such a high dose produced any toxic long-term effects.\nTo find out more about painful menstrual periods, head to the U.S. National Library of Medicine.\nThe Italian study participants all had blood levels of vitamin D measuring in the lowest 25 percent of normal at the study's outset, although the researchers didn't report the womens' blood levels afterward.\nbut it needs further explanation.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story actually didn\u2019t make any claims about the novelty of this area of research. Vitamin D at this dosage and for this condition are novel approaches.", "answer": 2}, {"article": "Women in the acupressure group also used less pain medication than women in the control group and reported lower levels of pain overall.\nSo far, research into the clinical effectiveness of apps has been limited, and only a few have been tested using randomized controlled trials,\" says Dr. Daniel Pach of the Institute of Social Medicine, Epidemiology and Health Economics.\nHowever, the women who were involved during the planning stages, all of whom were affected by menstrual pain, wanted an app,\" reports the study's principal investigator, Prof. Dr. Claudia Witt of the Institute of Social Medicine, Epidemiology and Health Economics.\nThese questions addressed in a new study by researchers from Charit\u00e9 - Universit\u00e4tsmedizin Berlin, the results of which have been published in the American Journal of Obstetrics and Gynecology*.\nOne advantage of an app-based intervention is its ability to provide visual descriptions of the pressure points users need to target in order to achieve the desired effect.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes that there\u2019s been only limited research into the therapeutic benefits of smart phone apps and that only a few have been randomized controlled trials. It does not claim to be the first to test an app for acupressure and menstrual pain.", "answer": 1}, {"article": "For participants with more severe vision loss (20/50 or worse), aflibercept improved vision on average nearly four lines, bevacizumab about 2.5 lines, and ranibizumab almost three lines.\nIn light of these positive results, \u201cit is more important than ever for patients with diabetes to be evaluated on a regular basis for eye disease and receive treatment promptly once indicated as we now have excellent success in treating patients with DME,\u201d says Dr. Aiello.\nJoslin Clinic patients, and others with diabetes, have the option of participating in clinical trials at Joslin to help translate basic research into treatment innovations.\nParticipants on bevacizumab and ranibizumab received, on average, 10 injections, versus nine for those on aflibercept.\nOver the past few years, drugs that target VEGF have become a standard treatment for DME, providing a preferred alternative or adjunct to laser treatment.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Novelty is established in the first line of the release, which states that this is \u201cthe first clinical trial directly comparing three drugs most commonly used to treat diabetic macular edema.\u201d", "answer": 1}, {"article": "But in some individuals too many platelets are produced \u2013 a condition known as thrombocytosis, thought to affect about half a million people in the UK over the age of 40.\nFor about a third of cases of lung and colorectal cancer in patients with thrombocytosis, there had been no other symptoms that raised the suggestion of cancer.\n\u201cThis is an excellent study that demonstrates the potential for a commonly used blood test to identify some patients with cancer earlier,\u201d he said.\nResearchers say that raised platelet counts are as good a predictor of getting any cancer as a lump in the breast is for breast cancer.\nBut if a patient has a blood test for another reason and a high platelet count is found, then one of the possible diagnoses doctors should consider is cancer.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did a good job of pointing out previous research suggesting associations between cancer and thrombocytosis, and how the new study strengthened those associations.", "answer": 1}, {"article": "TUESDAY, Jan. 19, 2010 (HealthDay News) -- DNA testing for the human papillomavirus should replace the Pap smear as the main way to screen women for cervical cancer, according to Italian researchers.\nDNA testing for HPV, though, does have drawbacks -- namely that it is less specific, meaning it is likely to pick up more false-positives, than a Pap smear.\nScreening for HPV DNA appeared more effective in older women, but the testing in younger women led to over-diagnosis of a particular type of cervical lesion, the study found.\nThe HPV test should become the screening tool of choice for women 35 and older, the researchers said.\nTheir recommendation is based on a study that found that the human papillomavirus (HPV) test prevented more cases of cervical cancer than the conventional Pap smear.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story accurately represents the novelty of HPV DNA testing, which is not a new idea but as of yet in the US has not been the standard of care for cervical cancer screening on a national basis.", "answer": 1}, {"article": "Holick and others say there is little or no downside to ingesting even high levels of vitamin D.\n\n\"I've been treating patients with 50,000 units of vitamin D once a week for eight weeks followed by 50,00 every other week for over a decade, and I've not seen any untoward toxicity,\" Holick says.\nThe fact that the government is funding the study is an indicator that the idea has traction.\nThe National Institutes of Health is devoting $22 million for a five-year study.\nThe Institute of Medicine panel has a difficult task.\nNeither study subjects nor investigators will know until the end which regimen they are on.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The new 5-year NIH study on Vitamin D was emphasized.\u00a0", "answer": 1}, {"article": "(Editing by Pravin Char)\n\u201cNow we urgently need to see if it works like lithium in people.\u201d\n\nSome 60 years after it was first discovered, lithium - a mood stabiliser that can protect against both depression and mania, and reduce the risk of suicide - remains the most effective long-term treatment.\nScientists say the drug, ebselen, may be a swift answer to long-sought after better medications for patients with the manic depressive disorder, since it is already known to be safe.\n\u201cThis is one of the first handful of examples of drug repurposing, where a new use has been found for an existing drug,\u201d Vasudevan said.\nBut it is very toxic - at only twice the right dose it could kill a patient, Churchill said - and its adverse side-effects mean many people stop taking the drug and relapse into episodes of mania and depression.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "About the only claim of novelty is the statement that \u201cThis is one of the first handful of examples of drug repurposing, where a new use has been found for an existing drug.\u201d Interesting approach.", "answer": 1}, {"article": "The American Heart Association recommends that adults eat less than 1.5 g of sodium per day.\nNeither the researchers nor the participants knew who was receiving the seaweed supplement.\nQuestions remain about the safety of the fiber supplement over the long term.\nAlginate as an aid to weight loss is already commercially available in pill form and costs around $45 for a seven-day supply.\nIn terms of calories, flavor and appearance, the placebo and treatment drink were identical.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "References to past research on seaweed supplements were made.", "answer": 1}, {"article": "Maguire said, recalling the question.\n\"It will succeed not only for me, but also for other people with visual problems so that they can have a hope for their future,\" said Manuela.\n\"We were worried that there'd be too much scar tissue in the retina itself to be able to deliver the material to the correct spot,\" he said.\nFor the first time, researchers have shown that gene therapy can be used to improve vision for blind children and young adults.\nThe area treated is tiny, just three by three millimeters \u2014 about the size of Franklin Delano Roosevelt's cheek on a dime.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "While making it seem like the patient profiled was the first to receive this treatment, the same group of investigators reported on a patient, Robert Johnson, last year at this time. \u00a0(This was covered by the BBC and in TIME magazine). \u00a0It would have been very interesting to do a follow-up story with this person to see what effect(s), if any, the treatment has had.\nThat said, pursuit of this approach is novel.\u00a0", "answer": 1}, {"article": "Parkinson's disease is a degenerative condition that affects the central nervous system.\nBut, when the researchers looked at the dietary compounds individually, it was clear that berries could benefit both men and women, lowering the risk of Parkinson's disease by about 25 percent for those who had at least two servings of berries a week.\nWhen researchers compared those who ate the most flavonoids with those who ate the least, they found that only men saw a statistically significant benefit, lowering their risk of Parkinson's by 40 percent.\nFor the study, the researchers reviewed nutrition and health data from almost 50,000 men enrolled in the Health Professional Follow-Up Study and more than 80,000 women participating in the Nurses' Health Study.\nDr. Michael Okun, medical director of the National Parkinson Foundation, said, \"It is exciting to see research emerging about modifiable dietary issues that may affect the risk of getting diseases such as Parkinson's.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "While this may be the first study to document a relationship specifically between berries and Parkinson\u2019s, there have been studies documenting possible benefits from similar dietary approaches that involve antioxidant-rich foods, such as the Mediterranean diet. The story could have mentioned this research.", "answer": 0}, {"article": "Advanced online publication: http://www.\nThe manuscript, titled \"Clinical Benefits of Tramiprosate in Alzheimer's Disease Are Associated with Higher Number of APOE4 Alleles: The 'APOE4 Gene-Dose Effect',\" is featured in the advanced online publication of The Journal of the Prevention of Alzheimer's Disease (JPAD) with lead authors from Alzheon, Inc., a biopharmaceutical company focused on treatments for neurodegenerative and neuropsychiatric disorders.\nThis new insight shows how we can apply a precision medicine approach in AD and develop this drug for the right patients, namely patients with the APOE4 genotype, which carries the highest risk as well as the earliest onset and faster disease progression,\" said Martin Tolar, MD, PhD, Founder, President and CEO of Alzheon.\nThe published results showed a gene-dose effect at the high dose of tramiprosate (150 mg, twice daily), with patients with two APOE4 alleles (APOE4/4 homozygotes) showing the largest clinical benefit, those with one APOE4 allele (APOE4 heterozygotes) showing an intermediate benefit, while APOE4 non-carriers showed no benefit from tramiprosate.\nThe \u03b54 allele is significantly overrepresented in the Alzheimer's disease population compared to the general population: up to 65 percent of Alzheimer's patients carry one or two copies of the \u03b54 allele compared to about 25 percent of the general population.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that this is the first time a correlation has been seen between an Alzheimer\u2019s drug and the genetic status of the patient, where the dose appears to show the most effect in patients with two alleles for APOE4.\nHowever, since the overall analysis did not show a benefit, the author\u2019s claims are questionable. And there are many, many drugs being developed targeting amyloid, which an increasing number of researchers regard as folly.", "answer": 0}, {"article": "Feb. 17, 2011 (Orlando, Fla.) -- Taking a pomegranate pill a day may help slow the progression of prostate cancer, preliminary research suggests.\n\"The results were similar regardless of whether the men took one capsule or three,\" Carducci tells WebMD.\nThe study is the latest to demonstrate pomegranate's promising antitumor effects, says study head Michael Carducci, MD, professor of oncology and urology at Johns Hopkins Medical Institutes.\nHowever, men who took three pills daily were more likely to suffer mild to moderate diarrhea: 14% vs. 2% of those who took one pill.\nIn 2009, other researchers reported that pomegranate juice may also prevent prostate cancer from getting worse.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Barely satisfactory.\u00a0 The story at least notes earlier research:\u00a0 \u201cIn 2009, other researchers reported that pomegranate juice may also prevent prostate cancer from getting worse.\u201d\u00a0 But it didn\u2019t evaluate the quality of that evidence either.", "answer": 1}, {"article": "The American Cancer Society has more on lymphoma.\n\"As physicians, we recommend physical activity for all cancer survivors to improve overall quality of life, but we did not know if physical activity would have an impact on survival in lymphoma patients,\" said study author Dr. Priyanka Pophali, a hematologist at Mayo Clinic.\nThat finding comes from a new study by Mayo Clinic researchers of nearly 4,100 people with lymphoma, a cancer that starts in the white blood cells that normally help fight infection.\nOn the other hand, people whose physical activity level had declined after their diagnosis had higher death rates from lymphoma and other causes than those who had not changed their level of physical activity.\nThrough periodic questionnaires, the researchers tracked the participants' physical activity levels from before their cancer diagnoses until three years afterwards.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story addresses this early on with a quote from one of the researchers: \u201cwe did not know if physical activity would have an impact on survival in lymphoma patients.\u201d Frankly, we still don\u2019t know that \u2014 it was an observational study. But there does appear to be a correlation, and identifying that correlation is what is novel here.", "answer": 1}, {"article": "\"These are exciting results.\nThe study was approved by ethics committees in Brazil, he said, adding that he personally believes it was appropriate to do the research in children as well as adults, as long as the Brazilian ethics panels approved.\nThe treatment involves stem cell transplants from the patients' own blood.\nThe hazards of stem cell transplantation also raise questions about whether the study should have included children.\nThough too early to call it a cure, the procedure has enabled the young people, who have Type I diabetes, to live insulin-free so far, some for as long as three years.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions this is the first time this treatment (adult stem cells) has been used to control type 1 diabetes (although the story states adult stem cells have been used to treat leukemia).\u00a0", "answer": 1}, {"article": "FDA approves first drug aimed at women with inherited breast cancer\n\nU.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.\n\nThe Food and Drug Administration on Friday approved AstraZeneca PLC\u2019s Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story describes this as \u201cthe first drug aimed at women with advanced breast cancer caused by\u00a0an inherited flawed gene\u201d and \u201cthe first in a new class of medicines called PARP inhibitors to be approved for breast cancer.\u201d", "answer": 1}, {"article": "\"While reductions in [cardiovascular] death still trump these bleeding events, if rivaroxaban is approved, we should expect a number of bleeding events that will require medical attention,\" Hicks wrote.\nXarelto already is approved for use by those with atrial fibrillation (irregular heartbeat) and by people who are having hip- or knee-replacement surgery.\nPeople who took Xarelto -- and suffered from the most common type of atrial fibrillation and didn't have heart valve damage -- were about one-third less likely to experience bleeding in the brain than those who took warfarin, the investigators found.\nA final decision is expected by the end of June, according to the documents.\nThe U.S. National Institute of Neurological Disorders and Stroke has more about stroke.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains that this is one of a new class of blood thinners \u201cdeveloped to overcome some of the problems that exist with the standard treatment.\u201d", "answer": 1}, {"article": "CHICAGO -- Acupuncture gets a thumbs-up for helping relieve pain from chronic headaches, backaches and arthritis in a review of more than two dozen studies -- the latest analysis of an often-studied therapy that has as many fans as critics.\nThe center offers acupuncture and other alternative therapies for cancer patients with hard-to-treat pain.\nThe researchers concluded that the needle remedy worked better than usual pain treatment and slightly better than fake acupuncture.\nThe analysis was more rigorous than most research based on pooling previous studies' results, because the authors obtained original data from each study.\nThat kind of analysis is not the strongest type of research, but the authors took extra steps including examining raw data from the original studies.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story gives appropriate background on acupuncture research and how the new study differs from previous approaches.", "answer": 1}, {"article": "\u201cThe number of dementia cases could drop by half.\u201d\n\nNov. 20: MRI scan may predict which people will develop Alzheimer's disease\n\nLambracht-Washington said the study marks major progress toward a safe and effective vaccine.\nTesting in mice showed that the vaccine safely prevents the buildup of substances in the brain associated with the fatal disease, the team reported this week in the journal Alzheimer's Research & Therapy.\nThere has been research in monkeys and rabbits as well, and the researchers hope the vaccine will progress to human trials.\nAbout 5.7 million Americans have Alzheimer's disease, according to the University of Texas.\nIf the vaccine proves safe and effective in humans, it could slice the number of dementia diagnoses in half, the study's senior author told USA TODAY.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s clear that a vaccine would be a new approach to Alzheimer\u2019s.", "answer": 1}, {"article": "WEDNESDAY, Feb. 15, 2012 (HealthDay News) -- The quit-smoking drug Chantix may also help problem drinkers cut their alcohol consumption, a small new study suggests.\nRecently, the drug was linked to a small but significant risk of heart attack and stroke among people with pre-existing heart disease.\n\"We have many options for depression and need more for alcoholism, considering it is one of the most common diseases around the world.\"\n\"We need a lot more options in terms of medicines to help curb drinking,\" he said.\nWhether the drug might someday be approved to help problem drinkers cut back remains to be seen, said the researchers, who acknowledged that the study's small size is a limitation.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "As mentioned above, other drugs are already used to treat alcohol addiction. Readers of this story should have been given that background.", "answer": 0}, {"article": "Although many guidelines rely on self-reports, Hennekens and his collaborators from Baylor College of Medicine and Meharry Medical College, used the Surveillance, Epidemiology, and End Results (SEER) program file linked to the Medicare administrative claims file, which allowed them to identify screening mammography use from 1995 to 2009 from 64,384 non-Hispanic women (4,886 black and 59,498 white).\nThe researchers selected 69 as the lower age limit because Medicare coverage of the general population begins at age 65, and the exposure of interest was regular mammography screening in the four years immediately preceding breast cancer diagnosis.\nAlthough a number of randomized trials demonstrate the clear benefits of mammography screening in women up to age 74 on reducing mortality, data are sparse in women over the age of 74, especially minorities.\nThey looked at data from non-Hispanic, white or black women; Hispanics were not included because Hispanic white women have substantially lower mortality than non-Hispanic whites, and the number of Hispanic blacks is small.\nFrom 1995 to 2005, according to Science Watch, Hennekens was the third most widely cited medical researcher in the world and five of the top 20 were his former fellows and/or trainees.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Unlike other studies that are based on surveillance data and \u201cself reports,\u201d as noted in the release, this study looked at Medicare administrative claims filed from 1995 to 2009 to gather data on incidence and mortality rates.", "answer": 1}, {"article": "Before Starting A Statin, Talk It Over With Your Doctor\n\nA study published Monday is pushing back against the notion that up to 40 percent of Americans should be taking statin drugs to reduce the risk of heart disease.\nHe disagrees with a lot of the particulars in the Swiss study.\n\"The elderly do not benefit as much as previous studies might have thought,\" he says.\n\"In our approach we very explicitly considered the harms.\"\nThe most common side effect of these drugs is muscle pain, which usually goes away if patients stop taking the medicines.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story states this an attempt to better weigh the benefits and harms of statin use.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070723/23healytip.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story included information that the observed association between LDL cholesterol level attained and cancer risk is something that has been previously reported.", "answer": 1}, {"article": "Another took part in an exercise program.\n\"People need to begin to push themselves in the face of their fatigue, because if you don't, you become deconditioned and you get caught in a cycle which ... makes fatigue worse,\" says Barsky.\nIts cause is still unknown, but over the years, researchers have identified various brain, immune system and energy metabolism irregularities involved.\nNearly three decades have passed since the debate began about a series of symptoms that have come to be known as chronic fatigue syndrome.\nWhen symptoms abate and they feel better, they may go all out, exercising, doing errands and socializing.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story never tells us enough about the type of therapy involved to decide whether it is novel. CBT is not novel and has been tested before for chronic fatigue, but only in small trials. It is a recommended therapy in some guidelines. This trial is a large head-to-head comparison of viable treatment options, so, in this respect, the findings are novel and quite important.", "answer": 0}, {"article": "Correction: February 16, 2006, Thursday A front-page article on Feb. 8 about a new study finding that low-fat diets have no effect on the risk of cancer or heart disease misstated the incidence of breast cancer among women in the study.\n\"People are always thinking it's what they ate.\nNot everyone was convinced.\n(The difference was deemed statistically insignificant.)\nDr. Rossouw said the observational studies that led to the hypothesis about colon cancer and dietary fat included men and women.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 1}, {"article": "Doctors used the self-learning computer to detect changes in brain scans too subtle for humans to see.\n\"This study highlights the potential of machine learning to assist with the early detection of diseases like Alzheimer's, but the findings will need to be confirmed in much larger groups of people before we can properly assess the power of this approach.\"\n\"Although the sample sizes and test sets were relatively small, the results are so promising that a much larger study would be worthwhile.\"\nDr Carol Routledge, from Alzheimer's Research UK, said: \"The diseases that cause dementia begin in the brain up to 20 years before any symptoms start to show, presenting a vital window of opportunity for us to intervene before widespread damage occurs.\nBritish AI expert Prof Noel Sharkey, from the University of Sheffield, said of the findings: \"This is exactly the sort of task that deep learning is cut out for - finding high-level patterns in data.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s unclear from the story if this is the first time such an algorithm has been used to \u201cpredict\u201d the diagnosis of Alzheimer\u2019s diseases or other diseases. Some context was greatly needed.", "answer": 0}, {"article": "But such evidence often does not pan out in human studies.\nHe theorizes that the risk of developing Type 1 rises when excess demand for insulin is placed on the pancreas in children who are even slightly overweight.\nSo much metformin is taken in the United States \u2014 some 72 million prescriptions were written for it in 2013 \u2014 that a recent study found higher trace levels of it (presumably from the urine of people taking it) in Lake Michigan than of any other drug, including caffeine.\nIf the theory is true, then people who age more gracefully have a slower rate of cell division.\nMoreover, the drug was being studied in clinical trials as a way to lower the risk of cancer, heart disease and dementia \u2014 not just for diabetics, but for everyone.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes that this is an old drug for diabetes that is receiving renewed interest for use in other disorders. It doesn\u2019t overstate the claim to novelty.", "answer": 1}, {"article": "\u201cIf we had a simple blood test, a cholesterol test for Alzheimer\u2019s disease, that would help,\u201d says Dr. Ronald Petersen, director of the Alzheimer\u2019s Disease Research Center at the Mayo Clinic, \u201cbut we don\u2019t.\u201d But Petersen has a potential solution, and according to a new paper released Wednesday in the journal , his Alzheimer\u2019s test has promise.\n\u201cWe have either expensive techniques or invasive techniques and it\u2019s not practical to do them from a public health screening standpoint,\u201d says Petersen.\n\u201cWhat we are trying to do is give them some help so they can be as efficient as possible without ignoring these important cognitive issues,\u201d he says.\nThat would look for known genetic factors linked to Alzheimer\u2019s, including the presence of certain versions of the ApoE gene.\nBut those who scored higher on the test of risk factors had a seven-fold higher chance of developing mild cognitive impairment than those with lower scores.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that the elements used in the rating scale have not been combined in this way previously and that the test overall is new", "answer": 1}, {"article": "\u201cYou can say, \u2018O.K., let\u2019s dismiss the observational studies because they have all these problems.\u2019 \u201d But, he said, despite the virtues of a randomized controlled clinical trial, such a study \u201cwill never ever be done.\u201d It would be impossible to keep people on a low-sodium diet for years with so much sodium added to prepared foods.\nDr. Alderman said that he once was an unpaid consultant for the Salt Institute but that he now did no consulting for it or for the food industry and did not receive any support or take any money from industry groups.\nBut that study, others say, will never happen.\n\u201cIt\u2019s a problematic study,\u201d Dr. Sacks said.\nDr. Briss adds that it would not be prudent to defer public health actions while researchers wait for results of a clinical trial that might not even be feasible.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 1}, {"article": "PAE reduced the symptoms of frequency and urgency of urination without causing side effects like incontinence, sexual dysfunction, retrograde ejaculation (ejaculation into the bladder), or bleeding.\n\u201cWe don\u2019t know how well these particles are localized to the prostate or if they\u2019re going to the pelvis or other parts of the body.\u201d\n\nMalizia notes that in one serious complication reported in the study, the particles appeared to migrate and kill a small part of the bladder wall.\n\u201cThe results are excellent.\u201d\n\nIn a small pilot study, most men were able to leave the hospital four to eight hours after the procedure, which is called prostatic artery embolization (PAE), researchers report.\nWe really don\u2019t know what the short- and long-term success or complication rates are,\u201d says Anthony Malizia Jr., MD, president and director of the Malizia Clinic, a nonprofit urology specialty center in Atlanta.\nIt\u2019s the same kind of growth,\u201d says study researcher Joao Martins Pisco, MD, chief radiologist at Hospital Pulido Valente and director of interventional radiology at St. Louis Hospital, both in Lisbon, Portugal.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story seem to suggest that the procedure reported on was repurposed from the field of Ob/gyn where it is used for managing uterine fibroids. \u00a0If this is the case, then it might have been of interest to report on what side effects, if any, are common.\nNonetheless, we\u2019ll give the story the benefit of the doubt on this criterion, since it didn\u2019t establish this approach as totally new.", "answer": 1}, {"article": "LONDON (Reuters) - An \u201celectronic nose\u201d could be used as a simple breath test to detect lung, breast, bowel and prostate cancers, Israeli scientists said Wednesday.\n\u201cIf we can confirm these initial results in large-scale studies, this new technology could become a simple tool for early diagnosis of cancer along with imaging,\u201d said Abraham Kuten of Technion Israel Institute of Technology.\nWhile more work is needed to develop the technology, the early success could lead to the development of a cheap, easy-to-use and portable test to help diagnose cancer earlier.\nUsing the sensor to pinpoint chemical variations, the team found they could not only distinguish between healthy and malignant breath but also identify the four different common tumor types.\nTheir findings, published in the British Journal of Cancer, build on earlier research published by scientists at the same institute last year showing that a sensor made with gold nanoparticles could detect lung cancer in breath.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "On the plus side, it tells us that the study builds on earlier research from last year, and we give it the benefit of the doubt. On the minus, the story is vague about the novelty of breath testing for cancer, which was not a new approach invented by this group in even its last study.\u00a0\n\u00a0", "answer": 1}, {"article": "The other new drug, ipilimumab (pronounced ip-ee-LIM-yoo-mab), when combined with dacarbazine, extended median survival to 11.2 months compared with 9.1 months for those who received dacarbazine alone.\nDoctors are eager to try the two drugs together.\nIn the latest trial, a big one was liver damage.\nBecause of that, researchers do not yet know the median survival.\n\u201cIf it weren\u2019t for the trial I wouldn\u2019t be here,\u201d she said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of both drugs was well explained.", "answer": 1}, {"article": "Jan. 13, 2010 (Coronado, Calif.) -- A blood test under study to help diagnose lung cancer looks promising, researchers reported Tuesday at a cancer meeting in California.\nHe is the senior author on the study, presented at the American Association for Cancer Research-International Association for the Study of Lung Cancer's joint conference in Coronado, Calif.\n\nAbout 219,000 new cases of lung cancer were expected to be diagnosed in the U.S. in 2009, according to the American Cancer Society, and about 159,000 deaths were expected.\nAccording to Dubinett, about one in 500 chest X-rays shows a lung nodule of ''indeterminant significance.\"\nIf perfected, the test could help spare patients the need to undergo invasive procedures such as biopsies when lung cancer is suspected, they predict.\n''Currently, 20% to 25% of surgeries done for suspected lung cancer turn out to be benign diagnoses,\" says Steven Dubinett, MD, professor of medicine and pathology and director of the Lung Cancer Research Program at the Jonsson Comprehensive Cancer Center at the David Geffen School of Medicine, University of California, Los Angeles.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story suggests that there is no clinically useful blood test to diagnose lung cancer currently available, and it implies the novelty of this test when it states that it builds on previous research. It also mentions that several other investigators are currently looking into blood tests for early-stage lung cancer.", "answer": 1}, {"article": "The study is published in the journal BMJ.\nThe researchers also computed whether it would be cost-effective to spend money on a public education campaign about dark chocolate's benefits.\nReid and his team constructed a mathematical model to predict the long-term health effects of eating dark chocolate daily in high-risk people.\nSeveral studies have found that dark chocolate, with its heart-healthy flavonols, can lower blood pressure and improve cholesterol.\nThey did not study actual people eating actual chocolate.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explained that the study was an evaluation of \u201cstudies already published\u201d and that the researcher believed \u201ctheirs is the first study to model the long-term effects of eating dark chocolate in reducing cardiovascular risk.\u201d", "answer": 1}, {"article": "Allergan Inc. said that two large human tests of its Botox drug, best known for smoothing wrinkles, showed that periodic injections prevent headaches in adults who suffer from chronic migraines.\n\nEven though details of the study weren't released, the announcement, which surprised many physicians and investors, sent Allergan's shares soaring 11%, or $5.95, to $60.53 at 4 p.m. in New York Stock Exchange composite trading. Botox has been used to treat severe headaches for many years, but some researchers have long been skeptical...", "question": "Does the story establish the true novelty of the approach?", "explanation": "Clearly Botox is not\u00a0a new idea, but it is not approved to treat chronic\u00a0migraines.", "answer": 1}, {"article": "A surgically implanted electrical device that stimulates the sacral nerve can calm an overactive bladder, according to a company that sells it. Physicians say sacral neural stimulation works well for many patients, but a test period with an external device is recommended first.\n\nMillions of Americans suffer from \"urge incontinence,\" accidents caused by a strong, sudden need to get to the bathroom, or overly frequent urination, defined as eight or more times a day. Quality of life is affected, as sufferers must...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story accurately represents the novelty of the device.", "answer": 1}, {"article": "You should go through six to eight weeks of conservative management.\u2019 \u201d\n\nAt the Partners Healthcare System in Boston, spine experts have the same struggle to convince patients that an M.R.I.\nBut in many cases it is just not known whether what is seen on a scan is the cause of the pain.\nBut even the data on knees comes from just one study, and researchers say the problem is far from fixed.\nSixty percent had herniated disks, the scans showed.\nThey tended to occur along with arthritis and were a part of the disease process itself.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Clearly scanning is not a new idea, but it is being increasingly used earlier in the diagnostic process.", "answer": 1}, {"article": "WASHINGTON -- A new study shows patients taking the anticlotting drug Plavix along with a type of drug used to block stomach acid have an increased risk of a subsequent hospitalization for heart trouble.\n\nThe study, which is being published in this week's Journal of the American Medical Association, adds to other recent studies that suggest proton pump inhibitors like Aciphex, Nexium, Prevacid and Protonix reduce the effectiveness of Plavix, which is marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis SA.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Given that the data presented were generated from patients discharged between 2003 and 2006, the story made clear that these medications have been given in combination for a while.", "answer": 1}, {"article": "For now, much of the attention in the world of liver disease is on two drugs -- telaprevir and boceprevir -- that Schiff expects will become available within the next year and a half.\nThe study, published online April 21 in Nature, examines an experimental drug designed to combat the hepatitis C virus.\nThe disease, transmitted through infected blood, can lead to liver cancer, scarring of the liver, known as cirrhosis, and death.\nExisting treatments can cure about half of the cases.\nThe drugs now under development, like the one in the new study, could be added to the regimen, he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that there are other drugs\u00a0like BMS-790052 currently in development for\u00a0hepatitis C. \u00a0", "answer": 1}, {"article": "And Medicare has established a registry to see how well large-scale screening works.\nThe post-surgical death rate in the national trial was just 1 percent, but that involved major medical centers with specialized radiologists and surgeons \u2014 the ideal setting.\nResearchers call it \u201ccompeting mortality.\u201d Finding lung cancer is a hollow victory if patients endure testing and treatment, then die of another illness before the cancer would have killed them.\nIn fact, if screening finds cancer, some seniors won\u2019t withstand the surgery, usually a lobectomy, that may cure it.\nSo those required \u201cshared decision-making visits\u201d with doctors will involve lots of very individual questions and judgments.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that low-dose CT scans are now in use. What is novel here \u00a0is a recent decision by Medicare to cover the cost of such scans for current or former heavy smokers who meet specific criteria.", "answer": 1}, {"article": "Despite the fact that there have been no randomized controlled trials on whether metformin really can prevent cancer, researchers expressed excitement both over this animal study and previous epidemiological evidence pointing to this possibility.\nIn the September issue of Cancer Prevention Research, researchers report that metformin was associated with a substantial reduction (up to 73 percent) in the number of tumors mice developed when they were given a common carcinogen found in tobacco.\n\"Almost every epidemiological study I can think of found a decreased cancer incidence in diabetics taking metformin.\nIt's also possible, however, that metformin is working more directly on the tumor process, the researchers said.\nOthers believed that the finding might influence the choice of drugs in people with diabetes.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story gives at least a brief overview of past research \u2013 including evidence of impact of metformin diabetic people. ", "answer": 1}, {"article": "D'Amico, chief of the Department of Plastic Surgery at Englewood Hospital and Medical Center in Englewood, N.J.\nWhile the surgical techniques used in contouring operations have been around for decades, bariatric patients present \"a unique challenge\" to plastic surgeons, says D'Amico.\nThere are no guidelines requiring bariatric surgeons to warn their patients, although recently professional societies of plastic surgeons and bariatric surgeons have begun holding seminars to discuss the idea.\nBut there's a catch often not understood by those who undergo the procedure: Once they lose the weight the surgery helps them lose, there may be more surgery to come -- surgery that is costlier and riskier and that requires a longer recovery time than the original operation.\nThe cost of contouring can run into the tens of thousands of dollars, depending on how many procedures are needed.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article states that surgery to remove excess skin \u201cis still relatively new\u201d. While the numbers of people who may seek removal of hanging skin following weight loss surgery is undoubtedly increasing, plastic surgery to remove excess skin and for recontouring is actually not new. The fact that there are few studies of complication rates may relate more to the individualized nature of the procedures than to their novelty.", "answer": 0}, {"article": "He said: \u201cBlood tests for cancer promise to be truly revolutionary.\n\u201cNot only could the test have a major impact on treatment of prostate cancer, but it could also be adapted to open up the possibility of precision medicine to patients with other types of cancer as well.\u201d\n\nBy testing cancer DNA in the bloodstream, the researchers found they could pick out which men with advanced prostate cancer were likely to benefit from treatment with the drug.\nThey are cheap and simple to use, but most importantly, because they aren\u2019t invasive, they can be employed or applied to routinely monitor patients to spot early if treatment is failing \u2013 offering patients the best chance of surviving their disease.\u201d\n\nThe research was funded by the Prostate Cancer Foundation, Prostate Cancer UK, Movember, Cancer Research UK and the National Institute for Health Research.\nProf Johann de Bono, Regius professor of cancer research at the ICR, and consultant medical oncologist at the Royal Marsden NHS foundation trust, said: \u201cOur study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaparib.\nThe ICR chief executive, Prof Paul Workman, said the test could \u201cusher in a new era of precision medicine for prostate cancer\u201d.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article makes clear that this is a new test for circulating DNA that provides specific information about a cancer patient\u2019s individualized cancer profile. However, the only people to say so are the researchers testing the liquid biopsy. This claim would carry more weight if it came from an independent source.", "answer": 1}, {"article": "Those who received fluorouracil and folinic acid chemotherapy had lived an average of 23 months.\nThe finding, reported in the Sept. 8 issue of the Journal of the American Medical Association, stems from work conducted by Dr. John P. Neoptolemos, of the Cancer Research U.K. Liverpool Cancer Trials Unit at the University of Liverpool in England, and colleagues.\nThe pool of nearly 1,100 patients that the researchers focused on were part of the large European Study Group for Pancreatic Cancer trial that took place across 159 pancreatic cancer centers located in Europe, Canada, Australasia and Japan.\n\"So this is not a revolutionary finding, but it's part of an effort to look at what we have and even to find newer regimens with more combinations of drugs,\" he noted.\n\"But the point is that pancreatic cancer is a terrible disease, and really just a minority of patients are candidates for surgery.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We would have liked to see more context about why did they\u00a0select these\u00a0two regimens. Was gemcitabine a new or uNPRoven agent, as it is somewhat positioned in the story?\u00a0(Gemcitabine is currently available and is accepted as the standard of care.)\u00a0What was known about it before? It sounds like we\u2019re asking a lot for a brief article, but we really want to know, perhaps in\u00a0one sentence, why the study was done, in part to help us understand what the study adds to our understanding of how to treat pancreatic cancer.\nAlso, the story does not make it clear which of the two regimens performed better? The way the authors of the editorial\u00a0interpreted the results is at odds with the tone of the story, underscoring why more outside voices could have helped make this story stronger.", "answer": 0}, {"article": "A popular new type of prenatal test intended to find genetic flaws in a fetus can in rare cases also reveal previously undiagnosed cancer in the mother.\n\nThe unexpected finding emerged in a study involving eight women who initially had abnormal results from the prenatal blood test, but for whom a subsequent assessment showed their babies were normal. When the mothers\u2019 DNA was reanalyzed, researchers said, the anomalies were linked to cancer in each of the women.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story points out that the findings are new and serendipitous, then ties them in\u00a0nicely to the broader issue of maternal and fetal DNA testing and the serious debate about testing\u2019s\u00a0\u00a0benefits and potential harms.", "answer": 1}, {"article": "This story has been updated with additional information.\nThe early results are \u201cpromising and exciting,\u201d said Dr. Allison Baker, a psychiatrist at Massachusetts General Hospital\u2019s Center for Women\u2019s Mental Health, but \u201cwe need to see replication of this data over a much wider range in terms of numbers.\u201d\n\nThe study is small and has not been peer-reviewed; Sage disclosed the results in a press release.\nIn cases of severe depression, that equilibrium gets out of whack, and Sage\u2019s drug is meant to restore it, modulating those GABA receptors to allow NMDA to do its job.\nThe data could represent a \u201cparadigm shift in how the disease is thought about,\u201d CEO Jeff Jonas said in a conference call.\nThe drug has a \u201cvery, very short half-life\u201d in the body, Jonas said, meaning that it can be metabolized quickly.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not mention other GABA-receptor drugs in development. Indeed, it includes a quote from the company CEO calling the study data a \u201cparadigm shift in how the disease is thought about,\u201d thus giving the incorrect impression that this drug is the only one like it being studied.", "answer": 0}, {"article": "Elizabeth Williams, from the School of Biomedical Sciences at Queensland University of Technology, tells Newsweek the two studies \u201cdescribe tantalizing complementary and consistent results in Phase 1 trials in melanoma patients using vaccines.\"\nWhile they are very small scale\u2014one was on six participants, the other 13\u2014the findings mean researchers can move ahead with the vaccines, which could potentially lead to new, more effective cancer treatments.\nAdditional clinical trials will be required to determine the utility of these individualised neoepitope vaccines.\u201d\n\nCatherine Pickworth, science communication officer at Cancer Research UK said: \u201cThe promising results from these two small, early-stage studies show that personalized cancer vaccines designed to treat skin cancer are safe to use, and that for some patients, they can successfully harness the power of the body\u2019s own immune system to kill cancer cells.\n\u201cThe data shows that it is a safe and well tolerated strategy that stimulates relevant anti-tumor immune responses.\u201d\n\nHowever, the treatment has its downsides: \u201cAs the vaccine therapies are designed and generated specifically for each individual there is a lag time from enrollment to commencement of treatment\u2014approximately four months\u2014which may be too long from some patients with advanced cancer.\nBut working out the unique mutations of each person\u2019s cancer, a time-consuming and complicated process, must first be identified before a vaccine can be developed for them.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article discusses what is and isn\u2019t new about the research\u00a0in this section: \u201cCancer vaccines that are personalized to the patient\u2014designed to\u00a0help the immune system identify tumors as foreign bodies and destroy them\u2014have been considered as a potential treatment for a number of years. But working out the unique mutations of each person\u2019s cancer, a time-consuming and complicated process, must first be identified before a vaccine can be developed for them.\u201d", "answer": 1}, {"article": "A new study confirms that long-acting forms of contraception such as intrauterine devices and implants are better than birth control pills and patches at preventing pregnancies, giving doctors new ammunition to recommend these methods.\n\nThe study, to be published Thursday in the New England Journal of Medicine, involved about 7,500 women in a project promoting long-acting birth control to reduce unintended pregnancies. There are an estimated three million unplanned pregnancies a year in the U.S., often because of incorrect or...", "question": "Does the story establish the true novelty of the approach?", "explanation": "Older studies have looked retrospectively at the effectiveness of different contraceptive methods, but this study provides a prospective look at how well\u00a0they\u00a0work in the real world, among typical users.\u00a0The novelty is that this study was prospective, allowing\u00a0more reliable\u00a0measurement of outcomes such as pregnancy, and that it involved a large, diverse population of U.S. women.\u00a0 The story appropriately referred to the confirmatory nature of the study and how it gives doctors \u201cnew ammunition to recommend these (long-lasting) methods.\u201d", "answer": 1}, {"article": "The agency, he added, remains concerned about \u201cthe proliferation and illegal marketing of unapproved CBD-containing products with unproven medical claims.\u201d\n\nIn April, an advisory committee unanimously recommended approval of the drug for the two types of epilepsy.\nThe FDA previously cleared medications containing synthetic versions of THC for nausea for patients getting chemotherapy and for other uses, but it had not approved any drug derived from the plant itself.\nThe drug contains only trace amounts of the psychoactive element THC and does not induce euphoria.\nThe Food and Drug Administration on Monday approved the first drug derived from marijuana, which will be used to treat two rare and severe forms of childhood epilepsy.\nThe drug is the first treatment approved for Dravet syndrome.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article makes clear that this is a \u201cmilestone\u201d FDA approval and in what way.", "answer": 1}, {"article": "Twenty-seven percent in the intervention group experienced depression compared with 41 percent in the control group.\nSimilar programs have been used to treat depression, but this may be the first one tested to prevent it, the researchers say.\nFor the problem-solving therapy, people were asked to create a list of the things that matter most to them in their lives and brainstorm on how to incorporate those things into daily life.\nIt took the trainers about 30 minutes to provide feedback for each session, and they also stayed in touch with participants via instant messaging, Buntrock says.\nIn this experiment, half of the participants were asked to do six half-hour-long exercises that were based on cognitive behavioral therapy and problem-solving therapy, which are techniques commonly used for in-person therapy.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes this early on, noting that \u201cSimilar programs have been used to treat depression, but this may be the first one tested to prevent it.\u201d", "answer": 1}, {"article": "\"It's intriguing [that the finding applied to] just ibuprofen and not aspirin or acetaminophen or other commonly prescribed medications for inflammation because it implies something more specific to ibuprofen that should be investigated,\" Tagliati said.\nThe findings came from an analysis of data on 136,474 people who did not have Parkinson's at the start of the study.\nThe exact cause is unknown, but experts believe it's a combination of genetic and environmental factors.\nIt affects an estimated 1 million people in the United States, men far more often than women.\n\"There is thus a need for better preventive interventions,\" Gao said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story failed to put the new analysis into the context of existing research, as MedPageToday.com did, for example:\u00a0", "answer": 0}, {"article": "For more information visit http://www.\nThe trial, called TOPARP-A, received support from a wide range of funders including Cancer Research UK, the Prostate Cancer Foundation, Stand Up To Cancer, Prostate Cancer UK and the Movember Foundation.\nTrial chief investigator Professor Johann de Bono, Head of Drug Development at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, said:\n\n\"Our trial marks a significant step forward in the treatment of prostate cancer, showing that olaparib is highly effective at treating men with DNA repair defects in their tumours.\nThe results have led on to the start of TOPARP-B, a second part of this trial in which only men whose prostate cancers have detectable DNA repair mutations will receive olaparib.\nIt also proves the principle that we can detect prostate cancers with specific targetable mutations using genomic sequencing to deliver more precise cancer care by matching treatment to those men most likely to benefit.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that this is the \u201cFirst trial to show benefit of \u2018precision medicine\u2019 in prostate cancer.\u201d We suspect that this kind of prostate cancer mutation-specific targeting is novel for prostate cancer. It isn\u2019t in the field of oncology in general, however.", "answer": 1}, {"article": "But it is increasingly clear that DTI can also be used to identify very small structural changes in the gray matter of the brain, which is critical for learning and memory, researcher Giovanni A. Carlesimo, MD, PhD, of Italy's Tor Vergata University tells WebMD.\n\"This might help doctors when trying to differentiate between normal aging and diseases like Alzheimer's.\"\n\"This type of brain scan appears to be a better way to measure how healthy the brain is in people who are experiencing memory loss,\" Carlesimo says in a news release.\nIn a study published in the Jan. 19 issue of Neurology, Carlesimo and colleagues found that DTI scanning predicted declines in memory performance with more accuracy than traditional MRI.\nThe technique, known as diffusion tensor imaging (DTI) or diffusion MRI, is used to assess changes in the white matter regions of the brain.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0While the story reported on a most recent study using DTI technology for assessment of Alzheimer\u2019s disease, there is medical literature on this dating back several years, a context the story didn\u2019t provide. ", "answer": 0}, {"article": "Broccoli has been linked to a growing list of health benefits, such as a reduced risk of cancer and osteoporosis. New research suggests consuming broccoli could also slow or reverse blood-vessel damage and atherosclerosis due to high cholesterol.\n\nThe study, in Experimental Biology and Medicine, found that a high-cholesterol diet combined with supplements containing sulforaphane, a natural compound in cruciferous vegetables such as broccoli and Brussels sprouts, significantly reduced levels of LDL, the so-called bad cholesterol,...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The text asserts that this study of sulforaphane\u2019s effects on atherosclerosis is the first to examine that link.", "answer": 1}, {"article": "Dr. Jae Jung, a dermatologist at City of Hope cancer center in Duarte, California, agreed.\n\"If you can reduce the new skin cancer rates for these patients, it would be an enormous benefit,\" she told CBS News.\nNearly 5 million people are treated for skin cancer in the U.S. each year, and the Skin Cancer Foundation says 1 out of 5 Americans will develop skin cancer in their lifetime.\n(Another popular form of Vitamin B3 called niacin was not used in this study.)\nOne patient who could benefit from the vitamin treatment is Charity Wiese, who has been diagnosed with skin cancer more than two dozen times in the last five years.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There\u2019s no explicit acknowledgment of the novelty of the research or where the research fits within the large body of studies that have looked at vitamins for cancer prevention.", "answer": 0}, {"article": "Scheduled biopsies were performed two and four years after they entered the trial.\n\"We now have two studies showing that two different drugs in this category can reduce the overall risk of prostate cancer,\" American Cancer Society Director of Prostate and Colorectal Cancers Durado Brooks, MD, tells WebMD.\nWhile the studies suggest a role for Avodart and Proscar in the prevention of prostate cancer, experts tell WebMD that important questions remain about using the drugs for this purpose.\nStudy researcher Gerald L. Andriole, MD, says a significant proportion of men screened for prostate cancer fall into this clinically ambiguous category of having elevated PSAs and negative biopsies.\nIn a trial involving more than 8,000 men from 42 countries, those who took the drug Avodart had a 23% lower risk of being diagnosed with prostate cancer over four years of treatment, compared to men who did not take the drug.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Clearly, Avodart is not a new drug, however, the idea that it could be used to prevent prostate cancer is relatively new.", "answer": 1}, {"article": ".\nEverybody now has a donor, and that is a major advance.\u201d\n\nYet doctors and patients may not be aware there are choices other than conventional bone-marrow transplants, Jones said.\nIt\u2019s an indescribable feeling.\u201d\n\nIn haploidential transplants, rather than wiping out the patient\u2019s immune system, doctors use just enough drugs to suppress it.\n\u201cHe decided he would be focused on being the patient and said, \u2018Do whatever you have to do with me because I want to walk my girls [who were then 12 and 16] down the aisle.\u2019 \u201d\n\nOn advice of their hematologist, the Gordons traveled to Hutchinson, which has established a national reputation as a bone-marrow transplant center, but quickly discovered there was no good donor match.\n\u201cThere are still lots of patients in need of transplants that are not getting them because of lack of matched donors, and that is unacceptable in the year 2016.\u201d\n\nJones estimates that about 7,500 transplants of donated stem cells were done in 2014 \u2014 primarily for leukemia and lymphoma but also for nonmalignant blood disorders such as sickle cell and aplastic anemia \u2014 but that more than 15,000 could easily be done annually if more doctors embraced the new methods now available.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There is a very bold statement of novelty in the piece that is not backed up by evidence or independent sources.\n\u201cThis expanded cord-blood technique has been a \u2018huge home run\u2019 for patients,\u201d said Colleen Delaney of the Fred Hutchinson Cancer Research Center in Seattle, who helped create it.\u201d\n\u201c\u2018No one had successfully taken stem cells and gotten them to grow and put back in a person,\u2019 she said. The advance should be particularly valuable for minorities and people of mixed-race background, whose chances of finding a matched donor were slim to none.\u201d", "answer": 0}, {"article": "They then measured concentrations of a hormone called the anti-Mullerian Hormone (AMH) that is produced by cells in women\u2019s ovaries.\nThe researchers took two more blood samples at three yearly intervals and also collected information on the women\u2019s socioeconomic background and reproductive history.\nThe average age for menopause is 51, with ovulation in most women ending sometime between age 40 and 60.\n\u201cWe developed a statistical model for estimating the age at menopause from a single measurement of AMH concentration,\u201d Tehrani explained in a report on the study.\n\u201cThe possibility of an accurate predictor for menopause is very exciting.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not say whether the AMH test is new or not. In fact, it is not new and is one of group of tests that are intended to evaluate ovarian reserve.", "answer": 0}, {"article": "Overall, this is very exciting.\u201d\nThese promise that patients could become more independent.\u201d\n\nWhen healthy, retinal cells transmit visual information to the brain.\nThe new prosthesis is designed to be implanted onto the back wall of the eye, where it absorbs light and transforms it into an electrical signal that stimulates the still-active retinal cells to restore vision.\nThe researchers were unable to determine how well the rats were able to see, if at all, but they noted that the animals\u2019 eyes continued to react to light more than six months after the implant was installed.\nNeither of the implants is able to restore color to vision yet, and Bharti has questions about the durability of organic eye implants.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The\u00a0story distinguishes the new devices from a\u00a0current version by describing the external camera required by the FDA-approved artificial retina. These experimental devices are designed to stimulate still-functioning retinal neurons in the diseased eye.", "answer": 1}, {"article": "Incidence of hypercalcemia (the presence of abnormally high levels of calcium in the blood) was lower with abaloparatide (3.4 percent) vs teriparatide (6.4 percent).\nAs a result of its mechanism of action, it has been hypothesized that the drug abaloparatide, a synthetic peptide, would have a more pronounced anabolic (i.e., bone growing) action on bone compared with the osteoporosis drug teriparatide.\n\u201cFurther research is needed to understand the clinical importance of risk difference, the risks and benefits of abaloparatide treatment, and the efficacy of abaloparatide vs other osteoporosis treatments,\u201d the authors write.\nThe way forward for fracture prevention involves not only the development of better therapies to prevent fracture and easier delivery systems but also improved adoption of existing osteoporosis therapies for patients with prior fractures and minimization of adverse effects, particularly those associated with long-term use.\u201d\n\n: Both authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.\nIt has been estimated that the lifetime risk of osteoporotic fracture for a 60-year-old woman is 44 percent.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does not make the novelty of the findings clear. In the second paragraph, the piece discusses how this medicine works and that the study is comparing a new medicine with one already available. But what isn\u2019t stated is why we need a new medicine. Isn\u2019t the existing one good enough?", "answer": 0}, {"article": "Future studies aim to examine how the algorithm affects long-term outcomes and clinical benefits in patients at high risk for dislocation.\nA corresponding Scientific Exhibit, by lead author Nima Eftekhary, MD, an orthopedic surgery resident, and senior author Vigdorchik, called, \"The Spinopelvic Relationship: A Stepwise Approach to Ensuring Stability in High-Risk Dislocation Patients Undergoing Total Hip Arthroplasty\" also was selected by the AAOS Central Program Committee as one of the three Best Scientific Exhibits at the 2018 AAOS Annual Meeting.\nThis poster, \"A New Risk-Assessment Score and Treatment Algorithm for Patients at High Risk of Dislocation following Total Hip Arthroplasty,\" was selected by the AAOS Central Program Committee as the Best Poster in the Adult Reconstruction Hip classification at the 2018 AAOS Annual Meeting.\nA novel risk assessment tool helps identify which patients undergoing total hip replacement may be at higher risk for an implant dislocation after surgery, according to a new study from researchers at NYU Langone Health and described in the Best Poster in the Adult Reconstruction Hip at the American Academy of Orthopaedic Surgeons (AAOS) 2018 Annual Meeting in New Orleans.\nHowever, no guidelines currently exist to aid clinicians in deciding when to use these more flexible implants, which are often more expensive than conventional implants, may not be medically necessary, and may carry added risks if implanted unnecessarily.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release clarifies the problem this new assessment tool is trying to solve and why it\u2019s worth reading about:\nSome newer hip implants are designed with dual mobility cups that allow for increased range of motion, which helps reduce dislocation risk. However, no guidelines currently exist to aid clinicians in deciding when to use these more flexible implants, which are often more expensive than conventional implants, may not be medically necessary, and may carry added risks if implanted unnecessarily.", "answer": 1}, {"article": "DURHAM, N.C. - Most high-risk lung cancer patients might not need annual low-dose computed tomography (LDCT) screenings if they are cleared of disease in their initial test, according to a study led by a Duke Cancer Institute researcher.\nAn additional 75 patients (0.4 percent of the initial negative group) were diagnosed with lung cancer between the first and second annual screening.\nThe researchers identified study participants in the CT-scan group whose initial screening was negative.\nThe researchers found that even former heavy smokers appear to have a reduced incidence of lung cancer if their initial LDCT screening is negative, suggesting that less frequent screening might be warranted.\nPatients were ages 55-74 who had smoked for the equivalent of 30 years (one pack a day for 30 years, two packs a day for 15 years, etc.).\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There were no misleading statements of novelty of the CT screening, just novelty of interval which were appropriate.", "answer": 1}, {"article": "The volunteers drank a 10-ounce glass of cherry-flavored liquid that contained two and a half ounces of fructose or glucose.\nBut it also sends a signal to the brain that says \u2018you\u2019ve eaten.\u2019 Fructose doesn\u2019t stimulate insulin secretion, and if there\u2019s no insulin, you don\u2019t get the information that you\u2019re full.\u201d\n\nDoes this mean that it is a good idea to avoid fruit, because it contains fructose?\nAnd it is packed with fiber, which helps slow down the absorption of food, which makes you feel full.\u201d\n\n\n\n For more fitness, food and wellness news, \u201clike\u201d our Facebook page.\nThe study, published in the journal PNAS, found that compared with glucose, consuming fructose produced greater responses to food cues in the orbital frontal cortex of the brain, a region that plays an important role in reward processing.\nBefore having their drinks, the participants rated their desire to eat on a one-to-10 scale from \u201cnot at all\u201d to \u201cvery much.\u201d Then they drank the liquids and had functional magnetic resonance imaging brain scans while looking at images of food and of neutral objects like buildings or baskets.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not address how this fits into the context of previous work that examines sugars, diet and food cravings or behavior. Is it consistent with earlier findings? Is this the first time anyone has asked this specific question? How does it differ from previous work? The story doesn\u2019t tell us.", "answer": 0}, {"article": "Nadworny, who now works as a public policy advocate for people with disabilities, had knee replacement surgery last April.\n\u201cThe person who struggles is the one who\u2019s done long-distance running for years and just doesn\u2019t want to give it up.\u201d\n\nTechnology could eventually change that.\nSo I said, \u2018OK, let\u2019s get this done.\u2019 \u201d\n\nSmith, who played hockey in college and as an adult and spent years lifting heavy equipment on building sites, plans to return to his job this spring.\nLast year, the average salary for joint-replacement specialists topped $575,000, reported the Dallas consulting firm Merritt Hawkins & Associates, compared with just over $230,000 for family doctors.\nBecause of improvements in materials and the way they\u2019re treated and sterilized, implants \u2014 which include polyethylene and titanium alloys \u2014 don\u2019t wear down as fast as they once did.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story said \u201cjoint implants have become more customized to suit individual patients, but a Billerica company is pushing the personalization trend further. ConforMIS Inc. uses 3-D printing and imaging software to more precisely tailor replacement joints.\u201d\nThis seems to be a new trend although we weren\u2019t able to find any independent research about whether customization leads to better for patients.", "answer": 1}, {"article": "As a nicotine-gum addict, Mike Metzger used to worry about the warning on its label: \"Stop using the nicotine gum at the end of 12 weeks.\"\n\nBut that was before a prominent smoking-cessation scientist, K. Michael Cummings, told him to keep chewing the gum as long as it helped him stay off cigarettes. So 15 years after quitting smoking, Mr. Metzger, a 63-year old retired New York telephone worker, still chews 16 pieces of nicotine gum a day.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a good job establishing what\u2019s truly novel here \u2013 \u201cPublic health officials are backing away from recommending against the long-term use of nicotine gum, lozenges and patches. The Food and Drug Administration is considering whether to eliminate the 12-week warning and instead recommend nicotine-based quit-smoking aids for extended\u2014perhaps even permanent\u2014use.\u201d", "answer": 1}, {"article": "\u201c[PRP] works, and the results have been amazing,\u2019\u2019 says John Ferrell, the sports medicine physician who treated me.\nIt showed tissue healing in five of seven of the patients who received PRP, as well as improvements in their pain and function.\n\u201cI\u2019ve heard some skeptics call PRP a cure looking for a disease, but it is being used in so many areas of medicine now with promising outcomes,\u201d says Marni Wesner, a sports medicine physician at the clinic and one of the study\u2019s authors.\nThose who seek this treatment must look for a clinician with considerable PRP experience \u2014 someone who does the procedure several times a day, not once or twice a month \u2014 and who has a good success rate, Ferrell says.\nThe centrifuges already are licensed, and the procedure uses a patient\u2019s own blood, which is regarded as safe.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not make it clear that\u00a0PRP is not a new treatment, and that has been studied for many years now, including in rotator cuff tears.", "answer": 0}, {"article": "With a cure rate approaching 90 percent, acute lymphoblastic leukemia (ALL) - the most common type of childhood cancer - is often hailed as one of the \"success stories\" of modern cancer treatment.\nThe investigators found that patients in either arm responded very well overall to treatments, but those in the high dose group had a significantly better outcome, by 5 to 6 percent, which translated into a significantly decreased relapse rate for these patients.\nDuring this clinical trial, the investigators decreased the duration of decadron from 28 days to 14 to determine if patients could avoid the side effect of increased infection while still benefiting from the steroid's anti-leukemic effects.\nThat could change with the results from a clinical trial co-led by investigators from NYU Langone Medical Center, which shows giving high doses of a commonly-used chemotherapy drug increases the survival rate for these patients.\nThe high-dose methotrexate protocol outlined in the study - along with a parallel finding that the steroid decadron is beneficial for younger (but not older) patients - has quickly become the standard practice for the treatment of high-risk ALL patients in North America, the researchers report in the April XX issue of the Journal of Clinical Oncology.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release suggests the study findings could change the way childhood leukemia is treated. Modifying existing treatments to enhance a patient\u2019s survival is certainly novel enough to warrant a release.", "answer": 1}, {"article": "The drug is approved for metastatic melanoma patients who show no response to other treatments and for advanced squamous non-small cell lung cancer (NSCLC) with progression on or after chemotherapy.\nWe have a real opportunity to change clinical practice for patients when other therapies have failed,\" said principal investigator Padmanee Sharma, MD, PhD, professor, Departments of Genitourinary Medical Oncology and Immunology and scientific director of the Immunotherapy Platform, part of MD Anderson's Moon Shots Program.\nPublished online by the New England Journal of Medicine and being presented this week at a Presidential session of the European Cancer Congress (ECC), the findings of CheckMate-025 provide definitive evidence that an immune checkpoint inhibitor is a valid treatment strategy for patients with advanced RCC, and supports a paradigm change in the standard of care treatment, according to the authors.\n\"The overall survival benefit shown in this study sets a new benchmark for therapeutic strategies for advanced RCC patients in need of a second-line therapy.\"\nAmong these patients, partial responses were observed in 24% of those treated with nivolumab and 5% of patients treated with everolimus; complete responses were observed in 1% (four patients) treated with nivolumab and fewer than 1% (two patients) treated with everolimus.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release establishes novelty in the lead sentence: \u201cFor the first time, an immune checkpoint inhibitor has been proven to increase survival among patients with advanced renal cell carcinoma (RCC), a patient population for whom treatment options are currently limited.\u201d It also establishes that the drug \u201cis currently used to treat metastatic melanoma and advanced non-small cell lung cancer.\u201d", "answer": 1}, {"article": "The Ache: In the digital age, many people spend hours daily bent over computers, phones and tablets\u2014our necks craned forward. Some scientists say this unnatural position can lead to pain, headaches and other symptoms, sometimes collectively called \u201ctext neck.\u201d\n\nThe Claim: Technology itself comes to the rescue. An Android app called the Text Neck Indicator measures the angle of your phone and lets you know when you\u2019re holding it in a favorable viewing position. And a new wearable device, Alex, monitors the angle of your neck...", "question": "Does the story establish the true novelty of the approach?", "explanation": "There are a lot of devices out there that are designed to assess posture in general and, to varying degrees, neck posture. How is Alex different? The story doesn\u2019t make that clear. Similarly, there are a lot of apps out there that are focused on neck posture, such as HeadUp, Forward Head Posture, and Watch Your Neck. How do they differ from the Text Neck Indicator? The story doesn\u2019t tell us.", "answer": 0}, {"article": "But this could take a few years to develop.\n\"It will probably be helpful to someone who gets a low-level exposure [to glutens] by accident,\" he said.\nIf the researchers opt to make a prescription drug, the process of clinical trials and obtaining U.S. Food and Drug Administration approval could take a decade or more, he said.\nIt dismantled more than 95 percent of a gluten peptide that is thought to cause celiac disease, according to the study, which was published recently in the Journal of the American Chemical Society.\nIdeally, the team could develop the enzyme into a food additive such as the gas remedies Beano or Gas-X and offer it without a prescription, said lead study author Justin Siegel, assistant professor of chemistry and biochemistry at the University of California, Davis.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it sound like this is the only pill-type treatment that is currently being developed for celiac disease. In fact, at least one other pill is already in phase 2 human testing.", "answer": 0}, {"article": "Here's the scientific proof.\nHowever, the reanalysis regarding psychotic disorders contradicted the earlier conclusions -- that there indeed appeared to be a higher risk of psychotic disorders among marijuana users in the study versus non-users that approached statistical significance when using a more liberal test.\nOne major limitation of the study is that it ends when the men are in their 30s \"which may be too early for decrements in health to emerge,\" the authors acknowledge.\nUpdate: The study's findings generated significant controversy along with requests for supplemental analysis, according to the editors of the Psychology of Addictive Behaviors.\nWith the widespread availability of marijuana in recent years thanks to its legalization in a growing number of states, there has been increasing concern about the long-term health consequences on teens who might be able to get easier access to it illegally.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story suggests that the study highlighted was novel in that it did not find an association between marijuana use in adolescent and harms seen by other researchers. \u00a0However, the story did little to provide any context to the differences. \u00a0Since the intent of this criterion is to establish the true novelty of a finding,\u00a0we judge the story to be unsatisfactory.", "answer": 0}, {"article": "Sacco notes that both the AHA and the American Academy of Pediatrics now recommend cholesterol screening in children with risk factors for heart disease other than family history, such as obesity, high blood pressure and diabetes.\nBut because West Virginia has one of the nation's highest rates of death from heart disease, since 2000, the state has offered free, universal cholesterol screening to all fifth-graders enrolled in public schools.\n\"The weight of the child, his waist circumference and whether he has siblings who are overweight would help to select a group that is at greater risk of having high cholesterol,\" he says.\nBased on the results of the screen, doctors may then advise families to change their children's diet or exercise routines or prescribe medication to lower their cholesterol.\nFurther, Neal says, the findings apply not only to heart-disease risk but also to the risk of diabetes, since high cholesterol at a young age is a strong predictor of prediabetes and diabetes.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe novelty of cholesterol screening and treatment is not at issue here.", "answer": 2}, {"article": "For more information, visit http://www.\nThis new radionuclide drug shows strong binding to the protein PSMA and is readily and safely taken up by malignant PSMA-positive tumors.\nDiagnostic imaging was followed by a therapy-grade radionuclide, lutetium-177, which delivers a more powerful dose of radiation that penetrates and destroys the cells and tissues of tumors when combined with PSMA-617.\nThe current clinical methods are not sensitive enough for detecting disease beyond the prostate, but we are convinced that this novel theranostic radiotracer represents a significant step forward that could have a major impact on the future of prostate cancer care.\"\nResults of the human study showed that imaging was effective for the evaluation of metastatic prostate cancer, and subsequent therapy resulted in a drop in prostate-specific antigen levels from 38.0 to 4.6 nanograms per milliliter.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The story mentions that while this is not the first time a drug of this nature has been attempted, it is the first time that one has been developed that hopefully does not have serious side effects or other problems.", "answer": 1}, {"article": "(Reuters Health) - The experimental orphan drug teprotumumab significantly reduces the eye bulging associated with Graves\u2019 disease, according to results of a small trial.\nThe eyes don\u2019t have that bulging appearance, he said, and many of them return to the degree of bulging they had before they got the disease.\nThe typical treatment for Graves\u2019 eyes is glucocorticoids, which are not always effective and also have side effects, the study team notes.\nGraves\u2019 disease is the most common cause of overactive thyroid in the United States, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).\nAmong the 88 participants with moderate-to-severe disease who were given intravenous infusions of either teprotumumab or a dummy drug every three weeks for eight treatments, 43 percent who got the real drug had a reduction of at least 2 millimeters in eye protrusion by the sixth week compared to 4 percent in the placebo group.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There are other treatments for both Graves\u2019 disease and the eye bulging that often accompanies it and these range from medications to surgery.\u00a0 A medication that might provide relief from the condition without invasive efforts is certainly novel enough to warrant a story.", "answer": 1}, {"article": "MUSC operates a 750-bed medical center, which includes a nationally recognized Children's Hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), Hollings Cancer Center (a National Cancer Institute designated center) Level I Trauma Center, and Institute of Psychiatry.\nThis is because the accuracy of the device simplifies the decision made by emergency personnel about where to take patients first, according to Raymond D. Turner, M.D., professor of neurosurgery and chief of the Neuroscience Integrated Center of Clinical Excellence at MUSC.\nIt is also not clear how the device would work for patients with cranial implants, as metal interferes with the device's operating radio frequencies.\nEndovascular therapy within 24 hours is the standard of care for emergent large-vessel occlusion, but the chance of achieving a good outcome decreases by approximately 20 percent for each hour that passes before treatment.\nA new device worn like a visor can detect emergent large-vessel occlusion in patients with suspected stroke with 92 percent accuracy, report clinical investigators at the Medical University of South Carolina (MUSC), Mount Sinai, the University of Tennessee Health Sciences Center and elsewhere in an article published online on March 6, 2018, in the Journal of Neurointerventional Surgery.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The device itself is new technology so it earns a Satisfactory for the novelty claim.\nHowever, the idea of pre-hospital diagnosis is not novel. Putting CT scanners in ambulances has been tried and seems to be (at least preliminarily) successful. This may be a low-cost alternative to that, but that still needs to be proven.  ", "answer": 1}, {"article": "\u201cI prescribe them all the time,\u201d she said.\n\u201cA 5 percent loss of weight is associated with a 50 percent lower risk of diabetes and a 10 percent loss is associated with an 80 percent lower risk.\u201d\n\nPatients in Bohula\u2019s study did see improvements in hypertension and blood sugar levels with weight loss.\nThat\u2019s how we need to start looking at drugs for obesity.\u201d\n\nWhat many don\u2019t understand is that weight gain leads to changes in the brain that may not be reversible, Aronne said.\n\u201cRather than thinking about how good you\u2019ll look in that dress, you need to be thinking, \u2018I won\u2019t get diabetes now.\u2019\"\n\nBeyond that, a little patience goes a long way.\nThe Food and Drug Administration called on drugmakers to pull fenfluramine \u2014 the culprit part of the combo \u2014 which they did.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story described that the \u201clatest generation\u201d of weight loss drugs that can \u201cpare away the pounds without harmful effect.\u201d But it remains to be seen whether that\u2019s in fact the case.", "answer": 0}, {"article": "He reviewed the study but was not involved in it.\nIn their study, published in the Feb. 23 issue of the Journal of the American Medical Association, Miglioretti and her colleagues found that false positives and interval cancers were both higher in women with a history of breast cancer than in those without such history.\nIt points to the need, she said, for women to remain vigilant about screening after their breast cancer treatment -- and to report any symptoms to their doctor immediately.\nAs for false positives, 1 percent of the women without a history of breast cancer were referred for biopsy but ended up being cancer-free, compared with 1.7 percent of those with a breast cancer history.\nThe researchers evaluated 12 years of data from 58,870 screening mammograms in 19,078 women with early-stage breast cancer and an equal number of mammograms in another 55,315 women who had never had breast cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Satisfactory. The novelty of mammography is not in question, and the whole point of the story was the new study about mammography\u2019s performance in breast cancer survivors vs. controls.\nIt may have been helpful for readers to know\u00a0that the study\u00a0was the first to examine the accuracy of screening mammography for women with a personal history of breast cancer.", "answer": 1}, {"article": "Few of the programs studied, though, included exercise.\nBut a unique worry raised by these regimens, extending back to the heyday of the original Atkins diet in the 1970s, was that indulging in repeated fatty, glistening meals would lard your arteries and cause heart disease.\nAnd like most of the recent studies about the health effects of low-carbohydrate diets, \u201cthese are very short-term results,\u201d said Dr. Dena Bravata, an internist and research associate at the Center for Primary Care and Outcomes Research at Stanford University, who was not involved with this experiment but has conducted dietary studies.\nThe study did not include a control group of men and women who performed no exercise, making it impossible to tease out the exact physiological role that exercise played, Dr. Stewart said.\n(In the current study, participants followed a diet based on the New Atkins for Life approach, which includes more vegetables than the original Atkins diet, Dr. Stewart said, adding that he and his colleagues have no ties to and receive no financing from the Atkins diet organization.)\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear that the diets being compared were not new. \u00a0The story tried to suggest that adding an exercise component was somehow a new wrinkle for managing the weight loss conundrum but exercise has long been included in the Atkins diet strategy.", "answer": 1}, {"article": "Newswise \u2014 LOS ANGELES (Dec. 5, 2018) - Vascular surgeon Ali Azizzadeh, MD, was the first to use a newly approved, minimally invasive device to perform a series of innovative surgeries on patients with aneurysms of the aorta, the main vessel that delivers blood from the heart to the rest of the body.\n\u201cNow, patients can undergo a minimally invasive procedure to fix complex problems of the aorta without having open surgery.\u201d\n\nThe Valiant Navion\u2122 thoracic stent graft system is delivered from a groin blood vessel into the aorta, is positioned above the affected aneurysm, and is deployed under x-ray guidance.\nAfter my recovery, I know I will feel stronger and healthier, and will remain forever grateful.\u201d\n\nSince Angelino\u2019s surgery, Azizzadeh who, in conjunction with medical device company Medtronic, served as the national principal investigator in clinical tests of the device \u2013 has performed several additional, successful surgeries.\n\u201cPrior to gaining approval from the Food and Drug Administration, patients with many types of aneurysms and aortic conditions had limited treatment options,\u201d said Azizzadeh, director of Vascular Surgery at the Smidt Heart Institute at Cedars-Sinai.\nThough aneurysms can happen anywhere in the body, they most commonly happen in the brain, or in the main vessels that lead to the heart, legs and arms.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release mentions that the stent is new, however, it fails to acknowledge that stents are already commonly used to treat aneurysms, particularly aneurysms of the aorta located in the abdomen. This stent may offer some advantages, perhaps for aneurysms higher up and closer to the heart where the aorta is curved, but the release doesn\u2019t explicitly state that.", "answer": 0}, {"article": "Her team reviewed MRI images from 130 patients treated for clot-caused strokes at Sainte-Anne Hospital in Paris between May 2006 and October 2008.\nThe MRI is \"trying to act as a surrogate clock,\" said Kallmes, who edited Oppenheim's journal article.\nThe study, reported online Nov. 2 and in the December issue of the journal Radiology, reinforces results from similar research, Oppenheim said.\nA study in The Lancet Neurology also found that a slight increase in deaths and bleeding in an extended treatment group over a three-month follow-up period underlined the notion that treatment within 3 hours -- although not required -- is still optimal.\nWith the MRI data, radiologists could predict with more than 90 percent accuracy which patients had experienced stroke symptoms for longer than three hours.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear about the \u2018novelty\u2019 of using MRI technology in this way. \u00a0The story did not hype MRI as a new technology but rather as a \u00a0technology that was not commonly used for the purpose reported on. \u00a0The story did include a quote from the lead study author that the current study supported results that have been published in the past.", "answer": 1}, {"article": "Neuronix received European approval several months ago and has installations in the UK and Germany.\n\u201cIf out of 10 years the patients have left to live we can keep them at home in a relatively mild state of the disease for three, four, five years, it\u2019s a lot.\u201d\n\nAccording to Alvaro Pascual-Leone, director of the hospital\u2019s Berenson-Allen Centre for Non-invasive Brain Stimulation, brain stimulation - or transcranial magnetic stimulation - involves a very low current applied to a specific part of the brain and is approved by the FDA for treatment of a variety of ailments and diagnostic applications.\nThe device, which consists of a chair containing an electronic system and software in the back and a coil placed at the head, has been tested on mild to moderate Alzheimer\u2019s patients who suffer from dementia but are not totally dependent.\n\u201cYou stimulate the brain on a biological level as well as on a cognitive level,\u201d Neuronix CEO Eyal Baror told Reuters, saying this double approach created longer-lasting benefits.\nThe device, which combines electromagnetic stimulation with computer-based cognitive training, is already approved for use in Europe, Israel and several Asian countries such as Singapore.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story quotes Dr. Pascual-Leone saying \u201cThe application in Alzheimer\u2019s disease and in combination with cognitive training is novel.\u201d\nIt may be novel but this group is not the first to develop a therapeutic use for TMS (FDA approved device is available for the treatment of depression) and other groups have demonstrated small but reproducible effects of TMS in patients with Alzheimer disease. (see,\u00a0 http://www.ncbi.nlm.nih.gov/pubmed/19049544)\nSo the lack of clarity about exactly how \u201cnovel\u201d this approach is leads to rule this unsatisfactory.", "answer": 0}, {"article": "Wu and her colleagues tested human adipocytes from volunteers representing a range of ages, ethnicities and body mass indices.\n\"It's only been relatively recently that energy surplus has become a problem,\" Wu said.\nTheir findings, which appear in the December issue of the journal Metabolism, indicated that cinnamaldehyde improves metabolic health by acting directly on fat cells, or adipocytes, inducing them to start burning energy through a process called thermogenesis.\nWith the rising obesity epidemic, researchers like Wu have been looking for ways to prompt fat cells to activate thermogenesis, turning those fat-burning processes back on.\nThe study is titled \"Cinnamaldehyde induces fat cell-autonomous thermogenesis and metabolic reprogramming,\" DOI: 10.1016/j.metabol.2017.08.006.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release establishes novelty and acknowledges past research with this statement: \u201cScientists had previously observed that cinnamaldehyde, an essential oil that gives cinnamon its flavor, appeared to protect mice against obesity and hyperglycemia. But the mechanisms underlying the effect were not well understood.\u201d  ", "answer": 1}, {"article": "Sixty-eight study participants received either a monthly vitamin D supplement of 100,000 international units or placebo delivered with their MOW meal.\nThe study is published in the early online edition (8/16/2015) of the Journal of the American Geriatrics Society.\n\"Falls in homebound older people often lead to disability and placement in a nursing home,\" said Denise Houston, Ph.D., R.D., associate professor of gerontology and geriatric medicine at Wake Forest Baptist and lead author of the study.\nThe study included the participants' history of falls and their fear of falling, blood tests at the beginning and at end of the trial to measure 25-hydroxyvitamin D (biomarker for vitamin D in blood), and a monthly diary recording falls during the trial period.\nAt the beginning of this pilot study, the research team found that more than half of the participants had insufficient concentrations of vitamin D in the blood (less than 20 ng/ml), while less than a quarter had concentrations in the optimal range (30 ng/ml or more).\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release says that \u201csome studies suggest vitamin D may reduce the risk of falls,\u201d but this area has been more thoroughly studied than this statement would suggest. On the basis of available research summarized in a systematic review, the U.S. Preventive Services Task Force recommends vitamin D supplementation\u00a0in community-dwelling adults aged 65 years or older who are at increased risk for falls.\nIn addition, the study authors state that they believe their work to be the first such study conducted in homebound older adults \u2014 an important statement of novelty. The release doesn\u2019t mention this.", "answer": 0}, {"article": "Most bills do allow parents to opt out, because the question remains: Where to make this decision - at the statehouse ... or your house.\nThe vaccine promises to reduce the number of HPV related cervical cancers by more than 70 percent, CBS News correspondent Cynthia Bowers reports.\nBut some worry that may sends a mixed signal by protecting girls against a sexually transmitted disease while at the same time telling them they shouldn't have sex.\nNot yet,\" Alexander says.\n\"Even if you think you aren't at risk, you are,\" adds Audrey.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly states that the vaccine was only recently approved and that this represents a novel approach to preventing HPV infection.", "answer": 1}, {"article": "CHICAGO - A minimally invasive procedure in which pulses of energy from a probe are applied directly to nerve roots near the spine is safe and effective in people with acute lower back pain that has not responded to conservative treatment, according to a study being presented today at the annual meeting of the Radiological Society of North America (RSNA).\nThe results of the study are superior to those typically reported for usual care strategies and injections and may help a substantial number of patients with sciatic disk compression to avoid surgery, Dr. Napoli added.\nIn some cases, the entire disk must be removed and the vertebra fused together for stability.\nFor comparison, a group of 120 patients received one to three sessions of CT-guided steroid injection on the same anatomical target with no pRF.\nAn alternative technique, CT-guided pulsed radiofrequency (pRF), applies energy through an electrode under CT guidance to the portion of the nerve responsible for sending pain signals.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t explain what\u2019s novel about the research.\nThe rPF procedure has been\u00a0used extensively for a variety of chronic pain conditions for years.", "answer": 0}, {"article": "Most recently, the F.D.A.\nAlthough smoking rates in the United States have declined in recent decades, tens of millions of adults continue to smoke, and the habit causes more than 440,000 deaths a year, according to the Centers for Disease Control and Prevention.\nThe most widespread therapies currently available are nicotine-replacement products, like nicotine patches and gum, which are designed to wean the smoker by administering trickles of nicotine to the body, replacing the surges delivered by cigarettes.\nWhile the market for smoking cessation therapies is estimated to be more than $1 billion annually, many smokers continue to fail in their efforts to quit even while using the available products, with long-term success rates generally peaking at about 20 percent.\nThe multishot sequences being tested are designed to extend the antibody response for many months, although eventually the body will stop producing the anti-nicotine antibodies, he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story discusses a vaccine to prevent relapse in people trying to quit smoking. The vaccine is designed to diminish pleasure from nicotine, and it is a new approach for treating smoking addiction, though it is still being tested. The article does a good job describing other therapies and the way this approach differs.", "answer": 1}, {"article": "He hopes to make periodontal treatment a standard part of treating prostate disease, much like cardiac patients are often encouraged to visit their dentist before undergoing heart procedures and a dental checkup is advised for women who are pregnant or considering pregnancy.\nThe researchers reported their findings in the Dentistry article, \"Periodontal Treatment Improves Prostate Symptoms and Lowers Serum PSA in Men with High PSA and Chronic Periodontitis.\"\nResearchers found 21 of the 27 participants had no or mild inflammation, but 15 had biopsy-confirmed malignancies.\nThe dental school has previously found a link between gum disease and fetal deaths, rheumatoid arthritis and heart disease.\n\"This study shows that if we treat the gum disease, it can improve the symptoms of prostatitis and the quality of life for those who have the disease,\" said Nabil Bissada, chair of Case Western Reserve's Department of Periodontics and the new study's corresponding author.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does a good job of noting that this is not the first time a link has been suggested between gum and prostate disease and refers to previous studies by the research group.", "answer": 1}, {"article": "It\u2019s not the first study to show a potential anticancer effect of aspirin and other similar painkillers \u2014 a class of medications known and nonsteroidal anti-inflammatory drugs, or NSAIDs.\nOverall, 18,532 cases of skin cancer were included in the study.\nEach case was compared to 10 matched controls who did not develop the disease.\nFind her on Twitter at @aliceparkny.\n\u201cAlso, this potential cancer-protective effect should be taken into account when discussing benefits and harms of NSAID use.\u201d\n\nAlice Park is a writer at TIME.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story nods to previous research suggesting cancer prevention benefits from NSAIDs.", "answer": 1}, {"article": "Lona Sandon, a registered dietitian and assistant professor of clinical nutrition at the University of Texas Southwestern Dallas, reacted with cautious optimism to the findings.\nThe authors concluded that fish oil supplementation appears to be a safe and effective way to prevent malnutrition among cancer patients, and may ultimately prove to be of benefit for other groups of people, such as elderly patients who also face a significant ongoing risk for muscle loss.\n\"And other similar studies have looked at omega-3 and muscle preservation and have also suggested that fish oil can act to prevent inflammation caused by both disease and hardcore medications, like chemotherapy agents.\"\n\"Fish oil may prevent loss of weight and muscle by interfering with some of the pathways that are altered in advanced cancer,\" study author Dr. Vera Mazurak, of the University of Alberta in Edmonton, Canada, said in a news release.\n\"This holds great promise, because currently there is no effective treatment for cancer-related malnutrition.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story quoted the researcher from a news release saying \u201cThis holds great promise, because currently there is no effective treatment for cancer-related malnutrition.\u201d\u00a0 But there was no discussion of any other research or any other approaches to cancer-related malnutrition.\u00a0 So this claim of novelty by the researcher was never explored or substantiated.", "answer": 0}, {"article": "The first CT scan was OK.\n\"So I don't need any chemotherapy, I don't need any radiation.\nIf Lazarus hadn't had any studies, says Dr. Harvey Pass of the NYU Medical Center in New York, the tumor would have grown causing pain, cough bleeding and maybe not have been able to be surgically removed.\nI am cancer-free,\" he says.\nA chest X-ray showed nothing suspicious.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does say that lung cancer screening is not new, but that using CT for screening is a new idea.", "answer": 1}, {"article": "Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting up to 12% of women.\nThe findings suggest that irisin could be a marker for PCOS allowing the condition to be diagnosed more easily.\nThey found that teenagers with PCOS had significantly higher irisin levels compared to the control group, and that this was associated with higher levels of the male sex hormone testosterone, a key marker of PCOS.\nPrevious studies have associated high levels of irisin, a newly discovered hormone which is released from muscles and regulates energy metabolism, with PCOS in adults.\nThe potential of irisin as a meaningful drug target in PCOS is very promising,\" said Dr Bacopoulou.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release refers to previous work regarding irisin and PCOS in adults, and that this is the first such study to look at irisin levels in teens.", "answer": 1}, {"article": "The results offer fresh evidence that transcatheter aortic valve replacement can help ease symptoms like shortness of breath and fatigue that limit the ability to handle physical exertion, said Dr. David Cohen, director of cardiovascular research at Saint Luke\u2019s Mid America Heart Institute in Kansas City, Missouri.\nThe analysis focused on people with what\u2019s known as aortic stenosis, which occurs when the large blood vessels leading away from the heart narrow, forcing it to work much harder to pump blood.\nThe smaller studies in the analysis ranged in size from 36 to 484 patients, and most of them followed patients for as long as six to 12 months after surgery.\nIn addition, patients reported clinically meaningful improvements in their quality of life and their ability to complete daily tasks after surgery.\nOverall, the current analysis included 2,775 patients from a total of 20 previously published studies on outcomes for this type of surgery.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story helpfully quotes outside experts who say the analysis supports the idea that transcatheter aortic valve replacement can help ease symptoms and be a viable option even for elderly patients who tend to be at high risk for surgery.", "answer": 1}, {"article": "The men in the trial received the ADT drugs for two years.\n\u201cIt really builds on some prior data and combines prior findings to ask and answer a new question that is quite relevant for men affected by prostate cancer.\u201d\n\nSome patients benefitted from adding the drugs more than others.\nThe findings should trickle down to clinical settings \u201cpretty quickly,\u201d said Dr. William Shipley, chair of the genitourinary oncology unit at Massachusetts General Hospital and one of the researchers behind the study, which was published Wednesday in the New England Journal of Medicine.\nThe specific ADT drug used in the study, bicalutamide, has since been largely replaced by another kind of drug that decreases the amount of testosterone the body produces.\nThe results were especially dramatic for men who had prostate-specific antigen (PSA) levels above .07 ng/ml when they started the trial.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "STAT is straightforward in its headline: This is an old drug, but this use is novel.\u00a0An outside source helps put into context the results,\u00a0calling it an \u201cincremental\u201d step for doctors \u2014\u00a0a more careful position than The Times\u2019 outside source take (he calls it \u201ca big deal;\u201d see our review).", "answer": 1}, {"article": "Reiki, a therapy in which hands are placed lightly on the body or just above it, is increasingly being used to reduce cancer-related fatigue, anxiety, nausea and pain. Several studies suggest a benefit to patients, but scientists say more large, rigorous studies are needed.\n\nCancer patients\u2014due to the disease and to side effects of chemotherapy\u2014often suffer from severe mental and physical fatigue, doctors say. Anxiety, nausea and pain are also common. In recent years, many cancer centers have been offering Reiki, a form of...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains that Reiki originated in Japan in the early 1900s.", "answer": 1}, {"article": "[Breast cancers predicted to rise by 50 percent by 2030]\n\nThe study released Sunday showed that the tests were about 97 percent accurate on 639 subjects.\nThe current advance was a long time in coming and shows the difficulty of bringing research from the lab to the consumer.\nThe second is serious surgery that requires general anesthesia and results in the loss of lung tissue.\nOther research is being conducted to find markers for lung cancer, though much of it focuses on substances that can be found in the blood, Spira said.\nThe next logical question is whether those changes might be detected early enough to predict and prevent lung cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article does an excellent job of describing the current methods of diagnosing lung cancer and how the genomic classifier differs.", "answer": 1}, {"article": "That also applies to adults who suffer lack of oxygen from a near-drowning, drug overdose, or carbon monoxide poisoning.\nThe odds are that the person is having cardiac arrest - the heart suddenly stops - which can occur after a heart attack or be caused by other heart problems.\nIn a major change, the American Heart Association said Monday that hands-only CPR - rapid, deep presses on the victim's chest until help arrives - works just as well as standard CPR for sudden cardiac arrest in adults.\nOne person who's been spreading the word about hands-only CPR is Temecula, Calif., chiropractor Jared Hjelmstad, who helped save the life of a fellow health club member in Southern California\n\nHjelmstad, 40, had read about it in a medical journal and used it on Garth Goodall, who collapsed while working out at their gym in February.\nIt's less complicated and the outcomes are better,\" said Dallas emergency medical services chief Dr. Paul Pepe, who also chairs emergency medicine at the University of Texas Southwestern Medical Center.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "By mentioning that previous research has found the technique as effective as traditional CPR, the segment implies it is not novel. This meets the minimum standards for a satisfactory rating for this criterion. \nThe story would have been stronger, however, if it had mentioned that the most recent guidelines indicated compression-only CPR is an acceptable option, and that some medical experts have been urging this switch in recommendations for over a decade.\u00a0\nNonetheless, we\u2019ll give the story the benefit of the doubt on this criterion. \u00a0", "answer": 1}, {"article": "The paper \"Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening\" is available at: https:/\n\nTo request a copy of the study, please contact: Daniel Luzer\n\n daniel.luzer@oup.com\nThe accumulated evidence supports inclusion of HPV testing in screening; thus, the main choice moving forward is between cotesting and primary HPV testing alone.\nThe HPV test captures the known cancer causing viruses, but there are gynecologists who believe that there may be unknown cancer causing viruses and so continue to do the Pap smear (plus HPV testing).\nAn HPV test, in which doctors test a cervicovaginal specimen for the presence of the nucleic acids of carcinogenic types of HPV, is more sensitive than the Pap test (a microscopic examination of exfoliated cells) for detection of precancers.\nAlternatively, current guidelines recommend cotesting but, in recognition of the additional reassurance provided by this approach compared with the Pap test alone, the screening interval is extended to every five years.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release addresses novelty with this summary of the work: \u201cthe most extensive experience of HPV testing incorporated into routine screening in the world.\u201d The long-term study comparing outcomes from two long used screening tests is novel.", "answer": 1}, {"article": "For more information, visit http://www.\nLeesburg, VA, March 13, 2018 - When compared to the screening population ages 50 and over, screening mammography in women ages 40-49 detects 19.3% additional cancers at the expense of an overall 1.5% increase in callbacks and 0.1% in increased biopsies, according to a study to be presented at the ARRS 2018 Annual Meeting, set for April 22-27 in Washington, DC.\nThe study results showed that there was a higher number of callbacks among women ages 40-49 compared to women ages 50-59 (17% compared with 12.5%) and to women ages 60-69 (17% compared with 10.2%).\nWith educational activities representing the entire spectrum of radiology, ARRS will host leading radiologists from around the world at the ARRS 2018 Annual Meeting, April 22-27, at the Marriott Wardman Park Hotel in Washington, DC.\nBy adding the women ages 40-49 to the screening population of 50 and over, the overall callback rate increased 1.5%, the biopsy rate increased 0.1% and 19.3% more cancers were detected.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "One thing that the news release didn\u2019t mention is that this debate is not new\u2013 organizations have been going back and forth on when to recommend mammograms for almost a decade. There are compelling arguments for both sides, but this study is only one in a body of evidence that advocates for earlier mammograms. It would have been better if the news release had added some context about the mammogram debate to help readers understand why (or why not) this research was important.", "answer": 0}, {"article": "CHICAGO (Reuters) - Measuring certain proteins in spinal fluid can accurately diagnose Alzheimer\u2019s and predict which patients with memory problems will develop the fatal brain-wasting disease, Belgian researchers said on Monday.\n\u201cThe unexpected presence of the Alzheimer\u2019s disease signature in more than one-third of cognitively normal subjects suggests that Alzheimer\u2019s disease pathology is active and detectable earlier than has heretofore been envisioned,\u201d Geert De Meyer of Ghent University in Belgium and colleagues wrote.\nThey said measuring traces of beta amyloid and tau \u2014 two proteins associated with the telltale plaques and tangles that form in the brains of patients with Alzheimer\u2019s \u2014 accurately detected Alzheimer\u2019s in 90 percent of patients with the disease.\nWhen they looked to see how accurate these signatures were at spotting the disease, they found 90 percent of those with Alzheimer\u2019s had the disease pattern in their spinal fluid.\nCurrently, only an autopsy can confirm that a person has Alzheimer\u2019s, a fatal and incurable deterioration of the brain that affects more than 26 million people globally.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story notes that this study is the latest to show that spinal fluid testing \u201cis useful in diagnosing Alzheimer\u2019s disease,\u201d thus indicating it is not the first such report.", "answer": 1}, {"article": "Drinking cow\u2019s milk produced at night may be a treatment for anxiety and insomnia, suggests an animal study in the Journal of Medicinal Food.\n\nA glass of milk at bedtime has long been touted as a sleep aid. But the study found that milk collected at night, or night milk, had enhanced sedative effects in mice compared with milk produced during the day. Night milk significantly decreased the rodents\u2019 physical activity, balance and coordination and increased sleep time compared with day milk, the research showed.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article does not establish the context of the study adequately, making it hard to judge the novelty of using night milk to treat anxiety and insomnia. Is this the first such study to be conducted? This is where an independent expert could\u2019ve helped out.", "answer": 0}, {"article": "The scans are cheaper, quicker and safer than angiograms.\nThe SCOT-HEART study tracked more than 4000 patients who were referred to a hospital clinic with symptoms of angina - a condition that restricts the blood supply to the heart.\nThe number of patients undergoing additional procedures increased within the first year but had levelled out by the end of the five-year period.\nThis is the first time that CT guided management has been shown to improve patient outcomes with a major reduction in the future risk of heart attacks.\nThe study had previously found that around a quarter of patients had their diagnoses reclassified after receiving the scan, prompting new treatments in many cases.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The lead author is quoted as saying:\nThis is the first time the CT-guided management has been shown to improve patient outcomes with a major reduction in the future risk of heart attacks.\nThere are other studies \u2014 most notably the PROMISE trial \u2014 which followed patients for just 2 years and found no changes in patient outcomes when comparing CTA with other noninvasive screening tests. This study followed patients for 5 years to see if the differences persisted and they didn\u2019t.", "answer": 1}, {"article": "(Reuters) - A combination of two Bristol-Myers Squibb drugs that help the immune system fight melanoma led to significantly greater tumor shrinkage than treatment with one of the medicines, according to a midstage study presented on Monday.\n\u201cLonger follow-up will be helpful to see the durability of these responses and what happens to patients who had complete responses,\u201d said Hodi, who presented data from the Checkpoint-069 study at the American Association for Cancer Research meeting in Philadelphia.\n\u201cThe response rates and the depth of responses are quite impressive,\u201d Dr. Stephen Hodi, director of the Melanoma Center at Dana-Farber Cancer Institute and co-lead author of the study, said in an interview.\n\u201cMost of the patients who stopped for toxicity continued to benefit,\u201d said Fouad Namouni, Bristol\u2019s head of development for Yervoy and Opdivo.\nOpdivo (nivolumab) belongs to a promising new class of drugs called PD-1 inhibitors that block a mechanism tumors use to hide from the immune system.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does explain that Yervoy \u201cis the first immunotherapy to extend survival in patients with advanced melanoma,\u201d and that Opdivo \u201cbelongs to a promising new class of drugs called PD-1 inhibitors.\u201d But the story doesn\u2019t tell readers whether this is the first study to use multiple immunotherapy drugs in combination to treat melanoma. If it is the first such study, that\u2019s worth including. And it\u2019s not the first such study, the story would benefit from explaining how the new study differs from previous ones.", "answer": 0}, {"article": "The study, \"Survival Outcomes in Men Undergoing Radical Prostatectomy after Primary Radiation Treatment for Adenocarcinoma of the Prostate,\" recently was published by Clinical Genitourinary Cancer, a peer-reviewed journal on the detection, diagnosis, prevention and treatment of genitourinary cancers.\nThe procedure is challenging because tissue that surrounds the prostate is scarred during radiation treatment, making it difficult for the surgeon to identify and cut out tissue that needs to be removed.\n\"However, this study shows that it is a viable treatment option.\n\"Because radical prostatectomy is a complex surgery, there can be a reluctance to undergo the procedure,\" Pokala said.\nIf the cancer is localized, a highly skilled surgeon can remove the gland and surrounding tissue using a robotic minimally invasive technique or through an open surgery.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t make any claim to novelty and that\u2019s appropriate because it\u2019s understood that the surgery in question has been performed since at least 1988.", "answer": 2}, {"article": "\"How bulging is the eardrum?\nBut here's the rub \u2013 diagnosing ear infections in very young children, who tend to squirm, is not easy.\nIf many children in prior studies didn't really have ear infections, then it's not surprising the antibiotics didn't work for them, says Dr. Jerome Klein of Boston University, who wrote an editorial that accompanies the new studies.\nBut Spiro thinks \"the pendulum will swing the other way\" \u2013 that is, toward immediate antibiotic treatment \u2013 because of the new studies.\nBoth studies, which appear today in the New England Journal of Medicine, find these kids get over painful ear infections faster, and have less severe symptoms, if they get prompt treatment with Augmentin, an inexpensive antibiotic often used to treat respiratory infections.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Both the blog post and the radio piece explained why these studies might start changing the way clinicians behave and might give parents more information for helping them demand the right kind of treatment. \u201cMuch of the confusion, experts say, has been caused by studies that weren\u2019t careful enough about the diagnosis.\u00a0\u00a0If many children in prior studies didn\u2019t really have ear infections, then it\u2019s not surprising the antibiotics didn\u2019t work for them, says Dr. Jerome Klein of Boston University, who wrote an editorial that accompanies the new studies.\u201d", "answer": 1}, {"article": "\"I think [the results] are very encouraging,\" Bruce Lanser, a pediatric allergist who directs the Pediatric Food Allergy Program at National Jewish Health in Denver, told us.\nNow, a new study sheds light on the effectiveness of a test called a food challenge to determine whether a person can tolerate a food they once reacted to.\nThe blood test measures the levels of a certain type of antibody, immunoglobulin E (IgE).\n\"If the symptoms were treated with just Benadryl or another antihistamine, they were considered mild or moderate.\n\"All they can tell us is how likely you are to react when you eat the food.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The study on which this story was based is described by the researchers as being the\u00a0largest national survey of allergic reactions of clinical open oral food challenges in a nonresearch setting in the United States. The story doesn\u2019t note this, making it unclear what\u2019s novel about the research.", "answer": 0}, {"article": "Co-authors include: Drs.\nOTTAWA, ON - August 21, 2017 - Researchers at the Children's Hospital of Eastern Ontario (CHEO) looked at the incidence of and risk factors associated with sedation-related adverse events in pediatric emergency departments as part of a multi-centre observational study published today in JAMA Pediatrics.\n\"Although sedation-related serious adverse events occur infrequently, recognition and early intervention is necessary to ensure patient safety,\" said Dr. Maala Bhatt, lead author, director of pediatric emergency research at CHEO, and assistant professor at the University of Ottawa.\n\"While all sedation medications and combination of medications are effective and safe in the hands of experienced providers, ketamine-alone is associated with the fewest serious adverse events and significant interventions, making it a logical choice for providing procedural sedation for children in emergency departments.\"\nThe results of the study show that choice of sedation medication had the biggest impact on the incidence of adverse events and need for significant interventions in response to those events.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release addresses novelty with the statement:\n\u201cAccording to the authors, this study represents the largest and most robust prospective emergency department procedural sedation cohort to date. It includes children from six emergency departments across Canada, sedated with six different medication combinations.\u201d\nWhile not definitive, this large well-designed study does add to clinician understanding of the best approaches to pain management in children arriving in the emergency room.", "answer": 1}, {"article": "The depth of anesthesia was monitored using bispectral index (BIS) technology, which processes electroencephalogram signals to measure drug-induced unconsciousness.\nThe researchers evaluated 140 patients aged between 60 and 87 who underwent surgery under propofol-induced general anesthesia at the Central Institute of Hospital das Cl\u00ednicas, FM-USP's teaching hospital, in most cases for removal of gallstones.\nOne of the obstacles to reliable diagnosis and rehabilitation is a lack of practical and secure instruments for pre- and post-operative cognitive assessment.\nThe problem has become more frequent as the population ages and also as a growing number of older adults undergo surgical procedures made possible by more advanced medical technology.\nPatients who failed to achieve a cutoff score were excluded.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It\u2019s clear from the release that this is a new (and, ergo, novel) approach addressing a well-established problem.  ", "answer": 1}, {"article": "A hijab, a turban, a beard: What aren\u2019t you seeing?\nNewsday's coverage of the Class of 2019, led by Mariano Rivera and Mike Mussina.\nOver 24,000 employees at 116 LI companies were polled on what makes their employers great.\nA former gang member recently recalled when he decided to join the gang.\nFrom a Catholic school uniform to a hijab, LIers talk about their religious clothing.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Though presented as something new (\u201cthe notion is gaining such ground\u201d) there is a literature about the use of exercise and physical movement in the treatment of Parkinson\u2019s disease that dates back at least to the 1960\u2019s. ", "answer": 0}, {"article": "\u201cIt\u2019s really recommended to replace white rice with the same amount of brown rice or other whole grains.\u201d\n\nThe researchers who did the study analyzed rice consumption among 39,765 men and 57,463 women who participated in the Health Professionals Follow-up Study and the Nurses\u2019 Health Study I and II; participants in the three groups ranged in age from 26 to 87.\nAnd correlation does not necessarily mean a cause-and-effect relationship, since factors other than brown rice consumption may have accounted for the decreased diabetes risk that was observed.\nThe researchers tried to control for the fact that Americans who eat brown rice tend to be more healthy overall \u2014 they eat more fruits and vegetables and less red meat and trans fats, and they also tend to be thinner, more active and less likely to smoke than those who don\u2019t eat brown rice.\nA 2007 study of Chinese women in Shanghai found that middle-aged women who ate large amounts of white rice and other refined carbohydrates were also at increased risk for diabetes compared to their peers who ate less.\n\u201cThe bottom line is we showed evidence that increased consumption of white rice \u2013 even at this low level of intake \u2014 is still associated with increased risk,\u201d said Dr. Sun, who was at the Harvard School of Public Health when the study was done.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story was clear to indicate that this is not the first data analysis that has suggested that brown rice is a healthier alternative to white rice.", "answer": 1}, {"article": "The positive results surprised even Stagl.\n\u201cWhile I certainly wouldn\u2019t say that anyone could take a 10-week course and be set for life, I think anyone could take a 10-week course and be much better at coping with stress.\u201d\n\nNext, the study team, led by Michael Antoni of the University of Miami, hopes to show that an easier-to-manage five-week group class works as well as the 10-week one.\n\u201cThis is really a teachable moment.\u201d\n\nThe skills taught in the course are useful at many stressful moments, Porter said, not just when cancer is diagnosed.\nThe women who took the 10-week stress-management class shortly after surgery reported feeling better and having fewer depressive symptoms such as anxiety than those who took a one-day, breast-cancer education session.\nIf a woman\u2019s stress level remains high indefinitely after diagnosis, she may have a worse outcome than if she can bring it back down, Stagl said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that the recent study is a follow-up to a previous study on depressive symptoms among breast cancer survivors. But it doesn\u2019t put the research into any larger context. Long-term studies of women\u2019s quality of life \u2014 not just survival \u2014 10 or more years after a breast cancer diagnosis are relatively few.\u00a0 The story could have emphasized more the value of the study in contributing to what is known. \u00a0", "answer": 0}, {"article": "Lona Sandon, a registered dietitian and assistant professor of clinical nutrition at the University of Texas Southwestern Medical Center at Dallas, agreed.\n\"The important thing to keep in mind is that although we diagnose obesity on the basis of a mathematical formula -- a BMI of 30 and up -- the basis for obesity may differ from one individual to another.\"\n\"But for many people, this kind of drug might absolutely be of great help, by doing something that helps the regulation of these appetite hormones and the regulatory pathway,\" she said.\n\"The question was to see if more weight loss could be achieved if we provided decent quality lifestyle intervention, mostly dietary counseling, along with this medication,\" said study lead author Dr. Kishore Gadde, director of the Obesity Clinical Trials Program at Duke University Medical Center in Durham, N.C.\n\n\"And the answer was yes,\" Gadde said.\nJust a few prescription medications are approved in the United States for long-term treatment of obesity, including orlistat (brand name Xenical) and lorcaserin hydrochloride (Belviq).\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does explore the novelty of the drug in question and makes it clear that the current study is building on past work. The story says, \u201cGadde and colleagues set out to follow up on a 16-week investigation they conducted in 2003 that had indicated that zonisamide (Zonegran) at a dosage of 400 milligrams a day might offer an alternative.\u201d", "answer": 1}, {"article": "The researchers noted that thousands of people in this final group were participants in the Women\u2019s Health Initiative, a long-term study sponsored by the National Heart, Lung and Blood Institute in the U.S. Earlier reports based on data gathered by the Women\u2019s Health Initiative found that calcium and vitamin D supplements were associated with a lower risk of fractures, but only for women who took hormone therapy after menopause. To get a clearer picture of the direct link (if any) between supplements and fracture risk, Zhao and his colleagues opted not to include data from women on hormone therapy.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a good job of making clear previous claims of benefit from calcium and vitamin D supplementation. This large meta-analysis will provide some clarity of the questions surrounding using these supplements for bone health.", "answer": 1}, {"article": "Doctors who have turned surgery into a popular treatment for obesity are setting their sights on a burgeoning new market: diabetes patients.\n\nA growing amount of research suggests that bariatric surgery, which shrinks the stomach and sometimes reroutes the intestines, has a lasting effect on the most common form of diabetes, and not just because patients lose weight. Studies have found that more than 75% of patients with this type of diabetes who undergo the surgery see their disease disappear. They can go on to live diabetes-free...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The reporter emphasizes that the proposed treatment is an extension to a new patient population of\u00a0an existing procedure. The story does a good job clarifying the differences between the two major types of bariatric surgery and their histories.", "answer": 1}, {"article": "\"What we've had available the last 16, 17 years has made a big difference,\" Richert says, \"and what we have coming onboard now, these are going to make even a larger difference.\nEasier To Take, More Impact\n\nThis week's issue of The New England Journal of Medicine reports on two new drugs that can be taken orally to slow the progress of MS.\n\"People will be more prone to take them early, more prone to stay on the drugs,\" Richert says.\n\"In reality, these are extremely potent pills that have the potential to cause a variety of serious side effects,\" he says.\nThe new pills also appear to be more effective than most current drugs.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story appropriately addressed the novelty of the oral drugs \u2013 and added something the AP and LA Times stories did not \u2013 about approval of another new oral MS drug that may occur soon. ", "answer": 1}, {"article": "''I am of the opinion that every child deserves this diagnostic intervention,\" researcher Lidy Pelsser, PhD, of the ADHD Research Centre in Eindhoven, the Netherlands, tells WebMD.\nThe diet studied, known as the restricted elimination diet (RED), can work, the researchers say, because they believe ADHD symptoms in some children might be affected by eating specific foods.\nU.S. experts had some caveats, saying that the results of the study, which included 100 children, should be repeated in other populations to see if the findings hold up.\nFeb. 3, 2011 -- Children with attention deficit hyperactivity disorder (ADHD) should be offered a special ADHD diet to see if eliminating certain foods might reduce their symptoms, Dutch researchers say.\nIn the study, published in The Lancet, 78% of children who stuck with the diet did respond by having fewer symptoms.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We would like to give this story a passing grade on the question of novelty, but the way the information is presented only amplifies the cheerleading effect of the rest of the story. The story provides important context by saying, \u201cWhile previous studies have found a link between foods and ADHD symptoms, the researchers say the studies were typically small or only included children known to have a tendency to allergies.\u201d If the story had then gone on to quote the Lancet piece and say that all previous studies combined only included 188 children while this one study covered 100 kids, that would have been strong evidence for the study\u2019s novelty. Instead, it says, \u201cTheir study is more applicable to the population as a whole.\u201d", "answer": 0}, {"article": "Though its exact mechanism is uncertain, the diet appears to work by throwing the body into ketosis, forcing it to burn fat rather than sugar for energy.\nBreaking the diet with so much as a few cookies can cause seizures to flare up.\nEvery gram of food is weighed, and carbohydrates are almost entirely restricted.\nShe is a principal investigator on the study, which will appear in the June issue of The Lancet Neurology.\nBreakfast on the diet might consist of bacon, eggs with cheese, and a cup of heavy cream diluted with water; some children drink oil to obtain the fats that they need.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentioned the long history of using a ketogenic diet to aid in the management of epilepsy.", "answer": 1}, {"article": "Despite all the headlines about swine flu, which has become the main influenza strain circulating in the world, doctors do expect some garden-variety flu to hit this fall too \u2013 the kind that every year kills 36,000 Americans and hospitalizes 200,000.\nThe report from the Centers for Disease Control and Prevention Friday also came with good news: Testing of vaccines for swine flu show that they work with a single dose and take effect rapidly.\nHealth officials say influenza is circulating unusually early this year with cases in every state \u2013 and nearly all the infections are swine flu.\nBut scientists had feared that people of all ages would need two shots about a month apart because the new H1N1 strain is so genetically different from normally circulating flu strains that most of the population has little if any immunity.\nAustralian and U.S. researchers said Thursday that one dose of the new swine flu vaccine looks strong enough to protect adults \u2013 and can begin protection within 10 days of the shot.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story reports that the H1N1 flu vaccine is new and makes clear the distinction between H1N1 flu shots and seasonal flu shots.", "answer": 1}, {"article": "\"We do need something,\" he said.\n\"This is probably not going to be used for wide-scale screening but it could be used for children who we have some sense that they have autism and want to gather more information,\" said David Amaral, president of the International Society for Autism Research and research director of the University of California Davis MIND Institute.\n\"We're focusing on this earliest time period, when the brain is still developing and still changing,\" explained study author Lisa Eyler, an assistant professor of psychiatry at the University of California, San Diego.\nWEDNESDAY, May 19, 2010 (HealthDay News) -- Researchers hope that a simple brain scan performed in infants and toddlers can presage the development of autism, leading to early detection and early intervention.\n\"Whereas the typical developing kid will have an explosion of their language ability starting at about 12 months in both comprehension and production, kids in autism delay don't start comprehending or producing until later, and they don't ever have that kind of explosion.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There\u2019s no context for what similar research has come before, and what competing research is out there. Even though the reporter did the right thing by talking with two outside experts, there should have been some clear statements in here about how much fMRI has been studied in relation to autism and whether other diagnostic tools have been studied.", "answer": 0}, {"article": "Iron is essential to the developing brain, he said, and deficiencies during early months \u2014 perhaps linked to early clamping \u2014 could affect nerve and muscle control, making it harder for the child to later control a pen or interact comfortably with peers.\nFor nine months, the developing fetus is attached to its mother by the umbilical cord.\nThen, moments after birth, that cord is severed.\nBabies who are anemic often appear tired and pale.\nThe benefits of those extra few minutes may last a long time.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains that this idea is not novel, and indeed is already recommended for premature infants.", "answer": 1}, {"article": "Additionally, change in IRLSSGS score was significantly greater for the RLS device (17.22) compared to historic reports for ropinirole versus the placebo (12 versus 8.9 respectively).\nThese results show promise in otherwise healthy individuals for a nonpharmaceutical option that appears to have rather minor, temporary adverse effects for some users,\" said Rob Danoff, DO, an osteopathic family physician and program at Aria Health Care in Philadelphia.\nClinical Global Impression responses indicated significantly greater improvement with the RLS device (90 percent) compared with ropinirole (63 percent), the current standard dopamine therapy for RLS.\nThe RLS device was designed to put adjustable targeted pressure on two muscles in the foot known to relax symptoms of RLS, the abductor hallucis and the flexor hallucis brevis.\nUntil recently, potent drugs including opioids, depressants and dopamine agonists have been used to ease symptoms, but each of these is accompanied by negative side effects such as dizziness, nausea, vomiting and the added risk of addiction.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "As noted above, the release does not mention compression sleeves or other similar devices. Nor does the release mention that data from this \u201cnew\u201d study was submitted to the FDA more than five years ago and has been widely used to market the restiffic device.", "answer": 0}, {"article": "For more information about the AACR, visit http://www.\nIn addition, the AACR publishes eight prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers.\nAuthor Comment: \"These data show that abemaciclib is an oral drug that can be taken on a continuous schedule and achieve durable clinical activity against multiple tumors including breast and lung cancers,\" said Shapiro.\nAmong the 36 patients with hormone receptor-positive breast cancer, 11 had a partial response, with four of the 11 responders having continued prior endocrine therapy, and an additional 18 patients had stable disease.\nFor example, abemaciclib has greater selectivity for CDK4 compared with palbociclib, which may explain why it does not affect white blood cell counts as severely, allowing it to be taken on a continuous schedule without treatment holidays, he said.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release explains that although there are other drugs that attack cancer cells in a similar way, this drug has some differences. As noted above, the release casts all the differences with existing drugs as advantages, when of course these features have yet to be adequately tested.", "answer": 1}, {"article": "GenomeDx is based in San Diego, California and Vancouver, British Columbia.\nThe Decipher results increased agreement in treatment recommendations between urologists and radiation oncologists, as the odds of a recommendation for adjuvant treatment by urologists vs radiation oncologists increased from 0.27 (95% CI, 0.17-0.44) to 0.46 (95% CI, 0.29-0.75) after results of the Decipher test were made available.\nIn addition, the 19% of the patients with the highest risk based on Decipher had a nearly 10-fold higher risk of distant metastases by 5 years.\n\"Conflicting treatment recommendations by different specialists looking at the same disease can be highly confusing for patients and is a problem for the health care system in general,\" said Paul Nguyen, M.D., of Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School.\nThe study was designed to evaluate how the Decipher Prostate Cancer Classifier, which predicts the risk of metastasis after prostatectomy, would impact adjuvant treatment recommendations made by urologists and radiation oncologists.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "A bit of boilerplate text toward the end of the release gets at novelty with this statement: \u201cDecipher generates a risk result that is completely independent and distinct from PSA, Gleason score and other clinical risk factors. Clinical studies from leading cancer centers published in over a dozen medical journals demonstrate that Decipher can accurately predict metastatic disease, which men may benefit from radiation therapy following prostate surgery, and can lead to significant cost-savings for healthcare systems.\u201d That\u2019s good enough for Satisfactory rating, although we caution again that the amount of independent value added from Decipher is unclear.", "answer": 1}, {"article": "MONDAY, July 6, 2015 (HealthDay News) -- A scan of calcium deposits inside your arteries can help doctors deduce how long you're likely to live, a new study has found.\nAnalysis revealed that the risk of premature death steadily increased with the amount of calcium deposits found in a person's major arteries.\n\"If you had no calcium or very small amounts, we were able to track over a very long time that you actually had a very outstanding survival,\" Shaw said.\nIn this new study, doctors referred 9,715 healthy patients in the Nashville area between 1996 and 1999 to a cardiology outreach screening program provided by the military's Tricare Healthcare System.\nThe results of a calcium scan can be reassuring for people with few or no calcium deposits, and can provide people with high calcium levels with added impetus to take better care of themselves, Shaw said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story specifically notes that CAC testing is not new, and that previous research hasn\u2019t assessed long-term health risks associated with CAC.", "answer": 1}, {"article": "Overweight people on low-carbohydrate and Mediterranean diets lost more weight and got greater cardiovascular benefits than people on a conventional low-fat diet, according to a study that endorses alternative diets published in a major medical journal.\n\nThe study, which tracked 322 Israelis for two years, surprisingly found that a low-carb diet, often associated in the U.S. with high levels of meat consumption -- was better than a low-fat diet in boosting blood levels of \"good\" cholesterol, or high-density lipoproteins...", "question": "Does the story establish the true novelty of the approach?", "explanation": "These diets are not new or novel and are not presented as such in this\u00a0article.\u00a0 This article is clear that the new information being presented is the comparison of health benefits.\u00a0", "answer": 1}, {"article": "He is also the co-founder of Neuro-Luminance Ketamine Infusion Centers.\nThe study, \"Practical application of the neuroregenerative properties of ketamine: real world treatment experience,\" addresses key points in the controversy surrounding the use of intravenous ketamine for the treatment of depression.\n\"The wealth of clinical experience from treating hundreds of patients with ketamine has supplanted the preliminary data that emerged from the initial open-label and small double-blinded studies,\" said Dr. Henderson, who is a board certified psychiatrist, specializing in diagnosing and treating complex conditions, based in Denver, Colorado.\nThe study also challenges concerns about neurotoxicity and a recent hypothesis that patients must experience hallucinations during ketamine infusion in order to have an anti-depressant benefit.\nKetamine infusion therapy, the controversial treatment for depression, has been resisted by many physicians due to concerns about short-lived benefits, risks of addiction, and the lack of large scale studies.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release attempts to give readers a sense of what\u2019s new here, even if we disagree with its characterization of the importance of that news. It suggests that the study provides useful new information about the clinical experience with ketamine.\u00a0\u201cThe wealth of clinical experience from treating hundreds of patients with ketamine has supplanted the preliminary data that emerged from the initial open-label and small double-blinded studies,\u201d says Henderson.", "answer": 1}, {"article": "On the other hand, that analysis also found aspirin increased the rate of bleeding from 0.7 to 1 per 1,000 people per year, making the authors conclude the drug was of \u201cuncertain net value.\u201d\n\nHeart disease is the leading killer worldwide and accounts for more than a third of deaths in the U.S., according to the American Heart Association.\n\u201cI like to say you have to make the recommendation about aspirin one patient at a time,\u201d Dr. Michael L. LeFevre, who was not linked to the study, told Reuters Health.\n\u201cIt refines our knowledge of how beneficial aspirin is,\u201d Dr. Graham Nichol, an expert in emergency care at the University of Washington in Seattle, said about the study.\nOne recent study has suggested that despite the increase in bleeding ulcers from aspirin, the reduction in heart attacks might make the cheap drug cost-effective for men over 45.\n\u201cWe can\u2019t tell from the existing study if that is going to hold up or not,\u201d he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explained that \u201cThe new work\u2026pooled the results of the nine trials that have tested the drug in the prevention of heart disease so far, including three that weren\u2019t part of the 2009 USPSTF review.\u201d", "answer": 1}, {"article": "And the results, just published by The Cochrane Library, are likely to disappoint people who swear by vitamin C.\n\nAccording to their analysis, daily vitamin C basically had no effect on the incidence of the common cold in the general population, except for very specific groups of people, all of them small groups.\nIt makes us look toward other methods, aside from vitamin C, Senay concluded.\nPreventing colds just isn't one of them.\nFor adult males, the recommended amount is 90 milligrams per day.\nBut they were the exceptions.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The report accurately describes vitamin C as widely used. ", "answer": 1}, {"article": "He is vice president for health care outcomes and policy at Roswell Park Cancer Institute in Buffalo, N.Y.\nOverall, the guidelines say there's enough evidence to show radiation treatment after a mastectomy decreases the risk of breast cancer recurrence, and that even women with smaller tumors and three or fewer lymph nodes involved can benefit from the therapy.\nFor instance, he explained, ''a woman 65 who has microscopic involvement in a single lymph node and an estrogen-receptor positive cancer would be very different from a 38-year-old who has three lymph nodes involved and so-called triple-negative breast cancer.\"\n\"In the past, if a woman had a small tumor, less than 5 centimeters, and not more than three or four positive lymph nodes, many doctors would say she does not need [post-mastectomy radiation therapy],\" she said.\n\"The guideline is timely,\" said Dr. Janna Andrews, an attending physician in radiation medicine at Norwell Health Cancer Institute, in Lake Success, N.Y. \"The field of post-mastectomy radiation is changing.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a good job here, explaining that \u201cthe new guidelines help clarify what used to be a gray area,\u201d and noting that whether to pursue radiation treatment would still need be to determined on a case-by-case basis by a patient and her (or his) healthcare provider.", "answer": 1}, {"article": "Compared with the 35 stroke patients who got clot-dissolving medicine alone, the 35 who got the two-pronged treatment were nearly twice as likely to regain some neurological function after three days. Imaging results revealed that for those who got both treatments, 100% of the brain tissue initially affected by a clot had blood flowing to it after 24 hours. Among the subjects who only got alteplase, the median level of restored blood flow was 37%.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story provides a good deal of background information and discusses how the new study results are different from previous experience. Readers are told that the procedure cannot be done by all hospitals, and only very specialized centers are capable of performing it. We would have appreciated a bit more information on why experts think the new results are so different from those of previous studies. In other words, why did these treatments succeed now when they\u2019ve failed to show benefit in the past?", "answer": 1}, {"article": "Research reported in this article was partially funded through a Patient-Centered Outcomes Research Institute (PCORI) award CE12-11-4667.\n\u201cThis study shows that, despite technological advances in the treatment of prostate cancer, both surgery and radiation still have a negative effect on quality of life,\u201d said co-author David Penson, M.D., MPH, Paul V. Hamilton, M.D., and Virginia E. Howd Professor of Urologic Oncology and professor and chair of the Department of Urologic Surgery.\nThe authors also reported that:\n\n- Surgery was associated with fewer urinary irritative symptoms, like weak urine stream or urinary frequency, compared to active surveillance.\nSurgery is considered by some to be the most definitive treatment, and there is evidence from other studies that it has better long-term cancer outcomes than radiation for higher-risk cancers, but it has more sexual and urinary side effects than radiation.\nThe Vanderbilt University Medical Center study led by Daniel Barocas, M.D., MPH, associate professor of Urologic Surgery, compared the side effects and outcomes of contemporary treatments for localized prostate cancer with active surveillance in order to guide men with prostate cancer in choosing the best treatment for them.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release did not make a strong claim of novelty. It states, \u201cThis study shows that, despite technological advances in the treatment of prostate cancer, both surgery and radiation still have a negative effect on quality of life.\u201d That\u2019s not a new finding, but what makes the study newsworthy is that it compared the degree of side effects associated with each treatment.\nIn addition, the published study states that it was designed to be more diverse, representative and more broadly applicable than former studies.\n\u201cIn contrast to previously published studies, this study may be more generalizable, since the cohort is racially diverse, population based, and includes a range of disease severity.\u201d\nThat would have been good to include in the release.", "answer": 1}, {"article": "New medtech apps put specialist knowledge in patients' pockets\n\nDeep-learning networks have already been applied to produce algorithms capable of diagnosing diseases like melanoma and blindness caused by diabetes.\nThe researchers concluded: \u201cThe opportunity to one day readily understand the health of a patient\u2019s blood vessels, key to cardiovascular health, with a simple retinal image could lower the barrier to engage in critical conversations on preventive measures to protect against a cardiovascular event.\u201d\n\u201cMost cardiovascular risk calculators use some combination of these parameters to identify patients at risk of experiencing either a major cardiovascular event or cardiac-related mortality within a pre-specified time period, such as 10 years,\u201d the paper states.\nThe method\u2014detailed in a paper published on Monday in the Nature journal Biomedical Engineering\u2014involves analyzing blood vessels in an area of the eye called the retinal fundus.\nThe risk factors include the person\u2019s gender, smoking status, blood pressure and age\u2014estimated to within four years of the patient\u2019s actual age.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The idea\u00a0that a non-invasive scan of a person\u2019s retina could yield enough information to calculate that person\u2019s risk of a heart attack appears to be novel.", "answer": 1}, {"article": "All were enrolled in the CHARGE study (CHildhood Autism Risks from Genetics and Environment) from 2003 to 2009.\nThe risk rose if the mothers or the children had a high-risk gene form.\nExactly why the prenatal vitamins may protect against autism is not clear, she says.\nIt may be that the vitamins contribute to high levels of folate.\nThe research needs to be duplicated, Hertz-Picciotto tells WebMD.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The association between prenatal vitamins and autism does appear to be a novel and newsworthy finding, as the story suggests.", "answer": 1}, {"article": "Claudia Kawas, a geriatric neurologist at the University of California, Irvine, said a patient strode into her office soon after the FDA approved the procedure and asked for the \"Alzheimer's test.\" In one hand, he held an article about the approval of Amyvid. In the other, he had a document from a right-to-die group. If the test was positive, he told her, he would get his affairs in order and kill himself within 60 days.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of this approach is clear from the story.", "answer": 1}, {"article": "Nov. 28, 2011 (Chicago) -- Researchers are using high-energy waves similar to those used to make microwave popcorn to destroy inoperable lung tumors.\nThe procedure, which costs about $2,000, takes about an hour, and the patient is typically kept overnight in the hospital for observation.\nIn a preliminary study, the technique, called microwave ablation, eliminated lung tumors in 19 of 28 patients.\nTumors shrank or stopped growing in the other nine patients, says study researcher Claudio Pusceddu, MD, a specialist in radiation and oncology at Oncological Hospital in Cagliari, Italy.\nDuring microwave ablation, radiologists place a thin microwave antenna directly into the tumor.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "As with the \u201cavailability\u201d criterion, the novelty of the technique is a bit of a mystery, although the story does say that \u201cmicrowave ablation is being studied for the treatment of liver, kidney, and bone cancers.\u201d\u00a0 How long has it been studied or in use?\u00a0 We\u2019re not given a clue.", "answer": 0}, {"article": "Medtronic Inc. and Eli Lilly & Co. agreed to collaborate on an early stage research project for a potential Parkinson's-disease treatment that involves delivering medication directly to the brain\u2014a goal that has long eluded drug makers.\n\nThe pact, announced Tuesday, adds to Medtronic's roster of projects aimed at using implantable drug pumps and catheters to circumvent the blood-brain barrier. The tightly packed network of cells in brain capillaries only lets certain substances through, such as key nutrients, making brain-based...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did an adequate and appropriate job of wrapping this approach into the context of other related research.", "answer": 1}, {"article": "The hormone combination did protect against hip fractures and reduce the risk of colorectal cancer, but for the overwhelming majority of menopausal women, the risks of H.R.T.\n\u201cWomen today have so many options \u2014 a wide array of doses, from low to traditional, and ways to use them.\u201d In addition to pills, there are patches, gels and sprays applied to the skin.\nBut now, new research suggests that the benefits of short-term hormone treatment to control life-disrupting menopausal symptoms outweigh the risks \u2014 as long as the treatment is started at or near menopause.\nFor women without a history of cancer, blood clots or heart disease, most professional medical societies concerned with women\u2019s health now recommend treatment for menopausal symptoms for up to five years using therapy that combines estrogen and progesterone and even longer for those who take estrogen alone.\n), created a kind of menopausal panic, prompting millions of middle-age women to stop or not start hormone treatments and doctors to not prescribe them.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was confusing. The beginning implies that there is new research on the value and safety of hormone replacement, but the only clinical research studies quoted are years old.", "answer": 0}, {"article": "Control subjects were recruited from volunteers at the locations where the study was being conducted.\n\"This is the first paper demonstrating an objective method of diagnosing mTBI that relies on physiologic parameters,\" said Hoffer, who is professor of otolaryngology at the University of Miami Miller School of Medicine.\nThe goal was to identify OVRT performance metrics that differentiated between mTBI and control groups and to create a model that could accurately evaluate mTBI neurologic status in patients.\nThese findings illustrate how use of the I-Portal goggle can better identify oculomotor, vestibular and reaction time (OVRT) differences between those with mild traumatic brain injury (mTBI) and non-affected individuals.\nA team of researchers from the University of Miami Miller School of Medicine has shown that the I-Portal Neuro Otologic Test, which uses the head-mounted goggle that gauged eye movement through video cameras and computers, can successfully diagnose concussion with 95 percent specificity and 89 percent sensitivity.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release makes it clear that this is a new technology, since one of the study authors had only been evaluating the goggle for two years. An Internet search shows that University of Miami received a NFL grant to test the new I-Portal goggle only in November 2014.\nA researcher also comments in the news release that the PLoS One paper is the first to demonstrate \u201can objective method of diagnosing mTBI that relies on physiologic parameters.\u201d\nTherefore, we suggest the news release merits a Satisfactory rating here.", "answer": 1}, {"article": "A recent study has found evidence suggesting text messages could reduce one\u2019s odds of a second heart attack.\n\nA six-month clinical trial in Australia found that patients recovering from a heart attack were more likely to maintain lower blood pressure, less body fat and lower cholesterol levels than a control group when the patients received text messages asking and giving suggestions about their health routines. Patients receiving the texts also were more likely to be active and to quit smoking than the patients in the control...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The text does a decent job of explaining the novel aspects of the study compared to some similar efforts, though more could have been included on the results of the previous research.\nAlso, since this particular study was actually published nearly a year ago, in September 2015, an effort to update our understanding of message effects would seem to make sense.", "answer": 1}, {"article": "Schneider\u2019s team has been following the patient, taking samples from his colon, liver, spinal fluid and brain as he developed various conditions that justified the tests.\nNearly four years after the transplant, the patient is free of the virus and it does not appear to be hiding anywhere in his body, Thomas Schneider of Berlin Charite hospital and colleagues said.\nThis patient appears to have a fully functioning immune system, they found, which appears genetically identical to cells from the donor \u2014 not the patient\u2019s own immune cells.\n\u201cIt\u2019s not practical and it can kill people,\u201d said Dr. Robert Gallo of the Institute of Human Virology at the University of Maryland, who helped discover the human immunodeficiency virus that causes AIDS.\n\u201cIt is possibly a cure, that\u2019s for sure, you won\u2019t know for absolute sure until the person dies and undergoes extreme PCR (genetic) analysis of post-mortem tissue.\u201d\n\nThe mutation affects a receptor, a cellular doorway, called CCR5, that the AIDS virus uses to get into the cells it infects.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story apppropriately points out the uniqueness of the report. The patient presented with leukemia and HIV and a donor was available who happened to have te CCR5 mutation.", "answer": 1}, {"article": "TUESDAY, March 20, 2018 (HealthDay News) -- Tiny pellets could treat arthritic knee pain, delaying the need for knee replacement surgery, a small study has found.\n\"Patients overall were able to improve their physical function in the knee after the procedure, and there were no adverse events related to this treatment,\" said lead researcher Dr. Sandeep Bagla.\nThe results were presented Monday at the Society of Interventional Radiology's annual meeting, in Los Angeles.\nFinal results from this clinical trial are expected to be released this summer.\n\"You don't normally have this degree of increased blood supply to this lining.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story stated that this is the \u201cfirst U.S. clinical trial\u201d of this procedure.", "answer": 1}, {"article": "Glover seized the opportunity to participate in a study on the safety and effectiveness of an experimental treatment that could give her daughter protection against accidental exposure to peanuts.\nThe risk paid off: Two-thirds of the kids in the study were able to eat the equivalent of two peanuts without any symptoms after following the months-long experimental treatment regimen, the researchers found.\n\"It's intuitive that that process would trigger some allergic symptoms in many patients,\" Vickery said.\n\"I'm telling patients when I see them that my hope is that patients will have access by late next summer, something like that,\" Vickery said.\n\"The purpose is not to get them to be no longer peanut allergic and allow them to eat whatever they want.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story says that the treatment would be a new one, making clear that no other approved product exists for treating peanut allergy. \u00a0\u00a0\nIt doesn\u2019t explain that immunotherapy \u2014 which attempts to desensitize people with food allergies by giving them tiny doses of the food they\u2019re allergic to over time \u2014 is an old idea.", "answer": 1}, {"article": "Still, with an infection that currently has no good treatment and leads to an estimated 275 million lost work days a year in the U.S., well, what a difference a day makes.\nBy comparison, a normal cold lasts about a week.\nThe researchers did not study nasal zinc remedies, however.\nA typical adult has a few colds every year.\nSingh said there was no evidence of a similar danger from the lozenges or syrups.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story talked about how this review fits into the growing amount of research around zinc.", "answer": 1}, {"article": "The AHA further breaks down the unsaturated-fat advice by suggesting that people devote about 5% to 10% of their daily calories to foods containing linoleic acid.\nThis information involved deaths from heart-related causes, and the new analysis showed that the omega-6 group had a 17% higher risk of dying during the study period from heart disease, compared with 11% among the control group.\nThe study is actually a reanalysis of data that had not been included in the original publication of results from the Sydney Diet Heart Study, a trial that was conducted from 1966 to 1973.\nA study shows that not all good fats are the same when it comes to protecting your health\n\nA study shows that not all good fats are the same when it comes to protecting your health.\n\u201cOne of the things we learned is that we need to look at the whole picture,\u201d says Lichtenstein.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that the mortality findings of this study were previously reported in 1978, and that the cardiovascular findings are new. That\u2019s more detail than HealthDay provided.", "answer": 1}, {"article": "There was a great need, the authors concluded, to \u201cimprove awareness of this important advice.\u201d\n\nThe fact that fish oil is also sold as a nutritional supplement has made it harder for some doctors to regard it as a powerful drug, experts said.\nLack of F.D.A.\n\u201cIf people paid more attention to guidelines, more people would be on the drug,\u201d Dr. Jacobson said.\n\u201cBut pharmaceutical companies can\u2019t drive this change.\nhas not approved it for that use.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 1}, {"article": "There\u2019s ample reason for caution.\nAll were taking statins to lower LDL cholesterol.\nInflammation is a sign of damage from cholesterol.\nHDL cholesterol is not fully understood, but essentially sucks cholesterol out of cells, to be flushed from the body through the liver.\nThe first patients will be enrolled in April, according to Dr. Rory Collins of Oxford University, where the research will be overseen.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story points out that this drug is one of a new class of drugs intended to alter cholesterol levels using a different biological mechanism than statins. ", "answer": 1}, {"article": "Why would an immune-related gene affect aging eyes?\nWhile there\u2019s no treatment for the advanced dry form, the \u201cwet\u201d form occurs when leaky blood vessels grow under the retina \u2014 and there are several therapies that can help those patients preserve vision.\nThose are the only patients who appeared to benefit from the drug; they had 44 per cent less eye damage than the untreated patients, the Genentech team reported Wednesday in the journal Science Translational Medicine.\nThe experimental drug, lampalizumab, aims to slow the destruction of light-sensing cells in the retina, creeping lesions that characterize the stage of dry AMD called \u201cgeographic atrophy.\u201d When those cells die, they can\u2019t grow back \u2014 the vision loss is irreversible.\nThe hypothesis: Genentech\u2019s drug, lampalizumab, essentially offers a backup method for tamping down the immune reaction.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story claims this is the first treatment found to be effective for geographic atrophy macular degeneration. This claim appears accurate, so the novelty of the drug is appropriately established.", "answer": 1}, {"article": "A new generation of treatments for severe eczema is on the horizon, which doctors say could help millions more patients gain relief from chronic outbreaks of the oozing, itchy and sometimes debilitating rashes that come with the disease.\n\nAt least two new eczema medicines could be approved by the U.S. Food and Drug Administration in 2017, and a half-dozen more drugs are being tested in clinical trials.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that, if approved, \u201ccrisaborole would be the first new nonsteroidal treatment for eczema in more than a decade.\u201d \u00a0But at least two\u00a0immune modulators have been available to treat eczema for some 15 years (in 2001 the FDA approved tacrolimus and a related drug, pimecrolimus, for such use). \u00a0The story does not acknowledge these existing drugs and makes no effort to compare the patient outcomes of the drugs-in-waiting with those of the already available immune modulators.", "answer": 0}, {"article": "Bardwell hasn't worked since November because his condition, inherited, makes breathing so difficult.\nThe study calls for Torre to implant the system, done through small puncture holes in the lower back, in 20 patients with advanced heart failure, then conducting tests on them after one, two and three months to measure heart function.\nThe hope is that such stimulation will modulate nervous system responses, such as toning down the release of hormones that typically occur at times of stress and increasing the flow of blood.\nThe method, commonly used to treat pain, activates nerves that Methodist Hospital doctors think will improve the heart's ability to pump effectively, lowering blood pressure, reducing the amount of irregular heartbeats and stopping stress hormones from overreacting and causing cardiac damage.\nNew pathway to the heart\n\nElectrical stimulation of the spinal column may ease cardiac problems without drugs\n\nIn a possible new way to treat heart failure, Houston surgeons implanted a device and wire in a Pearland man Monday that will electrically stimulate portions of his spinal cord.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The approach being discussed is, indeed, innovative, but we think it\u2019s a stretch to state categorically, as this story did,\u00a0that \"no one\" has attempted to take therapeutic advantage of the relationship between the brain, nervous system, and heart before. Research for example has long described a link between depression and heart risks, and some investigators have tried to exploit this knowledge previously by offering psychotherapy or antidepressant therapy to patients with heart disease.\u00a0There\u2019s also some question about whether this research team is in fact the first to implant a neurostimulation device for treatment of heart failure; a press release issued on July 29 claims\u00a0another team studying this issue had already enrolled its first patient. Regardless of who was first,\u00a0the story could have mentioned that other researchers are actively investigating this area.", "answer": 0}, {"article": "So who wouldn't want a pill to fight the doldrums caused by skipping too many time zones too fast?\nFinally, it should be said that the Drug Enforcement Administration has made Nuvigil a federally controlled substance because it has the potential for abuse and dependence.\nThe regulators just gave a second thumbs down to drugmaker Cephalon's application to sell Nuvigil as a remedy for jet lag.\nBut the regulators weren't buying the evidence put forward by the company to prove the medicine's benefits in treating travelers' \"excessive sleepiness\" outweighed its risks.\nThe medicine has also been linked to rare but life-threatening skin rashes, including Stevens-Johnson syndrome, and carries a prominent warning about that risk.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "In a brief piece, the story gave a good history of this drug and now its second \u201cthumbs down\u201d from regulators on the application for marketing approval for jet lag.", "answer": 1}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nThe test approximates the average blood glucose levels over the previous 2 or 3 months, based on the amount of glucose that has accumulated on the surface of red blood cells.\nAccording to the authors, comparatively few studies have examined whether the HbA1c test could help identify the risk for gestational diabetes, and these studies have been limited to women already at high risk for the condition.\nThe authors noted that further studies are needed to confirm whether measuring HbA1c levels in early pregnancy could determine a woman\u2019s later risk for gestational diabetes.\nSimilarly, research is needed to determine whether lowering HbA1c with lifestyle changes, either in early pregnancy or before pregnancy, could reduce the risk for the condition.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release is clear about the theoretical potential of the test to determine early risk, and eventually, the theoretical potential of lifestyle changes to modify that risk.", "answer": 1}, {"article": "Here is how I would think about asking the question instead: What is the easiest way to reduce my chance of death?\nBut a closer look at the data suggests that this is probably just a statistical artifact: This intense running group contains only 36 people and two deaths, versus hundreds of people in the more casual running groups.\nThe goal here is to use these METs and their relationship to health to analyze the value of walking compared with jogging or running.\nLet\u2019s first look at the results from two papers \u2014 here and here \u2014 that relate energy expenditures from walking (in MET hours per day) to the risk of death.\nThe chart below shows results for two studies of runners that, again, relate METs to hazard rates of death.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story not only points to multiple studies, published between 2013 and 2015, but it also includes links to several stories in other news outlets on similar subjects. The novelty here is the author\u2019s own analysis of the literature and the conclusions that she reaches. It is not presented as breaking news, but rather as the author\u2019s interpretation of the available evidence.", "answer": 1}, {"article": "Alzheimer's disease is the most common age-associated neurodegenerative disorder that has no cure.\n\"Taken together, our findings from these people confirm the data obtained with animal models and support, for the first time in human subjects, our notion that calcineurin inhibition has a protective effect on the development and possible progression and even reversal of Alzheimer's disease,\" said senior author Giulio Taglialatela, Professor and Vice Chair for Research in the department of neurology and director of UTMB's Mitchell Center for Neurodegenerative Diseases.\nHowever, the question of whether such a strategy would prevent the onset and progression of Alzheimer's in people is challenging because treatment with a calcineurin-blocking agent suppresses the immune system.\nTo bypass this issue, the UTMB team analyzed data from the medical records of 2,644 patients who received organ transplants and must take calcineurin inhibitor-based medications, such as Tacrolimus or cyclosporine, for the rest of their lives to prevent rejection of the transplanted organ.\nThe UTMB research team and others have shown previously that this enzyme plays a central role in the harmful effects of the A\u03b2 oligomers and that elevated calcineurin is found in the nervous system of Alzheimer's patients.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The story described previous animal research leading up to the current study in humans. And the findings from the study are interesting and novel. Given that these drugs have been used for decades, at least in the case of cyclosporine, it\u2019s surprising that this effect hasn\u2019t been noted before \u2014 all the more reason the finding needs replicating and examination with a stronger study design.", "answer": 1}, {"article": "Lanctot and Fargo do not recommend that relatives or friends of those with agitated Alzheimer's provide them medical marijuana to ease their suffering.\n\"This is the first clinical trial to show that a cannabinoid can decrease agitation,\" said lead researcher Krista Lanctot, a senior scientist at Sunnybrook Health Sciences Center in Toronto.\nHowever, many study patients suffered from sedation due to the drug, noted Keith Fargo, director of scientific programs and outreach at the Alzheimer's Association.\nA form of synthetic THC is available in the United States, called dronabinol and sold under the trade name Marinol, Lanctot said.\n\"We wouldn't want to change clinical practice based on one study,\" Lanctot added.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "An independent source cited in the story says:\nMarinol is now being tested for its usefulness in treating Alzheimer\u2019s symptoms. People interested in trying it should reach out to one of the big clinical trials; Johns Hopkins is one of the centers testing Marinol.", "answer": 1}, {"article": "I'm not waking up.\u201d\n\nSigns of sleep apnea, according to the National, Heart, Lung and Blood Institute, include:\n\u2022 Dry mouth or sore throat when you wake up\nInspire is an invasive procedure, so it is not recommended as a first-line treatment and not everyone is a candidate.\nThis causes breathing to stop multiple times throughout the night, and oxygen levels in the body to fall \u2014which was happening to Turner.\n\u201cI was exhausted all the time, from the time I woke to the time I went to bed,\u201d says Turner.\n\u201cIt was 41 times per hour that I would stop breathing,\u201d says Turner.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We know that there are a number of \u201cremote-controlled\u201d internal devices already on the market so what makes this one novel is open to question yet not clearly answered in the story.", "answer": 0}, {"article": "But scientists also realized it could have other uses.\nIn trials on mice, the antibody was found to increase bone mass and reduce adipose tissue (fat)\u2014and while human studies are some way off, the findings could lead to new treatments for weight loss and osteoporosis.\nBut it could also be a unique drug because it lowers body fat and makes bones stronger.\nTen years ago, scientists started looking at the hormones made in the pituitary gland to see how they act on certain targets.\nIt\u2019s a fairly dramatic effect.\u201d Mice also showed increased oxygen consumption, higher levels of physical activity and more heat production in beige fat (which dissipates energy around the body).\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story provides sufficient background on the research to make clear how researchers reached this point. The story would have been stronger if it had noted that this was the first study to look specifically at the role of this antibody in addressing obesity in lab mice.", "answer": 1}, {"article": "\"Although we do not know why the men who took saunas more frequently had greater longevity (whether it is the time spent in the hot room, the relaxation time, the leisure of a life that allows for more relaxation time, or the camaraderie of the sauna), clearly time spent in the sauna is time well spent,\" Redberg wrote.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentioned that the results of this study were not novel and built on existing research.", "answer": 1}, {"article": "; Karen L. Margolis, M.D., M.P.H.\nThe study was also limited by the relatively small number of strokes that occurred during the follow-up period (just 3.4 percent of the women experienced a stroke during the study period and 1.6 percent reported having had a stroke prior to the study) and by the Women's Health Initiative's exclusion of women who had already had severe strokes at the time of recruitment.\nBecause the study was observational, it couldn't establish a cause-and-effect relationship between breastfeeding and lower stroke risk, meaning that it is possible some other characteristic that distinguishes between women who breastfeed and those who don't is the factor changing the stroke risk.\nHowever, because the Women's Health Initiative is large, researchers were able to adjust for many characteristics, and the effects of breastfeeding remained strong, Jacobson said.\nThis is among the first studies to examine breastfeeding and a possible relationship to stroke risk for mothers, as well as how such a relationship might vary by ethnicity.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes that \u201cThis is among the first studies to examine breastfeeding and a possible relationship to stroke risk for mothers.\u201d It would have been helpful to briefly note what the other studies found and whether the results were different or had similar conclusions.", "answer": 1}, {"article": "Still, some researchers not involved in the study said the topic required more work.\nWe need more studies, funded by someone other than the company that makes the product.\u201d\n\nSmoking is the largest cause of preventable death in the United States, killing more than 480,000 Americans a year.\nThe smoking rate has declined substantially since the 1960s, but the pace of decline has slowed in recent years and health experts are trying to figure out how to get more smokers to quit.\n\u201cThe approach taken here is a very reasonable one that appears to have been successful,\u201d said Gary A. Giovino, a professor of health behavior at the State University of New York at Buffalo.\nThe practice is common for smoking cessation therapies, said Robert West, director of tobacco studies at University College London, who was among the study\u2019s authors.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that gradually cutting down on smoking, with the help of patches and gum, is an established way to change habits. However, it suggests that the current study \u201cis the first that appears to show the same for pills,\u201d which is not entirely accurate. As noted above, the competing drug\u00a0bupropion has been studied in this context and shown to offer potential benefits. Since this is essentially the same problem that we noted above under \u201cAlternatives,\u201d however, we won\u2019t penalize the story again for this omission.", "answer": 1}, {"article": "The researchers are continuing the treatments and compiling data.\nThe procedure was repeated in 28 patients whose fibroids had not been fully treated, as shown by MRI, and 11 of those patients subsequently got pregnant.\nAfter an average follow-up of almost six years, 149 of the 359 women, or 41.5 percent, had become pregnant one or more times, and 131 gave birth to a total of 150 babies.\nHowever, myomectomy is not always possible or effective and can result in major complications including hysterectomy, according to study co-author Jo\u00e3o Martins Pisco, M.D., Ph.D., from the Department of Interventional Radiology at Saint Louis Hospital in Lisbon, Portugal.\nFor the new study, Dr. Pisco and colleagues assessed pregnancy rates in 359 women with uterine fibroids who were unable to conceive and who underwent either conventional or partial UFE.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t make an outward claim of novelty. However, there is novelty here in that there\u00a0is\u00a0little published evidence on fertility rates after UFE and this adds to the body of available research.", "answer": 1}, {"article": "In this study, the average age was about 59 years old - six years younger than the age at which the U.S. Preventive Services Task Force, a government-backed panel, recommends all women begin being screened for osteoporosis.\nThe researchers then found that their ability to accurately diagnose those same patients with osteoporosis from a CT scan depended on what threshold for bone density they used.\n\u201cI don\u2019t think at this point this one test is going to prevent further testing.\nI think it will identify patients who are at a higher risk and need more testing,\u201d said Hull, who wasn\u2019t involved with the new research.\nAt the lower threshold, the researchers found 9 percent of those diagnosed with osteoporosis were misdiagnosed.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of the study and its findings were clear in the story.", "answer": 1}, {"article": "Revenues from pharmaceutical and device corporations and health insurance providers are available at http://www.\nPrevious separate studies have shown that a Mediterranean diet reduces certain risk factors for cardiovascular disease, as does a vegetarian diet; however, this was the first study to compare effects of the two distinct eating patterns\n\nCurrent study authors said they wanted to evaluate whether switching to a lacto-ovo-vegetarian diet would also be heart-healthy in people who were used to eating both meat and fish.\nThe study included 107 healthy but overweight participants, ages 18-75, who were randomly assigned to follow for three months either a low-calorie vegetarian diet, which included dairy and eggs, or a low-calorie Mediterranean diet for three months.\nStill, \"the take-home message of our study is that a low-calorie lacto-ovo-vegetarian diet can help patients reduce cardiovascular risk about the same as a low-calorie Mediterranean diet,\" Sofi said.\n\"To best evaluate this issue, we decided to compare a lacto-ovo-vegetarian diet with a Mediterranean diet in the same group of people,\" said Francesco Sofi, M.D., Ph.D, lead study author and professor of clinical nutrition at the University of Florence and Careggi University Hospital in Italy.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release clearly establishes the novelty of this study (which is also mentioned in the published study):\nPrevious separate studies have shown that the Mediterranean diet reduces certain risk factors for cardiovascular disease, as does a vegetarian diet; however, this was the first study to compare effects of the two distinct eating patterns.", "answer": 1}, {"article": "But you can't make any conclusions about definite health benefits\" based on the study findings, said lead author Suzanna M. Zick, a naturopathic physician and research associate professor at University of Michigan Medical Center, Ann Arbor.\nTUESDAY, Oct. 11, 2011 (HealthDay News) -- A small, preliminary study finds that ginger root supplements seem to reduce inflammation in the intestines -- a potential sign that the pills might reduce the risk of colon cancer.\nBut for now, she said, \"if you want to embrace ginger because you like the taste, go ahead,\" but there's no solid evidence that it prevents colon cancer.\nHowever, more study needs to be done, and the researchers aren't yet recommending that people head to the supplements' aisle or start gobbling up more ginger at meal times.\nResearch has supported its use to treat stomach problems such as nausea and vomiting; the U.S. National Library of Medicine says it's \"likely safe,\" although some people may develop mild side effects.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story at least gives this context:\n\u201cPrevious research in animals has suggested that ginger can reduce inflammation but isn\u2019t potentially toxic to the stomach like aspirin, Zick noted. And scientists have linked chronic inflammation in the gut to colon cancer, suggesting that easing this inflammation could reduce the risk of the disease.\u201d", "answer": 1}, {"article": "Dr. Len Horovitz, a pulmonary specialist at Lenox Hill Hospital in New York City, agreed.\nBut he believes \"the use of overhead, low-level far-UVC light in public locations would be a safe and efficient method for limiting the transmission and spread of airborne-mediated microbial diseases, such as influenza and tuberculosis.\"\nIt appears that low-dose far-UV light is safe and effective, and has the advantage of inactivating a wide range of disease-causing viruses.\"\nAs the researchers explained, broad-spectrum UVC light kills viruses and bacteria, and it is currently used to decontaminate surgical equipment.\nHowever, \"because viruses and bacteria are much smaller than human cells, far-UVC light can reach their DNA and kill them,\" he said in a university news release.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It is made clear the authors have studied this type of light in killing methicillin-resistant staph. aureus (MRSA), but it\u2019s not clear if the current study is the first to apply far-UVC light to an influenza virus (in the published study the authors claim this is the first time far-UVC light has been assessed for inactivating aerosolized viruses).", "answer": 0}, {"article": "Patches in the mouse study contained an array of 100 needles, each some 650 microns in length, or about the width of a few strands of human hair.\nThe microneedle technology may also be used for other vaccinations, such as polio and measles, said Prausnitz.\nHe also said that although initially there will be start-up costs, he thinks the price will be no more than traditional flu vaccines once it is mass-produced.\nInfected with the influenza virus 30 days later, both groups that received the vaccine remained healthy while mice in the control group contracted the flu and died.\nIt is estimated to affect more than 10 percent of the adult population.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There are a variety of methods\u00a0under development for delivering painless injections, including a similar patch technology being investigated by Japanese researchers. A nasal spray vaccine also is available. The story did not mention these.", "answer": 0}, {"article": "\"'Promising' is the perfect way to describe our findings,\" said study lead author Dr. David Woodrum, an interventional radiologist at the Mayo Clinic in Rochester, Minn. \"But whether or not this minimally invasive approach would ultimately become a primary method of treatment in the future will depend on the long-term results of this trial, which is still under way.\nRather, they said that for certain patients who may not be eligible for more standard surgical approaches, the therapy has potential as an alternative means for offering an improved quality of life for a longer period of time.\nThe authors noted that side effects were minimal, typically involving air or fluid around the lungs after the procedure, and in all cases were resolved quickly.\nFor his part, Dr. David Carbone, a professor and director of the James Thoracic Center at the Ohio State University Wexner Medical Center, said that the findings regarding cryoablation are \"not incredibly novel,\" given that the procedure has been around for years.\nThe study authors cautioned that while the initial findings are encouraging, the treatment should not be seen as a cure for this type of metastatic (spreading) lung disease.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We\u2019ll give the story the benefit of the doubt for at least quoting the \u201cindependent\u201d expert as saying the findings \u201care not incredibly novel\u201d although there was no meat hung on those bones to help reader comprehension.", "answer": 1}, {"article": "You know, they go to rehab and there\u2019s not much more [more] they can recover usually.\u201d\n\nFor the study, Steinberg and his team recruited 18 patients who had suffered their first and only stroke six months to three years prior to the trial.\nIn Steinberg's study, it did not \u201ccause problems by differentiating into unwanted tissues or forming tumors.\u201d And even when the stem cells came from an unrelated donor, the participants did not experience a strong immune reaction.\nResults showed that the implanted stem cells didn\u2019t survive very long in the brain, disappearing about one to two months after injections; however, patients still showed significant motor recovery at six and 12 months post-surgery.\nThe findings suggest that stroke-damaged areas of the brain, once thought to be dead or irreversible, can actually be \u201cresurrected.\u201d\n\nSource: Steinberg G, Kondziolka D, Wechsler L, et al.\n\u201cThe recovery some patients showed was not just minimal, it was significant,\u201d said Steinberg, who has researched stem cell therapies for more than 15 years.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We\u2019ll\u00a0give this a Satisfactory rating here because the article does make the point that the stem cell therapy trial in question does demonstrate safety and some efficacy; and it also notes\u00a0that the benefits were detected regardless of the severity, duration, or location of the stroke in the test population.\nAnd it does well by mentioning that previous research showed the stem cells used can \u201ctreat\u201d brain cell damage caused by loss of oxygen, essentially what happens in an ischemic stroke. The article could have done better by saying whether that past research was done in lab-grown cells or in animals.", "answer": 1}, {"article": "Other Northwestern authors include Kate Tomasino, Emily Lattie, Hannah Palac, Mary J Kwasny, Kenneth Weingardt, Leland R Bardsley, Lauren Caccamo, Colleen Stiles-Shields and Stephen Schueller.\nThe preliminary study did not include a control arm, so it's possible that some people who enrolled in the trial would have improved anyway, partly because they may have been motivated to try something new, Mohr said.\n\"We designed these apps so they fit easily into people's lives and could be used as simply as apps to find a restaurant or directions,\" said lead study author David Mohr, professor of preventive medicine and director of the Center for Behavioral Intervention Technologies at Northwestern University Feinberg School of Medicine.\n\"Some of the participants kept using them after the study because they felt that the apps helped them feel better,\" Mohr said.\nAlthough the apps are not validated, each one was designed by Northwestern clinicians and based on validated techniques used by therapists.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The releases says, \u201cMost apps designed for mental health typically offer a single strategy to feel better or provide too many features that make them difficult to navigate. Users may get bored or overwhelmed and may stop using the apps after a few weeks.\u201d\nThis statement doesn\u2019t adequately explain why the same problems wouldn\u2019t apply to the apps described in the release. (After all, the study was only 8 weeks long.) \u00a0Nor are we told how these apps differ from the thousands of others on the market.", "answer": 0}, {"article": "Scientists have used a form of stem-cell therapy to improve survival rates for the most severely sick lupus patients, a group that usually has no remaining treatment options.\n\nLupus is an autoimmune disease that attacks an individual's own organs, causing symptoms that range from swollen joints and skin rashes to severe damage to kidneys, lungs and other parts of the body.", "question": "Does the story establish the true novelty of the approach?", "explanation": "This article reported on \nusing nonmyeloablatic hemapoetic stem cell transplantation (HSCT) to treat patients with systemic lupus erythematosus (SLE) \nwho not responding to the standard therapy. This medical therapy is currently in use as a means of treating several kinds of \ncancers.", "answer": 1}, {"article": "In a separate analysis published in the same issue of JAMA Cardiology, researchers used data from the PARADIGM-HF trial to model the health consequences and cost-effectiveness of Entresto over a 30-year time period.3 They compared Entresto to the ACE-inhibitor enalapril and found Entresto was associated with more than a year longer average survival time, and that it was cost-effective compared to enalapril when these medications were used with other standard of care therapies.3 For every 1,000 patients treated with Entresto vs. enalapril, potentially 59.7 HF hospital admissions could be averted per each year alive in the model.3 In addition, Entresto increased life expectancy at an incremental cost-effectiveness ratio consistent with other high-value widely accepted cardiovascular interventions such as implantable cardioverter defibrillators (ICDs) and cholesterol-lowering statins before they became generic.3\n\nAbout Heart Failure\n\nHeart failure is a debilitating and life-threatening condition, which impacts nearly 6 million Americans and is the leading cause of hospitalization among Americans over the age of 65.4,8 About half of people with heart failure have heart failure with reduced ejection fraction (HFrEF).5 Reduced ejection fraction means the heart does not contract with enough force, so less blood is pumped out.9 Heart failure presents a major and growing health-economic burden that currently exceeds $30 billion in the United States, which accounts for both direct and indirect costs.10\n\nAbout Entresto\n\nEntresto is a twice-a-day medicine that reduces the strain on the failing heart.\n\"In addition to survival benefits, the study also recognizes other treatment effects of Entresto, particularly in reducing HF hospitalizations.1 Coupled with the recent Class I recommendation, the strongest endorsement, in the focused update to the US HF Guideline,2 these findings underscore the potential of Entresto as a standard therapy for chronic HFrEF patients.\"\nIn particular, management's expectations regarding Entresto could be affected by, among other things, the uncertainties inherent in research and development, including unexpected clinical trial results and additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain proprietary intellectual property protection; general economic and industry conditions; global trends toward health care cost containment, including ongoing pricing pressures; unexpected safety, quality or manufacturing issues, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission.\nIt does this by enhancing the protective neurohormonal systems (Natriuretic Peptide system) while simultaneously inhibiting the harmful effects of the overactive renin-angiotensin-aldosterone system (RAAS).11 Other heart failure medicines only block the harmful effects of the overactive RAAS.12 Entresto contains the neprilysin inhibitor sacubitril, and the angiotensin receptor blocker (ARB) valsartan.11\n\nEntresto is indicated in the US to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.11 Entresto is usually administered in conjunction with other heart failure therapies, in place of an Angiotensin Converting Enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB).11 Entresto film-coated tablets are available in three dosage strengths: 24/26 mg, 49/51 mg, and 97/103 mg (sacubitril/valsartan).11 These doses are referred to as 50 mg, 100 mg, and 200 mg in the clinical trial literature including the New England Journal of Medicine publication of the results of PARADIGM-HF.\nThe target treatment dose of Entresto is 97/103 mg twice daily.11\n\nNovartis is committed to providing patients with affordable access and resources through Entresto Central.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that this analysis is not the first, but is novel because it quantifies \u201cpossible\u201d impact in reducing death.\n\u201cThis analysis, based on an application of the results of PARADIGM-HF to published heart failure statistics, is the first to quantify the possible impact of Entresto\u2019s potential benefit in reducing death.1\u2033", "answer": 1}, {"article": "Error code 404. Something went\n\nwrong and we can't seem to find\n\nthe page you're looking for.\n\n Report a broken link.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions a \u201csmall but growing\u201d number of hospitals that offer this microsurgery along with a backdrop of concern that women aren\u2019t being adequately monitored for lymphedema following breast cancer treatment:\nYet too often women aren\u2019t warned about symptoms or checked for early signs, when lymphedema is more easily treated, said Dr. Sheldon Feldman of New York\u2019s Montefiore Einstein Center for Cancer Care. He co-authored physician guidelines issued this fall by the American Society of Breast Surgeons on prevention and treatment of breast cancer-related lymphedema.", "answer": 1}, {"article": "For the study, Lumeng's team collected data on more than 43,700 Michigan preschool-age children between 2005 and 2013.\nWhether those children were in another preschool program wasn't stated.\nAlmost one-quarter of preschool-aged children in the United States are overweight or obese, and obesity rates within Head Start populations are higher than national estimates, the study authors noted.\nThe program is designed to build stable family relationships, improve children's physical and emotional well-being and develop strong learning skills.\nThe daily routine might translate into less TV time and more regular sleep schedules, she said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Is this the first time that researchers have investigated the effects of Head Start participation on childhood obesity? The story doesn\u2019t say.", "answer": 0}, {"article": "Moscona said tests were needed that would show the drug actually helped reduce disease symptoms in animals.\n\u201cDevelopment of effective antiviral drugs and vaccines for human parainfluenza virus has lagged far behind influenza, despite the recognized impact of these diseases in children\u201d and adults, \u201cparticularly the elderly, immunocompromised and patients with underlying airway disease.\u201d\n\nParainfluenza viruses are not closely related to flu but belong to another family of viruses called paramyxoviruses.\nThe researchers said that means patients with flu-like symptoms could get the drug without the need for a test to show whether their infection was caused by influenza or parainfluenza.\nBecause Fludase affects the human cells that viruses infect, not the virus itself, it is less likely to cause the virus to develop resistance, the company believes.\nAdding parainfluenza to its approved indications would provide a unique and potentially large market for San Diego-based NexBio.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "       \n \nThe story mentioned that there is no existing vaccine or treatment for parainfluenza viruses. Furthermore, the story rightfully notes that the  study drug works on the human cell and not directly on the virus and as  such is a unique mechanism of action.\n\n ", "answer": 1}, {"article": "\"In addition, it is unknown whether bevacizumab [Avastin] increases survival when added to cisplatin-based chemotherapy in patients with advanced non-squamous non-small-cell lung cancer,\" Pirker said.\n\"The practical implication is the possibility to incorporate Avastin with any chemotherapy regimen in the frontline therapy of metastatic non-squamous lung cancer,\" he added.\n\"Today we have a new option to treat non-squamous lung cancer, incorporating Avastin in chemotherapy regimens and in maintenance therapy,\" said lead researcher Dr. Lucio Crino, director of medical oncology at S. Maria della Misericordia Hospital in Perugia, Italy.\nOther serious adverse events associated with Avastin were blood clots in the lungs and nosebleeds, low white blood cell counts, fever along with a low white blood cell count and deep vein thrombosis (DVT), all of which occurred in 1 percent of the patients.\nFor the study, Crino's team studied Avastin in more than 2,200 patients with advanced or recurrent non-squamous non-small-cell lung cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story was clear to indicate that Avastin is used to treat several other types of cancer and to mention in passing that at least for one type, breast cancer, the drug has failed to demonstrate that it has any benefit to patients. \u00a0However \u2013 the story included no insight about any novel mechanism for this drug or why this drug is being examined for use in combination with standard chemotherapy.", "answer": 0}, {"article": "\u201cBut if adults believe in echinacea, they\u2019re going to get benefits \u2014 maybe from placebo \u2014 but they\u2019ll get benefits.\u201d\n\nDr. Coleman, who described himself as \u201cnot much of a pill taker,\u201d hedged a bit when asked if he planned to use echinacea himself.\nFor example, they did not examine the safety of the herbal remedy, only its effectiveness.\nSome might not have a large enough sample to find a small but statistically significant effect.\nIn addition, some studies might not use large enough doses of the herb; others might use a species of echinacea that is less effective.\nThere are several possible reasons that even a carefully devised single study might fail to show an effect that actually exists.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article makes very clear that this treatment has been studied many times before, with contradictory results. ", "answer": 1}, {"article": "In 37 years as a police officer, Edwin Michel coped with a plane crash, a sniper, wildfires and three bullet wounds.\n\nNothing much rattled him until he was diagnosed with prostate cancer in November 2016. His doctor said the cancer wouldn\u2019t kill him but Mr. Michel, now 76 years old, wasn\u2019t entirely reassured. He felt more confident after a genomics test later revealed his prostate cancer was very low risk. The test, known as Oncotype DX, takes a sample from a prostate biopsy and analyzes 17 genes in it to estimate how aggressive...", "question": "Does the story establish the true novelty of the approach?", "explanation": "A diagnostic test that night provide an alternative to the sometimes risky treatments for prostate cancer is certainly novel enough to warrant a story.", "answer": 1}, {"article": "\u201cAlthough there is still research to be done, the system has great potential to bring a new way for breast cancer diagnosis.\u201d\n\nCarolyn Rogers, clinical nurse specialist at Breast Cancer Care in the U.K., says in an emailed statement: \u201cEvidence is needed to demonstrate the accuracy and uses of this device.\nCosts are reduced and the electronics fit into a case the size of a lunchbox.\nThis group, the team says, accounts for 20% of all breast cancer cases.\nThe breast is placed in a scanner cup and an image appears on screen.\nThe patented real-time radiofrequency scanner uses computer tomography and works by using the same technology as a mobile phone, but with only a tiny fraction of its power.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "A paragraph explains that the novelty of this technique lies in its speed and portability.", "answer": 1}, {"article": "For 6.7 million American women of child-bearing age, getting pregnant is not an easy task.\n\u201cThey\u2019ve lost family members generation after generation after generation, or they\u2019ve had family members who\u2019ve suffered from chronic disease that\u2019s totally preventable.\u201d\n\nThese procedures not only help limit the passing on of diseases\u2014 they may also help couples get pregnant faster.\n\u201cWhen we do pre-implantation genetic screening, we can ensure that the embryos are chromosomally normal before transferring them back to the intended mother\u2019s uterus, and that increases the likelihood of implantation,\u201d Dr. Jared Robbins, an associated professor in obstetrics and gynecology-reproductive endo & infertility at Northwestern University Feinberg School of Medicine, told Fox News.\nAccording to the Centers for Disease Control and Prevention (CDC), birth defects caused by genetic disorders affect one in every 33 births in the United States.\n\u201cWe can\u2019t fix the embryos yet, but we can determine which embryos are affected by the disease and which aren\u2019t and only transfer back those that are not affected,\u201d Robbins, who is also a fertility doctor at Northwestern Memorial Hospital, said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Based on this story, readers could be forgiven for assuming that preimplantation genetic screening is a relatively recent development. But that\u2019s not the case.\nAs noted in\u00a0the paper in Nursing for Women\u2019s Health: \u201cTwo decades have passed since preimplantation genetic diagnosis was successfully used to benefit high-genetic-risk couples with a known genetic disorder\u201d (emphasis added). And that paper came out five years ago.", "answer": 0}, {"article": "For those at high risk, doctors recommend blood pressure medicine, quitting smoking, exercising more and eating a healthier diet \u2014 but so far chocolate isn\u2019t on the list.\nResearchers studying more than 33,000 Swedish women found that the more chocolate women said they ate, the lower their risk of stroke.\nScientists speculate that substances known as flavonoids, in particular so-called flavanols, may be responsible for chocolate\u2019s apparent effects on health.\n\u201cGiven the observational design of the study, findings from this study cannot prove that it\u2019s chocolate that lowers the risk of stroke,\u201d Susanna Larsson from Karolinska Institutet in Stockholm told Reuters Health in an email.\nThe women ranged in age from 49 to 83 years.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that previous research has linked higher levels of chocolate consumption with improved heart health.", "answer": 1}, {"article": "The results are chronicled in Robison\u2019s new book, \u201cSwitched On: A Memoir of Brain Change and Emotional Awakening.\u201d\n\nIn a moving, often harrowing narrative reminiscent of \u201cAwakenings\u201d and other popular works by the late neurologist and writer Oliver Sacks, Robison writes of the transformations these sessions helped unlock, the welcome ones \u2014 and the not so welcome.\n\u201cAnd what I wrote about in the book isn\u2019t 10 percent of what they\u2019re doing now.\u201d\n\n\u201cSwitched On\u201d ends in 2013.\nBut his book does illustrate that the consequences can be long-lasting, and detrimental.\u201d\n\nRobison remains optimistic that as research continues, the potential benefits will outweigh the risks.\nStill, there are a number of clinics currently offering TMS as an autism treatment, a practice that concerns many researchers.\nRather, it may be best used to alleviate certain symptoms associated with spectrum disorder, including depression.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Though TMS isn\u2019t new, its use for autism should still be considered novel. As the story states \u201cTMS is not yet recommended as an autism treatment.\u201d", "answer": 1}, {"article": "It was funded by Arena Pharmaceuticals, Inc., which developed lorcaserin.\nBut lorcaserin is far more selective than the drug fenfluramine and much safer, its manufacturer says, because it specifically targets the serotonin receptor associated with hunger while having no impact on the heart.\nThe drug lorcaserin works on the serotonin receptor -- the same appetite-controlling hormone targeted by the notorious drug fenfluramine, the \"fen\" component of combination medication fen-phen.\nJuly 14, 2010 -- An experimental weight loss drug that targets the brain\u2019s hunger center was shown to be safe and effective for helping dieters shed pounds in a two-year study, researchers say.\nPeople who continued on the drug for two years were able to maintain their weight loss better than those switched to placebo after one year, researcher Steven R. Smith, MD, of the Florida Hospital and the Sanford-Burnham Institute tells WebMD.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story places this drug into a sort of horse race of diet drugs galloping toward approval by the FDA. It does a pretty good job explaining why this one is different than the others, but it doesn\u2019t do a great job of explaining how this works in comparison to the OTC\u00a0drugs out there now.", "answer": 1}, {"article": "\u201cPatients readmitted after surgery almost always have a postoperative complication, either medical or surgical,\u201d Drs.\n(Reuters Health) \u2013 Patients who need to be rehospitalized within a month after major surgery have a lower risk of death over the next two months if they return to the hospital where they had the surgery rather than going to a different facility, according to a new study.\nIt might be harder for patients to get appropriate care at the other hospitals, where they don\u2019t have a pre-existing relationship with a surgeon, and so treatment might be delayed, Dimick and Miller wrote.\n\u201cMost clinicians or surgeons feel like if you take the time to do a big operation on someone, you know the area operated on, how the operations went, if there were complications,\u201d lead author Dr. Benjamin S. Brooke of the University of Utah School of Medicine in Salt Lake City told Reuters Health by phone.\n\u201cA lot of readmissions are patients who have time to be transferred or triaged, if they are not bleeding to death or having a heart attack,\u201d he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t establish whether this is the first study of its kind or whether it builds upon previous research. The study authors noted that they found no prospective or retrospective studies that were applicable to the subject and were published between 1990 and February 1, 2014.\u00a0But they also say that, while their data were being analyzed, two observational studies were published \u2014 containing conflicting results.\u00a0The story doesn\u2019t provide this context.\nThe story also could\u2019ve met the standard here by noting that there are policies in place that attempt to reduce readmissions. So the idea of focusing on readmissions as a way to improve care is not novel, although this study provides important new data on the issue.", "answer": 0}, {"article": "Chronic rhinosinusitis (CRS) affects a sizable minority -- 14 percent to 16 percent -- of U.S. residents.\n\"Some people with stage 1 and 2 diseases may even get cured.\nFollowing the surgery, about 76 percent of patients had \"clinically significant\" improvement in quality of life, as measured by various validated scales.\n\"I don't think it means everyone with CRS should consider surgery.\nThis is a wonderful renewed hope of feeling better.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 1}, {"article": "To place an electronic embedded link to this study in your story This link will be live at the embargo time: http://jamanetwork.\nNicholas S. Reed, Au.D., of the Johns Hopkins School of Medicine, Baltimore, and colleagues compared five of these devices (costs, approximately $350 to $30) with a conventional hearing aid (cost, $1,910) among 42 adults (average age, 72 years) with mild to moderate hearing loss.\nPersonal sound amplification products (PSAPs) are less-expensive, over-the-counter devices not specifically labeled for hearing loss treatment, but some are technologically comparable with hearing aids and may be appropriate for mild to moderate hearing loss.\nPresently, hearing aids can only be purchased in the United States through a licensed professional, with an average cost of $4,700 for two hearing aids (uncovered by Medicare).\nEditor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The novelty seems so obvious in hindsight, but it is clear: How do PSAPs really stack up against hearing aids? The answer is surprising and worthy of a release, even though the sample size was small and the methodology lacked some real-world challenges (e.g. putting on a PSAP correctly and properly adjusting it).", "answer": 1}, {"article": "If you'd like to find out more about this procedure, please click here\n\"I was so happy that I was OK, that I had escaped the open heart,\" Barletta says.\nIn less than a week, she was starting back to her regular routine, including exercise.\nInstead of 10 days in the hospital, there long months of recovery and a lasting scar like her mother \u2014 one that she had to have plastic surgery to repair \u2014 Barletta was out of the hospital in two days.\nI was absolutely terrified because I saw my mom go through it, and I saw how much pain she was in,\" Barletta says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "While the story was about a new\u00a0medical device being tested to treat heart valve problems, percutaneous valve replacement dates back to the 1960's.", "answer": 0}, {"article": "Together, stomach and oesophageal cancer account for around 1.4 million new cancer diagnoses each year worldwide [2].\nAmsterdam, The Netherlands: A test that measures the levels of five chemicals in the breath has shown promising results for the detection of cancers of the oesophagus and stomach in a large patient trial presented at the European Cancer Congress 2017 [1].\nThe trial was based on the results of previous research that suggested differences in the levels of specific chemicals (butyric, pentanoic and hexanoic acids, butanal, and decanal) between patients with stomach or oesophageal cancer and patients with upper gastrointestinal symptoms without cancer.\nThe team is also working on breath tests for other types of cancer, such as colorectal and pancreatic, which could be used as first-line tests in general practice surgeries.\nIn the new study, the research team collected breath samples from 335 people at St Mary's Hospital, Imperial College Healthcare NHS Trust; University College London Hospital; and the Royal Marsden Hospital, London.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "We\u2019ll give the release a pass on this since a breath test for screening for these specific cancers would be a new development, if proven effective, and the release does reference other research that formed the foundation for the new study.\nHowever, the release did not explain how this research is distinct from other work in the area. It would have been helpful had the release noted that many research teams around the world are evaluating breath tests to detect various types of cancer and other diseases. A report out of Israel in 2015 sparked wide news coverage of research into a breath test that appeared to be able to distinguish stomach cancer from pre-cancerous lesions, many of which do not develop into cancer.", "answer": 1}, {"article": "\"Data have consistently shown declines in these important measures among prostate cancer patients undergoing cancer therapy without any structured fitness interventions, so the stable scores seen with our yoga program are really good news,\" Vapiwala said.\nThe full results from the feasibility study are expected to be published early 2016.\nAnd all of this ultimately improves general quality of life,\" she added.\nIn addition to yoga, patients can receive training in stress-reduction techniques, meditation, reiki therapy, acupuncture, and massage.\nThese latter aspects may in turn improve erectile dysfunction and urinary incontinence, said Vapiwala.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release said this is the first such effort to assess the potential value of yoga in this setting.", "answer": 1}, {"article": "Benign prostate hyperplasia, also known as enlarged prostate, is a non-cancerous condition familiar to millions of aging males.\nSince the study is being presented at a medical meeting and has not yet been published in a peer-reviewed journal, the findings should be considered preliminary.\nThe catheter delivers tiny \"grains\" to the arteries that lead to the prostate, which block blood flow and lead to shriveling of the gland.\n\"Because medication is so effective, most of the patients that we treat surgically are in pretty bad shape,\" she added.\nOther minimally invasive treatments for enlarged prostate that are currently available are less effective and have a greater risk of a need for reoperation, according to background materials that accompanied the study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story seemed to suggest that the procedure reported on was novel; it should have mentioned (as the competing WebMD story did) that it is already in use to treat other non-cancerous, hyperplastic conditions.", "answer": 0}, {"article": "For more information, go to www.bayer.us.\nThe trial was a multicenter, multi-national, randomized, open-label study conducted in 11 countries in Europe, Latin America, the U.S. and Canada.\nIn the clinical trials, serious adverse reactions occurring in more than a single subject included: ectopic pregnancy/ruptured ectopic pregnancy (10 subjects); pelvic inflammatory disease (6 subjects); missed abortion/incomplete spontaneous abortion/spontaneous abortion (4 subjects); ovarian cyst (3 subjects); abdominal pain (4 subjects); depression/affective disorder (4 subjects); and uterine perforation/embedded device (myometrial perforation) (3 subjects).\nIndication for Kyleena \n\nKyleena\u2122 (levonorgestrel-releasing intrauterine system) is a hormone-releasing IUD that prevents pregnancy for up to 5 years.\nWHIPPANY, N.J., Sept. 19, 2016 /PRNewswire/ -- Bayer announced today that the U.S. Food and Drug Administration (FDA) approved Kyleena\u2122 (levonorgestrel-releasing intrauterine system) 19.5 mg, a progestin-containing intrauterine system (IUS), for the prevention of pregnancy for up to five years.1 Kyleena will be available by prescription only in October 2016.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "As noted above, it\u2019s not clear from this release (at least to a non-expert audience) how Kyleena differs from other, intrauterine levonorgestrel-releasing products that are already on the market.", "answer": 0}, {"article": "New blood tests will speed up diagnosis for the most common GI disorder\n\nLOS ANGELES (May 14, 2015) - Millions of people afflicted by irritable bowel syndrome can now be diagnosed quickly and accurately with two simple blood tests developed by a Cedars-Sinai gastroenterologist.\nAn estimated 10 percent of the world's population suffers from the condition.\n\"With these new blood tests, many patients will now be able to proceed right to therapy for their condition.\"\nFatigue and the stress of trying to plan one's life around visits to the bathroom can be debilitating.\nIBS is the most common gastroenterological disorder in the United States, affecting nearly 40 million people.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "These are the first blood tests for diagnosing IBS caused by food poisoning, and the release says so.", "answer": 1}, {"article": "\u201cThere\u2019s definitely a major need for a permanent, total artificial heart,\u201d Laman A.\nThe Lasker Foundation, which is based in New York, praised their work in the development of artificial heart valves, saying they had \u201cprolonged and enhanced the lives of millions of people with heart disease.\u201d\n\nIn the November 2009 bulletin of the Acad\u00e9mie Nationale de M\u00e9decine, Dr. Carpentier wrote that, instead of picking up from older models of artificial hearts built on animal research, the developers of the new device had sought to use the tools of the digital revolution, namely computer-assisted design, hemodynamic modeling, regulation algorithms and simulations.\nIn the United States, the National Heart, Lung and Blood Institute, a unit of the National Institutes of Health, is supporting efforts by two separate groups, one led by Dr. O. H. Frazier of the Texas Heart Institute in Houston, the other by Dr. Leonard A. R. Golding of the Cleveland Clinic.\nImplanted in the patient\u2019s chest after the diseased heart is removed, it uses information gleaned from sensors to mimic the activity of the natural organ.\nThe French company is not the first to make total artificial hearts, which are meant to completely replace damaged and diseased organs.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Insufficient explanation of what sets this device apart from others.\u00a0 Only this:\u00a0 \"instead of picking up from older models of artificial hearts built on animal research, the developers of the new device had sought to use the tools of the digital revolution, namely computer-assisted design, hemodynamic modeling, regulation algorithms and simulations.\"\u00a0 But what does that mean about its novelty?\u00a0 No explanation or details given. ", "answer": 0}, {"article": "\"I could ride a bike!\n(CNN) By the time Cynthia Falardeau read about Alex Pring, a little boy who got a battery-powered robotic arm last summer, she had made peace with her son Wyatt's limb difference.\nPetresky says they ask every family about the child's favorite color, superhero and interests, so the new limb can \"not just be a piece of plastic ... but be a part of them.\"\n\"We quickly found out this is much less about fitting in and feeling normal, and much more about expressing yourself,\" Petresky said.\n\"His main interest was to create a shocking response from onlookers by pulling it off in the grocery store,\" Falardeau wrote on CNN iReport .\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Although the story reports that the featured college students are the only ones making an electronic arm using 3D printers, it does not tell readers what is actually new, if anything, about how this device performs for users as compared to other prosthetic arms.", "answer": 0}, {"article": "While the American Cancer Society, the American College of Physicians and other gastroenterology experts recommend virtual screening every five years, the U.S. Preventive Services Task Force, a congressionally mandated but non-federal, independent group of medical experts, concluded the evidence wasn\u2019t strong enough to justify Medicare coverage of the service.\nAs its name implies, virtual colonoscopy is way to survey the colon without actually using a scope.\nIn McHugh\u2019s survey, hospitals reported that these patients make up the bulk of their use.\nThe images can be viewed as two dimensional CT scans, which display any possible abnormalities protruding from the lining of the colon.\nThe night before the test, they start drinking clear liquids and take agents to loosen their stools and empty their colon so any remaining debris isn\u2019t mistaken for a tumor during the screen.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story adequately frames the growing use of this technology.", "answer": 1}, {"article": "Guadecitabine works to reverse a so-called epigenetic change in cancer cells known as methylation, which may alter genetic activity in cells in a way that can block the action of tumor-suppressing genes, pushing cells to become cancerous and resistant to therapy.\n\"We did see that giving a higher dose of the drug seemed to produce a better methylation response among patients,\" says Valerie Lee, M.D., a fellow at the Johns Hopkins Kimmel Cancer Center.\nThe current study was based on previous studies in the laboratory of Nita Ahuja, M.D., director of the Sarcoma and Peritoneal Surface Malignancy Program and professor of surgery at the Johns Hopkins University School of Medicine, which showed that guadecitabine limited the growth of colorectal cancer cell lines when combined with irinotecan, says Azad.\nAmong the side effects of the combined treatment, 16 patients experienced neutropenia, a low count of the infection-fighting white blood cells called neutrophils; five patients with neutropenia had fevers; three patients became anemic; and two patients developed thrombocytopenia, a lowered count of blood-clotting platelets.\nAlthough the study's main purpose was to test the safety rather than the effectiveness of guadecitabine doses, \"we were very happy to see some patients who benefited from the combination of the therapies for many months to more than a year,\" says Nilofer Azad, M.D., professor of oncology at the Johns Hopkins University School of Medicine.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "As noted above, there are a lot of drugs and combinations\u00a0approved for use\u00a0in colorectal cancer chemotherapy. The release does a good job of explaining how\u00a0guadecitabine may act against colorectal cancer. \u00a0There are currently two FDA approved drugs that are classified as\u00a0DNA methyltransferase inhibitors; decitabine (Dacogen) and azacitidine (Vidaza). \u00a0Both had been used in clinical trials in the treatment of colon cancer.", "answer": 0}, {"article": "Women taking oxybutynin also reported improvement in work, social activities, leisure activities, sleep and overall quality of life.\n\"Because of this, we can take advantage of the 'side effect' and decrease involuntary sweating associated with hot flashes, and decrease the hot flashes as well,\" he explained.\nFor example, the drugs may raise the risk for problems with short-term memory, reasoning and confusion, and may also hike the risk for dementia among older patients, studies indicate.\nThe drug could be game-changing for certain women, said Dr. Alice Police, regional director of breast surgery at Northwell Health Cancer Institute in Sleepy Hollow, N.Y.\n\n\"This is a really important advance in survivorship and compassionate cancer care,\" added Police, who wasn't involved in the study.\n\"I will never forget the first time a patient said, 'Thank you for curing my breast cancer, but you ruined my life,' \" she said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is the first time that a drug is this class has been shown to have an effect on hot flashes, and so is newsworthy for this reason. That could have been more explicit in the story, though.", "answer": 1}, {"article": "These studies have been done with people, but other promising research has only been done with lab animals so far. In one 2009 study in the Journal of Medicinal Food, tart cherries helped fat rats. Not our favorite role models perhaps, but the obese beasties' risk of Type 2 diabetes and heart disease were reduced significantly, and parallel studies are now in the works with members of our own species, says lead author E. Mitchell Seymour: \"There are some interesting and potentially exciting results on the horizon. Stay tuned.\"", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story attempted to paint a broader picture of other cherry research that\u2019s been conducted.", "answer": 1}, {"article": "Evivo has commenced rigorous clinical trials with the prototype to demonstrate the results from infant stool samples.\nThe liquid will remain pink if a sample has low levels of acetate and lactate, indicating that Bifidobacterium is missing and that key nutrients from breast milk, human milk oligosaccharides (HMO), are being wasted.\nPoint-of-Care Diagnostic Expert Turns Focus to the Infant Gut\n\nThe development of the prototype is led by Dr. Bethany Henrick, Ph.D., Director of Immunology and Diagnostics for Evivo.\n\"Currently there is no way to easily determine whether a baby is colonized with healthy bacteria,\" said Mark Underwood, M.D., Chief of Neonatology at UC Davis Medical Center.\n\"This is the first and only point-of-care screening test designed to identify infants that do not have enough Bifidobacterium levels to create a stable infant gut microbiome,\" said Dr. Henrick.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The novelty is not made clear, and especially so for the stool test. A study linked to by the release also does not contain any methods \u2014 they are available only by request \u2014 making it doubly difficult to assess the novelty of the device.", "answer": 0}, {"article": "Galipeau was not involved in the Porter study.\n\"Here's this guy, the handwriting is on the wall, any hematologist will tell you he is a goner -- this guy was essentially cured,\" Galipeau tells WebMD.\nMoreover, the signal does not call down the deadly all-out immune attack -- the feared \"cytokine storm\" -- that can do more harm than good.\n\"I think it is a big deal,\" says Jacque Galipeau, MD, professor of hematology and medical oncology at Emory University Winship Cancer Center.\nOne of the molecules, CD19, makes the T cells attack B lymphocytes -- the cells that become cancerous in CLL.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story did a great job placing the findings into context and showing exactly why they have been found so promising by the study\u2019s authors and other researchers. \u201cAll this has been done before. These genetically engineered cells are called chimeric antigen receptor (CAR) T cells. They kill cancer in the test tube. But in humans, they die away before they do much damage to tumors. What\u2019s new about the current treatment is the addition of a special signaling molecule called 4-1BB. This signal does several things: it gives CAR T cells more potent anti-tumor activity, and it somehow allows the cells to persist and multiply in patients\u2019 bodies. Moreover, the signal does not call down the deadly all-out immune attack \u2014 the feared \u201ccytokine storm\u201d \u2014 that can do more harm than good.\u201d", "answer": 1}, {"article": "\"What we found was a very coherent pattern of less cervical cancer among people who\u2019ve used the IUD based on thousands of women \u2014 and the pattern wasn't subtle at all, it was stunning,\" Dr. Victoria Cortessis, the study's lead author and associate professor of clinical preventive medicine at the Keck School of Medicine at the University of Southern California, told BuzzFeed Health.\n\nIUDs are small, T-shaped devices that are placed in the uterus to prevent sperm from reaching an egg. They are a highly effective form of birth control and they can offer protection against pregnancy for up to three, five, or ten years.\n\nThe study is the first of its kind to combine and analyze data from multiple studies to look at the issue. \"We went through all of the relevant human epidemiological data on this topic and narrowed it down to 16 high-quality observational studies of over 12,000 women from all over the world,\" Cortessis says.", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story reported the findings of a systematic review. That means it\u2019s not going to be breaking news. What it does, though, is to synthesize existing research and make clear exactly what the state of current knowledge about the topic is.", "answer": 1}, {"article": "Also, can we distinguish autism from other forms of developmental delay?\"\n\"It is during the toddler/preschool years that autism typically presents and needs to be diagnosed,\" he explained.\nRegardless, this research is promising as a method for identifying young children at risk for autism,\" Dawson said.\nIndeed, the researchers found a difference between autistic brains and typical brains in the level of responsiveness in language areas, Hirsch noted.\nThe report was released in the May 31 online edition of Radiology, in advance of publication in the August print issue.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story shows that there is still a lot of work to be done before MRIs could be used as a novel screening device for autism.", "answer": 1}, {"article": "\"But I would say it would be perhaps more helpful for primary care physicians in an outpatient setting, because that is where it's most challenging to identify heart failure.\nAnd the blood work that would be taken in a doctor's office might not come back until the next day, delaying identification,\" he noted.\nThese include medical history and symptoms, and a physical exam in which a doctor will listen to a patient's heart and lung sounds, and check ankles, feet, legs and abdomen for signs of fluid buildup.\nThe result: The breath test correctly identified all the patients with heart failure, clearly distinguishing them from those cardiac cases where heart failure was not an issue.\nBlood tests and an electrocardiogram can help confirm that heart failure exists.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This sort of breath test would be a new addition to heart failure diagnosis, if it works.", "answer": 1}, {"article": "Scientists in Britain say they have developed a blood and urine test that can detect autism in children.\nThis may help us improve the diagnosis of ASD and point the way to new causes of ASD.\u201d\n\nThe research has been published in the journal Molecular Autism.\n\u2022 Note added 27 February 2018: The UK autism research charity, Autistica, provided the following comment to the Guardian: \u201cThis is a small, early-stage study which may explain one biological difference in autism.\nThe research was led by Naila Rabbani, reader of experimental systems biology at the University of Warwick, who said: \u201cOur discovery could lead to earlier diagnosis and intervention.\nResearchers at the University of Warwick said the test, believed to be the first of its kind, could lead to earlier diagnosis of autism spectrum disorders (ASD) in children who could then be given appropriate treatment much earlier in their lives.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We\u2019re told the study identifies blood and urine tests \u201cthat can detect autism in children\u201d and the tests are believed to be \u201cthe first of its [sic] kind.\u201d\nHowever, as mentioned above, the study does not prove these blood and urine tests can predict or diagnose autism. So suggesting novelty in this way is, at the very least, premature if not sensationalistic.", "answer": 0}, {"article": "\"The [brains of] children who received the ESDM looked virtually identical to typical 4-year-olds,\" Dawson says.\nAs measured by an electroencephalogram (EEG), small children's brains show a specific pattern of activity when they look at a picture of a human face.\nThe treatment, dubbed Early Start Denver Model or ESDM, offers a child 20 hours a week of one-on-one treatment with a trained therapist.\n\"We jump-started and improved the responses of children's brains to social information,\" says Dawson, professor of psychiatry at the University of North Carolina and chief science officer at Autism Speaks.\nBut that's not all, researchers Geraldine Dawson, PhD, and colleagues report.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Although the study itself makes the claim that \u201cThis was the first trial to demonstrate that early behavioral intervention is associated with normalized patterns of brain activity,\u201d the story does not address that stated claim of novelty.\nBasically, this is a reasonably novel treatment with a novel outcome (EEG activity \u2013 although one of uncertain importance).\nIn the nature of news, what\u2019s really new should be pointed out and if it\u2019s not new, that should be pointed out as well.", "answer": 0}, {"article": "\u201cWe believe the benefits increase with age.\nDr. Constance Lehman, a professor of radiology at Harvard Medical School and director of breast imaging at Massachusetts General Hospital, who is not on the task force, said she was pleased to see that although its advice had not changed, the group had placed more of an emphasis than before on the importance of women\u2019s having the freedom to decide how often to be screened and when to start.\nThe guidelines relied in part on a study of records from 405,191 women who had digital mammograms from 2003 to 2011, which found that false positives were common, especially in younger women.\nThe guidelines state that from ages 40 to 74, screening will reduce the odds of dying from breast cancer, with women 40 to 49 benefiting the least and those 60 to 69 benefiting the most.\nBut there are harms, and particularly in their 40s, women have to make a decision for themselves.\u201d\n\nOne potential harm is false positives, in which a suspicious mammogram finding leads to more tests, sometimes even biopsies, but turns out to be harmless.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a nice job of placing the new recommendations in context, discussing its similarities (and differences) to the USPSTF\u2019s 2009 recommendations on mammograms and breast cancer screening \u2014 and how it fits into a broader, ongoing debate on the subject.", "answer": 1}, {"article": "Gelsinger suffered from a genetic liver condition kept under control with pills and diet, but he volunteered for the study to help find a cure for infants with a fatal form of his disorder.\nAt that moment, \u201cI knew what I would do for the rest of my life\u2014find a cure for the disease,\u201d says Gao.\nThe AAV9 therapy is so good at slipping into the brain that one can deliver the drug intravenously into the blood, and it passes through the blood-brain barrier to penetrate all areas of the brain.\n\u201cAnd other than gene therapy, there was no other way.\u201d\n\nGene therapy is well-suited for treating inherited brain diseases.\nThe most promising candidate was adeno-associated virus (AAV)\u2014a virus that grows in the presence of adenovirus but is a completely different type.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is clear that scientists have been trying to develop effective gene therapy strategies for years. \u00a0It also makes a good case that the recent modifications in delivery mechanisms discussed here are indeed news.", "answer": 1}, {"article": "Neurontin causes sleepiness, and soy extracts can produce gastrointestinal troubles.\nThe researchers also examined studies of nonprescription extracts from soy and red clover, which contain plant estrogens called isoflavones and are marketed as a \"natural\" treatment for hot flashes.\nThough hormones cause small increases in the risks for breast cancer and heart disease, a short course may still be the best choice for women with very severe symptoms, she said, though she added that women who have had breast cancer should definitely not take hormones.\nNone of the drugs or extracts are approved by the Food and Drug Administration to treat hot flashes \u2014 only hormones are approved for that purpose \u2014 but doctors are free to prescribe medicines for any use they see fit, and many recommend the drugs or plant products for hot flashes, based on study findings and their patients' experiences.\nThe drugs include the antidepressants Paxil (paroxetine), Effexor (venlafaxine), Prozac (fluoxetine) and Celexa (citalopram), the blood pressure drug Catapres (clonidine), and the seizure drug Neurontin (gabapentin).\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that the use of anti-depressants and certain blood pressure and anti-seizure medications as non-hormonal treatment for hot flashes is not new. However, these prescription medications are not yet FDA approved for this treatment. ", "answer": 1}, {"article": "THURSDAY, April 21, 2011 (HealthDay News) -- For men who believe size matters -- and that their penises don't measure up -- success can be found in certain non-surgical penile lengthening treatments, a new study analysis by Italian researchers contends.\nIn a review of five evidence-based surgical studies of 121 men and six non-surgical studies of 109 men published between 2000 and 2009, the researchers found that penile extenders -- which stretch the organ over a period of months through traction -- were the most effective among non-invasive methods.\nThese devices yielded average flaccid length increases of between 0.2 inches and 1 inch, Gontero said, and men achieving better results noted their satisfaction.\n\"Application of progressive and constant traction forces is a very old-fashioned technique used by the ancestors and currently by some tribal populations to elongate the penis or the neck,\" he said.\n\"On the contrary, more complex lengthening procedures are to be considered experimental and potentially dangerous,\" he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Because the story adequately explained that it was reporting on a retrospective review of the medical literature \u2013 by definition it was not reporting on novel conclusions \u2013 only the overview of past studies.", "answer": 1}, {"article": "The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about diabetes medicines.\nIn a journal commentary, Clifford Bailey of Aston University in Birmingham, England, cautioned that, \"on the journey to approval of a new class of treatment for type 2 diabetes, many questions will be asked of [drugs such as TAK-875],\" including questions of how long they might remain effective, as well as safety issues.\nAs for TAK-875, it targets a separate mechanism \"but again, until more is known about short-term and long-term cardiovascular effects, we need to proceed with moderated enthusiasm for each new drug and drug mechanism,\" Wissner Greene said.\nShe said that, \"though this study includes a small sample size followed for a short period of time, the results are promising in that TAK-875 appears to be effective for glycemic [blood sugar] control without significant risk for hypoglycemia or weight gain.\nThe trial, led by Dr. Charles Burant of the University of Michigan Medical School, included 426 patients with type 2 diabetes who were not getting adequate blood sugar control through diet, exercise or treatment with the first-line diabetes drug metformin.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story includes this appropriate caveat in the context of \u201cnovelty\u201d:\nIn a journal commentary, Clifford Bailey of Aston University in Birmingham, England, cautioned that, \u201con the journey to approval of a new class of treatment for type 2 diabetes, many questions will be asked of [drugs such as TAK-875],\u201d including questions of how long they might remain effective, as well as safety issues.", "answer": 1}, {"article": "\"The risk of MS among daughters whose mothers consumed four glasses of milk per day was 56% lower than daughters whose mothers consumed less than three glasses of milk per month,\" Harvard researcher Fariba Mirzaei, MD, says in a news release.\nHowever, few foods naturally contain the vitamin.\nThe disease most often strikes adults after age 20, but it can develop in children.\nIt revealed that women born to mothers who had the highest intake of vitamin D had a much lower risk of developing MS as an adult.\nThe study involved more than 35,000 female nurses whose mothers answered questions about their diet habits during pregnancy.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story indicates that other studies have found a link between vitamin D and MS.\u00a0 ", "answer": 1}, {"article": "Thourani V, Jensen H, Babaliaros V, Kodali S, Rajeswaran J, Ehrlinger J, Blackstone E, Suri R, Don C, Aldea G, Williams M, Makkar R, Svensson L, McCabe J, Dean L, Kapadia S, Cohen D, Pichard A, Szeto W, Herrmann H, Devireddy C, Leshnower B, Ailawadi G, Maniar H, Hahn R, Leon M, Mack M. Outcomes in Nonagenarians Undergoing Transcatheter Aortic Valve Replacement in the PARTNER-I Trial.\nFor the study, the researchers used two different approaches: transfemoral TAVR (TF-TAVR), which is the traditional approach performed via the groin, and transapical TAVR (TA-TAVR), which is performed via the heart muscle.\nThe ability to safely treat AS patients has become increasingly important; the US government predicts that the number of Americans over the age of 85 will exceed 11 million in the next 20 years.\nAs part of the PARTNER-I trial, Vinod H. Thourani, MD, from Emory University in Atlanta, and colleagues from 12 other institutions in the United States found that transcatheter aortic valve replacement (TAVR) is a safe and effective way to treat aortic stenosis in nonagenarians who qualify for the surgical technique.\nWhile the current study did not evaluate other alternative options for TAVR, these techniques may include transaortic, transcaval, transcarotid, or trans-subclavian.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes that this study is \u201cthe largest series published to date.\u201d However, the release would have been better if it had added a little bit of additional context. Does this work expand on an already robust literature in the field? Or is it relatively new?", "answer": 1}, {"article": "WASHINGTON\u2014The Food and Drug Administration questioned the clinical benefit of using GlaxoSmithKline PLC's Avodart to cut the risk of prostate cancer.\n\nAvodart is currently approved to treat benign enlargement of the prostate. The company is seeking FDA approval to market the drug to certain men to reduce the risk of prostate cancer. The drug will be reviewed by an FDA advisory panel on Wednesday along with Merck & Co.'s Proscar, a drug similar to Avodart.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t try to oversell the novelty of using Avodart to prevent prostate cancer. But it could have made it clearer that the effects seen with Avodart\u00a0(i.e. prevention of low-risk tumors, increased risk of aggressive tumors) are very similar to those reported previously with Proscar, a drug in the same family. This increases our confidence that the findings are a real effect and not random fluke of the data.", "answer": 1}, {"article": "A new method for performing a \u201cvirtual\u201d colonoscopy that requires less unpleasant preparation was shown in a new study to accurately detect larger precancerous polyps\u2014and was a better experience for patients.\n\nThe second-leading cause of cancer deaths in the U.S., colon cancer can be prevented if precancerous polyps\u2014known as adenomas\u2014are found and removed during a colonoscopy\u2026.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of the \u201cnew method\u201d using a software program to electronically \u201ccleanse\u201d the bowel was clear in the story.", "answer": 1}, {"article": "Foods and fruits high in these antioxidants have been dubbed as \"super foods\" or \"super fruits\" by the media.\nAntioxidants are a group of compounds known to fight the damaging effects of oxidative stress on cells within the body and are increasingly thought to have many heart-healthy properties.\nResearchers found the antioxidant activity of dark chocolate and cocoa powder was equivalent to or higher than that found in some other so-called \u201csuper fruit\" powders or juices, including acai berry, blueberry, cranberry, and pomegranate.\nTwo groups of antioxidants in particular, polyphenols and flavonols, which are found in various fruits and seeds, have been the focus of much research due to their potentially healthy effects.\n\"These substances help keep the arteries healthy and are protective against cardiovascular disease,\" says preventive cardiologist Suzanne Steinbaum, MD, of Lenox Hill Hospital in New York City, in an email.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Researchers have been exploring the\u00a0health\u00a0effects of chocolate\u00a0for more than a decade.\u00a0There have been\u00a0dozens of studies on the subject (and\u00a0perhaps\u00a0as many Valentine\u2019s Day news stories), and yet this story makes it sound like\u00a0this study might be the first to document\u00a0potential benefits. The story should have referenced the extensive literature that supports\u00a0consumption\u00a0of very small amounts\u00a0of minimally\u00a0processed dark chocolate for better health.", "answer": 0}, {"article": "Almost 20 years ago, Gray studied how babies respond to a heel prick to draw blood, a procedure that screens newborns for genetic disorders.\nIt is as it sounds: Like a kangaroo's pouch, mothers hold their naked newborns on their bare chest for the first few hours of life.\nIt's not just that mother and baby are together, Gray says, but also that the mother is in some way \"programming the baby, the breathing, temperature and heart rate.\"\nHe found that when healthy newborns had kangaroo care, there was less facial grimacing and crying suggesting pain, compared to babies who had been swaddled and had the procedure in their bassinets, \"sort of alone.\"\nThe close contact also allows the baby to be exposed to the same bacteria as the mother, which can protect against allergies and infection in the future.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It is clear from the story that this practice is not novel around the world, but is somewhat novel in the U.S. That appears to be accurate.", "answer": 1}, {"article": "This posed a conundrum.\nBut the downsides to getting a vaccine are extremely minimal, and flu shots may still be helpful in reducing some illness and saving lives, which is why public health experts say you should get vaccinated anyway.\nIn kids, the highest-quality evidence \u2014 a randomized controlled trial \u2014 suggests the vaccine works well enough: On average, if you give six kids under the age of 6 a flu shot, you can expect to prevent one case of the flu.\nAs Roger Baxter, the co-director of the Kaiser Permanente Vaccine Study Center, told me, \"Flu vaccines are not a panacea, and do not prevent all cases of flu, even in the best years, when there are no manufacturing problems and the match is perfect.\"\nIn a good year, when the WHO guesses correctly and the flu shot matches the strains in circulation, you need to give 33 adults flu shots, on average, to prevent one case of illness.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story appropriately explains that this vaccine has been around for decades. The story is taking a second look at the vaccine\u2019s effectiveness, which as it explains varies from year to year and may not be as high as most people think.", "answer": 1}, {"article": "Our research shows for the first time that mefenamic acid, a simple [NSAID] can target an important inflammatory pathway called the NLRP3 inflammasome, which damages brain cells,\u201d David Brough, lead author of the study said, in a statement.\nBut, they also warned that these \u201cdrugs are not without side effects and should not be taken for Alzheimer\u2019s disease at this stage - studies in people are needed first.\u201d\n\nThe research was published in the journal Nature Communications on Thursday.\nResearchers, who conducted the study on mice, found that mefenamic acid \u2014 a common Non-Steroidal Anti Inflammatory Drug (NSAID) used to relieve menstrual pain \u2014 can completely reverse memory loss and brain inflammation that are hallmark changes of Alzheimer\u2019s, which currently affects over five million Americans.\nBecause this drug is already available and the toxicity and pharmacokinetics of the drug is known, the time for it to reach patients should, in theory, be shorter than if we were developing completely new drugs,\u201d Brough said.\nAlzheimer\u2019s disease, the most common form of dementia, can be fully cured with an anti-inflammatory drug commonly used for period pain, a new research by the University of Manchester shows.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There is a discussion about how this class of drugs may be developed as \u201ca\u00a0class of existing drugs that are likely to treat Alzheimer\u2019s.\u201d\n\u201cLikely\u201d is probably a stretch here, but certainly there seems to be an effort underway to investigate the use of known drugs and \u201cre-purpose\u201d them. So there is some discussion of novelty here.", "answer": 1}, {"article": "(CNN) The first large head-to-head comparison of two opioid addiction medications found that, although they were equally effective in getting people off of high levels of opioids, users had a significantly more difficult time starting a regimen of naltrexone, compared with buprenorphine.\nIf a person is using opioids and takes naltrexone, it can induce a feeling of withdrawal.\nBuprenorphine is commonly known by the the brand name Suboxone, and naltrexone is sold under the brand name Vivitrol.\nMethadone may be the best-known form of medicated-assisted treatment, but it requires patients to have the drug administered daily in a clinic.\nBuprenorphine and methadone, which are opioids, work by reducing people's cravings.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The lead touts the study as \u201cthe first large head-to-head comparison of two opioid treatment drugs.\u201d", "answer": 1}, {"article": "Fish-oil supplements don't appear to help pregnant women prevent post-partum depression or boost the baby's brain development as previously believed, according to a large trial published Tuesday in the Journal of the American Medical Association.\n\nThe 2,400-woman, randomized study complicates the advice for pregnant women. It adds to a body of mixed research on some potential benefits of the popular omega-3 fatty acid known as DHA, or docosahexaenoic acid. DHA, which can move from the mother to the baby during pregnancy, accumulates...", "question": "Does the story establish the true novelty of the approach?", "explanation": "Past research on this topic is covered quite clearly. ", "answer": 1}, {"article": "This was especially true in the left hemisphere regions of the brain responsible for language.\n\"Although autism is still principally a clinical diagnosis, this study ... may allow for a new approach to classifying children with autism and may even assist in the early identification of affected children at a younger age,\" said Dr. Andrew Adesman, chief of developmental and behavioral pediatrics at the Steven & Alexandra Cohen Children's Medical Center of New York in New Hyde Park, NY.\nTUESDAY, June 26, 2012 (HealthDay News) -- Electroencephalogram (EEG), a test that shows the electrical activity of the brain, might be used to spot autism in children, a new study suggests.\n\"Synchronization between different brain regions indicates that those regions are functioning in a coordinated, rather than independent, fashion -- in other words, they are functionally connected and communicating with each other,\" she said.\n\"Consistent with many previous studies using EEG and functional MRI with both children and adults with autism, these investigators found that, overall, children with autism show reduced coordination (coherence) across brain regions.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story nicely explains that this research builds on earlier research by including a larger group of children being studied. It says, \u201c\u2018What was unique about this study is the very large number of children studied,\u2019 Dawson noted. \u2018Consistent with many previous studies using EEG and functional MRI with both children and adults with autism, these investigators found that, overall, children with autism show reduced coordination (coherence) across brain regions.'\u201d", "answer": 1}, {"article": "This study received funding from the Divers Alert Network and U.S.\n\"During immersion in water, particularly cold water, susceptible people have an exaggerated degree of the normal redistribution of blood from the extremities to the chest area, causing increased pressure in the blood vessels of the lungs and leakage of fluid into the lungs,\" said Richard Moon, M.D., an anesthesiologist and medical director of the Duke Center for Hyperbaric Medicine & Environmental Physiology.\nIt dilates blood vessels, giving it the potential to ease an abrupt cold water-induced constriction of blood vessels in the arms and legs that can lead to blood pooling in the heart and lungs.\nThe drug -- best known as Viagra\u2122 -- is normally used for treatment of male impotence, but also for pulmonary arterial hypertension.\n\"It appears that the drug, which dilates the blood vessels, could be creating more capacity in the blood vessels in the arms and legs, reducing the tendency for blood to redistribute to the thorax, and therefore reducing the high pressure in the pulmonary vessels.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes that the drug is already used as a treatment for another lung condition \u2014 pulmonary arterial hypertension \u2014 so this application would be an extension of sildenafil to another lung condition. Health professionals have speculated in the past on the ability of drugs such as sildenafil to help individuals cope with swimming-induced pulmonary edema. The published research notes that this study tested that hypothesis.", "answer": 1}, {"article": "Gout occurs when uric acid builds up in the body and forms crystals in the joints or in soft tissue.\nKrystexxa, which is made by Savient Pharmaceuticals Inc. of East Brunswick, N.J., is an enzyme that lowers uric acid levels by metabolizing it into a chemical that does not cause bodily damage and is then passed through the urine.\nSept. 17, 2010 -- The FDA has approved Krystexxa (pegloticase) for the treatment of gout.\nThe condition is associated with obesity, high blood pressure, high cholesterol, and diabetes.\nTwo six-month clinical trials of 212 total patients showed that the drug lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story states:\u00a0\"Krystexxa is the first-ever and only treatment approved by the FDA for adult patients who suffer with chronic gout that is refractory to conventional therapy,\" Paul Hamelin, RPh, president of Savient Pharmaceuticals, says in a news release.\"\u00a0\nBut why couldn\u2019t we have heard that from an independent expert?\u00a0 \nWe\u2019ll give the story the benefit of the doubt, but barely. ", "answer": 1}, {"article": "A new study offers a fresh strategy for treating patients suffering from both coronary artery disease and heart failure, afflictions linked to poor quality of life and high risk of death that affect as many as two million Americans.\n\nThe 1,212-patient study calls into question the need for immediate bypass surgery in these patients\u2014an approach commonly recommended by doctors. The study, called Stich, found benefits in treating people with medication only, and in treating people with a combination of bypass surgery and medication....", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that there is a great need for more evidence in this field and that this study will be surprising to many clinicians because of a long-held assumption that surgery is the superior option. tudies published in the early 1990s supported the view that bypass surgery provided a better long term outcome.", "answer": 1}, {"article": "And while the percentage of American adults who smoke is at the lowest level since the CDC began tracking such data, there are still an estimated 40 million adult smokers in the U.S.\nWith a year-round campaign we could save even more lives and money.\u201d\n\nTips, the first federally funded anti-smoking paid media campaign, features former smokers talking about their smoking-related illnesses.\n\u201cThe money spent in one year on Tips is less than the amount the tobacco industry spends on advertising and promotion in just 3 days.\u201d\n\nThe most recent Surgeon General\u2019s Report, The Health Consequences of Smoking\u201450 Years of Progress, called for airing effective messages such as the Tips ads with high frequency and exposure for 12 months a year for a decade or more.\nFor more information on the Tips campaign, including profiles of the former smokers, other campaign resources, and links to the ads, visit www.cdc.gov/tips.\n\u201cThe Tips campaign is an important counter measure to the $1 million that the tobacco industry spends each hour on cigarette advertising and promotion,\u201d said Corinne Graffunder, Dr.P.H., director of CDC\u2019s Office on Smoking and Health.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release clearly articulates how the 2014 Tips campaign differed from an earlier Tips campaign, and notes that Tips was the \u201cfirst federally funded anti-smoking paid media campaign.\u201d That\u2019s enough to earn it a pass here. However, again, it would have been great to draw comparisons to other major anti-smoking campaigns. What makes Tips different? Special? More effective?", "answer": 1}, {"article": "For more information, visit http://medicine.\nThe bottom line is that patients who used statins were more likely to survive during and after an elective endovascular procedure.\"\n\"However, further research is needed to assess the benefits of using statins before surgical repair of other types of aneurysms.\"\nThese cholesterol-lowering medications protect blood vessels from plaque formation and stress, and in some cases can even slow the progression of aortic aneurysms.\n\"This information could be beneficial to patients who are about to have elective endovascular abdominal aortic aneurysm repair,\" Vogel said.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "While the release doesn\u2019t explicitly state the study\u2019s novelty, we think it is implicit that no one has studied the outcome of patients who had been taking cholesterol lowering drugs prior to their surgery for aneurysm.", "answer": 1}, {"article": "Doctors and patients\u2019 advocates urged women considering the procedure to go for counseling and take their time before making a decision, noting that other risk-reducing options were available, like tamoxifen therapy for estrogen receptor-positive breast cancer and the use of more sensitive magnetic resonance imaging screening for earlier detection.\nThough the researchers had limited information about the patients, Dr. Tuttle suggested that younger women might be choosing the procedure because their cancers tended to be very aggressive, and they had more years ahead of them in which a second cancer might develop.\nThe numbers were much higher among women who had the breast with cancer removed, rather than a lumpectomy.\nMore women are undergoing genetic testing after a diagnosis of breast cancer, and improvements in both mastectomy and breast-reconstruction techniques have made the option of a double reconstruction less daunting.\nSeveral developments may be driving the trend toward prophylactic mastectomies, experts said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The increase in double mastectomy as prophylaxis after a cancer diagnosis is a new finding. The focus of the story discusses this data and attempts to explain this trend. ", "answer": 1}, {"article": "Last year 61.5m prescriptions for antidepressants were issued in England.\nThese initial findings are interesting, but, as with all areas of mental health, there is still more research to be done.\u201d\n\nMental health problems, including depression, are estimated to cost \u00a3105bn a year in England.\nIt would accelerate our therapeutic interventions and make them more tailored to the needs of the patient.\u201d\n\nBut further clinical research is needed to see if the findings can be applied in a clinical setting, Hallstrom added.\nThe Royal College of Psychiatrists said that, if it worked, the test could prove to be a key moment in the quest for the holy grail of biological psychiatry.\nIf the test proves effective it is hoped that by measuring patients\u2019 level of blood inflammation it would identify which of them would benefit from receiving antidepressants soon after their diagnosis to stop their condition worsening.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "A blood test to predict patient response to antidepressants would likely have value, but not necessarily as a \u201choly grail\u201d as mentioned in the story. There is other active research in this area, and as we\u2019ve discussed before, there are lots of important caveats to keep in mind.", "answer": 0}, {"article": "# # #\nThe new treatment, called HF10\u2122 therapy, uses proprietary high frequency pulses of 10,000 Hz, compared to traditional SCS which uses frequencies of 40 to 60 Hz.\nMore than 1.5 billion people worldwide suffer from chronic pain, with lower back pain being the most frequent condition affecting 23 to 26 percent of the population.\nIdentifying a new intervention that does not rely on paresthesia to mask pain is novel to SCS and has the potential to improve pain relief and quality of life for these complex patients.\nHF10 therapy also provides pain relief without paresthesia \u2013 a stimulation-induced sensation commonly perceived as tingling or buzzing, which masks a patient\u2019s perception of pain \u2013 typical of traditional SCS.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release says, \u201cThis is the first long-term study to compare the safety and effectiveness of high frequency and traditional SCS therapy for back and leg pain.\u201d", "answer": 1}, {"article": "(Reuters Health) - When the results of a test wouldn\u2019t change how doctors manage a patient\u2019s care, most say it\u2019s not worth doing.\n\u201cThe interpretation of these tests is not a simple color-by-numbers thing.\u201d The vast majority of uncertain genes will be benign, but a misinterpretation could lead a patient to a drastic, unnecessary surgical procedure, he said.\nThe BRCA1 and BRCA2 gene mutations put women at high risk for breast, ovarian and other cancers, but mutations of other genes are believed to confer extra risk as well.\nEven among all appropriate candidates who are sent for genetic testing, only nine percent will test positive for the BRCA mutations, so an additional four percent who have non-BRCA mutations is a significant number, Ellisen said.\nBut new tests for breast cancer risk mutations beyond the well-known BRCA genes would offer actionable information for many women and their doctors, a new study finds.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of the research \u2014 the fact that there\u2019s now some evidence that these tests may provide actionable information \u2014 is discussed. It would have been great to put this research and the tests themselves in context with recent legal and scientific advances in the field.", "answer": 1}, {"article": "\"Cardiovascular disease is the number one cause of death in the U.S., and while statins are very effective, a good proportion of people are not meeting their goals, and in this setting the shot could be a valuable addition,\" he said.\nThe study was funded by AMG145 manufacturer Amgen Inc.\n\nHigh cholesterol is a major risk factor for heart disease.\nThere were also decreases seen in levels of total cholesterol and apo-B (tiny fat particles in the blood that also increase the risk for heart disease).\nThe new drug did hit its target, PCSK9, and decreased levels of LDL cholesterol by up to 64 percent.\nThe shot turned off a newly identified cholesterol regulator, PCSK9, which interferes with the liver's ability to clear bad cholesterol from the bloodstream.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that this drug focuses\u00a0on one of the \u201chottest targets\u201d\u00a0for new treatments to lower LDL cholesterol. So readers get the sense that there are other similar drugs in development.", "answer": 1}, {"article": "(Reuters) - Vanda Pharmaceuticals Inc said its experimental drug for a rare sleep disorder proved effective in a second late-stage trial, and the company now plans to apply for a U.S. approval for the drug in mid-2013.\nWhile the first two are efficacy studies, the remaining two are intended to establish the safety profile of the drug.\nThey have gained nearly 8 percent since December 18.\nThe drug is being tested for \u2018non-24-hour disorder\u2019 that has no approved treatment.\nAn orphan drug, if approved, can usually fetch a premium pricing in the market.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of this experimental approach was never explained.", "answer": 0}, {"article": "Line Kessel, an ophthalmologist at Glostrup Hospital of the University of Copenhagen in Denmark, and colleagues have come up with what they say is a promising alternative to replacement surgery.\nThe pulses are so fast, Dr. Kessel said, that two photons hit a target molecule simultaneously, with the same effect as if UV light was used.\nMuch more research and development work remains, Dr. Kessel said, but the goal is a relatively simple procedure that would last half an hour at most and use largely automated equipment in mobile clinics.\nCataracts can be treated by lens-replacement surgery, but the procedure is invasive and costly, requiring special equipment and skilled eye surgeons.\nCataracts are the leading cause of blindness in the world, and are often related to aging.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Not applicable.\u00a0 There aren\u2019t any claims made about novelty, but neither is there any context about any other experimental approaches to cataracts. ", "answer": 2}, {"article": "First author is Dipen Parekh, MD, of the University of Miami.\n\"It is important to conduct these trials before widespread adoption of technology, as has been the case with robotic prostatectomy (removal of the prostate),\" he said.\nBut apart from the RAZOR trial, there have been no prospective, randomized multicenter trials to assess how robotic surgery compares to open surgery in cancer survival.\nThe study is titled \"Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomized, phase 3, non-inferiority trial.\"\nThe RAZOR trial found that two years after surgery, 72.3 percent of patients in the robotic surgery group were alive, with no disease progression and essentially cured, compared with 71.6 percent in the open surgery group.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "While the release does tell readers that what is really new here is the use of randomization to compare robot-assisted surgery to open surgery for bladder cancer, it manages to bury that lead so deep under the poorly worded description of the results of this non-inferiority trial that the thrust of the release is unsatisfactory.", "answer": 0}, {"article": "In an earlier pilot study supported by Life Extension, Drs.\n\"It's an important trial,\" says Dr. Steven Hirsh, director of clinical research for Life Extension in Fort Lauderdale, Fla. \"The findings are very noteworthy and support further study in randomized controlled trials with larger sample sizes and durations.\nThe team of researchers, led by Dr. Rafael de la Torre, program director of IMIM Hospital del Mar Medical Research Institute and study co-principal investigator, and Dr. Mara Dierssen, group leader at Center for Genomic Regulation, Barcelona, Spain, and study co-principal investigator, proposed that EGCG might have conferred these benefits by inhibiting an enzyme called DYRK1A, which has been implicated in Down syndrome and neurodegenerative conditions including Alzheimer disease.\nIn acknowledging the novelty of their findings and calling for more research, the Spanish research team noted that \"\u2026this study is the first well-powered trial that shows improvement in adaptive behavior (functional academics) and brain-related changes in young adults with Down's syndrome.\n\"We are excited that the benefits observed in the early pilot and preclinical research extended to this larger trial,\" says Luke G. Huber, ND, MBA, vice president of product innovation and scientific development at Life Extension.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release does a satisfactory job providing context and detailing what this study brings to the current body of literature. An earlier pilot study supported by Life Extension looked at mice with a \u201cDown-syndrome-life condition\u201d and EGCG intervention. The current study is the first trial to show improvement in adaptive behavior and brain-related changes in young adults with Down\u2019s syndrome, according to researchers. The news release then cautions that more research is needed to understand the correlation between EGCG and cognitive training intervention.\nFor these reasons, we give the news release a Satisfactory rating here.", "answer": 1}, {"article": "He struggled to sleep.\n\u201cThe MDMA alone or the therapy alone don\u2019t appear to be as effective,\u201d Dr. Mithoefer said.\n\u201cWhen it kicked in, it was like an epiphany,\u201d he said.\nA handful of medications meant to help left him feeling like a zombie, and he gave them up.\nI realized I had viewed myself as a monster, and I was able to start to have some compassion for myself.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "In the section \u201cIs MDMA therapy new?\u201d we learn that MDMA-assisted psychotherapy has been both formally, and informally, used in the past.", "answer": 1}, {"article": "Based on the overall results, Devinsky believes CBD should be evaluated for epilepsy types beyond Dravet syndrome, which is caused by a genetic mutation and affects about one in 20,000 to 40,000 children in the United States.\nOn the need for more scientific research, all these experts agree.\nDespite the generally positive results, most study participants reported side effects that included vomiting, fatigue, diarrhea and some liver issues.\nShe was not involved in the new study.\nHowever, there was a downside.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes that these are not novel findings but rather an incremental addition to the body of knowledge around marijuana-derived therapies.", "answer": 1}, {"article": "TUESDAY, Jan. 17, 2012 (HealthDay News) -- Combining two drugs that target an aggressive type of breast cancer known as HER2-positive appears to work better than using either drug alone, researchers report.\nBaselga stressed that the study looked only at women with early-stage HER2-positive breast cancers, and that the drug Tykerb is approved now only for advanced breast cancers.\nThe important question, however, has not been answered yet, Lichtenfeld said.\n\"What we observed was a massive improvement in response,\" Baselga said.\nThose given Tykerb alone had a 25 percent response.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We\u2019ll give the story the benefit of the doubt for at least offering this perspective:\n\u201cLapatinib (Tykerb) was approved for advanced breast cancer in 2007,\u201d Baselga said. \u201cThe question we had was, what is the efficacy if we give it in early-stage breast cancer prior to surgery?\u201d", "answer": 1}, {"article": "For those who have resolved to get fit in the New Year, O\u2019Donovan recommends to start with moderate exercise, such as brisk walking, and then to set realistic, incremental goals to boost confidence without running the risk of setbacks due to injury.\n\u201cThe novel finding is that it appears the duration, and possibly the intensity, of leisure time physical activity is more important than the frequency,\u201d Ekelund said.\n\u201cMillions of people enjoy doing sport once or twice a week, but they may be concerned that they are not doing enough,\u201d said Gary O\u2019Donovan, a physical activity researcher and author on the study at Loughborough University.\n\u201cMy take home message is that the greatest risk reduction and the greatest gain for the individual and for public health is if those who are physically inactive take up some activity,\u201d he added.\nIn the study, those who met the physical activity target by exercising through the week had a 35% lower risk of death than the inactive adults, with cardiovascular deaths down 41% and a 21% lower risk of cancer death.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Unlike the Newsweek story, the Guardian does discuss what\u2019s novel:\n\u201cThe novel finding is that it appears the duration, and possibly the intensity, of leisure time physical activity is more important than the frequency,\u201d Ekelund said.", "answer": 1}, {"article": "The new beds, Fuh said, are much different than similar beds made 20 years ago where patients would lie on their stomachs, put a strap around their pelvis and \u201chold onto handle bars for dear life.\u201d\n\n\u201cThe table now, you just lay on your back, and the machine does all of the work.\nSome of them returned to Earth 1 inch to 2 inches taller.\nIt is less than half the cost of surgery but is rarely covered by insurance.\nThere is a group in Iowa that doesn\u2019t do surgery anymore because they have found more success with this,\u201d Fuh said.\nThe back is gently stretched over a number of treatments, allowing the disc to rehydrate and heal.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Although the story refers to the treatment as \u201cnew,\u201d this is not sufficient information on the novelty of decompression.", "answer": 0}, {"article": "But, lead author Dr. Giacomo Koch said, \u201cWhat we found is that the improvement was more marked in those patients that were more impaired.\u201d\n\nKoch, from the Santa Lucia Foundation in Rome, told Reuters Health he thinks those patients with more severe problems would likely see a benefit outside of just test results.\nThe \u201creal\u201d magnetic stimulation group improved by about 16 percent right after the treatment and 23 percent at the later time point, while there was no significant benefit seen in patients given the fake stimulation.\nSimilar types of stimulation treatment are used in some patients with depression or during spinal surgery, according to Barrett.\nBefore treatment, right after and another two weeks later, stroke patients were given tests to measure their visual-spatial skills, as well as attention and concentration.\nThe researchers said that it\u2019s not clear what the amount of improvement they observed would mean for patients in their daily lives.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains that TMS is currently used for depression and during spinal surgery, and that its use for stroke patients is novel.", "answer": 1}, {"article": "[3]\n\nWriting in a linked Comment, Professor Avan Aihie Sayer from the University of Southampton, Southampton, UK, and Professor Thomas Kirkwood from Newcastle University, Newcastle upon Tyne, UK discuss whether grip strength could be a new biomarker of ageing, writing that, \"This is not a new idea, but findings from PURE add support.\nThe study, published in The Lancet, also found that grip strength is a stronger predictor of death than systolic blood pressure, and the authors suggest that it could be used as a quick, low-cost screening tool by doctors or other healthcare professionals to identify high-risk patients among people who develop major illnesses such as heart failure and stroke.\nA low grip strength was linked with higher death rates in people who develop cardiovascular (eg, heart attack or stroke) and non-cardiovascular diseases (eg, cancer), suggesting that muscle strength can predict the risk of death in people who develop a major illness.\nThe findings show that every 5kg decline in grip strength [2] was associated with a 16% increased risk of death from any cause; a 17% greater risk of cardiovascular death; a 17% higher risk of non-cardiovascular mortality; and more modest increases in the risk of having a heart attack (7%) or a stroke (9%).\nLoss of grip strength is unlikely to lie on a single final common pathway for the adverse effects of ageing, but it might be a particularly good marker of underlying ageing processes, perhaps because of the rarity of muscle-specific diseases contributing to change in muscle function.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes that this association between grip strength and health risks has been documented previously in high-income countries, and that a key feature of this study is the inclusion of people from low- and middle-income countries.", "answer": 1}, {"article": "Knee surgery for a torn meniscus is done about half a million times each year in the U.S.\nAs it is now, \"millions of people are being exposed to potential risks associated with a treatment that may or may not offer specific benefit, and the costs are substantial,\" she wrote.\nIt would be quite reasonable to try physical therapy first because the chances are quite good that you'll do quite well,\" said one study leader, Dr. Jeffrey Katz, a joint specialist at Brigham and Women's Hospital and Harvard Medical School.\nWhen that happens, it's tough to tell if the pain is from the tear or the arthritis \u2014 or whether surgery is needed or will help.\n\"There are patients who would like to get better in a 'fix me' approach\" and surgery may be best for them, said Elena Losina, another study leader from Brigham and Women's Hospital.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story could have done a better job of explaining what was new and novel about the study in question.\u00a0 The researchers wrote:\n\u201c(Two prior) landmark trials established that arthroscopic treatment was not superior to the other interventions in the treatment of knee osteoarthritis, but they did not focus on management of a symptomatic meniscal tear, which is a frequent indication for knee arthroscopy in patients with osteoarthritis of the knee. The efficacy of arthroscopic partial meniscectomy in symptomatic patients with a meniscal tear and osteoarthritis has been evaluated, to our knowledge, in only one randomized, controlled trial, which was a single-center study involving 90 patients. This study did not show a significant difference in pain relief or functional status between arthroscopic partial meniscectomy plus a physical-therapy regimen and physical therapy alone. Given the frequency and cost of arthroscopic partial meniscectomy and the paucity of data, we designed the Meniscal Tear in Osteoarthritis Research (METEOR) trial to assess the efficacy of arthroscopic partial meniscectomy as compared with a standardized physical-therapy regimen for symptomatic patients with a meniscal tear and concomitant mild-to-moderate osteoarthritis.\u201d", "answer": 0}, {"article": "Still, growing numbers of doctors are using the method already to help decide when to order a biopsy, and \"I think the study does raise the question as to whether PSA velocity may at some point be a helpful factor in determining prognosis,\" he said.\nIt's not even clear when is the best time to do a biopsy.\nOnly a biopsy can tell the difference.\nSome men have cancer despite a \"normal\" PSA count of 4 or below.\n\"This is a test that doesn't just diagnose prostate cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It's clear from the article that PSA tests and measurements of PSA velocity are not new.\u00a0\u00a0 ", "answer": 1}, {"article": "Nov. 22, 2010 -- Exercising to piano music may help improve balance and prevent falls among the elderly.\n\nA new study shows older men and women who participated in a piano-music-based exercise program were less likely to suffer a fall than those who didn't. Those who exercised to piano music also showed improvements in balance and the manner or style of walking.\n\n\u201cEach year, one-third of the population 65 years and older experiences at least one fall, and half of those fall repeatedly,\u201d write researcher Andrea Trombetti, MD, of University Hospitals and Faculty of Medicine of Geneva, Switzerland, and colleagues in the Archives of Internal Medicine. \u201cExercise can counteract key risk factors for falls, such as poor balance, and consequently reduce risk of falling in elderly community-dwelling individuals.\u201d\n\nResearchers say a large proportion of falls in elderly people occur while walking, so improving gait and balance can have a major impact on fall prevention.", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\nThe story does not include any claims of novelty of this approach.\n\u00a0\nAnother New York Times article did call attention to this form of exercise with the headline: \u201cDalcroze Eurhythmics Have Come to New York.\u201d The article was published on January 25, 1914. There is indeed nothing new about the method of exercise.\n\u00a0\nReference:\nhttp://query.nytimes.com/mem/archive-free/pdf?res=F20E12FF355D13738DDDAC0A94D9405B848DF1D3\n", "answer": 2}, {"article": "WASHINGTON -- A U.S. Food and Drug Administration panel of outside medical experts backed a Novartis AG drug, Exelon, for treatment of dementia in patients with Parkinson's disease.\n\nExelon is currently on the market to treat mild to moderate Alzheimer's disease. The FDA said it wasn't sure whether dementia associated with Parkinson's was much different than dementia associated with Alzheimer's. Dementia is a condition that typically first presents itself as memory loss greater than what would be expected as part of the normal...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story tells readers that the drug is currently on the market for treatment of mild to moderate Alzheimer\u2019s disease. In other words, the story adequately reports the drug is not new, but is being considered for a new purpose. ", "answer": 1}, {"article": "Remember, Senay urged: Most people can achieve the recommended calcium intake by eating three or four servings of dairy products and other foods that contain calcium per day.\nSupplements are an additional tool to be used when needed.\nThe maximum recommended intake of calcium is 2,500 milligrams.\nAdults over 50 need 1,200 milligrams per day.\nCalcium recommendations vary according to age.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not mention if the supplements are new or different from existing supplements.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/09/national/a005536S75.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear that this drug has been around and been under study for some time. Prophylactic use in reducing mother to child HIV transmission is not new and has been established as effective in clinical trials.", "answer": 1}, {"article": "The results are interesting but need to be duplicated in larger, more ethnically diverse populations, said Dr. Laura Svetkey, director of Duke University's Hypertension Center.\nShe stressed that the study results should not be viewed as license to gorge on chocolate.\nChocolate-makers have embraced these findings and have developed new ways to satisfy the sweet tooth and curb the guilt by introducing more varieties of dark chocolates, fortifying them with vitamins and anti-oxidants, reports Miller.\nThe researchers note that eating a small amount of dark chocolate daily is a dietary change that's \"easy to adhere to,\" reports CBS News partner WebMD.\nEvery day for 18 weeks, the volunteers were instructed to eat one-square portions of a 16-square Ritter Sport bar, or a similar portion of white chocolate.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This piece appropriately mentioned that the study reported on was part of a growing body of evidence that finds consumption of small amounts of dark chocolate has a blood pressure lowering effect.", "answer": 1}, {"article": "A 33-year-old Queens woman who was treated by Batzofin last week fits that bill. Married for two years, she failed to get pregnant through intercourse, with and without drugs. When Batzofin told her about his new procedure, she said, \"Let's go for it.\"", "question": "Does the story establish the true novelty of the approach?", "explanation": "The focus of the story is IVM as a newer method of fertility treatment.\u00a0 The story is clear that there have not been many births from this method. ", "answer": 1}, {"article": "\"You're going through all this suffering and stuff and you want to know, am I going to survive?\nBut researchers are exploring a new use for medical imaging that could shorten the stay in purgatory, possibly revealing within a few days whether chemo is working.\nBut except for lymphoma, PET scans aren't routinely used to get a quicker answer on how cancers are responding to therapy.\nThe hope is that, over time, FLT PET would prove reliable for giving a faster answer on whether an experimental treatment is working.\nThe standard scan, which looks for blood sugar usage, has gotten good results in tests with a variety of tumors including breast, prostate, colorectal and esophageal cancers, said Dr. Steven Larson of the Memorial Sloan-Kettering Cancer Center in New York.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The report makes clear that PET scans are commonly used, but [with the exception of lymphoma] not to determine whether a cancer treatment is working. ", "answer": 1}, {"article": "Eteplirsen, which Sarepta says has shown no side effects so far, is vying with a similar drug being developed by GlaxoSmithKline to become the first medicine that works by directly countering the cause of the disease.\nMr. Garabedian said Sarepta did not have the money or the manufacturing capacity to make the drug available outside of clinical trials.\nThose with the disease make barely any dystrophin, a protein necessary for muscles to function.\n\u201cHe\u2019s no longer riding the handicap bus to school,\u201d she said.\n\u201cThat would be the quickest path to insolvency,\u201d he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that this is new and novel in the treatment of Duchenne muscular dystrophy", "answer": 1}, {"article": "However, they say these findings \u201craise questions that warrant investigation\u201d and call for verification in randomised studies \u201cbefore recommending a change to current practice.\u201d\n\nNotes to Editors\n\n Research: Antenatal nutritional supplementation and autism spectrum disorders in the Stockholm youth cohort: population based cohort study\n\n Journal: The BMJ\nThe researchers stress that their findings cannot establish cause and effect, but say they raise questions about a possible association that warrant further investigation.\nGiven the current understanding and strength of evidence supporting the importance of nutritional supplementation during pregnancy, \u201cit is impossible to imagine that these results, on their own, should change current practice,\u201d they write.\nThere was no consistent evidence that either iron or folic acid use were associated with a reduced risk of ASD.\nResearch indicates that ASD most likely develops in the womb and that a mother\u2019s diet during pregnancy could have an influence.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release informs readers that previous work on maternal nutrition and ASD have been inconsistent and that this study used different and multiple analyses to assess the link.", "answer": 1}, {"article": "We know early intervention is extremely important.\nThe technology has been around for awhile -- developed in the late 1920s, it has been used for more than 60 years to detect seizures in epileptics.\n\"My hope is we would have a simple way of measuring brain activity in every child and see the patterns emerging that might track autism characteristics,\" Bosl said.\n\"In this study, we have taken the first step in showing that there is definitive information in the electrical signals measured by EEG to distinguish normal controls from infants at high risk for developing autism,\" Bosl said.\nTUESDAY, Feb. 22, 2011 (HealthDay News) -- By analyzing patterns in the brain's electrical activity, researchers say they've been able to assess autism risk in children as young as 6 months of age.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story accurately states that EEG is an old test, and that the novel piece is applying new technology to interpret patterns. We do wish that the story had mentioned some of the similar research that has been published in recent months. The study comes on the heels of a very similar study released in December that claimed that a 10-minute MRI scan could find six physical differences in the brain that could correctly identify autism. Doesn\u2019t that seem like an even better, more definitive screening system, assuming that brain scans or EEGs are the route to take?", "answer": 1}, {"article": "\u2022 Keep up to date with Tenovus Cancer Care by following them on Twitter @tenovuscancer or Liking their page on Facebook http://www.\nSinging in a choir for just one hour boosts levels of immune proteins in people affected by cancer, reduces stress and improves mood, which in turn could have a positive impact on overall health, a new study by Tenovus Cancer Care and the Royal College of Music published today in ecancermedicalscience has found.\nFollowing on from this research, Tenovus Cancer Care is launching a two year study looking in more depth at the longitudinal effect of choir singing over several months.\nDr Daisy Fancourt, Research Associate at the Centre for Performance Science, a partnership between the Royal College of Music and Imperial College London and co-author of the research, said: \"Many people affected by cancer can experience psychological difficulties such as stress, anxiety and depression.\nTo find out more call the Tenovus Cancer Care free Support Line on 0808 808 1010 or visit tenovuscancercare.org.uk\n\nFor more information contact Ruth Taylor, PR and Communications Manager on 07429 103084 / ruth.taylor@tenovuscancercare.org.uk.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does not clearly explain whether this is the first study ever to measure stress hormones in the blood of singers before and after singing. The release makes the findings appear more novel than they are. As we\u2019ve said above, there are hundreds of research articles about the impact of stress-reduction techniques of all sorts on people, including cancer patients. This territory is not new.\nMusic therapy is widely available in many cancer centers across the country, as well as pet therapy and art therapy. All of these modalities are aimed at easing stress.", "answer": 0}, {"article": "Another sensor, just approved by the F.D.A.\nWhen everything was in, I had two catheters and the transmitter all taped to my body, plus the pump hanging on my belt.\nAs luck would have it, the conductivity is directly proportional to how much glucose is floating around in the juice.\nThe sensor has a coated tip that measures the electrical conductivity of the interstitial fluid, the juice floating between fat cells right under the skin.\nThe main problem was that the sensor was simply not as accurate as a blood-glucose tester.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story tells readers that the device was approved in June, which lets people know this is new to the market. ", "answer": 1}, {"article": "A three-year-old Silicon Valley start-up, Counsyl Inc., won the Bronze Innovation Award for its simple, low-cost genetic test that can alert prospective parents who might be carrying genes that could cause hereditary diseases in their children.\n\nCounsyl's technology promises a \"high quality-of-life impact for families at risk for conceiving children with familial diseases,\" says Larry Bock, an Innovation Awards judge and special limited partner at venture firm Lux Capital. \"This technology bundles previously...", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story clearly states that until now, testing for diseases that parents might pass onto their children has been available, but due to the expense and hassle, it has been little used. For most parents interested in knowing as much as they can about the potential health of future children, this clearly represents a step forward.", "answer": 1}, {"article": "Dr. Oken said the new study might have shown no benefit in 18-month-olds because effects in infants might be \u201chard to measure\u201d or \u201cit may be that the benefit of DHA is not as important as when you\u2019re 4.\u201d\n\nDr. Makrides\u2019s team plans assessments at 4 and 7.\nincreases at age 4, although no cognitive benefit was seen in infants or 7-year-olds.\n\u201cThere\u2019s no harm that we know of at all, in contrast to many antidepressants,\u201d he said.\nAnd the new study showed small reductions in postpartum depression in women with histories or high risk of depression.\nThe lead researcher, Dr. Maria Makrides of the University of Adelaide in Australia, said this suggested that full-term babies already get enough DHA in the womb, and that \u201cthere\u2019s no extra boost\u201d from getting more.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The past research on this topic was made clear. ", "answer": 1}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nThe clinical trial was conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net), which is funded by the National Eye Institute, part of the National Institutes of Health.\nA two-year clinical trial that compared three drugs for diabetic macular edema (DME) found that gains in vision were greater for participants receiving the drug Eylea (aflibercept) than for those receiving Avastin (bevacizumab), but only among participants starting treatment with 20/50 or worse vision.\n\u201cThis rigorous trial confirms that Eylea, Avastin, and Lucentis are all effective treatments for diabetic macular edema,\u201d said NEI Director Paul A. Sieving, M.D., Ph.D. \u201cEye care providers and patients can have confidence in all three drugs.\u201d\n\nEylea, Avastin, and Lucentis are all widely used to treat DME, a consequence of diabetes that can cause blurring of central vision due to the leakage of fluid from abnormal blood vessels in the retina.\nIn many states, a corrected visual acuity of 20/40 or better in at least one eye is required for a driver\u2019s license that allows both day- and nighttime driving.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release missed an opportunity to explain why this kind of research is new and important. Without studies that compare the effectiveness of existing treatments, doctors and patients have incomplete information about which treatments work best and which ones deliver the most value. Such studies are uncommon but much needed.", "answer": 0}, {"article": "Zee says that the effectiveness of pink noise is all in the timing.\nA small new study published in suggests that one easy way for older adults to get deeper sleep and stronger memories is to listen to a certain soothing sound called \u201cpink noise\u201d\u2014a mix of high and low frequencies that sounds more balanced and natural than its better-known cousin, \u201cwhite noise.\u201d\n\nIt may sound strange, but previous studies have found that playing so-called pink noise during sleep improves the memory of younger adults.\n\u201cIt\u2019s just noticeable enough that the brain realizes it\u2019s there, but not enough to disturb sleep.\u201d The sounds were timed to match their slow-wave oscillations.\n\u201cWe wanted to see if it would work in older people, too,\u201d says senior author Dr. Phyllis Zee, professor of neurology at Northwestern University Feinberg School of Medicine.\n\u201cThat\u2019s very much tied to what part of the slow wave the stimulus is hitting on.\u201d\n\nThat doesn\u2019t mean there aren\u2019t benefits to other soothing background sounds.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The writer addresses previous work by this researcher, which shows improvement in sleep and memory measure in young adults. The current study is new in that it tested the intervention in older adults. It\u2019s not clear how much research has been done\u00a0on pink noise and its effect on sleep and memory. We did find a study published in the journal Neuron in 2013 suggesting that pink noise helped participants achieve deeper sleep.", "answer": 1}, {"article": "CHICAGO -- The diabetes drug Actos was able to slow the progression of plaque buildup in artery walls, while an older diabetes drug failed to stop the progression in patients with diabetes and coronary-artery disease, according to a study released Monday.\n\nUntil now, no diabetes-therapy regimen has been shown to reduce the progression of coronary atherosclerosis within the arterial walls among patients with Type 2 diabetes, a disease characterized by high blood-glucose levels that result from the body's inability to use insulin.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story accurately represents the novelty of Actos, although this is not the only drug in this class of drugs. ", "answer": 1}, {"article": "What's that like for Mason?\nIf I would have survived through that, I wouldn't have been able to live with myself,\" he said.\nMore research will be needed to try to establish whether they actually repair damage to the spinal cord.\nResearchers have followed Mason and five other patients -- all with the most severe spinal cord injuries.\nToday, the company sponsoring the trial reported four of the six patients experienced improvement in both motor strength and function.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not misrepresent the novelty of the procedure.\nHowever, we\u00a0would have liked to\u00a0read\u00a0a bit more about how stem cells are being used (experimentally) for other related medical applications.", "answer": 1}, {"article": "Armed with her previous research, Bahn and her team detailed a panel of blood biomarkers in individuals who have an increased risk of schizophrenia but have no visible symptoms yet.\n\u201cPsychiatric disorders often present with other diseases such as diabetes and some immune disorders,\u201d says Bahn.\nMeanwhile, she continued to struggle and entered the hospital for suicidal ideation her sophomore year.\n\u201cI was just frustrated because the stigma attached to borderline is very strong,\u201d Orlando says.\nThen, when she was 17, it was settled: She suffered from borderline personality disorder.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s made clear that lab-based biomarker diagnostic tests for mental illnesses would be novel.", "answer": 1}, {"article": "The study appears in the latest issue of the journal Ophthalmology.\nAbout 3 million Americans and 60 million people worldwide have glaucoma, and the numbers are projected to rise over the next few decades as the population ages.\nCompared with the group as a whole, those people who were diagnosed with the eye disease during the following decade were older, had higher blood pressure, and were more likely to be female.\nEarly detection is key, but without regular eye exams, most people don\u2019t know they have a problem, says ophthalmologist Andrew Iwach, MD.\nIn the study, researchers were able to predict who was at increased risk of developing the eye disease with some accuracy by measuring blood vessel thickness in the retinas of study participants using a computer-based imaging tool.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Related to the unsatisfactory \u201cAvailability\u201d score above, since no details were given about the \u201ccomputer-based imaging tool,\u201d we don\u2019t know anything about how novel it is (or isn\u2019t).", "answer": 0}, {"article": "Researchers said they had identified a family of retroviruses in patients with chronic fatigue syndrome, opening up a potentially promising new avenue of treatment for a debilitating disease that afflicts as many as four million Americans and 17 million people world-wide.\n\nThe finding will likely spur patients with the condition to seek treatment with drugs used to fight HIV, the virus that causes AIDS. Although HIV and the newly identified virus group are different, they are both retroviruses.", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 0}, {"article": "Medical researchers are well aware that the dummy pills used in clinical trials often provide as much relief as the actual drugs being tested. This is what's known as the placebo effect, and it's quite common in people with Parkinson's, a movement disorder that causes tremors, stiffness and balance problems. A 2008 meta-analysis found that placebos used in clinical trials of Parkinson's treatments improved symptoms by an average of 16%.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes that the placebo effect has been around for quite some time and that many studies have explored this effect in Parkinson\u2019s disease. The new study looked at how the perceived cost of the placebo treatment would affect its efficacy. The story explains this.", "answer": 1}, {"article": "\u201cAlthough the randomized controlled trial is the gold-standard methodology in comparing between conditions,\u201d said Thomas G. Brown, an assistant professor of psychiatry at McGill University, \u201cit washes out a factor that may be important in potentiating A.A.\u2019s benefits, namely patient choice and preference.\u201d In other words, having a patient choose the form of treatment, rather than being assigned to it as in most studies, could be an important factor.\nhas helped a lot of people,\u201d Dr. Nunes said.\nNone of the studies compared A.A. with no treatment at all, and the researchers said that made it more difficult to draw conclusions about effectiveness.\nMen and women are equally affected, and age does not appear to affect prognosis.\n\u201cDoes A.A. or some other mutual-help group work for people who seek it voluntarily?\u201d she said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "A.A. has been around since the 1930s and its\u2019 mutual self-help groups are not a new approach to relapse prevention for alcoholics.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070520/28diet.b.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The news brief begins by saying that women already know they \u201cneed calcium to protect against osteoporosis,\u201d suggesting that the treatment has a longstanding history.", "answer": 1}, {"article": "Among iron-deficient adolescent women there is a future risk of maternal iron deficiency and negative effects on infant health.\n\"We're basically waiting until their red light goes on.\nBlood tests for iron deficiency without anemia have been developed but they are more costly and difficult to obtain in the doctor's office compared to hemoglobin testing for anemia.\nYou have to be really low on your iron storage before you're going to flag as anemic.\"\nNinety-six female adolescents participated in this study, published in The Journal of Pediatrics.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does not make a claim of novelty.", "answer": 2}, {"article": "ATTRIBUTION TO THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING IS REQUESTED IN ALL COVERAGE.\nAlthough the difference between treatment groups is modest, a statistically significant improvement shows that, overall, people with advanced squamous lung cancer can benefit when immunotherapy is added to standard treatment, according to the authors.\nAlthough the rate of severe side effects was higher with the combined modality treatment than with chemotherapy alone (68% vs. 57%), it had a manageable safety profile, consistent with known safety risks of the individual therapies.\nOutcomes for only two of the groups, however, are being reported in this presentation:\n\nOutcome data for the third treatment group, which received atezolizumab with a slightly different chemotherapy regimen (carboplatin and paclitaxel), are not yet available.\nKey Findings \n\n In this study, 29% of all patients, regardless of PD-L1 expression, had a reduced risk of disease worsening or death, compared with those who received chemotherapy alone.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release characterizes this trial as one example of a broader effort to explore the addition of immunotherapy to chemotherapy when treating people with lung cancer. It is perhaps prophetic that the release more often refers to immunotherapy in general, rather than the specific drug used in this trial, since the makers of another immunotherapy drug announced at the ASCO meeting that their product improved the overall survival of similar patients, something the drug used in this trial has not demonstrated.", "answer": 1}, {"article": "\u201cThis is still investigational and requires more research.\n(Reuters) - Medtronic Inc, a manufacturer of pacemakers, heart stents and spine products, has developed a device to tackle another common health problem: erectile dysfunction.\nInitial findings showed two-thirds of men who underwent the 1- to 2-hour procedure improved by at least 4 points on the 30-point Internal Index of Erectile Dysfunction scale, he said.\n\u201cED is largely a vascular disease and that\u2019s why Medtronic was interested in this,\u201d said Dr. Jason Rogers of UC Davis Medical Center, one of the researchers of the company-sponsored trial.\nThe medical device maker said it completed an initial feasibility study of 30 men, average age of 60, who suffered from erectile dysfunction (ED).\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story includes a quote that \u201cthis is the incepton of an entirely new way of treating ED that has never been seen before.\u201d\nWe don\u2019t question the investigator\u2019s comment.\u00a0 We only question the editorial decision-making.\u00a0 We easily found news stories from at least two years ago that talked about Medtronic\u2019s development of this approach.\u00a0 How many \u201cinception\u201d stories will we get before there is actually some meaningful, longterm experience to report in large numbers of men?\nIf it was \u201cnew\u201d two years ago, is it still new today?\u00a0 Is there still anything meaningful to report?", "answer": 0}, {"article": "How can this bile acid affect the heart in such a dramatic way?\"\nThe collaborative study, funded by the Canadian Institutes of Health Research and published in PLOS One, examined the molecular mechanisms that lead to cardiac fibrosis in a pre-clinical model.\n(Edmonton, AB) Groundbreaking research from the University of Alberta and McGill University has opened the door towards the future prevention of cardiac fibrosis--a condition leading to heart failure for which there is currently no treatment.\n\"It offers hope to those who are living with heart failure,\" adds Luis Agellon, co-principal investigator and a professor at McGill University's School of Dietetics and Human Nutrition.\n\"This is something that nobody has ever seen before,\" says Marek Michalak, co-principal investigator and a distinguished professor in the Department of Biochemistry at the University of Alberta's Faculty of Medicine & Dentistry.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Groundbreaking discoveries are very rare events. Rather, medical discovery is more commonly a process of iteration, adding to existing information. Bile acids have been tested in humans suffering from heart failure previously, adding to an accumulating knowledge.\u00a0(See:\u00a0J Am Coll Cardiol. 59(6):585-92, 2012 Feb 7, a human trial that found improvement in peak post-ischemic blood flow, an obscure test sometimes used in heart attack and stroke research, but no improvement in how well patients functioned).\nThe Edmonton study importantly adds to the discussion. The release notes:\u201dGroundbreaking research from the University of Alberta and McGill University has opened the door towards the future prevention of cardiac fibrosis.\u201d \u00a0We suggest that the door was opened by previous research and this study opened it a bit wider.", "answer": 0}, {"article": "The U.S. Institute of Medicine says the amount of weight women should gain during pregnancy varies depending on their non-pregnancy weight.\nAfter including the new studies, the new review found \u201chigh-quality evidence\u201d to show diet, exercise or both can reduce the risk of excessive weight gain during pregnancy, write the researchers in The Cochrane Library.\nThe review incorporates dozens of new studies to update a previous review that did not find enough evidence to support the use of diet and exercise during pregnancy.\nThere was no clear benefit among the women in the diet and exercise groups when the researchers looked at other complications, such as cesarean delivery, but it did look like there may be some benefit, they write.\nThe women who took part in diet, exercise and combination programs were also less likely to develop high blood pressure during pregnancy, compared to those in the standard care group.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear that this paper is an update to a previous review, published in 2012, that did not find conclusive evidence to support claims of health benefits from diet and exercise programs during pregnancy.", "answer": 1}, {"article": "MONDAY, Feb. 22, 2010 (HealthDay News) -- Women who experience depression during pregnancy may have another treatment option, new research suggests.\nThe depression-specific protocol was designed just for this study, and the control acupuncture was specifically designed to avoid using acupuncture needles in any areas known to affect depression.\nThe researchers found a 63 percent response rate in women who received the depression-specific acupuncture, while the response rate was 44.3 percent in the control acupuncture and massage groups.\nBut, she added, because this is the first study of its kind, and the acupuncture protocol used was specifically designed for this study, \"you always need replication of the findings.\"\nAs many as 20 percent of women may experience depression during pregnancy, according to the March of Dimes.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is clear that while acupuncture itself is not a new idea, this particular pattern of pressure points developed for this study is indeed new.", "answer": 1}, {"article": "\"Unfortunately, that is not the case.\nIn fact, previous research has found that when everything goes well, the guidance system produces targeting errors of about 2 millimeters but, in about one operation out of seven, the target error is much larger, forcing the surgeon to redo the registration process.\nIn essence, that is what a team of Vanderbilt University engineers are proposing in an effort to improve the reliability of the sophisticated \"GPS\" system that surgeons use for these delicate operations.\n\"These are very delicate operations and a sophisticated image guidance system has been developed to help the surgeons, but they don't trust the system because sometimes it is spot on and other times it is off the mark,\" said Robert Webster, associate professor of mechanical engineering and otolaryngology, who is developing a surgical robot designed specifically for endonasal surgery.\nThe computer uses this information to combine a CT scan, which provides a detailed 3-D view of the bone and soft tissue hidden inside the patient's head, with the position of the instruments the surgeon is using and displays them together in real time on a monitor in the operating room.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release states developers are presenting the \u201cnovel design and data on its effectiveness\u201d at an upcoming scientific meeting. It also describes the cap as \u201can effort to improve the reliability of the sophisticated \u2018GPS\u2019 system that surgeons use for these delicate operations.\u201d", "answer": 1}, {"article": "Geier published a 2006 study contending that 11 autistic children taking Lupron did better on tests of awareness, sociability and behavior.\nIn addition, the Food and Drug Administration is investigating complaints that Lupron causes diabetes in adults.\nThe area's largest autism treatment center jointly run by the University of Miami and Nova Southeastern University, as well as another at Florida Atlantic University, frown on Lupron and other untested therapies, officials at the centers said.\nIt's what happens when you have high testosterone,\" Badillo said.\n\"We were basically under seige in this house,\" Badillo said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "No inordinate claims of novelty.\u00a0 In fact, the story establishes that the one Maryland researcher has been testing this for at least five years. ", "answer": 1}, {"article": "From a crusty baguette to a big thick steak, some foods may be hard to digest, particularly as we age. Enzyme capsules taken before a meal can relieve discomfort by helping the body to break down problem foods, say companies that sell the pills. Doctors say some enzyme supplements work well, but others need more human studies.\n\nDigestive enzymes are proteins that work like scissors to break down foods. The pancreas, where many of these enzymes are made, can slow down as we age, which can result in bloating and other gastrointestinal...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains that newer enzyme products are following in the footsteps of established enzymes that have been around for years.", "answer": 1}, {"article": "In fact, Dr. Weinstein's findings, released today in the Journal of the American Medical Association, conclude that surgery is only slightly more effective in some cases than a non-surgical approach.\nThe operation was a success and she's been pain-free for four years.\n\"It was just to find the truth for patients.\"\n\"I think that it be important for people to have good information,\" he adds.\nHis back pain was excrutiating,reports.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It's clear from the story that surgery is not a new idea.", "answer": 1}, {"article": "Today, the most common reason for the surgery is \"sleep disordered breathing,\" a broad diagnosis that includes sleep apnea and snoring.\nIt's usually done as an outpatient procedure now, but with general anesthesia.\nObviously, parents could use some help in deciding whether surgery is needed.\nBut growing up with tonsils can create another problem: snoring.\nThere have been very few randomized studies on the effects of tonsillectomy for sleep-disordered breathing.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It is clear from the story that surgery is not novel.", "answer": 1}, {"article": "SAN DIEGO, April 24, 2015 /PRNewswire/ -- University of Louisville announced today results from the Soft Tissue Ablation Registry (STAR), demonstrating that irreversible electroporation (IRE) with the NanoKnife\u00ae System, in combination with chemotherapy, doubled the overall survival rate of locally advanced (Stage III) pancreatic cancer patients to nearly 24 months.\nPerioperative 90-day outcomes, local failure, and overall survival were recorded and compared to standard of care data for Stage III LAPC.\nIRE overcomes rapid growth of the tumor by killing all malignant cells at once so they cannot continue to grow and spread.\nMedian length of stay was 6 days (range, 4-58) with a median follow-up of 25 months.\nPancreatic cancer has one of the highest mortality rates of all cancers and is expected to climb from the fourth leading cause of cancer-related death in the U.S. to the second by 2020.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Ablative therapy is not new to pancreatic cancer treatment, but if true, extending 1-year survival to nearly 2 years\u00a0could be a\u00a0large and significant improvement.", "answer": 1}, {"article": "The average age of people in both groups was 73.\nThe findings, presented Sunday, Nov. 25 at the Radiological Society of North America meeting in Chicago, suggest that doctors may one day be able to use widely available tests to tell people their risk of developing dementia before symptoms arise.\n\"We could tell that the individuals who went on to develop dementia have these differences on diffusion MRI, compared with scans of cognitively normal people whose memory and thinking skills remained intact,\" Raji said.\n\"Right now it's hard to say whether an older person with normal cognition or mild cognitive impairment is likely to develop dementia,\" said lead author Cyrus A. Raji, MD, PhD, an assistant professor of radiology at Washington University's Mallinckrodt Institute of Radiology.\nAlthough there are no drugs available yet to prevent or delay the onset of Alzheimer's disease, identifying those at high risk of developing dementia within the next few years could still be beneficial, the researchers said.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release said the study showed that by using MRIs doctors \u201cmight soon be able to tell people whether they are likely to have Alzheimer\u2019s develop in the next few years.\u201d\nThe novelty suggested here is that the changes detected were in the white matter, rather than the gray cerebral cortex, where we traditionally think plaques, tangles and nerve cell loss of Alzheimer\u2019s are occurring.\nHowever, the concept of using MRIs and diffusion tensor imaging to predict Alzheimer\u2019s isn\u2019t new, and the news release didn\u2019t explain how these findings add to the body of evidence about Alzheimer\u2019s detection.", "answer": 0}, {"article": "When it comes to the most popular type of osteoporosis treatment, bisphosphonates, the question is not so much about how much to take, but whether there are harmful consequences from long-term use.\nOne of the first dilemmas patients typically encounter is when to get screened for osteoporosis, and then how often to repeat the test \u2014 a painless body scan that measures bone density.\nThe task force offers no advice for women younger than 60 or for men of any age, though men account for at least 20 percent of US patients with osteoporosis.\nIn a statement, the FDA said it is reviewing the data and is considering changing the labeling on bisphosphonates.\nBut in September, a different group of scientists used the same database and concluded in an article in the British Medical Journal that bisphosphonates appeared to double the risk of esophageal cancer after about 5 years of use.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article discussed management approaches to osteoporosis that are well established\u2014though in some cases uNPRoven. Discussion of their novelty wasn\u2019t necessary. ", "answer": 2}, {"article": "There is only \u201cmoderate\u2019\u2019 evidence that the newly approved prostate cancer drug Provenge helps patients, according to an analysis done for Medicare that was made public on Wednesday.\nThe Medicare review might be more designed to limit off-label use of the expensive drug, such as for patients who already have symptoms.\nSome analysts have assumed that Medicare will pay for Provenge when used for the patients specified in the drug\u2019s label \u2013 those with advanced prostate cancer that is resistant to hormone-deprivation therapy but who are experiencing no or minimal symptoms.\nThe review for Medicare said there was insufficient evidence to judge whether Provenge would work if used off-label.\nAfter Dendreon completed another trial, which reaffirmed a survival advantage for the drug, Provenge was approved this April.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story reports that Provenge is the first approved treatment that is designed to try to stimulate a patient\u2019s immune system to attack tumors.", "answer": 1}, {"article": "They all drank caffeine regularly.\n\u201cThere was no boundary, apparently.\u201d\n\nIn the study, Furman and his colleagues analyzed blood samples from 100 young and old people.\nWe are able to point, with a much higher resolution picture, at aging and the things that should be markers for inflammation.\u201d\n\nThe key will be to figure out when the inflammatory response starts to spiral out of control.\n\u201cThe more caffeine people consumed, the more protected they were against a chronic state of inflammation,\u201d says study author David Furman, consulting associate professor at the Institute for Immunity, Transplantation and Infection at Stanford University.\nIn an upcoming study, Furman and others will soon investigate the immune systems of 1,000 people; he hopes to use that information to develop a reference range of immune-system components to tell people whether their levels are normal, or if they\u2019re at higher risk for developing chronic conditions driven by inflammation.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There is a significant body of work related to caffeine and various types of inflammation and inflammatory response. The story does not address that body of work at all. However, we do give the story credit for linking to a previous story that offered an overview of research on coffee consumption and health. However, that previous story was not focused on links between caffeine and inflammation.", "answer": 0}, {"article": "Although the technique's potential to identify brain disorders and diseases was noted years ago, fcMRI-based diagnostic tests have yet to make their way into doctors' offices.\nIt's exciting to think that these individual differences may be related to personality, cognitive ability, or psychiatric or neurological disease.\nThere are no laboratory tests to diagnose migraines, depression, bipolar disorder and many other ailments of the brain.\nThanks to this work, we know we have a reliable tool to study these possibilities.\"\nAll of the scanned brains belonged to young, healthy scientists and doctors.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release explains why findings in the study are news and why they could, in the words of the lead authors, \u201copen\u00a0the door to an entire new field of clinical testing.\u201d", "answer": 1}, {"article": "A limitation of the study is that the evidence on acetaminophen was mainly for acute low back pain, but as the University of Leeds's Philip Conaghan explained, \"There is very little long-term data [on chronic back pain], and if a drug doesn't work in the acute problem, it seems unlikely to work in the chronic phase \u2014 though back pain may be even more complex than osteoarthritis pain.\"\nThe study also noted that patients on acetaminophen \"are nearly four times more likely to have abnormal results on liver function tests compared with those taking oral placebo.\"\nEither the outcomes in studies are badly defined, the studies have too few participants to say anything concrete, or many people in the studies actually seem to have chronic headaches as opposed to the ordinary ones the researchers are allegedly studying.\nThere's also some evidence that NSAIDS may increase the risk of psychosis and cognitive impairment in the elderly, so doctors may avoid prescribing these drugs for older patients.\nNow, Moore was referring here to acute pain that strikes after a specific event, like a surgery, a cut, or a burn, but his message was simple: Ibuprofen seems to work best, followed by acetaminophen, and then aspirin.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes that it\u2019s responding to a reader question about three well-known and widely used medications. It also notes the gap between public perception about these drugs and what pain researchers think of them.", "answer": 1}, {"article": "She said primary care physicians, gynecologists and women \u201cneed to be more aware that these tests exist.\u201d\n\nDr. Sandhya Pruthi, a breast cancer expert at the Mayo Clinic in Rochester, Minnesota, who counsels women with BRCA mutations, said the study adds more evidence that the surgery can help save lives, but the choice is never easy.\n\u201cMost of these women will die of ovarian cancer, so you can save 20 percent of them with the prophylactic surgery,\u201d Kaklamani said.\nAccording to the American Cancer Society and the International Agency for Research on Cancer, 1.3 million new breast cancer cases are diagnosed around the world every year and it kills 465,000 women annually, making it the leading global cancer killer of women.\nBecause of this, many women make the difficult choice to have their breasts or ovaries and fallopian tubes surgically removed to reduce their risk.\nThe study shows the benefits of genetic tests that give women with a family history of cancer the chance to take steps to increase their chances of survival, they said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story leaves out any mention of earlier research on this topic and does not point out that some women have been opting for preventive surgery for many years.", "answer": 0}, {"article": "A colonoscopy isn\u2019t something you get just for giggles. Beyond the obvious unpleasantness, there\u2019s the small but real risk of complications that in rare cases can lead to hospitalization or even death.\n\nThat\u2019s why the American Cancer Society and other groups recommend that people screened for colorectal cancer using a colonoscopy wait a decade in between tests if no polyps or other signs of potential cancer are found. Polyps are slow-growing, and the benefits of being screened more frequently than that don\u2019t seem to outweigh the risks \u2026", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of this study was made clear in the story.", "answer": 1}, {"article": "Before the trial, one 40-year-old, who said he had fears starting at age 10 that he was going to die in his sleep, rated his certainty that he was suffering from a serious illness as an 8 on a scale of 1 to 10.\nResearchers suggested that a combination of this talk therapy and medication might be especially effective.\nIt was funded by an \"educational grant\" from Glaxo SmithKline, which makes Paxil.\nAnd now, a real pill for your unreal illness.\nMen who had only daughters were more likely to have developed the disease than those who had at least one son, researchers found, and the relative risk of prostate cancer decreased as the number of sons increased.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story suggested that this was a new use for the drug Paxil.", "answer": 1}, {"article": "It is for use only in those aged 12 or more, the F.D.A.\nThe new antiviral, generically known as baloxavir marboxil but sold under the brand name Xofluza, is a single dose treatment.\nThe pill will cost $150, according to a spokeswoman for Genentech, which will sell Xofluza in this country.\nThe first new flu drug in 20 years won approval Wednesday from the Food and Drug Administration.\nFlu season has already begun, and last year\u2019s was one of the most lethal in decades; about 80,000 Americans died of flu or its consequences, the Centers for Disease Control and Prevention said earlier this month .\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "As noted above, the drugs similarities and differences to existing pharmaceutical treatment options was laid out clearly. The news peg here was FDA\u2019s approval of the drug, which is also made clear.", "answer": 1}, {"article": "Kerry Aldrich, 15, suffered a concussion playing varsity soccer for The Potomac School in McLean, Va., three weeks ago when she did a face-first dive and violent somersault.\n\"The brain, in its development, while it is actively developing, seems to be less able to take these forces and to really rebound from these forces,\" Dr. Gioia observed.\n\u2026 It's like a sophisticated video game, but the numbers that are generated from the report are critical in helping to better identify the severity and recovery from the injury.\"\nBut, Regan adds, diagnosing them can be daunting: While there are some physical symptoms such as headaches, nausea, dizziness and blurred vision, concussions don't cause bleeding or swelling in the brain and don't show up on X-rays.\nBut for students such as Aldrich, who don't know their baseline, extra caution is the doctor's order.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\nThe Impact system has been available for many years. Indeed, some 1500 athletic teams reportedly employ the system, according to the broadcast. Research suggesting that children's brains may be more vulnerable to injury than adults' brains has also been around for years. The broadcast does not report the news that likely stimulated the report\u2013findings of a case control study of the Impact system by Michael Collins, PhD that were recently announced in a press release and published in the American Journal of Sports Medicine. \n", "answer": 0}, {"article": "For more information about Wolters Kluwer's solutions and organization, visit http://www.\nThe researchers emphasize that DTI isn't an option for every patient, depending on breast shape and other factors.\nThe researchers believe the DTI technique may expand the options for older women, who are less likely to undergo breast reconstruction.\nIn the year after surgery was completed, women in the DTI group made an average of 6.5 office visits, compared to about 12 visits in the TEI group.\nThe women undergoing DTI reconstruction were older (73.5 versus 69.2 years) and had a higher body mass index, compared to the TEI group.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It\u2019s never really fully explained how the direct-to-implant approach differs from the tissue expander approach. But it is made clear that DTI is better studied in younger women than older ones.", "answer": 0}, {"article": "\u201cNo matter how sophisticated, they shouldn\u2019t trump data from real people who participated in the randomized trials\u201d \u2014 which in PLCO found zero lives saved from PSA screening.\nIn April, however, the task force proposed instead that men aged 55 to 69 discuss PSA\u2019s pros and cons with their doctor and then decide what to do, factoring in that if 1,000 men get regular PSA screening for a decade it will save about one life.\nAmong other drawbacks, the tests lead to overdiagnosis (meaning a biopsy finds malignant cells but they are so innocuous they would never harm, let alone kill, the man) as well as incontinence and impotence from treatment (including of harmless cancers).\nAn earlier one for the PLCO study concluded that more men died in its screening group than in the don\u2019t-get-screened group.\nThey all rely on estimates of \u201clead time,\u201d or how much sooner a cancer is detected because of PSA instead of because symptoms are detected.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The report of this study establishes, correctly, how it might expand our view of the value of PSA testing and reminds us that what is \u201cnovel\u201d here is the interpretation of previous research.", "answer": 1}, {"article": "\u201cIt\u2019s reasonable to screen for something that\u2019s common, dangerous and has a treatment that\u2019s effective and safe.\u201d\n\nDr. William Cooper, a pediatrics and preventive medicine professor at Vanderbilt University, called it \u201can innovative approach\u201d that finds not just kids at risk but also parents while they\u2019re still young enough to benefit from preventive treatment, such as cholesterol-lowering statin drugs.\nThe study also revealed parents who had the condition but didn\u2019t know it, and had passed it on to their children.\nThe study authors in England estimated that if cholesterol testing costs $7 and gene testing costs $300, it would cost $2,900 for every person identified as having the disorder.\nThe work was funded by the Medical Research Council, the British government\u2019s health research agency.\nIf a child was found with the disorder, parents were tested.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes the novelty of the study by explaining that it found that this genetic condition is more common than originally thought.", "answer": 1}, {"article": "But the scientific evidence has been slim.\nThere's no question that the hormone helps the brain tell a.m. from p.m.--regulating sleep cycles and circadian timing--when it is produced naturally by the body at night.\nWhat was lacking was clear evidence that taking melatonin in supplement form had the same sleep-inducing effect.\nMillions of jet-lagged and sleep-deprived Americans--citing countless self-help articles--insist they do.\nThat's why there's so much interest in a study in the current issue of the journal Sleep.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article reports on some new evidence for what melatonin can and can\u2019t do in terms of sleep. The story did not present melatonin as a novel treatment but rather that the results of a recent study provided some new insight about its use.", "answer": 1}, {"article": "\u201cToday, marks another milestone in the development of a whole new scientific paradigm for the treatment of serious diseases,\u201d FDA Commissioner Scott Gottlieb said in a statement, adding that the approval demonstrates \u201cthe continued momentum of this promising new area of medicine.\u201d\n\nA CAR T-cell therapy involves a complicated and customized procedure in which T cells \u2014 sometimes called the foot soldiers of the immune system \u2014 are removed from the patient.\nOnce the modified cells are returned to the patient, their numbers expand exponentially as they become an army of cancer fighters.\nThis type of cancer begins in the immune system and can be fast- or slow-growing, the FDA noted.\nShe received chemo and underwent a bone-marrow transplant.\nKite announced Wednesday that the treatment's brand name will be Yescarta and its price will be $373,000.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains that this is a new therapy and is the second approved treatment of its kind.", "answer": 1}, {"article": "Sadly, disappointment is part of it, according to Pharr, who typically hears the frustration of people who go through a study that worked for another person but not for them.\nSomeone can go for two years without being diagnosed properly, and that was the case with my father,\" Pharr said.\nThe idea was that they would find a familiar and supportive environment,\" explained Glass.\n\"It may have had a different effect on someone else,\" she said.\nWhen communication between the brain and muscles ceases, the result is a gradual weakening and wasting away of muscles.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story sufficiently provides context on past studies in this area to help readers understand where this research fits into the big picture.", "answer": 1}, {"article": "LONDON (Reuters) - Scientists in Canada and Sweden have used laboratory-made biosynthetic corneas to restore vision to patients in a small human trial, and shown for the first time that they can help to repair damaged eye tissue.\n\u201cThe results were pretty encouraging and there is great potential here,\u201d Fagerholm said in a telephone interview.\nThe researchers found that, eventually, the cells and nerves from nine of the 10 patients regrew completely and packed themselves into the implant, resulting in a kind of \u201cregenerated\u201d cornea that looked and functioned like normal, healthy eye tissue.\nAlthough the fragile film is easily destroyed by trauma or infection, replacement human corneas can be used to restore vision, although this depends on a steady supply of donors.\nThe patients were monitored for two years after surgery.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The WebMD story makes it clear at the top how unique this procedure is. This story does not make it clear at all.", "answer": 0}, {"article": "Further,Dr.\n\u201cIt\u2019s wonderful to have this option to offer this special set of patients.\u201d About UT Southwestern Medical CenterUT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education.\nFrank Brown of Dallas, grandfather of six and the owner of Frank\u2019s Wrecker Service in Dallas, has familial hypercholesterolemia, an inherited condition that causes high levels of cholesterol, especially low-density lipoprotein (LDL) cholesterol or \u201cbad cholesterol.\u201d High levels of LDL cholesterol are strongly associated with heart disease.\nWe\u2019d exhausted the other options in trying to control his cholesterol.\u201d\n\nTwo months after he started his biweekly injections of the new drug, Mr. Brown\u2019s LDL cholesterol level was down to 111 \u2013 not quite normal, which is 100 or less \u2013 but an almost 50 percent reduction from the level it had been for years.\nTheir research led to the development by drug companies of evolocumab and alirocumab, the two approved PCSK9 inhibitors, which are delivered by monthly or semimonthly injections.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release explains what is novel about this particular class of drugs. However, it\u2019s not at all clear why this release is coming out now. The drugs themselves were approved by the FDA last summer and the release does not appear to be related to the publication of research findings. There is virtually no information here that was not available six months ago, other than the anecdotal data on one patient.", "answer": 0}, {"article": "SUNDAY, Jan. 17, 2010 (HealthDay News) -- Giving a vaccine through a scratch on the skin (scarification) triggers a stronger immune response than injected vaccines, say U.S. researchers, who also found that scarification requires 100 times less vaccine to prompt an immune response.\nNearly all modern vaccines are given via injection, according to background information in a news release about the study, which is published in the Jan. 17 issue of Nature Medicine.\n\"We should also continue to explore the implications for developing powerful cancer vaccines, like the one demonstrated by melanoma vaccine results in this study.\"\nAfter all, our immune system evolved over millions of years to respond to infections of injured skin, not vaccines delivered by hypodermic syringe into muscle,\" he noted.\n\"The lessons we are learning from these studies of vaccination by scarification could help us develop new and more powerful vaccines for influenza, HIV, malaria and other infectious diseases,\" Kupper explained.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did say that \"Scarification was first used nearly two centuries ago to give the first smallpox vaccinations.\"", "answer": 1}, {"article": "It also found that the protective effect increases with age.\nThis 20-year follow-up established that the risk of cancer death remained 20% lower among those who had been allocated aspirin than those in the control group for all solid cancers, including lung, prostate, brain, bladder, and kidney cancers, and by 35% for gastrointestinal cancers.\nDec. 6, 2010 -- Taking aspirin over a long period of time can substantially cut the risk of dying from a variety of cancers, according to a study showing that the benefit is independent of dose, gender, or smoking.\nA previous study by the same authors showed that low doses of aspirin (75-300 milligrams) reduced the number of cases of colorectal cancer by a quarter and deaths caused by the disease by more than a third.\nFor instance, it only became apparent after about five years for esophageal, pancreatic, brain, and lung cancer; about 10 years for stomach and colorectal cancer; and about 15 years for prostate cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story did a good job of putting the study in the context of earlier studies by saying, \u201cA previous study by the same authors showed that low doses of aspirin (75-300 milligrams) reduced the number of cases of colorectal cancer by a quarter and deaths caused by the disease by more than a third. The latest study confirms the earlier results and concludes that similar effects can be shown for other types of cancers.\u201d", "answer": 1}, {"article": "\"Although alemtuzumab [Lemtrada] treatment is associated with safety risks, those risks are manageable in most patients,\" Miskin said.\nBecause of serious side effects, the drug -- Lemtrada (alemtuzumab) -- is approved in the United States only for patients who have failed other treatments.\nAlso, when the immune system rebuilds itself, \"a significant number of people, about 40 percent, will develop another autoimmune disease,\" Giovannoni said.\nThe new trial of more than 600 patients with relapsing-remitting MS was funded by Sanofi Genzyme and Bayer HealthCare Pharmaceuticals, the drug's makers.\nBy the study's end, nearly 28 percent of those given Lemtrada had improved by at least one point on a 10-point disability test, versus about 15 percent of those receiving interferon, the researchers found.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes the novelty by explaining that this study showed the drug could be used in more newly diagnosed patients:\nBecause of serious side effects, the drug \u2014 Lemtrada (alemtuzumab) \u2014 is approved in the United States only for patients who have failed other treatments. But the authors of a new study believe giving it early may slow and even reverse some disease-related disability.", "answer": 1}, {"article": "But there are other theories about how fluoride works.\nIf you pay out of pocket, a varnish treatment costs from $23 to $55, compared with a filling, which ranges from $86 to $606, according to the American Dental Association.\n\"OK, Alice, we are going to put the fluoride varnish on your teeth,\" says Marion Manski, director of the dental hygiene program at the University of Maryland School of Dentistry.\n\"Prevention has always been a part of the world of dentistry,\" says Richard Valachovic, president of the American Dental Education Association.\n\"Some of the stuff in our study has been known for 50 years,\" Evans says, referring to the use of fluoride treatments.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reports that the concepts are not new, and that fluoride varnishes have normally been the purview of pediatric dentistry, but are now catching on among adult dentists.\nHowever, it never really explains why practice would be changing now\u2013did research spur this change? There is a reference to \u201cmore effective preventive techniques,\u201d but it\u2019s not clear what that means, and how a reader might act on that.", "answer": 1}, {"article": "The frequency of screening mammograms -- and the appropriate age to begin them -- has been debated since the U.S. Preventive Services Task Force in 2009 recommended that women routinely get screening mammograms every other year starting at age 50.\n\"Hopefully, there will be less anxiety about getting a recall.\"\nInformation about the women and their mammograms came from the Breast Cancer Surveillance Consortium, funded by the National Cancer Institute.\nThey found a small but not significant increase in the chance that women diagnosed with breast cancer had a more advanced case if they underwent screening every other year instead of every year.\nAfter 10 years of annual screening, more than half of women will be called back at least once for another mammogram.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The study did not examine a new procedure.", "answer": 2}, {"article": "The devices had been developed at EV3 Inc., a Plymouth med-tech company that Covidien acquired in 2010.\nThe results showed that atherectomy, the practice of trimming away the plaque that causes peripheral artery disease (PAD), is just as effective at restoring blood flow as traditional angioplasty and stents.\nIt's a key finding, because patients with diabetes usually suffer from more advanced PAD and the blood vessels re-clog faster than for those who do not.\nDoctors found that Covidien's SilverHawk and TurboHawk devices, which are snaked down through a small incision near the groin and basically shave away and remove the plaque, performed as well after 12 months as angioplasty and stenting.\nAlso of note, Garcia said, is that the procedure proved as effective at improving blood flow for patients with diabetes as those without diabetes.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Following up on the point just made, there is no explanation of what makes this company\u2019s tools different or novel in comparison with other atherectomy tools/approaches.\n\u00a0\n\u00a0", "answer": 0}, {"article": "British Journal of Nutrition.\nMilk was the most commonly used product in this category, and a very high consumption was defined as an average daily milk intake of 0.9 litres.\nFor instance, the consumption of milk and sour milk have declined, while many fermented dairy products, such as yoghurt, quark and cheeses, have gained in popularity,\" Adjunct Professor Jyrki Virtanen from the University of Eastern Finland says.\nExamples of fermented dairy products include cheese, yoghurt, quark, kefir and sour milk.\nAll the mechanisms are not understood yet, but they may be linked to compounds forming during the fermentation process.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release claims that the new research gives more weight to earlier study findings. It states:\n\u201cearlier studies have shown that fermented dairy products have more positive effects on blood lipid profiles and on the risk of heart disease than other dairy products.\u201d\nAnd that\n\u201cThe new study provides further evidence on the health benefits that fermented dairy products may have over non-fermented ones.\u201d\nLinks to the earlier studies would have been helpful. As yet, it\u2019s still speculative to claim that fermented dairy products lower the risk of CHD.", "answer": 1}, {"article": "Professor Vieta was not involved in this work, it is an independent comment.\nOur result is statistically significant, but because the study wasn't specifically designed to test the effect of diet quality,\n\ninflammatory diets and BMI on drug response in general, it is necessary to see the work replicated in a larger study before any firm conclusions can be formed\".\n\"If we can confirm these results, then it's good news for people with Bipolar Disorder, as there is a great need for better treatments for the depressive phase of Bipolar Disorder\" said lead researcher Melanie Ashton of Deakin University in Australia.\nA total of 133 participants were randomly assigned to take a combination of nutraceuticals (compounds derived from foods such as vitamins or minerals that treat or prevent a disease or disorder) including the anti-inflammatory amino acid n-acetylcysteine (NAC), or NAC alone, or a placebo (a dummy pill) for 16 weeks.\nNow a group of Australian, German and American scientists have shown those who have a high quality diet, a less inflammatory diet, and/or a low BMI (Body Mass Index) may respond better to an add-on nutraceutical treatment provided as part of a clinical trial.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that if the results can be replicated in a larger trial then it would show that diet and weight affect treatment for bipolar disorder.\nHowever, this doesn\u2019t appear to be novel research since there are a host of dietary studies in the bipolar literature. Researchers are looking at dietary interventions in more controlled ways in bipolar disorder, depression and dementia.", "answer": 0}, {"article": "For more information about Hebrew SeniorLife, visit http://www.\nThe study was recently published in the Journal of Bone and Mineral Research.\nResearchers analyzed the bone density scans of over 1000 older women from Australia for the presence of calcium deposits in the large artery in the abdomen called the aorta.\nThey graded the severity of these calcium deposits using scans done for osteoporosis screening.\n, follow us on Twitter @H_SeniorLife, like us on Facebook or read our blog.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "As we noted earlier, a link between bone density and cardiovascular disease has been explored for a number of years.\nBanks, L.M., Lees, B., MacSweeney, J.E. and Stevenson, J.C., 1994. Effect of degenerative spinal and aortic calcification on bone density measurements in post\u2010menopausal women: links between osteoporosis and cardiovascular disease?. European journal of clinical investigation, 24(12), pp.813-817.\nHowever, this may be the first use bone density scanning machines to explore the issue. Previous studies have used computed tomography (CT) scanners.", "answer": 1}, {"article": "The research is part of a larger University of Exeter study called PRO-BONE.\nAdolescence is the key period for bone development, and poor development at this stage is linked to reduced peak bone mass (the amount of bone mass at the end of the skeletal maturation, around age 30), increased fracture risk and osteoporosis later in life.\nThough swimming and cycling have proven health benefits, the scientists said their study \"raises a question\" about whether they are good for bone development due to the non-weight bearing training - and they say young swimmers and cyclists could benefit from more weight-bearing exercise in training regimes.\nDr Gracia-Marco said: \"The sports we studied are the three most popular in the UK, and it's important to know what effects they have in relation to bone health.\n\"Our research shows that playing football can improve bone development in comparison to swimming and cycling,\" said first author Dimitris Vlachopoulos, of Sport and Health Sciences at the University of Exeter.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The original article notes that this was the first study to comprehensively evaluate bone acquisition in adolescent male athletes. However, health experts have long understood that exercise is a key to healthy bone growth. The most important finding of the study, which is addressed in the news release, actually may have been that participation in non-weight-bearing sports such as cycling or swimming does not seem to produce better bone growth.", "answer": 1}, {"article": "+ Total fat loss was much greater when participants combined diet plus walking (about 16 pounds) and diet plus weight training (about 17 pounds).\nThese results may be even more important for older adults who gain and lose weight with frequency, because seniors typically don't regain muscle - they regain fat mass - which is \"all the more reason for older adults to try and preserve muscle mass during weight loss,\" Beavers said.\nThe findings, \"Effect of Exercise Type During Intentional Weight Loss on Body Composition in Older Adults with Obesity,\" appear in the November issue of the journal Obesity.\nPut another way, the percentage of weight loss coming from muscle mass was 20% in the weight loss plus walking group, 16% in the weight loss alone group, and 10% in the weight loss plus weight training group.\nThe participants were randomly assigned to one of three groups: a weight-loss-only group, who followed a calorie-restricted diet with no exercise regimen; a weight loss plus cardio (i.e., walking) group; and a weight loss plus weight-training group.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release quoted a study author discussing the novelty of the weight lifting intervention and why the finding was so important.\u00a0\u201cSurprisingly,\u201d the researcher said, \u201cwe found that cardio workouts may actually cause older adults with obesity to lose more lean mass than dieting alone.\u201d", "answer": 1}, {"article": "And if patients are given a choice of catheterization sites, what factors should they consider?\nIn the cath lab, he noted, \"time is money\" and radial procedures are \"among the most challenging things we do.\"\nThe approach allows patients to sit up immediately afterward and even walk, an impossibility in femoral procedures, which require that they lie flat on their backs for several hours to prevent severe bleeding.\nThe femoral artery, approximately the width of a pinkie, presents a direct route to the heart; to a physician, it's a straight stretch of freeway that can be navigated easily.\nOnly 1 percent of the 1.2 million cardiac catheterizations performed annually in the United States are done through the wrist; the newer approach is often preferred for patients who are extremely obese or have poor leg circulation.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did a good job placing the novelty of the approach into context. \u00a0Reading the various physicians\u2019 experiences with this technique, it is clear that it is not novel and yet is also not commonly utilized.", "answer": 1}, {"article": "For more information, go to http://www.\n\"We were pleasantly surprised to see that just a small increase in dietary zinc can have such a significant impact on how metabolism is carried out throughout the body,\" says King.\nThis was a novel approach, different from the commonly used method of looking at zinc in the blood or using stunting and morbidity for assessing zinc status.\nCHORI is at the forefront of translating research into interventions for treating and preventing human diseases.\nThey used the parameter of DNA damage to examine the influence of a moderate amount of zinc on healthy living.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release states that this research is the first to show how modest increases in dietary zinc reduces oxidative stress and damage to DNA.", "answer": 1}, {"article": "LONDON -- AstraZeneca PLC said Monday its experimental heart pill Brilinta was more effective at preventing heart attacks and strokes in a large clinical trial than the blockbuster pill Plavix, boosting commercial prospects for the U.K. drug maker's still unmarketed treatment.\n\nPlavix, which is marketed by Sanofi-Aventis SA and Bristol-Myers Squibb Co., was the second-biggest-selling drug in the world last year, with global revenue of $8.6 billion, according to IMS Health. Any competitor to it could have a shot at big sales.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story states that analysts claim that Brilinta\u2019s effects appear to be more reversible than Plavix\u2019s, which would be useful in helping heart patients prepare for heart procedures involving surgery, where a risk of bleeding is very serious. But that\u2019s almost a worthless claim and clause in the story.\u00a0 Science \u2013 and evidence \u2013 not analysts \u2013 should establish novelty. \u00a0 \n\u00a0", "answer": 0}, {"article": "How miserable is combing a child's hair, lock by lock, to pick off head lice? So miserable that some parents are buying $30 shampoos and other washes that promise to ward off the tiny, grayish bugs.\n\nThe parents get peace of mind that they are doing something. Conveniently for the product makers, there's no way to tell if they kept lice at bay, or if children wouldn't have gotten lice anyway. Makers say sales are growing fast.", "question": "Does the story establish the true novelty of the approach?", "explanation": "No claims of novelty were made.", "answer": 2}, {"article": "SOURCE: bit.ly/zZIYa1\nAmong patients who had their prostate removed, none died from laparoscopic or robotic surgery, whereas two out of every 1,000 died after the open procedure.\nThe analysis, which appeared in the Journal of Urology, compared increasingly common robotic surgery with two other techniques for the same surgery and found that direct costs can be up to several thousand dollars higher for the robotic type.\nAbout five percent of the men who had open surgery needed a blood transfusion, compared to less than two percent of men who had robot-assisted surgery.\nThe open-surgery group also stayed in the hospital about one day longer than the robotic group.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story didn\u2019t provide any context on the growing body of literature about comparative effectiveness questions in this field as robotic surgery proliferates.", "answer": 0}, {"article": "Hartmann said doctors could take pressure off women by performing lumpectomies first to eliminate their cancer tumors.\nIt\u2019s an emotional decision that women often make quickly, considering that surgeries often take place within days of their cancer diagnosis.\nThat is an increase from 4.2 percent in 1998.\nThe safety concerns have been reduced and cosmetic procedures have improved, but some women still probably regret the decision, she said.\nThen the women can have genetic tests and assess their risks for follow-up cancers before deciding whether to have one or both breasts removed.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article makes clear that this is the first large federal study of the issue. As for the procedure itself, no claims are made for its novelty. ", "answer": 1}, {"article": "\"In 2012, scientists took that particular frog and wanted to know why is it, why do these frogs keep milk fresh?\n\"I need to come up with a strategy to deliver it systemically as well; maybe an injectable, which goes in the bloodstream and kills influenza viruses,\" Jacob mused.\n\"This peptide works by directly killing the virus, and it is specific for all influenza viruses that have a H1 type of hemagglutinin,\" Jacob said.\nThe urumin peptide could be a novel treatment since it targets the hemagglutinin, unlike current drugs on the market which target other parts of the virus, resulting in less impact, Jacob said.\n\"The peptide described in the Immunity report is somewhat unusual because of the apparent specificity,\" Rollins-Smith said about how urumin specifically targets H1 viruses.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "As part of the explanation for how this peptide kills flu viruses, the story offers a brief history of the use of frogs (and, apparently, their peptides) to prevent illness in human beings. Sources then make clear that this study\u2019s finding that a specific peptide seems to target only the H1 variants of influenza A is indeed novel.", "answer": 1}, {"article": "The fact that recognizing and acknowledging a familiar person is such...\nA glimpse of Mom must first register on your occipital lobes as a pattern of light and shadow.\nIt's harder than you think to say hello to your mother--at least in terms of the work your brain has to do.\nYou must then summon the speech centers in your frontal lobes, which recruit your breath and muscles and at last allow you to utter the words Hi, Mom.\nA little bit of current may calm the tremors of Parkinson\ufffds disease, ease depression and epilepsy, and awaken those with terrible injuries.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story provided an engaging look at the potential benefit for\u00a0deep brain stimulation to improve the condition of people in a minimally conscious state.", "answer": 1}, {"article": "Dr. Neu said the broad-spectrum antibiotics prescribed to the mother before a surgical delivery were another concern; the antibiotics can be transmitted to the baby through breast milk if not before birth, decreasing the diversity of natural bacteria.\nDr. Mairead Black, the University of Aberdeen obstetrician who led the study, said that as cesarean births had increased in Scotland and worldwide, the researchers wondered what, if anything, children born by C-section \u201care missing out on.\u201d\n\n\u201cOur thinking was: If a baby is born naturally, it comes into contact with bacteria from the mother, which might help with immune system development,\u201d Dr. Black said.\nThe findings are a reminder that although C-sections are appropriate in some circumstances, they are a poor substitute for labor.\nAlthough all of the C-section babies were more likely to be obese at age 5, the differences were not statistically significant after adjusting for differences among the mothers.\nNo one knows exactly why labor may be protective, but the spontaneous onset of labor prompts fluid to clear from a baby\u2019s lungs, said Dr. Aaron Caughey, who helped draw up 2014 guidelines for the American College of Obstetricians and Gynecologists that urged providers to let women spend more time in labor and avoid an unnecessary C-section.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "As the story points out, the existence of additional health risks for babies born by C-section are already well known. That is not a novel finding. What was new was the comparison between planned and unplanned C-sections.", "answer": 1}, {"article": "But tests of the concept since the late 1980s have been overwhelmingly disappointing.\nThe new report, however, is believed to be the first time that genetically engineered immune system cells -- specifically, T lymphocytes -- have produced the same effect.\nIn the study, Rosenberg and his colleagues took lymphocytes from the blood and inserted into them genes for a receptor capable of \"recognizing\" a protein on melanoma cells called MART-1.\nThe report, published online by the journal Science, is the latest result of a three-decade effort by surgeon Steven A. Rosenberg to find ways to manipulate the human immune system to fight cancer.\nFour years ago, Rosenberg and his colleagues treated a group of melanoma patients with naturally occurring anti-cancer cells extracted from their tumors, and some of those patients also have had long-term disappearance of their cancers.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The approach of using cells from a patient\u2019s own immune system, engineered to recognize a specific marker protein on the surface of the tumor cells as part of a therapeutic approach to the treatment of cancer is an area of active investigation. This is a first report of success with this type of approach. ", "answer": 1}, {"article": "\u2022 4.9 million babies are born with a serious birth defect worldwide every year\n\u2022 3.3 million children under five die from serious birth defects annually\n\u2022 Congenital heart disease is the most common form of birth defect, affecting 1 in 100 babies\n\u2022 42 babies are born with a heart defect in Australia every week\n\u2022 30 babies will undergo heart surgery in Australia every week\n\u2022 Heart defects account for 30% of deaths in children under five\n\n[1] Baker H, DeAngelis B, Holland B, Gittens-Williams L, Barrett T Jr. Vitamin Profile of 563 Gravidas during Trimesters of Pregnancy.\nThis will enable doctors to identify those women who are at greatest risk of having a baby with a birth defect, and ensure they are getting sufficient vitamin B3.\nThis has the potential to significantly reduce the number of miscarriages and birth defects around the world, and I do not use those words lightly,\u201d says Professor Dunwoodie.\nThe findings have been released today by the New England Journal of Medicine \u2013 the most prestigious clinical research publication in the world.\nIt\u2019s extremely rare to discover the problem and provide a preventive solution at the same time.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release made it clear that the discovery of NAD deficiencies, and how niacin may treat it, are both new. ", "answer": 1}, {"article": "CHAPEL HILL - University of North Carolina Lineberger Comprehensive Cancer Center researchers have found that mailing self-collection kits to test for high-risk human papillomavirus infection has the potential to boost cervical cancer screening - especially for low-income women who are overdue for testing.\n\"We found in this sample, all of the women who had high-grade lesions had HPV-positive home self-collection results,\" Smith said.\n\"We didn't miss any of those high-grade cases by conducting home self-collection.\"\nThis will allow us to determine the effect that self-collection has on screening uptake.\"\nOffering HPV testing using self-collection by mail has a lot of potential to reach women who are the highest risk of being screened: those who don't access regular medical care.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It\u2019s clear that this was a proof-of-concept study aimed at evaluating a new technique to improve patient access to HPV screening.", "answer": 1}, {"article": "Instead, the chief usefulness of the \"ALVAC-AIDSVAX\" vaccine is likely to be what it can teach virologists about what is happening in the immune system when a person is even somewhat protected from HIV.\nIt is unlikely -- but not impossible -- that any country would consider it effective enough to be used as a public health measure against HIV.\n\"It is in a kind of gray zone, and I think we should really get the data and look at it and see what it all means.\"\nHe predicted that information gained from the trial after the results are fully analyzed will have \"important implications for the design of future HIV vaccines.\"\nThe study cost $105 million, most of it provided by the National Institutes of Health.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story gave lots of detail about the novelty of this approach, but questions: \"How a vaccine that induces both a weak antibody response and a poor cell-mediated one can protect some people from HIV infection is the big initial mystery of this study.\" ", "answer": 1}, {"article": "However, the treatment failed to improve secondary goals of the trial, such as heart-pumping efficiency and six-minute walking distance, and Vericel shares fell more than 31 percent by afternoon trading on Monday.\nWith advanced heart failure, a leading cause of hospitalizations, blood-pumping ability is diminished as the heart\u2019s left ventricle becomes enlarged and weakened.\nIf the disease worsens despite all available medicinal and interventional therapies, the only options are heart transplant or a pumping assist device.\n\u201cThe idea is to find a treatment for this group of people before they get to that stage,\u201d Henry said.\nAfter one year, the Vericel treatment led to a 37 percent reduction versus placebo in a composite of adverse events, including death, heart-related hospitalizations and unplanned clinic visits related to heart failure.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not attempt to portray this stem cell therapy as a significant scientific breakthrough, but presents the information in a way that allows the audience to believe this may be a viable alternative to existing treatments.", "answer": 1}, {"article": "We are seeing results comparable to those of childhood vaccinations.\nMany vaccines are made from a weakened form of the virus, but Shingrix is made from just a single protein--known as glycoprotein E--that comes from the outer shell of the herpes zoster virus.\nThe research, published in the Journal of Infectious Diseases, shows that Shingrix offers protection for up to four years, but Professor Cunningham believes it will last much longer.\nA new study has shown how the body's immune system responds to the new shingles vaccine, Shingrix, making it more than 90% effective at protecting against the virus.\n\"This is quite remarkable because there are no other vaccines that perform nearly so well for people in their 70s and their 80s.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It states:\nThe vaccine also contains an adjuvant\u2013a substance that helps your body fight off the virus. It is the first shingles vaccine to combine a non-live antigen with a specifically designed adjuvant.\nHowever, there are non-shingles vaccines that use this approach in vaccines recommended for older adults. According to a report in the American Osteopathic Association:\nStrategies that may improve vaccine effectiveness in older individuals include using higher doses, adding extra boosters, changing the route of vaccination, or combining vaccine antigens with adjuvants (adjuvanted vaccines) or a more immunogenic protein (conjugated vaccine). Adjuvanted and conjugated vaccines, as well as altering the vaccine dose, have all been applied to 3 vaccines currently recommended for older adults: influenza virus, Streptococcus pneumonia, and VZV vaccines.", "answer": 1}, {"article": "\u2018\u2018I\u2019ve had chemotherapy.\nThe study involved the most common type of breast cancer \u2014 early stage, without spread to lymph nodes; hormone-positive, meaning the tumor\u2019s growth is fueled by estrogen or progesterone; and not the type that the drug Herceptin targets.\nThe test accurately identified a group of women whose cancers are so likely to respond to hormone-blocking drugs that adding chemo would do little if any good while exposing them to side effects and other health risks.\nIn the study, women who skipped chemo based on the test had less than a 1 percent chance of cancer recurring far away, such as the liver or lungs, within the next five years.\n\u2018\u2018These patients who had low risk scores by Oncotype did extraordinarily well at five years,\u2019\u2019 said Dr. Hope Rugo, a breast cancer specialist at the University of California, San Francisco, with no role in the study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The Associated Press article does a good job providing some context to the NEJM study and states that past studies have looked into how women with varying levels of risk have fared. This is the first study to assign women treatments based on their scores and to track recurrence rates, the story says.\nThe initial studies that led to widespread use of the test were (very large) retrospective validation studies. This is the first prospective study of its kind.", "answer": 1}, {"article": "But for now this category is useful only to researchers.\nThe guidelines say, for instance, that newly developed \"biomarker\" tests, such as assays for proteins in spinal fluid, and some specialized brain scans can be used for early diagnosis of Alzheimer's.\nBut the new criteria, which were developed by the National Institute on Aging and the Alzheimer's Association, are almost guaranteed to prompt confusion, even in people who are thinking quite clearly.\nRather, the goal in creating this category is to see if scientists can define when the disease starts, and track it through biomarker tests, brain imaging, or other yet-to-be-invented tests.\nBut, the guidelines say, the tests are to be used only for research, and not for diagnosing Alzheimer's in the general public.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story summarizes key components of the new definitions of the stages of Alzheimer\u2019s disease that are different from those used in the 1984 guidelines. It points out that lab tests and brain scans have not been shown to be accurate and reliable in ways that would make them useful in clinical settings, as well as some of the questions that remain about how the results would be used.  A more complete description of which biomarkers are being studied would have been a good addition.", "answer": 1}, {"article": "Sept. 28, 2010 -- Intrauterine devices (IUDs) -- used to prevent pregnancy -- may also be an effective treatment for some patients with early-stage uterine cancer who want to preserve their fertility.\n\nIn a small, early study, carefully selected patients with cancer that had not spread beyond the inner lining of the uterus were treated with IUDs that released the hormone progesterone.\n\nThe treatment was found to be as effective as oral hormone therapy, which is the most widely used nonsurgical, fertility-sparing treatment for the cancer.\n\n\u201cOur results show promise for the treatment of younger endometrial cancer patients with early disease who desire pregnancy in the future,\u201d gynecologic oncologist Lucas Minig tells WebMD. \u201cBut patients must be screened very carefully to make sure their disease has not spread.\u201d", "question": "Does the story establish the true novelty of the approach?", "explanation": "Although the progestin IUD is not new, using it to treat endometrial cancer is a relatively new idea.", "answer": 1}, {"article": "THURSDAY, July 20, 2017 (HealthDay News) -- A laser treatment can reduce spots in people's vision known as \"floaters,\" a new study finds.\nThe patients in the YAG group also had improvements in several other measures, including general vision and independence, compared with those in the placebo group, the findings showed.\nFloaters become more common with age, and although some people simply get used to them, others are bothered by them or their vision is impaired.\nA limitation of the study was its small size and short follow-up period, the researchers said.\nHowever, Shah and Heier said there are few published studies on the laser treatment's effectiveness in treating floaters.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story suggests that this is a possible newer approach to dealing with bothersome \u201cfloaters\u201d in the eye, and an alternative to eye surgery.", "answer": 1}, {"article": "That was longer than we expected, and it's great news for this group of women.\"\n\"If a woman's bone density at age 67 is very good, then she doesn't need to be re-screened in two years or three years, because we're not likely to see much change,\" says study author Margaret L. Gourlay, MD, MPH, of the University of North Carolina at Chapel Hill, in a news release.\nResearchers say the 10-year interval is OK because the women\u2019s risk of developing the brittle bone disease osteoporosis in that time is low.\n\"Our study found it would take about 16 years for 10 percent of women in the highest bone density ranges to develop osteoporosis.\nTheir findings are based on the women's T-score, which is a measure of bone density.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty here is not bone density screening, but less frequent use of this widely used test. Sadly, research that looks at screening intervals is a novelty.\u00a0But neither story establishes that novelty. The study appears to be quite significant given the size of the cohort and the time period of the study.", "answer": 0}, {"article": "Other studies are further along.\nIn the past 15 years or so, scientists have tried to use the cells to help repair some of the damage seen in heart failure.\nIn an early study of 27 patients, Japanese researchers used patients' own muscle stem cells to create a \"patch\" that was placed on the heart.\nIt takes later-phase trials -- where some patients receive the treatment, and others do not -- to prove that a therapy actually works.\nThe scientists extracted stem cells from each patient's thigh muscle, then cultured the cells so that they formed a sheet.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is very clear on this, explaining that previous heart failure treatments involving stem cells relied on injecting stem cells into the heart, whereas this study involved the creation of the stem cell patch and placing it on the heart.", "answer": 1}, {"article": "And it needs to be strong enough and elastic enough that it actually affects the recoil of the skin.\u201d\n\nThat, he said, \u201cis the challenge I put to them.\u201d\n\nDr. Robert Langer, a biomedical engineer who is a professor at M.I.T.\n\u201cA lot of what happens when we age and skin starts wrinkling and sagging is loss of elastic recoil,\u201d he said.\nOne of the first applications, said Dr. Barbara A. Gilchrest, a dermatology professor who is part of the research team, was on undereye bags, a condition that plagues so many middle-aged and older people.\nThe skin still has to be able to breathe through this stuff.\n\u201cWe wanted something that is elegant, and the ultimate test is right there on your face,\u201d she said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s made clear that a cream that changes into a second skin that is somewhat protective, ostensibly harmless, and cosmetically appealing is clearly novel.", "answer": 1}, {"article": "Wine rounds out the list of of 10 \"brain healthy\" food groups that help protect against Alzheimer's: green leafy vegetables, other vegetables, nuts, berries, beans, whole grains, fish, poultry, olive oil and wine.\nNow here are the five food groups it says you should avoid to reduce your risk of developing dementia...\n\nYou already know they're not so good for your waistline, and it turns out pastries and other sweets could have a negative effect on brain health as well.\nThe study, published in the journal Alzheimer's & Dementia, looked at more than 900 people between the ages of 58 and 98 who filled out food questionnaires and underwent repeated neurological testing.\nDiet appears to be just one of \"many factors that play into who gets the disease,\" said nutritional epidemiologist Martha Clare Morris, PhD, the lead author of the MIND diet study.\nA new study by researchers at Rush University Medical Center in Chicago shows a diet plan they developed -- appropriately called the MIND diet -- may reduce the risk of developing Alzheimer's disease by as much as 53 percent.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "While diets for cardiac health and to control diabetes and hypertension are common, evaluation of diets to prevent cognitive degradation are unusual. But the story missed the point that this study is the first published article finding that Alzheimer\u2019s (not just cognitive decline) is less common in the people who adhered to the MIND diet.", "answer": 0}, {"article": "\"This is [similar] to the effect that we and others have shown for [cholesterol-lowering] statins,\" he said, noting that \"bisphosphonates and statins share the same metabolic pathway.\"\nThe findings in this study show that bisphosphonates are associated with a reduced risk of developing colorectal cancer, but they cannot confirm a causal effect -- that is, the study doesn't prove that the use of bisphosphonates is responsible for the lower risk of colorectal cancer.\nHowever, the lowered risk of colorectal cancer seen with bisphosphonates may be due to the way the drug acts in the body, which is similar to how cholesterol-lowering drugs called statins work, according to Rennert.\n\"The magnitude of the reduced risk is less important because this is an association study; however, it is very significant after controlling for a dozen other known risk factors,\" Rennert said.\nCommenting on the study, Eric Jacobs, Strategic Director of Pharmacoepidemiology at the American Cancer Society, said that \"the lower risk of colorectal cancer risk seen among bisphosphonate users in this study is intriguing.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story made it clear that the findings are part of a series of findings, some of them contradictory, about the side benefits of different drugs for cancer prevention. It says, for example, \u201cHowever, the lowered risk of colorectal cancer seen with bisphosphonates may be due to the way the drug acts in the body, which is similar to how cholesterol-lowering drugs called statins work, according to Rennert.\u201d\n", "answer": 1}, {"article": "He is also founder of Durin Technologies Inc., the company that is developing the test.\n''This is a simple test that has high accuracy and can be run from a single drop of blood,\" says Robert Nagele, PhD, a professor of medicine at the University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine.\nAn estimated 5.4 million Americans have Alzheimer's disease, the most common form of dementia, according to the Alzheimer's Association.\nAug. 3, 2011 -- A new blood test for Alzheimer's disease is 96% accurate at identifying the disease and can perhaps detect it even before symptoms such as memory loss appear, says the test's developer.\nIt works by determining the amount of amyloid plaque, associated with the disease, in people's brains.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThis rating is a close call. The story does include comments pointing out that there are a number of other tests for Alzheimer\u2019s Disease being developed, but it might have been better to frame the headline and lead in a way that immediately makes clear to readers where this test fits in the context of other research. The lead could have used a phrase such as \u201cone more potential test for Alzheimer\u2019s enters the pipeline.\u201d", "answer": 1}, {"article": "If a pill could prevent teenagers from taking dangerous risks, would you consider it for your children?\n\nI\u2019d be tempted. My skateboard- and bicycle-riding son was hit by a car\u2014twice\u2014when he was a teenager. I would have welcomed anything that could have averted those dreadful phone calls from the emergency room.\n\nWhile some bumps and scares...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The piece does not establish the novelty of the findings. Again, this was something better handled by the news release, which states \u201cWhile previous research has demonstrated the effectiveness of medications in treating the core symptoms of ADHD, little has been known about the effects of treatment on health, behavioral and educational outcomes in the long run. Evidence so far points to positive effects on some outcomes but not others.\u201d", "answer": 0}, {"article": "WHAT'S NEXT: Researchers said they want to see whether moderate drinking also benefits women with hypertension.\nThe researchers found that people who drank moderate amounts of beer, wine, or liquor had fewer heart attacks, though their risk of death was not significantly different from that of the other subjects in the study.\nThe negative-message subjects made 14 percent more errors than the positive, with the control subjects falling in between.\nBefore the test, one group was exposed to a negative stereotype: They were told that women do not perform well at spatial reasoning.\nA group of 11,711 men with hypertension were surveyed about their drinking habits every four years from 1986 to 2002.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The idea that moderate alcohol consumption can reduce cardiovascular disease is not a new one, however the story points out that it had never been advocated in those with hypertension.", "answer": 1}, {"article": "Before undergoing surgery, cancer patients could be given the Zika vaccine to \"let the viruses hunt down the GSCs [glioblastoma stem cells] and eliminate them,\u201d said virologist Dr. Cheng-Feng Qin of the Chinese Academy of Military Medical Sciences in Beijing, who worked on the study.\nShi said: \u201cScientists may turn the 'bad' side of a devastating pathogen\u2014Zika virus\u2014for potential cancer therapy.\u201d\n\nHowever, he cautioned any potential treatment which could emerge from the study is far from being rolled out.\nThe study showed that a live-attenuated Zika vaccine (containing a weakened version of the virus that does not cause disease in humans) could selectively infect and kill human glioblastoma stem cells, explained Shi.\n\u201cFor example, we need to make sure that the therapeutic vaccine virus does not infect and kill normal neurons in humans.\u201d\n\nDr. Harry Bulstrode, brain tumor expert funded by the charity Cancer Research U.K. who is researching how Zika could be used to treat aggressive brain tumors, who was not involved in the study, told Newsweek: \"This study is another interesting piece in the jigsaw, but it is never going to demonstrate what we believe to be the really exciting properties of the virus.\nHowever, as the disease spreads, it becomes difficult to differentiate healthy brain cells from cancerous glioblastoma stem cells, and the condition is therefore almost impossible to completely remove.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We do not learn from this story that multiple versions of oncolytic viruses have been explored for virotherapy against human Glioblastoma, with promising results. Thus, although the use of Zika virus may be new, research into using viruses to treat this cancer is well under way.", "answer": 0}, {"article": "nutritional guidelines, which I\u2019ve discussed before, says that coffee is not only O.K.\nFinally, while the coffee may be healthy, that\u2019s not necessarily true of the added sugar and fat that many people put into coffee-based beverages.\nIt\u2019s important to remember that we usually conduct those trials to see if what we are observing in epidemiologic studies holds up.\nMost of us aren\u2019t drinking coffee because we think it will protect us, though.\nIt\u2019s a completely reasonable addition to a healthy diet, with more potential benefits seen in research than almost any other beverage we\u2019re consuming.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not claim that research showing potential benefits of coffee is new, and it describes the publication dates of numerous studies.\nWe\u2019ll rate the story Satisfactory on that basis. However, the news hook for the story is that it\u2019s pointing out research that has been overlooked \u2014 that it\u2019s helping to change the public\u2019s perception of coffee from vice to something more virtuous. We think that premise is dubious at best. Given the countless thousands of articles about the benefits of coffee in recent years, is it really news to anyone that coffee\u2019s image may deserve a makeover?", "answer": 1}, {"article": "SWE technology is already used in diagnosing breast cancer and liver diseases.\n\u201cWith an average of one man dying every 45 minutes from prostate cancer in the UK, the need for a more reliable test that can identify dangerous forms of the disease earlier is greater than ever.\u201d\n\nIn the past few years, a number of celebrities have revealed that they had been diagnosed with prostate cancer and have joined campaigns to raise awareness of the disease, including Michael Parkinson, Ian McKellen and most recently Stephen Fry, the comedian and former rector of Dundee University, who this year described how he had surgery to deal with a prostate tumour.\n\u201cOur new method is far more accurate and also allows us to identify the difference between cancerous and benign tissue in the prostate without the need for invasive surgery.\u201d\n\nThe prostate is a small gland in the male reproductive system and is normally about the shape and size of a walnut.\n\u201cThe technique now needs to be tested in a much larger number of men to confirm just how well it can detect the aggressive cancers, while also ruling out those who do not have prostate cancer,\u201d said Simon Grieveson, head of research funding at Prostate Cancer UK, which funded the Dundee project (with support from the Movember Foundation).\n\u201cNow we need to use this on a wider scale to build more data but there is clearly the potential to really change the way we manage prostate cancer,\u201d Nabi said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "If backed up by valid information, the discovery of a new approach to diagnosing prostate cancer, as well as delineating between fast- and slow-growing tumors would certainly justify doing a news story.\u00a0 But in this case, the writer provides little to no substantive information that would allow readers to benefit from this offering.\u00a0 Far better to have not done a story rather than offer this little.", "answer": 0}, {"article": "AstraZeneca PLC's cholesterol drug Crestor sharply lowered risk of heart attacks among apparently healthy patients in a major study that challenges longstanding heart-disease prevention strategies. The findings could substantially broaden the market for statins, the world's best-selling class of medicines.\n\nHeart experts said the findings, presented Sunday at the annual scientific meeting of the American Heart Association in New Orleans, could reshape cholesterol-treatment guidelines used for more than a decade to fight cardiovascular...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reported that the study indicated a new target population for a medication that was currently approved for use. However, the story failed to note that other studies (e.g. AFCAPS) have found benefit from lipid lowering in patients with no history of heart disease and non-elevated LDL levels, using the statin lovastatin, a drug with is now available as generic. The reductions reported were somewhat smaller, but not radically different.", "answer": 0}, {"article": "reconstructions\u201d currently being conducted on injured knees \u201ccould be avoided without adversely affecting outcomes.\u201d\n\nThis possibility should reverberate across playing fields nationwide, where, at the moment, preseason high school, collegiate and adult-league sports practices are under way, with a concomitant surge in A.C.L.\nThe first group began physical therapy and then underwent surgical reconstruction of the ligament, considered by many people to be the best option for injured athletes.\nA study published late last month in The New England Journal of Medicine is raising provocative questions about how best to treat a torn anterior cruciate ligament.\nHe points out that in The New England Journal of Medicine study, only 8 percent of the patients in the first surgical group subsequently tore a meniscus, a fragile pillow of cartilage that can rip if a knee gives way.\nIn an important 2009 study published in The British Journal of Sports Medicine, researchers retrospectively compared outcomes after 10 years in competitive athletes who had surgery or had opted for conservative treatment of their torn A.C.L.\u2019s.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s obvious that ACL surgery and nonsurgical treatment aren\u2019t novel approaches.", "answer": 1}, {"article": "The study, conducted at the University of Texas M.D.\nThe study focused on more than 3,000 women \u2014 average age 53 \u2014 who had been treated successfully for early-stage breast cancer.\n\"I went into the study expecting to see a difference between the two groups,\" he said.\nThey were followed for six to 11 years.\nPrevious research into diet and breast cancer has shown mixed results, but the authors of this study said the earlier ones were not rigorous.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was explicit that it was reporting on the results of a recently published study. ", "answer": 1}, {"article": "Researchers say breast cancer survivors often experience side effects from cancer treatments that can persist months or years after completion of treatment.\nFor example, because many treatments designed to prevent breast cancer recurrence inhibit the body's production or use of estrogen, the hormone that can fuel breast cancer growth, breast cancer patients often experience hot flashes and night sweats, among other side effects.\nThe lead author on the study, Sarah Oppeneer Nomura, PhD, of Georgetown Lombardi, said that while further research is needed in larger study populations and with more detailed dietary data, this project addresses an important gap in research on the possible role of lifestyle factors, such as dietary habits, in relation to side effects of treatments.\nIn the study, published in Breast Cancer Research and Treatment, higher intake of cruciferous vegetables and soy foods were associated with fewer reports of menopausal symptoms.\nThe Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization, which accounts for the majority of externally funded research at GUMC including a Clinical and Translational Science Award from the National Institutes of Health.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does a pretty good job of explaining \u201cwhat\u2019s new\u201d about the study, particularly as it relates to the study population. We can\u2019t be sure how generalizable the results are to all breast cancer patients.", "answer": 1}, {"article": "Psoriasis is a skin condition that causes patches of skin redness and flaking.\nThe most common adverse reactions reported with the use of Siliq include joint pain (arthralgia), headache, fatigue, diarrhea, throat pain (oropharyngeal pain), nausea, muscle pain (myalgia), injection site reactions, influenza, low white blood cell count (neutropenia) and fungal (tinea) infections.\n\"Moderate-to-severe plaque psoriasis can cause significant skin irritation and discomfort for patients, and today\u2019s approval provides patients with another treatment option for their psoriasis,\" said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research.\nSiliq is also approved with a Medication Guide to inform patients of the risk of suicidal ideation and behavior, and that because Siliq is a medication that affects the immune system, patients may have a greater risk of getting an infection, or an allergic or autoimmune condition.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release makes it clear that this is a drug for patients who have not responded to other established methods of therapy. A FDA director comments that Siliq provides psoriasis patients with \u201canother treatment option.\u201d\nWe feel this is good enough for a Satisfactory rating.", "answer": 1}, {"article": "\u201cI don\u2019t think a blood will be the be-all and end-all but it would be a beautiful tool for us to have in the clinic to support a lot of our decision making.\u201d\n\nTesting for levels of UCH-L1, for example, might be helpful for emergency medical teams in an ambulance trying to assess whether a patient has any serious head injuries, since its levels peak in the hours immediately after a trauma.\nEven at that point, the study shows, GFAP levels might be higher than normal and therefore might indicate TBI and need for further tests.\nAnd because the expose patients to radiation, doctors are often reluctant to use them on every patient, especially young children, who come to the emergency room with a head injury.\nBy tracking changes in the levels of the two proteins over this time, Papa could see how they changed, and correlate that with the people\u2019s symptoms.\nAll of the people had their blood drawn 19 times, starting at within four hours of their injury and up to 7 days later.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes the novelty of this study\u2019s premise by letting us know \u201cthe research team focused on two blood proteins that have already been linked to brain injury.\u201d", "answer": 1}, {"article": "Arjmandi was to present the findings Tuesday at the Experimental Biology meeting in Washington D.C.\n\"The pulp of an apple gets to be a very viscous gel-like substance that grabs cholesterol and pulls it out of the body.\nTUESDAY, April 12, 2011 (HealthDay News) -- Eating apples every day may be good for your cardiovascular health, new research suggests.\nIt's a substance that's used to make jellies or jams, and pectin contributes to the viscosity of what's going through the body, and bulks it up to help remove it.\n\"Apples really are an amazing fruit for many reasons,\" said Shapiro, who is a clinical nutritionist who counsels cardiac patients at Montefiore Medical Center in New York City.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "If apples have ever been studied before by anyone else for cardiovascular heatlh, we weren\u2019t told about it in this story. But since no claims of novelty were made, we\u2019ll rule this Not Applicable.", "answer": 2}, {"article": "Mumford, who's now 30, says he's never felt better.\nIf collected and stored for private use, the procedure can cost as much as $2,000 or more, plus annual storage fees.\nIn such transplants, patients have chemotherapy, radiation or both to kill the cancer cells and to suppress the immune system so that the new stem cells are not rejected.\nOn Saturday, her husband, Jake, finally wore the suit he had been saving for his wife's funeral -- at a family wedding.\nThe nonprofit, named for his mother, who died of breast cancer while he was being treated, provides emotional and financial assistance to cancer patients.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Since the story states that more than 200 hospitals nationally accept cord blood donations, a reader can see that this is not a new procedure.\u00a0", "answer": 1}, {"article": "\"The biological mechanism of labor initiation remains unknown, and a large percentage of preterm pregnancies do not respond well to current medications,\" said Ronghua Zhuge, Ph.D., associate professor within the University of Massachusetts Medical School's Department of Microbiology and Physiological Systems in Worcester, Massachusetts.\nOur mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.\nBitter taste receptors as targets for tocolytics in preterm labor therapy.\nThe researchers first exposed the tissue to native hormones such as oxytocin and chemical compounds to make it contract, mimicking normal or premature labor.\nBy activating the bitter taste receptors in the uterus, the bitter substances relaxed the contracted uterine muscle tissue more completely than the current drugs used to prevent preterm labor in humans.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The research focuses on a novel approach to preterm contractions but it is still far from human testing.", "answer": 0}, {"article": "A week later, under no medication, participants returned to repeat the experiment.\nThis is called 'reconsolidation', and we now plan to test the effect of doxycycline on reconsolidation of fear memories.\nThe common antibiotic doxycycline can disrupt the formation of negative associations in the brain, according to new research from UCL and the University of Zurich.\nTo treat such diseases, we already have clinically approved drugs that block these enzymes, including the antibiotic doxycycline, so we wanted to see if they could help to prevent fear memories from forming in the brain.\n\"When we talk about reducing fear memory, we are not talking about deleting the memory of what actually happened,\" explains lead author Professor Dominik Bach (UCL Wellcome Centre for Neuroimaging, Max Planck UCL Centre for Computational Psychiatry and Ageing Research and University of Zurich Division of Clinical Psychiatry Research).\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release claims novelty through this statement by the study author: \u201cWe have demonstrated a proof-of-principle for an entirely new treatment strategy for PTSD,\u201d explains Professor Bach. \u201cThe theory is based on the recent discovery that our brains need proteins outside nerve cells, called matrix enzymes, to form memories.\u201d\nHowever, the current study is not the first to identify a drug that may block\u00a0fear learning, as noted above under the \u201calternatives\u201d criteria.", "answer": 0}, {"article": "Learn more about brain health at http://www.\nMINNEAPOLIS - People who eat vegetables, fruit and whole grains may have lower rates of depression over time, according to a preliminary study released today that will be presented at the American Academy of Neurology's 70th Annual Meeting in Los Angeles, April 21 to 27, 2018.\n\"Depression is common in older adults and more frequent in people with memory problems, vascular risk factors such as high blood pressure or high cholesterol, or people who have had a stroke,\" said study author Laurel Cherian, MD, of Rush University Medical Center in Chicago and a member of the American Academy of Neurology.\nThe study found that people whose diets adhered more closely to the Dietary Approaches to Stop Hypertension (DASH) diet were less likely to develop depression than people who did not closely follow the diet.\nOn the other hand, the more closely people followed a Western diet--a diet that is high in saturated fats and red meats and low in fruits and vegetables--the more likely they were to develop depression.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This is far from the first study to assess relationships between diet and depression. For example, a 2013 paper in Annals of Neurology that looked at (among other things) nine different studies involving the Mediterranean diet and depression. How does this forthcoming conference paper fit into that expansive body of work? It\u2019s not clear. Based on the release, readers may think this is the first study to consider a link between diet and depression. To be clear, this research may well address novel research questions, but the release doesn\u2019t make clear what those are \u2014 particularly in the context of previous work in the field.", "answer": 0}, {"article": "Commenting on the Nature Medicine study, he tells Newsweek the paper is \u201cvery interesting on a number of levels.\u201d\n\n\u201cFirst of all there\u2019s clearly growing interest in the potential therapeutic role of cannabinoids and in this particular case THC on various human conditions,\u201d he says.\n(The study\u2019s authors noted that this was in \u201cgood agreement with the known detrimental effects of THC on cognition in young animals and humans.\u201d\n\nNext, they created a task where mice had to locate a specific object.\n\u201cThis paper is addressing a possible role for that compound in memory and cognition, which is relevant to disorders such as Alzheimer\u2019s and other dementias.\u201d\n\nHe said that while it is important to remember the study was carried out on mouse models, the differences in the effect of the drug on younger animals versus older animals tells us a lot about our understanding of the differences between old and young brains.\nThe team argues that while they do not yet know if these findings would be same in humans, it could lead to new treatments to prevent cognitive decline in older people: \u201cCannabis preparations and THC are used for medicinal purposes,\u201d they write.\nTo study what effect THC has on the aging brain, scientists gave low doses of THC to mice at three different life stages\u2014two months, 12 months and 18 months.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is a barely passing satisfactory\u2013the story establishes that there is a lot of current interest in studying marijuana compounds for human conditions, and that this one is a foray into memory and cognition. Still, it\u2019s not clear if this is a new finding, or not.", "answer": 1}, {"article": "WASHINGTON (AP) -- A medical implant that slowly dissolves into the body could be the answer to long-standing safety concerns with devices used to treat clogged arteries.\nLong-term safety results aren't expected until 2020.\nThey are still implanted in about 850,000 U.S. patients annually.\nThat 1.7 percent difference is not considered statistically significant.\nStone was not paid by Abbott for his work on the trial.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear what is new about this type of stent.", "answer": 1}, {"article": "Co-authors on the paper, all from Boston University, are T.A.\n\"The potential of digital UV technology for phototherapy is enormous,\" said Dr. Robert C. Walker, RayVio's CEO.\nRayVio's 293nm LED showed the most significant potential for vitamin D3 production in the shortest amount of time,\" said Dr. Holick, a Professor of Medicine, Physiology and Biophysics at Boston University School of Medicine, and endocrinologist at Boston Medical Center.\n\"This study will lead to a new generation of technology that can be labeled as photopharmacology in which the use of LEDs with targeted wavelengths can cause specific biologic effects in human skin to help treat and prevent chronic illnesses.\"\nResearch published today in Scientific Reports shows that light from RayVio's 293nm ultraviolet (UV) LED is more efficient than sunlight at producing vitamin D3 in skin samples.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release makes it sound as if UV LED therapy is a novel treatment option, since it states \u201cthis study will lead to a new generation of technology\u2026labeled as photopharmacology.\u201d It adds that \u201cthe use of LEDs with targeted wavelengths can cause specific biologic effects in human skin to help treat and prevent chronic illnesses.\u201d\nUV light therapy, also known as phototherapy, has been widely used as an option to treat skin diseases, like psoriasis, T-cell lymphoma, vitiligo and atopic dermatitis. UV lamps to synthesize vitamin D have been around since the 1940s, when the Sperti lamp was available in US pharmacies to prevent and treat rickets.\nIn addition, UV LED therapy has been previously explored. A 2016 study in Food Chemistry looked into the efficiency of UV LEDs in producing vitamin D3 in pig skin. Another 2014 study published in the National High School Journal of Science also looked at the effect of UV LEDs on vitamin D production.\nWe especially would have liked more context surrounding UV LED research, which is why we rate this one Not Satisfactory.", "answer": 0}, {"article": "Brooks hopes that more health workers will consider incorporating pets into care plans for people with mental illness.\nThe social workers at McLean also incorporate pets into their aftercare planning, encouraging patients to make walking and grooming their pets a part of their routine.\nWhen he was hearing voices, he said that they \"help me in the sense, you know, I'm not thinking about the voices, I'm just thinking of when I hear the birds singing.\"\nYou know what I mean, so it's \u2014 it's nice to come home and, you know, listen to the birds singing and that, you know.\"\n\"I think there's significant value in considering the common everyday pet to be as important as the relationships one has with one's family in the course of their treatment,\" says Longsjo.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "While not directly addressed, the story does hint at what\u2019s novel about this new study\u2013that the relationship between pets and people with severe mental illnesses hasn\u2019t been researched with the same vigor as the benefits of trained therapy animals.", "answer": 1}, {"article": "Hialeah bucket list: All the things you need to do in Hialeah before you die\n\nYou can spend your whole life working on this list.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story tells readers that interest in this technology increased in the late 1990s as a result of early work with lung cancer screening, providing some historical information about when lung cancer screening came onto the scene.\u00a0 The story also indirectly states that this is not widely available, implying that widespread lung cancer screening would be new, although a CT scan, the technology used for lung cancer screening,\u00a0is not new.\u00a0 ", "answer": 1}, {"article": "For more industry information, health research and recipe ideas, visit =.\nThe study results found that a smaller tumor size was associated with greater percentage of omega-3s in tumor tissues, suggesting that ALA may provide a protective benefit.\nAfter 25 days, researchers found that in walnut-fed mice, key miRNA that may affect cancer cell inflammation, vascularization (blood supply) and proliferation were positively engaged.\nThe tumors of mice fed the walnut-containing diet were found to have 10 times the amount of total omega-3 fatty acids, including plant-based alpha-linolenic acid (ALA), in the tissue compared to the mice fed the control diet.\nOne group was fed the equivalent of two servings (2 ounces) per day of walnuts for humans, while the second group received a similar control diet with no walnuts.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There has already been research on the potential protective influence of omega-3 fatty acids for inflammation. The release clearly explained the novelty of this specific mouse study investigating underlying chemistry and how it may work.", "answer": 1}, {"article": "Commenting broadly on fast-style diets, James Catterson of the Institute of Healthy Ageing at University College London, who was not involved in the study, previously told Newsweek the jury is still out on fasting diets.\nThe authors noted that the results mirror those from previous studies of other forms of intermittent fasting, including alternate day fasting, where an individual eats normally every other day.\nFollowers of the popular regime eat during an eight-hour window, in this case between 10 a.m. and 6 p.m. And for the 16 hours in between, they consume only calorie-free drinks, such as water.\nHe concluded, \"So far, the consensus seems to be \u2018let\u2019s wait until more rigorous studies, with larger sample sizes that adjust for confounding lifestyle behaviors, have been performed before we conclude anything prematurely.'\"\nKrista Varady, one of the study's authors and associate professor of kinesiology and nutrition at the University of Illinois at Chicago's School of Applied Health Sciences, said in a statement that the take-home message from the study is that cutting out certain foods or counting calories aren\u2019t the only effective methods for losing weight.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reported that the findings \u201cshed light on what one type of time-restricted eating does to the body.\u201d\nAccording to the study authors, the trial is the first to examine whether time-restricted eating is effective for weight loss and reducing the risk of metabolic disease risk in people with obesity.\n", "answer": 1}, {"article": "The new awards provide up to $600,000 each over three years to support the work of collab...\n\nUW to test using MDMA to treat PTSD\n\nThe Department of Family Medicine and Community Health of the UW School of Medicine and Public Health will take part in a multisite Food and Drug Administration-approved Phase III trial investigating MDMA as an adjunct to psychotherapy for the tre...\nThe search committee for the Science and Medicine Graduate Research Scholars (SciMed) program director position enthusiastically announces four finalists who have been invited to give public presentations.\nThomas Mackie to lead new joint innovation initiative between UW Health and School of Medicine and Public Health\n\nUW Health has selected Thomas \u201cRock\u201d Mackie to be the inaugural leader of the health system\u2019s innovation initiative, which it is pursuing in partnership with the UW School of Medicine and Public Health.\nRyan Coller wins federal challenge for app to help children with complex care needs\n\nA team of researchers at the University of Wisconsin School of Medicine and Public Health and the College of Engineering have won a share of a $100,000 award to develop technology for families caring at home for children with complex medical needs...\nFor the first time in Wisconsin, a research team will test a personalized cell therapy to treat a common and serious complication in bone-marrow transplant patients.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release notes that there is previous research suggesting that Lupron may be beneficial for the prevention of Alzheimer\u2019s disease. It establishes that this is the first drug combination that could maintain stability in cognitive function\u00a0for Alzheimer\u2019s patients over the course of a year.", "answer": 1}, {"article": "\u201cFacing biosimilar competition... we see Tecentriq sales coming timely to support Roche\u2019s profitability going forward.\u201d\nThe latest trial success follows Roche\u2019s announcement last week about a separate study in which Tecentriq mixed with chemotherapies carboplatin and Abraxane boosted progression-free survival, compared with chemotherapy alone, in first-line treatment of patients with advanced squamous non-small cell lung cancer.\nThe world\u2019s biggest maker of cancer drugs is counting on growing sales of Tecentriq, which notched 487 million Swiss francs in 2017, to help offset falling revenue from its older cancer medicines Avastin, Rituxan and Herceptin whose patent expirations are exposing them to rivals\u2019 cheaper copies.\nWhile Roche did not provide specific overall survival data, the headline result helps its bid to catch up to better-established immunotherapies from Merck and Bristol-Myers Squibb and its shares rose about 1 percent in early trading.\n\u201cWe continue to see Roche efficacy more than sufficiently competitive to grant a 43 percent market share in the indication, translating in 4.9 billion francs Tecentriq peak sales and 1.2 billion francs in 2018,\u201d Baader\u2019s Bruno Bulic said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This was a close call. The article does not address the ways in which Roche\u2019s cocktail of drugs works better or differently than its own older therapies, or others on the market that are similar.\nBut it does reveal that it\u2019s probably more of a financial move than a patient care concern:\nThe world\u2019s biggest maker of cancer drugs is counting on growing sales of Tecentriq, which notched 487 million Swiss francs in 2017, to help offset falling revenue from its older cancer medicines Avastin, Rituxan and Herceptin whose patent expirations are exposing them to rivals\u2019 cheaper copies.\nThis is useful and so we\u2019ll lean toward satisfactory on this one.", "answer": 1}, {"article": "No doubt you have heard that yogurt is teeming with bacteria--and no doubt you try not to think about that as you dig into a cup of the stuff. Yes, they're supposed to be good bacteria, ones that not only don't make you sick but actually improve your health. Still, a spoonful of critters with unlovely names like Lactobacillus reuteri, Lactobacillus rhamnosus and Bifidus regularis will never sound like a palate pleaser to even the most dedicated health nut.\n\nWhether or not you've ever developed a taste--or even a tolerance--for living things in your lunch, more are on the way. Food...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear that many currently available foods contain probiotics and that there is an industry developing to enhance foods with probiotics. However, one could ask, is yogurt novel? ", "answer": 1}, {"article": "\"There is a growing sense that VE [vasogenic edema] or ARIA [amyloid-related imaging abnormalities] is a manageable side effect and may actually be a sign that the drug is clearing amyloid from the brain and the blood vessels,\" said Salloway.\nThe edema was symptomless in most cases, he said.\nThese imaging abnormalities may indicate inflammation of the brain caused by water retention.\nOf these, 85 percent were mild or moderate.\nThe researchers, who said monitoring of bapineuzumab will continue, are now awaiting the results of a larger Phase III trial on the drug.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story did not overstate the novelty of the drug reported on. But the story also could have mentioned that there are several similar drugs undergoing preliminary testing.", "answer": 1}, {"article": "New research analyzing more than 22,000 U.S. cases of aortic aneurysm repair is likely to hasten the trend toward more procedures being done with a device called a stent-graft instead of the typical surgery that requires up to eight weeks of recovery.\n\nThe study by doctors at Harvard Medical School and the federal Centers for Medicare and Medicaid Services found the death rate in surgery, 4.8%, was four times that of the 1.2% death rate in placing stent-grafts to seal off the aneurysm. Surgery tended to provide a more permanent...", "question": "Does the story establish the true novelty of the approach?", "explanation": "This was a story about a new comparison of treatments for the management of aortic aneurysms.", "answer": 1}, {"article": "Sha says it\u2019s not clear what might be found in plasma from young people that might help the symptoms of Alzheimer\u2019s.\nResearchers trying to answer the question say they found the treatments are at least safe.\nAnd they got a tiny hint that they just may help.\nWhole plasma must be matched to blood type.\nAnd a few of the patients seemed to do a little better in the skills of everyday living, although memory and thinking skills were not affected.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes that the testing of this idea in humans is new.", "answer": 1}, {"article": "U.S. News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual \"America's Best Hospitals\" survey.\nThe former indication is potentially useful for using IsoPSA for screening by primary care physicians, while the second is helpful for urologists in identifying patients who would benefit from curative intent therapy and other applications.\nThe study directly compared the clinical performance of a new test based on PSA, called IsoPSA, to PSA itself with patients already scheduled for prostate biopsy.\n\"The methodology used in the IsoPSA assay represents a significant departure from conventional ways to define biomarkers in blood, and may be applicable to improving other cancer biomarkers,\" said Dr. Klein.\nIn 2016, there were 7.1 million outpatient visits, 161,674 hospital admissions and 207,610 surgical cases throughout Cleveland Clinic's health system.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It is clear that this release is about the search for a better test. It\u2019s not exactly clear what\u2019s new here, since having a structurally-based PSA test is not a novel idea. IsoPSA is also known as PSA/SIA (Solvent Interaction Analysis) \u2014 an assay that has been described in medical literature since at least 2009.\nIn a Journal of Urology article, researchers used the same technique to differentiate structural PSA forms in urine. In the study, the PSA/SIA assay had been developed by AnalizaDx, Inc., a Cleveland-based biotech company. Interestingly, the first author of this article is Mark Stovsky, the principal investigator of the current European Association of Urology article.\nSince the news release doesn\u2019t include this background information, we give it a Not Satisfactory rating.\u00a0", "answer": 0}, {"article": "At the top of the list?\n\"The good news is that we now understand which foods we need to target to prevent Americans from dying prematurely from cardiometabolic diseases,\" says lead study author Renata Micha, a public health nutritionist and epidemiologist at the Friedman School at Tufts University.\n\"This is a remarkable burden, nearly 1,000 deaths each day\" linked to dietary habits, says senior study author Dariush Mozaffarian, dean of the Friedman School at Tufts.\n\"Our research suggests that nearly half of the risk can be reduced [by] eating a healthy diet,\" Mozaffarian says.\nHe says the bigger point is this: \"Whether poor diet is causing 1,000 cardiovascular and diabetes deaths per day, or 500, it remains among the leading causes of preventable suffering.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t establish what exactly is novel about the research. All of the factors described in the story have been previously associated with higher risk of death and disease, yet the story didn\u2019t distinguish these findings from that past research. And it did let this quote go by unchallenged:\n\u201cThe good news is that we now understand which foods we need to target to prevent Americans from dying prematurely from cardiometabolic diseases,\u201d says lead study author Renata Micha, a public health nutritionist and epidemiologist at the Friedman School at Tufts University.\n\u201cWe now understand\u201d is a claim of novelty \u2013 yet it\u2019s a causal claim that should have been more forcefully challenged somewhere in the story.", "answer": 0}, {"article": "Both drugs could win approval from the Food and Drug Administration by this summer.\nThe drugs, evolocumab from Amgen and alirocumab from Sanofi and Regeneron, inhibit a protein in the body called PCSK9 that helps regulate cholesterol.\n(However, the PCSK9 drugs are taken by injection every two weeks or four weeks, which could deter some users.)\nStill, the findings could help smooth the way for regulatory approval, wider use of the drugs by doctors and possibly reimbursement by insurers.\nAnalysts say the drugs will have billions of dollars in annual sales and will be taken by millions of people who cannot lower their cholesterol enough using statins alone or cannot tolerate statins.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story states that the new drugs are \u201calready known to sharply reduce so-called bad cholesterol.\u201d It explains that the new studies looked at LDL levels for a longer amount of time and tried to address whether these drugs could protect against heart attacks, strokes and other cardiovascular events.", "answer": 1}, {"article": "MIT scientists find evidence that Alzheimer\u2019s \u2018lost memories\u2019 may one day be recoverable\n\n\u2019Siri, I want to commit suicide\u2019 and other statements likely to yield unhelpful responses from your phone\n\nRoots of Napoleon complex may be justified: Study finds short men get short of end stick in life.\nThe study did caution that 30 of the 103, or about one-third, of the participants in the meditation group reported an \"adverse event,\" most often an increase in pain due to yoga.\n\"These findings suggest that MBSR may be an effective treatment option for patients with chronic low back pain,\" the authors wrote.\nIn an editorial, Madhav Goyal and Jennifer A. Haythornthwaite of the Johns Hopkins University School of Medicine said that the mechanisms for why meditation might work on back pain is still a mystery but that this question is merely \"academic\" for many clinicians and their patients who need immediate relief.\nThe two wrote that despite this and other unknowns, the study provides \"a compelling argument for ensuring that an evidence-based health care system should provide access to affordable mind-body therapies.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Given the constraints of a brief news story, the piece does a nice job of articulating the differences between MBSR and CBT. It would\u00a0have been even more helpful for the story to mention previous studies on the impact of MBSR and CBT on low back pain, to help us understand how novel this new study is.", "answer": 1}, {"article": "\u201cThis legitimises current guidelines which recommend treating this population with statins.\u201d\n\nRay said people with lower levels of cholesterol, around 4mmol/L, who otherwise appear healthy, should also be treated with statins.\nThere was also an 18% reduced risk of dying from any cause over the 20-year period.\nResearchers from Imperial College London and the University of Glasgow found impressive results among those on statins, who were given the widely-prescribed type pravastatin.\nAll the men had very high levels of LDL, or \u201cbad\u201d cholesterol, (higher than 4.9mmol/L) but had no evidence of heart disease at the start of the study.\nStatins cut the risk of dying from heart disease by 28% among men, according to the longest study of its kind.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that the length of the trial is what\u2019s novel.", "answer": 1}, {"article": "While HSDD is a controversial diagnosis -- some experts see it as the medicalization of what is for many women a relationship issue -- the 1,378 premenopausal women enrolled in the clinical trials were suffering distress over their lack of sexual desire.\nFlibanserin is taken nightly at bedtime.\nThe drug didn't work for all women.\nKychman is an advisor to Boehringer Ingelheim and serves on their speakers' bureau, services for which he is compensated.\nHowever, it's not an on-demand treatment.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it fairly clear that this is a new treatment \u2013 also for a new and controversial diagnosis. ", "answer": 1}, {"article": "This barrier works to protect the brain from toxins.\nIn a study published today in the Journal of NeuroOncology, TGen researchers report that PPF works to limit the spread of glioblastoma multiforme, or GBM -- the most common primary tumor of the brain and central nervous system -- by targeting a protein called TROY.\n\"GBM is one of the most aggressive of all cancers and it affects people of all ages,\" said Catherine (Bracken) Ivy, founder and president of The Ben & Catherine Ivy Foundation.\n\"New therapeutic strategies that target the molecular drivers of invasion are required for improved clinical outcome,\" said Dr. Harshil Dhruv, a TGen Research Assistant Professor and lead author of the study.\n\"Our data suggests that PPF, working in combination with TMZ and radiation, could limit glioblastoma invasion and improve the clinical outcome for brain tumor patients,\" said Dr. Tran, the study's senior author.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release fails to note that other researchers have previously released similar findings based on tests on propentofylline in rats and cell culture.\nPropentofylline decreases tumor growth in a rodent model of glioblastoma multiforme by a direct mechanism on microglia.\nPropentofylline Targets TROY, a Novel Microglial Signaling Pathway", "answer": 0}, {"article": "MUSC operates a 700-bed medical center, which includes a nationally recognized children's hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), Hollings Cancer Center (a National Cancer Institute-designated center), Level I Trauma Center, Institute of Psychiatry, and the state's only transplant center.\n\"Addiction goes along with virtually every psychiatric disorder at a higher percentage than it does in the general population\" said Peter W. Kalivas, Ph.D. the senior author on the article and chair of the Department of Neuroscience at MUSC.\nThe amount of craving was reduced by 81% and the frequency of craving by 71% in the NAC group, compared with 32% and 29% in the placebo group.\nThe 149-bed hospital includes six community based outpatient clinics, a 20-bed nursing home, women's health, and the full range of inpatient and outpatient care, including medical and surgical intensive care.\nAlthough these early, promising findings show that NAC reduced PTSD symptoms, craving, and depression, NAC should not be used as a monotherapy or substitute for evidence-based behavioral treatment, but instead be seen as an adjunct therapy that enhances it.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release claims novelty with these statements: \u201cThis trial is the first to use NAC as a pharmacotherapy for PTSD and a broad range of SUDs\u201d and \u201cNAC treatment with CBT would be a novel approach to treat co-occurring PTSD and SUD.\u201d\nThis does appear to be the first such clinical trial of the supplement to address this combination of disorders.", "answer": 1}, {"article": "Autism is a group of complex brain developmental disorders characterized by impairments in social interaction, communication, and stereotypical and repetitive behaviours.\nIt is also the first clinical trial investigating the efficacy, tolerability and safety of intranasal-administered oxytocin in young children with autism.\n\"We found that following oxytocin treatment, parents reported their child to be more socially responsive at home, and our own blind independent clinician ratings also supported improved social responsiveness in the therapy rooms of the Brain and Mind Centre,\" he said.\nThe study, led by researchers at the University's Brain and Mind Centre, is thought to be the first evidence of a medical treatment for social impairments in children with autism.\n\"We used some of the most widely used assessments of social responsiveness for children with autism,\" said autism expert, Associate Professor Adam Guastella of the Brain and Mind Centre.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release asserts the trial\u2019s novelty but the claims aren\u2019t very strong.\nFirst, the release states the trial is \u201cthought to be the first evidence of a medical treatment for social impairments in children with autism.\u201d Second is the claim, \u201cIt is also the first clinical trial investigating the efficacy, tolerability and safety of intranasal-administered oxytocin in young children with autism.\u201d\nThere have been larger multi-center trials of oxytocin for children in recent years. For example, investigators in Chapel Hill, NC, undertook an 8-week, placebo-controlled trial of oxytocin in 24 children, ages 3-17. Those results don\u2019t appear to have been reported yet, but a look at clinicaltrials.gov shows that this is an active area of investigation with many studies underway or recently completed.\nWe\u2019ll give the benefit of the doubt here but we wished for more context.", "answer": 1}, {"article": "Other Phase 2 data presented over the weekend showed that treatment with cabozantinib led to significant tumor shrinkage in 24 percent of patients with metastatic ovarian cancer.\nThe disease remained stable in 23 other patients, or 21 percent, and worsened in three.\nExelixis expects to have initial results around midyear from a pivotal trial of the drug as a treatment for thyroid cancer.\n\u201cFor the first time, cabo is showing dramatic activity against both soft tissue and metastatic bone lesions,\u201d said Exelixis Chief Executive Officer Michael Morrissey.\nExcluding patients on placebo, the median survival without disease progression was 29 weeks.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We\u2019re not told much about the relative novelty of the drug \u2013 only that it\u2019s being studied in ovarian and thyroid cancer as well.", "answer": 0}, {"article": "The human collagen used to develop the corneas was provided by biotechnology company FibroGen Inc.\n\u201cThis is the first time we have been able to regenerate a cornea in humans,\u201d researcher May Griffith, PhD, of the Ottawa Hospital Research Institute and the University of Ottawa tells WebMD.\n\u201cWe are still in the prototype stage, but this shows that regenerating a human cornea is possible.\u201d\n\nTwo years after having the corneas implanted, six of the 10 patients had improved vision .\nA shortage of human donor tissue coupled with the threat of graft rejection from donor corneal transplants has driven the search for other ways of treating corneal damage.\nIt has been 10 years since Griffith and colleagues first reported the development of a material with the potential to grow healthy new tissue in people with damaged corneas.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story states that this is the first time a biosynthetic cornea has been tested on humans. The story establishes that high but does not take a \"gee whiz\" approach.", "answer": 1}, {"article": "Lozano acknowledges that retrieving childhood memories, which he says has occurred in about one-third of his patents \u2014 requires lofty voltages that he would be uncomfortable sending patients home on.\nThe technique is also approved for obsessive-compulsive disorder and is being looked at for a number of other brain disorders, including depression, chronic pain and, as in Lozano's work, dementia.\nThough no bigger than a pea, the hypothalamus is a crucial bit of brain involved in appetite regulation and other bodily essentials such as temperature control, sleep and circadian rhythms.\nReferring to Lozano's second clinical study, Dr. Nader Pouratian, a neurosurgeon and DBS researcher at UCLA, comments, \"The recent deep brain stimulation trial for Alzheimer's disease clearly demonstrates the safety of this approach for trying to treat the progression of disease.\nAs Alzheimer's progresses, not only does the hypothalamus atrophy, but electrical communication between neurons in the region also gradually becomes impaired.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story appropriately states that deep brain stimulation is approved by the Food and Drug Administration to treat Parkinson\u2019s disease, essential tremor and obsessive-compulsive disorder. It also included a description of research on DBS in dementia, which helps provide context.", "answer": 1}, {"article": "\"You need to be monitored by your surgeon during that period of time.\u201d\n\nOne downside: the implants aren\u2019t covered by insurance or Medicare, says Hamilton, adding \u201cthe cost is around $4,000 to $5,000.\u201d\n\nThere are other risks with the procedure, but they are rare, according to clinical trials.\nIn a little over a year, the FDA approved two new devices to help with age-related vision loss.\nBoth of the new implants, Raindrop and KAMRA, go into only one eye.\nAlso, Hamilton notes, the implants aren\u2019t a \u201cbe all end all.\n\u201cThis is more than just about convenience.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explained that both of these devices have recently been approved by the FDA.", "answer": 1}, {"article": "A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website: http://www.\nThe article entitled \"Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder\" is coauthored by Steven Pliszka, MD, from The University of Texas Health Science Center at San Antonio and colleagues from Massachusetts General Hospital (Boston, MA), Westside Medical Family Practice (Clinton, UT), University of Tennessee Health Science Center (Memphis, TN), Meridien Research (Maitland and Bradenton, FL), Children's Development Center (Winter Park, FL), Ironshore Pharmaceuticals & Development (Grand Cayman, Cayman Islands), and Mount Sinai Medical Center (New York, NY), on behalf of the HLD200-108 Study Group.\nThe medication was well tolerated, with the main adverse effects of appetite suppression and insomnia being those commonly reported for other formulations of methylphenidate.\nNew Rochelle, NY, September 25, 2017--A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.\n\"Developing new formulations of effective medications for patients with ADHD improves the lives of children with the disorder,\" says Harold S. Koplewicz, MD, Editor-in-Chief of the Journal of Child and Adolescent Psychopharmacology and President of the Child Mind Institute in New York.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release suggests that the trial showed the delayed release form of an existing drug\u00a0 positively affected the quality of life for young children with ADHD and their families.\u00a0However, it remains unclear whether this formulation is indeed superior \u2014 or novel \u2014 in comparison to standard dosing of methylphenidate since that wasn\u2019t part of the trial.", "answer": 0}, {"article": "Researchers then analyzed health status information collected after the women turned 70.\nIn the study, researchers looked at the effects of drinking alcohol at midlife on the risk of diseases commonly associated with aging in a group of 13,894 women enrolled in the Nurses' Health Study.\nSept. 6, 2011 -- \"A drink a day keeps disease away\" may be the new motto for middle-age women hoping to age gracefully.\nFor example, compared to nondrinkers, women who drank up to one alcoholic drink per day were 20% more likely to be disease-free at age 70 than nondrinkers.\nA new study shows women who drank the equivalent of a beer or small glass of wine each day were less likely to develop chronic diseases like heart disease, cancer, and diabetes as they got older compared to nondrinkers or those who drink four or more drinks at one time.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story didn\u2019t really capture what is novel about this research. Many studies show potential health benefits for light to moderate alcohol consumption, but this is one of the few studies to look at whether the positive effects extend into older adulthood. The story didn\u2019t hype the \u201cnewness\u201d of the\u00a0findings, but it didn\u2019t quite earn a satisfactory here, either.", "answer": 0}, {"article": "In a study published in the journal Aging, Bredesen and colleagues showed how 10 patients who were experiencing age-related memory decline showed brain scan improvements after following an approach called metabolic enhancement for neurodegeneration (MEND), a 36-point individualized regimen of diet, exercise, brain stimulation, sleep improvements, medication and vitamins and other specific protocols for five to 24 months.\nThe study noted that some of the patients who had to quit working as a result of their memory decline, were able to return to work after adopting MEND and participants who were struggling at their jobs reported an improvement in job performance.\nThe MEND protocol, outlined in a 2014 study in the journal Aging, calls for interventions to treat conditions that could be associated with Alzheimer's such as inflammation, stress and diabetes.\nHowever, MEND also requires the use of supplements which are not well studied and do not require FDA approval.\nBut Bredesen believes that the only way to treat Alzheimer's is to treat all of the underlying problems, which may require intervention with supplements.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not provide enough context about this intervention\u2019s novelty\u2013besides the one 2014 study mentioned, what else has been tried that uses this approach? We don\u2019t get a sense of\u00a0where this concept fits into the larger research effort.", "answer": 1}, {"article": "\u201cHowever,\u201d she added, \u201cunlike a pill, which always has the same ingredients, acupuncture, like psychotherapy, varies from one provider to the other.\u201d\n\nSo while the specific regimen used in this study appeared effective, Manber said, \u201cI do not think we can say that our study proves that acupuncture is effective for depression during pregnancy.\u201d\n\nIt\u2019s estimated that 3 to 5 percent of pregnant women are diagnosed with depression, Manber and her colleagues note in their report.\nFourteen women who received depression-specific acupuncture reported pain during the needling, as did seven in the control-acupuncture group.\nAfter eight weeks, patients in the depression-specific acupuncture group had a higher rate of response to treatment.\nAccording to traditional medicine, specific acupuncture points on the skin are connected to internal pathways that conduct energy, or qi (\u201cchee\u201d), and stimulating these points with a fine needle promotes the healthy flow of qi.\nAcupuncture has been used for more than 2,000 years in Chinese medicine to treat a wide variety of ailments.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story described the use of acupuncture for treating patients with chronic pain, but it did not mention previous studies that evaluated its use in depression. ", "answer": 0}, {"article": "\"While ENDS may have the potential to benefit established adult smokers ... [they] should not be used by youth and adult non-tobacco users because of the harmful effects of nicotine and other risk exposures,\" says Tim McAfee, director the Office on Smoking and Health at the U.S. Centers for Disease Control and Prevention.\nThe number of people using a combination of tobacco and e-cigarettes is on the rise, according to Etter, resulting in smokers switching and consuming less tobacco each day.\nBut as it seems e-cigarettes are here to stay, most calls are for informed regulation rather than prohibition.\nHowever, further evidence on the long-term health effects of e-cigarettes or nicotine is needed.\nThe growing fear is the increasing domination of big tobacco in the e-cigarette market, which was once seen as a competitor.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that e-cigarettes have been around since 2006, and that there is growing debate as to the balance of benefits and harms surrounding their use.", "answer": 1}, {"article": "Obesity puts children at greater risk of developing preventable conditions like heart disease and diabetes at a younger age, and suffering poor health later in life.\nDr. Evangelia Charmandari, associate professor pediatric and adolescent endocrinology at at the Medical School of the National and Kapodistrian University of Athens and lead author of the study, said: \"These findings suggest that simple vitamin D supplementation may reduce the risk of overweight and obese children developing serious heart and metabolic complications in later life.\u201d\n\nThe findings are set to be presented at the 57th Annual European Society for Pediatric Endocrinology Meeting, and have therefore not yet been reviewed.\nAccording to findings presented at the European Society of Endocrinology annual meeting in Barcelona, individuals with higher levels of total body and abdominal fat appeared to have lower levels of vitamin D.\n\nRachida Rafiq, the lead author of the study told Newsweek at the time: \"Our results are significant as vitamin D deficiency and obesity are very common problems in our society nowadays,\" she told Newsweek, and argued that it is an important potential relationship to explore.\nProfessor Mary Fewtrell, assistant officer for health promotion at the U.K.-based Royal College of Paediatrics and Child Health, told Newsweek: \"Although the effect sizes are not given, these outcomes are certainly positive.\n\"Although these initial findings indicate that vitamin D could be used in the treatment of obesity, there remains a lack of evidence on the safety and long-term effects of supplementation, particularly if there is no vitamin D deficiency,\u201d said Charmandari.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story highlights recent research into vitamin D and belly fat levels in adults, but claims the study is the first to \u201cinvestigate the links between vitamin D supplementation and the weight and health of obese children and adolescents.\u201d But this is not accurate. In 2017, the authors of an ongoing study published partial results that echo the ones of the latest study.", "answer": 0}, {"article": "He said his team is now working with other scientists to try to design a drug which could interrupt the gene\u2019s activity.\nSurinder Soond, who worked on the study, said it was a \u201cnovel and exciting approach to treating cancer and the spread of tumors which holds great potential.\u201d\n\n\u201cThe challenge now is to identify a potent drug that will get inside cancer cells and destroy the activity of the rogue gene,\u201d said Andrew Chantry of UEA\u2019s school of biological sciences, who led the research.\nLONDON (Reuters) - British scientists have discovered a \u201crogue gene\u201d which helps cancer spread around the body and say blocking it with the right kind of drugs could stop many types of the disease in their tracks.\nThe culprit gene, called WWP2, is an enzymic bonding agent found inside cancer cells, the researchers explained in their study, published in the journal Oncogene Monday.\nResearchers from the University of East Anglia said their findings could lead within a decade to the development of new medicines to halt a critical late stage of the disease known as metastasis, when cancer cells spread to other parts of the body.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story says, \u201cSurinder Soond, who worked on the study, said it was a \u201cnovel and exciting approach to treating cancer and the spread of tumors which holds great potential.\u201d\u201d Quoting the author, though, does not prove that the approach is novel.\u00a0The study itself also says that the findings are novel: \u201cSignificantly, this is the first report of an interdependent biological role for distinct HECT E3 ubiquitin ligase isoforms, and highlights an entirely novel regulatory paradigm that selectively limits the level of inhibitory and activating Smads.\u201d Of course, that would not make much sense to most readers. So the story should have found a way to explain to readers why the approach to cancer treatment identified was a true advance that opened a new world of possibilities or whether it was a small improvement. And having an independent source evaluate the novelty would have helped as well.", "answer": 0}, {"article": "The German analysis found only five such studies.\n\"This article holds no surprises whatever,\" said Dr. Uwe Joseph Schoepf, a professor of radiology and cardiology at the Medical University of South Carolina.\nThough that difference is well established among radiologists, the new study may be of assistance in the general medical community, including general cardiologists, because \"it summarizes the advantages of CT at this point in time,\" he said.\nIndeed, CT and MRI are not contenders in clinical practice but are used for different reasons to make different assessments, Schoepf said.\nThe German researchers looked at results of 109 published studies of noninvasive heart artery imaging, including 89 that used CT and 20 that used MRI and involving 8,505 people.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story quotes an outside source as stating that \"this article holds no surprises whatever,\" and that the underlying difference between CT and MRI were somewhat common knowledge already.", "answer": 1}, {"article": "\"That's the amount you'd burn off in an hour of moderate intensity physical activity without lifting a finger,\" says senior author David Ludwig, director of the New Balance Foundation Obesity Prevention Center at Boston Children's Hospital.\nThe study, funded by the National Institutes of Health, was designed to see if changing the type of diet people consumed helped with weight maintenance because dieters often regain lost weight.\nThe research finds that dieters who were trying to maintain their weight loss burned significantly more calories eating a low-carb diet than they did eating a low-fat diet.\nFindings, published in this week's Journal of the American Medical Association: Participants burned about 300 calories more a day on a low-carb diet than they did on a low-fat diet.\nThe authors note a downside to the low-carb diet: It appears to raise some risk factors for heart disease.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The independent experts allude to the fact that there have been other studies that found no difference in weight loss between diets with varying proportions of fat, protein, and carbohydrate.", "answer": 1}, {"article": "Chicago (CNN) -- For the first time, patients with the deadliest form of skin cancer have two new treatment options that prolong survival, according to new research presented at a cancer conference in Chicago on Sunday.\nThis is very unusual in the world of drug development, he said.\nPatients with and without the BRAF mutation were eligible to participate.\nThat is what is so remarkable here,\" Schuchter said.\nNearly 90% benefited from this new targeted drug, Schuchter said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of the two drugs was established.", "answer": 1}, {"article": "The company's website can be accessed at http://www.\nThis is because in hormone receptor-positive cancer, the most common form of the disease, there are some concerns that high estrogen levels help cancer cells grow and spread, though this remains controversial.\n\"Isoflavones--the component of soy that has estrogen-like properties--have been shown to slow the growth of breast cancer cells in laboratory studies, and epidemiological analyses in East Asian women with breast cancer found links between higher isoflavone intake and reduced mortality; however, other research has suggested that the estrogen-like effects of isoflavones may reduce the effectiveness of hormone therapies used to treat breast cancer,\" explained Fang Fang Zhang, MD, PhD, of the Friedman School of Nutrition Science and Policy at Tufts University.\nIn an accompanying editorial, Omer Kucuk, MD, of the Winship Cancer Institute of Emory University, noted that the United States is the number 1 soy producer in the world and is in a great position to initiate changes in health policy encouraging soy intake.\nThe objective of CANCER is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology, course, and treatment of human cancer.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release did a creditable job of explaining what the study was designed to do and how it differed from past studies.\nOne of the key findings of the study was that soy consumption was not detrimental. During the 1990s, many doctors and breast cancer organizations were urging women not to consume soy products because they could be harmful. Survivors may be relieved to know this study, at least, did not find soy consumption harmful since soy products are now found in many foods. But as noted in the review summary, study results have been mixed and conflicting.", "answer": 1}, {"article": "\"Gardasil has the potential to meet an unmet medical need as the first vaccine to prevent cervical cancer,\" Merck's Dr. Patrick Brill-Edwards told the Vaccine and Related Biological Products advisory committee.\nAll four virus types are sexually transmitted.\nHPV is the most common sexually transmitted disease.\nAn agency decision is expected by June 8.\nThe committee's HPV vaccine group is recommending giving the vaccine to girls 11 and 12.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story states that this is a new vaccine.", "answer": 1}, {"article": "As part of the new study, published online Monday in the journal Lancet, researchers examined the cancer death rates of 25,570 patients who had participated in eight different randomized controlled trials of aspirin that ended up to 20 years earlier.\nThe specific dose of aspirin taken did not seem to matter \u2014 most trials gave out low doses of 75 to 100 milligrams \u2014 but the participants in the longest lasting trials had the most drastic reductions in cancer death years later.\nParticipants who had been assigned to the aspirin arms of the studies were 20 percent less likely after 20 years to have died of solid tumor cancers than those who had been in the comparison group taking dummy pills during the clinical trials, and their risk of gastrointestinal cancer death was 35 percent lower.\nThe risk of lung cancer death was 30 percent lower, the risk of colorectal cancer death was 40 percent lower and the risk of esophageal cancer death was 60 percent lower, the study reported.\nMany Americans take aspirin to lower their risk of heart disease, but a new study suggests a remarkable added benefit, reporting that patients who took aspirin regularly for a period of several years were 21 percent less likely decades later to die of solid tumor cancers, including cancers of the stomach, esophagus and lung.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes the novelty of using aspirin as a cancer prevention measure.", "answer": 1}, {"article": "Please visit http://www.\nWhile there were fewer cases and less detailed data collected in the physicians' study, the score was similar in both populations, indicating the potential benefit of healthy lifestyle habits in warding off lethal prostate cancer, said the authors.\n\"This study underscores the ongoing need for more effective prevention measures and policies to increase exercise, improve diet quality and reduce tobacco use in our population,\" said senior author June M. Chan, ScD, from the departments of Urology, and Epidemiology and Biostatistics at UCSF.\n\"We estimated that 47 percent of lethal prostate cancer cases would be prevented in the United States if men over 60 had five or more of these healthy habits,\" said Kenfield, assistant professor in the Department of Urology at UCSF Medical Center, and formerly of the Department of Medicine at Harvard Medical School in Boston, where the study was initiated.\nIn the study, published today, Nov. 17, 2015, in the Journal of the National Cancer Institute, the researchers analyzed data from two U.S. studies: the Health Professionals Follow-Up Study that tracked more than 42,000 males ages 40 to 75, from 1986 to 2010; and a second, the Physicians' Health Study that followed more than 20,000 males ages 40 to 84, from 1982 to 2010.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There are a lot \u2014 a lot \u2014 of papers out there on lifestyle choices and prostate cancer. In fact, the opening sentences in the abstract for the journal article says as much, while articulating what sets this research apart: \u201cSeveral lifestyle factors have been associated with risk of lethal prostate cancer, but little is known about their combined effect. Our objective was to develop and apply a lifestyle score for prevention of lethal prostate cancer.\u201d However, the release does not acknowledge all of the existing work on lifestyle and prostate cancer, and therefore fails to highlight how this paper fits into that broad body of work.", "answer": 0}, {"article": "American veterans coping with PTSD are traveling to lodges in the Amazon that offer ayahuasca, a hallucinogenic brew. Some say it has helped them manage emotional trauma from war, but others say it\u2019s not worth the journey. Photo: Ryan Dube/WSJ\n\nAfter surviving firefights and a roadside bomb in Afghanistan, U.S. Army veteran Asa Barrett tried antidepressant drugs and therapy to overcome depression and bouts of anger. Nothing worked.\n\nBut then, like many other foreigners, he journeyed to Peru\u2019s remote Amazonian jungle to drink ayahuasca, a centuries-old, sacred indigenous brew that some Western scientists think can help to heal psychological traumas.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story calls ayahuasca \u201ca centuries-old, sacred indigenous brew.\u201d", "answer": 1}, {"article": "\"The challenge in prostate cancer is how to look at all of these patterns within a cell, but hone in on the gene activity that suggests cancer, and not only this, what type of cancer - dangerous or manageable?\nThis is part of the normal functioning of the human body and can tell individuals apart, but the process can sometimes go wrong, resulting in various diseases.\nThey were able to do this using a computer algorithm, which left the team with 17 possible genetic markers for prostate cancer.\nIt is now understood that to find the different levels of cancer, scientists have to identify genes that have been altered in different cancer types.\nIt is believed that success rates could be hindered as a result of treating all prostate cancers in the same way.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release does attempt to describe the novelty of the test, although the release struggles to describe scientific terms.", "answer": 1}, {"article": "An experimental drug has proved effective at treating an aggressive form of breast cancer in patients who aren't responding to the widely used drug Herceptin, giving hope to women with otherwise limited treatment options, said drug maker GlaxoSmithKline PLC, presenting the results Saturday at the American Society of Clinical Oncology meeting in Atlanta.\n\nWhen taken with a standard chemotherapy treatment in a clinical study, the new drug, Tykerb nearly doubled the time to 8.5 months before the average patient's breast cancer...", "question": "Does the story establish the true novelty of the approach?", "explanation": "Tykerb (generic name lapatinib) is a new drug for the treatment of metastatic HER-2 positive breast cancer. The story discusses the mechanism by which this drug would inhibit tumor-cell growth.", "answer": 1}, {"article": "O'Neil said it's important to help people, not blame them.\nWhile the Weight Management Center has a high success rate at helping patients lose weight to fight diabetes, many people with the condition don't live near a specialized program and need help that's readily available.\nThe MUSC Health Weight Management Center takes a scientific approach to weight loss, focusing on changes in activity levels, behavior, thinking, diet and support systems.\nLeft uncontrolled, the condition can damage blood vessels and nerves, putting people at risk of having a heart attack or stroke.\nA study coordinated by the MUSC Health Weight Management Center shows the scales tipping in Weight Watchers' favor instead of standard care when it comes to helping people with Type 2 diabetes.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release claims that \u201cThe Weight Watchers study is new evidence of what that help might include when it comes to a side effect of weight gain: Type 2 diabetes.\u201d But the research doesn\u2019t appear truly novel. Earlier this year Indiana University publicized its own Weight Watchers-funded study relating to type 2 diabetes, weight loss and glucose control.", "answer": 0}, {"article": "As part of a longer term project funded by F. Hoffman-La Roche, the team previously tested a collection of approximately 550 potential tracer molecules and identified six promising tracers, eventually narrowing them down to three to be made and tested as candidate Tau PET radiopharmaceuticals.\nAn additional six older healthy controls were recruited for full-body scanning.\nThe third part of the study examined six older controls undergoing whole-body scanning.\nIt was published in the December 2018 issue of the journal.\nSusan Resnick and Madhav Thambisetty are employees of the NIH, National Institute on Aging.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The background and context provided in the release do a good job of making clear what sets the work apart.", "answer": 1}, {"article": "A new study raised questions about the benefits of a relatively common procedure for heart patients\u2014implanting tiny devices that prop open clogged arteries to relieve chest pain.\n\nThe 200-patient study conducted by U.K. researchers found that patients with stable chest pain, or angina, who received stent devices experienced no significant improvement in exercise time on a treadmill, compared with similar patients who received no stents during sham procedures.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear that what is novel about this research is the use of a placebo group whose participants underwent procedures but didn\u2019t receive a stent.", "answer": 1}, {"article": "A flu drug \u2014 shown to reduce the duration of symptoms \u2014 could upend treatment in U.S.\n\nNext winter, there may be a new drug for people who contract influenza \u2014 one that appears to be able to shut down infection quickly and, unlike anything else on the market, can be taken as a single dose.\n\nThe Food and Drug Administration on Tuesday said that it would give the drug, baloxavir marboxil, a priority review, and approval has the potential to upend the way influenza is treated.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains that it\u2019s been more than 20 years since a new class of flu drug has been developed and marketed. (It is available in Japan.)", "answer": 1}, {"article": "Five of the participants met the criteria for clinical response and remission.\n\"The purpose of our study was to investigate the effects of ketamine for TRD in younger patients for whom this indication for ketamine administration is not well studied,\" Mark Roback, a professor of pediatrics at the University of Minnesota, told Newsweek.\nThe study serves to point out the need for further, rigorous, study designed to answer the many questions that remain about ketamine for TRD, such as optimal dosing and route of administration, dosing interval and treatment length, and long-term effects\u2014just to name a few.\"\nResearchers from the University of Minnesota (UM) and the nonprofit Mayo Clinic found that ketamine caused an average decrease of 42 percent on the Children\u2019s Depression Rating Scale (CDRS)\u2014the most widely used rating scale in research trials for assessing the severity of depression and change in depressive symptoms among adolescents.\n\"Adolescence is a very important time for studying depression, first because depression often starts during these years, and second because it is an important time for brain development,\" Kathryn Cullen, from the Department of Psychiatry at UM, told Newsweek.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story missed the real significance of this study, which is that it appears to be the first published on the use of ketamine for depressed teens. At least one other study on this topic is underway.\nUnfortunately, the headline and lead wrongly focused on a possible benefit \u2014 which is impossible to show from this extremely skimpy data \u2014 rather than the fact that this is an initial glimpse of an area of emerging research.\nIn sum, using ketamine for adolescent depression is definitely novel and bears coverage, but the optimistic assertions in the headline and lead aren\u2019t supported by the data.", "answer": 0}, {"article": "The Ache: The bathroom scale shows how much you\u2019ve gained or lost in pounds, but gives no information about whether the change is fat or muscle.\n\nThe Claim: A whole-body scan, called Dual-Energy X-ray Absorptiometry, or DXA for short, gives a detailed snapshot of your body composition, including how your body weight breaks down into fat, bone and lean tissue.", "question": "Does the story establish the true novelty of the approach?", "explanation": "DXA scans are clearly distinct from other techniques for assessing body composition, but it\u2019s not new. Researchers have been writing about using DXA scans to assess body composition since the early 1990s.\u00a0The story gives a sense of why this is newsworthy now when it says, \u201cA DXA scan (pronounced dexa) is commonly used to measure bone density, but recently has been increasingly used to measure body composition.\u201d We\u2019ll call that good enough for a Satisfactory rating.", "answer": 1}, {"article": "Researchers then narrowed their analysis to see how the urine test scores matched the men\u2019s Gleason score, which helps doctors gauge how aggressive a cancer may be.\nThose scores were then compared to the biopsy results.\nNow that the researchers have validated the test, further studies in larger, more diverse populations will be important to understand how it is best used.\nBased on the levels of PCA3 and TMPRSS2:ERG detected, the men were given numerical scores that were classified as being high, medium, or low.\n\u201cThe men in the highest group have a risk of cancer on biopsy of about 70% and those in the lowest group have a risk of cancer of about 20%,\u201d says Tomlins.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "If this approach were truly confirmed, it would be a novel and important advance, and the story appropriately addressed that potential.", "answer": 1}, {"article": "We are simply talking about restoring normal thyroid hormone balance in heart disease, not over-stimulating the heart.\"\nIn the study entitled \"Long-term physiological T3 supplementation in hypertensive heart disease in rats,\" aging female rats with hypertension progressing to heart failure were treated for one year (half their lifetime) with a low oral dose of the active form of thyroid hormone, T3.\nThyroid hormones administered to female rats with high blood pressure led to encouraging cardiac improvements, according to a study in the American Journal of Physiology led by NYIT College of Osteopathic Medicine researcher Martin Gerdes.\n\"What we have tried to do here is show the effect of safe doses of thyroid hormones and we're seeing amazing results in multiple studies, with dramatic improvements in heart function, gene expression, and collagen levels, just by restoring depressed thyroid levels in the heart,\" said Gerdes.\nAbout half of the human patients with heart failure suffer from this particular condition, known as diastolic heart failure.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does a good job of placing the new study into context, and articulating what sets the most recent study apart. The release notes that the lead author has published on 32 animal studies that looked at links between thyroid hormone levels and heart health, and offers some discussion of at least two of these other studies and why they\u2019re relevant. The release also mentions other studies in the field (though it refers to them as \u201coutdated\u201d.", "answer": 1}, {"article": "The current study, she added, shows that \u201chigh quality (stroke) care is available in hospitals on the weekends and weekdays.\u201d In fact, care might even be more aggressive on weekends.\nIn fact, that authors note that patients who received tPA were more likely to die in the hospital.\nNonetheless, the odds of survival are about the same for weekend and weekday admission for stroke, the study found.\n\u201cAnyone who thinks they are having a stroke should seek care at a hospital immediately.\nA total of 543 weekend stroke sufferers got the drug versus only 229 weekday stroke patients.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story does not suggest that tPA is a novel treatment for stroke.", "answer": 1}, {"article": "\"Doctors are already doing these [glucose and HbA1c] tests together -- if a patient is obese, for example, and has other risk factors for diabetes, the physician is likely to order tests for both glucose and HbA1c from a single blood sample.\nSelvin's group analyzed that data, and reported that a positive result for glucose and HbA1c from just a single blood sample can confirm type 2 diabetes.\nThe study began in the 1980s, and along the way has recorded valuable data from participants, including diabetes test data.\nThe new study \"helps us move quicker to treat diabetes,\" he said.\nIn the new study, researchers led by Hopkins epidemiologist Elizabeth Selvin looked at data on more than 13,000 people in a long-running U.S. heart disease study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explained that that some doctors already do conduct dual tests from a single blood sample, and that the study\u2019s findings might support adding that strategy to clinical guidelines.", "answer": 1}, {"article": "Women were defined as light drinkers if they had no more than one or two drinks a week.\n\"Our results suggest that children born to mothers who drank at low levels were not at any risk of social or emotional difficulties or any risk of emotional impairments compared to mothers who did not drink,\" Kelly tells WebMD.\nIn the U.S., pregnant women are strongly advised not to drink at all, says Eva Pressman, MD, director of maternal/fetal medicine at the University of Rochester, N.Y.\n\nPressman points out that women who are light drinkers during pregnancy tend to be from households with relatively high incomes.\nIn the U.K., women are advised not to drink at all during the first trimester of their pregnancy and to drink no more than a drink or two a week after that.\n\"But that is a world away from recommending that expectant mothers should drink,\" Kelly is quick to add.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There should have been something in this report about the nature of this study and its place in the broader field of research. Like so many stories like this, it sort of drops out of the sky leaving readers to wonder how seriously they should take the findings. In this case, this is a massive study over a long period of time, and the findings are likely to have serious public policy implications as a result.", "answer": 0}, {"article": "\"It's known that EPA and DHA can inhibit breast tumour growth, but no one has looked directly at how effective these omega-3s are compared to ALA.\"\n\nMa found overall exposure to marine-based omega-3s reduced the size of the tumours by 60 to 70 per cent and the number of tumours by 30 per cent.\nThe next step is to investigate the effects of omega-3s on other forms of breast cancer.\nHowever, higher doses of the plant-based fatty acid were required to deliver the same impact as the marine-based omega-3s.\nPublished in the Journal of Nutritional Biochemistry, the study involved feeding the different types of omega-3s to mice with a highly aggressive form of human breast cancer called HER-2.\nThere are three types of omega-3 fatty acids: a-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release notes in the seventh paragraph that it\u2019s the first to compare the impact of different omega-3s on breast cancer tumor growth in mice.", "answer": 1}, {"article": "She notes that using trastuzumab to selectively treat uterine serous carcinoma that express HER2/neu is part of a broader trend at Johns Hopkins and other cancer centers to use the tools of tailored therapy, or precision medicine, based on the molecular and genetic makeup of tumors and patients.\nFader no longer holds that role.\nAll tested positive for the HER2/neu receptor.\nThe researchers say this may lead to new national guidelines for treating this cancer subtype, known as uterine serous carcinoma.\nCOI: Amanda Fader has reported a consulting or advisory role for Merck, which also makes HERher2- blocking drugs.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes clear what is novel about the research.", "answer": 1}, {"article": "\u201cIt may provide more of a one-stop shop.\u201d\nThe developer, Ironwood Pharmaceuticals, said the drug, linaclotide, met all the goals in the first late-stage trial testing it as a treatment for the type of irritable bowel syndrome accompanied by constipation.\nAbout one-third of the cases involve constipation, another third diarrhea and the rest both constipation and diarrhea, according to Dr. William D. Chey, an expert at the University of Michigan.\nIf the drug succeeds in a second Phase 3 trial, with results expected by the end of the year, Ironwood plans to file for regulatory approval next year.\nAs many as 20 percent of American adults have some symptoms of irritable bowel syndrome, according to the National Institutes of Health.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story could have mentioned the many other drugs that are in development for treatment of IBS, including one\u2013prucalopride\u2013which was recently approved in Europe. However, we don\u2019t think this story oversold the novelty of the new treatment.", "answer": 1}, {"article": "MONDAY, Nov. 7, 2011 (HealthDay News) -- An investigational drug called pridopidine seems an effective and safe treatment for people with the progressive movement disorder Huntington's disease, researchers report.\nHuntington's patients have an imbalance in the signaling chemical dopamine.\nMore than 70 percent of the patients taking the higher dose of the drug showed a significant benefit, according to the researchers.\n\"Pridopidine has the potential to complement available treatments by improving a different range of motor deficits.\nSide effects among patients taking the drug were similar to the placebo group.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Pridopidine is an experimental drug candidate for Huntington\u2019s disease and has been in clinical trials for the past several years.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Taking multivitamins may help women without cardiovascular disease to ward off a heart attack, new research shows.\nThey usually smoke less, are more physically active and have a healthier diet,\u201d the researcher wrote.\nTaking vitamins for 10 or more years cut risk by 41 percent.\nThe women ranged in age from 49 to 83 at the study\u2019s outset, and about 60 percent in each group used some type of dietary supplement.\nShe concluded: \u201cThe question of whether multivitamins are good for you still remains!\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story accurately conveyed the lack of novelty of this treatment studied.", "answer": 1}, {"article": "-- Practice good sleep hygiene.\nIf your teen has to get up at, say, 6:30 to be at school by 7:30, that means bedtime's at 9:15 or 9:30 p.m.)\n\nVorona says he'd like to delve deeper into the sleep-obesity question.\nAnd alcohol, which Aziz says \"can make us go to sleep, but it's not the deep sleep\" that we need to produce growth hormone (which in turn helps regulate insulin).\nIf sleep extension could have a salutary effect on helping people lose weight,\" he says, we'd have another tool in the fight against obesity.\n\"When our insulin is very high, we can't get to sleep,\" he says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear this is not a new question, and that it reviewed \"a handful of studies, including a 2008 analysis of the existing research on the subject of sleep and obesity.\"", "answer": 1}, {"article": "Fried, a dermatologist and clinical psychologist, points out that psoriasis itself can be associated with mental health problems.\nBecause of these events, the labeling for Siliq will include a Boxed Warning, and the drug will only be available through a restricted REMS (Risk Evaluation and Mitigation Strategy) program.\nThe most common side effects of the drug were joint and muscle pain, headache, fatigue, diarrhea, throat pain, nausea, flu, low white blood cell count, fungal infections and reactions at the injection site.\nBecause of an association with suicidal thoughts and behaviors, Siliq will be sold with a \u201cblack box\u201d warning and should be considered only for patients whose psoriasis has not responded\u2014or has stopped responding\u2014to phototherapy or to other systemic medicines taken orally or via injection.\nBy blocking the receptor from being activated, it keeps the body from receiving signals that can fuel inflammatory responses and psoriasis progression.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is a tough call, but we\u2019re leaning toward satisfactory.\nThe story mentions that the drug targets a specific receptor on the interleukin-17 protein and that this is distinct from other available treatments that also target this protein in a different way.\nHowever, whether these differences result in outcomes that are distinct in terms of benefit/risks isn\u2019t at all clear from the article, but we suspect that\u2019s because they aren\u2019t yet known. There are many examples of drugs that target different aspects of the same cell, protein, etc. that behave in ways that aren\u2019t all that different.\nSo while this represents a novel target, whether it results in a safer, more effective treatment remains to be seen.", "answer": 1}, {"article": "\u201cAnd when stimulation arrived in a good state, the average was about 15 to 20 percent worse than usual.\u201d\n\nDr. Doris Greenblatt, a psychiatrist who participated in the trial at Emory, said she sought the surgery because her epilepsy had long caused memory problems.\nThe new study is the latest chapter in an extraordinary, decades-long collaboration among cognitive scientists, brain surgeons and people with severe epilepsy being evaluated for an operation.\nIn a series of experiments, the researchers had patients memorize lists of words and later, after a distraction, asked them to freely recall as many of the words as they could.\nThe team then statistically analyzed the results and found that people scored slightly higher than usual on words when stimulation arrived during a low or foggy state \u2014 and worse, when the pulse arrived in a high state.\nThis approach \u2014 called direct neural recording, and piggybacking entirely on the clinical placement of the electrodes \u2014 has become the leading edge of research into the biology of human memory.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story\u00a0sums up decades of conflicting work on stimulating the brain to improve memory, and how changing the timing of stimulation \u2014 specifically, during times when memory encoding may be poor \u2014 seems to represent a significant advancement in the field.", "answer": 1}, {"article": "Rydapt should not be used in patients with hypersensitivity to midostaurin or other ingredients in Rydapt.\n\u201cRydapt is the first targeted therapy to treat patients with AML, in combination with chemotherapy,\u201d said Richard Pazdur, M.D., acting director of the Office of Hematology and Oncology Products in the FDA\u2019s Center for Drug Evaluation and Research and director of the FDA\u2019s Oncology Center of Excellence.\n\u201cThe ability to detect the gene mutation with a diagnostic test means doctors can identify specific patients who may benefit from this treatment.\u201d\n\nRydapt is a kinase inhibitor that works by blocking several enzymes that promote cell growth.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nIn addition, patients who received Rydapt in combination with chemotherapy in the trial went longer (median 8.2 months) without certain complications (failure to achieve complete remission within 60 days of starting treatment, progression of leukemia or death) than patients who received chemotherapy alone (median three months).\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes clear that the use of this drug for AML patients with the FLT3 mutation is a new approach for a situation where previous therapies have been marginally successful.\nIt also claims that the\u00a0drug is \u201cthe first targeted therapy to treat patients with AML, in combination with chemotherapy,\u201d according to an FDA official.", "answer": 1}, {"article": "\"Flu kills every year.\nThe most recent global pandemic was the 2009 H1N1 flu pandemic, in which the estimates of deaths ranged as high as 12,500 in the U.S. alone, according to the Centers for Disease Control and Prevention.\nThe initial results are positive, says Peter Palese, professor and chair of microbiology at Mount Sinai School of Medicine, New York, but more research is needed before the new treatment is approved.\n\"It's fairly certain flu vaccines are going to change a lot in the next few years,\" she said.\nGilbert explained: \"With the swine flu pandemic it took four months before the first doses of the vaccine were available and there was only a small amount available,\" Gilbert explained.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "In reality, this approach\u00a0to developing vaccines was originally suggested in a study in 1983. The approach used by scientists at the Jenner Institute is novel in that a Modified Vaccinia Ankara (MVA)\u00a0virus was used. It would have been an interesting sideline to point out that this is a close relative to the smallpox virus that has shown promise as a delivery system for a variety of vaccines.\u00a0 ", "answer": 0}, {"article": "\"Although it is not clear if bisphosphonates are the cause, these unusual femur fractures have been predominantly reported in patients taking bisphosphonates,\" the FDA says.\nThese unusual fractures can occur suddenly without any trauma, such as a fall.\nThat is, long-term users have a risk of about a tenth of 1 percent.\nAnd they can be complex breaks that are difficult to fix and slow to heal.\nThat's called the relative risk, and it seems alarming.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The drugs are not novel, and the story says so.", "answer": 1}, {"article": "The team recruited 45 healthy participants aged 21-70 years who were either obese or overweight.\nIt is well known that avocados are high in fat, but the majority of an avocado's fat is monounsaturated, which is deemed a \"good\" type of fat.\nIt should be noted that this research was supported by the Hass Avocado Board, but the researchers say the organization played no other role in the study.\nIt is known that monounsaturated fats can help lower levels of bad cholesterol, reducing the risk of heart attack and stroke.\nThe researchers, including senior author Penny M. Kris-Etherton, PhD, distinguished professor of nutrition at Pennsylvania State University, publish their findings in the Journal of the American Heart Association.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The role of foods high in monounsaturated fats in reducing total and LDL cholesterol has been known for quite some time, and the authors note that \u201cIt is known that monounsaturated fats can help lower levels of bad\u00a0cholesterol.\u201d However, the story does not specifically establish the novelty of studying the LDL-lowering properties of\u00a0avocado. Is this first time this issue has been studied? The story doesn\u2019t tell us.\n\u00a0", "answer": 0}, {"article": "The CDC estimated the medical cost of obesity in the U.S. at approximately $147 billion in 2008.\nIt should be considered as another tool available to clinicians and patients in the fight against obesity.\"\nDuring the one-year follow-up period, patients went to an academic bariatric center of excellence as part of their treatment.\nDr. Sharaiha did not have any disclosures for DDW research.\nWhile endoscopic sleeve gastroplasty is performed with an endoscopic device through the mouth, laparoscopic sleeve gastrectomy involves a small surgical incision in the belly to place a tube in the abdomen, allowing doctors to reduce the stomach's volume.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes that this is the first study to compare the outcomes associated with these three procedures.", "answer": 1}, {"article": "TRENTON, N.J. (AP) - GlaxoSmithKline PLC on Wednesday applied for approval in the U.S. and Europe to sell an existing breast-cancer drug as a first-line treatment.\nApproval as an initial treatment likely would boost that sharply.\nIt targets cancer cells more than healthy ones, Roychowdhury said.\nAbout two-thirds of breast cancers are hormone sensitive.\nTykerb works by attaching to two other cell receptors and ultimately making the cells die or stop multiplying.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The past use of Tykerb was clearly explained in the story. ", "answer": 1}, {"article": "Current treatments target the immune cells involved in the disease and none are specific for FLS.\nA group of researchers led by Dr. Christine Beeton at Baylor College of Medicine has found that one of the hundreds of components in scorpion venom can reduce the severity of the disease in animal models, without inducing side effects associated with similar treatments.\n\"We think that this venom component, iberiotoxin, can become the basis for developing a new treatment for rheumatoid arthritis in the future.\"\n\"Here, we investigated whether this venom component, called iberiotoxin, would be able to specifically block the FLS potassium channel and reduce the severity of the rheumatoid arthritis in rat models of the disease.\"\nOther contributors of this work include Michael W. Pennington, Brayden H. Chamberlain, Redwan Huq, Elizabeth J. Gehrmann, Teresina Laragione and P\u00e9rcio S. Gulko.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release does a good job here, stating in the first paragraph that \u201cone of the hundreds of components in scorpion venom can reduce the severity of the disease in animal models, without inducing side effects associated with similar treatments.\u201d  ", "answer": 1}, {"article": "Hair changes about as fast as grass grows, which is to say it\u2019s extraordinarily slow and not visible to anyone checking impatiently in the mirror every day.\nProspective users are questioned about their ability to stick to a regimen because the extract must be applied every day, and they are told that the more conscientious they are, the better.\nIn the 1990s, clients mixed it with Rogaine, Mr. Skjoth said, \u201cand then we took the Rogaine part away and started focusing on the actual liquid.\u201d\n\nSmall studies have shown the efficacy of various plant-derived ingredients, mostly in mice.\n\u201cThere aren\u2019t a lot of options, and I\u2019d love to be able to say to my patients, \u2018This is something you can try that is worth the money.\u2019 But I can\u2019t do that yet.\u201d\n\nHarklinikken\u2019s formula, refined over 20 years, is derived from plants and cow\u2019s milk.\nFor now, Maryanne Senna, a dermatologist and the director of the Hair Academic Innovative Research Unit at Massachusetts General Hospital in Boston, said the best she can tell patients who ask \u2014 and a lot of them do \u2014 is that Harklinikken won\u2019t do any harm.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Since the company won\u2019t disclose what the product contains, we can\u2019t establish how novel the treatment is, so we\u2019ll rate this N/A.", "answer": 2}, {"article": "Parents get frustrated with the FDA recommendations not to use cold medicines in kids under the age of 4 because they are left with few options.\nIn the study, funded by an unrestricted research grant from Procter & Gamble, makers of Vicks, researchers took 138 children between the ages of 2 and 11, with symptoms like cough, congestion, runny nose and restless sleep that lasted seven days or more.\n\"I have found that when used properly it can be a good option for parents who want to relieve some cold symptoms in their children.\n\"This was based in part on some of the studies that we have conducted at Penn State.\nThat night, 30 minutes before bedtime, Vicks or petroleum jelly was rubbed onto the child's chest and neck.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nAlthough, there\u2019s nothing new about VapoRub, the story does point out that the product claims have not been tested in this way before.", "answer": 1}, {"article": "That, in turn, may rev up inflammation in their tissues.\n\u201cMuch higher than red wine, for instance.\u201d\n\nThe researchers figured an antioxidant-rich diet might help patients with kidney failure, because the level of free radicals in their blood increases as the blood circulates through the dialysis device.\n\u201cThe effects of juice were compared to a placebo, not to any other kind of juice that might have exactly the same effect.\u201d\n\n\u201cThe pomegranate people are spending millions to prove what I could have told them in the first place,\u201d she added.\nThe findings were presented at the American Society of Nephrology\u2019s meeting in Denver \u2014 aka Renal Week \u2014 and have not yet been vetted by independent experts.\nThe results come in the wake of a U.S. crackdown on allegedly false advertising by POM Wonderful, which claims its pomegranate products can help everything from heart disease to prostate cancer and erectile dysfunction.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Good job on this, citing research over at the last 3 years, but also concluding with this quote from Marion Nestle:\n\u201cThis study does not demonstrate anything special about pomegranate juice.The effects of juice were compared to a placebo, not to any other kind of juice that might have exactly the same effect. \u2026The pomegranate people are spending millions to prove what I could have told them in the first place. Pomegranate juices \u2014 like most if not all fruit and vegetable juices \u2014 have antioxidant activity. Does this make pomegranates better than any other fruit? Investigators have yet to show this.\u201d", "answer": 1}, {"article": "Omalu found traces of the disease in the brain of legendary Pittsburgh Steelers player and pro Hall of Famer Mike Webster in 2002.\nWhen compared to the brains without CTE, researchers found those brains with CTE had significantly higher amounts of CCL11, even when compared to those brains with Alzheimer's, another degenerative brain disease.\nHowever, contrary to the popularly held belief that a greater number of concussions are linked to CTE , no connection was found between levels of CCL11 and reported number of concussions.\nIn this new study, researchers found an increased amount of the protein CCL11 in patients previously diagnosed with CTE.\n\"This may be one of the abnormalities [of the disease], but it may take 2-3 to be useful to diagnose CTE,\" said McKee.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story quotes one of the researchers involved in the work as saying \u201cThis is something new.\u201d What is new is, apparently, the discovery that CCL11 levels are correlated to CTE. Whether other biomarkers have been identified (as discussed above, under \u201cCompare Alternatives\u201d) but not yet incorporated into diagnostic tools is not clear from the story.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - A large waistline more than doubles the risk that people in their 40s will develop precancerous cells in the colon, according to Korean researchers.\nDuring widely used colonoscopy, for instance, bleeding or perforation of the colon may happen in rare cases.\nIn younger people, it is unclear that the benefits of screening offset the risks.\nA camera at the tip shows the inside of the gut, so that unusual cell clumps can be found and removed.\nOne in 40 of those younger than 50 years had late-stage polyps, but no one actually had colon cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Clearly screening colonoscopy is not new, however screening younger people who are overweight is a new idea.", "answer": 1}, {"article": "Bleier said the device, which consists of a lead wire and a neurostimulator the size of a stopwatch, is implanted on top of a buttock muscle. Patients don't feel it when they sit down and you can't see its imprint under a tight pair of pants. Patients can try the stimulation for two weeks with the pacemaker outside the body before deciding whether to have it implanted, an outpatient procedure. Medicare pays about $21,500 for the device and treatment.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Except for the discussion of the pacemaker InterStim, the story didn\u2019t include any overt claims of novelty.\u00a0 And on InterStim it explained that this is a device originally approved for urinary incontinence and that it uses the same technology as a heart pacemaker.", "answer": 1}, {"article": "EMBARGOED UNTIL AUG. 14, 2017, AT 10 A.M. EDT\nResults of those tests show lab rats that received the cardiosphere-derived cells:\n\u2022 Demonstrated longer heart cell telomeres, compound structures located at the ends of chromosomes that shrink with age\n\u2022 Improved their exercise capacity by an average of approximately 20 percent\n\u2022 Regrew hair faster than rats that didn't receive the cells\n\n\"This study didn't measure whether receiving the cardiosphere-derived cells extended lifespans, so we have a lot more work to do,\" said Lilian Grigorian-Shamagian, MD, PhD, co-primary investigator and the first author of the study.\n\"We have much to study, including whether CDCs need to come from a young donor to have the same rejuvenating effects and whether the extracellular vesicles are able to reproduce all the rejuvenating effects we detect with CDCs.\"\n\"Our previous lab studies and human clinical trials have shown promise in treating heart failure using cardiac stem cell infusions,\" said Eduardo Marb\u00e1n, MD, PhD, director of the Cedars-Sinai Heart Institute and the primary investigator of the study.\nThe CDCs, manufactured by Capricor Inc. (NASDAQ: CAPR) as their product CAP-1002, have been used in other human clinical trials.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There\u2019s no attempt to put this study in the context of numerous stem cell studies that have been performed in recent years. Many studies have attempted to show that stem cells can be used to improve heart function or slow the aging process, including a recent study that concluded stem cells in the hypothalamus control aging.", "answer": 0}, {"article": "Drinking concentrated blueberry juice improves brain function in older people, according to research by the University of Exeter.\n\"In this study we have shown that with just 12 weeks of consuming 30ml of concentrated blueberry juice every day, brain blood flow, brain activation and some aspects of working memory were improved in this group of healthy older adults.\"\nThe new paper, \"Enhanced task-related brain activation and resting perfusion in healthy older adults after chronic blueberry supplementation\", is published in the journal Applied Physiology, Nutrition and Metabolism.\nDr Joanna Bowtell, head of Sport and Health Sciences at the University of Exeter, said: \"Our cognitive function tends to decline as we get older, but previous research has shown that cognitive function is better preserved in healthy older adults with a diet rich in plant-based foods.\nPrevious research has shown that risk of dementia is reduced by higher fruit and vegetable intake, and cognitive function is better preserved in healthy older adults with a diet rich in plant-based foods.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The study does not make a claim of novelty, and includes this statement about previous research:\n\u201cPrevious research has shown that risk of dementia is reduced by higher fruit and vegetable intake, and cognitive function is better preserved in healthy older adults with a diet rich in plant-based foods.\u201d", "answer": 1}, {"article": "If media wish to link to the paper once it's published, they can use the following link, which will go live when the embargo lifts: http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(16)30179-5/abstract\n\"This new drug could be a game changer for future treatment of asthma\" - Professor Chris Brightling, NIHR Senior Research Fellow at the University of Leicester\n\nThe first new asthma pill for nearly 20 years has the power to significantly reduce the severity of the condition, a study led by the University of Leicester has found.\nThe study was designed primarily to examine the effects on inflammation in the airway by measuring the sputum eosinophil count.\nThe sputum eosinophil is an inflammation measurement of a white blood cell that increases in asthma and is used to assess the severity of this condition.\nWhen a person with asthma comes into contact with something that irritates their sensitive airways it causes the body to react in several ways which can include wheezing, coughing and can make breathing more difficult.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release claims novelty with the statement, \u201cThe first new asthma pill for nearly 20 years has the power to significantly reduce the severity of the condition.\u201d\u00a0That\u2019s not correct. In recent years, several new drugs known as leukotriene receptor antagonists have come on the market in the U.S. as tablets.", "answer": 0}, {"article": "amyloids, lipopolysaccharides, endotoxins and small non-coding RNAs) to access Central Nervous System compartments.\"\nWalter Lukiw, Professor of Neurology, Neuroscience and Ophthalmology and Bollinger Professor of Alzheimer's disease at Louisiana State University, who reviewed the study but was not involved in the research, said: \"This early study is interesting and important because it provides evidence for gastrointestinal (GI) tract microbiome components playing a role in neurological function, and indicates that probiotics can in principle improve human cognition.\nAt the beginning and the end of the 12-week experimental period, the scientists took blood samples for biochemical analyses and tested the cognitive function of the subjects with the MMSE questionnaire, which includes tasks like giving the current date, counting backwards from 100 by sevens, naming objects, repeating a phrase, and copying a picture.\nBut scientists have long hypothesized that probiotics might also boost cognition, as there is continuous two-way communication between the intestinal microflora, the gastrointestinal tract, and the brain through the nervous system, the immune system, and hormones (along the so-called \"microbiota-gut-brain axis\").\n\"In a previous study, we showed that probiotic treatment improves the impaired spatial learning and memory in diabetic rats, but this is the first time that probiotic supplementation has been shown to benefit cognition in cognitively impaired humans,\" says Professor Mahmoud Salami from Kashan University, the senior author of the study.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This release highlights the novelty of the intervention, stating that this was the first time that human research has shown that probiotic bacteria can improve cognitive function. However, the release took a cautious approach to interpretation of the results, highlighting that the study was an early clinical trial and that researchers plan to examine the information in more detail in future studies. The release also included a comment from an independent researcher who is working in the same area of gut microbiome and brain function.", "answer": 1}, {"article": "A study in the United States last year found that routine prostate cancer screening had resulted in more than a million being diagnosed with tumors who might otherwise have suffered no ill effects from them.\nThe men in this study \u2014 205 with confirmed BRCA1 or BRCA2 mutations and 95 who had tested negative for the mutations \u2014 were all offered annual PSA blood testing, and 24 who had raised PSA levels were given a follow-up biopsy.\nScreening for prostate cancer is controversial because the prostate-specific antigen (PSA) tests used cannot differentiate between men with aggressive cancer and men who would never have symptoms or need treatment, and this can lead to overdiagnosis.\n\u201cAlthough these are early results, it appears that (prostate cancer) screening is reasonably accurate at predicting potentially aggressive prostate cancer among men at higher risk of the disease due to a genetic predisposition,\u201d said Ros Eeles, who led a research team from Britain\u2019s Institute of Cancer Research (ICR) and Royal Marsden hospital.\nThe ICR-led study is aiming to find out whether screening men who have genetic variants that increase their prostate cancer risk could lead to earlier diagnosis.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Clearly PSA screening is not a new idea, however screening higher risk men based on BRCA mutations is relatively new. This story makes that clear.", "answer": 1}, {"article": "Switching to AstraZeneca PLC's breast-cancer drug Arimidex after treatment with older drug tamoxifen not only helps women live longer, but also increases their chances of staying cancer-free after initial therapy for breast cancer, according to a study in the online edition of the Lancet Oncology medical journal.\n\nThe data, which come from more than 4,000 patients in three clinical trials, have shown that switching treatment from tamoxifen to Arimidex reduces the risk of dying by 29%.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions that switching from tamoxifen to\u00a0anastrozole would be a newer approach to hormone therapy treatment for women diagnosed with estrogen-positive breast cancer.", "answer": 1}, {"article": "WEDNESDAY, May 4, 2011 (HealthDay News) -- Among men under 65 with early stage prostate cancer, those who have the prostate gland removed are less likely to die than those who adopt a \"watchful waiting\" approach, according to a new long-term study out of Europe.\nThe earlier study also found that undergoing a radical prostatectomy lowered the risk of the cancer spreading, as well as the death rate from prostate cancer or any other cause.\nThe benefit was primarily seen among men younger than 65 and the authors estimated that seven men under the age of 65 and 8 over the age of 65 would need to be treated to save one life.\nAfter an average follow-up of about 13 years, 14.6 percent of the men who had undergone surgery had died, versus 20.7 percent in the watchful waiting group, a 38 percent reduced risk.\nAlso, the men in this study were diagnosed only after they had symptoms, unlike the majority of men in the United States, Greenberg said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story provided a reasonable view of the novelty of the treatment options detailed in the study along with the critically important caveat that the majority of the men in the study had their prostate cancer first detected at a later state than is seen with the current screening practices in the US.", "answer": 1}, {"article": "In late July, Sen. David Vitter, R-Louisiana, wrote a letter to the FDA saying that there are no new safety concerns and that \"the [FDA advisory] committee's concerns appear to have been based on cost-effectiveness.\"\nIn 2008, the FDA granted Avastin what's known as accelerated approval as a therapy for metastatic breast cancer.\nThe issue has been taken up by critics of the health care overhaul signed into law last year.\nIn neither study did patients actually live longer, and there was a high rate of side effects, including high blood pressure and internal bleeding.\nShe had it removed, went through a round of radiation and chemotherapy, and was symptom-free for the next nine years.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that the FDA gave this drug preliminary approval in 2008 for the treatment of metastatic breast cancer. ", "answer": 1}, {"article": "Results from a pivotal study of the treatment were reported today in the American Heart Association (AHA) journal Circulation Research.\nJuly 7, 2011 -- An experimental therapy involving stem cell injections from the patient's own blood is showing promise in the treatment of people with chest pain that is not responsive to drugs, angioplasty, or surgery.\n\"Coronary artery disease involves not only the blockage of major arteries, but the death of small vessels, or capillaries, of the heart muscle,\" he says.\n\"These are patients who have been on drugs and may have had multiple angioplasties or CABG surgeries,\" AHA President Gordon Tomaselli, MD, tells WebMD.\n\"Their activities are severely restricted by their chest pain and right now we have little to offer them.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We are given some sense that this isn\u2019t brand new research:\n\u201cThe new treatment came from the discovery about a decade ago that CD34 stem cells stimulate the formation of new blood vessels\u2026The approach also showed promise in a 2007 pilot study involving fewer than 30 patients.\u201d", "answer": 1}, {"article": "Carhart-Harris said no serious side effects were reported during the study, although all volunteers said they were slightly anxious before and during initial drug administration.\nWe\u2019re just learning how to do this treatment.\u201d\n\nMagic mushrooms grow worldwide and have been used since ancient times, both for recreation and for religious rites.\nThat kind of approach could be risky.\u201d\n\nNutt said the results showed that psilocybin \u201cis safe and fast acting, so may - if administered carefully - have value for these patients.\u201d\nThe World Health Organization estimates that some 350 million people worldwide are affected by depression, a common mental disorder characterized by sadness, loss of interest or pleasure, tiredness, feelings of guilt or low self-worth, disturbed sleep and appetite, and poor concentration.\nBlood pressure, heart rate and the self-reported intensity of the effects of psilocybin were monitored during each session, and the patients were seen by a psychiatrist the next day and one, two, three and five weeks after the second dose.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There are no claims to novelty in the story. The story would have provided more useful context if it had discussed the larger body of research on this drug, and what makes this trial unique. (For example, it has been studied for OCD, anxiety in cancer patients and alcohol dependency.)", "answer": 1}, {"article": "The website for LipoFuze says that the supplement \"increases the metabolic mechanism in your body.\" The site also says the green tea and caffeine will \"rev up your metabolism\" and \"increase energy, focus and physical performance.\" The site features testimonials it says are from users who claim they have lost huge amounts of weight with the help of LipoFuze. One man says he dropped more than 100 pounds, although it's unclear how long that took. A woman says she lost 40 pounds in less than a year, including 20 pounds in her first month.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Not applicable.\u00a0 No claims of novelty are made. The column reminds readers that trying a shortcut to weight loss, though tempting, is unlikely to work.", "answer": 2}, {"article": "Since amniocentesis carries a small risk of spontaneous miscarriage \u2014 Patsalis put it at around one or two percent \u2014 scientists have been looking for new less invasive ways to test for Down\u2019s and other potential genetic problems.\nIt involves taking a small amount of blood from the mother when she is between the 11th and 13th week of her pregnancy and detecting extra copies chromosome 21 in the fetus by analyzing the maternal blood.\n\u201cWe believe we can modify this test and make it much easier and simple... (and then) we can have something ready to be introduced into the clinic,\u201d he told Reuters in Nicosia.\nIn a study in the Nature Medicine journal researchers from Cyprus said a trial on 40 pregnancies using the test, which involves analyzing the woman\u2019s blood to detect DNA differences between the mother and the fetus, showed it accurately predicted which fetuses were at risk of developing the syndrome.\n\u201cSuch a non-invasive approach will avoid the risk of miscarriages of normal pregnancies caused by current, more invasive procedures,\u201d the scientists wrote in their paper.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story didn\u2019t explain that the test used in the study is actually a group of existing tests.\u00a0 And it didn\u2019t even mention any of the other research being done in this field to improve prenatal diagnosis.", "answer": 0}, {"article": "Chavarro and colleagues studied 926 men who had prostate cancer that hadn\u2019t spread.\n\u201cOur findings with Western diet and prostate cancer-specific mortality, however, were surprising, in part because there are very little data regarding how diet after diagnosis may impact disease prognosis.\u201d\n\nThe findings could be important for many men.\n\u201cOur results suggest that the same dietary recommendations that are made to the general population primarily for the prevention of cardiovascular disease may also decrease the risk of dying from prostate cancer among men initially diagnosed with nonmetastatic disease (cancer that has not spread),\u201d said Dr. Jorge Chavarro of Brigham and Women\u2019s Hospital and Harvard Medical School, who led the study.\nIt\u2019s yet another piece of evidence showing that the so-called Western diet can worsen the risks for cancer, as well as all sorts of other diseases from heart disease to Alzheimer\u2019s.\nThey were more than 2.5 times as likely to die of their prostate cancer than patients eating the healthiest diet and they were more than one and a half times as likely to have died of anything over the 10 years, Chavarro\u2019s team reports in the journal Cancer Prevention Research.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article does a good job of noting that hard data are scarce for the impact of diet on this population of men with cancer, and of the unexpected finding of increased (risk of) prostate cancer- specific deaths. And we liked the way it presented the study results as \u201cyet another piece\u201d of evidence for the benefits of a healthy diet, rather than something entirely \u201cnew.\u201d", "answer": 1}, {"article": "But should a woman undergoing natural menopause try acupuncture for hot flashes?\nThe results with the sham acupuncture, which bested gabapentin, suggest that \"there is more than a placebo effect with the sham acupuncture,\" said Dr. Gary Deng, interim chief of the integrative medicine service at Memorial Sloan Kettering Cancer Center in New York City.\nFurthermore, the effects of acupuncture were \"significant and enduring for hot flashes while gabapentin's effect only happened when a patient was taking the medication,\" said study first author Dr. Jun Mao, an associate professor of family medicine and community health at the University of Pennsylvania in Philadelphia.\nOne big distinction between the two populations, though, is that breast cancer survivors do not have the option of hormone replacement therapy open to them because those hormones are linked to breast cancer.\n\"For patients suffering symptoms, they can look for all kinds of possible solutions and are better off talking to their doctor to find out what's most appropriate for them,\" Deng said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Close call here, but the story doesn\u2019t really establish what is new about the research. There are questions raised in previous studies about whether real acupuncture is more effective than a sham treatment or if the benefit from the needling is all essentially a placebo effect. Researchers also wonder whether the acupuncture placebo effect is bigger than the effect seen with placebo pills because of all the attention patients get from the acupuncture session that they don\u2019t get with a pill. The story does allude to the question, but doesn\u2019t specifically address the fact that these issues have been raised in previous research on pain and that\u2019s why the new study in women with hot flashes is important.", "answer": 0}, {"article": "The 7 percent figure works out to about 18 pounds for someone who weighs 250.\nIn the longest study of Orlistat, participants who took the drug in addition to eating fewer calories and increasing exercise shed up to 12 percent of their body weight the first year.\nWhile Americans spend an estimated $1 billion on nonprescription weight loss products, few if any of those products have undergone the rigorous testing that is required by the FDA for prescription medications.\nOrlistat was approved as a weight loss and weight maintenance drug by the FDA in 1999 to treat obese and overweight people -- those with a body mass index of 30 or higher -- and overweight people (with BMI of 27 or higher) who already have weight-related health problems including diabetes, heart disease or high blood pressure.\nThey range from flatulence and increased bowel movements to diarrhea and anal leakage.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Article is about a \nmedication, xenical, available by prescription that is being considered for sale as an over-the-counter (OTC) drug.", "answer": 1}, {"article": "But there\u2019s one big stumbling block for both of them, a problem that has dogged medical genetics for decades: Data for non-white populations is sorely lacking.\nFace2Gene is meant to be more like a search engine for diseases \u2014 a means to an end.\nFor another, people in many parts of the world don\u2019t have access to genetic tests at all.\nThat\u2019s inspired years of effort to train a computer to do the same thing.\n\u201cWe are not a diagnostic tool, and we will never be a diagnostic tool,\u201d said FDNA CEO Dekel Gelbman.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s clearly established that\u2019s what \u201cnew\u201d here is using facial recognition software to diagnose genetic disorders.", "answer": 1}, {"article": "The University of Texas at Arlington has successfully patented in Europe an implantable medical device that attracts and kills circulating cancer cells that was invented by a faculty member.\nWhile there are drugs given to patients after surgery to prevent cancer cells from adhering to each other or other tissues, these drugs do not rid the body of cancer cells or collect them to allow an assessment of the patient\u2019s status.\n\u201cOur cancer trap works just like a roach motel, where you put in some bait and the roach goes there and dies,\u201d said Liping Tang, UTA bioengineering professor and leader of the research.\n\u201cThis method is effective for both diagnosing and treating metastasis cancer and can be used in combination with traditional chemotherapy and radiation therapy,\u201d he added.\n\u201cWe have made a nano-sized device that we can put under the skin using an injection needle to recruit the cancer cells into a small area where we can treat them with less overall side effects to the whole body,\u201d Tang said.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The language in the release is so broad that it is difficult to know what to compare it to. However, a quick search has no trouble finding other research efforts aimed at \u201ctrapping\u201d cancer cells, such as this 2015 paper, this 2017 paper, or these news releases from 2014 and 2016. What sets this newly patented \u201ccancer trap\u201d apart? The release doesn\u2019t tell us, because the release provides no context related to previous work in the field.", "answer": 0}, {"article": "Epclusa carries a warning for patients and health care providers that serious slowing of the heart rate (symptomatic bradycardia) and cases requiring pacemaker intervention have been reported when amiodarone is used with sofosbuvir in combination with another HCV direct-acting antiviral.\nEpclusa is a fixed-dose combination tablet containing sofosbuvir, a drug approved in 2013, and velpatasvir, a new drug, and is the first to treat all six major forms of HCV.\nThere are at least six distinct HCV genotypes, or strains, which are genetically distinct groups of the virus.\n\u201cThis approval offers a management and treatment option for a wider scope of patients with chronic hepatitis C,\u201d said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA\u2019s Center for Drug Evaluation and Research.\nEpclusa also carries a warning not to use with certain drugs that may reduce the amount of Epclusa in the blood which could lead to reduced efficacy of Epclusa.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that this is a wholly new combination drug that has not been available until this approval by the FDA. It also states that it is the first drug that works for all six strains of the virus.", "answer": 1}, {"article": "\u201cIf you gave this dataset to a clinician and asked him to predict the age\u201d of one of the cyclists based on his or her test results, Dr. Harridge said, \u201cit would be impossible.\u201d On paper, they all look young.\nAll in all, the numbers suggest that aging is simply different in the active.\nOn almost all measures, their physical functioning remained fairly stable across the decades and was much closer to that of young adults than of people their age.\nBut even so, both of those measures were higher among the oldest cyclists than would be considered average among people aged 70 or above.\nThis conundrum is particularly true in terms of inactivity.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a good job of laying some groundwork for why this research took a different approach than other studies.", "answer": 1}, {"article": "\"Women still want their annual Pap and doctors still want to give them,\" and think it's rationing care to test less often, Saslow said.\nThe new study was the first big one to examine a newer screening tool, HPV tests, with or without Pap smears in routine practice.\nThe last study is a warning to people who get screening tests that aren't recommended, or who question whether screening can ever hurt.\n\"They're identifying a group of guys who don't need to be screened, or need to be screened less often,\" said Dr. Otis Brawley, the cancer society's chief medical officer.\nHPV tests are approved as an option along with Paps for women 30 and older, and the cancer society says that if a woman tests negative on both, she can wait three years to be screened again.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Where novelty was at issue, the story establishes novelty, saying, for example, \u201cThe new study was the first big one to examine a newer screening tool, HPV tests, with or without Pap smears in routine practice.\u201d", "answer": 1}, {"article": "Scientists have also found impulsive behaviour is a factor in leading to food addiction and Ivo Vlaev, of Warwick Business School, plus Myutan Kulendran, Laura Wingfield, Colin Sugden, and Ara Darzi, of Imperial College London, discovered that a drug called Modafinil, usually used for narcolepsy, shift work disorder and excessive daytime sleepiness, can reduce impulsivity and thus food addiction.\n\"We found Modafinil, which is already on the market, did reduce people's impulsive behaviour,\" said Professor Vlaev.\nThe drug, which is sold under a wide variety of brand names around the world, was one of two drugs tested by researchers, the other being Atomoxetine.\n\"Modafinil was found to have an effect on impulsivity in healthy individuals and so would be able to have an even bigger effect on food addicts, who are lacking in certain types of dopamine,\" said Professor Vlaev.\nThe tests revealed that those who had taken Modafinil had a significantly reduced level of impulsiveness, whereas Atomoxetine produced no difference compared to the placebo group.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release suggests that the researchers\u2019 \u201cinitial tests\u201d back up the theory that Modafinil can aid impulsive eaters as it has shown to be effective in reducing impulsiveness in alcohol dependence, schizophrenia and ADHD. But the present study doesn\u2019t do that. Nor is it novel. There have been previous studies observing Modafinil\u2019s effect on food intake. For example, here.", "answer": 0}, {"article": "What if doctors had a pill that prevents breast cancer and nobody wanted to take it? That has pretty much been the situation with tamoxifen, an estrogen-like drug that was proved in 1998 to cut in half the chance of developing breast cancer if taken for five years by women with increased risk of the malignancy. The trouble is, tamoxifen also triggers menopausal symptoms like hot flashes and slightly increases the chances that a woman will develop blood clots and uterine cancer. As a result, women haven't been too eager to take the medication--nor have many doctors been all that enthusiastic...", "question": "Does the story establish the true novelty of the approach?", "explanation": "Notes that use of raloxifene (Evista) as chemoprevention is new. Evista is already approved to prevent osteoporosis. ", "answer": 1}, {"article": "Where did this Ron DeSantis come from? Florida\u0092s governor surprises everyone but himself.\n\nA month into his term, Gov. Ron DeSantis has shattered assumptions that he would govern exclusively from the right. He has drawn unexpected praise from Republicans and Democrats.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story captured the exploration of different approaches to tackle the problem. ", "answer": 1}, {"article": "Previous studies indicated that chemicals in green tea called polyphenols are absorbed and alter the energy metabolism in the liver.\nIn a study of mice, the scientists showed that black tea alters energy metabolism in the liver by changing gut metabolites.\nThe study found that both black and green tea changed the ratio of intestinal bacteria in the animals: The percentage of bacteria associated with obesity decreased, while bacteria associated with lean body mass increased.\nAccording to Henning, the molecules in green tea are smaller and can more readily be absorbed into the body and reach the liver directly, while black tea molecules are larger and stay in the intestine rather than being absorbed.\nThe findings build on a 2015 UCLA study that demonstrated that both green tea and black tea helped prevent obesity in mice that consumed a high-fat, high-sugar diet.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release provides some background about previous research in this area and how the black tea hypothesis grew out of that previous research, a 2015 UCLA study.", "answer": 1}, {"article": "This press release contains forward-looking statements.\nStatements in this press release that are not purely historical are forward-looking statements.\nIn comparison, those patients receiving lower doses via non-adaptive treatments experienced 15.8 percent grade 3 or higher toxicities.\nMRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology.\nSuch statements are subject to risks and uncertainties that could cause future results to differ materially from those referenced.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This technology is indeed novel and unique to ViewRay, though it is becoming available in more and more cancer treatment centers.", "answer": 1}, {"article": "Although the difference between the treated patients and those given the placebo in the trial might appear modest, Dr. Joan T. Merrill, a lupus expert at the Oklahoma Medical Research Foundation, said Benlysta\u2019s safety and its ability to reduce steroid use would make it attractive to doctors.\nBecause the disease\u2019s symptoms wax and wane on their own and vary considerably from one patient to another, it has been hard to demonstrate the efficacy of drugs in clinical trials.\nIf Benlysta gets to market, it will be the first drug from the company, and one of the first in the industry, to result from genomics.\nIt also changed the measurement of success and lengthened the trial to give the drug more time to work.\nOn Friday, it closed at $3.32 a share.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The pipeline for effective lupus drugs has indeed been dry for quite a while. The article indicates that this is a novel product of genomic technology. ", "answer": 1}, {"article": "The findings were published in the journal BMC Complementary and Alternative Medicine in August.\n\u201cThey show that a behavioral intervention can have effects of similar magnitude as an antidepressant.\u201d\n\nControlled breathing may also affect the immune system.\nIn coherent breathing, the goal is to breathe at a rate of five breaths per minute, which generally translates into inhaling and exhaling to the count of six.\nIf you have never practiced breathing exercises before, you may have to work up to this practice slowly, starting with inhaling and exhaling to the count of three and working your way up to six.\nAfter 12 weeks of daily yoga and coherent breathing, the subjects\u2019 depressive symptoms significantly decreased and their levels of gamma-aminobutyric acid, a brain chemical that has calming and anti-anxiety effects, had increased.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Deep breathing has been a fixture in the West since the 1970s, when cardiologist Dr. Herbert Benson of Harvard Medical School published the book, \u201cThe Relaxation Response.\u201d It seems like a stretch to say that \u201cscience is just beginning to provide evidence that the benefits of this ancient practice are real.", "answer": 0}, {"article": "[1]\n\nWriting in a linked Comment, Dr Nahid Bhadelia from Boston University School of Medicine and Boston Medical Center, Boston, USA says, \"[This study] validates the accuracy of the ReEBOV RDT in patients who are well into their illness...suggesting it could be used to triage this subset of patients if RT-PCR is not available, particularly in those with a high index of clinical suspicion for a differential diagnosis...the data presented provide crucial information about the point of-care function of this rapid diagnostic test, such as ease of use, quality of samples taken at the bedside, and the concordance with venous samples...the results raise caution regarding the performance of the widely used altona RT-PCR assay, which the authors suggest might have underperformed because of laboratory specific technical and performance factors.\"\nThe study is the first to show that a point-of-care EVD test (ReEBOV Antigen Rapid Test; Corgenix) is faster than and as sensitive as a conventional laboratory-based molecular method used for clinical testing during the recent outbreak in Sierra Leone.\nThe authors caution that given the limitations of the performance of the altona RT-PCR reference test in patients with low levels of the virus in their blood, more research is needed to assess how the new RDT will perform in patients very early in the course of EVD.\nThis method poses substantial risks to the healthcare workers responsible for blood collection, transport, and testing, and efforts to contain the Ebola epidemic in west Africa have been hampered by this slow and complex diagnostic test.\nAlthough the RDT requires refrigeration, this is already available in many health centres in endemic areas, particularly those that store vaccines and other medical products.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does a fine job of establishing novelty: this new test takes minutes instead of what might take days; results can happen on-site; it only takes a few drops of blood from a finger instead of a vial\u2019s worth by vein.", "answer": 1}, {"article": "MONDAY, June 6, 2011 (HealthDay News) -- There's too little evidence to say definitively whether treating early, localized prostate cancer with radiation is a better option than \"watchful waiting,\" new research finds.\nThere was also \"moderate strength evidence\" that a higher external beam radiation was more effective than a lower dose.\nThey should also consider age and overall health status, including whether or not the patient has other conditions more likely to cause death than the prostate cancer.\nThe National Cancer Institute has more on prostate cancer.\n\"Some of the distinctions being made are not really supported by the evidence.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story made clear that this is one in a series of federally funded studies on prostate cancer treatment options.", "answer": 1}, {"article": "The results showed no differences in IQ.\nFour years later, the children underwent a series of assessments for IQ, motor skills, social skills, problem-solving, communication skills and behavior.\nIt is unclear whether the practice could harm infants' health.\nMuch of the research has focused on preterm infants, who appear to benefit most from delayed cord clamping, Rabe said.\n\"There is growing evidence from a number of studies that all infants, those born at term and those born early, benefit from receiving extra blood from the placenta at birth,\" said Dr. Heike Rabe, a neonatologist at Brighton & Sussex Medical School in the United Kingdom.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The delay in clamping is not novel. The story establishes that there have been earlier studies, but none that followed children for four years.", "answer": 1}, {"article": "For more information, visit www.aao.org.\nIn addition, the non-invasive nature of the device and its relatively large surface area make this technology a potential candidate for delivering multiple ocular drugs at once, further reducing the burden of self-administration on patients.\nThe authors noted the device could also be used for non-glaucoma medications, with potential applications for dry eye, allergies and inflammation.\n\"What is exciting is that this is just one of several sustained-release drug delivery methods designed to help patients who have trouble taking daily eye drops.\"\n\"In making effective treatments easier for patients, the hope is that we can reduce vision loss from glaucoma, and possibly other diseases,\" said study author James D. Brandt, M.D., director of the UC Davis Medical Center Glaucoma Service.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release does not seem to make any unfounded claims about the novelty of this device. In fact, it quotes a study author as saying that the device \u201cis just one of several sustained-release drug delivery methods designed to help patients who have trouble taking daily eye drops.\u201d", "answer": 1}, {"article": "The U.S. Centers for Disease Control and Prevention has more about healthy eating for a healthy weight.\nWhen it comes to speedy weight loss, the HMR program and Biggest Loser diet shared the top ranking, followed by the Atkins diet in second place and Weight Watchers in third.\nOn the opposite end of the list, the Whole30 diet -- a 30-day program that bans processed foods, legumes, grains, dairy, alcohol and added sugar -- ranked as the worst overall diet on the list, the new report said.\nThe MIND diet ranked first in the \"Easiest Diet to Follow\" category in a three-way tie with Weight Watchers and the Fertility diet, which asserts that certain dietary changes can boost fertility.\nThe DASH diet scored highest when it comes to healthy eating, followed by the TLC diet.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The fact the diet was selected as the top ranked diet for six years running is apparently the news hook. It\u2019s hard to find the novelty in this story or why this is important to publish now. The DASH diet has been around a long time and is heavily promoted by government agencies including but not limited to the NIH, USDA and CDC.\nThe fact that the diet was selected as the top ranking diet for six years is not really news. (Generalisimo Franco is still dead.) The lede for the story is that for the first time the magazine ranked quick weight loss diets.\u00a0 That is news, albeit not very compelling.", "answer": 0}, {"article": "This held true even after treatment stopped.\n\u201cThis is very strong support for changing clinical practice to include gradual reduction aided by medication.\u201d\n\nSmoking is the leading cause of preventable death in the U.S., according to the Centers for Disease Control and Prevention.\nWhile the study shows that Chantix, which is known generically as varenicline, can be effective for some smokers, the group taking the pill also experienced more side effects such as nausea, abnormal dreams, insomnia, constipation, vomiting, and weight gain.\n\u201cThis is the first study of its kind to enroll a group of smokers who are not traditionally enrolled in clinical trials because they are not ready to quit,\u201d said Dr. Caryn Lerman, professor of psychiatry and deputy director of the Abramson Cancer Center at the University of Pennsylvania in Philadelphia.\n\u201cThis allows us to reach a much broader population of smokers who aren\u2019t willing to quit abruptly or set a quit date, and it shows that people can quit without going cold turkey,\u201d said lead study author Dr. Jon Ebbert, a professor in primary care and internal medicine at the Mayo Clinic in Rochester, Minnesota.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes (quoting Dr. Lerman): \u201cThis is the first study of its kind to enroll a group of smokers who are not traditionally enrolled in clinical trials because they are not ready to quit.\u201d While it\u2019s true that this seems to be the first such study involving Chantix, nicotine replacement products and bupropion have both been studied in this context. Since we\u2019ve already penalized the story for this omission above under \u201cAlternatives,\u201d we won\u2019t do so again here.", "answer": 1}, {"article": "TUESDAY, Sept. 11, 2012 (HealthDay News) -- A new device meant to help surgeons determine in the operating room if they have removed all cancerous breast cancer tissue may help reduce repeat surgeries after lumpectomy without compromising cosmetic effects, according to a new study.\nBut the MarginProbe is another tool that might help reduce the odds of needing a subsequent surgery, she said.\nThe study of nearly 500 patients undergoing breast-conserving surgery found little difference in the volume of tissue removed when the device was used compared to traditional detection methods.\nThe device, called MarginProbe, emits an electric field and senses a return signal from the tissue examined.\nIf the results are repeated in larger studies, it could be a welcome addition to doctors' techniques, she said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The device is described as new in both the first paragraph and the headline but readers are not told if other devices or methods are currently being used or tested to reduce the need for repeat surgeries for patients having a lumpectomy for breast cancer.", "answer": 0}, {"article": "\"For all practical purposes, the programs all worked about the same,\" said Kelly D. Brownell, director of Yale University's Rudd Center for Food Policy and Obesity and creator of the Lifestyle, Exercise, Attitudes, Relationships and Nutrition (LEARN) program for weight management, one of the diets studied.\nAll the participants reported eating about 2,000 calories a day when the study began.\nReactions to the findings were mixed.\nAt first, the Atkins group lost weight faster.\nHigh levels of LDL are a major risk factor for heart disease.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The information presented is not novel and was not presented as a new finding.\u00a0", "answer": 1}, {"article": "He's about to start a new study that involves giving chronic back pain sufferers lessons in the Alexander Technique and exercises, and then measuring how far their spines can twist and the size and strength of their deep lumbar muscles \u2013 which Little thinks might work poorly in people with chronic low back pain.\nHe cautions though that it may be something else entirely that accounts for the apparent success of the Alexander Technique.\nAnd those who went the distance got the best results.\nThose who had six Alexander lessons showed some improvement.\nIn particular, Joe now holds himself differently during his solos because of Alexander Technique.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article makes it clear that the Alexander Technique dates back to the 19th century.\n", "answer": 1}, {"article": "Only about half the patients who were screened qualified for treatment, known as thrombectomy, which uses a mechanical device to pull clots out of a blood vessel.\nThe researchers used a special type of brain imaging to identify the patients who still had live brain tissue that could be saved if the blood supply was restored.\nThe study showed that the time window could be expanded to 16 hours.\n\u201cI really cannot overstate the size of this effect.\u201d\n\nThe key finding is that there is often more time than doctors realized in which brain cells can still be rescued by a procedure to remove the clot.\n\u201cThese striking results will have an immediate impact and save people from lifelong disability or death,\u201d Dr. Walter J. Koroshetz, director of the National Institute of Neurological Disorders and Stroke, said in a statement.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of this research is the extended time frame for treatment rather than the treatment itself. The story does a good job of making this distinction clear.", "answer": 1}, {"article": "Pooling data from 522 trials including nearly 120,000 patients, researchers found all drugs analysed were more effective than placebos in the treatment of adults with acute depression.\n\u201cAlthough antidepressants are of proven benefit\u2014as this study shows,\u201d she said, \u201cno doctor wants their patients to become reliant on medication.\u201d\n\nCarmine Pariante, a professor at the UK\u2019s Institute of Psychiatry, Psychology and Neuroscience and spokesperson for the Royal College of Psychiatrists, said the study \"finally puts to bed the controversy on antidepressants.\"\nThe results add up to a complex treatment picture for what authors called \u201cone of the most common, burdensome, and costly psychiatric disorders worldwide in adults.\u201d\n\nAntidepressants do not improve symptoms in about 40 percent of people, study author Andrea Cipriani of Oxford University told a press briefing.\nShe said in a statement: \u201cTaking antidepressants is frequently portrayed as a negative thing or something done only when other therapies are not available or have failed, but this in itself can add to the unfortunate stigma that sometimes exists around people with mental health conditions.\u201d\n\nBut she also urged caution.\nIn the U.K, where a number of the study authors are based, at least one million more people could benefit from drugs or psychotherapy, senior author John Geddes said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The lead bluntly states: \u201cAntidepressant drugs really do work, a major new international study has proven.\u201d\nWe think that\u2019s the wrong takeaway. It wrongly implies there\u2019s been widespread doubt that antidepressants in general are effective, and this analysis somehow puts all doubts to rest.\nStudy author Andrea Cipriani offered a more nuanced view, saying the findings should reassure people with depression that drugs can help.\nThe stated purpose of the analysis was to \u201ccompare and rank antidepressants\u201d based on the totality of available data.\nThe lead apparently emanates from this quote in the second-to-last paragraph, by a researcher with an acknowledged conflict.\nCarmine Pariante, a professor at the UK\u2019s Institute of Psychiatry, Psychology and Neuroscience and spokesperson for the Royal College of Psychiatrists, said the study \u201cfinally puts to bed the controversy on antidepressants.\u201d", "answer": 0}, {"article": "The study was funded by MD Anderson's HPV Moon Shots Program and the HPV Anal Cancer Foundation, the E.B.\nThe phase II study, for which findings are being presented at this week's American Association for Cancer Research's annual meeting in New Orleans, was designed and led by researchers at The University of Texas MD Anderson Cancer Center's Human Papillomavirus-Related (HPV) Cancers Moon Shot Program.\nStudy team members for the correlative analysis included Armeen Mahvash, M.D., Interventional Radiology; Luis Vence, Ph.D., Jorge Blando, D.V.M., and James Allison, Ph.D., all of Immunology; Robert Wolff, Cancer Medicine; Aki Ohinata, GI Medical Oncology; Chimela Ohaji, Investigational Cancer Therapeutics; and Padmanee Sharma, M.D., Ph.D., Genitourinary Medical Oncology.\n\"In this first prospective phase II trial for refractory metastatic SCCA, our exploratory analysis of pre- and on-treatment tissues samples revealed potential correlations between immunologic biomarkers and clinical outcomes to nivolumab,\" said Cathy Eng, M.D., professor of Gastrointestinal Medical Oncology and national study principal investigator.\nOf note, patients who scored as responders had higher frequency of CD8 T-cells and PD-L1 CD45 immune cells in pre-treatment samples.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There is no question of the newness of immunotherapy drugs for treating cancer. The news release heralds this as the \u201cfirst-ever\u201d study of nivolumab on aggressive anal cancer. Still, the news release could clarify whether this is the first trial of any immunotherapy drug for anal cancer and if so how this study contributes to body of evidence of the potential for immunotherapy drugs to improve treatment options for patients.", "answer": 1}, {"article": "Dec. 1, 2011 (Chicago) -- An experimental treatment that involves spinal injections of ozone gas and steroids relieved pain in over two-thirds of 327 people with back problems related to a herniated disc.\nAnother 22% reported only a little improvement, with pain persisting.\nAnd 7% had no improvement or their pain got worse.\nA few patients resorted to back surgery.\nBefore the treatment, patients had tried everything without success and were considering an operation, he says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story made clear that this is a relatively new experimental approach for a disc herniation.", "answer": 1}, {"article": "Plenary sessions feature the latest research on the use of and testing for cannabis, combating premature death due to preventable causes such as tobacco and alcohol, the development of an \"intelligent\" surgical knife, programmable bio-nano-chips, and the epigenetic causes of disease.\n\"This is the first time that we have used this biochip technology to test for an increased risk of Alzheimer's disease,\" said Emma C. Harte, PhD, a research scientist at Randox Laboratories.\nThe apolipoprotein gene is inherited from each parent and when a patient inherits the ApoE4 variant from one parent they have a three times greater risk of developing Alzheimer's disease, whereas a patient who inherits ApoE4 from both parents is eight-to-12 times more likely to develop the disease.\n\"Cerebrospinal Fluid Angiotensin-Converting Enzyme Activity Levels of Patients With Alzheimer's and Parkinson's Disease\" (A-118)\n\u2022 Researchers have shown that a specific protein in blood plasma could serve as a biomarker for early detection of AD.\n\"Plasma neuron derived exosomal protein biomarkers in the diagnosis of Alzheimer's Disease\" (A-135)\n\u2022 A new meta-analysis of studies over 12 year suggests that a possible relationship between thyroid function and an increased risk of dementia.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release claims \u201cThis is the first time that we have used this biochip technology to test for an increased risk of Alzheimer\u2019s.\u201d\nBut a quick online search found that a biochip assay for AD was reported (also by the University of Vienna) in Acta Neuropathologica in 2014.", "answer": 0}, {"article": "MONDAY, March 19, 2012 (HealthDay News) -- New research finds that a minimally invasive surgical procedure to treat hernias results in less chronic pain and a faster recovery when compared to a traditional approach.\nAlmost all the patients were men, and their average age was around 55.\nThe other approach is older and is performed through a 2- to 2.5-inch incision in the groin, Brunt said.\nIt was developed in the 1990s, Brunt said.\nBrunt said the costs of the two procedures are comparable, although the laparoscopic procedure may cost more.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that the laparoscopic approach has been around since the 1990s and that the traditional approach is older.", "answer": 1}, {"article": "For more industry information, health research and recipe ideas, visit http://www.\nBeyond finding that tree nuts lower total cholesterol, triglycerides, LDL cholesterol and ApoB, researchers also found that consuming at least two servings (two ounces) per day of tree nuts, such as walnuts, has stronger effects on total cholesterol and LDL.\n\"Our study results further support the growing body of research that tree nuts, such as walnuts, can reduce the risk of cardiovascular diseases,\" said Dr. Falk.\nWalnuts are the only nut that provide a significant amount (2.5 grams per one ounce serving) of alpha-linolenic acid (ALA), the plant-based form of omega-3s.\"\nAdditionally, results showed that tree nut consumption may be particularly important for lowering the risk of heart disease in individuals with type 2 diabetes.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It\u2019s not really clear from the release what\u2019s new about this study, beyond the fact that the meta-analysis conducted involved more studies than previous research. The study itself includes an extensive discussion of what\u2019s new here, including the fact that previous studies looked only at specific types of nuts and not all tree nuts.", "answer": 0}, {"article": "MONDAY, Aug. 15, 2011 (HealthDay News) -- A traditional Chinese herbal treatment may reduce fever from H1N1 (\"swine flu\") influenza just as well as the prescription medication Tamiflu, a new study suggests.\nHowever, finding the medicine in the United States is difficult, if not impossible, given that it contains the stimulant ephedra.\nBut the herbal formula is working on symptoms to help people become more comfortable.\nThe authors discuss their findings in the Aug. 16 issue of the Annals of Internal Medicine.\n\"We have our prescription drugs on the one hand, and then we have dietary supplements on the other.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that herbal remedies like the one tested in this study have been used for thousands of years in China.", "answer": 1}, {"article": "Carmichael and Segura collaborated on the study.\nThe results suggest that such an approach may someday be a new therapy for stroke in people, said Dr. Tatiana Segura, a former Professor of Chemical and Biomolecular Engineering at UCLA who is now a professor at Duke University.\nThis research was designed to explore recovery in acute stroke, or the period immediately following stroke - in mice, that is five days; in humans, that is two months.\n\"We tested this in laboratory mice to determine if it would repair the brain in a model of stroke, and lead to recovery,\" said Dr. S. Thomas Carmichael, Professor and Chair of neurology at UCLA.\nIn addition to Carmichael and Segura, other authors of the paper are Lina Nih and Shiva Gojgini, both of UCLA.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Although we\u2019re told this is a \u201cfirst-of-its-kind finding,\u201d and the treatment is a \u201cnew\u201d stroke-healing gel, readers may have benefited from learning how this approach compares to other, related techniques currently under investigation.\nA quick search of ongoing research in this area reveals several things are being tried including drugs, growth factors, monoclonal antibodies, stem cells, and even brain stimulation techniques.", "answer": 0}, {"article": "A birth-control pill that eliminates women's monthly periods could hit pharmacy shelves later this year, marking the latest effort by a drug company to expand a contraceptive's features beyond preventing pregnancy.\n\nSince \"The Pill\" was introduced nearly a half-century ago, most regimens have mimicked a woman's cycle by having a pill-free week each month when women can have bleeding and other symptoms.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains that while the concept is fairly new, this particular product is not the first of its kind. ", "answer": 1}, {"article": "The new study was presented at the annual meeting of the American Pain Society.\nXyrem, which is approved by the FDA for the treatment of narcolepsy, corrects the same disturbed sleep patterns that studies have shown are common in fibromyalgia patients, Jones says.\nMay 12, 2010 (Baltimore) -- The powerful sleeping medication Xyrem can help relieve the hallmark symptom of pain in people with fibromyalgia, suggests a study that pitted the drug against a placebo.\nThe National Fibromyalgia Association estimates that about 10 million Americans, mostly women, have fibromyalgia, an unexplained condition characterized by chronic pain and fatigue.\nMore than half of people who took Xyrem reported at least a 30% improvement in pain, says Kim Dupree Jones, PhD, of Oregon Health & Science University in Portland.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We learn of prior studies of Xyrem in this population and the drug\u2019s indicated use for narcolepsy. The investigator tell us the mechanism of action in fibromyalgia, although we\u2019re not told what evidence is behind it. There\u2019s also an sideways acknowledgement of off-label use via the patient quote, but we\u2019ll discuss that more later.", "answer": 1}, {"article": "WEDNESDAY, May 11, 2011 (HealthDay News) -- It may be possible to assess a man's fertility by checking his \"anogenital distance,\" the gap between his scrotum and anus, a new study suggests.\n\"This paper also provides new data on infertile men, who have shorter (less masculine) anogenital distance.\"\nThey measured the scrotum-anus distance as well as the penis length of 117 infertile and 56 fertile men visiting an andrology clinic.\nIn the new study, the Baylor group investigated whether anogenital distance differed in fertile and infertile men.\nFurther research is needed to compare techniques for measuring anogenital distance and assess their accuracy, he and his colleagues said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story describes other research on short anogenital spans, so it\u2019s clear there is other research on this topic.", "answer": 1}, {"article": "(Reuters Health) - When a migraine strikes, patients might one day be able to make the experience less painful by using a smartphone-controlled device to deliver mild electric shocks to their arm, a company-funded experiment suggests.\n\u201cWe worked on stimulation at a far away location, which makes the treatment more convenient and more discrete so people can use it even during working hours without anyone noticing,\u201d Yarnitsky added by email.\nThe study involved 71 people with episodic migraines who had two to eight attacks a month and had not taken drugs to prevent the episodes for at least two months.\n\u201cThe percentage of attacks for which TENS is sufficient as sole treatment and allows sustained pain relief remains to be determined,\u201d Schoenen cautioned.\nPeople who started using the device within 20 minutes of the start of a migraine reported average pain reductions of 47 percent, compared to a 25 percent reduction in pain for people starting the device later.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Readers are told how most TENS therapy for migraines applies to the head, not the upper arm (as this devices is designed for), so this would be a somewhat new way to use the treatment.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070805/13knee.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The news brief explains that the Gender Knee is new, but asks whether it is really all that different from existing implants designed for smaller patients.", "answer": 1}, {"article": "Chest compressions or CPR can help restore circulation, increasing the odds of survival.\n\u201cIn contrast, if CPR is not initiated before the arrival of the emergency medical services, only 1 in 30 people survive a cardiac arrest.\u201d\n\nFor the current study, researchers looked at 30-day survival for patients who had cardiac arrests outside of a hospital between 2005 and 2011.\n\u201cOnce a victim has sustained a cardiac arrest with little or no blood supply going to the heart or brain, the time to reestablishing blood flow with oxygenated blood is critical,\u201d said Dr. Lenworth Jacobs, director of trauma and emergency medicine at Hartford Hospital in Connecticut.\n\u201cEarly CPR saves lives, and the lack of CPR efforts from bystanders could result in significantly decreased chances of survival,\u201d said lead study author Dr. Shahzleen Rajan of Copenhagen University Hospital in Denmark.\n\u201cWe know from previous research that 1 in 8 people survive after a cardiac arrest if a bystander initiates CPR before the arrival of the emergency medical services,\u201d Rajan said by email.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "While the story doesn\u2019t make it explicitly clear what\u2019s novel, it does provide enough context for the reader to understand that this study builds upon past research that was more general. That\u2019s done via this quote:\n\u201cWe know from previous research that 1 in 8 people survive after a cardiac arrest if a bystander initiates CPR before the arrival of the emergency medical services,\u201d Rajan said by email. \u201cIn contrast, if CPR is not initiated before the arrival of the emergency medical services, only 1 in 30 people survive a cardiac arrest.\u201d", "answer": 1}, {"article": "\u201cI\u2019m thinking, is this the way it\u2019s going to be for the rest of my life?\nIf the patient answers yes to one or both, a questionnaire is recommended to determine if the patient is depressed and the severity.\nDepression is about three times more common in heart attack survivors and those hospitalized with heart problems than the general population, according to the recommendations published in the journal Circulation.\n\u201cYou can\u2019t sit in your house and just vegetate,\u201d she said.\nShe said she spent most of her time at her Englewood, Ohio, home sitting in her chair, frequently crying for no reason.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Clearly depression screening is not new but it is increasingly being advocated in the context of heart patients.", "answer": 1}, {"article": "One was a low-fat diet that included lots of fruits, low-fat dairy, poultry, whole grains and small amounts of red meat.\nThe only difference between the two was the avocado \u2014 the other diet had the same amount of fat from other sources.\nIt was also supported by a grant from the Hass Avocado Board, an industry group that the researchers say had no role in the design of the study or the interpretation of the data.\nAnd given the reduction in funds available for research, it's become increasingly common for researchers to carry out these kinds of industry-supported studies.\nNew research finds that eating an avocado per day, as part of an overall diet rich in healthy fats, may help cut the bad kind cholesterol, known as LDL.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "A great deal of research has been done related to avocado consumption and cholesterol levels. The story doesn\u2019t explain how this study either fits into the existing research on avocados and LDL cholesterol levels in humans or how it is different from previous studies on cholesterol and avocado consumption.", "answer": 0}, {"article": "\"We need to be mindful of the fact that the majority of human studies of oxytocin have been conducted using adults, including this study, and only one paper has included individuals between the ages of 12 and 18.\nIt plays a key role in social interaction, promoting maternal behavior and monogamy in animals.\nAnother study being published in the journal Biological Psychiatry found that 16 autistic males in Australia ages 12 to 19 who received the hormone through a nasal spray were better able to recognize other people's facial expressions.\nOxytocin is produced naturally in the bodies of humans and animals.\nOxytocin has been in use for several years as an \"alternative\" therapy for autism.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that there have been previous studies of oxytocin in autism.", "answer": 1}, {"article": "There are substantial risks.\nThe modified virus retains the ability to infect and kill brain tumor cells, and also appears to trigger the patient's own immune system cells to attack the tumors, the researchers say.\nThe Duke researchers decided to try to use a genetically modified version of the poliovirus, which can cause a devastating form of paralysis, because of the virus's ability to infect nervous system cells.\nThe scientists removed one of the virus's genes to prevent it from causing polio and replaced that gene with one from a harmless virus known as a rhinovirus, which ordinarily causes the common cold.\nThe experimental treatment seems to have extended survival in a small group of patients with glioblastoma who faced a grim prognosis because standard treatments had failed, Duke University researchers say.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story made it sound like this was a new concept, but this research has been dancing in and out of the sensational spotlight for years.", "answer": 0}, {"article": "But definitively proving these benefits is challenging, requiring years of costly research.\n\u201cBy opposing one group of muscles against another, it stimulates osteocytes, the bone-making cells.\u201d\n\nMost experts argue that it\u2019s difficult, perhaps impossible, for adults to gain significant bone mass.\nThe findings, as reported last month in Topics of Geriatric Rehabilitation, showed improved bone density in the spine and femur of the 227 participants who were moderately or fully compliant with the assigned yoga exercises.\nAt the time the study was submitted for publication, \u201cwith more than 90,000 hours of yoga practiced largely by people with osteoporosis or osteopenia, there have been no reported or X-ray detected fractures or serious injuries of any kind related to the practice of yoga in any of the 741 participants,\u201d Dr. Fishman and his colleagues wrote.\nIf you don\u2019t fall, you greatly reduce your risk of a serious fracture.\u201d\n\nFor more fitness, food and wellness news, follow us on Facebook and Twitter, or sign up for our newsletter.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The report doesn\u2019t make any claims for novelty where none exists. The overall benefits of yoga are fairly well-established, even if those benefits may not be strictly \u2018evidence-based\u2019. \u00a0What is \u2018new\u2019 is the research trying to demonstrate effects of yoga on a single parameter (bone density) and we think the researchers should be lauded for trying to apply some rigor to answering these kinds of specific questions.", "answer": 1}, {"article": "Study Limitations: Imbalances caused by matching groups of obese patients for comparison based on age, sex, body mass index and diagnoses of diabetes.\nSome previous research has been limited by a number of factors, including the lack of a comparison group of obese patients who did not undergo bariatric surgery.\nResults: The rate of death from any cause over about 4.5 years was lower among obese patients who underwent bariatric surgery compared with patients who managed their obesity with nonsurgical care.\nStudy Conclusions: The association between bariatric surgery and a lower rate of death from any cause adds to the limited literature describing the beneficial outcomes of these surgical procedures for obese patients.\nWhy The Research Is Interesting: Much is known about the short-term outcomes of bariatric surgery for weight loss but relatively little is known about its long-term effects.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release notes that there are many studies looking at the short-term outcomes of bariatric surgery, but less that address longer-term effects, as this one does.", "answer": 1}, {"article": "They think I am crazy, even a [Defeat Autism Now doctor] we once saw,\" said a message posted by a parent on the AutismWeb.com bulletin board in March\n\nParents \"research anything they can get their hands on and there are so many things saying 'Try this or try that' that aren't necessarily safe.\nHis findings are complicated, but basically blood tests show 70 percent of his autistic patients have zinc deficiencies (pointing to problems with processing heavy metals), and the vast majority also have immune system problems of varying kinds.\nBut we wonder -- we speculate -- that it's possible if we have children living in a unique environment that has not [previously] been created scientifically that we can make a difference.\nNo cause for autism has been found, and debates rage as to whether the brain development disorder is purely genetic or caused in part by environmental factors, including air and food-borne chemicals.\nThe room would house only one patient at a time and be similar to other spaces at the institute's Center for Autism, with educational and play spaces, and a table for dining.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The proposed \"clean room\" experiment for autism described in this article is new.\u00a0\u00a0\u00a0However, this novelty should be viewed with caution as the treatment\u00a0does not appear to be\u00a0based in sound scientific theory. ", "answer": 1}, {"article": "LONDON (Reuters) - The first new asthma pill in decades has produced promising results in a small clinical trial, potentially paving the way for another treatment option for patients by the end of the decade.\nThe latest research, published in the journal Lancet Respiratory Medicine, comes at a time of considerable innovation in asthma care, with the recent launch of new injectable drugs for severe asthma that also target eosinophils.\nAt the same time, many drugmakers are developing improved asthma inhalers, including \u201csmart\u201d devices with sensors that monitor use.\nNovartis believes the medicine could be filed for regulatory approval in around 2019.\nLarger and longer studies are now needed to prove that the twice-daily pill can also reduce severe asthma attacks, known as exacerbations.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story\u00a0says it\u2019s the first asthma pill in decades\u2014-that\u2019s not correct. In recent years, several new drugs known as leukotriene receptor antagonists have come on the market as tablets.\u00a0(The statement about this being the first pill in decades appears to come from\u00a0the news release, which we also reviewed.)", "answer": 0}, {"article": "FRIDAY, Nov. 4, 2016 (HealthDay News) -- Obese patients who swallowed balloon capsules that helped them eat less lost an average of 15 pounds, roughly two times more weight than patients who just dieted and exercised, researchers report.\nThe findings were to be presented Friday at the annual meeting of the American Society for Metabolic and Bariatric Surgery and the Obesity Society in New Orleans.\nThe study lasted a year, but \"we don't know what happens after that,\" Pryor said.\nThe balloon treatment will be available starting in January, but the cost hasn't been announced, Pryor said.\nAn advantage of the balloons is that patients have no downtime and can go back to work the same day, the researchers said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "As noted above, the story reports that the Obalon device does not require patients to be sedated during insertion, which appears to be the main difference between this device and other similar balloons. It would have been better if it had more clearly informed readers that there are other intragastric balloon devices already on the market.\nThe story notes that these study results also were\u00a0presented back in May.", "answer": 1}, {"article": "The boxes are a new idea for many Americans.\nThe boxes can also be sent in the mail, if a nearby hospital is not designated as a distribution center.\nShe said the program was eye-opening for how much information she learned about how to prevent sudden unexpected infant death.\nEach box comes filled with a mattress, fitted sheet, onesie and diapers.\nThe Baby Box Co. is also handing out the boxes in Minneapolis, Phoenix and San Francisco, with the goal of expanding to all 50 states.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not claim boxes are novel everywhere, but suggests they are a growing initiative in the United States.", "answer": 1}, {"article": "Dr. Susan Huang, a professor of infectious disease at the University of California, Irvine, wrote an editorial accompanying the study.\n\"A lot of patients and families don't realize that there are problems with a urinary catheter, so they may request them because they think it will allow patients to stay in bed,\" Saint said.\n\"This program can reduce urinary infections in hospitals if a team is assembled to ensure adoption of best practices and to rapidly correct reasons for failing to comply with these processes,\" she added.\nThe program Saint helped develop -- called the \"bladder bundle\" -- includes protocols, checklists, training and information-sharing that help doctors and nurses reduce catheter use and prevent infections.\nShe said, \"While we've known the correct care processes for managing urinary catheters, we haven't been able to reliably reduce catheter-related infections.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The \u201cStop CAUTI\u201d program has been around for years, but it\u2019s implied that hundreds of hospitals have never implemented it before in a systematic way. The scale and duration of the study makes this novel and worth covering.", "answer": 1}, {"article": "Saper says yoga likely works by strengthening core and lower back muscles and helping with mind-body relaxation.\nOpiate overdoses are now the leading cause of death for adults under age 50 -- an especially compelling reason to find approaches to chronic pain that don't involve narcotics.\n\"I feel, the more that one can do for one's self and not depend on medication, the healthier it is for your body,\" Zaborowski said.\n\u2022 None New guidelines outline how to handle back pain \n\n\n\nIn the study, 320 adults with moderate to severe back pain received one of three approaches over 12 weeks:\n\u2022 Education about how to cope with back pain\n\n\n\nYoga was just as effective as physical therapy -- and both groups were about 20 percent less likely to use pain medication than patients receiving education alone.\n\"Yoga makes me think about my back and how I'm standing and if I'm standing properly, then I can function better.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Yoga and back pain has been studied a lot, yet this story didn\u2019t place this new study in context with past research.\nAn editorial that accompanied the study highlights what is novel about this study: It was made up of low-income patients and there was a longer evaluation period than most studies (1 year).\nIf the story had mentioned these differences, then it would be Satisfactory on this criterion.", "answer": 0}, {"article": "Lakhan tells WebMD in an email that the extracts were administered orally.\n\"Considering the distress and limitations spasticity brings to individuals with MS, it is important to carefully weigh the potential for side effects with the potential for symptom relief, they say in the news release.\nThe reviewed studies included the use of cannabis extracts delta9-tetrahydrocannabinol, or THC, and cannabidiol, or CBD, in people with MS.\n\n\"We found evidence that combined THC and CBD extracts may provide therapeutic benefit for MS spasticity symptoms,\" Lakhan says in a news release.\nThe review, by Shaheen Lakhan, PhD, and Marie Rowland, PhD, of the Global Neuroscience Initiative Foundation in Los Angeles, found that five of six published studies they analyzed reported a reduction in spasticity and an improvement in mobility in MS patients treated with marijuana extracts.\nIn the paper, published in the open access journal BMC Neurology, the researchers write that recently introduced therapies of combined THC and CBD have the potential to relieve symptoms and that past reviews have suggested that cannabinoid therapy is beneficial for people with MS.\n\nGenerally, use of the marijuana extracts were well-tolerated in patients, the researchers write.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "A HealthDay story quoted a Mayo Clinic neurologist saying, \"the idea of using cannabis to treat MS has been around for a long time.\" No such context appeared in this story. ", "answer": 0}, {"article": "Smoking was defined as having had one or more cigarettes in the last week.\nThe authors believe that future trials of vitamin C supplementation in pregnant smokers should determine whether the benefits are greater if the supplementation starts earlier and continues postnatally in the babies themselves.\nThat study used passive methods to measure lung function, and the authors note that FEFs provide a more direct assessment of airway function and are similar to methods used to diagnose lung disease in adults and older children.\nThe researchers wrote that study results support the hypothesis that oxidative stress caused by cigarette smoking reduces the amount of ascorbic acid, a component of vitamin C, available to the body.\nIn the current study, 251 pregnant women who smoked were randomly assigned at 13 to 23 weeks of gestation to either receive vitamin C (125 women) or a placebo (126 women).\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release makes it clear the authors of this study have done previous research in this area, are trying to find more accurate ways to assess lung function in infants, and will continue to follow the infants in this study to assess their lung function over the long-term.", "answer": 1}, {"article": "Strawberries have the potential to prevent esophageal cancer, according to a preliminary study released Wednesday.\n\nResearchers, led by Ohio State University, were able to show that freeze-dried strawberries slowed the growth of dysplastic, or precancerous, lesions in about 30 people who consumed the fruit for six months.", "question": "Does the story establish the true novelty of the approach?", "explanation": "At least the story noted that \u201cPrevious work showed that freeze-dried strawberries were able to significantly inhibit tumor development in rats.\u201d So there was no claim that this was first-in-its-field research.", "answer": 1}, {"article": "Studies suggest that for more than half of depressed patients, antidepressants alone don\u2019t eliminate symptoms.\n\u201cIt provides clues to new treatments, and it provides clues to understanding what causes depression as well as what goes on biochemically when people get better from depression.\u201d\n\nThe researchers studied the use of SAMe or a placebo in 73 adults with depression who were not responding to prescription antidepressant treatment.\nIt\u2019s a medication that works differently than everything else.\u201d\n\nThe study was funded by a grant from the National Institutes of Mental Health, but the SAMe pills and placebo pills were provided by the dietary supplement maker Pharmavite.\nAs a result, doctors are looking for additional treatments to help these patients, referred to as \u201cnonresponders.\u201d\n\nModern antidepressants essentially work by building up concentrations of neurotransmitters, which amplifies their effect on the brain.\nAnd about 26 percent of patients in the SAMe group experienced a complete remission of symptoms, compared to just 12 percent in the placebo group, according to a report published in The American Journal of Psychiatry.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We learn that SAMe is a naturally occurring molecule in the body that is widely used in Europe for depression and other conditions. We also hear about the proposed ways SAMe might act in the body, and how its action seems different than those of modern antidepressants.\nIt was good to summarize the prior AHRQ research on SAMe in depression, but it left us more confused than enlightened. It was too vague when summarizing the 2002 analysis that found \u201cclinically meaningful benefits\u201d and that SAMe worked \u201cas well as tricyclic antidepressants.\u201d If its efficacy is already established, why is this 2010 study a \u201cbreakthrough\u201d 8 years later? More details were needed about that analysis and the novelty.\nWhy is it widely used in Europe for depression but not the U.S.? If the 2002 results were so clearly positive, why does the 2010 study open up \u201cmany directions of research\u201d and represent a \u201chuge advancement\u201d?\nThere are answers to these questions, but not in this blog piece. According to the editorial, this study was \u201cthe first placebo-controlled trial of SAMe for adjunctive use\u201d and also \u201cthe first placebo-controlled trial of oral SAMe since 1993.\u201d The novelty of this research, therefore, has to do with the observed synergy with prescription drugs, the oral route, and placebo-controlled nature of the study", "answer": 0}, {"article": "The woman died a year later.\nUnlike traditional chemo, which indiscriminately kills growing cells, the new generation of melanoma drugs work in a precise way, based on a better understanding of the specific genes and proteins that drive cancer growth, says Timothy Turnham, executive director of the Melanoma Research Foundation.\nThe most noticeable side effects from nivolumab have been moderate fatigue and vitiligo, a loss of pigment on some areas of her hands and arms, says Herry, 57, from Santa Cruz, Calif. She's been able to continue working as a registered nurse throughout these latest treatments.\nMany of the new drugs aim to remove melanoma's \"cloaking device,\" allowing it to be recognized and killed by the immune system, says Roy Herbst, chief of medical oncology at the Yale Cancer Center.\n\"The number of new melanoma therapies is sort of astonishing,\" says melanoma researcher Lynn Schuchter, a professor at the University of Pennsylvania School of Medicine.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of the research was explained in various ways:\n\u201cThe number of new melanoma therapies is sort of astonishing,\u201d says melanoma researcher Lynn Schuchter, a professor at the University of Pennsylvania School of Medicine. \u201cThe pace is unbelievable.\u201d\n\u2026Unlike traditional chemo, which indiscriminately kills growing cells, the new generation of melanoma drugs work in a precise way, based on a better understanding of the specific genes and proteins that drive cancer growth, says Timothy Turnham, executive director of the Melanoma Research Foundation.\n\u201cThe reason we\u2019re seeing these breakthroughs is because we did the basic science research to help us understand how this cancer happens, how it escapes therapy and how it progresses,\u201d Turnham says.\nMany of the new drugs aim to remove melanoma\u2019s \u201ccloaking device,\u201d allowing it to be recognized and killed by the immune system, says Roy Herbst, chief of medical oncology at the Yale Cancer Center.\nOther drugs \u2014 such as the two approved Wednesday, trametinib and dabrafenib \u2014 target growth signals within cancer cells.\u201d", "answer": 1}, {"article": "The medications, which include Requip (ropinirole), levodopa, Neurontin (gabapentin) and Lyrica (pregabalin), appear to reduce symptoms of the syndrome in more than 60 percent of patients, researchers report.\n\"This may be due to restless legs syndrome or other conditions.\nThe legs become uncomfortable when lying down or sitting, and the condition can disrupt sleep and take a toll on the quality of life, the researchers said.\nThe researchers found that 61 percent of those taking dopamine agonists showed at least a 50 percent improvement in their symptoms, compared with 41 percent of those taking an inactive placebo.\nThe same is true for levodopa, Wilt said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "As noted above, the most confusing point in the presentation of this story was the point of \u201cwhat\u2019s new here?\u201d", "answer": 0}, {"article": "Aug. 12, 2012 -- Daily aspirin use, long recommended for people at high risk of heart attack, may also reduce the risk of dying from cancer, according to new research.\nThe benefit, however, may not be as great as believed, says researcher Eric Jacobs, PhD, of the American Cancer Society.\nThe new analysis is published in the Journal of the National Cancer Institute.\nA previous study by others found daily aspirin reduced cancer death risk by 37%.\nMany other strategies will also reduce the risk of cancer, he says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story at least acknowledges \u201ca previous study by others,\u201d making at least passing reference to the fact that this is not the only research on this question. Barely satisfactory, though, as the Reuters story gives additional context to be clear what contribution the new study makes/", "answer": 1}, {"article": "Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by red, swollen and cracked skin with intense itching.\n\"The results of the Phase 2 study suggest that MM36 represents a potentially safe, effective and well-tolerated non-steroidal treatment for mild-to-moderate atopic dermatitis,\" said Linda Stein Gold, MD, director of clinical research, Department of Dermatology at Henry Ford Hospital and co-author of the article.\nIt has been estimated that approximately 18 million people are living with AD in the U.S. and this disease accounts for up to 20% of patient visits to dermatology offices.\nThe successful results of the Phase 2 trial of MM36 have been published by the Journal of the American Academy of Dermatology (JAAD), the leading peer-reviewed journal in dermatology.\n\"We believe these Phase 2 results demonstrate compelling evidence of MM36's capacity to be a leading topical PDE4 inhibitor and are aggressively developing MM36 for atopic dermatitis in the US.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes in two places that MM36 would be the second topical PDE4 inhibitor after a competing product (cisaborole, manufactured by Anacor Phamaceuticals). Cisaborole is further along in the approval-seeking process than MM36.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070225/5laser.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions that LASIK (laser-assisted in situ keratomileusis) surgery has been available for 10+ years.\u00a0 The story includes information that these are not new therapies but rather have had FDA approval for long time.\u00a0 The story mentions that photorefractive keratectomy (PRK), a procedure where a laser is used to reshape the cornea after the top layer of cells are removed, is now being performed more in lieu of, or in conjunction with LASIK surgery.\u00a0 The PRK procedure was approved by the FDA in 1995, a few years prior to LASIK. ", "answer": 1}, {"article": "Six months after treatment, the YAG group reported significantly greater improvement in self-reported floater-related visual disturbance (54 percent) compared with sham controls (9 percent).\nThree management options exist for floaters: patient education and observation; surgery; and the laser procedure, YAG vitreolysis, of which there are limited published studies on its effectiveness for treating floaters.\nA total of 19 patients (53 percent) in the YAG laser group reported significantly or completely improved symptoms vs 0 individuals in the sham group.\n\u201cGreater confidence in these outcomes may result from larger confirmatory studies of longer duration,\u201d the authors write.\nSeveral measures of quality of life also improved compared with those in the sham laser group, including general vision and independence.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The journal article makes the claim that it reflects the first prospective, sham-controlled design of laser intervention for eye floaters, an assertion ignored by the release.\u00a0 ", "answer": 0}, {"article": "According to Professor Andrew Worster, also from McMaster University, \"This lab score may reduce both the number of blood tests and time spent in the emergency department for chest pain patients.\"\nPatients with chest pain symptoms require multiple blood tests over several hours before a diagnosis is reached.\nThis could result in the safest laboratory approach for physicians to use at presentation in the emergency department,\" says Dr. Kavsak.\nA positive (or high-risk) clinical chemistry score also identified about 75% of patients at high risk of heart attack or death when positive compared with a low of 40% detected when the high-sensitivity cardiac troponin test alone was positive.\nThe authors suggest the score can be useful for standardizing diagnoses and improving safety.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The novel element here is the strategy of combining three tests into a single scoring system. The news release makes that point clearly.", "answer": 1}, {"article": "The way it works: A doctor draws a vial of your blood and separates it into its key components, the red blood cells, the clear serum and the platelets. The physician then adds vitamins and amino acids to the mix, and the enriched serum is injected into your face.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Readers aren\u2019t given any sense of the novelty of this approach, nor how it compares with other wrinkle treatments. ", "answer": 0}, {"article": "Researchers reviewed data on all patients who have been exposed to JCV who are enrolled in TOUCH, the U.S. Food and Drug Administration-mandated Risk Evaluation and Mitigation Strategy (REMS) program for natalizumab that requires manufacturers to document all uses of a medication to ensure that the benefits of a drug outweigh its risks.\nThere have been 756 PML cases reported worldwide as of January 2018, with a global incidence rate of 4.19 per 1,000 PML cases in people treated with natalizumab.\nThe new study, however, reports safety data through up to 72 months, or 6 years, when the extended dosing regimens were applied, with risk reduction for PML as high as 94 percent.\n\"Our safety findings are clinically and statistically significant, and we believe that extending the dosing schedule of natalizumab is practice changing and may save lives.\"\nHowever, previous research led by Dr. Zhovtis-Ryerson's group found extending the dose up to 8 weeks did not negatively affect the medication's efficacy in a retrospective sample of 2,000 people.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There have been other studies looking at the role of extended-interval dosing (EID) with natalizumab, but the news release does not make it clear if this study is unique in using registry data to explore the relationship between EID and the subsequent development of PML.", "answer": 0}, {"article": "But as for whether they\u2019ll help a client prepare for an important presentation?\n\u201cThe only difference is it\u2019s kind of a beautiful environment.\u201d\n\nCustomers at Evolved Science shell out anywhere from $325 to $875 for an infusion.\nAnd though the IV lends a medical air to the procedure, the infusions suffer from the same problem as many supplements taken orally \u2014 there isn\u2019t any robust evidence to back up their health claims.\nThe ritzy Manhattan medical office \u2014 which says it serves high-powered clients and celebrities \u2014 shakes and stirs up tailored IV infusions using a slurry of vitamins and amino acids.\nThere\u2019s a Jet Lag Eraser, for use after hopping off a long international flight, a Detoxification saline smoothie for \u201cimproving alertness and mental acuity,\u201d and a Late Night Rescue cocktail to undo the effects of too many actual cocktails the night before.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did a good job establishing the lack of novelty.\n\u201cVitamin IV infusions aren\u2019t anything new. Celebrities from Simon Cowell and Rihanna to the Real Housewives have proclaimed their love for vitamin drips. They\u2019re part of a huge \u2014 and wildly popular \u2014 supplement industry which goes largely unregulated. Supplement makers aren\u2019t allowed to claim that their products can cure or treat a particular condition, but they are allowed to make sweeping claims that the products promote health.\nThe infusion treatments can be traced back to an intravenous supplement known as the Myers\u2019 cocktail, a slurry of magnesium, calcium, B vitamins, and other products developed decades ago by a Baltimore physician. There is a published review on the use of Myers\u2019 cocktail \u2014 but it\u2019s just a collection of anecdotal evidence. The author, Dr. Alan Gaby, has long promoted the use of intravenous vitamins for a wide range of clinical conditions.\u201d", "answer": 1}, {"article": "CHICAGO \u2014 Insulin pumps are used by tens of thousands of teenagers worldwide with Type 1 diabetes, but they can be risky and have been linked to injuries and even deaths, a review by federal regulators finds.\nIn the FDA study, appearing in the May issue of the journal Pediatrics, the reports of adverse events and deaths in adolescents using the pumps occurred from 1996 to 2005.\nAt times, the devices malfunctioned, but other times, teens were careless or took risks, the study authors wrote.\nHowever, she said, proper use can improve glucose control.\nThey didn\u2019t advise against using the devices.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This article accurately indicates that insulin pumps have been available and used for many years.", "answer": 1}, {"article": "This showed that they \u201cvalue the relationship more than being right,\u201d Williams said.\nIn analyzing the recordings, Williams identified 10 communication patterns that caregiving spouses used to connect with their partners and show affection.\nA relationship is obviously so much more than that.\u201d\n\nMembers of Williams\u2019s research team visited 15 couples in their home once a week for 10 weeks.\nThey included sharing news about friends or relatives or plans for the day as a way to involve their spouse in day-to-day events; waiting patiently and keeping eye contact while spouses searched for words; and finding alternate ways to communicate \u2014 for example, singing songs together when attempts to engage the spouse in certain topics failed.\n\u201cThe reality is, a person with dementia isn\u2019t going to have a dramatic breakthrough and remember things forgotten,\u201d Williams said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does point out that much of the existing research on communications for caregivers of Alzheimer\u2019s patients has centered on overcoming deficits while this study concentrated on those approaches which seemed to capitalize on successful efforts at enhancing the dialogue between patient and caregiver.\u00a0 That seems novel enough for us to deem this Satisfactory.", "answer": 1}, {"article": "The other groups showed no significant change.\nThe study, published Monday in The Proceedings of the National Academy of Sciences, appears to be the first to link calorie-restricted diets with improved memory in people.\nMembers of a second group kept their calories the same but were instructed to increase the unsaturated fat (healthy fat) they ate by 20 percent.\nStudies with animals have shown memory improvement, but there is debate about the impact of calorie restriction on humans\u2019 cognitive function.\nEating fewer calories may lead to better memory, a new study says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a good job of briefly sketching out the history of caloric restriction testing in animals and people, making clear that caloric restriction is not novel.\u00a0 ", "answer": 1}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\n\u201cThe technique used by researchers in this study enables very early detection of metastatic spread, which would allow adaptation of treatment more quickly and hopefully lead to better outcomes in the future.\u201d\n\nThe study, published online in the Aug. 12, 2015, issue of Nature Communications, was led by Zheng-Rong Lu, Ph.D., CWRU M. Frank Rudy and Margaret Domiter Rudy Professor of biomedical engineering and an expert in molecular imaging for cancer and other diseases.\nUsing a microscopic imaging approach, called cryo-imaging, and MRI, the researchers verified that the MRI technique could detect micrometastases, even observing bone micrometastases that were less than 0.5mm \u2014 the diameter of a very fine pencil lead.\nThese are two things that potentially can make a big impact on clinical practice and also management of cancer.\u201d\n\nOne-third of patients diagnosed with breast cancer eventually develop metastases in distant organs, with an increased risk of death.\n\u201cWe showed with this technique that we can detect very tiny tumors of just a few hundred cells,\u201d Lu said, adding that the study pushed imaging boundaries, revealing smaller cancers than can be detected with current clinical imaging modalities.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release never makes clear what the \u201cnews\u201d is \u2014 that indeed this, according to the researchers, is the first demonstration in animals of a technique that appears to detect micrometastases safely and perhaps better than \u201cgold standard\u201d imaging now in use.", "answer": 0}, {"article": "(CNN) Corey Thomas admitted to his pharmacist that he hated the blood pressure medications a previous doctor had prescribed for him.\nThe history of barbershops as havens for health\n\nIn the years to come, as racial segregation laws limited the spaces where black Americans could gather, the barbershop served as a safe meeting space for the black community.\nShape your hair and your blood pressure\n\nThe new study included 319 black men across 52 black-owned barbershops in California's Los Angeles County.\nThe researchers randomly assigned the men, based on their barbershop, to participate in the pharmacist-led program or to a control group between February 2015 and July 2017.\nAt his barbershop, Thomas said, many customers were hesitant to open up to the pharmacists and doctors and to meet with them for health consultations.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a good job discussing this study in the context of previous research, which has involved the use of barber shops and beauty salons as places where patrons might be receptive to health messages.", "answer": 1}, {"article": "Acupuncture designed to treat depression appears to improve symptoms in pregnant women, suggesting it as an alternative to antidepressant medication during pregnancy, a study found.\n\nThe study, published Monday in the journal Obstetrics & Gynecology, is the largest to date examining the effectiveness of acupuncture to treat depression in pregnant women. It was funded by a grant from the government's Agency for Healthcare Research and Quality. \"Acupuncture that we have tested works for pregnant, depressed women,\"...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains that the study is \"the largest to date examining the effectiveness of acupuncture to treat depression in pregnant women.\"\u00a0 However, the story could have mentioned that the regimen used in the study was a novel regimen specially-designed for the study.", "answer": 1}, {"article": "ZURICH (Reuters) - Novartis will seek regulatory approval this year for a new kind of anti-inflammatory heart drug, though some experts fear fatal infection risks and a high price may overshadow the medicine\u2019s limited benefits.\nThere was no significant difference in the rate of deaths from all causes between the placebo group and those on canakinumab.\n\u201cIn view of the additional oncology findings, we don\u2019t think you should just think about this as a cardiovascular drug,\u201d Narasimhan said.\nNovartis had said in June that the drug met its goal in the study but details were only unveiled at European Society of Cardiology meeting in Barcelona.\n\u201cSome have wondered whether a particularly high-risk subgroup could be identified where canakinumab\u2019s current price can be justified,\u201d he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a pretty good job of explaining what is novel about the the drug\u2019s effects and targeting.", "answer": 1}, {"article": "Researchers have found strong evidence that adenotonsillectomy \u2014 the surgery to remove the tonsils and adenoids \u2014 can help relieve childhood behavioral or attention problems, including attention-deficit hyperactivity disorder, or A.D.H.D.\nAccording to the paper, which was published yesterday in Pediatrics, it has been known that children with sleep disorders often have behavior problems.\nAlthough the surgery has become less common with antibiotics, more than 400,000 children under 15 have their tonsils, adenoids or both removed every year, according to estimates by the Metropolitan Insurance Company.\nCompared with the control group, the children scheduled for adenotonsillectomy were more likely to be hyperactive by their parents' estimates and more likely to experience behavior problems and sleepiness at school.\nThe rest have the operation to relieve breathing difficulty or nighttime sleep apnea, a serious disorder in which the sleeping child briefly stops breathing during the night.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear adenotonsillectomy is not a new treatment for sleep apnea, but that it is a new application when used to treat ADHD.", "answer": 1}, {"article": "\"They did show a higher recurrence or progression rate with endometrial cancer than with AEH and that is consistent with other data,\" said Bakkum-Gamez, who added that the IUD method would not be appropriate for later-stage cancers, which tend to be more aggressive.\nAbout 3 percent to 5 percent of women who get endometrial cancer, which affects the womb lining, are under the age of 40 and will lose their fertility if they undergo a hysterectomy.\nBakkum-Gomez has also used the method in her practice and is conducting a study of the IUD, which was originally designed as a contraceptive device, for this purpose.\nOral hormone treatment to slow down the cancer's growth is a systemic therapy, however, and can have adverse side effects such as skin rashes, nausea and vomiting, headaches and abnormal uterine bleeding, according to background material accompanying the study.\nAlthough the IUD is not yet approved to treat endometrial cancer, it is approved and widely used to treat endometriosis and abnormal uterine bleeding.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly states that the Mirena IUD is not a new idea, but using it to treat early-stage endometrial cancer is relatively novel.", "answer": 1}, {"article": "Jordan says the new findings will quickly change care for some patients.\nShockney asks.\nIn the U.K., tamoxifen costs only $5 a month.\nBreast cancer survivors have mixed reactions to the results.\n\"It's very exciting.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Adequate.", "answer": 1}, {"article": "The only once-and-be-done-with-it option for women has been tubal ligation (\"tying the tubes\") -- surgery that renders a woman sterile.\nUntil then, the patient must use another form of birth control.\nThere is the risk of infection or a puncture of the vagina or uterus while inserting the hysteroscope.\nThere is very little bleeding, and no stitches are needed to close the tiny openings (one on each side).\nAs with tubal ligation, there is also an increased risk of ectopic pregnancy -- a pregnancy that develops outside the uterus.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does state that Essure was relatively recently approved (in 2002) and represents a novel approach to sterility.", "answer": 1}, {"article": "\"Are there people gaming the system?\nThe question comes down to which side of the fence medical professionals fall on\n\nIt's worth noting that oral surgeons make a good chunk of their paychecks by removing wisdom teeth, so there is a financial incentive involved.\nSome think of removing the wisdom teeth early on as a way to lessen the crowding of other teeth\n\n\"You might not have symptoms now, but you can't assume it's gonna be that way for the rest of your life,\" says Dr. Ray White, an oral surgeon working at University of North Carolina.\nThe American Association of Oral and Maxillofacial surgeons says, \"There is no pat answer, cookbook recipe, or flow chart that is universally accepted regarding the decision making process\" in these cases.\n\"Many people don\u2019t have adequate space in their jaw for the teeth to come into full position, but that alone isn\u2019t justification of having them all removed,\" says Dr. Scott Tomar of University of North Carolina's School of Dentistry.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story suggests that this is a long-running debate and there is no attempt exaggerate the newsworthiness of the issue. With that being said, the story could have traced the origins of the debate even further back in time. The story seems to credit a 2007 editorial by Dr. Jay Friedman for sparking current discussion over the risks and benefits of preventative wisdom tooth removal. That may well be the case, but expert groups in the United Kingdom have been recommending against routine removal of wisdom teeth since 1998 at least.", "answer": 1}, {"article": "Risk reduction [was] probably in the range of 80 to 95 percent,\" said researcher Timothy Rebbeck, an epidemiologist at the University of Pennsylvania.\nThat's because all the tissue is never completely taken out.\n\"Breast tissue is found throughout the torso and can't be completely removed through surgical means.\nBreast cancer caused by BRCA mutations is particularly aggressive.\nBut she now feels an emotional empowerment, and that comforts her.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story points out that this latest study is building on earlier work.", "answer": 1}, {"article": "Massage Therapy May Rub It Out\n\nLow back pain is second only to cold symptoms when it comes to complaints that send people to the doctor.\nFor O'Brien-Murphy, the massage-therapy experience has been life-changing: She has traveled to China, where she walked all over without problems, and she's already planning her next trips.\n\"But it may also be there are simply more generalized effects of relaxation \u2014 in the caring and attention and someone laying hands on \u2014 that may all be important.\"\n\"We found that both types of massage were equally effective in helping people improve their function and diminish their symptoms,\" Cherkin says.\nAfter 10 weeks, the results were dramatic: Nearly two-thirds of the patients who received either type of weekly massage said their back pain was significantly improved or gone altogether.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explained one novel feature of the research:\u00a0 \u201cPrior studies of massage for back pain had tested only structural forms of massage, not relaxation massage. But relaxation massage is more widely available, and it\u2019s often less costly.\u201d", "answer": 1}, {"article": "The resource you are looking for might have been removed, had its name changed, or is temporarily unavailable.", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes vague statements meant to distinguish this program from other weight loss approaches, saying it is generally simpler and more fun. However, nothing is presented that shows this approach is novel.", "answer": 0}, {"article": "\"Weight loss was similar but substantial in both groups we studied, but blood pressure improved more in the low-carb dieters,\" said study author Dr. William Yancy Jr., an associate professor of medicine at Duke University Medical Center and a staff physician at the Department of Veterans Affairs Medical Center in Durham, N.C.\n\n\"There are options out there.\nTwo other studies in the same issue of the journal looked at the effects of the DASH diet and a physician-supervised plan.\nThe group taking orlistat received a 120-milligram dose of the drug three times daily and got less than 30 percent of their calories from fat.\nFor advice on selecting a weight-loss plan, visit the National Heart, Lung, and Blood Institute.\nYancy said the blood pressure and cholesterol drops might have been even more impressive if people had stayed on their medications, but as they lost weight and normalized these readings, the doctors took them off blood-pressure and cholesterol drugs.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Neither the diets nor the medication discussed in the story are new, and the story does not suggest that they are.", "answer": 1}, {"article": "She says patients should start asking doctors if they really need a particular CT scan, and if so, whether it can be done with minimal radiation exposure.\n\"For the same body part, the same patient with abdominal pain being evaluated for possible cancer, there can be a profoundly different radiation dose,\" says Dr. Rebecca Smith-Bindman, a radiologist at the University of California at San Francisco who led that study.\n\"Physicians [and their patients] cannot be complacent about the hazards of radiation or we risk creating a public health time bomb,\" says Dr. Rita Redberg, editor of Archives of Internal Medicine, which is publishing the paper in this week's issue.\n\"It's often said that the radiation dose of a chest X-ray is comparable to flying across the continent,\" Smith-Bindman says, referring to natural radiation exposures at high altitudes.\nThe number of scans has increased at a rate of 10 percent a year recently, jumping from 3 million scans in 1980 to more than 70 million a year today.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story highlights the risks associated with the increasingly common use of CT\u00a0scans.\u00a0 This issue is certainly not new.\u00a0 While the two cited articles in the story are important additions to our understanding of the risks, they are not seminal articles by any means.\u00a0 The issue of risk, necessity of testing and dose delivered per test have been discussed in the literature for at least a decade.\u00a0 Nonethless, we\u2019ll give the story a satisfactory score on this criterion. ", "answer": 1}, {"article": "\"Migraine is one of the most disabling conditions known to man, but patients need to know that there is hope,\" says Stephen Silberstein, a neurologist at Thomas Jefferson University in Philadelphia and lead author of the guidelines from the American Academy of Neurology and the American Headache Society.\nThe guidelines do not look at the options patients have once symptoms begin.\nThey were presented at an academy meeting and published in the journal Neurology.\nNot everyone with migraines needs prevention medicine.\nStudies find that just 3% to 13% use the treatments.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story didn\u2019t oversell the novelty of these drugs.", "answer": 1}, {"article": "Alyssa Gold had planned on getting married by age 26 and having kids by age 30 \u2014 but life worked out differently.\nIt\u2019s now being called the \u201cbaby deadline test.\u201d\n\n\u201cThere are some young, healthy women who are living their lives in shape and taking very good care of themselves who might not know that their reserve strength of their ovaries is lower than it should be.\u201d said Dr. Joshua Hurwitz a reproductive endocrinologist and infertility specialist with Reproductive Medical Associates of Connecticut.\n\u201cI was very career-minded and very focused and had relationships throughout my 20s and early 30s, but still wasn't in that forever relationship.\u201d\n\nWomen are born with a finite number of eggs: they start out with roughly one to two million in their ovaries.\nFor years, it\u2019s been a staple in fertility clinics; it\u2019s officially called the Anti-M\u00fcllerian hormone (AMH) test.\n\u201cIt's a question of having the knowledge and awareness of keeping your options open.\u201d\n\nThe test is a simple blood analysis that usually costs less than $100.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story\u00a0did mention that the AMH test is not a new test,\u00a0calling it a \u201cstaple\u201d at fertility clinics. That just passes as Satisfactory.\nHowever, the specific use of the test discussed in the story\u2013as a long-term fertility detection method among women who have no known fertility problems\u2013is a relatively new idea, and that could have been made clearer.", "answer": 1}, {"article": "\"This is outside the box. I've never used it this far out,\" Metz said. \"My radar is up if I see [such an injury] again. As we get more follow-up from David, it will be important to publish this case so people will be aware.\"", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article described that this is not a novel procedure and that hyperbaric therapy has been around since the 1900s.", "answer": 1}, {"article": "\"This is a case report, and not a treatment for anything,\" he said, adding, \"There are risks to this procedure and one has to really look at the tradeoffs.\"\n\"It's a really interesting paper,\" said Dr. Nicholas D. Schiff, director of the Laboratory of Cognitive Neuromodulation at New York-Presbyterian Hospital/Weill Cornell Medical Center.\nAccording to the U.S. Centers for Disease Control and Prevention, high blood pressure affects 30 percent of American adults.\nAbout 10 percent of high blood pressure cases either can't be controlled with medication or patients cannot tolerate them, study author Dr. Nikunj K. Patel, a neurosurgeon at Frenchay Hospital in Bristol, England, said in a journal news release.\nThe finding introduces the possibility that deep brain stimulation -- a surgical implant that delivers electrical pulses to the brain -- might one day become a treatment for drug-resistant hypertension or lead to clues about the brain's role in regulating blood pressure.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The observations discussed in the story about DBS and hypertension are apparently quite novel. The story\u2019s characterization\u00a0of the results is appropriate.\u00a0The story also mentions another novel\u00a0surgical technique known\u00a0as renal nerve ablation\u00a0that might be effective for hypertension that doesn\u2019t respond to medication.", "answer": 1}, {"article": "I would be in my 60s when I had to do this again, and who wants to have surgery unnecessarily when you are 60 something?\"\nFive years ago, revamped products returned to the market.\nHer doctor immediately recommended removing them, which she did.\n\"The actual silicone that's within the implants is inert.\nJust shy of two decades later she noticed something unusual.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "One focus of the story was the June FDA report \u2013 the new angle.", "answer": 1}, {"article": "\u201cThis is a very important claim for us to allow to be incorporated into food labels,\u201d said Dr. Scott Gottlieb, the commissioner of the F.D.A.\nA qualified claim means there is evidence supporting the claim, but it is not conclusive.\nThe label warns that evidence is limited.\nThe product, called Hello, Peanut, can be mixed into pur\u00e9ed baby food to expose infants to peanuts starting around five months old.\nA new powdered peanut product is the first food item allowed to claim it may reduce peanut allergies in infants, though parents of susceptible babies are urged to consult a doctor before trying it.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The main thrust of the story is the novelty of the FDA approving the claim of a health benefit with this product.", "answer": 1}, {"article": "* Anorexia among most common psychiatric disorders in girls\n\nLONDON, March 7 (Reuters) - Scientists have for the first time reported successful use of a brain-stimulating implant to help patients with severe anorexia whose condition had not improved with other treatments.\n\u201c(This) will go some way towards reassuring patients that DBS is not just another treatment designed to fatten them up without making them feel better.\u201d\n\nDBS is used to treat several neurological illnesses including Parkinson\u2019s disease and chronic pain.\nThree months after treatment, the weight loss began to reverse in some patients, and after nine months, three patients weighed more than before treatment - the longest period of sustained weight increase since they had become ill. Around half also had better moods and less obsessive-compulsive behaviour.\nFor their study, a team at the Krembil Neuroscience Centre and University Health Network in Canada identified an area of the brain known to be important when using DBS in depression.\nCommenting on the results of this small trial, Janet Treasure and Ulrike Schmidt of King\u2019s College London\u2019s Institute of Psychiatry said the technique looked promising and would give hope to patients with especially pernicious forms of anorexia.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "For the same reason as our \u201cAvailability\u201d criterion score above, we\u2019ll give a Satisfactory grade because of this line:\n\u201cDBS is used to treat several neurological illnesses including Parkinson\u2019s disease and chronic pain. Scientists are also investigating its use in depression and epilepsy, but this was the first time it had been used in patients with anorexia.\u201d", "answer": 1}, {"article": "Actuarial five-year OS was 95.6 percent for the entire cohort.\nOur trial confirms that SBRT may be preferable to other treatment approaches for newly-diagnosed cases of prostate cancer, including more aggressive disease.\u201d\n\nThe abstract, \u201cFive-Year Outcomes from a Multi-Center Trial of Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer,\u201d will be presented in detail during a scientific session at ASTRO\u2019s 58th Annual Meeting at 7:45 a.m. Eastern time on Monday, September 26, 2016.\n\u201cOur study is the first to contribute multi-center data that support the use of SBRT as front-line therapy for men with prostate cancer.\u201d\n\nA total of 309 men with newly diagnosed prostate cancer were enrolled in the trial at 21 community, regional and academic hospitals across the U.S.\nThe technique has become the standard of care for many non-surgical lung cancer patients, as it limits exposure to the heart and surrounding lungs.\nThe study is the first large, multi-institutional study of SBRT in prostate cancer with long-term follow-up.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release claims novelty with this statement: \u201cOur study is the first to contribute multi-center data that support the use of SBRT as front-line therapy for men with prostate cancer.\u201d But it also states that SRBT for prostate cancer has been studied at other institutions, and that the procedure has become a standard of care for some lung cancer cases. It does not claim that this is a novel procedure.", "answer": 1}, {"article": "In the study, published in the Annals of Internal Medicine, researchers reviewed 83 studies on the two methods.\n\"Based on currently available evidence, it appears reasonable to substitute core needle biopsy procedures for open surgical biopsy given the comparable sensitivity and lower complication rates,\" write researcher Wendy Bruening, PhD, of the ECRI Institute Evidence-Based Practices Center in Plymouth Meeting, Pa., and colleagues.\nIn addition, the study showed women initially diagnosed with breast cancer with needle biopsy were more likely to be treated with a single breast cancer surgery than those initially diagnosed by open surgical biopsy.\nResearchers say needle biopsy has fewer complications and a shorter recovery time than open surgical biopsy, but some women and doctors may have concerns about the accuracy of the procedure compared with traditional open surgery methods of breast cancer diagnosis.\nIn most cases, the lump or lesion is benign or noncancerous and does not require further treatment.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Only by back-door inference (the fact that 80 studies have been done)\u00a0does the reader get any sense that core needle biopsy is not new.\u00a0 Many treatment centers have offered this to average-risk women as an alternative to surgical biopsy for some time.\u00a0 The story mentions that some are hesitant to adopt it, although it is widely used and considered a \"best practice\" and first line biopsy option of many average risk women. We\u2019ll give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a180226S32.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 1}, {"article": "FRANKFURT (Reuters) - Merck KGaA said that its immunotherapy Bavencio, jointly developed with Pfizer, delayed the progression of kidney cancer when used in combination with Pfizer\u2019s Inlyta drug in a late-stage study.\n\nThe drug combination led to longer progression-free survival in patients with advanced renal cell carcinoma (RCC) when compared with a control group on older Pfizer drug Sutent, the German drugmaker said in a statement on Tuesday.\n\nThe trial will continue to show whether Bavencio plus Inlyta also prolongs patients\u2019 lives.\n\nWhile the company said the benefit was statistically significant, they did not specify the duration of progression-free survival. A detailed analysis would be submitted for presentation at a medical congress, it added.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story provides no context for the research. Are there limited treatment options for advanced renal cell carcinoma? Is the joint use of immunotherapy treatments and anti-cancer drugs a busy area of research? How is this work similar to or different from earlier research? The story addresses none of those questions.", "answer": 0}, {"article": "TUESDAY, March 23, 2010 (HealthDay News) -- An ingredient in agave -- the plant used to make tequila -- may help fight bone-weakening osteoporosis and other diseases, Mexican researchers say.\nThe fructans turn into alcohol when agave is processed into tequila, they said.\nThe study was to be presented Tuesday at the national meeting of the American Chemical Society in San Francisco.\nThe National Osteoporosis Foundation has more about osteoporosis prevention.\nBut drinking tequila won't help, the study authors noted.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story briefly mentioned past experimental studies suggesting benefits from fructans. ", "answer": 1}, {"article": "But what about Alzheimer\u2019s?\nThe claim that aspirin can prevent the disease stems from the notion that Alzheimer\u2019s is caused by inflammation that disrupts proteins in the brain.\nOne recent analysis of previous studies found that people who took a low dose of aspirin every day for several years reduced their risk of developing Alzheimer\u2019s by 13 percent.\nIt\u2019s believed that aspirin, and possibly other nonsteroidal anti-inflammatory drugs, may reduce or head off that process.\nAnother study in 2003 in The European Journal of Clinical Pharmacology found a similarly beneficial effect for aspirin and other nonsteroidal anti-inflammatory drugs.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story accurately explained that studies examining whether aspirin can reduce the risk of Alzheimer\u2019s disease have been conducted over a period of time.", "answer": 1}, {"article": "The study started in August 2010.\nThe high efficacy is in line with the results of the ZOE-50 trial, a study in people over 50 years old which was presented and published last year showing a 97% efficacy (95% confidence interval: 93-99%)2.\nIn addition to older adults, the candidate vaccine is being evaluated in immunocompromised patient populations, including solid and haematological cancer patients, haematopoietic stem cell and renal transplant recipients and HIV-infected people.\nThe candidate vaccine combines glycoprotein E, a protein found on the varicella zoster virus (VZV) that causes shingles, with an adjuvant system, AS01 , which is intended to enhance the immunological response to the antigen5.\nAnthony Cunningham, Executive Director of the Westmead Institute for Medical Research in Australia and Principal Investigator of the ZOE-70 study said: \"These data show that this investigational vaccine maintains high efficacy against herpes zoster in people over 70 and 80 years of age, the age groups who are most affected by the disease.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release acknowledges that the \u201cheadline results\u201d of this trial were reported in October 2015. That earlier release focused on the apparent efficacy of the vaccine but did not include any information about safety or side effects. The new PR release provides information about adverse reactions and also notes that the GSK vaccine retains its effectiveness for at least four years, representing an apparent fix to a shortcoming of the already available vaccine.", "answer": 1}, {"article": "The rate for 413 volunteers given placebo treatment was 7.7 percent.\nIn a commentary, Dr. Richard Wenzel of the Virginia Commonwealth University in Richmond said the chlorhexidine-alcohol mixture should replace the older disinfectant when scrubbing people for surgery, and the nasal disinfection technique should primarily be used for people undergoing cardiac surgery, receiving an implant, or whose immune system is likely to be affected.\nThe 504 patients treated with the antibiotic nose gel mupirocin, also known as Bactroban, and washed with chlorhexidine, a common ingredient in mouthwash, developed an S. aureus infection 3.4 percent of the time.\nA second infection study, also reported in the journal, found that a chlorhexidine-alcohol combination produced 41 percent fewer surgical-site infections as the commonly used mixture of povidone and iodine, which gives a yellow-orange tinge to the skin.\nBOSTON (Reuters) - If you\u2019re checking into the hospital for surgery, doctors may soon be swabbing your nose in an effort to prevent an infection from appearing after your operation.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "In our opinion, the story misses an obvious emphasis \u2013 that the drugs and the diagnostic test in question are routinely available, yet their use is not routine in US hospitals. Neither the diagnostic test nor the interventions are new. Yet the story doesn\u2019t give us a good sense of that. ", "answer": 0}, {"article": "In more than 22% of cases, implantable defibrillators are given to heart patients who don\u2019t meet the guidelines for receiving the pricey devices, according to a study just published in JAMA.\n\nThe research, based on 111,707 cases submitted to a national registry over a three-and-a-half-year period, also finds that those patients who didn\u2019t meet the guidelines had a higher risk of dying in the hospital and of complications from the implantation.\n\nICDs, which can cost north of $30,000, monitor the rhythm of the \u2026", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not make clear that this approach is novel.\u00a0Guidelines for the placement of ICD\u2019s have been in evolution for a number of years and have been based on cllinical trials. The use of a registry to identify the clinical outcomes in the real world has been used in a number of scenarios. The information provided by registries provides clinicians with an improved understanding of the value of a technology in a heterogenous patient population. We would have liked to have seen some mention of the intent of the registry in the story.", "answer": 0}, {"article": "\"I have to repent.\n\"There is no data on non-obese humans,\" said Eric Ravussin, chief of health and performance enhancement at the Pennington Biomedical Research Center at Louisiana State University.\n\"There's never been a study like this one,\" said Dr. Evan Hadley, director of geriatrics and clinical gerontology at the National Institute on Aging, which paid for the study.\nIt was probably preserved by evolution because it saved people from starving to death when food was scarce, but it is the bane of dieters because it means that the more weight they lose, the harder it is to keep reducing.\nA six-month study in 48 people directed by Dr. Ravussin, being published today in The Journal of the American Medical Association, is the first rigorous test of calorie restriction in people who are overweight but not obese.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is not a novel \u2018treatment\u2019 for the length of life, notwithstanding the quote from Dr. Hadley from the National Institute on Aging stating that \u201cThere\u2019s never been a study like this one\u201d. This research is actually one of three pilot projects; results of the other two were published in 2005. The story explains that this \u201cis the subject of intense research, and some people have already begun trying it on their own.\u201d And it explains that there is no data in non-obese but overweight people. ", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Tens of thousands of kids may benefit from cholesterol-lowering medication, but no one would know because screening guidelines exclude too many children, U.S. doctors said Monday.\nThe new study tapped into data from more than 20,000 children who had been screened at public schools in West Virginia over five years.\nIn a report published in the journal Pediatrics, they call for screening of all children, expanding one set of current recommendations that target only those whose parents or grandparents have heart disease or high cholesterol.\nNeal said treating youth with cholesterol-lowering drugs, the so-called statins, would curb the risk that they went on to develop heart problems in middle age.\nScreening all children would \u201cidentify a number of children who are of very significant risk of premature heart disease,\u201d said Dr. William Neal of West Virginia University in Morgantown, who led the new study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe novelty of cholesterol screening and treatment is not at issue here.", "answer": 2}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\n\"The nerve root is a sensitive structure that when pinched becomes inflamed and causes pain,\" said lead investigator Alessandro Napoli M.D., Ph.D., an interventional radiologist at Sapienza University of Rome.\n\"The body reacts with muscle constriction, which decreases the distance between vertebrae, and a vicious cycle is created.\"\n\"The probe delivers a gentle electrical energy, so there's no thermal damage,\" Dr. Napoli said.\nWith relaxation of the muscles, the distance between the vertebrae returns,\" Dr. Napoli explained.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Novelty is not established in this release. If the authors had mentioned that there are other minimally invasive procedures and that their limitations led to this new technique, that would have established the novelty of this procedure. It\u2019s not clear how the technique differs from other similar techniques or exactly how the low level energy reduces pain.", "answer": 0}, {"article": "\u201cThere is still quite a bit of work to be done.\u201d\n\nMazzone says the breath functions in the body in much the same way that the exhaust system functions in a car, and what comes out gives a sense of how things are working inside.\nA person\u2019s breath contains a variety of chemical compounds, and it has long been recognized that certain illnesses can affect how the breath smells.\nSimilar research is under way to develop breathalyzer-like devices to detect lung, breast, prostate, and other cancers.\n\u201cBut we are still in the research phase, and there is still the possibility that this technology will never prove clinically useful,\u201d he says.\nIn a new study from Italy, researchers were able to identify patients with colorectal cancer with an accuracy of over 75% by analyzing samples of their breath.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story acknowledges that similar technology is being tested for the detection of other cancers.", "answer": 1}, {"article": "This may predate the onset of other symptoms.\n\u201cBy pinpointing those who are beginning to lose their navigational skills, we hope to show that we can target people at a much earlier stage of the condition and one day become far more effective in treating them.\u201d\n\nThe discovery that loss of navigational skills was associated with Alzheimer\u2019s disease was made several years ago by Chan and colleagues based at several centres in the UK.\n\u201cThe aim of the study is very simple: can we detect changes in brain function before people are aware that they have them?\u201d\n\nResearchers recently pinpointed the significance of a tiny area of the brain known as the entorhinal cortex, which acts as a hub in a widespread brain network that controls navigation.\n\u201cThe entorhinal cortex is the first brain region to show degeneration when you get Alzheimer\u2019s, and that is where we shall be focusing our research,\u201d said Chan, whose work is funded by the Alzheimer\u2019s Society.\n\u201cIt is usually thought memory is the first attribute affected in Alzheimer\u2019s,\u201d said project leader Dennis Chan, a neuroscientist based at Cambridge University.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does note that previous work has been done determining that navigational skills are an early indicator of Alzheimer\u2019s risk. However, the story makes it seem like the use of VR technology is what\u2019s new here. That\u2019s not true. We found studies using VR to assess issues related to navigation ability and Alzheimer\u2019s dating back to at least 2008 and 2009. So, what sets the forthcoming study apart? We wish the story had made that clear.", "answer": 0}, {"article": "The findings were published today in the Journal of Bone and Mineral Research.\n\"The development of osteoporosis drugs by pharmaceutical companies has focused heavily on blocking CatK in recent years,\" said Dieter Br\u00f6mme, a professor in the faculty of dentistry and a Canada Research Chair in Proteases and Disease.\nUsing a compound derived from red sage, UBC researchers have found a way to selectively block an enzyme called Cathepsin K (CatK), which plays a major role in the breakdown of collagen in bones during osteoporosis.\n\"Our compound only locks the collagen -degrading CatK activity, preventing the unregulated breakdown of collagen in bones without any other negative impacts.\"\nThe study builds on previous research by Br\u00f6mme and his team that looked at the effectiveness of red sage, known as Danshen in Chinese and used to treat bone ailments, in stopping the activity of CatK in limited ways.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release states that a compound in red sage may block an enzyme called Cathespin K without the negative effects exhibited by osteoporosis drugs. It also notes that the study builds on the researcher\u2019s previous work that looked at red sage as a treatment for \u201cbone ailments.\u201d It quotes a researcher saying: \u201cAll clinical trials to date have failed due to side effects ranging from stroke, skin fibrosis and cardiovascular issues. We\u2019ve found a way to block CatK only in one tissue that we think will prevent these other negative effects.\u201d This research seems to be unique in that respect.", "answer": 1}, {"article": "Red and purple fruits owe their colors to...\nAlthough it's a challenge to eat the raw fruit without getting a mouthful of seeds and astringent pith, pomegranates are everywhere now in the form of juice, concentrates and extracts, all heavily promoted for better health.\nThe juice is a beautiful wine-red color and tastes delicious.\nMuch of the popularity is the work of a California-based company, Pom Wonderful.\nIt pays researchers to study the benefits of pomegranate juice, gives doctors information on positive studies and, of course, sells pomegranate products.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This article discusses the abundance of pomegranate products now available in the market in addition to the fruit in its uNPRocessed form. There were no claims made about the novelty, only that there are many products. ", "answer": 1}, {"article": "By far, the lowest incidence of colorectal cancers was seen in pesco-vegetarians, people who eat fish at least once a month but eschew all other types of meat. Compared to omnivores, pesco-vegetarians were 43% less likely to be diagnosed with these cancers during the course of the study.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story states that previous studies have explored correlations between diet and colorectal cancer risk, noting that \u201cit\u2019s not exactly surprising that vegetarians fared better than meat-eaters in this study.\u201d", "answer": 1}, {"article": "But confirmation would be good news for the prevention and control of gonorrhea.\nClinical trials will need to be conducted to see if the effect researchers have observed is actually due to the meningococcal B vaccine.\nA new study suggests that a vaccine that protects against a strain of meningitis may also ward off the sexually transmitted infection.\n\u201cA lot of these vaccines have been used widely globally,\u201d Petousis-Harris said.\nFinally, the world might be catching a break when it comes to drug-resistant gonorrhea.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Significance is conveyed in the headline: \u201cVaccine shows protection against gonorrhea for first time, study says.\u201d", "answer": 1}, {"article": "It's a substantial number of women,\" Lyman said.\nIn an accompanying editorial, Grant Walter Carlson and William Wood of Emory University in Atlanta called the study an \"important contribution\" that represents the latest development in breast cancer treatment, which has steadily been moving toward less-aggressive options, sparing women from unnecessary surgery and follow-up therapy.\nThe researchers noted that the study was limited to women with tumors known as T1 or T2, meaning they were relatively small, had no enlarged nodes that could be felt, and the cancer had not spread elsewhere.\nIn the new study, Armando Giuliano of the John Wayne Cancer Institute at Saint John's Health Center in Santa Monica, Calif., and colleagues analyzed data collected from 445 women who had their nodes removed and 446 who did not, along with radiation and chemotherapy.\nThe study, involving nearly 900 women who were treated at 115 sites across the country, found that those who did have their lymph nodes removed were no more likely to survive five years after the surgery than those who did not, the researchers reported in a paper published in the Journal of the American Medical Association.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of the study results were supported by quotes from an editorial that accompanied the study.\u00a0 The editorial referred to the study as an \u201cimportant contribution\u201d and noted the study provided \u201cstrong evidence\u201d that many women can safely forgo complete\u00a0lymph node removal. A representative of the American Society of Clinical Oncology characterized the study as \u201cpractice-changing\u201d and thought the findings will probably prompt ASCO to revise its recommendations for breast cancer patients with T1 or T2 tumors who have positive sentinel lymph nodes.", "answer": 1}, {"article": "ACOG already recommends that women who are at high risk of preeclampsia take a low-dose baby aspirin beginning between 12 and 28 weeks of pregnancy.\nWEDNESDAY, June 28, 2017 (HealthDay News) -- Something as simple as taking a low-dose aspirin every day may protect pregnant women from the life-threatening condition known as preeclampsia, new research suggests.\nThe exact cause of the disorder is unknown, but certain risk factors make it more likely to occur, including:\n\u2022 Being pregnant with more than one baby,\n\u2022 Having chronic conditions, such as type 1 or type 2 diabetes, autoimmune disease and kidney problems.\nIt can affect all of the organs in a woman's body, according to the American College of Obstetricians and Gynecologists (ACOG).\n\"Preeclampsia is one of the most serious complications of pregnancy, with a high risk of death for the mother and baby,\" said senior study author Dr. Kypros Nicolaides.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "What makes this story, and the trial, novel is that this is a higher dosage of aspirin \u2014 although still a low dose \u2014 than had been suggested for use in previous studies.\u00a0 And as a commonly available drug, aspirin seems to offer an easy, and cheap, way to reduce a patient\u2019s risk of developing preeclampsia.", "answer": 1}, {"article": "\"This is a groundbreaking study of extreme importance,\" Joshua Hare, MD, director of the University of Miami's Interdisciplinary Stem Cell Institute, tells WebMD via email.\n\"The improvement we have seen in patients is quite encouraging,\" he says.\nIt's the first time tissue-specific stem cells, other than bone-marrow cells, have been tested in humans, Hare says.\nIt's early -- results are in for only the first 16 patients -- but the results already are drawing praise from experts not easily impressed by first reports.\nThese adult stem cells already are committed to becoming heart cells, but they can transform into any of the three different kinds of heart tissues.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of the treatment is established. \n\n\n\nThe story does note that the technique is new and was developed by one of the researchers.", "answer": 1}, {"article": "For more information about the Cranberry Institute, along with the health benefits of cranberries and current scientific research, visit http://www.\nThe comprehensive meta-analysis and assessment of human clinical trials, published in the official journal of the American Urological Association, The Journal of Urology\u00ae, assures practitioners and their patients that cranberry products are a low cost, low risk and effective way to help prevent recurrent UTIs.1\n\nTo answer the question, \"Can Cranberries Contribute to Reduce the Incidence of Urinary Tract Infections?\"\nThe review explains that the medicinal properties of cranberries may be attributed to their unique polyphenol, proanthocyanidins - or PACs, for short.\nThe industry appreciates the efforts of these researchers and takes pride in the healthy attributes that cranberry products provide to consumers around the world,\" comments Terry Humfeld, executive director of the non-profit research and education-focused organization, The Cranberry Institute.\n\"Our investigation supports that cranberry products can be a powerful tool to fight off frequent UTIs,\" explains lead author, Dr. \u00c2ngelo Lu\u00eds.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This is not the first journal article to review the available research on whether cranberry consumption can help to prevent recurrent UTIs \u2014 only the most recent. See, for example, previous reviews from 2012 and 2007. The release does not refer to these previous reviews or make clear how this most recent review article advances our understanding of the subject.", "answer": 0}, {"article": "Companies like DexCom in San Diego now make small continuous glucose monitors whose sensors can be embedded in the skin.\nIndeed, even if device makers are able to develop fully automated prototypes of combination systems, they are likely to face regulatory hurdles, analysts said, and would have to factor in product liability concerns.\n\u201cThis is something that companies have been striving to do for years, and as computer chip technology evolves, it gets closer,\u201d said Rick Wise, an analyst at Leerink Swann, a health care investment bank.\nThe study not only indicated that the algorithm system prevented very low glucose overnight, Dr. Hovorka said, but it also indicated that the experimental system was better able to keep blood glucose in an acceptable range.\nBased on algorithms like the ones used in the Lancet study, the devices would continually monitor glucose levels, calibrate insulin dosages and then dispense insulin in real time \u2014 automating a delivery task performed by a nurse in the study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story describes the progression from skin prick glucose testing to continuous monitoring and insulin pumps. It places the new developments in this field on this continuum. There could have been\u00a0more discussion of many of the recent advances that have made daytime hyper- and hypoglycemia less of a problem such as\u00a0the newer short-acting insulins.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070603/11back.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "A reader might reasonably infer that the treatments described in the news story are not new, since the new studies seek to clarify an old question.", "answer": 1}, {"article": "About 15% of people with MCI develop full-blown Alzheimer's disease each year.\nThis is equivalent to drinking several cups of coffee a few hours before giving blood.\nAlzheimer's disease is the most common type of dementia.\nAccording to the findings, people older than 65 who had higher blood levels of caffeine developed Alzheimer's disease two to four years later than their counterparts with lower caffeine levels.\nCoffee was the main, or only source, of caffeine among people in the study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The independent expert notes that there are other studies supporting a possible beneficial effect of coffee on Alzheimer\u2019s disease.", "answer": 1}, {"article": "Until more research is in, what should a woman with a personal history of breast cancer do?\n\"There are some tumors that don't show up on mammography as well as they do on MRI,\" he explained.\n\"The findings are impressive,\" said Dr. Robert Smith, director of cancer screening for the American Cancer Society.\nCurrently, the American Cancer Society recommends annual breast MRI plus mammography for women at very high risk for breast cancer, such as those with a known genetic mutation known as BRCA or those with a very strong family history.\nStudying the effectiveness of MRI screening on all three groups of women, Dr. Wendy DeMartini, an assistant professor of radiology at the University of Washington Medical School, said MRI imaging found proportionally more cancers in women who had been treated for breast cancer than in the women considered at very high risk.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\n\nThe story does not include any claims that MRI scanning for breast cancer is a new test. It could have done a better job of telling readers that there have been many, many studies of MRI for breast cancer. It does not maker clear what is new about the information provided by this study.", "answer": 2}, {"article": "To learn more, visit stjude.org or follow St. Jude at @stjuderesearch\nThe team, led by Thirumala-Devi Kanneganti, Ph.D., a member of the St. Jude Department of Immunology, published their findings in a recent issue of the journal Cell.\n'Since reduced AIM2 activity in colorectal cancer patients is associated with poor survival, it might be useful to detect the level of AIM2 expression in polyps taken from colonoscopy and use this as one of the biomarkers for prognosis,' Kanneganti said.\nHowever, AIM2's established function in the cell was not in the machinery of cancer, said one of the paper's first authors Si Ming Man, Ph.D., a postdoctoral fellow in Kanneganti's laboratory.\n'We believe that this finding has important clinical relevance because we can potentially prevent or decelerate the progression of colorectal cancer in humans, especially in those who have mutations in the AIM2 gene, by simply giving them 'good' microbiota.'\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release basically reports on findings about one protein that plays a role in immunity and therefore, may have some significance in the progress of colon cancer.\u00a0 But the release couches all its information in the context of that disease, lending support that may be unwarranted to their hypothesis.\nWhile we\u2019re concerned about this characterization, the release does make clear that this work fits into a larger body of work on the role of AIM2 in the immune system and the role of gut bacteria in protecting against colorectal cancer. So we\u2019ll award a Satisfactory on that basis. However, it would have been great to get a little more information \u2014 for example, on how this fits into other recent work indicating that the gut microbiome could be used to screen for colorectal cancer or pre-cancerous polyps.", "answer": 1}, {"article": "\"This smartphone reader has the potential to improve access and speed up healthcare delivery,\" said Li.\nThe researchers tested the device, which is about the size of a hand, with 771 patient samples at Hospital of University of Pennsylvania and found that it provided false positives only about one percent of the time (was 97. to 99.9 percent accurate).\nThe smartphone reader, which includes a portable device, takes a photo of 96 sample wells at once and uses a computer program to carefully analyze color to determine positive or negative results.\nIf they send results off to a lab in a distant city, the doctors sometimes must wait for days -- by which time the infection may have become widespread.\n\"If we find out about infections, we can treat them more quickly, which makes a difference especially in low-resource, remote areas.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Although the release does not claim this device is the first or most advanced of its kind, it conspicuously avoids mentioning similar devices. A quick search of PubMed.gov and other online sources reveals a number of reports on similar products being tested at competing institutions including UCLA and Macquarie University in Australia. The release does not explain how this device compares to others.", "answer": 0}, {"article": "Please use our search feature and update your bookmarks. Thank you!", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Although the release mentions previous studies by the UCLA investigator dating back to 2002, the timeline for the relevance of some\u00a0findings is somewhat confusing, and it would have been useful to mention that the current data were substantially presented in 2014.", "answer": 0}, {"article": "CHICAGO\u2014Using whole-brain radiation to treat cancer that has spread to the brain is a treatment that for many patients is worse than the disease, a new study suggests.\n\nResearchers said the technique, when used after a more precise radiotherapy to kill the cancer, resulted in more memory loss and other cognitive deficits than treating with radiotherapy alone. While the more aggressive treatment was better at preventing recurrence of tumors in the brain, it didn\u2019t extend survival.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story cites one independent source as saying that this is the \u201cmost comprehensive study that lets us quantify the risk/benefit\u201d of whole-brain radiation treatment. However, the story would have been stronger if it had addressed some of the other research going on in regard to whole-brain radiation treatment. As this 2013 paper notes, concerns over the toxic effects of whole-brain radiation treatment have prompted a lot of studies in recent years. A quick search of ClinicalTrials.gov found more than 30 open studies on whole-brain radiation, so this is clearly an area of high interest to the research community. Even a cursory discussion of recent and ongoing work in the field would have made the story stronger.", "answer": 1}, {"article": "A new study finds that supplementing the Mediterranean diet with more olive oil or more nuts helps diminish age-related decline in cognitive function. Photo: Getty Images\n\nThe Mediterranean diet, supplemented with a handful of nuts or a few tablespoons of olive oil a day, can counteract the effects of aging on the brain\u2019s ability to function, a new clinical study suggests.\n\nThe study, published online Monday in JAMA Internal Medicine, was unusual in that it employed rigorous scientific practices to test the effect of the diet on health. Most previous evidence showing benefits from the Mediterranean diet was gathered through observational studies, a less conclusive research technique.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Very good explanation here. The story notes that \u201cprevious observational studies suggested that adhering to a Mediterranean-type diet [is] related to better cognitive function and a reduced risk of dementia.\u201d The story quotes the lead researcher as saying that \u201cthis is the first clinical, randomized study using a dietary pattern for good health.\u201d\nIt\u2019s worth noting that the study authors measured compliance through urine tests of the metabolites of the olive oil and nuts. One reason it\u2019s so difficult to do dietary studies is because compliance is so hard to monitor.", "answer": 1}, {"article": "CHICAGO (Reuters) - A computerized brain training program cut the risk of dementia among healthy people by 48 percent, U.S. researchers said on Sunday in reporting an analysis of the results of a 10-year study.\nThe preliminary findings, presented at the Alzheimer\u2019s Association International Conference in Toronto, are the first to show that any kind of intervention could delay the development of dementia in normal, healthy adults.\nResults of that study, published in 2014, found modest benefits in the reasoning and speed-of-processing groups, but not memory.\n\u201cI do think we will know more after the paper is reviewed.\u201d\nIn the speed training, which emphasized visual perception, individuals were asked to identify objects on a screen quickly.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The findings reported may be the first to show that\u00a0an intervention using brain games could \u201cdelay the development of dementia in normal, healthy adults.\u201d", "answer": 1}, {"article": "But TMS is expensive.\nBeginning Saturday, Medicare will cover the treatments when other therapies have failed.\nBeginning Saturday, Medicare will cover the treatments when other therapies have failed.\nA clinical trial funded by the National Institutes of Health revealed a \"significant effect of treatment\" when patients received TMS treatment.\n\"Most people are not scared of it,\" she said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that the device approved in 2008 is novel as is the underlying approach to treating depression", "answer": 1}, {"article": "Given those drawbacks, it\u2019s not appropriate to draw too many conclusions from this study, says Dr. Diane Harper, a prominent HPV researcher at the University of Missouri \u2013 Kansas City\u2019s School of Medicine.\nThe phase 1 results are very early in the experimentation of this vaccine.\nThe vaccine consists of three injections in the arm over three months, Kim said.\nThe experimental vaccine does not use the live HPV virus; it is formulated in synthetic DNA and pure water.\nAlso, 18 people is a small number for examining the effects of a medication.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear that the novel part is development of a vaccine using DNA only.", "answer": 1}, {"article": "\u201cAn aneurysm in no way means that you're going to die.\n\"The use of 3-D printing to personalize aortic repair is fascinating,\" said Dr. Ramesh Gowda, director of interventional cardiology at Mount Sinai Beth Israel.\n\u201cI\u2019m unsure where the technology will go but it is a very fascinating discovery.\u201d\n\nAfter her surgery, Berg is now back to back to enjoying her life.\nWhen they would open me up [the aorta] could just blow.\u201d\n\nThe bulge in the large artery that carries blood away from the heart can be immediately life-threatening if it grows large enough to rupture.\nIf an AAA is found, doctors sometimes use a stent to repair the aorta, but it doesn't always work since the aneurysms are often in places where a stent can\u2019t fit.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains that the approach allows a surgical team to \u201ccreate an individualized model of the patient\u2019s aorta.\u201d\n\u201cEach anatomy of the patient is different and that\u2019s the problem, that\u2019s why we need stents that are actually specific for the patient,\u201d it quotes vascular surgeon Dr. Gustavo Oderich, MD, saying. \u201cThe 3-D prints are used to rehearse the operation. We can anticipate challenges by practicing the procedure beforehand.\u201d", "answer": 1}, {"article": "Tomei, a self-proclaimed animal lover, expressed that the effort is close to her heart.\nSometimes, individuals with CDE have trouble opening their eyes, but Tomei said she went to the doctor and reported mild but incessant itchiness and dryness, and was diagnosed with CDE.\nIf you think you may be suffering from CDE, Tomei advised visiting your doctor to receive a diagnosis.\nThe quiz on Restasis.com can help individuals learn whether they\u2019re a candidate for the drug.\n\u201cIt was as simple as going to the doctor, getting a prescription and trying RESTASIS\u00ae,\u201d Tomei, 51, who stars in the upcoming \u201cSpider-Man: Homecoming\u201d movie, told FoxNews.com.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "How does this product differ from the other cyclosporine ophthalmic solutions on the market? This article does not tell us.", "answer": 0}, {"article": "For more information about Red Journal, visit www.redjournal.org.\nToxicity rates were extremely low, with essentially no major complications encountered in this initial group of 58 patients.\u201d\n\nWhile findings highlight the potential tolerability of a single fraction of HDR brachytherapy for localized prostate cancer, the article also emphasizes the need for additional follow-up to compare long-term cancer control rates with conventional treatment approaches, which generally administer larger cumulative doses than the 19 Gy dose used in this trial.\n\u201cWe found that patients generally can resume normal activities the following day with typical side effects.\u201d\n\nThe study, which appeared in the Red Journal\u2019s January 2017 issue, presented the results of a nonrandomized, prospective clinical trial of 58 patients with low- or intermediate-risk (non-metastatic) prostate cancer, with a median follow-up period of 2.9 years.\n\u201cWhile additional study and longer follow-up are necessary to confirm the optimal dose for single-fraction HDR brachytherapy, we are optimistic that the single-treatment approach can eventually become a standard practice for prostate cancer treatment.\u201d\n\nFor more information or a copy of the full study, contact ASTRO\u2019s media relations team at press@astro.org.\nNewswise \u2014 ARLINGTON, Va., March 1, 2017 \u2013 Results from a new prospective clinical trial indicate that high-dose-rate (HDR) brachytherapy administered in a single, 19 Gray (Gy) treatment may be a safe and effective alternative to longer courses of HDR treatment for men with localized prostate cancer.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release suggests that this is a new strategy based on new research but that doesn\u2019t appear to be the case.\nAccording to UpToDate, an evidence-based list of practice recommendations published by Wolters Kluwer, use of single, high dose brachytherapy for prostate cancer is not novel: \u201cThe HDR brachytherapy dose is usually administered in one to four large dose fractions over a period of time, typically 24 to 40 hours. Patients receiving more than one fraction are usually admitted to the hospital (typically a 23 hour \u201coutpatient stay\u201d) for treatment when delivering multiple fractions and retain the perineal catheters in place for the entire period.\u201d", "answer": 0}, {"article": "Patients were randomised to receive the combination of anti-TNF\u03b1 and anti-IFN?\nFlorence, Italy - 9 July 2016: Immunotherapy reduces cardiovascular risk in patients with rheumatoid arthritis, according to research presented today at Frontiers in CardioVascular Biology (FCVB) 2016 by Professor Aida Babaeva, head of the Department of Internal Medicine, Volgograd State Medical University, Volgograd, Russia.1 The combination of two extra-low dose anticytokine drugs reduced rheumatoid arthritis disease activity and cardiovascular events.\nThe incidence of cardiovascular events (unstable angina, severe hypertensive crisis, and deterioration of chronic heart failure) was more than double in the group on conventional disease-modifying drugs alone (37%) compared to those also taking the combination of anticytokines (13%).\nFor example, rheumatoid arthritis is associated with dysfunction of the blood vessel lining (called endothelium), which leads to lipid accumulation in the artery wall, plaque formation and atherosclerosis.\nIn patients with highly active disease, the standard biologics are better at preventing severe complications such as progressive joint destruction and/or systemic manifestations (vasculitis, uveitis, involvement of internal organs).\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This might be worth the benefit of the doubt. The news release does not misrepresent the novelty of the approach and the lead investigator asserts that not all rheumatoid arthritis patients should be using this combination, saying \u201cIn patients with highly active disease, the standard biologics are better at preventing severe complications such as progressive joint destruction and/or systemic manifestations (vasculitis, uveitis, involvement of internal organs).\u201d\u00a0 It appears that the use of the \u201cextra low\u201d doses are simply a novel use of standard drugs, possibly in patients who would never have used the drugs in the past.", "answer": 1}, {"article": "Though randomized controlled clinical trials of bright light are difficult to do properly \u2014 one expert is fond of saying that it is difficult to \u201cblind\u201d studies of bright light \u2014 the American Psychiatric Association considers bright-light therapy an effective low-risk treatment for both S.A.D.\nFace the light but do not stare at the light.\nSome say their patients don\u2019t have the patience to sit in front of a light for 30 to 45 minutes every morning.\nIf you choose to try light therapy, here are a few tips from experts.\nBut while bright-light treatment is helpful, he said, it is not sufficient for him.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t make any inappropriate claims about the novelty (or lack thereof) in light therapy.", "answer": 1}, {"article": "\"Cluster headache is a rare, debilitating and difficult to treat disorder with few effective acute therapies,\" Dr. Stephen Silberstein, director of the headache center at Jefferson University in Philadelphia, said in a statement.\nThe company, which says gammaCore is already available in the European Union, expects to start selling it later this year in the U.S.\n\nVagus nerve stimulation is used to treat a range if disorders, including epilepsy, depression and overeating.\nThe device is a vagus nerve stimulator and it\u2019s not entirely clear how it works.\n\"The FDA release of gammaCore is an important advance in the treatment of the pain associated with cluster headache,\u201d Silberstein said in the statement provided by the company.\nThe idea is to disrupt signals that run along the vagus nerve, a giant nerve that runs from the brain all the way to the colon.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article focused on the FDA\u2019s approval of the device as the news hook. It did not repeat the manufacturer\u2019s claim that the device is the first of its kind.", "answer": 1}, {"article": "Besides M.D.\nI can remember when doctors all rushed to adopt the Prostate Specific Antigen test, and we still don't know how to use it.\u201d\n\nLu acknowledged there are comparisons to the PSA test, which has come under fire in recent years for being better at detecting prostate cancer than improving survival.\nThe protein, known as CA-125, has not been good at identifying new early-stage ovarian cancer because it can become elevated for other reasons, leading to false positives.\n\u201cIf the study's findings are confirmed in larger studies, I think this new strategy will be practice-changing.\u201d\n\nThe method used in the nine-year study of 3,252 initially healthy postmenopausal women caught five ovarian cancers, three of them invasive.\nAnd if I can be saved, so can other people.\u201d\n\nThe study results were unveiled Thursday in advance of a major cancer conference next month.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "CA-125 is not new, as it is used to monitor and guide treatment for existing ovarian tumors. Its use as a screening tool for ovarian cancer is highly controversial. What is new is the idea of using a model and CA-125 testing over time to predict risk for ovarian cancer.", "answer": 1}, {"article": "BOSTON (Sept. 14, 2016) -- Although targeted drugs like Gleevec have revolutionized the treatment of chronic myelogenous leukemia (CML), patients generally must take them for the rest of their lives and may cease benefiting from them over time.\nIn laboratory experiments, the Dana-Farber/Boston Children's researchers found not only that Ezh2 is overabundant in leukemia stem cells but that it helps them survive and give rise to full-fledged CML cells.\nDrugs that target the protein are currently being tested in clinical trials for other cancers.\nIt offers a promising approach to shortening the duration of therapy in order to achieve a cure.\nAlthough second- and third-line targeted therapies can often return the disease to remission, some patients don't benefit from these drugs or develop severe side effects.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does a decent job of teeing up the connection between\u00a0the leukemia cells that drive CML and\u00a0a\u00a0biological pathway that\u00a0an existing drug might be able to target.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Robots may not help doctors do a better job on some surgeries, according to a new study.\nBut all I need to do is add 5 and 5.\u201d\n\nEspecially in a time of concern over rising medical costs, \u201cwe should not simply use the highly sophisticated technology just because it\u2019s there,\u201d Falcone said.\nWith the surgeon alone, \u201cthe incision is smaller (and) the manipulations are more controlled,\u201d Dr. Ceana Nezhat, an author on the study and the chair of Obstetrics & Gynecology at Northside Hospital in Atlanta, told Reuters Health.\n\u201cWe were surprised that (surgery with the robot) did not have better outcomes than (the surgeon alone), as we have always believed if you can see more and see better you can do more and do better,\u201d the authors write.\nUsing a robot for basic surgery, like the kind studied here, would be like using a computer to do addition, he told Reuters Health.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty here is that the humans beat the robots. It would have been nice to see at least a sentence about whether other studies had shown similar results with other types of surgeries. Was this the first man-vs.-machine study of this kind?", "answer": 0}, {"article": "But there are dangers to this approach.\n\u201cIt was not known that inflammation was a common feature of different types of epilepsy.\u201d\n\nNormal brain function is regulated by the glial cells, which protect neurons and induce an inflammatory response if the brain is injured.\n\u201cThe challenge for the next few years is to find out the limitations, the boundaries, the real mechanisms.\u201d\n\nStill, whatever the role of inflammation in epilepsy, Elisa Moller says that anti-inflammatories were a miracle intervention for her son.\nIt\u2019s not known what sets off a seizure, but lately scientists like Dr. Devinsky have been gathering evidence that inflammation, the immune system\u2019s response to injuries or foreign organisms, plays a pivotal role.\nBut this response also can contribute to seizures, some experts believe, either because components of the immune system stimulate neurons or because the glial cells\u2019 capacity to regulate the brain is diminished when they become \u201cdistracted\u201d by an injury.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There is one claim of novelty in the story. It says, \u201cThe amount of inflammation in the brain correlates with the frequency of seizures, she also has found. \u2018This is a novel finding,\u2019 Dr. Vezzani said in an interview. \u2018It was not known that inflammation was a common feature of different types of epilepsy.\u2019\u201d Given some of the other information in the story connecting inflammation to autopsy, we\u2019re unclear on how this particular finding is novel. We give Dr. Vezzani the benefit of the doubt, but we wish that an independent source had been tapped to verify this claim of novelty.", "answer": 1}, {"article": "News releases can also be found at http://www.\nThe case report highlights the journey a 39-year-old female endurance runner took from the end of her post-knee surgery rehabilitation to taking part in her sport again.\nIn a report titled Return to running following knee osteochondral repair using an anti-gravity treadmill, published in the journal Physical Therapy in Sport, Dr Hambly demonstrates how a graduated return to running using an anti-gravity treadmill can help to reduce fears about re-injury and increase self-belief in being able to run on the injured knee.\nThe Sports Ready clinic is student-led under supervision of experienced practitioners, with patients self-referring or sent by private clinics and NHS orthopaedic consultants.\nThe air pressure in the treadmill can be adjusted to take the patient from 100 per cent of their body weight to only 20 per cent, the same feeling as walking on the moon, and reducing the impact and pressure on joints during the run.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t tell us how this case study yields anything new beyond the previous research completed on anti-gravity treadmills used in rehabilitation.", "answer": 0}, {"article": "MONDAY, Feb. 15, 2010 (HealthDay News) -- People with high-functioning autism or Asperger's syndrome were better able to \"catch\" social cues after inhaling the hormone oxytocin, new research shows.\nOne study found that autistic people seem to have a lower sensitivity to oxytocin than people without the disorder.\nPrior studies have shown a strong effect of oxytocin on people with autism, as well as on people who are not on the autism disorders spectrum.\nThe new study, led by Angela Sirigu at the Center for Cognitive Neuroscience in Lyon, France, was published in this week's issue of Proceedings of the National Academy of Sciences.\nWhen observed playing a virtual ball game, individuals who had inhaled oxytocin were able to interact better with their virtual partners compared to untreated participants.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article notes that there have been prior studies that also demonstrated an effect of oxytocin in people with autism.", "answer": 1}, {"article": "Replacement, by contrast, preserves some range of motion.\n\"The last time I had an injection in my wrist, it was so painful, I thought I was going to have to pull over coming home and have someone else come and drive,\" she recalled.\n\"The cost is that you don't have the ability to lift heavy objects,\" Collins said.\nMore than a dozen bones lie beneath the skin and muscles of the hand and wrist, compared with two or three for those larger joints.\nUnder low-wear conditions, doctors expect joint prosthetics to last 10 to 15 years, another reason replacement might not be considered for younger people.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story points out that wrist replacement surgery has been around for decades. The story\u2019s single source of medical information\u2014a surgeon\u2013suggests that newer versions of the implants enable surgeons to retain more of the patient\u2019s native bone. ", "answer": 1}, {"article": "NEW YORK (Reuters) - Johnson & Johnson\u2019s Stelara helped a significantly higher percentage of Crohn\u2019s disease sufferers than those who received a placebo, according to a study of patients who had not been helped by other commonly used drugs.\nCommon symptoms are abdominal pain and diarrhea, and it can lead to bowel perforations.\nClinical remission was defined as a CDAI score down to 150.\nThose who received 1 mg/kg had a 36.6 percent response rate and the 3 mg/kg dose led to a 34.1 percent response rate.\nMany Crohn\u2019s patients require surgery when medicines no longer control symptoms.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 1}, {"article": "Newby and his team assessed how CTCA affected symptoms and quality of life six weeks and six months after the scan for 4,146 patients with suspected angina due to coronary heart disease.\n\u201cCertainly, this is something we now discuss in more detail with our patients, some of whom have declined CTCA.\u201d\n\n\u201cIt was striking for me that health status was very much related to receiving a (treatable) diagnosis or excluding such a diagnosis, rather than experiencing angina symptoms per se,\u201d said Dr. Paula M. C. Mommersteeg from the Center of Research on Psychology in Somatic Diseases, Tilburg University, The Netherlands, who has investigated associations between personality traits and coronary artery disease symptoms.\nWhen the CTCA results revealed something less than a blockage, so-called nonobstructive disease, as the cause for the patient\u2019s chest pain, patients\u2019 quality of life got worse in the following weeks and months.\n\u201cIn my opinion, CTCA does have added value in the diagnostic process (improved decision making), it is less invasive than coronary angiography (CAG), and can provide more clarity in the cardiac symptoms experienced by patients,\u201d Mommersteeg concluded.\n\u201cIf, however, a patient presents with atypical symptoms and is on no therapy, then the clinician needs to discuss with the patient the implications of potential CTCA findings, including nonobstructive disease that would mandate life-long preventative therapy,\u201d Newby said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story appropriately characterizes the research as providing new data on how patients feel, their symptoms and quality of life, depending on whether or not CTCA was used to further clarify their chest pain diagnoses. It does not claim that CTCA is itself new. It would have been nice to see some reference to other research into the quality of life of chest pain patients, especially whether counseling or the ways doctors communicate with patients have an effect on these measures.", "answer": 1}, {"article": "Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.\nCoolSculpting for the double chin is already clinically proven to reduce fat up to 20 percent in the treated area after one treatment.1\n\n\"Allergan is committed to advancing innovation for CoolSculpting\u00ae to meet the needs of patients seeking non-invasive aesthetic treatments,\" said David Nicholson, Chief Research and Development Officer at Allergan.\n\"A 2017 American Society for Dermatologic Surgery (ASDS) survey revealed that 73 percent of patients are bothered by excess fat under the chin.2 We are pleased this patient concern can successfully be addressed by CoolSculpting through a non-invasive approach, and furthermore improve the appearance of lax tissue in the treated area.\"\nThese factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS\u00ae, on our financial results; uncertainty associated with financial projections, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended September 30, 2017.\nIn the U.S., the CoolSculpting procedure is FDA-cleared for the treatment of visible fat bulges in the submental area, thigh, abdomen and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll), and upper arm.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "We don\u2019t think Allergan can claim novelty with this product since other non-surgical, FDA-cleared fat reduction technologies like Kybella (also made by Allergan) are already on the market.\nThe news release, as well as the CoolSculpting website, states this is the \u201cfirst and only non-surgical fat reduction technology to be FDA-cleared for improved appearance of lax tissue in conjunction with submental fat, or double chin, treatments.\u201d\u00a0 We also consider Kybella to be a \u201cnon-surgical fat reduction technology\u201d that was on the market before the CoolSculpting treatment. Therefore, we rate this one Not Satisfactory.", "answer": 0}, {"article": "However, Richmond says patients considering viscosupplementation should discuss this as a treatment option with their doctor.\nDr. John Richmond disagrees.\n\"This is not a first line treatment, but it's a reasonable treatment in those people who have been appropriately screened.\"\n\"This needs to remain one of those limited treatment options and should be used appropriately by the physician giving it.\"\nThe authors of the study discourage patients from getting this treatment.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "No claims of novelty were made.", "answer": 2}, {"article": "\"The first importance of the trial is that it shows hepatic [liver] targeting of hormonal action,\" Ladenson said.\nUse as a single drug treatment for elevated cholesterol levels could follow, first in selected patients, then more widely, he said.\nThe American Heart Association has more on cholesterol-lowering drugs.\nHe said that significant reductions of blood levels of those fats were seen in the trial.\n\"The second exciting part is its impact on lipids other than LDL cholesterol.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story didn\u2019t put this study into the context\u00a0 of other research on alternatives to statins. ", "answer": 0}, {"article": "The study was published Dec. 21 in the New England Journal of Medicine.\nWEDNESDAY, Dec. 21, 2016 (HealthDay News) -- A shorter period of antibiotic treatment for ear infections in young children does more harm than good, a new study finds.\n\"The results of this study clearly show that for treating ear infections in children between 9 and 23 months of age, a five-day course of antibiotic offers no benefit in terms of adverse events or antibiotic resistance,\" Hoberman said.\n\"Given significant concerns regarding overuse of antibiotics and increased antibiotic resistance, we conducted this trial to see if reducing the duration of antibiotic treatment would be equally effective along with decreased antibiotic resistance and fewer adverse reactions,\" Dr. Alejandro Hoberman said in a university news release.\n\"Though we should be rightly concerned about the emergence of resistance overall for this condition, the benefits of the 10-day regimen greatly outweigh the risks,\" he added.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story doesn\u2019t make it clear that researchers are trying to hone in on specifically how best to treat younger kids with ear infections, compared to older kids.", "answer": 0}, {"article": "What to do?\nHowever, the study also found that those risk factors -- a small body frame, a history of fractures, or taking medications that could thin bones -- had only a slight effect on a woman's decision to get her bones tested.\nThe researchers looked at whether or not women were getting a dual-energy X-ray absorptiometry (DXA) test, which measures bone mineral density.\n\"Health systems should invest in developing electronic health records systems that prompt providers at the point-of-care when screening is needed and when it can be postponed,\" study senior author Joshua Fenton, an associate professor of family and community medicine at UC Davis, said in the news release.\nMeanwhile, it was common among women at low fracture risk, such as younger women without osteoporosis risk factors,\" Amarnath said in a journal news release.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The study notes that, \u201cto our knowledge, the degree of DXA overuse across an entire screening population has not been reported.\u201d But the story does not tell us that.", "answer": 0}, {"article": "For more industry information, health research and recipe ideas, visit http://www.\n\"The simple message from this study is that eating an overall healthy diet, including certain foods, such as walnuts and other whole foods, may help women with the ability to do key everyday tasks as they age, like carrying groceries or dressing themselves.\"\n\"These results add to the large body of evidence that outline the many benefits of a healthy diet for women.\n(1)\n\nThis paper emphasized that overall diet quality, rather than individual foods, may have a greater impact on reducing risk of physical function impairments.\nIt is also possible that subjects may have misreported their dietary intake since this information was collected by questionnaires.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release does not overstate the novelty of the study. It provides this quote from a researcher: \u201cThese results add to the large body of evidence that outline the many benefits of a healthy diet for women.\u201d", "answer": 1}, {"article": "To learn more, visit http://www.\nThe paper, The Sternum-Nipple Distance is Double the Nipple-Inframammary Fold Distance in Macromastia, is published Ahead-of-Print online in the Annals of Plastic Surgery.\nOn that basis, the authors recommend that techniques such as the Boston modification of Robertson technique should be preferred by surgeons seeking to avoid pseudoptosis.\nBy measuring the sternal notch-nipple distance and the nipple-inframammary fold distance ( proxies for upper and lower sensory ligament strength, respectively), the study found a differential rate of stretch - for every 1 cm in upper sensory ligament stretch, the lower sensory ligament length increases by 0.45 cm.\n\"This study is one of the largest breast anthropometry (measurement) studies ever performed,\" says Lau.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t claim that the research is the first but it does state its \u201cone of the largest breast anthropometry (measurement) studies ever performed.\u201d We agree the study appears to be one of the largest reviews and does add to the literature on the subject.", "answer": 1}, {"article": "WEDNESDAY, July 13, 2011 (HealthDay News) -- For men who have prostate cancer that's considered \"intermediate risk,\" radiation plus four months of hormone therapy appears to improve survival, a new study finds.\nYou need to give long-term androgen deprivation therapy in addition to radiation to have the best results,\" Jones said.\nThe hormone therapy is known as androgen deprivation therapy.\nHe noted that the radiation treatments in use today differ from those given in 1994 when the trial began.\nIt could be four months, six months or longer.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear that the treatments in the study, with some modification, are currently available.", "answer": 1}, {"article": "Dr Francoise Soussaline, PhD, DSc, IMSTAR's president said: \"To bring a universal 'liquid biopsy' blood test for cancer to market, it must achieve a number of criteria, including high sensitivity and specificity and be fully automated with high throughput for a medical routine use.\nIn addition, test results must be available in 24hrs and at affordable cost.\nThese findings are published in FASEB BioAdvances journal.\nThe Bradford team had scored 100 cells per slide, but the Pathfinder\u2122 system is able to analyse up to 10,000 cells per slide, and uses Artificial Intelligence concepts in its proprietary software.\nThe longer the comet tail, the more DNA damage is present, which correlates with the presence of cancer.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release establishes what makes this test unique.", "answer": 1}, {"article": "Nov. 24, 2016.\nThis information opens the door to using decitabine in a more targeted fashion to treat not just older patients, but also younger patients who carry TP53 mutations.\u201d\n\nFirst author John Welch, MD, PhD, an assistant professor of medicine, added: \u201cIt\u2019s important to note that patients with an extremely poor prognosis in this relatively small study had the same survival outcomes as patients facing a better prognosis, which is encouraging.\n\u201cThe findings need to be validated in a larger trial,\u201d Ley added, \u201cbut they do suggest that TP53 mutations can reliably predict responses to decitabine, potentially prolonging survival in this ultra high-risk group of patients and providing a bridge to transplantation in some patients who might not otherwise be candidates.\u201d\n\nIn an accompanying editorial, Elihu Estey, MD, an AML expert at the University of Washington Medical Center and Fred Hutchinson Cancer Research Center in Seattle, noted that AML is not one disease but many, each driven by different genetic mutations.\n\u201cIt\u2019s exciting to think we may have a therapy that has the potential to improve response rates in this group of high-risk patients.\u201d\n\nThe research is supported by an AML-SPORE grant and the Genomics of AML Program Project grant, both from the National Cancer Institute at the National Institutes of Health (NIH), grant numbers P50 CA171963 and P01 CA101937.\nWe don\u2019t yet understand why patients with TP53 mutations consistently respond to decitabine, and more work is needed to understand that phenomenon.\u201d\n\nResponses to decitabine are usually short-lived, however, with remissions typically lasting for about a year.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release claims that patients with a specific gene mutation may live longer if treated with a less intensive chemotherapy drug. A researcher is quoted saying: \u201cWhat\u2019s really unique here is that all the patients in the study with TP53 mutations had a response to decitabine and achieved an initial remission.\u201d\nWhile the drug is not novel, its usefulness in treating this population of patients with a typically poor prognosis is a novel application.", "answer": 1}, {"article": "So mystery and grief hung heavy when he collapsed from a cardiac arrest Jan. 6 inside the Teutonia M??\nThe heart quits pumping blood, leaving vital organs depleted of oxygen -- a situation that can cause significant damage to the brain, kidneys and other organs, or death if quick emergency action is not taken.\n\"We believe the people who do go home have fewer neurological problems that impair the quality of life,\" Dr. Callaway said.\n\"My goal is to get back to a normal life,\" he said, noting he hates cold weather and is surprised he withstood hypothermic therapy.\nA heart attack can prompt cardiac arrest -- a situation in which the heart rhythm goes chaotic, making it quiver rather than beat, Dr. Granato said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It is not clear from this story whether this is a new treatment or just a newly introduced treatment at this particular hospital. \nThe story stated \"The American Heart Association has approved the procedure in the wake of extensive overseas clinical trials\", however at the American Heart Association web site, there is mention of this treatment from a media advisory of February 20, 2002 \u2013 more than five years ago. \nAnd the American Heart Association doesn't technically \"approve\" any procedures \u2013 making this a simplistic, naive and inaccurate statement in the story.\u00a0 ", "answer": 0}, {"article": "It\u2019s easy to get into the habit of popping a pill to have a good night\u2019s sleep. Insomnia, which affects a third of adults, becomes more common as we age.\n\nBut as evidence has mounted about the risks of drugging the brain to induce or maintain slumber, more doctors are steering patients away from sleep aids, including over-the-counter medications, and are offering innovative behavioral-change solutions.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story\u00a0does not suggest that cognitive behavioral therapy is new. It does, however, refer to the relatively new (as of May 2016) American College of Physicians guidelines recommending cognitive behavioral therapy over drug treatment for insomnia.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Taking extra vitamin D and calcium doesn\u2019t seem to prevent bone-thinning in older men, according to Australian researchers.\nThey measured the men\u2019s bone density before and after the study, which took place over 18 months, but they didn\u2019t look at fractures.\nOtherwise it might fall apart.\u201d\n\nSOURCE: bit.ly/i4tDqs The Journal of Clinical Endocrinology and Metabolism, online January 5, 2011.\nAt the end of the study, men who exercised had higher bone density than those who had supplemented their diet with 1000 milligrams of calcium and 800 international units (IU) of vitamin D per day.\nIn animal studies, a lack of vitamin D has been linked to several diseases, such as multiple sclerosis and some types of cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There was room for improvement here.\u00a0 The story could have done a better job of putting the new finding into the context of past research in this field.", "answer": 0}, {"article": "\"It is extremely common for patients with AF to seek treatment that does not involve the use of chronic oral anticoagulants therapy, as there are other risks associated with their long term use,\" said co-author Francis E. Marchlinski, MD, FHRS, director of Electrophysiology for the University of Pennsylvania Health System and Richard T. and Angela Clark President's Distinguished Professor in the Perelman School of Medicine at the University of Pennsylvania.\nPatients were provided with novel oral anticoagulants and were instructed to start taking the medication if they suspected or detected an AF episode lasting longer than one hour.\nOf these patients, 84 had been ablated, sixteen were being treated with drug therapy, and three had implanted devices that served as a quality control check.\nOral anticoagulation therapy is recommended in patients with infrequent AF and high risk of stroke, however, prolonged use of blood thinners is associated with a higher bleeding risk.\nNo patients experienced a stroke or transient ischemic attack - also called a mini-stroke -- and there was only one mild bleeding incident that required medical attention.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The \u2018novelty\u2019 here is in approach and the researchers were fair in describing what is authentic novelty.", "answer": 1}, {"article": "Men who received the combination of surgery and radiotherapy had higher rates of erectile dysfunction (28 percent vs 20 percent) and higher rates of urinary incontinence (49 percent vs 19 percent).\nA comparison of 2 of the most common combination therapies for locally advanced prostate cancer show the more aggressive option is linked with a higher rate of survival\n\n(Philadelphia) - High-risk prostate cancer, that which has continued to grow but not yet metastasized, is commonly treated with combination therapies.\nIn the largest population-based retrospective study to date, Dr. Lu-Yao and colleagues examined the records of 13,856 men in the Medicare-SEER registry diagnosed with locally advanced prostate cancer -- cancer growth that had not yet metastasized to distant sites in the body.\nSeveral large clinical trials are nearing completion that should validate these retrospective findings of the benefits of primary radical prostatectomy followed by additional therapies such as adjuvant radiation,\" said Leonard Gomella, Chair of the Department of Urology at Jefferson (Philadelphia University + Thomas Jefferson University), who was not involved in this research.\n\"However, the proportion of men undergoing prostatectomy plus radiation therapy decreased significantly over time and there were trade-offs for the survival advantages,\" said Dr. Lu-Yao.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release stated: \u201cFor the first time, researchers have shown that more patients live longer if treated with the combination of prostate removal plus radiation therapy.\u201d\nIt also called this \u201cthe largest population-based retrospective study to date\u201d and mentioned that \u201cseveral large clinical trials\u201d on the topic are nearing completion.\nWhile some of these descriptions tend to inflate the importance of the study, those concerns have been addressed elsewhere.", "answer": 1}, {"article": "Total hip replacement surgery is increasingly common, with more than 300,000 procedures done every year in the U.S.\nAccording to research done by the American Academy of Orthopaedic Surgeons, there are no significant differences between either approach in recovery outcomes six months after surgery.\n\"The people who are against the whole idea for same-day discharge for hip replacement are concerned about the very rare instances where somebody could develop a blood clot that goes to the lung, or a fracture of some sort,\" said Davidovitch.\n\"While I recognize there is no place like home, should there be the need for urgent or medical care the question is will that be available to the patient when they're in the setting of their own home,\" Padgett said.\nBut it's not the surgical approach alone that allows some of his patients to go home the same day -- it's a combination of what happens before, during and after surgery.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story implies \u201csame-day\u201d hip replacement is new. While the practice is becoming more common, it is part of a long-term gradual trend toward shorter hospital stays, rather than a sudden break with past practice. In fact, reports on the technique note that over a decade ago some hip replacement patients were discharged the same day. The impression that NYU Langone Medical Center has a new type of procedure appears to be more marketing spin than medical fact.", "answer": 0}, {"article": "\u2018What insanity is that?\u2019 Hundreds of NC children are being killed or injured by guns.\n\nDid you realize that in the past five years, hundreds of teens and youth have been killed or hurt by gunfire in North Carolina? Here\u2019s what some say you can do about it.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story said that FluMist was \"new,\" approved by the FDA in 2003. ", "answer": 1}, {"article": "Loading up on fiber-fortified processed foods isn\u2019t likely a good way to increase the kind of fiber that benefits the gut.\n\u201cWe discovered that the patients who exhibited higher amounts of were the patients who had a very strong improvement in cholesterol, in glycemia, in waist to hip ratio and also a reduction in different parameters in both cardiovascular disease and risk factors.\u201d\n\nHigher levels of , the findings suggest, seem to have favorable effects on health.\n\u201cOur diet and deteriorated microbiota are really a major piece of the puzzle in trying to understand why Western diseases are rising like crazy.\u201d\n\nSonnenburg says that when researchers try on mice what many of us do on a regular basis\u2014eat food depleted of dietary fiber\u2014their gut microbes behave erratically.\nBoth groups of people lost the same amount of weight, but the high- group had a stronger decrease in visceral fat than the others, says study author Patrice D. Cani, PhD, professor and group leader of the Metabolism and Nutrition Research Group at Universit\u00e9 Catholique de Louvain in Belgium.\n\u201cThat means if you\u2019re not eating dietary fiber, your immune system may be existing in kind of a simmering pro-inflammatory state,\u201d he says\u2014the very state that predisposes us to different Western diseases.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear that the recent BMJ study is part of a larger field of work evaluating both the role of gut bacteria in human health and the role of dietary fiber in influencing the make-up of the gut microbiome. (It even links to another study on fiber and the American diet.) However, the story would have been stronger if it had included slightly more information, or links to additional information, that would have helped readers place the new work in context.", "answer": 1}, {"article": "\"Although media coverage of the early release of data from the STAR trial suggests a clear 'winner' in raloxifene, the data from clinical endpoints and patient-reported symptoms suggest a less clear conclusion,\" Dr. William J. Gradishar and David Cella of Northwestern University wrote in an editorial in the medical journal.\nThe new data are not likely to settle the debate about which drug is better.\nThere was no overall difference between the drugs in the women's self-rated physical health, mental health or depression.\nBut Dr. Ganz said that side effects of both drugs were generally mild and that it was important that women at high risk of breast cancer take one of them.\nBut hot flashes, vaginal bleeding, bladder control problems and leg cramps were more common in the women who took tamoxifen, while pain during sexual intercourse and joint pain were more common in the raloxifene group.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It is clear from the story that neither drug is new.", "answer": 1}, {"article": "Contrary to earlier reports, giving acetaminophen (Tylenol, etc.)\n\"We found no matter how you slice it, there was absolutely no difference between Tylenol and Motrin,\" says senior investigator and corresponding author Wanda Phipatanakul, MD, MS, of Boston Children's Hospital's Division of Allergy and Immunology.\n\u2022 The percentage of days with full asthma control were virtually the same for acetaminophen and ibuprofen: 85.8 and 86.8 percent, respectively.\nThe 18-site study should settle a debate that originated when several retrospective studies seemed to indicate that children had exacerbations of their asthma when receiving Tylenol for pain and/or fever.\nSince the study was limited to young children with mild persistent asthma receiving asthma controller therapy, the authors also note that their findings may not apply to other age groups or children with more severe asthma.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Boston Children\u2019s Hospital was clear in explaining how this study contributes to the existing body of literature. In other words, what\u2019s \u201cnew\u201d about this study is that it \u201cis the only blinded, randomized, controlled trial to date to prospectively compare acetaminophen head-to-head with ibuprofen (Motrin, etc.) in children with asthma.\u201d The news release adds that it should settle the debate on whether taking acetaminophen for pain and fever worsens asthma symptoms in children.\nWe applaud this clarification and give the news release a Satisfactory rating here.", "answer": 1}, {"article": "Brian Alexander (www.BrianRAlexander.com) is co-author, with Larry Young Ph.D., of \"The Chemistry Between Us: Love, Sex and the Science of Attraction,\" (www.TheChemistryBetweenUs.com), now on sale.\nThis kind of work is important not just for prostate cancer, but all cancers.\nThe more of the 12 a man had, the greater his chances of radiation therapy complications.\nPatients were assessed every three to six months for signs of sexual dysfunction for up to five years.\nThis early-stage study represents a big step toward doctors and their patients making that decision.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Using genetic markers to determine the risk of treatment-related complications is novel.", "answer": 1}, {"article": "He was not involved in the research.\nIt\u2019s documentation that these techniques really work.\u201d\n\nAlthough 77 percent were judged by the Tripathi team to be seizure-free at the end of the study, some of those children actually had seizures immediately after surgery.\n\u201cMany could go back school earlier or go back to being tutored, and get on with their life.\u201d\n\nBut a major problem facing these children is getting insurance companies to pay for such surgeries, said Dr. Schomer of Beth Israel.\n(Reuters Health) - Brain surgery for children whose epilepsy is resistant to drug therapy can produce a 10-fold increase in the odds of being seizure-free after one year and can do it without affecting IQ, according to a new Indian study of 116 patients in The New England Journal of Medicine.\nBut even before surgery, some of them have this weakness.\u201d\n\nOther side effects depended on the area of the brain that was removed or disconnected from the rest of the brain.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article notes this is the first trial of its kind in children. This appears to be accurate. There have been very few randomized trials (a recent Cochrane review found only four, and only one compared surgery to medical therapy); there is a recent trial (ERSET) that went down to age 12, but was almost all in adults. One point that\u2019s important to note: There is nothing in the study to support the statement that the earlier surgery is done, the better; only that this shows that it appears to substantially decrease seizure frequency in children, as it has been shown to do in adults.", "answer": 1}, {"article": "But another finding from that study sheds an interesting light on one of 5-Hour Energy\u2019s central claims \u2014 that the energy shot, unlike competitors\u2019, produces \u201cNo Crash Later.\u201d\n\nAccording to the study, 24 percent of test participants who received 5-Hour Energy had reactions similar to a \u201cmoderately severe crash that left them extremely tired and in need of rest, another drink or some other action,\u201d lawsuit filings show.\nWhatever the case, the energy drink boom has come full circle in Asia, the region where it started.\nBut she declined to say why the results of the study, which was apparently conducted five years ago, had not yet appeared.\nShe added that another study showing the benefits of 5-Hour Energy was undergoing \u201cpeer review\u201d for possible publication in a scientific journal.\nAsked whether consumers mistakenly believe that the shot does not produce a caffeine-related crash, Ms. Lutz said that the use of the special mark and its explanation were clear.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story traces\u00a0the history of energy drinks in considerable detail.", "answer": 1}, {"article": "For more information about the School of Medicine, see http://www.\n\"In addition to providing a new treatment option for patients with treatment-resistant, moderate to severe COPD, the new results also are important because they identify a potential biomarker for the disease and demonstrate that eosinophilic inflammation plays a role in flare-ups in COPD,\" Sciurba said.\nThe new study reports the results from two Phase III clinical trials evaluating the efficacy of mepolizumab, an antibody treatment that reduces the number of eosinophils in the blood, in moderate to severe treatment-resistant eosinophilic COPD by blocking the pro-inflammatory effects of interleukin-5.\nSimilar to METREX, the exacerbation rate was reduced by 20 percent in the high eosinophil group after 100 milligrams of mepolizumab.\nIn a second, simultaneous trial, termed METREO, the team assessed the effect of a higher dose of mepolizumab in 675 patients with elevated eosinophil levels.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release claims that the study showed that eosinophilic inflammation plays a role in flare-ups in COPD, that mepolizumab provides \u201ca new treatment option for patients with treatment-resistant, moderate to severe COPD,\u201d and that the study identified a potential\u00a0 biomarker for the disease.\nIf this research proves that the drug mepolizumab is effective in these patients, then surely it is novel enough for a news release, but the results would require a larger confirmatory study to assure that.", "answer": 1}, {"article": "LONDON (Reuters) - Scientists have developed an eye implant that allowed three blind patients to see shapes and objects within days of treatment in a trial and say the device could become routine for some kinds of blindness in five years.\nAfter the light detection stage, it uses the eye\u2019s natural image-processing functions to produce a stable visual image.\n\u201cWe have shown that people can be provided with enough useful vision for daily life,\u201d he said in a telephone interview.\nTests were conducted starting from seven to nine days after the device was implanted.\nIt\u2019s of phenomenal significance in that regard,\u201d he told Reuters.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of the device is established.", "answer": 1}, {"article": "\"Previous patients got sick, but it wasn't clear at the time whether it was due to the T cells or an infection,\" said pediatric oncologist Stephan Grupp, who oversaw Emily's care at Children's Hospital of Philadelphia. \"Now we know the main reason they were sick was the cells. But now we can intervene. She taught us.\"", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions that 20 years of\u00a0studies\u00a0involving genetically engineering T cells preceded this research.", "answer": 1}, {"article": "Cowen & Co estimates that use of DNA blood tests for cancer screening will exceed $10 billion a year by the end of the decade.\nA positive test will require additional checks to find where the cancer is growing.\nThe tests must be ordered by a doctor, based on a patient\u2019s risk profile.\nDoctors will also need a clear assessment of their accuracy.\nThe company is focusing on mutations that are relatively well-understood, and for which there are specific treatments, said Chief Executive Jim Plante.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes what\u2019s novel about the test compared with existing tests.", "answer": 1}, {"article": ", and receive monthly highlights by signing up at http://www.\n\"Inflammation plays a critical role in acute and chronic tendon injuries and healing,\" said Chang H. Lee, Ph.D., a researcher involved in the work and an assistant professor at the Regenerative Engineering Laboratory (Columbia University Irving Medical Center, New York).\n\"Many would have predicted that tendon healing is inflammation-linked,\" said Thoru Pederson, Ph.D., Editor-in-Chief of The FASEB Journal, \"but that the anti-inflammatory roles of TSCs could be so potent, and so amplifiable, is a striking finding.\"\nIt is the world's most cited biology journal according to the Institute for Scientific Information and has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century.\nThe researchers found that CTGF stimulation induced TSCs' production of anti-inflammatory cytokines, consequently leading to improved tendon healing and matrix remodeling.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes a claim of novelty with this statement: \u201cMany would have predicted that tendon healing is inflammation-linked,\u201d said Thoru Pederson, Ph.D., Editor-in-Chief of The FASEB Journal, \u201cbut that the anti-inflammatory roles of TSCs could be so potent, and so amplifiable, is a striking finding.\u201d\nIt also suggests the research is a building block for future research. A\u00a0co-principle investigator is quoted saying the work is \u201can important foundation for the development of a new treatment.\u201d", "answer": 1}, {"article": "SUNDAY, March 1, 2015 (HealthDay News) -- A procedure that delivers the anesthetic lidocaine (Xylocaine) directly to nerves in the back of the nasal cavity appears to offer significant relief to migraine sufferers, preliminary research indicates.\nAnd, he said, the hope was that lidocaine would essentially short-circuit that bundle's headache-causing pathway.\nThe day after the procedure, average migraine pain levels had dropped from about 8 to just over 4.\nThe participants all underwent a session of \"image-guided therapy,\" in which a spaghetti-sized catheter was inserted through a nostril and into the nasal passage to deliver a dose of lidocaine to a nerve center known as the sphenopalatine ganglion.\n\"When a body gets used to having a chronic headache suppressor, the patient can experience a rebound in the absence of that suppressor.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Lidocaine as a drug intervention to treat migraines is not a new concept. Here is a similar study from 1999, in which patients suffering from migraines received drops of 4 percent lidocaine in their nostrils. The story didn\u2019t mention this context.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070225/5disease.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly states that Lucentis is a novel approach to treating wet AMD.", "answer": 1}, {"article": "Abby's father, Edward Schwartz, fears that this tool would just add to a child's anxiety about the testing process.\nThis was another small study -- 20 dyslexic volunteers and 21 participants without the condition -- testing how people identify shapes, navigate a virtual environment, and do other tasks involving spatial reasoning.\nIf made widely available, this kind of brain scan could be an important complement to the assessments -- based on reading and behavior -- already available for diagnosing dyslexia, Hoeft said.\nHere's another insight about dyslexia: men with the condition may have enhanced visual-spatial abilities, according to a study in the journal Learning and Individual Differences.\n\"The kids (are) much more likely to feel like they're broken in some way,\" Schwartz said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story implies that this study is the first to suggest young people with dyslexia use a certain area of the right hemisphere of their brains more than average readers. Actually, the study authors pointed out that their research provides some additional data to support the findings of many other studies of differences between the brains of people with dyslexia and those who read normally.", "answer": 0}, {"article": "The U.S. Preventive Services Task Force (USPSTF) says there is no proof that the benefits of routine mammogram screening outweigh the risks for average-risk women in their 40s.\n\"What we are seeing is that women with mammogram -detected breast cancer require less treatment,\" Malmgren tells WebMD.\n\"Let's say 10,000 women in the world were going to die of breast cancer that developed in their 40s,\" Brawley tells WebMD.\nThe women were carefully followed since their diagnosis in 1990 to 2008, says study co-leader Judith A. Malmgren, PhD, president of Seattle's HealthStat Consulting.\nThe finding comes from a careful study of nearly 2,000 women diagnosed with first-time breast cancer at age 40 to 49.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story never clearly established what\u2019s new or different or newsworthy about this latest study in a long string of studies on this topic.\u00a0 In fact, as already noted above, it never even mentioned that the study was comparing breast cancer tumors detected by patient/doctor to those detected by mammograms.", "answer": 0}, {"article": "The study of nearly 32,000 people in eight countries boosts hope that early detection by CAT scans may reduce the death toll of lung cancer, much as mammography has done for breast cancer.\nMany of these lump-shaped masses were watched with further scans to see whether they grew; others were examined with other imaging devices.\nOnly 15 percent of people with the disease survive five years from the time it is diagnosed.\nAbout 13 percent of the baseline scans and 5 percent of the later ones found abnormalities.\nWhat it will take to prove that CAT scans are either useful or a waste of time and money is a matter of great controversy.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story states that screening for lung cancer is not a new idea, but that screening with CAT scan is relatively new.", "answer": 1}, {"article": "Does it cross her mind what would have happened if she didn't have the ultrasound?\nBut this study - the most definitive so far - may encourage more doctors to consider ultrasound, which is easier and less expensive.\nAnd it's an important story, because about half of women under the age of 50 are found to have dense breast tissue when they get their mammograms.\nIn today's study of about 2,809 women with dense tissue and other risk factors, mammography alone found only half of the cancers.\n\"This could have gone on for years before anybody found it, and it could have been a whole different story,\" she said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It is not the usual standard to do any other screening (aside from mammogram) in women with dense breast tissue situations, except for super high-risk BRCA carriers who now get MRI as well. Ultrasound is already available, as implied in the story, and not a new method of treatment. The study provides good evidence of the value of ultrasound as an additional screening tool. ", "answer": 1}, {"article": "This abstract can be found at sirmeeting.org.\nBut GAE provides another option for patients struggling with pain and may even allow patients to avoid the painful recovery of knee surgery and the need for the kind of opioid pain medications associated with the dangerous epidemic in the United States.\"\nThe Society of Interventional Radiology is holding its Annual Scientific Meeting March 17-22, 2018 at the Los Angeles Convention Center in Los Angeles, Calif. Visit sirmeeting.org.\nAs an outpatient treatment, GAE does not require open surgery or physical therapy, and takes 45-90 minutes to perform.\n\"This procedure could have a significant impact in the treatment of osteoarthritis pain as a whole,\" said Bagla.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t claim novelty. It states that the research \u201cbuilds on the growing international research around GAE and osteoarthritis.\u201d", "answer": 1}, {"article": "A minimally invasive procedure designed to shrink prostate tissue with a series of nine-second blasts of steam offers men a new treatment for urinary symptoms commonly associated with enlarged prostates.\n\nThe procedure, called Rez\u016bm (pronounced \u201cresume\u201d) and developed by NxThera Inc. of Maple Grove, Minn., became widely available in the U.S. in the second half of 2016. Thermal energy in the form of steam is applied to the prostate with a needle. As it cools it releases heat energy into the tissue, killing cells and shrinking...", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u00a0isn\u2019t clear what makes this treatment novel, nor why the story is running now. Rez\u016bm has been on the market for since last year, and the related research was published more than four months ago. Maybe it\u2019s because two major health insurance companies decided earlier this month to cover the treatment?", "answer": 0}, {"article": "GW Pharmaceuticals funded the clinical trial.\nThe study included a liquid pharmaceutical formulation of CBD, called Epidiolex, which is manufactured by GW Pharmaceuticals and has not been approved by the U.S. Food and Drug Administration.\nIn addition to Dr. Devinsky, the co-authors in this study were: J. Helen Cross, PhD, FRCPCH, Linda Laux, MD, Eric Marsh, MD, Ian Miller, MD, Rima Nabbout, MD, Ingrid E Scheffer, MD, PhD , Elizabeth Thiele, MD, and Stephen Wright, MD on behalf of The Cannabidiol in Dravet Syndrome Study Group.\n\"Cannabidiol should not be viewed as a panacea for epilepsy, but for patients with especially severe forms who have not responded to numerous medications, these results provide hope that we may soon have another treatment option,\" says lead investigator Orrin Devinsky, MD, professor of neurology, neurosurgery, and psychiatry and director of the Comprehensive Epilepsy Center at NYU Langone Medical Center.\n\"We still need more research, but this new trial provides more evidence than we have ever had of cannabidiol's effectiveness as a medication for treatment-resistant epilepsy.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that this was \u201cthe first large-scale randomized clinical trial for the compound,\u201d adding that the results were both statistically and clinically significant. The release is timed with the publication of the trial results in the New England Journal of Medicine.\nMuch of what is found in the release was reported in the New York Times on March 14, 2016, but that story noted that full study data was not yet available.", "answer": 1}, {"article": "The resulting test hones in on these and the existing 100 known markers to pinpoint the 1 percent of men who are at six times greater risk of developing the condition, and the 10 percent of men who have a threefold greater risk of developing the disease, a study author told The Guardian.\nIt\u2019s a conversation that could save their life,\" he said.\nScientists have developed a spit test that could identify the men most at risk of developing prostate cancer.\nIf it is found to be effective, it could be an important tool for physicians.\nThe condition is rare in those below the age of 40; older men and African-Americans are most at risk.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story accurately reported that this is a \u201cnew method\u201d of detecting risk of prostate cancer.", "answer": 1}, {"article": "This study was presented at a medical conference.\n\"A key question now is to work out which patients will benefit from the drug -- clearly, some patients do and some don't,\" Johann de Bono, MD, PhD, of the U.K.'s Royal Marsden NHS Foundation Trust, says in a news release.\nAnd while the average patient survived only four months longer than those on standard chemotherapy -- 14.8 months vs. 10.9 months -- some patients did much better.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\nIt appears that abiraterone is able to shut down androgen production not only in the testes, but also from the adrenal gland and from within prostate tumors themselves.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story didn\u2019t provide any meaningful context about possible novelty of this approach.\u00a0 Again, let\u2019s turn to the competing Wall Street Journal story for comparison.\u00a0 It reported:\u00a0\"Androgen hormones, particularly testosterone, fuel prostate tumors. Conventional hormone therapy blocks androgens produced by the testes. Abiraterone appears to target androgens also produced elsewhere, even by the tumors themselves, said Dr. de Bono, who presented the study in Milan.\"\u00a0 This story only told us that \"It appears that abiraterone is able to shut down androgen production not only in the testes, but also from the adrenal gland and from within prostate tumors themselves.\"\u00a0 But that statement stands in isolation without any comparison to existing hormonal approaches. ", "answer": 0}, {"article": "A complex and expensive pacemaker-defibrillator can significantly improve the chance for survival among the tens of thousands of heart-failure patients with only mild symptoms, according to a major, multiyear clinical study.\n\nThe research, regarded as likely to change medical practice, showed that the device to \"resynchronize\" the hearts of such patients lowered the death rate by 29% in such patients over 40 months, compared to those who had a standard defibrillator implanted.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that there are multiple companies pursing a similar device and that one is already on the market.", "answer": 1}, {"article": "That's when they learned cocoa compounds named epicatechin monomers enhanced beta cells' ability to secrete insulin.\nBut here's the thing: BYU researchers have discovered certain compounds found in cocoa can actually help your body release more insulin and respond to increased blood glucose better.\n\"These results will help us get closer to using these compounds more effectively in foods or supplements to maintain normal blood glucose control and potentially even delay or prevent the onset of type-2 diabetes,\" said study co-author Andrew Neilson, assistant professor of food science at Virginia Tech.\nBut rather than stocking up on the sugar-rich chocolate bars at the checkout line, researchers believe the starting point is to look for ways to take the compound out of cocoa, make more of it and then use it as a potential treatment for current diabetes patients.\n\"You probably have to eat a lot of cocoa, and you probably don't want it to have a lot of sugar in it,\" said study author Jeffery Tessem, assistant professor of nutrition, dietetics and food science at BYU.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes near the bottom that this study advances earlier research by identifying a compound that improved beta cell function. However, the lead about chocolate misleads readers by implying there is something new about studying the effects of cocoa extracts on beta cells, even though the journal article includes a long list of previous research on the topic.", "answer": 1}, {"article": "While the disease is rare, with about 3,100 new diagnoses and 330 deaths in the United States each year, it often goes undiagnosed until it affects vision. Sacks \u2014 known for books including Awakenings and The Mind's Eye, in which he tells the story of his own cancer \u2014 said his symptoms hit suddenly, wiping out a triangular chunk of the vision in his right eye.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that Aura Biosciences chose to test the experimental drug on ocular melanoma because there currently is no drug useful in treating this disease. It says that the drug\u2019s artificial viral nanoparticles have been shown to \u201czero in on and bind to many types of malignant cells without harming normal cells\u201d \u2013 but only in lab experiments, which suggests that the drug\u2019s use in humans is new.", "answer": 1}, {"article": "from Washington University School of Medicine.\nAlthough further study is needed, these results highlight the importance of adrenergic receptor-\u03b22 (ADRB2), a signaling pathway important to ovarian carcinogenesis and targeted by NSBBs (versus the ADRB1 pathway targeted by SBBs).\nThere are currently two clinical trials, one led by MD Anderson, evaluating the combination of chemotherapy and propranolol (a type of NSBB) on cancer biology and on stress modulators in patients with newly diagnosed EOC.\nPublished today in the journal CANCER, the findings are the result of a multi-institutional retrospective analysis of the medical records of 1,425 women with ovarian cancer treated between 2000 and 2010.\nIn a first-of-its-kind study, researchers demonstrate a benefit in overall survival among epithelial ovarian cancer (EOC) patients receiving generic heart medications known as beta-blockers.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Several previous studies have examined the impact of beta blocker use on EOC patients, and did not find the same prolonged survival rates that are reported on in this release. The journal article addresses this by noting that those studies did not appear to distinguish between SBBs and NSBBs \u2014 and that the different modes of action for those drugs has a significant impact on how they affect EOC patients during treatment. But the idea of evaluating the impact of beta blockers on EOC treatment is neither new nor limited to the researchers at MD Anderson.", "answer": 0}, {"article": "More information can be found at http://www.\n\"This could ultimately change the way we diagnose concussions, not only in children, but in anyone who sustains a head injury,\" said Papa.\nThe organization is home to the area's only Level One Trauma Centers for adults and pediatrics and is a statutory teaching hospital system that offers both specialty and community hospitals.\nWhat makes them unique is that they pass the blood-brain barrier and enter the bloodstream, making them easy to detect with this particular test.\nThese proteins are found in glial cells, which surround neurons in the brain, and when an injury occurs, the GFAP are released.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release claims novelty through this statement, \u201cWe have so many diagnostic blood tests for different parts of the body, like the heart, liver and kidneys, but there\u2019s never been a reliable blood test to identify trauma in the brain. We think this test could change that.\u201d In addition, the release mentions the lead researcher\u2019s earlier research involving this blood test.", "answer": 1}, {"article": "\"We think it will be a very important tool in the toolbag of surgeons and physicians treating obesity and its co-morbidities,\" said Gregory S. Lea, senior vice president and chief financial officer of EnteroMedics. \"When patients leave the diet, counseling and drug world and have nothing more, they turn to surgical procedures, and only 1% to 2% of patients who might be eligible for bariatric surgery are getting it.\"", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story states that the device is the first medical device for obesity approved by the FDA since 2007.", "answer": 1}, {"article": "This type of drug development program, which enrolled patients with different tumors but a common gene mutation, wouldn\u2019t have been possible a decade ago because we knew a lot less about such cancer mutations,\" said Dr. Gottlieb.\n\"This new site-agnostic oncology therapy isn\u2019t specific to a cancer arising in a particular body organ, such as breast or colon cancer.\n\"Accelerated approval\" means that the FDA has fast-tracked the process of getting drugs to patients before the usual clinical trials are completed.\nThe FDA announced Monday that it had approved Vitrakvi (larotrectinib), a treatment for both adult and pediatric cancer patients.\nFor example, immunotherapy drugs can now tag cancer cells so that it's easier for a patient's own immune system to identify and attack them.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reports that this is the second drug to receive FDA approval for use based on genetic features of tumors, rather than the organ in which the tumor originated or is growing.", "answer": 1}, {"article": "And the chunky monkeys?\n\"If the promise holds true, I think this has the chance to change healthcare,\" Dr. Christoph Westphal tells\n\nDr. Westphal says we all may soon be taking a drug that just might beat the clock, a simple pill that could delay the inevitable.\nThe important thing is that we passed a milestone where we can now make drugs based on this knowledge and we can potentially slow down aging itself,\" Sinclair explains.\n\"When I Googled this resveratrol, I was shocked to find that red wine was the top hit,\" Sinclair remembers.\nMost researchers agreed that there was something in the wine that offered protection, and a few years later, even the highly cautious federal dietary guidelines say that moderate consumption of red wine can be beneficial.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The idea that there is something protective in red wine is not a new one. For at least 15 years, scientists have discussed the \"French Paradox\", particularly when it comes to heart disease. However, the story adequately represents the novelty of potentially discovering the \"active agent\" in the red wine.", "answer": 1}, {"article": "Barua is with the Kansas City (Mo.)\n\"It is the first study to demonstrate that significant benefit is observed only if the dose is adequate to normalize the total testosterone levels,\" Barua and his coauthors wrote.\nThe study team looked at national data on more than 83,000 men with documented low testosterone, all age 50 or above, who received care in VA between 1999 and 2014.\nFor example, the new VA study excluded men with a history of heart attacks or strokes, although it did include those with existing heart disease.\nMeanwhile, the Food and Drug Administration issued guidance earlier in 2015 advising clinicians about the over-use of testosterone therapy, and pointing to a possible increased risk of heart attack and stroke.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The reader will find a reasonable contextual discussion of research on the impacts of low testosterone, which suggests that the proposed health link is not new and that outcomes of testosterone therapy remain mixed in the research literature. The news release makes a pitch for the novelty of this particular study \u201cbecause of its large size and relatively long follow-up period.\u201d", "answer": 1}, {"article": "When the appendix had burst, however, the open surgery racked up a considerably higher bill.\nBut it does suggest that laparoscopy could actually save thousands of dollars for some patients, when all costs \u2014 including physician fees, hospital fees and readmissions \u2014 are considered.\nNEW YORK (Reuters Health) - Minimally invasive surgery for a burst appendix appears to be more successful and less costly in the long run than the traditional operation, a new study hints.\nBut experiments comparing the two kinds of procedure have yielded mixed outcomes, and some experts remain unconvinced that laparoscopy is worth its higher upfront cost.\nWith his colleagues, he looked back at some 40,000 such surgeries done at dozens of academic medical centers in the U.S. \u2014 roughly 14,000 open procedures and 26,000 laparoscopic ones.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story offered this helpful context:\n\u201c\u2026experiments comparing the two kinds of procedure have yielded mixed outcomes, and some experts remain unconvinced that laparoscopy is worth its higher upfront cost.The new study, in the Annals of Surgery, doesn\u2019t settle that question. But it does suggest that laparoscopy could actually save thousands of dollars for some patients, when all costs \u2014 including physician fees, hospital fees and readmissions \u2014 are considered.\u201d", "answer": 1}, {"article": "\u201cUsually everything is developed first for adults,\u201d he noted recently, \u201cand children are an afterthought.\u201d\n\n\u2018This is not the end\u2019: Using immunotherapy and a genetic glitch to give cancer patients hope\n\nThis 8-year-old is free of cancer \u2014 for now \u2014 after a \u2018breakthrough\u2019 treatment\n\nFor a 6-year-old with cancer, a future staked on medicine\u2019s hottest field\nThe approval of CAR T-cell therapy would represent the second big immunotherapy advance in less than a decade.\nThat study and a Kite trial have shown that the treatment can put about one-third of adults with advanced disease \u2014 those who have exhausted all options \u2014 into remission.\nThere, a crippled HIV fragment is used to genetically modify the T cells so they can find and attack the cancer.\nAnd childhood leukemia is just the start for a field that has attracted intense interest in academia and industry.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a good job here, articulating what makes this treatment novel and how it works relative to other immunotherapy treatments.", "answer": 1}, {"article": "\u201cThe most salient message is that the [Gardasil] vaccine can prevent HPV infection on the external genital region, which means that we can now prevent most cases of genital warts if the boy is vaccinated at a sufficiently early age,\u201d says study researcher Joel Palefsky, MD, a professor of medicine at the University of California, San Francisco.\nThe vaccine is recommended for optional use in boys and men.\nHPV, a sexually transmitted disease, can be transmitted through vaginal, anal, and oral sex and has been linked to genital warts as well as cervical, vaginal, vulvar, oral, penile, and anal cancers.\nOf 4,065 boys and men aged 16 to 26 from 18 countries, vaccination with an HPV vaccine that targets four types of HPV infection -- HPV-6, HPV-11, HPV-16, and HPV-18 -- protects against infection with these types of HPV and potentially the development of related external genital warts or lesions.\nThe vaccine is used in girls and boys and young adults ages 9 to 26 for prevention of genital warts caused by HPV types 6 and 11.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Good history and context given about the two vaccines \u2013 Gardasil and Cervarix. Better than competing HealthDay on this count.", "answer": 1}, {"article": "This determined the most effective treatment frequency.\nFurthermore, adding the MES+HS treatment to a DPP-4 inhibitor, which is the most often used therapeutic drug for diabetes in Japan, showed an even stronger blood glucose improvement.\nThe heat shock response (HSR) is activated as a response to stress in the human body, but its function decreased in those with type 2 diabetes.\nIn the researcher's next clinical trial, 60 obese patients with type 2 diabetes from both genders were given a 12-week treatment with the belt-shaped MES+HS medical device.\nOne can expect the effects to be similar to exercise therapy,\" said Dr. Tatsuya Kondo, who lead the research.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Heat shock protein has been explored as an important factor in Type 2 diabetes by other researchers. The researchers have taken the basic research and moved it one step closer to patients.", "answer": 1}, {"article": "But investors had been anticipating a bigger effect.\nThe findings, which involved following 9,340 patients for a median 3.8 years, were also published online in the New England Journal of Medicine.\nThe Victoza trial, known as Leader, had been designed to show Novo\u2019s drug did not increase heart risk, so its superiority is welcome news for the company, especially as Sanofi\u2019s (SASY.PA) rival Lyxumia failed to show heart benefits in an earlier test.\nMads Krogsgaard Thomsen, Novo\u2019s chief science officer, said the results should encourage doctors to use Victoza earlier, since they could now see it offered \u201clife-expanding\u201d treatment.\nNovo, the world\u2019s biggest diabetes company, had said in March that Victoza cut heart risks \u201csignificantly\u201d in the study but the scale of the benefit was only disclosed on Monday.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear that the purpose of this study was to meet FDA requirements. \u201cSince 2008, U.S. regulators have demanded studies for new diabetes medicines to show there is no increase in heart risk, opening a new battleground between different treatments,\u201d it says.", "answer": 1}, {"article": "A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, brain injury, Parkinson's disease and epilepsy.\n\"While such changes may be detected with MRI, we believe there may be a less expensive and portable way to measure these changes with a transcranial Doppler (TCD) device.\"\nThis is in contrast to traditional TCD ultrasound measurements like change in cerebral blood flow reactivity which differentiated between the two 60 percent of the time, average blood flow speed which differentiated 55 percent of the time and blood flow resistance which differentiated 53 percent of the time.\n\"This important work provides insight into a tool that may yet prove useful in the recognition and management of concussion,\" said Jeffrey Kutcher, MD, FAAN, with the The Sports Neurology Clinic in Brighton, Michigan.\nThe American Academy of Neurology, an association of 30,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The closest the release comes to claiming novelty is its assertions that the TCD ultrasound device is more accurate than other devices and that its application \u201cmay be a less expensive and portable way to measure these changes.\u201d\u00a0 We\u2019ll give that a satisfactory.", "answer": 1}, {"article": "A few previous small trials had already suggested that giving drugs like Prozac, which belongs to a drug class known as selective serotonin re-uptake inhibitors (SSRIs), might improve motor skill recovery after stroke.\nIn the largest study yet of the effect of this type of antidepressant on stroke recovery, French researchers found that stroke patients given Prozac improved their scores in motor skills tests more than those given a placebo, or dummy pill.\nExperts commenting on the findings said they had \u201cenormous potential to change clinical practice\u201d and raised the question of whether most stroke patients with motor skill problems should be treated with this relatively cheap type of antidepressant.\nCommenting on the study, Robert Robinson and Harold Adams from the University of Iowa in the United States, said it could change the way doctors treat stroke victims in future, but more research is needed to see if the effects continue over time.\nHemiplegia \u2014 paralysis to one side of the body \u2014 and hemiparesis \u2014 weakness on one side of the body \u2014 are the most common disabilities after stroke and scientists believe SSRIs might help improve movement by increasing the level of the brain chemical serotonin in the central nervous system.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It states that this study is the largest one conducted on this question, and it quotes some folks regarding potential mechanisms by which fluoxetine may exert an effect.", "answer": 1}, {"article": "For further information, please contact:\n\nThis information was brought to you by Cision http://news.cision.com\n\nThe following files are available for download:\nThe results of our study clearly support the use of SBRT for elderly patients, especially those who may not be able to tolerate longer courses of radiotherapy or more invasive treatment options,\" says Meredith Giuliani, MBBS, FRCPC, MEd, a radiation oncologist in the Cancer Clinical Research Unit at Princess Margaret Cancer Centre, University Health Network in Toronto and lead study author.\nThe results, which were based on data from more than 1,000 patients across five institutions that comprise the Elekta Lung Research Group, are available online and will be published in the July 15 print issue of International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics.\nThe cohort included 305 patients under 70 years of age, 448 patients ages 70 to 79 years, and 330 patients aged 80 years or more (which included 16 patients aged 90 years or more).\n\"This study is the largest series of its type to evaluate SBRT outcomes in patients aged 80 years and older,\" says Joel Goldwein, MD, Senior Vice President, Medical Affairs for Elekta.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that \u201cnew data\u201d shows SBRT is a safe treatment option for elderly patients and the study is the \u201clargest of its type.\u201d While the study may provide some new information on the use of SBRT in elderly patients the release didn\u2019t provide any context on any other studies on SBRT in the elderly, didn\u2019t provide information on harms nor did the release back up claims about safety.", "answer": 0}, {"article": "\u201cWe expected to see some response, but I don\u2019t think we expected to see a 45% significant response,\u201d says Forde.\nIn addition, \u201ca year after treatment, three times more people on immunotherapy were doing well compared to those who just got chemotherapy.\u201d\n\nThe results could play a role in changing standard treatments for people diagnosed with advanced NSCLC, by making a strong case for starting people immediately on the immunotherapy combination rather than giving them chemotherapy first, as many doctors currently do.\n\u201cAnd while our study is only with 21 patients, the early indications from this study are very positive.\u201d\n\nTaken together, the results could fundamentally change the way lung cancer is treated, significantly improving people\u2019s ability to both hold off lung cancer for longer periods of time, as well as live longer with the disease.\n\u201cTo give you some idea of how significant that is, with chemotherapy we normally see the same degree of response around 20% of the time.\u201d\n\nForde says that the strong response seen in people at the beginning of the disease could suggest that immunotherapies might be useful in re-training the immune system to fight cancer for long periods of time \u2014 possibly even a lifetime.\nPutting together everything that doctors currently know about lung tumors, \u201cmore than half of people with lung cancer can avoid chemotherapy and get more precision-based treatments,\u201d says Dr. Matthew Hellmann of the Memorial Sloan Kettering Cancer Center (MSKCC), lead author of the study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story states that these studies amount to \u201csome of the most encouraging results yet for treating lung cancer with the latest immune-based treatments, most of which have been approved to treat other types of tumors.\u201d\nIt also states that researchers have \u201cfound innovative ways to weaken lung tumors to improve people\u2019s chances of surviving the disease.\u201d\nWhile there is some truth to these statements, the story is misleading because it puts all of the trials on equal footing. In fact, only one is expected to have an immediate impact on patients by changing the way certain types of lung cancer are treated. That wasn\u2019t clear.", "answer": 0}, {"article": "But study author Dong Wang, a graduate student with the departments of nutrition and epidemiology at Harvard T.H.\nMONDAY, Nov. 2, 2015 (HealthDay News) -- Despite the stereotype that Americans are eating more unhealthful foods that leave them vulnerable to assorted diseases, a new study suggests the opposite may be true.\nAccording to study author Wang, trans fats have been almost eliminated from the food supply, so what is needed next is more taxation on sugary drinks and more regulations requiring salt to be reduced in food.\nTo get insight into the answer, they analyzed the results of seven health and nutrition surveys including almost 34,000 adults aged 20 and older between 1999 and 2012.\nDr. Sonia Anand, a professor of medicine and epidemiology at McMaster University in Hamilton, Canada, praised the study, saying it's \"reasonable\" to link changes in diet to death rates in this way.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article hooks the reader with the idea that contrary to the \u201cstereotype\u201d of the unhealthy Americans and their greasy kid stuff diets, the study at hand suggests the \u201copposite\u201d may be the case. While the researchers\u2019 conclusions struck a balance between good news and bad news about our collective eating habits, and the article may have slightly overstated the \u201csurprise\u201d findings, the text does its job of getting readers\u2019 attention and quickly qualifies the \u201cgood news\u201d with a quote citing \u201chuge room \u2026for further improvement.\u201d", "answer": 1}, {"article": "Information on ongoing trials is available at www.clinicaltrials.gov.\nFor a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Celator's Form 10-K for the year ended December 31, 2014, subsequent reports on Form 10-Q and 8-K, and other filings by the company with the U.S. Securities and Exchange Commission.\nCelator's pipeline includes the lead product, VYXEOS\u2122 (also known as CPX-351), a nano-scale liposomal formulation of cytarabine:daunorubicin being studied for the treatment of acute myeloid leukemia; CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine studied in colorectal cancer; and a preclinical stage product candidate, CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation.\nThe percentage of patients alive 24 months after randomization was 31.1% on the VYXEOS arm compared to 12.3% on the 7+3 arm.\nVYXEOS represents a novel approach to developing combinations of drugs in which molar ratios of two drugs with synergistic anti-tumor activity are encapsulated in a nano-scale liposome in order to maintain the desired ratio following administration.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release makes a few different claims to novelty. For example:\n\u201cFirst therapy to demonstrate statistically significant improvement in overall survival\u2026.\u201d\n\u201cVYXEOS represents a novel approach to developing combinations of drugs in which molar ratios of two drugs with synergistic anti-tumor activity are encapsulated in a nano-scale liposome in order to maintain the desired ratio following administration.\u201d\u00a0 While that statement may not be precisely true \u2014 a review of the literature finds that there are at least a dozen liposomal drugs in development \u2014 it does, however, appear to be the first drug to use a fixed molar ratio in the liposomal packets to deliver the drug to the cancer.", "answer": 1}, {"article": "Trying to diagnose prostate cancer is one of the most maddening tasks a doctor has.\nIt is a string of RNA that does not appear to have any function but that is overexpressed, or overactive, in prostate cancer.\nThe test had a sensitivity of 49 percent, meaning it correctly identified 49 percent of cancers.\nThe prostate is a walnut-shaped gland that produces semen and it is hard to get to.\nThis is far less sensitive than PSA, which catches 87 percent of tumors, but if the two tests are used together they can help rule out the need for unnecessary surgery or radiation.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story accurately reported that this test is used in Europe but is not approved for use in the US. \u00a0It would have been interesting for readers to hear some of the reasons why. ", "answer": 1}, {"article": "That\u2019s why doctors at the Cleveland Clinic will test deep brain stimulation (DBS)\u2014a procedure in which electrodes are implanted in the brain to provide small electric pulses as a way to help people recover control of their movements.\nThe stimulation will hopefully jump-start the brain\u2019s recovery process and help them gain more control while undergoing standard therapy.\nSince the procedure is experimental, there may be some unknown risks as well.\nDepending on how the first procedure goes, the hospital will enroll more people into its trial.\nThe electrodes will be placed on parts of the brain that communicate with the damaged region and surrounding areas.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of the investigation of\u00a0deep brain stimulation\u00a0for stroke patients is made clear.", "answer": 1}, {"article": "MONDAY, Feb. 21, 2011 (HealthDay News) -- When it comes to shedding pounds and improving or eliminating type 2 diabetes, gastric bypass surgery may be better than other surgical weight-loss procedures, two new studies find.\nIn the bypass group, patients lost an average of 64 percent of their excess weight, vs. 36 percent for those in the lap-banding group.\nAll patients were morbidly obese (with a body-mass index higher than 40), and 34 in each group had type 2 diabetes.\nLater complications may include malnutrition, hernias and a tendency in about one in 10 people to regain much of the weight they lost as a result of the procedure.\n\"Everyone thinks that all weight-loss operations are the same, even the doctors and the surgeons.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story didn\u2019t mention that many other studies have examined these procedures or establish what, if anything, is novel about these new findings. It should have.", "answer": 0}, {"article": "The key asset Pfizer wanted?\nThough its own PARP inhibitor, rucaparib, showed that it could help some women compared to chemotherapy alone, its data didn\u2019t measure up to the other two trials.\nWhile chemotherapy is still used as a first line of attack, PARP inhibitors are largely being studied as maintenance drugs.\nOvarian cancer has historically been one of the harder cancers to treat \u2014 but a promising new class of drugs, called PARP inhibitors, is proving powerful in delaying the growth of tumors by preventing cancer cells from repairing themselves after they\u2019ve been damaged by chemotherapy.\nThe field is so hot that over the summer, Pfizer agreed to spend an eye-popping $14 billion to buy San Francisco-based biotech Medivation.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t adequately establish what\u2019s new or different about these drugs compared to the one already approved PARP inhibitor drug\u2013why all these different ones are needed and are being so hotly researched by various drug companies.", "answer": 0}, {"article": "A compound in raspberries is being touted as the next new fat burner. But people looking to lose a few pounds may not want to go running to the produce aisle just yet. Scientists say there are no major human studies to support the idea that a berry holds the secret to weight loss.\n\nRaspberry ketones, the organic compounds that give raspberries their aroma, raised hopes as a weight-loss aid after a 2005 study by Japanese researchers found the ketones boosted fat-burning processes in rat cells in a laboratory as long as those...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t make any inappropriate claims about the novelty of these products or the related research.", "answer": 1}, {"article": "Rectal cancer affects some 2,000 men and women in Sweden every year.\n\"The results of the study will give rise to improved therapeutic strategies, fewer complications with a sustained low incidence of local recurrence, and better survival rates for rectal cancer patients,\" says Professor Martling.\nThe study now presented in The Lancet Oncology is based on the claim that the adverse effects of rectal cancer treatment can be reduced by administering more but lower doses of radiation for a longer time, or by increasing the interval between radiotherapy and surgery.\n\"Back then we showed that preoperative radiotherapy reduces the risk of local recurrence by over 50 per cent for patients with rectal cancer,\" says principal investigator Anna Martling, senior consultant surgeon and professor at Karolinska Institutet's Department of Molecular Medicine and Surgery.\nIt also showed that there is no difference between long-course and short-course radiotherapy other than that the former considerably lengthens the time for treatment.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release states that the trial tested the hypotheses that \u201cthe adverse effects of rectal cancer treatment can be reduced by administering more but lower doses of radiation for a longer time, or by increasing the interval between radiotherapy and surgery.\u201d\nOther trials such as\u00a0this one have studied the timing of surgery for rectal cancer, but we couldn\u2019t find any that examined the same variables as this study. That\u2019s enough to earn a satisfactory rating for novelty.", "answer": 1}, {"article": "For the really Type A personality, here's a chance to measure how well you are relaxing. Makers of home biofeedback devices that monitor your heart rhythms say the devices teach you to combat emotional stress. Psychologists and psychiatrists say the gadgets appear to help their stressed-out patients but warn that there isn't yet strong scientific evidence that they work.\n\nBiofeedback has long been used to treat stress in psychologists' offices -- with an expert who leads the patient in relaxing breathing exercises and...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly states that this is not a new technique; psychologists have been using it for a while in their offices. What is new is that these devices are now being marketed for home use. The story is not clear on whether or not some of the tools such as the computer program are novel.", "answer": 1}, {"article": "Jan. 5, 2011 -- A two-week course of the antibiotic rifaximin (Xifaxan) helps to relieve the symptoms of irritable bowel syndrome (IBS), and the relief lasts up to 10 weeks after stopping the medication, according to new research.\nThe drug is approved by the FDA only for traveler's diarrhea and hepatic encephalopathy, a brain disorder caused by chronic liver failure.\nWith the new antibiotic treatment, Pimentel tells WebMD, many participants ''say they are 80% improved, 90% improved, that kind of results.\nFor those with this type of IBS, symptoms can include abdominal pain, bloating, and changes in bowel function such as diarrhea.\nWith the drug treatment, Pimentel says, those with the IBS ''can enjoy social outings without the worry of having to run to the bathroom and having diarrhea.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not establish the true novelty of this approach. It lists a bunch of existing treatment options that are all not antibiotics\u00a0 and then transitions to \u201cWith the new antibiotic treatment\u2026\u201d and later briefly mentions other antibiotics \u201cwhich have produced mixed results for IBS patients.\u201d\u00a0 We find this confusing.\u00a0 How much have other antibiotics have been tested in IBS?\u00a0 Why weren\u2019t they listed among the \u201cexisting treatment options\u201d?\nThe story does state that researchers chose rifaximin because it might perform better than other antibiotics.\u00a0 But, again, any precedent for, or track record with, antibiotic therapy for IBS is not clearly explained.", "answer": 0}, {"article": "But they can be deadly in the modern era.\n\u201cThere\u2019s really no doubt that there have been cold feet in the industry about this issue.\u201d\n\nBut investigators around the world have shown they can carry out these \u201cfood challenge\u201d trials safely \u2014 which could help hasten the development of new drugs.\n\u201cThat hypothetically decreases the risk for adverse events.\u201d\n\nFor all the research on allergies, none of the drugs in the pipeline is a sure thing.\nIt was approved by the FDA in 2003 to treat a form of asthma often triggered by allergens, but Stanford researchers are now testing it on patients with food allergies \u2014 and finding that it might help speed along classic allergy desensitization therapy, in which patients are slowly introduced to escalating quantities of the allergen, via allergy shots or those \u201chome brew\u201d concoctions.\nIt\u2019ll be interesting to see how this translates into making it into a pharmacy, and into the hands of patients.\u201d\n\nCorrection: A previous version of the story misstated some aspects of Aimunne\u2019s work on peanut allergies.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article makes clear that the some of the proposed \u201cnew era\u201d treatment are actually old wine in new bottles\u2013commercial versions of things allergists have been hand-tailoring to their patients for years. And it does examine some novel twists in describing the development of a DNA vaccine, and the expanded use of a relatively new \u201cbiologic\u201d drug that exploits the immune system\u2019s weaknesses and strengths. However, it could have been stronger at pointing out that nothing here is really brand new.", "answer": 1}, {"article": "The researchers found that overall 30-day mortality decreased from 1.6 percent (84 of 5,275 patients) to 0.7 percent (26 of 3,878 patients) after FSI implementation.\nEMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, NOVEMBER 30, 2016\n\nAlso available at the For the Media website, the commentary \u201cA Call for Frailty Screening in the Preoperative Setting,\u201d by Anne M. Suskind, M.D., M.S., and Emily Finlayson, M.D., M.S., of the University of California, San Francisco.\nThe absolute reduction in 180-day mortality among frail patients was more than 19 percent, with improvement remaining robust even after controlling for age, frailty, and predicted mortality.\u201d\n\n: This investigation was supported by a grant from the U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development.\n\u201cThe ultimate cause of the survival benefit is likely multifactorial, including changes in preoperative decision making, intraoperative management, and postoperative rescue,\u201d the authors write.\nIt also suggests the potential to improve postoperative survival among the frail through systematic administrative screening, review, and optimization of perioperative plans.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release\u00a0establishes what\u2019s novel by stating: \u201c\u201cThis study reveals the feasibility of facility-wide frailty screening in elective surgical populations.\u201d We would have liked a bit more information on the risk analysis indicator used to assess frailty\u2013is this a well-established tool or being used uniquely here?", "answer": 1}, {"article": "EMF Australasia Chair, Associate Professor Sally McCarthy said this research had the potential to help millions of Australians suffering with this extremely painful condition.\n\"Kidney stones are a bit of a mystery, occur frequently in the community and generally affect young, healthy adults,\" Dr Furyk said.\n\"It can be extremely painful to pass these jagged little crystallized minerals and it's very common for sufferers to go to an emergency department for treatment.\n\"It may also have implications for patients living in rural and regional areas, where access to urologists - the specialist doctors who treat this condition - can be limited.\"\nPatients with kidney stones were treated with the drug Tamsulosin in an Emergency Medicine Foundation Australasia (EMF) funded clinical trial run across five Australian hospital emergency departments.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release claims that the researchers \u201cdiscovered\u201d that this drug has benefits which suggests to readers that this was the first and only study to look at the use of tamsulosin for kidney stones. Previous studies with similar findings have been published over the past few years.", "answer": 0}, {"article": "Less Fat.\u201d\n\nMeanwhile, Erchonia Medical, based in McKinney, Tex., has aggressively marketed its Zerona laser as \u201cthe first non-invasive body contouring procedure to effectively remove excess fat\u201d even though it has yet to receive F.D.A.\nThe low-level laser causes \u201cfat to seep out of a cell, almost like a balloon being struck by a needle,\u201d said Ryan Maloney, medical director for Erchonia Medical.\nIt has cleared the Zerona laser for pain reduction 24 hours after breast augmentation or as a way to decrease the pain associated with recovering from liposuction.\nThe fat enters the lymphatic system, and is eventually used as energy, Dr. Maloney said.\nPatient selection for any body contouring procedure is crucial, said Dr. Jeffrey M. Kenkel, vice chairman of plastic surgery at the University of Texas Southwestern Medical Center in Dallas.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story correctly suggests these two new technologies lie somewhere between the invasive, surgical liposuction and highly questionable infomercial products. It also says they\u2019ll shortly be joined in the market by competitors that use ultrasound technologies. ", "answer": 1}, {"article": "The main side effects, Vertex said, were headache, upper respiratory tract infections, nasal congestion, rash and dizziness.\n\u201cI\u2019ve been doing clinical trials for 30 years in C.F.\nVertex has not said how much it will charge for VX-770.\nNow, 22 years later, a drug that tries to compensate for the genetic defect might be nearing the market.\nThe company is hoping that by late May it will win approval to sell a new type of drug for hepatitis C, which analysts expect will be a blockbuster.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 1}, {"article": "Although DHEA is included in some dietary supplements, the efficacy and safety of those products have not been established for diagnosing, curing, mitigating, treating or preventing any disease.\nIntrarosa is the first FDA approved product containing the active ingredient prasterone, which is also known as dehydroepiandrosterone (DHEA).\nThe U.S. Food and Drug Administration approved Intrarosa (prasterone) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.\n\"Pain during sexual intercourse is one of the most frequent symptoms of VVA reported by postmenopausal women,\" said Audrey Gassman, M.D., deputy director of the Division of Bone, Reproductive, and Urologic Products (DBRUP) in the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research (CDER).\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "DHEA is not a new drug. Researchers have also looked at DHEA\u2019s effects on cardiovascular risk, memory and metabolism in older populations. And it\u2019s also sold over-the-counter as a dietary supplement, the news release points out.\nBut it also states Intrarosa is the first FDA approved product containing prasterone, or DHEA.\nTherefore, we give it a Satisfactory rating here.", "answer": 1}, {"article": "In years past, \"the message was that chocolate consumption might be associated with higher LDL [bad] cholesterol or perhaps higher incidence of cardiovascular disease,\" he said.\nBoth are good for heart health,\" he said.\nFor one thing, it's possible that some factor other than chocolate could be helping lower the risk of stroke.\nThe National Stroke Association has more on stroke.\nAntioxidants are thought to prevent cell damage.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explained this study was a review of existing studies. ", "answer": 1}, {"article": "Viagra is one of three licensed drugs to treat erectile dysfunction, Davies explained. The other two are Cialis and Levitra. They can take from half an hour to several hours to work, and they're not for everyone: Men who've had a stroke or heart attack are told to use the drugs with caution, reports the Daily Mail. Even those without medical issues simply don't like the wait.", "question": "Does the story establish the true novelty of the approach?", "explanation": "We\u2019ll give the story the benefit of the doubt on this one, since it quoted a researcher saying \"This is the first time nanoparticles have been used to treat erectile dysfunction. Other topical treatments have been tried, but not one like this.\"", "answer": 1}, {"article": "Panel Says Aspirin Lowers Heart Attack Risk For Some\n\nMillions of Americans take baby aspirin every day to prevent a heart attack or stroke.\nConcerns have been raised about whether aspirin is really effective enough, when so many other medicines are available to help control heart disease risk.\nThe independent panel also said that taking low-dose aspirin daily for at least 10 years may protect against colorectal cancer, at least in people who are already taking it to prevent heart attacks and stroke.\nFor example, uncontrolled high blood pressure, or high cholesterol, obesity, age and diabetes can all increase heart disease risk.\nSeveral groups including the American Heart Association offer online calculators to help people figure out their risk, which, along with discussion with a health care provider, can help determine whether daily aspirin might be useful.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that the USPSTF recommendation differs from current practice among healthy adults.", "answer": 1}, {"article": "Guyuron, chair of plastic surgery at University Hospitals Case Medical Center in Cleveland, went on to identify four common \"trigger sites\" and publish studies showing that, in selected patients, surgical decompression of nerves in one or more of these sites provides lasting migraine relief. He has also taught 250 plastic surgeons around the world (none in the Philadelphia area) to perform the outpatient operation, which costs an average of $10,000 and is not covered by many insurers.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does an adequate job referencing earlier research and using independent experts to put the work in question.", "answer": 1}, {"article": "This suggested the test could be used to tell the conditions apart.\nChanges in cytokine levels of cerebrospinal fluid offer a very early measurable sign of infection.\u201d\n\nDr. Curtis and colleagues decided to see if they could detect patterns within the cytokines that might differentiate infections from other brain diseases or disorders.\n\u201cOnce confirmed with additional research, our test could provide a first, rapid and less invasive way to look at what\u2019s happening in the brain and guide treatment or further testing.\u201d\n\nThe results were published in the journal PLOS ONE on October 31st.\n\u201cBeing able to rapidly identify a central nervous system disorder as infectious can be crucial in rapid response.\u201d\n\n\u201cIn addition, the test could distinguish viral from non-viral infections, a distinction that could spare a child with a viral infection from an unnecessary course of antibiotics, and tailor the care toward antiviral and supportive measures as needed,\u201d said Dr. Curtis.\nAdditionally, within the patients identified with central nervous system infections, the CSF cytokine fingerprint was different in cases of viral infection compared to those with non-viral pathogens, such as bacteria or fungi.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "If the test is validated it would add a new way to\u00a0identify bacterial infection and identify it faster. The speed component is novel.\nIt\u2019s clear that CNF, and perhaps the patterns of cytokines floating in it, could be a powerful diagnostic tool for doctors trying to diagnose elusive diseases of the central nervous system. The release also notes such signals could be detected early and avoid unnecessary treatments.", "answer": 1}, {"article": "OMT also reduced the in-hospital mortality rates of those with the highest severity of illness.\nWhile antibiotic therapy is the current standard of care, the emergence of resistant bacteria is a global threat and provides an incentive to explore adjunct treatments that can improve their efficacy,\" said James Bailey, DO, assistant professor in physical medicine and rehabilitation at Rowan University School of Osteopathic Medicine.\nDisclosures: The basis for this analysis, The Multicenter Osteopathic Pneumonia Study in the Elderly (MOPSE) clinical trial, was funded by a consortium of foundations including the Foundation for Osteopathic Health Services.\nThe data were analyzed by intention-to-treat analysis of all participants and by per-protocol analysis of participants who finished the study without missing any protocol treatments.\nThe study analyzed 375 patients ages 50 or older who were randomly assigned to three groups, either receiving OMT, a light touch or conventional care only.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t state that this study was a follow-up to a previously published report. It does say that the current study focuses on subgroup analyses and that may imply that the main analyses were previously released. But it\u2019s doubtful a lay person or even a professional would know this.\nThe release gets to the \u201cnews\u201d and describes the outcomes, but the release would have benefited from additional context and caveats as noted above.", "answer": 0}, {"article": "Well, maybe not.\nThis is potentially great news, since osteoarthritis--the painful disease where cartilage at the end of bones wears down and gradually worsens over time--affects about 27 million people in the United States.\n\"This study does not indicate that distance runners are any more likely to get osteoarthritis than any other person,\" Seeley said.\nRunning may also slow the process that leads to osteoarthritis\n\nWe all know that running causes a bit of inflammation and soreness, and that's just the price you pay for cardiovascular health.\nThe researchers found that the specific markers they were looking for in the extracted synovial fluid--two cytokines named GM-CSF and IL-15--decreased in concentration in the subjects after 30 minutes of running.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "As stated in the review summary, many previous studies tried to determine whether running increases the risk of osteoarthritis. But the release doesn\u2019t mention previous research and thus overstates the novelty of the new findings.\nPeople with osteoarthritis are usually advised to continue to exercise. Because running is a high impact aerobic exercise it may sound counter-intuitive to continue running, but not necessarily novel.", "answer": 0}, {"article": "THURSDAY, Sept. 2, 2010 (HealthDay News) -- An experimental test that can diagnose tuberculosis in less than two hours, making only one doctor visit necessary before treatment starts, is being hailed as a potentially significant advance against a disease that kills nearly 2 million people annually, most of them in developing countries.\nThe test costs about $63 in Europe, but the company has agreed to provide it for less than half that in poor countries, said John Bishop, Cepheid's chief executive officer, as quoted in a story by the Associated Press.\nMost people who are infected with tuberculosis bacterium (Mycobacterium tuberculosis) don't have symptoms, but some will develop the disease, according to the U.S. National Institutes of Health.\nThe test was created by the California-based corporation Cepheid, which plans to seek U.S. Food and Drug Administration approval for the test, which went on sale late last year in Europe.\n\"This is a very important discovery,\" said infectious disease expert Dr. Marc Siegel, an associate professor of medicine at New York University.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We don\u2019t think the story\u00a0oversold the novelty of this new TB test, which by all accounts does represent a noteworthy\u00a0advance over current methods. However, we feel the story could have mentioned that there quite a few companies working on similar tests.", "answer": 1}, {"article": "Everyone loses some bone with aging - women abruptly at menopause when estrogen levels decline, men more slowly as male hormones decline over time.\n\"All bones - spine bones and big leg bones - will respond to pressure from weight by forming more bone.\"\nIf a person simply stands, the muscles accommodate and do most of the work, he said - with no benefit to the bone.\nAnother 34 million are at risk because they have low bone density.\n\"Anything that makes bone bear weight is good for bone quality,\" said Dr. Kirkham Wood, head of orthopedic spine surgery at Massachusetts General Hospital.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "not applicable in this case", "answer": 2}, {"article": "PROVIDENCE, R.I. [Brown University] -- To the tantalizing delight of chocolate lovers everywhere, a number of recent studies employing various methods have suggested that compounds in cocoa called flavanols could benefit cardiovascular health.\nThose with lower doses of flavanols only saw a significant HDL benefit.\nThose consuming higher doses saw some of the insulin resistance benefits and a drop in triglycerides, but not a significant increase in HDL.\nThey saw significant declines in blood glucose and insulin, as well as another indicator of insulin resistance called HOMA-IR.\nIn all, 1,139 volunteers were involved in these trials.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release did not establish the novelty of the meta-nalysis itself nor the underlying studies.", "answer": 0}, {"article": "Postdoctoral fellow and first author Eva Palacios, PhD, led the data analysis for the fMRI experiments.\n\"This is an exploratory, proof-of-concept study showing that we can identify patients soon after mild brain trauma who may have more persistent symptoms, despite no other evidence of injury within the brain,\" said Pratik Mukherjee, MD, PhD, professor of radiology and biomedical imaging at UCSF and the senior author of the study.\nThe study was part of the ongoing Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) project, through which Mukherjee and study co-author Geoffrey Manley, MD, PhD, vice chairman of neurological surgery at UCSF and chief of neurosurgery at Zuckerberg San Francisco General Hospital, along with collaborators from many other research institutions are leading studies and gathering common data across research sites to more quickly advance TBI research.\nThe fMRI method and analysis developed for the study highlighted abnormal patterns of brain activity that pointed to a higher risk for long-term, post-concussive symptoms, even among the 44 study participants who had no evidence of bleeding or bruising in the brain in the immediate aftermath of brain trauma on computed tomography (CT) or ordinary MRI scans.\nIn their new study, published online January 13, 2017 in the Journal of Neurotrauma, the researchers used a technique called functional MRI (fMRI), coupled with sophisticated statistical analysis, to track activity in the brain networks of 75 patients, aged 18 to 55, within the first two weeks of their having experienced concussions.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release touts fMRI as a \u201cnew MRI method\u201d in the headline and talks about a \u201cnew non-invasive magnetic resonance imaging (MRI) method\u201d in the first sentence.\nBut fMRI is not exactly a new technology, as it\u2019s been around since 1991. And fMRI has already been used and studied as a possible detection tool to evaluate brain abnormalities in patients, who had previously suffered concussions. Other research has also looked into brain function, including resting state functional connectivity (like in the UCSF study), through fMRI in order to detect residual brain differences in the weeks to months after concussion.\nFrom the news release, it\u2019s difficult to understand how exactly this research is novel. Researchers wrote in the original journal article that their study was the first to \u201crelate alterations in early resting-state functional connectivity to long-term postconcussive symptoms and cognitive outcome in a large and clinically well-defined mTBI sample.\u201d\nFor these reasons, we give it a Not Satisfactory rating.", "answer": 0}, {"article": "RANKL and RANK also link sex hormones to breast cells by providing signals telling the breast cells to grow.\nMoreover, the scientists \u2013 together with colleagues in Barcelona and from the CIMBA* consortium mapping more than 23,000 women \u2013 showed that genetic variants in the RANK gene are associated with a higher risk of developing breast cancer in women who carry BRCA1 and also BRCA2 mutations.\nIn 2010, Josef Penninger, the scientific director of IMBA in Vienna and his team have shown that sex hormones can trigger breast cancer (Schramek et al., Nature) through proteins called RANKL and its receptor RANK, which are key factors in bone metabolism.\nUntil now, prophylactic surgery is the only procedure which significantly reduces the breast cancer risk, but which is also often associated with postoperative complications.\nBased on our discovery, the already approved drug Denosumab or other future drugs that will block RANKL/RANK, could be used for breast cancer prevention in BRCA mutation carriers,\" explains Verena Sigl.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release claims that the research led to the discovery that RANKL is the main driver BRCA1 mutation-driven breast cancer. A second claim is that an already approved drug could be \u201cthe first breast cancer prevention drug.\u201d However, that\u2019s misleading since Tamoxifen and raloxifene are FDA-approved drugs for reducing the risk of\u00a0breast cancer.", "answer": 0}, {"article": "\"Without sensory feedback, somebody would have to actually have to look at the prosthetic, look at the cup, start to close the hand, (and) visually see the cup is starting to deform,\" he says.\nFor several years now, people have been able to control robotic arms using thoughts alone.\nThen they waited for the brain to heal, as it adjusted to the presence of the electrodes.\n\"His hand has been disconnected from his brain because of his spinal cord injury,\" Gaunt says.\nThe first step was to monitor his brain activity using a technique called magnetoencephalography.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty is well-established by the story\u2019s explanation of the experimental therapy.", "answer": 1}, {"article": "Many older adults prefer psychotherapy to medication for the treatment of anxiety.\nThese two trends are inextricably linked in the area of geriatric mental health and our search for better, more effective treatments with greater reach.\u201d\n\nThe author made conflict of interest disclosure.\nGeneralized anxiety disorder (GAD) is one of the most common anxiety disorders in older adults and is associated with poor quality of life, increased health care utilization and impaired memory.\nTo place an electronic embedded link to this study in your story Links will be live at the embargo time: http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/jamapsychiatry.2015.1154 and http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/jamapsychiatry.2015.1306\n\nTelephone-based cognitive behavioral therapy was better at reducing worry, generalized anxiety disorder symptoms and depressive symptoms in older adults who live in rural areas, where access to mental health treatment may be limited, according to an article published online by JAMA Psychiatry.\nHowever, older adults who live in rural areas can face a number of barriers, including living in an area where psychotherapy is not available, so alternate methods of providing treatment could increase utilization, according to the study background.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Telephone-based support programs are not new and the release makes no claims that the approach is necessarily novel.\u00a0 It specifically says that it \u201cis one way to overcome some barriers to mental health treatment.\u201d", "answer": 1}, {"article": "CHICAGO, Dec. 2, 2015 /PRNewswire/ -- An analysis of clinical data from over 200 patients treated by Dr. Michael Stehling found that a new procedure that uses MR and ultrasound to guide treatment to the precise tumor location allows for faster recovery times and lower side effects in all stages of prostate cancer.\n\"The patients we have treated at The Prostata Center have had their cancers destroyed without the need for surgery, with a low incidence of side effects and in most cases have been back on their feet the next day,\" said Dr. Michael K. Stehling, an internationally recognized expert on image guided tumor ablation treatments and primary author of the study.\nThe IRE treatment also had very low toxicity on the rectum and bladder, even in cases of advanced cancer infiltrating these structures in patients who were not candidates for surgery or radiation therapy anymore.\nThe study which was conducted at the Prostata Center of Offenbach, Germany (www.prostate-center.org) will be presented today at the annual meeting of the Radiological Society of North America (RSNA).\nInitial tumor control was achieved in all patients, and during the follow-up period of up to 4 years, the recurrence rates were 0/55 (Gleason <7), 3/117 (Gleason 7) and 10/67 (Gleason >7).\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does not provide context about the use of IRE for prostate or other cancers. Readers could easily come away from this release thinking that this is the first time outcomes have been reported on the use of IRE for prostate cancer. But other researchers have been looking into this. Also, IRE has a longer track record of use in pancreatic cancer that wasn\u2019t mentioned.", "answer": 0}, {"article": "Oct. 26, 2011 -- An experimental drug called briakinumab appears to be more effective than a standard medication for treating psoriasis, a new study shows.\nThose same results were achieved by about 10% to 20% of 163 patients in the methotrexate group.\nBut with this drug, the word 'remission' is on the table.\"\nAt that time, the company said it wanted to evaluate the \"next steps\" for briakinumab and might try for approval again at a later date.\n\"Obviously, the price that this comes with is the increased rate of serious infections and cancers.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story at least explained that \u201ca similar drug, Stelara, was approved by the FDA in 2009.\u201d", "answer": 1}, {"article": "What's more, he added, there are already several good ways to catch colon cancer -- or, even better, precancerous growths called polyps, which can then be removed before a tumor develops.\nIt's still unclear which breath chemicals should be measured, or what statistical method is best for weeding out cases of colon cancer.\nIn the end, the researchers were able to correctly identify the cancer patients 76 percent of the time.\nThe study, of 78 people with and without colon cancer, found that those with the disease tended to have a distinct pattern of chemicals in their breath.\nThey then used a statistical model to see if certain VOC patterns separated the colon cancer patients from the healthy participants.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story acknowledges that the\u00a0idea of using a breath test to catch cancer is not new, and\u00a0mentions other relevant research.", "answer": 1}, {"article": "By comparison, the only approved long-term prescription weight loss medication available on the market today, Xenical, is associated with a seven-pound weight loss when combined with diet and exercise.\nAccording to the manufacturer's study, the two drugs, when taken together, and at controlled-release doses, were very safe.\nThe Food and Drug Administration denied the request, asking for more safety data from the company before moving forward.\nParticipants in the trial reported minor side effects such as dry mouth and constipation, however at higher doses, some participants did complain about some psychiatric side effects.\nPhentermine is commonly used as a short-term weight loss treatment, and was previously paired with fenfluramine to make the successful but now-discontinued weight loss drug Fen-phen.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Again, in comparison with the LA Times\u2019 reporting, we must give the CNN.com story an unsatisfactory score because of how it treated as \u201cnew\u201d something that really wasn\u2019t.", "answer": 0}, {"article": "\"We want this to be true, we hope that this is true, but we have learned through 30, 40, 50 years of cancer screening that we have to do the right studies at the outset to know that it's true,\" Prasad says.\nThen the researchers will need to show that the rate of false alarms remains very low, otherwise people will be sent on needless and expensive medical odysseys.\nThe scientists at Hopkins have already launched their next study, which could involve tens of thousands of apparently healthy volunteers who are enrolled in the Geisinger Health Plan in Pennsylvania.\nAnother problem is that the test results find signs of cancer, but often fail to pinpoint which part of the body is affected.\n\"We've come about one step in a thousand-mile journey,\" says Vinay Prasad, an oncologist and cancer researcher at the Oregon Health and Science University who was not involved in the study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s made clear that \u201cthere have been many attempts over the decades to develop blood tests to screen for cancers \u2026 but these methods don\u2019t give reliable results.\u201d It\u2019s also pointed out that what makes this screening test unique is that it combines two previously used methods (screening for proteins and for DNA) into one test.", "answer": 1}, {"article": "You've probably heard about it \u2014 maybe you even remember seeing it once \u2014 but you're not really sure what it is or even where to find it.\n\nThe female condom (FC2), or internal condom, is a non-hormonal barrier method of birth control. But instead of going on a penis, it goes in a vagina, which is why it's also sometimes referred to as an internal condom. For more information, BuzzFeed Health spoke with two experts who could demystify this lesser-known contraceptive:\n\n* Dr. Harry Fisch, clinical professor of urology and reproductive medicine at Weill Cornell Medical College, and chief corporate officer of Veru Healthcare, which distributes FC2\n\n* Dr. Lauren Streicher, associate clinical professor of obstetrics and gynecology at Northwestern University\u2019s Feinberg School of Medicine", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains that female condoms have been around for a while, but within the past few months one manufacturer made them available by prescription.", "answer": 1}, {"article": "Larger studies in many more patients are needed before the drug will be available, though, she says.\nOct. 8, 2012 (Boston) -- An experimental Alzheimer \u2019s treatment slowed memory loss by about one-third in people with mild Alzheimer's , offering hope that the drug can alter the course of the progressive disease.\nThe benefit is small and studies have been inconsistent, says researcher Rachelle Doody, MD, head of Alzheimer\u2019s disease research at Baylor College of Medicine.\nThe latest results come from a combined analysis of a 1,012-patient study and a 646-patient study, both of which involved people with mild to moderate Alzheimer's disease.\nWhen the findings of the two studies were looked at individually, patients given solanezumab for 18 months didn\u2019t do better on either a test used to measure patients' symptoms or a measure of how well patients are functioning than patients given a placebo.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reports that this experimental drug is intended to address a possible underlying cause of Alzheimer\u2019s disease, but it does not make clear that existing treatments address symptoms only. The AP story did a better job of putting this drug in context.\nA quick search comes up with many stories just in the past 5 years that made claims about drugs slowing the progression of Alzheimer\u2019s disease.\u00a0 What makes this approach different?", "answer": 0}, {"article": ".\nThe authors suggest further research should investigate the benefits of other spices and the effects of certain chili pepper subtypes.\n\u201cSuch evidence may lead to new insights into the relationships between diet and health, updated dietary recommendations, and the development of new therapies,\u201d they write.\nThe researchers note that people who ate hot red chili peppers tended to be \u201cyounger, male, white, Mexican-American, married, and to smoke cigarettes, drink alcohol, and consume more vegetables and meats .\nIf so, science has some good news for you: Eating hot chili peppers may help you live longer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t claim novelty but says the study \u201cstrengthens the growing body of evidence that spicy food may have protective health properties that can lead to a longer life.\u201d", "answer": 1}, {"article": "This news-agency article is no longer available on nytimes.com.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story describes how proponents of smartphone apps describe what\u2019s new about these smartphone apps.", "answer": 1}, {"article": "The participants completed the same cognitive tests each year during the four-year study, with 92 percent of the college-studies group displaying a significant increase in cognitive capacity, while the remaining 8 percent generally maintained their cognitive capacity.\nThe participants who took college classes volunteered for the study so they probably had a greater interest in continuing education that the general senior population, the journal article noted.\nThe study was too short to reveal any long-term effects so the researchers plan to follow the participants as they age to provide additional evidence of whether college studies may reduce the risk or delay the onset of dementia.\nThis study is the first to examine similar positive effects from college courses taken by older adults, said Lenehan, of the University of Tasmania.\nThe participants in the college studies group took a wide range of courses, including history, psychology, philosophy and fine art.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release noted that this study was the first to report the effect of college coursework over time in older adults.", "answer": 1}, {"article": "But Andrew Shao, an executive vice president at the Council for Responsible Nutrition, a trade group, said the panel was being overly cautious, especially in its recommendations about vitamin D. He said there was no convincing evidence that people were being harmed by taking supplements, and he said higher levels of vitamin D, in particular, could be beneficial.\nIn general, most people are not getting enough vitamin D from their diets, but they have enough of the vitamin in their blood, probably because they are also making it naturally after being out in the sun and storing it in their bodies.\nNow it is easy to find pills, even in places like , with 5,000 international units.\nNot only is it in orange juice and milk, but more is being added to breakfast cereals, and it now can be found in very high doses in supplement pills.\nTo assess the amounts of vitamin D and calcium people are getting, the panel looked at national data on diets.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of vitamin D and calcium is not really in question, so we\u2019ll call this not applicable.", "answer": 2}, {"article": "However future studies will include girls too.\nThe images of the brains helped researchers correctly identify those with autism with 94 percent accuracy, says Nicholas Lange, an associate professor of psychiatry at Harvard Medical School and one of the study authors.\nZachary Warren, who is the director of the Vanderbilt Kennedy Center Treatment and Research Institute for Autism Spectrum Disorders (TRIAD), says since there are many types of autism, \"it becomes very challenging to capture all these differences with one test.\"\nThe study included only males between the ages of 7 and 28 because they were part of a bigger research project at the University of Utah, which is following males with autism for a longer period.\n\"No one has measured what we measured,\" says Lange of the MRI test he and Dr. Janet Lainhart from the University of Utah developed.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story allows the lead author to claim complete novelty. \u201c\u201dNo one has measured what we measured,\u201d says Lange of the MRI test he and Dr. Janet\u00a0Lainhart from the University of Utah developed.\u201d The story also says, \u201cno one has looked at it the way we have and no on has gotten these type of results.\u201d These two comments would lead one to believe that diffusion tensor MRI scanning in people with autism and autism spectrum disorder has not been done in the past. Although the scanners appear to be commercially available and diffusion tensor MRI scans have been done in people with autism and related disorder, the programming of the scanner appears to be unique. The story leaves this point murky.", "answer": 0}, {"article": "Learn more about Mayo Clinic.\nWhile twice-daily injections of low-molecular-weight heparin has been the traditional treatment of choice for cancer patients who suffer a venous clot, Dr. McBane notes that there are numerous limitations to this therapy.\n\"Nearly 1 in 5 patients with cancer will develop a clot in the veins, referred to as either a deep vein thrombosis or pulmonary embolism,\" says Dr. McBane.\nThe drug was associated with fewer major bleeding events and fewer recurrent blood clots, compared to low-molecular- weight heparin.\n\"More recently, a number of new blood thinners called 'direct oral anticoagulants' have become available,\" says Dr. McBane.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release addressed novelty with this statement: \u201cit was unclear whether these drugs could be used safely in cancer patients until now.\u201d \nThis research is clearly aimed at using apixaban for a new indication that isn\u2019t yet FDA approved. Other research has focused on apixaban for those with cancer but no clots. Here the focus is on secondary prevention for cancer patients that already have blood clots.", "answer": 1}, {"article": "Ten percent of study participants who had not had a hysterectomy showed precancerous changes in the lining of the uterus, and all of those resolved with weight loss.\n\"The study results demonstrate that there is a huge alteration, but I don't even know what to say about that, except it is really new and intriguing area to look at in the link between obesity and cancer.\nIt found that bariatric surgery:\n\u2022 produced a mean weight loss of more than 100 pounds\n\nCHARLOTTESVILLE, Va., Oct. 1, 2015 - A study evaluating the effects of bariatric surgery on obese women most at risk for cancer has found that the weight-loss surgery slashed participants' weight by a third and eliminated precancerous uterine growths in those that had them.\n\"There are lots of studies showing if you exercise, it improves your insulin, your glucose, all of those sorts of things that go along with the cancer-causing effect.\n\"So I could never say that effect is definitive, but it is suggestive, given that we know already the incredibly strong link between endometrial cancer and obesity.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The findings are not presented as novel, and, in fact, are in some cases placed in the context of the larger body of research. For example, the release says:\n\u201cThe study results demonstrate that there is a huge alteration, but I don\u2019t even know what to say about that, except it is really new and intriguing area to look at in the link between obesity and cancer. For example, before groundbreaking work by Dr. John Marshall at UVA in the past, no one knew that ulcers were from bacteria. Who knows what role the gut bacteria play in promoting obesity, but metabolic parameter/markers of the bacteria definitely changed after [study participants] lost weight.\u201d", "answer": 1}, {"article": "There are plenty of questions left, said Dr. Ashesh Mehta, director of epilepsy surgery at the North Shore-LIJ Comprehensive Epilepsy Care Center in Great Neck, N.Y.\n\n\"This study is an important first step,\" said Mehta, who was not involved in the research.\nIt may be the people who fall in the middle -- who have disabling seizures at unpredictable intervals -- who would stand to benefit the most, he said.\nIn this study, the implants revealed that most patients were suffering more seizures than they thought; one patient who reported 11 a month was actually having more than 100.\nThose patients went on to the next four-month phase, where the devices were activated to give warnings.\nTwo patients ultimately had the implants removed.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There has been other research about implants/devices to control epileptic seizures. See our earlier comment on vagal nerve stimulation in the \u201cAlternatives\u201d criterion.\u00a0 The story could have easily given a brief overview of some of that competing research.", "answer": 0}, {"article": "P-Cure continues to develop advanced patient-centric solutions with a focus on adaptive therapy and real time motion management.\nP-Cure (P-Cure, Ltd.), a leading provider of Patient-Centric solutions for proton therapy, has received U.S. Food and Drug Administration (FDA) approval for its patented upright imaging solution.\nThe P-Cure team is committed to enabling all oncology centers and hospitals globally to establish cost-effective proton therapy services for the best possible care and cure,\u201d said Dr. Marash.\nIn addition to the clinical benefits of P-Cure\u2019s solution, there are also significant economic advantages to treating patients in a seated position.\nIt may also deliver less collateral radiation to sensitive organs while enabling greater accuracy in proton beam delivery,\u201d said Michael Marash, Ph.D., founder and CEO of P-Cure.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release refers to this as a \u201cclinical breakthrough.\u201d While that may be a heavy-handed statement, the device is a modification of prone delivery of proton therapy and is clearly a device that is not currently in wide use. ", "answer": 1}, {"article": "\"The truth is that quit smoking programs, like other programs that treat addictions, often have fairly low success rates. But that doesn't mean they're not worthwhile or that you should be discouraged. Your own success in quitting and staying that way is what really counts, and you have some control over that. Even if you don't succeed the first few times, keep trying. You can learn from your mistakes so that you'll be ready for those pitfalls next time.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Although the story uses the word \u201cnew\u201d when it means \u201clatest\u201d in the lead paragraph, we feel it did a good enough job referring to other studies to merit a Satisfactory rating.", "answer": 1}, {"article": "This post has been updated.\nLanguage was included in the spending bill that says any recommendations of the task force related to breast cancer screening, mammography and prevention refers to those \u201cissued before 2009.\u201d\n\nSen. Barbara Mikulski (D-Md.)\nPart of the problem is the common perception that women deserve free mammogram coverage and that the scientific community is basing its decision on cost or rationing, said Lawrence Gostin, a Georgetown University law professor and expert on public health.\nThe American Congress of Obstetricians and Gynecologists, for example, recommends that regular screenings begin at age 40, while the American Cancer Society calls for women to start yearly screening at age 45 and then move to screening every two years starting at age 55.\nWorried that millions of women under 50 could lose their free annual mammogram coverage if the guidelines became final, several health-care groups, including ACOG, the American College of Radiology and the Susan G. Komen Foundation, lobbied Congress to block that from happening.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does tell readers that the new recommendations on mammograms and breast cancer screening are consistent with the USPSTF\u2019s 2009 recommendations \u2014 which triggered a fierce (and still ongoing) debate over the issue. The story also offers a good primer on congressional action related to the debate, particularly as pertains to legislation that mandates insurance coverage of mammograms for breast cancer screening.", "answer": 1}, {"article": "The ongoing study, which used previous stroke estimates for comparison, was based on data from 4,789 patients from TIAregistry.org, an international registry designed to follow cases for as long as five years.\nOne year after symptoms, the stroke rate was 5.1 percent.\nThe study was also noteworthy because, over the long haul, patients did a particularly good job of taking the medications they were given.\nMore than two thirds of the patients in the study had a score of 4 or higher but the researchers caution that \u201climiting urgent assessment to patients with a score of 4 or more would miss approximately 20 percent of those with early recurrent strokes.\u201d\nOutcomes in this study were at least 50 percent lower than those reported in previous studies,\u201d Sacco and Rundek write.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "As with availability, we do wish the story had better explained to readers how novel a TIA unit is.", "answer": 0}, {"article": "The games are based on the work of Japanese neuroscientist Ryuta Kawashima, M.D.\nIn the future, the researchers hope to study whether the plasticity induced by video games in MS patients is also related to improvements in other aspects of their daily lives.\n\"Functional MRI allows you to study which brain areas are simultaneously active and gives information on the participation of certain areas with specific brain circuits,\" Dr. De Giglio said.\nDamage to the thalamus, a structure in the middle of the brain that acts as a kind of information hub, and its connections with other parts of the brain play an important role in the cognitive dysfunction many MS patients experience.\nThey used a collection of video games from the Nintendo Corporation, called Dr. Kawashima's Brain Training, which train the brain using puzzles, word memory and other mental challenges.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "A study showing that a video game used regularly in a home environment might improve the condition of MS patients, if confirmed, is certainly novel enough to warrant a news release, although the lack of substantive findings from the research weaken its value to readers.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/01/17/national/a130050S19.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story provides accurate\ninformation that watchful waiting vs. preventive surgery is a newer approach to treating men with mildly symptomatic hernias.", "answer": 1}, {"article": "BLOOMINGTON, Ind.\nThe larger number of people in the two more recent studies -- as well as the use of U.S. patients in the new analyses -- strengthens this earlier evidence.\nThe results, based upon nearly 3 million people with ADHD in the United States, are reported in the American Journal of Psychiatry.\nAs one of the largest analyses on the risks and benefits of ADHD medication, the study drew on anonymous health care data from 146 million people with employer-based health insurance in the United States from 2005 to 2014.\nThe majority of the ADHD medicines used in the study were stimulants such as Adderall, an amphetamine, and Ritalin, or methylphenidate.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release did not claim that this study was novel. In fact, it mentioned that it built upon previous work from the same authors which found benefits to ADHD medication in other studies based in the US and Sweden.", "answer": 1}, {"article": "Repatha, with a list price of more than $14,000 a year, was approved based on its ability to dramatically lower \u201cbad\u201d LDL cholesterol in patients who require more intensive therapy on top of widely-used statins, such as Lipitor, or who are unable to tolerate statins.\nAt the heart meeting in March, researchers will also provide details on risk reduction for each of the components, such as non-fatal heart attack, non-fatal stroke, and heart-related death.\nThe trial was widely expected to be positive, especially after a smaller study presented in November showed Repatha therapy led to regression of artery-clogging plaque, an underlying cause of heart disease.\nThe data should pave the way for greater acceptance by health insurers and pharmacy benefit managers, who have been rejecting about 75 percent of prescriptions written for the expensive medicine despite multiple appeals by physicians.\n\u201cThese results show unequivocally the connection between lowering LDL cholesterol with Repatha and cardiovascular risk reduction, even in a population already treated with optimized statin therapy,\u201d Amgen research chief Sean Harper said in a statement.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story attempts to\u00a0explain the novelty of the research several times; for example, when it states that the study possibly offers \u201cconcrete proof that the drug could actually reduce the risk of heart attacks and death.\u201d The story should have explained that this is unverified until the data is released.", "answer": 1}, {"article": "MONDAY, Dec. 17, 2012 (HealthDay News) -- For patients whose high blood pressure cannot be controlled despite taking several medications, a short burst of radio waves at the nerves around the kidneys may do the trick, a small new study says.\nThe 35 patients in this phase of the study had similar results to the initial group.\nThe treatment was effective for at least six months.\nThe procedure is safe as well as effective, the study authors said.\nThe findings were published Dec. 17 in the journal Circulation.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story didn\u2019t reference any of the other of a growing list of other approaches to resistant hypertension.\u00a0 See some of our recent blog posts on this issue:", "answer": 0}, {"article": "[3] Analysis only included cases occurring 10 days after receiving the vaccine to account for the incubation period of the Ebola virus.\nThe study found that the vaccine was safe and induced an immune response that peaked at 28 days, but decreased during the six months post injection.\nIn case of Ebola flare-ups prior to approval, access to the vaccine is being made available through a procedure called \"compassionate use\" that enables use of the vaccine after informed consent.\nIn January, GAVI, the Vaccine Alliance provided US$5 million to Merck towards the future procurement of the vaccine once it is approved, prequalified and recommended by WHO.\nThe vaccine is the first to prevent infection from one of the most lethal known pathogens, and the findings add weight to early trial results published last year.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release notes that no other Ebola vaccine is currently available, briefly summarizes results of a trial of an alternative vaccine and notes that the study findings being described \u201cadd weight to early trial results\u201d published previously on the same vaccine.", "answer": 1}, {"article": "DOI: 10.5435/JAAOS-D-17-00318\nThey found the following:\n\u2022 For pain reduction, cortisone injections provided the greatest short-term (4 to 6 weeks) pain relief, followed by ibuprofen, PRP injections, naproxen, and celecoxib.\n\"This is the first comprehensive mixed-comparison analysis comparing best-evidence scientific research and excluding lower quality studies that can bias the outcomes,\" said lead author and orthopaedic surgeon David Jevsevar, MD, MBA.\nAlthough the use of NSAIDs for arthritic conditions such as knee OA has potential risks, including heart attack and stroke, existing evidence indicates that naproxen has less potential for adverse cardiovascular events.\n\"Because knee OA has both a high disease burden and high treatment costs, additional prospective studies using similar outcomes, timelines, and measures of clinically important changes are needed,\" explained Dr. Jevsevar.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release includes a quote from an author that, \u201cThis is the first comprehensive mixed-comparison analysis comparing best-evidence scientific research and excluding lower quality studies that can bias the outcomes.\u201d A search of PubMed.gov did not find any other similar meta-analyses, except for one that the authors discussed in their journal article. They criticized that earlier meta-analysis for including lower quality studies that they said muddled the results.", "answer": 1}, {"article": "Nine were receiving an immunotherapy treatment for the first time as part of the study.\nThe results of the study suggest that the combination of pembrolizumab and SD-101 could provide an alternative treatment for people with melanoma whose tumors have not responded or would be unlikely to respond to other therapies.\n\"We have found that the reason patients with metastatic melanoma do not initially respond to immunotherapy with an anti-PD-1 is that their immune system was not ready,\" said Dr. Antoni Ribas, the study's lead author, a professor of medicine at the David Geffen School of Medicine at UCLA and director of the UCLA Jonsson Comprehensive Cancer Center Tumor Immunology Program.\nThe study highlights the need for more research into combination therapies like this one, because many people with cancer do not respond to immunotherapy or experience a reoccurrence of their tumors after treatment.\n\"This particular combination has been especially gratifying because not only does the SD-101 therapy drug induce tumor shrinkage at the actual site where it's injected, but it's working in conjunction with pembrolizumab to shrink tumors outside of the ones we're directly injecting.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release explains that injecting the drug into the metastatic sites to change the microenvironment is a new type of approach to improving response to Keytruda, though it could have provided more context.\nWithin the cancer research community, there is a lot of interest in the\u00a0tumor microenvironment. As the National Cancer Institute explains, the microenvironment consists of the normal cells, molecules, and blood vessels found around the primary tumor and metastatic sites. This environment affects how the cancer cells grow and spread, so scientists think if they can change the environment they might be able to change how the tumor responds to cancer treatments.\u00a0In this study, the researchers attempted to do that by injecting the experimental drug directly into the metastatic sites.", "answer": 1}, {"article": "Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others: the ability of HETIOZ\u00ae to provide significant benefit in the treatment of the symptoms of jet lag disorder; Vanda's ability to obtain marketing approval for the use of HETLIOZ\u00ae in the treatment of jet lag disorder; and other factors that are described in the \"Risk Factors\" and \"Management's Discussion and Analysis of Financial Condition and Results of Operations\" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2017, which is on file with the SEC and available on the SEC's website at www.sec.gov.\nThe results of that study were published in The Lancet in 2009.1 The observation that HETLIOZ\u00ae is effective in treating the symptoms caused by an abrupt advance of the circadian cycle of a magnitude of 5 or 8 hours suggests that HETLIOZ\u00ae will be an effective therapeutic tool in the treatment of individuals that experience symptoms of jet lag.\nThe risk of adverse reactions may be greater in elderly (>65 years) patients than younger patients because exposure to HETLIOZ\u00ae is increased by approximately 2-fold compared with younger patients.\nThe risk of adverse reactions may be greater in elderly (>65 years) patients than younger patients because exposure to HETLIOZ\u00ae is increased by approximately 2-fold compared with younger patients.\nIt is also reported that 8% (approximately 1.6 million) travel in Business or First class.2\n\n\"We are extremely pleased with the outcome of this study which establishes the utility of HETLIOZ\u00ae in the treatment of jet lag disorder as HETLIOZ\u00ae was shown to overcome a significant circadian challenge of an 8 hour phase advance.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release says essentially nothing about how the drug works, or how it is better than, or different from, other jet lag therapies and preventive measures such as melatonin and light therapy. The drug is a melatonin receptor agonist, meaning it\u2019s designed to work in the brain in ways similar to melatonin, but the release doesn\u2019t discuss any of this.", "answer": 0}, {"article": "Vahia cited several examples of the tablet's potential to improve a patient's condition.\nThe study also found that the tablets demonstrated significant effectiveness in reducing symptoms of agitation, particularly--but not exclusively--among patients with milder forms of dementia.\n\"Use of Tablet Devices in the Management of Agitation Among Inpatients with Dementia: An Open Label Study\" was recently published in the online version of The American Journal of Geriatric Psychiatry.\nThe researchers found that tablet use was safe for every patient, regardless of the severity of their dementia, and that with proper supervision and training, the engagement rate with the devices was nearly 100 percent.\nThis will allow researchers to develop more robust data and expand the scope of the study, including a focus on specific clinical factors that may impact how patients with dementia engage with and respond to apps.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release addresses novelty, but indirectly. First, it states that the research \u201cbuilds upon previous studies demonstrating that art, music, and other similar therapies can effectively reduce symptoms of dementia without medication. It also notes: \u201cOur preliminary results are a first step in developing much-needed empirical data for clinicians and caregivers on how to use technology such as tablets as tools to enhance care and also for app developers working to serve the technologic needs of this population.\u201d\nThe study itself was more explicit about novelty when the authors wrote that \u201cto our knowledge this is the first study to examine such an intervention in this cohort.\u201d That would have been a good line to include in the release.", "answer": 1}, {"article": "For more information visit http://www.\nThe research showed that using 'liquid biopsies' that measure cancer DNA circulating in the blood to detect PIK3CA, and tests for blood hormone levels, the palbociclib combination worked in all types of hormone-receptor positive, HER2 negative breast cancer.\nIn the trial, researchers from 144 research centres in 17 countries followed 521 women allocated to receive either palbociclib and fulvestrant, or a dummy pill and fulvestrant.\nSome 67 per cent of the 347 women in the palbociclib plus fulvestrant group showed clinical benefit - either a reduction in tumour size or control of disease for at least six months - compared with 40 per cent of the 174 women in the placebo plus fulvestrant group.\nIt provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release appropriately gives the context of the current study as related to previous studies on palbociclib. The novelty established is the new drug combination proves more potent than just one of the drugs alone.", "answer": 1}, {"article": "How an Activity Tracker Caught an Unexpected Pregnancy Fitness trackers, by nature of being worn around the clock, have the potential to capture unexpected insights about how your body works \u2014 and simplify laborious acts like manually figuring out your fertile days.\nAnd the study had one particularly unexpected outcome.\nResearchers were watching all these biometrics as the study participants went through their cycles.\nHowever, H\u00f6gqvist Tabor said, this information by itself should not be used as a birth control method.\nWearables have a well-worn reputation as step-counting machines.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story discusses other technologies that perform related functions.", "answer": 1}, {"article": "All had previous surgery to remove as much of the tumor as possible, and all received chemotherapy before, during or after proton therapy.\n\"Our results indicate that proton therapy maintains excellent cure rates in pediatric medulloblastoma while reducing long-term side effects, particularly in hearing and neurocognitive function, and eliminating cardiac, pulmonary, gastrointestinal and reproductive effects,\" says Yock, who is an associate professor of Radiation Oncology at Harvard Medical School.\nThe use of proton radiotherapy to treat the most common malignant brain tumor in children is as effective as standard photon (x-ray) radiation therapy while causing fewer long-term side effects such as hearing loss and cognitive disorders, according to a study receiving online publication in Lancet Oncology.\nThe MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $800 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.\nThe paper from a team led by Massachusetts General Hospital (MGH) investigators describes patient outcomes an average of seven years after proton therapy for medulloblastoma, a fast-growing tumor that develops in the cerebellum at the base of the brain.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Both the release and the study make a claim of novelty, meaning that this type of analysis had not been done before. The study establishes that this type of research is new based on its literature review and extensive citations of previous studies. It says, \u201cTo the best of our knowledge, no other data for the late effects or disease control of proton therapy for patients with medulloblastoma are as complete and mature as ours.\u201d The release adequately summarizes the state of current evidence by saying, \u201cWhile proton therapy may appear to be ideal for reducing these adverse effects, no previous study had prospectively examined the long-term results of children treated for medulloblastoma with proton therapy.\u201d", "answer": 1}, {"article": "Asthma has complicated Todd Anderson's life ever since he was 3 years old. Doing sports\u2014even stairs\u2014had been difficult. Cigarette smoke, pollen, disinfectants or a passing whiff of perfume could set off a severe asthma attack. \"It feels like your chest is clenching up like a fist,\" says Mr. Anderson, a 29-year-old music teacher in the New York City schools.", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\n\nBronchial thermoplasty is indeed a relatively new approach to treating asthma. However, almost all of the trial results reported in this story were announced more than a year ago. The news is that the researchers recently presented results from the second year of follow-up at a medical meeting. However, the new information was barely mentioned in the story.", "answer": 1}, {"article": "\u201cOver the next couple of years, we will find out what it means.\u201d\n\nOn Oct. 23, 2008, Avid and two other companies, and , that are developing fluorine 18-based dyes for amyloid scans, got a pointed question from an advisory committee to the F.D.A.\n\u201cSomething bad happens, and now something good happens.\u201d\n\nLate last year, Avid saw the initial results of its hospice study \u2014 data from the first six patients.\nOther tests are being studied \u2014 ones that look for amyloid in cerebrospinal fluid that bathes the brain; scans that look for shrinkage of the brain in areas needed for memory and reasoning; PET scans that look for uptake of glucose, a cellular fuel, to show areas where the brain was active and where it was not.\nAnd with such a high rate of misdiagnosis, some who are mistakenly told that they have Alzheimer\u2019s are not treated for conditions, like depression or low levels of thyroid hormone or drug side effects and interactions, that are causing their memory problems.\nMost of the time, the scans were as expected \u2014 those with Alzheimer\u2019s had lots of plaque, those with normal memories had little if any and those with mild memory impairment were in between.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that \"There is no treatment yet to stop or slow the progress of Alzheimer\u2019s. But every major drug company has new experimental drugs it hopes will work, particularly if they are started early.\" And it goes on to say that, \"Other tests are being studied \u2014 ones that look for amyloid in cerebrospinal fluid that bathes the brain; MRI scans that look for shrinkage of the brain in areas needed for memory and reasoning; PET scans that look for uptake of glucose, a cellular fuel, to show areas where the brain was active and where it was not. The tests, though, were not necessarily specific for Alzheimer\u2019s and none had been studied to see if they accurately predicted plaque on autopsy.\"", "answer": 1}, {"article": "However, the current non-invasive alternative \u2014 an ultrasound done at the end of the first trimester \u2014 isn\u2019t always good at spotting a baby\u2019s sex, Bianchi\u2019s team reported in the Journal of the American Medical Association.\nBecause such disorders mostly strike boys, knowing that the baby is a girl could spare the mother diagnostic procedures, such as amniocentesis, that carry a small risk of miscarriage.\nBut other researchers voiced concerns, saying it could be misused to terminate a pregnancy if the baby isn\u2019t of the desired sex.\nIn those procedures, doctors either extract a small amount of the fluid that surrounds the fetus (amniocentesis) or they take a sample of the placenta (chorionic villus sampling).\nAnd the blood test is reliable as early as seven weeks into the pregnancy, whereas ultrasound is not.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The test is not novel. The story explained this was a \u201cfresh look at the medical evidence for the blood test.\u201d", "answer": 1}, {"article": "For 10 years, researchers tracked 2,766 people nationwide with pre-diabetes -- a metabolic condition featuring slightly elevated blood-glucose levels that often serves as a precursor to type 2 diabetes.\n\"We were hopeful and now encouraged that modest lifestyle changes produce benefits,\" she said.\n\"I feel that it's keeping me healthy,\" said the retired metallurgist.\n\"We used solid behavioral principles and teachings, and a community of support.\"\nBenefits of intensive lifestyle changes were most pronounced in the elderly, with people 60 or older reducing the rate of developing type 2 diabetes by half.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "No claim of novelty is made for the lifestyle or drug interventions. ", "answer": 1}, {"article": "Revenues from pharmaceutical and device corporations are available at http://www.\nThe international DAWN trial previously demonstrated that patients with a small area of irreversible brain damage and a large area of brain at jeopardy of being lost if the clot remains are more likely to recover with minimal disability if the clot is removed up to 24 hours after symptoms begin or were noticed.\nIn the current analysis of treatment between 6 and 24 hours after symptoms were observed, or after the person was last seen to be well, researchers found:\n\u2022 each 1-hour delay reduces the chance of recovery with minimal or no disability by 11 percent; and\n\u2022 treatment remains beneficial through 24 hours, with patients who had their clots removed being 35.5 percent more likely to have minimal or no disability 90 days later, but the overall effect of treatment declines with time.\nThe current results demonstrate the importance of prompt imaging and treatment of patients with clot-caused stroke, even in those who wake up having experienced a stroke or who for other reasons are not identified in the first few hours after the onset of symptoms.\nIt is already well-established that the benefit of clot removal declines each hour during the first 6 hours after symptoms are detected.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release established that this study was one of the first to demonstrate that clot removal between 6 and 24 hours can still be beneficial. It did not mention, however, another trial that also found similar results. The\u00a0DEFUSE 3 trial, published last week, found that thrombectomy can be beneficial between 6 and 16 hours after the onset of a stroke. Both of these trials together were used to influence the updated AHA/ASA guidelines.", "answer": 1}, {"article": "In the first year of a two-year trial, 5 of the 31 of those on medication developed full-blown psychosis, compared with 11 of 29 of those who were taking dummy pills.\nSome left the study without explaining why; others moved; and 10 of those on medication quit the study because they felt the drug was not working, could not make the appointments or did not like the side effects, among other reasons.\nThe new study was intended in part to clarify the trade-off between the risks and the potential benefits of preemptive treatment.\nBut by then, more than two-thirds of the young people in both groups had dropped out, making it difficult to interpret differences between them.\n\"It's clear we need more efficacious drugs with milder side effects.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions that this is a clinical trial. Anti-psychotic drugs are not typically used in clinical practice for the prevention or reduction in severity of psychotic episodes because of the potential for harmful side effects.", "answer": 1}, {"article": "The average reduction in blood pressure caused by a single anti-hypertension drug is 9/5 mmHg.\nThe trial was double-blind, which means neither the administering clinicians nor the patients knew whether the beetroot juice they were given was the placebo or the active supplement.\nThey found the following results:\n\nFor the trial, Prof. Amrita Ahluwalia of the vascular pharmacology department at QMUL and her colleagues recruited 64 people aged between 18 and 85 years.\nBecause of the widespread impact of high blood pressure, researchers are likely to investigate in some depth any simple dietary interventions that could potentially benefit the wider population.\nThe authors note that the reduction achieved in the active supplement group is close to that achieved by medication.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that the new study builds on previous research by this team, and a quick search confirms that these researchers were among the first to investigate the blood pressure effects of beet juice.", "answer": 1}, {"article": "The Food and Drug Administration approved Provenge this spring to treat advanced prostate cancer.\nThe way the study was done, he says, \"does not allow one to conclude\" that Provenge is working because it mobilizes the immune system specifically against prostate cancer.\nThe primary mystery is how Provenge extends life, since it doesn't shrink prostate tumors, as far as anyone can tell.\n\"Prolongation of survival without a measurable antitumor effect is surprising,\" writes Dr. Dan Longo of the National Institute on Aging in a NEJM editorial.\nAnd it's clear that experts are still scratching their heads about just how Provenge works.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story leads with:\u00a0\"After decades of dreaming about getting patients\u2019 immune systems to fight cancer, immunotherapy is finally here.\" And later: \"\u2026after all, Provenge is just the first cancer immunotherapy on the market.\"\u00a0", "answer": 1}, {"article": "Wilmington, DE, December 17, 2018 - The CRISPR-Cas9 gene editing system may be able to restore the effectiveness of first-line chemotherapies used to treat lung cancer by deleting or \"knocking out\" a gene in cancer tumors that helps the tumors develop resistance to the drugs.\nThe study reports that in both tissue culture and in a mouse, tumor growth stopped and there was a dramatic decrease in the volume of existing tumors when chemotherapy was combined with CRIPSP-Cas9, which was used to disable a tumor gene known as NRF2.\nHe said for now, his team is focused on \"using CRISPR in its native form, which is to just cut out a section of DNA,\" and to start with applications that do not directly impact the patient's DNA.\nBut he said some patients with non-small-cell lung cancer, the most common form of lung cancer, are resistant to chemotherapy agents used to treat the disease or develop resistance after being exposed to the drugs.\nCas9 is a reference to an enzyme, sometimes described as a form of \"molecular scissors,\" that is used by CRISPR to cut out a section of DNA code.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The lead researcher calls the study\u00a0\u201can exciting step in the journey of exploring the health benefits of gene editing\u201d and says it is focused on a technique\u00a0of cutting out the resistance gene using CRISPR. This would be a novel approach and a novel use of CRISPR.\nIn the study, the authors say that to their knowledge, \u201cwe are the first to generate\u201d cells that are deficient in a gene NRF2, which helps promotes chemotherapy resistance in lung tumors.", "answer": 1}, {"article": "Studies have been inconclusive, but doctors and patients have voted with their feet in favor of the less-invasive procedure \u2014 clearing clogged arteries and propping them open with tiny scaffolds called stents.\nWhen doctors recommend surgery, these data suggest that that decision is a good one.\"\n\"It's a very big deal to recommend coronary surgery to patients,\" Weintraub says.\n\"I think doctors work very hard to weigh what's best for their patients.\n\"We would hope a study as powerful as this one will inform decision-makers to rethink the direction they're going in,\" the NHLBI's Dr. Michael Lauer told Shots.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Adequate: \u201cStudies have been inconclusive\u201d \u2026 \u201cNow the biggest collection of cases so far comes out in favor of surgery\u201d", "answer": 1}, {"article": "LOS ANGELES -- Researchers have demonstrated for the first time that the progression of Type-1 diabetes can be halted -- and possibly reversed -- by a stem cell transplant that preserves the body's diminishing ability to make insulin, according to a study published today.\nThe patients, who ranged in age from 14 to 31, were treated with drugs and hormones that prompted the body to produce hematopoietic stem cells and send them from the bone marrow into the bloodstream, where they were extracted by a special machine.\nThe treatment had no effect on one patient, whose disease had already progressed too far, doctors decided.\nOne subject, a 30-year-old male, hasn't taken insulin since his stem cell transplant more than three years ago, according to the study in the Journal of the American Medical Association.\nBut other doctors said that even if the benefits of the therapy are temporary, the research provides valuable insight into the mechanism behind the disease.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story states the research suggests a new avenue of treatment for people with Type I diabetes letting readers know this would be a new treatment (although the story states stem cell transplantation has been used with other conditions).\u00a0 ", "answer": 1}, {"article": "The Ache: Nearly 5,000 people a year die from choking in the U.S., according to the nonprofit National Safety Council.\n\nThe Claim: Two new easy-to-use devices work like plungers to suck out obstructions in the airway, providing another option if standard treatment\u2014such as abdominal thrusts developed in 1974 by Henry Heimlich\u2014fail to clear the airway, say the companies who sell them.", "question": "Does the story establish the true novelty of the approach?", "explanation": "It seems like one particular\u00a0novelty of the device is the demographic it targets:\nEarly adopters of the devices include people with chronic diseases at high risk for choking.", "answer": 1}, {"article": "The bad news is that there is no benefit of being less likely to develop heart disease, and any reduction in the risk of hip bone fractures evaporates with time, according to a report in the latest issue of the Journal of the American Medical Association.\nThere\u2019s some good news and some bad news for women who took estrogen to help them get through menopause until the health risks of taking the hormone were discovered.\nThe researchers found that the risk for heart disease during the follow-up period was similar to that seen while the women were taking the hormone.\nIn the new analysis, researchers analyzed data collected from 7,645 women who were in the part of the study examining the effects of taking estrogen alone an average of 10.7 years, after the study was halted because of the evidence the drugs were harming women.\nFor years, women took estrogen or a combination of estrogen and progestin to help alleviate hot flashes and other symptoms of menopause, and in the belief that the drugs had a host of health benefits, including protecting their hearts.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story didn\u2019t make any inappropriate claims of novelty about estrogen use, and it appropriately characterized the study as a new analysis of the landmark Women\u2019s Health Initiative. ", "answer": 1}, {"article": "They received acupuncture twice a week for 30 minutes over four weeks.\nStill, \"our study shows that physicians and patients have an additional treatment for something that affects many men undergoing prostate cancer treatment and actually has long-term benefits, as opposed to more side effects,\" said lead author Dr. Hani Ashamalla, a radiation oncologist at New York Methodist Hospital, in a news release from the American Society for Radiation Oncology.\nThe study, published in the April issue of the International Journal of Radiation Oncology, Biology, Physics, also found that acupuncture relieved the heart palpitations and anxiety often associated with hormone therapy for prostate cancer.\nIt's also possible, he said, that the symptoms went away on their own, which commonly happens to men on hormone therapy.\nThe question is whether the acupuncture reduced the hot flashes or a placebo effect played a role, said Freedland, who's familiar with the study findings.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "No context was given for placing this research into the bigger picture of what else is doing for the hot flash problem, or if other related acupuncture research has been done.\nA study (Harding C, et al) was published in the British Journal of Urology International in January 2009, reporting on a larger pilot study of 60 men with advanced prostate cancer who did show substantial symptomatic improvement. Those authors called for randomized trials to more definitively determine benefit.", "answer": 0}, {"article": "This test might help.\nIn a subgroup of women, the test accurately classified 4 of 5 preterm deliveries as being at-risk, and incorrectly suggested that 3 of 18 women who had a full-term pregnancy were at risk for early labor.\n\"Those molecules will circulate in the blood for some time, they can be measured, and you can see the contributions from essentially every tissue in the body,\" senior investigator Stephen Quake told BuzzFeed News.\nHowever, a new blood test \u2014 which is still experimental and not yet available outside of a research lab \u2014 can pick up on gene activity in the body that suggests a pregnancy is at risk for preterm delivery, according to a study published Thursday in the journal Science .\nThe study was funded by the March of Dimes and other nonprofit sources, although Quake and his colleagues have filed for a patent on the test.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story references other unnamed blood tests that use cfRNA, though it clinches the novelty of the experimental preterm pregnancy test through an anecdote from one of the researchers.\nHowever, the story does not comment on other biomarkers (blood tests to detect factors correlated with preterm birth).\u00a0 As context, there have been many other biomarkers studied that have not proven to have clinical utility.\u00a0 Over 72 studies of biomarkers involving almost 90,000 women were examined in a 2011 review, which concluded that none, alone or in combination, were clinically useful to predict spontaneous preterm birth in asymptomatic women.\u00a0 There is much more work to be done to establish whether this new test performs well, and readers need that critical context.", "answer": 0}, {"article": "Largely due to its anti-inflammatory and anti-bacterial properties, the herb thyme -- which is found with other herbs in the produce section of most food stores -- may well earn itself a place in the skin care section of your local drug store.\nThey all had greater antibacterial effect after five minutes compared to lab specimens exposed to plain alcohol, but thyme was the most potent.\nIn fact, the thyme tincture was more powerful than standard concentrations of benzoyl peroxide, which is the active ingredient in many acne products.\n\"The problem with treatments containing benzoyl peroxide is the side effects they are associated with,\" namely a burning sensation and skin irritation.\n\"Herbal preparations are less harsh on the skin due to their anti-inflammatory properties, while our results suggest they can be just as, if not more, effective than chemical treatments,\" she says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There was no discussion of any other current or past attempts to find herbal remedies \u2013 or any other remedies \u2013 for acne.", "answer": 0}, {"article": "For more information, click on www.hsrxbiopharmaceutical.com\nAfter 48 hours, the average pain reduction for OsteoRx\u2122 users was nearly three times greater than for patients using the competing brand.\n\"We demonstrated superior treatment outcomes with our acne product in a head-to-head clinical trial against the market-leader, and now we've done the same with OsteoRx\u2122.\n\"Research funded by U.S. National Academy of Medicine shows that 70 million adults suffer from joint pain, making it the most prevalent source of pain.\n\"Joint pain associated with normal aging and over-exercising is extremely common,\" said Thomas Sullivan, Jr., Chief Executive Officer of HSRx Biopharmaceutical.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release suggests newsworthiness by stating the subject product outperformed another. We are not told the ingredients for either product so it\u2019s impossible to judge the novelty of this combination with the limited information provided.", "answer": 0}, {"article": "The quality of life survey measured overall functioning (physical, emotional, cognitive, etc.\nThe study is titled \u201cQuality of Life in Patients Undergoing Pleurectomy and Decortication for Malignant Pleural Mesothelioma.\u201d The surgeries were performed by Dr. Vigneswaran at University of Chicago Medicine, where he practiced before recently joining Loyola.\nPrior to surgery, 31 percent of the patients had a performance status score of 0 (fully functional); 65 percent had a performance status score of 1 (able to do light house work or office work); and 4 percent had a performance status of 2 (ambulatory and capable of self-care, but unable to work).\n\u201cThe net benefit of pleurectomy and decortication justifies the procedure in the majority of patients with malignant pleural mesothelioma,\u201d Dr. Vigneswaran concluded.\nNewswise \u2014 MAYWOOD, IL \u2013 Although surgery can prolong the lives of patients with an aggressive type of cancer called malignant pleural mesothelioma, many patients avoid the operation for fear it will degrade their quality of life.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Pleurectomy and decortication (PD) have been around since the 1950s and are not considered novel treatments and have previously been shown to improve or maintain QOL. We\u2019re not sure what\u2019s exactly \u201cnew\u201d about this research. What insight does this study bring to the existing body of literature? \nTherefore, we give the news release a \u201cNot Satisfactory\u201d rating here. ", "answer": 0}, {"article": "Christian\u2019s team studied 676 school-age children whose mothers had been in a clinical trial in which some got iron and folic acid supplements and other nutrients while they were pregnant.\n\u201cThese results speak to a large swath of people residing in that part of the world.\n\u201cWhat we showed is prenatal iron and folic acid supplementation had a significant impact on the offspring\u2019s intellectual level and motor ability and ability during school age, which was a very exciting finding,\u201d she said.\nThe World Health Organization estimates that in developing countries, every other pregnant woman is anemic and about 40 percent of preschool children are anemic.\n\u201cWe had the opportunity to follow the offspring of women who had participated in a randomized trial of iron and folic acid and other micronutrients to assess neurocognitive function and outcomes,\u201d Christian said in a telephone interview.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "What\u2019s novel here is the real-world application of a supplementation program in a low-resource setting and then enough follow through to generate results connecting the intervention to actual improvements in health and behavior.", "answer": 1}, {"article": "I was missing my husband so badly.\u201d\n\nEven after seeing a therapist, which helped, she suffered from nightmares and couldn\u2019t bear to hear arias from their favorite operas.\n\u201cThe pain just didn\u2019t go away,\u201d she said.\n\u201cI volunteered, to get myself out and doing things, to fill the gaps,\u201d she said.\n\u201cI had many interests.\u201d She traveled and even tried dating again.\n\u201cI had terrible pangs of sadness and despondency.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes the novelty of complicated grief therapy.", "answer": 1}, {"article": "The change comes amid sharp controversy over new recommendations from a federal task force that women wait until age 50 before they begin having routine mammograms and that women age 50 to 74 scale back to getting the exams routinely every two years.\nThe National Cervical Cancer Coalition, a patient advocacy group, endorsed the recommendations.\n\"More testing is not always more intelligent testing.\"\nThese recommendations are sound,\" she said.\nBut in this case, if anything, we're taking money out of our own pockets.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of cervical cancer screening is not in question in this story. ", "answer": 2}, {"article": "The study's primary endpoint was OS.\nThe findings are the final results of the single institution, Phase II study and represent the longest follow-up to date of stage 3 lung cancer patients who have received proton therapy, said Joe Y. Chang, M.D., professor, Radiation Oncology and the study's corresponding author.\nWhile the study's survival, recurrence rates and toxic effects are still favorable when compared to rates associated with the most advanced traditional photon radiation therapy, intensity modulated radiation therapy (IMRT), technology to diagnose and stage the disease, as well all treatment modalities have significantly improved.\nHOUSTON - For patients with advanced, inoperable stage 3 lung cancer, concurrent chemotherapy and the specialized radiation treatment, proton therapy, offers improved survival compared to historical data for standard of care, according to a new study from The University of Texas MD Anderson Cancer Center.\n\"With our study, we hypothesized that proton therapy would offer a survival benefit to patients and reduce treatment-associated toxicities, which can be very serious,\" he said.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The novelty of the findings are summarized in this sentence: \u201cThe findings are the final results of the single institution, Phase II study and represent the longest follow-up to date of stage 3 lung cancer patients who have received proton therapy.\u201d\nThe release focuses on long-term efficacy and safety. This is what is supposedly novel. The treatment itself isn\u2019t. Again, this could have been made clearer, but it can be discerned on a careful read.", "answer": 1}, {"article": "This is relatively new thinking.\n\u201cIt is not clear that it is the specific early introduction of an allergenic food that renders immunological protection, rather than the accompanying increased diversity in the diet that occurs as a by-product,\u201d writes Dr. Matthew Greenhawt, an allergy and immunology specialist at Children\u2019s Hospital Colorado, in the accompanying editorial.\nWhen babies eat certain foods early in life\u2014the kinds so many end up allergic to, like eggs and peanuts\u2014they\u2019re less likely to develop allergies to those foods later on, finds a new analysis published in the ( ).\nBut, as an editorial published in the same issue of points out, in the next decade, food allergy prevalence nearly doubled in the United States.\nEarly introduction didn\u2019t seem to make a difference for autoimmune diseases, at least according to the available evidence; eating gluten young wasn\u2019t associated with the risk of developing celiac disease.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes the novelty of the research here:\n\u201cThis is relatively new thinking. Not so long ago, in 2000, the American Academy of Pediatrics recommended that allergenic foods be kept away from infants until they were at least a year old, and often older.\u00a0..That advice has been amended, and newer evidence has shown that introducing foods earlier is actually better for preventing food allergies.\u201d", "answer": 1}, {"article": "\u201cIf this is the case, dosage shouldn\u2019t matter.\nBut the fact that the fewest recurrences were seen in men who took the highest statin doses is compelling, says senior investigator Stephen J. Freedland, MD, of the Duke Prostate Center.\n\u201cStatin users may see their doctors more often and may be more health conscious in general, and it has been suggested that this could explain the observed reduction in risk,\u201d Freedland tells WebMD.\nIn a new study from Duke University Medical Center, men who took statins for their hearts were 30% less likely to have their cancers come back after their prostates were removed than men who did not take the drugs.\nThose who took the highest doses saw their recurrence risk drop by half.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There is this odd quote in the story from the study author. \u201cObviously this is just one study, and it is observational,\u201d he says. \u201cBut if these findings are confirmed, this is pretty profound.\u201d This could have been a great opportunity for the reporter to explain what he means by an observational study and how much, much, much more work on a much larger group of patients would be necessary before statins could be safely recommended as a cancer treatment. Instead, the quote just ends on a positive note.", "answer": 0}, {"article": "The page you are looking for has either moved or is not available (error 404).\n\nPlease return to the homepage or use the search box above to see if the page is available in a new location.\n\nIf you think this message is in error or need assistance, please email the webmaster.", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The study authors say that their work is unique: \u201cSo far, no study has prospectively compared blood transfusions with hydroxycarbamide [hydroxyurea] for children with sickle cell anemia and abnormal TCD [transcranial doppler] velocities, even though this is the largest group of children with sickle cell anaemia who currently receive chronic transfusions, and no alternative treatment to transfusions is currently available.\u201d\nIt concludes that the trial results \u201callow for a major conceptual shift in the long-term management of children with sickle cell anaemia and established cerebrovascular disease.\u201d\nThe news release contains none of that context.", "answer": 0}, {"article": "For more information, go to UHhospitals.org.\nA new investigational delivery method for localized vaginal estrogen therapy that utilizes an applicator free softgel to alleviate moderate-to-severe vaginal pain during intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), received high rates of patient satisfaction among post-menopausal women, according to post-trial survey results published in the journal Menopause.\nThe survey, which included 731 respondents with a 96 percent response rate, sought to quantify participants' satisfaction with the application method and overall treatment delivery system.\nThe majority of women taking either TX004HR or placebo (85.4 - 92.1 percent) found the product easy to use.\nThe main campus also includes University Hospitals Rainbow Babies & Children's Hospital, ranked among the top children's hospitals in the nation; University Hospitals MacDonald Women's Hospital, Ohio's only hospital for women; and University Hospitals Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release does not specify how the softgels differ from previously available vaginal tablets. The study itself suggested that the softgels were formulated to dissolve quickly and without vaginal secretions; it\u2019s somewhat surprising that the news release does not mention this and instead just refers to the product as \u201celegant.\u201d\nIt would have been helpful to have more description of the softgel delivery system to help the reader understand how it differed from existing tablets, creams, and rings.", "answer": 0}, {"article": "\u201cThis gives patients the information to make an informed decision.\nNow a placebo-controlled study has found that the treatments are equally useful in reducing the frequency of episodes of incontinence, but vary in side effects and long-term effectiveness.\n\u201cThese are both effective treatments,\u201d said the lead author, Dr. Anthony G. Visco, an associate professor of obstetrics and gynecology at Duke.\nThe medicine has to be taken daily, while Botox is given in a single injection that is effective for about 6 to 12 months.\nBoth are reasonable options.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There wasn\u2019t any claim of novelty in the story.\u00a0 But it could have commented on this claim by the authors:\n\u201cThis is the first study to compare the effectiveness of Botox treatments to oral medication,\u201d said study senior author Susan F. Meikle, M.D., M.S.P.H., of the Contraception and Reproductive Health Branch of the NIH\u2019s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and Program Director of the Pelvic Floor Disorders Network (PFDN). \u201cPreviously, Botox was reserved for women who had tried oral medications but found them ineffective. Because we included some women who had not been treated with oral medication before, these results suggest that Botox could be discussed as an option for first line treatment.\u201d", "answer": 2}, {"article": "Women who ate walnuts tended to weigh less, consume more fish and exercise more than those who did not.\nThough the findings are correlational, walnuts are uniquely high in omega-3 and omega-6 fatty acids, which may be of particular value in Type 2 diabetes prevention.\nBut researchers controlled for these and many other factors, and found that compared with women who ate no walnuts, those who consumed 8 ounces of walnuts or more a month reduced their risk for Type 2 diabetes by 24 percent.\nWalnuts may have some unique benefits.\u201d\n\nThe study was supported with grants from the National Institutes of Health and the California Walnut Commission.\n\u201cThere\u2019s been a lot of research on nuts in general in relation to cardiovascular health,\u201d said the senior author, Dr. Frank B. Hu, a professor of medicine at Harvard.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story provided some historical perspective:\n\u201cPrevious studies have suggested an inverse relationship between tree nut consumption and diabetes. \u2026 \u201cThere\u2019s been a lot of research on nuts in general in relation to cardiovascular health,\u201d said the senior author, Dr. Frank B. Hu, a professor of medicine at Harvard. \u201cThis is the first on walnuts and diabetes. Walnuts may have some unique benefits.\u201d", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070408/16healy.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Hormones are clearly not a novel therapy. ", "answer": 1}, {"article": "Researchers have long worried about the effects of psychoactive drugs on people whose brains are still developing.\nThe study, which used rats in lieu of human children, found evidence that reward pathways are severely altered following exposure to drugs that affect the brain.\nLike in nearly all areas of science, biomedical or otherwise, our understanding is limited, and further research is required to find out more about both potential treatment options.\nBut other research on antidepressants suggest they negatively affect brain plasticity and memory\u2014something that would be problematic while the brain is still developing.\nIt\u2019s notoriously hard to treat depression in kids\u2014the antidepressants we rely on to treat adults seem to be less effective and more dangerous when used on younger minds.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "While the story could have provided more context on previous research, it states that the findings confirm something that\u2019s already widely understood by clinicians.", "answer": 1}, {"article": "To conduct the study, the researchers asked 164 healthy participants with an average age of 30 to wear a wrist actigraph \u2014 a device that monitors sleep \u2014 for one week to establish their baseline sleep habits.\nThe study is unique because it used objective measures to show that poor sleep habits make people more vulnerable to a cold virus, says Badr, who was not involved in the research.\nThe study provides more evidence of the link between healthy sleeping habits \u2014 which experts say means at least seven hours of sleep each night \u2014 and overall good health.\nThe actigraphy measured sleep in a much more accurate way than information researchers get from self-reports, he says.\nLater, they sequestered the participants in a hotel and, using nasal drops, dosed each of them with a rhinovirus\u2014 aka the common cold bug.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that \u201cthe study is unique because it used objective measures to show that poor sleep habits make people more vulnerable to a cold virus.\u201d", "answer": 1}, {"article": "Bringing this program into the mainstream presents some challenges, however.\nOverall, the trained group found 51 early melanomas during the study, compared to 18 melanomas found by a comparison group of patients and partners who didn\u2019t receive training.\nFor now, she said people can go to the American Academy of Dermatology's website to learn the steps - known as the ABCDEs - of finding melanoma (bit.ly/2h9zl0Y).\n\u201cTheir confidence level goes up and plateaus at eight to 12 months, and it doesn\u2019t go down,\u201d said Robinson.\n\u201cThere was concern that they might be embarrassed by examining areas of the body that aren\u2019t normally seen close up,\u201d said lead author Dr. June Robinson, of Northwestern University Feinberg School of Medicine in Chicago.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The newsworthy results in this study are the measurements of\u00a0confidence levels and embarrassment among partners helping with self examinations for melanomas. The story does acknowledge this here:\nThe researchers previously found that skin cancer survivors and their partners could be trained to spot potentially cancerous moles by doing skin exams. The new report shows that during the two years, those same people had increasing confidence in their skills, with no increase in embarrassment or discomfort.\nHowever, this is proceeded by a sentence that states melanoma survivors \u201cmay want to enlist partners to help search their bodies for suspicious looking moles,\u201d\u00a0suggesting that this is a new approach. In reality, this research focused on a psychological aspect of a previously established practice. It is OK for some science to be looking at small details rather than looking for big breakthroughs, but the news story should not puff up small results for big headlines.", "answer": 1}, {"article": "In the first 24 hours, more than 80% of the children in the study needed pain relief at home.\n\"This result suggests that adequate pain management should be an important goal of care, even after minor outpatient surgery, and that more effective pharmacologic and nonpharmacologic strategies should be explored,\" writes Dr. Naveen Poonai, Clinician Scientist, Lawson Health Research Institute, and Associate Professor, Emergency Medicine, Department of Paediatrics, Schulich School of Medicine & Dentistry, Western University, with coauthors.\nThe study included 154 children aged 5 to 17 years who underwent minor orthopedic surgery, such as keyhole surgery on joints, ligament and tendon repair, suture or hardware removal at London Health Sciences Centre in London, Ontario.\nWidely available ibuprofen is a better choice for pain relief in children who have undergone minor orthopedic outpatient surgery, as it has fewer adverse effects compared with oral morphine, according to results from a clinical trial published in CMAJ (Canadian Medical Association Journal).\n\"Morphine did not provide superior analgesia, but was associated with significantly more adverse effects, making ibuprofen a better analgesic option,\" write the authors.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "We feel a little bit misled by this news release. This isn\u2019t the first study to demonstrate that ibuprofen can be equally as effective as morphine for mild to moderate pain by a long shot. It\u2019s not even the first to show an equal effect in children with orthopedic issues receiving care at home. The news release should have made clear why exactly this study is news.", "answer": 0}, {"article": "Lauren Pestikas sits as she receives an infusion of the drug ketamine during a 45-minute session at an outpatient clinic in Chicago on July 25, 2018.\nThere are about 150 U.S. ketamine clinics, compared with about 20 three years ago, said society co-founder Dr. Megan Oxley.\nKetamine has been around since the 1960s and is widely used as an anesthesia drug during surgery because it doesn\u2019t suppress breathing.\nShe said it was like \u201ca controlled acid trip\u201d with pleasant hallucinations.\nIts potential effects on depression were discovered in animal experiments in the late 1980s and early 1990s showing that glutamate, a brain chemical messenger, might play a role in depression, and that drugs including ketamine that target the glutamate pathway might work as antidepressants.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This was an overview story looking at the topic of ketamine for depression, vs. one new study, which is when we typically expect a news story to establish what novel information was uncovered by the study. For this reason, we\u2019ll rate it N/A.", "answer": 2}, {"article": "Amid a dry spell for breakthrough cancer drugs, recent U.S. approval of Eisai Co.'s Halaven represents some vindication for a small group of researchers who believe, contrary to recent pharmaceutical fashion, that molecules from nature hold promise against hard-to-treat diseases.\n\nThe Food and Drug Administration's approval of Halaven in November for treating late-stage breast cancer was a triumph of chemistry and tenacious research. Its path, extending nearly three decades from the first studies, demonstrates not only potential...", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 1}, {"article": "Feb. 1, 2012 -- A new drug appears to be effective for shrinking uterine fibroids and controlling the heavy menstrual bleeding they often cause, according to new research from Europe.\nIf trials now under way in the U.S. prove positive, New Jersey-based Watson Pharmaceuticals Inc. and Swiss-based PregLem hope to market ulipristal acetate as a fibroid treatment under the trade name Esmya, says Watson spokesman Charlie Mayr.\nIn another, ulipristal acetate was found to be as effective as monthly injections of the drug Lupron for reducing heavy bleeding in women with uterine fibroids.\nIn one study, the drug ulipristal acetate proved to be much more effective than a placebo for shrinking the non-malignant uterine tumors.\nUlipristal acetate is the active chemical in the emergency contraceptive sold in the U.S. as Ella, but the daily doses taken by the fibroid patients in the studies were much smaller than those in the contraceptive.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Neither story was very clear on this point, but the WebMD story did not make a claim of novelty the way the AP story did. Contrast the two leads:\nWebMD: \u201cA new drug appears to be effective for shrinking uterine fibroids and controlling the heavy menstrual bleeding they often cause, according to new research from Europe.\u201d\nAP: \u201cNew research offers hope for the first pill to treat a common problem in young women: fibroids in the uterus. The growths can cause pain, heavy bleeding and fertility problems, and they are the leading cause of hysterectomies.\u201d\nWe\u2019ll give a lukewarm \u201csatisfactory\u201d grade.", "answer": 1}, {"article": "\"One of the concerns about taking aspirin remains the potential for intestinal bleeding.\nProfessor Elwood said: \"Our review, based on the available evidence, suggests that low-dose aspirin taken by patients with bowel, breast or prostate cancer, in addition to other treatments, is associated with a reduction in deaths of about 15-20%, together with a reduction in the spread of the cancer.\nThe study identified five healthy behaviours as being integral to having the best chance of leading a disease-free lifestyle: taking regular exercise, non-smoking, a healthy bodyweight, a healthy diet and a low alcohol intake.\nIn a systematic review of the available scientific literature a team from Cardiff University's School of Medicine found a significant reduction in mortality and cancer spread by patients who took a low-level dose of aspirin in addition to their cancer treatment (average study follow-up length over 5 years).\nProfessor Elwood added: \"While there is a desperate need for more detailed research to verify our review and to obtain evidence on less common cancers, we'd urge patients diagnosed with cancer to speak to their doctor about our findings so they can make an informed decision as to whether or not they should take a low-dose aspirin as part of their cancer treatment.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes an indirect claim of novelty by summarizing the research as an effort to look at \u201cits role in the treatment of cancer.\u201d The novelty of the work is pretty clear: Take a whole bunch of smaller studies and, through strength in numbers and careful analysis, see how low-dose aspirin might help or hinder cancer patients. And the number that emerges is impressive. While aspirin and other NSAIDs have been proposed for use in cancer prevention, especially colon cancer, use as a treatment for cancer itself is novel.", "answer": 1}, {"article": "The Cochrane reviewers selected 15 studies that enrolled a combined 1,360 participants.\nThe first study to show that zinc might be a useful treatment for the common cold was published in 1984, but the research was criticized for its poor methods.\nSince that study, 18 more trials of zinc for colds have been conducted: 11 of them showed it to be a useful treatment, while seven of them showed no benefit, according to the review.\nWhile the findings are certain to send droves of miserable cold sufferers to the drugstore in search of zinc treatments, the study authors offered no guidance on what type of zinc product to buy.\nAll the studies compared zinc use with a placebo, but in several studies the zinc users complained about the taste of lozenges, suggesting that some people may have known that they were using zinc rather than a placebo.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that the first trial evaluating the efficacy of zinc for treating symptoms of the common cold was published in 1984. \u00a0\n", "answer": 1}, {"article": "Three trials had used zinc acetate lozenges and found that colds were shortened on average by 40%.\nThere is no significant difference between zinc acetate lozenges and zinc gluconate lozenges regarding their efficacy in shortening the duration of common colds according to a meta-analysis published in Journal of the Royal Society of Medicine Open.\nNevertheless, he also considers that \"the current evidence of efficacy for zinc lozenges is so strong that common cold patients should be encouraged to try them for treating their colds, but the patients should ascertain that the lozenges do not contain citric acid or its salt citrate.\"\nIf that outlier trial was excluded, the difference between the three zinc acetate and the three zinc gluconate trials shrinked to just 2%, i.e., a 40% vs. 38% reduction in common cold duration.\nThere was no difference in the efficacy between five trials that used 80 to 92 mg of zinc per day and the two trials that used 192 and 207 mg of zinc per day.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This release release doesn\u2019t claim the use of zinc lozenges to fight the common cold is a novel idea. The language about the purpose of the meta-analysis to determine whether there is a difference in effectiveness between types of zinc salts in lozenges is clear.", "answer": 1}, {"article": "(CNN) -- If you've just had your first heart attack, doctors may one day be able to reverse the damage done with stem cell therapy.\nThe particular kind of cells used in this research are called mesenchymal stem cells, and come from adults, not embryos.\nOn the other hand, it is unclear whether a donor could potentially transmit a disease to the recipient in the process.\n\"If we could increase the number of cells that could reach the heart, that would have significant advantages to this approach,\" Karp said.\n\"Mesenchymal stem cells are poised to really be the next major success in cell therapy that could be used to treat tens of thousands of patients,\" he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not make false claims for the procedure\u2019s novelty. See he criterion \u2013 \"Compare the new approach with existing alternatives\" \u2013 below.", "answer": 1}, {"article": "WEDNESDAY, July 29, 2015 (HealthDay News) -- The U.S. Food and Drug Administration's approval of a temporary, implanted balloon device for weight loss may have many wondering how -- and how well -- it works.\nThe device doesn't change the stomach's natural anatomy, according to the FDA.\nAbout 35 percent of patients in the clinical trial suffered ulcers, but researchers said most of the ulcers were small and superficial.\nThe device is available to obese people who often don't qualify for surgical weight-loss procedures, according to the FDA.\nThat clinical trial was funded by the company that makes the ReShape system, according to a presentation from the Obesity Society annual meeting in Boston.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear the device just won FDA approval and works differently than others.\n\u00a0", "answer": 1}, {"article": "\u2022 Shepstone et al (2017).\n\"If the SCOOP screening strategy was taken up in exactly the same way as in the study in all UK women aged 70-85 years, we estimate that the strategy could prevent up to 8000 hip fractures per year in the UK.\nThe research, involving more than 12,000 older women and carried out in collaboration between the universities of Birmingham, East Anglia, Bristol, Leicester, York and Sheffield, found that screening through GP practices allowed patients to be targeted for treatment.\nProfessor Shepstone added: \"This is the first trial to show that a community-screening approach based on the FRAX fracture risk tool is both feasible and effective.\nThe tool, launched by the then WHO Collaborating Centre for Metabolic Bone Diseases in 2008, was developed at the Centre for Metabolic Bone Diseases, University of Sheffield, UK in collaboration with international researchers.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Screening for risk factors is not currently advocated in the U.K., but the release doesn\u2019t tell us that. Readers who depend solely on this release for their information won\u2019t know whether the FRAX risk calculator is an improvement on an already existing practice, or whether doctors simply don\u2019t screen for osteoporosis currently. Without that information readers can\u2019t get a perspective on exactly how novel these results are.", "answer": 0}, {"article": "\"The consistency among the results lead to the unequivocal conclusion that there is no clinical benefit of the use of folic acid and vitamin B12 (with or without the addition of vitamin B6) in patients\" with heart disease, wrote Joseph Loscalzo of the Brigham and Women's Hospital in Boston in an editorial that will be published with the studies.\nAgain, while those receiving the supplements had lower homocysteine levels, they were no less likely to have another heart attack or a stroke, or to die from heart disease.\nAlthough homocysteine levels among those taking the supplements fell, they were no less likely to die from a heart attack or stroke, the researchers found.\nAlthough the new studies did show that the vitamins cut homocysteine levels, that did not translate into a reduction in the risk for heart attacks or strokes.\nInstead, they looked at whether B vitamins can treat or reverse heart disease in people who already have it.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s clear from the story that B vitamins have been in use for some time by many people for these purposes. ", "answer": 1}, {"article": "Just one center in the north of the country offers proton therapy for certain types of eye tumors.\n\"In this space we accelerate the protons and we give them a higher and higher velocity until they reach two thirds of the speed of light -- that's 200,000 km per second and this acceleration takes place in the shape of a spiral,\" he said.\n\"I started to designing equipment (for) proton therapy of cancer -- that was a radically new idea,\" Jongen told CNN.\n\"I have a number of letters from parents of young kids saying if it had not been for this treatment we would have lost our kid,\" he said.\nAt the moment, fewer than 1% of cancer patients are treated with proton therapy, but Jongen is hopeful that smaller and cheaper machines will be the game changer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Why the story suggests that proton beam therapy for cancer is new or novel is a mystery. Proton beam therapy has been available for over 20 years. What is not available and perhaps should have been the focus of the story\u00a0is\u00a0a smaller and less expensive device that is under development by Mr. Jorgen. Excerpt:\n\u201cIn Belgium, engineer and nuclear physicist Yves Jongen is pioneering a new therapy that targets cancers with proton radiation; a therapy that offers precision and minimal side effects. \u201cI started to designing (sic) equipment (for) proton therapy of cancer \u2014 that was a radically new idea,\u201d Jongen told CNN.", "answer": 0}, {"article": "But he also emphasized the structured nature of the program tested in his study.\nBy the end of the study, the mindfulness group was showing a significant improvement -- shaving about three points, on average, from their scores on the sleep-problem scale.\nThe problem, Spira said, is that behavioral therapy for sleep problems is not always easily found -- and even when it's available, the process takes some effort.\nIn general, \"mindfulness\" practices encourage people to focus their attention on the present moment, instead of the past or future, and to take an objective look at their thoughts and emotions.\nOn average, the effects of the mindfulness program were comparable to what's been seen in studies of sleep medications and \"talk therapy,\" said study leader David Black, an assistant professor of preventive medicine at the University of Southern California, in Los Angeles.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story addresses the novelty of the findings by explaining the difference between this relatively new area of mindfulness meditation and the much better understood and thoroughly researched area of cognitive behavioral therapy. A\u00a0quick segue into what the mindfulness technique is currently\u00a0used to\u00a0treat \u2014 e.g. anxiety/depression \u2014 and generally how effective it is for that application, would also have been useful.", "answer": 1}, {"article": "Researchers reintroduced the drug to 32 patients who were initially treated as part of a study of 634 patients.\nThe study is the first to test ipilimumab in patients whose skin cancer had spread to the brain, and the findings, released in an abstract or brief summary, support its potential use in these patients, the researchers said.\nIn the phase 2 trial, researchers said four out of 51 patients with at least one brain lesion had a partial response to the drug, and in 5 out of 51 patients, both brain and other tumors in the body stabilized after 12 weeks of treatment.\nEight of the 32 got ipilimumab alone, 23 got ipilimumab plus a vaccine called gp100, and one got the vaccine alone.\nThe team found that in patients whose cancer initially progressed while on ipilimumab, whose who were reintroduced to the drug had a disease control rate of 65 to 75 percent, compared to zero in the patient who got the vaccine only.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story points out that what is new about the highlighted trial is that it looks at using this experimental drug in a subset of patients, those with melanoma that has spread to the brain. However, readers might be misled by the apparently inaccurate description of the second trial in the story, as noted above.", "answer": 1}, {"article": "\u201cNo one should die of hypertension.\nThe study also measured changes in risk scores of developing heart disease and stroke in the next 10 years, diastolic blood pressure, dietary changes, smoking cessation, cholesterol levels excluding the good cholesterol (HDL) and pulse pressure, which is the difference between the higher and lower (diastolic) numbers on the blood pressure reading.\n\u201cThe electronic counseling (e-Counseling) intervention had an effect similar to that of adding an additional blood-pressure-lowering medication,\u201d said Robert P. Nolan, the lead author of the study, a senior scientist at the Peter Munk Cardiac Center at the University Health Network and an associate professor at the University of Toronto.\nIn part, most of the studies here today show what to do \u2014 not how to achieve it,\u201d said Eric Peterson, a professor at Duke University School of Medicine and an associate editor of the Journal of the American Medical Association, during the conference.\nSystolic blood pressure \u2014 the higher number in blood pressure readings \u2014 declined more for participants in the study who received Web-based lifestyle counseling than for those who were part of a Web-based control intervention, the study found.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story didn\u2019t explain how unique this treatment was. Is this the first of its kind? Or are similar models already available? The news release states it\u2019s \u201cthe first randomized, double-blinded trial of an online behavioral intervention for high blood pressure.\u201d This story would have been stronger if it had included a line or two establishing if this is indeed the case.", "answer": 0}, {"article": "Researchers conducted a systematic review of existing peer-reviewed research evaluating infusion care for several conditions, including cystic fibrosis, antibiotics following orthopedic surgery and several cancers requiring infused chemotherapies.\nThe research showed that patients receiving intravenous therapy at home had as good or better clinical outcomes as those patients who received the same therapy in a traditional health care setting.\nThis unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs.\nDespite this, clinical outcomes and quality of care have not previously been systematically evaluated.\nHome infusion services are a rapidly growing delivery model in the health care system with rising rates of chronic and acute conditions that require intravenous therapy.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release says \u201cclinical outcomes and quality of care have not previously been systematically evaluated.\u201d", "answer": 1}, {"article": "Moffitt is the No.\n\"The observed benefit of neoadjuvant radiation therapy aligns with the growing body of literature of the immune activation effects of radiation, including shrinking of untreated metastases outside the radiation field,\" explained Heiko Enderling, Ph.D., associate member of Moffitt's Integrated Mathematical Oncology Department.\nThese findings are worthy of a prospective clinical trial to confirm potential benefits of neoadjuvant vs. adjuvant radiation, and to identify the potential contribution of radiation-induced immunity to vaccinate against future disease,\" said Enderling.\nThe researchers discovered that among the breast cancer patients who tested positive for the estrogen receptor (ER) biomarker, patients who had neoadjuvant radiation therapy had a significantly lower risk of developing a second primary tumor than patients who had adjuvant radiation therapy.\nTAMPA, Fla. (July 17, 2017) - Moffitt Cancer Center researchers launched a first of its kind study comparing the long-term benefits of radiation therapy in women with breast cancer either before surgery (neoadjuvant) or after surgery (adjuvant).\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release alludes to \u201ca growing body of literature\u201d that suggests radiotherapy may trigger an immune response that suppresses future tumor growth and that this study supports that view.\nBut when the release claims novelty in its description of \u201ca first of its kind study\u201d that\u2019s misleading. It was not a controlled trial but a review of information captured in a database. This should have been spelled out clearly early on to avoid confusion.", "answer": 1}, {"article": "\"We estimate that use of [Brilinta] instead of [Plavix] for one year in 1,000 patients with acute coronary syndromes and who are planning to undergo an invasive strategy at the start of drug treatment would lead to 11 fewer deaths, 13 fewer myocardial infarctions, and six fewer cases of stent [clotting] without an increase in the rates of major bleeding or transfusion,\" conclude study researcher Christopher P. Cannon, MD, and colleagues.\nAnd since the drugs irreversibly bind to blood-clotting platelets, a patient has to stop taking these drugs for five to seven days before the body can make enough new platelets.\nThe new kid on the block is AstraZeneca's ticagrelor, to be named Brilinta if the experimental drug gets FDA approval.\nPlavix is the drug most often used to prevent this complication.\nAnd in the new study, patients had less bleeding after stent installation.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story mentioned in passing that\u00a0ticagrelor released platelets more readily than the available medications. \u00a0The story could have included more information about the unique aspects of this drug.\u00a0\u00a0", "answer": 1}, {"article": "Some small pilot studies have indicated that the newer class of antidepressants known as selective serotonin and serotonin norepinephrine reupdate inhibitors (SSRIs and SNRIs) might be effective.\nThe study is the first to examine whether there are any racial differences in how well an antidepressant works in alleviating hot flashes.\nBut hormone use plummeted after the federal government's massive Women's Health Initiative shocked women and doctors by concluding the risks of the medication outweighed its benefits.\nFor years, many women took hormones to alleviate hots flashes.\nWhen the study started, the women were having an average of nearly 10 hot flashes each day.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that other antidepressants have been tested in small studies for the treatment of hot flashes. It doesn\u2019t oversell the novelty of this approach.", "answer": 1}, {"article": "Vitamin D is called the \"sunshine vitamin\" because human bodies produce it when the sun's ultraviolet rays strike the skin.\nThe report, scheduled for presentation this week at the Gastrointestinal Cancers Symposium in San Francisco, adds more weight to suspicions that vitamin D might be a valuable cancer-fighting supplement.\n\"That is interesting because that's more of a cancer-specific endpoint as opposed to overall survival, which could be influenced by other factors like heart health,\" Krishnamurthi said.\nAfter adjusting for prognosis and healthy behaviors, the researchers found that patients in the group with the highest levels of vitamin D lived about eight months longer on average than those in the group with the lowest levels.\n\"Everyone comes to the same conclusion -- yes, there may be some benefit, but we really need to study it carefully so we can be certain there aren't other factors that make vitamin D look better than it is,\" Lichtenfeld said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a good job of telling readers that vitamin D has long been studied for its anti-cancer role, and that this new study \u00a0merely \u201cadds more weight\u201d to \u201csuspicions\u201d that it might be a valuable cancer-fighting factor.", "answer": 1}, {"article": "For older people who fracture a hip, the prognosis is grim: a third or more die within a year and only about 1 in 5 return to their pre-injury level of function.\n\nA new approach to care could mean it doesn\u2019t have to be that way.\n\nMore hospitals are putting hip fracture patients on a fast track from the emergency room to the operating room,...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story calls this a new approach, but in reality \u201cfast-track\u201d surgery has been used in many institutions for a long time (but it has not been standardized across the country).", "answer": 0}, {"article": "It affects cells that play important roles in helping the immune system battle bacteria, viruses and fungi that can cause infections.\nBabies with SCID often come down with recurrent, severe respiratory infections that can be life threatening, according to the American Academy of Allergy, Asthma and Immunology.\nDr. Kohn said of an experimental treatment for SCID, \"It's gone from a 'one day, maybe' to a real clinical reality.\"\nThat means an actual cure for the disease, said Kohn, who is also director of the Human Gene Medicine Program at UCLA.\nSo far, the treatment has restored immune systems in all 23 patients in the most recent clinical trials, including Evangelina.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "As we noted previously, most children with SCID undergo a bone marrow transplant. The use of gene modification for the disorder is more than 20 years old having started in France in the early 1990s. The approached highlighted in the story is indeed new but the general approach has been around for some time.", "answer": 0}, {"article": "But the supplement has largely failed to show benefits in human athletes.\nOf course, other substances containing polyphenols have shown early promise, and then underperformed in follow-up studies.\n\u201cWe do not know whether the side effects of alcoholic beer would cancel out the positive effects caused by the polyphenols,\u201d he wrote.\n\u201cIncidence of upper respiratory tract infections was 3.25-fold lower\u201d in the nonalcoholic beer drinkers, the scientists reported, in the journal Medicine & Science in Sports & Exercise.\nAlcoholic beer happens to be drenched in polyphenols, too \u2014 \u201ceven more than nonalcoholic beer,\u201d Dr. Scherr said \u2014 but has the signal disadvantage of being alcoholic.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The treatment, beer, is not novel, and is not presented as such. Other substances that also contain the purported active ingredient, polyphenols, are discussed.", "answer": 1}, {"article": "The committee reviewed recent studies which had investigated aromatase inhibitors and/or tamoxifen in women with this particular subtype of breast cancer.\n\"We've learned a huge amount about the various side effect profiles of these products,\" said Dr. Harold J. Burstein, co-chair of the ASCO committee which prepared the guidelines and associate professor of medicine at Harvard Medical School and Dana-Farber Cancer Institute in Boston.\nAnd sometimes we have to make decisions about using drugs that are probably a little less effective but at the same time we have to take into account the financial standpoint,\" said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge.\nAll three aromatase inhibitors on the market - Arimidex (anastrozole), Femara (letrozole) and Aromasin (exemestane) - were essentially equal in their benefit.\n\"In general, for postmenopausal women, we are offering them aromatase inhibitors based on the single studies that have been referenced [in these guidelines] and what has already been reported in national meetings.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s clear from the story that tamoxifen is not new and that aromatase inhibitors \u201care a more recent entry into the field.\u201d The story also states that aromatase inhibitors have been a standard part of care before the guidelines\u00a0were released.", "answer": 1}, {"article": "\u201cBut there were other components to it -- there was oppositional defiant disorder, there were some [autism] spectrum-like behaviors, and difficulty later on socializing with other children.\u201d\n\nOppositional defiant disorder is one of the most common conditions linked to ADHD in children and is characterized by anger, tantrums, opposition to authority and, sometimes, aggressive behavior.\nThe spectrum of ADHD and related disorders is broad, and there is no one-size-fits-all treatment.\nThat\u2019s when she found the Brain Balance Achievement Center in Allendale, N.J.\n\n\u201cWe went in for the assessment and her behaviors at the assessment were really terrible,\u201d Amy said.\n\u201cI think I knew from very early on that she was different, but she was my first child, so I figured anything that I saw, there was a chance that she would grow out of it,\u201d Amy Oakes told FoxNews.com.\n\u201cWhat thinking really is is really coordinating different networks in the brain so that we can bring all of those networks together at one time,\u201d Melillo told FoxNews.com.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "According to the story, the Brain Balance \u201cprogram uses a combination of sensory motor (physical) exercises and academic learning\u201d \u2013 approaches that\u00a0are widely available from physical and occupational therapists. The\u00a0story implies that these are novel approaches to the brand name centers.", "answer": 0}, {"article": "Phd Christian Fabiansen \n\nDepartment of Nutrition, Exercise and Sports, University of Copenhagen \n\nTelephone: +45 22440844 \n\nMail: chfa@nexs.ku.dk\n\nProfessor Henrik Friis \n\nDepartment of Nutrition, Exercise and Sports, University of Copenhagen \n\nTelephone: +45 26253968 \n\nMail: hfr@nexs.ku.dk\n\nKristian Levring Madsen \n\nCommunication Manager \n\nDepartment of Nutrition, Exercise and Sports, University of Copenhagen \n\nTelephone: +45 4048 1684 \n\nMail: kma@nexs.ku.dk\nIt has been a concern that LNS, with its very high fat content, would result mainly in weight gain composed of fat.\nThe study, published Monday 11 September in the open access medical journal PLOS Medicine, showed that corn-soy porridge should be replaced with a lipid-based nutrient supplement (LNS), a fortified peanut butter.\nThe study found that children who received LNS experienced greater weight gain, and the large majority of the weight gain was healthy lean tissue.\nBut by using a method based measurement of heavy water in the child's body we have found that LNS mainly increase lean mass, that is muscles and organs, which are important for immune function, survival and development.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This piece gives the impression that across the globe most current interventions for infants with moderate acute malnutrition use CSB as a nutritional supplement. The original study itself presents a somewhat different picture, noting that there is currently no consensus on which of the two food supplements is better, and citing a World Health Organization recommendation that more research needs to be done.", "answer": 0}, {"article": "Breast Cancer Patients Have Improved Immune And Neuroendocrine Functions Following Massage Therapy.\nIn a controlled study composed of HIV-positive adolescents, participants who received massage therapy showed enhanced immune function by the end of the 12-week study.\nIndividuals should consult with a professional massage therapist to determine the best massage therapy approach for their specific needs.\nAMTA works to advance the profession through ethics and standards, the promotion of fair and consistent licensing of massage therapists in all states, and public education on the benefits of massage.\nRegular massages have been shown to make the immune system stronger, according to studies.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Massage therapy is not a novel intervention in general but the authors of the news release make novel claims that it is an immune enhancer, and that it can prevent the flu and the common cold, which is not backed up by science.", "answer": 0}, {"article": "It may also prevent infections and exacerbations of Chronic Obstructive Pulmonary Disease (COPD) like emphysema.\nHe cautioned that the study is not definitive proof that vitamin D can prevent ARI but it suggests that it can and at little risk to the patient.\nAt the same time, Ginde found that those who received higher doses of vitamin D also saw an increase in falls.\nBut Ginde said the primary finding that vitamin D can reduce ARI is a major step forward in treating these dangerous infections.\n\"This finding requires a confirmatory trial, including whether high daily doses of vitamin D, rather than high monthly doses, makes patients less likely to fall,\" Ginde said.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes that the clinical trial was the first to examine vitamin D\u2019s impact on respiratory infections in nursing home residents, and explains clearly that the findings require a confirmatory clinical trial.", "answer": 1}, {"article": "U.S.News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual \"America's Best Hospitals\" survey.\nThe findings, published in the Journal of Nutrition today, suggest that whole grains can be a key regulator of blood pressure, and could provide an effective nutritional strategy to reduce cardiovascular-related deaths and disorders.\nThis research shows that eating whole grains reduces the risk of heart disease,\" said John Kirwan, Ph.D., principal investigator and director of the Metabolic Translational Research Center, which is part of Cleveland Clinic's Endocrinology & Metabolism Institute.\nIn the study, a group of 33 overweight and obese adults followed a whole grain diet (intervention) or a refined grain diet (control) for two eight-week periods.\nWednesday, Oct. 19, 2016, Cleveland: A team of Cleveland Clinic researchers, in collaboration with Nestl\u00e9 Research Center, conducted one of the largest controlled studies of its kind on whole grains and concluded that a diet rich in whole grains may significantly lower the risk of cardiovascular disease in overweight and obese adults under the age of 50.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release establishes novelty with its claim that the Cleveland Clinic and Nestl\u00e9 researchers \u201cconducted one of the largest controlled studies of its kind.\u201d A study group of 33 seems small to be called \u201cone of the largest\u201d but the release doubles down on novelty as it further explains:\n\u201cThe uniqueness of this study is that each of the 33 participants consumed both diets,\u201d said Kirwan (the lead researcher). \u201cThis level of control can only be performed for small numbers and provides the essential empirical data that cannot be obtained from large observational studies.\u201d\nWhile the release should have done more to clarify that \u201cone of the largest\u201d studies is still quite \u201csmall,\u201d we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "Was it the caffeine?\nBut the numbers came out this way: People who drink more than four cups of coffee each day have 39% lower odds of getting mouth or throat cancer, compared to people who don't drink coffee.\nThat's probably not what University of Milan researchers Carlotta Galeone, ScD, PhD, and colleagues thought they'd find when they analyzed nine studies comparing 5,139 people with head and neck cancer to 9,028 people without cancer.\nThough there weren't enough data on decaf drinkers to draw conclusions, drinking tea -- even massive quantities -- was not protective.\nNor was the effect boosted by consumption of fruits and vegetables, also shown to protect against head and neck cancers.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story didn\u2019t explain what is explained in the opening \"Background\" section of the published study:\u00a0 Only a few studies have explored the relation between coffee and tea intake and head and neck cancers, with inconsistent results.\u00a0 So this isn\u2019t a first look at the question. ", "answer": 0}, {"article": "Oppenheimer analyst Leland Gershell said he expects Amphora, the company\u2019s lead product, to bring in sales of up to $415 million by 2032.\n\u201cOur research and current understanding of women suggests the time is now for there to be a new non-hormonal category in contraception,\u201d Chief Executive Saundra Pelletier said on a conference call with analysts.\n\u201cThese results pave the way for Amphora\u2019s disruption of the contraception market as a novel, highly effective, non-hormonal and woman-controlled method that finally answers women\u2019s long-awaited desire to avoid hormones,\u201d Roth Capital Partners analyst Yasmeen Rahimi said.\nThe company plans to resubmit the marketing application for Amphora in the second quarter next year and if approved, plans to launch the product in January 2020.\nAn estimated 16.5 million women in the United States do not use any method of contraception, according to the company, on fear of side effects, leaving them highly susceptible to unwanted pregnancies and sexually transmitted diseases.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story describes how the new product differs from male condoms \u2014 \u201cwoman-controlled\u201d \u2014 and how it differs from oral pills \u2014 \u201cnon-hormonal.\u201d But this isn\u2019t novel, as we describe in alternatives.\nAlthough testing is still underway, as the story notes, what\u2019s interesting is that the gel may have some effectiveness against some sexually transmitted diseases, which would make it different from most other forms of female-based contraceptives. We think the story should have provided more information/evidence about this claim, though.", "answer": 1}, {"article": "To address this gap, researchers conducted a randomized controlled trial including 352 healthy infants from 3 pediatric outpatient clinics, including 7 physician practices, who received scheduled vaccinations in their first year of life.\nFor babies under age 1 year, lidocaine cream, combined with a small amount of sugar given by mouth and infant soothing, can help relieve pain from routine vaccinations, according to a study in CMAJ (Canadian Medical Association Journal).\n\"We found that, when used consistently during vaccine injections in the first year of life, only liposomal lidocaine combined with parental video instruction and orally administered sucrose showed a benefit on acute pain when compared with placebo, video alone, and video and sucrose together,\" wrote the authors.\n\"Vaccinations cause acute distress for both infants and their parents, contributing to vaccination avoidance,\" states Dr. Anna Taddio, a pharmacist and senior associate scientist at The Hospital for Sick Children (SickKids) and professor, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario.\nThe study was conducted by researchers at SickKids, the University of Toronto, York University and several Toronto-based pediatricians.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "A randomized controlled trial comparing different methods of pain relief (placebo control, the video, sugar water, and lidocaine in combination with the sugar water and video) appears to be a novel approach to studying pain relief in infants.\nThe release could have done a better job explaining why researchers chose to combine some methods but not test lidocaine alone. There is other published research available on treating \u201cprocedural pain\u201d in infants and children, but these are mostly focused on venipuncture. \u00a0There are many studies on sucrose (but almost all in neonates), some on other soothing actions (presumably what was in the video), and some on topical anesthetics. \u00a0However, the intramuscular aspect of immunizations may make them different. \u00a0Nonetheless, many pediatricians already use a topical agent (usually EMLA) for immunizations.", "answer": 1}, {"article": "(Reuters) - A new type of asthma drug meant to attack the underlying causes of the respiratory disease slashed episodes by 87 percent in a mid-stage trial, making it a potential game changer for patients with moderate to severe disease, researchers said on Tuesday.\nBut patients gradually tapered off on those drugs and were no longer taking either of them after 9 weeks.\nThe medicine, if approved, could hold promise for patients with moderate to severe persistent asthma that is not well controlled by standard drugs.\nThat represented an 87 percent reduction in exacerbations, which was highly statistically significant.\nLarger studies are slated to begin later this year.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of this drug, and of the findings, are appropriately described in the story.", "answer": 1}, {"article": "Stanford\u2019s Department of Medicine also supported the work.\nThe drug, an injectable monoclonal antibody, is already commercially available for the treatment of psoriasis, for which it has been remarkably effective, said Genovese.\nFor example, psoriatic arthritis manifests most often in the lower extremities and is associated with the autoimmune skin condition called psoriasis, in which raised red, scaly patches appear on the skin.\nAlthough the ultimate cause of the disease remains unknown, there was a good clinical rationale for hoping it might be responsive to ixekizumab.\nFor the last decade or so, Genovese said, another pro-inflammatory substance called IL-17 has been drawing the attention of immunologists focusing on psoriasis and psoriatic arthritis.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does an acceptable\u00a0job of describing the drug\u2019s place in the treatment landscape. It does not make an outward claim of novelty, but it appears to be the first such randomized trial for this type of arthritis. ", "answer": 1}, {"article": "CDC To Doctors: Anti-HIV Pill No Magic Bullet Against Virus\n\nIn November, researchers revealed a encouraging finding: taking a pill can greatly reduce the risk of getting HIV.\nIt's the first time anybody's shown that taking a pill can prevent HIV \u2013 and it was the first new weapon against HIV unveiled in many years.\nSome insurers might pay, but some might balk.\nBut the landmark study, involving 2,500 men who have sex with men, showed that taking Truvada faithfully can reduce the risk of infection by as much as 92 percent.\nAmong those whose tests showed they really did take it every day, the risk of HIV infection was 92 percent lower than those not on the drug.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story stated, \u201cIt\u2019s the first time anybody\u2019s shown that taking a pill can prevent HIV \u2013 and it was the first new weapon against HIV unveiled in many years.\u201d", "answer": 1}, {"article": "For more information, visit http://www.\nThe current study, based on data from a nationwide flu surveillance network including 14 states, focused on pregnant women hospitalized with laboratory-confirmed flu over four recent flu seasons, from 2010 to 2014.\nThe editors welcome major articles and brief reports describing research results on microbiology, immunology, epidemiology, and related disciplines, on the pathogenesis, diagnosis, and treatment of infectious diseases; on the microbes that cause them; and on disorders of host immune responses.\nFor expectant mothers hospitalized with flu, early treatment with the influenza antiviral drug oseltamivir may shorten their time in the hospital, especially in severe cases, suggests a new study published in The Journal of Infectious Diseases and available online.\nFor an embargoed copy of the study and the commentary, please contact Emily Zaideman (312-558-1770, ezaideman@pcipr.com).\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release establishes that previous studies have suggested antiviral therapy is beneficial in this patient group, and that this study supports the CDC\u2019s recommendation that symptomatic influenza in those with high risk of complications should be treated within the first 48 hours.\nThe journal article itself notes that \u201cThis is the first and largest study to report on clinical characteristics and outcomes of pregnant women hospitalized with laboratory-confirmed influenza since the 2009 pandemic;\u201d and that \u201cour study is the first to assess the impact of early vs. late antiviral treatment on [length of hospital stay] among pregnant women hospitalized with severe and non-severe influenza.\u201d", "answer": 1}, {"article": "Traditional heart catheterization through a vein in the neck can take 20 minutes or longer.\nA venous heart catheter inserted through the neck, the traditional approach, requires painstaking preparation of the insertion area and a \"pseudo-operative field,\" says Dr. Andrew Dennis, attending surgeon at Stroger Hospital's trauma and burn units and a clinical researcher.\nThe nurses have a success rate in the \"high 90s,\" Miller says, but \"very few\" hospitals have devoted the time or resources to create the discipline.\nDennis believes the ReavillMED CV shows a \"tremendous amount of promise,\" and he wants to test the first 50 catheters Reavill can provide.\n\"It's old technologies put together in a different way to enable established medical treatments to be done earlier,\" Reavill says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Peripherally-inserted central venous catheters for drug and fluid delivery as well as pressure management is not a new concept. This wasn\u2019t discussed at all in the story.\u00a0 While there may be advantages to the use of the arm for access, there are also potential disadvantages.\u00a0 While controversial, some studies have suggested that many patients in shock would benefit from a pulmonary artery catheter (usually inserted in a neck vein) that allows doctors to have a better understanding of a patient\u2019s blood volume and performance of the heart.\u00a0 While a pulmonary artery catheter takes time and skill to place and interpret, the debate about which approach is best is ongoing.\u00a0 This story didn\u2019t reflect the debate \u2013 making the inventor\u2019s approach seem like a slam dunk.", "answer": 0}, {"article": "Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs.\n\"We know from our previous studies that by losing weight, people can reduce their overall levels of inflammation, and there is some evidence suggesting that taking vitamin D supplements can have a similar effect if one has insufficient levels of the nutrient,\" said lead and corresponding author Catherine Duggan, Ph.D., a principal staff scientist in the Public Health Sciences Division at Fred Hutch.\nThere is also some evidence that increased body mass \"dilutes\" vitamin D, possibly by sequestering it in fat tissue.\nAt the end of the study, all of the participants had reduced levels of inflammation, regardless of whether they took vitamin D, \"which highlights the importance of weight loss in reducing inflammation,\" Duggan said.\n\"We were quite surprised to see that vitamin D had an effect on an inflammation biomarker only among women who lost at least 5 percent of their baseline weight,\" Duggan said.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes a case for this being the first clinical trial of its kind; although it\u2019s always difficult to make that statement absolutely, the writer of the release attributes the statement to the study author.\u00a0As a general rule, it\u2019s probably best to say \u201cbelieved to be the first.\u201d \u00a0While the release meets our standard here, we also wish it had delved a bit into the background of previous vitamin D research and the conflicting and confusing messages that research has generated. Without that context, the typical reader might wrongly\u00a0jump to the conclusion, based on the wording of the lede and other parts of the release, that this study of vitamin D supplementation \u2014 because it was a controlled clinical trial \u2014 has somehow settled the important questions about the role of vitamin D and inflammation in cancer risk. The debate remains alive and well.\u00a0", "answer": 1}, {"article": "In this study the researchers focused on the CPT1A enzyme.\n\u201cThis finding may have a huge impact on patients with CRPC that had very few options before,\u201d says Schlaepfer.\n\u201cThere is a critical need for improved therapies for this specific cancer type.\u201d\n\nMost cells use the energy of glucose (sugar).\nHowever, there are many steps involved in lipid metabolism and researchers have been working to break prostate cancer\u2019s ability to harness this energy source.\n\u201cThis is a huge development for men with CRPC that previously did not have many options,\u201d says Isabel Schlaepfer, PhD, CU Cancer Center member, assistant professor in the Division of Medical Oncology and senior author of the study.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release says: \u201cIn fact, we are already able to block the action of the CPT1A enzyme. The drug ranolazine is a fat oxidation inhibitor that earned FDA approval in 2006 to treat angina. When Schlaepfer and colleagues experimented with fat burning inhibitors and anti-androgens in cancer cell lines, they found that the addition of ranolazine to anti-androgen therapy made tumors more sensitivity to the anti-androgen drug enzalutamide.\u201d\nWe interpret this as saying in a round-about way that the drug is not claiming any novelty that it doesn\u2019t have.", "answer": 1}, {"article": "The updated recommendation was published online June 16 in the Journal of the American Medical Association.\nThis year about 134,000 people in the country will be diagnosed with the disease, and about 49,000 will die from it., the panel said\n\nThe USPSTF is an independent, volunteer panel of experts that makes recommendations about the effectiveness of specific preventive health services.\n\"There is only one test -- colonoscopy -- that can both diagnose a polyp/cancer and remove or sample it at the same time,\" said Swaminath, who directs the inflammatory bowel disease program at Lenox Hill Hospital in New York City.\n\"Evidence convincingly shows screening for colorectal cancer works, but not enough people are taking advantage of this highly effective service,\" said Owens, a general internist at the Veterans Affairs Palo Alto Health Care System and a professor at Stanford University.\nHowever, the U.S. Preventive Services Task Force stopped short of saying any one screening method was better than another.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story points out that this report and recommendation is an update of one the USPSTF issued in 2008. It is clear that all of the screening tests mentioned in the story have been available for years, except for a DNA-based stool test that the story notes was approved recently.", "answer": 1}, {"article": "\"But the [overall] rate of invasive breast cancer diagnosis was no different with or without CAD,\" Fenton said.\nHowever, among the women who did have invasive cancer, computer-aided detection was linked with a greater likelihood of finding the cancer while it was stage 1 or 2 compared to stage 3 or 4, they found.\n\"There should be no argument that finding invasive cancers at a smaller size and earlier stage is beneficial,\" he said, as they are more likely to be cured.\nOne limitation of the study, he said, is that the researchers cannot say for sure it was the computer-aided detection that made the difference.\nFor one thing, computer-aided detection (CAD) increases the amount of diagnostic testing among women who turn out not to have breast cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The piece points out that use of CAD increased from 3.6% in 2001 to 60.5% in 2006 & is at approximately 75% in 2013. \u00a0The \u00a0study examined mammography data obtained from 2001-2006.", "answer": 1}, {"article": "Now Dr.\nThe problem was to find a way to get more insulin to the brain but not to the body.\nIn her field, cardiovascular medicine, she has seen many exciting findings in small studies that fall apart in larger or longer ones.\nBut, she added, if her study goes forward, many will be able to participate in it.\nThe lower dose seemed more effective than the higher one.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story describes the earlier research that laid the foundation for the current study, and does not overstate the novelty of this approach.", "answer": 1}, {"article": "Also home to the world\u2019s largest community of hearing and vision researchers, Mass.\n\u201cThe development of cochlear implants, for example, didn\u2019t really accelerate until someone placed an electrode in the cochlea of a patient and found that the patient heard a frequency of some type.\u201d\n\nSmell loss, or anosmia, has an estimated prevalence of 5 percent of the general population.\nThis breakthrough in human patients opens the door for a \u201ccochlear implant for the nose\u201d to be developed \u2014 though the study authors caution that the concept of an olfactory stimulator is more challenging than existing technologies.\nIn the elderly, of whom there are estimates that greater than 50 percent of the population over the age of 65 has experienced smell loss, it can be difficult to get proper nutrition, as the sensation of flavor is closely tied to the sense of smell, and as flavor diminishes, appetite decreases in this population.\nThe most successful neuroprosthesic device in the world, cochlear implants have been on the market for more than three decades to electrically stimulate the auditory nerve to restore hearing in people with profound hearing loss.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes clear that the researchers have, \u201cfor the first time, induced a sense of smell in humans by using electrodes in the nose to stimulate nerves in the olfactory bulb.\u201d What they have not done, however, is shown whether that\u2019s relevant for patients whose sense of smell is caused by nerve damage.", "answer": 1}, {"article": "The study followed more than 1,600 people over the age of 60 for five years.\nAnd despite this study, there is not enough evidence to prescribe statins for the brain.\nSince cholesterol is part of the tell-tale plaques on the brains of Alzheimer's patients, it made sense to think that statins might help.\nThey were about half as likely to develop either early signs of trouble thinking or full-blown dementia.\n\"It seems as though the statins because they lower cholesterol reduce production of these plaques,\" said Dr. Gayatri Devi.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The segment does a good job explaining that the benefits of statins on cognitive function have been studied previously, with conflicting results. ", "answer": 1}, {"article": "Aug. 17, 2011 -- German researchers say that highly trained dogs are able to reliably sniff out lung cancer in human breath.\nRecently a large, government-funded study found that longtime smokers at high risk for lung cancer who received annual rapid computed tomography (CT) scans of their lungs cut their risk of dying of the disease by 20%.\nBut that test has caused controversy because it falsely detects cancer in about one out of four people, leading to further invasive procedures.\n\"This is the holy grail,\" says Suresh S. Ramalingam, MD, associate professor and director of the lung program at Emory University's Winship Cancer Institute in Atlanta.\n\"The whole field is focused on using something that's readily available that does not involve an expensive surgery or scan that would allow us to find early cancers,\" says Ramalingam, who is developing technology that aims to replicate the ability of dogs to smell trace amount of chemicals produced by cancerous tumors.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Yes, the story explains that this new research on canine cancer detection is for lung cancer, which is a new application of a sniff-testing that has already been done for colon and skin cancers.", "answer": 1}, {"article": "To him, diet underpins longevity.\nThe idea of caloric control improving your health, and therefore your lifespan, is nothing new, but researchers are now hoping to accurately determine the type of diet that could make you live longer.\nAccording to Toribio-Mateas, the results confirm earlier theories that \"some hormone-like growth factors that are required during development to grow, then become promoting agents of aging after development and sexual maturity have been reached\".\nUnlike the 5-2 diet, which requires two days of low calories at any point in the week, Longo's diet involves fasting for five consecutive days, which requires much more willpower.\nOne team at the University of Southern California ( USC) are reducing the calorie count as low as it can go, using specific foods to trick the human body into thinking it's fasting -- a process called fasting mimicry.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes a reference to something called the \u201c5-2\u201d fasting diet but is short on details. If one reads closely enough, it seems that the new diet plan is supposed to achieve the effects of fasting diets without actually fasting. We\u2019ll give the benefit of the doubt on this one, especially since the story acknowledges a history of similar research, for example when it says, \u201cThe idea of caloric control improving your health, and therefore your lifespan, is nothing new, but researchers are now hoping to accurately determine the type of diet that could make you live longer.\u201d", "answer": 1}, {"article": "She bases this bold claim on her experience with seriously obese patients and a detailed analysis of the best studies yet done showing weight-loss surgery\u2019s ability to reverse the often devastating effects of being extremely overweight on health and quality of life.\n\u201cMost say they wish they\u2019d done it 10 years sooner.\u201d She explained that the overwhelming majority of patients who undergo bariatric surgery have spent many years trying \u2014 and failing \u2014 to lose weight and keep it off.\n\u201cThe weight that it takes them one year to lose is typically back in two months,\u201d often because a body with longstanding obesity defends itself against weight loss by drastically reducing its metabolic rate, an effect not seen after bariatric surgery, which permanently changes the contours of the digestive tract.\n\u201cBariatric surgery is probably the most effective intervention we have in health care,\u201d says Laurie K. Twells, a clinical epidemiologist at Memorial University of Newfoundland.\nIn reviewing studies that followed patients for five to 25 years after weight-loss surgery, Dr. Twells and colleagues found major long-lasting benefits to the patients\u2019 health and quality of life.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story offers an overview of bariatric surgery outcomes, discussing multiple studies that have been published over the past two years. It is clearly intended to address common questions and concerns regarding bariatric surgeries, rather than serving as a \u201cnew-study-of-the-day\u201d story.", "answer": 2}, {"article": "Varicose veins are one of the more unsightly signs of aging. But new, less-invasive treatments are making it easier to remove them painlessly, bypassing a difficult surgical procedure that was often the only option in the past.\n\nAs many as 25% of women and 15% of men suffer from varicose veins; over the age of 50, one out of two people are affected. Heredity plays a part, but obesity, prolonged standing on the job and hormone therapy increase the risks. Sometimes, varicose veins have no signs or symptoms and require no treatment,...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that these are emerging approaches.", "answer": 1}, {"article": "Over-the-counter multivitamins typically contain 15 to 25 IU of vitamin E.\n\nThe newly-released Physicians Health Study showed an 8 percent reduction in total cancer occurrence for participants taking a multivitamin, but no benefit was seen for rates of prostate cancer, the most common cancer seen among the participants in the study.\nThe protective effect of the daily pill was described as \u201cmodest\u201d by the trial investigators who emphasized that the primary use of vitamins was to prevent nutritional deficiencies.\nA study examining whether vitamin E and selenium could reduce the risk of prostate cancer was stopped prematurely in 2008 after men taking 400 international units (IU) of the vitamin showed an increased risk of developing the cancer.\n\u201cThere have been some other trials that have tested combinations, often at high doses, of certain vitamins and minerals,\u201d said Dr. Howard Sesso, one of the study\u2019s authors and an associate epidemiologist at Brigham and Women\u2019s Hospital in Boston.\nThey also saw a 12 percent reduction in the risk of death from cancer, although those findings also were not statistically significant.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story states that this was the first large-scale\u00a0randomized study of multivitamins to prevent cancer. That\u2019s accurate.", "answer": 1}, {"article": "Dec. 21, 2009 -- A fatty substance found naturally in the lungs may provide a natural defense against respiratory syncytial virus (RSV) infection.\nThere is no vaccine or easy, effective treatment for RSV.\nResearchers say that until now, the function of POPG has been unclear.\nThe findings also suggest that POPG\u2019s role in the lungs may be to help the lungs tolerate the daily barrage of inhaled irritants.\nRSV is the major cause of hospitalization in young children under age 2 and is an increasingly problematic infection in adults with chronic lung disease, the elderly, and those with weakened immune systems.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story states, \"Researchers say that until now, the function of POPG has been unclear.\" ", "answer": 1}, {"article": "\"Now they tell me, 'You never say 'What?'\n\"There are little things that I probably heard when I was younger, before my hearing loss, but I don't remember them,\" she said.\n\"This really fills a need for adults with moderate to severe sensorineural hearing loss,\" Marzo said.\n\"When I wore a hearing aid, I turned it off when I got home because all the background noise was so agitating,\" said Merlo, 40.\nUnlike a hearing aid, which amplifies sounds, Esteem is a prosthetic inner-ear stimulator.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "According to the FDA, \u201cEsteem is the first totally implantable hearing system used to treat moderate to severe hearing loss caused by a defective inner ear function.\u201d The article could have made this fact clearer,\u00a0 but states that this implant, a prosthetic inner-ear stimulator, differs from a hearing aid, which \u201camplifies sounds.\u201d", "answer": 1}, {"article": "Greek researchers offered fresh evidence of the health benefits of the Mediterranean diet, reporting in a large study that it helps improve several risk factors linked to diabetes, obesity and heart disease.\n\nThe Mediterranean diet is high in monounsaturated fats such as olive oil and also relies heavily on whole-grain cereals, fruits and vegetables, fish and low consumption of animal fats. It has been shown in numerous studies and clinical trials to reduce mortality from such causes as cardiovascular disease and cancer.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear that the diet reported on was not new and that the outcome from the pooled results echo previously reported observations about this diet.", "answer": 1}, {"article": "More About: The Study\n\nNathalie Scheers had looked at parvalbumin before in another context.\nParvalbumin is a cause of fish allergies, so we knew that it passed over to the blood, and that this form of parvalbumin is specific for fish\"\n\nShe joined forces with Pernilla Wittung-Stafshede, and together they took the idea forward.\nWe already knew that they can meet in the gut, the blood, or the brain,\" explains Pernilla Wittung-Stafshede.\nParvalbumin effectively 'scavenges' the alpha-synuclein proteins, using them for its own purposes, thus preventing them from forming their own potentially harmful amyloids later on.\n\"Parvalbumin collects up the 'Parkinson's protein' and actually prevents it from aggregating, simply by aggregating itself first,\" explains Pernilla Wittung-Stafshede, Professor and Head of the Chemical Biology division at Chalmers, and lead author on the study.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This is not the first research attempting to link parvalbumin with a host of neurodegenerative diseases including Parkinson\u2019s. And while there is no direct clear claim of novelty, \u201cshining a light\u2026\u201d suggests this is a new discovery.", "answer": 0}, {"article": "For more information, visit http://www.\nCHICAGO (January 26, 2017): Patients with gastroesophageal reflux disease, known as GERD, who undergo laparoscopic anti-reflux operations compared with traditional \"open\" operations suffer fewer postoperative complications, experience faster recovery, and incur lower health care costs, according to study results published online as an \"article in press\" on the Journal of the American College of Surgeons website, ahead of print publication.\nThe study showed that the rate of laparoscopic procedures increased from 24.8 percent in 2000 to 84.3 percent in 2013.\nDuring the study period, 58.4 percent of patients underwent laparoscopic procedures and 41.6 percent had open anti-reflux operations performed through a long abdominal incision.\n\"Patients with GERD have an incompetent lower esophageal sphincter, which allows gastric acid to go back up into the esophagus,\" said lead study author Francisco Schlottmann, MD, a surgeon at the Center for Esophageal Diseases and Swallowing, University of North Carolina, Chapel Hill.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release was not about a novel procedure and made no claim of novelty. However, this isn\u2019t the first study to examine laparoscopic vs. open surgery. For example, the British Journal of Surgery published results of a randomized trial of the two methods and the Scandinavian Journal of Gastroenterology published research on long-term outcomes following laparoscopic and open procedures for GERD.", "answer": 0}, {"article": "\"Brain signals change from day to day (even hour to hour), the signals may be different depending on context (am I trying to lift a full or an empty glass, do I watch someone draw or do I want to draw myself), and brain signals change while we learn a new task,\" he told BuzzFeed news.\nThis is the first time a person with paralysis has regained movement in their hands and individual fingers using signals from their brain.\nThe study builds on previous work in which humans have been able to move computer cursors and robotic arms using their own brain signals, and a study in which monkeys with paralysed arms were able to move them again thanks to a similar intervention.\nThat could come from better electrode designs or looking for different signals that are more stable.\nOur understanding of how brain signals change will also be crucial to making this technology usable on a large scale.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story describes the specific new achievement of this experimental device: sensing electrical patterns in the brain and then translating them to electrical stimuli that trigger appropriate muscle movements.", "answer": 1}, {"article": "But after controlling for those risk factors, \"the difference [in brain aging] is still there so we conclude that omega-3 fatty acids likely explain them,\" Tan said.\nBrain scans also showed signs of less blood supply in the brains of people with the lowest omega-3 levels.\nThe participants were in the Framingham Offspring Study, which is predominately white.\nWhether the association would apply to other ethnic and racial groups needs to be explored, the authors said.\nFind out more about brain health at the Alzheimer's Association.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story nods to previous research suggesting that fish consumption might have benefits for the aging brain.", "answer": 1}, {"article": "April 28, 2010 -- Federal researchers say a new treatment can reverse vision loss in many patients with diabetic macular edema, a leading cause of blindness in people with diabetes.\n\nIn a news conference yesterday, researchers announced findings from a government study comparing treatments for swelling of the retina caused by leaking blood vessels in the eye.\n\nNearly 50% of patients given eye injections of the drug Lucentis along with laser treatments showed improvement in vision after a year of treatment, compared to just over a fourth of patients treated with laser alone.\n\nFor several decades, laser has been the standard treatment for diabetic macular edema, or DME, in which fluid builds up near the center of the retina.\n\n\u201cFor the first time in 25 years we have definitive proof that a new treatment can lead to better results for the eye health of people with diabetes,\u201d said Neil M. Bressler, MD, who oversaw the study as chairman of the Diabetic Retinopathy Clinical Research Network.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Story explains the drug is already approved for another use, and it also \u2013 at the very end \u2013 mentions that an older and much cheaper drug is also effective.\u00a0 ", "answer": 1}, {"article": "But the results do merit further research.\nThe results showed those who took salsalate at each of the dosage levels experienced a beneficial decrease in blood sugar A1c levels of 0.5% or more.\nHowever, it also has been shown to increase protein in the urine and its long-term safety will need further investigation.\nLike aspirin, salsalate is an anti-inflammatory drug derived from salicylate and is often used to treat arthritis.\nMore recently, inflammation has been implicated in development of the insulin resistance that leads to elevated blood sugar levels associated with type 2 diabetes.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article describes salsalate as a salicylate derivative, like aspirin, that is often used to treat arthritis. It even mentions that there are reports of its use in people with diabetes over a century ago.", "answer": 1}, {"article": "If you'd like more information about the ONCOblot\u00ae Test, please visit http://www.\nAlthough the fight against cancer often appears to be an overwhelmingly intransigent problem, significant progress is being made regarding the development of additional tools for cancer detection, such as the ONCOblot Test.\nIn this study, the serum presence of a mesothelioma-specific form of the ENOX2 protein (a recently identified marker of malignancy) was found within the serum of asbestos-exposed individuals an average of 6.2 years in advance of clinical symptoms by using the ONCOblot tissue of origin cancer detection test.\nThe results of this study showed that two mesothelioma-specific ENOX2 protein transcript variants were detected in the serum of asbestos-exposed individuals 4-10 years prior to clinical diagnosis of malignant mesothelioma, an exciting sign of progress in the cancer detection field.\n\"The completion of this trial is an exciting new chapter for our work,\" says Nick Miner, Vice President of Business Development.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The study backs up the characterization in the release that the results represent progress. Aside from the concerns mentioned above about implying the test will benefit patients, it is reasonable to say this test could be useful to researchers planning clinical trials of early treatment of mesothelioma.", "answer": 1}, {"article": "THURSDAY, June 28, 2012 (HealthDay News) -- A new drug for type 2 diabetes causes significantly less weight gain and may carry lower risks for hypoglycemia (low blood sugar), heart attack and stroke than standard medications, a new study indicates.\nThey added more research is needed to confirm their findings.\nNone of the patients had responded to metformin alone.\nThe researchers noted that which drug they should be prescribed is unclear.\nThe patients on linagliptin also had fewer heart attacks and strokes compared to those being treated with glimepiride.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There are no claims of novelty in the story.", "answer": 2}, {"article": "\u201cThat was the biggest drawback.\u201d\n\nDr. Neil Spielholz, of Nova Southeastern University in Fort Lauderdale, was involved with the initial study submitted to the FDA - the same one that showed the success of laser treatment in UK smokers.\nOther companies do a few shorter therapy sessions as part of their regular treatment plan.\nThose in the three treatment group, in turn, had better success rates than a control group that was given fake laser treatments.\nThere's limited research showing that laser therapy might help some smokers quit.\nThe lack of any drugs involved in laser therapy \u201cwould be the beauty of this,\u201d he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that the treatments are new but not necessarily different from acupuncture.", "answer": 1}, {"article": "THURSDAY, Jan. 5, 2012 (HealthDay News) -- Preliminary findings suggest a drug used to treat another disease might also reduce painful flare-ups in gout patients starting new medication regimens.\nHowever, he cautioned that the high cost of rilonacept will most likely curtail its use.\n\"This is a very expensive drug,\" he said.\nAbout half were also given an initial double-dose injection of rilonacept (320 milligrams) followed by a single dose for 16 weeks.\n\"And insurance will be an issue.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t provide any context about whether this is the first look at rilonacept for gout.", "answer": 0}, {"article": "[11]\n\nEVZIO (naloxone HCl injection) Auto-injector is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.\nAdditionally, there are nearly two times the number of prescription opioid-related deaths as compared to heroin-related deaths.1 On average, 3,300 children five years old and younger are admitted to emergency departments each year due to accidental opioid exposure.\nFor example, taking high doses of opioids, taking an opioid in combination with other drugs (e.g., benzodiazepines) or alcohol, or if there is a history of certain medical conditions (e.g., COPD, severe asthma) places individuals at significantly higher risk for life-threatening OIRD.\n\"The Cabell-Huntington Health Department is pleased to have EVZIO in our community,\" said Dr. Michael Kilkenny, Physician Director of the Cabell-Huntington Health Department in Huntington, West Virginia.\n\"By empowering more patients to have access to this potentially life-saving medicine, we believe that EVZIO will help reduce the burden of opioid overdose in the United States.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that the device is the first naloxone product approved for use by individuals without medical training. Further, the device employs \u201cintelligent\u201d voice and visual guidance for use. To our knowledge it is the only product to do so.", "answer": 1}, {"article": "Driscoll and her research colleagues used data from 6,467 community-dwelling, postmenopausal women aged 65 and older who reported some level of caffeine consumption.\n\"The mounting evidence of caffeine consumption as a potentially protective factor against cognitive impairment is exciting given that caffeine is also an easily modifiable dietary factor with very few contraindications,\" said Ira Driscoll, PhD, the study's lead author and a professor of psychology at the University of Wisconsin-Milwaukee.\nThe findings come from participants in the Women's Health Initiative Memory Study, which is funded by the National Heart, Lung, and Blood Institute.\n\"What is unique about this study is that we had an unprecedented opportunity to examine the relationships between caffeine intake and dementia incidence in a large and well-defined, prospectively-studied cohort of women.\"\nThe paper \"Relationships Between Caffeine Intake and Risk for Probable Dementia or Global Cognitive Impairment: The Women's Health Initiative Memory Study\" is available at: http://biomedgerontology.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release claims that the study is \u201cunique\u201d in that it is based on an \u201cunprecedented\u201d opportunity to study the relationship between caffeine and dementia in a \u201clarge and well defined\u201d ongoing study. The hyperbole may be justified, but there is no evidence that it is from the information given in the release.\nIn fact, there have been a large number of widely reported observational studies and literature reviews examining these associations over the last decades. ", "answer": 0}, {"article": "\"My basic message is that, overall, there may be some slight risks associated with the medication, but in balancing risks and benefits for most women, I would suggest they stay on their medication,\" she said.\nResearchers at Brigham and Women's Hospital in Boston looked at 3.8 million pregnant women nationwide and found that those taking popular antidepressants, called SSRIs, did not appear to be at significantly increased risk of having a baby with pulmonary hypertension.\n\"They take them because they have a disease that impacts their daily life,\" Economy says.\nMany women with depression faced a difficult decision: continue their medication during pregnancy, potentially putting their child at risk, or jeopardize their own mental health by going off the drugs.\nSo for many of these women, these medications are life-saving and life-altering.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes what is novel here: a large new study shows that the risk associated with antidepressants is much lower than previously believed based on a 2006 study.", "answer": 1}, {"article": "\"We have pioneered the development of a closed-loop artificial pancreas because we believe it will significantly impact the lives of individuals with both type 1 and type 2 diabetes, by providing exquisite control of blood sugar,\" Dr. Richard A. Insel, executive vice president for research at the Juvenile Diabetes Research Foundation (JDRF), said during a noon teleconference Saturday.\nA symposium on advances in the technology -- co-sponsored by the American Diabetes Association and the JDRF -- is slated for Sunday as part of the American Diabetes Association's annual meeting, in Orlando, Fla.\n\nFor people with type 1 diabetes, controlling their blood sugar levels is a full-time job.\nIn the first report, Dr. Roman Hovorka, a principal research associate in the department of pediatrics at the University of Cambridge, reported that the technology can significantly improve overnight blood sugar control in adults without the fear of developing hypoglycemia.\nWith the technology, patients maintained their blood sugar levels within the target range for 70 percent of the time, compared to 47 percent of the time among those not using the technology.\n\"The promise in the near term of these technologies is not only to help us reduce significantly the risk of long-term diabetic complications, but also to reduce the risk of having a catastrophic hypoglycemic event, and further help people with diabetes live easier,\" Aaron Kowalski, research director of the JDRF's Artificial Pancreas Project, said during the teleconference.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The end of the article explains the artificial pancreas technology, implying that the computer linkage between monitor and pump is the novel part that is still under development. However, we give this criterion an Unsatisfactory rating because a) that explanation was buried in the end, after the Ritholz study summary; b)\u00a0the article never explained that the aforementioned approach is the goal, not the one used in this study, which seems to have involved manual operators adjusting the patient\u2019s insulin pump as they slept. Little information about how the \"artificial pancreas\" actually works, and what it consists of physically \u2014 e.g., how big is the \"device\"? \u2014 is provided.", "answer": 0}, {"article": "\u201cDoctors and patients need to think about the cancer risk when ordering this test.\u201d\n\nThe study, published in the new edition of Archives of Internal Medicine, found a small but real risk from the average radiation \u2014 for every 100,000 men between 45 and 75 undergoing the test every five years, there would be 42 cancers; for every 100,000 women ages 55 to 75, there would be 62.\nOne Houston doctor said that there was just one scanner in Houston in the mid-'90s, and now the $1 million machines are all over the city.\nCT scanning, which costs from $100 to $500, has grown exponentially in recent years.\n1 killer, strikes many people without the sort of very high cholesterol that usually predicts it.\nIt eventually attracted attention in cardiology circles, where the scans' costs and benefits are the subject of much debate.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "not in question in this story", "answer": 2}, {"article": "The body naturally synthesizes vitamin D when the skin is exposed to sunlight.\nSome past research has indeed found that people with relatively lower vitamin D levels in their blood tend to have higher rates of respiratory infections than those with higher levels of the vitamin, said Dr. Ilkka Laaksi of the University of Tampere in Finland, the lead researcher on the new study.\nA study of Japanese schoolchildren published earlier this year found that those given 1,200 IU of vitamin D each day during cold and flu season were less likely to contract influenza A.\nThe findings, Laaksi said, offer \u201csome evidence\u201d of a benefit from vitamin D against respiratory infections.\nIn the U.S., health officials recommend that adults up to the age of 50 get 200 IU of vitamin D each day, while older adults should get 400 to 600 IU.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n \nThere was no claim that there is anything new about tests of vitamin D for prevention of respiratory illness.\nThis story missed the opportunity to explain what was different about this trial. In their article in the Journal of Infectious Diseases, the researchers pointed out that by studying military conscripts much of the variability that complicates population studies was filtered out. All the participants were from a narrow age group, had passed the same entry physical examination, lived in the same military housing, ate the same food, followed the same daily routines and so on. Also, the classification of their daily status (healthy or ill) was more uniform than would be expected in a study of people in varied civilian occupations. The strengths of the study would be expected to filter out much of the background noise that fogs typical population studies. It is notable that despite those features, this trial failed to reach statistically significant results (partly because of the high drop out rate, which the story should have mentioned.)\n One word usage nit: the story refers to military \u201crecruits,\u201d but the study participants were not recruited to join the military, they were performing mandatory service.", "answer": 2}, {"article": "Fear of doctors, the prospect of being poked and prodded in strange places, a lack of insurance to cover the costly test -- or a combination of all three -- are to blame for as many as half of the over-50 crowd putting off or avoiding the screening test altogether.\nIf results are abnormal, a colonoscopy would still be required.\nNot since 1998, when the FDA approved the PSA test for early detection of prostate cancer, had new technology been created in early cancer detection until the stool DNA test.\nWhile colonoscopy is still viewed as the best screening agent, it's not effective if it's not being used, he said.\nLabCorp has said it will come out with a new test this year.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains that stool DNA screening is relatively new, with one product on the market and others on the way. ", "answer": 1}, {"article": "Newly published research in the Journal of the American College of Nutrition showed that a hearty bowl of instant oatmeal helped curb food intake at lunch better than a leading oat-based, cold cereal -- even when each bowl provided the same number of calories.\nAfter an analysis of the types of fiber in each cereal, the researchers suspected that the higher molecular viscosity of the beta-glucan in the instant oatmeal contributed to its satiating effect over the oat-based, cold cereal.\nThe statistically significant results of the randomized, controlled crossover study (n=47) showed that a 250-calorie instant oatmeal serving (with an additional 113 calories of skim milk) enhanced satiety and feelings of fullness, reduced the desire to eat and may even lead to a lower caloric intake at lunch, compared to a 250-calorie serving of cold, oat-based cereal, also served with an additional 113 calories of skim milk.\nFor more information, please visit www.QuakerOats.com, www.Facebook.com/Quaker or follow us on Twitter @Quaker.\nThe lunches offered ranged from 2,600 to 2,800 calories and participants were told to \"eat to satisfaction.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t establish what is novel about this research, nor does it allude to a previous, very similar study that this experiment was meant to improve upon. How does this study advance the field or differ from other research on fiber?", "answer": 0}, {"article": "\"The results and especially the rapidity of the effects observed in the gantenerumab trial went beyond our expectations,\" Luca Santarelli, MD, study co-author and Roche senior vice president of neuroscience, writes in an email.\nIn the study, patients who received monthly gantenerumab injections showed reductions in such brain plaques.\nTherefore, it's not known if reducing the amount of them will slow or stop the disease.\nThe study is published in the online edition of Archives of Neurology.\nThe experimental compound, known as gantenerumab, is being developed by Roche, the Swiss pharmaceutical company.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The HealthDay competitor did a better job of explaining where this study fits in the history of research into beta-amyloid.", "answer": 0}, {"article": "LaCroix says her new study refutes that research and shows that older adults can still benefit at levels below the moderate-to-vigorous guidelines.\n\u201cBut what we have here is solid evidence that light physical activity reduces a woman\u2019s risk of dying over the next three to four years\u2014and we see the benefits are substantial and independent of moderate-to-vigorous physical activity.\u201d\n\nThe study could not show a cause-and-effect relationship between activity level and risk of death, only an association.\n\u201cIt\u2019s not one size fits all.\u201d\n\nBut national guidelines still recommend that adults over age 65 follow the same guidelines as younger people: to get at least 150 minutes of moderate-to-vigorous physical activity per week.\nAnd recent analyses, compiled from studies in which adults self-reported their levels of physical activity, have suggested that older adults have to log moderate-to-vigorous exercise in order to reduce their risk of early death.\nQuestionnaires used in self-reported studies don\u2019t do a good job of encompassing all the ways people get physical activity throughout the day, she says, which may have skewed previous study results.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story refers to national guidelines and some (nonspecific) \u201crecent analyses,\u201d noting that the \u201cnew study refutes that research.\u201d But is this the first study to show benefits like these from engaging in low-intensity daily activities? No. For example, this 2014 study published in Preventive Medicine examined \u201cexamine[d] the association between household physical activity and all-cause mortality in a cohort of older adults from Spain.\u201d The study relied on self-reporting from study participants, but found that \u2014 among other things \u2014 \u201cHousehold physical activity may have benefits for longer survival in older women.\u201d It would have been interesting to see the article look at how the new study compared to the 2014 study. Do the findings support each other? How do they differ? This sort of context would be valuable for readers.\nWhat does appear novel is the use of a device to assess activity\u2013versus recording what people report as their activity levels.", "answer": 0}, {"article": "Aging is never easy, particularly during menopause. But for 30 years women could at least depend on estrogen and progestin supplements, a comforting hormonal hand to hold that would not only ease the uncomfortable symptoms of getting older but also keep skin supple and hair lustrous. Doctors even encouraged women well into their 70s to take the treatments, on the basis of studies showing that they protected against heart disease and cushioned bones against osteoporosis-related fractures.\n\nIt seemed almost too easy--and it was. In 2002 the quick pharmaceutical fix was all but snatched away when a large government study found that...", "question": "Does the story establish the true novelty of the approach?", "explanation": "Hormone therapy is clearly not a new idea.", "answer": 1}, {"article": "The study published online May 16 in Circulation: Arrhythmia and Electrophysiology.\nIt has been suggested that as treatment for atrial fibrillation, the Watchman device may be preferable to standard blood thinning medications, such as warfarin, which raise the risk of bleeding.\nNew Haven, Conn.-- A new study by a Yale researcher may support the use of a device for patients suffering from irregular heart rhythms.\n\"What we know is that the PROTECT AF trial enrolled more patients and has longer follow-up at this time and this allows greater statistical certainty,\" said Dr. James Freeman, assistant professor of cardiology and first author on the paper.\nThe researchers found that while results from the trials varied, the device did appear to be more cost-effective in the larger, longer-term trial.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release makes a very weak claim of novelty. It does suggest that the study \u201cmay provide more certainty in terms of cost-effectiveness\u201d but quickly adds that longer term results are needed to be \u201ccompletely certain of the device\u2019s value in medical practice.\u201d", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Coffee, tea, or decaf-no matter what your choice, drinking any of these beverages may reduce your risk of diabetes, according to a new analysis of 18 studies including hundreds of thousands of people.\nFor every additional cup of coffee a person consumed each day, the study\u2019s authors found, a person\u2019s risk of diabetes was reduced by 7 percent.\nIn the six studies that looked at decaf coffee, the researchers found, people who consumed more than three or four cups a day were at 36 percent lower risk of diabetes.\nAnd in seven studies that examined tea drinking and diabetes risk, people who drank more than three or four cups daily were at 18 percent lower diabetes risk.\nThe current analysis could have overestimated the effect of these beverages on diabetes risk due to statistical issues with the smaller studies, Huxley and her colleagues note.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story began by explaining that this was a follow-up to a previous literature review of the impact of coffee and tea consumption on type II diabetes.", "answer": 1}, {"article": "Larry Holzman \u2014 avid mountain-biker, skier and guitarist in a band \u2014 plays hard.\nBut he understands the appeal: The FlexBar is easy to use and you can do it at home.\n(Performance Health Brands, maker of Thera-Band, provided the FlexBars for the study but did not fund it.)\nIn addition to tennis players, Bishop sees the injury in gardeners with their shovels and trowels; painters with brushes; and golfers with clubs.\nBishop says the benefit of the FlexBar, which costs between $16 and $33, over traditional hand weights is that it helps people strengthen without recreating the symptoms.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story earns credit for noting that there are other ways to achieve the effects attributed to the FlexBar (as an expert\u00a0source points out, \u201cThere\u2019s a variety of methods you can use to achieve the strengthening technique.\u201d). However,\u00a0the story didn\u2019t satisfactorily\u00a0address what is new and potentially important about this treatment\u2013which is that it allows patients to do isolated eccentric exercises for tennis elbow at home. The only way patients could do this previously was in the clinic using an expensive\u00a0machine. An at-home treatment would make this kind of therapy much more affordable and easier to access, which might\u00a0also make it more effective.\nNonetheless, we\u2019ll give the brief blog post the benefit of the doubt since it ended with the note:\u00a0\u201cThe FlexBar is easy to use and you can do it at home.\u201d", "answer": 1}, {"article": "Professor Brian Walker, Head of the BHF Centre for Cardiovascular Science at the University of Edinburgh, said: \"These findings suggest that corticosterone could provide a safer alternative to traditional cortisol replacement therapy for conditions such as Addison's disease and congenital adrenal hyperplasia.\"\nThe team found that corticosterone was as effective as cortisol, but had reduced effects on fat cells compared with cortisol.\nIn a mouse study, the team showed that the effects of corticosterone on fat cells were reduced compared with cortisol.\nAn improved therapy to replace essential steroids in the body is a step closer thanks to new research.\nThe researchers say that, with further research, these findings may one-day lead to improved therapies for other conditions that respond to steroid treatment, including asthma and rheumatoid arthritis.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The text notes that scant attention has been paid to the use of corticosterone.", "answer": 1}, {"article": "Antioxidants can also provide some protection but there has been controversy over the effectiveness of such food supplements, he said: \u201cPersonally, I think it is much better to eat lots of vegetables and fruit rather than taking any supplements.\u201d\n\nDr Richard Russell, a consultant respiratory physician in the NHS and medical advisor to the British Lung Foundation, who was not involved in the research, said the inhaler was both credible and promising: \u201cEctoine is a beautifully elegant molecule and it clearly works by helping water to stabilise, giving you a film of water in times of stress.\u201d\n\n\u201cThe work that has been published thus far, in credible, internationally recognised journals, show that this stuff has positive properties, protecting against triggered inflammation,\u201d he told the Guardian.\nI was in New York last week, and the air was also not very clean.\u201d\n\nThe protective effect of ectoine was discovered by Prof Jean Krutmann and colleagues at the Leibniz Research Institute for Environmental Medicine, while investigating whether the molecule could protect skin against sun damage.\n\u201cThe point that it can prevent the lung inflammation induced by ultrafine particles is established \u2013 there is no more doubt,\u201d Krutmann said.\nThis means large clinical trials are not required for official approval and the inhaler could be on sale soon, at an estimated cost of \u00a317 a month, after Bitop selects a marketing partner.\nBut on the other hand we have to be realistic and in many countries you cannot just switch traffic overnight to electric cars and do other drastic things.\u201d\n\n\u201cIt will take many more years, especially in countries like China, and I think there is an ethical need to provide something to the general population to protect them,\u201d he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The use of a ectoine for prevention of pollution-related illness is novel and the story provided sufficient backstory with this detail:\n\u201cThe protective effect of ectoine was discovered by Prof Jean Krutmann and colleagues at the Leibniz Research Institute for Environmental Medicine, while investigating whether the molecule could protect skin against sun damage. Bitop funded a series of studies, now published in prominent scientific journals.\u201d", "answer": 1}, {"article": "\"If you have your choice, you want to get poked with a needle or you want to try this?\nThe vaccine's effectiveness was just 3 percent, so low that \"no protective benefit could be measured\" for children ages 2 to 17, the CDC said in a statement.\nAnd the same vaccine continues to be recommended and used in European Union markets, AstraZeneca says.\n\"We continue to pursue a broad-based investigation to identify potential causes of lower effectiveness\" in recent years, the company said in a statement, adding that one of the four flu virus strains it used in the vaccine during the past two flu seasons may have been the problem.\nThe potential cost savings wouldn't happen until the patches were in \"routine use,\" the CDC noted.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The main focus of the story\u2013the possibility that flu vaccine could be delivered via a micro-needle patch\u2013comes across as an exciting new development. In actuality, the Georgia Institute of Technology team made that announcement three years ago. The new development this time around is that the immune response of study participants who used the patch was comparable to those who received a traditional injection.", "answer": 0}, {"article": "The all-Achillion regimen could hit the U.S. market by 2020 in a conservative scenario, Deutsche Bank\u2019s Alethia Young estimated.\nThe new-generation hepatitis C regimens use a two- to three-drug combination \u2013 a nucleotide analog inhibitor or \u201cnuke\u201d and a NS5A inhibitor in Gilead\u2019s case \u2013 to achieves a cure in about eight to 12 weeks, making them faster and more effective than older treatment options.\nThe main goal is to achieve a cure, or sustained virological response, 12 weeks after the completion of therapy.\nThe question then becomes whether ACH-3422 plus ACH-3102 - a weaker nuke and a stronger NS5A inhibitor - could be a good enough doublet as Harvoni, William Blair\u2019s Katherine Xu said.\nGilead\u2019s regimen Harvoni, with its own NS5A inhibitor and Sovaldi as the \u201cnuke\u201d, needs to be taken for at least eight weeks.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Although we question the story\u2019s definition of \u201ccure,\u201d the story does address novelty by describing how results for the new drug appear to improve upon findings with previous similar regimens.", "answer": 1}, {"article": "To learn more about the Society and the field of endocrinology, visit our site at http://www.\nThe drug also reduced major osteoporotic fractures by 55% compared with teriparatide and increased bone density to a greater extent in the hip region compared with teriparatide.\nThe data suggest that abaloparatide appears to be an effective treatment for a broad group of postmenopausal women with osteoporosis.\nThe study was funded by Radius Health, Inc.\n\nEndocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers.\nThe authors found that the risk of new vertebral or nonvertebral fractures dropped consistently among the participants taking abaloparatide-SC, irrespective of their baseline risk factors; and they found an increase in bone mineral density by abaloparatide in each of the baseline risk subgroups.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t make a explicit claim to novelty but it does note the greater hip bone density benefit and reduced fractures with the new drug compared to the existing drug and placebo. We\u2019ll give them the benefit of the doubt as this is a strong indication of new findings.", "answer": 1}, {"article": "Still, even starting the trial could be a boost to Advanced Cell, which often makes headlines but has struggled to raise money.\nThe hope is that the implanted cells will replace those injured by the disease.\nIn the eight-week arm, the first three doses were given every four weeks.\nThe disease is usually diagnosed during childhood and it causes a loss of central vision, though not usually peripheral vision.\nEmbryonic cells can also form tumors if injected into the body.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not try to oversell the novelty of the new treatment.", "answer": 1}, {"article": "The World Journal of Surgery article, by lead author breast surgeon Michael J.\nThe BioZorb device is placed at the time of surgical removal of tissue, such as during breast surgery, and the device's three-dimensional array of marker clips has unique clinical utility for patient imaging.\n\"Through our experience with this marker, we've observed that its use results in less radiation dose to the patient compared to whole breast radiation, plus a better overall cosmetic outcome,\" said Dr. Cross, a nationally known breast surgeon at Breast Treatment Associates, in Fayetteville Ark.\nIt is the first and only device that identifies in a reliable way the 3-D region where the tumor was removed.\nWhile seromas have customarily been targeted for radiation treatment, they do not always reflect where the cancer was and can overestimate the size of the target areas in need of radiation.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that the implant is the first and only device of its kind, and there do not appear to be any similar products on the market.\nIt should be noted that the surgical clips placed by the surgeon at the time of lumpectomy are helpful but do not always accurately reflect the area most at risk for recurrence, especially when oncoplastic surgical techniques are used.", "answer": 1}, {"article": "A Harvard researcher hopes an old arthritis drug, which he read about in a 19th century German medical journal, could be a cheap new treatment for diabetes.\n\nIn the late 1990s, Steven Shoelson's research suggested that the drug, called salsalate, might also help diabetics. The idea sent him into the basement stacks of a Harvard library to see whether anyone else had pursued the notion.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was very clear that this is a compound with a long history which is now being investigated for a new purpose.", "answer": 1}, {"article": "But she said she and her colleagues analyzed the data carefully to account for factors that could have influenced the findings, such as the subjects' ages and whether they had other health problems.\nSome doctors fear the cancer is being over-treated, particularly in older men, subjecting them to therapies that leave many impotent and incontinent when their cancer would never bother them if left untreated.\nIt is diagnosed in 235,000 U.S. men each year and kills more than 27,000, making it the most common cancer and second-leading cancer killer, after lung cancer, among men.\n\"We adjusted for as many of those differences as we could,\" Wong said.\n\"This suggests there may be a benefit of treatment, even in this age group.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It's clear from the story that it is reporting on established treatments \u2013 surgery, radiation, or observation (watchful waiting).\u00a0 ", "answer": 1}, {"article": "For more information about our products and the organization, visit http://www.\nAbout The Journal of Bone & Joint Surgery\n\nThe Journal of Bone & Joint Surgery (JBJS) has been the most valued source of information for orthopaedic surgeons and researchers for over 125 years and is the gold standard in peer-reviewed scientific information in the field.\nOctober 26, 2017 - For younger patients with severe damage to the rotator cuff muscles, a \"reverse\" shoulder replacement provides lasting improvement in shoulder function, according to a study in The Journal of Bone & Joint Surgery.\nA core journal and essential reading for general as well as specialist orthopaedic surgeons worldwide, The Journal publishes evidence-based research to enhance the quality of care for orthopaedic patients.\nDespite its high complication rate, Dr. Gerber and colleagues conclude that RTSA \"provides substantial and lasting improvement\" in shoulder function and pain, in a group of patients with limited treatment options.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release established novelty and earned a Satisfactory rating with this statement: \u201cWhen first introduced, RTSA was performed mainly in elderly patients who placed low demands on the shoulder. With refinements in technique and components in more recent years, the procedure has been used in younger, more active patients. But there are concerns about how well the results of RTSA will hold up over time in this group of patients.\u201d\nHowever, with the limited number of patients involved in this study, and the fact its results conflict with some earlier research, this may not be a case where the findings warrant a news release, even though it is based on a peer-reviewed paper.", "answer": 1}, {"article": "The researchers from Harvard's T.H.\nThe findings showed that breast cancer risk was 12 to 19 percent lower among women who ate more dietary fiber in their youth, depending on how much more they ate.\n\"The results of this study emphasize the role of an early life high-fiber diet on prevention of breast cancer in later life.\nOne weakness she pointed out in the study is that the women were asked to recall details about their adolescent diet when they were in their 30s and 40s.\n\"The sexy headline is eat this and you'll have a lower risk of breast cancer, but I'd shift the focus to, eat more fiber because it's better for you and you'll be a healthier person and you're less likely to be obese and have chronic inflammation and other things that will reduce your risk for heart disease and cancer along the way,\" said Attai.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This study is not the first to examine the possible link between dietary fiber and breast cancer risk. For example, a 2012 paper in the Annals of Oncology looked at 16 earlier studies on dietary fiber and breast cancer risk. There is no discussion of this earlier work, or how the new paper builds on or diverges from the previous research.", "answer": 0}, {"article": "\"There was a trend toward less severe psoriasis severity in people taking statins,\" says researcher Adam Perry, a fourth-year medical student at Emory University in Atlanta.\nAnd no one should start taking statins in an attempt to ward off psoriasis symptoms, doctors stress.\nThe study is preliminary and doesn't prove cause and effect.\nIn a study of 232 people taking medication for psoriasis, those who also took statins had fewer of the thick, red, scaly, itchy patches that are the hallmark sign of psoriasis, compared with people who didn't take the cholesterol-lowering drugs.\nAlready linked to a reduced risk of rheumatoid arthritis, diabetes, multiple sclerosis, and cancer, statins also may help to improve symptoms of psoriasis, researchers report.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story clealry indicated that it was reporting about a potential for a new benefit that might be associated with the use of statin medications.", "answer": 1}, {"article": "D'Amico stressed that men should not start taking vitamin D supplements in hopes of slowing or curing prostate cancer.\nFor the study, researchers randomly assigned 37 men who elected to have their prostate removed to receive either 4,000 international units (IU) of vitamin D or an inactive placebo daily for 60 days before their operation.\nThe findings also need to be replicated in a much larger number of patients, D'Amico said.\n\"Vitamin D decreases inflammation in tissues, and inflammation is a driver of cancer,\" explained Bruce Hollis, the study's lead researcher and a professor of pediatrics, biochemistry and molecular biology at the Medical University of South Carolina in Charleston.\nVitamin D, known as the \"sunshine vitamin,\" is produced by the body when it's exposed to sun.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "While the article successfully avoids promoting this research as anything resembling a \u201cfirst,\u201d it also offers no historical context. Of which there is plenty, including previous studies and inappropriate promotion of vitamins to men who fear or who have prostate cancer.", "answer": 0}, {"article": "The other half got a heart health education program.\nThe study authors say there's a usually a strong relationship between depression and heart failure, so the fact that tai chi helped cheer people up was an especially good sign.\nThe Chinese developed tai chi thousands of years ago, but it has recently piqued the interest of Western medicine as an alternative mind-body therapy to treat disease.\nThe movement is tai chi, an ancient martial art turned exercise, and a study out this week in Archives of Internal Medicine says it may help people suffering from heart failure feel better about life.\n\"Historically, patients with chronic systolic heart failure were considered too frail to exercise and, through the late 1980s, avoidance of physical activity was a standard recommendation,\" the study's authors write.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that tai chi is an ancient form of movement that has recently become interesting to Western medicine due to its potential health benefits. And while the story is correct to note that this study is the first large trial to test tai chi for heart failure (although we might quibble with the use of\u00a0\u201clarge\u201d to describe\u00a0a study involving only 100 patients), it could have noted that previous studies have reported benefits for tai chi in patients with heart failure. In addition, the story didn\u2019t attempt to explain why tai chi might have different effects compared with traditional exercise regimens that are already recommended for heart failure patients.\nA close call, but since the story\u00a0did a reasonable job of putting this research in the appropriate historical context and didn\u2019t portray it as exceedingly\u00a0novel, we\u2019ll award a satisfactory.", "answer": 1}, {"article": "The day after the article was released, the Mayo Clinic removed the headline, replacing it with the still misleading statement that smokeless tobacco was \u201cnot a safe product.\u201d\n\n\u201cPeople can only make as good a decision as the information available to them allows,\u201d said Sweanor, an adjunct professor in the University of Ottawa\u2019s Faculty of Law who has spearheaded the development of world-leading tobacco control initiatives in Canada since the early 1980s.\n\u201cThe public is dramatically misinformed about the relative risks of substitutable tobacco and nicotine products.\nThe risk differentials are huge, but this is simply not known by a vast majority of those whose lives are at risk,\u201d adds Sweanor.\n\u201cIt would be scandalous, even criminal, to keep such facts from consumers,\u201d the researchers write.\nEngland has an example of a website \u2014 Action on Smoking and Health (ASH) \u2014 that gets it right on vaping, the researchers said.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release does not establish that this study is an update of an earlier 2003 study that reported similar conclusions.", "answer": 0}, {"article": "By contrast, he said by e-mail, Asclera \u201cis very safe for skin.\u201d\n\nAn injector\u2019s experience matters, because if the injection misses the vein, (or open sores) can occur.\nShe now wears sundresses instead of just selling them in her boardwalk shop.\nShe is still due for treatments, so some veins remain visible, but they are no longer raised.\nA series of sessions is usually required for a large area.\nSo injecting it is an off-label use.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t suggest that any of these treatments are more novel than is actually the case.", "answer": 1}, {"article": "The results were published in January in Nature Medicine.\nThe drug, known as 10-1074, may also offer a new way to prevent viral infection in people who are at high risk to acquire HIV, the virus that causes AIDS.\nThe investigators found that among 13 HIV-infected people who received the highest dose of 10-1074, 11 showed a rapid decline in the amount of virus.\nThe purpose was to determine whether the antibody was safe and whether it had antiviral activity in humans.\nThe majority of the people in the trial were enrolled at The Rockefeller University Hospital, while some of the HIV-1 infected participants received the antibody at the University of Cologne, in Germany.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states this was the first human trial involving a new drug agent and that is indeed novel. The drug must still undergo considerable research on larger groups of patients before its value is proven.", "answer": 1}, {"article": "The shorter treatment duration encouraged McCartney to have brachytherapy.\nThe advantages of brachytherapy, also called \"accelerated partial breast irradiation,\u201d are shorter treatment time and a smaller area that is exposed to radiation.\nAlthough there are no large-scale national results, doctors say studies have shown brachytherapy to be as effective as traditional radiation therapy.\nIn the multiple-catheter method, a doctor places 10 to 20 \"needles\u201d about one centimeter apart around the tumor cavity, and a machine inserts the radioactive pellet.\nHowever, he said, \"I think it is becoming more popular, both from a physician perspective but also from a patient perspective.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article states that brachytherapy is a less common but increasingly used treatment for some breast cancers. It does not imply the technique is new or revolutionary. \nStatistics on use would have been valuable, however. ", "answer": 1}, {"article": "[Why it's so hard to find a mental health professional ]\n\nLam and his colleagues followed 122 patients and evaluated whether light therapy improved their mood when it was used both with and without fluoxetine, or Prozac, a commonly prescribed antidepressant.\nThe research, published Wednesday in JAMA Psychiatry, is significant because major depression is one of the most common mental health disorders in the United States and one of the leading causes of disability worldwide.\nThis study \"shows a new, proven-safe treatment of depression that is probably both more effective and less expensive than drug treatment or anything else,\" said Dan Kripke, a psychiatrist and professor emeritus at the University of California, San Diego, who has studied the topic but was not involved in the latest trial.\nThere's some evidence that depression, like jet lag, occurs when the biological clock is out of sync, and light helps to correct that, Lam said.\nMost people typically receive medication and psychotherapy \u2014 but medications don't work in all cases and there's a shortage of providers in many areas.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not say this was the first randomized trial about non-seasonal depression and refers to previous research. It does imply that this study reinforces a change in practice to include light therapy as another alternative. We wish the story had explained perhaps why this study could lead to a conclusive change in practice.", "answer": 1}, {"article": "\"I wasn't interested in going as far as getting an amniocentesis because of the risk associated with that,\" she explains, \"and so when I heard about this test, that was part of the reason that I was most interested in it.\"\nSome babies with these conditions grow up into adulthood and never know they have them, unless they face a symptom like infertility.\nThis can reveal if there's an increased risk of certain disorders, but it's not very accurate and produces a lot of false alarms.\nSome worry that the companies' websites and marketing materials don't make the limitations clear enough.\nThis kind of test , called cell free fetal DNA testing, uses a simple blood sample from an expectant mother to analyze bits of fetal DNA that have leaked into her bloodstream.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story discussed how this type of prenatal testing differs from traditional testing and emphasized that the tests were so new that their usefulness and limitations were not clearly understood.", "answer": 1}, {"article": "Researchers at Stanford University have developed a first-of-its-kind blood test that, according to preliminary studies, is able to identify patients with Alzheimer's disease - an ailment that has been notoriously difficult to diagnose.\nAlthough the studies were small in scale, researchers said the experiment proved that the concept of screening for chemical signals was promising and that the first Alzheimer's blood test might be within reach after further large scale studies.\nIn one experiment using stored blood samples, the test was positive for Alzheimer's disease in 38 out of 42 patients who had been independently diagnosed by clinicians as having the disease - a 90 percent accuracy rate.\nIt is important for us to increase the number of people who realize they are at risk and can still speak out for themselves,\" he said.\nThe 18 different molecules are drawn from a phrasebook of chemical chatter that occurs among cells in the body.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This was a story reporting on the development of a method for identifying individuals who will go on to devlop Alzheimer\u2019s disease.\u00a0 It was accurate in the portrayal of the novelty of the approach.", "answer": 1}, {"article": "The journal that published the new paper, Science, promoted the finding in a news release, but added a \u201cspecial note\u201d citing the Schiavo case and warning that the finding \u201cshould not be used to generalize about all other patients in a vegetative state, particularly since each case may involve a different type of injury.\u201d\n\nThe brain researchers, led by Adrian Owen at the Medical Research Council Cognition and Brain Sciences Unit in Cambridge, England, performed scans on the patient\u2019s brain five months after her accident.\nThe imaging technique, called functional M.R.I., reveals changes in activity in specific brain regions.\nAn estimated 100,000 Americans exist in this state of partial consciousness, and some of them eventually regain full awareness.\nAbout 50 percent of people with such injuries recover some awareness in the first year after the injury, studies find; very few do so afterward.\nOnly 15 percent of people who suffer brain damage from oxygen deprivation recover some awareness within the first three months.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Clearly the functional MRI technique is new for people in a vegetative state.", "answer": 1}, {"article": "\u201cToo often, parents fall victim to the false claims of charlatans who prey on desperate families.\nNevertheless, for parents of children with autism, even a modest reduction would be worthwhile.\u201d\n\nDr Max Davie, of the Royal College of Paediatrics and Child Health, said it offered \u201ca hugely cheering message for families\u201d, while Uta Frith, emeritus professor of cognitive development at University College London, called it \u201ca remarkably positive story, because the intervention itself was neither intensive nor invasive\u201d.\n\u201cThis is not a cure, in the sense that the children who demonstrated improvements will still show remaining symptoms to a variable extent, but it does suggest that working with parents to interact with their children in this way can lead to improvements in symptoms over the long term.\u201d\n\nThe trial involved 152 children aged two to four.\nThe absence of any hope, as well as the very sudden regression in children\u2019s behaviour, led many parents to believe in the discredited theory of Andrew Wakefield that the MMR (measles, mumps and rubella) vaccine was the cause of autism.\nThese results look promising for the many thousands of parents who want to find early interventions for their children based on solid science.\u201d\n\nThe researchers said children\u2019s communication with their parents was improved at the end of the six years.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story attempts to establish novelty with this statement:\n\u201cA new form of therapy has for the first time been shown to improve the symptoms and behaviour of autistic children, offering a potential breakthrough in care for millions of families.\u201d\nHowever, that\u2019s erroneous: The investigators make clear in the study that there was a previous trial of PACT with promising results. What is clearly novel in this study was its size (152 children), randomization and long-term follow up.", "answer": 0}, {"article": "Like a patch on faulty software, C.B.T.\nThat moment with my children, a couple of years ago, was the last time I fell asleep reading to them.\ntreatment, relative to no treatment.\nAnd as studies show, it works better than drugs.\nMy sleep log also helped me be more objective.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story carefully gives us context for the research described, which is not novel.", "answer": 1}, {"article": "[5]\n\nAccording to the Centers for Disease Control and Prevention (CDC), in 2011\u20132014, the prevalence of obesity was just over 36 percent in adults, with a higher prevalence among women than men (38.3% vs. 34.3%) and older than younger adults (37% vs. 32.3%).\n\u201cThe balloon and other technologies may help to fill the therapeutic gaps between diet and exercise and medical therapy, and medical therapy and surgery, where the gaps are quite large.\u201d\n\nPeople with obesity and severe obesity have higher rates of heart disease, diabetes, some cancers, arthritis, sleep apnea, high blood pressure and dozens of other diseases and conditions.\n\u201cThis combination of lifestyle modification and balloon therapy provides a new low risk option for patients struggling with obesity.\u201d\n\nThe Obalon 6-Month Balloon System, a swallowable, gas-filled intragastric balloon for weight loss in adults with obesity for whom diet and exercise has failed, was approved in September by the U.S. Food and Drug Administration (FDA).\nIt is a non-profit organization that works to advance the art and science of bariatric surgery and is committed to educating medical professionals and the lay public about bariatric surgery as an option for the treatment of morbid obesity, as well as the associated risks and benefits.\n\u201cThere is no magic pill for obesity, but this swallowable balloon and other intragastric balloons may offer new hope to people who otherwise would not seek treatment or not have as good a result with diet and exercise alone,\u201d said Raul J. Rosenthal, MD, ASMBS President and Chairman, Department of General Surgery, Cleveland Clinic Florida, who was not involved in the study.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "By omitting any details about the difference between the Obalon device and similar intragastric balloons, it is impossible for readers to know what is new about this device. The release could have noted that while the Obalon device is swallowed without an endoscopic procedure or sedation, the ReShape and Orbera balloons require endoscopic placement under mild sedation, and that all three devices require endoscopic removal. Also, it could have told readers that the Elipse brand balloon, which is available in Europe, is swallowed and then eventually excreted, so it normally does not require any endoscopic procedures.", "answer": 0}, {"article": "For more nutrition information and to access a vast collection of healthy potato recipes, please visit http://www.\nHowever, plate waste for white potatoes was the lowest among any type of vegetables; thus, including potatoes in school meals is one important way to help ensure children receive those key nutrients of concern.\nIn fact, a study of elementary school students demonstrated that students are not consuming the majority of vegetables offered to them in school lunches.\nToday, as the largest vegetable commodity board, the USPB is proud to be recognized as an innovator in the produce industry and dedicated to positioning potatoes as a nutrition powerhouse--truly, goodness unearthed.\nResearch published (January 2016) in a special supplement of the peer-reviewed journal Advances in Nutrition demonstrated that children ages 1-3 years of age consumed just 67 percent of the dietary reference intakes (DRI) for potassium and 55 percent of the DRI for fiber.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "By claiming that potatoes are the best hope for increasing potassium and fiber intake in kids, we think the release needed to prove the novelty of the research and this finding. But there\u2019s nothing new here.", "answer": 0}, {"article": "The end point also shifts the paradigm from palliation to cure,\" remarked Dr. Scher.\nThe results suggest that some men who have previously been considered incurable can possibly be cured; investigators also establish a new paradigm for testing various drug combinations in conjunction with local treatment of the prostate to determine which is the best approach (ie, has the highest undetectable disease rate).\nHowever, none achieved the primary end point of undetectable PSA with testosterone recovery at 20 months after initiation of therapy with ADT alone, although one patient had a PSA of Of the 15 patients with bone metastases, 14 (93%) reached an undetectable PSA when ADT, surgery, and radiation were used.\nAccording to lead investigator Howard I. Scher, MD, Chief of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center in New York City, \"The sequential use of the three different modalities helped illustrate the role and importance of each in achieving the undetectable PSA with normal testosterone level end point, which represents a 'no-evidence of disease' status.\"\nWhile the study is only a first step, one-fifth of the patients treated had no detectable disease, with an undetectable prostate-specific-androgen (PSA) and normal blood testosterone, after 20 months.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does a good job of articulating how this work takes a three-pronged approach and promotes the idea of working toward a means of curing metastatic prostate cancer. It would have been stronger if it had offered more discussion regarding the importance of \u201ca new paradigm for testing various drug combinations in conjunction with local treatment of the prostate to determine which is the best approach (ie, has the highest undetectable disease rate).\u201d That seems like a useful tool for both researchers and clinicians, and is largely glossed over.", "answer": 1}, {"article": "\u2022 Khin NA, et.al.\nTo put this into context, an analysis of placebo-controlled data from three prior studies conducted by Duru and Fantino determined that a minimum change in MADRS of 1.9 was clinically meaningful.2 In addition, the average difference is between 2-3 points for currently approved antidepressants vs. placebo.3\n\nSafety results were consistent with previous studies of esketamine in younger adult populations.\nIf approved by the U.S. Food and Drug Administration (FDA), esketamine would be one of the first new approaches to treat refractory major depressive disorder available to patients in the last 50 years.\nPrimary Efficacy Endpoint\n\nAlthough statistical significance for the primary endpoint for the overall patient population studied was narrowly missed, results favored the esketamine nasal spray plus a newly initiated oral antidepressant group (median unbiased estimate of the difference from placebo nasal spray plus a newly initiated oral antidepressant: -3.6, 95% CI: -7.20, 0.07; one-sided p=0.029).\nThe most common treatment-emergent adverse events (>10%) reported in the esketamine group were dizziness, nausea, headache, fatigue, increased blood pressure, vertigo and dissociation.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Although there are other medications used in combination with antidepressants, this treatment strategy is a novel use of a new medication class. We will see (presumably in additional trials) if the response is long-term.", "answer": 1}, {"article": "Cancer experts said Tuesday that the actress and filmmaker Angelina Jolie Pitt was wise to have had her ovaries and fallopian tubes removed last week because she carries a genetic mutation, BRCA1, that significantly increases the risk of ovarian cancer, a disease so difficult to detect that it is often found only at an advanced, untreatable stage.\n\u201cThere is no effective screening for ovarian cancer and too many women with advanced stage ovarian cancer die of their disease.\u201d\n\nWriting for The New York Times\u2019s Op-Ed page, Ms. Jolie Pitt, 39, said she had expected to have her ovaries and fallopian tubes removed, a procedure called a laparoscopic bilateral salpingo-oophorectomy, but that a cancer scare made her decide to undergo the procedure sooner.\nIt is unclear how common the mutations are in other racial and ethnic groups.\nThey also said Ms. Jolie Pitt\u2019s decision to discuss her own choices so frankly will encourage women in similar situations to consider their own options.\n\u201cProphylactic removal of ovaries and fallopian tubes is strongly recommended in women before age 40 in BRCA1 and BRCA2 mutation carriers,\u201d said Dr. Susan Domchek, executive director of the University of Pennsylvania\u2019s Basser Research Center, which specializes in BRCA mutations.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There is no claim to novelty here. The story is clear that it was prompted by Ms. Jolie Pitt\u2019s op-ed in the New York Times.", "answer": 1}, {"article": "Newswise \u2014 SAN FRANCISCO, March 16, 2017\u2014-Patients in their 80s and 90s who have early stage lung cancer but cannot undergo an operation can be treated safely and effectively with stereotactic body radiation therapy (SBRT), according to research presented today at the 2017 Multidisciplinary Thoracic Cancers Symposium.\nRecursive partitioning analysis (RPA) was conducted to determine which patients were most likely to benefit from therapy.\nFifty percent of patients who did not have a biopsy had a previous history of lung cancer.\nPatients complete SBRT treatment in three to five days, compared with several weeks for conventional RT.\nFor press registration and news briefing information, visit www.astro.org/thoracicpress.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It is clear that this study provides new information about the experiences of some elderly patients.", "answer": 1}, {"article": "For their analysis, Gibbons and his colleagues looked at outcomes for each individual patient in published and unpublished trials testing the effects of six weeks of treatment with antidepressants versus placebo pills.\nThe findings, he added, \u201craise other questions that need to be followed up (including), what\u2019s going on in the elderly?\u201d\n\nBoth types of Effexor, or venlafaxine, also seemed to help adults with mild to severe depression, with slightly more patients responding to the immediate-release dose.\nHowever, in the elderly the differences between the treatment and placebo groups were much smaller, and the researchers calculated that 17 older patients would have to be treated with Prozac for one to gain from it.\nStill, not everyone in the studies improved \u2014 on average, about five people had to be treated with one of the drugs for one person to feel better, and the benefits seemed to be diminished among some of the oldest patients.\nThe researchers said they couldn\u2019t be sure there would be similar improvements with other types of antidepressants \u2014 especially given the more limited data in kids and the elderly \u2014 or that the longer-term benefits would be as clear.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story didn\u2019t analyze the novelty claim that the researchers made:\n\u201cTo our knowledge, this is the first research synthesis in this area to use complete longitudinal person-level data from a large set of published and unpublished studies. The results do not support previous findings that antidepressants show little benefit except for severe depression.\u201d\nThe second point was made in the story, but perhaps the story should have explained a bit more about the methodological reasons for why this analysis was \u2013 or what made it \u2013 different or important.\nAs to the first (questionable) part of the claim, what\u2019s novel is this: more studies than the previous analysis, adolescents/adults/older adults included and analyzed by these groups.", "answer": 0}, {"article": "Still, little is known about its cause.\nThe authors suggest several biological mechanisms of breast milk may explain their results, including that breast milk contains many immunologically active components and anti-inflammatory defense mechanisms that influence the development of an infant\u2019s immune system.\nThe many potential preventive health benefits of breastfeeding should also be communicated openly to the general public, not only to mothers, so breastfeeding can be more socially accepted and facilitated.\nIn a review of all 18 studies, the authors found breastfeeding for six months or longer was associated with a 19 percent lower risk compared with no breastfeeding or breastfeeding for a shorter period of time.\nIn addition, more high-quality studies are needed to clarify the biological mechanisms underlying this association between breastfeeding and lower childhood leukemia morbidity,\u201d the study concludes.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release did not comment on the novelty of the research, and doesn\u2019t tell us how this study differs from other meta-analyses of studies of breastfeeding and childhood leukemia. As the study authors claimed in the published report, \u201cto our knowledge, this is significantly the largest and most up-to-date review and analysis of current knowledge on childhood leukemia and breastfeeding.\u201d", "answer": 0}, {"article": "For more information, visit http://www.\nPears are an excellent source of fiber and a good source of vitamin C. One medium pear provides about 24 percent of daily fiber needs for only 100 calories.\nA nationally representative analytic sample suggests that the consumption of fresh pears should be encouraged as part of an overall healthy diet\n\nPORTLAND, Ore. - Dec. 8, 2015 - It's National Pear Month and the perfect time to enjoy juicy, sweet pears.\nIn addition to discovering a correlation between fresh pear consumers and lower body weight, the study found that pear consumption was associated with higher diet quality (as defined by the Healthy Eating Index).\nA new study, 'Fresh Pear Consumption is Associated with Better Nutrient Intake, Diet Quality, and Weight Parameters in Adults: National Health and Nutrition Examination Survey 2001-2010,' published in Nutrition and Food Science, revealed new information regarding the health benefits of pear consumption.1 Of particular interest given the high rates of obesity in the United States, the study found that adult pear consumers had a lower body weight than non-pear consumers and they were 35 percent less likely to be obese.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "With or without pear eating. it is not exactly news that higher consumption of fruits (and vegetables) have long been associated with better overall diets, nutritional status, and healthy weight.", "answer": 0}, {"article": "Dr. Douglas Fraser, a physician in the Paediatric Critical Care Unit at Children's Hospital, London Health Sciences Centre and Lawson scientist, led the study with his co-investigator Mark Daley, a professor in the Departments of Computer Science, Biology and Statistics & Actuarial Sciences at Western University.\nThe scientists measure a panel of metabolites - small molecules that are the products of the body's metabolism - in the blood to search for distinct patterns that indicate a concussion has occurred.\n\"The discovery of a blood test that can aid in concussion diagnosis is very important,\" says Dr. Fraser.\nThe findings were recently published in the international journal Metabolomics.\nIn the new study, researchers have demonstrated that a blood test can now accurately diagnose a concussion using a form of blood profiling known as metabolomics.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It appears that the novelty of measuring metabolites has been well established in this study.", "answer": 1}, {"article": "Bethany, who manages occupational therapists for a nursing-home chain, and Jay, a rural mail carrier, shuttled between the Twin Cities visiting their daughters.\nShe has been in remission ever since.\nIt was no longer producing the CD19 protein, which meant her modified T cells could no longer recognize the disease.\nAva spent months in the hospital and then a year at home.\nThe majority have gone into remission, although some have had their cancer return.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is basically all about what makes this particular form of therapy novel.", "answer": 1}, {"article": "The number of prostate cancer diagnoses dropped by more than 12% (1363 cases) in the month after the USPSTF draft guideline was issued and the number continued to drop, resulting in an overall decline of 28% in incident prostate cancer diagnoses in the year after the draft guideline was issued.\nThe decreases were similar across all subgroups of age, comorbidity, race, income, and insurance.\nSimilarly, new diagnoses had fallen by 23.0-29.3% among men over age 70 and by 26.0% among infirm men, populations at risk for harms of treatment but unlikely to live long enough to benefit from early detection.\nProstate cancer remains the second leading cause of cancer death among men in the U.S., with nearly 30,000 deaths annually.\nDiagnoses of low, intermediate, and high risk prostate cancers all decreased significantly, but new diagnoses of non-localized disease did not change.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release establishes what is new and noteworthy about this study. There are no inappropriate claims to novelty.", "answer": 1}, {"article": "AOSSM is also a founding partner of the STOP Sports Injuries campaign to prevent overuse and traumatic injuries in kids\nThe Society works closely with many other sports medicine specialists, including athletic trainers, physical therapists, family physicians, and others to improve the identification, prevention, treatment, and rehabilitation of sports injuries.\nAfter treatment with an arthroscopic bankart repair, the postoperative dislocation rate in the first-time injury group was 29%, compared to 62% in those who did not have surgery after their initial injury.\nOf this group, 68 patients had experienced their first dislocation, while 53 had recurrent dislocations after being initially treated non-operatively.\n\u201cPhysicians should counsel those with first time injuries on these benefits moving forward.\u201d\n\nThe American Orthopaedic Society for Sports Medicine (AOSSM) is a global leader in orthopaedic sports medicine education, research, communication and fellowship, and includes national and international sports medicine leaders.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release does not say anything about the novelty of the surgical intervention or of the non-surgical approaches. Is this the first time this issue has been studied? The release gives no sense as to how this study fits into the wider body of research.", "answer": 0}, {"article": "Feb. 15, 2011 -- Taking zinc, either as a syrup or lozenge, through the first few days of a cold may shorten the misery of an upper respiratory infection, a new research review shows.\nIt also appeared to prevent colds in people who used it over the course of about five months.\nThe review also found that zinc cut the number of days that kids missed school because of being sick and reduced the use of antibiotics by cold sufferers.\n\u201cThe evidence from the recent trials does support the use of zinc lozenges in treatment of common cold,\u201d says study researcher Meenu Singh, MD, a pediatric pulmonologist at the Post Graduate Institute of Medical Research in Chandigarh, India.\n\u201cThis is great news,\u201d says Kay Dickersin, PhD, an epidemiologist with the Johns Hopkins School of Public Health and director of the U.S. Cochrane Center.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that zinc has been studied as a possible treatment or preventative measure for the common cold and that this study seems to provide the first significant body of evidence suggesting that zinc has benefits.", "answer": 1}, {"article": "By inhibiting transcription, ICEC0942 shuts down the ability of the cancer to spread.\nThe drug may not become available to patients for a number of years yet, but researchers believe that if clinical trials are successful, it could be used to tackle a variety of treatment-resistant cancers.\nThe discovery of the drug was spurred by an initial meeting between Professor Anthony Barrett, from the Department of Chemistry, and oncologist Professor Charles Coombes from the Department of Surgery & Cancer.\nProfessor Charles Coombes, from the Department of Surgery & Cancer, said: \"Treatment-resistant tumours represent a significant threat for patients, as once a cancer stops responding to treatments there is increasingly little clinicians can do.\n\"Drugs such as these could help to shift the balance back in favour of the patients, potentially providing a new option to patients for who existing treatments no longer work.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release states that researchers \u201chave discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies.\u201d We could not find evidence other research into this particular molecule.", "answer": 1}, {"article": "A downloadable photo of Dr. Mark Loeb is available here\nThe original intention of the study was to show that nasal spray vaccines would provide better protection than flu shots, but Loeb says the conclusions of the study are now especially important, given the ACIP's recommendations.\nFor the study, Loeb's team conducted a three-year trial in a Hutterite colony, where people live communally and are relatively isolated from cities and towns, to determine whether vaccinating children and adolescents with the flu nasal spray provided better direct and community protection than the standard flu shot.\nPublished today in the scientific journal Annals of Internal Medicine, the study shows that the nose spray had a similar effect to the standard flu shot.\nPrevious recommendations from the Centers for Disease Control's Advisory Committee on Immunization Practices (ACIP) had previously called for nasal sprays, or live attenuated influenza vaccine (LAIV), not be used during the 2016-2017 flu season.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes clear that the novelty of this study is its ability to examine both indirect effects of vaccination on the community as well as direct effects for persons receiving the vaccine.", "answer": 1}, {"article": "(Reuters) - Tiny Israeli drugmaker Oramed Pharmaceuticals Inc on Wednesday said its experimental oral insulin succeeded in significantly reducing night-time blood glucose in patients with type 2 diabetes, according to initial data from a midstage trial.\nThere were no reported serious adverse side effects and no issues with hypoglycemia, or dangerously low blood sugar, the company said.\nOramed uses a protective coating and a high-enough dose of insulin so that most of it can be destroyed and still deliver a clinically beneficial amount of the hormone.\nThey were dosed before bed time and had their overnight glucose levels continuously monitored.\nThose who received the oral insulin had a mean night-time glucose reduction of nearly 6.5 percent compared with a placebo.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that if this drug delivers the necessary insulin by mouth, then this would be a novel advance in treatment\u2013and a \u201cmultibillion-dollar product.\u201d", "answer": 1}, {"article": "Doctor are taking the first steps to move this treatment beyond the world of the elite athlete.\nI definitely had some pain, and there was a lot of gain.\"\n\"I was back running in around three weeks, and I was ready to play in about 4 1/2.\nThey say, 'no pain, no gain.'\nBut was the pain worth it?\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This would be a novel approach, as the story makes clear. ", "answer": 1}, {"article": "U.S.\nFigure 1a shows a tear at baseline on the posterior horn of the medial meniscus, while Figure 1b, taken 9 months after the first injection shows complete resolution of the tear.\nResults are published in the scientific publication the Journal of Medical Cases, and is authored by USRM Chief Science Officer Dr. Kristin Comella and colleagues Dr. Scott Greenberg of the Magaziner Center for Wellness, and Dr. Laura Ross of Ross Orthopedic.\nMeniscal injuries are the most common knee injury in the United States with an annual average of incidence of 66 per 100,000, according to a 2014 article in the Journal of Orthopedics.\n\"Use of one's own healing cells to help repair damaged tissue rather than having to cut open or manipulate the damaged area to try to reduce pain and restore function is the most elegant form of regenerative medicine we have today.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Certainly, a non-surgical method of repairing injuries to the meniscus \u2014 if it were readily available to patients \u2014 would warrant news coverage.\u00a0 In this case, however, this release is woefully premature.", "answer": 0}, {"article": "All the women were between the ages of 18 and 45 and their contraceptives were within six months of expiring before they enrolled in the study.\nThe study is still ongoing, and the researchers plan to recruit up to 800 women and ultimately test whether the IUDs and implants were effective for up to three years after their current FDA-approved duration.\nMORE: The IUD Answer: Why The Best Form of Birth Control is the One No One Uses\n\nThe researchers followed 237 women who were using an implant like Implanon and Nexplanon and 263 women using the Mirena hormonal IUD.\nThe women were informed of the pregnancy risk associated with using their device longer than recommended, and the researchers called them for followup every 6 months for 36 months or until the women had their device removed.\nThough the data is preliminary, the researchers say they believe that the hormonal IUD and the implant can both be used for an additional year longer than the FDA recommends.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Extended use of LARCs has been the subject of other studies and at least one review article that made clinical practice recommendations. A brief search and one sentence would have been sufficient to establish this context.", "answer": 0}, {"article": "Kalluri and his colleagues examined serum samples from 190 patients with pancreatic cancer, 32 patients with breast cancer and 100 healthy volunteers.\n\u201cUsing this test we were 100 percent accurate at identifying all cancer patients.\u201d\n\nIn 2015 48,960 Americans will be diagnosed with pancreatic cancer, according to estimates by the National Cancer Institute.\nIt is a good example of how this disease sneaks up on people and gives no warning.\u201d\n\nA test for pancreatic cancer could save lives, perhaps even Flippo-Morton\u2019s, Raghavan said.\n\u201cIt kills people and it kills them quickly.\u201d\n\nA screening test could have a huge effect, said Dr. Timothy Donahue, an associate professor of surgery and molecular and medical pharmacology and chief of pancreas and gastrointestinal surgery at the University of California, Los Angeles.\n\u201cSomething like this could potentially flatten that curve and change the epidemiology of pancreatic cancer.\u201d\n\nStill, Donahue said, the method needs to be \u201cheavily vetted and validated.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The findings are presented as novel, but novelty is not established. There\u2019s no discussion of whether there has been other research into tests for pancreatic cancer and how the new test builds upon those previous efforts. We can infer that this is new, but the context is not established.", "answer": 0}, {"article": "PHILADELPHIA - In a finding that suggests the potential for practice change that would reduce the use of antibiotics in dermatology, researchers in the Perelman School of Medicine at the University of Pennsylvania have found the diuretic drug spironolactone may be just as effective as antibiotics for the treatment of women's acne.\nThe study, published this month in the Journal of Drugs and Dermatology, found patients who were originally prescribed spironolactone changed to a different drug within one year at almost the same rate as those who were prescribed antibiotics.\nWithin a year, 14.4 percent of spironolactone patients and 13.4 percent of antibiotic patients had switched to alternative treatments, suggesting each treatment was working at almost the same rate, despite the fact that tetracycline-class antibiotics are prescribed five times as frequently.\nMore than 50 percent of women in the United States are treated for acne between the ages of 20 and 29, while more than 35 percent are treated between the ages of 30 and 39.\n\"This indicates spironolactone may have a better safety profile than oral antibiotics, which is another factor that makes it such an appealing option,\" Barbieri said.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t make a claim of novelty, nor should it. It\u00a0is not about a new drug, but a call for a new application for an old drug.", "answer": 1}, {"article": "(Reuters Health) - Many women with severe menopausal symptoms are not being treated for them even though safe, effective remedies are available, a study from Australia suggests.\nBut overall, he said, it is a combination of patients not wanting therapy or not having information about it, and also the provider not prescribing it.\nThe women who did use hormones were mostly taking pills containing estrogen, rather than preparations that are absorbed into the skin and that are potentially safer, the researchers found.\nThere is also, she said, a complete lack of understanding that for most women, these symptoms are not fleeting.\nVaginal dryness is common with menopause and affects sexual functioning.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story tells readers what\u2019s newsworthy about the results and doesn\u2019t make any inappropriate claims to novelty regarding these therapies.", "answer": 1}, {"article": "And studies suggest that fortifying corn masa with folic acid could prevent an additional 40 to 120 cases of neural tube defects among babies born to Hispanic mothers each year.\nInstead, they were consuming corn masa flour products, because that was the staple grain in that diet,\" says Cynthia Pellegrini, senior vice president of public policy and government affairs at the March of Dimes.\nUnder current FDA rules, tortillas, corn chips and other foods made with corn masa flour can't be fortified with folic acid.\nBut there's one notable exception to this success story \u2014 Hispanic women \u2014 and researchers think the reason may lie in a staple of their diet: tortillas.\nThe rates are highest among Hispanics: Latina women are roughly 20 percent more likely to have a baby with a neural tube defect compared to non-Latina white women.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There is nothing novel about the suggestion (made in 2012) that folic acid be added to corn flour, and the story explains why this issue is newsworthy now.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - When symptom-free people have heart scans to look for clogged arteries, they can end up with overtreatment and side effects, researchers said Monday.\nPeople who got scans also had more additional tests and major heart procedures.\nBoth drugs have side effects, notably joint problems and bleeding ulcers.\nBut after another 18 months, there was no such difference.\n\u201cWith these new imaging techniques, we are left with the dilemma of what to do with the results,\u201d he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of the screening test could be deduced from the story.", "answer": 1}, {"article": "Newly postmenopausal women who received estrogen via a skin patch had reduced beta-amyloid deposits, the sticky plaques found in the brains of people with Alzheimer\u2019s disease, a Mayo Clinic study published this month in the Journal of Alzheimer\u2019s Disease found.\nThe oral treatment was not associated with lower amyloid deposition.\nResearchers investigated the brain amyloid deposition in 68 women ages 42 to 59 who participated in the Kronos trial during this critical window.\nA rapid decline in estrogen with menopause may be associated with an increased risk of Alzheimer\u2019s disease risk in women.\nThe researchers used positron emission tomography, also known as a PET scan, to look for the brain amyloid deposits three years after the trial ended.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The lead author makes a priority claim in the release, which seems to be justified.", "answer": 1}, {"article": "The U.S. Food and Drug Administration today approved Trulance (plecanatide) for the treatment of Chronic Idiopathic Constipation (CIC) in adult patients.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe agency also is responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\nThe safety and efficacy of Trulance were established in two 12-week, placebo-controlled trials including 1,775 adult participants.\nIf severe diarrhea occurs, patients should stop taking Trulance and contact their health care provider.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release could have noted in a bit more detail how this drug works compared to other drugs used to treat CIC, and especially how it differs from over-the-counter and \u201chome\u201d remedies.", "answer": 0}, {"article": "Saturated fats can remain a part of a healthy diet, in limited amounts \u2013 but there are two easy ways to help:\n\u2022 Saturated fats should make up 10 percent of total caloric intake daily.\nIn fact, the study found that the lower the cholesterol, the greater the risk of death.\nAll that is known is the participants had a normal cholesterol levels and normal blood pressure.\nBut even when their cholesterol levels were lowered by the switch from saturated fats, there was no longevity benefit.\nWhether statins have additional properties to reduce risk, in addition to lowering serum cholesterol remain under study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains that the novelty is not with any treatment or discovery but rather a novel statistical examination of old data.", "answer": 1}, {"article": "The National Institutes of Health, as well as the Michael J.\nIn a proof-of-concept study, published in the journal Neurobiology of Disease, the drug nortriptyline, which has been used to treat depression and nerve pain, stopped the growth of abnormal proteins that can build up in the brain and lead to the development of the disease.\n\"What we've essentially shown is that an already FDA-approved drug that's been studied over 50 years and is relatively well tolerated could be a much simpler approach to treating the disease itself, not just the symptoms,\" Collier said.\n\"We found that those on a certain class of antidepressant, called tricyclics, didn't need the levodopa therapy until much later compared to those who weren't on that type of antidepressant medication,\" Collier said.\n\"Depression is a very frequent condition associated with Parkinson's, so we became interested in whether an antidepressant could modify how the disease progresses,\" said Tim Collier, lead author of the federally funded study and a neuroscientist at MSU.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release suggests researchers have taken a novel approach to finding a new treatment strategy for Parkinson\u2019s. It states:\n\u201cThe idea that this clustering effect is controlled by how fast or slow a protein reconfigures itself is typically not a standard way of thinking in research on proteins, but our work has been able to show these changes.\u201d\n\u201cUnderstanding how these proteins can clump together could point researchers in new directions and help them find other possible drugs that could potentially treat Parkinson\u2019s.\u201d\nBut as already noted above under Benefits, without testing the drug in humans, the claim of a novel finding seems unwarranted.", "answer": 1}, {"article": "The review identified a handful of drugs that \u201care probably effective and should be considered for migraine prevention.\u201d These include the antidepressants amitriptyline (Elavil, Endep or Vanatrip) and venlafaxine (Effexor); the beta blockers atenolol (Senormin or Tenormin) and nadolol (Corgard); and for menstrual migraines, naratriptan (Amerge) and zolmitriptan (Zomig).\nYou can read the new guidelines here, or check out the patient-friendly summary here.\nThey were developed in conjunction with the American Headache Society.\nThe guidelines will be published in Tuesday\u2019s edition of the journal Neurology.\nIt can cause throbbing pain in the head.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did not oversell the novelty of these drugs.", "answer": 1}, {"article": "For advice, information and support, visit http://www.\n\"We already know that rivastigmine works to treat dementia by preventing the breakdown of acetylcholine, however our study shows for the first time that it can also improve regularity of walking, speed, and balance.\nThe research, published today in The Lancet Neurology (1), shows people with Parkinson's who were given the oral drug rivastigmine were 45% less likely to fall and were considerably steadier when walking, compared to those on the placebo.\nDr Arthur Roach, Director of Research at Parkinson's UK, which funded the study said:\n\n\"People affected by Parkinson's, their carers, and health and social care professionals have said that preventing falls and improving balance is the biggest unmet need for people living with the condition, other than finding a cure.\nParkinson's UK Research Fellow Dr Emily Henderson and principal researcher on the study, based at the University of Bristol, said:\n\n\"With the degeneration of dopamine producing nerve cells, people with Parkinson's often have issues with unsteadiness when walking.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It\u2019s stated in the release that this is the first study to show that rivastigmine can improve movement in Parkinson\u2019s patients. According to the lead investigator, \u201crivastigmine works to treat dementia by preventing the breakdown of acetylcholine, however our study shows for the first time that it can also improve regularity of walking, speed, and balance.\u201d\nParkinson\u2019s is widely known to be associated with dopamine anomalies, and the idea that other neurotransmitters, such as\u00a0acetylcholine, can directly affect parkinsonism symptoms, is novel. Most other neurotransmitter drugs in Parkinson\u2019s work to modify or increase the effects of dopamine and have no direct effects on the specific symptoms of Parkinson\u2019s. The study itself states that this was \u201cthe first randomised controlled trial to examine the effect of rivastigmine on gait stability and falls in Parkinson\u2019s disease.\u201d", "answer": 1}, {"article": "The two-year survival rate of patients treated with both drugs in combination is 69 percent.\n\"The response rate is better than we've seen for other potential second-line treatments and nivolumab is really well-tolerated, which is important because bladder cancer patients are a fragile group after frontline treatment with platinum chemotherapy,\" said Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology at MD Anderson.\nAt a median follow up of 213 days, 33.3 percent remained on treatment, and 45.6 percent of patients survived for at least one year, which Sharma noted \"is better than anything we've seen in the past.\"\nThe immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Center.\n\"We can get good results without choosing to treat patients based on PD-L1 status,\" said Sharma, who also is scientific director of MD Anderson's immunotherapy platform and an investigator with the Parker Institute for Cancer Immunotherapy at MD Anderson.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes clear that nivolumab works by targeting so-called PD-1 proteins, allowing a patient\u2019s immune system to target cancer cells \u2014 and that the drug appears to work on patients regardless of the presence of related PD-L1 ligands in the cancer. That\u2019s enough to earn a satisfactory.\nIt also sets this therapy apart from others in its claim that:\n\u201cThe response rate is better than we\u2019ve seen for other potential second-line treatments and nivolumab is really well tolerated, which is important because bladder cancer patients are a fragile group after frontline treatment with platinum chemotherapy,\u201d according to the lead investigator.", "answer": 1}, {"article": "Even so, Allen says more research is needed to determine the specific strains of bacteria that are most effective.\nThe review confirms the findings of another review in 2004, which also showed that probiotics had some effect against diarrhea.\nAuthors of the review note that probiotics can work in several ways, including robbing the offending bacteria, viruses or parasites of nutrients.\n\"Surprising thing was it didn't really matter what type of probiotic was used or in which setting,\" Allen says.\nHowever, the impact of the probiotics varied greatly from study to study, researcher found.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story pointed out that this current review follows on the heels of a previous review published in 2004.", "answer": 1}, {"article": "Doctors in Seattle cured a late-stage cancer patient after tinkering with his body's defenses against infection, leading to cautious optimism about treating late-stage melanoma, a deadly skin cancer.\n\nThe surprising result, published in this week's issue of the New England Journal of Medicine, is the latest hopeful finding from the 30-year-old field of \"adoptive immunotherapy,\" which theorizes that the body can be taught to fight off its own cancers.", "question": "Does the story establish the true novelty of the approach?", "explanation": "\nThe story does a nice job of placing this story in its historical context, explaining that the new therapy comes out of the field of \"adoptive immunotherapy,\" which has evolved over the course of some 30 years.\n", "answer": 1}, {"article": "This was not statistically different.\nThe study suggests most patients can have just aspirin without increasing the risk for venous thromboembolism, but doctors need to consider factors such as a patient's history of clots, obesity and ability to mobilize after surgery when determining the best measure for clot prevention, Hallstrom adds.\n\"Aspirin alone may provide similar protection compared to anticoagulation treatments,\" says Brian R. Hallstrom, M.D., an orthopaedic surgeon and associate chair for quality and safety at the University of Michigan Department of Orthopaedic Surgery.\nThe critical care specialists who make up the American College of Chest Physicians favor heparin to reduce the risk of blood clots, while the American Academy of Orthopaedic Surgeons guidelines state that no one drug is better than another for preventing clots.\n\"The most important way to prevent blood clots is getting moving,\" says Hallstrom, noting that people are at risk for blood clots when they sit or lie in one position for too long, such as on an airplane or a hospital bed.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes that the question of the best clot-prevention strategy for knee replacement patients has been debated for years. It cites an advantage over one recent study. Comparing the language of the release to the more-specific description in the journal article, it does seem that the release appropriately portrays this study as adding to the evidence that surgeons can use when prescribing drugs.", "answer": 1}, {"article": "And if you\u2019re one of the thousands of people seeking to improve your cardiovascular and cognitive health \u2013 look no further than the MedDairy diet.\u201d\n\u2022 Cardiovascular disease (CVD) is a major cause of death in Australia, with 43,477 deaths attributed to CVD in Australia in 2017.\n\u201cThe MedDiet is fast earning a reputation as the world\u2019s healthiest diet and is renowned for delivering improved cardiovascular and cognitive health,\u201d Wade says.\nIn this UniSA study, published by the American Journal of Clinical Nutrition, researchers compared the health benefits of a MedDiet supplemented with two to three serves of dairy each day, and a generic low-fat diet.\n\u201cThis study delivers healthier options for Australians by tailoring the nutrients in the MedDiet to meet the needs of a non-Mediterranean population.\nIn Australia, it is the single leading cause of death in Australia, affecting 4.2 million Australians and killing one Australian every 12 minutes.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release doesn\u2019t explain how the diet is novel or discuss whether other research has examined how a dairy-supplemented Mediterranean diet impacts heart disease risk.", "answer": 0}, {"article": "In an editorial accompanying the study, Dr. Pamela Davis, of Case Western University paraphrased Winston Churchill, \u201cThis study is also a great victory in the war against genetic diseases and marks the end of the beginning for the treatment of the cystic fibrosis defect.\u201d\n\nIvacaftor has been submitted to the FDA for approval, and could be available next year, according to Konstan.\nThat trial is ongoing and the treatment is at least four or five years away from approval, but if it works, Beall says, it could help 90% of the people with cystic fibrosis.\nThere is no cure for this disease and existing treatments just help alleviate some of the symptoms.\nA study, funded in part by Vertex Pharmaceuticals, found the drug ivacaftor (pronounced eye va kaf tor) caused patients with a specific type of cystic fibrosis to improve lung function, gain weight, and fight other aspects of the disease.\n\u201cThis is the first time that we have a therapy that is directed at the cause of cystic fibrosis,\u201d says Dr. Michael Konstan, the chair of the Department of Pediatrics at Rainbow Babies and Children\u2019s Hospital in Cleveland and one of the authors of the study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story does highlight the fact that this is the first treatment for cystic fibrosis that works on a genetic mutation that is the underlying cause of the disease, rather than just managing the effects of the disease.", "answer": 1}, {"article": "Researchers used CAR-T to treat a man with brain cancer to some success\n\nGlioblastoma is one of the deadliest cancers \u2014 an illness that responds to few treatment options, and often poorly. But a single case study that uses an experimental immunotherapy to treat these brain tumors might give oncologists a new way to approach the disease.\n\nThe therapy, called CAR-T, is controversial and has faced hurdles in clinical trials. It has shown great promise in treating blood cancers like leukemia and lymphoma \u2014 but has proven challenging in treating other forms of the disease, including solid tumors.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article does a brief but adequate job of describing what is newsworthy here\u2013how this experimental CAR-T is being used for solid tumors for the first time.", "answer": 1}, {"article": "Bathing-suit season is here and with it, anxiety over cellulite. A new laser device that burrows under the skin is getting praise from some doctors who say it gives more dramatic and longer-lasting results than previous treatments, but others caution that more research is needed.\n\nCellulite is a dimpled, uneven appearance of skin caused by fat underneath. It affects some 85% of women and about 5% of men. Until recently, the main treatments to battle cellulite have been external treatments such as creams and radio-frequency and...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story at least mentioned one other \u201cnew laser treatment for cellulite and body contouring.\u201d (Although the only data cited on that approach also came from a tiny, unpublished study.)", "answer": 1}, {"article": "\u201cLike most studies, it probably raises more questions than it answers.\u201d\n\nIn the U.S., kids aged 9 to 13 should get a total of 300 micrograms of folate a day from food and supplements according to the Institute of Medicine\u2019s \u201cDietary Reference Intakes.\u201d Kids 14 and older and adults are urged to get 400 micrograms a day and pregnant women should get 600 micrograms.\nMost of the population is thought to get adequate amounts for that reason.\nFolic acid is naturally present in green, leafy vegetables and legumes.\nThose in the bottom third \u2014 less than 173 micrograms folic acid per day for girls and 227 for boys \u2014 had an average score of only 120.\nBecause a lack of the nutrient during pregnancy can cause severe birth defects in babies, certain foods are fortified with folic acid, also called folate, in North America.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story provided good background on folic acid intake.", "answer": 1}, {"article": "A blood test for 10 different types of cancers could one day help doctors screen for the disease before patients show symptoms, researchers at the world\u2019s largest gathering of oncologists have said.\n\u201cWe hope this test could save many lives.\u201d\n\nThe study, by a research team that also included scientists from Stanford University, was presented at the annual conference of the American Society of Clinical Oncologists in Chicago.\nThe test, called a liquid biopsy, screens for cancer by detecting tiny bits of DNA released by cancer cells into blood.\nThe blood test found lymphoma and myeloma with slightly less accuracy, at 77% and 73%, and bowel cancer in two out of three patients.\n\u201cNow, as the NHS marks its 70th anniversary, we stand on the cusp of a new era of personalised medicine that will dramatically transform care for cancer and for inherited and rare diseases,\u201d said Stevens.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There are a host of different liquid biopsies being tested. They look for a variety of markers associated with cancers such as proteins, cancer cells, and even circulating tumor DNA (ctDNA) is in the case of this study.\nThis was not mentioned in the article.", "answer": 0}, {"article": "\"According to the data, PSA velocity does not add any value, but it may add more anxiety,\" Lu-Yao said.\nBut when they factored in other things that can influence risk, including a family history of the disease, being older, being black, PSA level and results of a digital rectal exam, there was virtually no association between PSA velocity and biopsy outcome.\nThe thought was that since high PSA levels are correlated with prostate cancer, rapidly rising levels of PSA, called \"PSA velocity,\" from one year to another would also be an indicator of prostate cancer.\nThe National Cancer Institute has more on the PSA test.\nAnd many internal medicine and primary-care doctors, in part because of fears of litigation, do order biopsies based on fast-rising PSA levels, Brawley said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story made clear that the study was examining the relative merit of relying on a change in PSA level as indicated in some current guidelines.", "answer": 1}, {"article": "And for now, the research is preliminary, so it's too early to know for sure if the treatment is appropriate to be used for any kind of depression.\nFor now, research continues.\nThe cost of the surgery is about $50,000, she said.\nThe surgery necessary to allow deep brain stimulation is extremely expensive.\nThe level of stimulation is controlled by a pacemaker-like device implanted in the chest.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There are no claims of novelty made in the story.", "answer": 2}, {"article": "U.S. experts familiar with the study call it interesting but say the treatment needs more study and wonder if it would catch on in the U.S.\nSo Dennis Lam, MD, a researcher at the Joint Shantou International Eye Center of Shantou University and Chinese University of Hong Kong, and his colleagues evaluated 88 children, ages 7 to 12, with the condition known as anisometropic amblyopia, in which there is a difference in the degree of nearsightedness or farsightedness between the two eyes.\n''These results suggest that the treatment effect of acupuncture is equivalent to that of patching for anisometropic amblyopia in older children,\" Lam writes.\nDec. 13, 2010 -- Acupuncture treatments to treat one type of lazy eye proved as good as the traditional patching of the eye used to help the eyes work together, according to a new study.\nWhile some previous research has found acupuncture for lazy eye effective, the researchers couldn't find a study that directly compared acupuncture with conventional treatments such as patching.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "While we can\u2019t vouch for this story\u2019s contention that amblyopia has been successfully treated with acupuncture in the past (the studies which apparently show this are in Italian and Russian), we think it\u2019s important that the story at least mentioned this previous research and noted that there is\u00a0some scientific basis to believe that acupuncture\u00a0might be therapeutic.", "answer": 1}, {"article": "Four people taking curcumin, and two taking placebos, experienced mild side effects such as abdominal pain and nausea.\nThe research, published online Jan. 19 in the American Journal of Geriatric Psychiatry, examined the effects of an easily absorbed curcumin supplement on memory performance in people without dementia, as well as curcumin\u2019s potential impact on the microscopic plaques and tangles in the brains of people with Alzheimer\u2019s disease.\nIt also has been suggested as a possible reason that senior citizens in India, where curcumin is a dietary staple, have a lower prevalence of Alzheimer\u2019s disease and better cognitive performance.\nThe larger sample also would allow them to analyze whether curcumin\u2019s memory-enhancing effects vary according to people\u2019s genetic risk for Alzheimer\u2019s, their age or the extent of their cognitive problems.\nThe study was supported by the Ahmanson Foundation, the Marshall and Margherite McComb Foundation, the McMahan Foundation, Bob and Marion Wilson, the Fran and Ray Stark Foundation Fund for Alzheimer\u2019s Disease Research, the U.S. Department of Energy and the National Institutes of Health.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes that previous studies have examined whether curcumin affects\u00a0memory and mood, that \u201ccurcumin has previously been shown to have anti-inflammatory and antioxidant properties in lab studies\u201d and that regions with diets rich in curcumin tend to have a lower prevalence of Alzheimer\u2019s disease.", "answer": 1}, {"article": "Dec. 2, 2011 (Chicago) -- An experimental approach in which penile nerve tissue is frozen to knock out overactive nerves helped men with premature ejaculation last three times longer.\nAlso unknown: whether men would opt for the treatment.\nA time to ejaculation of more than two minutes is normal, he tells WebMD.\nIts supporters say the technique, or a similar one involving heat therapy, could someday become a standard treatment for the condition.\nThe findings were presented here at the annual meeting of the Radiological Society of North America.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t exaggerate the novelty of the procedure.", "answer": 1}, {"article": "As the only NCI-designated comprehensive cancer center in western Pennsylvania, UPCI is a recognized leader in providing innovative cancer prevention, detection, diagnosis, and treatment; bio-medical research; compassionate patient care and support; and community-based outreach services.\n\"Our findings will change the standard of care for women newly diagnosed with stage IV breast cancer,\" said principal investigator Atilla Soran, M.D., M.P.H., clinical professor of surgery, University of Pittsburgh School of Medicine, and breast surgical oncologist with UPMC CancerCenter.\nThe study received scientific advisement from UPMC and assistance with statistical analysis from epidemiologists at the University of Pittsburgh Graduate School of Public Health.\n\"We've shown that surgery to remove the primary tumor--either through lumpectomy or mastectomy--followed by standard therapy, is beneficial over no surgery.\"\nThe results of the phase III randomized, controlled trial will be presented Saturday at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release presents these findings as a novel breakthrough for surgery for breast cancer. It says:\n\u201cOur findings will change the standard of care for women newly diagnosed with stage IV breast cancer,\u201d said principal investigator Atilla Soran, M.D., M.P.H., clinical professor of surgery, University of Pittsburgh School of Medicine, and breast surgical oncologist with UPMC CancerCenter. \u201cWe\u2019ve shown that surgery to remove the primary tumor\u2013either through lumpectomy or mastectomy\u2013followed by standard therapy, is beneficial over no surgery.\u201d\nIt\u2019s pretty apparent what they\u2019re claiming is novel here \u2014 surgery for metastatic stage IV cancer is beneficial. But the problem is that\u2019s not a novel finding. This is a longstanding question and one which was discussed in a previous story review.\nWhat\u2019s different about this study and why is it practice-changing when other research has reported similar findings? The release doesn\u2019t say.", "answer": 0}, {"article": "Researchers agreed that until there\u2019s clearer evidence for benefit, men with healthy hearts shouldn\u2019t seek out statin prescriptions for the purpose of lowering their prostate cancer risks.\nClose to one in four of the men in both groups combined had ever taken a statin.\n\u201cIt gets very, very tricky to sort out,\u201d Freedland told Reuters Health.\nMost of the men were white and in their mid- to late-60s, on average.\n\u201cPeople may be on these medications for their heart, but it may actually be doing them some good for their prostate,\u201d said study author Dr. Stephen Marcella, from the University of Medicine and Dentistry of New Jersey in New Brunswick.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "No inordinate claims of novelty were made.", "answer": 2}, {"article": "For more information, visit http://www.\nIn order to test the effectiveness of the device, Christopher Bibbs and Rui-De Xue of the Anastasia Mosquito Control District in Florida studied how the device performed against hungry Aedes aegypti mosquitoes.\nA product called the OFF!\u00ae Clip-On\u2122 repellent device could be an effective tool for preventing bites from the Aedes aegypti mosquito -- the primary vector of Zika, chikungunya, dengue, and yellow fever -- according to an article in the Journal of Medical Entomology.\nThe Journal of Medical Entomology is published by the Entomological Society of America, the largest organization in the world serving the professional and scientific needs of entomologists and people in related disciplines.\n\"In vector control, we see more often than not that tools available for consumers don't work for the intended purpose,\" said Bibbs.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t explain what\u2019s novel about the study but it does imply novelty by saying it is a new delivery system for the OFF! product. The study itself makes a novelty claim when it states that it\u2019s the first to test metofluthrin and the associated device in well-ventilated outdoor areas. \u201cIn this study, the OFF! Clip-on device was tested to determine if it will cause mortality in a well-ventilated area and if these mortality effects could be observed at an increasing range from the source.\u201d\nThe device has been on the market since 2009 and there are competitors, too, so it\u2019s not a novel product.", "answer": 0}, {"article": "The main reason to take a multivitamin is to correct or prevent a deficiency, \"but there may be a modest benefit in reducing the risk of cancer in older men,\" Gaziano said.\nThe National Institutes of Health paid for most of the study.\nSide effects were fairly similar except for more rashes among vitamin users.\nThis material may not be published, broadcast, rewritten or redistributed.\nMany of those were single vitamins in larger doses than the \"100% of daily value\" amounts that multivitamins typically contain.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is clear about where this study stands in context with previous research.", "answer": 1}, {"article": "2017.\nProfessor Coleman said: \"If the test is negative for this gene, then they can be offered this bone strengthening treatment, which can give them a better chance of surviving their cancer.\u201d\n\nA test for the gene, known as MAFTest, has been developed by a Spanish medical company called Inbiomotion following work conducted at the Institute for Research in Biomedicine (IRB) in Barcelona.\n\u201cIt only seems to be effective in some patients, particularly older women, while others show no response and in some younger women it may even be harmful.\u201d\n\nThe new study, which is published in the journal Lancet Oncology, has shown it may be possible to identify women who will benefit from bisphosphonates by using a test that looks for a gene known as MAF.\n\u201cThe discovery made at IRB Barcelona and tested in the current study could be of great use to clinicians and would avoid unnecessary treatment of patients who would not benefit or could be harmed by the treatment,\" added Professor Roger Gomis, leader of the growth control and cancer metastasis group at IRB Barcelona, who was a co-author on the study.\nThe new study, which is published in the journal Lancet Oncology, was part of an international phase 3 clinical trial involving 3,360 women with stage II or III breast cancer.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release claims novelty with the statement that this is \u201c\u2026a potential new genetic test.\u201d \u00a0It would be more clear to readers if they were told whether there are existing tests for MAF amplification or whether this is the first test available to determine MAF amplification.\u00a0 It\u2019s not completely clear to us that the test is novel or a new application of an already available tool, but we\u2019ll give the benefit of the doubt here and rate it Satisfactory.", "answer": 1}, {"article": "However, based on some prior studies, independent experts say denosumab appears more effective at preventing spine fractures than three older pills \u2014 Fosamax, Actonel and Boniva \u2014 and calcitonin nasal sprays, which all use various pathways to slow down cells called osteoclasts that break down bone.\nSpine bone density loss was far smaller for those given the drug.\nThe biotech company designed the studies, handled data collection and analysis, and helped write the journal reports.\nThe effectiveness of denosumab and existing drugs appears to plateau after two or three years, she added.\nThat's important because many patients stop taking other drugs due to side effects or frequent dosing.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Up front the story states that this is a \u201cfirst-of-its-kind\u201d drug treatment for osteoporosis.\u00a0 \u00a0", "answer": 1}, {"article": "Results also indicate the percentage of patients who achieved four-week BE cessation was lower with the placebo group (21.3 percent) compared with the 50-mg/d (42.2 percent) and 70-mg/d (50 percent) treatment groups.\nThe study included 259 and 255 adults with BED in safety and intention-to-treat analyses, respectively.\nCognitive behavioral therapy, as well as psychotherapy, can reduce BE behavior but implementation of these treatments has not been widespread.\nThe medication was administered in dosages of 30, 50 or 70 mg/day or placebo.\nConsequently, many patients with BED are undertreated despite having functional impairments and difficulties in their social and personal lives.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes that at the time of its writing, no drug had yet been approved by the FDA for this problem.", "answer": 1}, {"article": "Larger people have higher bone density to support their larger frames.\n\"These women with healthier diets didn't lose bone as quickly as those with high-inflammation diets, and this is important because after menopause women see a drastic loss in bone density that contributes to fractures,\" Orchard said.\nFor the new analysis - the first of its kind - the research team looked at dietary data from 160,191 women and assigned inflammation scores based on 32 food components that the women reported consuming in the three months prior to their enrollment.\n\"This suggests that a high-quality, less-inflammatory diet may be especially important in reducing hip fracture risk in younger women,\" the researchers wrote.\n\"By looking at the full diet rather than individual nutrients, these data provide a foundation for studying how components of the diet might interact to provide benefit and better inform women's health and lifestyle choices,\" said Jackson, who is national chair of the Women's Health Initiative steering committee.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release established that this was the first study to look at dietary information from this large group of participants, assign their diet patterns an inflammation score based on previously established research, and determine the relationship between their diet, bone mineral density, and risk for bone fracture. The release nicely fit the current research into the larger body of research on inflammation and bone density. It said:\n\u201cPrevious studies have connected high levels of inflammatory markers in the blood to bone loss and to fractures in older women and men, which prompted Orchard and her colleagues to wonder what they\u2019d find if they took one more step back \u2013 to the dietary choices that contribute to inflammation in the body.\u201d", "answer": 1}, {"article": "\"These findings need to be replicated in larger trials, and you have to be able to predict whether improved heart function from cimaglermin will help people live longer and feel better,\" she noted.\nThe most common side effects were headache and nausea directly after receiving the drug.\nThe improvement lasted 90 days, with the maximum increase in heart function reached in 28 days, the researchers found.\n\"There haven't been breakthrough treatments for heart failure for a long time,\" she said.\n\"You don't see any sustained effect,\" he added.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The drug is clearly described in terms of its experimental nature at this point.", "answer": 1}, {"article": "Coffee or tea?\nThere's a growing body of research to suggest that both are probably good for you.\nWe've heard a lot about the health benefits of tea, especially green tea.\nIt is high in polyphenols--compounds with strong antioxidant activity that in test-tube and animal models show anticancer and heart-protective effects.\nThat's why I was so interested in a report last week in the Journal of the American...\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This article is not about a novel treatment but was stimulated by the results of one recent study.", "answer": 1}, {"article": "The trials lasted anywhere from three months to three years.\nEven though the effectiveness is less than that of allergy shots, the convenience of an at-home version of immunotherapy is a plus, and the sublingual therapy tends to have fewer side effects than shots, according to Nelson.\nThe ultimate cost-effectiveness of sublingual immunotherapy has also yet to be determined; in the UK, for example, Grazax treatment costs about 2.25 pounds ($3.50) per day.\nOn the other hand, Nelson said, allergy shots appear to outperform the oral versions, with a symptom reduction about twice that of sublingual immunotherapy.\nThe researchers, led by Dr. Gabriele Di Lorenzo of the University of Palermo, describe the benefits as \u201cmodest.\u201d\n\nIn an email, Di Lorenzo told Reuters Health that the findings suggest that sublingual immunotherapy is \u201chighly effective in many, but not in all patients.\u201d He said that more work is needed to identify which patients might be most likely to benefit.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "1clip_filelist.xml\"/>1clip_themedata.thmx\"/>1clip_colorschememapping.xml\"/>\n\n\n\n \nBy mentionsing that trials from 1995 were included in the meta-analysis, the story lets readers know that sublingual allergens are not novel. The concept of administering allergens orally has been proposed as early as 1900. \n", "answer": 1}, {"article": "Texas rep expects Trump to make case for a border wall at State of the Union\n\n\"We're going to keep working to secure the border, and not blink until we either get it done or the voters get to speak in 2020\"", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is clear that raloxifene is an existing drug that is currently used to treat osteoporosis.", "answer": 1}, {"article": "(With HIV, 50 to 60 percent is about the efficacy range researchers hope for.)\nIt\u2019s called a \u201cmosaic\u201d because it involves taking pieces of different viruses and sticking them together to generate immune responses that can cover a broad range of HIV subtypes.\nSo it\u2019s difficult to think about how a single shot might work against all the different HIV subtypes circulating around the world.\nWe need more human studies of this HIV vaccine\n\nBut we still don\u2019t know if the vaccine will protect humans from the virus, since the studies so far have only looked at safety and immune responses, not efficacy.\nDeveloping a vaccine to stop HIV is thought to be among the most daunting challenges in medicine for one big reason: The virus is extraordinarily genetically diverse, even more so than the flu.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "What is \u201cnovel\u201d here is the type of vaccine under development, since it attempts to encompass the diversity in HIV found around the globe. The story fairly establishes the vaccine\u2019s novel approach.", "answer": 1}, {"article": "\"And with the one oral option we have today, there has been a lot of concern over a possible risk for immune suppression and also an increased risk for cancer,\" added Zamvil, who was not a part of the current study team.\nIf the experimental medication is eventually approved for use, it would be only the second oral MS drug available to patients, alongside a number of long-standing injectable options.\nBut there's a lot of excitement about this new option and these results, because even though the injectables are safe and effective in terms of convenience and patient compliance, oral drugs are much better than shots.\"\nThe incidence of liver enzyme elevation was higher in patients treated with laquinimod, according to Comi, but he added that the elevations were temporary, reversible and did not lead to any signs of liver problems.\nSince the study is being presented at a medical meeting, it should be considered preliminary until the findings are published in a peer-reviewed journal.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Through the use of independent experts, the story explains that this would be one more oral drug and not necessarily anything truly unique. An important discovery, potentially, but not the only game in town.", "answer": 1}, {"article": "For more information, please visit http://www.\nThe research, conducted at LA BioMed, found a reduction in the amount of low-attenuation plaque, or \"soft plaque,\" in the arteries of patients with metabolic syndrome who took Aged Garlic Extract.\n\"We have completed four randomized studies, and they have led us to conclude that Aged Garlic Extract can help slow the progression of atherosclerosis and reverse the early stages of heart disease.\"\nA follow-up screening conducted a year after the initial screening found those who had taken Aged Garlic Extract had slowed total plaque accumulation by 80%, reduced soft plaque and demonstrated regression (less plaque on follow-up) for low-attenuation plaque.\n\"This study is another demonstration of the benefits of this supplement in reducing the accumulation of soft plaque and preventing the formation of new plaque in the arteries, which can cause heart disease,\" said Matthew J. Budoff, MD, an LA BioMed lead researcher.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This release appears to be touting the same research that was the focus of\u00a0a Los Angeles television station\u2019s news report from 2014 quoting the same main author and generally reporting similar results.\u00a0 If this is the case, this release fails to show any novelty that would warrant any additional news coverage, over and above any other weaknesses it includes.", "answer": 0}, {"article": "\u201cWe have to be mindful of the placebo effect, and we have to take [the findings] with a grain of salt,\u201d Matthew Sullivan, an associate professor of microbiology at The Ohio State University, said in the release.\nOne of the study\u2019s limitations is its small size, and researchers cautioned that families should not try to replicate the treatment at home.\nThe researchers built off of previous findings that children with autism typically have fewer types of important bacteria in their guts and less bacterial diversity overall.\nThe study, which was published in the journal Microbiome, included 18 children with autism and moderate to severe gastrointestinal problems.\nChildren without autism were used as a control for the study, the news release reported.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story provides some context with this statement: \u201cThe researchers built off of previous findings that children with autism typically have fewer types of important bacteria in their guts and less bacterial diversity overall.\u201d", "answer": 1}, {"article": "\"For high-risk people, those with heart disease or [who] have had a stroke who are taking a standard dose of a statin, further reduction in LDL cholesterol will give them extra benefit,\" said Dr. Colin Baigent of the Clinical Trial Service Unit and Epidemiological Studies Unit at University of Oxford in the United Kingdom, who was involved in both studies.\nThe researchers noted that the higher dose of Zocor (simvastatin) did result in a risk of a muscle disease 10 times higher than that associated with the lower dose.\nOver almost seven years of follow-up, those taking the higher dose statin had greater reductions in LDL cholesterol compared with those taking the lower dose.\nThis trial looked at the benefits of statin therapy with 80 milligrams (mg) versus 20 mg simvastatin (Zocor) among 12,000 heart attack survivors.\nIn addition, there were no significant effects of statins on deaths due to cancer or other non-vascular causes, and no excess risk of cancer, even at low LDL cholesterol concentrations.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear that the studies reported on were examining the potential for benefit by increasing dosage levels of widely used statin medications.", "answer": 1}, {"article": "\"It was a very aggressive cancer and we needed to start treatment right away,\" said Chris Mullin, Brian's father.\nThis new treatment is still experimental, but it's a step forward in the strategy of manipulating a person's own immune system to fight cancer.\nIt was neuroblastoma, a rare but deadly form of childhood cancer.\nAfter two years, 46 percent receiving standard treatment alone were free of tumor recurrence versus 66 percent of those like Brian who also received the antibody.\nOne tagged with antibody, the cancer can be more easily recognized and attacked by the body's own white blood cells.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear that this approach, an immunotherapy, \u00a0was something added in addition to other therapies and that it is an experimental approach to improving outcomes for neuroblastoma.", "answer": 1}, {"article": "Half got the new gel and the other half received an inactive placebo.\n\u201cThe shorter application period is what makes ingenol mebutate a breakthrough in the treatment of actinic keratosis,\u201d researcher Mark Lebwohl, MD, says in a news release.\nThe new study included 547 people with actinic keratoses on their face or scalp and 458 people with these lesions on their mid-section or arms and legs.\nThe new gel, Picato (ingenol mebutate), is applied once daily for two or three days, depending on the area being treated.\nAt the end of the two-month study, 42% of people in the first group and 34% of those in the second group who got the new gel showed complete clearance of their lesions.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story uses a quote from a news release that this is \u201ca breakthrough in the treatment of actinic keratosis.\u201d\u00a0 But there is no independent perspective, nor comparative data provided, to back up that breakthrough claim.", "answer": 0}, {"article": "San Francisco--A new study, presented today at the Society of NeuroInterventional Surgery's (SNIS) 15th Annual Meeting, found that new stroke imaging technology could decrease delays in care by up to 60 minutes, giving patients a better chance at making a full recovery.\nThe imaging allows accurate detection of hemorrhage, occlusion site, ischemic core, and tissue at risk, suggesting that baseline imaging can be performed in the angiosuite using cone beam imaging.\nThe time required to transfer a patient from their CT scan to the operating room could delay EVT by as long as 60 minutes.\nThe lead PI on this study, Professor Vitor Mendes Pereira, concluded by saying, \"By reducing intra-facility transfer times, patients can receive EVT treatment sooner, which can significantly impact patient outcomes\".\nThis study suggests that in the future, stroke patients can bypass the CT scan or emergency department and go directly to the angiosuite for imaging and proper care.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It\u2019s clear that this is a new technique, but the parts fitting the novelty bill could have been better described. The software appears to be what\u2019s new here.", "answer": 1}, {"article": "\"Although there appear to be some benefit of an overall lower death rate in both groups, the [special panel] recommended stopping the trial,\" Nabel said.\nMany earlier studies had shown that tightly controlling blood sugar significantly reduced the risk of many complications.\n\"The harm of the very intensive treatment outweighed the potential benefit.\"\nThey determined that it was not.\n\"This presents a real dilemma to patients and their physicians.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is about the results from a newly released study.", "answer": 1}, {"article": "\"Of concern is that complication rates are still higher than desirable for this procedure, and there was suboptimal use of stroke-preventing anticoagulation [anti-clotting] therapy after the procedure,\" added Fonarow, who was not involved with the study.\nAccording to Arbelo, 91 percent of patients choose to have ablation to relieve symptoms, while 66 percent do so to improve their quality of life.\n\"Further trials are needed to evaluate the benefits and risks of catheter ablation and its potential role as first-line therapy,\" he suggested.\nAfter the procedure, patients with two or more risk factors for stroke should be prescribed oral blood thinners, while those with no risk factors don't need them, Arbelo suggested.\nIt causes 20 to 30 percent of all strokes and can decrease quality of life due to palpitations, shortness of breath, tiredness, weakness and psychological distress, the study authors explained.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story indicates that the study is new, but it didn\u2019t explain what made it novel\u2013how does this build upon previous research? It implies that it\u2019s the less-than-impressive success rate vs complication rate, but that needs better clarification, if that\u2019s what\u2019s novel here.", "answer": 0}, {"article": "\"It is very big.\n\"This new technology has the potential to facilitate an easy-to-administer, noninvasive blood test that would allow us to count tumor cells, and to characterize the biology of the cells,\" said Robert McCormack, Veridex's head of technology innovation and strategy.\n\"The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy,\" the Veridex statement said.\n\"Researchers have been working on this and similar technologies for some time, and others have predicted a day when we will be able to diagnose cancers before they are otherwise visible by current techniques,\" said Dr. Len Lichtenfeld, the group's deputy chief medical officer.\n\"The challenging goal of sorting extremely rare circulating tumor cells from blood requires continuous technological, biological and clinical innovation to fully explore the utility of these precious cells in clinical oncology,\" Toner said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It was hard to judge the story on this criterion. It includes a quote that calls the technology \u201cnew\u201d and then in the next paragraph tells readers of a test the same company has been selling since 2004 that detect circulating cancer cells. There is no explanation of what the difference is between the \u201cnew\u201d test and the one that has been available for several years. Nonethless, we\u2019ll give it the benefit of the doubt. ", "answer": 1}, {"article": "[Added June 10] So Gokhale studied findings from anthropologists, such as Noelle Perez-Christiaens, who analyzed postures of indigenous populations.\nBut there's a whole bunch of reasons why Americans' postures \u2014 and the shape of their spines \u2014 may be different than those of indigenous populations, he says.\nIf you look at an American's spine from the side, or profile, it's shaped like the letter S. It curves at the top and then back again at the bottom.\nIt's what goes into making the J-shaped spine that matters: \"You have to use muscle strength to get your spine to look like a J shape,\" he says.\n\"I have a picture in my book of these two women who spend seven to nine hours everyday, bent over, gathering water chestnuts,\" Gokhale says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that Gokhale\u2019s claims to novelty aren\u2019t actually all that novel. It notes that the benefits achieved with Gokhale (and in the indigenous lifestyles upon which they are based) are probably due to an active life style and better muscle tone \u2014 rather than to any particular \u201csecret\u201d that the medical community was previously unaware of.", "answer": 1}, {"article": "\"Sure.\nBut we were surprised by how healthy he seemed seven months later, in August 2008, when we visited with him and his wife Marianne at their home in Erie, Pa.\n\n\"I must say you look like a completely different person to me.\nWhat he did have was a deadly form of leukemia and a determination to use whatever time he had left to come up with a better way to treat the disease.\nSo even though he had been feeling good for awhile, he admitted there was always fear his disease could take a turn for the worse.\n\"And I didn't think that one could feel this bad and still be alive as I did back in January.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\n \nThis story stumbles badly by portraying the Kanzius device as revolutionary, when it is actually just one of many applications of well-known principles and techniques for treating cancer. For example, radiofrequency ablation (the technical term for the Kanzius approach) is already used to treat tumors in the liver and elsewhere when conventional surgery isn\u2019t a good option. Indeed, searching www.pubmed.gov for studies of radiofrequency ablation of cancer yields almost 3,000 citations. \nThe added technique of using molecules that preferentially bind to cancerous cells in order to concentrate metallic nanoparticles within tumors is common to many targeted cancer treatments.\n The story ignored vast swaths of current cancer research and treatment.", "answer": 0}, {"article": "Representative Rosa DeLauro, Democrat of Connecticut, said that the new guidelines would have no effect on federal policy and that \u201cRepublicans are using these new recommendations as a distraction.\u201d\n\n\u201cMaking such arguments, especially at this critical point in the debate, merely clouds the very simple issue that our health reform bill would increase access to care for millions of women across the country,\u201d she said.\nIt is by no means clear that doctors or patients will follow the new guidelines.\nOnly some people who are exposed to it develop cancer; in most, the immune system fights off the virus.\nIf cancer does develop, it can take 10 to 20 years after exposure to the virus.\n\u201cThese are going to be set in stone,\u201d Mr. Coburn said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of cervical cancer screening is not in question in this story. ", "answer": 2}, {"article": "For the study, researchers looked at data on 27,347 women ages 50 to 79 who joined two WHI trials between 1993 and 1998 and were followed through 2014.\nOne limitation of the study is that the WHI didn\u2019t look at different dosages of hormone pills, and the findings may be different for other dosages or different types of therapy such as gels or creams or skin patches.\nAfter 18 years, including both the treatment period and a decade or more of follow-up, women\u2019s age when they joined the study no longer appeared to significantly influence death rates.\nThe current study, however, looked at longer-term data from the WHI study and found no increased risk of death from all causes, or from cancer or cardiovascular issues in particular, associated with hormone use.\nWith additional years of follow-up, it also appears that the increased heart attack risk associated with HRT in the initial results from the WHI trials is limited to older women, McNeil added.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that this is a new analysis that looks at long-term data on deaths years after use or non-use of hormone therapy.", "answer": 1}, {"article": "Routledge added that current evidence shows that not smoking, only consuming alcohol within recommended limits, staying active, monitoring cholesterol levels and eating a balanced diet can all help with the health of the heart and brain.\nVascular dementia is directly caused by reduced blood flow to the brain, and this can also play a role in the development of Alzheimer's disease, studies have found.\n\"What's good for the arteries is good for the brain,\" he added in summary of his findings.\n\"If you can detect [the risk] in people in mid-life, it really gives an impetus to those people to change their lifestyle,\" said Dr. Scott Chiesa, post-doctoral researcher at UCL.\nDementia is an umbrella term used to describe symptoms related to the loss of brain function.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t put this study in context of previous research. What is already known about FCW and dementia? Is the first study to find a pattern between the two?", "answer": 0}, {"article": "So what is it about tai chi that works?\nAbout 10 million Americans have fibromyalgia, and about 75 percent to 90 percent of them are women, according to estimates from the National Fibromyalgia Association.\nDoctors will often suggest exercise, sleep hygiene techniques and medications to treat the condition, but often with limited success, said Dr. Gloria Yeh, an assistant professor of medicine at Harvard Medical School, who wrote an accompanying editorial in the journal.\nResearchers divided 66 people with fibromyalgia into two groups: one group did hour-long sessions of tai chi twice a week for 12 weeks; the other had a twice-weekly wellness education class followed by gentle stretching.\nThe improvements were still evident at 24 weeks, according to the research reported in the Aug. 19 issue of the New England Journal of Medicine.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story explains that doctors routinely recommend exercise as one method of treatment for fibromyalgia patients, but with limited success. So in that sense, the story does undercut some of the novelty of the study\u2019s findings. An excellent question for the researchers would have been: What is it that potentially makes tai chi a better form of exercise for this condition?", "answer": 1}, {"article": "Ankle replacement has been around for three decades, but it has been slow to catch on.\nThough the four devices in common use have technical differences in design and in how they are implanted, doctors say the choice of device matters far less than the experience of the surgeon.\nUntil lately, such patients have had only one surgical option: ankle fusion surgery, in which the worn-out part of the joint is removed and the bones are permanently locked together with screws and plates.\nThe bodies of many older Americans are practically bionic: more than 770,000 hip and knee replacements are performed each year in the United States.\nThe ideal patient is around 60 years old and of normal weight, although doctors consider older patients, depending on their health.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story highlights a procedure that may readers may not be aware of because it is not commonly performed although it has been available for some time.\u00a0 ", "answer": 1}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\nThe new approach is not intended to replace current contrast-enhanced breast MRI protocols in general, Dr. Bickelhaupt emphasized, but to expand the spectrum of options available for answering specific clinical questions.\nCollaborating with Dr. Bickelhaupt and Jaeger were Frederik Bernd Laun, Prof. Dr., Wolfgang Lederer, M.D., Heidi Daniel, M.D., Tristan Anselm Kuder, Dr. rer nat, Lorenz Wuesthof, Daniel Paech, M.D., David Bonekamp, M.D., Alexander Radbruch, M.D., Stefan Delorme, Prof. Dr., Heinz-Peter Schlemmer, Prof. Dr., Franziska Steudle, and Klaus H. Maier-Hein, Ph.D.\n\nRadiology is edited by David A. Bluemke, M.D., Ph.D., University of Wisconsin School of Medicine and Public Health, Madison, Wis., and owned and published by the Radiological Society of North America, Inc.\n\nRSNA is an association of over 54,200 radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation.\nOAK BROOK, Ill. - An MRI breast imaging technique that requires no contrast agent, combined with sophisticated data analysis, could reduce the number of unnecessary breast biopsies, according to a new study appearing online in the journal Radiology.\n\"Diffusion kurtosis imaging has been introduced in DWI to provide important information on tissue structures at a microscopic level,\" said study lead author Sebastian Bickelhaupt, M.D., from the German Cancer Research Center in Heidelberg, Germany.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Diffusion kurtosis imaging is about a decade old technique for examining diffusion of water in human tissue. However, the application to identifying breast cancer malignancies appears to be novel.\nThe lead author notes: \u201cThe new approach is not intended to replace current contrast-enhanced breast MRI protocols in general, Dr. Bickelhaupt emphasized, but to expand the spectrum of options available for answering specific clinical questions.\u201d", "answer": 1}, {"article": "May 11, 2012 -- Starting your day off with an egg may help curb your appetite better than cereal, new research suggests.\nScientists suspect that egg protein may be better at making people feel full longer compared to the protein found in wheat.\nIn a small study, it took longer for people who ate eggs for breakfast to show signs of hunger than it did for those who had a bowl of ready-to-eat cereal.\nThe research was funded by the American Egg Board, and will be presented at the19th European Congress on Obesity in Lyon, France.\nFor people hoping to shed some pounds, changing the type of protein in the diet, rather than the amount of it, is an idea the researchers think deserves more study as a weight loss strategy.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This research builds upon many previous studies suggesting that protein calories may be more satiating than other types of calories. The story doesn\u2019t mention this background.", "answer": 0}, {"article": "The trial was registered at http://www.\nThe results showed that cortisone injection did not provide better outcomes than dry needling for either pain or function in patients with GTPS.\nAs a result, \"the identification of a comparable treatment alternative with minimal side effects, such as dry needling, offers valuable clinical advantages,\" she says.\nHowever, evidence now indicates that injuries to the muscles and tendons around the hip are the actual cause of this pain, and that inflammation is often not involved, calling injecting the bursa with a steroid into question.\nThe medical community once thought that a swollen hip bursa--a fluid-filled sac that acts as a gliding surface to reduce friction between moving tissues in this joint--was the source of this hip pain.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release says this is \u201cthe first to directly compare these two treatments for the syndrome.\u201d We found no other studies of a similar nature after a quick online search.", "answer": 1}, {"article": "Alzheimer's & dementia: The Journal of the Alzheimer's Association.\n\"We are working closely with neuroradiologists to redefine how we can reduce risk for Alzheimer's with quantitative neuroimaging that helps us pinpoint symptom-relevant volume loss in the brain and subsequent targets for tracking our lifestyle-based interventions,\" says Dr. David Merrill, a geriatric psychiatrist at UCLA Medical Center.\nThe concept that cognitive decline can be identified early and prevented by applying quantitative brain imaging techniques is the focus of \"Hot Topics in Research: Preventive Neuroradiology in Brain Aging and Cognitive Decline,\" a review published online in American Journal of Neuroradiology (AJNR).\nThe American Journal of Neuroradiology (AJNR) is published monthly by the American Society of Neuroradiology (ASNR), a professional association of more than 5,000 members who specialize in diagnostic radiology of the central nervous system, brain, head and neck through the use of X-ray, MRI, CT and angiography.\nIt is estimated that as many as 3 million cases of Alzheimer's dementia worldwide can be prevented with as little as a 10% reduction in the burden of preventable lifestyle.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Using quantitative MRI technology to diagnose Alzheimer\u2019s disease in its early stages is not a new concept. There have been blog posts and numerous studies in the past 10 years devoted to this topic. We\u2019re not really sure what\u2019s new here. The news release refers to \u201cnovel ways to improve patient care,\u201d but does not specify what these new approaches are.", "answer": 0}, {"article": "Ingber says some scientists are interested in using the chips to conduct research that would be unethical if performed on people, such as studying the effects of gamma radiation on the human body.\nThe sophisticated architecture of these organs-on-chips\u2014which are about the size of a thumb drive\u2014has also earned the Wyss Institute recognition in the art world with a Design of the Year award from the Design Museum and placement in the Museum of Modern Art\u2019s permanent collection.\n\u201cBiology is very complex.\u201d\n\nIncorporating the chips into drug testing could save millions of dollars and years of time on research.\n\u201cThe real power of this approach is that you have a window to the inner workings of life,\u201d says Don Ingber, founding director of the Wyss Institute and a professor of Vascular Biology and of Bioengineering at Harvard University.\nIt takes up to 15 years and $5 billion for a new drug to make it through testing and earn approval from the U.S. Food and Drug Administration (FDA).\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article mentions that the first \u201corganoid\u201d chip was built and tested in 2008 to mimic the mechanical function of human lungs. What\u2019s new in this story is that this project won the \u201cDesign of the Year\u201d award for 2015 from the Design Museum.", "answer": 1}, {"article": "CHICAGO (Reuters) - The common diabetes drug metformin may hold promise as a way to keep smokers from developing lung cancer, U.S. researchers said on Wednesday.\nThey treated the mice with metformin either orally or with an injection.\nOther studies have shown that metformin can cut diabetics\u2019 risk of pancreatic and breast cancers, and the latest finding now suggests it may defend the body against smoking-induced lung tumors.\nMetformin has been shown to switch on an enzyme that blocks mTOR \u2014 a protein that helps tobacco-induced lung tumors grow.\nMice that got the drug orally had 40 to 50 percent fewer tumors, while those injected with the drug had 72 percent fewer tumors.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did mention some other past research on metformin and cancer risk. ", "answer": 1}, {"article": "It is \"a significant problem in the military,\" said Taylor, who noted that military personnel often develop insomnia because of rapidly changing schedules and deployments that keep them constantly on alert.\nFor deployed military personnel, the side effects such as grogginess, slowed cognitive processing and slowed reaction time can be dangerous,\" Taylor said.\nBoth the in-person and Internet therapy had the exact same content, with the Internet lessons presented as audio recordings accompanied by visual graphics and animations.\nAll completed one week of sleep monitoring by keeping sleep diaries and wearing activity monitors.\nA third control group of participants was contacted by the researchers every other week during the six weeks, but did not receive cognitive behavioral therapy.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t claim novelty. It references previous work that showed CBTi helped reduce the dependence on sleeping medications in the general population.", "answer": 1}, {"article": "That study was funded by the device\u2019s manufacturer, Neuronetics, a company based in Malvern, Pa.\nThe procedure, which is more widely used than rTMS, requires two to three treatments a week for three to four weeks and is effective for many patients.\nThe use of rTMS for altering mood or affecting the brain has been studied since at least the early 1990s.\nThe costs of ECT \u2014 typically about $3,300 for four weeks of thrice-weekly treatments, according to AHRQ data \u2014 are covered by most private insurers as well as by Medicare and Medicaid.\nThe technique has been shown to work better than a placebo, but the proportion of patients who show complete relief ranges widely, from as few as 10 percent to as many as 57 percent, according to various studies.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that rTMS has been studied since the 1990s. It does not oversell the novelty of this treatment approach.", "answer": 1}, {"article": "For more information, please see www.arthrokinex.com\nThe cost of the USA-based IRAPjoint\u2122 treatment is $2,000 compared to the reported price of $10,000 for a foreign competitor.\nTypically, the treatment process is painless and just takes a few minutes and consists of one injection per week for three weeks, followed by quarterly injections, as needed.\nSignificantly better concentration, healing/pain reduction durability, faster production (just one hour), one-fifth the price, and chemical additive free, IRAPjoint\u2122 is now available in multiple physician practices throughout the United States.\nThe process works by using one's own blood \u2013 specifically the body's own anti-inflammatory proteins and human-growth elements \u2013 to end or ease pain and chronic injuries.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does a good job here. It emphasizes the novelty of this approach, especially in the United States. Reviews of published literature show that this has not been a well-explored field yet. ", "answer": 1}, {"article": "Tens of thousands of patients a year undergo the procedure \"off-label,\" however, paying around $5,000 out-of-pocket, based on the claims of doctors who say it can cure everything from Alzheimer's to autism.\nFurther analysis showed the benefits were limited to those with diabetes, rather than for patients overall.\nThe taxpayer-funded study tested whether a controversial alternative therapy, called chelation, could reduce heart attacks and other cardiovascular problems in people who had already survived a heart attack.\nYet some doctors say the study was far from rigorously performed, and so badly run that its marginally positive results are meaningless.\nThe overall benefits were very small, with 26.5% of those randomly assigned to chelation experiencing a cardiovascular problem, compared with 30% of those randomly assigned to a placebo infusion.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is the only large-scale trial of chelation for prevention of heart disease. The research is quite novel.", "answer": 1}, {"article": "In a proof-of-concept study, described online in Cancer Prevention Research on November 8, the investigators say their genetic markers test showed a \"sensitivity\" or accuracy rate of 90.9 percent in identifying so-called CIN2 lesions -- cervical lesions with abnormal cells likely to not only develop into cancer, but also to develop into cancers likely to spread.\nThe women ranged in age from 18 to 86.\nThey plan to continue modifying the test to improve the urine sensitivity to that of the cervical tissue samples.\nDuring the course of the study, the time to process cervical samples, blood or urine and get a test result took four days.\nThe test had an 88.9 percent specificity, meaning the percent of time the test correctly identified someone without the disease.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The writer does a good job of making the case for novelty here.", "answer": 1}, {"article": "Even so, Little, a coconut enthusiast, doesn\u2019t recommend loading up on coconut fats.\nI was meeting with a cardiologist recently, and he said he doesn\u2019t advise (coconut oil) for any clients.\u201d\n\nThe fat issue is complicated by the types of fatty acids found in coconut, versus other saturated fats.\nIt\u2019s simple all the way around.\u201d\n\nOne tablespoon of coconut oil contains 120 calories and 14 grams of fat, 12.5 grams of which is saturated.\n\u201cIt\u2019s trickling down to the mass market.\u201d\n\nThe company is growing so quickly, he said, it had to hunt for coconuts from outside of Brazil, where it previously harvested most of its fruit.\n\u201cA lot of rehydrating beverages have additives, whereas the coconut water \u2014 it\u2019s super clean.\u201d\n\nCoconut oil and milk, though, are receiving mixed reviews.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t make it clear how novel coconut products are or whether they offer any benefits not offered by a regular, balanced diet or why.\u00a0There is certainly nothing new about coconuts. The story does not explain whether there is any new information that provides a rationale for increased attention to coconuts or whether the attention is fueled entirely by marketing.", "answer": 0}, {"article": "The population studied was relatively homogenous, and \"the [body mass] findings were not the object of the study (wheezing or asthma in children was the primary objective), growth was a secondary finding,\" Rabin explained.\n\"This study highlights the fact that in utero exposure can have a profound effect on the fetus that lasts through childhood,\" said Dr. Jennifer Wu, an obstetrician-gynecologist from Lenox Hill Hospital in New York City.\n\"The body composition at age 6 years in children given fish oil supplementation was characterized by a proportional increase in lean, bone and fat mass, suggesting a general growth-stimulating effect,\" the researchers, who were led by Hans Bisgaard, from the University of Copenhagen, wrote in the report.\n\"For the past decade, the importance of fish oil and the omega-3 fatty acids have been stressed to patients,\" explained Wu, who was not involved in the study.\nHowever, the higher BMI was not due to a higher percentage of fat, but rather to higher percentages of lean muscle and bone mass, the researchers found.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story made very brief mention of other research in this area.\nPast trials of fish oil supplements during pregnancy or breast feeding, using different designs, doses, and follow up periods, have shown mixed results. The story would have been strengthened by some context, including findings of other studies and what is known of a possible mechanism for an effect of fish oil on growth of offspring.", "answer": 0}, {"article": "Buck scientists strive to discover new ways of detecting, preventing and treating age-related diseases such as Alzheimer's and Parkinson's, cancer, cardiovascular disease, macular degeneration, osteoporosis, diabetes and stroke.\nIt was approved by the FDA for the treatment of bipolar disorder in 1970 and has shown to be effective for treating mood disorders and suicidal thoughts.\n\"We clearly saw a prevention of the motor difficulties we would expect to see in the animals,\" said Andersen.\nIn earlier studies, Andersen's team found that low-dose lithium was protective in two different mouse models of PD.\n\"The treatment also protected the area of the brain that is normally damaged by Parkinson's.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It is clear that the use of lithium for this purpose is new. The release also establishes that there was previous research leading up to the study.", "answer": 1}, {"article": "New research is helping Pfizer Inc. build a case for getting an important drug in its portfolio approved to treat a mysterious pain condition that could offer a big additional source of sales.\n\nThe New York drug maker said Tuesday that Lyrica, already on the market to treat certain types of pain, reduced painful symptoms among sufferers of fibromyalgia, a chronic and controversial condition that may affect as many as six million Americans. And today, it will unveil results from another study that it says shows Lyrica has a lasting...", "question": "Does the story establish the true novelty of the approach?", "explanation": "This\u00a0is about a drug company developing a new market for a product already developed \u2013 which the story clearly explains. The story further explains that there is currently\u00a0no FDA-approved treatment for fibromyalgia.\u00a0 ", "answer": 1}, {"article": "An experimental spray improved sex for some men who regularly experience premature ejaculation, according to the results of two studies set to be presented Tuesday at a urology conference.\n\nMen who applied the aerosol spray, a mixture of the anesthetics lidocaine and prilocaine, reached orgasm a mean of 3 minutes 18 seconds after beginning sex, compared with about 56 seconds for those who got a placebo spray. The 539 men completing the two studies, who were randomly assigned to the real drug or the fake version, had an average...", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story really is all about the novelty, and it does a good job of exploring some of the other treatments available. ", "answer": 1}, {"article": "Founder and Chairman: Dr. Scott Morehouse, scott@clearpop.com\nDue to increasing concern about antibiotic overuse and its links to obesity, celiac disease, and Superbugs, the American Academy of Pediatrics now recommends against the use of antibiotics to treat routine ear infections in children over 2.\nIn light of this, Morehouse developed a lollipop with a patented shape optimized to pull congestion out of the middle ear and into the mouth.\n\"Eardrops don't work,\" says Dr. Scott Morehouse, founder of ClearPop, \"because the Eustachian tube, where the pain occurs, is connected to the mouth, not the outer ear.\"\nClearPop is made by Try This First, Inc. a physician-funded \"small pharma\" organization aimed at reducing the estimated 30 million antibiotics prescriptions written to children yearly for ear infection.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release\u00a0does not establish the novelty of the product. This is particularly notable because it seems there is little difference between this or any other lollipop except for the addition of Vitamin C. Stating that the shape of the lollipop is patented and \u201coptimized to pull congestion out of the middle ear and into the mouth\u201d doesn\u2019t prove it is more effective than other lollipops that come in many shapes and sizes.", "answer": 0}, {"article": "The other 10 received a fake treatment.\nDuring transcranial magnetic stimulation (TMS), a doctor places a large magnetic coil against the patient\u2019s scalp, which creates electric currents to stimulate nerve cells.\nResearcher Giacomo Koch, MD, PhD, of the Santa Lucia Foundation in Rome, Italy, and colleagues point out that the changes could be the combined effects of the mental tasks and the TMS.\nThis condition often occurs after a stroke on the right side of the brain and is typically treated with a combination of physical therapy and brain retraining or mental tasks using a pen and paper or computer.\nThe tests also measured activities of daily living affected by neglect, such as dialing numbers on a phone, reading a menu, and sorting coins.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story quotes an expert who calls TMS \u201ca very novel treatment\u201d for stroke, which is accurate.\u00a0However, the story could have given more details about TMS\u2019s more established use as\u00a0a treatment for depression. The story alludes to this use, but doesn\u2019t convey that depression is what TMS was originally designed to treat and where it is most frequently employed.", "answer": 1}, {"article": "Not the smells of their colognes or perfumes, not of the laundry detergents they use \u2014 the smells of them?\nModern medical research, too, confirms that the smell of someone\u2019s skin, breath and bodily fluids can be suggestive of illness.\nThese molecules offer a whiff of who we are, revealing age, genetics, lifestyle, hometown \u2014 even metabolic processes that underlie our health.\nThe breath of diabetics sometimes smells of rotten apples, experts report; the skin of typhoid patients, like baking bread.\nBut not every physician\u2019s nose is a precision instrument, and dogs, while adept at sniffing out cancer, get distracted.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes the newness of this technological development, even though, as we are told, the idea of using ones olfactory glands to detect disease has been around for thousands of years of human history.", "answer": 1}, {"article": "While a positive test result is highly suggestive of IBS, only 44 percent of patients with IBS tested positive, meaning that many people who test negative could in fact still have the condition.\nThe tests, which measure antibodies in the blood, were based on research suggesting that IBS may develop after infection from a bacterial toxin found in food poisoning.\nDr. Mark Pimentel of Cedars-Sinai Medical Center in Los Angeles developed the tests.\n\"We now have a test to say, you have a disease,\" Pimentel told CBS News.\nWithout proof of a physical cause, some doctors considered IBS a psychological disorder.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article says the tests (and maybe even the hypothesis underlying the test) are new.\nThe article also says this is the first time evidence has shown that IBS has an organic basis.", "answer": 1}, {"article": "Antidepressants frequently prescribed to help treat bipolar depression do little to help patients recover, according to a new study that adds fuel to a long-running debate over how to best treat an affliction that affects an estimated eight million Americans.\n\nBipolar disorder, also known as manic depression, is a serious mental illness that involves dramatic swings in mood, including frequent and lengthy periods of depression. Along with mood-stabilizing drugs like lithium, many physicians also treat the disorder with common...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reports on a recent\u00a0evidence that anti-depressants given in conjunction with mood stabilizer drugs do not significantly improve depression in bipolar patients.\u00a0 This was a novel research question and finding.\u00a0\n\u00a0", "answer": 1}, {"article": "Of those followed, 151 participants developed pancreatic cancer.\n\"Pancreatic cancer is really unique and different from other cancers,\" said study co-author Ka He, chair of the Department of Epidemiology and Biostatistics at the IU School of Public Health-Bloomington.\nUsing information from the VITamins and Lifestyle study, Dibaba and the other co-authors analyzed an enormous trove of data on over 66,000 men and women, ages 50 to 76, looking at the direct association between magnesium and pancreatic cancer and whether age, gender, body mass index, non-steroidal anti-inflammatory drugs use and magnesium supplementation play a role.\nThe study also found that the effects of magnesium on pancreatic cancer did not appear to be modified by age, gender, body mass index or non-steroidal anti-inflammatory drug use, but was limited to those taking magnesium supplements either from a multivitamin or individual supplement.\nBut few studies have explored the direct association of magnesium with pancreatic cancer; of those that did, their findings were inconclusive, said Daniel Dibaba, a Ph.D. student at the School of Public Health-Bloomington, who led the IU study.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release acknowledges that previous work has examined the relationship between magnesium intake and risk for pancreatic cancer.\nPrevious studies have found that magnesium is inversely associated with the risk of diabetes, which is a risk factor of pancreatic cancer. But few studies have explored the direct association of magnesium with pancreatic cancer; of those that did, their findings were inconclusive, said Daniel Dibaba, a Ph.D. student at the School of Public Health-Bloomington, who led the IU study.\nOf course, the implication seems to be that while other studies were \u201cinconclusive,\u201d this study has put the matter to rest. That\u2019s certainly not the case, but we\u2019ll give the benefit of the doubt since the release later states that more study is needed.", "answer": 1}, {"article": "Propping open clogged arteries with a tiny wire-mesh tube called a stent is no better at reducing the risk of heart attack or death in patients with stable heart disease than treatment with medications, according to a large new study that challenges routine use of a procedure that rapidly became standard medical practice.\nIn the meantime, a whole industry has been created around this.\"\nAfter nearly five years, 74 percent of those patients were free of chest pain, compared with 72 percent of those who had medical treatment alone.\n\"I hope this will make people realize that patients have more options.\n\"I think we're getting a midcourse correction.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story accurately states this has been routine practice for the past 20 years.\u00a0 ", "answer": 1}, {"article": "\u201cThe journal knew it.\u201d\n\n\u201cThe question for the journal, given that the authors worked for the company, is, \u2018Do we publish something like that?\u2019\u201d\n\nJohnston said there was an ongoing debate about whether or not scientists who review studies should know about potential industry interests.\nAccording to Bleiker, \u201cthe authors stated very clearly that there was no conflict of interest.\u201d\n\nHowever, more than half of the authors work for Laboratoires Inneov, as indicated on the cover page of the report.\nAs a result, said Schalock, the company\u2019s claim that women taking their product can sunbathe with less concern of getting burned might be a stretch.\nThe pill combines lycopene and beta-carotene \u2014 the red and orange substances in tomatoes and carrots, respectively \u2014 with a probiotic reported to impact the skin\u2019s response to UV light.\nWhile there had been some concerns about the methods, \u201con balance there was enough interest to publish it,\u201d she told Reuters Health.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story allows no inappropriate claims of novelty to be made.\u00a0 In fact, it wraps this product into the broader context of personal care products with questionable health claims. ", "answer": 1}, {"article": "This benefit was independent of other heart risk factors such as advancing age, high blood pressure, family history of heart attack, body mass index, exercise, smoking, and caffeine and alcohol intake.\nThe study can't say specifically what about the berries seemed to result in a lower risk of heart attack among these women, or that there was a direct cause-and-effect link between eating the berries and lowered heart attack risk.\nThe study included nearly 94,000 young and middle-aged women who took part in the Nurses' Health Study II.\nAlthough more research is needed to confirm these benefits, \"these data are important from a public health perspective because these fruits can be readily incorporated into the habitual diet,\" the study concluded.\nBesides flavonoids, berries also are loaded with other nutrients, including vitamin C, potassium and folate.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not mention that previous studies have addressed the beneficial effects of flavonoid consumption on heart risk. The researchers studied which specific classes of flavonoids might reduce the risk for heart attacks.", "answer": 0}, {"article": "Before treatment recommendations are made, doctors put most prostate tumors through other tests, too, like the Gleason score, and they look at the percentage of biopsies that are positive for cancer cells.\nThey say what's really needed is a set of tests that classify prostate tumors by what genes are turned on or off in the cells.\nOnce this is sorted out, doctors treating prostate cancer will be less like the blind men who try to guess what kind of creature they're dealing with when they grasp the elephant's trunk or tail.\nTen years ago, the American College of Surgeons Commission on Cancer decreed that doctors should use these types of clinical staging tests to help decide how to treat cancers.\n\"I use all those parameters to tell a patient what his chances of a good outcome are,\" Andriole says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reported that clinical staging has been recommended for use by the American College of Surgeons Commission on Cancer for the past 10 years and gave one doctor\u2019s statement that \u201cthis is the first study that quantifies the magnitude of the inadequacy.\u201d", "answer": 1}, {"article": "Behind that common piece of advice is a complex series of physiological processes that calm the body, slow the heart and help control pain.\n\nBreathing and controlling your breath is one of the easiest ways to improve mental and physical health, doctors and psychologists say. Slow, deep and consistent breathing...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not establish novelty. As mentioned above, there are other devices on the market that provide feedback on breathing patterns. There is nothing in this story about whether the Spire device does anything new or different.", "answer": 0}, {"article": "\u201cIf used perfectly, how much HIV protection could there be?\n\u201cThat individual control of prevention is so powerful.\u201d\n\nThe dapivirine ring has been in development for more than a decade, and the the new studies are the first to show that it prevents HIV transmission.\nBut 1 in 3 infections were prevented overall \u2014 and that\u2019s huge.\u201d\n\nWarren noted that other rings with antiretrovirals are also being developed, as well as rings that could offer multipurpose protection, against not only HIV but pregnancy.\nThe ring adds a new HIV prevention tool, which some experts say will be particularly useful in African countries where women are at highest risk for HIV infection.\nMuch like the contraceptive NuvaRing, the dapivirine ring should be kept in every day and replaced once a month for maximum effectiveness.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story tells us that vaginal rings already exist and are in widespread use but that the addition of the dapivirine antiviral agent makes this device novel. It also states that the well-known Nuvaring used to prevent pregnancy uses the same delivery method.", "answer": 1}, {"article": "Not everyone agreed with that notion, however.\nThe current study was randomized and double-blind (meaning neither the parents nor the researchers knew who was getting what), and compared regular baby formula to one that was made easier for babies to digest because the proteins were broken down (extensively hydrolyzed).\nWhen Finnish researchers randomly assigned 230 babies at high risk of type 1 diabetes to receive either a regular infant formula, or one that was extensively hydrolyzed -- which means the proteins in the formula are already partially broken down and more readily available for digestion -- they found that the extensively hydrolyzed formula cut the rate of developing diabetes-linked antibodies in the blood by about half.\n\"The data in this study is not sufficiently strong to support recommending any changes for parents,\" said the author of an accompanying editorial, Dr. David Harlan, co-director of the Diabetes Center of Excellence at the University of Massachusetts Memorial Medical Center in Worcester.\nWEDNESDAY, Nov. 10, 2010 (HealthDay News) -- Offering your baby a special formula when weaning off breastfeeding may offer some protection against the development of the antibodies associated with type 1 diabetes, if you have a family history of the disease, new research suggests.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It is known that breast feeding is preferable to formula, and that it may offer some protection against the development of Type 1 diabetes.\u00a0 Formula is an option, particularly when breast milk is not available, and using formula will not harm an infant. However, formula may somehow trigger the development of autoantibodies as these proteins are broken down for digestion.\u00a0 More research is needed, but this new information from a well-designed double-blinded RCT trial may guide recommendations and parents decisions in choosing a specialized infant formula that does not require breakdown of so many proteins during digestion.", "answer": 1}, {"article": "This is the first to correct an inherited genetic mutation.\n\"The new payment models announced today are merely a way to disguise a price that is simply too high,\" David Mitchell, president and founder of Patients For Affordable Drugs, said in a statement .\n\"For a one-time therapy, like Luxturna, a non-traditional payment and distribution model is necessary to ensure needs of all parties -- patients, payers and providers -- are addressed,\" said Jennifer Luddy, a spokeswoman for Express Scripts.\nThe drug will be available in the United States in early spring, with an estimated 1,000 to 2,000 people in the US standing to benefit from this treatment, according to Spark.\nThe mutation affects both eyes, usually at the same pace, so most patients would need treatment for both eyes, a Spark Therapeutics spokeswoman said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story noted how Luxturna is only the third gene-editing treatment ever approved by the FDA. It also gave readers important context by briefly noting and comparing the new drug to another gene-editing treatment and its cost and payment methods, i.e. Kymriah for leukemia cancer. Good job.", "answer": 1}, {"article": "The regular use of statins was associated with a 42% reduction in rheumatoid arthritis (RA) risk in a newly reported study of patients enrolled in one of Israel's largest health plans .\nThere is also a suggestion that statins reduce systemic inflammation and may be protective against RA and other chronic inflammatory diseases.\nSeveral studies have suggested a role for statins in slowing the progression of disease among patients with rheumatoid arthritis, but others failed to find a protective benefit for statin use.\nThe analysis revealed that patients who took statins for at least eight years during the decade-long study period were roughly 40% less likely to develop rheumatoid arthritis than people who did not take statins at all or who took them less persistently.\nBut it is not driven by inflammation, so statin use is not as likely to affect its development or progression.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story says there have been other studies that have looked into whether statin use may have any effect on rheumatoid arthritis.", "answer": 1}, {"article": "The research, supported by the European Research Council and titled Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells, is published by PNAS.\nThe paper describes the comprehensive systems biology approach used to elucidate the mechanism of osmium action of FY26, led by PhD student Jess Hearn.\nThe new drug works by forcing cancer cells to use their mitochondria, the \u2018power house\u2019 of a cell, to generate the energy necessary to function.\nThe researchers argue that the drug could be cheaper to produce, less harmful to healthy cells than existing treatments and has been shown to be active against cancer cells which have become resistant to platinum-based drugs.\nOur new compounds work by attacking the energy balance in cancer cells\u201d.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The novelty of this compound and potential advantages over existing treatments are clear from the story.\u00a0The release also notes that NIH is conducting similar studies.", "answer": 1}, {"article": "That was not statistically significant.\nJanuvia, an oral medication known chemically as sitagliptin that helps lower blood sugar levels, had sales of about $4 billion in 2014, plus another $1.8 billion for the related combination product Janumet\n\nOn the study\u2019s main focus, after about three years 11.4 percent of Januvia patients had experienced cardiovascular death, non-fatal heart attack, non-fatal stroke or hospitalization for unstable angina versus 11.6 percent in the placebo group.\nThe detailed results also showed no increase in hospitalization for heart failure, which had been a particular concern with DPP-4 inhibitors, the class to which Januvia belongs.\n\u201cNumerically this is hardly a major risk, just something we need to keep an eye on,\u201d Holman said.\n\u201cWe can be reassured we can use this drug for glucose lowering without affecting the already high cardiovascular risk in people with type 2 diabetes,\u201d said Professor Rury Holman, the study\u2019s lead investigator, who presented the data at the American Diabetes Association meeting in Boston.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We\u2019ll give the story the benefit of the doubt here. In the last line, the story explains that the study \u201cwas undertaken after heart safety concerns were raised over other diabetes medicines.\u201d So that\u2019s what\u2019s new here. However, the story does not make it clear why this drug would be preferable over other drugs or whether it does anything novel \u2014 and that context would have been very valuable.", "answer": 1}, {"article": "Taking statins the day of a coronary artery bypass operation may significantly improve survival, a study in the Annals of Thoracic Surgery found.\nThe 1,788 who continued statins up to the day of surgery had a risk of death within 30 days of 1.7 percent, compared with 2.9 percent for 452 who stopped one to three days before surgery, and 3.8 percent for 781 who did not take statins or stopped more than 72 hours before their operations.\nAfter controlling for many preoperative health and behavioral characteristics, they found that compared with other patients, those who took statins on the day of surgery had a 48 percent reduced risk of dying in the next 30 days.\n\u201cWe already knew that people on statins before surgery had a decreased risk of death,\u201d said a co-author, Dr. Yi Deng, an assistant professor of anesthesiology at Baylor College of Medicine.\nUnless you have some other reason to stop them, you should take statins right up to the morning of surgery.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of this study was established here, and this appears to be accurate:\n\u201cBut there\u2019s never before been data saying how harmful stopping shortly before surgery can be. Unless you have some other reason to stop them, you should take statins right up to the morning of surgery.\u201d", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/15/national/a141001S34.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the true novelty of the approach?", "explanation": "This article reports on a study to test the common use of calcium by women to ensure bone health.", "answer": 1}, {"article": "However this does not help them to overcome their fear in the long term.\nThe latest study, published in the British Dental Journal, looked at the characteristics of 130 patients (99 women and 31 men) attending a psychologist-led CBT service and the outcomes of their treatment.\nCBT provides a way of reducing the need for sedation in people with a phobia, but there will still be those who need sedation because they require urgent dental treatment or they are having particularly invasive treatments.\nA proportion of the patients surveyed were found to have other psychological conditions - 37% had high levels of general anxiety and 12% had clinically significant levels of depression.\nOf all patients referred, four-fifths (79%) went on to have dental treatment without the need for sedation and 6% had their dental treatment under sedation.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This study is not the first to address CBT as a treatment for dental anxiety. A quick search identified related research dating back at least as far as 1992, and as recent as 2013. The release would have been stronger if it had explained how the new U.K. study fit into the broader body of work on this subject.", "answer": 0}, {"article": "DePaolo pointed out, \u201c[Elagolix] doesn\u2019t have the pronounced side effects some of the other compounds have.\u201d That\u2019s because, he said, it doesn\u2019t drive down estrogen levels as severely.\nDoctors aren\u2019t sure why some women get it\n\nAdding to the mystery around endometriosis: No one knows exactly what causes it, but doctors have some theories.\n\u2022 Environmental factors: There\u2019s some evidence to suggest environmental exposures to certain chemicals may contribute to one\u2019s risk of developing endometriosis.\n\u2022 Somatic mutations: Researchers are also finding that somatic mutations \u2014 acquired changes to DNA that happen after a person is born \u2014 may also be an endometriosis driver.\nBut doctors have also found that the rate of retrograde menstruation is about the same in women with and without endometriosis, so they think additional factors spur the disorder in some.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Although the research report describing the trials was published in The New England Journal of Medicine\u00a0more than a year ago, this story is pegged to a more useful (to readers) \u201cnew event,\u201d the US Food and Drug Administration\u2019s approval of the drug.", "answer": 1}, {"article": "An ad for GE\u2019s 2-D digital system that ran during the Summer Olympics called it a \u201cmajor new breakthrough in the fight against breast cancer.\u201d Digital technology, the thinking went, would show nuances that film never could, because it could render, literally, many more shades of gray.\nThe technology does come with costs, financial and medical.\nBut the company, and the rest of us, should be careful not to overhype 3-D mammography.\nThe images aren\u2019t the only selling point.\nAnd no one yet knows if the new technique will actually save lives.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The piece\u00a0includes information\u00a0on the novelty of 3-D imaging and its fairly recent approval by the FDA.", "answer": 1}, {"article": "\u201cIf we feel like we have a safe method of getting drugs in there,\u201d he said, \u201cit will open up a whole new slew of clinical trials.\u201d\n\nMainprize said the patient, a \u201cremarkable woman,\u201d was chosen to go first, because of the status and large size of her tumor, because it was an area of the brain that the ultrasound machinery could easily reach, and because of her willingness to help the research.\nThe microscopic bubbles \u2014 roughly the size of red blood cells \u2014 had previously been injected into a vein, along with a chemotherapy drug called liposomal doxorubicin and a tracing molecule.\nBut it\u2019s just one of many.\nOn Tuesday, Dr. Todd Mainprize, a neurosurgeon at Sunnybrook Health Sciences Centre and the University of Toronto, announced at a news conference that he had successfully breached the blood-brain barrier in a 56-year-old Canadian woman whose brain tumor, diagnosed six years ago, had recently begun to grow.\nNew, safe doses of drugs will need to be determined, once medication is not being diverted by the blood-brain barrier, noted Dr. Gordon Li, a neurosurgeon at Stanford.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article notes this is a first-in-human case, using a creative way to use ultrasound waves. The novelty is apparent.", "answer": 1}, {"article": "\"I think people should consider it [TXA] following trauma on the basis of this study,\" he said.\nAlthough there was some worry that TXA might lead to more heart attacks, strokes or clots in the lungs, the researchers observed no such increase among patients getting the drug.\nIt works by significantly reducing the rate at which blood clots break down, the researchers explained.\nThe researchers believe that TXA could have even wider uses, such as reducing brain bleeds after brain injury.\nIn fact, a trial to see whether TXA can reduce postpartum bleeding has started, the team noted.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story quotes an expert who says that using TXA in trauma patients is a new idea. The approach does appear to be novel.", "answer": 1}, {"article": "Researchers acknowledge immunotherapy's promise is furthest from realization for bulky solid tumors, perhaps too advanced for the immune system to beat.\nThey say the greatest strides are being made against cancers where the immune system can fight them in manageable stages, such as in the blood or lymph nodes.\nAnd at the National Cancer Institute, a mix of cancer-specific T cells and a booster produced unheard-of improvement in patients with advanced melanoma.\nHowever, in the years after, the first real seeds of the science were being planted via a better understanding of immunology.\nNow, because drugs are mostly tested on patients whose cancer has resisted previous treatment, it's usually used on tumors advanced to often fatal stages.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly states that the idea of immunotherapy has been around for a long time but that recently the field has been burgeoning with new approaches.", "answer": 1}, {"article": "Standard treatments include painkillers, antidepressants, cognitive- behavioral therapy and exercise therapy.\nA key difference, Schubiner said, is that affective self-awareness asks people to \u201cdirectly engage\u201d the emotions that may be helping to drive their symptoms.\nNEW YORK (Reuters Health) - A form of \u2018mind-body\u2019 therapy that focuses on the role of emotions in physical pain may offer some relief to people with fibromyalgia, a small clinical trial suggests.\nThe study, of 45 women with fibromyalgia, found that those who learned a technique called \u201caffective self-awareness\u201d were more likely to show a significant reduction in their pain over six months.\nThe study is only the first clinical trial to test affective self-awareness for fibromyalgia, and it had a number of limitations, including its small size.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story earns\u00a0a satisfactory for not over-selling the novelty of the therapy.\u00a0Cognitive-Behavioral therapy (CBT), an established psychotherapy treatment,\u00a0deals with the recognition of emotions and their relationship to cognition, function and maladaptive responses.\u00a0Affective self-awareness seems to deal with similar issues, so It is not clear how novel this treatment really is.\u00a0The story\u00a0adequately describes this, and is not overly assertive", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Women who take bone drugs for several years have a slightly increased chance of suffering an unusual type of thigh fracture, according to a large Canadian study.\nThe risk of a thighbone fracture differed depending on how long the women had been taking the medicine.\n\u201cWomen with osteoporosis who are at high risk of fractures should not stop taking their treatment,\u201d she told Reuters Health.\nSo far, however, the cheap and effective bisphosphonate bone drugs remain the most popular treatment option.\nAfter taking bone drugs for five years, about one in 1,000 women went on to suffer a thigh fracture over the next year.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There isn\u2019t anything novel about the drugs and the story painted an appropriate picture of their use.", "answer": 1}, {"article": "Earlier this year, dementia overtook heart disease as the leading cause of death in England and Wales.\nDavid Reynolds, chief scientific officer at Alzheimer\u2019s Research UK, said: \u201cIt is conceivable that changing brain cell rhythms could be a future target for therapies, but researchers will need to explore how light flickering approaches could not only reduce amyloid in the visual area of the brain but in those areas more commonly affected in Alzheimer\u2019s.\u201d\n\nThe authors suggest that it may be possible to take a multi-sensory approach, using a combination of flashing lights and vibrating chairs.\nEd Mann, an associate professor of neuroscience at the University of Oxford, said: \u201cI was surprised, and it\u2019s exciting, that such a simple stimulus can target a molecular pathway and have such an effect in an hour.\u201d\n\nQuestions remain, however, about whether boosting gamma oscillations and sweeping amyloid plaques out of the visual brain region would help with memory, which is centred in the hippocampus, or broader cognitive abilities.\nThe study, published on Wednesday in the journal Nature, hinges on the observation that Alzheimer\u2019s patients show a loss of synchronised brain activity, known as gamma oscillations, which is linked to attention and memory.\n\u201cIf humans behave similarly to mice in response to this treatment, I would say the potential is just enormous, because it\u2019s so non-invasive, and it\u2019s so accessible,\u201d said Li-Huei Tsai, director of the Picower Institute for Learning and Memory at MIT, and the paper\u2019s senior author.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The study author and one external source are quoted explaining that the findings are surprising. Just how novel the approach is would have been better established if the story gave readers background facts about current treatments and results of similar research. For example, other researchers reported earlier this year that light stimulation could purportedly \u201cretrieve lost memories\u201d in Alzheimer\u2019s mice.\nAt the very end we\u2019re told two of the co-authors on the original study are starting a company to investigate therapeutic potential in humans. It would be helpful to know if this company is the first of its kind and whether other researchers are looking into specific types of sensory stimulation as treatment for this disease.", "answer": 0}, {"article": "Similar training is an effective component in treating amblyopia, also called \u201clazy eye,\u201d which is the most frequent cause of vision loss in infants and children, affecting 3 percent of the population.\nHowever, other studies with no commercial links obtained similar results, and several scientists I spoke to, including those without ties to GlassesOff, thought the science behind the app was credible.\nReading at our normal pace, the brain has only about 250 milliseconds to do this work until the eyes automatically move onto the next letter or word.\nAfter first taking in \u201craw data\u201d of an image through the eye, different sets of neurons in the brain process it as separate features like edges and colors.\nOnce they do so, we\u2019re taking in more information from whatever the eyes focus on next.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article duly notes that such training is trendy and girded by relatively new findings about the plasticity of the brain.", "answer": 1}, {"article": "John Anderson, president of medicine and science for the American Diabetes Association, says \u201cIt\u2019s very promising and opens up new avenues of research, but we are a long way from replacing insulin, or a cure, or even knowing how this [hormone] will work in human tissue.\u201d\n\nThose concerns aren\u2019t lost on Melton, who also recognizes that more research is needed to confirm that betatrophin may benefit patients.\nHis pursuit of a better understanding of this population, and the forces that cause them to falter in diabetes, led his team to the discovery of betatrophin.\nOver the course of a few weeks, mice bred to develop diabetes but injected with betatrophin were increased their beta cell population by 17 times.\nIt\u2019s also possible that diabetics could lower their dependence on insulin and might even be able to wean themselves off of the injection altogether if their beta cell production is robust enough to provide the insulin they need.\nEventually, the overwhelmed system leaves these sugars, in the form of glucose, to build up in the blood, which can lead to obesity, damage the heart, and cause other metabolic problems.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The research being reported on does seem to be a genuinely new discovery.", "answer": 1}, {"article": "MONDAY, Nov. 5, 2012 (HealthDay News) -- An experimental drug may help patients who can't tolerate statins lower their cholesterol, a new Australian study suggests.\n\"Of note is the reduction in the number of myalgias (muscle pains) for patients compared to the number of myalgias experienced by people taking statins.\nMore trials need to be done of this unique treatment, she added.\n\"In this phase 2 study, the results are certainly impressive and warrant further investigation,\" Ong said.\nThe reductions in LDL cholesterol seen in these patients were comparable to those that occur in patients taking the highest doses of the most effective statins, the researchers added.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reports that this drug might offer a new way to lower cholesterol in patients who can\u2019t tolerate statin drugs.", "answer": 1}, {"article": "A man whose P.S.A.\nBut once cancer is detected, many men, frightened by the diagnosis, opt for aggressive surgical and radiation treatments that do far more damage than their cancers would have, leaving many impotent and incontinent.\nBut the score does put them in a higher-risk group of men who have more to gain from regular screening, he concluded.\nThey still have a very low individual risk of dying from prostate cancer, judging from the new data.\ntest shows him to be at low risk at age 50 may decide not to be retested again until the age of 60.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story was about a readily available test; it provided information on the results of a recent study which may be useful for some men making decisions about whether to be tested and if they so chose, at what age(s).", "answer": 1}, {"article": "Dr. Arie Kaufman of SUNY Stony Brook demonstrated the virtual colonoscopy for CBS New York's Dr. Max Gomez.\n\"This will allow the physician to view 100 percent of the surface including lesions, which are hidden behind folds maybe seen on the side and back walls.\"\nThis next step in virtual colonoscopy, called \"immersive colonoscopy,\" projects 3D images of the colon large enough to fill the walls of a room.\nSuch highly specific screening may allow doctors to detect more abnormal growths, called polyps, when they are as small as .10 mm, so they can be removed before they become full-blown cancer tumors.\nColorectal cancer is the second leading cause of death among the combined group of men and women who have cancer, according to the National Institutes of Health.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Virtual colonoscopies are not exactly new, since the technology was first patented in 1996. In 2004, 3-D virtual colonoscopy was approved for colon cancer screening in the US by the Food and Drug Administration. It seems that what may be new here is the projection of 3-D images on the wall, providing an \u201cimmersive\u201d experience for the physician performing the procedure. But the story doesn\u2019t establish that fact or specify what exactly the news is here.", "answer": 0}, {"article": "One of the top research universities in the world, MSU focuses its vast resources on creating solutions to some of the world\u2019s most pressing challenges, while providing life-changing opportunities to a diverse and inclusive academic community through more than 200 programs of study in 17 degree-granting colleges.\nUp until then, it was unclear how these compounds, also known as cannabinoids, affected the immune system.\nYet, even with this therapy, certain white blood cells can still be overly stimulated and eventually become inflammatory.\n\u201cIt might not be people smoking marijuana,\u201d Kaminski said.\nWith antiretroviral therapy \u2013 a standard form of treatment that includes a cocktail of drugs to ward off the virus \u2013 these cells have a better chance of staying intact.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does not establish the novelty of the findings.", "answer": 0}, {"article": "Probabilities may not grab all patients by the collar. But telling someone he or she has a better than 1-in-3 chance of dying before the next decade's out (or even a better than 1-in-10 chance) would probably be a sobering reminder to hit the gym. The authors said the metric \"can be used to communicate fitness-related risk and motivate behavioral change after exercise stress testing.\"", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story nods in the direction of novelty when it quotes a researcher who says, \u201cThe notion that being in good physical shape portends lower death risk is by no means new, but we wanted to quantify that risk precisely by age, gender and fitness level, and do so with an elegantly simple equation that requires no additional fancy testing beyond the standard stress test.\u201d We wish the story had more thoroughly examined why exactly this is new, but we\u2019ll again give the benefit of the doubt here.", "answer": 1}, {"article": "Kaiser funded the study.\n\"Even after the rash has healed, the pain can last for months or even years,\" said lead study author HungFu Tseng, a research scientist at the Kaiser Permanente Division of Research and Evaluation in Pasadena, Calif.\n\nZostavax, as the vaccine is called, was approved in 2006, based on the results of clinical trials.\nIn vaccinated individuals, the rate of shingles was 6.4 cases per 1,000 people in a year while it was twice that -- 13 per 1,000 -- in the unvaccinated population, the investigators found.\n\"I think it's a very good vaccine, and it's a safe vaccine, but obviously there needs to be continuing surveillance of usage of the vaccine to make sure there are no adverse effects that are seen in one in a 100 million cases versus one in five or 10,000 people,\" said Sumaya, also a member of CDC's Advisory Committee on Immunization Practices.\n\"People 60 and over can consider talking to their physician about the possibility of receiving the vaccine to reduce their risk, and the doctor can evaluate if they are eligible,\" said Tseng.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\n\nThe story reports that this is the only approved vaccine to reduce shingles risk and that it has been available since 2006 in the United States. It also makes clear that this study provides information about how the vaccine performs in the real world, as opposed to the idealized conditions of a clinical trial.", "answer": 1}, {"article": "A number of new multiple-sclerosis medications are beginning to hit the market that promise to make it easier for patients to control flare-ups of the disease and slow its progression.\n\nThe drugs, designed to be taken orally, represent a new generation of treatment for MS. Currently, people with the disease can choose from a range of drugs that are administered by injection.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Gilenya belongs to a family of oral medications, which the story explains are novel in the method of administration for multiple sclerosis. (Oral instead of injectable.) It also outlines different dose forms, such as once-a-day or once-a-week injections.", "answer": 1}, {"article": "Researchers in Turkey conducted experiments with 53 postmenopausal women.\nA five-point scale was used to measure the severity of hot flashes, vaginal dryness, urinary symptoms, mood swings, and other symptoms in the postmenopausal women.\nThose in the comparison group were treated with shams needles at the same acupuncture points.\nLevels of estrogen and other hormones were measured before the study and after the first and last acupuncture sessions in both those receiving real and sham treatments.\nHalf of them received traditional acupuncture treatment.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "No mention of any of the other research that has looked at acupuncture for menopausal symptoms.\nJust last year a significant review of 106 previous papers on acupuncture and menopausal symptoms found exactly no benefit from the treatment.", "answer": 0}, {"article": "Three years later, researchers continue to detect the presence of the cloned cells they infused into the patient, 61-year-old high school history teacher Gardiner Vinnedge of North Bend, Wash.\n\nFor six years, Vinnedge endured painful rounds of chemotherapy, only to have his melanoma return.\nThe immunotherapy allowed him to return to work three weeks after treatments began.\nThe last step was to infuse the resulting army of cancer-fighting clones back into the patient.\nIn six of the 11 patients in the trial, the melanoma stopped progressing for 12 to 19 weeks.\nIt aims to charge up the patient's immune system to attack cancer cells and halt their out-of-control growth.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of this approach for melanoma was evident in the story.", "answer": 1}, {"article": "WATCH: The naked mole rat might help us cure cancer\nIn a related commentary in the journal, a pair of doctors from the University of Washington School of Medicine note that the estimates of overdiagnosis of breast cancer are \"frustratingly broad\" \u2014 from less than 10 percent to 50 percent or more of women who get screened.\nBut this isn't the first study to call into question the benefits of mammography and whether women are too often the victims of overdiagnosis.\nThe research, led by Richard Wilson of Harvard University, revealed that in more than 500 US counties, mammography screening programs were linked with more diagnoses of smaller breast cancers \u2014 but not with fewer deaths or with fewer larger breast cancers (which theoretically would be prevented by finding the disease early through screening).\nInstead, they note that the benefits of screening will probably be more favorable when screening is directed at people with a high risk of the disease \u2014 such as those with a family history of breast cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that \u201cthis isn\u2019t the first study to call into question the benefits of mammography and whether women are too often the victims of overdiagnosis \u2014 that is, being diagnosed with cancers that would not have been fatal or even harmful.\u201d", "answer": 1}, {"article": "Sandoval is alive today because of an experimental form of immunotherapy called CAR-T.\nWith CAR-T, a patient\u2019s own immune cells are removed from the body, reprogrammed to find and destroy cancer cells, then put back into the bloodstream.\nThe FDA will review these results and could make a decision on approval by the end of the year.\nBeing around for my daughter, my son, my wife.\nDespite chemotherapy and a stem cell transplant, the cancer returned before his daughter\u2019s first birthday.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t\u00a0report that Novartis is at a similar stage of testing a similar treatment, so the subject of this story is not unique.", "answer": 0}, {"article": "This was a phase 2 trial.\nIniparib inhibits a pathway that helps repair DNA; researchers call it the poly(ADP-ribose) polymerase (PARP) pathway.\nThe findings were enough to generate the interest of Dr. Lisa A. Carey, the co-author of an accompanying editorial.\nA similar drug, in fact, has shown benefit in patients with BRCA 1 or BRCA 2 mutations predisposing them to breast and ovarian cancer.\n\"Phase 2 was quite positive, but we really don't know if this is going to end up benefiting patients until we get to phase 3.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The piece states that Iniparib is from a new class of drugs called PARP inhibitors.\u00a0 It also notes that a similar drug has shown benefits in women with BRCA\u00a0I or BRCA\u00a0II mutations.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - People who took a newer type of pain pill over a three-year period were less likely to develop polyps that could lead to colorectal cancer \u2014 but at the expense of a higher risk of heart problems, new study findings report.\nApproximately half of the people who started the study agreed to continue.\nThe study, published in the American Journal of Gastroenterology, received financial support from Pfizer, which sells Celebrex.\nThose who had been on Celebrex were also more likely to develop advanced polyps during that final year.\nBut to people who have no underlying cardiovascular problems and a particularly high risk of colon cancer - they were diagnosed with it before perhaps, or have a strong family history - regular screening may not be enough, Chan noted.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There is appropriate acknowledgment of previous research on the potential for COX-2 inhibitors to prevent cancer.", "answer": 1}, {"article": "\u201cWill these peptides actually induce tolerance in people?\n\u201cThis technology could be very effective,\u201d says Timothy Coetzee, PhD, chief research officer for the National Multiple Sclerosis Society.\nWhat remains to be seen is whether the researchers have picked the right proteins that might turn off the disease in humans, he says.\nThe study was funded by grants from the National Institutes of Health, the Myelin Repair Foundation, the Juvenile Diabetes Foundation, and the Australian government.\nIt\u2019s rational, but we won\u2019t know until we get it into people,\u201d says Coetzee, who was not involved in the research.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story indicates that this approach in mice has never been tried before, but we aren\u2019t given a sense of the state of nanotechnology more broadly or whether there are similar mice studies being conducted for MS or other diseases.\nAs we noted earlier, attempts to selectively desensitize the immune system have been around for decades.\u00a0 The use of 21st century technology being applied to this age old approach is new and novel but it does not come across well in the story", "answer": 0}, {"article": "\u201cWhat about long-term safety issues?\u201d he asked.\nFor that reason, the finding that marijuana may actually help improve patients\u2019 sleep, she said, is \u201cparticularly noteworthy.\u201d\n\nThe cannabinoid family, which includes marijuana, is \u201cemerging as an interesting new class of drugs for pain management,\u201d Ware said.\n\u201cThe trial did not last long ... so the authors cannot really say whether any response would be sustained,\u201d Dr. Henry McQuay, who studies pain and pain relief at the University of Oxford, wrote in an editorial accompanying the study.\nNEW YORK (Reuters Health) - In a small study, people who had chronic pain as a result of damage to the nervous system reported feeling less pain, as well as less depression and anxiety, when they smoked marijuana compared to when they smoked a drug-free placebo.\nThe results support a limited number of trials that have suggested marijuana may be helpful for people suffering from chronic pain, but that it also has its limitations.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story alludes to the fact that this study \"supports a limited number of trials that have suggested marijuana may be helpful for people suffering from chronic pain,\" indicating that the treatment\u00a0is not very novel at all.\u00a0It would have been nice to see more context around that. The WebMD story provides a little more information in this regard. If the news release is to be believed, \"This is the first trial to be conducted where patients have been allowed to smoke cannabis at home and to monitor their responses, daily\". That could have been made clear.", "answer": 1}, {"article": "\"It's clear that these medications are beneficial,\" said Wadden, who has been a paid consultant to pharmaceutical companies as well as Weight Watchers. \"Unfortunately, there's a sense that they must not work if you have to take them indefinitely. But I think obesity medications should be used on a long-term basis for chronic weight management, just as I take a [cholesterol-lowering] statin and a blood-pressure medication for the long term.\"", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains\u00a0this is a recently published review of the literature on treatments and interventions for obesity, with both well-known and lesser-known takeaways.", "answer": 1}, {"article": "To be sure, the U.S. Preventive Services Task Force's currently recommends against taking aspirin to prevent colorectal cancer, the type of cancer for which there is the largest body of scientific work.\nTwenty years after people had started taking aspirin regularly (and kept it up for at least five years), their deaths from esophageal cancer were reduced by 60 percent compared to study subjects who got a placebo.\nThe biggest is stomach bleeding, although it also raises the risk of brain hemorrhage.\nAnd the researchers were able to gather more information about cancer deaths for up to 20 years after those studies ended about nearly 13,000 people.\n\"There's a little controversy about whether a baby aspirin dose is enough,\" says Harvard's Chan.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that aspirin has been studied as a potential preventative tool for other cancers but that aspirin is not in wide use for this purpose.", "answer": 1}, {"article": "He cites clinical data showing stroke and death rates of more than 10 percent within one year among those getting stents -- not much different from the results in the same study for surgery.\n\"My memory and energy levels are better now,\" she said.\nThen there are the interventional radiologists, who have extensive experience with stenting in arteries not near the heart, and neurologists, who specialize in treating brain diseases.\nBut Dr. Ricotta said that in most cases he would still probably prefer surgery, for which he has had a low complication rate.\nMeanwhile, patient demand for stents is growing.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Explains carotid stenting as \nrelatively new; piece later goes on to mention newer stenting systems with implanted filters", "answer": 1}, {"article": "TUESDAY, Aug. 17, 2010 (HealthDay News) -- Less invasive biopsies done with the help of imaging to guide the needle now make up the majority of biopsies being done, a new study finds.\nThis increase in less-invasive biopsies went along with a decrease in the number of more-invasive biopsies and through-the-skin biopsies where no imaging was used, the researchers found.\nFor these areas, open biopsies are easier to do and need less imaging guidance, Kwan's team noted.\nThe report is published online and in the September print edition of Radiology.\nThe only two areas where needle biopsies were not the majority of biopsies done were biopsies of lymph nodes and soft tissues.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story focused on the growth in use of \u2013 and therefore the relative lack of novelty anymore in \u2013 less invasive biopsies. ", "answer": 1}, {"article": "A medically supervised daily dose of peanuts may help children with peanut allergies greatly increase their tolerance to the food, according to two new studies that raise the possibility of a cure for this potentially life-threatening condition.\nThe findings, presented on Sunday at a meeting of the American Academy of Allergy, Asthma and Immunology in Washington, suggest that a treatment for peanut allergy may be developed in two or three years, said Dr. Wesley Burks, the chief of the division of pediatric allergy and immunology at Duke University Medical Center, who helped conduct the research.\nNearly half of the 150 deaths attributed to food allergies each year in the United States are caused by peanut allergies, according to Duke University.\nBecause even a minor exposure can set off a reaction, many people at risk strictly avoid foods that contain an allergen or were prepared in places where nuts or other allergens might have been used.\nAn estimated 12 million Americans suffer from food allergies, including about 2.2 million children.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The report explains that previous British studies of similar treatments have shown similar results. It also states that a U.S. based consortium is conducting studies as well. \nThe reader would not come away believing the treatment being tested is unique.\u00a0 ", "answer": 1}, {"article": "A California company has developed a genetic test that can predict whether patients treated for early-stage colon cancer are likely to suffer a recurrence of the disease, the third leading cause of cancer deaths in the U.S.\n\nThe results of the test, based on an analysis of seven different genes found in colon-cancer tumors, yield a score that tells whether patients are at low, intermediate or high risk of having the disease come back after it is removed through surgery.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear that the test is similar to the company\u2019s genetic test to identify more lethal breast cancers, yet that it is the first such test for colon cancer. ", "answer": 1}, {"article": "Information on breast cancer is available at cancer.gov.\nThe researchers suggested that the difference in results between low- and regular-dose aspirin may have been attributable to most women taking low-dose aspirin more often than three times a week, even daily, for cardiovascular protection as opposed to more-sporadic use of regular-dose aspirin for pain relief.\nAbout 23 percent of the women reported taking a low-dose aspirin (81 milligrams), 18 percent took ibuprofen, 11 percent took full-strength aspirin (325 mg) and about 10 percent took a COX-2 inhibitor or another nonsteroidal anti-inflammatory drug (NSAID).\nHowever, aspirin can increase the risk for internal bleeding, so women should talk with their doctors before starting a low-dose aspirin regimen, for any reason.\nThose who take a daily low-dose aspirin, also called a baby aspirin, usually do so to prevent cardiovascular disease, the leading cause of death for women older than 25.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s not clear from the story what is novel about this study. A reader who searches online for related material may run across this news release from the American Cancer Society on aspirin use and colorectal cancer. Is this different because of the type of cancer? Because of the dose of aspirin? Both? It\u2019s always good to help readers place new findings in context, and often dicey to assume that readers will automatically understand how the new findings fit into the broader research on the topic.\nAs the news release explained: \u201cThis study differed from other studies that have looked at aspirin and cancer risk because it focused on the dose levels of the aspirin women had taken and tracked the frequency of the use of low-dose aspirin as opposed to regular aspirin.\u201d", "answer": 0}, {"article": "Newswise \u2014 Omega-3 fatty acids may lower the risk of breast cancer in postmenopausal obese women, according to researchers.\nAt the conclusion of the two-year study, the researchers found that increasing levels of omega-3 in the blood were associated with reduced breast density\u2014but only in women with a body mass index above 29, bordering on obesity.\nThe researchers plan to test the effect of DHA alone in obese subjects, potentially in combination with weight loss, in a future trial.\nAlthough Lovaza contains both of the fatty acids DHA -- 375 milligrams -- and EPA -- 465 milligrams, only DHA blood levels were associated with breast density reduction.\n\"Omega-3 fatty acids have an anti-inflammatory effect, so that's one of the reasons why we suspected it may be particularly effective in obese women,\" Manni said.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes no evident claim of novelty. We\u2019ll give it a pass for reinforcing in at least two places that the research builds on previous research and the understanding that highly dense breasts are associated with greater risk for breast cancer.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Older people who use olive oil in their cooking and on their salads may have a lower risk of suffering a stroke, researchers reported Wednesday.\nAnd after they did, olive oil was still linked to a lower stroke risk.\nThe findings, reported in the journal Neurology, hint that the well-known connection between olive oil and heart disease might extend to stroke as well.\nOlive oil is one part of the Mediterranean diet that has been tied to heart benefits.\nHigh olive oil intake is also linked to a lower risk of heart attack, and a longer lifespan among heart attack survivors.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story attempted to put the new finding into the context of past research on olive oil and the Mediterranean diet.", "answer": 1}, {"article": "\u201cThe state of the science will be changing relatively quickly, so we\u2019ll have to keep looking at this.\u201d\n\nRight now, the American Cancer Society (ACS) and other medical groups recommend that women start Pap tests at age 21 or three years after they become sexually active, whichever comes first.\nThe problem with that higher false-positive rate is that it could lead to needless biopsies and other tests, or treatment to remove abnormal-looking tissue.\nBut there are still questions about the effects of HPV screening, and \u201cmore complete evidence\u201d is needed before it becomes widely used, Whitlock and her colleagues write.\nThe report, in the Annals of Internal Medicine, sums up a research review done for the U.S. Preventive Services Task Force (USPSTF), an expert medical panel supported by the federal government.\nBut it said there was not enough evidence to recommend for or against newer types of testing \u2014 including HPV tests and the \u201cliquid-based\u201d Pap tests that are now more often used than the old-fashioned version.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story states that \u201ca lot of research has been done since the 2003\u201d cervical cancer screening recommendations of the US Preventive Services Task Force, but that there are still questions remaining about the effects of HPV screening.", "answer": 1}, {"article": "SUNDAY, Oct. 23, 2011 (HealthDay News) -- Older women who take nonsteroidal anti-inflammatory drugs -- such as aspirin or ibuprofen -- appear to have a lower risk of death from colorectal cancer than women who don't use these medications, a large new study suggests.\nThe researchers confirmed 2,119 cases of colorectal cancer and 492 deaths due to the disease.\nThe findings were slated for presentation on Sunday at the AACR International Conference on Frontiers in Cancer Prevention Research, in Boston.\nThe U.S. National Cancer Institute has more about colon and rectal cancer.\nExperts say that for studies presented at medical meetings, data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Aspirin is not a new drug.", "answer": 2}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nThe NIAID group continues to adapt the RT-QuIC assay to detect additional types of neurological diseases with greater accuracy using the least invasive patient sample possible \u2014 whether that is blood, skin, nasal brushings, or other samples.\nThe group conducted the tests using Real-Time Quaking-Induced Conversion (RT-QuIC), an assay developed and refined over the past decade at NIAID\u2019s Rocky Mountain Laboratories.\nThe group, led by NIH\u2019s National Institute of Allergy and Infectious Diseases (NIAID), tested 60 cerebral spinal fluid samples, including 12 from people with Parkinson\u2019s disease, 17 from people with dementia with Lewy bodies, and 31 controls, including 16 of whom had Alzheimer\u2019s disease.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does a good job here, stating:\nEarly and accurate diagnoses of these brain disorders is essential for developing treatments and identifying patients eligible for clinical trials. The diseases typically progress for years before symptoms appear, and once they do, distinguishing one disease from another can be difficult.", "answer": 1}, {"article": "Scientists from the University of Gothenburg\u2019s Sahlgrenska Academy have developed a portable pocket-sized vestibular, or balance, stimulation device in a bid to improve the lives of Parkinson\u2019s sufferers.\nThe plan is now for the device to be tested in a longer-term study, where patients will be using it at home.\nThe difference is that we use a particular current profile which you can stimulate the balance organs with without creating a balance disturbance.\nThe device operates by providing stimulation via patches attached to the patient\u2019s head behind the ears, where the vestibular system is located.\nThere is extensive research in this field and I hope that it eventually will come up with a result.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that the TENS technology has found use in other areas of medicine.", "answer": 1}, {"article": "Cooper and his colleagues looked at 29,507 births to women covered by Medicaid in Tennessee between 1985 and 2000.\nThat such an effect was first noticed a quarter-century after ACE inhibitors arrived on the market points up the lack of data about the effect of drugs in pregnancy.\nAs a consequence, the labels on nearly all medications carry a statement saying their safety to fetuses has not been established.\nThe alternatives that clinicians might want to consider are diuretics, alpha-methyldopa, some beta-blockers, and the calcium-channel blocker nifedipine, according to the FDA officials and an editorial accompanying the study.\nStudies of large databases such as Medicare records or registries that enroll pregnant women already taking particular drugs are the chief ways to discover and measure possible risks to the fetus from prescription drugs.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It is clear from the story that ACE inhibitors have been used by pregnant women, and that \u201cThe number of women taking them early in pregnancy is unknown but probably is small, the study suggests.\u201d", "answer": 1}, {"article": "The studies that served as the basis for the FDA approval of the drugs, along with recently released guidelines from the American Society of Clinical Oncology (ASCO), set the threshold at a five-year Gail score of 1.67 percent.\nThe effect was even larger during the first five years of the study.\nA 2010 study found \u201cexceptionally low\u201d rates of usage.\nBoth the ASCO and the task force guidelines recommend such a conversation.\n\u201cA discussion on the use of preventive agents needs to become part of routine care in women at high risk,\u201d she says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes that there is nothing is novel about the therapies under discussion.", "answer": 1}, {"article": "The study\u2019s conclusions contrast with those of a report last year by the United States Preventive Services Task Force, an independent group that issues guidelines on cancer screening, questioning the benefit of screening women younger than 50.\nThe new study took advantage of circumstances in Sweden, where since 1986 some counties have offered mammograms to women in their 40s and others have not, according to the lead author, Hakan Jonsson, professor of cancer epidemiology at Umea University in Sweden.\nThe study\u2019s authors include Dr. Stephen Duffy, an epidemiologist at the University of London, and Dr. Laszlo Tabar, professor of radiology at the University of Uppsala School of Medicine in Sweden, who have long been advocates of mammography screening.\nTheir paper is published online in the journal Cancer and will be presented on Friday at a meeting sponsored by the American Society for Clinical Oncology and five other organizations.\nBut their results were greeted with skepticism by some experts who say they may have overestimated the benefit.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThis story could have done a better job explaining how this study \u2013 and its methods \u2013 are different from earlier research on the topic.But two things lead us to give it a barely satisfactory score. First, there was a brief attempt to mention the unique \"circumstances\" of the Swedish study.\u00a0 Second, the story also pointed out that there\u2019s a historical ideological pattern in the study authors\u2019 work \u2013 noting that they \"have long been advocates of mammography screening.\"\u00a0 ", "answer": 1}, {"article": "Whether you've been relatively inactive or fairly athletic, age is the enemy of one of the most important sets of muscles in the body: the group of four known as the rotator cuff that surround the ball of the shoulder joint.\n\nAbout 54% of adults older than 60 have a completely or partially torn rotator cuff, compared with just 4% of those between 40 and 60. But tears are most frequently caused by degeneration of the tendon due to age, rather than injury from sports or trauma. Studies show that tears can be managed without...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains that a variety of surgical repair techniques \u2013 all lumped in the non-open incision category \u2013 are available. None of these are truly novel.", "answer": 2}, {"article": "Some of the complaints related to the placement of the device.\nThis test is an alternative to the generally-prescribed modified hysterosalpingogram (HSG) test in which an x-ray of the uterus and fallopian tubes is used to check for proper device placement.\nBut since its approval in 2002, women using the device have sent the FDA more than 5,000 complaints, ranging from pain and menstrual problems to pregnancies and even deaths.\n(Reuters) - Bayer Healthcare said on Wednesday the U.S. Food and Drug Administration approved using transvaginal ultrasound as an alternate test to confirm if the company\u2019s Essure permanent birth control device has been placed properly.\nThe training will start in September, the same month the FDA will hold a public panel meeting to discuss the safety and effectiveness of Essure.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes that the TVU test has been approved by the FDA to confirm proper placement of the Essure device. Though we\u2019ll award a Satisfactory rating on that basis, we\u2019d note that the story doesn\u2019t provide any background about the test or inform readers that the test itself isn\u2019t new at all. Nor does it provide any\u00a0evidence, data, or rationale for why this is advantageous over the HSG (cost? safety? availability? accuracy? comfort?).", "answer": 1}, {"article": "Men whose prostate cancer comes back after surgery are more likely to survive if, along with the usual radiation, they also take drugs to block male hormones.\n\nThe finding, published Wednesday in The New England Journal of Medicine, comes from a long-running study that experts say will help clarify treatment for many patients.\n\nAfter surgery to remove the prostate, more than 30 percent of men have a recurrence, and until now there has not been clear evidence about the best way to stop the disease from killing them. Most are given radiation, but prescribing drugs to counter the effects of male hormones has been inconsistent.\n\nThe study, paid for by the National Cancer Institute, showed that among men who received radiation and hormonal treatment, 76.3 percent were still alive after 12 years, compared to 71.3 percent who had radiation alone.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a good job explaining that this study is novel because it helps clarify a previous unknown: how effective hormone blocking is for controlling prostate cancer recurrence. The story quotes an outside expert who says the study \u201cis a big deal,\u201d and hopefully enough to change medical practice. We feel this is a fair way to frame things, because the treatment did improve overall survival\u2013a big deal. Yet, this is an interesting difference with the STAT story, whose outside expert takes a more careful position of calling it an \u201cincremental\u201d\u00a0step for doctors, which is also fair, since the absolute difference between the two groups was small, about 5%. Ideally, both stories would have made both points.", "answer": 1}, {"article": "\u201cFor now, there is no magical cream that can make you look younger.\u201d\n\nOlivo will work first to develop the product to deliver drugs to the skin \u2013perhaps allergy or eczema medication, or long-lasting sunscreen, MIT said.\nThere are hundreds of skin products that do this now, but this one sticks better and doesn\u2019t pucker the skin, the team reports.\nLight-scattering particles are added to the second layer, and they reflect light off the skin, making it look clearer and smoother.\nThe cream\u2019s effects are detailed in a scientific report in the journal Nature Materials, but as part of the school\u2019s close association with the companies, it\u2019s being patented and produced at almost the same time.\nThey wanted something stretchy and strong that wouldn\u2019t pucker up when it dried on the skin and that would be breathable.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "A cream that changes into a second skin that is somewhat protective, ostensibly harmless, and cosmetically appealing is clearly novel enough to garner public attention, so we\u2019ll score this category as Satisfactory.", "answer": 1}, {"article": "Pill That Hits A Cause Of Cystic Fibrosis Beats Expectations\n\nMore than 20 years after the gene behind cystic fibrosis was identified, a pill that could fix the problem in some people is getting closer to reality.\nLisa Jarvis has more details on that at the Haystack blog.\nLung function got 10 percentage points better, on average, in people who got the drug compared with those taking a placebo.\nThe improvement at six months was still present almost a year after the study's start.\n\"It is larger than any other clinical intervention we've ever had in cystic fibrosis.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Adequate job establishing the novelty of this approach for the target population.", "answer": 1}, {"article": "Castle said there could be a few reasons that doctors opt to screen women more often than is recommended.\nResults from a survey of the same doctors have shown that many also give the HPV test alongside Pap smears to women under 30 \u2014 which is not recommended, because HPV is common in young women and often goes away on its own (see Reuters Health story of July 4, 2011.)\nGuidelines from the American Cancer Society and other organizations recommend that women age 30 and older are screened using Pap smears and tests for the human papillomavirus, or HPV.\nThat means more costs to women and the healthcare system, as well as a risk of unnecessary treatment for false-positive test results \u2014 with very little additional cancer-catching benefit.\nThat\u2019s because HPV \u2014 which causes changes in the cervix that can lead to cancer \u2014 may take a decade to progress to that point.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reminded readers that this type of survey \u2013 and its findings \u2013 don\u2019t stand alone:\n\u201cResults from a survey of the same doctors have shown that many also give the HPV test alongside Pap smears to women under 30 \u2014 which is not recommended, because HPV is common in young women and often goes away on its own (see Reuters Health story of July 4, 2011.)\u201d", "answer": 1}, {"article": "Five-year survival rates for lung cancer are low.\nThe results are in keeping with those of a much larger study published last month, which showed that these 3-D X-rays, or CT scans, reduced the death rate among 53,000 current and former heavy smokers by 20 percent compared with screening using regular chest X-rays.\nThis latest study, published in the journal Lung Cancer, looked at death rates in a different, smaller population of heavy smokers, and estimated that those who received up to two CT scans would have between a 36 and 64 percent lower risk of dying, compared to those who went unscreened.\nIn recent years, CT scans, in particular, have been promoted by some hospitals and advocacy groups for lung cancer screening, even though studies had not yet shown definitively whether such screening saves lives.\nFor instance, to compare death rates, the researchers tracked how many people died among those who were screened, then pulled out all the people with similar underlying characteristics in the other two groups and looked at their death rates, Hanley explained.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story puts this study into context with other recent reports, thus making it clear that the evaluation of CT screening for lung cancer is a process that has been going on for a number of years and is far from finished.", "answer": 1}, {"article": "In contrast, the risk of failure among recently recalled defibrillators has been estimated by the manufacturers at just 0.009 percent to 2.6 percent.\nAnd not every failure is deadly.\nAbout 80,000 patients received the implantable devices in 2004.\nSome patients \"might want to hang out and wait and see what happens,\" Krahn said.\nA new Canadian study provides the first estimate of the risk of major complications from replacement surgery, important information for patients facing the choice.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It is clear from the article that defibrillators are not a novel treatment. ", "answer": 1}, {"article": "Walnuts are the only nuts with appreciable levels of omega-3 fatty acids, which some studies of male infertility have linked to better sperm quality, says researcher Wendie Robbins, PhD, of the UCLA Fielding School of Public Health.\nTheir study is part of a growing body of evidence that men\u2019s dietary and lifestyle choices might affect their fertility.\nThe other men were told to continue their regular diet but not to eat any tree nuts.\nBefore and after the experiment, the men\u2019s semen quality was analyzed by a researcher who did not know which ones had eaten walnuts.\nThe researcher looked at sperm concentration, vitality, ability to move, shape and size, and chromosome abnormalities, all thought to be related to fertility.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions previous research on the use of omega-3 fatty acids in men with fertility problems.", "answer": 1}, {"article": "A procedure used to relieve chest pain in hundreds of thousands of heart patients each year is useless for many of them, researchers reported on Wednesday.\nThe devices are lifesaving when used to open arteries in patients in the throes of a heart attack.\nTheir study focused on the insertion of stents, tiny wire cages, to open blocked arteries.\nBut they are most often used in patients who have a blocked artery and chest pain that occurs, for example, walking up a hill or going up stairs.\nOther estimates are far higher.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The many expressions of surprise by practicing cardiologists makes clear that the study offers a novel finding.", "answer": 1}, {"article": "Aug. 4, 2010 -- The plant extract resveratrol, found in the skin of red grapes, appears to suppress inflammation and may fight aging in humans, according to a new study.\nThe researchers signed up 20 people and put them at random into two groups, one receiving a placebo and the other a supplement containing 40 milligrams of resveratrol.\nNow, Ghanim and colleagues say they have found that resveratrol reduces inflammation in humans that could lead to heart disease, stroke, and type 2 diabetes.\nPeople taking resveratrol also showed suppression of the inflammatory protein tumor necrosis factor, or TNF, and other compounds that increase blood vessel inflammation and interfere with insulin action, causing insulin resistance and the risk of developing diabetes.\nBlood samples from those on placebo showed no significant change in pro-inflammatory markers.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story discussed a little bit of past research, suggesting that interest in resveratrol is not new.\u00a0 ", "answer": 1}, {"article": "Campbell is one of only 14 people in the United States participating in an FDA-approved study of an artificial retina -- a microchip implanted in the eye to stimulate damaged cells.\n\"This is really the first step toward a really bionic eye,\" said Aries Arditi, a senior fellow in vision science at Lighthouse International, a nonprofit advocacy group for the blind and one of the study sites for the artificial retina.\nThere are 100,000 people in the United States affected by retinitis pigmentosa, according to the National Eye Institute, a division of the National Institutes of Health.\n\"This is an artificial device that essentially stimulates the retina electrically,\" Del Priore said.\n\"Patients were able to do things that we would not have anticipated with so few electrodes,\" Mech said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story incorrectly implies novelty of this device. \nMany companies and research teams worldwide are pursuing artificial retinas; some others\u2019 technologies are more technically advanced. Indeed, there is a federal government program to support the many development efforts. \nOther treatments to restore vision are being researched actively.\u00a0\nOddly, one of them was featured in a September 2009 story that appears on\u2026CNN\u2019s website. ", "answer": 0}, {"article": "(CNN) -- Eating a diet rich in healthy fats and limiting dairy and meat could do more than keep your heart healthier.\nIt is complicated in general to compare the benefits of a particular diet with the benefits of not following a different food regimen.\nThe study shows association, not causation, meaning there could be some other factors linking the Mediterranean diet to resilience against this form of brain damage.\nThe people involved in the brain infarcts study are a subset of that original group.\nThis study looked at people who had never had a clinical stroke, but may have had smaller strokes that went unnoticed.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story appropriately tried to put this research into the context of other resarch on the Mediterranean diet and health. ", "answer": 1}, {"article": "The people who do this are specially trained.\nYou need a lot of special training to get those catheters up into the brain and pull things out.\"\n\"They are not regularly performed by cardiologists or radiologists or neurologists.\nA lot of this at this point depends on logistics and manpower.\nThat last point is especially important, because the stent retrieval device will not fit into the smaller blood vessels that branch out further into the brain, Powers said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We believe the story establishes that the procedure has been under study for some time and that the guidelines issued are new.", "answer": 1}, {"article": "Moreover, though resting energy expenditure varies with each individual, this increase would yield almost 1 lb.\nA recent paper, Capsaicinoids Enhance Metabolic Rate in Normal Healthy Individuals using a Novel Metabolic Tracker Breezing Device-An Open Label Placebo Controlled Acute Study, published in the journal Obesity Open Access discussed the findings of the Metabolic Rate (MR) Study, which demonstrated that an extract from red hot peppers boosted metabolic rate (Chen, et al., 2017).\nThe company's centers of excellence are located in North America and India, whereas its cGMP and HACCP system-compliant manufacturing operations are located at multiple FDA inspected sites in India.\nThe MR Study was a placebo-controlled, crossover open label study with 40 healthy adults examining the effects of either 2 mg capsaicinoids from 100 mg of Capsimax or placebo on resting energy expenditure, heart rate and blood pressure.\nThe study showed that supplementing with this low dose of Capsimax increased metabolic rate which calculated to an equivalent to burning an extra 116 calories per day.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t claim that the compounds in hot peppers are a novel approach to weight control nor does it suggest that capsacian\u2019s ability to increase metabolism is a new concept. The release doesn\u2019t establish what is new about the findings.", "answer": 0}, {"article": "Over the 18-year period, the number of breast cancers diagnosed at very early stages increased 66 percent, while the number of more advanced cancers (stage 3) decreased by 66 percent.\nThe new study, like previous ones, re-ignites the ongoing debate about the best age to start routine mammograms and the best screening interval.\nIt also suggests that women aged 40 to 49 at average risk discuss the pros and cons with their doctors and decide on an individual basis if and when to start screening.\nThe researchers looked at the method of diagnosis, whether by mammogram or if the cancer was found by the doctor or the woman.\nWhile 4 percent of women whose cancer was found on mammogram died during a follow-up period that ranged from one to 20 years, 11 percent of those whose cancers were found by the doctor or the women died.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story at least acknowledged some past studies in the ongoing debate about \u201cthe best age to start routine mammograms and the best screening interval.\u201d", "answer": 1}, {"article": "So, should we be referring to physical therapists, osteopaths or chiropractors from the ER?\"\nThere are different pathways to healing, and whether you feel you're better off with chiropractic, home exercises or medications, this study shows that all three are basically just as effective.\nHe also noted that it's important for anyone receiving spinal manipulation to know that there are rare, but serious risks that can occur with neck manipulations.\nThis is especially true if you've been in a car accident, or if you have any neurological symptoms, such as repeatedly dropping things, or if you have pain radiating down your arm.\nSpinal manipulation is one type of treatment that's offered for neck pain, and it can be administered by chiropractors, physical therapists, osteopaths and other health care providers, according to the study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story points out that this trial was designed to address the lack of solid evidence comparing common treatments for back pain, while also noting that this trial doesn\u2019t answer all of the questions.", "answer": 1}, {"article": "But even when added to previous studies with similar findings, the new conclusions don't necessarily mark a death knell for calcium supplements, say the authors of a study released online April 19 in the BMJ.\nBut, as the current authors point out, more than half of the women in that study were already taking their own calcium supplements on top of what they had been prescribed for the trial, which may have clouded the results.\nIn this case, women who were randomized to take calcium and vitamin D as part of the study protocol had a modest 13 to 22 percent increased risk of cardiovascular problems, particularly heart attacks.\n\"The cautious way forward seems to be to encourage people to obtain their calcium from the diet, rather than from supplements, since food calcium has not been shown to carry this increased risk of heart disease,\" Reid added.\nThe National Osteoporosis Foundation has more on osteoporosis.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a great job explaining why these study findings are an important step in sorting out the role of calcium in heart health while showing that this study alone will not answer all the questions patients might have.\n", "answer": 1}, {"article": "\"Right then, I thought, \u2018Oh, why did I do this?\nHe warns people that there is a risk the implant will not work and that they may need to have it replaced if it stops working.\nBerryhill said the cost of the implant and surgery is in excess of $60,000, but it is covered by most insurance companies as well as Medicare and Medicaid.\nBy the time he was 14, he had lost about 70 percent of his hearing and was wearing hearing aids in both ears.\nNow, he hears the melodies and harmonies just as well as his bandmates.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article doesn\u2019t explain whether this is a new treatment, or provide enough context for a reader to accurately tease out its track record.", "answer": 0}, {"article": "Sept. 14, 2011 -- Low doses of the muscle relaxant cyclobenzaprine, taken at bedtime, help people with fibromyalgia sleep better and feel less pain, according to a small study.\nThe results of the study are published online in The Journal of Rheumatology.\nAbout 5 million Americans have fibromyalgia.\nTONIX is developing a lower-dose version and improving the formula, Lederman says.\nHowever, a rheumatologist not connected to the study does not expect the new drug to be a ''game-changer.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story does report that this drug is already used as a muscle relaxant and that the relatively novel approach is the investigation into the relationship of sleep quality to fibromyalgia symptoms. However, it would have been helpful to also report that some of these same researchers and other have already published the results of larger trials testing drugs that may improve the sleep of people with fibromyalgia.", "answer": 1}, {"article": "When it comes to health, I\u2019m skeptical of willpower. Sure, I talk to my students about personal responsibility, but when it comes to the health of populations, I look for big fixes more than for small acts of will.\n\nThat\u2019s why my ears perked up when I heard that two old physician friends had decided to start taking, as a preventive measure, some of the medications often included in what the field has dubbed the \u201cpolypill.\u201d My friends are both top doctors in their 60s, with good diet and lifestyle, and this is now part of their...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t make untoward claims of novelty and cites previous research on this concept, which provides context. The story could have alerted readers that the concept of a polypill for prevention goes back more than a decade.", "answer": 1}, {"article": "Compared with the 16% of people who didn't drink coffee at all, those who downed two or more cups each day were about 18% less likely to have died during the study period. In addition, those who drank just one to six cups of coffee per week were 12% less likely to die. Both of these figures were calculated after taking into account known risk factors for early death, such as smoking (which is often paired with coffee drinking), diet and body mass index.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear how the National Cancer Institute study extends previous research on coffee\u2019s health effects from studies of mostly white European-descent subjects to a multi-ethnic population.", "answer": 1}, {"article": "Researchers at Georgia State analyzed clinical data from a large cohort of breast cancer patients treated at Northside Hospital in Atlanta from 2005 to 2015.\nThis higher incidence of tumor recurrence can contribute to a poorer prognosis,\" said Nikita Wright, first author of the study and a senior Ph.D. student in Dr. Ritu Aneja's laboratory in Georgia State's Biology Department.\nDespite a similar number of reported cases of breast cancer among African-American and European-American women, African-Americans experience a more aggressive clinical course and a 40 percent higher death rate than European-Americans among premenopausal and menopausal breast cancer patients.\nCo-authors of the study include Jun Xia, Sergey Klimov, Pranay Neema, Dr. Dora Il'yasova, Dr. Padmashree C. G. Rida, Dr. Remus Osan and Dr. Aneja of Georgia State; Dr. Guilherme Cantuaria and Dr. Mildred Jones of the Northside Hospital Cancer Institute; Dr. Uma Krishnamurti, Dr. Xiaoxian (Bill) Li and Dr. Michelle D. Reid of Emory University; and Dr. Meenakshi Gupta of West Georgia Hospitals.\nThe researchers also found that among early stage patients (noninvasive or minimally invasive breast cancer), African-Americans displayed higher tumor recurrence than European-American patients.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release claims novelty with this statement: \u201cThis is the first clinical study to suggest that neoadjuvant chemotherapy (treatment prior to surgery) may improve breast cancer recurrence rates and patterns in African-Americans.\u201d\nTo the best of our knowledge and based on an online search of related studies this is factual. ", "answer": 1}, {"article": "Roslin said limiting grains and sugars reduces insulin surges, which sparks water loss, curbs hunger and can boost energy.\nBut the company said Efron is just one person and that more than 100,000 people have tried and succeeded on the plan, including the beauty director of Essence magazine, Mikki Taylor, who lost nine pounds in seven days.\nThe diets have found popularity in Hollywood, and one of the most Googled detoxes is one consisting of cayenne pepper, syrup and lemon juice, made famous by celebrities like Denise Richards and Beyonce Knowles, who reportedly lost 20 pounds for \"Dreamgirls\" using the detox.\n\"I can't believe how wonderful our bodies are, and when we're good, they really respond,\" she said.\n\"When I'd come home from work, I'd be very tired and have to go take a nap for like an hour and a half,\" Rick said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There was actually no discussion about the history of the products highlighted in this broadcast other than to indicate that they are all the rage. \u00a0Are they new? \u00a0One could not discern this from the segment.", "answer": 0}, {"article": "University of Miami cardiologists last week reported success in a small, preliminary human clinical trial of a new stem cell therapy they hope some day will routinely mend human hearts and reduce the need for lifelong medication, even for transplants.\nThe study shed new light on a question of prime interest to cardiologists: whether the injected stem cells actually transformed themselves into heart muscle, or improved heart function in some other way.\nBy implication, it almost certainly improves the patient's health, although that was not directly measured in the small, early study.\nIn the study, stem cells were taken from the patient's own bone marrow and injected by catheter into scar tissue in the patient's heart caused by an earlier heart attack.\nThe reduction was up to 25 percent, while current therapies including medication and pacemakers typically reduce the size by only about 5 percent, he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story quotes the study author as saying that researchers have been investigating stem cell therapy for the treatment of cardiomyopathy for \u201cclose to a decade,\u201d but to establish the novelty, the story should have explained why this tiny trial was a significant milestone in this field of research.\n", "answer": 0}, {"article": "Khalsa's article highlights the principles and practices of this 12-minute meditation, with corresponding SPECT scans showing how it successfully activates the posterior cingulate gyrus, an important region of the brain that helps regulate memory and emotional function.\n\"We've been studying the impact of meditation on memory for more than 20 years, and are as encouraged as we've ever been on its powerful role in maximizing brain health,\" said Khalsa, president and medical director of the Alzheimer's Research and Prevention Foundation and a clinical associate professor of integrative medicine at the University of New Mexico School of Medicine.\nWhile preliminary studies have suggested a link between meditation, a sense of spirituality or faith and the risk of Alzheimer's disease, the article's author, Dharma Singh Khalsa, M.D., states that a cultivation of higher levels of psycho-social well-being, such as independence, resilience and life purpose represents \"an important new frontier that deserves further research as it is freely available to anyone, anytime, anywhere.\"\nThe article reviews decades of research into the impact that various meditation techniques have had on the prevention of Alzheimer's disease, focusing on one evidence-based practice that Khalsa says can be a powerful part of any Alzheimer's prevention and spiritual fitness program, Kirtan Kriya (KK), a meditation technique which has been successfully used to improve memory in studies of people with subjective cognitive decline and mild cognitive impairment.\nTUCSON, Ariz., July 15, 2015 /PRNewswire/ -- Meditation and spiritual fitness are key components in reducing the risk of Alzheimer's disease according to a new article, \"Stress, Meditation, and Alzheimer's Prevention: Where the Evidence Stands\", published in an early online version of the Journal of Alzheimer's Disease 48(1).\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "We\u2019ll give the benefit of the doubt here. Quoting the study author, the release states, \u201cWe\u2019ve been studying the impact of meditation on memory for more than 20 years, and are as encouraged as we\u2019ve ever been on its powerful role in maximizing brain health.\u201d So the release is not claiming any breakthrough advance, and appropriately suggests that the study is summarizing a body of existing research. The release could have noted that meditation has been around for thousands of years, and that its popularity has spread globally in recent decades. The other aspect worth commenting on is that traditional\u00a0medicine and research is overwhelmingly focusing on a search for drug interventions \u2014 so lifestyle approaches in general are novel.", "answer": 1}, {"article": "\"CCSVI equals hope and a lot of MS patients just are completely devoid of hope,\" Stecker says.\nIt's so seductive, in fact, that Canadians and Americans with MS have been flocking overseas to get the \"liberation procedure.\"\nZamboni calls it \"the liberation procedure\" but it is actually a common technique known as angioplasty when it's used to open clogged arteries \u2014 not veins.\nThese discrepancies, and growing public controversy, prompted the National Multiple Sclerosis Society in the U.S. and the Multiple Sclerosis Society of Canada to take Zamboni's claims seriously.\n\"Even if the treatment is not useful for patients with MS, I don't think that we can abandon the idea of vascular involvement in MS,\" Zivadinov says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story\u00a0tells us that the idea behind the procedure was first proposed in 2008, making the concept quite novel.\u00a0It noted that despite the catchy name, the \u201cliberation procedure\u201d is actually very similar to balloon angioplasty performed regularly on coronary arteries.", "answer": 1}, {"article": "Almost all cases of cervical cancer occur as a result of infection with high risk types of HPV.\nHowever, it's crucial to remember that vaccination must be done before exposure to the virus.\nIn the UK, all girls aged 12 to 13 are offered HPV vaccination as part of the NHS childhood vaccination programme.\nMany people infected with HPV clear it from their systems with no lasting health concerns and some types of the virus are low risk, causing warts or verrucas.\nThe new vaccine, Gardasil 9, is not only safe but will offer greatly improved protection against cervical and other cancers.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes it clear that the study is the first of its kind comparing two types of HPV vaccine.", "answer": 1}, {"article": "Larsson and her colleagues combed through research databases spanning the last 45 years to find studies that tracked how much magnesium people took and how many of them had a stroke over time.\nThose are things that have low sodium, high potassium and high magnesium,\u201d said Larry Goldstein, director of the stroke center at the Duke University Medical Center in Durham, North Carolina.\nBut Larsson told Reuters Health in an email that she could not say whether other aspects of what the people ate partially or entirely explained the finding.\nMost of the studies allowed the researchers to rule out other factors, such as family history.\nOther experts said the results were consistent with dietary recommendations.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear that this study was an analysis of seven studies published in the past 14 years.", "answer": 1}, {"article": "Wolf notes, however, that chemoradiation often severely damages the larynx, which may cause problems with eating or swallowing years later.\nAfter a decade of using this approach, researchers are reporting \"exceptional\" survival rates nearing 80 percent, even for the most advanced patients.\nThe study did find lower functional preservation of the larynx in the induction chemotherapy group compared to those who elected chemoradiation.\nAnd it wasn't just those who responded to the chemotherapy.\nFor the most advanced patients, 50 percent survival was the norm, whether patients had surgery to totally remove the voice box or alternative treatment with chemotherapy and radiation to try to avoid surgery.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes clear what is novel about this approach and lays out the history and development of the approach over the past 10 years. That\u2019s good context.", "answer": 1}, {"article": "ISI Group analyst Mark Schoenebaum said although the vemurafenib results look the most encouraging, the findings are unlikely to make a difference for current sales estimates, since virtually all eligible patients will be treated with both drugs, either in sequence or in combination.\nSide effects included skin rashes and joint pain.\nAbout half of all melanomas have the genetic aberration.\nThe five-year survival rate for the aggressive cancer is just 15 percent.\nAbout 18 percent of patients developed a low-grade skin cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of the two drugs was described.", "answer": 1}, {"article": "Equally important, the response was long-lasting for most patients.\nThe selectivity of the drug means it does not cause the severe side effects associated with many traditional cancer treatments, and none of the patients with TRK fusions had to quit the study because of a drug-induced side effect.\nThe results of the larotrectinib trial in adult patients - a 75 percent response rate - were published last month in the New England Journal of Medicine.\nTo date, the response to this drug seems to be durable in most patients,\" said Dr. Laetsch, who investigates the use of tumor molecular profiling to guide therapy in UT Southwestern's Pediatric Hematology and Oncology Division.\nThe TRK-fusion mutation can be present in many types of cancers, including lung, colon, thyroid, and breast cancer, as well as certain pediatric tumors.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes at least two claims of novelty, calling the drug \u201cA first-of-its-kind drug targeting a fused gene,\u201d and also that \u201cLarotrectinib is the first cancer drug to receive FDA breakthrough therapy designation for patients with a specific fusion of two genes in the cancer cell, no matter what cancer type.\u201d\nAn emerging cancer drug for a cancer with limited treatment options is an important health update.", "answer": 1}, {"article": "Most angioplasties not necessary, study finds\n\nNEW ORLEANS \u2014 More than half a million people a year with chest pain are getting an unnecessary or premature procedure to unclog their arteries because drugs are just as effective, suggests a landmark study that challenges one of the most common practices in heart care.\nA tiny balloon is inflated to flatten the clog and a mesh scaffold stent is usually placed.\nAbout 40 percent had a prior heart attack.\nAbout 1.2 million angioplasties are done in the United States each year.\nThey had an average of 10 chest pain episodes a week \u2014 moderately severe.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The treatments reported on were not new and were not presented as being new.", "answer": 1}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\n\"The strategy of direct referral to invasive coronary angiography without noninvasive imaging is obsolete,\" Dr. Kaufmann said.\nThey are also looking at what they call \"triple hybrid\" imaging, which combines the CCTA/SPECT hybrid with information on coronary artery shear stress.\nThe approach has shown promise in studies focusing on short-term observations, but information is lacking on long-term outcomes.\nInvasive coronary angiography (ICA) is considered the gold standard for determining the percent of stenosis, or narrowing, due to plaque in a coronary artery.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The point of the study, according to the news release, is to determine whether the hybrid approach is useful for predicting long-term cardiac outcomes.", "answer": 1}, {"article": "The primary efficacy analysis of study 305 demonstrated that SHP465, administered as a daily morning dose, was superior to placebo on the change from baseline in ADHD-RS-IV (ADHD rating scale) total score, with a Least Squares (LS) mean difference from placebo at Week 4 of -9.9 (95% CI: -13.0 to -6.8, p<0.001), suggesting a significant improvement in ADHD symptoms.\nWe focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.\nIncluding study 305 and previous studies, Shire now has a robust database of 15 clinical studies evaluating SHP465 in more than 1,100 subjects.\nDr. Matthew Brams, M.D., Clinical Assistant Professor at Baylor College of Medicine and principal investigator for study 305, added: \"The study of SHP465 in children and adolescents is an essential next step to progressing the clinical program.\nThere are patents supporting Shire's overall ADHD franchise in the U.S. that extend to 2029.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It is unclear from this news release if the drug is novel and if so in what way. It is an amphetamine drug and others like it are already in use.", "answer": 0}, {"article": "But the triggers are different for different people.\nThere is just no single reason why people get chronic headaches, although we do know that migraines have a genetic component and usually a trigger.\n\"If you are a migraine sufferer and I expose you to the right trigger, you're going to have a migraine,\" Bernstein says.\n\"The majority of them have really been suffering a number of years and they're really miserable with the pain,\" Bernstein says.\n\"\n\nAnd while an informed patient is a good thing, Mafi says sometimes the patient gets it wrong.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Studies and articles documenting over-use of tests and their lack of benefit for specific diseases are still few in number. However, the story does not establish that fact or address the novelty of this line of research. Nor does it establish that the evidence presented about the efficacy of lifestyle changes for treating migraines is or isn\u2019t novel.", "answer": 0}, {"article": "\"The interesting thing about the Safety Planning Intervention is that it is a relatively brief intervention and can be used in a lot of different [health care] settings,\" says Brian Ahmedani, director of behavioral health research at the Henry Ford Health System in Detroit, who wasn't involved in the new study.\nThis is the first large-scale study of the Safety Planning Intervention, which Stanley and her group developed in 2008 and which has been adopted at hospitals and clinics around the country.\nAs part of the 2012 National Strategy For Suicide Prevention, many health care providers have adopted the approaches to prevention outlined in the Zero Suicide Initiative, which includes safety planning based on previous evidence showing it works.\nIf people contemplating suicide can distract themselves with something they enjoy doing, they can bypass that narrow window during which suicidal thoughts can overpower them, notes Stanley.\n\"It is a brief intervention that hospital workers, primary care staff, outpatient behavioral health, can all be trained in to utilize,\" she says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is the first large-scale test of the SPI intervention, so even though it is already being used in many emergency departments, the evidence for effectiveness is new.", "answer": 1}, {"article": "Infection rates dropped by 90% in patients who consistently used PrEP.\n\"It is clear we are not going to find one magic pill to solve the issue of HIV but by combining this approach with others we are beginning to get a better handle on combination packages.\nThe study, called TDF2, followed 1,200 uninfected heterosexual men and women between the ages of 18 and 39 years in Botswana, Africa.\n\u201cWe are in a critical moment in HIV prevention research,\u201d said Robert Grant, M.D., M.P.H, of the Gladstone Institutes and the University of California at San Francisco.\nThe news comes at the same time a second study looking at PrEP in heterosexual couples in Kenya and Uganda also found significant reductions in infection rates.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions earlier research showing that Truvada was effective for preventing HIV infections in men who have sex with other men. However, it did not reference the\u00a0results of a large study showing that Truvada failed to prevent HIV infections in heterosexual African women \u2014\u00a0findings that remain somewhat\u00a0of a mystery. The story could have done better here, but since it does not\u00a0give readers the impression that these are\u00a0completely\u00a0novel or unexpected results, we\u2019ll call it satisfactory.", "answer": 1}, {"article": "Bone-health experts are making a new push to reduce rates of osteoporosis, with a particular focus on controlling the bone-wasting disease in men.\n\nAn important goal is to get greater numbers of men to be tested for osteoporosis when they come to a hospital or clinic with a fracture to the wrist, vertebrae or other bones that wasn\u2019t from a major accident or trauma. Doctors call this a fragility fracture\u2014one that results from a decrease in bone density.", "question": "Does the story establish the true novelty of the approach?", "explanation": "What\u2019s new here is the recent push to improve osteoporosis treatment in men, sparked in part by the study referenced in this story. The article is clear about this.", "answer": 1}, {"article": "\"In Europe, we have been reluctant to recommend that all men get PSA testing as we have felt that there has been a lack of knowledge,\" agreed lead researcher Dr. Jonas Hugosson, a professor of urology at the University of Gothenburg.\n\"We need better tests that identify more accurately those men destined to develop problems in the future from this disease,\" he said.\nIn addition, men in the screened group were more likely to have their cancer diagnosed while it was in an early stage.\nFor men at high risk for the disease -- blacks and men who have a father, brother or son found to have prostate cancer at an early age (before 65) -- that discussion should start at age 45.\nThat's because if their prostate tumor is not aggressive they are more likely to die from the other, more serious conditions, he explained.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story accurately reflected that PSA testing for prostate cancer is not new and that there has been an on-going debate about the benefit of PSA screening.", "answer": 1}, {"article": "The page you are looking for has moved. Please go to the main EurekAlert! homepage to locate the section you are interested in and reset your bookmarks.\n\nFor further assistance, please contact webmaster@eurekalert.org.", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Existing research into screening for AD (in particular Abeta42), and the impact of NSAIDs on the disease are not mentioned. This leaves the reader with no idea regarding how novel this approach is or is not.\n\u00a0", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061008/16organ.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains when the first paired organ donation took place, letting readers know this is not \u201cnew,\u201d per se, although a national policy allowing widespread paired organ donation would be new. ", "answer": 1}, {"article": "Therefore, despite pancreatic cancer representing less than 3% of all cancer cases, more people currently die from it than breast cancer.\nThere is currently no cure and few treatment options for advanced pancreatic cancer, which is the late stage when pancreatic cancer is usually diagnosed\", explains Carl Borrebaeck, professor at the department of Immunotechnology at Lund University.\nA new blood test developed by researchers at Lund University in Sweden, Herlev Hospital, Knight Cancer Center and Immunovia AB, can detect pancreatic cancer in the very earliest stages of the disease.\nIn the future, the screening method could be used to screen people who are at a higher risk of developing pancreatic cancer, such as those with a hereditary risk, newly onset diabetes patients and patients with chronic inflammation of the pancreas.\nThe next step has already been initiated, which is a large US prospective study for high risk individuals.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t specifically claim novelty, nor should it based on this very preliminary research.\nThere are currently two other blood tests that are marginally useful (when taken in the context of other tests) in helping to diagnose pancreatic cancer or monitor treatment: CA 19-9 and CEA.\nThere are no other existing blood tests that are routinely used by oncologists to diagnose pancreatic cancer.", "answer": 2}, {"article": "NEW YORK -- Scientists acknowledged that an HIV vaccine recently tested in Thailand may be less effective than they originally suggested, but said it still provided valuable leads for further research.\n\nWhen first publicly disclosing the outcome of the vaccine trial in September, researchers said the vaccine had lowered the risk of infection by about 31%. That result was modest but statistically significant. Coming after two decades of failed HIV-vaccine trials, the announcement was welcomed by researchers around the world.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that researchers have been working on an AIDS vaccine for decades.", "answer": 1}, {"article": "Such an analysis is months away.\nAnd they pointed out that the study offers no reassurance about the safety of smoking or the advisability of CT scans for younger smokers or nonsmokers.\nThese false signals generally led to more worry, more CT scans and sometimes to lung biopsies and thoracic surgery.\n\u201cWhat we also have found is that low-dose CT scan gives information on cardiovascular disease, emphysema\u201d and other pulmonary diseases, Dr. Henschke said.\n\u201cNo one should come away from this thinking that it\u2019s now safe to continue to smoke,\u201d said Dr. Harold E. Varmus, director of the National Cancer Institute.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story recaps some of the history of research on screening for lung cancer and quotes one of the researchers saying, \u201cThis is the first time that we have seen clear evidence of a significant reduction in lung cancer mortality with a screening test in a randomized controlled trial.\u201d", "answer": 1}, {"article": "This study will be presented at a medical conference.\n\"This is the first study in humans to examine the association between flavonoids and risk of developing Parkinson's disease ,\" says researcher Xiang Gao, MD, PhD, of the Harvard School of Public Health in Boston, in a news release.\nBut when researchers looked at specific sub-groups of flavonoids, they found both men and women who ate the most foods rich in anthocyanins, which are found primarily in berries and apples, had a 22% lower risk of Parkinson\u2019s disease compared to those who ate the least.\nThe results showed that men who ate the most foods rich in flavonoids had a 35% lower risk of Parkinson\u2019s disease compared with those who ate the least.\nA new study shows men who ate the most foods rich in a group of antioxidants known as flavonoids were 35% less likely to develop Parkinson\u2019s disease than those who ate the least.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story allows the researcher to claim that \u201cthis is the first study in humans to examine\u201d this association.\u00a0 We don\u2019t know whether that\u2019s true or not.\u00a0 And the story didn\u2019t provide any independent perspective to reflect on whether this is novel or not. But there\u2019s been a lot of other flavonoid research which the story could have at least mentioned.\u00a0 From this story, one might assume that this is the first study that\u2019s ever recognized flavonoids.", "answer": 0}, {"article": "It worked.\nIt\u2019s not clear why, but viruses can also make tumors more visible to the immune system.\nThe medical team used polio viruses already weakened and altered for use in polio vaccines, and genetically engineered them to carry parts of a common cold virus, called a rhinovirus, known to be attracted to glioma cells.\nIt\u2019s no miracle cure \u2014 only about 20 percent of patients with gliomas were helped \u2014 but some are alive six years later, the team reported in the New England Journal of Medicine.\n\u201cWe inject the virus directly into brain tumors and it kills all the tumor cells it comes in contact with,\u201d Bigner said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story made it sound like this was a new concept, but this research has been dancing in and out of the sensational spotlight for years.", "answer": 0}, {"article": "Servan-Schreiber offered more words of wisdom to LaPook -- words he says doctors rarely impart to their patients -- and LaPook discussed with co-anchor Harry Smith on The Early Show Friday why he thinks it is that cancer survivors aren't offered more guidance by the medical establishment:\n\nServan-Schreiber appears in the joint CBS, NBC, ABC special \"Standing Up To Cancer\" Friday night.\nLive your life like you always did.'\nTo read an excerpt, click here.\nThen, he discovered in one of his own brain scanner experiments that he -- had brain cancer.\n\"Help it with the right nutrition, with physical exercise, with managing stress better, and avoiding contaminants that feed cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "A healthy diet is clearly not a new idea.", "answer": 1}, {"article": "Newswise \u2014 WINSTON-SALEM, N.C. \u2013 Sept. 28, 2016 \u2013 Hot flashes \u2013 the bane of existence for many women during menopause \u2013 can be reduced in frequency by almost half for about 50 percent of women over eight weeks of acupuncture treatment, according to scientists at Wake Forest Baptist Medical Center.\nWomen who had a reduction in their hot flashes saw a benefit beginning after about three to four weeks of weekly treatments.\u201d\n\nThe National Institutes of Health-funded study was designed to examine different patterns of responses to acupuncture.\n\u201cWomen bothered by hot flashes and night sweats may want to give acupuncture a try as a relatively low-cost, low-risk treatment,\u201d said Nancy Avis, Ph.D., lead author of the study and professor of Public Health Sciences at Wake Forest School of Medicine, a part of Wake Forest Baptist.\nOf the 170 women who received acupuncture, a small group of women (11.9 percent) had an 85 percent reduction in hot flashes by the eighth week of the study, Avis said.\nIn a study published in the Sept. 28 issue of the journal Menopause, scientists reported that about half the women in the study reduced the frequency of hot flashes, while half did not.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "On first reading this release, we wondered why no one had studied the use of acupuncture to reduce hot flashes in the past. A quick internet search found that it had. As in this study, or this one, or this one, or this one (and there are quite a few more). These studies are all over the map in terms of positive and negative findings. The release\u2019s failure to address the existing literature on this subject makes it impossible to place the new study\u2019s findings in context. How, if at all, does this research differ from all of the previous work done on the use of acupuncture to address hot flashes?", "answer": 0}, {"article": "Two studies published Tuesday lend support to controversial new cholesterol guidelines that could vastly increase the number of Americans advised to take cholesterol-lowering drugs called statins.\nOne study suggests that the new guidelines are better at identifying who is truly at risk of a heart attack and should be given statins than the older guidelines are.\nBut they could help dispel some of the criticism of the new guidelines and strengthen the position of those who contend treatment should be extended to more people.\nThe other suggests that treating people based on the new guidelines would be cost-effective, even with the tremendously increased use of statins.\nThe new studies are not large clinical trials that will definitively settle the matter of whether to expand drug treatment to millions more people in hopes of preventing cardiovascular disease, the leading killer of Americans.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story established that the findings of the studies were not novel but rather were in keeping with earlier findings about statins.", "answer": 1}, {"article": "A drug derived from this bushy sea creature showed modest, preliminary promise as an Alzheimer's treatment.\n\nIn small Alzheimer\u2019s study, hints of modest benefit from unusual drug\n\nA little-known drug company announced modestly encouraging results for its experimental Alzheimer\u2019s drug on Monday, a rare but still preliminary glimmer of hope in a field that has been battered by failure after failure.\n\nA mid-stage study by a tiny company wouldn\u2019t usually attract much attention, but the results unveiled by Neurotrope BioScience have been eagerly anticipated because its drug \u2014 derived from a bushy, hermaphroditic sea creature \u2014 takes a novel approach.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The piece does a good job of describing how this drug is working in a different way than existing medicines and other drugs undergoing clinical evaluation. And how the patients being studied have far more advanced disease than most clinical trial participants.", "answer": 1}, {"article": "Turner says the findings don\u2019t suggest that red wine is a cure for Alzheimer\u2019s.\nI think resveratrol is an engaging target that\u2019s very interesting and could be pharmacologically manipulated to develop a treatment.\u201d\n\nMORE: Red Wine Not That Healthy After All, Study Shows\n\nThe resveratrol group showed no change in the levels of a protein that builds up in the brains of Alzheimer\u2019s patients.\nIn what the authors describe as the largest and longest study of resveratrol in people with mild to moderate Alzheimer\u2019s disease, there\u2019s encouraging news that the component, which is found in red wine, grapes and dark chocolate, may keep the disease from progressing.\nThe amounts of resveratrol in the purified doses that the participants took were extremely high and beyond those found on the market currently \u2014 around what would be contained in about 1,000 bottles of red wine.\nWe need more studies to see if it really does have benefit and then it could be turned into more effective drugs that can better target Alzheimer\u2019s.\u201d\n\nCorrection: The original version of this story misstated that all the participants were men.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This study is, as the story notes, \u201cthe largest and longest study of resveratrol in people with mild to moderate Alzheimer\u2019s disease.\u201d We\u2019ll rate the story Satisfactory for that reason, but we wished for additional context. A quick internet search turned up dozens of other studies on resveratrol and Alzheimer\u2019s \u2014 and a quick paragraph on what those other studies have told us would have been both interesting and useful.", "answer": 0}, {"article": "TUESDAY, Aug. 2, 2011 (HealthDay News) -- There's still no cure for the common cold, but there may be a way to shorten its misery: A new study suggests that higher doses of zinc lozenges in certain formulations may cut the length of colds by more than 40 percent.\nAllowing the lozenge to dissolve instead of swallowing it seemed to provide a therapeutic effect.\nThe U.S. National Library of Medicine has more about the common cold.\nDespite the popularity of zinc supplements, controversy over their effectiveness has continued since a much-publicized 1984 study first suggested a cold-limiting effect.\nSince then, more than a dozen studies have been carried out, but data on the trace mineral's effectiveness has been mixed.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There is nothing novel about zinc lozenges as an over-the-counter aid for cold symptoms. The story is about research reviewing previously published articles on the use of zinc lozenges.", "answer": 1}, {"article": "Migraines are throbbing, one-sided headaches that can be accompanied by nausea as well as sensitivity to light, sound, smell, and movement.\nThey found that injecting the peptide into the blood of people prone to migraines triggers migraine-like headaches, whereas people not prone to migraines experienced, at most, mild pain.\nIn women of childbearing age, who are the ones most prone to frequent migraines, \"you can imagine that might have effects on fertility or placental function.\"\n\"In a field where, over time, the progress and pace of research in understanding the underlying biology and mechanism of disease has been slow, this was very exciting,\" he says.\nThe new therapies are based on research begun in the 1980s showing that people in the throes of a migraine attack have high levels of a protein called calcitonin gene\u2013related peptide, or CGRP, in their blood.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The lead states \u201cthere isn\u2019t a drug on the market today that prevents (migraines) by targeting the underlying cause.\u201d", "answer": 1}, {"article": "Although the data, which covered breast cancer patients who were treated at M.D.\nSpeaking at the teleconference, Dr. Jennifer Obel, chair of the American Society of Clinical Oncology's communications committee, said: \"This study adds to our knowledge of mammogram performance in this age group.\nTo further stir the pot, a Norwegian study released last week found that routine mammograms accounted for only about one-third of the decline in breast cancer death rates seen recently.\nThe findings will no doubt do little to quell a controversy that has existed since the 1980s over the value of mammography screenings for women in their 40s.\nThat recommendation met with outrage from breast cancer specialists, while other organizations, including the American Cancer Society, continued to recommend annual mammograms for women in their 40s.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story just didn\u2019t capture what was new and different and noteworthy about the way in which this research was done.\u00a0 Someone who\u2019s not a journalist, Dr. Len Lichtenfeld of the American Cancer Society, still captured the \"novelty\"\u00a0of the research succintly on his blog. He began his explanation, \"There is a bit of a twist in the study which is important to understand.\"\u00a0 Indeed, you can read more about what\u2019s important to understand and why on Dr. Len\u2019s blog, because it wasn\u2019t provided in this story.\u00a0 The answer gets at the heart of the methodology used \u2013 and whether it renders the research strong or questionable. ", "answer": 0}, {"article": "Harvard T.H.\n\"From many other studies we know that breast tissue is particularly influenced by carcinogens and anticarcinogens during childhood and adolescence,\" said Walter Willett, Fredrick John Stare Professor of Epidemiology and Nutrition at Harvard Chan School and senior author of the study.\n\"This work on the role of nutrition in early life and breast cancer incidence suggests one of the very few potentially modifiable risk factors for premenopausal breast cancer.\"\n\"Previous studies of fiber intake and breast cancer have almost all been non-significant, and none of them examined diet during adolescence or early adulthood, a period when breast cancer risk factors appear to be particularly important,\" said Maryam Farvid, visiting scientist at Harvard Chan School and lead author of the study.\n\"We now have evidence that what we feed our children during this period of life is also an important factor in future cancer risk.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release suggests that this is the first analysis of how adolescent diet affects future risk for developing breast cancer. It states that previous studies on dietary fiber and breast cancer have not looked at diet during adolescence or early adulthood. \u201cThis work on the role of nutrition in early life and breast cancer incidence suggests one of the very few potentially modifiable risk factors for premenopausal breast cancer,\u201d according to lead author Maryam Farvid.", "answer": 1}, {"article": "[5] UK Biobank http://www.\nThe results allow researchers to compare the predictive ability of a large number of health-related risk factors which were formerly studied separately and using different populations, although the predictive ability of risk factors does not necessarily imply they are causally related to the risk of dying.\nThe score, which uses measures that can be obtained by simple questionnaires without any need for physical examination, such as self-rated health and usual walking speed, could be used by individuals to improve awareness of their health status, and by doctors to identify high-risk individuals for further treatment, say the authors.\nUsing these findings, the researchers then developed an easy-to-calculate risk score for an individual's risk of dying in the next 5 years, based on the most predictive self-reported information, including 13 questions for men and 11 for women.\nAccording to study co-author Dr Ganna, \"The fact that the score can be measured online in a brief questionnaire, without any need for lab tests or physical examination, is an exciting development.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release is explicit about the novelty of the approach to prediction, as well as regarding the scale of the study itself. We suspect it is correct in this assessment, as the epidemiological study on which the work is based is truly huge.", "answer": 1}, {"article": "\"Apixaban is now the first oral anticoagulant [blood thinner] to show a statistically significant improvement in survival over warfarin in atrial fibrillation patients,\" Fonarow said.\nAnother similar drug, Pradaxa (dabigatran), has been on the market for about a year and many patients with atrial fibrillation have been switched or started on it, he said.\nThe new trial comes on the heels of another study on apixaban that was stopped early due to safety concerns.\n\"This represents a very important therapeutic advance in the care of patients with atrial fibrillation.\"\nFor the trial, more than 18,000 patients with atrial fibrillation and a heightened risk for stroke were randomly assigned to receive either apixaban or warfarin.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear that there is already a similar type of drug that has recently been approved for use by the FDA.", "answer": 1}, {"article": "The drug used in the study was manufactured by Organix Inc. in Woburn, Mass.\nHe also says \u201cPsilocybin therapy may not work for everyone, and some groups, such as people with schizophrenia, as well as adolescents, should not be treated with it.\u201d\n\nBoth the NYU Langone and Johns Hopkins studies were principally funded by the Heffter Research Institute, a non-profit, scientific institution with the principal mission of helping to design, review and fund studies on the use of psilocybin for a wide range of ailments (Ross previously served as a board member).\n\u201cAnd if it\u2019s true for cancer care, then it could apply to other stressful medical conditions.\u201d\n\nBossis cautions that patients should not consume psilocybin on their own or without supervision by a physician and a trained counselor.\n\u201cOur results represent the strongest evidence to date of a clinical benefit from psilocybin therapy, with the potential to transform care for patients with cancer-related psychological distress,\u201d says study lead investigator Stephen Ross, MD, director of substance abuse services in the Department of Psychiatry at NYU Langone.\n\u201cIf larger clinical trials prove successful, then we could ultimately have available a safe, effective, and inexpensive medication \u2014 dispensed under strict control \u2014 to alleviate the distress that increases suicide rates among cancer patients,\u201d says Ross, also an associate professor of psychiatry at NYU School of Medicine.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does a good job here, in two ways. First, it notes that this study (presumably in conjunction with the one from Johns Hopkins) provides \u201cthe strongest evidence to date of a clinical benefit from psilocybin therapy.\u201d That\u2019s important context. Second, the release states that psilocybin \u201chas been studied for decades and has an established safety profile.\u201d Again, that\u2019s important context. These points earn it a satisfactory rating. That said, we would like to have seen how this work compares to previous research done specifically on the use of psilocybin to treat anxiety in cancer patients \u2014 such as this 2007 study, this one from 2011, or this one from 2013. We don\u2019t necessarily expect an exhaustive comparison, but the release would have been stronger if there had been some acknowledgment that other work has been done in this field over the past 10 years. More specifically, it would have been nice to see a sentence or two highlighting how the new findings are similar to, or different from, the existing body of work in the field.", "answer": 1}, {"article": "The blisters heal in a week or two to form crusty scabs that eventually fall off.\nAnother difference is that Zostavax contains a live, weakened virus, making it unsuitable for people with poor immunity, whereas Shingrix contains a nonliving virus particle and may eventually be approved for those with compromised immunity, who are especially susceptible to a severe case of shingles.\nWhat makes Shingrix so much better is the inclusion of a substance called an adjuvant that boosts the body\u2019s immune response to the vaccine.\nThe shot itself is painful and can cause a sore arm for a day or two.\nIf you\u2019re lucky you may detect the onset of shingles before the rash appears.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes novelty in this way:\u00a0\u201cstudies involving 16,600 people showed it to be far more effective at preventing this disease than the first shingles vaccine, Zostavax, which I had had a decade earlier.\u201d", "answer": 1}, {"article": "\"A lot of the time, people have quite painful and challenging experiences revisiting the trauma, and [MDMA] can help them do it without being overwhelmed or numbed out,\" he says.\nOn two separate occasions, 12 of the people took a dose of MDMA and then spoke for several hours with a pair of trained therapists.\nThe study was funded by the Multidisciplinary Association for Psychedelic Studies, a California-based nonprofit organization that also sponsors research on medical marijuana and psychedelic drugs such as LSD and psilocybin.\nBy contrast, just two of the eight people in the placebo group experienced a substantial improvement in their symptoms.\nAnd when purchased on the street it can be contaminated.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "At least the story stated, \"This was the first clinical trial to explore the therapeutic potential of MDMA since the drug was outlawed in 1985.\" ", "answer": 1}, {"article": "\u201cThis collaborative venue enabled two then-residents [Drs.\n\u201cSestamibi SPECT/CT offers an inexpensive and widely available means of better characterizing kidney tumors, and the identical test is now being performed as part of a large trial in Sweden, for which the first results have just recently been published and appear to confirm our conclusions.\u201d\n\nAlthough further study is needed to validate the accuracy of sestamibi SPECT/CT, this test appears to be a less expensive, faster, noninvasive alternative to surgery, says Michael A. Gorin, M.D., the other resident involved in developing this approach and now chief resident with The James Buchanan Brady Urological Institute of the Johns Hopkins University School of Medicine.\nThese results are hugely encouraging, but we need to do more studies.\u201d\n\nFor this study, 48 patients who were diagnosed with a kidney tumor on conventional CT or MRI were imaged with sestamibi SPECT/CT at Johns Hopkins prior to surgery.\n\u201cSestamibi SPECT/CT lets radiologists and urologists \u2018see\u2019 the most common benign kidney tumor, something CT and MRI have not succeeded in doing alone,\u201d says Mohamad E. Allaf, M.D., MEA Endowed Professor of Urology at the Johns Hopkins University School of Medicine.\n\u201cIn the absence of diagnostic certainty, surgeons tend to remove kidney tumors in an abundance of caution, leading to an estimated 5,600 surgically removed benign kidney tumors each year in the United States.\u201d\n\nOther authors on this paper include, Sara Sheikhbahaei, Christopher S. Jones, Kristin K. Porter, Alex S. Baras, Phillip M. Pierorazio, Mark W. Ball, Lilja B. Solnes, Jonathan I. Epstein, and Mehrbod S. Javadi, all of the Johns Hopkins University School of Medicine, and Takahiro Higuchi of Wurzburg University in Germany.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that radiologists at Johns Hopkins designed the approach of combining sestamibi SPECT/CT with CT or MRI to improve diagnostic accuracy in kidney tumors.\nSestamibi SPECT/CT itself is not new. It is the standard imaging choice for assessing problems with the parathyroid glands, which are adjacent to the thyroid gland.", "answer": 1}, {"article": "This data can be sent to a mobile phone.\n\"The rate of false positive and false negative diagnosis that breath tests give is a real problem in gastroenterology,\" Berean, who is also Chief Technology Officer at Atmo Bioscience, said.\n\"This gives us confidence that our new technology could potentially solve many mysteries of the gut and help the large portion of the population who have not been able to find a useful diagnosis or treatment for their symptoms,\" Kalantar-zadeh said.\nThe findings show the revolutionary gas-sensing capsule developed by researchers at RMIT University in Melbourne, Australia, could surpass breath testing as the benchmark for diagnosing gut disorders, paving the way to solving previously undiagnosed conditions.\nStudy lead and capsule co-inventor Professor Kourosh Kalantar-zadeh said the results showed high sensitivity and signal-to-noise ratio in measuring the concentration of intestinal hydrogen, providing valuable information at the site of intestinal gas production.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It\u2019s unclear from the news release if this is the first time this sort of capsule has been used for this particular purpose.\nHowever, this article from MIT suggests swallowable technology has been investigated since at least 2006.", "answer": 0}, {"article": "\"Three year follow-up results of photodynamic therapy versus imiquimod versus fluorouracil for treatment of superficial basal cell carcinoma: a single blind, noninferiority, randomized controlled trial,\" by Marieke H. Roozeboom, MD, Aimee H.M.M.\n\"Throughout the last two decades there has been a growing interest in these non-surgical therapies, which offer the possibility of avoiding surgery and reducing demands on busy medical practices.\"\nHowever, prior to this study there has been a lack of randomized controlled trials with a long-term follow-up that compare the effectiveness of noninvasive treatments.\nThe prognosis is excellent, but it can cause significant disfigurement by invading surrounding tissues.\nHowever, between one- and three-year follow-up, more recurrences were diagnosed in the fluorouracil group compared with the imiquimod group.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that this is the first study to look at long-term outcomes from use of ointments for superficial skin cancers.", "answer": 1}, {"article": "TUHS neither provides nor controls the provision of health care.\nTo recapitulate the clinical situation of dementia in humans, in which patients are already symptomatic by the time they are diagnosed, Dr. Pratic\u00f2 and colleagues used specially engineered tau transgenic mice, which develop tau pathology - characterized by neurofibrillary tangles, disrupted synapses (the junctions between neurons that allow them to communicate with one another), and declines in memory and learning ability - as they age.\n\"We show that we can intervene after disease is established and pharmacologically rescue mice that have tau-induced memory deficits,\" explained senior investigator Domenico Pratic\u00f2, MD, Scott Richards North Star Foundation Chair for Alzheimer's Research, Professor in the Departments of Pharmacology and Microbiology, and Director of the Alzheimer's Center at Temple at LKSOM.\nThey show, for the first time in an animal model, that tau pathology - the second-most important lesion in the brain in patients with Alzheimer's disease - can be reversed by a drug.\n\"At the onset of dementia, leukotrienes attempt to protect nerve cells, but over the long term, they cause damage,\" Dr. Pratic\u00f2 said.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release could have been improved if it noted that the current research is an extension of work done by these researchers. \u00a0A 2013 publication in PLOS Medicine previously demonstrated cognitive improvements in mice treated with zileutin and alterations in levels of tau. The suggestion that this was a breakthrough seems a bit of a stretch given their previous work.", "answer": 0}, {"article": "The results, published in March in the New England Journal of Medicine, have been promoted by the drugmaker, Ireland-based Alkermes, as it markets Vivitrol to U.S. correctional systems.\nIn some programs, prisoners get an injection before release, then follow-up shots from any clinic.\nThe federal Bureau of Prisons ran a field trial in Texas and plans to expand the program to the Northeast next year.\nWhen the injections stopped, many in the study relapsed.\nMany experts view prisons \u2014 where addiction\u2019s human toll can be seen most clearly \u2014 as a natural place to discover what works.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is a trend story looking at the use of this drug among prison populations (and the recently incarcerated).", "answer": 2}, {"article": "While the value of CT scans for screening remains the focus of debate, no one questions the value of the tests for allowing doctors to quickly diagnose a wide variety of health problems, including head injuries, heart problems, cancer, appendicitis, fractures and gallstones.\nThe use of CT scans is expected to continue to rise as possible new applications, such as for lung and colon cancer screening, become more widespread.\nThere are many reasons for the increase, including improvements in the technology that have speeded the procedure, a growing list of uses and a proliferation of the machines.\nThe upsurge in CT use has fueled a big jump in the annual amount of radiation that each American is receiving from medical procedures of all kinds.\nBecause it would take decades to follow a large number of patients who have undergone CT scans to determine the exact risks posed by the exams, there are no direct data demonstrating the danger.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly describes that CT scanning is not a new idea but the story speculates that it is being overused with many new indications and uses that may be unnecessary.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070506/14healthwatch.lede.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does point out that this treatment represents a novel way of treating osteoporosis.", "answer": 1}, {"article": "One such tool is called a CT chest scan, which produces detailed images with high-dose x-rays and is being used in millions of patients every year in the U.S.\nThe new findings add to other evidence showing that medical testing is on the rise across the U.S., although in many cases the impact on overall health remains unclear.\nNEW YORK (Reuters Health) - U.S. researchers say they have found clear signs that blood clots in the lungs are being overdiagnosed, exposing patients to potentially dangerous side effects from unnecessary drugs.\nThe number of deaths caused by the condition dropped only little, however: from 12.3 per 100,000 in 1998 to 11.9 per 100,000 in 2006.\nAccording to the new results, such complications rose from three to five per 100,000 people hospitalized with PE per year after doctors began using chest CT scans.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of the new analysis was clear from the story. It stated: \u201cThe new findings add to other evidence showing that medical testing is on the rise across the U.S., although in many cases the impact on overall health remains unclear.\u201d\n", "answer": 1}, {"article": "\"There are a lot of pundits who remain skeptical or feel we need to research this ad infinitum before it's ready, which doesn't make sense to me,\" Feifel says.\nAnd in 2006, a team from the National Institute of Mental Health published a landmark study showing that a single intravenous dose of ketamine produced \"robust and rapid antidepressant effects\" within a couple of hours.\n\"If there was even a 1 percent chance that this worked, it would have been worth it to me,\" he says.\nAnd ketamine's safety record is so good that it's often the painkiller of choice for children who arrive in the emergency room with a broken bone.\n\"It became clear to me that the future of psychiatry was going to include ketamine or derivatives of ketamine,\" says David Feifel, a professor of psychiatry at the University of California, San Diego, who began administering the drug to patients in 2010.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that the key study it mentions was published almost a decade ago. And it suggests that the recent surge in clinics that are offering this treatment makes the story worthy of coverage now.", "answer": 1}, {"article": "Buck scientists strive to discover new ways of detecting, preventing and treating age-related diseases such as Alzheimer\u2019s and Parkinson\u2019s, cancer, cardiovascular disease, macular degeneration, osteoporosis, diabetes and stroke.\n\u201cWe think addressing multiple targets within the molecular network may be additive, or even synergistic, and that such a combinatorial approach may enhance drug candidate performance, as well.\u201d\n\nWhile encouraged by the results of the study, Bredesen admits more needs to be done.\n\u201cFollow up testing showed some of the patients going from abnormal to normal.\u201d\n\nOne of the more striking cases involved a 66-year old professional man whose neuropsychological testing was compatible with a diagnoses of MCI and whose PET scan showed reduced glucose utilization indicative of AD.\n\u201cEven though we see the far-reaching implications of this success, we also realize that this is a very small study that needs to be replicated in larger numbers at various sites.\u201d Plans for larger studies are underway.\nNow we\u2019re recommending that people find out their genetic status as early as possible so they can go on prevention.\u201d Sixty-five percent of the Alzheimer\u2019s cases in this country involve APOE4; with seven million people carrying two copies of the ApoE4 allele.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release claims that the research \u201cis the first to objectively show that memory loss in patients can be reversed, and improvement sustained\u201d using the complex protocol. We rate this unsatisfactory since the release implies throughout that the protocol can reverse memory loss in Alzheimer\u2019s patients when that is not indicated by the limited evidence.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070520/28healthwatch.lede.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not mention whether the observation that excessive vitamin consumption is associated with increased prostate cancer risk was new or not.", "answer": 0}, {"article": "Researchers found that even though people on the FOLFIRINOX had a longer average survival rate of 11.1 months, versus the gemcitabine group with 6.8 months, the quality of life for patients on FOLFIRINOX was not as good.\nThe purpose of the study was to record the overall survival rates of each group.\nFor most patients, the prognosis is grim.\nPart of the group was given gemcitabine, the most favored treatment according to oncologists.\nOnly about 6 percent of those with the diagnosis live longer than five years.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of Folfirinox was never established or explained.", "answer": 0}, {"article": "All of these study participants \u2014 largely people in their 70s, all with a diagnosis of either \"mild cognitive impairment\" or atypical dementia \u2014 are living with the unconfirmed suspicion that they have Alzheimer's. The study is underwritten by the Centers for Medicare & Medicaid Services and the Alzheimer's Assn. It set out to find out whether knowing \u2014 getting the costly test that would offer either confirmation or reprieve \u2014 would change the way that patients with cognitive troubles are treated, or the way that they plan their lives.", "question": "Does the story establish the true novelty of the approach?", "explanation": "This isn\u2019t a new area of research\u2013we reviewed a Wall Street Journal story on nearly an identical topic more than 10 years ago. This LA Times story could have made that more clear, and talked about how this newer effort adds (or doesn\u2019t) to what\u2019s already known.", "answer": 0}, {"article": "Give these a click:\n\nPersonalized cancer vaccines have already helped treat three patients\n\nSmartwatches might cause cancer, says article based on \u2018expert\u2019 who pushes holistic breast cancer treatments\n\nSun damage keeps happening even after you go inside, new study says\nA modified version of the Herpes Simplex 1 virus (known for causing cold sores and some cases of genital herpes) called T-Vec has successfully been used to treat melanoma in a phase III clinical trial.\nBut cancer therapies like the one described in the new paper take things a step further, manipulating existing viruses to turn them into cancer-fighting tools.\nBut there's more work to be done to determine just how T-VEC can fit into the cancer-treatment landscape.\nThis compared with an average survival of 21.5 months in the 66 earlier-stage patients who received the control immunotherapy.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The blog states that while some types of viral treatment, such as phage therapy, have been used in Europe and other places, this is the first time a modified virus has been used as immunotherapy against melanoma.", "answer": 1}, {"article": "\u201cEverything got better,\u201d says Lustig.\nNow, in a paper published Tuesday, he and his colleagues believe they have come up with the definitive evidence that sugar, as Lustig says, \u201cis toxic.\u201d\n\nIn most lab studies, the doses of sugar that scientists test are quite high; they want to see what the effect is quickly and, depending on the research, they may not have time to wait to study the more gradual effects that might emerge.\nBut I worry that people are going to hang everything on this when we still need to reduce consumption.\u201d\n\nLustig hopes that won\u2019t happen as more data emerges that details how sugar is altering the body in unhealthy ways outside of its caloric contribution.\nThat\u2019s the point.\u201d\n\nMORE: The Trouble With Sugar Free Kids\n\nNot everyone is convinced that the results definitely prove sugar, and not weight loss, is the culprit, however.\n\u201cThis is causation.\u201d\n\nThe diet he provided the children isn\u2019t considered ideal from a health perspective \u2014 starches are still a considerable source of calories and can contribute to weight gain.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s always risky at best to call something a first of its kind as this story does, without citing any evidence for that or being more specific about what, exactly, was a \u201cfirst.\u201d But the story does give the general sense of what\u2019s new and important about the study \u2014 the fact that it suggests beneficial changes of reducing sugar independent of weight loss. And it also draws a line between previous correlation studies and this experiment. Close call here but we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "Adamas is also testing the drug to treat walking impairment in patients with multiple sclerosis.\nThe main ingredient of Gocovri, amantadine, has been available in the market as an antiviral drug for several decades.\nA majority of patients diagnosed with Parkinson\u2019s are treated with levodopa, whose use often leads to dyskinesia - involuntary movements that are non-rhythmic, purposeless and unpredictable.\n(Reuters) - The U.S. Food and Drug Administration (FDA) said it had approved Adamas Pharmaceuticals Inc\u2019s treatment for a side effect caused by a commonly prescribed Parkinson\u2019s drug, sending the shares of the drugmaker soaring in after-market trading.\nAn estimated 90 percent of levodopa-treated patients, about 200,000 people in the United States, suffer from LID, the company said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that this is the first time this drug has been approved by the FDA for this indication. However, we wanted to know: How does this version compare to the currently available amantadine that has been used off label for this condition? Is it worth the extra cost and hassle of switching?\n", "answer": 0}, {"article": "\u201cMany babies with Down syndrome appear normal on an ultrasound,\u201d she says.\n\u201cWe are not quite there yet, but it may become a real possibility for finding out real information without having to risk a pregnancy.\u201d\n\nFor example, \u201cIf this comes back negative, you don\u2019t need an amniocentesis, but if it comes back positive, we would probably still do an amniocentesis to confirm the results,\u201d she says.\nWhile the new screen only looks for Down syndrome, Sullivan says that some of the other trisomy birth defects can be more easily identified on an ultrasound exam.\nStill, he adds, \u201cit\u2019s an important step forward.\u201d\n\nThe technology is likely prohibitively expensive and time-consuming at this point, he says.\nJoyce Fox, MD, the chief of medical genetics at Cohen Children's Medical Center in New Hyde Park, N.Y., definitely sees a role for a test such as the one described in the new study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not establish the test\u2019s novelty, and this is largely because it does not provide the proper context. The study itself says, \u201cIn the past 20 years maternal age has been combined with ultrasonographic examination of the fetus and biochemical measurement of various proteins or hormones in the maternal circulation to improve identification of high risk pregnancies. This combined approach of screening can now identify more than 90% of affected fetuses, but there is still a need for invasive testing in 3\u20135% of the population.\u201d This means that as many as 95% of all women would not need invasive testing to begin with, so this test is only potentially a breakthrough for a small minority of women. BMJ actually makes the novelty question easy to answer by breaking it down this way: \u00a0What is already known on this topic:\u00a0Non-invasive prenatal detection of fetal trisomy 21 is achievable by massively parallel sequencing of maternal plasma DNA\u00a0Its diagnostic performance and practical feasibility in the clinical setting has not been tested on a large scale.\u00a0What this study adds:\u00a0Among high risk pregnancies clinically indicated for invasive prenatal diagnosis, non-invasive detection of fetal trisomy 21 can be achieved with the use of multiplexed massively parallel sequencing of maternal plasma DNA at 100% sensitivity and 97.9% specificity, giving a 96.6% positive predictive value and 100% negative predictive value.\u00a0The sequencing test could be used to rule out trisomy 21 among high risk pregnancies before proceeding to invasive diagnostic testing to reduce the number of cases requiring amniocentesis or chorionic villus sampling.\u201d", "answer": 0}, {"article": "Colby says if you think of the eye as an old-style camera with film, then the retina is the film.\nBut if they're scanning the room to see exactly where the clock is, they use the other eye, which also has end-stage macular degeneration.\nFor example, if they're looking to see what time it is on a clock, they use the eye with the implanted telescope.\n\"In order to implant this device, we need to remove the natural lens, or the cataract, and then use a portion of the natural lens to position and support the telescope,\" says Williams.\nWhat happens with age-related macular degeneration is that the center of the retina deteriorates, and people gradually lose sight.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story puts the procedure into the right context. It could be more clear about whether there are similar devices out there that improve vision. (There are.)", "answer": 1}, {"article": "None did.\nAnd the data showed that the scans were completely accurate in ruling out Alzheimer\u2019s pathology: unlike doctors, they never said people had Alzheimer\u2019s pathology when they did not.\nIn one patient who had Alzheimer\u2019s, the pathologist and the radiologist analyzing the scan did not see much plaque, but the computerized analysis of the scan and the two autopsy reports did.\nAlthough the scans looked promising, the companies needed to show that what they revealed was the same as what a pathologist would see on autopsy.\nIn addition, the company scanned the brains of 76 younger people who would not be expected to have plaque in their brains.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story discussed the results of a recent study that were just presented at a meeting; in addition, it sounded as though one of the experts questioned about the study was involved in another study funded by the company but it was not clear as to whether it looked at the impact of the same or a different compound/ method. \u00a0It was not clear from the story whether the results presented are the first examination of this test or not.\u00a0", "answer": 0}, {"article": "in July to prevent clots in hip and knee replacement surgeries, goes to an F.D.A.\nThere is great appeal and demand for new drugs that do not vary so much and deliver the same stroke-preventing benefits.\nAlthough the study was financed by the drug makers, which raises the issue of bias, it met the gold standard for medical research as a randomized, double-blinded trial in which doctors and patients did not know who took which pill until the end.\nThe first new drug, Pradaxa, from the German drug maker Boehringer Ingelheim, was introduced in the United States last fall.\nThe study included 18,201 people in 1,034 clinical sites in 39 countries and was consistent worldwide, the sponsors said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear that this was a new medication, though there are two other medications (warfarin and Pradax) that are currently available.", "answer": 1}, {"article": "The folks who carried out this egg industry-funded research were from the Pennington Biomedical Research Center in Baton Rouge, La.\nSo to assess whether people who ate egg breakfasts were better off than their counterparts who ate cereal, they took blood samples and measured the concentration of two key hunger hormones: acylated ghrelin (which stimulates hunger) and PYY3-36 (which is how the intestines let the brain know that you\u2019re full).\nBoth types of breakfasts had the same number of calories, but the egg breakfasts contained \u201chigher protein quality,\u201d according to an abstract for the study, posted online here.\nThat\u2019s right \u2013 the folks who sell eggs paid for a study that comes to the shocking conclusion that eggs are an ideal breakfast food.\nSure enough, in the week when they ate eggs, volunteers had lower acylated ghrelin and higher PYY3-36 compared with the week when they ate cereal.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This research builds upon many previous studies suggesting that protein calories may be more satiating than other types of calories. The story doesn\u2019t mention this background. Even one more line could have addressed the fact that this is not a new notion; related research has looked at the quality of breakfast food choices and later hunger/eating behaviors.", "answer": 0}, {"article": "MONDAY, July 9, 2012 (HealthDay News) -- A daily drink combining several nutrients appears to help people with early Alzheimer's disease improve their memory, a new study suggests.\nFor more about Alzheimer's disease, visit the Alzheimer's Association.\nDuring the first three months of the study, patients in both groups showed improved memory.\nBut more research is needed before the drink could be made available to the public.\nAfter that, however, patients taking the placebo had a decline in memory.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story briefly mentioned earlier animal and human clinical studies.", "answer": 1}, {"article": "Newswise \u2014 CHAPEL HILL, NC \u2013 UNC researchers say the results from the multi-site phase 2 and 3 trials of brexanolone injection are not only promising, but could change the way postpartum depression (PPD) is treated.\nA New Drug Application is currently under review by the FDA and brexanolone injection has been granted Breakthrough Therapy Designation.\nA unique dose group of brexanolone 60 \u00b5g/kg/hr in one of the studies was not included in the integrated efficacy analysis, but was included in integrated analyses of safety.\nAnother 107 women were administered a placebo and evaluated during the same timeframe.\nSage Therapeutics is the developer of brexanolone injection and sponsor of the trials.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes that the new drug would be a novel treatment for postpartum depression, if approved.", "answer": 1}, {"article": "Megan L. Kavanaugh, a senior research scientist at the Guttmacher Institute, which studies reproductive health, said in an interview that \u201call new insurance plans obtained through the act\u2019s exchanges fully cover all contraceptive methods without any co-payments or other out-of-pocket costs.\u201d Title X family planning clinics and Planned Parenthood clinics are more likely than other sources to offer LARC methods, she said.\nWith both implants and IUDs, fertility returns quickly as soon as the devices are removed.\nFully 43 percent of these pregnancies follow incorrect or inconsistent uses of contraception.\nCommon side effects include irregular bleeding during the first few months following the insertion of an implant or IUD.\nThe latter is also associated with some cramping at the time of insertion.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "LARCs are not novel and the story establishes this.", "answer": 1}, {"article": "Developed in the laboratory of UHN transplant surgeon Dr. Markus Selzner, with the help of UHN transplant surgeons Drs.\n\u201cThis can make a difference to other patients, so I am glad to be the first one helping them with my experience.\u201d\n\nAs soon as the donor kidney was reattached to the patient, it turned ruby-red and started to pour out urine, indicating that it was functioning well.\nThe technique, unique solution, and device are part of a Phase I clinical trial at Toronto General Hospital (TG), University Health Network (UHN), assessing the safety of the device, with subsequent phases examining its efficacy.\n\u201cIt behaved like a normal kidney, despite it being an extended criteria donor kidney.\u201d\n\nHe points out blood tests within 48 hours showed that the kidney was removing wastes and excess fluid from the blood normally.\n\u201cThis new technology can help us answer the critical question, \u2018What\u2019s the best way to improve function and recover and repair the kidney before transplantation to get the best results for our patients?\u2019\u201d\n\nDr. Grant, who is also Professor of Surgery at the University of Toronto, emphasized that high-impact research projects such as this require strong collaborative teams \u2013 including researchers, surgical residents, nurses, Canadian Blood Services, perfusionists, colleagues at SickKids - working together on experimental and clinical trials.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release refers to this as the first time such a transplant has been done \u201cin North America.\u201d Which begs the question: Has it previously been done elsewhere? As it happens, the first trial of a similar approach was published in 2013 in the UK.", "answer": 0}, {"article": "So far, Freedman noted, the only hot-flash treatment that has consistently worked in studies is hormone replacement therapy (HRT).\nAfter four weeks, the study found, women on the antidepressant saw their score on the interference scale fall by half, on average.\nThose findings appear in a separate report in the journal Menopause.\nBut no one knows if altering serotonin levels actually does affect women\u2019s hot flashes.\nTheir exact cause is unknown, but hormonal regulation of body temperature is thought to be involved.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article did state that antidepressants are not FDA approved to be used to treat hot flashes and that doctors prescribing this are doing so off-label.", "answer": 1}, {"article": "At Cooper, cardiologist Phillip Koren said he and colleagues have used the Lariat on the left atrial appendage of about 10 patients in the last six months. The closure was unsuccessful in a few of those cases, but in those, there have been no strokes, said Koren, deputy director of the Cooper Heart Institute. None of the 10 patients suffered adverse events from the device.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did a good job of establishing the novel use of the Lariat device by doctors.", "answer": 1}, {"article": "The researchers achieved similar results in work with pigs, whose heart closely resembles the structure of the human heart.\nIn essence, the new intervention -- known as \"visually guided laser-balloon catheter\" -- enables doctors to much more accurately target the so-called \"misfiring cells\" that emit the irregular electrical impulses that can cause an erratic heartbeat.\nAmong individuals over the age of 65, it is the most common \"serious\" form of heart rhythm irregularities, according to background information in a news release from the American Heart Association.\nThe findings are reported by study author Dr. Vivek Y. Reddy, a senior faculty member in medicine and cardiology at the Mount Sinai Medical Center in New York City, and colleagues in the May 26 online edition of Circulation: Arrhythmia and Electrophysiology.\nThe current study focused on 27 patients (66 percent men), all of whom were diagnosed with a form of atrial fibrillation.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The word \"new\" was used five times in the short story.\u00a0 Yet the real novelty of this approach is only scantily and insufficiently described \u2013 especially if the implication is that this has relevance for 2.2 million Americans. ", "answer": 0}, {"article": "Urba is a co-author of the\n\non ipilimumab published in the New England Journal of Medicine Saturday.\nWhile far from a cure, the treatment is the first to improve survival in people with melanoma that has spread, or metastasized, says Dr. Walter Urba, director of cancer research at the Providence Cancer Center.\nThe 47-year-old pre-school teacher from Eugene was stunned when her biopsy came back positive for melanoma \u2013the most life-threatening form of skin cancer.\nThe antibodies temporarily jam the switch, allowing T cells to continue attacking cancer tissue for weeks or months \u2013 for as long as patients continue to receive injections of the engineered antibody.\nSome patients received ipilimumab alone, others it combined with a cancer vaccine called gp100, and a third group received only the cancer vaccine.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of the approach is clear in the story \u2013 \"one of the first antibody-based therapies that use the body\u2019s immune defenses to destroy cancer cells\" and \"Drug companies are racing to develop competing versions of the immune-enhancing therapy, an antibody produced through genetic engineering.\"", "answer": 1}, {"article": "Can these tiny tumors affect the lymph nodes and spread cancer to other areas of the body?\n\"These findings allow surgeons to select which patients with microinvasive tumors may actually benefit from lymph node sampling, while sparing other patients from this procedure,\" said Tamera Lillemoe, M.D, pathologist and a study co-author.\nThe study, funded by Engelsma Family Foundation and Abbott Northwestern Hospital Foundation, was published recently in The Breast Journal, the official journal of the National Consortium of Breast Cancers.\nThe Virginia Piper Cancer Institute\u00ae, part of Allina Health, provides comprehensive care through all aspects of cancer prevention, early detection and treatment to help individuals maintain quality of life and find ways to live with and beyond cancer.\nHow to treat patients who have microinvasive breast cancer - tumors that are 1 mm or less in size (the thickness of a dime) -- is somewhat controversial.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes it clear that the treatment of Tmic remains controversial. It may have been worthwhile to include that the authors claim this study is the \u201c3rd largest published series\u201d on this topic. But that\u2019s not a major point; hence the N/A rating.\nIf there is anything \u201cnovel\u201d about this study it\u2019s that the primary result of finding just 1.5% positive lymph nodes is the lowest rate recorded of about a dozen similar studies.\u00a0 That may have been something worth bringing up in the news release.", "answer": 2}, {"article": "Taiwanese scientists say a blood thinner drug based on venom from the Wagler's pit viper was effective in mice, and might prove safer than current anti-clotting meds for humans one day.\n\"Blood thinner medications have a long and storied history with snake venom,\" said Dr Satjit Bhysri, a heart specialist at Lenox Hill Hospital in New York City.\n\"The potential development of a new agent based on snake venom that could have similar beneficial effects on preventing blood clotting, and potentially cause less bleeding side effects, is an exciting discovery that warrants future investigation,\" Marzo added.\nThe serpent-medicine connection isn't new, one cardiologist noted, since venom typically kills by disrupting the blood's clotting mechanisms.\nIn fact, \"many current blood thinners are based on initial experiments from proteins found in snake venom,\" he added.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Although the story\u2019s lede makes it sound like this is a novel idea, the story later explains it isn\u2019t:\n\u201cBlood thinner medications have a long and storied history with snake venom,\u201d said Dr Satjit Bhysri, a heart specialist at Lenox Hill Hospital in New York City. In fact, \u201cmany current blood thinners are based on initial experiments from proteins found in snake venom,\u201d he added.\nYet, we never learn why this new compound is different than other products already on the market.\nWe could go either way with this one but again, we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "In humans and many animals the lateral sleeping position is the most common one.\nIn the paper, \u201cThe Effect of Body Posture on Brain Glymphatic Transport,\u201d Dr. Benveniste and colleagues used a dynamic contrast MRI method along with kinetic modeling to quantify the CSF-ISF exchange rates in anesthetized rodents\u2019 brains in three positions \u2013 lateral (side), prone (down), and supine (up).\nBy using dynamic contrast magnetic resonance imaging (MRI) to image the brain\u2019s glymphatic pathway, a complex system that clears wastes and other harmful chemical solutes from the brain, Stony Brook University researchers Hedok Lee, PhD, Helene Benveniste, MD, PhD, and colleagues, discovered that a lateral sleeping position is the best position to most efficiently remove waste from the brain.\n\u201cIt is interesting that the lateral sleep position is already the most popular in human and most animals \u2013 even in the wild \u2013 and it appears that we have adapted the lateral sleep position to most efficiently clear our brain of the metabolic waste products that built up while we are awake,\u201d says Dr. Nedergaard.\nTheir colleagues at the University of Rochester, including Lulu Xie, Rashid Deane and Maiken Nedergaard, PhD, used fluorescence microscopy and radioactive tracers to validate the MRI data and to assess the influence of body posture on the clearance of amyloid from the brains.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that SBU researchers discovered that lateral sleeping is the best method for removing waste from the brain. The researchers are apparently building on the research of University of Rochester scientists who discovered and named the glymphatic system, a network that drains waste from the brain, in 2013.", "answer": 1}, {"article": "\"Based on the current safety and clinical benefit data, the dose of the vaccine was increased to 40 million dendritic cells per injection and the trial opened to patients who have previously been treated with a HER2-targeted therapeutic, including patients with breast cancer,\" said Berzofsky.\nIn the dose escalation portion of the phase I clinical trial, patients were injected with the vaccine on weeks 0, 4, 8, 16, and 24 after enrollment in the study.\nThe final product, which is administered intradermally (between the layers of the skin), comprises patient-derived dendritic cells genetically modified with an adenovirus to produce parts of the HER2 protein.\n\"Moving forward, we would like to investigate whether we can increase the proportion of people who benefit from treatment with the vaccine by combining it with checkpoint inhibitor therapy,\" he added.\nAmong the six patients who received the lowest dose of the vaccine, 5 million dendritic cells per injection, no clinical benefit was seen.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Although using immunotherapy to combat cancer is becoming a well known field, the approach the authors are taking with this treatment appears to be novel. The release also mentions how the vaccine was previously studied in animal models.", "answer": 1}, {"article": "\u201cFollowing a 'healthy diet' emerges as an important strategy for prevention of neurological disease, but remains to be proved.\u201d\n\nCathy A. Sila, MD, the George M. Humphrey II Professor of Neurology and the director of the Stroke & Cerebrovascular Center at the Neurological Institute Case Medical Center of Case Western Reserve University School of Medicine in Cleveland, Ohio, says the benefits of diet and lifestyle choices in disease prevention are more important than ever, given the rising costs of health care.\n\u201cNow, we see it may reduce stroke risk in people older than 65.\"\n\u201cWe do not know for sure, and we do not know which particular aspect of olive oil is the most relevant to stroke,\u201d he says.\n\u201cOlive oil is a healthy fat and it can reduce cholesterol and inflammation, and has been shown to help reduce the incidence of heart disease,\u201d she says.\n\u201cMaybe olive oil improves vascular risk factors such as hypertension, dyslipidemia, diabetes, heart disease, obesity, which may in turn reduce stroke risk, or it may be that olive oil is anti-inflammatory or an antioxidant.\u201d Scarmeas writes an accompanying editorial.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of the study\u2019s focus was clear in the story.", "answer": 1}, {"article": "In a statement, she said the trial would help address how the procedure, if approved by federal regulators, \u201cshould be appropriately managed to minimize complications.\u201d\n\nSome experts have speculated that the adverse effects were dose-related.\nThe study published Tuesday found that patients who had received the bioengineered proteins during spinal fusions for lower or middle back pain did not have increased complications when compared with those who did not get the product.\nOne form of the bioengineered protein is marketed by Medtronic under the brand name Infuse, and another form is sold by Stryker as OP-1 Putty.\nHe added that the study also confirmed how quickly physicians had adopted the proteins both for approved and unapproved uses.\nWhile use of the products in such operations has since fallen, one expert said the new report should convince doctors to stop using them in anterior cervical fusions, as the procedure is known.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\n\nThe story notes that bone-growth proteins have been used in spinal fusion procedures in the U.S. since 2002.", "answer": 1}, {"article": "In effect, those guidelines say there's no particular benefit from working out harder, other than saving time.\nBut there was also a benefit from going just a bit faster: Only participants in the higher-intensity group saw an improvement in glucose tolerance, a risk factor for heart disease.\nNow we have some answers: You may want to go just a tad longer and harder than you'd thought.\n(It's unclear whether the 9 percent improvement seen will be enough to cut their risk of heart disease, though.)\nAt the end of the study, members of all three exercise groups lost an average of about 2 inches from their waist circumference.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reminds readers that these results build on material already explored and reported. It establishes that the current study was investigating potential benefits \u2014 beyond saving time via a shorter workout \u2014 of higher exercise intensity.", "answer": 1}, {"article": "ISNES, Belgium, Aug. 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (\"Volition\") today announced preliminary data from a prospective, multi-centered Proof of Concept Study of 84 men into the utility of Volition's Nu.Q\u2122 assays to diagnose men with high-grade prostate cancer.\nBased on this data, we believe that this test could assist clinicians in more accurate patient selection for prostate biopsy and treatment and substantially reduce the amount of unnecessary procedures in men with low-grade tumors or no tumor.\nIf these results are validated in larger trials, they will present a potentially significant new market opportunity.\nHowever, most men with elevated PSA levels referred for prostate biopsy either have no cancer or have low-grade cancer which needs monitoring but not treatment.\nWe will further investigate the data in relation to disease stage as well as additional factors used for pre-treatment risk stratification.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Based on what is provided in the news release (we could not find any published or unpublished studies) this appears to be a new approach to screening for prostate cancer.", "answer": 1}, {"article": "In September, the journal Pain published the largest-ever clinical trial of spinal cord stimulators, comparing their use with conventional pain therapies, including drugs, nerve blocks and physical therapy.\nPain is normal after an injury or because of a health problem.\nIn August, the medical journal Neurosurgery showed that spinal cord implants were far cheaper than additional operations to treat pain.\nEvery patient received conventional pain treatment, but half were also given a spinal cord implant.\n\u201cSometimes efficacy wanes over time, but I still believe in them,\u201d said Dr. Kaufman, also an assistant professor of anesthesiology at the New Jersey Medical School.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The news story doesn\u2019t explain whether this is a new treatment, old treatment, or a new twist on an old idea. ", "answer": 0}, {"article": "Some 68% of the country is either overweight or obese, but there\u2019s not much clinical evidence on the best way to lose weight, outside of research on bariatric surgery. (True, \u201cEat less and exercise more\u201d is great advice if you can manage to follow it, but public-health authorities have repeated that line until they\u2019re blue in the face and as a population we\u2019ve only gotten fatter.)\n\nResearch presented over the weekend at the annual meeting of the Obesity Society and published online in the Journal of the American Medical Association suggests a few specific strategies that may help \u2026", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story could have put this study into the larger context of cash payments for health incentives. This has been demonstrated to work on a number of fronts, including encouraging mothers to give birth in health centers, discouraging risky sex, and smoking cessation.", "answer": 0}, {"article": "But she cautions that a lot more work needs to be done.\nThe EEG technique is much easier to use because the baby can be awake and moving and wiggling around, says Dr. Geraldine Dawson, chief science officer for the advocacy group Autism Speaks, which partially funded this research.\nBut he says by using an electroencephalogram and new, sophisticated computer programs to analyze the EEGs, he and his co-authors were able to correctly identify with 80% accuracy, which babies were at higher risk for autism and which were not.\nThis will now allow the researchers to evaluate them for autism and then look back at the brain activity patterns of the children who do fit the clinical criteria for autism.\nOverall, the biggest differences in brain activity were seen at 9 months \u2013 which is much earlier than when a child typically shows behavioral problems associated with autism.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is quite clear that EEG is not new but that the analysis method is new. The study was a novel contribution to the literature in that the study screens earlier, during infancy, in siblings of affected children. At the same time, we wish the story had placed this finding into a broader context.\u00a0In December, CNN ran a story that sounded so similar we had to check the dates on this story to make sure it was not the same one. That story said, \u201cScientists are finding more pieces of the autism puzzle of with the help of MRI scans of brain circuitry, according to a study published Thursday online in the journal Autism Research.\u201d Why not offer more context on other research that you\u2019ve already reported on?", "answer": 1}, {"article": "Actually, nitrous is making a comeback in U.S. maternity circles. It has remained a staple of childbirth in Canada, Australia, and Britain \u2014 Catherine, Duchess of Cambridge (the former Kate Middleton), who welcomed her third royal baby, Louis Arthur Charles, last month, reportedly has used it. But it basically disappeared in the United States in the 1970s. American women preferred to be numbed below the waist with epidural anesthesia, or at least that became the gold standard for pain relief.", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s well established that obstetric nitrous oxide is widely used in several countries.", "answer": 1}, {"article": "TUESDAY, Dec. 29, 2009 (HealthDay News) -- Many older adults consume ginkgo biloba, hoping to keep their minds sharp, but a new study finds that the herbal product doesn't stave off cognitive decline.\nAlso, the age of the subjects is quite advanced, at an average of 79 years at the beginning of the trial.\nHowever, ginkgo was safe and no serious side effects were noted, DeKosky added.\nThe American Botanical council took issue with the findings, however.\nThese results remained the same regardless of sex, age, race or education, the researchers noted.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of these products is not in question. ", "answer": 2}, {"article": "The requested URL /2011-08-30/business/29945941_1_mark-kris-cancer-cases-lung was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nBased on this story, readers may believe that this drug is the first of its kind. However, the FDA news release says the gene test is the truly novel part of the combination approved and the release goes on to point out, \u201cIt is the second such targeted therapy approved by the FDA this year.\u201d Nevertheless, the approach taken with this sort of gene test and specfic drug combination is new and very different from typical chemotherapy, which is the angle highlighted in the story.\n", "answer": 1}, {"article": "The Food and Drug Administration has approved DBS therapy for movement disorders such as Parkinson's disease, tremor and dystonia \u2014 usually in people who haven't responded well to medications.\nThe results point to a real-time biomarker for impulsive behavior, says Dennis Turner, a Duke University neurosurgeon who was not involved in the study but wrote an October review about ongoing research on a range of potential brain stimulation biomarkers.\nAs reported in the PNAS paper, the characteristic anticipatory signal appeared when he expected to make $5 but not for smaller sums, suggesting some level of specificity.\nThe intermittent system controlled overeating much better than the continuous or random protocols \u2014 and nearly as well as in a separate group of mice that got zapped manually by a researcher watching their behavior on video.\nSince food isn't allowed in the operating room, the researchers monitored the patient's brain as he anticipated payoffs in a computerized money-making task.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The \u201cgee whiz\u201d aspects of this research \u2014 particularly the researchers ability to map the troublesome neuronal activity pretty accurately \u2014 are well portrayed. The research is intriguing and the article brings that across.", "answer": 1}, {"article": "Another method involves a specially designed treadmill tank.\n\u201cThe study proposes a different, very innovative approach\u201d to rehabilitation after stroke, said Dr. Gisele Wolf-Klein, director of geriatric education at Northwell Health in Great Neck, New York.\n\u201cIt\u2019s a very pleasant way of achieving exactly what you\u2019re trying to do \u2013 allowing a cardio-respiratory response,\u201d Wolfe-Klein told CBS News.\nIt\u2019s also an easy-on-the joints form of exercise for seniors and others who suffer from arthritis, and a recent study shows it can speed recovery from stroke faster than using a traditional treadmill.\n\u201cI personally prescribe it for knee issues and low back issues.\u201d\n\nHydrotherapy uses a water-friendly treadmill that can be placed in a pool.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Underwater treadmills are not particularly new (the research literature on them goes back to at least 1989). Frankly, it\u2019s not clear why this story was written now, or what is novel about underwater treadmill exercise (given how the story indicates that it is comparable to walking in a pool with a foam vest).", "answer": 0}, {"article": "Caution was urged by Dr. Richard B. Lipton, vice chairman of neurology at Albert Einstein College of Medicine in New York City, who has done work on the genetics of Alzheimer's disease.\nCalled angiotensin receptor blockers, these drugs have a greater protective effect against dementia than ACE inhibitors, the study found.\n\"Any study like this is hypothesis-generating,\" he said.\nIt is produced when enzymes act to convert a precursor molecule, angiotensinogen.\nAngiotensin causes blood vessels to constrict, raising blood pressure.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t frame the new study into the context of past research linking high blood pressure to dementia. ", "answer": 0}, {"article": "\u201cThe findings published today substantially increase our optimism for the potential for the development of a Zika vaccine for humans.\u201d\n\nBeyond that, \u201cthis is a promising [vaccine] candidate that can be easily produced in large quantities,\u201d said coauthor, Col. Nelson Michael, an Army doctor who specializes in flaviviruses, such as Zika and dengue.\nThe urgency for a vaccine to protect against Zika infection has intensified as the virus spreads rapidly across Latin America and the Caribbean.\nRelated: New Study Shows Just How Tricky the Zika Virus Is\n\nThe two other experimental vaccines described in the new report also sparked an immune response in monkeys.\nTo continue the development of the vaccine, the researchers will be partnering up with the largest pharmaceutical company solely devoted to vaccines, Sanofi Pasteur.\nBoth of these vaccines depend on new technology in which scientists learn the exact DNA of proteins on the surface of the virus and then create copies to be put in a vaccine.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The news story does a good job of explaining how the Harvard-Walter Reed vaccine differs from another one further along in development.", "answer": 1}, {"article": "\u201cDoes everybody need to practice at least 20 minutes a day three times a week?\n\u201cAt a certain point in time you learn what your back needs.\u201d\n\nAs an alternative to yoga, stretching may be a viable option.\nThis is a much larger study, and the findings are robust.\u201d\n\nAbout four out of five people experience low back pain at some point in their lives, prompting Americans to spend $50 billion a year on medications, physical therapy and related costs.\n\u201cMore participants in the yoga and stretching groups were very satisfied with their overall care for back pain.\u201d\n\nDr. Sherman said that like many other therapies for low back pain, yoga probably would not work for everyone.\nThe study is the largest and most thorough to date to look at whether yoga has an effect on chronic low back pain, a problem that affects millions and has no surefire long-term remedy.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article did not discuss the novelty of the treatment interventions. The intensive stretching class would appear be a novel intervention developed for the clinical trial\u2014and similar programs aren\u2019t widely available around the country. The \u201cviniyoga\u201d program may be less novel, but is distinctive nonetheless.\n\n\n\n ", "answer": 0}, {"article": "Liao feared that cutting open Holmes\u2019 chest and sternum for an open bypass surgery would disrupt his rehabilitation from the cardiac arrest and delay his plans to return to athletics.\nThe robotic systems come with million-dollar price tags and are used for a limited number of surgeries \u2014 mostly the removal of cancerous prostates in men or uteruses in women.\nThe number of da Vinci robots has doubled in Minnesota in less than two years, with two at the university and four at the Mayo Clinic in Rochester.\n\u201cThe system and instruments have kind of caught up to the point where heart surgeons are taking a close look at this now,\u201d he said.\nA stabilizer held a section of the beating heart in place so he could secure the new coronary artery.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes no false claims of novelty. It does a good job of describing the state of the machines\u2019 use in the paper\u2019s circulation area.", "answer": 1}, {"article": "Examining more than 500,000 Facebook posts from both groups, researchers determined which words, post lengths, frequency of posting and timing of posts were most associated with a depression diagnosis. They found people with depression used the words \"I, my, and me,\" as well as such words as \"hurt, tired, and hospital,\" more often than others in the months preceding their diagnosis. Using indicators such as these, they built a computer model that could predict which people would receive a depression diagnosis with comparable accuracy to commonly used clinical surveys.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does mention an earlier study that demonstrated how Twitter could be used to evaluate depression risk, and provides some good background (with supporting links) on the body of work addressing social media and depression. All of that is sufficient to garner a satisfactory rating here.\nHowever, the story would have been stronger if it had addressed a straightforward question: Is this the first model that can be used to diagnose depression based on someone\u2019s Facebook activity? One assumes the answer is yes, but it\u2019s not clear whether that\u2019s the case.", "answer": 1}, {"article": "You've seen high-definition televisions. Now some medical centers are marketing their high-definitioncolonoscopes, which they say will detect more pre-cancerous polyps. Several recent studies have found a small benefit to high-definition colonoscopy over the standard variety, but gastroenterologists say physician technique is more important in detecting polyps than equipment.\n\nColonoscopy, a screening test doctors recommend for most people starting at age 50, allows doctors to remove pre-cancerous growths before they become...", "question": "Does the story establish the true novelty of the approach?", "explanation": "It is rare when a story manages to fit in two treatment protocols. This one discusses the new advance in colonoscopies, the standard method, an emerging technology and an alternative procedure.", "answer": 1}, {"article": "The research was funded in part by Cystic Fibrosis Canada.\nThe findings, published in the journal ACS Central Science, shed new light on the underlying mechanisms of CF and could lead to improved prognosis and better therapies for a disease which is quite variable, affecting different children in different ways, say researchers.\nBut there are some obstacles that complicate clinical decision-making, explains Britz-McKibbin, because sweat chloride can result in ambiguous diagnoses in some borderline cases and does not reveal how the disease might progress for individual patients.\n\"We set out to discover whether there were chemical indicators detected in sweat that could complement the gold standard for CF diagnosis: the sweat chloride test.\"\n\"The easier it is to detect CF, the earlier it can be diagnosed, and the better people's chances are at living a longer, healthier life\", says Joanna Valsamis, Chief Healthcare, Research and Advocacy Officer at Cystic Fibrosis Canada.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The story does a good job of explaining what is new here \u2014 researchers have found specific chemicals in the sweat of infants with CF that appear to be related to the disease. The release only stumbles when presenting what these findings mean or how they may be used in the context of clinical diagnosis and care.", "answer": 1}, {"article": "In fact, the only clue TMS treatment contains magnets at all is that patients must remove any jewelry and stow their credit cards (to prevent demagnetization) before treatment.\nThe most common, not surprisingly, are headaches.\nHope for both groups may have arrived through an unlikely source: magnets.\nA physician then tests the machine to see how much power is needed to affect the patient\u2019s reflexes.\nAt this point, specific symptoms can be targeted depending on the patient\u2019s needs.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "TMS has indeed been around for decades now, 1985 according to the NIMH web site.", "answer": 0}, {"article": "Severely premature babies are more likely to live if they receive intensive-care treatments rather than palliative care to keep them comfortable, according to a U.S. government-funded study published Thursday.\n\nWhether babies born at the extreme edge of viability, generally considered to be 22, 23 or 24 weeks of gestation, should be aggressively medically treated is a controversial issue among pediatric experts. These infants often don\u2019t survive and, even if they do, many have substantial long-term health problems.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Although studies exploring survival and neurodevelopmental impairment have been published, the story explains that this new research is thought to be the best, most large-scale data in the US on this topic \u2014 namely how the decision to pursue active treatment across hospitals influences rates of survival and impairment for extremely preterm babies, or those born at 22 to 24 weeks of gestation.", "answer": 1}, {"article": "TUESDAY, Oct. 16, 2018 (HealthDay News) -- Stimulating a specific set of nerves that are nestled along the spine may deliver relief to those who suffer from chronic back pain and cut the need for opioid painkillers, new research suggests.\nThe therapy, which targets the root ganglion nerves, is more effective than other spine stimulation procedures because it places tiny leads precisely at the area where pain originates, unlike other devices that provide more generalized stimulation, the researchers said.\nThe dorsal root ganglions are nerve cells, on both sides of each of the spine's vertebra, and are the gateway to pain between nerves in different parts of the body, spinal cord and brain.\nFor uninsured patients, the cost of having spine stimulation devices can range from $15,000 to $50,000 or more, according to a 2008 report funded by the Washington State Department of Labor and Industries.\n\"In certain patients who have not gotten relief from other treatments, this therapy may give sustained pain relief and may allow them to reduce opioids for at least 18 months and perhaps longer,\" said lead researcher Robert McCarthy.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did not establish novelty\u2013what other studies have been done on this type of therapy for chronic back pain? Is this the first?\nThe new device mentioned here, that stimulates the dorsal root ganglion, is argued to be more specific than the older stimulation devices. A number of issues not raised in this piece make the potential value of DRG stimulation less clear. First, is that being more precise, doctors need to identify the pain generator site (the source of the pain). For many patients this can be hard to find. Moreover, there may be more than one pain source, arguing that multiple DRG\u2019s may need to be targeted. This may explain why pain is not eliminated, but only decreased, for this study population.", "answer": 1}, {"article": "Dr.\nThe practical value of the tests depends critically on details like their sensitivity, meaning the proportion of tumors that are detected, and their specificity, meaning how many of the positive results are in fact false alarms.\nThe specificity of the Exact Sciences test is 88 percent, meaning that 12 percent of the time the patient will be given a false alarm.\nCompliance with colonoscopy is low, since people don\u2019t want to have one, and the overall cost per detection is high because most people are healthy, and even colonoscopy misses many tumors in the upper part of the intestine.\nBut the blood-based test may have a similar problem, since a positive signal could come from cancers anywhere in the body.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Although the story doesn\u2019t discuss existing stool tests like fecal immunochemical testing or other fecal occult blood testing, on the issue of relative novelty, the story scores points for being the only we reviewed that mentioned that the Exact Sciences DNA test is only one of two leading technologies being developed right now.", "answer": 1}, {"article": "JACKSONVILLE, Fla. \u2014 Researchers at Mayo Clinic\u2019s campus in Florida have conducted the world\u2019s first prospective, blinded and placebo-controlled clinical study to test the benefit of using bone marrow stem cells, a regenerative medicine therapy, to reduce arthritic pain and disability in knees.\n\u201cThis is just a theory that can explain our results, so it needs further testing.\u201d\n\nAnother explanation is that merely injecting any substance into a knee offered relief from pain.\nThe researchers say such testing is needed because there are at least 600 stem cell clinics in the U.S. offering one form of stem cell therapy or another to an estimated 100,000-plus patients, who pay thousands of dollars, out of pocket, for the treatment, which has not undergone demanding clinical study.\nThe findings in The American Journal of Sports Medicine include an anomalous finding \u2014 patients not only had a dramatic improvement in the knee that received stem cells, but also in their other knee, which also had painful arthritis but received only a saline control injection.\n\u201cOur findings can be interpreted in ways that we now need to test \u2014 one of which is that bone marrow stem cell injection in one ailing knee can relieve pain in both affected knees in a systemic or whole-body fashion,\u201d says the study\u2019s lead author, Shane Shapiro, M.D., a Mayo Clinic orthopedic physician.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "We give them the benefit of the doubt here since the release reports on the meticulous stem cell count and the use of the patients\u2019 own knees serving as both treatment recipients and controls. These are newsworthy parts of the study protocol. But the claim that it\u2019s the \u201cworld\u2019s first\u201d probably should have been explained better or in the abscence of an explanation, avoided altogether.", "answer": 1}, {"article": "Intriguingly, it appeared to be more effective among people with two copies of the APOE4 gene, a genetic combination that increases risk for Alzheimer\u2019s by a factor of 20 or higher.\nThe research was funded by the National Institute on Aging, but some of the authors also receive pharmaceutical industry funding and one reported funding from Philip Morris.\nHowever, patients on nicotine did lose a few pounds, which is a known side effect.\nThe randomized controlled trial included 74 people, mainly in their late 70\u2019s, with mild cognitive impairment (MCI).\nFind her on Twitter at @maiasz.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story didn\u2019t make any claims of novelty. However, the story could have briefly explained whether there has been other research studying nicotine\u2019s effects on memory. (There has been.)", "answer": 2}, {"article": "The results from the clinical study saw an increase in omega-3-PUFA levels in blood and a positive shift in what is described as the 'omega-3 Index'-a test that measures the amount of the omega-3 fatty acids, Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) in red blood cell membranes, which reflects the levels in your heart and other tissues.\nThe chicken meat and eggs used in the study came from birds offered OmegaPro, a sustainable and algae-based source of omega-3 PUFA, developed by Devenish.\nThe science shows the importance of food nutrients to promote good health in consumers and the innovation starts on the farm.\n\"Omega-3 enriched chicken and eggs offer consumers an attractive alternative to eating oily fish or to the lifelong taking of supplements, with the potential for substantial health benefits,\" Professor Stanton said.\nThe study showed that consuming omega-3 enriched chicken and eggs resulted in a halving of the number of subjects with such a high-risk omega-3 Index.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Since the news release fails to provide real information about the research and instead concentrates on grooming the market for a new product, it\u2019s questionable how novel this work is.", "answer": 0}, {"article": "TUESDAY, June 14, 2011 (HealthDay News) -- Not only do cooler heads prevail, they might also sleep better, according to researchers who say they have developed a cooling cap that, when worn during sleeptime, may help treat insomnia.\n\"The theoretical concept is correct, in that we do know from many previous studies that as the body core temperature cools, our sleep improves, and with warming of the core temperature, we have more restless sleep,\" Kohler said.\n\"It does reduce brain metabolism in the frontal lobes, and it improves sleep.\"\nThe cooling cap was, however, associated with an increased amount of slow-wave sleep -- or the deepest, restorative portion of sleep, the researchers reported.\nDr. William Kohler, medical director of the Florida Sleep Institute, said the concept was exciting and worth further research in larger studies that include body temperature measurements and brain imaging tests.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "A quote from an independent researcher establishes that this is not a totally new field of research:\u00a0 \u201cwe do know from many previous studies that as the body core temperature cools, our sleep improves, and with warming of the core temperature, we have more restless sleep.\u201d", "answer": 1}, {"article": "\"Are you angry?\"\nThese results provide strong evidence for using advanced technology as a decision-support tool to help clinicians and caregivers identify and prevent suicidal behavior, says John Pestian, PhD, professor in the divisions of Biomedical Informatics and Psychiatry at Cincinnati Children's Hospital Medical Center and the study's lead author.\nCINCINNATI -- Using a person's spoken or written words, new computer tools can identify with great accuracy whether that person is suicidal, mentally ill but not suicidal, or neither.\nThe study is published in the journal Suicide and Life-Threatening Behavior, a leading journal for suicide research.\nThe scientists also noticed that the control patients tended to laugh more during interviews, sigh less, and express less anger, less emotional pain and more hope.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release touts novel applications, such as screening in schools and other public places \u2014 but that\u2019s a notional, anticipated use of the research. But it does establish novelty pretty clearly here: \u201cWhen you look around health care facilities, you see tremendous support from technology, but not so much for those who care for mental illness. Only now are our algorithms capable of supporting those caregivers.\u201d\nAlso, another novelty here, per our reading of the study, is combining promising speech and text machine-learning algorithms in hopes of classifying a more diverse group of people, including age and mental health status.", "answer": 1}, {"article": "The receiving operator characteristic (ROC) curve had an area under the curve (AUC) of 0.967.\nDr. Ashley Brenton, Associate Director of R&D for Proove states, \"This validation study builds on the peer-reviewed evidence supporting Proove Opioid Risk\u00ae and its components as an optimal model to predict opioid abuse risk.\"\nThis study, entitled \"Evaluation of a Predictive Algorithm that Detects Aberrant Use of Opioids in an Addiction Treatment Centre\", is published in the peer-reviewed Journal of Addiction Research and Therapy (Impact Factor: 1.4).\nFurthermore, the sensitivity of the \"moderate risk\" cut-off score was 98%, while the specificity of the \"high risk\" score was 100%.\nDiscovered by NIH-funded scientists, Proove\u00ae has translated into clinical practice the genetic variants and phenotypic factors contributing to pain sensitivity and chronic pain risk.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Rather than claiming novelty the release states that the study validates previous research. The release quotes a company official: \u201cThis validation study builds on the peer-reviewed evidence supporting Proove Opioid Risk\u00ae and its components as an optimal model to predict opioid abuse risk.\u201d\nThe study itself does appear to provide some missing data on the predictive value of the proprietary genetic test algorithm, but the test itself is not new.", "answer": 1}, {"article": "Soy may keep breast cancer from coming back\nIt wouldn\u2019t be difficult to eat enough soy to be protected, Patel noted.\nThese may be affecting a cell compound called estrogen receptor beta, she said.\nIt accounts for 27 percent of all cancer deaths, according to the American Cancer Society.\nStudies suggest that people who eat the most soy have a lower risk of heart disease and osteoporosis.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions previous research showing an association between intake of soy and rates of new lung cancers.", "answer": 1}, {"article": "Oral infections, such as thrush, also may be diminished.\nThe transdisciplinary team, including William Ray, Department of Biochemistry; Andrea Dietrich, of the Charles E. Via Jr. Department of Civil and Environmental Engineering in the College of Engineering; and Glenn Lesser, from Wake Forest Baptist Medical Center, previously identified the role of lactoferrin, a specific milk protein, in diminishing the metallic flavor stimulated by chemotherapy medications.\n\"Our research shows that daily lactoferrin supplementation elicits changes in the salivary protein profiles in cancer patients - changes that may be influential in helping to protect taste buds and odor perception,\" said Duncan.\n\"By suggesting lactoferrin as a dietary supplement, we can reduce TSA for many patients, restoring their ability to enjoy foods during a time in which nutrition can play a key role in their recovery.\nThe substance is well-known as a first-line defense, aiding the body's immune response, but little is known about its ability to impact salivary proteins.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Using an agent that binds iron is not novel.\nAlso, the release does not make it clear if there are other agents currently being investifated that \u201celicit changes in the salivary protein profiles in cancer patients that may be influential in helping to protect taste buds and odor perception\u201d as lactoferrin is postulated (but not proven) to do.", "answer": 0}, {"article": "The average age of the study participants was 69, and 57 percent were male.\nIn this study, however, the investigators said they found that even a short delay in giving blood thinners to patients at low risk for stroke increases the risk for dementia.\nFor the study, Bunch and his colleagues looked at information from more than 76,000 atrial fibrillation patients who had no history of dementia.\nAccording to Dr. Byron Lee of the University of California, San Francisco (UCSF), \"There is a growing body of literature supporting the connection between atrial fibrillation and dementia.\"\nAlthough the study looked at patients taking warfarin (Coumadin), newer drugs -- including rivaroxaban (Xarelto) and apixaban (Eliquis) -- should reduce the risk of dementia even more, Bunch said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that what\u2019s new here is how these researchers are recommending blood thinner therapy start immediately after an atrial fibrillation diagnosis, and for a wider group of patients.", "answer": 1}, {"article": "For further information, please contact:\nThe previously unrecognized PMS/PMDD benefit of PS Plus came about when 2,000 volunteers received and consumed Lipogen's PS Plus for brain health and stress management.\n\"We also have begun an ongoing, double-blind, randomized, placebo-controlled clinical trial with daacro GmbH, Trier, Germany, to learn more how Lipogen's formulation can help alleviate PMS and PMDD symptoms.\nAt the end of the 2-month study, out of 220 women under the age of 40 who consumed the product regularly, 23 women (10.45%) reported that they noticed relief of premenstrual syndromes.\nWith 25 years of specializing in natural phospholipid research, development and production, Lipogen guarantees its customers ingredient systems that are supported by the highest level of scientific data, technical quality and safety to meet the growing demand for natural cognitive health solutions.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does, albeit somewhat confusingly, make the point that the observation about its purported benefits in PMS were made, apparently serendipitously, during a study of its effects on brain health and stress. That\u2019s newsworthy, but could have benefited from more detail.", "answer": 1}, {"article": "The study was funded by the P.J.\nFor example, according to the researchers, those with systolic blood pressures below 140 millimeters of mercury and no calcium had an event rate of 12.7 events per 1,000 person-years, and similar people with systolic blood pressures between 140 and 159 millimeters of mercury had an event rate of 13.6 events per 1,000 person-years.\nIn late 2015, the SPRINT trial showed improved outcomes for participants with increased risk for heart disease whose physicians targeted their systolic (the top number) blood pressures to 120 millimeters of mercury, rather than the traditional 140 millimeters of mercury.\nThe researchers divided the participants by their coronary artery calcium scores into one of three groups: those with a score of zero, those with a score of one to 100 and those with a score greater than 100.\nTo determine if coronary artery calcium scores could inform blood pressure recommendations too, the researchers used data from 3,733 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) who had systolic blood pressures between 120 and 179 millimeters of mercury.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release offers perspective via this quote from a researcher: \u201cOur study, along with others, such as SPRINT and HOPE, positions cardiac risk and coronary artery calcium as helpful ways to determine if a given patient would either benefit from more intensive blood pressure control or do just fine with a more traditional blood pressure target.\u201d\nAccording to the study itself, it\u2019s the \u201cfirst to incorporate information on individual coronary artery calcium (CAC) burden to personalize the risk-based treatment of hypertension.\u201d\nIt should be noted that the release is comparing an observational study with the HOPE and SPRINT trials which were randomized treatment trials. The former examines an association while the latter provides experimental evidence.", "answer": 1}, {"article": "Antibodies \"are easily accessible in the blood, so it provides a fantastic test to identify an early-stage cancer,\" said project lead Professor Mel Ziman, leader of the university's Melanoma Research Group on Monday.\nSurgery to remove the growth is the most common form of treatment.\n\"We're in the wrong place with the wrong skin color.\nOver three years, the research team identified a combination of 10 types of antibodies that best signal the presence of a melanoma.\n\"In order for it to be valued by clinicians we would need to get to 90% accuracy in detection,\" she said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This report appears to be the first of its kind related to melanoma.", "answer": 1}, {"article": "The potential use of psilocybin in patients diagnosed with life-threatening diseases comes at a moment when medical care at the end of life is a subject of growing concern among patients and physicians. Research finds it's still common for dying patients to get painful and futile procedures. Palliative and hospice care, both aimed at easing the discomfort of the seriously ill, are growing specialties in American hospitals. An increasing number of patients, meanwhile, are demanding the right to die with a physician's help.", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is a close call. The story does do a good job of placing the work in context in regard to overall research involving hallucinogens. That\u2019s enough to earn it a \u201cSatisfactory\u201d rating. However, the story doesn\u2019t mention any of the work done in the past 10 years on the use of psilocybin specifically to address anxiety in cancer patients, such as this 2007 study, this one from 2011, or this one from 2013. Are the results from the two new studies consistent with these earlier findings? Do they differ in a meaningful way? That would be good to know.", "answer": 1}, {"article": "Continued weight loss may affect fetal nutrition and could influence growth.\"\n\"The number of women who are obese in early pregnancy has increased dramatically over the last decades,\" said study author Kari Johansson, a postdoctoral researcher and nutritionist at Karolinska Institute in Stockholm.\n\"It has been reported that gastric bypass [a form of bariatric surgery] increases the risk of protein, iron, vitamin B12, vitamin D and calcium deficiencies,\" she said.\nWEDNESDAY, Feb. 25, 2015 (HealthDay News) -- After undergoing weight-loss surgery, women are significantly less prone to diabetes during pregnancy but twice as likely to deliver smaller-than-normal infants, a new study suggests.\nBecause obesity is linked to poor outcomes for expectant mothers and babies -- including birth defects, gestational diabetes, high blood pressure, premature birth and even childhood obesity -- efforts to lose weight before pregnancy are important, said Dr. Aaron Caughey, chair of the department of obstetrics and gynecology at Oregon Health and Science University's School of Medicine.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story quotes the study author about previous research in this area. \u201cThe positive effects of bariatric surgery on health outcomes \u2014 such as diabetes and cardiovascular disease \u2014 are reasonably well-studied, but less is known about the effects on pregnancy and [post-delivery] outcomes.\u201d We\u2019ll call that statement barely good enough for a satisfactory rating. The NEJM paper refers to a number of studies and reviews of studies examining this issue. It would have been nice to describe how the current study confirms or differs from those studies and why.", "answer": 1}, {"article": "Peramivir is given intravenously, making it usable by hospitalized patients who are too ill to take two approved flu drugs that work against the virus in similar ways \u2014 Tamiflu by Roche, which is typically given as a pill, or Relenza from GlaxoSmithKline, which is inhaled.\nBut peramivir will soon have competition.\nThe drug is then sent overnight from a central stockpile.\nSome doctors said they were satisfied with the existing system.\nThe government has the right to buy up to 30,000 more treatment courses at the same price.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story is quite clear that peramivir is still being tested.", "answer": 1}, {"article": "Dr. Mary E. Olson, an assistant professor of psychiatry at the University of Massachusetts Medical School, who has worked to promote approaches to psychosis that are less reliant on drugs, said the combined treatment had a lot in common with Open Dialogue, a Finnish program developed in the 1980s.\nBut by the end, those who had been in the combined program had more symptom relief, and were functioning better as well.The researchers expect to have lowered average doses in the combined program but had not yet finished analyzing that data.\nFor example, some patients can learn to defuse the voices in their head \u2014 depending on the severity of the episode \u2014 by ignoring them or talking back.\nAnd finally, one-on-one talk therapy in which the person with the diagnosis learns tools to build social relationships, reduce substance use and help manage the symptoms, which include mood problems as well as hallucinations and delusions.\n\u201cOne way to think about it is, if you look at the people who did the best \u2014 those we caught earliest after their first episode \u2014 their improvement by the end was easily noticeable by friends and family,\u201d Dr. Kane said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that this was the most rigorous trial of this particular version of treatment in the United States. It notes that such treatment has been more widely used in Europe.", "answer": 1}, {"article": "Ilaris can lower the immune system\u2019s ability to fight infections.\n\u201cFor the first time, patients with TRAPS and HIDS/MKD, two painful and life altering diseases, have access to a treatment that may help improve their quality of life,\u201d said Badrul Chowdhury, M.D., Ph.D, director of the Division of Pulmonary, Allergy and Rheumatology Products in FDA\u2019s Center for Drug Evaluation and Research.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe new indications are for rare and serious auto-inflammatory diseases in adult and pediatric patients:\n\nAll three syndromes are hereditary diseases that are characterized by periodic attacks of fever and inflammation, as well as severe muscle pain.\nThe agency is also responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release claims novelty with the following statement: \u201cFor the first time, patients with TRAPS and HIDS/MKD, two painful and life altering diseases, have access to a treatment that may help improve their quality of life,\u201d according to an FDA official.\nBut is novelty demonstrated? All we learn is there are \u201cnew\u201d indications for the drug, two of which have no previously approved treatments. This is presented as a \u201ctake our word for it\u201d kind of way which seems unacceptable.", "answer": 0}, {"article": "\"Phasing out drugs in favour of training is not realistic.\n\"Over the past six years, we have been pursuing the idea that physical training has effects on more than just the symptoms, and this study provides the first indications that physical exercise may protect the nervous system against the disease,\" says one of the researchers behind the study, Associate Professor Ulrik Dalgas from the Department of Public Health at Aarhus University.\nThis is the main finding of a study conducted by a research partnership between Aarhus University, Aarhus University Hospital, the University of Southern Denmark and the University Medical Center Hamburg-Eppendorf, that has just been published in Multiple Sclerosis Journal.\n\"For the past 15 years, we have known that physical exercise does not harm people with multiple sclerosis, but instead often has a positive impact on, for example, their ability to walk, their levels of fatigue, their muscle strength and their aerobic capacity, which has otherwise often deteriorated.\nBut the fact that physical training also seems to have a protective effect on the brain in people with multiple sclerosis is new and important knowledge,\" says Ulrik Dalgas.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release makes it seem as if this study is the first to show the correlation between resistance training and slowing MS progression. The principal investigator of the study says in the lead quote, \u201c\u2026this study provides the first indications that physical exercise may protect the nervous system against the disease\u201d and adds that this is \u201cnew and important knowledge.\u201d\nThis comment is ambiguous and only half true. Iranian researchers found in 2015 that resistance training could slow MS disease progression and improve muscle strength and motor function. Another 2009 study by Spanish researchers showed resistance training could improve muscle function without injuries and \u201cdelay the functional deterioration in multiple sclerosis patients.\u201d\nWhat is new about this study, according to the original journal article, is that it\u2019s the first randomized, controlled trial looking at \u201clong-term exercise intervention\u201d (24 weeks) with accompanying MRI images measuring brain degeneration and regeneration. They reported that patients engaging in resistance training also had thicker cerebral cortexes compared to controls.\nWe wish this information was more clearly and explicitly stated, which is why we give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": "Screening patients for heart disease with a heart-imaging test prompted greater follow-up care but had little to no effect on the number of heart attacks and other cardiovascular events in those patients, a new study found.\n\nResearchers at Johns Hopkins Hospital in Baltimore led the study, which was published online Monday in the Archives of Internal Medicine.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reported that CCTA use is becoming more common, though it is not currently recommended for use in people without symptoms to screen for heart disease.", "answer": 1}, {"article": "Recent research indicates that vitamins C, E and zinc can help vision.\nCompared to coffee, soft drink and iced tea drinkers, study participants who consumed a cup or more of hot caffeinated tea daily had 74 percent lower odds of having glaucoma, the study authors report in the British Journal of Ophthalmology.\nThat includes more than three million Americans, only half of whom are aware they have the disease, according to the Glaucoma Research Foundation.\nThe research team found no associations between coffee, iced tea, decaffeinated tea or soft drink consumption and the likelihood of having glaucoma.\n(Reuters Health) - People who drink hot tea daily may be less likely than others to develop glaucoma symptoms, U.S. researchers say.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Although there is existing research investigating the role of caffeine in glaucoma, this study specifically compared the effects of caffeinated and decaffeinated coffee, tea, and soft drinks on glaucoma. The story makes that clear.", "answer": 1}, {"article": "Probiotic organisms are non-pathogenic bacteria that, when present in the gut flora, are known to improve the overall health of the host.\nOverall, these results indicate that changes in intestinal inflammation can alter the trajectory of psychiatric mood disorders and that modulating the intestinal microbiota may be a new avenue of treatment for patients suffering from these diseases.\nThe GI tract is also home to the intestinal microbiome, a complex population of roughly 100 trillion microorganisms (more than ten times the number of cells that make up the human body) that interacts with the mucosal lining of the GI tract.\nThere is also mounting evidence linking imbalances in the microbial species that make up the gut microbiome to a number of health problems including allergies, autoimmune disorders, and psychiatric mood disorders.\nIn the case of bipolar disorder and the GBA, previous studies have shown that inflammation, or overstimulation of the body's immune system, is a contributing factor in the disease.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "While the use of probiotics to treat bipolar disorder is part of an \u201can emerging field of research\u201d and therefore novel, it hasn\u2019t been established through this or other research as an effective intervention.\nThe release implies that the study builds on previous research in this area. In that case, it would have been helpful for the news release to disclose those aspects of the study had been previously published.", "answer": 0}, {"article": "The Claim: Red palm oil, a deep orange fat pressed from the palm tree fruit, is a superfood\u2014packed with healthy antioxidants and good for the heart, say companies who sell it.\n\nThe Verdict: The colorful oil is rich in tocotrienols, nutrients in the vitamin E family, and carotenoids, which the body converts into vitamin A. Several studies suggest possible benefits in stroke and liver disease from vitamin extracts made from the oil, but so far there isn\u2019t proof that consuming the oil can ward off disease, scientists say.", "question": "Does the story establish the true novelty of the approach?", "explanation": "There is no claim of novelty.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Monitoring high-risk pregnancies with ultrasound tests may help prevent some fetal and newborn deaths, a new research review finds.\nIn some cases, early delivery may be the best course, but it is unclear whether other options \u2014 such as bed rest or tighter blood pressure control in a woman with high blood pressure \u2014 are effective.\nSome had flaws in their design, while in other cases the researchers failed to provide details on key elements of the study design.\nAbnormal findings indicate that the fetus may be under stress.\nThere have been concerns that abnormal findings on Doppler ultrasound may prompt doctors to sometimes unnecessarily intervene \u2014 by, for instance, performing a cesarean section.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story notes that Doppler ultrasound is an established technology and that most of the studies reviewed were done in the 1990s.", "answer": 1}, {"article": "To learn more about NAMS, visit http://www.\n\"This study shows that, for women who need or choose to avoid medications, electro-acupuncture may be an option because it has minimal risks, but blinded controlled trials are needed,\" says Dr. JoAnn Pinkerton, NAMS executive director.\nAlthough it is not exactly understood how acupuncture affects sleep, it has been shown to affect a number of neurotransmitters associated with sleep, such as serotonin and melatonin.\nThe study showed electro-acupuncture to be comparable to, if not better than, gabapentin in helping to reduce hot flash severity and frequency and improving overall sleep quality (including falling asleep faster and fewer sleep disruptions).\nCLEVELAND, Ohio (November 28, 2016)--It's somewhat of a little-known adverse effect of having breast cancer, but studies suggest that approximately 30% to 40% of women with breast cancer report persistent hot flashes.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release claims in the subhead that the \u201cStudy confirms benefits versus gabapentin for helping breast cancer survivors suffering from hot flashes achieve better sleep\u201d but given that no additional information is provided in the release, it is hard to find such a vague conclusion is novel enough to warrant issuing a news release. Moreover, it appears that acupuncture has been used extensively in previous studies for hot flashes in breast cancer patients, so some comment on that approach, and how \u201celectro-acupunture\u201d might differ, is warranted.", "answer": 0}, {"article": "Staying sexually active\u2014and considering sexuality an important part of life\u2014may be linked to higher cognitive functioning as people age, according to a study in the March issue of the American Journal of Geriatric Psychiatry.\n\nOlder men and women who were satisfied with their sexual relationships and considered sexuality an essential component of aging performed better on tests of cognitive function than those who felt sexuality and intimacy were unimportant, the research showed.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story says, \u201cPrevious studies have focused on the prevalence of sexual activity in older people. But the influence of cognitive decline on how sexuality is perceived in later life wasn\u2019t known, researchers said.\u201d\nA quick search didn\u2019t identify any studies to contradict that claim.", "answer": 1}, {"article": "The U.S. Food and Drug Administration approved the first therapy to treat an underlying cause of cystic fibrosis, a pill that targets a genetic mutation affecting a small minority of patients suffering from the life-threatening breathing disorder.\n\nThe drug, Kalydeco, from Vertex Pharmaceuticals Inc., will be among the most expensive therapies on the market, costing $294,000 a year.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The opening sentence explained that this was \u201cthe first therapy to treat an underlying cause of cystic fibrosis.\u201d", "answer": 1}, {"article": "The new circulating tumor cell (CTC) chip identified such cells in nearly half of 20 people with early-stage prostate cancer and in two-thirds of people with advanced cancer, providing important prognostic information, researchers at Massachusetts General Hospital reported.\nThe new PSA test is given twice a year, along with a digital rectal exam to determine the size of the tumor, and a yearly biopsy.\nIt is the pro-PSA level that is most valuable as a predictor, Veltri said, but it is only one part of the study.\nThe study included 71 men originally diagnosed as having small, low-grade and low-stage prostate cancer, the kind whose ultimate aggressiveness is often in doubt.\nThe test is awaiting approval by the U.S. Food and Drug Administration and already is approved for use in Europe, Catalona said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0It is not clear from the story what \u00a0the actual components of the Prostate Health Index and the DNA content measures were. \u00a0The story did not detail whether the individuals tests are being combined in a new way or whether some were new.", "answer": 0}, {"article": "The electronic nose detected nearly 90 percent of people with asthma compared to about 70 percent who were accurately diagnosed in the traditional way with lung function tests, according to new research published in the April issue of the journal Chest.\n\"This device is interesting and warrants a further look, but it still needs to be perfected and the researchers need to figure out its niche,\" said Dr. Jennifer Appleyard, chief of allergy and immunology at St. John Hospital and Medical Center in Detroit.\nDr. David Rosenstreich, director of the division of allergy and immunology at Montefiore Medical Center in New York City, added: \"An objective and fast test for diagnosing asthma would be helpful, and this test seems to be a non-invasive way of sampling for the underlying problem.\nCurrently, asthma is diagnosed \"based on your medical history and symptoms, and with spirometry (lung function testing) and exhaled nitric oxide,\" said Dr. Thomas Leath, director of allergy and immunology at Scott & White Healthcare in Round Rock, Texas.\nThe Italian researchers wanted to compare the electronic nose to the other commonly used tests -- spirometry and FENO -- to see which test was best at confirming a diagnosis of asthma.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explained in reasonable detail how the device differs from traditional diagnostic methods.\u00a0The story could have done a bit more to explain that \"electronic nose\" technology has been in development for quite some time and is already in use in other fields (i.e. explosives detection).\u00a0However,\u00a0the story\u2019s description of the device was pretty restrained and\u00a0it didn\u2019t try to hype the technology as \"new.\"", "answer": 1}, {"article": "But there is debate about whether the eye movement makes a difference, said Stephen Holland, founder of the Capital Institute for Cognitive Therapy and co-author of the textbook \u201cTreatment Plans and Interventions for Depression and Anxiety Disorders.\u201d \u201cThe question is whether stimulation adds to it.\u201d He does not use it in his practice because he considers it no more effective than cognitive behavioral therapy.\nShe occupied herself with press inquiries and funeral arrangements.\n\u201cDoes EMDR deal with the future?\u201d she asked Kalin.\nThree years later, she founded the EMDR Institute, which has trained more than 100,000 practitioners.\nKalin nodded, and they began processing memories again.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes when EMDR was developed (1987).", "answer": 1}, {"article": "\"We show that patients taking anticoagulant [blood thinning] medication had better outcomes with regards to prostate cancer death and that this benefit was most prominent in patients who had high-risk disease,\" said study lead author Dr. Kevin Choe, a radiation oncologist with the University of Texas Southwestern Medical School in Dallas.\nA second study, conducted in the United States, Canada and Great Britain and also being presented at ASTRO, suggests that a combination of hormone therapy plus radiation may be the best treatment for men who have locally advanced prostate cancer with a high risk of returning.\nIn looking at the records of more than 5,000 men with prostate cancer, 2,000 of whom were taking aspirin or another blood-thinning drug, researchers presenting at the annual meeting of the American Society for Radiation Oncology (ASTRO) in San Diego report that the risk of dying from the cancer was reduced by more than half.\nAfter an average follow-up of about seven years, only 1 percent of men who had been taking an anticoagulant had died versus 4 percent of those in the control group.\nAn initial review at six years suggested that those taking the combination therapy had a 43 percent reduced risk of dying from prostate cancer, while side effects were not \"major,\" Mason said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story notes that lab tests and other clues about cancer and blood coagulation have suggested that anticoagulants might have some effects, but that there has been little work that looks at these questions in people who have tumors that have not spread beyond the prostate.", "answer": 1}, {"article": "Researchers are separately looking at a drug called omalizumab (Xolair), approved by the U.S. Food and Drug Administration for the treatment of severe asthma, to see if it could help people with food allergies, too.\nThe results suggested that children who went through a year of sublingual therapy followed by one to two years of oral immunotherapy were less likely to have significant allergic reactions when undergoing the oral immunotherapy.\nThis is the first time the sublingual therapy has been studied in terms of its benefit as a precursor to the oral immunotherapy, Wood said.\nOral immunotherapy, swallowing small amounts of the allergen, has shown to be more effective than sublingual therapy, which involves putting even tinier quantities of milk under the person's tongue.\nIt's not known yet whether children respond better to this kind of treatment than adults, since there have been so few participants in this research.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story noted other immunotherapy research that\u2019s been done, but stated \u201cThis is the first time the sublingual therapy has been studied in terms of its benefit as a precursor to the oral immunotherapy.\u201d", "answer": 1}, {"article": "Abroms and her team wanted to find out if a more intensive mobile phone program called Quit4baby would be more effective.\n\"Our findings show that a text messaging program helped some groups of pregnant women quit smoking during pregnancy,\" says lead author Lorien C. Abroms, ScD, MA, an associate professor of prevention and community health at Milken Institute School of Public Health (Milken Institute SPH) at the George Washington University.\nThe messages help educate the women about the health risks associated with smoking and they are interactive--allowing a woman to text back for more help if she is experiencing a craving or goes back to smoking.\nThe study, \"A Randomized Trial of Text Messaging for Smoking Cessation in Pregnant Women,\" was published October 2 in the American Journal of Preventive Medicine.\nThe combo of Text4baby and Quit4baby helped women age 26 and older and those in the second and third trimester of pregnancy quit through the delivery date and in some cases beyond.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes that very little is available to assist pregnant women with smoking cessation, so a new intervention is noteworthy. The original research article references a small number of pilot studies of attempts to use social media and text messaging to convince pregnant women to stop smoking.", "answer": 1}, {"article": "\"It didn't stop the drinking,\" says researcher David M. Penetar, PhD, assistant professor of psychology at McLean Hospital and Harvard Medical School.\nIt is one of the substances known as isoflavones found in kudzu.\nThe study is published in Drug and Alcohol Dependence.\nMay 17, 2012 -- An extract from the Chinese herb kudzu may help drinkers cut down on drinking, according to a new pilot study.\nHe studied the extract puerarin.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions that kudzu is already touted as a hangover remedy and that studies of its effects have produced mixed findings.", "answer": 1}, {"article": "Nine rode exercise bikes in a gym to compare the sweat patches\u2019 performance with the decidedly lower-tech method of sweat-testing used today \u2014 taping on absorbent pads and carting the resulting wet samples to a laboratory.\nThe experimental gadget goes well beyond activity monitors like the Fitbit.\nHow it works: Stick the patch on the skin and start moving.\nTogether, those measurements can indicate such things as hydration levels or electrolyte loss.\nHold a smartphone over the patch, and an app takes a picture of the colors and interprets what they mean.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions other researchers working on similar technology.", "answer": 1}, {"article": "After her mother unexpectedly died from a tear in the wall of her heart at age 63, Patricia Walters talked to her doctor, Leslie Cho, about how to better monitor her own heart health.\n\nPregnant at the time with her own daughter, Ms. Walters, now 46, says she was \"a nervous wreck\" worrying that she, too, might face serious cardiac risk.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that the c-reactive protein has been around for many years and provides a partial listing of the important studies performed.", "answer": 1}, {"article": "NEW YORK (Reuters Life!)\nThe study, led by Hung Fu Tseng, a research scientist at Kaiser Permanente in Southern California, compared about 75,000 vaccinated members of the Kaiser Permanente Health plan with about 225,000 similarly aged members who weren\u2019t vaccinated.\nCost is one hurdle, with the vaccine sometimes costing up to $200 for people whose insurance doesn\u2019t cover it.\nDespite the FDA\u2019s approval, the vaccine has not caught on as much as some had hoped.\nEveryone in the study, published in the Journal of the American Medical Association, was at least 60 years old, and the researchers didn\u2019t include anybody for whom the live vaccine is not recommended.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\n\nThe story makes clear that this vaccine is the only approved shingles vaccine and that it has been available in the United States since 2006. It also makes clear that this study provides information about how the vaccine performs in the real world, as opposed to the idealized conditions of a clinical trial.", "answer": 1}, {"article": "There were also big improvements in their parenting style.\nWhile studies have highlighted the short-term benefits of CBT, until now question marks have been raised about whether it can have long-term effects.\nWithin a year, more than half of the women in a control group (58%) were still depressed, whereas only a quarter of the mothers who had been treated with CBT reported depression.\nThe study, one of the largest randomised control trials to be held in the developing world, followed women diagnosed with depression mid-pregnancy in 40 communities in rural Pakistan.\nThe international research project into the impact of depression on pregnant mothers and their babies, led by Professor Sonia Bhalotra from the Institute for Social and Economic Research at the University of Essex, could have major implications for public policy.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story established novelty in this way:\nWhile studies have highlighted the short-term benefits of CBT, until now question marks have been raised about whether it can have long-term effects.", "answer": 1}, {"article": "City of Hope is an independent research and treatment center for cancer, diabetes and other life-threatening diseases.\n\"We already knew that aspirin is a weak aromatase inhibitor and we treat women with breast cancer with stronger aromatase inhibitors since they reduce the amount of estrogen postmenopausal women have circulating in their blood,\" said Bernstein.\nThis study -- which is the first to suggest that the reduction in risk occurs for low-dose aspirin -- was proposed by City of Hope's Leslie Bernstein, Ph.D., professor and director of the Division of Biomarkers of Early Detection and Prevention, and published online in the journal, Breast Cancer Research.\n\"We thought that if aspirin can inhibit aromatase, it ought to reduce the likelihood that breast cancer would develop and it could also be an effective way to improve breast cancer patients' prognosis once they no longer take the more potent aromatase inhibitors.\"\n\"We did not by and large find associations with the other pain medications like ibuprofen and acetaminophen.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release claimed novelty head on, noting that the study \u201cis the first to suggest that the reduction in risk occurs for low-dose aspirin\u201d and \u201cThis study differed from other studies that have looked at aspirin and cancer risk because it focused on the dose levels of the aspirin women had taken and tracked the frequency of the use of low-dose aspirin as opposed to regular aspirin. It was also able to look in detail at subtypes of breast cancer.\u201d\nThat may be a bit of hair-splitting. Aspirin (perhaps at different dosages) has been studied as a potential preventative in breast cancer previously. The American Cancer Society noted on its website in 2015 that \u201cNone of these studies are randomized trials, the most reliable type of study, where people are randomly assigned to take either aspirin or a placebo pill.\u201d", "answer": 1}, {"article": "Warren says he wishes the solution were as simple as just taking folic acid.\nThe Norwegian study is the largest to date on the benefits of folic acid for autism prevention, and marks one of the first tangible things a woman can do to reduce her risk of giving birth to a child with the disorder.\n\"This is pretty exciting,\" said Alycia Halladay, senior director for environmental and clinical sciences for Autism Speaks, an autism advocacy group.\nAmerican Congress of Obstetricians and Gynecologists (ACOG) guidelines call for all women of child-bearing age - not just those who plan to get pregnant - to take 400 micrograms of folic acid daily to prevent birth defects.\n\"This is another piece of evidence that supports the beneficial uses of folic acid during pregnancy,\" said Halladay, who was not connected with the study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains that folic acid is already recommended for the prevention of neural tube defects. But it could have noted that at least one other study has documented an association between folic acid use and reduced autism risk. The JAMA paper on which the story is based cites several prior research efforts showing association with folate in early pregnancy and severe language delay or autism.", "answer": 0}, {"article": "Your cells might be aging faster than you are, and new tests purport to help you find out.\n\nA few companies are offering mail-order testing to measure the length of people\u2019s telomeres, the protective caps of DNA on the ends of chromosomes that have been likened to the plastic tips that prevent shoelaces from fraying. Telomeres gradually shorten as people age and eventually may disappear, leaving cells vulnerable to disease and death.", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s misleading to call these \u201cnew tests.\u201d Commercial telomere testing is dates back at least to 2005, according to one report.", "answer": 0}, {"article": "The American Diabetes Association has more about diabetes-related eye complications.\nThe condition is common in people with diabetic retinopathy, which affects up to 45 percent of people with diabetes.\nBut researchers say it can also improve vision in people with DME, a common form of diabetic retinopathy.\nThe American Academy of Ophthalmology will review the study findings and make recommendations on whether Lucentis plus laser treatment should be the preferred treatment for a large number of patients with DME.\nFor 25 years, laser treatment has been the standard of care for DME, the main cause of vision loss in people with diabetes.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story calls it \"a new drug.\"\u00a0 It\u2019s not. It\u2019s already approved for another eye disease, age-related macular degeneration.", "answer": 0}, {"article": "Even participants who had normal-range blood pressure, triglycerides or cholesterol levels before surgery saw improved measures.\nBefore surgery, only 3 percent of the teens had no cardiac risk factors at all, but three years later, just over half of them (52 percent) had no risk factors.\n\"However, three years is not a long time overall in the life of a child,\" Raghuveer says.\n\"This is not a procedure you would consider for any obese patient who walks through the door,\" Raghuveer says.\nThe findings are important because many of the participants in this study likely already had some level of cardiac damage, such as thickened arteries or heart walls, says Geetha Raghuveer, a pediatric cardiologist at Children's Mercy Kansas City in Missouri who was not involved in the study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions that this study includes more patients than some previous studies that looked at the impact of surgery on teens with severe obesity, and it quotes the study\u2019s author saying it \u201cserves to reinforce the benefits of bariatric surgery as a safe and effective treatment strategy that should be considered sooner rather than later.\u201d Also, the the study of cardiac risk factors and how they are affected is novel, as well, and that\u2019s clear in the story.", "answer": 1}, {"article": "A type of sleeping pill that several major pharmaceutical companies are racing to develop received good news yesterday when Swiss biotech company Actelion Ltd. reported positive clinical data.\n\nSleep experts say the drug class needs further study but could potentially offer some benefits beyond Ambien, the top-selling drug in the $3.8 billion global market for sleeping pills. While Ambien and similar drugs, called nonbenzodiazepine drugs, are effective and easily tolerated by most people, some insomniacs don't respond to the...", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story appropriately reported that the drug described was a new drug with a novel mechanism.", "answer": 1}, {"article": "What would happen if screening for male infertility was just about as easy as taking a pregnancy test in your home bathroom?\nSeveral other home-based tests are already on the market, but Boston researchers say their version can analyze additional aspects of the sample, checking how well the sperm move (known as motility) as well as their concentration.\nThe smartphone-based test involves several distinct parts: one, a disposable device on which to place the sample, including a disposable microchip that handles the sample; two, an optical attachment that connects to a smartphone; three, an app that guides the user through each step of testing.\nThe test delivered impressive results, identifying abnormal semen samples with approximately 98 percent accuracy according to the researchers, who published their findings Wednesday in the journal Science Translational Medicine.\nThe testing kit also includes a tiny weight scale that connects wirelessly to the testing app and measures the total number of sperm swimming in the sample.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story takes the stance that this device is superior to others, stating the new prototype \u201ccould eventually shake up the world of fertility testing by allowing men to evaluate their sperm in their own homes.\u201d However, at least two\u00a0at-home, relatively low-cost, and FDA-approved test kits are already on the market. SpermCheck is a simple chemical test that costs about $40-$50, for example, and The Trak is physical test that uses a miniature centrifuge and retails for about $200. Both achieve similar or greater reliability as the prototype described in the story.\nAnd while the novelty of using a smartphone may be an attractive bell-and-whistle for some men, it\u2019s not necessarily unique. For instance, The Trak has an app \u2014 though it doesn\u2019t directly measure samples. (It instead functions as a log for tests and lifestyle guide to improve sperm count and help men conceive with their partners.)\nThe real novelty, as LiveScience\u2019s story points out, is that smaller fertility clinics can\u2019t afford semen analysis devices, which can cost between $50,000 and $100,000. They could, however, afford a smartphone-assisted device.", "answer": 0}, {"article": "Lipton directs the Montefiore Headache Center at the Albert Einstein College of Medicine in the Bronx.\n\"There is a lot of unmet medical need out there in the treatment of migraine,\" he says.\n\"Some people don't tolerate the drug treatments very well and others just want to avoid them.\"\nMarch 3, 2010 -- A handheld device that magnetically zaps pain may be a promising new treatment for patients with a common type of migraine.\nDrugs commonly used in the treatment of severe headaches are generally not considered effective in the aura phase of migraine attacks, and many patients want to treat their migraines without using drugs, neurologist and headache specialist Richard B. Lipton, MD, tells WebMD.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story points out that a similar device has received FDA approval for the treatment of depression. \n\u00a0", "answer": 1}, {"article": "\"Our results demonstrate that [Opdivo] is more effective in treating patients with stage III and IV melanoma, cutting the risk of relapse by a third,\" lead researcher Dr. Jeffrey Weber, professor of medicine at NYU School of Medicine, said in a university news release.\nMONDAY, Sept. 11, 2017 (HealthDay News) -- New research suggests that Opdivo -- a drug that works with the immune system to fight melanoma -- is more effective than the current standard of care for patients who've had surgery to remove advanced tumors.\n\"It is amazing that there is now an alternative that is superior to conventional chemotherapy for advanced metastatic disease,\" Green said after reviewing the new study findings.\nAccording to the Skin Cancer Foundation, metastatic melanoma accounts for only about 1 percent of skin cancer cases but causes the majority of skin cancer deaths.\nThe international study was funded by Opdivo's maker, Bristol-Myers Squibb, and included more than 900 patients with stage III and stage IV melanoma.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes in its opening paragraph that this research \u201csuggests that Opdivo \u2014 a drug that works with the immune system to fight melanoma \u2014 is more effective than the current standard of care for patients who\u2019ve had surgery to remove advanced tumors.\u201d", "answer": 1}, {"article": "NEW ORLEANS (Reuters) - Abbott Laboratories Inc\u2019s experimental Absorb heart stent, designed to dissolve and thereby restore the blood vessel\u2019s natural flexibility, has proven safe and effective a year after being implanted in patients, researchers said.\n\u201cThe baby will grow and the biodegradable material will disappear,\u201d he said.\nIt hopes to seek U.S. approval for the product in 2015, several years before any competitor.\nDuring the same period, no blood clots were reported among patients who were far enough along in testing to be evaluated in the 101-patient study.\nAbsorb, like traditional metal stents, is meant to prop open heart arteries that have been cleared of plaque.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of the new device is apparent from the story.", "answer": 1}, {"article": "(Boston)--Despite the continued controversy surrounding the use of testosterone in men who have testosterone deficiency (hypogonadism), a new study has found that long-term use of testosterone therapy not only improves vigor and vitality, but may reduce the risk of death due to cardiovascular (CV) disease.\nTo date, there are limited studies comparing the effects of long-term TTh in hypogonadal men who were treated or remained untreated with T.\n\nResearchers at Boston University Schools of Medicine (BUSM) and Public Health (BUSPH), along with researchers in Germany, established a registry to assess long-term effectiveness and safety of T in men.\n\"The low CV events observed in the T-group compared to the untreated (control) group strongly suggest that TTh is protective.\nWe believe that the protective effect of T on the CV system provides clinicians with the opportunity to utilize this approach for secondary prevention for hypogonadal men with a history of CV events,\" explained corresponding author Abdulmaged M. Traish, PhD, professor of biochemistry and urology at BUSM.\nIn the absence of large, prospective, placebo-controlled clinical trials of longer duration, substantial evidence regarding the safety and risk of testosterone therapy (TTh) with regard to cardiovascular outcomes can only be gleaned from observational studies.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes that testosterone therapy is controversial but then makes a pitch for the novelty of the study\u2019s ability to clarify that landscape. Unfounded hyperbolic conclusions are not novel. As noted above, randomized trials have addressed this issue.", "answer": 0}, {"article": "For more information, visit http://www.\n\"This is a well-designed trial that demonstrates how a prebiotic could potentially help combat one of the most prevalent and costly conditions afflicting children in the developed world -- overnutrition -- by targeting the gut microbiome,\" said Geoffrey A. Preidis, MD, PhD, a member of the AGA Center for Gut Microbiome Research and Education scientific advisory board.\nBased on four-month intervention data, the annual projected body weight increase in the prebiotic group would be 3 kilograms (6.6 pounds), within the expected healthy range, whereas the projected increase in the placebo group was 8 kilograms (17.6 pounds), almost triple the expected yearly weight increase.\nPrebiotics reduce body fat in children who are overweight or obese by altering their gut microbiota, according to new research published in Gastroenterology, the official journal of the American Gastroenterological Association (AGA).\nGastroenterology, the official journal of the AGA Institute, is the most prominent scientific journal in the specialty and is in the top 1 percent of indexed medical journals internationally.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release says this is the \u201cfirst randomized controlled study to assess comprehensive changes\u201d in gut microbial composition with prebiotics in overweight kids, but gives so little supporting information it\u2019s hard to accept that claim. There have been other studies that cover at least some of the same territory in adults.\nPubMed contains a number of studies (including those in adults) relating to prebiotics, gut microbiomes and weight loss, including some showing no difference from placebo.", "answer": 0}, {"article": "\u201cThere are no longer going to be permanent metal implants in the artery.\u201d\n\nAbsorb releases the drug everolimus to combat the growth of scar tissue that can form within a stent and cause the artery to narrow again, the U.S. Food and Drug Administration, which approved the stent, said.\n\u201cThis is a game changer,\u201d he said in an interview.\nAbsorb\u2019s appeal is that it allows the blood vessel to return to a natural state, free from a permanent metal implant.\nAbsorb will be priced at a \u201cmodest\u201d premium to Xience, he said.\nAbbott plans to roll out the device to about 100 hospitals in the next several months as it trains surgeons on the implant procedure before ramping up sales, said spokesman Jonathon Hamilton.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Novelty is established in the first paragraph of this story and appears to be an accurate statement about what\u2019s \u201cnewsy\u201d here.", "answer": 1}, {"article": "But the mind is a powerful thing.\nThe earliest report on whether gluten could muck with some digestive tracts comes from the late 1970s.\nAnother possibility is simply that given how small the studies were, the differences occurred by chance.\nThe authors found that 40 percent of patients on the entirely gluten-free diet reported a continuation of symptoms, compared with 68 percent of those who had consumed gluten.\nThe probability is 1 in 30, not 1 in 100.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes the history of research into NCGS, which dates back to the 1970s.", "answer": 1}, {"article": "\u201cThat\u2019s the miracle.\u201d\n\u2022 New hope for young patients with rare genetic disease (\u201cCBS Evening News,\u201d 10/16/15)\n\u2022 Follow the Calliope Joy Foundation on Twitter, Facebook and Instagram\nThe trial in Italy is closed to new patients.\nHe should have been on a feeding tube.\nGene therapy has a checkered history.\nIt\u2019s been slow going, but the money added up.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes that this experimental gene therapy is\u00a0novel.", "answer": 1}, {"article": "\u201cJet lag itself is really a nuisance syndrome as it is self-resolving,\u201d said senior author Jamie Zeitzer, assistant professor of psychiatry and behavioral sciences at the Stanford University School of Medicine in California.\nIn experiments, the technique \u2013 which is based on the way non-visual parts of the brain respond to light \u2013 was much more effective than sustained bright light similar to that from devices sometimes used to combat sleep disorders or seasonal depression.\nThe study included 39 people, 31 of whom were exposed to a series of two-millisecond light flashes with changing intervals while sleeping, and eight of whom were exposed to 60 minutes of continuous bright light.\n\u201cThis is one of the real advantages of this system - you can change circadian timing while you sleep, without interfering with sleep,\u201d he said.\nIn a previous study, the short flashes of light at night did not interrupt sleep or reduce its quality, he added.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article is clear that the study is based on substantial theory about the effects of light on circadian rhythms and mentions previous research that the team had carried out, so there is no misleading representation as to the technique\u2019s novelty.", "answer": 1}, {"article": "Why is this important?\nThe good news, we're told, is that there are many things we can do \u2013 or not do \u2013 in our adult lives to lower our risk of developing different types of cancer.\nFurthermore, \"The moist environment under the preputial skin may help pathogens survive for extended periods prior to direct infection.\"\nIt's important to note, right off the bat, that this study is not purporting to establish a cause and effect relationship.\nIt has long been established that men who are uncircumcised are more prone to contracting sexually transmitted infections.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that previous studies have shown a link between circumcision and reduced risk of sexually transmitted infections \u2014 the same mechanism that is proposed to explain the association with reduced prostate cancer incidence.", "answer": 1}, {"article": "Bochner teamed up with Northwestern oncologist Dr. Leo Gordon and colleagues to test if this BTK inhibitor could shut down an enzyme inside cells that is involved when you have an allergic reaction.\nCurrently, the study is being expanded to adults with food allergy to see if their skin test and basophil activation test responses show a similar reduction with just a few doses of ibrutinib and how long such benefits might last.\nWhile the study was small - only two patients qualified out of about 35 that were screened for allergies - the implications are much larger for later phases of this study.\nThe cancer patients who were allergic to allergens such as cat dander and ragweed saw their allergic skin test reactivity reduced by 80 to 90 percent in one week, and this persisted with continued use of the drug for at least one to two months.\n\"The hope is that drugs like BTK inhibitors will protect people with food allergies from having anaphylaxis, or at least increase how much of that food they can eat without reacting,\" Bochner said.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It is appropriate to call this approach new. Indeed, this is the first test in humans of the effect of a BTK blocker on allergic reactions. However, other than the data from just two patients, most of the release refers to speculation that began with laboratory and animal experiments by a variety of researchers in recent years.", "answer": 1}, {"article": "Finally, the researchers note, expenses associated with the procedure\u2014the robot costs at least 1.8 million ($2.6 million) to install, 100,000 ($145,000) a year to run, and 1,500 ($2,200) extra for each surgical case-mean the procedure is \u201cprohibitively\u201d expensive \u201cfor many hospitals and indeed many countries.\u201d\n\nThe researchers conclude: \u201cThe significant learning curve should not be understated, and the expense of this technology continues to restrict access to many patients.\u201d\nIn about one in 250 surgeries, the robot failed to work properly.\nYou might want to see a surgeon who has done at least 80 operations for the best results, according to the authors of a new research review.\nThere was also a lack of data on how well patients functioned after surgery, and how patients with high-risk prostate cancer fared long-term.\nThe authors did not compare robotic surgery complication rates to traditional surgery rates.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story indicated that robotic prostatectomy is not a new procedure.", "answer": 1}, {"article": "\"LaVonne has had Alzheimer's disease longer than anybody I know, and that sounds negative, but it's really a positive thing because it shows that we're doing something right,\" Moore said.\nTUESDAY, Jan. 30, 2018 (HealthDay News) -- Stimulating the brain with an implantable device may be safe -- and possibly helpful -- for some people with Alzheimer's disease, a small pilot study suggests.\nOn a broader level, he noted, this study highlights an important point: \"Alzheimer's disease is more than just amnesia.\"\nAnd those issues have a huge impact on daily life, for patients and their caregivers, Scharre added.\nIt would not be appropriate, for example, for people who are frail or have other serious medical conditions.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story lets us know that this therapy is used in Parkinson\u2019s patients, and that this small pilot study is exploring its potential for Alzheimer\u2019s disease. It says the study highlights that \u201cAlzheimer\u2019s disease is more than just amnesia\u201d and \u201cproblems with abilities like judgment and planning can actually be more challenging.\u201d", "answer": 1}, {"article": "To learn more about the Society and the field of endocrinology, visit our site at http://www.\n\"Our study is the largest and longest controlled study of growth hormone treatment for osteoporosis in postmenopausal women to date,\" said one of the study's authors, Emily Krantz, MD, of S\u00f6dra \u00c4lvsborgs Hospital in Bor\u00e5s, Sweden.\nWashington, DC--For years after it was administered, growth hormone continued to reduce the risk of fractures and helped maintain bone density in postmenopausal women who had osteoporosis, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.\nMore than 10 million American adults have osteoporosis, and 80 percent of the people being treated for the condition nationwide are women, according to the Society's Endocrine Facts and Figures Report.\nThe study, \"Effect of Growth Hormone Treatment on Fractures and Quality of Life in Osteoporosis - A 10-year Follow-up,\" was published online at http://press.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release establishes what\u2019s new about the study, calling it the largest and longest of any study of growth hormone for osteoporosis to date. However, it would have been useful to inform readers about the long history of research in this area. The release does not mention any previous work, making it difficult for anyone (and impossible for non-experts) to place this new work in context with earlier research \u2014 whether that work is 40 years old or more recent.", "answer": 1}, {"article": "MONDAY, Jan. 11, 2010 (HealthDay News) -- As a major organization of pediatricians considers revising its recommendations on circumcision of newborn boys, two new reviews of existing research offer conflicting conclusions about the bitterly debated procedure.\n\"There are some clear benefits to circumcision,\" he said.\n\"These may be considered unacceptable for an elective procedure,\" she said.\n\"There are some risks to circumcision, although the significant ones appear to be rare.\"\nTwo studies involved neonatal circumcision, and six involved older males, roughly 14 to 49 years old.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 2}, {"article": "(That\u2019s a high dose; a 3 oz.\nWhat\u2019s more, the people who showed the highest blood levels of the omega-3 fats (people absorb it at different rates) showed the greatest reduction in scarring \u2014 13% \u2014 compared to those with the lowest levels.\nFor the study, published in the journal , they studied nearly 360 people who recently had a heart attack, who were randomly assigned to take 4g of omega-3 fatty acids or a placebo pill for six months.\nThe effects remained strong even after the researchers accounted for the fact that all of the people were taking standard heart disease treatment drugs, including cholesterol-lowering statins and blood pressure medications.\n\u201cThe omega-3 fatty acids seem to be preventing scarring of the otherwise healthy muscle that now has to overwork because of the heart attack,\u201d says Kwong.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article demonstrates a good understanding that the novelty of the study lies in examining the protective benefits of fish oil right after a heart attack. That is, the study is novel in its patient population.\nA further discussion of using\u00a0MRI to assess heart conditions would\u2019ve further highlighted the novelty of the study.", "answer": 1}, {"article": "Elsevier is a global information analytics company that helps institutions and professionals progress science, advance healthcare and improve performance for the benefit of humanity.\nAmsterdam, July 3, 2017 - Doctors should consider radiosurgery earlier for patients with severe facial pain, according to a new study in the International Journal of Radiation Oncology*Biology*Physics (the \"Red Journal\") - the official journal of the American Society for Radiation Oncology (ASTRO).\n\"We knew radiosurgery results in pain relief, but we didn't know if the patients actually felt better,\" said Dr. Samuel Chao, corresponding author of the study.\nAccording to the new study, radiosurgery, which is normally a second line treatment to be used following the medication, helps improve quality of life and reduce depression in patients with TN.\nIn the new study, Dr. Chao, Dr. Kotecha and his colleagues prospectively collected data from 50 patients they treated with radiosurgery using two questionnaires: EuroQOL 5-Dimension and Patient Health Questionnaire 9.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release directly addresses the novelty of the procedure in these statements:\nAccording to the new study, radiosurgery, which is normally a second line treatment to be used following the medication, helps improve quality of life and reduce depression in patients with TN. By considering it earlier as a treatment option, doctors could help improve the lives of patients with TN more quickly.\n\u201cWe knew radiosurgery results in pain relief, but we didn\u2019t know if the patients actually felt better,\u201d said Dr. Samuel Chao, corresponding author of the study.", "answer": 1}, {"article": "The study also found other benefits.\nMore than a third of the U.S. population is considered obese.\n\"We can get that whole process of what a meal does without actually having the meal,\" he said.\nOther researchers are working on similar approaches, he said, but this drug, so far, passes harmlessly out of the intestine after doing its work.\nBetter yet, the drug, fexaramine, works only in the intestine, never entering the bloodstream.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It does appear that this approach is novel.", "answer": 1}, {"article": "Ho's implant was inspired by previous research involving sex workers in Kenya.\n\"We know that some drugs taken orally never make it to the vaginal tract, so this implant could provide a more reliable way to encourage T cells not to respond to infection and therefore more reliably and cheaply prevent transmission,\" said Emmanuel Ho, a professor in the School of Pharmacy at Waterloo.\nThe tool, a vaginal implant, decreases the number of cells that the HIV virus can target in a woman's genital tract.\nUnlike conventional methods of HIV prevention, such as condoms or anti-HIV drugs, the implant takes advantage of some people's natural immunity to the virus.\n\"What we don't know yet is if this can be a stand-alone option for preventing HIV transmission or if it might be best used in conjunction with other prevention strategies.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Although the release does not claim novelty specifically, it does mention the past failure of\u00a0a related attempted preventative (nonoxynol-9).\nThe researchers do emphasize in the published paper that this study is the first of its kind to use a vaginal implant to deliver HCQ to reduce the response of T-lymphocytes in the vagina.\nFurthermore, they point out this is a uniquely women-oriented strategy against HIV infection (versus a male-dominated one such as condoms).", "answer": 1}, {"article": "LONDON (Reuters) - First results from a human trial of an Ebola vaccine from GlaxoSmithKline show it is safe and generates an immune response, scientists said on Wednesday, but larger trials are needed to see if it protects and if a booster is needed.\n\u201cThe safety profile is pretty much as we\u2019d hoped and the immune responses are okay, but not great,\u201d he told Reuters.\n\u201cHowever, we still don\u2019t know whether it will provide protection against Ebola infection in a real-world situation,\u201d he said.\nJohnson & Johnson and Bavarian Nordic have a vaccine in early-stage clinical tests.\n\u201cPeople typically experienced mild symptoms that lasted for one or maybe two days, such as pain or reddening at the injection site, and occasionally people felt feverish,\u201d Hill said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that these are the first human results for this particular vaccine.", "answer": 1}, {"article": "Water jets also were linked with a decrease in the amount of half-pints of milk students bought, which could be a potential mechanism of weight reduction, the researchers found.\n\"We associated these water dispensers with almost a one percentage point reduction in the likelihood of being overweight for boys and a little over a half a percentage point reduction for girls,\" said lead researcher Brian Elbel, an associate professor of population health and health policy at NYU School of Medicine.\nThe study, published in JAMA Pediatrics, analyzed data collected from 1,227 elementary and middle schools across New York City - some with and some without \"water jets.\"\nThe large, clear, electrically cooled jugs with a push lever for fast dispensing were placed in 483 school cafeterias, about 40 percent of schools during the 2008-2009 and the 2012-2013 school years.\nSchools with water dispensers saw a modest weight drop among students, according to the study by researchers from NYU Langone Medical Center, New York University's Institute for Education and Social Policy, and the Center for Policy Research at Syracuse University's Maxwell School of Citizenship and Public Affairs.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We would have liked to have seen a bit more context in the CBS story. Research looking at water availability is nothing new and has been conducted in the US and abroad \u2013 for example in Germany, researchers said. One US study found that water consumption nearly tripled after the installation of water jets, while the German study saw a decreased risk for students being overweight if more water was available in the classroom.\nHowever, the CBS article does quote the JAMA editorial, which pointed out this study \u201cadds to the growing body of evidence supporting the importance of providing drinking water access in schools.\u201d\nWe think that\u2019s good enough for a Satisfactory rating.", "answer": 1}, {"article": "\"It is a huge step\" and a first for the field of genetics, said John Rossi, a researcher at City of Hope in Duarte, Calif., where he and Zaia plan another study to test Sangamo's approach.\nThe gene-snipping compound was added in the lab, and about one-fourth of the cells were successfully modified.\nOther gene therapy attempts tried to add a gene or muffle the activity of one, and have not worked against HIV.\nIt's far too early to know if this scientific first will prove to be a cure, or even a new treatment.\nIn the study, six men with HIV had their blood filtered to remove a small percentage of their T-cells.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explained this was the first test of the new approach and that a report on a second, federally-funded study was due in another day.", "answer": 1}, {"article": "Gaziano and colleagues created a computer simulation to see if giving statins to more people would be worth the risk of side-effects and the extra cost.\n\u201cThere is no longer any question as to whether to offer treatment with statins for patients for primary prevention, and there should now be fewer questions about how to treat and in whom,\u201d Dr. Philip Greenland, an expert in preventive medicine at Northwestern University and a senior editor of the journal, and Dr. Michael Lauer of the National Heart, Lung and Blood Institute wrote in a commentary.\nBut in the new report, Dr. Thomas Gaziano of the Harvard School of Public Health and colleagues say they\u2019re in fact simpler than the old guidelines, which advised people to aim for a total cholesterol level of less than 200, keeping \u201cbad\u201d LDL cholesterol to 130 for average people and under 100 for those considered at risk of a heart attack.\nIn 2012, the Food and Drug Administration updated labeling on statins to include warnings about confusion and memory loss, elevated blood sugar leading to Type 2 diabetes, and muscle weakness.\n\u201cYou have to be at extremely low risk before the risk of statins outweighs their significant, profound benefits,\u201d Gaziano said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions that the new report addresses concerns about guidelines issued in 2013, so in that sense it provides enough context for a Satisfactory rating. But we\u2019d note that the story gives the impression that this study\u2019s findings are the definitive word on whether otherwise healthy people should start taking statins. But, as the competing New York Times story notes, there is still serious debate about how important these new findings are.", "answer": 1}, {"article": "Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs.\nBecause of the data from this clinical trial, avelumab (brand name Bavencio) has become the first systemic therapy approved by the FDA for MCC, and the first treatment of any kind approved for metastatic MCC.\nHis team foundational work on the role of immune cells in MCC paved the way for immunotherapy trials in the disease, including one he leads of another immunotherapy drug with a similar mechanism of action (Merck\u2019s Keytruda), whose results were published last year and changed the field overnight.\nAn independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation\u2019s first and largest cancer prevention research program, as well as the clinical coordinating center of the Women\u2019s Health Initiative and the international headquarters of the HIV Vaccine Trials Network.\nA rare and aggressive form of skin cancer, MCC, is 35 times less common than melanoma, but on average, it is about three times more likely to be deadly.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release focuses on the fact that \u201cAvelumab is the first FDA-approved treatment for metastatic MCC and the first disease that the drug has ever been approved to treat.\u201d Immunotherapy is an emerging area of research, and the release appropriately explains why this particular approval is important.", "answer": 1}, {"article": "The experimental treatment, a decades-old generic vaccine for tuberculosis called bacillus Calmette-Gu\u00e9rin (BCG), seems to alter both cellular metabolism and the immune system, said Dr. Denise Faustman of Massachusetts General Hospital, senior author of the study published Thursday in npj Vaccines.\nThe new paper describes how the BCG vaccine, which has been used for nearly 100 years against tuberculosis and is considered extremely safe, might affect diabetes.\nThe new paper and a presentation scheduled for a meeting of the American Diabetes Association this weekend focus on the patients who have been followed for more than five years.\nPatients in the trial, whose blood sugar levels have remained near normal for five to eight years, take about one-third less insulin than they did before, reducing their risk of hypoglycemia, in which insulin lowers blood sugar to dangerously low levels.\nShe has been a voice in the diabetes wilderness for nearly two decades, angering the establishment diabetes community by pursuing low-tech research very different from more popular approaches, such as embryonic stem cells and immunosupression.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that generic BCG vaccine has been used for nearly 100 years to treat tuberculosis and that it has been studied in other countries worldwide for its effects on diabetes, multiple sclerosis and other autoimmune diseases.", "answer": 1}, {"article": "Before the introduction of whooping cough vaccine in the 1940s, more than 200,000 cases a year were reported in the U.S. By 1965, that number plummeted to fewer than 10,000 a year. But the disease made a comeback in the 1990s, as the newer \"acellular\" vaccine \u2014 containing only cellular material but not whole cells \u2014 was phased in. While it is safer and has fewer side effects than the old version, studies have found that its protective effects wane more quickly than originally expected.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty is touched on, though indirectly \u2014 this is a\u00a0relatively new recommendation by the CDC, in 2012, to immunize every pregnant patient during every pregnancy, and this study is an attempt to figure out how protective it is to babies, looking at which trimester the vaccine was given.", "answer": 1}, {"article": "In Manhattan some raw-milk drinkers hire a mule to bring the white stuff to an agreed-upon location in...\nNow that's trickier.\nNo biggie--just zip to your local supermarket and pick up a carton.\nAnd they consider themselves lucky.\nGot raw milk?\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentioned that the FDA requirements about the sale and distribution of raw milk date back to 1987.", "answer": 1}, {"article": "\"To address inconsistencies in prior studies on vitamin D and to investigate associations in population subgroups, we analyzed participant-level data, collected before colorectal cancer diagnosis, from 17 prospective cohorts and used standardized criteria across the studies,\" said Stephanie Smith-Warner, PhD, an epidemiologist at the Harvard T.H.\n\"In the past, substantial differences between assays made it difficult to integrate vitamin D data from different studies,\" explained Regina G. Ziegler, PhD, a National Cancer Institute epidemiologist and co-senior author on the article.\n\"This study adds new information that agencies can use when reviewing evidence for vitamin D guidance and suggests that the concentrations recommended for bone health may be lower than would be optimal for colorectal cancer prevention.\"\nThe analysis included over 5,700 colorectal cancer cases and 7,100 controls from the United States, Europe, and Asia.\n\"Currently, health agencies do not recommend vitamin D for the prevention of colorectal cancer,\" said Marji L. McCullough, ScD, American Cancer Society epidemiologist and co-first author of the study.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There are no unwarranted claims to novelty here and it is pretty clear that this is a subject that has a fairly long history of research.\nThe release also makes it clear what was new about the latest study compared to previous research. For example:\nA single, widely accepted assay and laboratory was used for new vitamin D measurements and calibration of existing vitamin D measurements. \u201cIn the past, substantial differences between assays made it difficult to integrate vitamin D data from different studies,\u201d explained Regina G. Ziegler, PhD, a National Cancer Institute epidemiologist and co-senior author on the article. \u201cThis calibration approach enabled us to systematically explore risk over the broad range of vitamin D levels seen internationally.\u201d", "answer": 1}, {"article": "The guidelines also suggest limiting screening to men with more than a 10-year life expectancy.\nBut, he added, \u201cIf we biopsied every man with a PSA below 4, we\u2019d be looking at a sea of cancers that would never grow to be life threatening.\u201d\n\nThese facts and the results of a recent study by Dr. Carter, among others, indicated that rather than acting on the basis of a single PSA test, the rate of change in levels over time is a better indicator of who might have a serious cancer.\nThis rate, known as PSA velocity, will be part of the new guidelines, which will suggest that in men with low readings, doctors consider the changes in levels over the course of three measurements.\nThe larger a man\u2019s prostate, the more PSA is produced, which makes the test very confusing in older men with benign enlargement of this gland.\nIts purpose is to liquefy the semen to release sperm, freeing them to fertilize an egg.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article describes the time PSA testing began to be used \u2013 in the early 1990's.\u00a0 It also talks about several variations of PSA testing (PSA velocity, free-PSA, complexed PSA), which are relatively new.\u00a0 ", "answer": 1}, {"article": "About 10 percent of the students had an abnormal EKG.\nThe severity of this and the other two problems that turned up as a result of the abnormal EKGs are reason enough, Debauche says, to screen all school athletes nationwide.\n\"It's pretty much while they're in training or while they're on the field performing, because that's when the adrenalin is flowing,\" and that's when they're calling on the heart for peak performance.\n\"Few of the kids actually experience sudden death while they're in class or at home,\" says Thomas Debauche, a Houston cardiologist.\nThe American Heart Association suggests that athletes who are identified as at risk for heart problems as a result of a family history or physical exam be referred for further cardiovascular examination, which could include an electrocardiogram.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n       \n \nScreening athletes for heart problems is not a new idea, and the story does not suggest that it is. However, the story could have done a better job of explaining how athletes are currently screened and the role of EKGs in this process. Current American Heart Association guidelines recommend EKG and other diagnostic testing for children presumed to be at higher risk of heart problems based on personal history, family history and physical examination. The report does not provide this important information until the final sentence of the story.\u00a0 \n \n", "answer": 1}, {"article": "Their editorial accompanies the Marban report in the Feb. 14 advance online issue of The Lancet.\n\"We have been trying as doctors for centuries to find a treatment that actually reverses heart injury,\" Eduardo Marban, MD, PhD, tells WebMD.\n\"These findings suggest that this therapeutic approach is feasible and has the potential to provide a treatment strategy for cardiac regeneration after [heart attack],\" write University of Hong Kong researchers Chung-Wah Siu and Hung-Fat Tse.\nThe finding, just in time for Valentine's Day, is the clearest evidence yet that literally broken hearts can heal.\nIt's the first completed, controlled clinical trial showing that scarred heart tissue can be repaired.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story hints at novelty but leaves readers confused. It says that this \u201cis the first completed, controlled clinical trial showing that scarred heart tissue can be repaired. Earlier work in patients with heart failure, using different stem cells or bone-marrow stem cells, also showed that the heart can regenerate itself.\u201d The press release for the study also makes a claim of novelty, saying that \u201cthis has never been accomplished before, despite a decade of cell therapy trials for patients with heart attacks.\u201d We wish the story had more clearly explained how this study was a significant improvement on earlier studies.\n\u00a0", "answer": 0}, {"article": "Newswise \u2014 New Brunswick, N.J. \u2013 June 2, 2016 \u2013 According to the American Cancer Society, the chance of being diagnosed with thyroid cancer has risen rapidly in the United States in recent years.\nIt\u2019s an exciting time in early phase drug development when we are observing these results in so many different types of cancer.\nThis appears to be due to increased use of technology to detect thyroid nodules that may not otherwise been found previously.\nThey target a certain protein that has the ability to shut down T cells \u2013 a part of white blood cells that help the body fight infection and disease naturally.\nNew treatments called \u2018immunotherapies\u2019 are being explored.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release clearly states this was the first time the drug was administered to thyroid cancer patients.", "answer": 1}, {"article": "By eating bread containing 4% of dried seaweed the overweight men ingested more dietary fiber (4.5 g more fiber per.\nBut the responsibility should also be shared by society, argues University of Southern Denmark professor of biophysics, Ole G. Mouritsen, who has authored several books on seaweed as food.\nAn important feature is also that the seaweed has umami - the fifth basic taste, which is known to promote satiety and hence regulate food intake in addition to reduce the craving for salt, sugar and fat.\n\"It is difficult to determine how much seaweed a person should consume to benefit from its good qualities.\nIt is also possible to add seaweed to meat products and thereby provide the consumer with an increased intake of dietary fiber and antioxidants - or maybe the aim is lower cholesterol levels.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The idea of adding \u201chealthier\u201d ingredients to processed foods to make them better is not new (e.g. fiber, vitamins, potassium, \u201chealthy\u201d oils) and hasn\u2019t produced much if any tangible benefit. Why will seaweed be any different? Many wild claims are made in this release. None are backed up.", "answer": 0}, {"article": "LONDON -- GlaxoSmithKline PLC said it has produced an effective bird-flu vaccine for humans and could begin producing the shots at year's end, leaving it to governments to decide whether to begin ordering the shots.\n\nGlaxo, the world's second-biggest drug maker by sales behind Pfizer Inc., called the findings a breakthrough but said it needs to gather additional data before it can answer several important questions, including how much of the vaccine it will be able to manufacture.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly states that this is a new vaccine.", "answer": 1}, {"article": "Breast cancer test kits by genetic testing company 23andMe just received Food and Drug Administration approval.\nMore: Breast cancer: Study finds tumor risk increased by use of oral contraceptives\n\nBut \u201cit has a lot of caveats,\u201d warned Donald St. Pierre, acting director of the FDA's Office of In Vitro Diagnostics and Radiological Health.\nStill, the company, which already tests DNA for other health risks as well as ancestry, said this cancer test is \"a step in the right direction.\"\nThese tests might help with prevention, but cannot diagnose cancer and cannot rule out your chances of getting cancer, 23andMe said.\n\u201cThe test should not be used as a substitute for seeing your doctor for cancer screenings or counseling on genetic and lifestyle factors that can increase or decrease cancer risk,\u201d he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does address the novelty here, but does so in an awkwardly phrased way. However, we addressed that under \u201cCompare alternatives.\u201d We don\u2019t want to ding the story twice for the same thing, so we\u2019ll let it pass here.", "answer": 1}, {"article": "The benefits were still seen after a year.\n\"Both acupuncture and traditional medicine have a place in treating fibromyalgia,\" said Dr. Alexander Rances, an acupuncturist, pain management specialist and attending physician at North Shore University Hospital in Manhasset, N.Y.\n\n\"A combination of Western as well as traditional Chinese medicine probably offers these patients the best possible therapy,\" he said.\nFibromyalgia treatment usually starts with medications such as the nerve pain medication Lyrica (pregabalin), and if that fails or is only partly effective, doctors might add acupuncture to the mix, Rances said.\nAccording to the study authors, nine out of 10 patients try some form of alternative therapy, such as massage or acupuncture, in addition to their regular pain medication.\n\"Individualized acupuncture is a safe and good therapeutic option for the treatment of patients with fibromyalgia,\" said lead researcher Dr. Jorge Vas, of the pain treatment unit at Dona Mercedes Primary Health Center in Seville, Spain.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Previous studies of acupuncture among fibromyalgia patients showed conflicting results. In this case, the story identifies that the acupuncture was individualized to the particular patients, as opposed to some general acupuncture approach, and compares an experimental group of participants with a control group, something missing in some earlier studies.", "answer": 1}, {"article": "Previous reports22,23 of the overall randomized clinical trial found locoregional control and survival advantages associated with the addition of cetuximab to radiotherapy.\nHistorically, locoregionally advanced squamous cell cancers of the larynx or hypopharynx have been treated with surgical resection, usually involving laryngectomy with or without postoperative radiotherapy.1 Although laryngectomy is an effective treatment, investigators have sought therapeutic strategies that result in voice preservation.\nFurthermore, there were greater severe acute toxic effects from the chemoradiotherapy treatments compared with radiotherapy alone,13 but no significant differences in severe late toxic effects were noted in the comparison of the 3 treatment arms.14 Unfortunately, the concomitant chemoradiotherapy arm had an increase in deaths not attributable to cancer compared with the other 2 arms; this finding needs to be explored further to determine whether undetected fatal late treatment toxic effects are greater with concomitant regimens.\nIn a recent trial from France, 269 patients were queried about the treatment choices they might make if they faced the diagnosis of advanced laryngeal cancer.30 Only 29% stated that they would not consider options with a lower chance of cure if told that the best option, with respect to survival, was total laryngectomy.\nVarious modifications of surgical techniques have been explored.2-5 Alternatively, in the early 1980s, investigators evaluated curative primary radiotherapy with salvage surgery as an option for these patients.6,7 Retrospective studies8,9 that compared primary radiotherapy with salvage surgery to initial surgery with postoperative radiotherapy found similar rates of survival in patients with advanced laryngeal or hypopharyngeal cancers.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Earlier studies have looked at the use of cetuximab and radiation therapy in treating head and neck cancers. For example, \u201cConcurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer\u201d was published in 2011. And \u201cCetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab\u201d came out in 2004. Granted, these are not necessarily addressing the same thing as \u201claryngeal preservation\u201d in patients with larynx or hypopharynx cancers \u2014 but it\u2019s certainly worth mentioning. Readers could easily infer from the release that using cetuximab and radiation therapy in conjunction to treat throat cancers is relatively new \u2014 and it\u2019s not.", "answer": 0}, {"article": "Researchers from the United Kingdom conducted a randomized controlled trial on the effectiveness of advice from primary care physicians to use nasal irrigation and/or steam inhalation for chronic sinusitis.\n\"We found potentially important changes in other outcomes; in particular, fewer participants in the nasal irrigation group than in the no-irrigation group had headaches, used over-the-counter medications and intended to consult a doctor in future episodes,\" write the authors.\n\"We have found that even a very brief intervention of a video showing patients how to use saline nasal irrigation can improve symptoms, help people feel they do not need to see the doctor to manage the problem, and reduce the amount of over-the-counter medication they need to use,\" said Dr. Paul Little, Primary Care and Population Sciences Unit, University of Southampton, Southampton, United Kingdom.\nThe study involved 871 patients from 72 primary care practices in England who were randomly assigned to 1 of 4 advice strategies: usual care, daily nasal and saline irrigation supported by a demonstration video, daily steam inhalation, or combined treatment with both interventions.\nAdvising patient with chronic sinus congestion to use nasal irrigation - a popular nonpharmacologic treatment - improved their symptoms, but steam inhalation did not, according to a randomized controlled trial published in CMAJ (Canadian Medical Association Journal).\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does not make a claim for the novelty of this trial. However, the study itself states it is \u201cone of few studies to address the effectiveness of brief advice to use nasal irrigation\u201d and \u201cthe largest trial in any setting.\u201d Both of those facts belonged in the release.", "answer": 0}, {"article": "Andersson will be available to the media in an embargoed web briefing on Tuesday, March 7, 2017, at 2 p.m.\nHowever, previous studies have associated the use of PDE5 inhibitors with a decreased blood pressure in the left ventricle, which reduces the amount of work required to pump blood and therefore could help explain why the drugs might benefit people with heart failure.\nThe researchers also were unable to account for socioeconomic status; as a next step, they are planning a larger study that will include more health records and complete information on marital status, educational level and disposable income.\nA limitation of the study is that the researchers did not assess the effects of untreated erectile dysfunction, or conversely, the effect of having an active sex life without taking erectile dysfunction drugs.\nAfter adjusting for cardiovascular risk factors including diabetes, heart failure and stroke, those taking PDE5 inhibitors were found to be markedly less likely to die than those taking alprostadil or no erectile dysfunction drugs.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "As noted in the release, the study appears to be the first to examine\u00a0if there is an\u00a0association between treatment for ED and death or cardiovascular outcomes after a first heart attack.", "answer": 1}, {"article": "Eli Lilly announced promising data on its efforts to have its Cymbalta depression treatment also used as pain medicine, saying a study showed the drug \"significantly\" reduced chronic lower-back pain.\n\nLilly has been looking at the potential of Cymbalta for relieving the discomfort of fibromyalgia and osteoarthritis pain as well as back pain. The company's results of late have been boosted by the antidepressant, whose second-quarter sales jumped 26% to $654.4 million.", "question": "Does the story establish the true novelty of the approach?", "explanation": "We know it\u2019s a depression treatment now in search of a broader market for various forms of pain control.\u00a0 What is truly novel about this approach is never explained.\u00a0 What is the mechanism of action that would make this novel? There are other medicines of a similar nature that have been tried for chronic pain.\u00a0 ", "answer": 0}, {"article": "The new research paper also demonstrates how the plant-based chemicals work together.\nThe most promising active ingredients were then tested on model animals: ursolic acid, a waxy natural chemical found in apple peels and rosemary; curcumin, the bright yellow plant compound in turmeric; and resveratrol, a natural compound common to red grapes or berries.\nNew research from The University of Texas at Austin identifies several natural compounds found in food, including turmeric, apple peels and red grapes, as key ingredients that could thwart the growth of prostate cancer, the most common cancer afflicting U.S. men.\n\"After screening a natural compound library, we developed an unbiased look at combinations of nutrients that have a better effect on prostate cancer than existing drugs,\" says corresponding author Stefano Tiziani, assistant professor in the Department of Nutritional Sciences and Dell Pediatric Research Institute at UT Austin.\nThe experiment was designed, analyzed and written up with coauthors Alessia Lodi, John DiGiovanni and Achinto Saha, all of UT Austin.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release provides perspective, stating that the research \u201cuses a novel analytical approach to screen numerous plant-based chemicals instead of testing a single agent as many studies do, discovering specific combinations that shrink prostate cancer tumors.\u201d The claim of novelty seems appropriate regarding the approach to\u00a0screening.\nIt also states that the research \u201cdemonstrates how the plant-based chemicals work together. Combining ursolic acid with either curcumin or resveratrol prevents cancer cells from gobbling something that they need to grow, glutamine.\u201d\nFinally, it acknowledges previous research that has \u201chighlighted the potential therapies found in plants, including chemicals found in foods such as turmeric, apple peels and green tea.\u201d", "answer": 1}, {"article": "Merck & Co. and Schering-Plough Corp. said a long-awaited trial showed their cholesterol drug Vytorin failed to slow progression of heart disease better than a cheaper drug, threatening the companies' $5 billion-a-year cholesterol-fighting franchise.\n\nSchering-Plough's shares fell 8% to $25.52 and Merck declined 1.3% to $59.78 at 4 p.m. in New York Stock Exchange composite trading.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear about the novelty aspect of the product reported on. What is important for consumers is that although the combination may be novel, the treatment of elevated cholesterol and reduction in plaque burden may be accomplished using either one of the test drugs (simvastatin) or one of the other statins. ", "answer": 1}, {"article": "To book an interview, please contact: \n\nTucker Wilson \n\nMedia Relations \n\nFaculty of Health Sciences \n\nMcMaster University \n\n(905) 525-9140, ext.\nIn a study, recently published in the journal Vaccine, the researchers show that a novel chlamydial antigen known as BD584 is a potential vaccine candidate for the most common species of chlamydia known as Chlamydia trachomatis.\nThis is why the promise of a vaccine would be extremely beneficial, says David Bulir, co-author of the study.\nThe results look very promising, said senior author James Mahony, a professor of Pathology and Molecular Medicine for McMaster's Michael G. DeGroote School of Medicine and a researcher at St. Joseph Healthcare Hamilton's Research Institute where the work was performed.\nThe antigen also decreased hydrosalpinx, another C. trachomatis symptom which involves fallopian tubes being blocked with serous fluids, by 87.5 per cent.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There\u2019s no shortage of claims of novelty in the release, including in the headline. Although the release is misleading about the study cohort, it is a novel study given the absence of any available chlamdyia vaccines.", "answer": 1}, {"article": "Flavonoids have been found to relax blood vessels and thereby improve blood flow, inhibit platelets from sticking together in the blood, and have a beneficial antioxidant effect. What still is not known is whether regularly eating dark chocolate, especially with its high sugar and fat content, eventually will lead to an unhealthy weight gain that would erase the beneficial effects of the flavonoids found in the cocoa.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story says this is the \u201clatest in a growing number\u201d of studies in this area. ", "answer": 1}, {"article": "The distorted valve functions poorly, its flaps swinging apart.\nIn the new study, a device called the MitraClip was used to repair the mitral valve by clipping its two flaps together in the middle.\nIn the new trial, 614 patients with severe heart failure in the United States and Canada were randomly assigned to receive a MitraClip along with standard medical treatment or to continue with standard care alone.\nThe enlarged organ tugs apart the mitral valve, which controls blood flow from the left atrium into the left ventricle.\nThe result was to convert a valve that barely functioned into one able to regulate blood flow in and out of the heart.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story quoted several doctors who spoke of the trial results in glowing terms: \u201chuge advance\u201d \u201cvery, very powerful message,\u201d \u201cgame changer,\u201d and \u201cmassive.\u201d\nBut it downplayed another recent trial that showed the clip offered no benefit, saying \u201cthat research included many patients with less severe valve problems, the procedure was not performed as adeptly, and the patients\u2019 medications were not as well optimized as in the new study.\u201d\nAnd the story didn\u2019t mention that there\u2019s a third trial, results of which are due to be released soon.\nWhat the story also didn\u2019t say is that some physicians are apparently waiting to see the results of all three trials before rendering a verdict.\nAs cardiologist John Mandrola, MD, put it on his blog:\nWhat we have then is two randomized trials with conflicting results. That means we don\u2019t know whether the device works, and we need a tie-breaker trial. Fortunately, one is coming soon.", "answer": 0}, {"article": "Natural remedies have an obvious appeal, but how do you know which ones to choose and whether the claims are backed by science?\nThe thinking is that sweet substances of any kind help soothe the back of the throat and break up mucus in the airways.\nUltimately, the honey produced the greatest improvements when it came to better sleep and reduced cough frequency and severity.\nHoney is also known to have antioxidant and antimicrobial properties.\nThe children were given a cough syrup with dextromethorphan, a cough syrup containing an antihistamine, or a placebo, which was essentially flavored water.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that honey is commonly used to treat the symptoms of colds.", "answer": 1}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.\nThe most common exam offered for asymptomatic patients seeking supplemental screening is a whole breast screening ultrasound examination.\nIn addition to Weinstein, additional authors include Mitchell D. Schnall, Elizabeth S. McDonald, Alice Chong, and Emily F. Conant.\nIn a study of 195 asymptomatic women with dense breast tissue who had a negative mammogram within the previous 11 months, AB-MR detected five additional cancers after a negative screening mammography, according to preliminary findings from a Penn Medicine team presented this week at the Radiological Society of North America meeting in Chicago.\nBased on the preliminary results at Penn Medicine, the cancer detection rate of AB-MR screening is 25 cancers per 1,000 patients.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It\u2019s unclear how abbreviated breast MRI is different from full breast MRI. The difference is not explained in the release. It\u2019s also unclear if the abbreviated breast MRI is novel for screening versus diagnostic testing.", "answer": 0}, {"article": "Arena then hopes to file its request for market approval with the Food and Drug Administration by the end of 2009.\nThe experimental drug stimulates the 5-HT2C serotonin receptor, which is located in the hypothalamus, an area of the brain associated with regulation of food intake and metabolism.\nThe drug also proved to be highly selective, meaning it hit the intended targets inside the body and did not cause troubling side effects.\nBut one of the two components of that drug made by Wyeth, fenfluramine, also hit a second target in the heart, which was linked to heart valve problems.\nThose people taking the drug also saw reduced cholesterol levels and waist size, changes that have been linked to lessening cardiovascular risk factors such as blood pressure.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story described that lorcasein targeted the 5HT-2c serotonin receptor but was specific to the brain receptor as opposed to fenfluramin which was less selective and was found to also target a serotonin receptor in the heart.", "answer": 1}, {"article": "Avastin is undercutting sales of Lucentis, which totaled $1.1 billion in the United States last year.\nAlthough it is a cancer drug, Avastin is often used off-label for eye diseases because it is far cheaper than Lucentis, costing only $20 to $100 a dose, compared with $2,000 for Lucentis.\nIn macular edema, fluid from those damaged vessels leaks into the macula, the part of the retina that is responsible for the straight-ahead vision important for driving, recognizing faces and reading.\nAfter the first year, only 3 to 4 percent of the eyes treated with Lucentis suffered a visual loss of two or more lines compared to 13 percent that got only laser therapy.\nDr. Neil M. Bressler of Johns Hopkins University, the chairman of the group that conducted the trial, said a two-line improvement in vision would allow some people to read normal-size print or to drive again.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story was very clear that this was a new use for a medication that is already on the market. \u00a0The story provided some insight that the company underwriting the costs of this study had a very similar but less expensive drug which was FDA approved for other use. \u00a0It would have been useful to include a little more information comparing the two medications. \u00a0It might also have been nice to include some information about how the drug studied works as compared to laser treatment, the current standard.", "answer": 1}, {"article": "WASHINGTON (Reuters) - Screening smokers and former smokers for lung tumors using three-dimensional X-rays reduced their risk of dying from lung cancer by 20 percent, researchers said on Thursday.\nHer ideas were controversial to start with and widely disregarded when other researchers found her work had been paid for by a tobacco company.\nThe researchers said their findings could save thousands of lives.\n\u201cThis screening does not prevent lung cancer and it does not protect the large majority of subjects from death by lung cancer,\u201d Varmus said.\nThis is huge,\u201d said Regina Vidaver, executive director of the National Lung Cancer Partnership.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does note previous work in the early detection of lung cancer using spiral CT scanning.", "answer": 1}, {"article": "Oct. 25, 2010 -- Aspirin , already linked in some studies to a lower risk of developing colon cancer , may also cut the risk of dying of prostate cancer by more than half, a large study suggests.\nResearchers stress the findings are preliminary and that men with the cancer should not reach for the aspirin bottle in an attempt to improve their health.\nAlso, lab and animal studies suggest drugs that anticlotting drugs like aspirin may interfere with cancer growth and spread.\nThe findings were released at a news briefing held in advance of the annual meeting of the American Society for Radiation Oncology (ASTRO) in San Diego.\nBy 10 years after diagnosis, 10% of men not taking one of these medications had died from prostate cancer vs. 4% of those who took an anticlotting medication.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story notes that this study builds on clues from clinical experience as well as lab and animal experiments suggesting there may be a relationship between blood clotting and how cancer spreads.", "answer": 1}, {"article": "(Boston) -- To date, there are no methods that can quickly and accurately detect pathogens in blood to allow the diagnosis of systemic bloodstream infections that can lead to life-threatening sepsis.\nBiomarkers that report elevated inflammation are used clinically in the treatment of patients with sepsis; however, they fail to distinguish inflammation triggered by infectious pathogens from that induced by non-infectious causes, such as burns, traumas and surgeries.\nThe diagnostic assay is built on FcMBL, a genetically engineered pathogen-binding protein previously developed by Ingber and Michael Super, a Wyss Senior Staff Scientist who co-leads the Institute's pathogen-detecting effort.\n\"In our latest work, we show that the FcMBL-based pathogen-detecting assay is considerably faster and more accurate than any other available assay for systemic infection.\nWe are currently working to ready it for high-throughput use in clinical and point of care situations and to accelerate it even further,\" said Mark Cartwright, Ph.D., a Staff Scientist at the Wyss Institute and a lead-author on the study.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes that the new test fills \u201ca void\u201d among tests that detect for infectious pathogens. The release also does a good job of explaining what is new and different about the assay\u2019s underlying technology.", "answer": 1}, {"article": "Despite popular lore, agency won't allow labels to say drink is good for consumers' hearts\n\nWASHINGTON - There is no credible scientific evidence that drinking green tea reduces the risk of heart disease, federal regulators said last week in rejecting a petition that sought to allow tea labels to make that claim.\nUnlike black and oolong tea, it is made from unfermented tea leaves.\nGreen tea is brewed from Camellia sinensis, also known as Thea sinensis.\nA health claim, in the language of the FDA, characterizes the relationship between a substance and a reduction in the risk of contracting a particular disease.\nThe Food and Drug Administration said it reviewed 105 articles and other publications submitted as part of the petition but could find no evidence to support claims of the beverage's health benefits.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Consumption of green tea was not touted as being new or novel. The history of green tea consumption is centuries old.", "answer": 1}, {"article": "\u201cIt\u2019s one and done,\u201d he said.\nIt has been shaking for years and they look at it as though, \u2018Hmm, is this really my hand?\u2019 It\u2019s really a remarkable moment.\u201d\n\nFor Samuels, who underwent the procedure on June 29, the recovery has been surprising.\nThe therapy, called focused ultrasound thalamotomy, uses the energy generated by sound waves to burn off certain cells in the thalamus, a region of the brain where the essential tremor is thought to originate.\nIt has been developed by InSightec, which is funding the trial along with the Focused Ultrasound Foundation and the Binational Industrial Research and Development Foundation.\nThe doctors at Brigham will follow up with Samuels \u2014 and others who undergo the treatment \u2014 for up to five years and run more MRI scans and neurological exams to find out for how long the lesion lasts and keeps the tremor suppressed.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is indeed a new treatment option for essential tremor, though the story may leave readers with the false impression that the concept of killing off neurons in the thalamus is new. Rather, it\u2019s the use of focused ultrasound to destroy brain tissue, rather than a probe inserted in the brain, that constitutes an advance.", "answer": 1}, {"article": "Source: Stewart RAH, Wallentin L, Benatar J, et al.\nParticipants eating a Mediterranean diet showed a lower risk of heart attack and stroke, the researchers discovered; yet, eating healthy food appeared to be more important than avoiding unhealthy foods identified as typical of a so-called Western diet, such as French fries, fatty red meats, and, yes, even cake.\nNow here\u2019s the interesting part: eating more foods thought to be less healthy \u2014 those typical of Western diets \u2014did not link to an increase in heart attacks, strokes, or deaths.\nIn fact, every one-point increase in a participant\u2019s Mediterranean diet score was linked with a 7 percent reduction in risk of heart attack, stroke, or death.\nThis classic diet does not exclude a dinnertime glass of wine, however, sugary drinks, fried food, and sweets are not on the menu.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Novelty is addressed with these statements, \u201cSurprisingly, the results suggest it might be possible they can have their cake and eat it, too.\u201d and \u201cNow here\u2019s the interesting part: eating more foods thought to be less healthy \u2014 those typical of Western diets \u2014did not link to an increase in heart attacks, strokes, or deaths. Eating more healthy foods was the key, even if some unhealthy foods were also consumed along the way.\u201d", "answer": 1}, {"article": "He'd read about advances in targeted therapies \u2014 drugs that go after cancer cells at the molecular level.\nBut in the meantime, patients like Anselmo are grateful to have time they wouldn't have had otherwise.\nWhy Doctors Are Trying A Skin Cancer Drug To Treat A Brain Tumor\n\nMaryAnn Anselmo feared for the worst when she was diagnosed with a brain tumor called a glioblastoma in late 2013.\nCalled a basket trial, the study is designed to include people whose tumors have the same kind of genetic fingerprint regardless of where in the body the tumors are found.\nOur series is produced with member station WNYC, and with Ken Burns Presents: Cancer: The Emperor of All Maladies, which will air on PBS starting March 30.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The fact that GBM patients respond to a drug commonly used in skin cancer patients (i.e. those with the BRAF mutation) is novel and clearly portrayed. It would have strengthened the article, however, to more clearly explain how genetic testing can generate new leads in treating cancer by briefly expanding on other types of mutations in cancer and the drugs that can target them.", "answer": 1}, {"article": "Wiley is a global provider of knowledge and knowledge-enabled services that improve outcomes in areas of research, professional practice and education.\nThis can result in a significant decrease in sperm count--leading to infertility--because the body needs its own testosterone to produce sperm.\nThe findings, which are published in BJU International, could change the way men are treated for low testosterone.\nTwo phase III clinical trials show that a drug that restores the body's natural production of testosterone has no negative effect on a man's sperm count while a topical testosterone gel causes a significant drop.\nAn alternative approach to testosterone replacement is based on restoring the body's natural production of testosterone with drugs similar to those used to help women ovulate.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release doesn\u2019t provide any information about other alternatives to testosterone replacement therapy.\nIs there other research in this field? Are other drugs being investigated in a manner similar to these studies about\u00a0Enclomiphene? We\u2019d never know based on this news release.\nGiven the on-going disease mongering surrounding \u201clow T\u201d perpetrated by pharmaceutical companies, one obvious alternative is no treatment.", "answer": 0}, {"article": "See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.\n\"The CaverStem\u2122 procedure involves obtaining a small amount of bone marrow from the patient, purifying the stem cells using a closed system device that is FDA cleared, and then administering these cells in the same procedure into the patient's penis,\" said Thomas Ichim, Ph.D, Chief Scientific Officer and Co-Founder of the Company.\n\"Based on establishment of safety of the CaverStem\u2122 procedure in a formal university-based clinical trial, and independent confirmation of efficacy in an European clinical trial1, we have launched commercialization for the CaverStem\u2122 procedure,\" said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings.\nThe goal of this procedure is to regenerate blood vessels and smooth muscle, parts of the penis that are not functioning properly in this patient population.\nAccording to the National Institutes of Health, approximately 30 million men in the United States suffer from Erectile Dysfunction2, of which 9 million do not respond to pharmacological treatments such as Viagra, Levitra and Cialis.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release itself does not claim that the\u00a0CaverStem is a novel procedure but the release is obviously promoting the treatment as a new option for patients. The release does refer to a European study as proof of efficacy and appears to claim that the same researchers were involved in this work. ", "answer": 1}, {"article": "As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit.\nThe researchers conducted this study to further clarify the association between metformin use and lung cancer risk.\nThis study was funded by the National Institutes of Health.\nInformation on their diabetes medications was collected from electronic pharmacy records.\nSome laboratory studies and a number of observational studies suggest that metformin may prevent cancer, but the data from human studies, however, are conflicting, explained Sakoda.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does reference earlier research that offered conflicting findings and supports the need for this larger study.", "answer": 1}, {"article": "The results were presented Thursday at the American College of Neuropsychopharmacology annual meeting in Hollywood, Fla.\n\"We saw a robust, rapid-acting, long-lasting effect,\" said lead researcher Joseph Moskal, a research professor of biomedical engineering at Northwestern's McCormick School of Engineering and Applied Science and director of the school's Falk Center for Molecular Therapeutics.\nFRIDAY, Dec. 7, 2012 (HealthDay News) -- An experimental antidepressant that targets the brain in a different way appears to both act fast and last long, researchers say.\nThe new drug -- called GLYX-13 -- is so far given in an intravenous form and was recently tested in patients who had not responded to other antidepressants.\nAn advantage is that the drug doesn't have the side effects of other drugs that target these same areas, such as hallucinations and schizophrenia-like symptoms, the researchers noted.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is also a mixed bag. The story got rid of some of the more scientific jargon that was included in the press release, but in the process, some bits became ambiguous. Establishing novelty is one example. This is a novel approach; no drugs on the market have the same mechanism.\u00a0 There is intense interest in this field by the National Institutes of Health. The story states, \u201cMoskal\u2019s team developed a new way to target the brain\u2019s NMDA (N-methyl-D-aspartate) receptor\u2026\u201d but in fact, other antagonists, such as the anesthetic ketamine, work in a somewhat similar fashion.\u00a0 GLYX-13 targets brain receptors responsible for learning and memory, which is a different approach from most popular antidepressants that work by improving levels of the hormone serotonin. Although pieces of this information are stated in the article, this does not clearly come across to the reader. Nonetheless, we\u2019ll give the story the benefit of the doubt on this criterion.", "answer": 1}, {"article": "(CNN) A new blood test may be as accurate as a test requiring a painful spinal tap for differentiating Parkinson's disease from similar disorders, according to a study published Wednesday in Neurology, the medical journal of the American Academy of Neurology.\nThis protein is a component of nerve cells, and when these cells die, it can be detected in both spinal fluid and blood.\nBecause spinal fluid is not easily obtained by a primary care doctor, this diagnostic test is not very useful, so Hansson developed a blood test and investigated its accuracy in the new study.\nHowever, the test cannot distinguish between the different atypical disorders, which doctors must rely on symptoms to diagnose.\nYet patients with atypical disorders \"usually have a much worse prognosis, with faster disease progression, (with) more disabling symptoms\" than Parkinson's patients, so early identification is crucial.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that the novelty here is that this would be a blood test to\u00a0distinguish among Parkinson\u2019s disease and similar disorders, versus the more invasive spinal tap.", "answer": 1}, {"article": "Fleming and Dilger's co-authors include Supida Monaikul, Alexander Patsavas, Rosaline Waworuntu, and Brian Berg.\nThe article, \"Dietary polydextrose and galactooligosaccharide increase exploratory behavior, improve recognition memory, and alter neurochemistry in the young pig,\" is published in Nutritional Neuroscience.\nAlthough more work is needed to tackle remaining questions, the study adds to the growing body of research suggesting a strong and potentially modifiable link between the gut and the brain: a link that makers of infant formula should strongly consider.\nThe preference for novel objects, an indication of natural curiosity, is a sign of healthy brain development and points towards positive development of learning and memory.\n\"We found that, yes, VFAs are absorbed in the blood of pigs that were fed PDX/GOS.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release hints that the novelty of the research is that the formula testing involved piglets instead of the traditional rodents used in such studies. \u201cPiglets are widely considered a more informative model for human infants than mice and rats; their digestive systems, behavioral responses, and brain development are remarkably similar to human infants,\u201d the release claimed.", "answer": 1}, {"article": "An experimental drug designed by Roche Holding AG's Genentech unit against a new cancer target yielded encouraging results against two rare tumors, researchers said, potentially opening up a new front in the battle against the disease.\n\nIn a small study, the drug, known as GDC-0449, shrank tumors in 18 of 33 patients, or 55%, with an advanced form of a skin cancer called basal cell carcinoma. In addition, the drug had a dramatic, though temporary, effect on a 26-year-old patient who had undergone multiple surgeries, chemotherapy...", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is story makes it clear this is a novel drug in the\u00a0early phase of testing. ", "answer": 1}, {"article": "In 2012, a federally funded panel of experts on preventive care concluded there are more risks than benefits to screening American men for prostate cancer with the PSA test. And in April 2017, the U.S. Preventive Services Task Force dumped the decision squarely into the laps of patients and their doctors. Some men between 55 and 69 years of age might well decide to get their PSA checked, the task force said. After hearing the ledger of pros and cons, however, others in that age bracket might just as reasonably skip the screening test, the panel concluded.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not explain how or why this analysis of two trials is potentially more informative than the original separate studies themselves.", "answer": 0}, {"article": "Ingelfinger, who wrote an editorial published with the study, echoed Montgomery's cautious optimism.\nBut the findings mark another step forward for patients like these, according to Jordan, who is medical director of the kidney transplant program at Cedars-Sinai, in Los Angeles.\n\"The desensitization protocols now in use are time-consuming, and they don't always work,\" she said, noting that they can leave dangerous antibodies behind.\nThe enzyme is derived from a strain of Streptococcus bacteria, and it essentially chops up the antibodies that would attack the organ.\nJordan acknowledged that the source \"sounds scary,\" but stressed that patients do not receive the bacteria itself -- but an engineered version of the enzyme.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article makes it clear that this treatment is novel, but could have been much strengthened if it had explained more of the biology of the enzyme and the way it was developed. One of the experts quoted was clearly astonished enough at the effects of the enzyme that he would consider it a \u201cgame changer\u201d if further studies verify its impact. But just why the enzyme works is not clearly explained.", "answer": 1}, {"article": "Kappelmann, N et al.\nThe research was mainly funded by the Wellcome Trust, with further support from the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre.\nDr Golam Khandaker, who led the study, says: \"It's becoming increasingly clear to us that inflammation plays a role in depression, at least for some individuals, and now our review suggests that it may be possible to treat these individuals using some anti-inflammatory drugs.\n\"It's too early to say whether these anti-cytokine drugs can be used in clinical practice for depression, however,\" adds Professor Peter Jones, co-author of the study.\n\"We will need clinical trials to test how effective they are in patients who do not have the chronic conditions for which the drugs have been developed, such as rheumatoid arthritis or Crohn's disease.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The implication is that the meta study is one of the first to look across the board at the secondary results of anti-inflammatories on depression. However, this has been an active area of research for at least a decade.", "answer": 0}, {"article": "About 15 percent of dialysis patients have HCV, the researchers said.\nTUESDAY, Aug. 7, 2018 (HealthDay News) -- Dialysis patients waiting for kidney transplants might safely accept an organ from a donor infected with hepatitis C virus (HCV), a new study finds.\nAnd the average wait time for a non-infected kidney is more than two years, compared to eight months for an HCV-infected kidney.\n\"Because of the opioid crisis, there are many people who die from a drug overdose and have HCV and want to donate their organs.\"\nThough some patients might not want to take the risk associated with an infected kidney, others might consider it a good option, given the high death rates for dialysis patients awaiting transplants, the researchers suggested.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explained that more effective and safer treatments to rid the body of HCV \u2014 along with the availability of kidneys from younger donors \u2014 have made this a potentially viable strategy to increase the kidney pool.\nIt also mentioned related research: \u201cAnother study, published in the same journal in July, reported similar success in transplants of HCV-infected kidneys into HCV-infected patients. About 15 percent of dialysis patients have HCV, the researchers said.\u201d", "answer": 1}, {"article": "Learn more at www.cancer.unm.edu.\nWhenThe paper, \u201cEfficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study,\u201d was published in the June 28, 2016 online edition of The Lancet (www.thelancet.com/infection).\nNewswise \u2014 WhatA research paper published in The Lancet Infectious Diseases reported that the human papillomavirus (HPV) vaccine is safe and efficacious across a wide age range of women.\nThrough its partnership with the New Mexico Cancer Care Alliance, an \u201cexemplary national model for cancer health care delivery,\u201d the UNM CCC offers access to more than 175 clinical trials to New Mexicans in every part of the state.\nAuthors are: Cosette M Wheeler, S Rachel Skinner, M Rowena Del Rosario-Raymundo, Suzanne M Garland, Archana Chatterjee, Eduardo Lazcano-Ponce, Jorge Salmer\u00f3n, Shelly McNeil, Jack T Stapleton, C\u00e9line Bouchard, Mark G Martens, Deborah M Money, Swee Chong Quek, Barbara Romanowski, Carlos S Vallejos, Bram ter Harmsel, Vera Prilepskaya, Kah Leng Fong, Henry Kitchener, Galina Minkina, Yong Kuei Timothy Lim, Tanya Stoney, Nahida Chakhtoura, Margaret E Cruickshank, Alevtina Savicheva, Daniel Pereira da Silva, Murdo Ferguson, Anco C Molijn, Wim G V Quint, Karin Hardt, Dominique Descamps, Pemmaraju V Suryakiran, Naveen Karkada, Brecht Geeraerts, Gary Dubin, and Frank Struyf, for the VIVIANE Study Group.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release doesn\u2019t make a claim of novelty, and rightly so. There wasn\u2019t a basis for it.\nThe study and its results aren\u2019t novel. The vaccine has been tested in older women before and not found to be very effective because of prevalence of HPV infection prior to vaccination. This study shows some benefit but needs to be compared and contrasted to previous studies on this topic.", "answer": 0}, {"article": "Other expert groups have made similar statements.\nIf you are allergic to mold spores or to pollen from trees, grasses or ragweed, that means knowing when levels are high (by checking pollen.com or the National Allergy Bureau) and then taking steps such as these recommended by the American Academy of Allergy, Asthma and & Immunology:\n\u2022 Keep windows closed at home and in your car.\nThese drugs work by fighting inflammation and they are in the \"single most effective drug class\" for treating nasal allergies, according to the American College of Allergy, Asthma & Immunology.\nFor example, Walmart sells Equate loratadine tablets (the same active ingredient as Claritin) for about $7 for 60 24-hour doses\n\nAntihistamines make perfect sense for someone who suffers a few sneezy days each season and doesn't want to use a spray for weeks or months, Eghrari-Sabet says.\n\"These are first-line treatments\" that can prevent allergy symptoms, not just treat them, says Jackie Eghrari-Sabet, an allergist in Gaithersburg, Md.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Nasal steroids are not a new concept: They have been developed since at least the 1950s and have been tested in lab and clinical trials since the 1990s.\nWhat is new about Flonase is that it\u2019s now available over the counter, after the US Food and Drug Administration approved its use without a prescription last July, according to media reports at the time.\nSince this fact is clear early in the story, we give it a satisfactory rating.", "answer": 1}, {"article": "LOS ANGELES (Reuters) - Scientists for the first time have used gene therapy to successfully destroy cancer tumors in patients with advanced disease \u2014 a goal that has taken 20 years to achieve.\nIn addition, the long-term viability of the treatment is still unknown.\nWe are going to give you an immune response,\u201d Kalos said.\n\u201cWe are saying forget about stimulating an immune response.\nA third had a strong anti-tumor response, and his cancer remains in check.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Satisfactory job establishing the novelty \u2013 even in the first line of the story.", "answer": 1}, {"article": "The restrictive diet lasted for five weeks.\n\"Since none of the children stayed on the diet beyond five weeks, it is hard to know if this dietary intervention offers sustained benefit,\" he said, adding, \"Since it is more difficult to enforce restricted diets in older children, this approach may not be suitable for the majority of older children with ADHD.\"\n\"We think that dietary intervention should be considered in all children with ADHD, provided parents are willing to follow a diagnostic restricted elimination diet for a five-week period, and provided expert supervision is available,\" they concluded.\n\"If parents have noticed that a child's behavior seems to get worse with certain foods, it may be worth considering,\" said Ghuman, who is an associate professor of psychiatry and pediatrics at the University of Arizona in Tucson.\nTHURSDAY, Feb. 3, 2011 (HealthDay News) -- A special restrictive diet may significantly reduce symptoms of attention-deficit hyperactivity disorder (ADHD) in young children, a new study suggests.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story missed a key fact from the study itself. The researchers reviewed the literature and found seven previous clinical trials on diets and ADHD that included 188 children. This one study covered 100 kids. If presented, that would have been strong evidence for the study\u2019s novelty.", "answer": 0}, {"article": "A widely anticipated study suggests that hormone therapy started soon after menopause can ease depression, anxiety, hot flashes and other adverse symptoms that many women face, without increasing risks for cardiovascular disease.\n\nThere was no increase in breast cancer, stroke, heart attack or blood clots, but the study's researchers said the sample size was too small and the study time too short to draw firm conclusions.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article explains that this type of study had been conducted before with the WHI.\nBut we would have hoped for a little more explanatory background and context.\u00a0 The article doesn\u2019t adequately address the point that it is a novel study, because it looks specifically at early menopausal women and effects of hormone therapy on blood vessels \u2013 a not unreasonable early surrogate for harder endpoints such as CV disease events. The findings are actually not novel. The WHI analysis of a subset of younger menopausal women, published in 2007, showed that there was less coronary artery calcification in women treated with Estrogen and Progesterone compared with those who took placebo; a finding the KRONOS researcher thought they would also see, but did not. (They report a nonsignificant trend toward less calcification).", "answer": 0}, {"article": "MONDAY, Aug. 1, 2011 (HealthDay News) -- When women take a supplement of the omega 3 fatty acid DHA during pregnancy, their babies have fewer cold symptoms and shorter illnesses, new research indicates.\nAnd, at 6 months, the babies whose mothers had DHA had shorter duration of fever, runny nose and breathing problems.\nThe babies were assessed at 1, 3 and 6 months of age, and the mothers completed questionnaires about their babies' health.\nAlso at 1 month, babies whose mothers had gotten the DHA supplement had 26 percent shorter duration of cough, 15 percent less time with phlegm and 30 percent shorter duration of wheezing.\nAnd, in the case of colds, the probability of a cold was slightly less.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story indicated that the study reported on was unique in that it looked at whether providing pregnant women with DHA supplements had an impact on the subsequent health of their offspring.", "answer": 1}, {"article": "The U.K.\u2019s new at-home HIV test won\u2019t reach all the undiagnosed or guarantee that the people who test positive wind up receiving the care they need from a doctor, but letting people check their status quickly and accurately is likely to produce cascading positive effects, as HIV-positive people find it easier to seek care for themselves, warn past partners about exposure, and reduce risk for future partners.\nThat suggests that both countries still face serious gaps in diagnosis.\nThe United Kingdom\u2019s National Health Service offers free HIV testing.\nThis wasn\u2019t because they had never been screened; 81 percent of the undiagnosed men had been tested for HIV previously.\nThe British test will probably make it easier for people to be screened for the first time and will allow people to re-screen themselves more frequently.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains some of the differences between this HIV test and others.", "answer": 1}, {"article": "He and his colleagues are now planning a multicenter trial of fish oil for the prevention of psychotic illness in 320 at-risk people.\nThe researchers included people who met at least one of the following three criteria: having low-level psychotic symptoms; having transient psychotic symptoms; or having a schizophrenia-like personality disorder or a close relative with schizophrenia, along with a sharp decline in mental function within the past year.\nFurthermore, only about a third of people at high risk for psychotic disorders will go on to develop full-fledged mental illness in a given year.\nThe effect of fish oil capsules, Amminger noted, was similar to that seen in two trials of antipsychotic drugs in at-risk individuals.\nThere\u2019s considerable evidence that abnormal fatty acid metabolism may contribute to the development of schizophrenia, Amminger and his team note in the Archives of General Psychiatry.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story doesn\u2019t indicate that prior research has examined the role of fish/oil/omega-3 PUFAs in patients with psychiatric disorders.\u00a0 Previous studies have shown mixed results. The research discussed in this story adds to that\u00a0body of knowledge.", "answer": 0}, {"article": "He said the 80 mg dose was likely more than most people need.\nThe drug, MK-4305, helped patients sleep for a larger percentage of eight hours spent in bed at one night and at the end of four weeks of treatment, Merck said.\nThe most common side effects included upper respiratory tract infection, urinary tract infection, dizziness, drowsiness on waking, headache and vivid dreams.\nThe improvement was 11.6 percent at 40 mg, 6.6 percent at 20 mg and 6.2 percent at the lowest dose.\nOn average, it took patients 21.6 fewer minutes to fall asleep with the 40 mg dose of MK-4305 than a placebo on night one, Merck said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is perhaps the story\u2019s biggest failing. We have been bombarded with sleep aid ads in recent years. Ambien, Sominex, Unisom. These are all household names. How can one write a story about a new sleep drug and not talk about what\u2019s already on the market?\u00a0Making matters even more frustrating, the story says \"MK-4305 belongs to a new class of sleep drugs that inhibits production of orexins in the brain, blocking stimulation of the brain\u2019s arousal system. Orexin is a neuropeptide that is believed to play a key role in regulation of the brain\u2019s sleep/wake process.\" But it never says whether other drugs in this class are already on the market or how many drugs like this have been tried and failed.", "answer": 0}, {"article": "\"Great.\n\"So before we activated the device, we have all sorts of problems\u2026 This is basically your brain saying, 'I'm not breathing.'\nIt's been a game changer,\" Dr. Maurits Boon said.\nA study published in the New England Journal of Medicine found that 68 percent of patients experienced less sleep apnea after getting the implant.\n\"I knew I was in trouble,\" Siravo said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is a tough one. On the one hand, the story does clearly explain how the Inspire technology works \u2014 which is good. However, doesn\u2019t state how this is different from any other treatment options \u2014 the only other option mentioned is CPAP. If Inspire takes a completely different approach from other treatment technologies, it\u2019s important for the story to come right out and say so.", "answer": 0}, {"article": "Dr. Lazova is currently the Director of Dermatopathology at California Skin Institute in San Jose, California.\n\u201cThis test integrates anatomic pathology and analytical chemistry in a very useful and meaningful way.\u201d\n\nThe finding suggests that IMS analysis, based on proteomic signatures, may improve both diagnosis and prediction of outcomes for patients with ambiguous moles, the researchers said.\n\u201cInstead of pathologists being dependent solely upon the physical appearance of the cells, they now have the additional advantage of molecular information regarding the protein makeup [of cells] provided by mass spec imaging,\u201d said Dr. Lazova, who is corresponding author on the study.\nThe researchers found that in nearly all cases, the IMS analysis was a more accurate predictor, both of benign lesions and melanomas, than standard microscopic examination.\nIn a prior study, the researchers used IMS to identify a molecular signature comprised of five proteins to differentiate between one type of benign mole and melanoma.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release does not exaggerate the novelty of this test. However, it could have clarified its description of mass imaging spectrometry to analyze moles as a \u201crecently developed test.\u201d\u00a0 Mass imaging spectrometry has been around since the 1960s, but it\u2019s only recently been used to analyze moles.", "answer": 1}, {"article": "Adding small amounts of powdered ginger to food may help take the edge off seasonal allergy symptoms, according to an animal study published online in the Journal of Nutritional Biochemistry. Daily intake of dried ginger significantly reduced sneezing and other signs of allergy in rodents with induced allergic rhinitis, or hay fever.\n\nA major component in ginger, 6-gingerol, suppresses the activation of T lymphocytes, or T cells, a type of white blood cell that plays an important role in sensitizing people to specific allergens,...", "question": "Does the story establish the true novelty of the approach?", "explanation": "As the story says, ginger has never been given to human patients for allergic rhinitis.", "answer": 1}, {"article": "Patients treated with a placebo saw a 1 percent increase in LDL cholesterol.\nThe trial, presented here at the annual scientific meeting of the American Heart Association, included 168 patients with heterozygous familial hypercholesterolemia, in which a defective gene inherited from one parent impairs the ability to properly metabolize LDL.\nThe new drug, given by injection every four weeks, is part of a promising new class of biotech medicines known as PCSK9 inhibitors designed to target a protein that prevents the body from removing artery blocking LDL cholesterol from the bloodstream.\nStatins, such as Pfizer Inc\u2019s Lipitor and AstraZeneca\u2019s Crestor, work by preventing the liver from making cholesterol.\nLOS ANGELES (Reuters) - Amgen Inc\u2019s experimental drug AMG145 reduced levels of bad cholesterol by as much as 55 percent in combination with statin drugs in patients genetically predisposed to high cholesterol, according to data from a midstage trial presented on Monday.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story briefly mentions that other similar drugs are being tested. It would have been better if the story had pointed out this trial is not the first to test this drug in patients with inherited high cholesterol. For example:http://www.nejm.org/doi/full/10.1056/NEJMoa1105803", "answer": 1}, {"article": "THIS STUDY randomly assigned 60 adults with mild cognitive impairment or mild to moderate Alzheimer\u2019s disease to be given, via nasal spray, 20- or 40-milligram doses of insulin detemir (Levemir), a man-made insulin that is longer acting than natural insulin, or a placebo daily for three weeks.\nAlso, among those in the 40-milligram group, people carrying what is sometimes called the Alzheimer\u2019s gene (APOE-e4) showed more improvement than non-carriers.\nMemory loss is often the first sign of dementia, which in later stages can interfere with such things as the ability to solve problems, control emotions or do such daily tasks as eating and dressing.\nCAVEATS The study involved a relatively small number of participants and lasted a short time; a larger and longer study would be needed to adequately test effectiveness and safety.\nSome research has suggested a link between lower levels of insulin in cerebrospinal fluid and the formation of plaques often found in the brain tissue of people with Alzheimer\u2019s.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not address the novelty of this research. Nasal insulin has previously been studied for treatment of Alzheimer\u2019s disease. The current study used a longer-acting form of insulin than was used in previous research.", "answer": 0}, {"article": "Generally, massage is not covered by insurance, Medicaid or Medicare.\nWhile the study results are promising, much more work needs to be done, Munk said: \"The fact of the matter is that chronic lower back pain is very complex and often requires a maintenance-type approach versus a short-term intervention option.\"\nThe study, \"Real-World Massage Therapy Produces Meaningful Effectiveness Signal for Primary Care Patients with Chronic Low Back Pain: Results of a Repeated Measures Cohort Study,\" was published online March 14 in the journal Pain Medicine.\n\"The study can give primary care providers the confidence to tell patients with chronic low back pain to try massage, if the patients can afford to do so,\" Munk said.\nINDIANAPOLIS -- In the first study of its kind, researchers found real-world massage therapy to be an effective treatment for chronic low back pain.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release claims this is \u201cthe first study of its kind\u201d to assess massage for low back pain. Many studies have evaluated outcomes of massage in uncontrolled studies (where there was no comparison to another treatment). A search at the National Library of Medicine resulted in almost 300 results. While some of the studies may not precisely compare to this one \u2014 the release does not back up its claim by explaining the novelty.\nTo further complicate things, the release includes a confusing paragraph about the \u201creal-world\u201d massages given to the research patients:\n\u201cPrevious studies of the effectiveness of massage were conducted in controlled research situations. In this study, patients were referred by a physician to a massage therapist. The massage therapist designed and provided a series of 10 massages \u2014 at no cost to the patient \u2014 in a clinical treatment environment, mimicking the experience of people who choose to seek massage therapy in the real world.\u201d\nWhen we read that paragraph, we get the impression that a therapist came to a \u201cclinical environment\u201d to provide the 10 massages. How is that \u201cmimicking the experience\u201d of the real world any better than previous studies?", "answer": 0}, {"article": "The device is being developed by Cameron Health, a small company in San Clemente, Calif., that was co-founded by Dr. Bardy.\nIn recent years, the safety of defibrillator wires has come in particular focus because a model made by Medtronic has been prone to fracturing.\nThe device will not be suitable for a significant number of heart patients, particularly those who require units that also include a pacemaker, which regulates a heart that is beating too fast or too slowly.\nSince the cardiologist began work on the project about a decade ago, the defibrillator he helped design has gone through several iterations.\nIn the study published Wednesday, Dr. Bardy and others reported that the new device had undergone several successful initial trials, including one in which it was used for a year in about 60 patients.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\nThe story notes that the device has been under development for several years and requires further research before it can be considered for clinical use.", "answer": 1}, {"article": "It's the first study to specifically examine...\nA study published in this month's issue of the Archives of Neurology found that the diet might protect against blood-vessel damage in the brain, reducing the risks of stroke and memory loss.\nJennifer Corbett Dooren has details on Lunch Break.\nNow, it may be good for the brain as well.\nNow, it may be good for the brain as well.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reported:\nIt\u2019s the first study to specifically examine the effects of the diet centered around vegetables, fruits, fish, whole grains, nuts, olive oil and a moderate amount of alcohol, with limited consumption of red meat, sweets and refined grains like white bread or white rice\u2014on the brain\u2019s small blood vessels.\nPrevious studies have suggested adhering to a Mediterranean-style diet is associated with a lower risk of heart disease, stroke and cognitive disorders like Alzheimer\u2019s disease.", "answer": 1}, {"article": "The other is that, for tens of thousands of years, parasites and other infections unusual in modern society were a major problem in humans. The body developed a defense mechanism - inflammation - to fight them. Now, there aren't as many of these infectious diseases for our bodies to deal with, but we still have this defense mechanism. It has begun to target other things, such as allergens in the environment. Immunotherapy helps teach the body to better tolerate these harmless parts of our environment.", "question": "Does the story establish the true novelty of the approach?", "explanation": "It seems reasonably clear that the timing is related to the fact that this is prime allergy season for readers.\u00a0Although the intro makes a grab for a news hook, it\u2019s a pretty weak one, given that the \u201cnewest\u201d immunotherapies have been available for at least a couple of years. But again, we don\u2019t think the article was intended to break any news or present anything as especially novel.", "answer": 1}, {"article": "Rosenfeld says it's never wrong to prescribe an antibiotic for a well-diagnosed ear infection.\nBut just 2 months ago, a new study confirmed practice guidelines from 2004, which recommend that children older than 2 with a confirmed diagnosis of an acute ear infection do not need to be given antibiotics because the drugs do not significantly speed up recovery.\nThe foundation for the \"watchful waiting\" treatment recommendation instead of taking drugs is based on this and previous studies that did not have very many children under age 2 in the clinical trials.\nAccording to one of the studies, ear infection, or acute otitis media, is the most frequently diagnosed illness in children in the United States, and most children with these ear infections are routinely given antibiotics.\nParents need to weigh the benefits of what antibiotics can do in terms of killing the bacteria (if the ear infection is caused by a bacteria and not a virus) and the side effects their child may have to endure, as well as the possibility that exposing bacteria to antimicrobials may make the drugs less effective in the future.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story correctly characterized the novelty of the research:\u00a0it establishes\u00a0that antibiotics are more effective for infants and toddlers with a conclusive ear infection diagnosis, and supports current U.S. guidelines for providing immediate antibiotics to such children.", "answer": 1}, {"article": "In the Swiss research, animals took a drug that dissolved a barrier around the part of the brain where mammals store their fear memories. Afterward, they stopped being afraid of noises that were linked to electric shocks, which meant their bad memories had been erased, according to the Mail. Human brains, explains NYU neuroscience Prof. Joseph LeDoux, could actually \"overwrite\" memories with happier thoughts if the medication is developed for people, according to the Daily Mail.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear this would be a novel approach. ", "answer": 1}, {"article": "Iowa Democrats may have saved the caucuses\n\nIf the proposed Democratic plan is adopted, the Iowa Democratic caucuses will be both familiar and new and may well endure as first in the nation.", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 1}, {"article": "WASHINGTON (Reuters) - Statin drugs may lower the risk of colon cancer by as much as 12 percent, U.S. researchers reported on Monday.\nThe longer people took the highly popular cholesterol-lowering pills, the lower their risk of later developing colon cancer, the researchers told a meeting of the American College of Gastroenterology.\nMany researchers have found that statin drugs, which include Pfizer Inc\u2019s Lipitor and AstraZeneca Plc\u2019s Crestor, have effects far beyond lowering cholesterol and reducing the risk of heart disease.\n\u201cOur findings suggest that randomized controlled trials designed to test the hypothesis that statins reduce the risk of colorectal cancer are warranted,\u201d Samadder added in a statement.\nAnd U.S. health officials have been watching data that suggests some statins such as Merck & Co\u2019s blockbuster drug Vytorin may actually raise the risk of cancer, although they have saidf this is unlikely.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story reported that it was about a meta-analysis of data on the impact of statin use on risk of colon cancer.\u00a0 But the story gave no context or background on other studies on statins and colon cancer, some of them dating back many years. We always urge journalists to put new research into the context of existing research. \n", "answer": 0}, {"article": "When considering where to give birth, most parents-to-be and doctors in Western nations believe a hospital is the best place.\n\nNot so Jean Stevens, 32, who chose to deliver two children at home in the U.K. She says her two labors were nearly pain-free.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty here, which the story emphasizes, is the\u00a0evidence-based statement\u00a0from an expert medical group that hospital births may be riskier than home births for uncomplicated second or later pregnancies.\u00a0 It is unusual to see a medical group recommending against a higher level of medical intervention.\nWith that being said, there is a fairly broad body of work on risks associated with childbirth, and home birth in particular, but the story only mentions the U.K. and Canada studies we noted above. While other research findings may not offer as convenient a comparison to the study used to inform the NICE guidance, they could help readers understand the levels of absolute risk facing mothers and infants at home, in hospitals, or at birth centers. And if the U.K. and Canada studies offer insights that were simply not to be found in other work, that would have been worth mentioning too.\nBut the story earned a Satisfactory here.", "answer": 1}, {"article": "Then President Richard Nixon declared drugs \u201cpublic enemy No.\n\u201cThose kinds of changes are not delusional, because blinded interviews with family members, friends and work colleagues [confirm these reports].\u201d\n\nSimilar work has shown psilocybin can help treat anxiety associated with cancer, at UCLA and New York University.\nIn the past 20 years or so, a small amount of research has once again begun to focus on these chemicals, showing that they have promise for treating a range of conditions, from addiction to depression and anxiety, says Evan Wood, a psychiatric researcher at the University of British Columbia.\nBut at the same time, many of these substances were taken in uncontrolled settings by large numbers of people, and certain proselytizers (like Timothy Leary) advocated their widespread use.\nThe idea that you can take a medicine one or a few times and become \u201ccured,\u201d or at least significantly helped, conflicts with current standard practices, which often involve taking medications every day for years, or life.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes that what is \u2018novel\u2019 here is the research, as we know many of these substances have been around for decades, or in the case of the\u00a0Ayahuasca, probably thousands of years.\u00a0There\u2019s especially some novelty in studying the drugs\u2019 usefulness in treating anxiety in terminal patients. But otherwise, the idea of quick fixes in the forms of pills containing psychoactive substances for these serious and chronic problems is not all that new.", "answer": 1}, {"article": "PROVIDENCE, R.I. [Brown University] -- New results from a clinical trial involving more than 900 military veterans at high risk for keratinocyte carcinoma skin cancer provides evidence that using the generic skin cream fluorouacil 5 percent for two to four weeks may reduce the risk of a squamous cell carcinoma (SCC) needing surgery by 75 percent within a year.\nThe finding that less than one month's use of fluorouacil 5% (5-FU) appeared to prevent cancer for up to a year is encouraging, said lead author Dr. Martin A. Weinstock, a professor of dermatology in the Warren Alpert Medical School of Brown University and chief of dermatology at the Providence Veterans Affairs Medical Center.\nThe cream does have common side effects including reddened, more sensitive and often crusty skin, effects that resolve when the application of the cream stops, Weinstock acknowledged.\nBut after six months and again at the end of the four-year trial, 87 percent of participants in the 5-FU group said they'd be willing to repeat the treatment if it proved effective in reducing skin cancer.\nBut in the new study, 5-FU appeared to provide prolonged protection after discontinuation and could be combined with sunscreen, Weinstock said.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release quotes the study author claiming this was \u201cthe first study of its type. I\u2019m hopeful there will be other studies that show other sorts of regimens that last longer and do a better job over time as science progresses. This is an important first step.\u201d\nIt also notes that further research is planned.", "answer": 1}, {"article": "A capsule of Probiotic Immunity from New Chapter Inc., based in Brattleboro, Vt., contains 1 billion each of 10 different organisms, including Streptococcus salivarius subsp. thermophilus and Lactobacillus acidophilus, two species of bacteria often found in yogurt. Other ingredients include herbs such as cumin, ginger and spinach. Users are instructed to take two capsules each day, preferably one in the morning and one in the evening, on an empty stomach. You can buy a bottle of 90 capsules for about $20 at many health food stores.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Not applicable; no overt claims of novelty were made.", "answer": 2}, {"article": "Such screening is increasingly used in research.\nThe largest analysis to date of amyloid plaques in people\u2019s brains confirms that the presence of the substance can help predict who will develop Alzheimer\u2019s and determine who has the disease.\nThe findings also confirm that amyloid screening, by PET scan or cerebral spinal fluid test, can help identify people for clinical trials of drugs to prevent Alzheimer\u2019s.\n\u201cThe papers indicate that amyloid imaging is important to be sure that the drugs are being tested on people who have amyloid,\u201d said Dr. Roger Rosenberg, the director of the Alzheimer\u2019s Disease Center at the University of Texas Southwestern Medical Center at Dallas, who wrote an editorial about the studies.\nTwo linked studies, published Tuesday in JAMA, also support the central early role in Alzheimer\u2019s of beta amyloid, the protein that creates plaques.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "These are meta-analyses, useful in that they pulled together a lot of data, but the findings aren\u2019t truly novel, although the story makes them seem so. We\u2019ve known for many years that amyloid begins to be deposited decades before symptoms begin, that educated people have more of it, that not everyone with mild cognitive impairment goes on to develop AD, and that not everyone diagnosed with AD has amyloid. The story doesn\u2019t acknowledge this background explicitly. One association found that was different from other recent studies was that those with subjective cognitive complaints didn\u2019t differ in amyloid load from individuals with normal cognition. As the study authors said though, studies differ on this point and more work needs to be done.", "answer": 0}, {"article": "DALLAS, Oct. 20, 2015 -- Botox -- known for reducing facial wrinkles -- may also prevent irregular heart rhythms when injected into fat surrounding the heart after bypass surgery, according to research in the American Heart Association journal Circulation: Arrhythmia and Electrophysiology.\n\"This first-in-man study has opened a whole new line of thinking and research,\" Steinberg said.\nTo avoid bias, neither patients nor doctors knew whether the injections contained Botox or saline.\nThe Russian State Research Institute of Circulation Pathology and the Siberian Division of Russian Academy of Medical Sciences funded the study.\nThe association has strict policies to prevent these relationships from influencing the science content.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Dr. Steinberg\u2019s comments on the study being the \u201cfirst in man\u201d establishes the novelty of the approach.", "answer": 1}, {"article": "The topical painkillers are not for everyone.\nStill, in one of the only head-to-head trials between topical and oral Nsaids, subjects taking the pills had a much higher rate of indigestion, diarrhea, abdominal pain, abnormal liver tests and anemia than those using the creams.\nThe main advantage of a skin cream is that it bypasses the stomach and much of the bloodstream, theoretically minimizing serious side effects.\nAnd the three topical Nsaids sold in this country \u2014 Voltaren gel, the Flector Patch and Pennsaid, a liquid \u2014 all contain the Nsaid diclofenac, whose oral version has been linked to liver damage.\n\u201cThe turning point for topical Nsaids was the fright over heart problems with Vioxx,\u201d Dr. Moore said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n\nPart of the focus of the story is that NSAIDS have been around for a long time but only recently are being given a more serious scientific reassessment.\u00a0As the story says, \"But a number of new controlled trials and meta-analyses like Dr. Moore\u2019s suggest that topical Nsaids are as effective as their oral counterparts for treating osteoarthritis in the knee and hand as well as musculoskeletal injuries like soreness and tendinitis.\"", "answer": 1}, {"article": "Griebling said the American Geriatrics Society includes desmopressin in the Beers Criteria for potentially inappropriate medications for older adults, primarily because of concerns about resulting low blood sodium levels.\n\"Nocturia is very common in patients over 50 years old, and can cause significant problems by causing loss of sleep, and injury due to falls,\" said study lead author Dr. Jed Kaminetsky.\n\"Other researchers have examined the utility and safety of desmopressin for the treatment of nocturia in the past,\" he said.\nThe new drug, while promising, is of concern because of its potential to lower blood sodium levels in the elderly, one doctor said.\nThe researchers also found that those in the higher-dose spray group experienced a \"significant improvement\" in overall quality of life, compared with the untreated group.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does say that this is the first drug under consideration for treatment of nocturia, which would make it novel, however, there are already drugs available for treatment of frequent urination, although not only for nighttime use.", "answer": 1}, {"article": "Politi said a serving of walnuts is about 14 halves, which adds up to 180 calories.\nAfter one year, both groups experienced minimal body weight, triglyceride, and HDL cholesterol changes, but the walnut-eaters had significant reductions in LDL cholesterol (\"bad\" cholesterol) compared to the nut-free control group.\n\"Given walnuts are a high-energy food, a prevailing concern has been that their long-term consumption might be associated with weight gain,\" said study author Dr. Emilio Ros, director of the Lipid Clinic, Endocrinology & Nutrition Service at the Hospital Clinic of Barcelona, in a press statement.\nThe research shows the well-known cholesterol-lowering effect of eating walnuts works equally well in the elderly, even in the long term, the authors reported at the Experimental Biology conference in San Diego.\nOther walnut studies presented at the conference, funded in part by the California Walnut Commission, suggested the omega-3 fatty acid-rich nut may also benefit gut bacteria and help reduce inflammation.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There have been many studies done on nuts and their effects on cardiovascular health, but these past studies were not referenced. How does this study specifically add to the body of research? There\u2019s an implied reference that this might be the first time cholesterol-lowering benefits were tested in older adults, but it\u2019s not clear.", "answer": 0}, {"article": "They compared gene expression changes between regions that correspond to different disabilities.\nIn addition to senior author Dr. Rhonda Voskuhl, who directs UCLA's Multiple Sclerosis Program and holds the Jack H. Skirball Chair in Multiple Sclerosis Research, study co-first authors were Noriko Itoh, Yuichiro Itoh, and Alessia Tassoni, with other co-authors including Emily Ren, Max Kaito, Ai Ohno, Vista Farkhondeh, Hadley Johnsonbaugh, Yan Ao, Josh Burda and Michael Sofroniew, all of UCLA.\nInflammation strips the myelin coating from nerve cell extensions, called axons, and connections at the ends of nerves, called synapses, are lost, together disrupting signaling and eventually causing permanent disability depending on where this occurs.\nCholesterol does not leave the blood and enter the brain, instead it is made in astrocytes and plays a role in making myelin, the nerve coating, and synapses, the nerve connections.\nThe work was supported with funding from the Conrad N. Hilton Foundation, the National Institutes of Health, the California Community Foundation, the Tom Sherak MS Hope Foundation, the Rhoda Goetz Foundation for Multiple Sclerosis, and other partners of the UCLA Multiple Sclerosis Program.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release claims that this small animal study points the way to \u201ca more precise, neuroprotective approach than traditional treatments.\u201d It also states that this strategy is \u201ctailored to repair damage for each disability, one at a time, in contrast to a \u201cone size fits all\u201d treatment approach.\u201d\nWe take this to mean that the \u201cprecision\u201d comes from measuring outcomes on specific functions such as walking and eyesight that are affected by the disease, rather than traditional global measures such as number of lesions on an MRI scan or overall functioning.", "answer": 1}, {"article": "The idea of a psychiatric evaluation sent chills down the spine of Caroline's mother, Mathy Milling Downing, who believed that her younger daughter, Candace, had committed suicide because of an adverse reaction linked to a psychiatric drug -- the antidepressant Zoloft.\nWhen Candace turned 12, the psychiatrist upped the dose on the grounds that it would help her academically.\nSoon after her sister committed suicide, Caroline Downing started doing poorly at school.\nIt is safe and effective.'\nShortly after Candace's death, the Food and Drug Administration placed black-box warnings on several antidepressants to say they elevated suicidal thinking among some children.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story discussed treatments that are not novel; it did not portray them as such. \u00a0A novel aspect is extending screening to adolescents.", "answer": 1}, {"article": "The bar was developed over the past 10 years by a team of scientists led by Drs.\n6 McCann, J. C., and Ames, B. N. (2009) Vitamin K, an example of triage theory: is micronutrient inadequacy linked to diseases of aging?\nThe power of nutrient-rich, properly formulated food-based supplements, such as the CHORI-bar, to move dysregulated metabolism in a healthy direction may help reverse obesity-associated conditions, and thereby reduce the risk of future chronic diseases.\nThe full potential of food-based supplements to do the work of some drugs without their negative side effects is just beginning to be seriously investigated.\nThe CHORI-bar is intended to fill these gaps with components present in the bar in normal dietary amounts.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The text makes a strong pitch for novelty, indicating that the CHORI bar is unlike the typical nutrient bar that one can buy in the store.\u00a0And yet the news release notes that this has been in development for 10 years and there have been prior publications from the authors in clinical tests.", "answer": 1}, {"article": "The researchers did two brief sleep experiments.\n\u201cIt is likely though that if any group of people suffer from sleep loss, getting extra sleep will be beneficial.\u201d\n\nTo assess the impact of sleep on diabetes risk, Broussard and colleagues focused on what\u2019s known as insulin sensitivity, or the body\u2019s ability to use the hormone insulin to regulate blood sugar.\nIn the real world, when people don\u2019t get enough sleep they tend to overeat, which may limit how much results from this lab experiment might happen in reality, the authors note in a report scheduled for publication in the journal Diabetes Care.\nOn one occasion, the volunteers were permitted just 4.5 hours of rest for four nights, followed by two evenings of extended sleep that amounted to 9.7 hours on average.\n\u201cThe results from the present study are unlikely to be fully reflective of what may occur in persons who are older, overweight or obese, or have other potent risk factors for diabetes,\u201d said James Gangwisch, a researcher at Columbia University who wasn\u2019t involved in the study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article did point out the calorie control part of the protocol, and the possibly novel notion that two days of non-deprived sleep can reverse the insulin resistance increase observed in the subjects.\u00a0It is clear what this small study aimed to add to the science.", "answer": 1}, {"article": "For more information, visit http://www.\nIn the accompanying editorial titled, \"Can a Toothpaste Reduce Heart Attacks and Strokes?,\" Joseph S. Alpert, M.D., an internationally renowned cardiologist, noted the importance and timeliness of these findings and commented on how his father, a dentist, had told him even before he went to medical school, that dental health may affect heart attacks and strokes.\nThe results released today from a randomized trial of a novel plaque identifying toothpaste, (Plaque HD\u00ae), show statistically significant reductions in dental plaque and inflammation throughout the body.\nBased on these findings, Hennekens and colleagues are drafting an investigator initiated research grant proposal to the National Institutes of Health (NIH) under the direction of co-author Patrick E. McBride, M.D., M.P.H., professor of medicine and interim associate dean for faculty affairs at the University of Wisconsin School of Medicine and Public Health.\nThe original research from the landmark Physician's Health Study, in which Hennekens was the founding principal investigator, was the first to demonstrate that hs-CRP predicted future heart attacks and strokes.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that \u201cthe findings on decreasing inflammation are new and novel\u201d and \u201cPlaque HD\u00ae is the first toothpaste that reveals plaque so that it can be removed with directed brushing.\u201d However, the study doesn\u2019t present strong evidence for the first claim and in regard to the second, neither the release nor the journal article address whether plaque-identifying toothpaste is superior to plaque-disclosing tablets.\u00a0 ", "answer": 0}, {"article": "But such drugs tend to be extremely expensive.\nScaling up the procedure should make it even less expensive, he said, but he added, \u201cOur costs do not include any profit margin, facility depreciation costs or other clinical care costs, and other research costs.\u201d\n\nThe research is still in its early stages, and many questions remain.\nHerv\u00e9 Hoppenot, the president of Novartis Oncology, called the research \u201cfantastic\u201d and said it had the potential \u2014 if the early results held up \u2014 to revolutionize the treatment of leukemia and related blood cancers.\nShe woke up a week later, on May 2, the day she turned 7; the intensive-care staff sang\n\nSince then, the research team has used the same drug, tocilizumab, in several other patients.\nThe cells do have a drawback: they destroy healthy B-cells as well as cancerous ones, leaving patients vulnerable to certain types of infections, so Emma and the other patients need regular treatments with immune globulins to prevent illness.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reports on the first use of the treament on a child with\u00a0acute lymphoblastic leukemia\u2013certainly a novel application. While focusing on the U Penn work, the story explains that \u201cSimilar approaches are also being tried at other centers, including the National Cancer Institute and Memorial Sloan-Kettering Cancer Center in New York.\u201d\n\u00a0", "answer": 1}, {"article": "Jet lag occurs when sleeping and waking patterns are not synchronized to circadian rhythms.\nIt will enable us to have more potent countermeasures to jet lag than continuous light, which is the current prescribed light therapy treatment,\" Zeitzer said.\nA team of researchers led by neurobiologist Jamie Zeitzer is working on a technique that exposes people to short flashes of light while they sleep to help them adjust more quickly to time zone changes.\nThis study builds on previous research published in 2014, which found that light therapy works best at night because the body's circadian rhythms are more sensitive to light at night, even through closed eyelids.\nOr they do nothing and suffer the exhausting consequences; the body eventually adjusts at a slow pace of about one hour a day, taking up to three days to catch up.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article notes that the current study builds on the team\u2019s previous \u201cproof-of-principle\u201d research that suggested exposure to light at night speeds up time zone adjustment. The latest study found short light flashes had an advantage over continuous light exposure. There is no misleading representation as to the technique\u2019s novelty.", "answer": 1}, {"article": "Partial replacements are also cheaper, say researchers from Oxford University.\n\u201cThis has allowed us to provide strong proof that partial knee replacements are both better for patients and cheaper for the NHS.\u201d\n\nWhether people had a partial or total replacement varied by surgeon, as did the success of the operation, the researchers discovered.\n\u201cThe main strength of this study is that we were able to use real data, from very large numbers of people, about their actual operations, their GP visit, and their own reported quality of life outcomes in a way that is not always possible,\u201d said Dr Rafael Pinedo-Villanueva, the co-lead researcher and NDORMS senior health economist, who is funded by the National Institute of Health Research Oxford Biomedical Research Centre and the Medical Research Council.\nAbout half of all patients should be suitable for a partial replacement, but an analysis of data routinely collected by the National Joint Registry showed that of 98,147 knee replacements undertaken in 2016, only 9% were partial.\nThe NHS, however, needs to get the support of surgeons, many of whom rarely carry out the less invasive procedure.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is not the first study to evaluate the outcomes of partial knee procedures (see this 2011 paper, for example). It is not even the first study to compare the outcomes from partial surgery to the outcomes from total knee replacements (see these two studies on the same cohort of patients from 1998 and 2009). So what sets this new study apart? The story does cite a researcher as saying \u201cThe main strength of this study is that we were able to use real data, from very large numbers of people, about their actual operations, their GP visit, and their own reported quality of life outcomes in a way that is not always possible.\u201d However, without at least some discussion of the previous work, any comparison is impossible.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/29/national/w155455S59.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the true novelty of the approach?", "explanation": "This article reported on the efficacy of the first vaccine against the bird flu which has been added to the nation\u2019s vaccine stockpile.", "answer": 1}, {"article": "And AbbeVie is in the midst of phase 3 trials for elagolix to treat uterine fibroids and endometriosis, a disorder in which the tissue that lines the inside of the uterus grows outside of it, causing pelvic pain.\nThe first oral treatment for women with the common condition of uterine fibroids could be available as soon as summer 2018, with two other medications in the pipeline.\n\u201cThis particular drug also works directly on the lining of the uterus\u2014the endometrium\u2014so it also quite fast and dramatically decreases and stops the vaginal bleeding,\u201d says Ayman Al-Hendy, director of interdisciplinary translational research at Augusta University in Georgia and a member of Allergan\u2019s advisory board.\nThe most common symptom is long and excessive bleeding during menstrual periods, which can lead to anemia and the need for blood transfusions.\nThe cause of fibroids remains unknown, though those with a family history have an increased risk of developing them.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article makes clear that the advantage of the new drug is that it is an oral medication, and is taken for a limited time.\nHowever, ulipristal is not the first oral medication. There are some older oral hormonal medications, including pills in some cases, that have been tried. GnRH agonists (delivered by injection or nasal spray) such as Lupron have been used in limited situations to treat fibroids, but their use is limited by side effects related to medically induced menopause.", "answer": 1}, {"article": "Laxminarayan did not dismiss the notion of this type of use out of hand, however.\nA commentary published with the study argued that reducing infection rates in men who have sex with men and who are highly sexually active might lower STI infection rates more generally in a community.\nThe authors noted, however, that the study length was short and they can\u2019t tell if the strategy would work as well over the long term.\nThe rate of infection increased in every age group over the age of 15, in both men and women, and in all ethnic groups.\nBut such a strategy, which was tested in a population of men who had frequent unprotected sex with a number of male sex partners, could spark a controversy over the use of antibiotics and the general threat of growing antibiotic resistance.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "A summary box in the\u00a0journal article\u00a0states that what is new about this study is that it tested an antibiotic in a group of very high-risk men who have sex with men and who were already enrolled in a trial of a drug that may reduce the risk of HIV infection. This very narrow scope is largely lost in the story.", "answer": 0}, {"article": "\"If the fish improves sleep, great.\nFor the work, a cohort of 541 9- to 11-year-olds in China, 54 percent boys and 46 percent girls, completed a questionnaire about how often they consumed fish in the past month, with options ranging from \"never\" to \"at least once per week.\"\nThis work, conducted by Jianghong Liu, Jennifer Pinto-Martin and Alexandra Hanlon of the School of Nursing and Penn Integrates Knowledge Professor Adrian Raine, reveals sleep as a possible mediating pathway, the potential missing link between fish and intelligence.\nThe researchers also want to add to this current observational study to establish, through randomized controlled trials, that eating fish can lead to better sleep, better school performance and other real-life, practical outcomes.\n\"It adds to the growing body of evidence showing that fish consumption has really positive health benefits and should be something more heavily advertised and promoted,\" she said.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "We rate this marginally satisfactory for the release\u2019s description of how this study differs from earlier work.\n\u201cPrevious studies showed a relationship between omega-3s, the fatty acids in many types of fish, and improved intelligence, as well as omega-3s and better sleep. But they\u2019ve never all been connected before. This work, conducted by Jianghong Liu, Jennifer Pinto-Martin and Alexandra Hanlon of the School of Nursing and Penn Integrates Knowledge Professor Adrian Raine, reveals sleep as a possible mediating pathway, the potential missing link between fish and intelligence.\u201d", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Hormone replacement therapy may work slightly better than soy at reducing menopausal hot flashes, a new study says.\nThe researchers looked at 19 studies on how a treatment, either hormones or soy, compared to a placebo.\nThey compared the average number of hot flashes in 760 women who had treatment with 770 who did not.\nAnd not every woman needs treatment, notes Bachmann, who was not involved in the study.\nWomen with severe or frequent hot flashes or whose hot flashes keep them up at night, should consider treatment, she said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "No inordinate claims of novelty for either approach.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - A small U.S. study suggests daily hormone injections may boost mental agility in older people with and without mild cognitive problems.\nPeople who got growth hormone-releasing hormone (GHRH), as opposed to inactive injections, improved on tests of attention and concentration skills - what psychologists call executive function.\nThe researchers found no serious side effects in the study, although people who got the hormone more often complained of symptoms like skin reactions and joint pain.\nIt\u2019s possible health problems could show up down the road, and the mental boost may be short-lived.\nAt the end, those who got the drug did better on psychological tests of executive function - whether or not they had mild cognitive impairment.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We think there could have at least been a line in the story about whether this is groundbreaking research looking at GHRH and mental function or whether there\u2019s been some track record.", "answer": 0}, {"article": "To learn more about DOs and the osteopathic approach to medicine, visit http://www.\nThe blood test developed by Dr. Nagele has also shown promise in detecting other diseases, including Parkinsons's, multiple sclerosis and breast cancer.\nDetecting Alzheimer's antibodies at the preclinical stage would give patients an opportunity to work with their physician to make lifestyle changes or receive available treatments before they become symptomatic.\nPotentially, this early intervention could help those with preclinical Alzheimer's avoid or delay the most devastating symptoms.\nDr. Nagele's work focuses on utilizing autoantibodies as blood-based biomarkers to accurately detect the presence of myriad diseases and pinpoint the stage to which a disease has progressed.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "No information is provided to establish the novelty of this particular research approach, compared with myriad other research studies pursuing possible tests for Alzheimer\u2019s.", "answer": 0}, {"article": "They returned at weeks 26, 39 and 52 for safety assessments, which included an evaluation of adverse events, clinical laboratory tests and physical examinations.\nThere is currently no oral form of testosterone therapy approved for use in the United States by the Federal Drug Agency; however researchers from Houston, TX and Torrance, CA have been evaluating the long-term safety and tolerability of LPCN 1021, a novel oral testosterone undecanoate formulation for the treatment of low testosterone.\n\u2022 LPCN 1021 was well tolerated and had a favorable safety profile in the long-term management of hypogonadal patients\n\u2022 No hepatic, cardiac or drug-related serious adverse events were reported\n\u2022 The most common drug-related adverse events for LPCN 1021 and T gel 1.62 percent were acne (2.9 percent vs. 2.9 percent, respectively), headache (0.5 percent vs. 3.8 percent, respectively), weight increase (2.4 percent vs. 0 percent, respectively), hematocrit increase (1.9 percent vs. 0 percent, respectively), liver enzyme level increase (1.4 percent vs. 0 percent, respectively), fatigue (0.5 percent vs. 1.9 percent, respectively), and hypertension (0.5 percent vs. 1.9 percent, respectively)\n\u2022 Lipid parameters (i.e., cholesterol, LDL, HDL, and TG) were comparable between treatment groups at Week 52\n\u2022 Androgenic parameters including hematocrit, hemoglobin, platelet, prothrombin, and prostate-specific antigen (PSA) showed no significant differences in change from baseline to end of study between treatments\n\n\"Based on the results of this study, we might be closer than ever to having an oral form of therapy to treat the millions of men with hypogonadism,\" said Dr. K\u00f6hler.\n\"Making sure an oral treatment is safe and effective for men and for the children and partners at risk for inadvertent testosterone transference is the top priority, and what we've found so far has shown we're on the right track.\"\nIt is often administered as a gel, patch, injection or implant (pellet).\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release states this would be the first oral method of testosterone treatment, and in that regard it\u2019s novel. However, it repeatedly calls this product a \u201cnovel\u201d therapy, echoing a word used in Lipocine\u2019s PR materials, without an explanation. The reader may assume that the treatment is novel because it\u2019s taken orally, but a different delivery method does not seem to constitute a huge departure from existing therapies.", "answer": 1}, {"article": "Feb. 10, 2011 (Los Angeles) -- Giving clot-busting drugs to people with mild strokes could prevent more than 2,000 of them from becoming disabled each year, researchers say.\nBut people with mild strokes are typically denied tPA because the studies that established its effectiveness excluded mild cases, says Pooja Khatri, MD, of the University of Cincinnati.\nThose parts of the brain soon start to die.\nIn fact, one in three people who suffer a mild stroke are disabled three months later, Khatri says.\nA drug called tissue plasminogen activator (tPA) dissolves clots and restores blood flow.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s clear from the story that it would be a relatively novel approach to give tPA to mild stroke patients, since it appears it is hardly ever done now.", "answer": 1}, {"article": "Researchers analyzed 24 randomized control trials to assess the efficacy and safety of the new drugs, called PCSK9 antibodies, in adults with high cholesterol levels.\nBut some patients can't tolerate the side effects, which can include headache, difficulty sleeping, muscle aches, diarrhea, constipation and nausea or vomiting.\nThese new drugs \"could be for someone who needs an addition to statin, or it could be instead of statin,\" Martin said.\nThe results, published in the Annals of Internal Medicine, also show that the drugs have a significant effect on reducing heart attacks and overall mortality.\nNow, researchers believe a a new type of experimental drug may help change that.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is clear about what\u2019s new here \u2014 an analysis of previous studies of this new class of drugs.\u00a0.", "answer": 1}, {"article": "Visit redrazz.org for more information, and follow us on our social media channels:\nIn a secondary objective of the blood sugar control study, researchers found that subjects in the PreDM group who reported the highest level of hunger at baseline experienced greater satiety after the control meal compared to raspberry containing meals (p<0.05).\nIn an eight-week pilot study, researchers from the Institute for Food Safety and Health from the Illinois Institute of Technology examined the impact of consumption of red raspberry pur\u00e9e or fructo-oligosaccharide on the gut microbiota and the subsequent bioavailability of red raspberry polyphenols in healthy volunteers.\n\"We are excited about this new flurry of studies, which builds on previously published research aimed to better understand the potential health benefits of red raspberries,\" said Tom Krugman, Executive Director of the National Processed Raspberry Council (NPRC).\nIn a mouse model, red raspberry supplementation of 5% dry feed weight was found to suppress inflammation and facilitate epithelium repair compared to mice with induced colitis (inflammation of the colon) and fed a standard chow diet.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This news release was a summary of new research presented at the 2017 Experimental Biology conference in Chicago. But just because the research was new, doesn\u2019t mean the ideas are. Though the studies looked at five different health issues (blood sugar, satiety, gut health, type 2 diabetes, and inflammation), the release itself didn\u2019t indicate whether these discoveries were new, or simply building on past research.\u00a0", "answer": 0}, {"article": "For more information, please visit http://www.\nThis study, conducted by researchers from Italy's University of L'Aquila and Mars, Incorporated, reinforces the results of several recent cognitive studies--throwing more light on the important role diet plays in maintaining cognitive health.\nDespite these findings, the question of the benefits of cocoa flavanols on cognitive function among individuals without MCI remained uncertain.\nIt is not yet fully understood how cocoa flavanols bring about improvements in cognitive function, but the study's authors suggest that the improvements in insulin resistance and blood pressure could be revealing.\nAs cognitive function was normal for this aged population, this study shows that even cognitively healthy individuals can quickly benefit from the regular inclusion of cocoa flavanols in their diets.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release makes clear that this experiment is grounded in a larger research context, and that other studies of the effects of cocoa flavanols on cognitive function have been conducted.", "answer": 1}, {"article": "While there\u2019s evidence that this technique, known as transcranial magnetic stimulation (TMS), helps depressed people get better-and the US Food and Drug Administration has approved TMS for this purpose-many skeptics have questioned whether it really works, notes Dr. Mark S. George of the Medical University of South Carolina in Charleston, the lead author of the new study.\nAfter three weeks, 14 percent of patients in the real TMS group had recovered from their depression, compared to 5 percent of the sham TMS group; people who had the real treatment were four times as likely to get better as those who got the fake treatment.\nIn a second phase of the study, all patients were given the real TMS treatment.\nBut George and his team say they\u2019ve solved that problem by developing a dummy device that clicks in a similar way to the real thing and causes a person\u2019s eye muscles to twitch, just like real a TMS device.\nThirty percent of the patients in the second phase recovered from depression.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not attempt to portray TMS as\u00a0more novel than\u00a0is\u00a0appropriate\u00a0and notes similarities between TMS and a more\u00a0established treatment approach known as electroconvulsive therapy. \u00a0", "answer": 1}, {"article": "Among 242 patients (137 intervention, 105 control) initially identified as high risk for caries, only a quarter of the patients remained at high risk in the CAMBRA group at 24 months, while just over half (54 percent) of the control group did.\nThe authors published their initial validation of CAMBRA for ages 6 through adult in 2006, followed by several additional years of data published in 2011, 2012, 2015 and 2016.\nThose in the control group also reduced their risk to a lesser degree, simply by using over-the-counter products that also protect teeth and affect the bacteria.\"\nThe researchers said the risk reduction among the control group may have been caused by the fluoride toothpaste enhancing tooth repair, as well as the mouth rinse enhancing saliva flow and having bactericidal effects.\nThe authors said now that this has been shown to be effective in a non-academic clinical setting, there also is potential for insurance companies to reimburse CAMBRA and other preventive therapies for adults, thereby lowering patient costs while increasing profits for dental practices.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release clearly explains that this research began in 2002, and small incremental steps in its validation have been published over many years. This is one more step.", "answer": 1}, {"article": "Dr. Scolnick has not seen the results of the Novartis trial, but was told of them and concluded that if the drugs work in fragile X, \u201cthere\u2019s nothing to say that they won\u2019t work in some cases of broader autism-spectrum disorders.\u201d\n\nThe roots for the Novartis results began in 1982 when Stephen T. Warren, then a graduate student in genetics at Michigan State University, was looking for a job and something to research.\nThe absence of this protein in cells causes the wide-ranging effects of fragile X syndrome.\nThe Novartis drug and others like it are intended to lower the volume of this noise so memory formation and high-level thinking can take place, allowing children to develop normally.\nIt does this by sopping up the genetic instructions needed to produce proteins that encourage brain signaling.\nFor ethical reasons, Novartis tested the drug only in adults.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This drug does by all accounts represents a novel approach to the treatment of fragile X syndrome. \u00a0", "answer": 1}, {"article": "For Patients and the General Public:", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Both neratinib and veliptarib are\u00a0described as new drugs in the news release, but they are talked about in the context of augmenting standard cancer therapy. No suggestion is made that these drugs are a sea change in how breast cancer is treated.", "answer": 1}, {"article": "New drug may help MS\n\u201cEven if it doesn\u2019t work, it\u2019s going to be another step down the road.\u201d\n\nIn autoimmune disease, the body\u2019s immune cells mistakenly attack and destroy healthy tissue.\nWhat\u2019s great about the approach, Miller says, is that it can be used to treat any autoimmune disease.\nThe idea would be to \u201cintroduce\u201d the myelin to the T-cells at the same time they were \u201cmeeting\u201d the healthy tissue, and educate them to leave the myelin alone.\nIt\u2019s also clear the approach would not repair any damage already done by the disease, so the best candidates would be patients having their very first symptoms.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "As with a competing story in WebMD, the story makes it appear as if this is the first time this approach has been used but does not cast a wide enough net in terms of research or independent sourcing to make that case definitively.", "answer": 0}, {"article": "The study was supported by the National Institutes of Health (grants F32 GM114948 and CA041101).\nEven if they found a solution to one of those, the organisms would still be killed by the other two.\u201d\n\nTested against Enterococci bacteria, the new version of vancomycin killed both vancomycin-resistant Enterococci and the original forms of Enterococci.\nThe researchers, led by Dale Boger, co-chair of TSRI\u2019s Department of Chemistry, discovered a way to structurally modify vancomycin to make an already-powerful version of the antibiotic even more potent.\nCombined with the previous modifications, this alteration gives vancomycin a 1,000-fold increase in activity, meaning doctors would need to use less of the antibiotic to fight infection.\nThe new study shows that scientists can make a third modification\u2014which interferes with a bacterium\u2019s cell wall in a new way\u2014with promising results.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t offer much in the way of specific details, but does make clear that this provides an additional mechanism of action for vancomycin. Presumably it is a mechanism of action not found in other drugs, which is what makes it more valuable in addressing antibiotic resistance, but that is not clear.", "answer": 1}, {"article": "Kris-Etherton and colleagues did an intensive study with 45 typical Americans \u2013 all overweight or obese, but with healthy cholesterol and blood pressure levels.\nSo that was the only difference between the two diets, which then tells us that it's the avocado that has additional benefits which are beyond the unsaturated fat.\u201d\n\nThe findings are similar to a batch of studies that showed people who were given olive oil and nuts and told to add them to their diets ended up healthier.\n\u201cI love guacamole and with my recipe, I'll use avocados, cilantro, lime juice and garlic... and then sometimes I'll put salsa in, or red pepper flakes.\u201d\n\nBut like anything, too much of a good thing can be harmful.\nIt\u2019s tough to test diets in real life, because people eat so many different things, but the team controlled what everyone ate, feeding them carefully calibrated diets.\nAnd so the current message is to replace saturated fat with unsaturated fat, and in so doing, consume a moderate-fat diet, not too much, and also not too little,\u201d Kris-Etherton told NBC News.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "While the story does place the work in context with other diet studies linked to cardiovascular health risk (which is great), it does not mention the multitude of other studies that have been done on avocados and cholesterol (many of which are \u2014 worth noting \u2014 not human diet studies). We wish the article had explained how the study fit into that larger body of literature on this specific subject, or why it was sufficiently novel that it falls outside of the previous work.", "answer": 0}, {"article": "Lee believes ibuprofen strips could be useful for sports participants, helping alleviate conditions such as tendonitis, and repetitive strain injuries.\nAn ibuprofen patch that delivers the painkiller directly through the skin to the site of pain, at a consistent dose for up to 24 hours, has been developed by UK researchers.\n\u201cWhat we do is dissolve the active ibuprofen, for example, into the adhesive so we can have quite a high loading - so up to 30 percent of the adhesive will be the ibuprofen,\u201d said Haddleton.\nAlthough TEPI patch remains highly tacky and adheres well to skin, it is not uncomfortable to peel off, unlike many traditional plasters.\nThe team says that popular ibuprofen gels make it difficult to control dosage and can be easily rubbed off.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes what\u2019s new about the patch compared with existing transdermal technologies, including that it might be applied to drugs that previously haven\u2019t been suitable for this approach.", "answer": 1}, {"article": "The procedure, called a prostatic urethral lift, does not improve flow as much as surgery, in which a physician cuts away some of the inside of the prostate to allow better flow. But the lift procedure and recovery are much quicker, with no hospital stay and fewer complications. And patients who get the sutures can always come back for surgery later.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story provides a lot of detail on how the device was invented and what sets it apart from other treatment options. However, we\u2019re not sure why the story was written now\u2013what\u2019s the news here?", "answer": 1}, {"article": "\"CMS made the right decision,\" said John Petrini, a Santa Barbara, Calif., gastroenterologist who heads the American Society for Gastrointestinal Endoscopy.\nRowe planned to be at his desk an hour or so later.\nKlein disagrees.\nMedicare's decision has sparked a furious lobbying campaign.\nLike other mass screening tests including mammography, the overarching question is whether the benefits of virtual colonoscopy outweigh the risks.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story adequately describes the novelty of the procedure.", "answer": 1}, {"article": "\"There is some limited evidence from my study and others that fish oil may be good for preventing breast cancer, but there is not sufficient evidence to make a public health recommendation right now,\" cautions study researcher Emily White, PhD, an epidemiologist at the Fred Hutchinson Cancer Research Center in Seattle.\nDuctal breast cancer is the most common type of breast cancer and forms in the milk ducts.\nLobular breast cancer forms in the milk glands.\nIn the study, 880 women developed breast cancer during six years of follow-up.\nThe use of fish oil was linked to lower risk of invasive ductal breast cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We were given some context by the following quotes: \nand", "answer": 1}, {"article": "Outside of heart attacks, doctors are often too quick to use a common $20,000 procedure to treat patients suffering from coronary artery disease, a new study suggests.\n\nAbout 600,000 angioplasty procedures, which almost always involve placement of a tiny metal tube called a stent, are done in the U.S. each year. Roughly 70% of these procedures are performed on patients suffering symptoms of a heart attack and aren't medically controversial. But the remainder are done on stable patients who are suffering mild symptoms or no symptoms...", "question": "Does the story establish the true novelty of the approach?", "explanation": "In the story Yale cardiologist Harlan Krumholz \u201csaid it represents one of the first times a professional medical society has looked at the appropriateness of its care in such a comprehensive fashion. \u201cIt needs to be a wake-up call for the rest of medicine to say this is what we need,\u201d he said.", "answer": 1}, {"article": "Former NASA astronaut Mark Kelly announced that he is running for John McCain's Senate seat in Arizona in the 2020 election.", "question": "Does the story establish the true novelty of the approach?", "explanation": "While we were uncomfortable with this story\u2019s characterization of thermoplasty as a \"new medical breakthrough\" (for reasons discussed here), the treatment is relatively new and different from existing techniques. We don\u2019t think the story misled in this regard.\u00a0\u00a0", "answer": 1}, {"article": "There are caveats.\nThe yoga used in this study was a gentle form, Hegde said, and parts of the practice were adapted for people who had additional health problems; certain poses were avoided in people who had heart disease, for example.\nHegde said that if such a decline in oxidative stress were sustained over time, it might lower the chances of diabetes complications, which include heart and kidney disease, nerve damage and damage to the blood vessels of the eyes.\nMeanwhile, their average blood sugar levels held steady \u2014 in contrast to the non-yoga-practicing \u201ccontrol\u201d group, whose blood sugar levels rose.\nThey found that, on average, the yoga group\u2019s levels of the chemicals dipped by 20 percent.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story didn\u2019t give any context about prior reports examining the potential for people with type II diabetes to benefit from participation in regular series of yoga classes.", "answer": 0}, {"article": "ASM advances the microbial sciences through conferences, publications, certifications and educational opportunities.\n\"During the Zika epidemic, we learned that the virus preferentially infects neural progenitor cells in the fetus, and causes the devastating microcephaly seen in babies born to infected mothers,\" says Pei-Yong Shi, a virologist at University of Texas Medical Branch in Galveston.\nIn a study published this week in mBio\u00ae, an open-access journal of the American Society for Microbiology, the team shows that a live, attenuated version of the Zika virus could form the basis of a new treatment option for this fatal brain cancer.\n(image: transmission electron micrograph of Zika virus, NIAID)\n\n\"If we could find a way to specifically target those GSCs that are the source of recurrence, then that might provide an option to prevent recurrence or even a cure,\" says Qin.\nComparing those profiles, the team found that in the treated cells, the virus triggered a strong antiviral response in the cells, which induced inflammation and eventually cell death.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does not mention that\u00a0multiple versions of oncolytic viruses have been explored for virotherapy against human Glioblastoma, with promising results. Thus, although the use of Zika virus may be new, research into using viruses to treat this cancer is well under way.", "answer": 0}, {"article": "GALVESTON, Texas -Researchers from The University of Texas Medical Branch at Galveston found that testosterone replacement therapy may slow disease progression of chronic obstructive pulmonary disease.\n\"However, we are the first to conduct a large scale nationally representative study on this association.\"\nThe goal of the study was to find out whether testosterone replacement therapy reduced the risk of respiratory hospitalizations in middle-aged and older men with COPD.\n\"The findings suggest that testosterone replacement therapy may slow the progression of disease in men with COPD.\"\nSpecifically, middle-aged testosterone replacement therapy users had a 4.2 percent greater decrease in respiratory hospitalizations compared with non-users and older testosterone replacement therapy users had a 9.1 percent greater decrease in respiratory hospitalizations compared with non-users,\" said Baillargeon.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes that there are some previous hypothetical links between TRT and lung function in men and that this is the first \u201clarge scale nationally representative study on this association.\u201d", "answer": 1}, {"article": "A rare form of blindness inched closer to a cure, after two groups published preliminary studies on replacing the bad gene that causes the condition. The results are likely to boost the prospects of gene therapy, a technique that shows promise but has yet to prove it can be used to cure many diseases.\n\nAbout 2,000 people in the U.S. have Leber's congenital amaurosis No. 2, caused when a child inherits a certain flawed gene from both parents. Patients with the bad gene can't make a protein that is supposed to nourish the eye's...", "question": "Does the story establish the true novelty of the approach?", "explanation": "This article describes the first reports of trials examining the potential gene therapy for Leber\u2019s congenetial amaurosis.", "answer": 1}, {"article": "\"Our concern is there are so many CT scans being done right now that we should really be starting to think: Do we need to all of these CT scans?\"\nThe radiation and risk from one CT scan is low, but it carries a dose 50 to 100 times greater than a traditional X-ray, reports LaPook.\nThe dose depends on the type of machine and the person - obese people require more radiation than slim ones - and the risk accumulates over a lifetime.\n\"The CT scan is a wonderful tool for examining internal organs, organs that are below the depth of where a poking finger or a listening stethoscope can hear, and yet don't show up on routine X-rays,\" Dr. Michael Brant-Zawadzki, a clinical professor of radiology at Stanford University tells CBS News.\nA previous study by the same scientists in 2001 led the federal Food and Drug Administration to recommend ways to limit scans and risks in children.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear that it wasn\u2019t reporting on a new approach but rather on the increased use of an existing diagnostic method.\nWhile mentioning that \u2018many of these CT scans are unnecessary\u2019 the story did little in terms of better enabling a viewer to distinguish between necessary and unnecessary scans.", "answer": 1}, {"article": "Erenumab, a laboratory-made antibody that blocks a neural brain pathway called CGRP, is the first drug in 20 years proven to prevent migraine attacks.\n\u201cThe results of Strive represent a real transition for migraine patients from poorly understood, re-purposed treatments, to a specific migraine-designed therapy.\u201d\n\nSimon Evans, chief executive of the charity Migraine Action, said: \u201cMigraine is too often trivialised as just a headache when, in reality, it can be a debilitating, chronic condition that can destroy lives.\nThe research revealed that by months four to six, at least a 50% reduction in mean migraine days per month was achieved for just over 43% of patients injected under the skin with 70-mg of erenumab each month, while half of patients injected with the higher dose of 140-mg had such results.\nAmgen and Novartis, the codevelopers of erenumab, funded the trial, while Amgen also supplied the drug and conducted the data analyses.\n\u201cThis is probably the first example of a migraine preventing drug that was rationally designed, rather than serendipitously found,\u201d he added.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did describe the novelty of laboratory-made antibodies to prevent migraines. \u00a0But, as already noted in the \u201cAlternatives\u201d criterion above,\u00a0The Guardian didn\u2019t even mention in this story that another migraine study was reported in the same issue of the New England Journal of Medicine\u00a0\u00a0involving another antibody drug \u2013 fremanezumab. \u00a0So\u00a0erenumab \u2013 the subject of this story \u2013 isn\u2019t the only game in town. \u00a0It\u2019s not even the only game in this class. \u00a0What were the results from the fremanezumab study? \u00a0And how are the two agents different? \u00a0We got nowhere near those questions \u2013 much less answers \u2013 from The Guardian in this story.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061015/23addict.b.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story reports on a prescription medication, rimonabant, for treating obesity that is currently unavailable in the US and if approved, would be new.", "answer": 1}, {"article": "To learn more about NAMS, visit http://www.\nIn the case of microablative fractional CO2 laser surgery, a series of microscopic laser beams using fractionated energy penetrate the skin to remove old and damaged skin cells, intended to rebuild the vaginal pathway.\nHowever, more robust randomized, sham-controlled data are needed, with larger numbers of women, to evaluate long-term safety, benefits, and risks,\" says Dr. JoAnn Pinkerton, NAMS executive director.\nAlthough there is ongoing debate regarding the safety and effectiveness of vaginal laser surgery, a new study suggests that it may be effective, especially after multiple treatments.\nCollectively known as the genitourinary syndrome of menopause (GSM), the various genital and urinary problems associated with menopause have created a market for new therapies and treatments to help women regain sexual function and bladder control.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release doesn\u2019t say what\u2019s new about the study.\u00a0 Lasers have been used for vaginal atrophy for at least 5 years. It\u2019s not clear from the release how long CO2 lasers have been used for genitourinary symptoms.", "answer": 0}, {"article": "Celgene\u2019s drug Abraxane prolonged the lives of patients with advanced pancreatic cancer by almost two months in a clinical trial, researchers reported Tuesday, signifying an advance in treating a notoriously difficult disease but not as big a leap as some doctors and investors had hoped.\n\n\u201cIt was not the breakthrough we were anticipating,\u201d said Dr. Andrea Wang-Gillam, an assistant professor and pancreatic cancer specialist at Washington University in St. Louis, who was not involved in the trial.\n\nStill, Dr. Wang-Gillam and others said any progress was welcome against metastatic pancreatic cancer, which has defied most treatments, with patients tending to live only about six months after diagnosis.\n\nPancreatic cancer is the fourth most common cause of cancer death, with 38,000 Americans expected to die this year, almost as many deaths as from breast cancer, according to the American Cancer Society. Yet there are only 45,000 new cases of pancreatic cancer a year compared with more than 230,000 new breast cancer cases.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reported:\n\u201cAbraxane is a novel form of the widely used cancer drug paclitaxel, also known by the brand name Taxol. In Abraxane, the paclitaxel is bound to albumin, a human protein in tiny particles. That is said to enhance delivery of the drug to tumors and reduce side effects.\nAbraxane was approved to treat advanced breast cancer in 2005 and to treat non-small-cell lung cancer in October.\u201d", "answer": 1}, {"article": "LONDON (Reuters) - A non-surgical treatment for low-risk prostate cancer in which doctors inject a light-sensitive drug derived from deep-sea bacteria into a patient\u2019s bloodstream was shown in a trial to kill cancer cells without destroying healthy tissue.\nIn the trial, only 6 percent of patients treated with VTP needed radical therapy compared with 30 percent of patients in the control arm who were under active surveillance.\nThe light-sensitive drug used, called WST11, is derived from bacteria found at the bottom of the ocean.\n\u201cThese results are excellent news for men with early localized prostate cancer, offering a treatment that can kill cancer without removing or destroying the prostate,\u201d said Mark Emberton, a University College London consultant urologist who led the trial.\nThe trial involved 47 treatment sites in 10 European countries, most of which were performing VTP for the first time.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This coverage establishes the novelty of the study. It\u2019s puffery to call this \u201ca huge leap forward\u201d but we\u2019ve addressed that concern elsewhere.", "answer": 1}, {"article": "Obese children who cut sugar from their diets saw improvements in markers of heart disease after just nine days, a study in Atherosclerosis found.\nFor the study, researchers evaluated 37 children ages 9 to 18 who were obese and at high risk for heart disease and Type 2 diabetes.\nAfter nine days, the researchers found a 33 percent drop in triglycerides, a type of fat tied to heart disease; a 49 percent reduction in a protein called apoC-III that is tied to high triglyceride levels; and large reductions in small, dense LDL cholesterol, a risk factor for heart disease.\nThe only change was their sugar intake: The researchers swapped foods high in added sugars, like pastries and sweetened yogurts, for options like bagels and pizza.\nThough this study is small and short-term, it builds on this group\u2019s previous research implicating added sugars as a contributor to metabolic disorders and heart disease.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The extent to which the research is novel is left unexplored.\u00a0 The blog post does reference a 2015 post about a research report that, while examining different physiological end points, reaches similar conclusions about sugar as a bad actor.", "answer": 0}, {"article": "On The Early Show Friday, Family Circle magazine Editor in Chief Linda Fears discussed everyday lessons that can make a big difference.\nIn fact, according to a recent survey we conducted on the emotional lives of tweens and teens, kids want more time just hanging out with their parents, and more time talking about important issues.\"\nIt's a tremendous challenge for parents to teach their teenagers and \"tweens\" everything they ought to know.\nTo watch the segment,\n\nFor much more on folic acid, from the federal Centers for Disease Control and Prevention, click here.\nWomen of child-bearing age are strongly encouraged to take it, because it can prevent birth defects.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Although presenting some new data on a different type of birth defect, the story was clear that the importance of adequate folic acid consumption is not new.", "answer": 1}, {"article": "In a study suggesting that red wine might be the next big thing in breast cancer prevention, a study has found that women who drank just under two servings of red wine daily experienced hormonal changes that mimic the effects of a drug used to prevent malignant breast tumors from coming back.\n\nThe study, published Friday in the Journal of Women's Health, found that consuming the same amount of white wine did not have the same effect in premenopausal women participating in the study.\n\nWomen intent on warding off breast cancer have been warned about alcohol consumption: as recently as November, a study found that women who consumed as few as three servings of alcohol a week increased their risk of developing the disease, which strikes one in eight American women at some point in life.\n\nWhite wine and other alcoholic beverages are believed to promote the conversion of androgens--\"male hormones\" such as testosterone, which circulate in all women's blood--into estrogen. And the greater a woman's lifetime exposure to estrogen--whether her own or estrogen that comes from medication or environmental sources--the higher her risk of developing breast cancer.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story offered some context about other wine-breast cancer research and pointed out how and why this result was different.", "answer": 1}, {"article": "Overall, more than half of people who run will experience some sort of injury from doing so, while the percentage of walkers who will get hurt is around 1 percent.\nJulia Belluz will sift through the research and consult with experts in the field to figure out how science can help us live happier and healthier lives.\nYou're also more likely to trip and fall while running than you are during a walk.\nTo recap: Running improves your health more efficiently than walking does and has greater health benefits per time invested.\nToo little isn't helpful for health, but too much might be harmful.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Humans have been walking and running for our entire history on the planet,\u00a0and\u00a0the story doesn\u2019t claim to be discussing any new approach.", "answer": 2}, {"article": "The U.S. Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis).\nThe most common side effects include injection site reactions; cold sores in the mouth or on the lips; and eye and eyelid inflammation, including redness, swelling and itching.\n\u201cFDA\u2019s approval of Dupixent demonstrates our commitment to approving new and innovative therapies for patients with skin disease,\u201d said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research.\nOverall, participants who received Dupixent achieved greater response, defined as clear or almost clear skin, and experienced a reduction in itch after 16 weeks of treatment.\nDupixent can be used with or without topical corticosteroids.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It\u2019s newsworthy whenever the FDA approves a new drug. This appears to be the first biologic, injectable treatment for eczema.", "answer": 1}, {"article": "Newswise \u2014 Bethesda, Md.\nIn some studies, the research team found that statins reduced inflammatory molecules that are typically elevated with liver disease and improved inflammation in the endothelium (cells that line the blood vessels).\nThe researchers acknowledge that statin drugs can contribute to liver damage in some people, but for people with advanced liver disease, \u201c[s]tatins are cost-effective, generally well-tolerated by patients and the benefits of statin treatment in most patients outweigh their potential hepatotoxic risk.\u201d\n\nRead the full article, \u201cRationale for the use of statins in liver disease\u201d published ahead of print in the American Journal of Physiology\u2014Gastrointestinal and Liver Physiology.\nEstablished in 1887, the American Physiological Society (APS) was the first U.S. society in the biomedical sciences field.\nStatin use may also lead to:\n\u2022 Decreased fibrosis (hardening or scarring of tissue),\n\u2022 Less development of fatty liver,\n\u2022 Slowed or halted spread of hepatitis C virus,\n\u2022 Improvement of portal hypertension (high blood pressure in the liver\u2019s blood vessels),\n\u2022 Destruction of existing liver tumor cells, and\n\u2022 Reduced risk of developing liver cancer.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The concept of using statins to treat underlying liver disease as part of routine clinical care would be considered novel.\u00a0 The study\u2019s novelty (as well as its limitations) could have been described with more clarity.", "answer": 1}, {"article": "(Reuters) - The U.S. Food and Drug Administration (FDA) on Friday expanded the use of Novartis AG\u2019s relapsing multiple sclerosis (MS) drug Gilenya to treat children and adolescents.\n\nMS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body and is among the most common causes of neurological disability in young adults.\n\nGilenya is the first FDA-approved drug to treat pediatric patients suffering from relapsing MS, the U.S. health regulator said.\n\nIn a clinical trial 86 percent of patients receiving Gilenya remained relapse-free after 24 months of treatment, compared to 46 percent of those who were administered another MS drug.\n\nGilenya was first approved by the FDA to treat adults with relapsing MS.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reported that Gilenya is the first FDA-approved drug to treat pediatric patients suffering from relapsing MS. This appears to be accurate.", "answer": 1}, {"article": "A lot changed in between the births of my second and third daughters. For one thing, this time around I really am getting no sleep; for another, the pediatrician recommended something for our 1-month-old that is different from what had been suggested for our other children. She said we needed to pick up a liquid multivitamin that contains 400 international units (IUs) of vitamin D. It was a little confusing, because with our first daughter, now almost 4, the doctor told us to simply get her out in the sun from time to time to let her body produce vitamin D,...", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story described a change in recommendation for babies experienced by the author.\nIt was made a bit murky by then expanding the discussion to include a variety of maladies for which an association with vitamin D levels have been reported, without an effort to explain the strength of the data or other factors (a change in the way circulating levels of vitamin D are measured) that may affect the recommendations.", "answer": 1}, {"article": "Cassandra Quave, an Emory University scientist who studies how indigenous people use plants in healing practices, said researchers pulled apart the chemical ingredients of the berries and tested them in mice infected with these superbug strains.\n\u201cWe\u2019re trying to answer the question: Does this work against bacteria, and how does it work, and is it safe to use?\u201d\n\nThe Brazilian peppertree, a shrubby tree native to South America, is an invasive species throughout the southern United States, particularly in Florida, where it\u2019s sometimes called the Florida holly or broad-leaf peppertree, and is considered a noxious weed.\nThe discovery may hold the potential for new ways to treat and prevent antimicrobial-resistant infections, an enormous global problem that was the focus of a rare high-level United Nations summit last fall.\nFrom an ecological standpoint, Quave said, it makes sense that invasive weeds have a chemical advantage that may help protect them from diseases so they can spread more easily in a new environment.\nFighting bacteria with drugs designed to kill them helps fuel the problem of antibiotic resistance if stronger bacteria can survive and evolve to become \u201csuperbugs.\u201d\n\n\u201cBut instead of always setting a bomb off to kill an infection, there are situations where using an anti-virulence method may be just as effective, while also helping to restore balance to the health of the patient,\u201d said Quave.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did not establish the novelty of this finding. (This topic was given a lengthy look in the New York Times Magazine last year, indicating this isn\u2019t a particularly new result.)", "answer": 0}, {"article": "At the meeting, Ahlquist presented the results of the first clinical evaluation study, which enrolled 1,100 patients.\nAhlquist called the 85% figure ''very high\" and adds: \"It would be very hard to find a noninvasive approach that could get that range.\"\nThe new test, a next-generation stool test known as a DNA methylation test, detects tumor-specific alterations or methylations in the DNA in the cells shed into the stool from cancerous or precancerous lesions.\nThe research was presented at the American Association for Cancer Research's special conference, Colorectal Cancer: Biology to Therapy.\nEstimates of how many adults undergo screening vary, but Ahlquist says probably only 40% adhere to the screening schedule over time.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Some attempt was made to explain what might be novel about this approach, but the story never mentioned that there are competing tests now in development. The New York Times was much better on this point, mentioning the competition in its very first words.", "answer": 0}, {"article": "The trial, which was conducted in Sri Lanka, enrolled 700 patients with an average age of 56 and blood pressure of 154/90 mm Hg.\nWhile the most pressing need, from the perspective of the global burden of disease, is low-and middle-income countries, it's equally relevant in a country like Australia where we're still achieving only 40%-50% control rates for high blood pressure.\"\nA trial led by The George Institute for Global Health revealed that most patients - 70 per cent - reached blood pressure targets with the 'Triple Pill', compared to just over half receiving normal care.\nThe Triple Pill, consisted of the blood pressure medications telmisartan (20 mg), amlodipine (2.5 mg), and chlorthalidone (12.5 mg).\nThis includes examining the acceptability of the Triple Pill approach to patients and their doctors, as well as cost-effectiveness which will be important for governments and other payers to consider.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Despite the fact that other combination blood pressure-lowering medications are available (but not mentioned), the headline and first paragraph of this news release suggest novelty. That\u2019s potentially misleading for readers.\nAn editorial accompanying the study put this research in context in terms of what has been learned previously:\nThe TRIUMPH investigators have demonstrated the effects of a promising intervention in a triple half-dose combination therapy, which logically extends findings from prior research to improve BP control among patients with mild to moderate hypertension. This study contributes to the existing literature demonstrating the essential role of fixed-dose combination therapy as a viable strategy for BP control on a global scale.", "answer": 0}, {"article": "MONDAY, Feb. 20, 2017 (HealthDay News) -- Stem cell transplants may halt the progression of aggressive multiple sclerosis (MS) in nearly half of those with the debilitating disease, but picking the right patients for the treatment is key, a new study suggests.\nMore than 2 million people in the world suffer from MS, in which the body attacks the central nervous system, according to the National Multiple Sclerosis Society.\nThose deaths are a major concern, one neurologist said, because MS is not in itself life-threatening.\nSpecifically, younger patients with a relapsing form of MS who were not severely disabled and who hadn't found relief with other treatments fared better than others over five years, the international team of researchers found.\nA trial that compares stem cell transplants with other therapies to see whether stem cell transplants can become a treatment for patients who have progressive MS is about to start, added Racke, who co-authored an editorial that accompanied the study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Researchers have been publishing papers about this type of stem cell transplant for at least 20 years. The story would have been much stronger if it had placed these recent findings in the context of the broader field of stem cell treatment for MS.", "answer": 0}, {"article": "The results were published in Wednesday\u2019s edition of the Journal of the American Medical Assn.\nAs a result, a cup of enriched white long-grain rice now contains 797 micrograms of folic acid, for example, and a cup of Cheerios has 493 mcg, according to this report from the Harvard Women\u2019s Health Watch.\nIn an editorial that accompanies the JAMA study, they write that the discrepancy \u201cmay be attributable to changes in diagnosis and surveillance but also may reflect a concurrent real increase in the risk of ASDs attributable to as-yet undescribed risk factors and exposures.\u201d They also note that data from the National Health Examination and Nutrition Survey published in 2009 show that the typical American consumes only 150 mcg of folic acid per day even with mandatory fortification.\nOn the other hand, pregnant women here are also far more likely to consume a healthy amount of the B vitamin because the Food and Drug Administration has required manufacturers of enriched breads, cereals and other grains to fortify them with folic acid since 1998.\nAmong the 85,176 children in the study, 270 (or 0.32%) received an ASD diagnosis \u2013 114 (0.13%) had autistic disorder, 56 (0.07%) had Asperger syndrome and 100 (0.12%) were diagnosed with \u201cpervasive developmental disorder-not otherwise specified,\u201d or PPD-NOS.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reports the long-standing recommendation that women considering pregnancy take folic acid supplements and that many common foods are already fortified with the vitamin.\nBut it could have noted that at least one other study has documented an association between folic acid use and reduced autism risk. The JAMA paper on which the story is based cites several prior reseach efforts showing association with folate in early pregnancy and severe language delay or autism.", "answer": 0}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\n\"The results show that multicentric cancer detected on breast MRI after mammography appears to represent a larger tumor burden in approximately a quarter of patients and can result in potential changes to cancer grade and treatment,\" Dr. Iacconi said.\n\"Patients with clinically insignificant cancers undergoing potential overtreatment versus patients who may be undertreated is at the heart of the controversy surrounding breast MRI,\" said the study's lead author Chiara Iacconi, M.D., from the Breast Unit at USL1 Massa-Carrara in Carrara, Italy.\n\"In general, it is accepted that radiation can likely treat invasive cancer less than 1 centimeter, but lesions larger than 1 centimeter, especially invasive carcinomas, may not be reliably treated with conservation.\"\nOAK BROOK, Ill. - Additional breast cancers found with MRI are sometimes larger and potentially more aggressive than those found on mammography, according to a study published online in the journal Radiology.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release nods to the fact that previous research in this area has been done. And it establishes what\u2019s new when it acknowledges that \u201cthere has been some debate about the clinical significance of multicentric cancers found with MRI.\u201d These new results, in the researchers\u2019 view, suggest that these cancers are in fact clinically significant.", "answer": 1}, {"article": "Asthma on the Rise in U.S.\nThere is no cure, but most people can control their symptoms, reduce the severity of their disease, and prevent asthma attacks by avoiding asthma triggers and correctly using prescribed medicines, such as steroid inhalers, the CDC says.\nYoshiteru Shimoide, MD, head of the Yoshiteru Shimoide Clinic of Internal Medicine in Kagoshima City, Japan, presented the results here at the annual meeting of the American Academy of Allergy, Asthma, & Immunology (AAAAI).\nOf those, 52 were given standard treatment (typically an inhaled steroid and a bronchodilator), and 226 were treated with kampo herbs.\nIn contrast, about three-fourths of those taking standard asthma medications still had daily wheeze and other symptoms.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "At the end, the story stated that the\u00a0American Academy of Allergy, Asthma, & Immunology \u201cdoes think there is evidence for herbal therapy having an anti-inflammatory effect that would fight asthma\u2019s underlying cause and is supporting research in the field.\u201d\nBut that evidence wasn\u2019t discussed, and there was no discussion of what that supported research is.\nSo the true novelty of this work was not clear in the story.", "answer": 0}, {"article": "When planning a day at the beach, should you add Polypodium leucotomos to your picnic basket? The company that sells the natural fern extract says a daily dose can help protect against sunburn, sun-related aging and even genetic mutations that cause skin cancer. Dermatologists say preliminary evidence suggests the extract does protect against the sun -- but don't throw away your sunscreen yet.\n\nEvery year, 36% of U.S. adults get at least one sunburn, according to the federal Centers for Disease Control and Prevention....", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not comment on the novelty of this idea. Is oral sun protectant novel? The story should not leave it up to the reader to research whether this is a new idea or not.", "answer": 0}, {"article": "And functional electrical stimulation is using low levels of electricity in order to activate nerves and muscles in order to restore movement,\" explains Dr. Hunter Peckham, director of the Cleveland F.E.S.\n\"This is a multi-channel implantable device,\" Peckham explains.\nis functional electrical stimulation.\n\"Electrodes are implanted in the body.\nThen one day, the life you've always known comes to a sudden end.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story states that this is a new approach.", "answer": 1}, {"article": "(Forget to weigh in or track your meals?\nA recent pilot study with Utah-based Intermountain Healthcare that included about 200 people, all of whom were at high risk of Type 2 diabetes, found that 75 percent of the participants completed the Omada program and lost at least 5 percent of their body weight.\nIf it were easy, there wouldn't be more than 80 million adults in the U.S. with prediabetes.\nAdditionally, traditional players in the weight loss space, such as Weight Watchers, now offer some similar incentives, such as personal coaching.\nAfter all, pulling off these changes is difficult\n\n\"I'm still on the journey to get to more optimal, health\" says Lonny Northrup, who lives in Utah.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story made clear that the Omada program includes a suite of features, including education, diet and exercise tracking, coaching, electronic nudging, and peer support, delivered to one\u2019s smartphone. What\u2019s relatively new is an app taking such a comprehensive approach.", "answer": 1}, {"article": "Millions of Americans suffer from pet allergies that prevent them from enjoying the benefits of owning a dog or a cat.\n\u201cBut now I don\u2019t really feel allergy symptoms anymore.\u201d\n\nTo find a prescribing doctor for Allerdent in your area or to find more information, visit Allovate.com.\n\u201cThe patients who came in were treated for the very things that they were sensitive to, and that included indoor allergens, like dustmite and pet dander, as well as outdoor allergens such as tree pollen, grass pollen, ragweed pollen,\u201d Dr. William Reisacher, an associate professor of otolaryngology and director of allergy services at Weill Cornell Medicine/New York-Presbyterian Hospital, told FoxNews.com.\nI was really uncomfortable and miserable.\u201d\n\nJoyce tried over-the-counter medications but couldn\u2019t find relief.\nJoyce, who lives in the Bronx, New York, signed on for the year-long study that required six of the 12 volunteers to brush their teeth for two minutes using two pumps of the toothpaste in either the morning or night, and the other six to use drops under their tongue.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The idea that a toothpaste containing material that might alleviate allergy symptoms seems novel enough to warrant a news story. But what specifically are the advantages of the toothpaste over other approaches such as shots or drops? This story isn\u2019t explicit about what\u2019s new or better. A CBS story published back in 2014, by contrast, quoted a researcher on the toothpaste\u2019s specific novelty appeal. Talking about the drops, he said, \u201cPeople forget to do it and also it\u2019s difficult for small children to keep a liquid under their tongue for two minutes.\u201d", "answer": 0}, {"article": "Unlike the rubber insulation around wires, however, myelin helps electrical signals in neurons move faster and more efficiently.\nThat myelin increases the speed of neural transmission is one of the most well-established concepts in neurobiology, and combined with the clear evidence from Chan's preclinical research showing that clemastine fumarate promotes myelin formation, myelin regeneration is the only plausible explanation for the VEP results, the authors said.\nIn light of previous laboratory studies of the antihistamine compound at UCSF, the researchers said, the drug most likely exerted its effect by repairing damage MS had inflicted on myelin, an insulating membrane that speeds transmission of electrical signals in the nervous system.\nThe drug tested in the trial, clemastine fumarate, was first identified as a candidate treatment for MS in 2013 by UCSF's Jonah R. Chan, PhD, Debbie and Andy Rachleff Distinguished Professor of Neurology, vice chief of the Division of Neuroinflammation and Glial Biology, and senior author of the new study.\nIt's not a cure, but it's a first step towards restoring brain function to the millions who are affected by this chronic, debilitating disease,\" said the trial's principal investigator, Ari Green, MD, also Debbie and Andy Rachleff Distinguished Professor of Neurology, chief of the Division of Neuroinflammation and Glial Biology, and medical director of the UCSF Multiple Sclerosis and Neuroinflammation Center.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release does a good job explaining what exactly is new in this study. This is the first time to the best of their knowledge, according to the principal investigator, that a drug therapy can reverse nerve damage. Participants had been living with MS for years, but their nerves showed \u201cstrong\u201d evidence of repair, the first author added.\nHowever, this is not the first time an older, generic drug showed it could restore nerve function. There have been previous reports that high doses of the immune-suppressing drug cyclophosphamide could also slow MS progression and bring back neurological function lost to the disease.\nAlthough this background could have been provided, we feel the news release does a Satisfactory job here.", "answer": 1}, {"article": "TUESDAY, Nov. 23, 2010 (HealthDay News) -- Implantable devices designed to control heart rhythm and efficiency while preventing sudden death among heart failure patients are as effective at ensuring patient survival in real-world situations as they are in controlled study environments, new research suggests.\nThe study team also found that patients whose implants were monitored remotely, on a continual basis, by a health facility network were about half as likely to die as patients who only had intermittent in-person assessments.\n\"So we don't really know what it all means, and it's inappropriate to suggest that we could, based only on this compilation of data.\"\n\"It's highly likely the reason these patients did better is that they were receiving earlier diagnoses, and they were also empowered to take charge of their own health care more,\" Saxon said.\nThe study authors noted that the observation is somewhat surprising, given that some of the patients not enrolled in structured studies have already experienced a cardiac event and are therefore prescribed such devices to prevent a recurrence.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of these devices or of remote monitoring is never established. The story also could have established the relative novelty of the dataset.\u00a0 The manufacturers\u2019 patient registry allowed the researchers to study the real world events in people living with ICD\u2019s and CRT-D\u2019s. The story does not note the rather unique circumstances allowing the research to be conducted; a manufacturer\u2019s patient registry.", "answer": 0}, {"article": "\"Large trials of other widely used supplements have sometimes found benefits,\" Manson wrote, \"but in other cases--such as with high doses of beta carotene, vitamin E and selenium--have disproven some health claims for these supplements and identified health risks that may not have otherwise been detected.\"\nYou should be consuming 600 international units daily if you're between the ages of 1 and 70, and 800 IU each day if you're 71 or older, according to the Institute of Medicine, the health arm of the National Academcy of Sciences.\n\"Clinical enthusiasm for supplemental vitamin D has outpaced available evidence on its effectiveness,\" JoAnn E. Manson and Shari S. Bassuk of the Division of Preventive Medicine at Brigham and Women's Hospital in Boston wrote last week in the journal's online version.\nOver the past 15 years, those studies \"have looked promising, and very often they've been reported by the media as suggesting that vitamin D has these benefits.\nBut somehow we've arrived at a point when some physicians are prescribing large doses of Vitamin D supplements for their patients in the hope of preventing cancer, cardiovascular disease, diabetes, autoimmune disorders and other maladies, despite a lack of evidence that this works, according to a new commentary in the Journal of the American Medical Association.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story provides the background on why this issue is worth writing about now. It notes that over the past 15 years, observational studies \u201chave been reported by the media as suggesting that vitamin D has these benefits\u201d (i.e. cancer and cardiovascular disease prevention). It explains that these studies have promoted a \u201cmore is better\u201d approach that isn\u2019t supported by the evidence. It notes that there\u2019s a large clinical study of vitamin D underway that should help answer many of the questions surrounding vitamin D.", "answer": 1}, {"article": "\"PSA can identify those at low risk of prostate cancer and once you have done that, you can remove almost 50 percent of men in the age group 55 to 74 [from undergoing biopsies],\" said study senior author Monique Roobol, an epidemiologist in the department of urology at Erasmus University Medical Center in Rotterdam.\nFor this study, about 20,000 men aged 55 to 74 in the Rotterdam area were screened, with those having PSA scores at or above the cut-off of 3.0 sent for biopsies and additional screenings every four years.\nThis compares with 15.7 percent of those with scores from 2 percent to 2.9 percent developing a malignancy and 0.36 percent dying of the disease.\nA final study of almost 4,000 patients found that surgeons needed to perform 1,600 procedures known as robotic-assisted laparoscopic radical prostatectomies (RALP) to become adept at the procedure.\nIn comparison with typical laparoscopic surgery, RALP offers surgeons three-dimensional vision and such improvements as better magnification and hand tremor filtering.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It is possible to infer from the story what is the relative novelty of the three approaches reported on: a potential modified schedule for PSA testing; off label use of an already FDA approved medication; and new data on the learning curve for a robotic surgical approach.", "answer": 1}, {"article": "That view is shared by Deborah Giaschi, a professor of ophthalmology and visual sciences at the University of British Columbia in Vancouver who has conducted MRI studies of the brains of people with dyslexia. \"There's really no scientific basis\" for ChromaGen lenses, she says. In her opinion, the claim that the lenses slow down visual processing doesn't make sense. Even if the lenses had that effect, she doesn't see how that would help anyone read.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Not applicable.\u00a0 No claims of novelty are made in the column.", "answer": 2}, {"article": "Type 2 diabetes is caused by the body\u2019s in ability to break down sugars from the diet.\n\u201cIt isn\u2019t an irreversible, inexorable condition that you can never escape from \u2014 at the moment, people are told that.\u201d\n\nPrevious studies have suggested that lifestyle changes, including diet and exercise, can be powerful ways to lose weight and combat diabetes.\nThe diet, which was designed to help people lose up to 30 pounds, involved three to five months of a strict low-calorie liquid formula diet averaging no more than 850 calories a day, followed by two to eight weeks of reintroducing food, along with nutritional education and cognitive behavioral therapy to help people stick with the new eating plan.\nIf more people can benefit from losing weight alone, then that would mean less cost to the health care system, as fewer people will suffer the serious complications of advanced disease, which can include heart problems, neuropathy, vision issues and even amputations.\nBut in a paper published in the , researchers in the UK describe a landmark study in which people with diabetes went into remission\u2014just by losing weight.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story distinguishes the study\u2019s finding from other diabetes-related evidence. Weight loss has previously been shown to prevent people with prediabetes from progressing to diabetes and to help manage diabetes itself. This study shows that a short, extreme intervention can lead to longer term remission.", "answer": 1}, {"article": "As with other atypical antipsychotic drugs, Nuplazid has a Boxed Warning alerting health care professionals about an increased risk of death associated with the use of these drugs to treat older people with dementia-related psychosis.\nThe FDA\u2019s program provides for an expedited review of drugs that offer a significant improvement in the safety or effectiveness for the treatment, prevention, or diagnosis of a serious condition.\nNuplazid was shown to be superior to placebo in decreasing the frequency and/or severity of hallucinations and delusions without worsening the primary motor symptoms of Parkinson\u2019s disease.\nThe neurological disorder typically occurs in people over age 60, when cells in the brain that produce a chemical called dopamine become impaired or die.\nThe agency also is responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release states that this is the \u201cfirst drug approved to treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson\u2019s disease.\u201d", "answer": 1}, {"article": "protection.\u201d\n\nAlgenist literature touts alguronic acid\u2019s superiority to hyaluronic acid, retinol and vitamin C, among other anti-aging ingredients, in encouraging elastin synthesis and cell regeneration.\nBut Dr. McDaniel, who does research into using plant-derived products to lengthen the life of cells, says he thinks the comparative data must be viewed with caution because the studies that yielded it are \u201cchallenging to do accurately, hard to interpret and not necessarily predictive of final products.\u201d\n\nSoon, consumers will judge whether Algenist products are a breakthrough.\n\u201cIt was a brand nobody has ever heard of,\u201d said Allen Burke, the senior adviser for beauty strategy and development at QVC.\nDr. Dana Sachs, an associate professor of dermatology at the University of Michigan, Ann Arbor, wrote in an e-mail after looking at Algenist\u2019s dossier that \u201cthe claims on cell regeneration and elastin synthesis are based on in vitro models, which is hard to extrapolate to in vivo, and again no statistical significance is presented, so this is a weak claim.\u201d\n\nDr. Day, who has a doctorate in biochemistry, said that statistical significance was found but not included in press materials.\n\u201cWe want to give it a lot of visibility all at the same time.\u201d But Mr. Burke knows that marketing has its limits.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a good job describing why the company selling this product is excited about its prospects, but it never establishes what sort of edge, if any, this product would have on the thousands of other \u201canti-aging\u201d products being sold. There are hundreds of anti-aging products containing a product derived from seaweed. The suggestion that this one is somehow unique remains to be proven", "answer": 0}, {"article": "Dr. Beth Karlan, director of gynecologic oncology at Cedars Sinai Medical Center in , said the results of the new trial would \u201cmake us all rethink the approach to treating patients with recurrent ovarian cancer.\u201d\n\nDr. Karlan, who was not involved in the study but presented a commentary on it, said CA125 testing should be done less frequently.\nDr. Rustin said the explanation for the counterintuitive results was not that CA125 was a poor predictor of cancer\u2019s return.\n\u201cMany women often say they live from one CA125 to the next,\u201d she said.\n\u201cI was in a constant state of , waiting for the test, waiting for the results,\u201d she said.\n\u201cThis makes me feel in control of this disease,\u201d said Carol Tawney of Shawnee, Kan., a seven-year survivor who has her CA125 tested every two months.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Clearly CA-125 testing for recurrent Ovarian Cancer is not a new idea.", "answer": 1}, {"article": "The studies also varied in quality, with only nine of 26 considered \"low [in] bias,\" according to background information accompanying the study.\nWhile chiropractors often perform SMT on patients, it is also administered by physical therapists and osteopaths.\nReviewing 26 studies comparing spinal manipulative therapy (SMT) to other treatments such as medication, exercise or physical therapy, researchers from the Netherlands found that SMT appears to be no better or worse than other options at relieving back pain long-term.\n\"Nobody has the answer at this time,\" Perle said.\n\"Spinal manipulation should be considered a viable treatment option for those with non-specific, chronic low back pain.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Manipulation is an age-old treatment. There was no reason for the article to discuss its novelty.\n\n \n", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Colonoscopy may miss as many as one in every 13 colon cancers, suggests a new study.\nHowever, Lieberman cautioned against the over-interpretation of the results.\nTumors may simply have gone unidentified on the exam, or were seen but not completely removed.\n\u201cThese patients were referred for colonoscopy, most commonly due to symptoms,\u201d Lieberman said.\nBoth groups could do things to improve the detection rate, they said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that colonoscopy is the dominant screening for colon cancer.", "answer": 1}, {"article": "They're forgetful,\" Ashare said.\nIn a study consisting of a rat trial and a human trial, Ashare and Schmidt studied the effects of two acetylcholinesterase inhibitors, or AChEIs, called galantamine and donepezil on overall nicotine intake.\n\"At the doses shown to reduce nicotine self-administration, the AChEIs did not make our animals sick,\" Schmidt said.\nThere's no data to suggest that a clinician treating a smoker should prescribe one of these AChEIs now.\n\"We know from the literature that upward of 30 percent of patients will report nausea and vomiting [when taking these drugs], and this will limit their compliance,\" he said.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release makes a tepid reference to novelty with the phrase that researchers are \u201cforging a path\u201d with this research. The study itself says,\u00a0\u201cTo the best of our knowledge, this is the first translational study to demonstrate that repeated AChEI administration decreases nicotine taking in both rats and human smokers.\u201d\nWhile this may well be the first \u201ctranslational\u201d study on this question, a look on PubMed shows that quite a lot has been done in rats on nicotine\u00a0and the cholinesterase inhibitor drugs. There has been much less in humans, although trials have been done, with mixed success, such as this modestly successful one in alcoholics. (A randomized, controlled trial in 114 patients for 12 weeks, it showed those on galantamine smoked 20% fewer cigarettes than those on placebo.) To earn a Satisfactory rating, we think the release should have acknowledged some of this previous research.", "answer": 0}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\nThe trial results \u201cprovide crucial evidence for a safe and effective alternative to laser therapy against PDR,\u201d said NEI Director Paul A. Sieving, M.D., Ph.D.\n\n\u201cPatients who received Lucentis showed a little bit better central vision, much less loss of their side vision, and substantially less risk for surgery than patients who received laser treatment,\u201d said Lloyd Paul Aiello, M.D., Ph.D., director of the Beetham Eye Institute at Joslin Diabetes Center and Professor of Ophthalmology at Harvard Medical School.\nThe use of anti-VEGF treatment rather than laser for PDR could help prevent these symptoms.\u201d\n\nAdditionally, the need for vitrectomy surgery was lower in the Lucentis group (8 of 191 eyes) than in the laser group (30 of 203 eyes).\nBecause Lucentis is commonly injected to treat diabetic macular edema (DME)\u2014a build-up of fluid in the center of the retina\u2014the study permitted the use of Lucentis for DME in the laser group, if necessary.\nFunded by the National Eye Institute (NEI) and conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net), the trial compared Lucentis injections with a type of laser therapy called panretinal photocoagulation, which has remained the gold standard for PDR since the mid-1970s.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The clinical trial at issue here appears to be the first to look at the use of Lucentis as a treatment for PDR, particularly in a randomized study with direct comparison to laser treatment. However, the release doesn\u2019t tell readers that. On the other hand, the release does make clear that this is the first significant advance in clinical treatment for PDR since the 1970s \u2014 that\u2019s good context.", "answer": 1}, {"article": "MONDAY, March 16, 2015 (HealthDay News) -- A new study calls into question the value of removing blood clots from a patient's heart arteries during angioplasty, a procedure to open blocked arteries.\nIt needs to be tested in large trials,\" he said.\n\"This is an unexpected finding, and we want to confirm this in other studies,\" Jolly said.\nIt is possible that parts of the clot break off and travel elsewhere in the heart or brain, he said.\n\"These findings will likely have important implications for clinical practice,\" Fonarow said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear that there was prior research on this topic showing benefit from clot removal.", "answer": 1}, {"article": "For more information visit http://www.\nAfter one year of the study, 36 per cent of patients treated with nivolumab were still alive compared with 17 per cent for the comparator arm.\nThis phase III clinical trial expands the repertoire of nivolumab even further, showing that it is the first treatment to have significant benefits in relapsed head and neck cancer.\nSo it's great news that these results indicate we now have a new treatment that can significantly extend life, and I'm keen to see it enter the clinic as soon as possible.\"\nIt provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release addresses this explicitly: \u201cNivolumab became the first treatment to extend survival in a phase III clinical trial for patients with head and neck cancer in whom chemotherapy had failed.\u201d", "answer": 1}, {"article": "So far, however, there is little scientific proof of their effectiveness\u2014many studies of probiotics have involved less-than-rigorous...\nBut some researchers are investigating the beneficial bugs for conditions that have nothing to do with the digestive tract.\nProbiotics are widely used to aid digestion and help restore gut bacterial balance after antibiotics.\nOne of the fastest-growing dietary supplements, probiotics are now prominent on drug and big-box store shelves.\nThey are live microorganisms\u2014or \"good\" bacteria\u2014that when consumed in capsules or yogurt are said to confer a health benefit.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t inappropriately\u00a0emphasize the novelty of research on probiotics.", "answer": 1}, {"article": "'This is not the end': Using immunotherapy and a genetic glitch to give cancer patients hope\nThe researchers presented earlier findings on the gene therapy a year ago at the American Society of Hematology's annual meeting, but the latest data covers a larger patient group and a longer time period.\nThe follow-up period was relatively short, from 28 to 78 weeks in the new report; longer-term studies are needed to prove safety and effectiveness over extended periods.\nIn addition, he said, researchers need to find ways to provide the therapy to a broader group of people, including children, and to figure out how to reduce the costs involved.\nOn Wednesday, researchers reported that a single intravenous infusion of Spark's novel gene therapy enabled patients to safely produce sufficient clotting factor to prevent dangerous bleeding episodes.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes novelty with this:\nThe researchers presented earlier\u00a0findings\u00a0on the gene therapy a year ago at the American Society of Hematology\u2019s annual meeting, but the latest data covers a larger patient group and a longer time period.", "answer": 1}, {"article": "But Gee believes reimbursing patients to play games could cut other health costs \u2014 by promoting exercise and preventing disease, for example, or even reducing the amount of expensive drugs people take.\nThe worst fear is that the technology will become outdated by the time the FDA process is complete.\nSome of the people recruited for drug trials end up not having Alzheimer's at all.\nIt might seem like a strange vision for an industry known best for issuing denial letters.\n\"It's just essentially a digital version of otherwise typical kinds of psychological and cognitive behavioral therapy,\" he says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not explain how these video games are different from other computer-based cognitive therapy approaches that have been tried before.", "answer": 0}, {"article": "Revenues from pharmaceutical and device corporations are available at http://www.\n\"The biggest problem we face in preventing stroke in patients with atrial fibrillation is that almost half of patients don't take any blood thinner at all,\" Bernstein said.\nThe new results are part of a large on-going phase III study testing idarucizumab in a range of patients who take dabigatran and have dangerous bleeding or need urgent surgery or other procedures that carry serious bleeding risks.\nLOS ANGELES, Feb. 19, 2016 - A new medication reverses the blood-thinning effects of the anticoagulant dabigatran in patients suffering a brain bleed, potentially limiting the extent of bleeding, according to research presented at the American Stroke Association's International Stroke Conference 2016.\nIn patients who received two 2.5-gram of idarucizumab infusions in a 15-minute period, blood tests revealed that dabigatran's blood-thinning effect was 100 percent reversed in all 18 patients with brain bleed.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release\u2019s claim to novelty is that idarucizumab works to counteract the blood-thinning effects of dabigatran in patients with cranial hemorrhage. We agree it\u2019s borderline novel since we would expect the drug to reverse the effects regardless of the underlying condition. It\u2019s reasonably clear that we already knew idarucizumab countered the effects of dabigatran in other populations (given that the FDA has already approved it to do just that).", "answer": 1}, {"article": "\u201cHospitalization is often necessary when patients start to retain fluid, develop congestion and experience shortness of breath.\nThis is a big game-changer.\u201d\n\nFunded by the Ted Rogers Centre for Heart Research, the device called CardioMEMS\u2122 HF System was successfully implanted by interventional cardiologists at the Peter Munk Cardiac Centre in March 2017.\nProduced by Abbott, the CardioMEMS\u00d4 HF System is approved in the United States by the Food & Drug Administration (FDA) and is currently awaiting approval by Health Canada.\nWith this device, we can see warning signs days in advance, and adjust treatment accordingly.\u201d\n\nThe most rapidly rising cardiovascular disease in Canada, heart failure affects close to one million Canadians, and an estimated 26 million people globally.\nEach year, approximately 55,000 patients receive innovative and compassionate care from multidisciplinary teams in the Peter Munk Cardiac Centre, and the Centre trains more cardiologists, cardiovascular surgeons and vascular surgeons than any other hospital in Canada.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "CardioMEMS may be a novel procedure in Canada, but it\u2019s been around in the US since September 2007, when patients were first enrolled in a clinical trial looking into the device\u2019s effectiveness. In 2016 the Lancet published the results of the CHAMPION trial, which followed 550 heart failure patients. Participants were then randomized to receive CardioMEMS heart failure sensors or traditional heart failure therapies.\nThe news release points out that CardioMEMS was approved by the US FDA, but is awaiting approval by Health Canada.\nWe wish this information would have been higher up in the story, along with more context on the device\u2019s history and clinical trial. The term \u201cnovel\u201d in the headline may also be misleading to readers, since it refers to the novelty of CardioMEMS in Canada.\nDespite this, we feel the news release did a good enough job for a Satisfactory rating here.", "answer": 1}, {"article": "Doctors numbed the lower half of O'Brien's body.\nThe new surgery simply moves them to the side in order to fit the knee with titanium and plastic caps \u2014 creating a knee joint free of pain and arthritis.\nThe day of the surgery, Berger has his patients conquer what amounts to a knee-bending obstacle course before they're able to leave \u2014 walking up and down a hallway and up and down a flight of stairs.\n\"I'll be chipping and putting in three weeks \u2014 maybe four,\" joked O'Brien from the operating table.\n\"With this kind of surgery we don't cut into the muscle at all,\" Dr. Bergersaid.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This surgical procedure is relatively new; the company website (Zimmer) mentioned that the first MIS Quad-Sparing total knee replacement was in February 2002. (Does 4 years qualify as \u2018new\u2019?)\n It is a story about a less commonly used device for total knee replacement and as such would be of interest to those considering knee replacement.", "answer": 1}, {"article": "Newswise \u2014 CHAPEL HILL, NC \u2013 For patients whose hearing is considered \u201ctoo good\u201d for traditional cochlear implants, but whose hearing loss is too advanced to benefit from hearing aids, there hasn\u2019t been a device to meet their needs.\n\u201cThe technology is remarkable and so were the results.\u201d\n\nThe implant relies on two auditory technologies \u2013 the SYNCHRONY cochlear implant that stimulates the auditory nerve for high-frequency hearing loss and the EAS audio processor, which has a built-in acoustic amplification for low-frequency hearing loss.\nBut a hearing implant system that just received FDA approval will now meet that previously unmet need and benefit those patients, according to Harold C. Pillsbury, MD, chair of the Department of Otolaryngology/Head and Neck Surgery at the UNC School of Medicine.\nThe SYNCHRONY EAS implant best assists people whose hearing loss is referred to as \u201cski-slope\u201d hearing loss, based on the steeply sloping image that appears on an audiogram when a patient has more trouble hearing higher-frequency sounds.\n\u201cOn average, patients performed more than twice as well on tests of speech understanding with EAS than they did with their hearing aids preoperatively, which speaks to the benefits of this technology,\u201d Pillsbury said.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does a good job of explaining what is different about this device compared to other cochlear implants, notably that it is combines two technologies to address both high frequency and low frequency hearing loss. But the release would have been strengthened by noting that newer \u201copen fit\u201d \u00a0hearing aids also try to tackle the dual hearing loss problem for many people.", "answer": 1}, {"article": "The page may no longer exist or may have moved to another web address. Try again to locate what you want by choosing a section from the navigation menu at left, viewing our Site Map or using the search box below.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article mentions that alternative therapies are not new and says that hypnosis \u201cis among the many non-drug treatments to which women turn for hot flash relief.\u201d", "answer": 1}, {"article": "For decades, researchers have searched unsuccessfully for ways to automatically coordinate insulin delivery with real-time changes in blood sugar to essentially create an artificial pancreas that maintains target blood sugar levels with minimal effort.\n\"This is hugely promising and very significant research,\" he tells WebMD.\nNow new technology is making this possible, and new research shows that an experimental system can improve nighttime blood sugar control.\nThe system proved better than a conventional insulin pump for maintaining optimal blood sugar levels during the night in a study from the U.K.'s University of Cambridge.\n\"Nighttime is the time of day that strikes fear into patients and parents of children with diabetes.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions that this technology has been in the works for decades and mentions the current availability of continuous glucose monitors and insulin pumps.", "answer": 1}, {"article": "A study of a proposed diabetes drug, Januvia, from Merck & Co. showed it lowered a key measure of blood sugar when taken in combination with another common diabetes drug.\n\nThe study, due to be presented Thursday at the European Association for the Study of Diabetes in Copenhagen, involved 1,056 patients diagnosed with Type 2 diabetes who hadn't previously been treated with diabetes medications.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story describes a study evaluating a new drug, which works differently than other drugs for lowering blood sugar. However, while it may work differently, its effects are not different and appears to offer no distinct advantages over what is currently available. ", "answer": 0}, {"article": "But Cytori\u2019s machine hasn\u2019t been approved by the .\nThe study, which Dr. Khouri plans to publish in a peer-reviewed journal, found that the procedure does not impede the reading of mammograms and that on average, 85 percent of transplanted fat survived to give patients natural-feeling larger breasts.\n\u201cAnyone can take fat and inject it into the breast, and the patient will look good immediately afterwards,\u201d Dr. Khouri said, but a few months later, the fat injected by a doctor with sub-par skills may result in \u201coil cysts, masses, and scarring.\u201d\n\nTo some, this kind of fat recycling seems simple.\nThat hasn\u2019t stopped Dr. Todd Malan, a board-certified ob-gyn in , Ariz., who is the surgeon in the ABC news clip, from anointing himself the \u201cFirst in U.S. to perform Stem Cell Enhanced Breast Augmentation!\u201d on his Web site.\nLast month, new guidelines from the recommended that most women should start mammograms at 50, instead of 40, to try to reduce the number of tests, including biopsies for false positives.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story describes fat grafts to the breast as a procedure that has been tried for decades, but that may gain popularity in part because the American Society of Plastic Surgeons eased its warnings against the procedure earlier this year .", "answer": 1}, {"article": "Studies Say Meditation May Help\n\n\u201cThe main finding [of our research] is that, added on top of usual medical care, intervention with a mind-body technique \u2014 transcendental meditation \u2014 can have a major effect on cardiovascular events,\u201d says Robert Schneider, lead author on the study published in Circulation: Cardiovascular Quality and Outcomes and a professor at the Maharishi University of Management, an institution in Iowa that was founded by the creator of transcendental meditation.\nThe participants were randomly assigned to participate in either a health education class about heart-friendly diet and exercise, or to attend a transcendental meditation program.\nAll of the participants continued to receive their normal medical care as well, including appropriate medication.\nThe meditating group enjoyed an average drop of 4.9 mm Hg in systolic blood pressure compared to the control group and also reported less stress and less anger.\nThe scientists adjusted for the effects of weight, smoking behavior, and diet, all of which can influence heart attack, stroke and early heart death rates.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story provides\u00a0a good sense of where this study sits in the universe of meditation research.", "answer": 1}, {"article": "That\u2019s Stage IV cancer and it\u2019s almost always deadly at that stage.\nThat compares to about 5 percent of patients given the standard therapy, interleukin, the American Society for Clinical Oncology (ASCO) says.\nThe cancer drug that former president Jimmy Carter says made his melanoma seemingly disappear has helped about 40 percent of similar patients survive for as long as three years, oncologists said Wednesday.\nThat doesn\u2019t mean a cure \u2014 it\u2019s too soon to say that \u2014 but it does mean months or years of cancer-free life that they otherwise could not have hoped for.\nThe drug, called Keytruda, takes a new approach to treating cancer by stopping tumor cells from cloaking themselves against the normal, healthy immune system response.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is made clear by a succinct walkthrough of how pembrolizumab might work, and a source\u2019s statement about average life expectancy.", "answer": 1}, {"article": "The requested document is forbidden. Please try your operation again .", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story included the trajectory of use for the treatment.", "answer": 1}, {"article": "In a twist in the debate about the safety of menopause hormones, new research suggests the real problem may not be the hormone itself, but the fact that it's typically swallowed as a pill.\n\nThis week, the medical journal Circulation offers some of the strongest evidence yet that the risks of hormones are dramatically reduced when the drugs are absorbed through the skin in patches and gels rather than taken as pills. The study by French researchers showed that one of the most serious risks associated with hormone use -- blood...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions that millions of women use hormones to treat menopausal symptoms, so clearly they are not new.", "answer": 1}, {"article": "Autism has always been a tricky disorder to diagnose.\n\"Why some toddlers with ASD get better and develop good language and others do not has been a mystery that is of the utmost importance to solve,\" Eric Courchesne, one of the study\u2019s authors and co-director of the University of California-San Diego's Autism Center, said in a statement.\nThe images of the children in the study -- MRIs of the brain -- were taken at 12 to 29 months while their language was assessed one to two years later at 30 to 48 months.\nThe spectrum is wide and some are destined to be on the mild end and be very talkative, sometimes almost indistinguishable from those without the disorder in some settings, while others will suffer from a more severe form and have trouble being able to speak basic words.\nScientists at a growing number of research centers are pinning their hopes that these images will help them unlock some of the secrets of everything from what causes childhood disorders like Attention Deficit Hyperactivity Disorder to how neurons in the brain process vision and memory.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We\u2019ll give the benefit of the doubt on this one. While the article doesn\u2019t clearly articulate what\u2019s novel about this research \u2014 the fact that it\u2019s the first study to use magnetic resonance imaging (MRI) in very young children diagnosed with autism as a way to predict their future level of language abilities \u2014 it does establish the diagnosis problem and suggests that the study represents a new approach to dealing with it. A San Diego Union-Tribune story on the same study expertly stated the novelty this way: \u201cIf the results hold up, this would be the first time that brain imaging of living children has been used successfully to guide autism diagnosis and help choose appropriate therapy. Currently, autism assessments are based on behavior.\u201d", "answer": 1}, {"article": "People with Type 2 diabetes get an earful of grim lectures about their health prospects and endure much hardship to manage their condition well. But new research offers those who do so a rare reward. A glass of wine every day not only won't hurt, says a new study: It can actually improve cardiac health, help manage cholesterol and foster better sleep.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that this study is based on randomizing people to either drink wine or mineral water and then following them for two years, in contrast to most studies in this area, which are generally based on observational data or small, short-term trials.", "answer": 1}, {"article": "The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives in a future epidemic of the deadly disease.\n\nThe research, by doctors from the U.S. and Liberian governments and elsewhere, was published Wednesday in the New England Journal of Medicine. The study looked at 1,500 patients in Liberia, and took place amid and after the outbreak of Ebola in Liberia from 2014 into 2015.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Since hemorrhagic fevers such as Ebola are so deadly, the possibility of new vaccines that might be successful against them is certainly novel enough for a story.\u00a0 In this case, it reports a strong antibody response against the virus suggesting a possible protection against an often-fatal disease. The story does a good job of putting the new studies in context.", "answer": 1}, {"article": "Using electromagnetic radiation, infrared lamps warm your body directly.\nThe existing evidence, though scanty, suggests spending up to 15 minutes a day in one could benefit your heart and ease symptoms associated with chronic pain.\nStill, the big questions surrounding sauna bathing\u2019s safety have always centered on its occupant\u2019s (and her heart\u2019s) ability to withstand the heat.\nBut if you\u2019re wondering whether an infrared sauna is worth a try, the evidence suggests you have little to lose and possibly something to gain by checking one out.\nWhile there\u2019s not a ton of published research looking specifically at infrared saunas, Beever has published a review of all the existing studies he could turn up on the subject.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The column is titled \u201cYou asked\u201d so we\u2019re assuming this story was prompted by a reader query. One thing we would have liked to have seen included is why they\u2019re asking right now--a Google search revealed lots of news outlets writing about infrared saunas in the past few months, with\u00a0health claims that might be exaggerated.", "answer": 1}, {"article": "\u201cWe are just feeding off of this cancer phobia.\u201d\n\nWhat is needed, and what the new test does not provide, is a way to decide which cancers are dangerous and which are not, Dr. Isaacs said.\nThen they found that family history of the cancer added an independent risk.\nUnlike traditional genetic links to disease, the variants are not mutations that destroy a gene\u2019s function.\nThe next step was to ask whether those variants really could predict who had prostate cancer.\nThat resulted in the discovery, by several groups of investigators in Iceland and the United States, of the gene variants, small alterations in gene sequences.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear that the genetic screen to predict risk of developing prostate cancer was not yet commercially available.", "answer": 1}, {"article": "Paul's group tested buckwheat honey instead of the lighter, more popular varieties because it's known to have more antioxidant and antimicrobial effects, which have been shown in other studies to help wounds heal.\nHoney also beat out no treatment at all.\nUnder the provisions of the grant, the group was not involved in the study or the published results, Paul said.\nHoney is not only cheap and readily available, it's also generally safer than cough medicine, which can have side effects or be administered in the wrong dose.\nHoney has long been used by some parents as an alternative treatment for cough, although it should not be given to children under 1 year old.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions that using honey as a treatment is not a new idea.", "answer": 1}, {"article": "\"For consumers desiring immediate results, HSRx 2121 is the clear choice,\" said Thomas Sullivan, Jr., Chief Executive Officer of HSRx Group.\nAfter 48 hours, the percentage of subjects with unsightly acne-associated redness was reduced nearly three times as much with HSRx 2121 as with the competing product.\nAt 24 hours, the percentage reduction in total acne count with HSRx 2121 was 20 times greater than it was for subjects using the competing product.\nAt seven days, the percentage of subjects exhibiting reduced severity was six times greater for those using HSRx 2121, compared to those using the competing product.\nAfter 24 hours treatment, the percentage of subjects with reduced acne count was 64% greater for those using HSRx 2121 than for subjects using the competing product.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "We don\u2019t know if this is a novel compound or not since we don\u2019t know what\u2019s in it. We get no useful information here about what\u2019s in the formulation and why is it new (type of ingredient, new dose, novel delivery model? new combo of existing ingredients?).", "answer": 0}, {"article": "What does that mean?\n\"Although it's promising, we really have to see the benefit long-term to justify the cost,\" she added.\n\"The experimental therapy, focusing on functionality, not using pain as a reliable symptom, and not as a guideline to adapt movements or activities, leads to better treatment outcomes,\" Malfliet said.\n\"These positive effects were found until the last follow-up measurement at one year after treatment,\" Malfliet said.\nThey should \"learn to put pain into the right perspective, should remain active or increase their activity levels gradually, and should avoid fear of moving,\" said Malfliet, of Vrije University Brussel in Belgium.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Even the careful reader may have a hard time figuring out what is novel about the therapy or the study protocol. This is especially the case with respect to the use of MRI to scan the brains of participants for \u201cmorphological\u201d changes \u2014 a part of the research that was especially meaningful to the investigators because, in their view, the absence of such changes in the experimental group suggests that such changes are not necessarily a good indicator of pain control or pain abatement.", "answer": 0}, {"article": "The most effective screening tests currently available are based on a single biomarker called prostate specific antigen (PSA).\n\u201cThe protein is easy to detect because it is found in urine and would potentially be a very simple test to carry out on men to identify those most at risk of developing the disease,\u201d said Hayley Whitaker of the Cambridge institute, who led the study.\nScientists from the Cancer Research UK Cambridge Research Institute and the Institute of Cancer Research (ICR) said the protein, called microseminoprotein-beta or MSMB, is found at reduced levels in men diagnosed with the disease and are also lower in men with more aggressive forms of the cancer.\n\u201cAt the moment, PSA testing is the best method we have to detect prostate cancer but it has significant limitations, so there is an urgent need to find new biomarkers such as MSMB that could be used in screening and diagnosis,\u201d said Rosalind Eeles of the ICR and The Royal Marsden Hospital, who also worked on the study.\nThe results, published in the Public Library of Science (PLoS) ONE journal, showed that MSMB is found at significantly lower levels in the urine of men diagnosed with prostate cancer than those without the disease.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story neglected to mention that there are other urine tests (PCA3 for example) that are already available. What\u2019s the relative advantage/novelty of this urine test over those others? \nThe story would have been improved by indicating that the study reported on is among several that have indicated the utility of this protein for the purpose of diagnosing and predicting the aggressiveness of prostate cancer that have been published in the last couple of years.\n", "answer": 0}, {"article": "The study, \"Efficacy and Safety of an Injectable Combination Hormonal Contraceptive for Men,\" will be published online at http://press.\n\"Although the injections were effective in reducing the rate of pregnancy, the combination of hormones needs to be studied more to consider a good balance between efficacy and safety.\"\nDuring this period known as the efficacy phase of the study, the men continued to receive injections every eight weeks for up to 56 weeks.\nThe hormones were effective in reducing the sperm count to 1 million/ml or less within 24 weeks in 274 of the participants.\nOnce a participant's sperm count was lowered to less than 1 million/ml in two consecutive tests, the couple was asked to rely on the injections for birth control.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release does not overstate the novelty of this research, quoting a researcher who says the findings \u201cconfirmed the efficacy of this contraceptive method previously seen in small studies.\u201d", "answer": 1}, {"article": "Angiotensin II restricts blood flow through vessels, raising blood pressure.\n\"This is the first time that we have a clear and consistent message from the three buckets of trials of ACE inhibitors and ARBs, all of which show that there is no outcome difference between the two agents, except for better tolerability of ARBs,\" Bangalore said.\n\"There has been debate for many years over the safety and efficacy of ACE inhibitors compared to ARBs, with many of them using an 'ACE inhibitor-first' approach, with ARBs regarded as less effective,\" study author Dr. Sripal Bangalore said in a medical center news release.\n\"We believe that our study ends the debate and gives physicians the option to prescribe either drug for their patients,\" added Bangalore, an associate professor in the division of cardiology, in the department of medicine at NYU Langone.\nBut, this latest analysis attributed that difference to changes in the standard of care over the decade between trials of the two types of drugs, greater emphasis on quitting smoking, and wider use of cholesterol-lowering drugs called statins.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reports, perhaps too conclusively, that the new analysis finds both ACE inhibitors and ARBs to be equally effective, possibly ending a debate among physicians for some time over which medication is preferable to treat cardiovascular disease.\u00a0 Given the prevalence of the disease among the population, and attention paid to it as a public health concern, the story is justifiably novel.", "answer": 1}, {"article": "CHICAGO\u2014For patients facing a choice between bypass surgery and a popular, less-invasive procedure to treat heart blockages, surgery improves chances of long-term survival, researchers said Tuesday.\n\nIn a study that analyzed data on nearly 190,000 Medicare patients treated between 2003 and 2007, 16.4% of surgery patients had died after four years, compared with 20.8% treated with angioplasty and a stent to prop open diseased vessels.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Adequate:\u00a0 \u201cThe latest research, which is generally consistent with other recent studies that give an advantage to bypass surgery\u201d\u2026\u201dHe cautioned that all of the studies\u2014including the new one\u2014have limitations\u201d", "answer": 1}, {"article": "Take this test to see how well you're managing your diabetes\n\nThe researchers looked at over half a million people from 50 previous studies on the Mediterranean diet, which included people in Spain, Greece, the U.S., France, Sweden, Italy and Australia, among other countries.\nBy now, you've probably heard all the buzz about the Mediterranean diet, or perhaps you've tried it.\nThe study notes physical activity is also an important part in preventing the risk factors for the metabolic syndrome.\nPanagiotakos added that the diet includes all main food groups, but in a balanced way.\nAnd just a few years earlier, over 9 percent of adolescents ages 12-19 were classified as having the syndrome.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear that the\u00a0\u2018Mediterranean diet\u2019 is not new.", "answer": 1}, {"article": "People who carry a faulty BRCA1 gene are at high risk of developing aggressive breast cancer.\nBy pinpointing the cells that give rise to breast cancers in women who have inherited a faulty version of the BRCA1 gene, Walter and Eliza Hall Institute researchers have identified that the drug denosumab may have potential to prevent breast cancer from developing.\n\"We therefore investigated what effect RANK inhibition had on the cancer precursor cells in BRCA1-mutant breast tissue.\"\n\"It is very exciting to think that we may be on the path to the 'holy grail' of cancer research, devising a way to prevent this type of breast cancer in women at high genetic risk.\"\nThe research, which also involved researchers at the Australian familial cancer consortium kConFab and US biotechnology company Amgen was published today in Nature Medicine.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes clear that researchers are targeting a specific protein (RANK), which they found is a marker of pre-cancerous cells. That finding may, in fact, be the real news here \u2014 but it is overshadowed in the release by the discussion of denosumab.", "answer": 1}, {"article": "Related links:Department of PsychologyCentre de recherche interdisciplinaire en r\u00e9adaptation du Montr\u00e9al m\u00e9tropolitain\u00c9cole d'optom\u00e9trie at the Universit\u00e9 de Montr\u00e9alMAB-Mackay Rehabilitation Centre\n\u201cThis cost saving can be both to the individual, and if appropriate, to the insurance companies that may provide individuals with assistive devices.\u201d\n\nPartners in research: This work was supported in part by the Vision Health Research Network, the Fonds de recherche du Qu\u00e9b\u00e9c - Sant\u00e9, the Antoine Turmel Foundation, CRIR, and the MAB-Mackay Foundation.\nBut there were no significant differences in the reading rates of participants who had previous experience using the CCTV, compared to the reading rates of first-time CCTV users.\u201d\n\nAnother benefit is that many older adults feel stigmatized by using the traditional devices, because they identify them as having an impairment or disability.\n\u201cTablet computers offer many of the same benefits while being socially acceptable,\u201d says Aaron Johnson, the study\u2019s senior author, and an associate professor in the psychology department, and a member of the Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal (CRIR).\nNewswise \u2014 Montreal, March 22, 2016 \u2014 The proportion of older adults with age-related vision loss is estimated to be as high as one in three over the age of 50.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It is novel to suggest that expensive and traditional vision aids can be replaced with a common and cheaper alternative. The release makes that claim with this phrase, \u201c\u2026the first experimental evidence that the Apple iPad is as good as technology traditionally used in reading rehabilitation for individuals with visual impairment.\u201d\nAs stated earlier, we wish the release had provided a link to the actual research study so we could assess the findings. Based on the release contents, the research finding itself is not much of a surprise. Many of us already know that you can increase the font size in order to read better on almost any computer device.", "answer": 1}, {"article": "LONDON (Reuters) - British scientists conducting early-stage research have found that a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia(MLL) \u2014 the most common form of leukemia in babies.\nAccording to Cancer Research UK, eight out of 10 children with leukemia in Britain now survive for five years or more, compared with one in 10 in the late 1960s.\n\u201cEven though this is still lab-based ... it validates the idea of developing small molecules against epigenetic switches,\u201d he said in an emailed comment.\nKevin Lee, head of epigenetics discovery research at GSK, who also worked on the study, said he too was excited about the findings, although it will probably be many years before the drug could potentially reach the market.\nUsing I-BET151 to treat leukaemias in mice and human cancer cells in a lab, the researchers found that the chemical could halt the disease, paving the way for more research to be done in first-stage, or so-called Phase I, human trials.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t put this research into the context of what else is being investigated in this field.", "answer": 0}, {"article": "\"We would therefore recommend that a future prospective study should be performed to further assess the impact of alcohol consumption on rheumatoid arthritis, a study recording alcohol consumption at the time rather than asking about it later.\"\nAccording to background information in the study, published online July 28 in Rheumatology, previous studies were mostly conducted in mice.\nThe association was seen in both men and women, though it was stronger in males.\nAlcohol consumption may also protect people who already have the autoimmune disease from developing a more debilitating form.\nThis finding is slightly different than what is reported in the current study (that the severity of the disease decreased with more alcohol).\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explained \"This actually isn\u2019t a new concept\" but that most previous research was in mice. ", "answer": 1}, {"article": "A large, new study may be reassuring to women considering mastectomies because of a history of breast cancer in their families.\n\nStanford University researchers affirmed that women with mothers and sisters who carry one of the BRCA gene mutations but who aren't carriers themselves don't have an especially heightened risk of breast cancer.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not overstate the novelty of the BRCA test or the current\u00a0research findings.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - A less common form of obesity surgery may spur more weight loss than its far more popular cousin, gastric bypass \u2014 but at the price of greater long-term risks, researchers reported Tuesday.\nThe surgeon also creates a bypass around the rest of the stomach and a portion of the small intestine, which limits the body\u2019s absorption of food.\nThe surgeon removes part of the stomach, and the remaining \u201csleeve\u201d-like stomach is attached to the final section of the small intestine; that puts even greater limits on the body\u2019s absorption of calories and nutrients.\nAnd studies suggest that a sizable percentage of those people will still have a BMI higher than 40 after gastric bypass.\nIn this study, three of the 29 duodenal switch patients developed protein malnutrition, two developed night blindness, and one had a severe iron deficiency that needed to be treated with iron infusions.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that the duodenal switch procedure has been around for a number of years but is rarely used.", "answer": 1}, {"article": "Timothy Hardy, Mujdat Zeybel, Christopher P. Day, Christian Dipper, Steven Masson, Stuart McPherson, Elsbeth Henderson, Dina Tiniakos, Steve White, Jeremy French, Derek A. Mann, Quentin M. Anstee and Jelena Mann.\nIt is the first time an epigenetic signature in blood has been discovered which is diagnostic of the severity of fibrosis for people with Non-alcoholic Fatty Liver Disease (NAFLD).\nNewcastle University is a world leader in the field at its Campus for Ageing and Vitality, the location for a new \u00a340m National Centre for Ageing Science and Innovation (NASI).\n\"We know that the presence of even mild fibrosis of the liver predicts a worse long-term outcome for patients with NAFLD and so it's important to be able to detect liver scarring at an early stage.\"\nSenior author Dr Jelena Mann of Newcastle University's Institute for Cellular Medicine added: \"This is the first time that a DNA methylation 'signature' from the blood has been shown to match the severity of a liver disease.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes clear that this is the first diagnostic tool to assess fibrosis based on DNA methylation, which it describes as \u201cchemical changes on tiny amounts of \u2018cell-free\u2019 DNA that are released into the blood when liver cells are injured.\u201d", "answer": 1}, {"article": "There aren't strong guidelines regarding the use of tonsillectomy to treat sleep disorders, so the doctors reviewed the evidence to see whether the surgery outperformed so-called watchful waiting -- monitoring the situation.\nThe study results showed \"there may be new evidence that supports expanding the criteria and opening up the procedure to more individuals,\" said Dr. Alyssa Hackett, an otolaryngologist with the New York Eye and Ear Infirmary of Mount Sinai in New York City.\nAn evaluation of current medical evidence suggests more kids would receive significant short-term improvement in their daily life if the guidelines were relaxed, said Chinnadurai, a pediatric otolaryngologist with Vanderbilt University Medical Center in Nashville.\nThere's an even clearer benefit for kids whose sleep is disturbed due to inflamed tonsils, Chinnadurai said.\nThese days, the procedure is done 20 percent of the time for infections and 80 percent of the time for sleep problems, according to the academy.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story puts an odd spin on a report of two fairly cautious research studies and if that spin was accurate, it would surely be novel enough. But the approach of the story is not rooted in the actual content of\u00a0either study. Readers were not well-served by its publication.", "answer": 0}, {"article": "Links will be live at the embargo time http://jamanetwork.\nWho and When: More than 140,000 U.S. women who had DCIS between 1998 and 2014; this study compared lumpectomy plus radiation vs. lumpectomy alone, lumpectomy vs. mastectomy, and lumpectomy plus radiation vs. mastectomy\n\nWhat (Study Measures and Outcomes): Use of radiation and/or extent of surgery (exposures); breast cancer mortality rates within 15 years (outcomes)\n\nHow (Study Design): This was an observational study.\nStudy Limitations: Some data were missing; investigators didn't have information on tamoxifen use; treatments in the study population weren't randomly assigned; and the possibility remains that the decision to undergo radiotherapy was associated with other favorable prognostic factors.\nRelated Material: The invited commentary, \"Systemic Effects of Radiotherapy in Ductal Carcinoma In Situ,\" by Mira Goldberg, M.D., and Timothy J. Whelan, B.M., B.Ch., of McMaster University, Ontario, Canada, also is available on the For The Media website.\nBottom Line: Lumpectomy plus radiation was associated with a small clinical benefit in reduced risk of breast cancer death compared with lumpectomy or mastectomy alone in women with ductal carcinoma in situ (DCIS), a noninvasive early form of breast cancer.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There was no claim of novelty. The release stated that results are based on an association study of a national database containing more than 140,000 patient records. It\u2019s unclear if similar studies have been completed.", "answer": 2}, {"article": "[But] Kalydeco controls CF at the basic defect, so I'm OK with the other 'c' word, control, because I'm living it and I've never felt better in my life.\"\nThe time from gene discovery to successful drug may be shortening, but there are only a handful of successful drugs so far, and for a while at least, the appearance of new ones will be slow.\n\"But it wasn't until 20 years later that we were able to find drugs that directly target the underlying cause of cystic fibrosis,\" says Fred Van Goor, who led the team at what is now Vertex Pharmaceuticals that developed Kalydeco.\nThe only way to fix that would be gene therapy, where a healthy form of the gene would supplant the damaged one.\nThe announcement was supposed to be made in conjunction with three papers in the Sept. 8 issue of Science, but a reporter for Reuters got hold of the story early.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We\u2019re torn about how to apply this criterion to this story.\u00a0 The story doesn\u2019t make any overt claims of novelty \u2013 nothing about being \u201cfirst\u201d or \u201conly.\u201d\u00a0 We\u2019ve already dinged the story on the \u201cCompare With Alternatives\u201d criterion, so we\u2019ll rule this one Not Applicable.", "answer": 2}, {"article": "\u201cThe ability to activate white matter cells in the brain, as shown in this study, opens up an exciting new avenue of therapy development for myelin disorders such as multiple sclerosis,\u201d said Ursula Utz, Ph.D., program director at the NINDS.\nThey also found that the drugs acted through two very different molecular mechanisms.\nAs a result, almost all of the animals regained the use of their hind limbs.\nThey are currently approved for use as creams or powders on the surfaces of the body but their safety administered in other forms, such as injections, in humans is unknown.\nWe are working tirelessly to ready a safe and effective drug for clinical use,\u201d Dr. Tesar said.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This is indeed first of its kind research and that is appropriately noted in the news release.", "answer": 1}, {"article": "(And) because the game is interesting, even those patients with a general lack of motivation are spurred on to continue the training.\u201d\nThe game, \u201cWizard\u201d, is designed to help so-called episodic memory \u2014 the type of memory needed to remember where you left your keys several hours ago, or to remember a few hours later where you parked your car in a multi-storey car park.\n\u201cWe need a way of treating the cognitive symptoms of schizophrenia, such as problems with episodic memory, but slow progress is being made toward developing a drug treatment,\u201d said Barbara Sahakian from the department of psychiatry at Cambridge University.\nThis study, published in the journal Philosophical Transactions of the Royal Society B, found that 22 patients who played the memory game made significantly fewer errors and needed significantly fewer attempts to remember the location of different patterns specific tests.\nWhile some psychotic symptoms can be reasonably well treated with medication, patients often still have debilitating problems with memory and cognitive function, meaning they struggle to get back to work or stay in education.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The idea that brain games may be able to help schizophrenia patients deal with memory issues is not a new one. As the Washington Post noted in a 2013 story on using brain games to address schizophrenia symptoms, \u201cClinical trials aimed at FDA approval are being conducted at a dozen sites in collaboration with the Schizophrenia Trials Network, a group of university-based researchers.\u201d Some discussion of this other work would have been good.", "answer": 0}, {"article": "But his thoughts were out of control.\nAnd it has all been possible, he says, because for the past six years he has been taking a drug called ketamine.\n\"I think it's having multiple effects, and that means it's probably useful for multiple different disorders,\" Teicher says.\n\"My wife took a summer off to be with me because she was scared of what was going to happen to me,\" he says.\nAnd there is now growing evidence it can help people with anxiety, bipolar disorder, post-traumatic stress disorder, and perhaps even obsessive-compulsive disorder.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There is little that differentiates this story from others reported by the same journalist on numerous occasions; for example, in early 2012, later in 2012, 2015 and again last year.", "answer": 0}, {"article": "Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance.\nThe company is based in Redwood City, California, with European headquarters in Geneva, Switzerland.\nThe company's flagship product, the Oncotype DX breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.\nThese forward-looking statements speak only as of the date hereof.\nThe Oncotype DX DCIS Score result provides patients with an individualized estimate of local (in the same breast) recurrence, which could be either invasive breast cancer or DCIS.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release states that there is no other commercially available tumor genomic test for DCIS.", "answer": 1}, {"article": "THURSDAY, May 24, 2018 (HealthDay News) -- Because vertigo can have many causes, treating it can be difficult, but researchers have identified a new type that may be effectively treated with medication.\nThose with the new form of vertigo were also more likely to have severe motion sickness than those with other forms of the condition, the study showed.\nThe researchers noticed that uncontrolled eye movements, called nystagmus, lasted longer in people with this new form of vertigo.\nAfterwards, a video recorded the patients' eye movements.\nFive had no more attacks, 14 had an improvement in their condition, and only one person had a worsening of symptoms.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The diagnosis of a new form of a medical condition, if confirmed by later research, seems novel enough to justify news coverage.", "answer": 1}, {"article": "Funding for the study was provided by F. Hoffmann-La Roche and Biogen Idec.\nThe errant behavior of the cells in question -- known as \"B cells\" -- is viewed as key to the development of this chronic and disabling nervous system disease, commonly called MS.\nThe patients were divided into four groups, treated with: a low dose of ocrelizumab (600 milligrams); a high dose of ocrelizumab (2,000 mg); a well-known MS inflammation treatment known as \"intramuscular interferon beta-1a\"; or a sugar pill (placebo).\nInc.\n\nFor more on multiple sclerosis, visit the U.S. National Library of Medicine.\nThe new therapy's potential is only in the early stages of exploration, cautions an international study team comprised of researchers from the United States, Canada, Switzerland and the Netherlands, in the report published in the Nov. 1 online edition of The Lancet.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is perhaps the most glaring weakness in the story.\nThe headline says calls it a \u201cnew therapy.\u201d\u00a0 (It\u2019s not a therapy until it\u2019s proven to be one.)\nThe body of the story uses \u201cnew\u201d or \u201cnovel\u201d three times.\nBut then the Mayo expert says \u201cthere\u2019s nothing novel about this at all.\u201d\nSo which is it?", "answer": 0}, {"article": "WASHINGTON -- Bacteria live on everyone\u2019s skin, and new research shows some friendly germs produce natural antibiotics that ward off their disease-causing cousins.\nThis community \u2014 what scientists call the microbiome \u2014 plays critical roles in whether we stay healthy or become more vulnerable to various diseases.\nIn lab tests and on the surface of animal skin, those substances could selectively kill Staph aureus, and even a drug-resistant strain known as MRSA, without killing neighboring bacteria like regular antibiotics do, the team reported in the journal Science Translational Medicine.\nThose patches of dry, red, itchy skin are at increased risk of infections, particularly from a worrisome germ known as Staphylococcus aureus.\nBut those good bugs are rare in the skin of people with atopic dermatitis, Gallo said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It appears to be a novel approach using one\u2019s own bacteria to treat skin infections, and\u00a0the article was clear there are other applications of using a person\u2019s own bacteria to develop treatments.", "answer": 1}, {"article": "For more information, visit http://www.\n\"We set out to come up with a protocol where patients could become active participants in their care and allow us to be in closer communication and monitor their wounds after they leave the hospital,\" said lead study author and general surgery resident Rebecca L. Gunter, MD.\nSSIs are the most common hospital-acquired infection and the leading cause of hospital readmission following an operation.1,2,3 Due to the prevalence off SSIs, the WiSOR research team decided to see if postoperative wound monitoring could be effectively achieved by having patients upload photos through the WoundCare app and answer a few brief questions to gather information not easily captured through images.\n\"If you could imagine saving the cost from the number of patients whose readmission you were able to prevent, that result could provide significant savings to the health system,\" Dr. Gunter said.\nThe nurse practitioners responsible for reviewing the submitted images attested to the value of the photos and patient satisfaction, although they also noted it was difficult to find time to review the submitted images on top of an already heavy clinical workload.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release provides this quote from the study: \u201cWe have demonstrated that a population of complex and high-risk patients, many of whom are older adults and novice smartphone users, can complete this protocol with high fidelity and satisfaction.\u201d\nWound management by \u201ctelemedicine\u201d is not unique but the use of cell phones is innovative enough to pass on this criteria. The study showed that patients who are given a phone and taught to use it can send pictures of their wounds.", "answer": 1}, {"article": "\"In this long-term study of lorcaserin for treating patients for obesity, there was good weight loss, outstanding safety profile and the drug was extremely well-tolerated,\" said lead researcher Dr. Steven Smith from the Translational Research Institute for Metabolism and Diabetes in Winter Park, Fla.\n\n\"As patients are looking for additional options and physicians are looking for new tools, [lorcaserin] provides us with a look into the future for what's going to be available for helping patients lose weight,\" he added.\nThe report is published in the July 15 issue of the New England Journal of Medicine, and was sponsored by Arena Pharmaceuticals, of San Diego, Calif., which used its own doctors as part of the study group.\nThe third new drug is Orexigen Therapeutic's Contrave, which is a combination of the antidepressant Wellbutrin and the addiction drug naltrexone.\n\"If weight-loss drugs are tailor-made to hit only the right receptor, based on physiological knowledge, it seems to be possible to develop weight-loss medications that do not possess any serious adverse effects,\" Astrup added.\nA potential player in fighting the obesity epidemic, lorcaserin is a new type of weight-loss drug that works by acting on serotonin, a chemical associated with feelings of well-being and feeling full, and does not appear to increase blood pressure or cause any other heart problems, according to the researchers, whose work was sponsored by the drug manufacturer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story shows how this drug builds on the successes and failures of fen-phen, although it takes a while to do so. It also explains what the other in-trial drugs do better than was done in the other two stories we reviewed on this study \u2013 by WebMD and AP. ", "answer": 1}, {"article": "The new research, reported Oct. 10 in the journal Nature Communications, was led by Charles Brenner, PhD, professor and Roy J.\nIn particular, the researchers compared the ability of all three NAD+ precursor vitamins - NR, niacin, and nicotinamide - to boost NAD+ metabolism and stimulate the activity of certain enzymes, which have been linked to longevity and health benefits.\nThe study showed for the first time that oral NR is superior to nicotinamide, which is better than niacin in terms of the total amount of NAD+ produced at an equivalent dose.\nThe next step will be to study the effect of longer duration NR supplementation on NAD+ metabolism in healthy adults, but Brenner also has plans to test the effects of NR in people with diseases and health conditions, including elevated cholesterol, obesity and diabetes, and people at risk for chemotherapeutic peripheral neuropathy.\nIn addition to showing that NR boosts NAD+ in humans without adverse effects, the trial confirmed that NAAD is a highly sensitive biomarker of NR supplementation in people.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release calls this \u201cnew research.\u201d However, last year NR maker ChromaDex issued a news release stating that \u201cinitial results\u201d of the trial of NR in humans showed it is safe and increases the NAD+ coenzyme. So apparently this isn\u2019t entirely news. It seems that the real news is that the study results were published in the journal Nature Communications.", "answer": 0}, {"article": "A study believed to be the largest of its kind suggests that the physical aspects of yoga are effective at relieving low back pain, but it didn't find any evidence that yoga provided broader mental benefits.\n\nThe study, funded by the National Institutes of Health's National Center for Complementary and Alternative Medicine, was published online Monday in the Archives of Internal Medicine. It was lead by researchers at Seattle's Group Health Research Institute.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The journalist probably assumed that neither yoga nor stretching programs are novel so didn\u2019t address these issues in detail. And that is a reasonable assumption.\n\n\n\n\nBut as mentioned above, the intensive stretching intervention does appear to be somewhat novel. At least it is not widely available. \u00a0And the standardized \u201cviniyoga\u201d program is a rather distinctive program oriented around back pain patients.\n", "answer": 1}, {"article": "In a first, U.S. trial to test Cuban lung-cancer vaccine\nThe studies simultaneously were published by the New England Journal of Medicine on a day that some experts called the \u201cSuper Bowl of lung cancer immunotherapy.\u201d\n\nThe reports underscore the increasingly important first-line role that immunotherapy, which unleashes the immune system to destroy cancer cells, is taking against the deadliest cancer.\n\u201cInstead of chemo being the backbone on which to improve, immunotherapy is now the backbone on which we build.\u201d\n\nLung cancer is the second-most-common malignancy in the United States, after breast cancer.\nH. Jack West, an oncologist at Swedish Medical Center in Seattle, said, \u201cIt is literally practice-changing \u2014 immediately.\u201d\n\nRoy Herbst, an oncologist at Yale Cancer Center said that most lung cancer patients now will be offered immunotherapy in some form much earlier than before.\nThe patients experienced a significantly longer period during which their disease did not worsen, compared with people who received only chemotherapy, said Memorial Sloan Kettering Cancer Center oncologist Matthew Hellmann, who led the study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story describes this as \u201ca new study that is expected to change the way such patients are treated.\u201d\nIt also says several reports \u201cunderscore the increasingly important first-line role that immunotherapy, which unleashes the immune system to destroy cancer cells, is taking against the deadliest cancer.\u201d\nWe think it\u2019s interesting that one of the quotes is: \u201cInstead of chemo being the backbone on which to improve, immunotherapy is now the backbone on which we build.\u201d This may technically be true but the over-arching fact is that cancer treatment is a multi-pronged approach.", "answer": 1}, {"article": "\u201cJust understanding that it\u2019s possible is exciting.\u201d\n\nBut it will take further studies following C-section babies for many years to know to what degree, if any, the method protects them from immune and metabolic problems, he said.\nUntil more is known, physicians are hesitant to participate.\nThus far the swabbing has proved entirely safe.\nSeven were born vaginally and 11 by elective C-section.\nThey were all covered with lactobacilli.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article places this concept in proper context.", "answer": 1}, {"article": "Common warning signs include snoring and excessive daytime sleepiness.\n\"Quality of life is one of the most vital outcomes for patients and often one of the primary reasons to seek medical attention,\" said lead author and principal investigator Dr. Harneet Walia, assistant professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and staff at the Cleveland Clinic's Sleep Disorders Center.\nFor a copy of the study, \"Impact of Sleep-Disordered Breathing Treatment on Quality of Life Measures in a Large Clinic-Based Cohort,\" or to arrange an interview with a study author or an AASM spokesperson, please contact the AASM at 630-737-9700 or media@aasm.org.\nThe study was funded by a scholar award from the Cleveland Clinic Neurological Institute-Center of Research Outcomes and Evaluation and by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH).\nThe monthly, peer-reviewed Journal of Clinical Sleep Medicine is the official publication of the American Academy of Sleep Medicine, a professional membership society that improves sleep health and promotes high quality, patient-centered care through advocacy, education, strategic research, and practice standards.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This is the main problem with the news release: how is the fact that PAP helps sleep apnea news? CPAP machines were first used in the early 1970s, and since then there has been a large body of evidence that PAP is helpful for sleep apnea patients. In the study discussion, the authors include one sentence that attempts to establish the novelty of their research: \u201cOur study differs from the existing clinical studies because it includes a robustly large number of patients and utilizes both sleep-related and global QoL instruments.\u201d\nThey seem to be saying that their study is novel on two accounts: the large sample size, and the fact that they use two different questionnaires as measurements. But is this enough to warrant a news release on a treatment that has already been studied extensively? Including this information would have helped readers to draw their own conclusions on this question.", "answer": 0}, {"article": "(Reuters) - Merck & Co\u2019s blockbuster drug Keytruda met the main goal of a late-stage trial testing the treatment in patients with cancers of the digestive tract, the U.S. drugmaker said on Wednesday.\n\u201cThis marks the sixth tumor type where Keytruda has demonstrated a survival benefit, and represents the first time an anti-PD-1 therapy has achieved overall survival for this patient population,\u201d said Roy Baynes, chief medical officer of Merck Research Laboratories.\nKeytruda, among a class of medicines called PD-1 inhibitors, is Merck\u2019s top selling drug and has already been approved to treat several forms of cancer including skin and lung cancer.\nPD-1 or PD-L1 inhibitors work by blocking a mechanism of tumors that allows them to evade detection by cancer-fighting cells.\nKeytruda, when compared to chemotherapy, enabled certain patients with esophageal cancer to live longer, helping the drug meet the main goal of the late-stage study, Merck said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story quotes a Merck executive saying this was \u201cthe first time an anti-PD-1 therapy has achieved overall survival for this patient population.\u201d\nHowever, as we noted earlier, published reports suggest otherwise.", "answer": 0}, {"article": "Todd McAllister of Cytograft Tissue Engineering in California and colleagues implanted lab-grown blood vessels into 10 patients with advanced kidney disease in Argentina and Poland from 2004 to 2007.\nThe vessels failed in three of the patients, which experts said was not surprising in patients so seriously ill. One other patient withdrew from the study and another died of unrelated causes.\nSome experts said the results suggested that doctors might one day be able to custom-produce blood vessels for patients with circulatory problems in their hearts or legs.\n\"This technology is very, very promising,\" said Vladimir Mironov of the Medical University of South Carolina, who co-wrote an accompanying commentary in the Lancet that praised the study as \"a revolutionary milestone.\"\nBut because dialysis is done so regularly, kidney patients often run out of healthy vessels and need an artificial one, often made out of gortex.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear that this technology is in the earliest stages of human experimentation and that the purpose of the trials is to eventually develop tissue-engineered grafts to replace the standard artificial grafts used when native grafts are not available.", "answer": 1}, {"article": "WASHINGTON (Reuters) - A new, longer-lasting \u201cmorning-after\u201d pill to prevent unwanted pregnancy appears to work with no unexpected side effects, U.S. health regulatory staff said in documents released on Tuesday.\nIt was not clear what effect the drug had, if any, when a woman still became pregnant despite taking it, they added.\nAt the meeting, an FDA panel of outside experts will decide whether to recommend the agency approve the emergency contraceptive for the U.S. market.\nEfforts in 2001 to make it available without a prescription stirred fierce opposition from conservatives, and the bid stalled under the George W. Bush administration.\n\u201cThere is a medical need for an efficient emergency contraceptive product which acts consistently over a prolonged time period,\u201d HRA Pharma said in a separate document released by the FDA.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Clearly the drug is not new since it is already available in Europe. The FDA is now considering its approval for use in the US.", "answer": 1}, {"article": "They found people in the bottom 25% scored lower on such mental tests as problem solving, multi-tasking and abstract thinking.\nDHA has the added benefit of improving mood and reducing symptoms of depression, he said.\nA third of the brain by volume is composed of blood vessels.\nThe only people who should avoid DHA are patients on a blood thinner like Cumadin, he added.\nThey controlled for such risk factors as age, smoking, gender, body mass index, physical activity and APOE, the one known gene linked to dementia risk.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did not reference previous research suggesting a link between fish and cognitive function during aging.", "answer": 0}, {"article": "After six months, nearly 82 percent of those in the briakinumab group had at least a 75 percent improvement in the psoriasis area-and-severity index (PASI), a commonly used measurement to assess the severity of psoriasis.\nFor people living with psoriasis, Bebo said the message from this study is that \"dramatic progress has been made from where we were just five years ago.\"\nThe study volunteers had had psoriasis for at least six months, and the condition affected at least 10 percent of their bodies.\nThere were also two cases of cancer in people taking briakinumab and none in the methotrexate group.\nAfter a year, about 66 percent of those taking briakinumab had a 75 percent improvement in their PASI score compared to almost 24 percent for those on methotrexate, according to the study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "On this point, WebMD\u2019s version of the story was better because it at least reminded readers that \u201ca similar drug, Stelara\u2026was approved by the FDA in 2009.\u201d", "answer": 0}, {"article": "The incidence has more than doubled in developed countries in recent decades.\nThe author of that editorial, Dr. Christopher E. Ramsden, from the National Institutes of Health, said the findings would help doctors develop a \u201cprecision medicine\u201d approach in which fish-oil treatment could be tailored to women who are most likely to benefit.\nBut many other types are considered safe, especially smaller fish like sardines that are not at the top of the food chain and therefore not likely to accumulate mercury and other contaminants from eating other fish.\nMore than six million children in the United States have asthma, according to the Centers for Disease Control and Prevention, as do more than 330 million children and adults worldwide, according to the Global Asthma Network.\nDoctors are eager to find ways to prevent asthma, a chronic disease that causes wheezing, coughing and breathing trouble, and that sends many families to the emergency room again and again.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We learn that previous studies on this topic were inconclusive, and so the inference is that this is the first time more conclusive results were seen, especially regarding the benefit in women who had lower-than-normal levels of the fatty acids in their blood.", "answer": 1}, {"article": "An \"investigational new drug\" application was required by the U.S. Food and Drug Administration to test the pure synthetic (pharmaceutical-grade) resveratrol in the study.\nGUMC was one of 21 participating medical centers across the U.S.\n\nFurther studies, including analysis of frozen blood and cerebrospinal fluid taken from patients, are underway to test possible drug mechanisms.\nThe highest dose of resveratrol tested was one gram by mouth twice daily -- equivalent to the amount found in about 1,000 bottles of red wine.\nThe biggest risk factor for developing Alzheimer's is aging, and studies with animals found that most age-related diseases--including Alzheimer's--can be prevented or delayed by long-term caloric restriction (consuming two-thirds the normal caloric intake).\nThe results, published online today in Neurology, \"are very interesting,\" says the study's principal investigator, R. Scott Turner, MD, PhD, director of the Memory Disorders Program at Georgetown University Medical Center.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release sends a clear message in the first paragraph on what this clinical trial brings to the existing body of knowledge. \u201cThe study Turner led\u2026 is the largest, longest and highest dose trial of resveratrol in humans to date,\u201d it states.\nThe release also does a nice job of mentioning other research applications of resveratrol.", "answer": 1}, {"article": "In addition, availability of a blood test for mTBI/concussion will likely reduce the CT scans performed on patients with concussion each year, potentially saving our health care system the cost of often unnecessary neuroimaging tests.\u201d\n\nAccording to the U.S. Centers for Disease Control and Prevention, in 2013 there were approximately 2.8 million TBI-related emergency department visits, hospitalizations and deaths in the U.S. Of these cases, TBI contributed to the deaths of nearly 50,000 people.\nThe FDA is permitting marketing of the Brain Trauma Indicator to Banyan Biomarkers, Inc.\nThe FDA reviewed and authorized for marketing the Banyan Brain Trauma Indicator in fewer than 6 months as part of its Breakthrough Devices Program.\nThe agency also is responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\nA majority of patients with concussion symptoms have a negative CT scan.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The FDA states that the blood\u00a0test is a first of its kind to be approved for marketing. ", "answer": 1}, {"article": "With statins you get toxicity \u2013 with these drugs we don\u2019t see any side effects with the antibody.\u201d\n\nIn an accompanying editorial, authors Dr. Stephen G. Young, and Loren G. Fong, Ph.D. write: \u201cAt this point, the status of PCSK9 therapeutics appears to be full speed ahead.\nThe cost of this drug will also play a role in determining which patients might use it, Fong and Young say.\nOther companies including Amgen, Merck & Company, Novartis and Pfizer, are also hot on the trail developing their own PCSK9 inhibitor drugs.\nEarlier studies had shown this effect in primates, but this new study, published Wednesday in the New England Journal of Medicine, provides the first clinical trial data for testing the drug on humans.\nIf these initial results pan out in larger trials, the drug could prove to be more effective than statins, the widely prescribed drugs which have been very successful in lowering levels of LDL - or bad cholesterol.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explained that \u201cOther companies including Amgen, Merck & Company, Novartis\u00a0and Pfizer, are also hot on the trail developing their own PCSK9 inhibitor drugs.\u201d", "answer": 1}, {"article": "WEDNESDAY, Aug. 31, 2016 (HealthDay News) -- Weight-loss surgery helps people drop a significant amount of weight, and now a new study confirms that much of the weight appears to stay off for at least 10 years.\nThe new finding, he added, validates his belief that the gastric bypass could be a \"durable procedure.\"\nFor example, the study included mostly men, so the findings may not apply to women.\nThe study helps address a knowledge gap about long-term outcomes of bariatric surgery, said Dr. Jon Gould, chief of general surgery at the Medical College of Wisconsin in Milwaukee.\nGastric bypass surgery involves making the stomach smaller, and attaching the lower part of the small intestine directly to the stomach, so much of the small intestine is bypassed.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is clear that this study contributes to a growing set of data about long-term weight-loss effects of these surgeries.", "answer": 1}, {"article": "Hwang compared lumpectomy and radiation with mastectomy alone, not mastectomy plus radiation.\nEarlier research had also concluded that the two procedures are similarly effective, but Hwang's is a more \"real-world\" study.\nThe findings, published online Jan. 28 in the journal Cancer, are especially strong for women over 50 with hormone-sensitive cancers, the researchers found.\n\"We wanted to look at early stage disease, and those patients typically don't get radiation after mastectomy,\" she said.\n\"The group that benefited the most -- who had the biggest difference in breast cancer survival -- were those women over 50 with estrogen-receptor positive disease,\" Hwang said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "All the story said was that \u201cEarlier research had also concluded that the two procedures are similarly effective, but Hwang\u2019s is a more \u201creal-world\u201d study.\u201d\u00a0\u00a0 But the story never adequately explained what that means and why it makes this analysis different.", "answer": 0}, {"article": "\"There are 150,000 new cases of colon cancer each year in the United States, treated at an estimated cost of $14 billion,\" noted Dr. David A. Ahlquist, professor of medicine and a consultant in gastroenterology at the Mayo Clinic in Rochester, Minn.\n\n\"The dream is to eradicate colon cancer altogether and the most realistic approach to getting there is screening,\" he said.\nCologuard is not yet available for sale.\n\"We learned there are still some bugs and we can make the test even better,\" he said.\nIt is expected to cost more than a fecal occult blood test, but far less than a colonoscopy.\n\"And screening not only in a way that would not only detect cancer, but pre-cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "No comparison with \u2013 not even a mention of \u2013 other competing research as the New York Times did.", "answer": 0}, {"article": "For most patients the cravings really do disappear.\nBut here's something the medical world is just realizing: that the gastric bypass operation has other even more dramatic effects.\nAsked how many people gain the weight back, Dr. Hutcher tells Stahl, \"You know I think when you're dealing with an incurable disease that kills many people, if you have an 85 to 90 percent success rate, that's pretty darn good.\"\n\"If you listen to your patients, they come back and they say, 'Doctor, you put the fire out,'\" Hutcher says.\nIt's pretty well known to doctors that the most successful treatment for obesity is surgery, especially the gastric bypass operation.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The segment makes clear that the operation is common, citing 200,000 surgeries per year. It also reports that the surgery was done as early as the 1950s.\n\u00a0", "answer": 1}, {"article": "MORE: How Better Habits Can Make Your Day\nAnd yet, assuming fertility aids of some sort successfully pave the way to parenthood, SpermCheck could also prove of some use at the other end of the spectrum: the company also manufactures a do-it-yourself test for postvasectomy screening.\nBy addressing the issue, SpermCheck will join a crowded infertility market that includes more than 20 types of female-fertility tests in Walgreen stores alone.\nWhile it\u2019s just as likely that infertility is related to the male half of the couple, only 20% of men in duos struggling to make a baby get a sperm-count analysis early on or at all, according to data from SpermCheck Fertility, which earlier this month announced the availability of its at-home screening test for men.\nThese tests can be expensive (costing hundreds of dollars and not typically covered by insurance), inconvenient and are often embarrassing.\u201d\n\nMORE: \u2018Sonicated\u2019 Sperm: Could Ultrasound Be the Next Male Contraceptive?\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The FDA approved the SpermCheck diagnostic test under a 510K approval process and decided it was the substantially equivalent to three previously approved products.\u00a0 While it may be the only product commercially available, it is certainly not the first to have received approval.", "answer": 1}, {"article": "Those are also symptoms of a deficiency of B12, a key nutrient needed to make red blood cells and DNA and keep the nervous system working right.\n\nVitamin B12 deficiency is officially considered rare, affecting about 1 in 1,000 Americans, according to a 2005 study. But the incidence...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did not indicate that vitamin B12 was a new or novel treatment for any of the possible complaints listed.", "answer": 1}, {"article": "All had hyperhidrosis, a condition where a person sweats much more than the body needs to cool itself.\nResearchers used a ''microfocused\" ultrasound to target the sweat glands in 14 men and women, aged 18 to 75, says Mark Nestor, MD, PhD, a dermatologist and voluntary associate professor of dermatology at the University of Miami Miller School of Medicine.\nThe sweating can occur even when the temperature is cool and the person is at rest.\n\"Microfocused ultrasound appears to be effective and safe in the treatment of hyperhidrosis,\" Nestor says.\nMarch 19, 2012 (San Diego) -- Ultrasound treatment can reduce excessive sweating in the underarms by nearly 80%, according to a new study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The headline says \u201cnew procedure\u201d but we quickly found online references going back at least 6 years about other ultrasound research for hyperhidrosis.\u00a0 Some broader context about other uses and past attempts in this field should have been referenced.", "answer": 0}, {"article": "Call 911 or your doctor for all medical emergencies.Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.\nPatients with chronic kidney disease are advised to follow dietary recommendations that restrict individual nutrients such as phosphorus, potassium, protein, and sodium; however, empirical evidence suggests that these restrictions\u2014which can be difficult to abide by\u2014have limited effects on reducing patients\u2019 risk of premature death.\nHighlight\n\u2022 A healthy diet high in fruits, vegetables, fish, legumes, cereals, whole grains, and fiber, and low in red meat, salt, and refined sugars was linked with a reduced risk of early death in an analysis of 7 studies.\nThe content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN).\n\u201cIn the absence of randomized trials and large individual cohort studies, this study is the best available evidence to drive clinical decision-making by patients and doctors on whole dietary approaches in chronic kidney disease.\u201d\n\nDisclosures: The authors reported no financial disclosures.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does state reasonably that \u201cIn the absence of randomized trials and large individual cohort studies, this study is the best available evidence to drive clinical decision-making by patients and doctors on whole dietary approaches in chronic kidney disease.\u201d", "answer": 1}, {"article": "The patients' cognitive performance, life quality and life expectancy is also affected by having the condition.\nIt is known that newborn babies who suffer perinatal asphyxia may develop permanent brain injury resulting in cerebral palsy or other conditions, like epilepsy.\nEven if a lesser severity of perinatal asphyxia is accounted for, cooling therapy has increased the number of healthy survivors and there are very few children with epilepsy needing drug treatment.\nProfessor Marianne Thoresen said: \"Even if we account for a lesser severity of perinatal asphyxia, our research has shown that therapeutic hypothermia reduces the number of children who develop epilepsy later in childhood.\nFor up to eight years, the researchers followed 165 infants who were born in the south west and who received cooling therapy at St Michael's Hospital, Bristol, part of University Hospitals Bristol NHS Foundation Trust.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The novelty here would appear to be that this is the first study to look specifically at the extent to which therapeutic hypothermia reduces the rates and severity of epilepsy in children who suffered from perinatal asphyxia as newborns. However, the release doesn\u2019t tell us that. Nor does it do anything to let readers know that this subject has been the focal point of at least half a dozen large, randomized, clinical trials. To be clear, this new journal article may offer important new information to researchers, clinicians and parents \u2014 but the release needs to do a better job of articulating what is new and how this work builds on (or differs from) previous work.", "answer": 0}, {"article": "Saturated fat has been thought to promote cardiovascular diseases by raising the \"bad\" LDL cholesterol in the blood.\n\u2022 The Study is named (FATFUNC) and was performed by researchers at the KG Jebsen center for diabetes research, Department of Clinical Science at the University of Bergen.\n\"The very high intake of total and saturated fat did not increase the calculated risk of cardiovascular diseases,\" says professor and cardiologist Ottar Nyg\u00e5rd who contributed to the study.\nBut even with a higher fat intake in the FATFUNC study compared to most comparable studies, the authors found no significant increase in LDL cholesterol.\nBoth groups had similar intakes of energy, proteins, polyunsaturated fatty acids, the food types were the same and varied mainly in quantity, and intake of added sugar was minimized.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does not establish any novelty for this research. There are a number of studies looking at cardiometabolic markers in response to higher fat diets.", "answer": 0}, {"article": "\u201cIt shows the relative impacts of screening versus therapy in an era in which therapy has been improving.\u201d\n\nDr. Otis Brawley of the said in a statement that the investigators used \u201ccareful methodology.\u201d The society, Dr. Brawley said, \u201cbelieves that the total body of the science supports the fact that regular mammography is an important part of a woman\u2019s .\u201d\n\nDr. Carol Lee, a radiologist at and chairwoman of the breast imaging commission of the American College of Radiology, said the new study affirmed that mammography saves lives.\nBut, cancer experts said, no one would do such a study today when mammograms are generally agreed to prevent breast cancer deaths.\n\u201cMortality from breast cancer is decreasing, and I have to believe that screening mammography has played a part,\u201d Dr. Lee said.\nAfter all, mammography had improved and, in Norway, each mammogram was independently read by two radiologists, which should make it less likely that cancers would be missed.\nWhen the study was planned, the scientists expected that screening would be even more effective than it was in studies from decades ago.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\n \nMammography is not new, but this story does a good job of explaining what is new about the way these researchers examined the effects of screening.", "answer": 1}, {"article": "She worked with a group of mice that are genetically bred to have healthy ratios of omega 3 fatty acids.\n\u201cOur study shows that there may be some relationship between dietary factors and things like egg quality so one idea may be recommending supplementation with omega 3s to improve fertility.\u201d\n\nExactly how the healthy omega 3 fatty acids are helping the ovary to produce better quality eggs isn\u2019t clear yet.\nWhat she found: The mice with the higher levels of omega 3 fatty acids seemed to have more precursors to egg cells than control mice with lower levels of the fat, meaning they had a larger reserve of eggs-to-be.\nThe study, presented at the American Society of Reproductive Medicine annual meeting, was in mice, so more research needs to be completed before omega 3 foods or supplements become part of treatment for infertility.\nThere may also be other benefits linked to omega 3 fatty acids for the fetus as well, in helping nerve development \u2014 that\u2019s why many prenatal vitamins include forms of omega 3 fats.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not say explicitly that this study is the first to link omega 3 fatty acids with improved fertility in either mice or humans, but the wording implies that the study provided new evidence of such a link: \u201cNow, according to scientists at the University of Colorado, there is even evidence that the healthy fat can boost your chances of getting pregnant.\u201d What the story fails to note is that there already appears to be a significant body of research \u2014 in humans \u2014 dealing with the\u00a0connection between omega 3 fatty acid levels and successfully achieving and maintaining pregnancy.", "answer": 0}, {"article": "(Weathers noted more than 100 other drug-resistant patients also have been successfully treated with DLA tablets.)\n\"We have done a lot of work to understand the biochemistry of these compounds, which include a number of flavonoids and terpenes, so we can better understand the role they play in the pharmacological activity of the dried leaves,\" Weathers said.\nIn addition, while the combination therapy is designed to be less prone to the drug resistance that has rendered previous antimalarial agents ineffective, increasingly the malaria parasite is showing signs of resistance to ACT, particularly in Southeast Asia.\nAnd, in an experiment that accelerated the evolution of the malaria parasite by passing it through up to 49 generations of mice, the parasite showed no signs of resistance to DLA.\nIn a 2015 study in the Proceedings of the National Academy of Sciences, the WPI researchers, with colleagues at the University of Massachusetts Amherst, showed that dried Artemisia leaves cured rodents infected with malaria strains that were known to be resistant to artemisinin.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release quotes the researchers as saying they are the first to study and report on administering these dried leaves in tablet form. It explains that one of the ingredients in the plant is already a component of a drug administered to patients, but the dried leaves seem to hold extra potency.", "answer": 1}, {"article": "Some people do need supplements.\nA second, wider-ranging study found no heart risks and was the basis of new guidelines from two medical groups saying that calcium supplements should be considered heart safe.\nCalcium-rich foods, such as milk (300 mg a cup), plain yogurt (400 mg per cup) and kale (100 mg a cup), come with added nutritional benefits.\nCalcium intake from food has been rising, he says, with recent surveys finding averages around 1,000 mg a day \u2014 close to or meeting the 1,000 mg. to 1,200 mg recommended for adults (the higher level is advised for women over 50 and men over 70).\nAmong others who might need a boost: Vegans, people with lactose intolerance and anyone who, for whatever reason, does not consume enough calcium, says Taylor Wallace, an affiliate professor of nutrition at George Mason University in Fairfax, Va., and a co-author of the new cardiovascular statement.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does note that \u201cOver the past decade, some studies have raised the possibility that calcium\u2026might raise heart risks.\u201d That is enough \u2014 barely \u2014 to earn it a \u201csatisfactory\u201d rating, in part because one of the two studies being discussed is a meta-analysis of 31 previous studies. However, a brief dive into the history of calcium supplementation and the public\u2019s perceptions on the issue would add weight to the impact of these newer studies.", "answer": 1}, {"article": "Of more than 710,000 women, 2.4 percent ended up with breast cancer.\nWhile earlier research has yielded mixed conclusions on the link between cancer and fiber, it would make scientific sense: According to the Chinese researchers, people who eat high-fiber diets have lower levels of estrogen, which is a risk factor for breast tumors.\nStill, it\u2019s impossible to rule out that big fiber eaters had healthier habits overall that would cut their risk, Jia-Yi Dong of Soochow University in Suzhou and his colleagues write in the American Journal of Clinical Nutrition.\nThe results \u201ccan identify associations but cannot tell us what will happen if people change their behavior,\u201d said John Pierce, a cancer research at the University of California, San Diego, who was not involved in the work.\nThe guidelines recommend that women eat 25 grams of fiber per day and men eat 38 grams, while the average Americans gets just 15 grams a day.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story wrapped the new analysis into the context of prior work:\n\u201cWhile earlier research has yielded mixed conclusions on the link between cancer and fiber, it would make scientific sense: According to the Chinese researchers, people who eat high-fiber diets have lower levels of estrogen, which is a risk factor for breast tumors. \n\u00a0So to get more clarity, the researchers combined 10 earlier studies that looked at women\u2019s diets and followed them over seven to 18 years to see who developed cancer.\u201d\n", "answer": 1}, {"article": "The Merck drug boceprevir and Vertex Pharmaceutical\u2019s similar drug telaprevir are expected to win FDA approval within months, following phase III trials showing that both drugs boosted cure rates to around 70% when used with standard therapy.\n\u201cTriple-drug therapy represents a major advance in the treatment of hepatitis C for patients,\u201d he says.\nResults from two phase III boceprevir trials are published in the New England Journal of Medicine.\nAdding one of the drugs to the current two-drug regimen of peginterferon and ribavirin will make the treatment of hepatitis C more complex, but it will also cure a lot more people, hepatitis C specialist Donald M. Jensen, MD, of the University of Chicago Medical Center, tells WebMD.\nThe drugs will be used in patients with HCV genotype 1 -- the hardest to treat form of the viral infection.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s clear from the story that triple-therapy is a new treatment approach for chronic hepatitis C.\n", "answer": 1}, {"article": "Chattoo also offers patients a nutritionist and trainer with the procedure.\nShe told FoxNews.com that the balloon \u201cmakes you feel full all the time to the point where you\u2019re not angry about having to lose things like chocolate and cake.\u201d\n\nBrown said that the balloon acted like a \u201crestart button\u201d and retrained her body to adapt to a new lifestyle of healthy eating and exercise.\n\u201cThe beauty of the procedure is that it is a nonsurgical procedure,\u201d Chattoo said.\nNow, there is a new solution for people with a body mass index (BMI) between 30 and 40 that want to lose weight called the Orbera gastric balloon.\nThe balloon remains in the patient\u2019s stomach for six months and is then removed the same way it was inserted, through the mouth.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This fails for a couple of reasons. First, the story does not explain how Orbera is different (if at all) from other gastric balloon techniques designed to aid patients with weight loss. For example, here\u2019s a 2014 story from HealthDay News about a gastric balloon product called the ReShape Duo. Is this different from Orbera? Better? Worse? Safer? Cheaper? Exactly the same? Impossible to say. What\u2019s more, the FDA approved Orbera in August 2015 \u2014 so why is Fox News running a story on this now? The story doesn\u2019t tell us.", "answer": 0}, {"article": "2014;311(24):2499-2507.\nThis study brought together the principal investigators from the groundbreaking 2014 study on 3D MAMMOGRAPHY\u2122 exams, also published in JAMA, this time led by Elizabeth Rafferty, MD, a co-author on the prior study.3 A total of 452,320 examinations (278,906 conventional mammograms compared to 173,414 Genius\u2122 3D MAMMOGRAPHY\u2122 exams), were analyzed.\nWomen with heterogeneously dense breasts make up about 40 percent of the U.S. screening population (women ages 40-74) \u2014 approximately 25 million women in the U.S.\n\n\"Utilizing Genius\u2122 3D MAMMOGRAPHY\u2122 exams for breast cancer screening will reduce the need for subsequent unnecessary testing, and decrease the number of unnecessary breast biopsies\u2014 addressing concerns that were previously raised as limitations of conventional mammography while also reducing costs for health systems,\" said Pete Valenti, Hologic's Division President, Breast and Skeletal Health Solutions.\n\"Density creates challenges for conventional mammography by obscuring the images, which often results in additional visits and exams for women,\" said Edward Evantash, MD, board certified OB/GYN and Medical Director for Hologic.\nHigher breast density may increase a woman's chance of getting breast cancer, make detection of cancer on conventional mammography more difficult, and increase the chances that a woman will be recalled for additional imaging.1,2 Mammograms are categorized into four density groups: almost entirely fat, scattered fibroglandular densities, heterogeneously dense, and extremely dense.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The claim to novelty is found in this statement in the release:\n\u201cThis new analysis confirms that Genius\u2122 3D MAMMOGRAPHY\u2122 exams reduce unnecessary follow-up exams in dense-breasted women. This has the potential to provide health systems and insurance companies with significant cost savings, reduce patient stress and expenses, and alleviate challenges for referring physicians who are tasked with relaying mammography results to their patients.\u201d\nFor the reasons stated above, we think the release makes questionable claims and therefore fails the novelty test so we\u2019re rating this not satisfactory. In addition, the 3D screening technology has been available since 2011.", "answer": 0}, {"article": "(Reuters) - Eli Lilly and Co\u2019s new Jardiance pill slashed deaths by 32 percent in patients with type 2 diabetes at risk of heart attack and stroke, a finding that could make it a mainstay diabetes treatment and triple its use, according to researchers and analysts.\nIn the study, patients taking Jardiance had a 38 percent reduction in cardiovascular death, including from heart attacks and strokes.\nBecause about one-half of the deaths in people with type 2 diabetes are caused by cardiovascular disease, reducing cardiovascular risk is considered essential to diabetes care.\nThere was no significant difference in non-fatal heart attacks or non-fatal strokes.\nThe benefits were especially impressive because they added to protection that patients received from taking cholesterol fighters and other life-saving heart drugs, Zinman said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The drug is newsworthy because it is the first drug to have shown a significant reduction in cardiovascular events in people with type 2 diabetes \u2014 and the story makes this clear.", "answer": 1}, {"article": "The best moment in Rene\u00e9 Ford's life came the day her son Chase, then 2, tried to kick his doctor. It was July 2005, and that angry gesture marked the first time the boy had moved below the neck in more than a month.\n\nThese days when you look at Chase, you don't at first notice any sign of what happened to him that year--not the fall he took while jumping on the couch nor the paralyzing blow to the neck as he hit the wooden armrest. More and more, Chase can do the kinds of things any other 4-year-old can...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story implies that locomotor training is not a new idea, but that it is one that is gaining in acceptance.", "answer": 1}, {"article": "Boutot and Bertone-Johnson suggest that more prospective studies of their findings are warranted, including studies that compare soy-based and non-soy vegetable proteins.\nBoutot and Bertone-Johnson add, \"Though relatively few women in our study consumed very high levels of vegetable protein and our power for analyses of more extreme intake levels was limited, women consuming 9 or more percent of their calories from vegetable protein had a hazard ratio of 0.41 (95 percent confidence interval = 0.19-0.88)\" compared to those eating less than 4 percent.\n\"A better understanding of how dietary vegetable protein intake is associated with ovarian aging may identify ways for women to modify their risk of early onset menopause and associated health conditions,\" write first author and then-graduate student Maegan Boutot, with her advisor, professor Elizabeth Bertone-Johnson.\nFor a woman with a 2,000 calorie per day diet, the authors explain, this is equal to three to four servings of such foods as enriched pasta, breakfast cereal, tofu and nuts, or about 32.5 grams a day.\nBoutot, Bertone-Johnson and colleagues in the School of Public Health and Health Sciences at UMass Amherst, with others, evaluated the relationship between diet and risk of early menopause among members of the Nurses' Health Study II (NHS2), an ongoing prospective study of 116,000 women aged 25-42 when they entered it in 1989.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states: \u201cFew studies have evaluated how protein intake is associated with menopause timing, (researchers) add, and to their knowledge this is the first to look specifically at early menopause.\u201d A researcher is also quoted saying, \u201cA better understanding of how dietary vegetable protein intake is associated with ovarian aging may identify ways for women to modify their risk of early onset menopause and associated health conditions.\u201d", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070513/21sunscreen.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "This article explains that some sunscreens have been around a long time and others have recently entered the market, formulated with new and supposedly better ingredients.", "answer": 1}, {"article": "UW-Madison radiology professor Weibo Cai is also a senior author on the study.\n\"One potential advantage of the new device over existing vagus nerve stimulators is that it does not require external battery charging, which is a significant advantage when you consider the inconvenience that patients experience when having to charge a battery multiple times a week for an hour or so.\"\nThat existing unit, \"Maestro,\" approved by the Food and Drug Administration in 2015, administers high-frequency zaps to the vagus nerve to shut down all communication between the brain and stomach.\n\"Our expectation is that the device will be more effective and convenient to use than other technologies,\" says Wang.\nMeasuring less than 1 centimeter across, or about a third of the area of a U.S. penny, the tiny devices -- which are safe for use in the body and implantable via a minimally invasive procedure -- generate gentle electric pulses from the stomach's natural churning motions and deliver them to the vagus nerve, which links the brain and the stomach.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release says this device could be an improvement on an approved device that also stimulates the vagus nerve to alter hunger perception. It states that what is new is that the experimental device uses motion of the stomach, rather than batteries, to produce electrical pulses that stimulate the vagus nerve. It also claims that the pulse patterns are superior because they are triggered by stomach motion; however, since the new device has not been compared to the existing model, it is too early to make this claim.", "answer": 0}, {"article": "Cocaine use is widespread in the Western World.\nThe results of this pilot study, published in the peer-reviewed journal European Neuropsychopharmacology, suggest that this may become an effective medical treatment for patients with cocaine addiction, although a larger trial is needed to confirm the initial findings.\nIn addition, 69% (11/16) patients) in the experimental group showed no relapse to cocaine use, whereas only 19% (3/16) patients) in the control group showed a similar positive result (the results are adjusted for patients who dropped out of the trial).\nAt the end of the first 29 days of the experiment, the experimental group was given the option of continuing the treatment, whereas those in the control group were given the possibility of receiving the same rTMS treatment as the experimental group for 63 days.\nWe have continued to follow patients from the trial, and the improvement seems to be sustained over time, up to 12 months, although we don't have any hard data on that yet.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that, \u201cAs far as we know, this work represents the first clinical report indicating that rTMS treatment results in significant reduction in cocaine use.\u201d That pretty clearly states the novel nature of the work, especially given the fact that there are no other effective treatments for cocaine addiction.", "answer": 1}, {"article": "Why Biogen is breathing a sigh of relief with the latest Alzheimer\u2019s data\n\nWe already know Eli Lilly\u2019s big bet on Alzheimer\u2019s disease didn\u2019t work. But a deep dive into just how it failed has provided a bit of encouragement to Biogen and the many companies still hoping to succeed where their rival fell short.\n\nLilly\u2019s treatment, solanezumab, had no significant effect on the buildup of toxic brain plaques believed by many to be responsible for Alzheimer\u2019s neuron-destroying effects. The company had already disclosed that the treatment failed to improve patients\u2019 cognition and function, but the new data, released Thursday night, shed some important light on the underlying biology.", "question": "Does the story establish the true novelty of the approach?", "explanation": "As noted earlier, this was not a \u201cbreaking news\u201d story, but a round up of sorts of what\u2019s happened since the Lilly drug trial for solanezumab reported negative results.\u00a0But there is news-like information here about the optimism of the companies still working the amyloid hypothesis. Whether a high level of optimism is warranted or not is a good question, but the article could at least inform a healthy discussion.", "answer": 1}, {"article": "CBS News correspondent Kelly Wallace reports Kate Miller's 15-year-old son Cody killed himself just 17 days after starting the drug.\nIn clinical trials of asthma patients, the most common side effects were headache, flu, abdominal pain and cough.\nHis mom now believes that Singulair cost him his life.\n\"But because suicide is a life-threatening event we thought it was important to provide this information in the product label.\"\nFDA said it is also reviewing reports of side effects with those drugs.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Singulair is widely used, so its novelty is not in question. ", "answer": 2}, {"article": "\u201cI wouldn\u2019t say it\u2019s a cure.\n\u201cI was used to being treated in a condescending manner because they couldn\u2019t diagnose me: \u2018She\u2019s menopausal, she\u2019s crazy.\u2019 \u201d\n\nBefore the study, \u201cI didn\u2019t know tai chi from a sneeze,\u201d said Ms. Petersen, who has diabetes and other conditions.\nAnd Dr. Gloria Yeh, a Beth Israel Deaconess internist and co-author of the editorial, said others \u201cwill say, \u2018It\u2019s too slow, I can\u2019t do that.\u2019 \u201d\n\nBut she said it offered a \u201cgentler option\u201d for patients deterred by other physical activities.\nSo, that these results were so positive for something that\u2019s very safe is an impressive accomplishment.\u201d\n\nRecent studies have suggested that tai chi, with its slow exercises, breathing and meditation, could benefit patients with other chronic conditions, including arthritis.\n\u201cThe mind-body connections set it apart from other exercises,\u201d she said, adding that doctors are seeking \u201canything we can offer that will make patients say \u2018I can really do this.\u2019 \u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story says, \"Recent studies have suggested that tai chi, with its slow exercises, breathing and meditation, could benefit patients with other chronic conditions, including arthritis. But not all of these reports have been conclusive, and tai chi is hard to study because there are many styles and approaches.\" This is all important context, succinctly presented. This story shows that you can pull together a lot of information and still keep the story tight.", "answer": 1}, {"article": "A growing group of scientists and physicians say that hyperbaric treatment, which exposes patients to pure oxygen at higher-than-normal air pressure, may work.\nThe nature of the human brain makes it particularly susceptible to chronic injury.\nThe hyperbaric treatment healed his feet \u2014 and also revived his ability to speak.\nOf course, such anecdotes are not the same as rigorous scientific research.\nIn addition, tests showed that the subjects had improved memory and processing speed.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story established this is an emerging and unproven therapy for post-concussion syndrome.", "answer": 1}, {"article": "The results are remarkable.\n\"We found that the current practice of feeding children in an early stage does not contribute to their recovery\", says lead author Professor Greet Van den Berghe from KU Leuven / University Hospitals Leuven.\n\"On the contrary, the children who had built up a nutritional deficiency after receiving little to no feedings had fewer infections, less organ failure, and a quicker recovery than children who had been fed through the IV.\nTherefore, the method that is applied worldwide is to artificially feed these children during the first days of their stay in intensive care.\nThe effect was present in everyone, regardless of the type of disease, the children's age, or the hospital in which they were staying.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that a new nutrition protocol has disproven a theory about standard care. That\u2019s novel. But while the release points out that assumptions about parenteral feeding in children needed \u2014 and got \u2014 a good challenge, it fails to note that children most vulnerable to malnutrition sustained the most benefit from delayed parenteral feeding. That\u2019s another novel finding that could have been included.", "answer": 1}, {"article": "Calorie levels, as well as protein, carbohydrate, and total fat, were kept the same.\n\"Pecans are naturally high in monounsaturated and polyunsaturated fats, so replacing a portion of the saturated fat in the diet with these healthier fats can explain some of the cardio-protective effects we observed,\" said lead researcher, Diane McKay, Ph.D. \"But pecans also contain a number of bioactive plant compounds as well as vitamins and essential minerals that all likely contributed to this benefit.\nThe study entitled \"A Pecan-Rich Diet Improves Cardiometabolic Risk Factors in Overweight and Obese Adults: A Randomized Controlled Trial\" is available online and will be presented at the American Society for Nutrition Annual Conference, Nutrition 2018 held in Boston this June.\nA new study published in Nutrients shows that eating just 1.5 ounces of pecans - one small handful - every day may protect adults at risk for developing cardiovascular disease (CVD) and type 2 diabetes (T2D).\nWhile a growing body of evidence has linked tree nuts such as pecans to reduced risk of CVD, this is the first study to look at the effects of pecan consumption on factors other than blood lipid levels and specifically those related to T2D.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that this study is \u201cthe first study to look at the effects of pecan consumption on factors other than blood lipid levels and specifically those related to T2D. Obesity is a risk factor for T2D, and both obesity and T2D increase CVD risk.\u201d\nWe don\u2019t know whether pecans are similar enough to other well-studied nuts that perhaps there is already quite a bit of evidence.", "answer": 1}, {"article": "Studies have found that adding thermal therapy to standard treatments can significantly shrink tumors and can improve survival for some patients.\nIt\u2019s this type of innovation that sets MPTC apart from other proton treatment centers.\u201d\n\nAbout the University of Maryland School of Medicine\n\nCommemorating its 210th Anniversary, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States.\n\u201cBy continuing to develop a comprehensive thermal oncology program, we are giving patients more effective treatment options and therefore another reason to hope for better outcomes.\u201d\n\n\u201cThe Maryland Proton Treatment Center has achieved another milestone by becoming the first center to offer both deep-thermal therapy and proton therapy,\u201d says E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs at UM Baltimore and the John Z. and Akiko K. Bowers Distinguished Professor and dean at UMSOM.\n\u201cWe are very pleased to be able to offer deep-tissue thermal therapy, which can be combined with standard radiation therapy as well as proton-beam therapy to enhance the cancer-killing effects of the radiation,\u201d says Zeljko Vujaskovic, MD, PhD, a professor of radiation oncology and director of the Division of Translational Radiation Sciences (DTRS) in the Department of Radiation Oncology at the University of Maryland School of Medicine (UMSOM).\nThe acquisition of the deep-tissue thermal therapy system was made possible by donations from Jack and Emily Howell and the Middendorf Foundation, Inc.\n\n\u201cWithin the Department of Radiation Oncology and throughout our cancer center, we strive to make every available tool in the cancer-fighting toolbox available to our patients,\u201d says William F. Regine, MD, FACR, FACRO, the Isadore & Fannie Schneider Foxman Endowed Chair and Professor of radiation oncology at UMSOM and chair of radiation oncology at UMGCCC.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release mentions several times that the Maryland Proton Treatment Center is the only facility in the world to offer both treatments in the same location. However this is either so vague as to be misleading, or just plain untrue. Does \u201clocation\u201d mean at the same department, or in the same building? A quick google search shows that even in the United States there are several other centers that offer both treatments, including the UCSF Department of Radiation Oncology and Texas Oncology.", "answer": 0}, {"article": "The compound WAY-316606 could therefore be used to treat baldness, without patients suffering the same side effects as they would on CsA.\nThe scientists were then able to identify that WAY-316606, a compound used to treat osteoporosis, has a similar effect on how SFRP1 is expressed.\n\u201cFor individuals with hair loss, treatments can be very hit and miss, there isn\u2019t one which is universally effective.\nAn existing drug used to treat a common bone disorder could hold the key to the cure for baldness, according to a new study.\n\u201cIt is also important to realize that this is being proposed as a treatment for hair loss, not a cure as such.\u201d\n\nThis piece has been updated with a comment from the British Association of Dermatologists.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story quoted the lead researcher saying WAY-316606 \u201chad never even been considered in a hair-loss context.\u201d", "answer": 1}, {"article": "TUESDAY, June 5, 2012 (HealthDay News) -- A simple blood test may help gauge prognosis and tailor treatments for women who have been diagnosed with early stage breast cancer.\nCommenting on the findings, Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City, said, \"We are moving into a state where we're looking at a person's individual tumor and this is another way to do that, potentially leading to treatment.\"\nThe problem is that just having circulating tumor cells may not be enough information to foretell the future, she noted.\nEven so, a substantial number of patients whose cancer has not spread to the lymph nodes will have a recurrence while some of those who do have lymph-node involvement won't relapse.\n\"The cells also need to have a propensity to grow elsewhere,\" she said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The writer notes that similar blood tests are used to test women with metastatic cancer.\u00a0 We wish the story had been more explicit about whether this is a totally new blood test and if other blood tests like this are also being tested.", "answer": 1}, {"article": "People who had worse vision at the beginning of the study had worse scores on the cognitive exam as well.\nPoor eyesight and weakening mental function are common in older people and related to one another, but the question of whether vision influences cognition, or vice versa, has not been clear, the study team writes in JAMA Ophthalmology.\nEven incurable causes of age-related vision loss such as glaucoma and age-related macular degeneration \u201care highly treatable, so we can reduce the amount of vision loss that people suffer from if they\u2019re detected early.\u201d\n(Reuters Health) - Waning eyesight may hasten the pace of cognitive decline in older people, suggests a U.S. study.\nThe good news, Whitson added, is that poor vision is one of the few risk factors for cognitive decline that is potentially modifiable.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Although the commentary in the JAMA Ophthalmology issue where the research appears makes the point that this study\u2019s effort to introduce causality into the vision/cognition relationship is a \u201cnew dimension,\u201d that novel element is not made clear in the story.", "answer": 0}, {"article": "The U.S. National Institute of Neurological Disorders and Stroke has more about autism.\nThe goal of the therapy -- delivered over five months while the infants were ages 7 to 10 months -- was to improve the infant's attention, communication, early language development, and social engagement.\n\"Although it would be wonderful if a relatively simple, video-based intervention could reduce the recurrence risk of autism spectrum disorder in later offspring, further studies are needed to examine this very issue,\" he said.\n\"But our findings suggest that targeting the earliest risk markers of autism -- such as lack of attention or reduced social interest or engagement -- during the first year of life may lessen the development of these symptoms later on.\"\nUsing the therapy during the baby's first year of life may \"modify the emergence of autism-related behaviors and symptoms,\" lead author Jonathan Green, a professor of child and adolescent psychiatry at the University of Manchester in England, said in a journal news release.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t adequately establish what is new about this approach and the research being reported on. Is this first time this approach has been studied? Does it build on existing approaches? That\u2019s what we look for in this criterion, and it was missing.", "answer": 0}, {"article": "Bushra Imtiaz, Heidi Taipale, Antti Tanskanen, Miia Tiihonen, Miia Kivipelto, Anna-Mari Heikkinen, Jari Tiihonen, Hilkka Soininen, Sirpa Hartikainen, Anna-Maija Tolppanen.\nThe study also showed that the postmenopausal removal of ovaries, uterus or both was not significantly linked to the risk of Alzheimer's disease, irrespective of the indication of surgery or hormone therapy use.\nThe protective effect of hormonal therapy may depend on the health status of neurons at baseline and may be lost if therapy starts years after menopause,\" Dr Imtiaz concludes.\nHormonal therapy may protect cognition if started at the onset of menopause\n\nIn the present study, long-term use of hormonal replacement therapy was associated with a better performance in certain cognitive domains - global cognition and episodic memory - and a lower risk of Alzheimer's disease.\nThe study explored the association between postmenopausal hormone replacement therapy, Alzheimer's disease, dementia and cognition in two nation-wide case-control studies and two longitudinal cohort studies.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "We\u2019ll give the release a pass here because it cites several avenues of past research and doesn\u2019t make a direct claim of novelty.\nThe release makes it seem that the sheer size of the studies mentioned here make the findings novel, but it does not prove that these findings are novel.", "answer": 1}, {"article": "Tim Barham, the vice president of HBB, the maker of Lazy Cakes, said, \u201cWe look at the brownie as a supplement.\u201d\n\nNews reports have classified Lazy Cakes as dietary supplements, but last month, Douglas Karas, an F.D.A.\n\u201cA hangover effect has been reported\u201d with large doses, said Anna Rouse Dulaney, a toxicologist with the Carolinas Poison Center.\nBut Dr. David S. Seres, the director of medical nutrition at Columbia Medical Center, cautioned that consumers should consult their doctors before trying such products.\nDr. Lewy dismissed the idea that harm might lurk in a melatonin-laced brownie.\n\u201cIt should not be permitted by the F.D.A.\u201d\n\nTechnically, it is not.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of these products \u2013 and their spread \u2013 is clear from the story.", "answer": 1}, {"article": "\"Lung cancer is the leading cause of death from cancer worldwide due to the high incidence of the disease, and the low rate of diagnosis at early and more curable stages,\" stated Prof. Mina Gaga, the President of the European Respiratory Society (ERS) and a lead investigator in the study.\nSuch promising results combined with the simplicity of the test, could allow us to detect lung cancer at the early stages and hence improve 5-year survival from about 15% to about 50-70%.\nIt is estimated that there are about 1.8 million new cases of lung cancer annually worldwide and about 1.55 million die from the disease each year.\nThe technology is based on identification and analysis of subtle changes in DNA methylation patterns, a powerful tool for distinguishing between cancer and healthy cells and thus for detection of tumors in the body.\nIn the US, low-dose CT is available for screening of individuals 55-79 years old who smoked at least 1 pack a day for 30 years, which represent less than half of the lung cancer population.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release claims the test is a novel detection method but there are many other screening tests \u2014 often called \u201cliquid biopsies\u201d for lung cancer at various stages of development.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070805/13folate.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentioned that it was based on a new publication (in the July issue of the journal Cancer Epidemiology Biomarkers and Prevention).\u00a0 The story specifically comments on the timeline of the addition of folate to the grain supply in two different countries.", "answer": 1}, {"article": "Research on a bacterial toxin first discovered in Adelaide has led to the development a new blood test for the early diagnosis of ovarian cancer - a disease which kills over 1000 Australian women and 150,000 globally each year.\nThe team has now engineered a harmless portion of the toxin to enhance its specificity for the cancer glycan and used this to detect it in blood samples from women with ovarian cancer.\nA research team from the University of Adelaide and Griffith University have been studying the interactions between the toxin and an abnormal glycan (sugar) expressed on the surface of human cancer cells and released into the blood.\nThe team is currently seeking scientific and commercial partners to further test the technology with larger numbers of patient samples and to adapt it for mass screening.\nProfessor Michael Jennings, Deputy Director of the Institute for Glycomics at Griffith University, said: \"Detection of this tumour marker may also play a role in a simple liquid biopsy to monitor disease stage and treatment.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It\u2019s stated that the bacterial toxin used in the test was \u201cdiscovered\u201d by the Adelaide researchers, and that this is a \u201cnew blood test.\u201d", "answer": 1}, {"article": "In the study, the research team profiled blood samples collected in a blinded study from children and adolescents 9-19 years to explore whether patients with spastic CP showed differences at the cellular level that routine orthopedic patients (needing ACL repairs, spinal fusions or other surgeries) did not.\nThe researchers identified a strong set of methylation markers, or patterns, that indicate differences in the genome between children with spastic CP and those without it.\nIf successful, the researchers say the type of blood test in development also may be useful for other disorders, such as infant leukemia.\nWilmington, DE -- A Delaware team including Erin Crowgey, PhD, associate director of Bioinformatics with Nemours Biomedical Research, has published a study in the peer-reviewed journal BMC Bioinformatics, showing that DNA patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients (Crowgey et al.).\nWhen we find that epigenetic response, or signal, in the genetic sequencing, it provides another line of evidence for clinicians to use in making decisions,\" said Marsh.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states there is no established diagnostic blood test for identifying cerebral palsy patients but it\u2019s too early to claim that this test, still under development, is the novel \u201cgame changer\u201d to fill that need.", "answer": 0}, {"article": "Analytics firm GlobalData has forecast that CGRP antibodies will generate combined sales of $4 billion by 2026.\nSimilar drugs are under development at companies including Eli Lilly & Co and Teva Pharmaceutical Industries Ltd, but Amgen emphasizes that Aimovig is the only one that targets the CGRP receptor pathway, rather than CGRP itself.\nLOS ANGELES (Reuters) - A late-stage trial of Amgen Inc\u2019s experimental drug Aimovig found that it reduced episodic migraines by at least half in 30 percent of patients who had failed up to four previous treatments, while 14 percent of placebo patients achieved that goal, the company said on Tuesday.\n\u201cThis is a trial in really difficult to treat patients,\u201d professor Uwe Reuter, trial investigator and managing medical director at Charit\u00e9 Universit\u00e4tsmedizin in Berlin, told Reuters in a telephone interview.\nAimovig, currently under review by the U.S. Food and Drug Administration, is likely to be the first drug in a new class designed to target calcitonin gene-related peptide (CGRP), which plays a key role in migraine activation.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story tells us that similar drugs are under development, and that the new medication is meant for people who haven\u2019t benefited from prior treatment.\nAnother claim to novelty is made when the story says that\u00a0 Aimovig is the only drug under development \u201cthat targets the CGRP receptor pathway, rather than CGRP itself.\u201d It\u2019s unclear what this means or why it\u2019s important.\nWe\u2019re on the fence with this one but will give the benefit of the doubt.\u00a0", "answer": 1}, {"article": "But therapies have been improving steadily.\nThe therapy is exciting, AIDS specialists say, even though it is at least three years from market, because it could offer a completely new tool to combat a 25-year-old foe.\n``The proof of the pudding is always what happens when you give it to people and look at what the potency of the antiviral effect is,\" said Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.\nThe experimental therapies include drugs that bolster the body's ability to block the doorways that HIV uses to enter cells, that enhance the body's ability to neutralize the virus, and that limit the damage caused by HIV infection.\nThat hints at the opportunity to use bevirimat in potent combination with existing drugs, said Dr. Daniel R. Kuritzkes, director of AIDS research at Brigham and Women's Hospital and an associate professor of medicine at Harvard Medical School.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reports that bevirimat is a novel treatment and discusses how it may work to improve current treatment regimens. The story states this drug is made from an herb that\u2019s been used for other indications, but is quite clear that the pharma product is novel. ", "answer": 1}, {"article": "For more information, visit http://www.aaojournal.org.\n\u201cWhile we cannot totally avoid developing cataracts, we may be able to delay their onset and keep them from worsening significantly by eating a diet rich in vitamin C.\u201d \u201cGenetic and Dietary Factors Influencing the Progression of Nuclear Cataract,\u201d Yonova-Doing, et al.\nAbout OphthalmologyOphthalmology, the official journal of the American Academy of Ophthalmology, publishes original, peer-reviewed, clinically-applicable research.\nDespite the advent of modern cataract removal surgery, cataracts remain the leading cause of blindness globally.1 Researchers at King\u2019s College London looked at whether certain nutrients from food or supplements could help prevent cataract progression.\nNewswise \u2014 SAN FRANCISCO \u2013 A diet rich in vitamin C could cut risk of cataract progression by a third, suggests a study being published online today in Ophthalmology, the journal of the American Academy of Ophthalmology.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release says, \u201cA diet rich in vitamin C could cut risk of cataract progression by a third, suggests a study being published online today in Ophthalmology, the journal of the American Academy of Ophthalmology. The research is also the first to show that diet and lifestyle may play a greater role than genetics in cataract development and severity.\u201d\nElsewhere in the release is another claim to novelty, \u201cThese results make the study the first to suggest that genetic factors may be less important in progression of cataract than previously thought.\u201d\nIn the study the authors gave themselves wiggle room: \u201cThis study is the first, to our knowledge, to show that dietary vitamin C intake protects against progression of nuclear lens opacity.\u201d", "answer": 1}, {"article": "We're sorry, but we seem to have lost this page.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that both approaches are available (and therefore not new), but it should have made it more clear how rare (or not) diffusion MRI is.", "answer": 1}, {"article": "The 80% by 2018 campaign from the National Colorectal Cancer Roundtable, for example, which aims to increase the rate of screening, emphasizes a suite of options.\nThe United States Preventive Services Task Force says the net benefit for screening adults age 50-75 is \u201csubstantial,\u201d adding that colorectal cancer is the second-leading cause of cancer death in the country.\nThere is indirect evidence it reduces colorectal cancer deaths, in the form of a large study following people who did and didn\u2019t get the test over time.\n\u201cThey were very clear: We\u2019re going to stick to the evidence, and right now we don\u2019t have evidence for colonoscopy,\u201d said Aasma Shaukat, section chief of gastroenterology in the Minneapolis VA Health Care System.\nThe group said that while some tests are backed by more evidence than others, it found no head-to-head studies suggesting any strategy \u2014 including colonoscopy \u2014 is better than another.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that what\u2019s novel here is that the U.S. Preventive Task Force recently finalized their guidelines on colon cancer screening.", "answer": 1}, {"article": "While it may seem counterintuitive to treat bacteria with more bacteria, experts say this approach seeks to restore the natural microbial balance of healthy skin.\n\"The trial coordinator explained that it's like a probiotic for your skin,\" said Rodriguez.\nIt can be very painful,\" said Cassandra Rodriguez, 33, who has struggled with eczema all her life.\nNational Jewish Health is the leading respiratory hospital in the nation.\nIt is then applied to eczema patients' skin as a lotion twice a day for a week.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There are a number of probiotic creams for sale, according to a quick search of Amazon.\u00a0 What is different about the one being tested?", "answer": 0}, {"article": "What would that look / sound / smell like?\nProfessor Jackie Andrade, Professor in Psychology at the University of Plymouth, is one of the co-creators of FIT, and she explains: \"FIT is based on two decades of research showing that mental imagery is more strongly emotionally charged than other types of thought.\nLed by Dr Linda Solbrig from the School of Psychology, the research involved 141 participants, who were allocated either to FIT or Motivational Interviewing (MI) - a technique that sees a counsellor support someone to develop, highlight and verbalise their need or motivation for change, and their reasons for wanting to change.\n\"As well as being delighted by the success of the study in the short term, there are very few studies that document weight loss past the end of treatment, so to see that people continued to lose weight despite not having any support shows the sustainability and effectiveness of this intervention.\"\nThe study showed how after six months people who used the FIT intervention lost an average of 4.11kg, compared with an average of 0.74kg among the MI group.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release refers to FIT as \u201cnovel\u201d and \u201cnew\u201d \u2014 but (as noted above), researchers have been publishing on FIT since at least May 2016. We\u2019ll give the release the benefit of the doubt here since reasonable people can disagree on what constitutes novelty or \u201cnew-ness.\u201d\nThis 2016 paper looked at the use of FIT to inform dietary choices for people who wanted to lose weight. The new paper appears to be the first to look specifically at weight loss, but that context is missing since the release does not place the work in context with other research in the field.", "answer": 1}, {"article": "Paul J.D.\n\u201cThis new technology may also provide physicians with a safer, more controllable option for treating patients.\u201d\n\nThe team co-authored the paper, \u201cUltrasonic modulation of tissue optical properties in ex vivo porcine skin to improve transmitted transdermal laser intensity,\u201d which recently was accepted for publication by the society\u2019s journal, Lasers in Surgery and Medicine.\n\u201c\u2018Sonoillumination\u2019 will be extremely beneficial for clinicians and the ASLMS presentation allowed us to demonstrate the system to the people who actually will be using the technology once it\u2019s commercialized.\u201d\n\nNicholas Golda, associate professor of dermatology and director of dermatology surgery at the MU School of Medicine, echoed the merits of the sonoillumination system and the effect it will have on dermatology.\n\u201cWe\u2019ve named the technique \u2018sonoillumination,\u2019 and we\u2019re hopeful that the procedure will be available widely in the near future.\u201d\n\nWhiteside and his team, including adviser, Heather K. Hunt, an assistant professor of bioengineering in the MU College of Engineering, tested the sonoillumination system on porcine skin tissue samples.\nIn 2016, the Office of Technology Management and Industry Relations reported that Mizzou received $14.9 million in revenue from more than 40 technology licenses.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release mentions that lasers have been used to treat skin conditions for decades. However, it fails to note that other researchers have been looking into using ultrasound to improve laser light transmission for a number of years. Judging the release on this criterion is made harder by the muddled references to two distinct attributes of the device. The second paragraph of the release refers to reducing open-air transmission of laser light, and thus the risk of eye damage. But that statement is immediately followed by a quote about \u201csonoillumination.\u201d This distinct component of the device uses ultrasound in an attempt to help the laser light pass through skin without heating it as much as conventional lasers, but that feature is explained only in the conference abstract and draft journal article. This burn risk, and how ultrasound might reduce it, is not mentioned in the release, which makes it very difficult for readers to understand just what is new about this device.", "answer": 0}, {"article": "\u2022 The sensitivity of C-Tb was comparable to the IGRA in confirmed TB cases (77 percent vs. 81 percent), indicating similar abilities to detect infection.\nThe TESEC-06 trial included 979 participants from 13 clinical trial sites in Catalonia, Galicia and Basque Country (Spain) with various risk profiles of M.tuberculosis infection.\nThe study, conducted in South Africa, enrolled 1,090 participants, including 299 patients with HIV and 402 children as young as 28 days.\nC-Tb combines the field friendliness of the PPD-based Tuberculin Skin Test (TST), with the high specificity of the interferon gamma release assays (IGRA).\nThe TST is the most commonly used test to detect TB infection, with about 50 million tests worldwide each year, according to the World Health Organization.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release basically says that this is a new test that\u2019s cheaper and at least as effective, if not more effective, than existing diagnostic tools \u2014 and is less complicated to perform. That certainly qualifies as novel enough for a release.", "answer": 1}, {"article": "To contact Editor's Note author Mitchell H. Katz, M.D., email mediarelations@jamanetwork.org\nThe authors note a number of limitations in their study including that breast cancer was not the primary end point of the trial for which the women were recruited; the number of observed breast cancer cases was low; the authors do not have information on an individual basis on whether and when women in the trial underwent mammography; and the study cannot establish whether the observed beneficial effect was attributable mainly to the EVOO or to its consumption within the context of the Mediterranean diet.\nThe authors report that women eating a Mediterranean diet supplemented with EVOO showed a 68 percent (multivariable-adjusted hazard ratio of 0.32) relatively lower risk of malignant breast cancer than those allocated to the control diet.\nThe study was conducted within the framework of the large PREDIMED (Prevenci\u00f3n con Dieta Mediterr\u00e1nea) trial, which was designed to test the effects of the Mediterranean diet on the primary prevention of cardiovascular disease.\n\"The results of the PREDIMED trial suggest a beneficial effect of a MeDiet [Mediterranean diet] supplemented with EVOO in the primary prevention of breast cancer.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release establishes that the effects of diet on breast cancer risk have been studied previously with this line: \u201cDiet has been extensively studied as a modifiable risk factor in the development of breast cancer but epidemiologic evidence on the effect of specific dietary factors is inconsistent.\u201d", "answer": 1}, {"article": "But natural family planning is not for everyone.\nAnd if the app gives you a \"red day\" \u2013 meaning you could be fertile \u2013 you have to abstain from sex, or use another method of protection such as condoms.\nThe app was approved as a class IIb medical device by T\u00fcv S\u00fcd, a notified body in Sweden where it is based.\nAt first she starts to use the app to prevent pregnancy, and when she's ready [to get pregnant] she switches to plan, and usually she gets pregnant quite quickly, because the app already knows her body and cycle.\"\nEven so, the FPA advises that natural family planning is most effective if you\u2019re taught how to do it by a specialist teacher, and you monitor all three fertility indicators \u2013 temperature, menstrual cycle length, and cervical secretions.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story\u00a0differentiates this app from other menstrual cycle trackers for fertility information by pointing out the temperature taking aspect of the device. Indeed, subscribers are supplied with a sensitive thermometer that provides\u00a0body temperature reading to two decimal places.", "answer": 1}, {"article": "The results of the study, funded by the U.S. National Institutes of Child Health and Human Development, were presented at the recent Endocrine Society annual meeting, held in Houston.\nThe gels were applied every day for six months.\nOne important and unanswered question is what the long-term side effects of this regimen might be.\nThe testosterone/progestin combination works by shutting off the hormones that control production of sperm in the testes, Wang explained.\nUnfortunately, condoms and vasectomy have remained the only commercially available contraception options for men.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions previous research involving this combination of hormones for contraception.", "answer": 1}, {"article": "For more information about Pitt Public Health, visit the school's Web site at http://www.\n\"If a patient who is on an anticoagulant to avoid a stroke has a major bleeding event, doctors are faced with a catch-22: Discontinue the anticoagulant to avoid future bleeding, but again place their patient at increased risk of stroke; or resume the anticoagulant to continue avoiding a stroke, but then have to worry about another bleeding event,\" said lead author Inmaculada Hernandez, Pharm.D., Ph.D., an assistant professor in Pitt's School of Pharmacy, who completed this work as a doctoral student at Pitt's Graduate School of Public Health.\nThe analysis, published today in the journal Stroke, determined that resuming anticoagulation therapy after a person suffers a major bleeding event was associated with a higher likelihood of stroke-free survival than discontinuing anticoagulation.\n\"Our results should encourage clinicians to seriously consider resuming anticoagulation among patients who survived a major bleeding event, particularly if the source of bleeding was identified and addressed,\" said senior author Samir Saba, M.D., associate professor of medicine and associate chief of cardiology at UPMC Heart and Vascular Institute.\nThey then followed nearly 90,000 people who had filled prescriptions for the anticoagulants warfarin, which has been used as a medication since 1954, and dabigatran, which was approved by the U.S. Food and Drug Administration in 2010.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release overstates the novelty of this study by calling it \u201cthe first analysis of how to treat patients on anticoagulants who suffer a major bleeding event.\u201d There have been other analyses of this question, for example:\nRestarting anticoagulation therapy after warfarin-associated intracerebral hemorrhage.\nOptimal timing of resumption of warfarin after intracranial hemorrhage.\nThe study itself describes the novelty of the research more precisely: \u201cTo the best of our knowledge our study is the first real-world analysis comparing clinical outcomes after a major hemorrhage among patients who reinitiated anticoagulation therapy with dabigatran or warfarin and those who never resumed anticoagulations.\u201d They say the analysis \u201ccontributes significantly to the existing literature\u201d by comparing patients who used different anticoagulant drugs after a hemorrhage.", "answer": 0}, {"article": "Your skin vs. the sun: A sunscreen pill?\nAs an alternative, there's a relatively new product called Fernblock, which claims to protect the skin internally by systemically inhibiting the absorption of ultraviolet rays.\nA cautionary note:The damning evidence against vitamin A, which has long been used as a skin-cancer treatment, came from experiments done on mice, which have a far higher susceptibility to skin cancers than humans.\nThe basics: Almost everybody would love to have a \"healthy\" bronze glow, but almost everybody now also understands that the sun isn't our friend and that our skin needs to be protected from its stealthy attacks.\nOur two cents' worth:There's no reason not to take a flyer on Fernblock \u2014 actress Reese Witherspoon gives it a hearty endorsement - but keep slathering up, too.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Terribly vague.\u00a0There\u2019s nothing in this article to allow readers to assess whether this is novel. First, what is it?\u00a0Fernblock is a \u201crelatively new product\u201d and a \u201cnatural fern extract used by indigenous peoples.\u201d What people and where? Does it have a chemical name, or ingredients, besides the brand name?\u00a0 Second, what does \u201crelatively new\u201d mean? How long has it been out?\u00a0The only answer we are provided is:\u00a0Long enough for Reese Witherspoon to throw her name behind it. A simple search shows that is scientific literature on the product dating back years. Jumbling the vitamin A story with the Fernblock one conflates the possible roles of this product.\u00a0The article explicitly positions Fernblock as an alternative to sunscreens with vitamin A. But Fernblock, apparently, does not replace sunscreen, which even the manufacturer says needs to be used in combination with Fernblock. So how is Fernblock an alternative to sunscreen without vitamin A \u2014 or to any sunscreen?", "answer": 0}, {"article": "When treating a patient suffering from depression, Brent Forester considers which anti-depressant to prescribe\u2014ideally, one that will ease psychic pain without side effects.\n\nIt can be a tough call.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is pretty careful to put the findings of the study \u2014 presented at a conference in New York \u2014 in the context of overall advances in the use of pharmacogenetics and precision medicine, treatments increasingly tailored to an individual\u2019s genetic makeup. And it notes that the Myriad Genetics test is not the only player in the gene-based medicine field. The story also includes the information that the study was \u201cblinded\u201d and randomized, but (happily) avoids the hyperbole of the news release which calls it a \u201clandmark\u201d study and the largest ever of its kind.", "answer": 1}, {"article": "Colic is usually defined as excessive and inconsolable crying for at least three hours a day for more than three days a week over more than three weeks.\n\"This is pertinent given that simethicone is considered the best available and most commonly prescribed treatment for colic, although it previously has been shown to be no more effective than the placebo,\" according to the authors.\nThis implies the improvement may \"have more to do with the therapeutic effect of touch than the actual therapy itself,\" Dr. Edzard Ernst, of the department of complementary medicine at Peninsula Medical School, Universities of Exeter and Plymouth, in the United Kingdom, and colleagues wrote in the report.\nA study of probiotics, which are reputed to help digestion, found that 95 percent of infants given L. reuteria probiotics seemed to reduce their average crying time compared to 7 percent of babies given simethicone, which is marketed to relieve gas under the brand names Mylicon and PediaCare Infants' Gas Relief.\n\"The notion that any form of complementary and alternative medicine is effective for infantile colic currently is not supported from the evidence from the included randomized clinical trials,\" the researchers from the United Kingdom wrote.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story shows that these treatments are not novel and, for the most part, not very effective. The MSNBC site\u2019s \u201cToday Moms\u201d story, by contrast, made it sound as if herbal tea should be the first and best option for chlidren with colic, a statement not supported by the evidence.", "answer": 1}, {"article": "In traditional transplants, hair follicles are taken from an area that runs an inch or two above the ears and temples to the back of the head.\n\u201cHe had resorted to cropping his hair short to obscure the problem.\u201d\n\nWith the patients under local anesthesia, Dr. Umar used a device that creates microscopic wounds around hair follicles in the back of the leg; the follicles were then removed and transplanted to the hairline.\n\u201cThe hairline was fully grown and soft-looking by nine months\u201d in the 35-year-old, he wrote, \u201cat which time the patient started combing his hair backward and sporting a ponytail, exposing his hairline comfortably.\u201d\n\nSince then, Dr. Umar has done eight more of the procedures, including one in a woman.\nIf you take that hair and use it in the hairline, it can end up looking harsh and pluggy, because the hair is too thick.\u201d\n\nDr. Umar was inspired to develop the procedure in part from personal experience.\nThe procedure has the potential to restore the hairlines of millions of men with male pattern baldness, the most common cause of hair loss and often an enormous source of stress.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "In the first sentence, the story makes a claim of novelty: \u201cA new report highlights a novel way for doctors to replace thinning hairlines: transplanting leg hair.\u201d Later it says that, \u201cMen\u2019s leg hair had successfully been transplanted before to the back of the head\u201d. All it takes is a cursory review of the types of hair transplant methods being hawked to find multiple references to leg hair being used all over the head, including this Australian cosmetic surgeon promising, \u201cyou can even use your own body hair (chest, legs, arms) as donor and transplant them to thinning areas in your scalp.\u201d Given that this is a review of what happened with just two patients, it is difficult to even call it a study, let alone back up the claim made in the story that, \u201cbelieved to be the first documented cases of leg hair being used to restore the hairline.\u201d", "answer": 0}, {"article": "They did so to offer support, but also to spread awareness, because they say too often life and death for someone having a cardiac arrest comes down to chance. If a bystander performs CPR while medics are on their way, survival rates more than double, doctors say.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did not claim to reveal anything new or novel about CPR or its use among the survivors who were the subject of the story. But if there\u2019s nothing new here, why run the story?", "answer": 1}, {"article": "Funding of this work was supported by the Nemours Foundation along with the regional economic development initiative of the Florida High Tech Corridor.\nThis research demonstrates a novel method of treating this tumor without the toxicity of aggressive therapy that can also have late effects on the patient's health,\" said Tamarah J. Westmoreland, MD, PhD, a pediatric surgeon at Nemours Children's Health System and senior author of the study.\n\"This shows that nanoparticles can be an effective delivery vehicle for cancer drugs,\" said Professor Sudipta Seal, who directs of UCF's NanoScience Technology Center and Advanced Materials Processing Analysis Center, and is a collaborator on the study.\nThe study, conducted in partnership by researchers at Nemours Children's Hospital and the University of Central Florida, demonstrates a potentially novel treatment for neuroblastoma, the most common cancer in infants.\nAttaching curcumin, a component of the common spice turmeric, to nanoparticles can be used to target and destroy treatment-resistant neuroblastoma tumor cells, according to a new study published in Nanoscale.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Although the news release makes it sound as if this research is completely novel, using curcumin-loaded nanoparticles to treat neuroblastoma is not exactly new. In fact, researchers from Nemours and UCF only confirmed (not found, as the news release claims) that nanoparticles can be used to deliver curcumin to tumor sites.\nIn 2012, an international team of researchers looked at how curcumin-containing nanoparticles induced cell death in neuroblastoma cells in vitro. Another study from 2012 looked at the toxicity of curcumin-loaded nanoparticles.\nSince none of this was mentioned in the news release, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "Russo says, \"One of our main findings is that there was no overall relationship between most types of physical activity and the likelihood of becoming pregnant for women who had already had one or two pregnancy losses, except for walking, which was associated with higher likelihood of becoming pregnant among women who were overweight or obese.\"\nFor the 1,214 women in the study, the association of walking with the ability to become pregnant, known as fecundability, varied significantly by body mass index, the authors report.\nThe researchers conclude that \"these findings provide positive evidence for the benefits of physical activity in women attempting pregnancy, especially for walking among those with higher BMI.\nThe study was conducted by recent graduate Lindsey Russo and her advisor Brian Whitcomb, associate professor of biostatistics and epidemiology in the School of Public Health and Health Sciences at the University of Massachusetts Amherst.\nHowever, he adds, \"We were happy to be able to conduct research considering women having the most difficulty getting and staying pregnant, and to provide messages about common lifestyle factors they may be able to address.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Although the study authors provides a nice summary of other research in which the results do and do not agree with their study, this is not included in the news release and would have been a helpful addition.", "answer": 0}, {"article": "It\u2019s a single.\u201d\n\nSaying that even a single was helpful, Dr. Kahl was part of a majority on the panel that recommended approval of the drug, 10 to 4.\n\u201cIt creates these huge ethical quandaries about trying a drug that has a modest benefit for the average patient at enormous expense.\u201d\n\nFolotyn is given by a rapid intravenous procedure once a week for six weeks out of every seven.\nIn the clinical trial that led to approval of the drug, 27 percent of the 109 patients experienced a reduction in tumor size.\n\u201cIt\u2019s a two-edged sword that we have to live with and deal with,\u201d said Louis J. DeGennaro, chief scientific officer of the Leukemia and Lymphoma Society, which has received donations from Allos and other companies.\nIn the clinical trial, the median duration of use was 70 days, which would cost roughly $70,000 to $80,000.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly states that Folotyn is new.\u00a0 It could have stated that a host of older and less expensive treatment options are currently available.", "answer": 1}, {"article": "itself the first clear and reproducible example of cancer immunotherapy, developed at Fred Hutch ?\nThe findings in this group of trial participants contrast with the outcomes the researchers observed in a cohort of similar patients who received transplants around the same time but did not receive engineered T cells.\nBecause it was the first study of this particular approach, the researchers focused on a high-risk group -- AML patients undergoing bone marrow transplant who had certain genetic or disease characteristics that decrease the chance of long-term transplant success -- \"a hard population of patients,\" Chapuis said, many of whom \"were horribly sick.\"\nThis is the team's first trial of this strategy, which was initially developed in the lab of Dr. Phil Greenberg, one of the study's leaders and the head of Fred Hutch's Program in Immunology.\nIn the experimental T-cell therapy tested in this trial, certain T cells from each patient's transplant donor were genetically engineered to produce receptors that allowed the T cells to recognize, very specifically, a target molecule called WT1.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does not discuss similar experiments, including one that was outlined in the conference abstract, so readers cannot get a sense of how this experiment fits into a broad view of efforts to improve treatment of AML.", "answer": 0}, {"article": "PARIS (Reuters) - Sanofi-Aventis\u2019 cabazitaxel candidate prostate cancer drug combined with prednisone reduced the risk of death by 28 percent compared with another treatment, the outcome of a final-stage trial showed.\n\u201cThe development of cabazitaxel is one of many investigational compounds we hope to present to the cancer community in the months and years to come,\u201d Debasish Roychowdhury, Sanofi\u2019s oncology senior vice president, said.\nThe French drugmaker said on Thursday that the combination of the treatments led to an improved median overall survival of 15.1 months against 12.7 months in patients who took a chemotherapy of mitoxantrone with prednisone/prednisolone.\nFiling for approval in the EU has been completed.\nThe primary endpoint of the so-called Tropic trial was overall survival.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0Not applicable because no claims of novelty were made.\u00a0 Conversely, readers didn\u2019t learn anything about what\u2019s different and important about this drug in the way it works \u2013 if anything. ", "answer": 2}, {"article": "That heat can then be used to interrupt the troublesome brain connections responsible for the tremor.\n\u201cFor the first time in a randomized controlled trial, we have shown that ultrasound can be precisely delivered through the intact human skull to treat a difficult neurological disease.\u201d\n\nPioneering Tremor TrialThe multi-site clinical trial included 76 participants with moderate to severe essential tremor, a condition that often robs people of their ability to write, feed themselves and carry out their normal daily activities.\nThe paper outlines the results of an international clinical trial, led by Jeff Elias, MD, of the University of Virginia Health System, that evaluated the scalpel-free approach called focused ultrasound for the treatment of essential tremor (ET), a condition that afflicts an estimated 10 million Americans.\nNewswise \u2014 CHARLOTTESVILLE, Va., Aug. 25, 2016 \u2013 A study published today in the prestigious New England Journal of Medicine offers the most in-depth assessment yet of the safety and effectiveness of a high-tech alternative to brain surgery to treat the uncontrollable shaking caused by the most common movement disorder.\nNot only did the researchers determine that the procedure was safe and effective, they found that it offered a lasting benefit, reducing shaking for trial participants throughout the 12-month study period.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release points out that the trial is \u201cthe most in-depth assessment yet of the safety and effectiveness\u201d of this new approach to dealing with essential tremors.\u00a0 And since the procedure is less invasive than the standard surgical intervention now in use, it is certainly novel enough to warrant a news release.", "answer": 1}, {"article": "\u201cAre DORAs the perfect hypnotics?\n\u201cThese treatments work by forcing the brain to go to sleep,\u201d said study leader Jason Uslaner of Merck in an interview on the website of Science Translational Medicine, which published the study.\nOnly long-term use in large numbers of insomnia patients will reveal whether these drugs will be preferred to GABAergic hypnotics, and whether they produce rare complications, including narcolepsy-like symptoms in predisposed individuals,\u201d Mignot wrote.\n\u201cWhen you hit those, you don\u2019t just hit the sleep system,\u201d John Renger, executive director and head of neruoscience basic research at Merck and one of the study\u2019s authors, said in a telephone interview.\nMost sleep aids, including Sanofi\u2019s Ambien or Sunovion Pharmaceuticals\u2019 Lunesta, act on a key neurotransmitter in the brain called GABA.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does describe how this drug works on a different part of the sleep-wake mechanism in our brains than currently-available drugs. However, it is odd that there is no mention of results from the human clinical trials that must have preceded Merck\u2019s FDA approval application.", "answer": 1}, {"article": "WEDNESDAY, Aug. 17, 2011 (HealthDay News) -- People who have narrowed carotid arteries in the neck and show no symptoms may be at risk for stroke and not know it, but a simple ultrasound test can identify the problem, a new study suggests.\nAnother expert, Dr. Larry B. Goldstein, director of the Duke University Stroke Center, said that \"what remains uncertain is whether surgical intervention would result in an overall improvement in stroke-free survival.\"\nThis can cause less blood to reach the brain and, in rare cases, may also trigger a stroke if plaque breaks off and becomes lodged in the small vessels in the brain.\n\"Patients with symptomatic carotid stenosis don't get the surgical procedure early enough, and patients with asymptomatic carotid stenosis have too many surgical interventions,\" Marquardt said.\nWhen treating asymptomatic carotid stenosis, Marquardt doesn't think the case has been made for distinguishing between high- and low-risk patients.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It is really not clear from this story whether the 2 ultrasound techniques are new, are currently in use for other applications, are both in use for visualizing carotids but are not usually used in combination as in the study.\u00a0 Is this something new or not?", "answer": 0}, {"article": "Using the two drugs together as a one-two punch may be even more powerful.\nPaul Workman, professor and chief executive of the Institute of Cancer Research in London, said in a statement accompanying the publication of the journal article that \"the evidence on aromatase inhibitors has been accumulating for well over a decade, but it has taken this huge and complex study to make sense of all the data, and provide a firm basis for clinical guidelines.\u201d\n\n\"It tends to be the discovery of new treatments that grabs the headlines, but it is just as important to maximize the benefit patients get from existing treatments through major, practice-changing studies like this,\" Workman said.\nThe study reported that \"taking aromatase inhibitors for 5 years reduced the risk of postmenopausal women with breast cancer dying of their disease by 40 percent within 10 years of starting treatment, compared with no hormonal treatment.\"\nIf this had not happened, \"the benefit of aromatase inhibitors over tamoxifen would probably have been somewhat greater,\" they surmised.\n\u201cThe drugs are complementary, because the main side effect of aromatase inhibitors is an increase in bone loss and fractures, while bisphosphonates reduce bone loss and fractures as well as improving survival,\" he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "In the first paragraph, the story makes it sound as if aromatase inhibitors were just discovered by researchers: \u201c\u2026and despite decades of research scientists have not been able to find anything comparable \u2014 until now.\u201d\nResearchers have known about aromatase inhibitors as an alternative to tamoxifen for at least a decade, something which the story later points out while describing\u00a0the finding about aromatase inhibitors reducing mortality rates as a \u201csurprise.\u201d That might be overstating the case, since the original study says the evidence on this point is \u201cuncertain\u201d \u2014 suggesting that researchers were at least aware of the likelihood that these drugs might reduce death rates. We\u2019ll give the benefit of the doubt, since the story does, eventually, get around to describing what\u2019s new here and why \u2014 even if that description is somewhat questionable.", "answer": 1}, {"article": "Nothing worked.\nBy middle age, Ms. Gallagher, 51, the owner of a pet-sitting business in Torrance, Calif., was avoiding mirrors and considering liposuction, but she worried about the effects of anesthesia and the recovery time.\nShe enrolled in a trial, and by the third treatment session, \u201cI noticed a dramatic difference,\u201d she said.\nThen she discovered another option: a series of fat-reducing injections intended to slim down a double chin.\n\u201cIt was receding.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story says that the drug is the first nonsurgical way of reducing double chins. We wonder if diet and exercise would also be considered nonsurgical treatments for at least some cases of double chins. But we can find no literature to support that idea. Perhaps it\u2019s too obvious an idea for anyone to have studied it?", "answer": 1}, {"article": "Arterburn and Simon's coauthors are GHRI Senior Investigator Denise M. Boudreau, PhD, Research Project Management Director Emily O. Westbrook , Programmer Analyst Mary Kay Theis, and Andy Bogart; Tamar Sofer, PhD, a biostatistician at the UW School of Public Health and post-doctoral research fellow at Harvard University; and Sebastien Haneuse, PhD, an associate professor of biostatistics at the Harvard T.H.\nBut patients should consult their doctor about which medication is right for them, before making any changes, including starting, switching, or stopping medication.\nAfter two years, nonsmokers lost an average of 2.4 pounds on bupropion--compared with gaining an average of 4.6 pounds on fluoxetine (Prozac).\nBut in some cases, an overweight or obese patient has reasons why bupropion is not for them--like a history of seizure disorder--and it would be better for them to choose a different treatment option.\nPreviously, Group Health researchers showed a two-way street between depression and body weight: People with depression are more likely to be overweight, and vice versa.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release claims that the study was the first to examine weight gain in people using antidepressants for more than a year, in this case up to two years.", "answer": 1}, {"article": "Tensions ran so high at one point that two prostate cancer specialists, who had urged the F.D.A.\nAt the end of three years, 34 percent of the men taking Provenge were alive, compared with only 11 percent for those who received a placebo.\nCancer vaccines of the type represented by Provenge, known as immunotherapy, are different from conventional vaccines in that they do not aim to prevent disease, but to enlist the body\u2019s defenses in attacking the disease after it occurs.\nIn an earlier trial, men who received Provenge lived a median of 25.9 months, compared with 21.4 months for those who received a placebo.\nThe only approved treatment for them now is the chemotherapy drug Taxotere, from Sanofi-Aventis, which extended median survival by about three months in trials.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story accurately describes Provenge as a novel type of cancer vaccine therapy. It describes the history of similar drugs, none of which has been approved. ", "answer": 1}, {"article": "So his team designed a randomized controlled clinical trial to see if short-term use of a curcumin supplement could reduce inflammation in people with metabolic syndrome, a cluster of risk factors for heart disease.\nHaving a large waistline, high blood pressure, high blood sugar, low levels of HDL (good) cholesterol and high levels of triglycerides, are among the factors that make up metabolic syndrome.\nThe study team also analyzed data from eight previous studies and confirmed that curcumin had shown a significant reduction of CRP concentrations in a total of 281 patients.\n\u201cCurcumin is a very safe natural supplement, and there is no severe adverse event associated with its use, even at high doses,\u201d Sahebkar said.\n\u201cCurcumin is the active ingredient of the famous spice turmeric and has a long history of culinary and medicinal use in the Asian countries,\u201d said the study\u2019s senior author Amirhossein Sahebkar.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story places this study in context, referring to both previous animal studies and the (few) previous human studies.", "answer": 1}, {"article": "No more than a few days later, the samples were transported to labs at the university, where they remained frozen until they were processed by researchers. This ensured that none of the bacteria had a chance to grow or change from the time the sample was collected. Also, it guaranteed that all samples were treated the same way.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The news story did establish the novelty of the research with this quote:\n\u201cTo our knowledge, this is the first study to systematically assess such a broad range of host and environmental factors in relation to gut microbiome and at such a large scale,\u201d said Jingyuan Fu, a systems geneticist at the University of Groningen who worked with Zhernakova.", "answer": 1}, {"article": "Injections of botulinum toxin, best known as a wrinkle treatment, are now being used increasingly to prevent chronic migraine sufferers. Scientific data are mixed, but two large recent studies show Botox can reduce the number of headache days in chronic sufferers.\n\nMigraine headache is a debilitating neurological condition that manifests itself as an intense throbbing pain on one or both sides of the head, according to the Migraine Research Foundation, a New York nonprofit. Some 14 million people experience migraine attacks...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article makes it clear that Botox is in use for other clinical conditions and has been studied extensively in the headache arena.", "answer": 1}, {"article": "He was fascinated by certain powerful cells of the immune system \u2014 T cells.\n\"I've been doing this sort of stuff for years, and I'd never seen anything like that,\" Allison says.\nAnd at Belvin's follow-up appointment a year later, Wolchok delivered news that was hard for her to take in: \"Sharon, you no longer have cancer.\"\nStill, the approach offers promise to some people that other therapies can't, and has transformed the way doctors think about cancer treatment.\nEach case is different, and using a patient's own cells to destroy tumors won't work in every patient or in every type of cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "In a sense, the entire story revolves around the novelty of ipilimumab \u2014 particularly on the (then-novel) mode of action it uses to fight cancer in melanoma patients.", "answer": 1}, {"article": "For this case-control study, researchers recruited 5,307 colonoscopy patients, 60 percent of them men, at two Tennessee hospitals over a seven-year period ending in April 2010.\nThe researchers found no effect in men, and no effect of omega-3 consumption on hyperplastic polyps, which are more likely to be benign.\nA new study has found that consumption of omega-3 fatty acids from fish is associated with a reduced risk for one kind of colon polyp, but only in women.\nAfter controlling for age, race, body mass index, smoking and other factors, the researchers found that women in the highest fifth for omega-3 consumption \u2014 those who consumed three or more servings of fish a week \u2014 were 33 percent less likely than women in the lowest fifth to have adenomatous polyps, a type likely to become cancerous.\nAnimal studies have suggested that omega-3 fatty acids may have anti-cancer effects, but the results from human epidemiological studies have been inconclusive.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story at least provided one line of context about past research in this field: \u201cAnimal studies have suggested that omega-3 fatty acids may have anti-cancer effects, but the results from human epidemiological studies have been inconclusive.\u201d", "answer": 1}, {"article": "\"It does.\nWhat's happening now is that the vast majority, about 70 percent, are done the old-fashioned way, with a large surgical incision, lots of pain, and a six-to-eight-week recovery.\n\"If patients really know that they have options when it comes to hysterectomy, we will start seeing some of the changes that I feel need to happen,\" Warren said.\nIt's all over in about an hour, and patients are usually home within a day and back to normal within a week or two.\nLike all laparoscopic procedures, a camera is inserted through a tiny incision to see into the abdomen; two other small incisions are made so that tools can be inserted to perform the surgery.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story adequately represents the novelty of laparoscopic surgery. Although the story makes it seem like the procedure is \"new\" it does mention that laparoscopic surgery has been around for 15 years.", "answer": 1}, {"article": "But stimulating the vagus nerve requires surgery to implant a device near the collarbone.\n\"For me it's extremely effective,\" says Jennifer Rees, 49, who lives in the Los Angeles area and has been using the nerve stimulator for six years.\nThe approach, which is not yet approved by the FDA, could offer an alternative or enhancement to treatment with drugs, says Christopher DeGiorgio, the neurologist at UCLA who invented the new approach.\nThe trigeminal nerve stimulator, in contrast, never penetrates the skin and is powered by an external device about the size of a large cell phone, DeGiorgio says.\n\"For me, all it involved was putting two gel pads above my eyebrows, one on each eyebrow,\" she says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We\u2019ll give the story a satisfactory score because it at least explained the following:\n\u201cthe trigeminal nerve stimulator is not the first time researchers have used electrical pulses to prevent seizures.In 2005, the FDA approved a device that stimulates another nerve that leads to the brain \u2014 the vagus nerve. But stimulating the vagus nerve requires surgery to implant a device near the collarbone.\nThe trigeminal nerve stimulator, in contrast, never penetrates the skin and is powered by an external device about the size of a large cell phone.\u201d\n", "answer": 1}, {"article": "They estimated the scans done in 2007 will cause 29,000 cancers.\nThe findings, published in the Archives of Internal Medicine, add to mounting evidence that Americans are overexposed to radiation from diagnostic tests, especially from a specialized kind of X-ray called a computed tomography, or CT, scan.\nA third of the projected cancers will occur in people who were ages 35 to 54 when they got their CT, two-thirds will occur in women and 15 percent will arise from scans done in children or teens.\nBy comparison, the average American is exposed to about 3 millisieverts of radiation a year from ground radon or flying in an airplane \u2014 a level not considered a risk to health.\nThat is a lot of excess deaths.\u201d\n\nCT scans give doctors a view inside the body, often eliminating the need for exploratory surgery.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story highlights the risks associated with the increasingly common use of CT\u00a0scans.\u00a0 This issue is certainly not new.\u00a0 While the two cited articles in the story are important additions to our understanding of the risks, they are not seminal articles by any means.\u00a0 The issue of risk, necessity of testing and dose delivered per test have been discussed in the literature for at least a decade.\u00a0 Nonetheless, we\u2019ll give the story a satisfactory score on this criterion.", "answer": 1}, {"article": "Currently, we\u2019re in limbo as to how to advise patients.\u201d\n\nHe acknowledged that the need for such a study for men is \u201cless compelling\u201d because, in contrast to women, who experience an abrupt drop in estrogen at menopause, often with disruptive symptoms, hormone decline in aging men is far more gradual, and symptoms, when they occur, are commonly viewed as normal signs of aging, not hormone deficiency.\nBut oral administration is rarely used because of toxic effects on the liver.\nA large European study published in the same issue of the journal sought to better determine who, among middle-aged and elderly men, might be candidates for testosterone replacement.\nInjections could result in harmful thickening of the blood, however, especially if above-normal blood levels of the hormone result.\nBefore the most recent study, at doses considered normal, the testosterone gel showed little or no effect on cardiovascular risk, the two doctors reported.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article does not try to oversell the novelty of testosterone replacement therapy.", "answer": 1}, {"article": "MONDAY, May 16, 2011 (HealthDay News) -- A daily dose of the antioxidant selenium doesn't appear to elevate \"bad\" cholesterol levels, and may in fact prompt a very modest boost in \"good\" cholesterol, a new British study reveals.\nHowever, the safety of selenium has not been studied, and the authors said the findings weren't significant enough to recommend supplementation of the trace mineral.\nThe finding comes from a six-month examination of the impact of various dosages of the supplement on the cholesterol levels of healthy people in England.\nNone of the patients experienced any serious side effects as a result of selenium supplementation.\nFor six months, some participants were assigned to take daily selenium yeast supplements in either low, intermediate or high doses, while others were given a dummy pill for the duration.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story states that many other studies have looked at the cholesterol impact of selenium supplements, with differing results.", "answer": 1}, {"article": "The actual brain scan costs around 100 pounds ($157.5).\n\u201cWe would hope that it would work just as well ... there is no reason why not.\u201d\n\nThe ability to base a diagnosis on an objective biological test, rather than having to rely on personality traits, should mean patients get treatment more quickly, he added.\nThe speed of the test makes it some 20 times cheaper than traditional tests, which can take a team of doctors four to eight hours to conduct.\nIt could be a boon for patients and their doctors by reducing reliance on time-consuming and emotionally trying assessments based on interviews and behavioral observation.\nThe new scanning method \u2014 which picks up on structural changes in the brain\u2019s grey matter \u2014 could be ready for general use in a couple of years.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Researchers have long studied the brains of patients with autism using MRI scans. However, the ability to make a clinical diagnosis of autism using MRI would be noteworthy progress.", "answer": 1}, {"article": "BMI loss was between 7.1 and 14.7 kg/m2.\nLed by University of Adelaide researchers, in collaboration with Flinders Medical Centre, and published in the journal Obesity Surgery, the study is the first to show medium to long-term follow-up (3-5 years) of lap band surgery in Australian adolescents.\n\u201cWe are talking about a group of adolescents with severe obesity and significant health and psychological problems related to their increased weight \u2013 this is not for everyone,\u201d says corresponding author and Paediatric Endocrinologist Dr Alexia Pe\u00f1a, who is a Senior Lecturer with the University of Adelaide\u2019s Robinson Research Institute.\nAustralian revised National Health and Medical Research Council guidelines for obesity management say that lap band surgery should be considered in adolescents with severe obesity \u2013 that is with a body mass index (BMI) over 40 kg/m2 or over 35 kg/m2 (weight/height2) with the presence of obesity-related diseases and who don\u2019t respond to medical treatment.\n\u201cOur findings support lap band surgery as a safe and effective option for management of adolescents with severe obesity \u2013 provided it is performed by an experienced surgeon and managed afterwards in a paediatric multidisciplinary environment with regular follow-up until adulthood.\u201d\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes it clear that this study\u2019s novel contribution is its effort to gather date from \u201clap-banded\u201d patients over\u00a0longer periods of time than did previous studies.", "answer": 1}, {"article": "Might non-opioid painkillers work just as well as these addictive drugs?\nResearch has shown that even short-term opioid use, such as that stemming from an initial prescription for pain from an injury or surgery, can make people predisposed to a dependence on the powerful drugs \u2014 partly from their effectiveness at relieving pain and partly from the euphoria they produce.\nThe drug industry\u2019s triumph over the DEA, even as opioid-related deaths rise\n\nShingles can be intensely painful; it may also mean health problems ahead\nThe study involved 416 adults (average age, 37) who had gone to an emergency department with an extremity injury causing moderate to severe pain (averaging 8.7 on a scale of 1 to 10).\nEven for people who initially had rated their pain as a 10 (for the worst pain possible) or had broken a bone, there was virtually no difference in pain reduction between those who had and had not taken an opioid.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is the weakest point of the story. It was also the weakest point of a news release on the work, and we\u2019ll make the same observation here that we did there. First, here\u2019s a key quote from the JAMA article: \u201cRelatively few ED [emergency department] studies have compared the efficacy of the 3 most commonly used opioid analgesics in the ED and none has compared them in a single study. Although opioids are considered to provide stronger analgesia than nonopioid analgesics, 1 ED-based study found that adding combination oxycodone and acetaminophen to naproxen did not improve pain relief at 1 week in patients with acute low back pain. Several postsurgical studies have found combination nonopioids to be as effective as a combination of codeine and acetaminophen.\u201d This is really useful information. Among other things, it tells us that previous studies have found similar results \u2014 but not in the context of addressing acute pain in the emergency room. In other words, it makes clear how this study builds on and is different from earlier research. That\u2019s important. What\u2019s more, as we noted in the \u201cWhy This Matters\u201d section at the top of the page, the studies cited in the JAMA paper had comparable findings. This is not the first time someone has found that non-opioids are comparable to opioids. If you\u2019re trying to tell people that there may be a way for doctors to meaningfully address one contributing factor to the opioid crisis, you should point to all of the supporting information \u2014 not just the most recent.", "answer": 0}, {"article": "In devising their models, the researchers updated assumptions that have cast doubt on the relevance of existing breast-cancer risk calculators, which relied on the experiences of women who got an earlier generation of screening mammograms and were more likely to die of breast cancer than is currently the case. Here, teams of modelers from Erasmus University in the Netherlands, Albert Einstein College of Medicine in New York and Harvard Pilgrim Healthcare assumed that women were getting digital mammograms, which offer improved cancer detection rates at lower radiation dosages than earlier mammographic methods. They took into account improved rates of breast cancer treatment effectiveness, and changing causes of mortality for women older than 50. They also took account of the fact that breast density decreases in older women.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article does a very good job of pointing out what\u2019s new here: the affirmation of the value of density calculation in determining risk and mammography frequency. The news article went into some detail about the epidemiological \u201cmodeling\u201d and the outcomes simulations the researchers used.\nThe story would have benefitted from expert commentary about the numerous risk factors and comfort levels women and their physicians have when considering the frequency of mammography; and about the fact that there are no definitive answers for the ideal screening protocol for any individual woman.\nAs noted earlier, the journal carried an editorial by a Johns Hopkins University scientist, offering an opinion about who needs annual screening, and some of the weaknesses and strengths of the new study. Too bad this wasn\u2019t cited.", "answer": 1}, {"article": "Radiotracers work by injecting a small amount of a compound tagged with a radionuclide into patients.\nIn studies involving mice with prostate cancer, the researchers had the radiotracer hone in on prostate-specific antigen (PSA), the same prostate cancer marker used in the PSA test.\nThe findings were to be presented Saturday at the American Association for Cancer Research annual meeting in Chicago, and are also being published in Cancer Discovery.\nIf a treatment showed a marked change, it could continue to be used in that patient, hence \"personalized\" medicine.\nIf a specific change did not occur, that treatment could be abandoned and another tried instead.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of the approach was not clearly established.\u00a0 How/why is this better than existing PET scans? Or how is it better (more accurate or useful or cheaper or safer) than using a bone scan and PSA results and clinically assessing the signs and symptoms of progression?", "answer": 0}, {"article": "Then the researchers, led by Dr. Frank Hu of the Harvard T.H.\nFirst Take: The new research, published in Circulation on Monday and funded by the National Institutes of Health, mined three large, ongoing epidemiological studies (74,890 women in the Nurses\u2019 Health Study, 93,054 women in the Nurses\u2019 Health Study 2, and 40,557 men in the Health Professionals Follow-up Study), following them for at least 20 years.\nBut given the 2013 research suggesting \u201ctoxicity of high coffee doses\u201d in some people, he said, \u201cto me the most reasonable approach would be to keep coffee intake to two to three cups most days.\u201d\n\nSecond Take: STAT knows better than to get between coffee lovers and their cup o\u2019 joe, so if you want to take this study as permission to keep beating a path to your Keurig, we\u2019re not going to slow you down.\nFewer studies link coffee to a higher likelihood of dying prematurely, but this classic found a link between 6-plus cups a day and dying of cardiovascular disease, while this 2013 paper, on 43,727 people followed for a median of 17 years, concluded that adults under 55 who averaged more than 4 cups a week had a 56 percent (men) or 130 percent (women) higher risk of dying over the study period than non-coffee drinkers.\nOverall, the heaviest coffee-drinkers (more than five cups a day, regular or decaf) had a tiny 2 percent additional risk of dying compared with coffee abstainers.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The STAT story, like its CNN counterpart, duly noted the novelty of the researchers\u2019 analysis of the non-smoker subset of records analysis, and STAT did so with a bit more easily-accessible language.", "answer": 1}, {"article": "By the six-month follow up, 43 percent of participants (7 of 14) who completed the RCT had remitted, with five remitting at amounts below the commonly-used dose of 0.5 mg/kg.\nLed by a team of researchers from UNSW Sydney and Black Dog Institute, the trial tested different doses of ketamine amongst 16 older age participants (aged over 60 years) who had treatment-resistant depression, administered at Wesley Hospital.\n\"Not only was ketamine well-tolerated by participants, with none experiencing severe or problematic side effects, but giving the treatment by a simple subcutaneous injection (a small injection under the skin) was also shown to be an acceptable method for administering the drug in a safe and effective way.\"\n\"These results are a promising early piece of the puzzle, but the risks of ketamine use are still not wholly understood.\nParticipants received increasing doses of ketamine over a period of five weeks, with doses optimised for each individual participant using a new dose-titration approach developed by Professor Loo's Sydney research team and collaborators.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does a good job of explaining what is new about the study and the research team\u2019s particular way of carefully tailoring ketamine doses to each patient.", "answer": 1}, {"article": "Their conclusion?\nBut the CDC keeps delaying it and still has not said when that will happen.\nThe statement, and accompanying technical report, marks the first revision of the organization's position since 1999, when the academy backed away from circumcision.\nFor one thing, the studies about HIV have only been done in Africa, where AIDS is much more common among heterosexuals.\nIt also reduces the chances that men will spread HPV to their wives and girlfriends, protecting them from getting cervical cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that the AAP has previously issued recommendations on the topic of circumcision and points out that this latest recommendation is a bit contrary to that previously issued.", "answer": 1}, {"article": "TUESDAY, March 27, 2012 (HealthDay News) -- When taken as a supplement, unroasted -- or green -- coffee-bean extract can help people shed pounds, according to a small preliminary study.\nThe study was conducted in India and funded by Applied Food Sciences, the American manufacturer of two green-coffee-extract products.\nIt has not been published in a journal, and therefore has yet to undergo peer review.\nBut here, with higher extract doses than have been used before, the patients experienced what I would call rather large weight loss.\"\nAll the patients were instructed to maintain their usual dietary habits, while the study team monitored them for weight loss over a period of nearly six months.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story nods to previous research which apparently found mild weight loss effects from green coffee extract. Although we wish some detail about that previous work had been provided.", "answer": 1}, {"article": "But testimonials are not scientific proof.\nFor now, here\u2019s what consumers should know:\n\nPhysical therapists say it is not, \u201cthough superficially, it may look the same,\u201d says Justin Elliott, vice president of government affairs for the American Physical Therapy Association.\nFor one thing, he says, dry needling as performed by a physical therapist is not rooted in ancient Chinese medicine \u2014 there\u2019s no talk about redirecting the body\u2019s energy flow by placing needles at certain points in the body.\nMark Crislip, an infectious-disease doctor in Portland, Ore., who recently wrote about dry needling for Science-Based Medicine \u2014 a website critical of alternative medicine \u2014 says the version practiced by physical therapists doesn\u2019t \u201ccome with the mystical baggage that accompanies acupuncture.\u201d But he says it may well be a \u201ctheatrical placebo.\u201d\n\nWhat do published studies say?\nIn rare cases, deep needling can lead to a punctured lung or injuries to nerves and blood vessels, and acupuncturists fear non-specialists will be more likely to make such mistakes, Burgoon says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes\u00a0what\u2019s new and why it\u2019s being written about with this statement: \u201cAnd there, Briggs says, is where dry needling is lacking. While some studies have shown promise, he says, \u201cthe quality of the evidence is not strong.\u201d That\u2019s why Briggs and his colleagues are starting a study looking at dry needling in \u201crunner\u2019s knee,\u201d the condition that has plagued Pierce. Their goal, and the goal of other researchers now looking at dry needling, is to produce results rigorous enough to show whether it really works.\u201d", "answer": 1}, {"article": "With better drugs and radiation techniques available, the proportion of women with Stage 4 breast cancer who had surgery dropped from 67.8 percent in 1988 to 25.1 percent in 2011, according to a study published Wednesday in the journal JAMA Surgery.\nIn interviews, Schroeder and Thomas stressed that each decision about whether to have surgery is based on many factors that only a woman and her doctors can assess, in particular how far the cancer has spread and how sick she is.\nOver the past few decades, as breast cancer has increasingly been treated as a systemic disease, the number of surgeries performed on the most serious cases has plummeted.\nBut with better therapies to control the cancer systemically and improved imaging that finds ever-smaller deposits of cancer in other parts of the body, it may be time to see whether surgery also can help increase the length of survival times, they said.\nAs other research has shown, African American women were over-represented among women who have Stage 4 breast cancer at the time they are first diagnosed.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article makes it clear that surgery is not a new intervention to treat breast cancer, stating that women and their clinicians have opted for surgery since at least 1988.", "answer": 1}, {"article": "The latest health and science updates, breakthroughs, research, and the best in investigative and informative journalism.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentioned that highlighted inclusion of B vitamins in energy drinks is a relatively new phenomena.", "answer": 1}, {"article": "When left untreated, however, B.P.H.\n\u201cMy father used to be up 10 times a night and said it wasn\u2019t a problem for him,\u201d said Dr. Franklin C. Lowe, professor of urology at Columbia University College of Physicians and Surgeons.\nSurprisingly, his case is not unique.\u201d\n\nMany doctors are now urging men to become proactive earlier to prevent chronic problems in the future.\n\u201cThere is a big difference between having the symptoms and being bothered by the symptoms,\u201d said Dr. Kevin T. McVary, professor of urology at the Feinberg School of Medicine at Northwestern University.\nBut for patients who have trouble getting back to sleep, \u201cthere are many effective options, and patients almost always end up with less bothersome symptoms once they choose to do something,\u201d he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did an acceptable job laying out the currently available approaches to BPH management; it also mentioned research with Botox for use in treating BPH as well as the novel use\u00a0of erectile dysfunction drugs for treating BPH.", "answer": 1}, {"article": "In the new study of 24 patients, scores on a standard test measuring the disturbances of memory, language, attention, and other cognitive skills that are hallmark symptoms of Alzheimer's disease dropped an average of slightly more than five points in those treated with IVIG.\nThe findings were presented at the American Academy of Neurology meeting.\nThe IVIG treatment also appeared to slow the rate of brain shrinkage by about 45%, he tells WebMD.\nIt's a form of intravenous immunoglobulin, or IVIG, drugs that are usually used to treat immune system disorders.\nThe drug is called Gammagard.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "No extraordinary claims of novelty were made. ", "answer": 1}, {"article": "Keytruda \u2014 known generically as pembrolizumab \u2014 targets the activity of genes called PD-1 (anti-programmed-death-receptor-1) and PD-L1.\nIt worked at least as well if not better than the chemo, so the researchers have stopped the study to give everyone a chance to take Keytruda, Merck, the company that makes the drug, said.\nThe company now can ask the Food and Drug Administration if it will approve Keytruda to use as the first treatment a lung cancer patient tries.\nSo it\u2019s an important break for a company if its drug is the first one a patient gets and it works better than the so-called standard of care.\nIndependent committees look at the details of the patients and how well they are doing in drug trials like these.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes that this is the first trial in patients who have not been treated any other way for lung cancer, hence the excitement around these findings.", "answer": 1}, {"article": "Psoriasis is an immune-mediated disease that causes itchy, dry and red skin.\nThe disease affects nearly 3 percent of the world's population, according to the World Psoriasis Day consortium, but about half of all patients with psoriasis do not get any treatment, Dr. Gordon said.\nAt week 40, for example, 81 percent of patients taking a 200-mg dose of guselkumab had a score of 0 or 1, compared to 49 percent of patients taking adalimumab.\n\"Research like this study is leading to a series of new medications that promise high levels of response for an increasing number of patients,\" said first author Kenneth Gordon, MD, professor in Dermatology.\n\"The possibility of getting almost all patients nearly clear and able to live their lives without the burden of this disease impacting them every day is getting close to reality.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release explains that guselkumab is novel because of its mode of action (i.e., how it works), compared to other, similar drugs. Specifically, the drug blocks a protein that\u2019s implicated in psoriasis. It would have been nice if the release had included another sentence or two on how blocking that protein disrupts psoriasis (or its symptoms).", "answer": 1}, {"article": "Why has it taken so long for hip arthroscopy to catch up to its shoulder and knee counterparts?\nIt acts as a cushion when the leg bends and provides stability to the joint.\nThis means that a bone deformity causes the ball and socket to rub against each other in a way that pinches the labrum.\nThe labrum is a thin ring of cartilage that lines the acetabulum, or hip socket.\nRest and physical therapy might be prescribed, but no other solutions were available.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\n \nThe story provides accurate information on the novelty of the treatment and its growth in popularity over the past 15 years.", "answer": 1}, {"article": "A new asthma drug being developed by Sanofi and Regeneron Pharmaceuticals may help patients whose condition is not well controlled by existing medicines, according to the results of a small clinical trial released Tuesday.\n\nIn the 12-week study, the number of asthma attacks or other outbreaks of symptoms decreased by 87 percent in those getting the drug, dupilumab, compared with those getting a placebo.\n\nOther measures of lung function and disease control also improved, according to the study results, which were published online Tuesday in The New England Journal of Medicine and presented at the annual meeting of the American Thoracic Society in Philadelphia.\n\nDupilumab blocks the action of interleukin-4 and interleukin-13, two inflammatory chemicals made by the body that are believed to contribute to asthma. Sanofi and Regeneron say there are also preliminary signs dupilumab works against the skin condition atopic dermatitis, suggesting it can be blocking a biological pathway that contributes to multiple allergic conditions.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of this drug, and of the findings, are appropriately described in the story.", "answer": 1}, {"article": "For them, a combination of two existing CFTR modulators can ease breathing problems -- but the overall effects are only \"modest,\" Rowe said.\nPatients as young as 12 are included in the larger ongoing trials, Rowe said.\nThe trials were short-term, finding that the drug combinations improved adult patients' lung function over four weeks.\nAfter four weeks, the trial found, the triple-drug therapy had improved lung function in patients with both types of mutations.\nOver time, extensive lung damage leads to respiratory failure.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story gives a little bit of background on the other drugs, and how the drugs in this trial are novel.", "answer": 1}, {"article": "\u201cThere is a great deal of interest in developing other uses of bimatoprost,\u201d Heather Katt, a spokeswoman for Allergan, wrote in an e-mail message, \u201cand Allergan is exploring ways to pursue that pathway through the F.D.A.\nThe result is an enhanced, refortified hairline rather than a brand new head of hair.\nIt is, however, expensive: a month\u2019s supply of Latisse can cost up to $150, and that is in amounts appropriate for use merely on the eyelashes.\nBy the third week, he said, both he and friends he asked for reactions were seeing results.\n\u201cI even busted out the old \u2018before\u2019 and \u2018after\u2019 pictures,\u201d he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The product definitely appears to be novel, and the story does a good job placing it in the right context.", "answer": 1}, {"article": "The paper, co-written by Hayes and four colleagues from UCL and Oxford University, concluded that: \u201cLithium remains an important treatment for individuals with bipolar disorder.\u201d It accepts that \u201cthere is clear evidence that its use is associated with a number of adverse events.\u201d\n\nHowever, it adds: \u201cThese risks need to be offset with the potentially superior effectiveness and anti-suicidal benefits of the drug compared to other treatment options.\u201d\n\nThe researchers studied a nationally representative sample of 6,671 patients across the UK who were treated for bipolar disorder between 1995 and 2013.\nThere should be more sensible use of it.\u201d\n\nStephen Buckley, head of information at the charity Mind, said: \u201cWe welcome research which adds to our understanding of treatments and medications for people experiencing mental health problems, including bipolar disorder.\nThe findings are contained in the first study comparing the side-effects of the four main mood-stabilising drugs the NHS prescribes.\nThat superseded its previous view, outlined in 2006, that any of the four drugs were useful first lines of treatment for the condition, which affects about one in 100 people.\nResearchers claim that although the drug does carry some health risks, its overall effectiveness, especially its ability to reduce self-harm and suicide, mean it should be much more widely used.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story begins with: The new study is the first to compare the side-effects of the four main mood-stabilising drugs prescribed by the NHS.\u201d \u00a0Based on our review of the medical literature, we agree.", "answer": 1}, {"article": "The studies were reported at an American Heart Association conference this week in New Orleans.\nIn Florida, Dr. Paul Kurlansky led a study of 1,062 octogenarians who had heart bypass surgery at Mount Sinai Medical Center in Miami Beach from 1989 through 2001.\nMany elderly patients are hale and hearty, and if they need surgery, \u201cthere\u2019s no reason to deny them that.\u201d\n\u201cThe key issue here is not only, \u2018Can we operate and are they alive?\u2019 but \u2018How are they doing?\u2019 \u201d he said.\nNEW ORLEANS \u2014 Eighty-year-olds with clogged arteries or leaky heart valves used to be sent home with a pat on the arm from their doctors and pills to ease their symptoms.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reported on bypass outcomes over the 12 year period from 1989 \u2013 2001. \u00a0This implies that it took a long time to compile information of sufficient numbers of patients in order to report on the outcomes. \u00a0This suggests that at least at the institution reporting these outcomes, it is not novel nor is it extremely common to conduct these types of surgery in this population.", "answer": 1}, {"article": "; Eur Uro 2016 \n\niii Loeb et al.\nThe test helps to reduce the need for MRI procedures and invasive prostate biopsies by up to 50%, thereby improving quality of life and lowering healthcare costs per patient.\nThe company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy.\nThis press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates.\nThe primary objective was to characterize changes in health outcomes, measured in quality-adjusted life years, and a secondary objective was evaluating healthcare costs.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The lead correctly identifies the research as a \u201cnew\u201d study but fails to acknowledge the publication of a very similar piece of research more than a year earlier that generated almost identical results in Europe.", "answer": 0}, {"article": "CHICAGO (Reuters) - A new analysis of evidence used by a U.S. advisory panel to roll back breast cancer screening guidelines suggests it may have ignored evidence that more frequent mammograms save more lives, U.S. researchers said on Tuesday.\nBut Helvie and colleague Edward Hendrick of the University of Colorado wrote that \u201cthe USPSTF chose to ignore the science available to them and overemphasized the potential harms of screening mammography, to the serious detriment of U.S. women who follow their flawed recommendations.\u201d\n\nDr. Carol Lee who chairs the American College of Radiology\u2019s Breast Imaging Commission said the new study highlights the risk of setting policy based on the conclusions of one group of scientists.\nWhen they were issued, the task force\u2019s guidelines contradicted years of messages about the need for routine breast cancer screening starting at age 40, kicking off a fury of protest among breast cancer experts and advocacy groups who argued the recommendation of fewer screenings would confuse women and result in more deaths from breast cancer.\nMany groups, including the American Cancer Society, have stuck by their long-standing recommendations of a yearly breast exam for women starting at age 40, stressing that the breast X-rays have been proven to save lives by spotting tumors early, when they are most easily treated.\nShe said breast mammograms have contributed significantly to reducing deaths from breast cancer, a fact that should not be ignored in favor of mathematical models.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article does note that it is reporting on a new analysis of evidence that was also used by the USPSTF when it determined its 2009 mammography screening recommendations.\nThe article does not adequately explain why this new analysis arrived at different conclusions than the USPSTF.\u00a0 By failing to do this, the article does not provide readers with sufficient information to judge the new analysis.", "answer": 0}, {"article": "Data were collected for eight years, ending in 2014.\nThe study reported at the INS 12th World Congress builds on observations that electrical motor cortex stimulation\u2019s effectiveness in relieving central post-stroke pain can be predicted by rTMS, suggesting the techniques share similar pain-relief mechanisms.\nHe added that the remaining question to answer is whether the level of the patients\u2019 severe uncontrollable pain would continue to decrease if rTMS continued for several years.\nNewswise \u2014 MONTREAL June 8, 2015 \u2013 Weekly sessions of non-invasive repetitive transcranial magnetic stimulation provided sufficient long-term pain relief in 61 percent of patients with central post-stroke pain, and delivered long-term relief for patients who continued for one year, according to a study presented at the International Neuromodulation Society 12th World Congress by Masahito Kobayashi, MD, PhD, of the Department of Neurosurgery, Saitama Medical University \u2013 Department of Neurology, Institute of Brain and Blood Vessels, Mihara Memorial Hospital in Saitama, Japan.\nIn addition to the potential of rTMS in pain relief, there has been growing research into noninvasive stimulation to augment progress in physical rehabilitation soon after stroke.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The role of rTMS in the management of chronic post stroke pain has been evolving for the past several years with a number of clinical trials suggesting efficacy. The news release notes that \u201cthere has still been controversy about the efficacy of rTMS in post-stroke pain,\u201d and that this study is intended to help clarify the role of rTMS in these patients and establish optimal dosing.", "answer": 1}, {"article": "Two new devices\u2014one that deflates fat cells, one that destroys them\u2014have just been cleared for \"body contouring\" in doctors' offices by the Food and Drug Administration.\n\nZeltiq grabs onto love handles and belly pouches and freezes the fat cells inside, causing them to self-destruct over several months. Zerona...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story shows that these types of\u00a0devices are being used now and more are in the pipeline.", "answer": 1}, {"article": "Moffitt is the No.\nIn order to determine if the HER2-dendritic cell vaccine is safe and effective, the researchers performed a clinical trial in 54 women who have HER2-expressing early-stage breast cancer.\n\"These results suggest that vaccines are more effective in DCIS, thereby warranting further evaluation in DCIS or other minimal disease settings, and the local regional sentinel lymph node may serve as a more meaningful immunologic endpoint,\" said Brian J. Czerniecki, MD, PhD, Chair of the Department of Breast Oncology at Moffitt Cancer Center.\nThe study was published in the December 13th online issue of Clinical Cancer Research and was supported by funds received from R01-CA096997, P30-CA016520, Pennies-in-Action\u00ae, and the Henle Foundation.\nThis suggests that strategies that can restimulate the immune system to recognize and target HER2 early during cancer development may be effective treatment options.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release acknowledges that this treatment is not a unique approach when it states: \u201cMany therapeutic strategies aim to re-stimulate the immune system to recognize cancer cells and target them for destruction.\u201d\nAccording to the study paper, its main goals were to compare the safety and efficacy of using various vaccination sites and explore relationships between immune and clinical responses.", "answer": 1}, {"article": "GeneSight's test is covered by Medicare for patients under the care of psychiatrists and who have failed to achieve satisfactory results with at least one antidepressant. The company has coverage with some commercial payers and is working to widen that coverage, said Myriad Genetics spokesman Ron Rogers. The Genomind Genecept Assay is partly covered by Medicare and Medicaid. If the out-of-pocket cost for people with commercial plans is more than $300, Genomind will contact the client before processing the test. The company also has a financial assistance program for uninsured patients.", "question": "Does the story establish the true novelty of the approach?", "explanation": "By featuring both the work of Myriad Genetics and Genomind, the reporter makes it clear that this is already a competitive arena within so-called \u201cprecision medicine.\u201d", "answer": 1}, {"article": "For more information about NIH and its programs, visit http://www.\nThe study, funded by the National Heart, Lung, and Blood Institute's (NHLBI) asthma network (AsthmaNet), appears in the August 18, 2016, issue of the New England Journal of Medicine.\nCLEVELAND, Ohio - A new study finds young children with mild, persistent asthma, can tolerate acetaminophen without the worsening of asthma, when compared with ibuprofen use.\nTo assess the impact of acetaminophen use on children's asthma, AsthmaNet investigators studied 300 children, aged 1 to 5 years old, who had mild, persistent asthma, defined as symptoms on more than 2 days out of a week but not daily.\n\"Previous observational studies had suggested that acetaminophen use was associated with asthma symptoms,\" says Kristie Ross, MD, MS, Clinical Director, Division of Pediatric Pulmonology, Allergy/Immunology and Sleep Medicine at University Hospitals Rainbow Babies & Children's Hospital (UH Rainbow) and co-author on the study.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This release\u00a0was not explicit in describing what this study brings to the existing body of knowledge. Instead, it hints the new study\u2019s findings go against previous observational studies in the long comment from the study\u2019s co-author, but the reader doesn\u2019t have a clear idea what makes this study so important and newsworthy, especially when this topic has been looked at before. It would have been helpful to mention\u00a0that this study really was the first trial that was blinded, randomized and controlled in comparing acetaminophen and ibuprofen in young children with mild asthma.\nDespite the ambiguity, we think the news release gave just enough information for a Satisfactory rating here.", "answer": 1}, {"article": "To find out more about mercury in seafood, go to the Got Mercury?\nThe report also acknowledges the risk of mercury exposure from certain kinds of seafoods, and notes that women who are pregnant, nursing or may become pregnant should avoid certain kinds \u2014 tilefish, shark, swordfish and king mackerel \u2014 because of their high mercury content.\n\u201cSo why would the proposed 2015 dietary guidelines recommend that pregnant women eat more of it?\u201d\n\nBut Dr. Steve Abrams, a panel member involved in the seafood recommendations and medical director of the Neonatal Nutrition Program at Baylor College of Medicine, said that while women need to be aware of the types of fish they are eating, the evidence is strong that fish consumption by mothers is good for the brains of their babies.\n\u201cIt may be that the issue is re-evaluated and there is no change.\u201d\n\nMercury levels in our oceans are on the rise due to an increase in industrial mercury emissions.\nAs a result, health officials recommend fish like sardines, salmon, tilapia and trout that are lower on the food chain and have accumulated less mercury in their tissue.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear that the debate over tuna consumption by pregnant and nursing women is longstanding, and points to the new report from the Dietary Guidelines Advisory Committee as the reason for renewed interest in the issue.", "answer": 1}, {"article": "WASHINGTON (Reuters) - It may be possible to predict which women will develop a dangerous complication of pregnancy called pre-eclampsia weeks before they ever show the first symptoms, an international team of researchers reported Monday.\nThe babies are usually born prematurely and suffer complications all their lives.\nThey ran the test at about 15 weeks gestation.\nThey found a series of 45 different compounds linked with metabolism that were different in the women destined to develop the condition, and said that could form the basis of a test.\nIf mothers and their babies survive, the women later have a higher risk of high blood pressure, heart disease, stroke and diabetes.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The article makes it clear that this is a novel diagnostic test.\n\u00a0\n", "answer": 1}, {"article": "A new study has an intriguing finding: Advanced cancer patients who received early palliative care in conjunction with standard care for their disease not only reported better quality of life, but lived a few months longer than patients who received only standard care.\n\nThe research, published in the New England Journal of Medicine, included 151 patients diagnosed with metastatic non-small-cell lung cancer who were randomly assigned to one of those treatment plans. At 12 weeks, 86% of those who were still alive filled out assessments \u2026", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story doesn\u2019t do a good enough job explaining what\u2019s newsworthy about the research.\u00a0Palliative care is widely viewed as synonymous with hospice care provided in the last days of life. But this study suggests that it can be initiated early after diagnosis to improve outcomes \u2014 something that hasn\u2019t been demonstrated previously in a rigorously conducted trial. This important distinction isn\u2019t explicitly discussed.", "answer": 0}, {"article": "(CNN) A new review of the \"little pink pill\" for women with low sexual desire says the drug doesn't work very well -- but some doctors and patients who've been using the treatment disagree.\nAnd while I was willing, part of me dreaded it.\n\"What (Addyi) does is give just enough support so I can think about that part of our relationship with anticipation of pleasure rather than anxiety,\" she wrote.\nSome doctors and patients who've been using Addyi say the drug has been helpful.\nShe says she's written Addyi prescriptions for about 10 women, and three or four have emailed her back to say it's worked.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is definitely a novelty and the article reflects that accurately.", "answer": 1}, {"article": "This is something the study\u2019s authors readily acknowledge.\nThere\u2019s good evidence this happened to many \u2014 but not all \u2014 opioid painkiller users: A 2014 study in JAMA Psychiatry found 75 percent of heroin users in treatment started with painkillers, and a 2015 analysis by the CDC found people who are addicted to painkillers are 40 times more likely to be addicted to heroin.\n\u201cOne day in June, in my inbox were 42 deaths.\u201d\n\nThe findings show the balancing act of opioid policy: Even if doctors need to pull back opioids, they must be careful to ensure patients suffering from debilitating pain and other problems can still meet their other care needs.\nAll of this shows why the policy solution to the opioid epidemic isn\u2019t as easy as simply pulling back prescription opioids: To avoid exacerbating existing problems or causing new ones, policymakers need to consider the other needs of people who were perhaps getting opioids they didn\u2019t really need.\nHe added, \u201cI want patients and their doctors to use caution in applying this.\u201d\n\nA few pain patients will still benefit from opioids\n\nOne of the study\u2019s implications is that opioids actually aren\u2019t a good treatment for chronic pain.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "While the approach of tapering itself itself isn\u2019t new, this article explains that the review is novel in that it increases confidence in the idea of tapering as an effective \u2014 though with many caveats, since the studies used in the review were mostly of \u201cpoor\u201d or \u201cfair\u201d quality.", "answer": 1}, {"article": "\"\nWhile there are more than 100,000 health-related apps on the market, the evidence to date is lacking as to whether many of those apps are safe or effective, according to Zubin Eapen, a cardiologist and assistant professor of medicine at Duke University School of Medicine.\nNot only does this research provide evidence that a text-based program can improve heart disease risk factors, but it also shows that a bunch of bells and whistles aren't required for successful health outcomes.\n\"I like to look for things that are able to be used in multiple corners of our world, from low-income settings to high-income settings,\" Chow says.\nYet those daily decisions \u2013 whether to smoke that cigarette, eat that piece of cake or skip the gym \u2013 are often \"far removed from the rewards or consequences,\" Eapen says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "From the start, the story frames this research in the context of the much larger \u201cmobile health\u201d field. For example, the story notes that \u201cWhile there are more than 100,000 health-related apps on the market, the evidence to date is lacking as to whether many of those apps are safe or effective.\u201d", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061210/18vitamin.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "As is clear from the story, the possible benefits of Vitamin D have been discussed and researched within the scientific community for a long time. ", "answer": 1}, {"article": "While Drs.\nIn situations where the heart's arteries narrow less suddenly and do not cause a heart attack but induce chest pain during exercise - a condition known as stable coronary artery disease - it has remained unclear whether PCI in addition to medication was better than medication alone in preventing future heart attacks.\nPublished today in the New England Journal of Medicine and simultaneously presented at EuroPCR 2018 in Paris, France, the five-year analysis of the FAME 2 trial shows that initial PCI along with medication was associated with a significant reduction in urgent hospital admissions and revascularizations to restore blood flow in the blood vessels of the heart and a likely reduction in heart attacks as compared to medication as the only treatment.\nWhile the FAME 2 trial showed that PCI reduced urgent hospital admissions and revascularizations and likely reduced heart attacks, it did not provide evidence for a difference between PCI and medication alone in the prevention of deaths.\n\"Our trial over its entire follow-up shows us that the longer you observe these patients, the more pronounced the benefits of the initial PCI become,\" said Dr. J\u00fcni, who is also a Canada Research Chair and a Professor of Medicine at the University of Toronto.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Novelty is appropriately established with this statement:\nPCI is commonly used to treat sudden blockages of a coronary artery that cause a heart attack. In situations where the heart\u2019s arteries narrow less suddenly and do not cause a heart attack but induce chest pain during exercise \u2013 a condition known as stable coronary artery disease \u2013 it has remained unclear whether PCI in addition to medication was better than medication alone in preventing future heart attacks.\nIf there\u2019s a problem, it\u2019s that the release makes it seem as though today\u2019s\u00a0standard practice is not evidence based\u00a0or simply evolved based on trial and error. In fact,\u00a0current practice is based on the results of large randomized controlled trials \u2014 and is still evolving.", "answer": 1}, {"article": "But some pain experts defend the value of the diagnostic tests.\nPatients don't care much about the finer points of diagnostic accuracy.\nOf about 150 patients, the group that got radiofrequency treatment immediately had more people who felt better.\nCoping with an aching back isn't easy.\nThe results appear in the August issue of Anesthesiology.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Not applicable.\u00a0 No claims of novelty made. And none needed to be. ", "answer": 2}, {"article": "Although tenecteplase appears to be more effective for stroke patients, it's not approved for that use in the United States, according to Dr. Rohan Arora, director of stroke at Long Island Jewish Hospital in Forest Hills, N.Y.\nThe investigators found that 22 percent of the patients treated with tenecteplase had more than 50 percent of blood flow return to the brain, compared with 10 percent of those treated with alteplase.\n\"Tenecteplase is likely to become the preferred medication for clot-dissolving in stroke patients,\" said lead researcher Dr. Bruce Campbell, head of the stroke department at the Royal Melbourne Hospital in Parkville.\nAmong more than 200 stroke victims, TNKase (tenecteplase) was about twice as effective as alteplase in restoring blood flow to the brain, and it also resulted in less disability, the scientists found.\nFor the new study, which did not receive drug company funding, Campbell and his colleagues randomly assigned 202 stroke patients to either alteplase or tenecteplase before surgery to remove clots.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story didn\u2019t establish what was novel about this study. This was the first study to examine the performance of these drugs in patients who went on to have blood clot removal surgery. A\u00a0previous trial\u00a0comparing these two drugs differed slightly than this one because the patients didn\u2019t have surgery in that trial. The study found that tenecteplase was shown to be not superior to alteplase and similar in safety in treating patients with mild stroke.", "answer": 0}, {"article": "They also limit saturated fats, which are found in meat and diary products.\n\"The reason we talk about it so much is in the 1960s and 70s, researchers discovered people living there had lower blood pressure problems, cholesterol problems so they started to analyze the diet,\" Dr. Senay told The Early Show co-anchor Julie Chen.\nThe Mediterranean diet can vary from country to country but the foods consumed from Greece to Spain tend to be high in fruits, vegetables, fish, legumes, nuts, bread, pasta, cereals, potatoes and unsaturated fats like olive oil.\n\"Those who moderately adhered to the diet had a 53 percent reduction in risk of developing Alzheimer's disease,\" The Early Show medical contributor Dr. Emily Senay.\n\"The next step would obviously be to do an intervention trial where one group eats the diet, the other eats a traditional American diet and then look at the outcome.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story presents this study of Mediterranean diets as having a protective effect on cognitive decline associated with age. The story mentions that researchers have known since the 1960s that this diet may have a positive influence on health. Recent research not mentioned in this news story suggests that inflammation and vascular changes caused by uncontrolled blood sugar and high blood pressure may increase the risk of Alzheimer\u2019s Disease. Adherence to this diet (with the addition of exercise) may help prevent this inflammatory process. ", "answer": 1}, {"article": "gov.\nNonetheless, conclusive evidence about a treatment's effectiveness is rarely found in a single study.\nThey were given MRI brain scans and a battery of tests to measure memory and thinking abilities; they also had blood drawn to check the level of omega-3 fatty acids in their red blood cells.\nTesting and measurements were done once, providing no data for comparison over time or to determine any link to dementia.\nThe research described in Quick Study comes from credible, peer-reviewed journals.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Previous research has suggested possible benefits of fish and other components of a healthy diet on cognitive function during aging. This story didn\u2019t mention any of that research.", "answer": 0}, {"article": "Visual analog pain scores at 6 weeks after the injections improved by a mean 3.8 points or 61.47 percent in patients who had the PRP injections compared to the autologous blood group, a mean 2.5 points or 41.6 percent improvement.\nThe findings were published in The American Journal of Sports Medicine.\nBoth groups experienced more improvement at 3 and 6 months after the injections, with no significant in pain scores between the treatments.\n\u201cWhole blood treatment is a god alternative in remote areas or in health systems that do not support financially the use of PRP,\u201d he told Reuters Health in an email.\nAnalogous blood injections, in which the patient\u2019s own blood is taken and then injected into a specific area of the body, is used to help harness the healing power of blood to treat the degeneration of tendons.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The true novelty is never established.", "answer": 0}, {"article": "For more information about NIH and its programs, visit http://www.\nThe findings suggest that fenofibrate therapy may be beneficial in the way the researchers hoped: by reducing cardiovascular events in patients with type 2 diabetes who take statins but still have especially high triglycerides levels and low HDL cholesterol levels.\nThe study, funded by the National Heart, Lung, and Blood Institute (NHLBI), appears in the December 28 issue of JAMA Cardiology.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\nIn addition to NHBLI, the study received funding from the NIH's National Institute of Diabetes and Digestive and Kidney Disease, the National Institute of Aging, and the National Eye Institute.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does not establish the novelty of the findings and really can\u2019t do so because there are so few details in the release.\u00a0 As noted above, this is a follow-up report that evaluated longer term outcomes. The reported results are the same as the initial. While longer follow-up is important, the prior information about this drug and this study could have easily been added.", "answer": 0}, {"article": "And we were thrilled to see such a huge impact.\nAlthough the study could not determine why the patients lived longer, the authors and other experts had several theories: depression is known to shorten life, and patients whose pain is treated often sleep better, eat better and talk more with relatives.\nBut the National Institutes of Health is under budget pressure, and the other major source of money for medical research, the pharmaceutical industry, has little incentive to study palliative care.\nBut it also includes how much suffering a patient wishes to bear, effects on the family, and legal, insurance and religious issues.\n\u201cBut I couldn\u2019t have completed the program without the psychosocial support.\u201d\n\nPalliative care experts now want to study patients with other cancers, heart disease, stroke, dementia and emphysema.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "By all accounts, this is the first randomized controlled study to show that providing palliative care\u00a0early after a\u00a0diagnosis of advanced cancer improves survival and other outcomes. The story accurately characterizes the significance of this. ", "answer": 1}, {"article": "Although the company selling Xiaflex will be Auxilium Pharmaceuticals of Malvern, Pa., the F.D.A.\nIt now has only five employees and a business of collecting a roughly 11 to 12 percent royalty on sales of Xiaflex.\nWith its belated success, BioSpecifics has sold off its ointment business.\nFounded in 1957, it struggled for decades to find uses for the product, almost going out of business before licensing the drug to Auxilium in 2004.\nHope Ed is looking on.\u201d\n\nMeanwhile, Dr. Mandl, the biochemist who first isolated collagenase from the bacteria, is nearing 93.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story chronicles Xiaflex\u2019s 50-year journey from discovery to FDA approval. It\u00a0does not attempt to portray the drug as \"new.\"", "answer": 1}, {"article": "CHICAGO (Reuters) - Lightly shocking a person\u2019s brain just before they learned a new task appeared to strengthen memory in a handful of patients with epilepsy, a tantalizing result that could have implications for Alzheimer\u2019s disease, U.S. researchers said on Wednesday.\nIn Alzheimer\u2019s disease, this area of the brain is affected early on, when signs of dementia begin to appear.\nThe current study was done at the University of California at Los Angeles in seven epileptic patients awaiting surgery who had electrodes implanted deep in their brains to help pinpoint the source of their seizures.\nIt was really stimulation in the gateway to the hippocampus - the entorhinal cortex - where we got the beneficial effect in terms of memory,\u201d Fried said.\n\u201cThe question would be whether this can help memory in patients with memory impairments,\u201d he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "As mentioned above, the story points out that this sort of technique is used to treat other problems.", "answer": 1}, {"article": "What (abnormality) is going to contribute to the overall health versus something that just looks funny?\nIn the most complete test of its kind, the institute is using both an electrocardiogram and limited echocardiogram to see the rhythm and structure of the heart.\nIf an ongoing program of testing happens, the hospital would try to tap into third-party funding, donations and grants, Towbin says.\nThe weather was rotten, an earlier appointment ran long \u2014 and 15-year-old Jordan was the picture of health.\nIf proved effective, it could become the norm for identifying heart conditions that put one in 10,000 people at risk when doing top-level physical activities, researchers say.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear that this study uses existing technology in a way that is not currently standard. It also refers to a somewhat similar program in Italy. However, the story fails to tell readers about the many other studies of testing young athletes (including this one reported by Gannett just a year ago, \u201cStudy: Tests for heart defects in young athletes inaccurate\u201c), nor does it inform readers that there is no consensus and strong debate among experts about the value of such testing.", "answer": 1}, {"article": "Frustrated by the high relapse rate of traditional addiction treatments, scientists are working on a strategy that recruits the body's own defenses to help addicts kick drug habits.\n\nThe new approach uses injected vaccines to block some addictive substances from reaching the brain. If a vaccinated addict on the path to recovery slips and indulges in a drug, such as tobacco or cocaine, no pleasure will result.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Although the story could have\u00a0provided more background on the history of\u00a0anti-addiction vaccines (a\u00a0heroin vaccine was explored in the 1970s), the treatments being explored now are different from\u00a0anything currently available. So we don\u2019t think this story overstates the\u00a0novelty\u00a0of the research.", "answer": 1}, {"article": "Israel is director of the respiratory therapy department at Brigham and Women's Hospital in Boston.\n\"There was a small but significant improvement in the airway narrowing in these patients, which we didn't expect because we didn't think the mast cells were necessarily promoting that airway narrowing all the time,\" Israel said.\n\"It has been a while since a new approach and treatment for severe asthma has emerged,\" Horovitz said.\nGleevec (imatinib) reduced the \"twitchiness\" of airways, making them less likely to reflexively constrict when exposed to an allergen or asthma trigger, said senior researcher Dr. Elliot Israel.\n\"All in all, we were expecting a significantly greater pattern of side-effects, and we didn't see it,\" Israel explained.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story gets at the potential significance, saying it may apply to patients \u201cwhose severe asthma isn\u2019t controlled despite use of high-dose steroid medications are at risk of declining lung function and poor quality of life.\u201d It also quotes one expert saying, \u201cIt has been a while since a new approach and treatment for severe asthma has emerged.\u201d", "answer": 1}, {"article": "On Saturday, the results of two large clinical trials of a new drug offered hope to the estimated 1.6 million adult Americans with an uncontrolled, moderate-to-severe form of the disease, atopic dermatitis, which is a type of eczema.\nThe constant itch, to say nothing of the disfigurement, can be so unbearable that many patients consider suicide.\nFor some, relief was almost instantaneous.\nWithin a couple of weeks, the ugly red rash that had covered 90 percent of her body was almost gone.\nThere has never been a safe and effective treatment.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It is clear that this drug would be the first biologic treatment for moderate to severe eczema.", "answer": 1}, {"article": "Autism is characterized by difficulties in social interaction, communication, and understanding other people\u2019s emotions and behavior.\n\u201cThese results are the best yet in the search for a biological basis in terms of being able to distinguish those with and without the disease,\u201d said Nicholas Lange of Harvard Medical School, who directs the Neurostatistics Laboratory at McLean Hospital in Belmont, Massachusetts.\nBy measuring six aspects of the brain\u2019s circuitry, the test was able to correctly pick out people who had been diagnosed with autism with 94 percent accuracy.\nThe test, which uses conventional magnetic resonance imaging or MRI machines, detected 94 percent of individuals with a high-functioning form of autism, they reported on Thursday.\nAnd it may also offer an early diagnosis, which could help affected children get earlier intervention, when it is most likely to do some good.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of the test is unclear from this story. Diffusion tensor imaging is not new and it has been used in previously published reports, a fact not provided to the reader. The way in which it was used was new and novel. We usually take people to task for suggesting a drug or medical device or procedure is novel when it is perhaps not. The story should have indicated that although the scanners used were conventional and others have employed the technique described, the programming is novel and not routinely available.", "answer": 0}, {"article": "\u201cThe decreased risk of breast cancer in this group is something we totally didn\u2019t expect when we started the W.H.I.\nBut most of those fears are related to the use of a combination of two hormones, estrogen and progestin, which are prescribed to relieve hot flashes and other symptoms of menopause, and have been shown to increase a woman\u2019s risk of breast cancer.\nNobody knows why estrogen treatment alone appeared to lower breast cancer risk in the study, but one explanation may be that in menopausal women with low levels of natural estrogen, the effects of estrogen drugs induce cell death in existing tumors.\nThe trial has, however, been held up for years as the gold standard for medical research, and its findings linking combination hormones to breast cancer and heart problems led to significant changes in the way doctors around the world treated menopause.\nIt is not known whether the benefits of estrogen shown in the Women\u2019s Health Initiative would be replicated using a different type of estrogen.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t make any inappropriate claims about estrogen, and it does appropriately try to frame the novelty of the research \u2013 \u201ca finding that challenges the conventional wisdom about the risks of some hormones used in menopause.\u201d", "answer": 1}, {"article": "While the procedure may look straightforward, it's extremely delicate, said Linda Cormier, a sales representative for Cambridge Endo, whose headquarters is in Framingham, Mass.\nThe hook, grasper and scissors are on the ends of shafts less than one-fifth of an inch wide.\nHe also knew that the cancer happened to be a spot where the small instruments couldn't reach it, the operation might have to be much more extensive.\nThe recovery has been pain-free, and the cancer hasn't returned, he said.\nWhile kidney cancer can have symptoms such as back pain and bloody urine, it's difficult to detect early, said Lee, who said about half of these tumors are found when people undergo X-rays for other reasons.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is very unclear about the novelty of cryosurgery, perhaps suggesting to some that it is newer than it actually is. ", "answer": 0}, {"article": "THURSDAY, Oct. 12, 2017 (HealthDay News) -- Breast cancer is the second leading cause of cancer death among women in the United States, and routine screenings remain the most reliable way to detect the disease early, a breast cancer expert says.\n\"All women should know how their breasts look and feel so they can recognize any changes in them.\n\u2022 Mammogram: An X-ray of the breast used to examine breast changes.\n\"I advise women to speak with their physician to determine what is right for them,\" Evers said.\n\"With today's state-of-the-art treatment options and less extensive surgery, patients are experiencing better outcomes.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s not clear what\u2019s \u201cnovel\u201d or new about this information. If this piece ran because of Breast Cancer Awareness Month, that should have been more clear.", "answer": 0}, {"article": "The Ache: Common cholesterol-lowering drugs called statins can have unpleasant side effects, including muscle aches and weakness.\n\nThe Claim: An extract from a bitter, fragrant citrus fruit called bergamot, commonly known as a flavoring in Earl Grey tea, can lower cholesterol with minimal side effects, some scientists say. It also boosts good cholesterol, reduces fatty deposits in the liver and lowers blood sugar, they add.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story shares that several prior reports from the same research group have shown cholesterol reductions with the product.", "answer": 1}, {"article": "LONDON (Reuters) - British liquid biopsy company Angle said its Parsortix blood test had beaten current methods in identifying ovarian cancer, a breakthough that could help women receive the best possible outcome from surgery.\nThe performance of the test would now be validated in another study designed to meet European CE Mark and US FDA regulatory requirements, he said.\nThe test was nearly twice as successful in eliminating false-positives than current tests, he said.\nThe test will enable women with ovarian cancer to be referred to gynaecological surgeons who specialize in the care of women with ovarian cancer, while patients with a benign tumor will not have to travel to specialist centers.\n\u201cThe vision is that a woman who has been diagnosed with having an abnormal pelvic mass will have a simple blood test and from that we will deduce whether or not she has cancer and if she does which drug would be most suitable for her,\u201d he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There are multiple efforts to utilize the detection of circulating tumor cells (CTC\u2019s) as a method of early redirection of cancer. \u00a0The technology has been under study for a number of years. \u00a0So, while perhaps an improvement over existing methods, the test method is not novel. We have repeatedly taken issue with the use of \u201cbreakthrough\u201d in stories and this one is no exception. \u00a0If the results of this relatively small study are repeatable, the Angle test would be an improvement over existing methods.", "answer": 0}, {"article": "The new study ''adds to the trickle of evidence that cannabis may help some of the patients who are struggling [with pain] at present,\" Henry McQuay, DM, an emeritus fellow at Balliol College, Oxford University, England, writes in a commentary accompanying the study.\nThe research is published in CMAJ, the Canadian Medical Association Journal.\n\"About 10% to 15% of patients attending a chronic pain clinic use cannabis as part of their pain [control] strategy,\" he tells WebMD.\n''It's been known anecdotally,\" says researcher Mark Ware, MD, assistant professor of anesthesia and family medicine at McGill University in Montreal.\nBut Ware's study is more scientific -- a clinical trial in which his team compared placebo with three different doses of cannabis.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 1}, {"article": "Collaborators for the paper published in Bioorganic & Medicinal Chemistry include Hsiuchin Yang, Hao Zhang, Krishna Damera, Ying-Hsin Hsieh, Arpana Sagwal Chaudhary, Jianmei Cui and Jinshan Jin of Georgia State.\n\"We've found that SecA inhibitors are broad-spectrum antimicrobials and are very effective against strains of bacteria that are resistant to existing antibiotics,\" said Binghe Wang, Regents' Professor of Chemistry at Georgia State, Georgia Research Alliance Eminent Scholar in Drug Discovery and Georgia Cancer Coalition Distinguished Cancer Scholar.\nThis study also confirmed that SecA inhibitors have the potential for being broad-spectrum antimicrobials, can directly block virulence factor production and can null the effect of efflux pumps.\nTheir study showed that small molecule analogs that target the functions of SecA, a central part of the general bacterial secretion system required for viability and virulence, have potent antimicrobial activities, reduce the secretion of toxins and can overcome the effect of efflux pumps, which are responsible for multi-drug resistance.\nIn previous work, the researchers developed novel small molecule SecA inhibitors active against the bacteria strains Escherichia coli and Bacillus subtilis by dissecting a SecA inhibitor called Rose Bengal (RB).\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release does an admirable job framing the context of the study. We are made to understand that the researchers of the study have previously published results on a similar antimicrobial strategy inhibiting SecA for different types of bacteria. The current study examines the efficacy\u00a0of this strategy for MRSA. The news release concludes with a reference to the most recent study by this same team of researchers, confirming SecA inhibitors are broad-spectrum antimicrobials.", "answer": 1}, {"article": "\u201cWhat effects that might have had on the results is unclear.\u201d\n\nCorey-Bloom said that should not have influenced the spasticity findings, since an independent researcher (who didn\u2019t know whether patients were smoking marijuana or the placebo) rated spasticity using a standard scale.\nAnd studies have suggested the cannabinoid receptors on our cells help regulate muscle spasticity.\nThe cost, her team found, is that smoking caused fatigue and dizziness in some users, and generally slowed down people\u2019s mental skills soon after they used marijuana.\n\u201cI think this study shows that yes, (marijuana) may help with spasticity, but at a cost,\u201d said Corey-Bloom, of the University of California, San Diego.\nBut another limitation, she pointed out, is that the study looked at the effects, and side effects, of marijuana over only a few days.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The study briefly referenced past research suggesting that cannabinoid receptors on cells help regulate muscle spasticity.", "answer": 1}, {"article": "Researchers collected data on occurrence and severity of respiratory symptoms, breastfeeding status and genotyping was performed.\nIt is already known that environmental factors have a modifying effect on specific genetic risk, so the aim of this new study was to find out whether this could also be true for breastfeeding and this specific gene related to asthma with the respect to respiratory symptoms in early infancy.\n\"Our study is the first to show that breastfeeding can modify the effect of asthma-related genetic profiles on respiratory symptoms in the first year of life\", commented Dr Olga Gorlanova, from the University Children's Hospital Basel (UKBB), and the University of Basel, Basel, Switzerland.\nThis is the first time that we were able to show the effect of the 17q21 variants on respiratory symptoms during the 1st year of life, depending on breastfeeding status.\nThe study is presented today (4 September, 2016) at the European Respiratory Society's International Congress.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release claims that \u201cOur study is the first to show that breastfeeding can modify the effect of asthma-related genetic profiles on respiratory symptoms in the first year of life.\u201d Research into the role of genetics in the development of asthma has been ongoing for years, so there is really nothing novel about this research in that regard. If this research could actually show a protective connection between breastfeeding and infants\u2019 reduced risk of asthma, then that surely would qualify as novel enough to warrant a news release.\u00a0 Unfortunately, this research cannot show that definitively.", "answer": 0}, {"article": "That\u2019s called secondary prevention.\nAlthough the totality of evidence is incomplete, it appears that aspirin has net benefits when the absolute 10-year risk of having a cardiovascular event is greater than 10 percent.\nHere\u2019s the problem: The lower an individual\u2019s risk of a future heart attack or ischemic stroke, the less he or she will benefit from taking daily low-dose aspirin.\nIt is important to note that this draft recommendation applies to people who are not at increased risk for bleeding, have at least a 10-year life expectancy, and are willing to take low-dose aspirin daily.\nIt is important to keep in mind that other therapies, such as statins, have also been proven to decrease the risk of cardiovascular events.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There are no spurious claims made here about the \u201cnovelty\u201d of aspirin\u2019s effects, or the recommendations in the report, yet maybe a bit of confusion when one of the physicians said that aspirin\u2019s effects on colorectal cancer were \u201cprovocative.\u201d \u00a0What is a reader to make of that relatively unhelpful statement? This could have been clearer.", "answer": 1}, {"article": "By using image processing and machine learning to teach computers how to spot signs of precancerous and cancerous cells, Asiedu hopes to remove the need for a trained physician at any point in the screening process and shift the task to midwives, community health workers and even the women themselves.\nThe colposcope is a magnified telescopic device and camera designed to allow medical professionals to look through the speculum to see the cervix, which is located three to six inches inside the vagina.\n\"Nearly everyone said they preferred it to a traditional speculum and more than 80 percent of the women who tried the device were able to get a good image.\n\"There have been a few other attempts to come up with a better solution, but none of them have succeeded,\" said Asiedu.\nThe \"pocket colposcope\" is a slender wand that can connect to many devices, including laptops or cell phones.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The article states that the device is the first of its kind. We agree that the inserter is a novel device as an alternative to the speculum. Its use together with the digital colposcope is also a novel concept.", "answer": 1}, {"article": "Doctors used MRI and mapping biopsies to locate the cancerous tissues.\nWhile the initial results were promising, they need to be replicated; HIFU also needs to be studied long-term and compared with other therapies.\nAhmed told Bloomberg that HIFU may also be cheaper than other standard treatments, noting that the cost of the MRI and mapping was an estimated $2,400, plus about $1,600 for HIFU; in comparison, removing the prostate costs about $7,100.\nUnlike more common and invasive treatments such as radiotherapy and surgical removal of the prostate gland, HIFU may be able to avoid side effects like urine leakage and impotence.\nIf the technology holds up, it could also work for other cell-based cancers like breast, thyroid, pancreas and liver, Ahmed said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story made no reference to any past research on HIFU for prostate cancer.\u00a0\u00a0 This isn\u2019t the first research in this area \u2013 yet the story may suggest that to readers.", "answer": 0}, {"article": "He contended that kratom does not act on the brain's opioid receptors the way prescription painkillers and heroin do. But back in 2016, the Journal of the American Chemical Society reported that kratom indeed works this way. Last month, an FDA study found that 22 of the 25 of the most prevalent compounds in kratom do bind to opioid receptors, and so should be considered an opioid. The study also said most deaths did occur in people who used kratom in addition to other drugs, though in one case, only kratom was detected.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes why this issue is newsworthy.", "answer": 1}, {"article": "For more information, recipes and facts about pasta, please visit http://www.\nThe research, \"Pasta Consumption in American Children and Adolescents is Associated with Greater Daily Intake of Shortfall Nutrients as Defined by the 2015 Dietary Guidelines, Improved Diet Quality and Lower Added Sugar Intake,\" was conducted by Nutritional Strategies, Inc. on behalf of the National Pasta Association.\nThe study examined associations between pasta consumption, shortfall nutrient intakes as defined by the 2015 Dietary Guidelines (2015 DG) and diet quality in comparison to non-pasta consumption in U.S. children and adolescents (ages 2-18).\nThey are:\n\n-Better overall diet quality (as measured by USDA's Healthy Eating Index-2010 scale) -Greater intake of key shortfall nutrients like dietary fiber, folate, iron, magnesium and vitamin E -No significant associations were seen with body weight, waist circumference and body mass index\n\nPasta has long been celebrated as one of America's favorite foods and is advocated by nutritionists for its good nutrition.\nThe association provides leadership to the industry on public policy issues, serving as its voice in Washington, D.C. NPA also forges alliances with key organizations, monitors and addresses technical issues and conducts nutrition and food safety research on behalf of the U.S. pasta industry.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that \u201cnew research shows that pasta consumption in children and adolescents is associated with a better diet quality than that of children who do not eat pasta.\u201d\u00a0 Due to the limitations of the research and the lack of outcomes data we don\u2019t believe the release demonstrates any new or novel conclusions that could impact children\u2019s health. In fact, readers should probably question whether the study was commissioned to increase knowledge in this area or to help increase pasta sales.", "answer": 0}, {"article": "So why do routine lab tests that doctors order often come back negative or not informative in ME/CFS patients?\nThe multidisciplinary Stanford team is now working on developing a panel that could be used commercially, that would test for around five of the 17 cytokines and would likely involve the doctor first classifying patients by severity in order to interpret the results.\nThe link to gradation in severity, rather than simply seeking a positive versus negative result, represents a new approach to the search for biological markers for the illness.\nIndeed, a major drug trial is now being conducted in Norway investigating whether the immune-modifying drug rituximab alleviates ME/CFS symptoms, after preliminary studies suggested that it did in some patients.\nInterestingly, the drug is approved to treat certain autoimmune diseases and also non-Hodgkin lymphoma, a cancer that one study found uniquely occurs at a higher rate among older people with ME/CFS.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes novelty in this way: \u201cThe link to gradation in severity, rather than simply seeking a positive versus negative result, represents a new approach to the search for biological markers for the illness.\u201d And: \u201cWhat the latest research shows, Komaroff tells Shots, is that \u201clevels of many cytokines do correlate with symptoms: The higher the blood level, the worse the symptoms. That supports the theory that the cytokines are a cause of the symptoms.\u201d\nBut, the story doesn\u2019t note previous publications by the same researchers and others that also point to some of the same cytokines as potential targets for tests and treatments. A flurry of stories two years ago (examples here, here and here) appear to include broad statements that are remarkably similar to those reported in this latest story. Readers of this story do not get a clear picture of how the results of this study compare to those of earlier studies.", "answer": 1}, {"article": "Without strong evidence for its efficacy, the American Congress of Obstetricians and Gynecologists does not include the treatment in its Practice Bulletin for Urinary Incontinence in Women. L. Elaine Waetjen, professor of obstetrics and gynecology at the University of California, Davis Medical Center, who has spent more than 15 years treating women for this problem, said that there is \"no scientific evidence that the O-Shot works for incontinence and there is also no clear biological mechanism for why it should treat this condition.\"", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes why this treatment is novel\u2013in that it\u2019s something of a \u201ctrendy\u201d concept being used without any evidence for it, and patients have to pay out-of-pocket if they want to try it.", "answer": 1}, {"article": "After a two-week break, they moved, round-robin style, to another arm of the trial.\nThough the study was small, the results were striking: Subjects lost an average of 17.5 pounds in 22 weeks and reduced their overall body weight by 10.5%.\nBut for the full-bodied person who is not so rich, unroasted coffee beans \u2014 green as the day they were picked \u2014 may hold the key to cheap and effective weight loss, new research suggests.\nThe study used a \"cross-over\" design, which allowed each subject to serve as his or her own comparison group.\nBut he said nutrition experts would want assurances that green coffee beans do not cause \"malabsorption\" within the human gut \u2014 a condition that would lead to weight loss as well as malnutrition, heart arrhythmias and other problems because vitamins and minerals are not passing through the intestine.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story seems to imply that this is a first of its kind study \u2013 \u201cthe findings should pave the way for more rigorous research.\u201d\nBut HealthDay, in its story, explained that \u201cprior research had been conducted in both France and Japan.\u201d", "answer": 0}, {"article": "NEW YORK (Reuters Health) - The inexpensive tests that look for hidden blood in a person\u2019s stool are effective for colon cancer screening, a study out Tuesday confirms.\nThe downside of iFOBT being specific to colon tumors is that it is not useful for catching cancers of the stomach or throat.\nA newer version called immunochemical FOBT (iFOBT) is supposed to zero in on colon growths better than an older version known as guaiac FOBT \u2014 which often picked up bleeding originating in the upper digestive tract, such as from a stomach ulcer.\n\u201cIt means that almost every case with colon cancer can be identified by iFOBT,\u201d Lee told Reuters Health in an email.\nOf three study participants who were found to have cancers of the stomach or esophagus, for instance, none had a positive result on the iFOBT test.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The growing popularity of the FOBT test\u2026and that this study addresses the fact that \u201cthere\u2019s been surprisingly little evidence that it really is highly specific to colon cancer were established in the story.", "answer": 1}, {"article": "The current study compared the use of traditional medical options -- tranexamic acid pills, mefenamic acid (Ponstel), combined estrogen-progestogen and progesterone alone -- to the use of the levonorgestrel intrauterine system.\nBritish researchers found that the treated IUD was more effective at reducing the effects of heavy menstrual bleeding (also called menorrhagia) on quality of life compared to other treatments.\nFor women who may be hesitant to use an IUD because of pelvic infections linked to an early version called the Dalkon Shield, Gupta said that as long as women are screened for sexually transmitted diseases before getting an intrauterine system, the risk of infection is low.\nFor women who do want to get pregnant, Gupta said, taking the blood-clotting drug tranexamic acid during periods is an alternate method of treating heavy periods.\n\"This study really adds to the evidence that shows how useful this intrauterine system is for heavy menstrual bleeding,\" said Dr. Eve Espey, professor of obstetrics and gynecology at the University of New Mexico School of Medicine in Albuquerque.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did not do a good job of making clear that what was novel about this study was that it was a large randomized trial and that it followed women for 2 years, whereas earlier studies only went up to 12 months.", "answer": 0}, {"article": "The results of the Women's Health Initiative (WHI)--the largest, most scientifically rigorous study of older women's medical issues ever conducted--continue to startle researchers, confuse the public and frustrate headline writers. Case in point: last week's report that taking estrogen for seven years does not increase the risk of breast cancer for many women. There is a lot of good news in that finding, as well as some important caveats.\n\nIn many ways, the story began four years ago when researchers halted a different part of the WHI--one that looked at the long-term health effects of taking the hormone combination estrogen and progestin...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article provides context that makes it clear that this is not a new therapy.", "answer": 1}, {"article": "\"There is a fear among clinicians that if you ask questions about suicide, you are giving the patient an idea that this could be an option,\" says Espiritu, \"and if you ask about guns or pills, that you are giving them some hints on how they can carry out a plan.\"\nThe story of the health system's success is a story of persistence, confidence, hope and a strict adherence to a very specific approach.\nWith a relentless focus on finding and treating people with depression, the Henry Ford Health System has cut the suicide rate among the people in its insurance plan dramatically.\nThe mental health division failed to win the grant, but the health system went ahead with the proposed changes anyway.\nThe depressive part of her illness \"is like the pain of having a cancer,\" she says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is very clear that Henry Ford Health System took a novel approach to addressing mental health in its patients with the particular goal of eliminating suicide.", "answer": 1}, {"article": "With the FDA's announcement, drugs like pembrolizumab have also begun to change the way that physicians, patients and government regulators think of cancer. No longer will they see all cancers of the lung, breast, colon, brain, liver, pancreas and prostate as distinct from one another. Instead, they will look for the common genetic mutations that give rise to cancers no matter where they're found. And they'll treat those cancers with a drug that uses that common signature as a homing beacon, either for the immune system or for targeted cancer drugs to attack.", "question": "Does the story establish the true novelty of the approach?", "explanation": "A key element of the story, that this is the first FDA approval based on a biomarker, rather than the organ in the body where the tumor originated, is accurate and newsworthy.", "answer": 1}, {"article": "A video of him walking with and without aid of the system can be found here: https:/ .\n\"I went in there and I could barely take two steps,\" said Bush, 42, who researchers believe is the world's first MS patient to \"test-drive\" an implanted FES system.\n\"In both cases, there is a disconnect between the brain and muscles,\" said Stephen Selkirk, MD, a neurologist at the VA's Spinal Cord Injury Division and assistant professor of neurology at Case Western Reserve School of Medicine.\nTwo studies, published in the American Journal of Physical Medicine and Rehabilitation, show that functional electrical stimulation (FES) significantly helped McGlynn and Bush to effectively walk at the medical center.\nIn each patient, \"the pulses are sent in a pattern that is close to how normal muscles work,\" said Rudi Kobetic, a principal investigator at the Stokes Cleveland VA and APT Center.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "While functional electronic stimulation has been used for many decades to aid patients with spinal cord injuries, stroke, multiple sclerosis and cerebral palsy, among other conditions, this release suggests in the fourth paragraph that this is the first time an implantable FES device has been used in a patient with multiple sclerosis.\nWe think the release should have been more transparent about the fact that research into this implantable technology has been going on for many years. For example, a 2005 study reported in the journal Spinal Cord describes how researchers implanted FES systems in nine pediatric patients with spinal cord injuries.\nThe release does offer some context, stating that researchers \u201chope these studies will lay the foundation for implanted systems that restore some independence to people with MS or who have suffered a stroke.\u201d Further, it quotes a researcher saying that this technology has been used primarily for therapy in stroke patients and this application constitutes \u201ca more long-term assistive system\u201d for those patients.", "answer": 0}, {"article": "This post has been updated.\nBut the patch costs less and has fewer side-effects than varenicline (including nausea, difficulty sleeping and abnormal dreams), so the researchers concluded that slow metabolizers should be put on the patch.\nThe ratio of two metabolites, or byproducts, of the body's processing of nicotine allows easy identification of the two groups.\nThe researchers, led by Caryn Lerman, a professort of psychiatry, divided 1,246 subjects into slow metabolizers of nicotine and normal metabolizers of the addictive chemical, based on the length of time it took for them to rid their bodies of the drug.\nThe results of the comparison showed that slow metabolizers did just as well on a nicotine patch or the drug varenicline (marketed as Chantix), a drug that works on the nicotine receptors in the brain.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story includes a comment from the researcher that this was an obvious question to study, but \u201cno one had done it.\u201d Again, we would have liked for someone other than the author to agree and add credibility. However, the story\u2019s description of the study\u2019s novelty appears accurate.", "answer": 1}, {"article": "People who develop stomach bleeding from aspirin are likely to get their bowels checked out by a doctor.\nIt includes a decade\u2019s worth of data from more than 100,000 men and women in the U.S., most over 60 and all of them non-smokers.\n\u201cThings are moving forward, but it is still a work in progress.\u201d\n\nMedical guidelines in the U.S. already urge people to take low doses of aspirin to prevent heart disease if the predicted benefits outweigh the risk of side effects, or if they have already suffered a heart attack.\nEarlier this year, an analysis of previous clinical trials showed that people on aspirin were less likely to die of cancer than those not on the medication, with a 37-percent drop in cancer deaths observed from five years onwards.\nNEW YORK (Reuters Health) - A new study bolsters the case that daily aspirin may help protect against cancer, although the effect seems weaker than previously thought.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story noted other research in this field:\n\u201cMedical guidelines in the U.S. already urge people to take low doses of aspirin to prevent heart disease if the predicted benefits outweigh the risk of side effects, or if they have already suffered a heart attack.\nWhether those recommendations should be broadened to include cancer prevention is still up in the air, however.\nEarlier this year, an analysis of previous clinical trials showed that people on aspirin were less likely to die of cancer than those not on the medication, with a 37-percent drop in cancer deaths observed from five years onwards.\nThe new report, published Friday in the Journal of the National Cancer Institute, is based on real-life observations instead of experiments. It includes a decade\u2019s worth of data from more than 100,000 men and women in the U.S., most over 60 and all of them non-smokers.\u201d", "answer": 1}, {"article": "Colic occurs during the first three months of an infant's life in which an otherwise healthy child cries and cannot be comforted for three hours or more every day.\nHowever, recent research suggests colic may linked to an immature immune system struggling with bacterial imbalances in the gastrointestinal tract, and that high levels of E. coli bacteria in particular may contribute to colic symptoms.\nResearchers from the University of Turin, Italy, found that a few daily drops of Lactobacillus reuteri, a bacterium that can help improve digestion, significantly reduced crying among infants with colic.\nAug. 16, 2010 -- A probiotic supplement may be an option for parents trying to soothe a colicky baby, according to a new study.\nTo test this theory, the Italian researchers compared 25 healthy infants who were randomly assigned to receive drops of Lactobacillus reuteri to 21 healthy infants randomly assigned to receive placebo drops.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story failed to mention important background here. The study reported on was actually a follow-up to a previous\u00a0open label study (the researchers knew which children were getting what treatment) conducted by these same investigators and which also found a benefit for L reuteri\u00a0on colic. The fact that this second, blinded trial has confirmed the previous\u00a0findings should increase our confidence that something real is happeneing here.\u00a0Still, as previously noted, larger, independent\u00a0studies\u00a0will be needed to\u00a0conclusively establish a benefit for probiotics on colic. \u00a0\u00a0", "answer": 0}, {"article": "Anti-cytokine drugs \"dampen down inflammation by blocking the actions of specific inflammatory cytokines ... with 'surgical precision' and are now routinely used for treating patients who respond inadequately to standard treatments for inflammatory conditions such as rheumatoid arthritis, psoriasis and Crohn's disease both in the US and Europe,\" explained Dr. Golam Khandaker, a clinical lecturer in Cambridge's department of psychiatry and lead author of the new study.\nThe findings also suggest that \"anti-inflammatory drugs may be helpful in treating patients with depression who are chronically inflamed.\"\nThe immune system acts like a thermostat, turned down low most of the time but cranked up when we have an infection, according to Khandaker.\n\"We need more studies,\" he said, particularly research involving patients with depression who are inflamed but healthy to investigate the effect of these drugs on depression.\nTheir potential side effects also must be investigated, Khandaker said, adding that \"we and other research groups from both sides of the Atlantic are currently planning and conducting such randomized control trials.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does note\u00a0what is novel about anti-cytokines and their possible link to mental illness, although the story would have been stronger had it connected the dots more specifically about the possible mechanism by which inflammation might affect the chemistry of the depressed brain and mind.", "answer": 1}, {"article": "In a related editorial, Drs.\n\"It would be interesting to see if the drug offers the same benefit in women that have not been treated with multiple drugs before exposure to eribulin,\" she added.\nCommenting on the study, Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City, said, \"The findings of this trial are exciting because they will propel eribulin into wider use.\nWEDNESDAY, March 2, 2011 (HealthDay News) -- The new chemotherapy drug eribulin extends the lives of metastatic breast cancer patients who have received extensive treatment, according to a new study.\nAnd that evidence suggests that the methods to treat advanced breast cancer are growing, the treatment challenge in refractory disease is a little bit less daunting, and the treatment results are a little bit better than they were before.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article establishes the novelty of eribulin by quoting from the study authors, as well as from a related editorial in The Lancet and from an independent authority, Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City.\u00a0 Dr. Bernik said \u201cThis drug shows much promise, and it should certainly be included in additional trials to fully establish its benefit.\u201d", "answer": 1}, {"article": "This is really about patient care.\nBut with advances we have in technology and equipment, those challenges are rapidly decreasing.\u201d\n\nThis work was supported by a grant from Vita Solutions, a subsidiary of The Medicines Company, for whom Amin has provided consultation; and by the National Institutes of Health (NIH), grant numbers UL1TR000448, KL2TR000450, TL1TR000449 and 1KM1CA156708-01.\n\u201cThe femoral artery is the traditional route, but when we go in through a vessel in the wrist, we see less bleeding, fewer complications, less pain and discomfort, higher patient satisfaction, shorter hospital stays, and lower costs.\u201d\n\nPatients may undergo coronary angioplasty \u2014 also called percutaneous coronary intervention (PCI) \u2014 to alleviate chest pain or shortness of breath.\nDespite the fact that all of these patients were capable of leaving the hospital the same day as their procedures, only about 5 percent of these patients actually were discharged without having stayed overnight.\nThe research, published Feb. 20 in JACC: Cardiovascular Interventions, suggests that the lower costs of the wrist approach largely are due to the fact that patients experience fewer complications and can be discharged earlier, compared with procedures that access the heart through the larger, deeper artery in the groin.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The idea of going through the wrist is not novel. In fact, the main author published a very similar paper in 2013\u00a0 and others have done similar work.\nThere is a large body of evidence on this issue and the news release could have acknowledged that.", "answer": 0}, {"article": "But there are still a lot of unanswered questions about immune therapy.\n\"It is early days for the successes of immune therapy,\" said Mark Fishman, president of the Novartis Institutes for BioMedical Research, a research arm of drug company Novartis, which is taking a different approach to turning the immune system against cancer.\n\"We are feeling more and more confident that we are on the cusp of a treatment revolution,\" said Roger Perlmutter, president of Merck Research Laboratories, which has its own, similar drug called Keytruda.\n\"We as a lung cancer community are incredibly excited about the activity of immunotherapy in various aspects of the disease,\" said Pasi Janne, director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute in Boston.\nThere have been no other recent treatment breakthroughs in squamous cancer, which most commonly occurs in smokers or former smokers, so this advance is particularly welcome, said Janne.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that Opdivo is one of a class of several drugs that work through a similar mechanism.The story also establishes what is novel when it notes that \u201cThere have been no other recent treatment breakthroughs in squamous cancer \u2026 so this advance is particularly welcome.\u201d While we don\u2019t countenance the use of the word \u201cbreakthrough\u201d based on a company press release that contains almost no useful information, we won\u2019t ding the story for hyping the novelty of this drug. It\u2019s clear that this is one of several drugs in development being tested on different types of cancer.", "answer": 1}, {"article": "The Food and Drug Administration cleared silver diamine fluoride for use as a tooth desensitizer for adults 21 and older.\nIt\u2019s been used for decades in Japan, but it\u2019s been available in the United States, under the brand name Advantage Arrest, for just about a year.\nBut studies show it can halt the progression of cavities and prevent them, and dentists are increasingly using it off-label for those purposes.\nNow there\u2019s an alternative: an antimicrobial liquid that can be brushed on cavities to stop tooth decay \u2014 painlessly.\nNobody looks forward to having a cavity drilled and filled by a dentist.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear that SDF is not new, focusing instead on the fact that it is increasing in popularity (and why).", "answer": 1}, {"article": "The research was funded by the National Institute for Health Research Imperial Biomedical Research Centre and the Biotechnology and Biological Sciences Research Council\nThe results showed when they drank the milkshake with the inulin-propionate ester supplement they rated the high calorie foods as less appealing.\nThe team found that when volunteers drank the milkshake containing inulin-propionate ester, they had less activity in areas of their brain linked to reward -- but only when looking at the high calorie foods.\nThis study also sheds new light on how diet, the gut microbiome and health are inextricably linked adding to our understanding of how feeding our gut microbes with dietary fibre is important for healthy living.\"\nIn a previous research study by the same team, published in 2013, they found that overweight volunteers who added the inulin-propionate ester supplement to their food every day, gained less weight over six months compared to volunteers who added only inulin to their meals.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does a good job of saying what is \u201cnew\u201d about this particular piece of research, compared to previous studies.", "answer": 1}, {"article": "Folic acid -- a synthetic version of folate found in many supplements and multivitamins -- has been shown to lower homocysteine in previous studies, but its effect on disease risk is disputed.\n\"A healthy diet likely remains important,\" Seshadri says.\n\"The role of supplementation remains unclear.\"\n\"Good nutrition should minimize the risk of Alzheimer's disease, but we can't say that any specific food has been proven to reduce this risk.\"\nHealth.com: 9 foods that may help save your memory\n\nOver the next seven years, 17 study participants were diagnosed with Alzheimer's disease.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 0}, {"article": "First published on July 1, 2008 at 12:00 am\nAnd, he said, the results cannot be simply applied to patients with chronic kidney disease, who then have acute kidney injury, since the study excluded any patients with advanced chronic kidney disease.\nIn the study, patients who did not need drugs to maintain blood pressure were assigned to either a six-day or three-day dialysis to filter toxins and extra fluid from the blood.\nIn an accompanying editorial, Dr. Joseph V. Bonventre of Harvard Medical School wrote that he had concerns about the change of therapy offered to patients in the study.\nThere was no difference in death rates in both groups, and both also had similar rates of recovering kidney function and other organ failure.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It was not clear from the story whether both approaches to treating acute kidney injury were currently in use; are there regional differences; or whether there were other factors affecting the type of treatment a patient with acute kidney injury would receive.", "answer": 0}, {"article": "The sport is also associated with good mental health and improving the overall health of those with disabilities.\nEvidence suggests it may not only be good for mind and body, but also for a long life\n\nThe consensus--one of the first of its kind--comes on the eve of the Ryder Cup, the biennial golf tournament between Europe and the US.\nCompared with other sports, the risk of injury is moderate, but as it's an outdoor activity, golfers may be more at risk of skin cancer.\nAnd the sport can do its bit for sustainability by \"practices that prioritise diversity, healthy societies, connection with, and care of, the environment, environmental integrity and health and wellbeing,\" the statement suggests.\nIt can provide moderate intensity aerobic physical activity, and its health benefits are greatest for players (and spectators) who walk round the course rather than opt for a golf cart.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This news release does not present golf as a novel form of exercise. But we think it clearly overreaches in suggesting a host of health benefits through a news release \u2014\u00a0 without any supporting evidence. There is no news here, just promotion.", "answer": 0}, {"article": "\u201cThe high degree of certainty in one report and the extreme caution in the other,\u201d said Rebecca Goldberg, a senior scientist with Environmental Defense, an advocacy group, \u201cwill make people more confused than ever.\u201d\n\nTo the surprise of Institute of Medicine officials, NOAA sponsored the hastily called press conference at which the Harvard report was released, even though that study conflicted with the one prepared by the institute.\nBoth reports have come under criticism from environmental groups and from the Consumers Union.\n\u201cWe\u2019re just trying to make consumers feel good,\u201d said William T. Hogarth, assistant administrator for fisheries of the National Marine Fisheries Service, part of NOAA.\nFor those who eat more fish, both reports advise eating a variety of species to reduce the level of contaminants.\nThe two studies, which conflict in important aspects, seem unlikely to provide much clarity.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The idea that fish consumption is protective against death and disease is not new, and the article provides sufficient context for readers to accurately judge this.", "answer": 1}, {"article": "\"Sixty to 80 percent [success] for something that somebody's not going to get guaranteed pain relief -- in my mind, it's not something I would go for,\" Duggal says.\nDuggal is not impressed with reported success rates.\nHe's interested in another experimental treatment that's just entering clinical trials.\nThe healing process takes place over several months after the shock-wave therapy, which Theodore does in a single treatment.\nSuddenly the room is filled with the rhythmic click-click-click of a metronome.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story doesn\u2019t try to oversell the novelty of shockwave therapy.", "answer": 1}, {"article": "Radical therapy causes lifelong erectile problems and around one in five patients also suffer from incontinence.\nWe also hope that VTP will be effective against other types of cancer - the treatment was developed for prostate cancer because of the urgent need for new therapies, but it should be translatable to other solid cancers including breast and liver cancer.\"\n\"The fact that the treatment was performed so successfully by non-specialist centres in various health systems is really remarkable,\" says Professor Emberton, who is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre.\nThe new treatment, 'vascular-targeted photodynamic therapy' (VTP), involves injecting a light-sensitive drug into the bloodstream and then activating it with a laser to destroy tumour tissue in the prostate.\nAt the moment, men with low-risk prostate cancer are put under 'active surveillance' where the disease is monitored and only treated when it becomes more severe.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release does not appear to overstate the novelty of this treatment. According to the research paper, \u201cTo our knowledge, our study is the first prospective comparative rial of the efficacy and safety of focal therapy and the first assessment of active surveillance for prostate cancer in a comparative setting.\u201d", "answer": 1}, {"article": "A diet that includes tomatoes could lower the chance of having a stroke.\n\nA new study shows that men who had the highest levels of lycopene\u2014an antioxidant found in tomatoes\u2014had fewer strokes than men who had the lowest level of lycopene in their blood. Overall, the risk of strokes was reduced by 55%.\n\nThe study, based in Finland, will be published...", "question": "Does the story establish the true novelty of the approach?", "explanation": "There was no mention of how this research fits with previous\u00a0studies on diet and stroke prevention. Also no mention about prior studies of antioxidant research on lycopene.", "answer": 0}, {"article": "In March of this year, based upon earlier studies utilizing the test, Palmetto GBA, a Medicare Administrative Contractor that assesses molecular diagnostic technologies, issued a draft local coverage determination (LCD) for the Oncotype DX\u00ae AR-V7 Nucleus Detect\u2122 test.\nThis independent, multicenter, blinded study is one of the first studies to validate that a liquid biopsy test can predict therapeutic response and demonstrate a survival benefit.\nEarlier this month, Dr. Andrew Armstrong of Duke Cancer Institute presented data validating the test in the PROPHECY clinical trial at the ASCO 2018 Annual Meeting.\nThe company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells.\nA full LCD for the test is expected in the upcoming months and would support Medicare reimbursement for applicable patients considering ARSI or taxane therapies.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release called this \u201cone of the first studies to validate that a liquid biopsy test can predict therapeutic response and demonstrate a survival benefit.\u201d", "answer": 1}, {"article": "\"The protection started at more than 45 grams [about 1.5 ounces] a week,\" says researcher Susanna C. Larsson, PhD, of the Karolinska Institutet in Stockholm, Sweden.\nThe group eating the most chocolate got the most benefit, reducing stroke intake by 20%.\nLarsson isn't sure why.\nWhile other studies have found a link between eating chocolate and reduced stroke risk, this research found a slight difference in protection, depending on type of stroke.\nThose who ate the most chocolate were protected a bit more from strokes caused by hemorrhage than strokes caused by obstruction such as blood clots.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions other research suggesting that\u00a0chocolate consumption is linked to reduced risk of strokes.", "answer": 1}, {"article": "Merck filed in February for FDA approval of Keytruda for both initial and secondary treatment of advanced urothelial cancer, the most common type of bladder cancer.\nThe Merck drug is awaiting U.S. Food and Drug Administration approval, but Tecentriq was approved by the agency last year, contingent on verification of its clinical benefit.\nIn addition to Tecentriq\u2019s approval for bladder cancer patients whose disease has stopped responding to chemotherapy, the FDA last month approved the Roche drug as an initial treatment for people with a specific type of advanced bladder cancer and in people whose cancer progressed despite at least one prior platinum-containing chemotherapy.\nThe agency has also granted contingent approval to AstraZeneca Plc\u2019s Imfinzi, Bristol-Myers Squibb\u2019s Opdivo and Bavencio, developed by Pfizer Inc and Merck KGaA, as second-line bladder cancer treatments.\nAfter 18 months, 36 percent of Keytruda patients were alive, compared with 20.5 percent of chemotherapy patients, according to research published by ASCO.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The implied novelty here is that this drug seemed to have demonstrated effectiveness in phase 3 trials, unlike a similar competitor\u2019s drug, which had lackluster phase 3 results for the same purpose.", "answer": 1}, {"article": "She cited a 2010 review estimating that 11 million to 12 million women a year will suffer from a UTI, accounting for 1.6 billion antibiotic prescriptions a year.\nWhat's more, the amount of time that passed before a woman's next UTI and between recurrent infections was longer in the water group than in the control group.\n\"In addition, the bother associated with the higher urine output, and feasibility of implementing this water intake strategy across a range of occupations and ages, requires further study as well,\" he said.\nHalf of the women in the study were asked to consume 1.5 liters of water, or about 6 cups, each day in addition to their usual daily fluid intake.\n\"It is the urine output which is of course the key factor leading to the effect seen in the study,\" said Wessells, chair of the department of urology at the University of Washington School of Medicine in Seattle.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s well-known that increasing fluid intake might help prevent UTIs, so the story should not have described this as an \u201cunexpected benefit\u201d and it should have addressed how this new study fits into the larger body of evidence.", "answer": 0}, {"article": "Scientists say they have created a new drug that can attack ovarian and lung cancers in patients for whom other treatments have failed.\nThe cocktail also stopped the cancer growing for almost six months, which is unexpected for patients with advanced-stage cancers who were unresponsive to currently available treatments, including chemotherapy, the authors said.\nDr. Susana Banerjee, consultant medical oncologist at The Royal Marsden NHS Foundation Trust and team leader in gynecological cancers at ICR, who is leading the phase II trial, commented in a statement: \u201cEffective treatment options for women with relapsed ovarian cancer are limited, so these results are very encouraging.\nConfirmatory studies will be essential and if positive would broaden our armamentarium for fighting this cancer.\u201d\n\nThis article has been updated with comment from Professor Udai Banerji\u200b.\nCommenting on the next stage of the research, she said: \u201cIn the larger phase II trial we\u2019ve recruited 140 women with relapsed ovarian cancer across the U.K. to standard chemotherapy (paclitaxel) or paclitaxel in combination with vistusertib.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story didn\u2019t put this trial into context. Multiple other targeted therapies have been tested in phase 1 and 2 trials for ovarian cancer, with results that warranted further study. This seems to be one more avenue of research.", "answer": 0}, {"article": "By contrast, the lifetime risk of breast cancer among women generally is about 12 percent, and for ovarian cancer, it's less than 2 percent.\nRoughly half of the women in the study had undergone either mastectomies (surgery to remove their breasts) or salpingo-oophorectomies (surgery to remove the ovaries and fallopian tubes) between 1974 and 2008, in order to proactively lower their risk of cancer.\nHe said the surgery today is often done in an outpatient setting, with the use of laparoscopes, which limits scarring and shortens a patient's recovery time.\nAccording to Rebbeck, doctors usually recommend that women who test positive for the genes have their ovaries removed at around age 35, but are okay with putting it off until age 40 if they haven't finished having children.\n\"There really isn't anything else that can reduce a woman's risk by this much.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThis story doesn\u2019t imply that preventive surgery is new, but it could have pointed out more clearly that the procedure has been offered to certain women for more than a decade.", "answer": 1}, {"article": "European regulatory bodies recommend pharmaceutical-grade chondroitin sulfate as well as pharmaceutical-grade glucosamine sulfate as first-line treatments for osteoarthritis, Reginster said by email, because of the side effects associated with celecoxib and other non-steroidal inflammatory drugs (NSAIDs) including stomach ulcers, bleeding, liver and kidney problems.\n\u201cStudies like this highlight that medicine is still an art - we do not have perfect answers, and we have to individualize for each patient.\u201d\n\nThe study was sponsored by IBSA Institut Biochimique SA, a pharmaceutical company based in Lugano, Switzerland, that makes the chondroitin sulfate supplements used in the test.\nThose who took chondroitin sulfate or celecoxib had similar levels of pain relief at the end of the study, and in both groups the improvement was greater than for those taking just a placebo, according to the report in Annals of the Rheumatic Diseases.\nDr. Michael Shepard of Hoag Orthopedic Institute in Orange, California, noted that the study had a relatively low number of participants and that most U.S. studies of this type would run two years rather than six months.\nSome have found the supplements to be as effective as ibuprofen (also an NSAID), and some have found that chondroitin sulfate is no more effective than placebo, he told Reuters Health.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "With the help of one of the outside sources, the article makes clear that pain-relieving effects of chondroitin have been studied previously. This fact makes us wonder whether this study should have been covered at all. We might guess that pharmaceutical-grade aspect of the supplement is the novelty, but readers should not be left guessing.", "answer": 1}, {"article": "This new approach to drug discovery is a promising technology that is rapidly moving in the translational research space , .\nAmong these, the abstract \"Tivanisiran a new treatment for Dry Eye Disease, that improved signs and symptoms in clinical trials\" (Posterboard number: 925 - B0103) is highlighted, the compound improving the ocular inflammatory parameters, tear quality and a reduction in ocular pain associated with dry eye disease is also underlined1.\nTivanisiran is a product under development for the treatment of signs and symptoms related to dry eye syndrome and has the potential to be developed for other pathologies that cause ocular pain (corneal lesions, refractive surgery, etc.)\nDry eye can be treated with cyclosporin drops or autologous serum, but there is as yet no specific product for chronic treatment of the ocular pain related to dry eye syndrome; oral analgesics or anaesthetics are used in general.\nIn this context, the phase III \"Helix\" study is being carried out in more than 30 hospitals in Spain, Germany, Estonia, Portugal, Slovakia and Italy, in 300 patients to evaluate the efficacy of this compound in the treatment of the sign and symptoms of dry eye syndrome.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This treatment, at least for dry eye, is novel since it is using a different approach to dealing with dry eyes than currently available medications use. But it\u2019s important to keep in mind that the treatment is still preliminary and must be studied in larger trials before being submitted for FDA approval.", "answer": 1}, {"article": "We and other researchers are now investigating whether retinal changes are related to brain structure and function changes in schizophrenia.\"\n\"While the portable device clearly distinguished people with schizophrenia from those without a psychiatric diagnosis, it's too soon to call this a diagnostic tool,\" said lead author Docia Demmin, a graduate assistant in UBHC's Division of Schizophrenia Research and a doctoral student in Rutgers Department of Psychology.\n\"For example, we know that certain changes in the retina, like thinning tissue [due to cell loss] or weakening electrical activity, occur alongside loss of brain tissue and reduced brain activity in patients with neurological disorders like multiple sclerosis and Parkinson's disease.\nThe results show the device accurately indicated reduced electrical activity in the retina in multiple cell layers in the participants who had schizophrenia, including in cell types that had not been studied before in this disorder.\nIn the study, published in the May 2018 issue of the Journal of Abnormal Psychology, researchers used RETeval, a hand-held device developed to record electrical activity from the retina, to replicate and extend prior studies showing that people with schizophrenia had abnormal electrical activity in the retina.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release said was this is the first time a portable device was used for these tests.\nThe news release also notes that, \u201cLooking at biomarkers in the eye as a way to understand psychiatric disorder is a new field of study,\u201d but the journal article cites studies as far back as 1999. So not so new.", "answer": 0}, {"article": "But scientists already did\n\nParents with children with autism should not rush to their pediatrician demanding brain MRIs for younger siblings, Shen said.\nRelated: See the special bond between a boy with autism and a deaf shelter dog\n\nThe study results are \u201cvery exciting,\u201d said Dr. Adriania Di Martino, a professor of child and adolescent psychiatry at NYU Medical School.\nThe scans showed that 70 percent of high-risk toddlers diagnosed with autism at age 2 had an elevated amount of cerebrospinal fluid around their brains at 6 and 12 months, compared to toddlers who were not diagnosed with autism.\nBut if the fluid is not flowing properly, these byproducts hang around and cause inflammation, which could \u201champer brain development\u201d and lead to autism, said Shen.\nIt may be possible to predict autism in infants as young as 6 months who have older siblings with the disorder, according to a new study by a national network of researchers.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t establish novelty. According to the study itself, this study \u201cconfirms and extends\u201d previous findings, so it is not a new idea.", "answer": 0}, {"article": "A family of medicines known as tricyclic antidepressants were more effective at relieving global symptoms of IBS, the analysis found.\nFor the current analysis, researchers examined data from 53 trials that compared the effects of antidepressants or psychotherapy, either alone or in combination, versus placebo treatments or \u201cusual management\u201d in people with IBS.\nAntidepressants may work better for certain types of IBS, and the study findings also suggest that the type of medication may matter, Kulak-Bejda said by email.\n(Reuters Health) - People struggling with irritable bowel syndrome (IBS) might feel better with antidepressants or psychotherapy, a recent study suggests.\n\u201cThe decision should be made after considering all the pros and cons.\u201d\n\nLead author Dr. Alexander Ford of the University of Leeds in the U.K. didn\u2019t respond to requests for comment.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The paper being reported on in this story is an update of an earlier journal article that reviewed the available research on whether antidepressants or psychotherapy may reduce the symptoms of IBS. Of the 53 trials incorporated into this most recent review, 48 of them also appeared in the previous review. In other words, the current review incorporates data from only 5 new trials \u2014 four on psychotherapy and one on antidepressants. To what extent, if any, did the incorporation of data from these five trials change the findings of the review? Did the new data support what researchers already knew? Or did the data change our understanding of the relationship between IBS and antidepressants or psychotherapy?", "answer": 0}, {"article": "Noctiva is taken daily, approximately 30 minutes before going to bed.\n\u201cIt is important to know that Noctiva is not approved for all causes of night-time urination, so patients should discuss their symptoms with their health care provider who can determine the underlying cause of the night-time urination and whether Noctiva is right for them.\u201d\n\nNocturia (wakening at night to urinate) is a symptom that can be caused by a wide variety of conditions, such as congestive heart failure, poorly controlled diabetes mellitus, medications, or diseases of the bladder or prostate.\n\u201cToday\u2019s approval provides adults who overproduce urine at night with the first FDA-approved therapeutic option to help reduce the number of times a night they wake up to urinate,\u201d said Hylton V. Joffe, M.D., M.M.Sc., director of the Division of Bone, Reproductive, and Urologic Products in the FDA\u2019s Center for Drug Evaluation and Research.\nThe U.S. Food and Drug Administration today approved Noctiva (desmopressin acetate) nasal spray for adults who awaken at least two times per night to urinate due to a condition known as nocturnal polyuria (overproduction of urine during the night).\nAlthough these trials showed a small reduction in the average number of night-time urinations with Noctiva compared to placebo, more patients treated with Noctiva were able to at least halve their number of night-time urinations, and patients treated with Noctiva had more nights with one or fewer night-time urinations.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release downplays the fact that this is not a new drug. It does acknowledge that there are other FDA-approved medications that also contain desmopressin, the active ingredient in this new product, but we would have liked to see this fact higher up in the release. In fact, desmopressin has been approved for use in the U.S. market since 1978 and has been used to treat a variety of conditions including diabetes and hemophilia A. Physicians have also been prescribing desmopressin to treat nocturia, although it wasn\u2019t officially approved for that use until now.", "answer": 0}, {"article": "The current standard treatments for metastatic melanoma -- chemotherapy and interleukin-2 (IL2) -- only have response rates in about 15 percent of these patients, said Dr. Paul Chapman, senior author of a study in which the findings are described.\nIt's not known at this time if the drug can improve overall survival, and a sizable proportion of participants developed resistance to the drug, the researchers say.\nThe findings join other recent reports of potential treatments for melanoma in what appears to be an exciting time for the field.\nThe drug, PLX4032, just completed a phase 1 clinical trial in which 81 percent of participants with a particular gene mutation had a partial response, meaning at least some shrinkage of the tumor.\nThere's more on metastatic melanoma at the U.S. National Cancer Institute.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story describes\u00a0the research that led to the development of the new drug. By all accounts the drug does represent a novel and exciting approach to the treatment of metastatic melanoma.", "answer": 1}, {"article": "In its marketing campaign, Cyberonics notes that VNS treatment does not cause the weight gain associated with antidepressants and the confusion and memory loss common after electroconvulsive therapy (ECT), psychiatry's term for shock treatments.\nThe generator emits regular pulses of electricity that are supposed to stimulate serotonin and other brain chemicals believed to regulate mood, according to Cyberonics.\nBoth are common side effects of VNS treatment.\nAt the end of three months, there was no statistically significant difference between the two groups.\nAt the time, the Georgetown University graduate said he was so depressed he told his doctor he hoped to die on the operating table.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that the device was approved by the FDA in late 2005.", "answer": 1}, {"article": "So, how best to reach these targets?\nThe researchers found that women who consumed high levels of fiber (28 grams per day, on average) had a 24 percent lower risk of developing breast cancer before menopause, compared with women who ate low levels of fiber (14 grams per day, on average).\nIn a commentary accompanying the study in Pediatrics, Blackwell writes, \"There is longstanding evidence that dietary fibers may reduce circulating estrogen levels.\"\nThe findings are based on a long-term study of 44,000 women who were surveyed about their eating habits in high school.\n\"The recollection of dietary habits more than a decade earlier must be questioned,\" writes Blackwell.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This study is not the first to examine the possible link between dietary fiber and breast cancer risk. For example, a 2012 paper in the Annals of Oncology looked at 16 earlier studies on dietary fiber and breast cancer risk. There is no discussion of this earlier work, or how the new paper builds on or diverges from the previous research.", "answer": 0}, {"article": "This was the second time a so-called \"female Viagra\" failed to make it on the market; in 2004, an FDA panel said no to Intrinsa, a testosterone patch meant to hormonally help women with a lack of desire for sex.\nHere's more information on the sexual effects of maca from New York University Langone Medical Center.\nYou can also visit a practitioner familiar with herbs to make a combination for you.\nBut in the absence of a drug to help women with sexual problems, here's what's recommended by some practitioners.\nWhatever you try to get your libido back, remember that your first attempt might not work.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of the treatments discussed in this story isn\u2019t in question.", "answer": 2}, {"article": "Check out more than one clinic and make sure you know what it defines as a \u201csuccess\u2019\u2019 \u2014 a viable transferring of an egg leading to a baby, or just a safely thawed egg.\n\u25a0 After a woman\u2019s mid-30s, her eggs may not be of high enough quality to produce a baby.\n\u25a0 The \u201csuccess\u2019\u2019 rates of egg freezing may vary widely from one fertility center to another.\nDiscarding an unused embryo, which has the potential to develop into a baby, has weightier implications for many than discarding unused eggs.\n\u25a0 A woman who freezes eggs rather than embryos avoids potential custody problems if she and her partner split up.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story states that it \"is new enough that there are few reliable statistics.\"\u00a0 Good context. And, at\u00a0 the end, it says that \"Still, several advances are nudging the use of egg-freezing forward.\"\u00a0 ", "answer": 1}, {"article": "SUNDAY, March 6, 2011 (HealthDay News) -- A simple blood test may one day offer a safe way to detect Down syndrome during pregnancy, researchers say.\nAlthough Down syndrome varies in severity, it usually causes some intellectual impairment and distinguishing facial features.\nOlder mothers are more likely to give birth to Down syndrome babies.\n\"We estimate we can introduce this to clinical practice in a couple of years.\"\n\"So they will be able to make a very personal decision without anyone realizing it,\" he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "No discussion of how this compares with any of the other approaches being studied in this field.", "answer": 0}, {"article": "But a P.P.I.\nBut while certain common foods \u2014 like raw onions, garlic, citrus juices, coffee and chocolate \u2014 are likely to cause reflux in most people with the condition, Dr. Aviv and other experts emphasize that everyone is different, and trial and error is the most effective way to determine an individual\u2019s trigger foods and drinks.\nSmoking and alcohol can loosen tension of the upper esophageal sphincter and cause symptoms of reflux like hoarseness, postnasal drip and shortness of breath by irritating the mouth, larynx and trachea, Dr. Aviv reports.\nAccordingly, the 28-day \u201chealing\u201d diet he suggests consists almost entirely of natural, unprocessed foods, especially lean protein foods like light-meat poultry, fish, egg whites and low-fat dairy, beans (combined with whole grains), and nonacidic vegetables and fruits.\nOne characteristic often associated with acid reflux \u2014 being overweight, especially with abdominal obesity \u2014 largely explains why the condition has become so common in Western countries.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is a column that looks at general health topics, and not a news story, so we\u2019ll rate this one N/A.\nThat said, the\u00a0timeliness appears to be due to\u00a0The Acid Watcher Diet, which was published earlier this year. There are quite a few other books in the same vein, so it\u2019s not clear what made this one worthy of a column feature.", "answer": 2}, {"article": "Recent tests show the cancerous nodules in Mejia's lungs are shrinking, and she hopes for more good news after scans later this summer.\nAt the time she was 39 and had experienced bleeding she blamed on hemorrhoids.\nThe findings are published in the Journal of the American Medical Association.\nBut doctors told Mejia they needed to investigate what caused the irregular finding.\n\"I am thankful for every minute I get to spend with them,\" she said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes what is new here and made reference to the research done at Tufts and reported in JAMA.", "answer": 1}, {"article": "And patients may need to continue treatment.\nThe thought that you could lose your vision is very, very depressing,\" Daniel says.\nFor more than 100 years, the Lighthouse has been the leader worldwide in helping people of all ages who are blind or partially sighted overcome the challenges of vision loss.\n\"Instead of seeing a lot of this squiggling, the lines straighten out,\" he says.\n\"These symptoms were these wavy lines \u2014 and especially on the periphery of your vision,\" says macular generation patient Daniel Davison.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly states that Lucentis is a new drug. The story should have mentioned that a very similar drug, Avastin, has been used in the same manner for a few years.", "answer": 1}, {"article": "\u201cDr.\n\u201cIt is very rewarding as a reconstructive surgeon to continuously refine these procedures for our patients.\u201d\n\nMs. Burt chose the Valley breast surgery team after carefully researching her treatment options for DCIS (ductal carcinoma in situ), a diagnosis that is often debated among clinicians as to whether it should be classified as breast cancer at all.\n\u201cHere at Valley, we are proud to offer this option for our patients and are excited about its potential for vastly improving patient care for women with breast cancer.\u201d The technique involves placing tissue expanders (interim implants) under the skin on top of a woman\u2019s pectoralis muscles after her breast tissue has been removed.\nThe technique has the potential to be a \u201cgame-changer,\u201d says Tzvi Small, M.D., Director of the Department of Plastic and Reconstructive Surgery at The Valley Hospital, who performed the breast reconstruction procedure on Hasbrouck Heights resident Vanessa Burt, 43.\nI want to also commend the pathologists at Valley, who were exceptional in their diagnostic results.\u201d Dr. Wilson and Laura Klein, M.D., Medical Director of the Breast Center, have extensive experience in performing nipple-sparing mastectomy, a technically demanding surgery that is performed within aesthetically appealing minimally invasive incisions.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This is definitely not a new technique. However it needs to be stressed that there are very good reasons why it is not commonly performed, and this release does not discuss any of them. The novelty is essentially lost in this release \u2014 the most we\u2019re told is that this is a \u201cvariation of a standard technique.\u201d\nAlmost all tissue-expanding breast surgeries place a balloon-like sac beneath chest muscles and on top of the ribs, where they\u2019re better held in place (and less likely to protrude through surgical cuts).\nThe procedure described here places the implant on top of the chest muscles \u2014 right below the skin. Breast surgeons typically avoid this because the breast skin alone might not be able to support a saline-filled sac after an aggressive surgery, even if filed gradually over weeks.\nAnd as much as this release tries to make the procedure seem new, it\u2019s not; it just appears to be new within this particular corner of New Jersey.", "answer": 0}, {"article": "Medical-device makers, venture capitalists and surgeons are racing to turn a once-controversial weight-loss procedure into the next big thing in elective surgery.\n\nOnce dismissed by some surgeons as a gimmick, gastric banding -- in which a silicone band is wrapped around the upper stomach to restrict food intake -- is now the focus of a fierce competition pitting consumer-products giant Johnson & Johnson against Botox maker Allergan Inc. Venture-capital-backed outpatient centers are popping up to implant the bands. Growing...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story provided a pretty complete history of the use of gastric banding.", "answer": 1}, {"article": "The patient had no prior history of high blood pressure or cirrhosis, the drugmaker said.\nTwo doses of Stelara, already approved for psoriasis, psoriatic arthritis and Crohn\u2019s disease, was tested in 961 patients with moderate-to-severe ulcerative colitis (UC) who had failed prior therapy.\nThe treatment and the placebo arms reported similar proportion of side effects, with one patient on the 6 mg/kg dose dying following excessive bleeding, J&J said.\n\u201cMore than half of UC patients have not experienced remission with currently available treatment options,\u201d the study\u2019s lead investigator Bruce Sands said.\n(Reuters) - Johnson & Johnson said on Tuesday its blockbuster drug Stelara was found to be effective in treating a chronic bowel disease in a late-stage trial.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The findings appear to be the first large-scale trial results assessing the effect of Stelara on chronic moderate-to-severe UC. That\u2019s not explicitly stated, but it is sufficiently inferred to give this a satisfactory rating.", "answer": 1}, {"article": "The report concluded that both are necessary for bone health but that as for preventing cancer, heart disease, diabetes and autoiummune disorders, the evidence was \u201cinconsistent, inconclusive as to causality, and insufficient to inform nutritional requirements.\u201d Even so, the committee recommended that children and adults up to age 70 get 600 IU of vitamin D daily \u2014 from food and, if necessary, supplements \u2014 and that adults age 71 and older get 800 IU.\nSome studies have found no ill effects from taking far higher amounts, and many of the prospective but not proven benefits against cancer and other diseases are believed to require doses ranging from 2,000 to 5,000 IU.\nThe one thing the research leaders are certain of is that the public\u2019s faith in vitamin D as a modern panacea has far outpaced what the scientific evidence proves.\nThe so-called D2d study, which will run for four years, is seeking to enroll 2,382 people older than 30 who are at high risk of developing diabetes due to weight or blood-sugar levels but who have not yet been diagnosed with the disease.\nThere is such controversy now that the only way to convince people who sit on those sides of the equation is to complete rigorous, randomized trials.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Although there\u2019s nothing novel about vitamin D, the story\u00a0makes it clear that there is old evidence, new evidence, and more research findings to be expected in the coming years.", "answer": 1}, {"article": "Pain patches have a number of benefits, Rosenquist and Dombrowski said, not the least of which is convenience.\nBefore the FDA action, pain-relieving patches were available in the United States only by prescription, said Dr. John Dombrowski, director of the Washington Pain Center in Washington, D.C. Their active ingredients include such medications as lidocaine, capsaicin and non-steroidal anti-inflammatory drugs, or NSAIDs.\nThe active ingredients in Salonpas are methyl salicylate and menthol, common components of pain-relieving gels and creams, such as Bengay.\n\"Salonpas is the Western world catching up with Asia,\" said Dr. Rick Rosenquist, a professor of anesthesia and director of pain medicine at the University of Iowa Carver College of Medicine and chairman of the American Society of Anesthesiologists' committee on pain medicine.\nThe U.S. Food and Drug Administration approved the country's first over-the-counter, pain-relieving transdermal patches in 2008.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story started out in a promising way, by showing that pain patches are commonly used in other countries. One of the quoted experts says that the US is simply late in beginning to use them: \u201cIf you are an Asian kid, you\u2019ve had these placed on you since time immemorial,\u201d he said. \u201cIt\u2019s just now starting to hit more mainstream in the United States. They\u2019re gaining more acceptance.\u201d They are not novel and have been available by prescription. The story, helpfully, explains that \u201cactive ingredients include such medications as lidocaine, capsaicin and non-steroidal anti-inflammatory drugs, or NSAIDs. The active ingredients in Salonpas are methyl salicylate and menthol, common components of pain-relieving gels and creams, such as Bengay.\u201d This is all good context.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061105/13healy.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 1}, {"article": "With knee-replacement surgery on the rise, more patients with two bad knees are opting for a controversial procedure that replaces both at the same time.\n\nSimultaneous bilateral knee replacement, as the surgery is known, is a subject of debate among orthopedic surgeons, with conflicting evidence about the risks and benefits. Proponents say it eliminates the need for a second hospital stay and grueling rehabilitation period, reduces time spent under anesthesia and costs less.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that, as of 2010, approximately 6 percent of patients who get both knees replaced have bilateral surgery \u2014 up from 4 percent in 1999. So, the technique is not new, but there has been some growth in the use of the surgery as younger and healthier patients become candidates for knee replacements \u2014 and the story establishes this. The story could have been clearer about the fact that this technique has been routinely used even longer than that. (Reviewer Jim Rickert can recall doing bilateral replacements not infrequently as far back as the 1980s.)", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Botox injections may provide some relief from arm tremors caused by multiple sclerosis, according to a small study published Monday.\nIn real life, the injections would have to be repeated every few months, or possibly every six months for some people, according to van der Walt.\nThe new study, published in the journal Neurology, tested the effects of Botox injections on MS-related arm tremors, which affect up to two-thirds of people with MS.\nPhysical therapy and exercise have been studied, but are usually not very effective, said LaRocca, who was not involved in the new study.\n\u201cThis study is fairly preliminary, and it had a small number of patients,\u201d LaRocca said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of this approach is not made clear in the story.\u00a0 Is this the first look at Botox for this use?\u00a0 Is there any comparable work?", "answer": 0}, {"article": "MONDAY, Nov. 16, 2015 (HealthDay News) -- Breast-feeding a premature infant may help reduce the risk of a serious eye problem known as retinopathy of prematurity (ROP), new research suggests.\nFor the study, researchers from China, Canada and the United Kingdom reanalyzed the results of five published studies on ROP.\nHe added that in China, a previous study showed the incidence of ROP was 50 percent in infants with a birth weight under 1,000 grams (2.2 pounds).\nThe studies included more than 2,200 preterm infants, comparing how often babies had been fed human milk or formula, and whether or not they developed ROP.\nIn re-evaluating the studies, Chen's team found that breast-feeding in any amount appeared to reduce the risk of ROP.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article clearly identifies the underlying study being\u00a0based on a reanalysis of five previously published studies on ROP (or what is known in the lingo as a meta-analysis). The article might have indicated that this is one of the first such meta-analyses done on ROP.", "answer": 1}, {"article": "Observational studies, which include all people with a condition, can never conclusively prove cause and effect, Keating acknowledged, because \"the thing we can't account for is whether people who are on a treatment are different from those who aren't.\"\n\"One third of men over 65 who don't have surgery or radiation get this therapy,\" she said.\nBut lots of men get the therapy where it has not been shown to have a benefit.\"\nAlbertsen wrote an accompanying editorial in the journal.\n\"We are beginning to realize that there can be significant problems in terms of cardiovascular risk.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story included the history about how the use of hormone therapy has expanded over time from the treatment of symptoms from metastatic prostate cancer to a treatment used before men have symptoms of prostate cancer. \u00a0\n", "answer": 1}, {"article": "Some doctors are raising concerns about a new cancer-treatment device that uses electrical jolts to zap tumors but that hasn't been through a large clinical trial to prove it's safe and effective in people.\n\nThe device, called NanoKnife, is currently being used in about 13 U.S. hospitals including Baptist Health Medical Center in Little Rock, Ark., University of Louisville, and Shands Hospital/University of Florida in Gainesville, Fla. Each machine costs as much as $300,000. Some of the hospitals are aggressively promoting...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story\u00a0 makes it clear that similar devices have been used for other procedures, but that this is a relatively new therapy for cancer.", "answer": 1}, {"article": "She tried decongestants, antihistamines and steroid nasal sprays.\nOften they were no better off, sometimes worse.\nA brief course of antibiotics will work better after surgery.\"\nShe rinsed out her sinuses faithfully with saltwater.\nStill, she's disappointed.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story didn\u2019t attempt to oversell the novelty of this procedure.", "answer": 1}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\nOf the 60 cancers detected in the study group over the observation period (7,007 screening rounds), 59 were found only using MRI, one was found also by mammography, and none by mammography or ultrasound alone.\nMRI screening has not been considered necessary for women at average risk, and there has been resistance to expansion of MRI into this population due, in part, to concern over higher costs.\nThe results also highlight the ability of MRI in the detection of more aggressive types of cancer.\nThe new study showed that, consistent with previous research, breast MRI can depict these rapidly growing cancers with high reliability.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release establishes that the novelty of the study lies in its challenge of the conventional wisdom that supplemental MRI screening should be recommended\u00a0to high-risk women but not average-risk women.", "answer": 1}, {"article": "MILAN (Reuters) - An established targeted therapy for bowel cancer may also help women with an aggressive form of breast cancer, a mid-stage clinical study revealed on Monday, opening up a potential new market for the medicine.\nNo question,\u201d he said.\nSales last year were $1.7 billion.\n\u201cThis study clearly opens the field ...\n\u201cWe are very excited by these results,\u201d lead researcher Jose Baselga of the Massachusetts General Hospital Cancer Center in Boston told the European Society for Medical Oncology (ESMO) \u2014 Europe\u2019s biggest cancer meeting.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 1}, {"article": "(\u201cEnjoyed\u201d?\nThe offspring of those mothers turned out to be about 50 percent more physically active than those born to mothers that hadn\u2019t had the exercise wheel option.\n\u201cOur study in a mouse model is important because we can take all those effects out of the equation,\u201d Waterland said.\nThe mice with running wheels voluntarily ran an average of more than six miles a night, decreasing to about two miles late in pregnancy.\nBut in the human studies, it wasn\u2019t always clear whether active mothers who have active children simply raised their kids to exercise a lot or whether there might have been a genetic predisposition to physical activity.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article notes that the current study goes beyond available observational studies in humans by utilizing an experimental design in mice.", "answer": 1}, {"article": "Down the road, the \"fantasy\" is that asymptomatic people will be able to get a biomarker test to determine whether they'll one day get Alzheimer's, but that's not possible right now, he adds.\nPatients were tracked from four to 12 years, with a median of 9.2 years.\nClinical trials can better focus their efforts if patients are known to be in the early stages of Alzheimer's.\nSome of the participants, who were originally found to be stable with mild cognitive impairment after about five years, went on to develop Alzheimer's disease during the longer follow-up.\nThe Alzheimer's Association runs a system called TrialMatch.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear that:", "answer": 1}, {"article": "Hitachi will continue to globally expand the healthcare business where proton therapy is its flagship solution, and contribute to cancer treatment around the world.\nThus, we foresee an exciting, long term relationship that will benefit cancer patients and cancer research.\u201d\n\nIn December 2007, Hitachi was the first company in the U.S. to clear FDA Premarket Notification Special 510(k) for the \u201cPROBEAT\u201d system with its spot scanning irradiation technology.\nThe next-generation system \u201cPROBEAT\u201d, which comes with IMPT (Intensity Modulated Proton Therapy) and cone-beam CT, will have improved spot scanning capability in all 3 gantry-type treatment rooms, along with a fixed irradiation room dedicated to cancer research.\nThree primary benefits are: (1) more accurate irradiation which reduces the side effects to healthy tissues surrounding the tumor compared with irradiation from conventional double scattering irradiation; (2) patient-specific collimators and boluses become obsolete, shortening set up times for patients; and (3) high proton beam usage factor reducing unnecessary secondary radiation.\nThis collaboration, which includes a 10-year maintenance service, marks the first multi-room PBT application in the nation\u2019s capital.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release fails on two fronts here. First, the news release claims, \u201cThis collaboration, which includes a 10-year maintenance service, marks the first multi-room PBT application in the nation\u2019s capital.\u201d The fact that this a \u201cmulti-room\u201d system is not a meaningful claim when there are other facilities under construction (at least one of which will apparently open before Sibley\u2019s) nearby. Second, the release did not meet our standard for establishing the novelty of the technology. The release states, \u201cThe proton center at Sibley Memorial Hospital will be an impressive demonstration of industry and academic medicine collaborating to bring a new technology and new cancer treatment modality to Washington, D.C. and the surrounding communities.\u201d But PBT is not a new cancer treatment modality, nor will it be new to Washington D.C.\u00a0Proton therapy has been used clinically since the mid-1950s. The first proton accelerator (cyclotron) was developed in 1932 by E. O. Lawrence and S. Livingston, and Nobel physics laureate Robert Wilson proposed using it for radiation therapy in 1946. The \u201cpassive scattering\u201d technique noted in the news release was used initially at the outset. The \u201cspot scanning\u201d technique described in the release was developed and first implemented in Switzerland during the 1990s. Most proton centers can accommodate treatment using both techniques.", "answer": 0}, {"article": "A variation of a drug commonly given to cancer patients with bone damage appears to be an effective tool for preventing repeat hip fractures in elderly patients, according to a study in the New England Journal of Medicine.\n\nThe study results, which were to be presented yesterday in Hawaii, have potentially big implications because hip fractures are a common and debilitating injury for older people. Most of the 300,000 hip fractures each year in the U.S. are related to osteoporosis in older people, as well as falls, according...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear that this was a new use (treatment of osteoporosis in elderly individuals who have already sustained a hip fracture) for a treatment that has FDA approval for a slightly different application.", "answer": 1}, {"article": "This research was supported by Gilead Sciences.\nDaily treatment with the antiviral drug tenofovir during the third trimester of pregnancy reduced the mother-to-child transmission rate of hepatitis B (HBV) from 18 percent to 5 percent, according to the findings of a clinical trial led by researchers from NYU Langone Medical Center and published on June 16 in the New England Journal of Medicine.\n\u201cWe believe that these findings will not only save many lives, but could also help to eradicate hepatitis B nationally and abroad.\u201d\n\nThe study was conducted in five locations in China, where HBV infection is endemic.\n\u201cThis study provides strong evidence on how best to care for women infected with hepatitis B during pregnancy and reduce the rate of disease transmission,\u201d says Mark Pochapin, MD, the Sholtz/Leeds Professor of Gastroenterology and director of the Division of Gastroenterology and Hepatology at NYU Langone.\n\u201cPreventing mother-to-child transmission is the most effective way to reduce the global burden of chronic hepatitis B infection and liver cancer,\u201d says Calvin Pan, MD, lead author of the study and a clinical professor of medicine at NYU Langone.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release just barely implies novelty with this statement which suggests a change in treating infected women who are pregnant:\n\u201cBased on the findings, the investigators recommend that women be tested for HBV viral load at week 28 of pregnancy. Those with a high viral load should receive tenofovir treatment starting at gestational week 30 until delivery to reduce the risk of transmission to their infants.\u201d\nWhile the drug itself isn\u2019t novel, positive outcomes from a controlled trial on pregnant women carrying the virus does seem to introduce a new treatment approach.", "answer": 1}, {"article": "the bigger issue though is, is the increased costs associated with protons worth it to society?\nIt's the most expensive device in medicine today.\nBut proton beam therapy is at the heart of the debate over rising health-care costs.\nHuge magnets direct the beam of radiation the length of a football field into treatment rooms.\nAnd with no side effects.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story adequately describes the novelty of proton beam therapy.", "answer": 1}, {"article": "They were so sure cancerous nodes had to come out that they said the study was unethical and would endanger women.\nIt\u2019s hard for us as surgeons and medical oncologists and radiation oncologists to accept that you don\u2019t have to remove the nodes in the armpit.\u201d\n\nDr. Grant W. Carlson, a professor of surgery at the Winship Cancer Institute at , and the author of an editorial accompanying the study, said that by routinely taking out many nodes, \u201cI have a feeling we\u2019ve been doing a lot of harm.\u201d\n\nIndeed, women in the study who had the nodes taken out were far more likely (70 percent versus 25 percent) to have complications like infections, abnormal sensations and fluid collecting in the armpit.\n\u201cIt\u2019s a little frustrating.\u201d\n\nEventually, he said, genetic testing of breast tumors might be enough to determine the need for treatment, and eliminate the need for many node biopsies.\nIt is not known whether the findings also apply to women who do not have radiation and chemotherapy, or to those who have only part of the breast irradiated.\nWomen know it.\u201d\n\nAfter armpit surgery, 20 percent to 30 percent of women develop lymphedema, Dr.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes that a change in treatment protocol away from removing all the lymph nodes under the arms of women with breast cancer would be novel.\u00a0There is some nuance, here, though that could be missed by a casual reader. Women who have one to two positive lymph nodes would avoid having additional lymph node surgery. The overall tone of the story may make it appear to some readers that women get to avoid lymph node surgery altogether, but they don\u2019t.", "answer": 1}, {"article": "\"Might this be a good application to help that person recover or prevent this decay from advancing?\nBut the third is a decay that is not so advanced, and Dr. Jin-Ho Phark, her dentist, is going to use a treatment he's testing that involves no drilling -- \"which is nice because many patients don't like the sound of the drill, and the feeling or the pain that might be associated with it,\" Phark says.\n\"We aim to treat these intermediate lesions -- not the very early ones, but the intermediate ones -- where usually, as a dentist, you are not sure whether you should make a filling or not,\" Paris says.\nWolff says that while the no-drill approach to treating this type of tooth decay has promise, fluoride treatments and other patient-applied methods are still more inexpensive, less invasive and have a much longer track record of success.\n\"An alternative could simply be brushing better in a certain location and not drinking Coca-Cola all day long,\" says Mark Wolff, a professor of dentistry at New York University who specializes in cariology, or the study of tooth decay.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\n\n \nThis story fails spectacularly on this criterion. The featured product is called \u201cone of several new cavity treatments that avoid drilling.\u201d But in its application for approval to the FDA, the manufacturer says the product is basically the same as other sealants that have been available for more than a decade:\n\u201cThe Infiltration Kit materials are substantially equivalent to several currently marketed dental restorative materials including the following:Infiltrant:3M CliNPRo Sealant K992326 (3M Company USA)Admira Seal K021842 (VOCO, GmbH)Grandio Seal K062344 (VOCO, GmbH)\nReferences:FDA 510k summary, March 26, 2010http://www.accessdata.fda.gov/cdrh_docs/pdf10/K100062.pdf\nFDA 510(k) Summary, Sep. 18, 2008http://www.accessdata.fda.gov/cdrh_docs/pdf8/K081493.pdf", "answer": 0}, {"article": "May 23, 2011 -- Researchers in Europe say a fermented dairy product containing a specific bacterium known as a probiotic did not relieve constipation in children more than a dairy product without a probiotic.\nThe study examined 159 children with constipation for at least two months with a defecation rate of less than three times per week.\nAbout half were given the probiotic product twice daily for three weeks; children in the comparison group were given a dairy product without the probiotic.\nThe finding is significant, the researchers say, because probiotics have helped some adults with constipation.\nBut in a new study the kids who consumed the fermented dairy product did no better, based on number of stools produced, than youngsters in a comparison group.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story provided information about other studies on constipation management that have been conducted with probiotic products in children and adults.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Hormone replacement therapy (HRT) can carry serious health risks, but a new study adds to evidence that menopausal women who use the hormones may have lower odds of developing colon cancer.\nAnd lab experiments have shown that estrogen may inhibit tumor development in the colon by affecting cell growth, or by lowering levels of a cancer-linked hormone called IGF-1.\nThe findings, reported in the American Journal of Epidemiology, support the theory that estrogen offers some protection against colon cancer.\nThe study, which followed nearly 57,000 California teachers, found that women who were using HRT at the outset were 36 percent less likely to develop colon cancer over the next decade than those who had never used HRT.\nHowever, no one is recommending that women take HRT to ward off colon cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did a decent job putting the new study in context, explaining, \"Some past studies have linked not only HRT, but also use of birth control pills, to a lower colon cancer risk\"\u00a0 ", "answer": 1}]